PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	TUNSTALLPEDOE, H				TUNSTALLPEDOE, H			VALUE OF THE DUNDEE CORONARY RISK-DISK - A DEFENSE	BRITISH MEDICAL JOURNAL			English	Article							HEART-DISEASE; MANAGEMENT; MORTALITY; MEN				TUNSTALLPEDOE, H (corresponding author), UNIV DUNDEE,NINEWELLS HOSP & MED SCH,CARDIOVASC EPIDEMIOL UNIT,DUNDEE DD1 9SY,SCOTLAND.							Cox B.D., 1987, HLTH LIFESTYLE SURVE; JARRETT RJ, 1982, BRIT MED J, V285, P535, DOI 10.1136/bmj.285.6341.535; KANNEL WB, 1986, AM HEART J, V112, P825, DOI 10.1016/0002-8703(86)90481-3; POULTER N, 1991, AM HEART J, V121, P246, DOI 10.1016/0002-8703(91)90851-8; Shaper A G, 1987, Health Trends, V19, P37; SMITH WCS, 1989, SCOT MED J, V34, P550, DOI 10.1177/003693308903400603; TUNSTALLPEDOE H, 1989, BMJ-BRIT MED J, V298, P1593, DOI 10.1136/bmj.298.6688.1593; TUNSTALLPEDOE H, 1991, BRIT MED J, V303, P744, DOI 10.1136/bmj.303.6805.744; WILSON PWF, 1987, AM J CARDIOL, V59, P91; 1991, BMJ, V303, P748; 1991, BMJ, V302, P1057; 1990, DIETARY NUTRITIONAL	12	6	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 25	1992	305	6847					231	232		10.1136/bmj.305.6847.231	http://dx.doi.org/10.1136/bmj.305.6847.231			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG112	1392830	Green Published, Bronze, Green Submitted			2022-12-01	WOS:A1992JG11200028
J	WATSON, EK; MAYALL, ES; LAMB, J; CHAPPLE, J; WILLIAMSON, R				WATSON, EK; MAYALL, ES; LAMB, J; CHAPPLE, J; WILLIAMSON, R			PSYCHOLOGICAL AND SOCIAL-CONSEQUENCES OF COMMUNITY CARRIER SCREENING-PROGRAM FOR CYSTIC-FIBROSIS	LANCET			English	Article								We have assessed the effect of screening for cystic fibrosis (CF) carrier status on anxiety levels, attitudes, knowledge and actions of participants in a pilot programme conducted through primary health care services. Over 3000 individuals were screened and 100 carriers with no previous family history were identified. Varying degrees of anxiety were found to be associated initially with a positive result, but most of this was allayed by genetic counselling, and we find no adverse long-term psychological consequences in carriers. Most discussed carrier status with their partner (89%), parents, other relatives and also with friends; 87% of partners to whom testing was suggested have been screened. Those testing positive indicated that knowledge of carrier status would be considered in future reproductive decisions, and after 6 months carriers retained a reasonable level of knowledge about CF and its inheritance. Carriers and non-carriers uniformly approve of screening and are glad to have been tested. Knowledge of CF in the sample of non-carriers has also increased after testing, suggesting screening may improve understanding of CF among the entire target population. Fears of possible social costs of screening may be ill-founded.	IMPERIAL COLL SCI TECHNOL & MED, ST MARYS HOSP,SCH MED,DEPT BIOCHEM & MOLEC GENET, REG DNA LAB, LONDON W2 1PG, ENGLAND	Imperial College London								BONDUELLE M, 1990, HUM GENET, V85, P436; EVERSKIEBOOMS G, 1979, CLIN GENET, V15, P465; HOLTZMAN NA, 1989, PROCEED CAUTION, P174; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; MARTEAU TM, 1992, J MED GENET, V29, P24, DOI 10.1136/jmg.29.1.24; Spielberger CD., 1970, SELF EVALUATION QUES; TSUI LC, 1992, CYSTIC FIBROSIS GENE; WATSON EK, 1990, HUM GENET, V85, P435, DOI 10.1007/BF02428303; WATSON EK, 1991, BRIT MED J, V303, P504, DOI 10.1136/bmj.303.6801.504; 1990, NEW ENGL J MED, V323, P70	10	91	92	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 25	1992	340	8813					217	220		10.1016/0140-6736(92)90477-K	http://dx.doi.org/10.1016/0140-6736(92)90477-K			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JE758	1353144				2022-12-01	WOS:A1992JE75800012
J	WHITE, HD				WHITE, HD			THROMBOLYTIC THERAPY FOR PATIENTS WITH MYOCARDIAL-INFARCTION PRESENTING AFTER 6 HOURS	LANCET			English	Editorial Material							LEFT-VENTRICULAR VOLUME; CORONARY-OCCLUSION; REPERFUSION; MORTALITY; TRIAL				WHITE, HD (corresponding author), GREEN LANE HOSP, CARDIOVASC RES UNIT, AUCKLAND 3, NEW ZEALAND.							[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1991, LANCET, V337, P271; [Anonymous], 1992, Lancet, V339, P1; [Anonymous], 1986, Lancet, V1, P397; BROWN EJ, 1991, J AM COLL CARDIOL, V17, P1641, DOI 10.1016/0735-1097(91)90660-2; CHAMBERLAIN DA, 1988, LANCET, V1, P545; COLLINS R, 1987, EUR HEART J, V8, P634; GANG ES, 1989, NEW ENGL J MED, V321, P712, DOI 10.1056/NEJM198909143211104; HACKETT D, 1987, NEW ENGL J MED, V317, P1055, DOI 10.1056/NEJM198710223171704; HOCHMAN JS, 1987, CIRCULATION, V75, P299, DOI 10.1161/01.CIR.75.1.299; HONAN MB, 1990, J AM COLL CARDIOL, V16, P359, DOI 10.1016/0735-1097(90)90586-E; JEREMY RW, 1987, J AM COLL CARDIOL, V9, P989, DOI 10.1016/S0735-1097(87)80298-X; REIMER KA, 1977, CIRCULATION, V56, P786, DOI 10.1161/01.CIR.56.5.786; RENTROP KP, 1989, J AM COLL CARDIOL, V14, P58, DOI 10.1016/0735-1097(89)90054-5; SAGER PT, 1988, J AM COLL CARDIOL, V12, P19, DOI 10.1016/0735-1097(88)90350-6; WHITE H, 1988, LANCET, V2, P914; WHITE HD, 1987, CIRCULATION, V76, P44, DOI 10.1161/01.CIR.76.1.44; WILCOX RG, 1988, LANCET, V2, P525; YUSUF S, 1985, EUR HEART J, V6, P556, DOI 10.1093/oxfordjournals.eurheartj.a061905; 1991, 40TH AM COLL CARD AN	20	21	22	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 25	1992	340	8813					221	222		10.1016/0140-6736(92)90478-L	http://dx.doi.org/10.1016/0140-6736(92)90478-L			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JE758	1353145				2022-12-01	WOS:A1992JE75800013
J	BARRALNETTO, M; BARRAL, A; BROWNELL, CE; SKEIKY, YAW; ELLINGSWORTH, LR; TWARDZIK, DR; REED, SG				BARRALNETTO, M; BARRAL, A; BROWNELL, CE; SKEIKY, YAW; ELLINGSWORTH, LR; TWARDZIK, DR; REED, SG			TRANSFORMING GROWTH-FACTOR-BETA IN LEISHMANIAL INFECTION - A PARASITE ESCAPE MECHANISM	SCIENCE			English	Article							INTERFERON-GAMMA; CUTANEOUS LEISHMANIASIS; IFN-GAMMA; EXPRESSION; FACTOR-BETA-1; MACROPHAGES; LYMPHOKINE; ANTIGENS; SUBSETS; CELLS	The course of infection with the protozoan parasite Leishmania is determined in part by their early replication in macrophages, the exclusive host cells for these organisms. Although factors contributing to the survival of Leishmania are not well understood, cytokines influence the course of infection. Transforming growth factor-beta (TGF-beta) is a multipotential cytokine with diverse effects on cells of the immune system, including down-regulation of certain macrophage functions. Leishmanial infection induced the production of active TGF-beta, both in vitro and in vivo. TGF-beta was important for determining in vivo susceptibility to experimental leishmanial infection.	SEATTLE BIOMED RES INST,SEATTLE,WA 98109; FED UNIV BAHIA,SCH MED,BR-40140 SALVADOR,BA,BRAZIL; CELTRIX LABS INC,PALO ALTO,CA 94303; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA 98121; CORNELL UNIV,MED CTR,COLL MED,NEW YORK,NY 10021	Center for Infectious Disease Research; Bristol-Myers Squibb; Cornell University			Barral-Netto, Manoel/B-3904-2009; Barral, Aldina/B-4191-2009	Barral-Netto, Manoel/0000-0002-5823-7903; Barral, Aldina/0000-0002-7177-464X	FIC NIH HHS [TW-00018] Funding Source: Medline; NIAID NIH HHS [AI-25038, AI-16282] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025038, P01AI016282] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASSOIAN RK, 1987, P NATL ACAD SCI USA, V84, P6020, DOI 10.1073/pnas.84.17.6020; BADARO R, 1990, NEW ENGL J MED, V322, P16, DOI 10.1056/NEJM199001043220104; BELOSEVIC M, 1989, J IMMUNOL, V143, P266; CZARNIECKI CW, 1988, J IMMUNOL, V140, P4217; DING A, 1990, J IMMUNOL, V145, P940; HARMS G, 1989, LANCET, V1, P1287; HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59; HEINZEL FP, 1991, P NATL ACAD SCI USA, V88, P7011, DOI 10.1073/pnas.88.16.7011; KEHRL JH, 1986, J EXP MED, V163, P1037, DOI 10.1084/jem.163.5.1037; KEHRL JH, 1986, J IMMUNOL, V137, P3855; MULE JJ, 1988, CANCER IMMUNOL IMMUN, V26, P95; NATHAN CF, 1983, J EXP MED, V158, P670, DOI 10.1084/jem.158.3.670; NELSON BJ, 1991, J IMMUNOL, V146, P1849; SADICK MD, 1991, INFECT IMMUN, V59, P4710, DOI 10.1128/IAI.59.12.4710-4714.1991; SAMUELSON J, 1991, J EXP MED, V173, P49, DOI 10.1084/jem.173.1.49; SCOTT P, 1988, J EXP MED, V168, P1675, DOI 10.1084/jem.168.5.1675; SILVA JS, 1991, J EXP MED, V174, P539, DOI 10.1084/jem.174.3.539; SILVA JS, 1992, J EXP MED, V175, P169, DOI 10.1084/jem.175.1.169; TITUS RG, 1988, SCIENCE, V239, P1306, DOI 10.1126/science.3344436; TSUNAWAKI S, 1988, NATURE, V334, P260, DOI 10.1038/334260a0; WAHL SM, 1988, J IMMUNOL, V140, P3026	21	395	406	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 24	1992	257	5069					545	548		10.1126/science.1636092	http://dx.doi.org/10.1126/science.1636092			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JE755	1636092				2022-12-01	WOS:A1992JE75500034
J	BERGER, SL; PINA, B; SILVERMAN, N; MARCUS, GA; AGAPITE, J; REGIER, JL; TRIEZENBERG, SJ; GUARENTE, L				BERGER, SL; PINA, B; SILVERMAN, N; MARCUS, GA; AGAPITE, J; REGIER, JL; TRIEZENBERG, SJ; GUARENTE, L			GENETIC ISOLATION OF ADA2 - A POTENTIAL TRANSCRIPTIONAL ADAPTER REQUIRED FOR FUNCTION OF CERTAIN ACIDIC ACTIVATION DOMAINS	CELL			English	Article							RNA POLYMERASE-II; TATA BINDING-PROTEIN; SACCHAROMYCES-CEREVISIAE; ACCURATE INITIATION; REGULATORY PROTEIN; S-CEREVISIAE; YEAST GENE; BOX FACTOR; CYC1 GENE; DNA	We have devised a genetic strategy to isolate the target of acidic activation domains of transcriptional activators based on toxicity in yeast cells of the chimeric activator, GAL4-VP16. Toxicity required the integrity of both the VP16 acidic activation domain and the GAL4 DNA-binding domain, suggesting that inhibition resulted from trapping of general transcription factors at genomic sites. Mutations that break the interaction between GAL4-VP16 and general factors would alleviate toxicity and identify transcriptional adaptors, if adaptors bridged the interaction between activators and general factors. We thus identified ADA1, ADA2, and ADA3. Mutations in ADA2 reduced the activity of GAL4-VP16 and GCN4 in vivo. ada2 mutant extracts exhibited normal basal transcription, but were defective in responding to GAL4-VP16, GCN4, or the dA:dT activator. Strikingly, the mutant extract responded like wild type to GAL4-HAP4. We conclude that ADA2 potentiates the activity of one class of acidic activation domain but not a second class.	MICHIGAN STATE UNIV, DEPT BIOCHEM, E LANSING, MI 48824 USA; MICHIGAN STATE UNIV, GENET PROGRAM, E LANSING, MI 48824 USA	Michigan State University; Michigan State University	BERGER, SL (corresponding author), MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA.		Piña, Benjamin/A-1671-2011	Piña, Benjamin/0000-0001-9216-2768; Triezenberg, Steven/0000-0003-4184-5221; Berger, Shelley/0000-0001-5398-4400; Silverman, Neal/0000-0002-4259-456X	NIAID NIH HHS [AI27323] Funding Source: Medline; NIGMS NIH HHS [GM 30454-10] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI027323, R01AI027323] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030454] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARNDT K, 1986, P NATL ACAD SCI USA, V83, P8516, DOI 10.1073/pnas.83.22.8516; ARNDT KT, 1987, SCIENCE, V237, P874, DOI 10.1126/science.3303332; ASO T, 1992, NATURE, V355, P461, DOI 10.1038/355461a0; BANERJI J, 1981, CELL, V27, P299, DOI 10.1016/0092-8674(81)90413-X; BECKER DM, 1991, P NATL ACAD SCI USA, V88, P1968, DOI 10.1073/pnas.88.5.1968; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CAVALLINI B, 1989, P NATL ACAD SCI USA, V86, P9803, DOI 10.1073/pnas.86.24.9803; CAVALLINI B, 1988, NATURE, V334, P77, DOI 10.1038/334077a0; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; CHEN W, 1987, CELL, V50, P1047, DOI 10.1016/0092-8674(87)90171-1; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DEZELEE S, 1989, EMBO J, V8, P3437, DOI 10.1002/j.1460-2075.1989.tb08508.x; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; EISENMANN DM, 1989, CELL, V58, P1183, DOI 10.1016/0092-8674(89)90516-3; FASSLER JS, 1988, GENETICS, V118, P203; FINKELSTEIN A, 1992, NATURE, V355, P464, DOI 10.1038/355464a0; FLANAGAN PM, 1991, NATURE, V350, P436, DOI 10.1038/350436a0; FORSBURG SL, 1989, ANNU REV CELL BIOL, V5, P153, DOI 10.1146/annurev.cb.05.110189.001101; FORSBURG SL, 1989, GENE DEV, V3, P1166, DOI 10.1101/gad.3.8.1166; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P7410, DOI 10.1073/pnas.79.23.7410; GUARENTE L, 1984, CELL, V36, P503, DOI 10.1016/0092-8674(84)90243-5; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; HIMMELFARB HJ, 1990, CELL, V63, P1299, DOI 10.1016/0092-8674(90)90425-E; HINNEBUSCH AG, 1985, P NATL ACAD SCI USA, V82, P498, DOI 10.1073/pnas.82.2.498; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; JOHNSTON M, 1987, P NATL ACAD SCI USA, V84, P2401, DOI 10.1073/pnas.84.8.2401; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; LAUGHON A, 1984, MOL CELL BIOL, V4, P260, DOI 10.1128/MCB.4.2.260; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LUE NF, 1989, P NATL ACAD SCI USA, V86, P486, DOI 10.1073/pnas.86.2.486; LUE NF, 1987, P NATL ACAD SCI USA, V84, P8839, DOI 10.1073/pnas.84.24.8839; MA J, 1987, CELL, V50, P137, DOI 10.1016/0092-8674(87)90670-2; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MATSUI T, 1980, J BIOL CHEM, V255, P1992; MCCRACKEN S, 1991, SCIENCE, V253, P900, DOI 10.1126/science.1652156; MOREAU P, 1981, NUCLEIC ACIDS RES, V9, P6047, DOI 10.1093/nar/9.22.6047; NG R, 1980, P NATL ACAD SCI-BIOL, V77, P3912, DOI 10.1073/pnas.77.7.3912; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; OHARE P, 1988, EMBO J, V7, P4231, DOI 10.1002/j.1460-2075.1988.tb03320.x; OHKUMA Y, 1991, NATURE, V354, P398, DOI 10.1038/354398a0; OLESEN J, 1987, CELL, V51, P953, DOI 10.1016/0092-8674(87)90582-4; OLESEN JT, 1990, GENE DEV, V4, P1714, DOI 10.1101/gad.4.10.1714; OSBORNE BI, 1988, GENE DEV, V2, P766, DOI 10.1101/gad.2.6.766; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PETERSON CL, 1991, CELL, V64, P1135, DOI 10.1016/0092-8674(91)90268-4; PETERSON MG, 1991, NATURE, V354, P369; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PINTO I, 1992, CELL, V68, P977, DOI 10.1016/0092-8674(92)90040-J; PRESTON CM, 1988, CELL, V52, P425, DOI 10.1016/S0092-8674(88)80035-7; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RANISH JA, 1992, SCIENCE, V255, P1127, DOI 10.1126/science.1546313; ROSE M, 1983, J MOL BIOL, V170, P883, DOI 10.1016/S0022-2836(83)80193-4; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; Sambrook J., 1989, MOL CLONING LAB MANU; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; STERN M, 1984, J MOL BIOL, V178, P853, DOI 10.1016/0022-2836(84)90315-2; STOFFERS DA, 1989, P NATL ACAD SCI USA, V86, P735, DOI 10.1073/pnas.86.2.735; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; SUMIMOTO H, 1991, NATURE, V354, P401, DOI 10.1038/354401a0; TRIEZENBERG SJ, 1988, GENE DEV, V2, P730, DOI 10.1101/gad.2.6.730; WINSTON F, 1984, GENETICS, V107, P179; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.bi.60.070191.003353	83	389	409	0	6	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 24	1992	70	2					251	265		10.1016/0092-8674(92)90100-Q	http://dx.doi.org/10.1016/0092-8674(92)90100-Q			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JE757	1638630				2022-12-01	WOS:A1992JE75700009
J	DONIACH, T; PHILLIPS, CR; GERHART, JC				DONIACH, T; PHILLIPS, CR; GERHART, JC			PLANAR INDUCTION OF ANTEROPOSTERIOR PATTERN IN THE DEVELOPING CENTRAL-NERVOUS-SYSTEM OF XENOPUS-LAEVIS	SCIENCE			English	Article							NEURAL INDUCTION; POSITIONAL INFORMATION; PROSPECTIVE AREAS; HOMEOBOX GENE; EXPRESSION; EMBRYOS; ANTERIOR; ECTODERM; MARKER; MOUSE	It has long been thought that anteroposterior (A-P) pattern in the vertebrate central nervous system is induced in the embryo's dorsal ectoderm exclusively by signals passing vertically from underlying, patterned dorsal mesoderm. Explants from early gastrulae of the frog Xenopus laevis were prepared in which vertical contact between dorsal ectoderm and mesoderm was prevented but planar contact was maintained. In these, four position-specific neural markers (engrailed-2, Krox-20, XIHbox 1, and XIHbox 6) were expressed in the ectoderm in the same A-P order as in the embryo. Thus, planar signals alone, following a path available in the normal embryo, can induce A-P neural pattern.	BOWDOIN COLL,DEPT BIOL,BRUNSWICK,ME 04011	Bowdoin College	DONIACH, T (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,301 LSA,BERKELEY,CA 94720, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019363, R37GM019363] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM19363] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTABA ARI, 1990, DEVELOPMENT, V108, P595; BALAK K, 1987, DEV BIOL, V119, P540, DOI 10.1016/0012-1606(87)90057-1; BOLCE ME, IN PRESS DEVELOPMENT; DEROBERTIS EM, 1989, CELL, V57, P189, DOI 10.1016/0092-8674(89)90954-9; DIXON JE, 1989, DEVELOPMENT, V106, P749; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; GIMLICH RL, 1985, DEV BIOL, V109, P509, DOI 10.1016/0012-1606(85)90476-2; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HATTA K, 1990, SCIENCE, V250, P802, DOI 10.1126/science.1978412; HEMMATIBRIVANLO.A, 1989, DEVELOPMENT, V106, P611; HEMMATIBRIVANLOU A, 1990, SCIENCE, V250, P800, DOI 10.1126/science.1978411; HEMMATIBRIVANLOU A, 1991, DEVELOPMENT, V111, P715; Holtfreter J., 1955, ANAL DEV, P230; HOLTFRETER J, 1933, ARCH ENTWICKLUNGSMEC, V129, P669; JACOBSON M, 1986, DEV BIOL, V116, P524, DOI 10.1016/0012-1606(86)90153-3; KELLER R, 1992, DEV DYNAM, V193, P218, DOI 10.1002/aja.1001930303; KELLER R, 1992, DEV DYNAM, V193, P199, DOI 10.1002/aja.1001930302; KELLER R, 1988, DEVELOPMENT, V103, P193; KELLER RE, 1976, DEV BIOL, V51, P118, DOI 10.1016/0012-1606(76)90127-5; KELLER RE, 1975, DEV BIOL, V42, P222, DOI 10.1016/0012-1606(75)90331-0; KINTNER CR, 1984, NATURE, V308, P67, DOI 10.1038/308067a0; KINTNER CR, 1987, DEVELOPMENT, V99, P311; LONDON C, 1988, DEV BIOL, V129, P380, DOI 10.1016/0012-1606(88)90385-5; Mangold O, 1933, NATURWISSENSCHAFTEN, V21, P761, DOI 10.1007/BF01503740; Nieuwkoop P.D., 1994, NORMAL TABLES XENOPU; NIEUWKOOP PD, 1952, J EXP ZOOL, V120, P1, DOI 10.1002/jez.1401200102; OLIVER G, 1988, EMBO J, V7, P3199, DOI 10.1002/j.1460-2075.1988.tb03187.x; PAPALOPULU N, 1991, DEVELOPMENT, V113, P1145; ROBERTS SA, UNPUB; SATER AK, UNPUB; SAVAGE R, 1989, DEV BIOL, V133, P157, DOI 10.1016/0012-1606(89)90307-2; SERVETNICK M, 1991, DEV BIOL, V147, P73, DOI 10.1016/S0012-1606(05)80008-9; SHARPE CR, 1987, CELL, V50, P749, DOI 10.1016/0092-8674(87)90333-3; SHARPE CR, 1990, DEVELOPMENT, V109, P765; SOKOL S, 1991, NATURE, V351, P409, DOI 10.1038/351409a0; Spemann H, 1988, EMBRYONIC DEV INDUCT; VINCENT JP, 1986, DEV BIOL, V113, P484, DOI 10.1016/0012-1606(86)90184-3; WILKINSON DG, 1989, NATURE, V337, P461, DOI 10.1038/337461a0; WILSON P, 1991, DEVELOPMENT, V112, P289; WOLPERT L, 1989, DEVELOPMENT, V107, P3; WRIGHT CVE, 1990, DEVELOPMENT, V109, P225	41	155	158	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 24	1992	257	5069					542	545		10.1126/science.1636091	http://dx.doi.org/10.1126/science.1636091			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JE755	1636091				2022-12-01	WOS:A1992JE75500033
J	FLORIG, HK				FLORIG, HK			CONTAINING THE COSTS OF THE EMF PROBLEM	SCIENCE			English	Article							ELECTRICAL WIRING CONFIGURATIONS; BRAIN-TISSUE INVITRO; ELF 1-120 HZ; ELECTROMAGNETIC-FIELDS; CHILDHOOD-CANCER; MAGNETIC-FIELDS; CALCIUM-IONS; RF FIELDS; EXPOSURE; CELLS				FLORIG, HK (corresponding author), RESOURCES FUTURE INC,1616 P ST NW,WASHINGTON,DC 20036, USA.							ADAIR RK, 1991, PHYS REV A, V43, P1039, DOI 10.1103/PhysRevA.43.1039; ADEY WR, 1981, PHYSIOL REV, V61, P435, DOI 10.1152/physrev.1981.61.2.435; [Anonymous], 1990, HLTH EFFECTS EXPOSUR; BALCERKUBICZEK EK, 1991, RADIAT RES, V126, P65, DOI 10.2307/3578172; BARRY RE, 1991, SEP COMP C ROCK MOUN; BERNHARDT J, 1979, RADIAT ENVIRON BIOPH, V16, P309, DOI 10.1007/BF01340569; BLACKMAN CF, 1985, BIOELECTROMAGNETICS, V6, P1, DOI 10.1002/bem.2250060102; BLANK M, 1988, BIOELECTROCH BIOENER, V19, P569, DOI 10.1016/0302-4598(88)80035-7; BOSTROM A, 1991, 13TH ANN M BIOEL SOC; COLE P, 1991, COMMUNICATION   0114; COOPER MS, 1984, J THEOR BIOL, V111, P123, DOI 10.1016/S0022-5193(84)80200-3; DAVIS MK, 1988, LANCET, V2, P365; FISHER A, 1989, J POLICY ANAL MANAG, V8, P88, DOI 10.2307/3324426; FITZSIMMONS R, 1991, 13TH ANN M BIOEL SOC; FLORIG HK, 1991, DEC ANN M SOC RISK A; FRANCESCHI C, 1991, 1991 ANN REV RES BIO; FULTON JP, 1980, AM J EPIDEMIOL, V111, P292, DOI 10.1093/oxfordjournals.aje.a112899; FURBY L, 1988, J ENVIRON MANAGE, V27, P69; FURBY L, 1988, J ENVIRON PSYCHOL, V8, P19, DOI 10.1016/S0272-4944(88)80021-5; GIBNEY KB, 1991, JUN RIGHT WAY ASS C; GOODMAN R, 1988, P NATL ACAD SCI USA, V85, P3928, DOI 10.1073/pnas.85.11.3928; GOODMAN R, 1989, BIOCHIM BIOPHYS ACTA, V1009, P216, DOI 10.1016/0167-4781(89)90105-X; GORDON I, 1990, 242 U MELB STAT CONS; GRAHAM C, 1990, DE90006671 NAT TECHN; GROTA LJ, 1991, 13TH ANN M BIOEL SOC; JOHN EM, 1991, AM J EPIDEMIOL, V133, P123, DOI 10.1093/oxfordjournals.aje.a115851; KUNREUTHER H, 1987, J ENVIRON ECON MANAG, V14, P371, DOI 10.1016/0095-0696(87)90027-1; LEDNEV VV, 1991, BIOELECTROMAGNETICS, V12, P71, DOI 10.1002/bem.2250120202; LIBOFF AR, 1984, SCIENCE, V223, P818, DOI 10.1126/science.6695183; LONDON SJ, 1991, AM J EPIDEMIOL, V134, P923, DOI 10.1093/oxfordjournals.aje.a116176; LOVELY RH, 1988, ELECTROMAGNETIC FIEL, P327; LUBEN RA, 1982, P NATL ACAD SCI-BIOL, V79, P4180, DOI 10.1073/pnas.79.13.4180; LYLE DB, 1991, BIOELECTROMAGNETICS, V12, P145, DOI 10.1002/bem.2250120303; MALTIN L, COMMUNICATION; MATANOSKI G, 1991, 13TH ANN M BIOEL SOC; MCLEAN JRN, 1991, BIOELECTROMAGNETICS, V12, P273, DOI 10.1002/bem.2250120503; MIZUSHIMA Y, 1975, EXPERIENTIA, V21, P1411; MORGAN MG, 1985, RISK ANAL, V5, P139, DOI 10.1111/j.1539-6924.1985.tb00161.x; MORGAN MG, 1986, SCIENCE, V232, P917, DOI 10.1126/science.3704631; MORGAN MG, 1988, PUBLIC UTILITIES FOR, V121, P49; MURTHY KK, 1991, 1991 ANN REV RES BIO; PILLA AA, 1992, CHARGE FIELD EFFECTS, V3, P231; POOL R, 1990, SCIENCE, V249, P1096, DOI 10.1126/science.2204111; POOLE C, 1991, CANCER CAUSES CONTRO, V2; Portney KE, 1991, HAZARDOUS WASTE TREA; RAYNER S, 1988, NONIONIZING RAD, P39; REESE JA, 1988, BIOELECTROMAGNETICS, V9, P237, DOI 10.1002/bem.2250090305; SANGHVI AP, 1990, EL6791 EL POW RES I; SAVITZ DA, 1987, J OCCUP ENVIRON MED, V29, P47; SAVITZ DA, 1988, AM J EPIDEMIOL, V128, P21, DOI 10.1093/oxfordjournals.aje.a114943; SAVITZ DA, 1989, EPIDEMIOL REV, V11, P59, DOI 10.1093/oxfordjournals.epirev.a036045; SMITH SD, 1987, BIOELECTROMAGNETICS, V8, P215, DOI 10.1002/bem.2250080302; SULZMAN FM, 1987, EFFECTS ELECTROMAGNE; Susskind L., 1987, BREAKING IMPASSE; TENFORDE TS, 1991, BIOELECTROCH BIOENER, V25, P1, DOI 10.1016/0302-4598(91)87015-9; THERIAULT GP, 1991, NIOSH91111 PUBL, P91; TOMENIUS L, 1986, BIOELECTROMAGNETICS, V7, P191, DOI 10.1002/bem.2250070209; TRAVIS CC, 1987, ENVIRON SCI TECHNOL, V21, P415, DOI 10.1021/es00159a001; TSONG TY, 1988, ANNU REV PHYSIOL, V50, P273; WALBORG EF, 1991, EXTREMELY LOW FREQUE; WALLECZEK J, 1990, FEBS LETT, V271, P157, DOI 10.1016/0014-5793(90)80396-Z; WEAVER JC, 1990, SCIENCE, V247, P459, DOI 10.1126/science.2300806; WERTHEIMER N, 1979, AM J EPIDEMIOL, V109, P273, DOI 10.1093/oxfordjournals.aje.a112681; WERTHEIMER N, 1980, AM J EPIDEMIOL, V111, P461, DOI 10.1093/oxfordjournals.aje.a112924; WILSON BW, 1981, BIOELECTROMAGNETICS, V2, P371, DOI 10.1002/bem.2250020408; Wilson R., 1982, RISK BENEFIT ANAL; ZAFFANELLA LE, 1985, ENV HLTH PERSPECT, V62, P297; 1991, 1991 P AM LAW FILM A; 1990, MICROW NEWS, V10, P5; 1991, MICROW NEWS, V11, P6; 1987, MAGNETIC FIELDS; 1987, MICROW NEWS, V7, P1; 1991, STATISTICAL YB ELECT; 1991, MICROW NEWS, V11, P7; 1987, BIOL EFFECTS POWERLI; 1991, ELECTRIC SUPPLY DEMA; 1991, NIOSH91111 NAT I OCC; 1989, OTABPE53 US C OFF TE	78	30	30	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 24	1992	257	5069					468	&		10.1126/science.1636078	http://dx.doi.org/10.1126/science.1636078			0	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JE755	1636078				2022-12-01	WOS:A1992JE75500005
J	FU, XY				FU, XY			A TRANSCRIPTION FACTOR WITH SH2 AND SH3 DOMAINS IS DIRECTLY ACTIVATED BY AN INTERFERON-ALPHA-INDUCED CYTOPLASMIC PROTEIN TYROSINE KINASE(S)	CELL			English	Article							GENE REGULATORY ELEMENTS; INDUCED NUCLEAR FACTORS; PHOSPHOLIPASE-C-GAMMA; CLASS-I GENES; SIGNAL TRANSDUCTION; STIMULATED TRANSCRIPTION; BINDING PROTEIN; PDGF RECEPTOR; CONSENSUS SEQUENCE; ENHANCER ELEMENT	Interferon-stimulated gene factor 3 (ISGF3), the primary transcription factor induced by interferon-alpha, is a complex of four (113, 91, 84, and 48 kd) proteins. This paper reports that the 113, 91, and 84 kd (ISGF3-alpha) proteins of ISGF3 contain conserved SH2 and SH3 domains. A specific interferon alpha-induced cytoplasmic protein tyrosine kinase(s) can form a transient complex with ISGF3-alpha proteins. These ISGF3-alpha proteins can be immunoprecipitated by anti-phosphotyrosine antibodies only after interferon-alpha treatment. Phosphoamino acid analyses of P-32-labeled ISGF3-alpha proteins confirm that ISGF3-alpha proteins are directly tyrosine phosphorylated both in vitro and in vivo in response to interferon-alpha, and this tyrosine phosphorylation can be inhibited by staurosporine and genistein. Phosphatase treatment of these ISGF3-alpha proteins results in inhibition of ISGF3 complex formation in vitro. These observations indicate that interferon alpha-induced direct tyrosine phosphorylation of ISGF3-alpha proteins is necessary for activation of the transcription factor ISGF3.			FU, XY (corresponding author), CUNY MT SINAI SCH MED, DEPT BIOCHEM, NEW YORK, NY 10029 USA.							AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BAGCHI S, 1989, P NATL ACAD SCI USA, V86, P4352, DOI 10.1073/pnas.86.12.4352; BANDYOPADHYAY SK, 1990, MOL CELL BIOL, V10, P5055, DOI 10.1128/MCB.10.10.5055; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COHEN B, 1988, EMBO J, V7, P1411, DOI 10.1002/j.1460-2075.1988.tb02958.x; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DALE TC, 1989, P NATL ACAD SCI USA, V86, P1203, DOI 10.1073/pnas.86.4.1203; DALE TC, 1989, EMBO J, V8, P831, DOI 10.1002/j.1460-2075.1989.tb03444.x; DECKER T, 1989, EMBO J, V8, P2009, DOI 10.1002/j.1460-2075.1989.tb03608.x; DEMAEYER E, 1989, INTERFERONS OTHER RE; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRIGGERS PH, 1990, P NATL ACAD SCI USA, V87, P3743, DOI 10.1073/pnas.87.10.3743; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; EISEMAN E, 1992, NATURE, V355, P78; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FRACKELTON AR, 1991, METHOD ENZYMOL, V201, P79; FRIEDMAN RL, 1985, NATURE, V314, P637, DOI 10.1038/314637a0; FRIEDMAN RL, 1984, CELL, V38, P745, DOI 10.1016/0092-8674(84)90270-8; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; FU XY, 1992, IN PRESS P NATL ACAD; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GLENNEY JR, 1991, METHOD ENZYMOL, V201, P92; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENBERG ME, 1986, SCIENCE, V234, P80, DOI 10.1126/science.3749894; GRIBAUDO G, 1987, J BIOL CHEM, V262, P11878; HANNIGAN GE, 1991, J BIOL CHEM, V266, P8765; HARLOW E, 1988, ANTIBODIES LABORATOR; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; Hunter T, 1989, CURR OPIN CELL BIOL, V1, P1168, DOI 10.1016/S0955-0674(89)80068-7; IMAM AMA, 1990, NUCLEIC ACIDS RES, V18, P6573, DOI 10.1093/nar/18.22.6573; ISRAEL A, 1986, NATURE, V322, P743, DOI 10.1038/322743a0; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; Karin M, 1991, CURR OPIN CELL BIOL, V3, P467, DOI 10.1016/0955-0674(91)90075-A; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KESSLER DS, 1991, J BIOL CHEM, V266, P23471; KESSLER DS, 1988, EMBO J, V7, P3779, DOI 10.1002/j.1460-2075.1988.tb03262.x; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LARNER AC, 1984, P NATL ACAD SCI-BIOL, V81, P6733, DOI 10.1073/pnas.81.21.6733; LEE TH, 1990, MOL CELL BIOL, V10, P1982, DOI 10.1128/MCB.10.5.1982; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LEVY D, 1990, New Biologist, V2, P923; LEVY D, 1986, P NATL ACAD SCI USA, V83, P8929, DOI 10.1073/pnas.83.23.8929; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LEW DJ, 1989, MOL CELL BIOL, V9, P5404, DOI 10.1128/MCB.9.12.5404; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MILLS GB, 1990, J BIOL CHEM, V265, P3561; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; NICOLA NA, 1989, ANNU REV BIOCHEM, V58, P45; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; Panayotou G, 1989, CURR OPIN CELL BIOL, V1, P167, DOI 10.1016/0955-0674(89)90082-3; PAWSON T, 1988, ONCOGENE, V3, P491; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PFEFFER LM, 1991, P NATL ACAD SCI USA, V88, P7988, DOI 10.1073/pnas.88.18.7988; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; PORTER ACG, 1988, EMBO J, V7, P85, DOI 10.1002/j.1460-2075.1988.tb02786.x; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; REICH N, 1987, P NATL ACAD SCI USA, V84, P6394, DOI 10.1073/pnas.84.18.6394; REICH NC, 1990, P NATL ACAD SCI USA, V87, P8761, DOI 10.1073/pnas.87.22.8761; REID LE, 1989, P NATL ACAD SCI USA, V86, P840, DOI 10.1073/pnas.86.3.840; RODAWAY ARF, 1990, MOL CELL BIOL, V10, P5388, DOI 10.1128/MCB.10.10.5388; RODAWAY ARF, 1989, NATURE, V342, P624, DOI 10.1038/342624a0; RUTHERFORD MN, 1988, EMBO J, V7, P751, DOI 10.1002/j.1460-2075.1988.tb02872.x; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SALTZMAN EM, 1989, J BIOL CHEM, V264, P19979; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SCHINDLER C, 1992, IN PRESS SCIENCE; SCHINDLER C, 1992, IN PRESS P NATL ACAD; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SHIRAYOSHI Y, 1988, P NATL ACAD SCI USA, V85, P5884, DOI 10.1073/pnas.85.16.5884; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; SUGITA K, 1987, MOL CELL BIOL, V7, P2625, DOI 10.1128/MCB.7.7.2625; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; TIWARI RK, 1987, EMBO J, V6, P3373, DOI 10.1002/j.1460-2075.1987.tb02659.x; TONKS NK, 1991, METHOD ENZYMOL, V201, P427; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; UCKUN FM, 1991, P NATL ACAD SCI USA, V88, P3589, DOI 10.1073/pnas.88.9.3589; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VEALS SA, 1992, IN PRESS MOL CELL BI; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VOGEL J, 1986, MOL CELL BIOL, V6, P3550, DOI 10.1128/MCB.6.10.3550; WATERFIELD MD, 1991, METHOD ENZYMOL, V200, P627; WATHELET MG, 1987, EUR J BIOCHEM, V169, P313, DOI 10.1111/j.1432-1033.1987.tb13614.x; WILLIAMS BRG, 1991, EUR J BIOCHEM, V200, P1, DOI 10.1111/j.1432-1033.1991.tb21041.x; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; [No title captured]; [No title captured]	125	379	400	2	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 24	1992	70	2					323	335		10.1016/0092-8674(92)90106-M	http://dx.doi.org/10.1016/0092-8674(92)90106-M			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JE757	1638633				2022-12-01	WOS:A1992JE75700015
J	GARCIA, KC; RONCO, PM; VERROUST, PJ; BRUNGER, AT; AMZEL, LM				GARCIA, KC; RONCO, PM; VERROUST, PJ; BRUNGER, AT; AMZEL, LM			3-DIMENSIONAL STRUCTURE OF AN ANGIOTENSIN-II FAB COMPLEX AT 3 ANGSTROM - HORMONE RECOGNITION BY AN ANTIIDIOTYPIC ANTIBODY	SCIENCE			English	Article							MONOCLONAL-ANTIBODIES; INTERNAL IMAGE; NETWORK; PEPTIDE	The elucidation of bioactive conformations of small peptide hormones remains an elusive goal to structural chemists because of the inherent flexibility of these molecules. Angiotensin II (AII), the major effector of the renin-angiotensin system, is an octapeptide hormone for which no clear structural models exist. Peptide hormones such as AII share the property that they bind to their receptors with high affinities, in spite of the fact that they must overcome an extremely large conformational entropy barrier to bind in one conformation. A "surrogate system" that consists of a high-affinity monoclonal antibody (MAb) and AII has been used to study a bound conformation of AII. The crystallographic structure of the complex reveals a structure of AII that is compatible with predicted bioactive conformations of AII derived from structure-activity studies and theoretical calculations. In the complex, the deeply bound hormone is folded into a compact structure in which two turns bring the amino and carboxyl termini close together. The antibody of this complex (MAb 131) has the unusual property that it was not generated against AII, but rather against an anti-idiotypic antibody reactive with a MAb to AII, which renders this antibody an anti-anti-idiotypic antibody. The high affinity for AII of the original MAb to AII was passed on to MAb 131 through a structural determinant on the anti-idiotypic antibody. Strikingly, the conformation of AII in this complex is highly similar to complementarity determining region loops of antibodies, possibly indicating that a true molecular mimic of bound AII was present on the anti-idiotypic antibody against which MAb 131 was elicited.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOPHYS & BIOPHYS CHEM,BALTIMORE,MD 21205; HOP TENON,INSERM,U64,F-75790 PARIS 20,FRANCE; YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06511; YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06511	Johns Hopkins University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Howard Hughes Medical Institute; Yale University; Yale University			Ronco, Pierre/AAC-8390-2022	Brunger, Axel/0000-0001-5121-2036; Amzel, L. Mario/0000-0002-0129-9572	NIGMS NIH HHS [GM44692] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044692] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUMELAS A, 1985, P NATL ACAD SCI USA, V82, P1881, DOI 10.1073/pnas.82.7.1881; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRUNGER AT, 1990, XPLOR MANUAL VERSION; BUDISAVLJEVIC M, 1990, J IMMUNOL, V145, P1440; BUDISAVLJEVIC M, 1988, J IMMUNOL, V140, P3059; CARSON MJ, COMMUNICATION; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; CORVOL P, 1989, CLIN EXP HYPERTENS A, V11, P463; COURAUD PO, 1986, J IMMUNOL, V136, P3365; COURAUD PO, 1987, J IMMUNOL, V138, P1164; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.biochem.59.1.439; EPP D, 1979, EUR J BIOCHEM, V45, P513; FESIK SW, 1991, BIOCHEMISTRY-US, V30, P6574, DOI 10.1021/bi00240a030; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; GARCIA KC, 1992, SCIENCE, V257, P528, DOI 10.1126/science.1636087; GARCIA KC, 1989, J BIOL CHEM, V264, P20463; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; JERNE NK, 1974, ANN INST PASTEUR IMM, VC125, P373; JORGENSEN WL, 1991, SCIENCE, V254, P954, DOI 10.1126/science.1719636; LARAGAH JH, 1973, HDB PHYSL, V8, P831; LENKINSKI RE, 1981, J INORG BIOCHEM, V15, P95, DOI 10.1016/S0162-0134(00)80295-0; LENKINSKI RE, 1985, PEPTIDES ANAL SYNTHE, V7, P301; LUZATTI V, 1952, ACTA CRYSTALLOGR, V5, P802; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MARSHALL GR, 1974, RECENT ADV RENAL PHY, P215; MIAN IS, 1991, J MOL BIOL, V217, P133, DOI 10.1016/0022-2836(91)90617-F; MICHNICK SW, 1991, SCIENCE, V252, P836, DOI 10.1126/science.1709301; MOORE JM, 1991, NATURE, V351, P248, DOI 10.1038/351248a0; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; NISONOFF A, 1981, CLIN IMMUNOL IMMUNOP, V21, P397, DOI 10.1016/0090-1229(81)90228-2; PHILLIPS MI, 1978, NEUROENDOCRINOLOGY, V25, P354, DOI 10.1159/000122756; REICHMAN L, 1988, NATURE, V332, P327; RINI JM, 1992, SCIENCE, V255, P959, DOI 10.1126/science.1546293; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; SHERIFF S, 1987, P NATL ACAD SCI USA, V84, P8075, DOI 10.1073/pnas.84.22.8075; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; VALLOTTON MB, 1974, HDB EXPT PHARM, V37, P185; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; WEBER C, 1991, BIOCHEMISTRY-US, V30, P6563, DOI 10.1021/bi00240a029; WEINSTOCK J, 1991, J MED CHEM, V34, P1514, DOI 10.1021/jm00108a043; Woody RW, 1985, PEPTIDES ANAL SYNTHE, P15; WUTHRICH K, 1991, SCIENCE, V254, P953, DOI 10.1126/science.1948082	42	168	173	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 24	1992	257	5069					502	507		10.1126/science.1636085	http://dx.doi.org/10.1126/science.1636085			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JE755	1636085				2022-12-01	WOS:A1992JE75500019
J	GARCIA, KC; DESIDERIO, SV; RONCO, PM; VERROUST, PJ; AMZEL, LM				GARCIA, KC; DESIDERIO, SV; RONCO, PM; VERROUST, PJ; AMZEL, LM			RECOGNITION OF ANGIOTENSIN-II - ANTIBODIES AT DIFFERENT LEVELS OF AN IDIOTYPIC NETWORK ARE SUPERIMPOSABLE	SCIENCE			English	Article							HEAVY-CHAIN GENES; 3-DIMENSIONAL STRUCTURE; MONOCLONAL-ANTIBODIES; REGION GENE; DIVERSITY; COMPLEX; ANTIGEN; IDENTIFICATION; GENERATION; EXPRESSION	Genetic and sequence information are reported for an angiotensin II-reactive antibody (Ab1, MAb 110) and an anti-anti-idiotypic antibody (Ab3, MAb 131) that have identical antigen binding properties and that are related by an anti-idiotypic antibody (Ab2-beta) that satisfies accepted biochemical criteria for an internal image-bearing antibody. The sequences of the variable regions of the Ab3 and of the Abl are nearly identical, even though the Ab1 is an antibody to a peptide and the Ab3 is an antibody to a globular protein. Significantly, amino acid residues that make critical contacts with antigen in the crystal structure of the Ab3-antigen complex are highly conserved in Ab1, suggesting that the epitopes of the Ab2-beta recognized by the Ab3 do indeed resemble the bound structure of the antigen.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOPHYS & BIOPHYS CHEM,BALTIMORE,MD 21205; HOP TENON,INSERM,U64,F-75790 PARIS 20,FRANCE; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205	Johns Hopkins University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University			Ronco, Pierre/AAC-8390-2022	Amzel, L. Mario/0000-0002-0129-9572	PHS HHS [6M 44692] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BENTLEY GA, 1990, NATURE, V348, P254, DOI 10.1038/348254a0; BUDISAVLJEVIC M, 1988, J IMMUNOL, V140, P3059; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; CLAFLIN JL, 1987, J IMMUNOL, V138, P3060; CLARKE SH, 1990, J IMMUNOL, V144, P2795; COSENZA H, 1976, EUR J IMMUNOL, V6, P114, DOI 10.1002/eji.1830060208; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.biochem.59.1.439; DESIDERIO SV, 1984, NATURE, V311, P752, DOI 10.1038/311752a0; GARCIA KC, 1989, J BIOL CHEM, V264, P20463; GARCIA KC, 1992, SCIENCE, V257, P502, DOI 10.1126/science.1636085; GARCIA KC, UNPUB; GOUGH NM, 1981, P NATL ACAD SCI-BIOL, V78, P509, DOI 10.1073/pnas.78.1.509; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; JEMMERSON R, 1986, SCIENCE, V232, P1001, DOI 10.1126/science.2422757; JEMMERSON R, 1987, P NATL ACAD SCI USA, V84, P9180, DOI 10.1073/pnas.84.24.9180; JERNE NK, 1974, ANN INST PASTEUR IMM, VC125, P373; Kabat E. A., 1987, SEQUENCES PROTEINS I, DOI 10.1016/0003-2697(84)90805-4; KOFLER R, 1988, J IMMUNOL, V140, P4031; KUROSAWA Y, 1981, NATURE, V290, P565, DOI 10.1038/290565a0; MARGET M, 1988, GENE, V74, P335, DOI 10.1016/0378-1119(88)90167-9; MARION TN, 1990, J IMMUNOL, V145, P2322; MAX EE, 1979, P NATL ACAD SCI USA, V76, P3450, DOI 10.1073/pnas.76.7.3450; MIAN IS, 1991, J MOL BIOL, V217, P133, DOI 10.1016/0022-2836(91)90617-F; MITCHELL T J, 1990, Peptide Research, V3, P277; NISONOFF A, 1981, CLIN IMMUNOL IMMUNOP, V21, P397, DOI 10.1016/0090-1229(81)90228-2; ORLANDI R, 1989, P NATL ACAD SCI USA, V86, P3833, DOI 10.1073/pnas.86.10.3833; PICARD C, 1986, IMMUNOLOGY, V57, P19; PONTILLON F, 1988, J IMMUNOL, V140, P3052; SAKANO H, 1981, NATURE, V290, P562, DOI 10.1038/290562a0; SAKANO H, 1979, NATURE, V280, P603; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0	36	47	48	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 24	1992	257	5069					528	531		10.1126/science.1636087	http://dx.doi.org/10.1126/science.1636087			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JE755	1636087				2022-12-01	WOS:A1992JE75500028
J	GRAF, T; MCNAGNY, K; BRADY, G; FRAMPTON, J				GRAF, T; MCNAGNY, K; BRADY, G; FRAMPTON, J			CHICKEN ERYTHROID-CELLS TRANSFORMED BY THE GAG-MYB-ETS-ENCODING E26 LEUKEMIA-VIRUS ARE MULTIPOTENT	CELL			English	Article							MYELOMONOCYTIC GROWTH-FACTOR; HEMATOPOIETIC STEM-CELLS; MYELOID CELLS; PHILADELPHIA-CHROMOSOME; MONOCLONAL-ANTIBODY; AUTOCRINE GROWTH; VULVAR INDUCTION; GENE-EXPRESSION; TARGET-CELLS; DIFFERENTIATION	The E26 avian leukemia virus encodes a transcriptional activator-type oncoprotein consisting of Gag, Myb, and Ets domains, and transforms early erythroid cells as well as myeloblasts. Surprisingly, we have found that "early erythroid" transformants obtained in culture are multipotent, since they can be induced to differentiate into myeloblasts and eosinophils after superinfection with retroviruses containing kinase-type or ras oncogenes. In addition, TPA is an efficient inducer that generates predominantly eosinophils at low concentrations and myeloblasts at high concentrations. The determination process involves the complete extinction of erythroid/thrombocytic markers and the subsequent activation of myelomonocytic/eosinophilic properties, including the acquisition of specific growth factor requirements. "Erythroleukemic" cells from virus-infected animals were likewise found to be multipotent, making this a unique system to study the genesis of stem cell leukemias and the molecular basis of lineage commitment during hematopoiesis.			GRAF, T (corresponding author), EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAMME,W-6900 HEIDELBERG,GERMANY.		Graf, Thomas/B-4252-2015; McNagny, Kelly/P-5239-2014	Graf, Thomas/0000-0003-2774-4117; McNagny, Kelly/0000-0003-4737-3499				ADKINS B, 1984, CELL, V39, P439, DOI 10.1016/0092-8674(84)90451-3; ANDERSSON LC, 1979, INT J CANCER, V23, P143, DOI 10.1002/ijc.2910230202; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BEUG H, 1981, VIROLOGY, V115, P295, DOI 10.1016/0042-6822(81)90112-4; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BEUG H, 1987, GENE DEV, V1, P277, DOI 10.1101/gad.1.3.277; BEUG H, 1982, EMBO J, V1, P1069, DOI 10.1002/j.1460-2075.1982.tb01298.x; BROWN G, 1986, LEUKEMIA, V1, P150; BRUNE K, 1973, J INFECT DIS, V127, P84, DOI 10.1093/infdis/127.1.84; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Dieterlen-Lievre F., 1988, P257; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; EWERT DL, 1984, J IMMUNOL, V132, P2524; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; GRAF T, 1988, LEUKEMIA, V2, P127; GRAF T, 1986, CELL, V45, P357, DOI 10.1016/0092-8674(86)90321-1; GREENBERG SM, 1988, BLOOD, V72, P1968; GREENBERGER JS, 1983, J NATL CANCER I, V70, P323; HOLMES KL, 1986, J EXP MED, V164, P443, DOI 10.1084/jem.164.2.443; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; KAHN P, 1986, CELL, V45, P349, DOI 10.1016/0092-8674(86)90320-X; KAPLOW LS, 1965, BLOOD-J HEMATOL, V26, P215, DOI 10.1182/blood.V26.2.215.215; KLINKEN SP, 1988, ONCOGENE RES, V3, P187; KLINKEN SP, 1991, CANCER CELL-MON REV, V3, P373; KNIGHT J, 1988, GENE DEV, V2, P247, DOI 10.1101/gad.2.2.247; KORNFELD S, 1983, EXP CELL RES, V143, P383, DOI 10.1016/0014-4827(83)90065-4; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LEUTZ A, 1989, EMBO J, V8, P175, DOI 10.1002/j.1460-2075.1989.tb03362.x; LEUTZ A, 1984, EMBO J, V3, P3191, DOI 10.1002/j.1460-2075.1984.tb02278.x; Lucas A.M., 1961, ATLAS AVIAN HEMATOLO; MANDI Y, 1987, IMMUNOBIOLOGY, V174, P292, DOI 10.1016/S0171-2985(87)80004-9; Maniatis T., 1982, MOL CLONING; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MCNAGNY K, 1992, IN PRESS LEUKEMIA; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; MOSCOVICI MG, 1983, VIROLOGY, V129, P65, DOI 10.1016/0042-6822(83)90396-3; NAVARRO S, 1991, EXP HEMATOL, V19, P11; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; OGAWA M, 1983, BLOOD, V61, P823; Orkin SH, 1990, CURR OPIN CELL BIOL, V2, P1003, DOI 10.1016/0955-0674(90)90149-9; ORKIN SH, 1975, P NATL ACAD SCI USA, V72, P98, DOI 10.1073/pnas.72.1.98; PAPAYANNOPOULOU T, 1988, BLOOD, V72, P1029; PAPAYANNOPOULOU T, 1983, BLOOD, V62, P832; PIERCE JH, 1989, BIOCHIM BIOPHYS ACTA, V989, P179, DOI 10.1016/0304-419X(89)90042-5; PLUMB M, 1989, NUCLEIC ACIDS RES, V17, P73, DOI 10.1093/nar/17.1.73; POOLE AR, 1977, LYSOSOMES LABORATORY; QUEVA C, 1992, DEVELOPMENT, V114, P125; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RAHMSDORF HJ, 1990, PHARMACOL THERAPEUT, V48, P157, DOI 10.1016/0163-7258(90)90079-H; RUSCETTI S, 1992, J VIROL, V66, P20, DOI 10.1128/JVI.66.1.20-26.1992; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SEIGNEURIN D, 1987, EXP HEMATOL, V15, P822; SOTIROV N, 1981, J NATL CANCER I, V66, P1143, DOI 10.1093/jnci/66.6.1143; SPANGRUDE GJ, 1991, BLOOD, V78, P1395; SPOONCER E, 1984, NATURE, V310, P228, DOI 10.1038/310228a0; TETTEROO PAT, 1984, LEUKEMIA RES, V8, P197, DOI 10.1016/0145-2126(84)90143-7; TILL JE, 1964, P NATL ACAD SCI USA, V51, P29, DOI 10.1073/pnas.51.1.29; YU G, 1989, J BIOL CHEM, V264, P10276	65	138	138	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 24	1992	70	2					201	213		10.1016/0092-8674(92)90096-U	http://dx.doi.org/10.1016/0092-8674(92)90096-U			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JE757	1322247				2022-12-01	WOS:A1992JE75700005
J	HELIN, K; LEES, JA; VIDAL, M; DYSON, N; HARLOW, E; FATTAEY, A				HELIN, K; LEES, JA; VIDAL, M; DYSON, N; HARLOW, E; FATTAEY, A			A CDNA-ENCODING A PRB-BINDING PROTEIN WITH PROPERTIES OF THE TRANSCRIPTION FACTOR E2F	CELL			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; LARGE T-ANTIGEN; ADENOVIRUS E1A PROTEINS; REGION 1A PROTEINS; SV40 LARGE-T; CELL-CYCLE; DNA-BINDING; RB GENE; REGULATORY SEQUENCES; TRANS-ACTIVATION	The retinoblastoma protein (PRB) plays an important role in the control of cell proliferation, apparently by binding to and regulating cellular transcription factors such as E2F. Here we describe the characterization of a cDNA clone that encodes a protein with properties of E2F. This clone, RBP3, was identified by the ability of its gene product to interact with pRB. RBP3 bound to pRB both in vitro and in vivo, and this binding was competed by viral proteins known to disrupt pRB-E2F association. RBP3 bound to E2F recognition sequences in a sequence-specific manner. Furthermore, transient expression of RBP3 caused a 10-fold transactivation of the adenovirus E2 promoter, and this transactivation was dependent on the E2F recognition sequences. These properties suggest that RBP3 encodes E2F, or an E2F-like protein.			HELIN, K (corresponding author), MASSACHUSETTS GEN HOSP, BOSTON, MA 02129 USA.		Helin, Kristian/HDM-8306-2022; Helin, Kristian/K-2526-2019	Helin, Kristian/0000-0003-1975-6097				BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAGCHI S, 1989, P NATL ACAD SCI USA, V86, P4352, DOI 10.1073/pnas.86.12.4352; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DUNN JM, 1988, SCIENCE, V241, P1797, DOI 10.1126/science.3175621; DYSON N, 1992, J VIROL, V66, P4606, DOI 10.1128/JVI.66.7.4606-4611.1992; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; EDWARDS GM, 1992, J BIOL CHEM, V267, P7971; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARLOW E, 1988, ANTIBODIES LABORATOR; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LATHANGUE NB, 1990, NUCLEIC ACIDS RES, V18, P2929, DOI 10.1093/nar/18.10.2929; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LOEKEN MR, 1989, J BIOL CHEM, V264, P6572; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; RAYCHAUDHURI P, 1987, EMBO J, V6, P4073, DOI 10.1002/j.1460-2075.1987.tb02753.x; RAYCHAUDHURI P, 1990, J VIROL, V64, P2702, DOI 10.1128/JVI.64.6.2702-2710.1990; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; Sambrook J., 1989, MOL CLONING LAB MANU; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHIVJI MKK, 1991, MOL CELL BIOL, V11, P1686, DOI 10.1128/MCB.11.3.1686; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUMEGI J, 1990, CELL GROWTH DIFFER, V1, P247; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YEE AS, 1987, EMBO J, V6, P2061, DOI 10.1002/j.1460-2075.1987.tb02471.x; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578	79	651	685	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 24	1992	70	2					337	350		10.1016/0092-8674(92)90107-N	http://dx.doi.org/10.1016/0092-8674(92)90107-N			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JE757	1638634				2022-12-01	WOS:A1992JE75700016
J	HIRANO, S; KIMOTO, N; SHIMOYAMA, Y; HIROHASHI, S; TAKEICHI, M				HIRANO, S; KIMOTO, N; SHIMOYAMA, Y; HIROHASHI, S; TAKEICHI, M			IDENTIFICATION OF A NEURAL ALPHA-CATENIN AS A KEY REGULATOR OF CADHERIN FUNCTION AND MULTICELLULAR ORGANIZATION	CELL			English	Article							CELL-ADHESION MOLECULE; CYTOPLASMIC DOMAIN; EXPRESSION; UVOMORULIN; CDNA; EMBRYOS; REGION	The function of cadherin cell adhesion molecules is thought to be regulated by a group of cytoplasmic proteins, including alpha-catenin. We identified a subtype of alpha-catenin, termed alpha-catenin, which is associated with N-cadherin and expressed mainly in the nervous system. cDNA transfection experiments showed that alpha-N-catenin can also bind with E-cadherin. To investigate the role of alpha-N-catenin, we transfected lung carcinoma PC9 cells, which express E-cadherin and beta-catenin but neither alpha- nor alpha-N-catenin, with alpha-N-catenin cDNA. While parental PC9 grew as isolated cells, the transfectant lines formed aggregates in which cells were tightly adhered to each other, showing epithelial arrangements, and they occasionally gave rise to cystic spheres. These results suggest that alpha-N-catenin is crucial not only for cadherin function but also for organization of multicellular structures.	NATL CANC CTR, RES INST, DIV PATHOL, CHUO KU, TOKYO 104, JAPAN	National Cancer Center - Japan	HIRANO, S (corresponding author), KYOTO UNIV, FAC SCI, DEPT BIOPHYS, SAKYO KU, KYOTO 606, JAPAN.		Takeichi, Masatoshi/G-5903-2012	Takeichi, Masatoshi/0000-0002-9931-3378				COUTU MD, 1988, P NATL ACAD SCI USA, V85, P8535, DOI 10.1073/pnas.85.22.8535; FUJIMORI T, 1990, DEVELOPMENT, V110, P97; GEIGER B, 1991, CELL MOTIL CYTOSKEL, V20, P1, DOI 10.1002/cm.970200102; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HATTA K, 1986, NATURE, V320, P447, DOI 10.1038/320447a0; HATTA K, 1987, DEV BIOL, V120, P215, DOI 10.1016/0012-1606(87)90119-9; HATTA K, 1988, J CELL BIOL, V106, P873, DOI 10.1083/jcb.106.3.873; HERRENKNECHT K, 1991, P NATL ACAD SCI USA, V88, P9156, DOI 10.1073/pnas.88.20.9156; HIRANO S, 1987, J CELL BIOL, V105, P2501, DOI 10.1083/jcb.105.6.2501; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; KATO K, 1990, MOL CELL BIOL, V10, P486, DOI 10.1128/MCB.10.2.486; KINJO M, 1979, BRIT J CANCER, V39, P15, DOI 10.1038/bjc.1979.3; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; MCCREA PD, 1991, J BIOL CHEM, V266, P4514; MCNEILL H, 1990, CELL, V62, P309, DOI 10.1016/0092-8674(90)90368-O; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; NOSE A, 1988, CELL, V54, P993, DOI 10.1016/0092-8674(88)90114-6; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1992, J CELL BIOL, V116, P989, DOI 10.1083/jcb.116.4.989; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; PEIFER M, 1992, IN PRESS J CELL BIOL; SANTERRE RF, 1984, GENE, V30, P147, DOI 10.1016/0378-1119(84)90115-X; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SHIMOYAMA Y, 1989, CANCER RES, V49, P2128; SHIRAYOSHI Y, 1986, CELL STRUCT FUNCT, V11, P245, DOI 10.1247/csf.11.245; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAKEICHI M, 1990, COLD SH Q B, V55, P319; WHEELOCK MJ, 1991, DIFFERENTIATION, V46, P35, DOI 10.1111/j.1432-0436.1991.tb00863.x	33	530	539	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 24	1992	70	2					293	301		10.1016/0092-8674(92)90103-J	http://dx.doi.org/10.1016/0092-8674(92)90103-J			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JE757	1638632				2022-12-01	WOS:A1992JE75700012
J	HWANG, SS; BOYLE, TJ; LYERLY, HK; CULLEN, BR				HWANG, SS; BOYLE, TJ; LYERLY, HK; CULLEN, BR			IDENTIFICATION OF ENVELOPE V3 LOOP AS THE MAJOR DETERMINANT OF CD4 NEUTRALIZATION SENSITIVITY OF HIV-1	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RECOMBINANT SOLUBLE CD4; AIDS-RELATED COMPLEX; MONONUCLEAR PHAGOCYTES; T4 ANTIGEN; ANTIBODIES; RECEPTOR; TYPE-1; GP120; RETROVIRUS	Laboratory isolates of human immunodeficiency virus type-1 (HIV-1) such as HTLV-IIIB are generally T cell line-tropic and highly sensitive to neutralization by soluble CD4 (sCD4), a potential antiviral agent that is undergoing clinical trial. However, many primary HIV-1 isolates are macrophage-tropic and sCD4-resistant. Envelope V3 loop sequences derived from primary HIV-1 isolates were sufficient to confer on HTLV-IIIB not only the tissue tropism but also the degree of sCD4 neutralization resistance characteristic of their HIV-1 strains of origin. Single amino acid changes in the V3 loop enhanced sCD4 resistance by up to tenfold. These observations suggest that the tissue tropism and sCD4 neutralization sensitivity of HIV-1 isolates are regulated by similar mechanisms.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,GENET SECT,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MICROBIOL & IMMUNOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT SURG,DURHAM,NC 27710	Duke University; Howard Hughes Medical Institute; Duke University; Duke University			Lyerly, Herbert Kim/AAX-4925-2020; Lyerly, Herbert K/B-6528-2014	Lyerly, Herbert Kim/0000-0002-0063-4770; Lyerly, Herbert K/0000-0002-0063-4770	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI028662, R29AI028233] Funding Source: NIH RePORTER; NIAID NIH HHS [AI28233, AI28662] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASHKENAZI A, 1991, P NATL ACAD SCI USA, V88, P7056, DOI 10.1073/pnas.88.16.7056; BRIGHTY DW, 1991, P NATL ACAD SCI USA, V88, P7802, DOI 10.1073/pnas.88.17.7802; BYRN RA, 1989, J VIROL, V63, P4370, DOI 10.1128/JVI.63.10.4370-4375.1989; CHENGMAYER C, 1988, SCIENCE, V240, P80, DOI 10.1126/science.2832945; CLAPHAM PR, 1989, NATURE, V337, P368, DOI 10.1038/337368a0; CLAPHAM PR, 1991, VIROLOGY, V181, P703, DOI 10.1016/0042-6822(91)90904-P; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; CLEMENTS GJ, 1991, AIDS RES HUM RETROV, V7, P3, DOI 10.1089/aid.1991.7.3; COLLMAN R, 1990, J VIROL, V64, P4468, DOI 10.1128/JVI.64.9.4468-4476.1990; DAAR ES, 1990, P NATL ACAD SCI USA, V87, P6574, DOI 10.1073/pnas.87.17.6574; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DEAN KC, 1988, NATURE, V331, P82; DEJONG JJ, 1992, J VIROL, V66, P757, DOI 10.1128/JVI.66.2.757-765.1992; FISHER RA, 1988, NATURE, V331, P76, DOI 10.1038/331076a0; FREED EO, 1991, J VIROL, V65, P190, DOI 10.1128/JVI.65.1.190-194.1991; GAMATOS PJ, 1990, J IMMUNOL, V144, P4183; GARTNER S, 1990, AIDS RES HUM RETROV, V6, P1017, DOI 10.1089/aid.1990.6.1017; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; GOUDSMIT J, 1988, P NATL ACAD SCI USA, V85, P4478, DOI 10.1073/pnas.85.12.4478; HART TK, 1991, P NATL ACAD SCI USA, V88, P2189, DOI 10.1073/pnas.88.6.2189; HO DD, 1988, SCIENCE, V239, P1021, DOI 10.1126/science.2830667; HUSSEY RE, 1988, NATURE, V331, P80; HWANG S, UNPUB; HWANG SS, 1991, SCIENCE, V253, P71, DOI 10.1126/science.1905842; JAVAHERIAN K, 1990, SCIENCE, V250, P1590, DOI 10.1126/science.1703322; KAHN JO, 1990, ANN INTERN MED, V112, P254, DOI 10.7326/0003-4819-112-4; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MCDOUGAL JS, 1985, J IMMUNOL, V135, P3151; MOORE JP, 1990, SCIENCE, V250, P1139, DOI 10.1126/science.2251501; MOORE JP, 1992, J VIROL, V66, P235, DOI 10.1128/JVI.66.1.235-243.1992; OBRIEN WA, 1992, J VIROL, V66, P3125, DOI 10.1128/JVI.66.5.3125-3130.1992; OBRIEN WA, 1990, NATURE, V348, P69, DOI 10.1038/348069a0; PAGE KA, 1992, J VIROL, V66, P524, DOI 10.1128/JVI.66.1.524-533.1992; PALKER TJ, 1988, P NATL ACAD SCI USA, V85, P1932, DOI 10.1073/pnas.85.6.1932; RUSCHE JR, 1988, P NATL ACAD SCI USA, V85, P3198, DOI 10.1073/pnas.85.9.3198; SATTENTAU QJ, 1991, J EXP MED, V174, P407, DOI 10.1084/jem.174.2.407; SCHOOLEY RT, 1990, ANN INTERN MED, V112, P247, DOI 10.7326/0003-4819-112-4-247; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; SCHUITEMAKER H, 1991, J VIROL, V65, P356, DOI 10.1128/JVI.65.1.356-363.1991; SHIODA T, 1991, NATURE, V349, P167, DOI 10.1038/349167a0; SKINNER MA, 1988, J VIROL, V62, P4195, DOI 10.1128/JVI.62.11.4195-4200.1988; SMITH DH, 1987, SCIENCE, V238, P1704, DOI 10.1126/science.3500514; TAKEUCHI Y, 1991, J VIROL, V65, P1710, DOI 10.1128/JVI.65.4.1710-1718.1991; TRAUNECKER A, 1988, NATURE, V331, P84, DOI 10.1038/331084a0; WARD RHR, 1991, NATURE, V352, P434, DOI 10.1038/352434a0; WESTERVELT P, 1991, P NATL ACAD SCI USA, V88, P3097, DOI 10.1073/pnas.88.8.3097	48	115	117	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 24	1992	257	5069					535	537		10.1126/science.1636088	http://dx.doi.org/10.1126/science.1636088			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JE755	1636088				2022-12-01	WOS:A1992JE75500030
J	JAGADEESH, B; GRAY, CM; FERSTER, D				JAGADEESH, B; GRAY, CM; FERSTER, D			VISUALLY EVOKED OSCILLATIONS OF MEMBRANE-POTENTIAL IN CELLS OF CAT VISUAL-CORTEX	SCIENCE			English	Article							DEPENDENT NEURONAL OSCILLATIONS; RESPONSES; MODEL	In response to visual stimulation, cells of the cat visual cortex fire rhythmically at frequencies between 30 and 60 hertz. This rhythmic firing can be synchronized among cells in widespread areas of the visual cortex. The visual stimulus conditions under which this process occurs suggest that the synchronization may contribute to the integration of information across broadly displaced parts of the visual field. An intricate mechanism must control the regularity of firing and its synchronization. In vivo whole-cell patch recordings from cells in area 17 have now shown that robust oscillations of membrane potential underlie the regularity of firing seen extracellularly. In the cells studied, the characteristics of the oscillations of membrane potential suggest that such oscillations are produced by rhythmic activity in synaptic inputs. These rhythmic synaptic inputs form the most likely mechanism for the synchronization of activity in neighboring cortical cells.	SALK INST BIOL STUDIES,SAN DIEGO,CA 92138	Salk Institute	JAGADEESH, B (corresponding author), NORTHWESTERN UNIV,DEPT NEUROBIOL & PHYSIOL,EVANSTON,IL 60208, USA.				NATIONAL EYE INSTITUTE [R29EY008686, R01EY004726] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY04726, R29 EY08686] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AGMON A, 1991, NEUROSCIENCE, V41, P365, DOI 10.1016/0306-4522(91)90333-J; ARIEL M, 1983, VISION RES, V23, P1485, DOI 10.1016/0042-6989(83)90160-8; BISHOP PO, 1964, J PHYSIOL-LONDON, V170, P598, DOI 10.1113/jphysiol.1964.sp007352; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BOUYER JJ, 1981, ELECTROEN CLIN NEURO, V51, P244, DOI 10.1016/0013-4694(81)90138-3; Bush PC, 1991, NEURAL COMPUT, V3, P19, DOI 10.1162/neco.1991.3.1.19; CONNORS BW, 1990, TRENDS NEUROSCI, V13, P99, DOI 10.1016/0166-2236(90)90185-D; ECKHORN R, 1988, BIOL CYBERN, V60, P121, DOI 10.1007/BF00202899; ENGEL AK, 1991, SCIENCE, V252, P1177, DOI 10.1126/science.252.5009.1177; ENGEL AK, 1990, EUR J NEUROSCI, V2, P588, DOI 10.1111/j.1460-9568.1990.tb00449.x; FERSTER D, 1990, VISUAL NEUROSCI, V4, P115, DOI 10.1017/S0952523800002285; FERSTER D, 1983, J PHYSIOL-LONDON, V342, P181, DOI 10.1113/jphysiol.1983.sp014846; FERSTER D, 1992, J NEUROSCI, V12, P1262; Freeman WJ, 1975, MASS ACTION NERVOUS; FUSTER JOAQUIN M., 1965, Z VER GLEICHENDE PHYSIOL, V49, P605, DOI 10.1007/BF00367161; GHOSE GM, 1990, SOC NEUR ABSTR, V16, P523; GRAY CM, 1990, EUR J NEUROSCI, V2, P607, DOI 10.1111/j.1460-9568.1990.tb00450.x; GRAY CM, 1989, P NATL ACAD SCI USA, V86, P1698, DOI 10.1073/pnas.86.5.1698; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; GRAY CM, 1992, INDUCED RHYTHMS BRAI, P29; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; JAGADEESH B, UNPUB; LAUFER M, 1967, VISION RES, V7, P215, DOI 10.1016/0042-6989(67)90086-7; LLINAS RR, 1991, P NATL ACAD SCI USA, V88, P897, DOI 10.1073/pnas.88.3.897; MILNER PM, 1974, PSYCHOL REV, V81, P521, DOI 10.1037/h0037149; SILVA LR, 1991, SCIENCE, V251, P432, DOI 10.1126/science.1824881; STERN P, 1992, J PHYSIOL-LONDON, V449, P247, DOI 10.1113/jphysiol.1992.sp019085; VANDERMALSBURG C, 1985, BER BUNSEN PHYS CHEM, V89, P703; VANDERMALSBURG C, 1981, CORRELATION THEORY B; VANDERMALSBURG C, 1986, BRAIN THEORY, P161; WILSON HR, 1972, BIOPHYS J, V12, P1, DOI 10.1016/S0006-3495(72)86068-5	31	128	131	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 24	1992	257	5069					552	554		10.1126/science.1636094	http://dx.doi.org/10.1126/science.1636094			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JE755	1636094				2022-12-01	WOS:A1992JE75500036
J	KAELIN, WG; KREK, W; SELLERS, WR; DECAPRIO, JA; AJCHENBAUM, F; FUCHS, CS; CHITTENDEN, T; LI, Y; FARNHAM, PJ; BLANAR, MA; LIVINGSTON, DM; FLEMINGTON, EK				KAELIN, WG; KREK, W; SELLERS, WR; DECAPRIO, JA; AJCHENBAUM, F; FUCHS, CS; CHITTENDEN, T; LI, Y; FARNHAM, PJ; BLANAR, MA; LIVINGSTON, DM; FLEMINGTON, EK			EXPRESSION CLONING OF A CDNA-ENCODING A RETINOBLASTOMA-BINDING PROTEIN WITH E2F-LIKE PROPERTIES	CELL			English	Article							LARGE T-ANTIGEN; SUSCEPTIBILITY GENE-PRODUCT; E2F TRANSCRIPTION FACTOR; SV40 LARGE-T; DNA-BINDING; REGULATORY ELEMENT; IMMUNE INTERFERON; MESSENGER-RNA; RB GENE; CELLS	An expression vector was modified to permit the rapid synthesis of purified, P-32-labeled, glutathione S-transferase (GST)-retinoblastoma (RB) fusion proteins. The products were used to screen lambda-gt11 expression libraries, from which we cloned a cDNA encoding a polypeptide (RBAP-1) capable of binding directly to a putative functional domain (the pocket) of the retinoblastoma gene product (RB). The RB "pocket" is known to bind, directly or indirectly, to the cellular transcription factor, E2F, implicated in cell growth control. We have found that RBAP-1 copurifies with E2F, interacts specifically with the adenovirus E4 ORF 6/7 protein, binds specifically and directly to a known E2F DNA recognition sequence, and contains a functional transactivation domain. Therefore, RBAP-1 is a species of E2F and can bind specifically to the RB pocket.	HARVARD UNIV,SCH MED,BOSTON,MA 02115; UNIV WISCONSIN,MCARDLE LAB CANC RES,MADISON,WI 53706; UNIV CALIF SAN FRANCISCO,SCH MED,HORMONE RES INST,SAN FRANCISCO,CA 94143	Harvard University; Harvard Medical School; University of Wisconsin System; University of Wisconsin Madison; University of California System; University of California San Francisco	KAELIN, WG (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115, USA.			Farnham, Peggy/0000-0003-4469-7914				ADAMS RLP, 1967, J BIOL CHEM, V242, P1314; Ausubel M., 1989, MOL REPROD DEV, V1, P146, DOI [10.1002/mrd.1080010210, DOI 10.1002/MRD.1080010210]; BAGCHI S, 1989, P NATL ACAD SCI USA, V86, P4352, DOI 10.1073/pnas.86.12.4352; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BIGGIN M, 1987, J VIROL, V61, P3120, DOI 10.1128/JVI.61.10.3120-3132.1987; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN S, 1990, J VIROL, V64, P3350, DOI 10.1128/JVI.64.7.3350-3357.1990; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; FLEMINGTON EK, 1992, J VIROL, V66, P922, DOI 10.1128/JVI.66.2.922-929.1992; FOSS K, 1987, GENE, V59, P285, DOI 10.1016/0378-1119(87)90336-2; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARLOW E, 1988, ANTIBODIES LABORATOR; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG MM, 1989, GENE DEV, V3, P1699, DOI 10.1101/gad.3.11.1699; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; JONES RE, 1990, J BIOL CHEM, V265, P12782; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KOVESDI I, 1987, P NATL ACAD SCI USA, V84, P2180, DOI 10.1073/pnas.84.8.2180; KUNG HF, 1986, METHOD ENZYMOL, V119, P296; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MARTON MJ, 1990, J VIROL, V64, P2345, DOI 10.1128/JVI.64.5.2345-2359.1990; MCGEE TL, 1989, GENE, V80, P119, DOI 10.1016/0378-1119(89)90256-4; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NEILL SD, 1990, P NATL ACAD SCI USA, V87, P2008, DOI 10.1073/pnas.87.5.2008; NEILL SD, 1991, J VIROL, V65, P5364, DOI 10.1128/JVI.65.10.5364-5373.1991; PRIMIG M, 1992, IN PRESS NATURE; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; RASHIDBAIGI A, 1985, J BIOL CHEM, V260, P8514; REICHEL R, 1988, P NATL ACAD SCI USA, V85, P387, DOI 10.1073/pnas.85.2.387; RICKSTEN A, 1988, NUCLEIC ACIDS RES, V16, P8391, DOI 10.1093/nar/16.17.8391; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHEW JY, 1990, CELL GROWTH DIFFER, V1, P17; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SINGH H, 1989, BIOTECHNIQUES, V7, P252; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAKADA K, 1989, J VIROL, V63, P445, DOI 10.1128/JVI.63.1.445-449.1989; YEE AS, 1987, EMBO J, V6, P2061, DOI 10.1002/j.1460-2075.1987.tb02471.x; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578	73	845	890	1	24	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 24	1992	70	2					351	364		10.1016/0092-8674(92)90108-O	http://dx.doi.org/10.1016/0092-8674(92)90108-O			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JE757	1638635				2022-12-01	WOS:A1992JE75700017
J	LIN, HC; SUDHOF, TC; ANDERSON, RGW				LIN, HC; SUDHOF, TC; ANDERSON, RGW			ANNEXIN-VI IS REQUIRED FOR BUDDING OF CLATHRIN-COATED PITS	CELL			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; LOW-DENSITY LIPOPROTEIN; ANTICOAGULANT PROTEIN; MEMBRANE-FUSION; CALCIUM; CALPACTIN; BINDING; KINASE; CELLS; PHOSPHOLIPASE-A2	Isolated plasma membranes attached to a solid substratum at 4-degrees-C have numerous clathrin-coated pits. These pits initially are flat but become deeply invaginated after warming to 37-degrees-C. The pits remain tethered to the membrane in this rounded condition unless supplied with ATP, Ca2+, and cytosol. We now show that when cytosol is treated to remove the Ca2+-dependent, phospholipid-binding protein annexin VI, coated pit budding no longer takes place. Addition of purified annexin VI back to the annexin VI-depleted cytosol restores budding activity to normal. Purified annexin VI alone shows only a modest budding activity, suggesting that the cytosol contains a factor(s) in addition to annexin VI that is required for full activity. Cytosol-dependent activation of annexin VI requires both ATP and Ca2+. Annexin VI appears to be not only an active component in the detachment of coated pits from the membrane but also a site for regulating the formation of coated vesicles.	UNIV TEXAS, SW MED CTR, DEPT MOLEC GENET, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	LIN, HC (corresponding author), UNIV TEXAS, SW MED CTR, DEPT CELL BIOL & NEUROSCI, DALLAS, TX 75235 USA.				NHLBI NIH HHS [HL39644, HL20948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948, R01HL039644] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALI SM, 1989, NATURE, V340, P313, DOI 10.1038/340313a0; Anderson R G, 1986, Methods Enzymol, V129, P201; ANDERSON RGW, 1977, CELL, V10, P351, DOI 10.1016/0092-8674(77)90022-8; Anderson RM, 1991, INFECT DIS HUMANS DY, P13; BARTON GJ, 1991, EUR J BIOCHEM, V198, P749, DOI 10.1111/j.1432-1033.1991.tb16076.x; BLUMENTHAL R, 1987, CURR TOP MEMBR TRANS, V29, P203; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRODSKY FM, 1988, SCIENCE, V242, P1396, DOI 10.1126/science.2904698; BRODSKY FM, 1985, J CELL BIOL, V101, P2047, DOI 10.1083/jcb.101.6.2047; BURGOYNE RD, 1989, CELL CALCIUM, V10, P1, DOI 10.1016/0143-4160(89)90038-9; COMERA C, 1990, EUR J BIOCHEM, V188, P139, DOI 10.1111/j.1432-1033.1990.tb15381.x; Darnell J., 1990, MOL CELL BIOL; ERNST JD, 1991, J IMMUNOL, V146, P3110; ERNST JD, 1991, J BIOL CHEM, V266, P6670; ERNST JD, 1990, J CLIN INVEST, V85, P1065, DOI 10.1172/JCI114537; GENGE BR, 1990, J BIOL CHEM, V265, P4703; GLENNEY J, 1986, P NATL ACAD SCI USA, V83, P4258, DOI 10.1073/pnas.83.12.4258; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; HAZARIKA P, 1991, J CELL BIOCHEM, V46, P78, DOI 10.1002/jcb.240460112; HAZARIKA P, 1991, J CELL BIOCHEM, V46, P86, DOI 10.1002/jcb.240460113; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; HUANG KS, 1986, CELL, V46, P191, DOI 10.1016/0092-8674(86)90736-1; HUBER R, 1992, J MOL BIOL, V223, P683, DOI 10.1016/0022-2836(92)90984-R; HUBER R, 1990, EMBO J, V9, P3867, DOI 10.1002/j.1460-2075.1990.tb07605.x; JOHNSTON PA, 1990, BIOCHEM SOC T, V18, P1097, DOI 10.1042/bst0181097; KRAUS FN, 1990, CELL CALCIUM, V11, P625; KWIATKOWSKA K, 1991, EXP CELL RES, V196, P255, DOI 10.1016/0014-4827(91)90259-W; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARKIN JM, 1986, J CELL BIOL, V103, P2619, DOI 10.1083/jcb.103.6.2619; LIN HC, 1991, J CELL BIOL, V114, P881, DOI 10.1083/jcb.114.5.881; MAHAFFEY DT, 1990, J BIOL CHEM, V265, P16514; MEERS P, 1991, BIOCHEMISTRY-US, V30, P2903, DOI 10.1021/bi00225a025; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; MOORE MS, 1987, SCIENCE, V236, P558, DOI 10.1126/science.2883727; NEWMAN R, 1989, J MOL BIOL, V206, P213, DOI 10.1016/0022-2836(89)90534-2; OHALLORAN TJ, 1992, IN PRESS J CELL BIOL; OSHRY L, 1991, BIOCHIM BIOPHYS ACTA, V1066, P239, DOI 10.1016/0005-2736(91)90192-B; PAPAHADJOPOULOS D, 1990, J BIOENERG BIOMEMBR, V22, P157, DOI 10.1007/BF00762944; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; ROJAS E, 1990, J BIOL CHEM, V265, P21207; ROSS TS, 1990, SCIENCE, V248, P605, DOI 10.1126/science.2159184; SARAFIAN T, 1991, J CELL BIOL, V114, P1135, DOI 10.1083/jcb.114.6.1135; SARIS CJM, 1986, CELL, V46, P201, DOI 10.1016/0092-8674(86)90737-3; SEKIMOTO S, 1991, J NEUROCHEM, V56, P1774, DOI 10.1111/j.1471-4159.1991.tb02080.x; SUDHOF TC, 1982, EMBO J, V1, P1167, DOI 10.1002/j.1460-2075.1982.tb00008.x; SUDHOF TC, 1984, BIOCHEMISTRY-US, V23, P1103; SUDHOF TC, 1988, P NATL ACAD SCI USA, V85, P664, DOI 10.1073/pnas.85.3.664; THIAGARAJAN P, 1990, J BIOL CHEM, V265, P17420; VANDEURS B, 1989, INT REV CYTOL, V117, P131; ZAKS WJ, 1990, J BIOENERG BIOMEMBR, V22, P97, DOI 10.1007/BF00762942; ZAKS WJ, 1991, BIOCHEMISTRY-US, V30, P9607, DOI 10.1021/bi00104a007	52	129	129	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 24	1992	70	2					283	291		10.1016/0092-8674(92)90102-I	http://dx.doi.org/10.1016/0092-8674(92)90102-I			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JE757	1386288				2022-12-01	WOS:A1992JE75700011
J	MELDRUM, FC; HEYWOOD, BR; MANN, S				MELDRUM, FC; HEYWOOD, BR; MANN, S			MAGNETOFERRITIN - INVITRO SYNTHESIS OF A NOVEL MAGNETIC PROTEIN	SCIENCE			English	Article							FE(OH)2 SUSPENSIONS; AIR OXIDATION; IRON(II) ION; FERRITIN; FE3O4	The iron storage protein ferritin consists of a spherical polypeptide shell (apoferritin) surrounding a 6-nanometer inorganic core of the hydrated iron oxide ferrihydrite (5Fe2O3.9H2O). Previous studies have shown that the in vitro reconstitution of apoferritin yields mineral cores essentially identical to those of the native proteins. A magnetic mineral was synthesized within the nanodimensional cavity of horse spleen ferritin by the use of controlled reconstitution conditions. Transmission electron microscopy and electron diffraction analysis indicate that the entrapped mineral particles are discrete 6-nanometer spherical single crystals of the ferrimagnetic iron oxide magnetite (Fe3O4). The resulting magnetic protein, "magnetoferritin," could have uses in biomedical imaging, cell labeling, and separation procedures.	UNIV BATH,SCH CHEM,BATH BA2 7AY,AVON,ENGLAND	University of Bath			Meldrum, Fiona C/E-2726-2014; Mann, Stephen/D-1332-2012	Mann, Stephen/0000-0003-3012-8964; Meldrum, Fiona/0000-0001-9243-8517				BUTLER RF, 1975, J GEOPHYS RES, V80, P4049, DOI 10.1029/JB080i029p04049; FORD GC, 1984, PHILOS T R SOC B, V304, P551, DOI 10.1098/rstb.1984.0046; KEMP W, 1986, NMR CHEM MULTINUCLEA, P154; KIYAMA M, 1974, B CHEM SOC JPN, V47, P1646, DOI 10.1246/bcsj.47.1646; LAWSON DM, 1989, FEBS LETT, V254, P207, DOI 10.1016/0014-5793(89)81040-3; LAWSON DM, 1991, NATURE, V349, P541, DOI 10.1038/349541a0; LEVI S, 1988, J BIOL CHEM, V263, P18086; LIVNE E, 1986, J HISTOCHEM CYTOCHEM, V34, P167, DOI 10.1177/34.2.3944455; MANN S, 1987, J MOL BIOL, V198, P405, DOI 10.1016/0022-2836(87)90290-7; MANN S, 1989, J CHEM SOC FARAD T 1, V85, P3033, DOI 10.1039/f19898503033; Mann S., 1989, BIOMINERALIZATION CH; MELDRUM FC, 1991, NATURE, V349, P684, DOI 10.1038/349684a0; MELDRUM FC, UNPUB; MOLDAY RS, 1977, NATURE, V268, P437, DOI 10.1038/268437a0; OZAKI M, 1985, J COLLOID INTERF SCI, V107, P199, DOI 10.1016/0021-9797(85)90162-6; TAMAURA Y, 1983, J CHEM SOC DALTON, P189, DOI 10.1039/dt9830000189; TAMAURA Y, 1981, J CHEM SOC DALTON, P1807, DOI 10.1039/dt9810001807; TAYLOR RM, 1984, CLAY CLAY MINER, V32, P167, DOI 10.1346/CCMN.1984.0320302; WADE VJ, 1991, J MOL BIOL, V221, P1443, DOI 10.1016/0022-2836(91)80137-J; ZHAO XK, 1990, J PHYS CHEM-US, V94, P2373	20	502	529	2	141	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 24	1992	257	5069					522	523		10.1126/science.1636086	http://dx.doi.org/10.1126/science.1636086			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JE755	1636086				2022-12-01	WOS:A1992JE75500025
J	MIZUUCHI, M; BAKER, TA; MIZUUCHI, K				MIZUUCHI, M; BAKER, TA; MIZUUCHI, K			ASSEMBLY OF THE ACTIVE FORM OF THE TRANSPOSASE-MU DNA COMPLEX - A CRITICAL CONTROL POINT IN MU-TRANSPOSITION	CELL			English	Article							STRAND-TRANSFER-REACTION; INTEGRATION HOST FACTOR; BACTERIOPHAGE-MU; PHAGE-MU; B-PROTEIN; SITE; ENHANCER; ENDS; TRANSPOSOSOMES; RECOMBINATION	Discovery and characterization of a new intermediate in Mu DNA transposition allowed assembly of the transposition machinery to be separated from the chemical steps of recombination. This stable intermediate, which accumulates in the presence of Ca2+, consists of the two ends of the Mu DNA synapsed by a tetramer of the Mu transposase. Within this stable synaptic complex (SSC), the recombination sites are engaged but not yet cleaved. Thus, the SSC is structurally related to both the cleaved donor and strand transfer complexes, but precedes them on the transposition pathway. Once the active protein-DNA complex is constructed, it is conserved throughout transposition. The participation of internal sequence elements and accessory factors exclusively during SSC assembly allows recombination to be controlled prior to the irreversible chemical steps.			MIZUUCHI, M (corresponding author), NIDDK,MOLEC BIOL LAB,BETHESDA,MD 20892, USA.							ADZUMA K, 1988, CELL, V53, P257, DOI 10.1016/0092-8674(88)90387-X; BAINTON R, 1991, CELL, V65, P805, DOI 10.1016/0092-8674(91)90388-F; BAKER TA, 1991, CELL, V65, P1003, DOI 10.1016/0092-8674(91)90552-A; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; Cox M. M., 1989, MOBILE DNA, P661; CRAIGIE R, 1986, CELL, V45, P793, DOI 10.1016/0092-8674(86)90554-4; CRAIGIE R, 1984, CELL, V39, P387, DOI 10.1016/0092-8674(84)90017-5; CRAIGIE R, 1985, P NATL ACAD SCI USA, V82, P7570, DOI 10.1073/pnas.82.22.7570; CRAIGIE R, 1987, CELL, V51, P493, DOI 10.1016/0092-8674(87)90645-3; DUNAWAY M, 1989, NATURE, V341, P657, DOI 10.1038/341657a0; ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C; Furth M., 1983, LAMBDA 2, P145; GROENEN MAM, 1985, P NATL ACAD SCI USA, V82, P2087, DOI 10.1073/pnas.82.7.2087; HARSHEY RM, 1985, P NATL ACAD SCI USA, V82, P7676, DOI 10.1073/pnas.82.22.7676; HEICHMAN KA, 1991, GENE DEV, V5, P1622, DOI 10.1101/gad.5.9.1622; KANAAR R, 1990, CELL, V62, P353, DOI 10.1016/0092-8674(90)90372-L; KLIPPEL A, 1988, EMBO J, V7, P3983, DOI 10.1002/j.1460-2075.1988.tb03286.x; KUO CF, 1991, EMBO J, V10, P1585, DOI 10.1002/j.1460-2075.1991.tb07679.x; LABHART P, 1985, NUCLEIC ACIDS RES, V13, P8999, DOI 10.1093/nar/13.24.8999; LANDY A, 1989, ANNU REV BIOCHEM, V58, P913, DOI 10.1146/annurev.biochem.58.1.913; LAVOIE BD, 1991, EMBO J, V10, P3051, DOI 10.1002/j.1460-2075.1991.tb07856.x; LAVOIE BD, 1990, J BIOL CHEM, V265, P1623; LEUNG PC, 1989, NATURE, V338, P656, DOI 10.1038/338656a0; MAXWELL A, 1987, P NATL ACAD SCI USA, V84, P699, DOI 10.1073/pnas.84.3.699; MIZUUCHI K, 1991, CELL, V66, P129, DOI 10.1016/0092-8674(91)90145-O; MIZUUCHI M, 1986, NUCLEIC ACIDS RES, V14, P3813, DOI 10.1093/nar/14.9.3813; MIZUUCHI M, 1991, P NATL ACAD SCI USA, V88, P9031, DOI 10.1073/pnas.88.20.9031; MIZUUCHI M, 1989, CELL, V58, P399, DOI 10.1016/0092-8674(89)90854-4; MOSKOWITZ IPG, 1991, GENE DEV, V5, P1635, DOI 10.1101/gad.5.9.1635; NAKAYAMA C, 1987, P NATL ACAD SCI USA, V84, P1809, DOI 10.1073/pnas.84.7.1809; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; SURETTE MG, 1989, J BIOL CHEM, V264, P3028; SURETTE MG, 1989, EMBO J, V8, P3483, DOI 10.1002/j.1460-2075.1989.tb08513.x; SURETTE MG, 1992, CELL, V68, P1101, DOI 10.1016/0092-8674(92)90081-M; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; SURETTE MG, 1991, J BIOL CHEM, V266, P3118; SURETTE MG, 1991, J BIOL CHEM, V266, P17306; THOMPSON JF, 1989, MOBILE DNA, P1; WEISBERG RA, 1983, LAMBDA, V2, P211	39	151	155	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 24	1992	70	2					303	311		10.1016/0092-8674(92)90104-K	http://dx.doi.org/10.1016/0092-8674(92)90104-K			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JE757	1322248				2022-12-01	WOS:A1992JE75700013
J	PAMER, EG; WANG, CR; FLAHERTY, L; LINDAHL, KF; BEVAN, MJ				PAMER, EG; WANG, CR; FLAHERTY, L; LINDAHL, KF; BEVAN, MJ			H-2M3 PRESENTS A LISTERIA-MONOCYTOGENES PEPTIDE TO CYTOTOXIC LYMPHOCYTES-T	CELL			English	Article							CLASS-I MOLECULES; MONOCLONAL-ANTIBODY; INTRACELLULAR GROWTH; CELL RECEPTOR; ANTIGEN; HEMOLYSIN; MOUSE; IMMUNITY; REGION; DELTA	We report evidence that a major histocompatibility complex-encoded nonclassic class I molecule presents a foreign peptide to cytotoxic T lymphocytes (CTL) during an infection. Mice immunized with virulent Listeria monocytogenes generate CD8+ CTL with alpha-beta receptors specific for a bacterial peptide presented by a conserved class I molecule encoded in the M region of the major histocompatibility complex. The Listeria peptide is digested by carboxypeptidase Y but resists aminopeptidase M, and only peptides with N-formyl methionine competitively block its presentation to CTL. Transfection with the H-2M3d ene enables a negative (H-2w17) cell line to present the bacterial peptide. One function, therefore, of H-2M3 is to present bacterial peptides to CTL during infection.	UNIV WASHINGTON,HOWARD HUGHES MED INST,DEPT IMMUNOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195; UNIV TEXAS,SW MED CTR,DEPT MICROBIOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; NEW YORK STATE DEPT HLTH,WADSWORTH CTR LABS & RES,ALBANY,NY 12201	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; State University of New York (SUNY) System; Wadsworth Center								ATTAYA M, 1992, NATURE, V355, P647, DOI 10.1038/355647a0; BERCHE P, 1987, J IMMUNOL, V138, P2266; BISHOP DK, 1987, J IMMUNOL, V139, P2005; BLUESTONE JA, 1988, J EXP MED, V168, P1899, DOI 10.1084/jem.168.5.1899; BROCKE S, 1991, INFECT IMMUNON, V59, P4561; BROWN ML, 1992, J IMMUNOL, V148, P555; BRUNT LM, 1990, J IMMUNOL, V145, P3540; CONLAN JW, 1991, J EXP MED, V174, P741, DOI 10.1084/jem.174.3.741; DELIBERO G, 1986, J IMMUNOL, V137, P2688; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLAHERTY L, 1990, CRIT REV IMMUNOL, V10, P131; GAILLARD JL, 1986, INFECT IMMUN, V52, P50, DOI 10.1128/IAI.52.1.50-55.1986; HARTY JT, 1992, IN PRESS J EXP MED; HERSHBERG R, 1990, P NATL ACAD SCI USA, V87, P9727, DOI 10.1073/pnas.87.24.9727; HIROMATSU K, 1992, J EXP MED, V175, P49, DOI 10.1084/jem.175.1.49; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; ITO K, 1990, CELL, V62, P549, DOI 10.1016/0092-8674(90)90019-B; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; KATHARIOU S, 1987, J BACTERIOL, V169, P1291, DOI 10.1128/jb.169.3.1291-1297.1987; KAUFMANN SHE, 1988, J IMMUNOL, V140, P3173; KUBO RT, 1989, J IMMUNOL, V142, P2736; LALANNE JL, 1982, NUCLEIC ACIDS RES, V10, P1039, DOI 10.1093/nar/10.3.1039; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LINDAHL KF, 1980, J EXP MED, V152, P1583; LINDAHL KF, 1989, COLD SH Q B, V54, P563; LINDAHL KF, 1991, ANNU REV IMMUNOL, V9, P351, DOI 10.1146/annurev.iy.09.040191.002031; LOVELAND B, 1990, CELL, V60, P971, DOI 10.1016/0092-8674(90)90345-F; LUCASLENARD J, 1971, ANNU REV BIOCHEM, V40, P409, DOI 10.1146/annurev.bi.40.070171.002205; LUKACS K, 1989, J IMMUNOL, V143, P3731; MACKANESS GB, 1962, J EXP MED, V116, P381, DOI 10.1084/jem.116.3.381; Maniatis T., 1982, MOL CLONING; MARASCO WA, 1984, J BIOL CHEM, V259, P5430; MILLIGAN GN, 1991, J EXP MED, V174, P133, DOI 10.1084/jem.174.1.133; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; MORRISON LA, 1986, J EXP MED, V163, P903, DOI 10.1084/jem.163.4.903; NOGUEIRA N, 1976, J EXP MED, V143, P1402, DOI 10.1084/jem.143.6.1402; PAMER EG, 1991, NATURE, V353, P852, DOI 10.1038/353852a0; PORTNOY DA, 1988, J EXP MED, V167, P1459, DOI 10.1084/jem.167.4.1459; POTTER TA, 1987, J IMMUNOL, V138, P1270; RIKIHISA Y, 1980, INFECT IMMUN, V30, P231, DOI 10.1128/IAI.30.1.231-243.1980; ROETZSCHKE O, 1990, Nature (London), V348, P252; ROSEN H, 1989, J EXP MED, V170, P27, DOI 10.1084/jem.170.1.27; SANSONETTI PJ, 1986, INFECT IMMUN, V51, P461, DOI 10.1128/IAI.51.2.461-469.1986; SARMIENTO M, 1980, J IMMUNOL, V125, P2665; SHAWAR SM, 1991, J EXP MED, V174, P941, DOI 10.1084/jem.174.4.941; SHAWAR SM, 1990, J EXP MED, V171, P897, DOI 10.1084/jem.171.3.897; SHOWELL HJ, 1976, J EXP MED, V143, P1154, DOI 10.1084/jem.143.5.1154; STROYNOWSKI I, 1990, ANNU REV IMMUNOL, V8, P501, DOI 10.1146/annurev.iy.08.040190.002441; TILNEY LG, 1989, J CELL BIOL, V109, P1597, DOI 10.1083/jcb.109.4.1597; VIDOVIC D, 1989, NATURE, V340, P646, DOI 10.1038/340646a0; VITIELLO A, 1990, SCIENCE, V250, P1423, DOI 10.1126/science.2124002; Wang C.-R., 1991, NATO ASI Series Series H Cell Biology, V59, P441; WANG CR, 1991, CELL, V66, P335, DOI 10.1016/0092-8674(91)90623-7; WOLF PR, 1990, J EXP MED, V172, P1795, DOI 10.1084/jem.172.6.1795; WU M, 1991, J EXP MED, V174, P213, DOI 10.1084/jem.174.1.213	56	201	203	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 24	1992	70	2					215	223		10.1016/0092-8674(92)90097-V	http://dx.doi.org/10.1016/0092-8674(92)90097-V			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JE757	1353418				2022-12-01	WOS:A1992JE75700006
J	PERKINS, LA; LARSEN, I; PERRIMON, N				PERKINS, LA; LARSEN, I; PERRIMON, N			CORKSCREW ENCODES A PUTATIVE PROTEIN TYROSINE PHOSPHATASE THAT FUNCTIONS TO TRANSDUCE THE TERMINAL SIGNAL FROM THE RECEPTOR TYROSINE KINASE TORSO	CELL			English	Article							SEGMENTATION GENE HUNCHBACK; DROSOPHILA EMBRYO; POSTERIOR PATTERN; BICOID PROTEIN; X-CHROMOSOME; BODY PATTERN; MELANOGASTER; MUTATIONS; REQUIREMENT; SYSTEM	We describe the characterization of the Drosophila gene, corkscrew (csw), which is maternally required for normal determination of cell fates at the termini of the embryo. Determination of terminal cell fates is mediated by a signal transduction pathway that involves a receptor tyrosine kinase, torso, a serine/threonine kinase, D-raf, and the transcription factors, tailless and huckebein. Double mutant and cellular analyses between csw, torso, D-raf, and tailless indicate that csw acts downstream of torso and in concert with D-raf to positively transduce the torso signal via tailless, to downstream terminal genes. The csw gene encodes a putative nonreceptor protein tyrosine phosphatase covalently linked to two N-terminal SH2 domains, which is similar to the mammalian PTP1C protein.	HARVARD UNIV, SCH MED, HOWARD HUGHES MED INST, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute	PERKINS, LA (corresponding author), HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02115 USA.			Perrimon, Norbert/0000-0001-7542-472X				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMBROSIO L, 1989, DEVELOPMENT, V106, P145; AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; Ausubel FA, 1990, CURRENT PROTOCOLS MO; BLACKMAN RK, 1987, CELL, V49, P497, DOI 10.1016/0092-8674(87)90452-1; BRONNER G, 1991, MECH DEVELOP, V35, P205, DOI 10.1016/0925-4773(91)90019-3; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BUSSON D, 1983, GENETICS, V105, P309; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CASANOVA J, 1989, GENE DEV, V3, P2025, DOI 10.1101/gad.3.12b.2025; CASANOVA J, 1990, DEVELOPMENT, V110, P621; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CHOU TB, 1992, IN PRESS GENETICS; DEGELMANN A, 1986, DEV BIOL, V115, P479, DOI 10.1016/0012-1606(86)90268-X; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; DURA JM, 1987, CELL, V51, P829, DOI 10.1016/0092-8674(87)90106-1; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; EDGAR BA, 1990, CELL, V62, P469, DOI 10.1016/0092-8674(90)90012-4; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FYRBERG EA, 1983, CELL, V33, P115, DOI 10.1016/0092-8674(83)90340-9; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; HAFEN E, 1984, CELL, V37, P833, DOI 10.1016/0092-8674(84)90418-5; HARIHARAN IK, 1991, P NATL ACAD SCI USA, V89, P1123; HULSKAMP M, 1989, NATURE, V338, P629, DOI 10.1038/338629a0; IRISH V, 1989, NATURE, V338, P646, DOI 10.1038/338646a0; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; Klingler M, 1990, Semin Cell Biol, V1, P151; KLINGLER M, 1988, NATURE, V335, P275, DOI 10.1038/335275a0; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; LINDSLEY D, 1987, DROS INF SERV, V65; LINDSLEY D, 1990, DROS INF SERV, V68; LINDSLEY D, 1986, DROS INF SERV, V64; LINDSLEY DL, 1985, DROS INF SERV, V62; LINDSLEY DL, 1968, CARNEGIE I WASH PUBL, V627; Maniatis T., 1982, MOL CLONING; MARK GE, 1987, MOL CELL BIOL, V7, P2134, DOI 10.1128/MCB.7.6.2134; MATTHEWS RJ, 1990, P NATL ACAD SCI USA, V87, P4444, DOI 10.1073/pnas.87.12.4444; MLODZIK M, 1987, GENE DEV, V1, P603, DOI 10.1101/gad.1.6.603; NISHIDA Y, 1988, EMBO J, V7, P775, DOI 10.1002/j.1460-2075.1988.tb02875.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; Perkins L A, 1991, In Vivo, V5, P521; PERRIMON N, 1985, GENETICS, V111, P23; PERRIMON N, 1986, GENETICS, V113, P695; PERRIMON N, 1984, DEV BIOL, V105, P404, DOI 10.1016/0012-1606(84)90297-5; PIGNONI F, 1990, CELL, V62, P151, DOI 10.1016/0092-8674(90)90249-E; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; ROBERTSON HM, 1988, GENETICS, V118, P461; ROUER E, 1989, GENE, V84, P105, DOI 10.1016/0378-1119(89)90144-3; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUPBACH T, 1986, ROUX ARCH DEV BIOL, V195, P302, DOI 10.1007/BF00376063; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SIEGFRIED E, 1990, TRENDS GENET, V6, P357, DOI 10.1016/0168-9525(90)90277-D; SMOUSE D, 1988, GENE DEV, V2, P830, DOI 10.1101/gad.2.7.830; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; STEVENS LM, 1990, NATURE, V346, P660, DOI 10.1038/346660a0; STJOHNSTON D, 1992, CELL, V68, P201; STRECKER TR, 1989, SCIENCE, V243, P1062, DOI 10.1126/science.2922596; STRECKER TR, 1988, DEVELOPMENT, V102, P721; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; STRUHL G, 1989, NATURE, V338, P741, DOI 10.1038/338741a0; TAUTZ D, 1987, NATURE, V327, P383, DOI 10.1038/327383a0; TAUTZ D, 1988, NATURE, V332, P281, DOI 10.1038/332281a0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; TIAN SS, 1991, CELL, V67, P675, DOI 10.1016/0092-8674(91)90063-5; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Van der Meer JM., 1977, DROS INFORM SERV, V52, P160; VEILLETTE A, 1992, TRENDS GENET, V8, P61, DOI 10.1016/0168-9525(92)90045-6; WEIGEL D, 1990, SCIENCE, V248, P495, DOI 10.1126/science.2158673; WEIGEL D, 1989, CELL, V57, P645, DOI 10.1016/0092-8674(89)90133-5; YANG XH, 1991, CELL, V67, P661, DOI 10.1016/0092-8674(91)90062-4; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836	83	374	379	0	0	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 24	1992	70	2					225	236		10.1016/0092-8674(92)90098-W	http://dx.doi.org/10.1016/0092-8674(92)90098-W			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JE757	1638629				2022-12-01	WOS:A1992JE75700007
J	SCHNEEWIND, O; MODEL, P; FISCHETTI, VA				SCHNEEWIND, O; MODEL, P; FISCHETTI, VA			SORTING OF PROTEIN-A TO THE STAPHYLOCOCCAL CELL-WALL	CELL			English	Article							ESCHERICHIA-COLI K-12; MEMBRANE-PROTEIN; OUTER-MEMBRANE; ENDOPLASMIC-RETICULUM; BACILLUS-SUBTILIS; TRANSMEMBRANE PROTEINS; ALKALINE-PHOSPHATASE; CYTOPLASMIC DOMAIN; LEADER PEPTIDASE; BINDING PROTEIN	The cell wall of gram-positive bacteria can be thought of as representing a unique cell compartment, which contains anchored surface proteins that require specific sorting signals. Some biologically important products are anchored in this way, including protein A and fibronectin binding protein of Staphylococcus aureus and streptococcal M protein. Studies of staphylococcal protein A and Escherichia coli alkaline phosphatase show that the signal both necessary and sufficient for cell wall anchoring consists of an LPXTGX motif, a C-terminal hydrophobic domain, and a charged tail. These sequence elements are conserved in many surface proteins from different gram-positive bacteria. We propose the existence of a hitherto undescribed sorting mechanism that positions proteins on the surface of gram-positive bacteria.			SCHNEEWIND, O (corresponding author), ROCKEFELLER UNIV,NEW YORK,NY 10021, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI011822, R01AI011822] Funding Source: NIH RePORTER; NIAID NIH HHS [AI11822] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHMSEN L, 1985, EMBO J, V4, P3901, DOI 10.1002/j.1460-2075.1985.tb04164.x; ANDERSSON H, 1991, P NATL ACAD SCI USA, V88, P9751, DOI 10.1073/pnas.88.21.9751; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BOSCH D, 1986, J MOL BIOL, V189, P449, DOI 10.1016/0022-2836(86)90316-5; BRAUN V, 1970, EUR J BIOCHEM, V14, P387, DOI 10.1111/j.1432-1033.1970.tb00301.x; BRAUN V, 1970, BIOCHEMISTRY-US, V9, P5041, DOI 10.1021/bi00828a001; BRAUN V, 1970, EUR J BIOCHEM, V13, P336, DOI 10.1111/j.1432-1033.1970.tb00936.x; BRISSETTE JL, 1990, J MOL BIOL, V211, P565, DOI 10.1016/0022-2836(90)90266-O; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; CHANG S, 1979, MOL GEN GENET, V168, P111, DOI 10.1007/BF00267940; CUTTING S, 1990, CELL, V62, P239, DOI 10.1016/0092-8674(90)90362-I; DATE T, 1981, P NATL ACAD SCI-BIOL, V78, P6106, DOI 10.1073/pnas.78.10.6106; DAVIS NG, 1985, CELL, V41, P607, DOI 10.1016/S0092-8674(85)80033-7; DAVIS NG, 1985, J MOL BIOL, V181, P111, DOI 10.1016/0022-2836(85)90329-8; FISCHETTI VA, 1990, MOL MICROBIOL, V4, P1603, DOI 10.1111/j.1365-2958.1990.tb02072.x; FREUDL R, 1985, EMBO J, V4, P3593, DOI 10.1002/j.1460-2075.1985.tb04122.x; GAREN A, 1955, VIROLOGY, V1, P347, DOI 10.1016/0042-6822(55)90030-1; GENNITY JM, 1991, J BIOL CHEM, V266, P16458; GETHING MJ, 1982, NATURE, V300, P598, DOI 10.1038/300598a0; GHUYSEN JM, 1968, BACTERIOL REV, V32, P425, DOI 10.1128/MMBR.32.4_Pt_2.425-464.1968; GOBER JW, 1991, CELL, V64, P381, DOI 10.1016/0092-8674(91)90646-G; GOMI H, 1990, J IMMUNOL, V144, P4046; GUSS B, 1984, EUR J BIOCHEM, V138, P413, DOI 10.1111/j.1432-1033.1984.tb07931.x; ITO K, 1981, CELL, V24, P707, DOI 10.1016/0092-8674(81)90097-0; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JOHNSON LM, 1987, CELL, V48, P875, DOI 10.1016/0092-8674(87)90084-5; JOSEFSSON LG, 1981, J BIOL CHEM, V256, P2504; KAUFMAN MR, 1991, GENE DEV, V5, P1834, DOI 10.1101/gad.5.10.1834; KLOSE M, 1988, J BIOL CHEM, V263, P13291; KORONAKIS V, 1991, EMBO J, V10, P3263, DOI 10.1002/j.1460-2075.1991.tb04890.x; KORONAKIS V, 1989, EMBO J, V8, P595, DOI 10.1002/j.1460-2075.1989.tb03414.x; KREISWIRTH BN, 1983, NATURE, V305, P709, DOI 10.1038/305709a0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUROKI K, 1989, MOL CELL BIOL, V9, P4459, DOI 10.1128/MCB.9.10.4459; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; LOEWY ZG, 1987, GENE DEV, V1, P626, DOI 10.1101/gad.1.6.626; LOFDAHL S, 1983, P NATL ACAD SCI-BIOL, V80, P697, DOI 10.1073/pnas.80.3.697; MACALISTER TJ, 1983, P NATL ACAD SCI-BIOL, V80, P1372, DOI 10.1073/pnas.80.5.1372; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; MCGOVERN K, 1991, J BIOL CHEM, V266, P20870; MODEL P, 1990, CELL, V61, P739, DOI 10.1016/0092-8674(90)90180-M; MOKS T, 1986, EUR J BIOCHEM, V156, P637, DOI 10.1111/j.1432-1033.1986.tb09625.x; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x; MURPHY E, 1981, PLASMID, V5, P292, DOI 10.1016/0147-619X(81)90006-8; NILSSON B, 1990, METHOD ENZYMOL, V185, P144; NILSSON B, 1985, EMBO J, V4, P1075, DOI 10.1002/j.1460-2075.1985.tb03741.x; NILSSON IM, 1990, CELL, V62, P1135, DOI 10.1016/0092-8674(90)90390-Z; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; NILSSON T, 1991, EMBO J, V10, P3567, DOI 10.1002/j.1460-2075.1991.tb04923.x; NOVICK R, 1967, VIROLOGY, V33, P155, DOI 10.1016/0042-6822(67)90105-5; Novick R.P., 1990, MOL BIOL STAPHYLOCOC; NOVICK RP, 1979, PLASMID, V2, P109, DOI 10.1016/0147-619X(79)90010-6; OLIVER DB, 1981, CELL, V25, P765, DOI 10.1016/0092-8674(81)90184-7; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; PARKS GD, 1991, CELL, V64, P777, DOI 10.1016/0092-8674(91)90507-U; PATEE PA, 1961, CAN J MICROBIOL, V82, P875; PELHAM HRB, 1988, EMBO J, V7, P1757, DOI 10.1002/j.1460-2075.1988.tb03005.x; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; PROJAN SJ, 1987, J BACTERIOL, V169, P5131, DOI 10.1128/jb.169.11.5131-5139.1987; PUGSLEY AP, 1990, MOL MICROBIOL, V4, P365, DOI 10.1111/j.1365-2958.1990.tb00604.x; RANDALL LL, 1989, SCIENCE, V243, P1156, DOI 10.1126/science.2646712; RANDALL LL, 1986, METHOD ENZYMOL, V125, P129; RANDALL LL, 1983, CELL, V33, P231, DOI 10.1016/0092-8674(83)90352-5; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SCHINDLER CA, 1964, P NATL ACAD SCI USA, V51, P414, DOI 10.1073/pnas.51.3.414; SCHNEEWIND O, 1990, J BACTERIOL, V172, P3310, DOI 10.1128/jb.172.6.3310-3317.1990; SHOCKMAN GD, 1983, ANNU REV MICROBIOL, V37, P501, DOI 10.1146/annurev.mi.37.100183.002441; SHORTLE D, 1983, GENE, V22, P181, DOI 10.1016/0378-1119(83)90102-6; SHUTTLEWORTH H, 1986, NUCLEIC ACIDS RES, V14, P8689, DOI 10.1093/nar/14.21.8689; SJODAHL J, 1977, EUR J BIOCHEM, V78, P471, DOI 10.1111/j.1432-1033.1977.tb11760.x; SJODAHL J, 1977, EUR J BIOCHEM, V73, P343, DOI 10.1111/j.1432-1033.1977.tb11324.x; SJOQUIST J, 1972, EUR J BIOCHEM, V29, P572, DOI 10.1111/j.1432-1033.1972.tb02023.x; SJOQUIST J, 1972, EUR J BIOCHEM, V30, P190, DOI 10.1111/j.1432-1033.1972.tb02086.x; STANLEY P, 1991, MOL MICROBIOL, V5, P2391, DOI 10.1111/j.1365-2958.1991.tb02085.x; STIRZAKER SC, 1989, CELL, V56, P741, DOI 10.1016/0092-8674(89)90677-6; STROM MS, 1987, J BACTERIOL, V169, P3181, DOI 10.1128/jb.169.7.3181-3188.1987; TAKESHITA S, 1987, GENE, V61, P63, DOI 10.1016/0378-1119(87)90365-9; TWETEN RK, 1983, J BACTERIOL, V153, P297, DOI 10.1128/JB.153.1.297-303.1983; UHLEN M, 1984, J BACTERIOL, V159, P713; UHLEN M, 1984, J BIOL CHEM, V259, P1695; VALLS LA, 1987, CELL, V48, P887, DOI 10.1016/0092-8674(87)90085-7; VANDERIJN I, 1980, INFECT IMMUN, V27, P444, DOI 10.1128/IAI.27.2.444-448.1980; VONHEIJNE G, 1988, P NATL ACAD SCI USA, V85, P3363; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; WU CH, 1971, INFECT IMMUN, V3, P784, DOI 10.1128/IAI.3.6.784-792.1971; YAMAGUCHI K, 1988, CELL, V53, P423, DOI 10.1016/0092-8674(88)90162-6; YU F, 1984, J BIOL CHEM, V259, P6013	93	444	466	0	26	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 24	1992	70	2					267	281		10.1016/0092-8674(92)90101-H	http://dx.doi.org/10.1016/0092-8674(92)90101-H			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JE757	1638631				2022-12-01	WOS:A1992JE75700010
J	TEPPER, RI; COFFMAN, RL; LEDER, P				TEPPER, RI; COFFMAN, RL; LEDER, P			AN EOSINOPHIL-DEPENDENT MECHANISM FOR THE ANTITUMOR EFFECT OF INTERLEUKIN-4	SCIENCE			English	Article							LYMPHOCYTES	Murine interleukin-4 (IL-4) exhibits potent antitumor activity when present at the site of tumor cell challenge. Associated with tumor cell death is the appearance of an inflammatory infiltrate comprised predominantly of eosinophils and macrophages, but with few lymphocytes. Antibodies that specifically block the accumulation of granulocytes at the site of inflammation were injected in vivo to define the cell type responsible for the antitumor action of IL-4. These studies implicate eosinophils in IL-4-mediated tumor cytotoxicity. The lymphoid-independent nature of IL-4 action is supported by the analysis of mutant mouse strains with defined lymphocyte immunodeficiencies. The observed regression of established tumor masses by localized IL-4 action provides a rationale for exploring IL-4-mediated tumor killing as a potential therapy for human malignant disorders.	DNAX RES INST MOLEC & CELLULAR BIOL INC,PALO ALTO,CA 94304; HOWARD HUGHES MED INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Howard Hughes Medical Institute; Harvard University; Harvard Medical School	TEPPER, RI (corresponding author), MASSACHUSETTS GEN HOSP,CTR CANC,BOSTON,MA 02114, USA.							COFFMAN RL, 1989, SCIENCE, V245, P308, DOI 10.1126/science.2787531; COLEY DG, 1972, EXP PARASITOL, V32, P520; GOLUMBEK PT, 1991, SCIENCE, V254, P713, DOI 10.1126/science.1948050; LEWINSOHN DM, 1987, J IMMUNOL, V138, P4313; LICHTMAN AH, 1987, P NATL ACAD SCI USA, V84, P824, DOI 10.1073/pnas.84.3.824; PENNLINE KJ, 1990, CYTOMETRY, V11, P823; SCHREIBER H, 1989, FUNDAMENTAL IMMUNOLO, P927; TEPPER RI, 1989, CELL, V57, P503, DOI 10.1016/0092-8674(89)90925-2	8	503	512	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 24	1992	257	5069					548	551		10.1126/science.1636093	http://dx.doi.org/10.1126/science.1636093			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JE755	1636093				2022-12-01	WOS:A1992JE75500035
J	VELAZQUEZ, L; FELLOUS, M; STARK, GR; PELLEGRINI, S				VELAZQUEZ, L; FELLOUS, M; STARK, GR; PELLEGRINI, S			A PROTEIN TYROSINE KINASE IN THE INTERFERON-ALPHA/BETA SIGNALING PATHWAY	CELL			English	Article							INDUCED NUCLEAR FACTORS; DOUBLE-STRANDED-RNA; TRANSCRIPTIONAL ACTIVATION; STIMULATED TRANSCRIPTION; PROMOTER ELEMENT; RESPONSE ELEMENT; SYNTHETASE GENE; DNA; BINDING; GAMMA	The mutant human cell line 11,1 is unresponsive to interferon-alpha. Here we describe the genetic complementation of this mutant and the identification and cloning of the wild-type gene that corrects the defect. Using transfection with genomic DNA in conjunction with a powerful back-selection, we isolated a cosmid that reverts the mutant phenotype of 11,1 cells. The cosmid encodes a single message whose level is greatly reduced in mutant cells. Complementary DNAs were cloned and found to be virtually identical to tyk2, a human mRNA encoding a non-receptor protein tyrosine kinase of previously unknown function. This finding shows that tyk2 links the interferon alpha/beta-receptor to the cytoplasmic transcription factor that mediates activation of interferon-responsive genes.	IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND	Cancer Research UK	VELAZQUEZ, L (corresponding author), INST PASTEUR, INSERM, U276, F-75724 PARIS 15, FRANCE.		Pellegrini, Sandra/Y-6351-2019; Pellegrini, Sandra -/G-5546-2015	Pellegrini, Sandra/0000-0001-5837-7589; Pellegrini, Sandra -/0000-0001-5837-7589				ALLEN G, 1982, J GEN VIROL, V63, P207, DOI 10.1099/0022-1317-63-1-207; ATWATER JA, 1990, ANNU REV GENET, V24, P519; BERNARDS A, 1991, ONCOGENE, V6, P1185; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COBB BS, 1991, MOL CELL BIOL, V11, P5832, DOI 10.1128/MCB.11.12.5832; COHEN B, 1988, EMBO J, V7, P1411, DOI 10.1002/j.1460-2075.1988.tb02958.x; DALE TC, 1989, P NATL ACAD SCI USA, V86, P1203, DOI 10.1073/pnas.86.4.1203; DALE TC, 1989, EMBO J, V8, P831, DOI 10.1002/j.1460-2075.1989.tb03444.x; DECKER T, 1991, MOL CELL BIOL, V11, P5147, DOI 10.1128/MCB.11.10.5147; DELUCA JG, 1977, MUTAT RES, V46, P11, DOI 10.1016/0165-1161(77)90106-6; Demaeyer E., 1988, INTERFERONS OTHER RE; FAN XD, 1988, P NATL ACAD SCI USA, V85, P5122, DOI 10.1073/pnas.85.14.5122; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; FRIEDMAN RL, 1985, NATURE, V314, P637, DOI 10.1038/314637a0; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; GOLDFARB M, 1982, NATURE, V296, P404, DOI 10.1038/296404a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HUNTER T, 1991, METHOD ENZYMOL, V200, P3; JOHN J, 1991, MOL CELL BIOL, V11, P4189, DOI 10.1128/MCB.11.8.4189; KESSLER DS, 1991, J BIOL CHEM, V266, P23471; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; KROLEWSKI JJ, 1990, ONCOGENE, V5, P277; LANGER JA, 1988, IMMUNOL TODAY, V9, P393, DOI 10.1016/0167-5699(88)91241-8; LEVY D, 1990, New Biologist, V2, P923; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEVY DE, 1990, EMBO J, V9, P1105, DOI 10.1002/j.1460-2075.1990.tb08216.x; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LEW DJ, 1989, MOL CELL BIOL, V9, P5404, DOI 10.1128/MCB.9.12.5404; LITT M, 1985, P NATL ACAD SCI USA, V82, P6206, DOI 10.1073/pnas.82.18.6206; Maniatis T., 1982, MOL CLONING; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; MERLIN G, 1985, J GEN VIROL, V66, P1149, DOI 10.1099/0022-1317-66-5-1149; MOGENSEN KE, 1989, EXPERIENTIA, V45, P500, DOI 10.1007/BF01990498; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; PERUCHO M, 1980, NATURE, V285, P207, DOI 10.1038/285207a0; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PFEFFER LM, 1990, P NATL ACAD SCI USA, V87, P6537, DOI 10.1073/pnas.87.17.6537; PORTER ACG, 1988, EMBO J, V7, P85, DOI 10.1002/j.1460-2075.1988.tb02786.x; REICH NC, 1990, P NATL ACAD SCI USA, V87, P8761, DOI 10.1073/pnas.87.22.8761; REID LE, 1989, P NATL ACAD SCI USA, V86, P840, DOI 10.1073/pnas.86.3.840; Ruddle F. H., 1984, GENETIC ENG, V6, P319; RUTHERFORD MN, 1988, EMBO J, V7, P751, DOI 10.1002/j.1460-2075.1988.tb02872.x; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; TIWARI RK, 1988, MOL CELL BIOL, V8, P4289, DOI 10.1128/MCB.8.10.4289; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; Wahl G. M., 1987, METHOD ENZYMOL, V152, P199; WATHELET MG, 1989, EUR J BIOCHEM, V184, P503, DOI 10.1111/j.1432-1033.1989.tb15043.x; WILBUR WJ, 1983, P NATL ACAD SCI-BIOL, V80, P726, DOI 10.1073/pnas.80.3.726; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WILLIAMS BRG, 1991, EUR J BIOCHEM, V200, P1, DOI 10.1111/j.1432-1033.1991.tb21041.x	59	774	814	0	5	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 24	1992	70	2					313	322		10.1016/0092-8674(92)90105-L	http://dx.doi.org/10.1016/0092-8674(92)90105-L			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JE757	1386289				2022-12-01	WOS:A1992JE75700014
J	AMIGORENA, S; SALAMERO, J; DAVOUST, J; FRIDMAN, WH; BONNEROT, C				AMIGORENA, S; SALAMERO, J; DAVOUST, J; FRIDMAN, WH; BONNEROT, C			TYROSINE-CONTAINING MOTIF THAT TRANSDUCES CELL ACTIVATION SIGNALS ALSO DETERMINES INTERNALIZATION AND ANTIGEN PRESENTATION VIA TYPE-III RECEPTORS FOR IGG	NATURE			English	Article							LAMBDA-REPRESSOR; ENDOCYTOSIS; MACROPHAGE; ANTIBODIES; MOLECULES	TYPE III receptors for IgG (Fc-gamma-RII; ref. 1), high-affinity IgE receptors (Fc-epsilon-RI; ref. 2), as well as the T- and B-cell antigen receptors3,4, consist of multiple components with specialized ligand-binding and signal transduction functions5-10. Fc-gamma-RII-alpha (ligand-binding) and gamma (signal-transducing) subunits are expressed in macrophages1, a cell type involved in the uptake of antigen, its processing and the presentation of the resulting peptides to major histocompatibility complex class II-restricted T lymphocytes11,12. Here we show that murine Fc-gamma-RIII, transfected into Fc-gamma-R-negative antigen-presenting B-lymphoma cells, mediate rapid ligand internalization and strongly increase the efficiency of antigen presentation when antigen is complexed to IgG. Efficient internalization and antigen presentation via Fc-gamma-RIII did not require the cytoplasmic domain of the ligand-binding alpha-chain, but did require the gamma-subunit. Using chimaeric molecules, we show that gamma-chain contains a signal for receptor internalization and that the mutation of either of the two tyrosine residues present in its cytoplasmic domain prevents efficient internalization and antigen presentation of immune complexes. Thus, associated chains and their tyrosine-containing motif are not exclusively involved in cell activation, but also determine multimeric receptor internalization.	INST CURIE, INSERM, U255, IMMUNOL CELLULAIRE & CLIN LAB, F-75005 PARIS, FRANCE; CTR IMMUNOL MARSEILLE LUMINY, CNRS, INSERM, F-13288 MARSEILLE 9, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite				fridman, wolf herman/0000-0002-1332-0973; salamero, jean/0000-0002-2610-5826; Davoust, Jean/0000-0002-3098-7665; Amigorena, Sebastian/0000-0001-8583-8416				AMIGORENA S, 1992, SCIENCE, V256, P1808, DOI 10.1126/science.1535455; BONNEROT C, 1992, EMBO J, V11, P2747, DOI 10.1002/j.1460-2075.1992.tb05340.x; BREYER RM, 1989, J BIOL CHEM, V264, P13348; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; DRAKE JR, 1989, J IMMUNOL, V143, P1768; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; HAIGLER HT, 1980, J BIOL CHEM, V255, P1239; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; ISERSKY C, 1983, J IMMUNOL, V131, P388; JONES B, 1986, J IMMUNOL, V136, P348; JUSTEMENT LB, 1989, J IMMUNOL, V143, P881; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; KSITAKIS NT, 1990, J CELL BIOL, V111, P1393; LAI MZ, 1987, J IMMUNOL, V139, P3973; LANZAVECCHIA A, 1990, ANNU REV IMMUNOL, V8, P773, DOI 10.1146/annurev.immunol.8.1.773; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; NOMURA J, 1991, INT IMMUNOL, V3, P117, DOI 10.1093/intimm/3.2.117; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; SALAMERO J, 1990, EMBO J, V9, P3489, DOI 10.1002/j.1460-2075.1990.tb07557.x; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; UNANUE ER, 1984, ANNU REV IMMUNOL, V2, P395, DOI 10.1146/annurev.iy.02.040184.002143; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; VENKITARAMAN AR, 1991, NATURE, V352, P777, DOI 10.1038/352777a0; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T	26	164	168	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 23	1992	358	6384					337	341		10.1038/358337a0	http://dx.doi.org/10.1038/358337a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JE684	1386408				2022-12-01	WOS:A1992JE68400066
J	AWGULEWITSCH, A; JACOBS, D				AWGULEWITSCH, A; JACOBS, D			DEFORMED AUTOREGULATORY ELEMENT FROM DROSOPHILA FUNCTIONS IN A CONSERVED MANNER IN TRANSGENIC MICE	NATURE			English	Article							CENTRAL-NERVOUS-SYSTEM; DIFFERENTIAL EXPRESSION; HOMEOTIC GENES; HINDBRAIN; ORGANIZATION; HOX-1.4; DOMAINS; MURINE; REGION; HOX	THE striking similarities in the structure, organization and anterior-posterior expression patterns between the murine Hox gene system and the Drosophila homeotic gene complexes1,2, called HOM-C (ref. 3), may point to highly conserved mechanisms for specifying positional identities (reviewed in ref. 4). Strong support for this concept lies in the observation of conserved colinearity between the genomic order of the Hox/HOM genes and their unique successive expression domains along the anterior-posterior axes of both mouse and fly embryos1,2. These unique and precise expression patterns appear to be facilitated by multiple cis-regulatory elements (reviewed in ref. 5). One of the few elements characterized in detail is the autoregulatory enhancer of the homeotic gene Deformed (Dfd)6-9, which supports expression in subregions of posterior head segments of Drosophila embryos7. Here we present evidence that this enhancer is capable of conferring reporter gene expression to a discrete subregion of the hindbrain in transgenic mouse embryos. Remarkably, this anterior-posterior subregion lies within the common anterior expression domain of the Dfd cognate Hox genes in the postotic hindbrain10,11. Our results indicate that the Dfd autoregulatory enhancer is part of a highly conserved mechanism for establishing region-specific gene expression along the anterior-posterior axis of the embryo.			AWGULEWITSCH, A (corresponding author), MED UNIV S CAROLINA,DEPT BIOCHEM & MOLEC BIOL,171 ASHLEY AVE,CHARLESTON,SC 29425, USA.							AKAM M, 1989, CELL, V57, P347, DOI 10.1016/0092-8674(89)90909-4; AKAM M, 1988, DEVELOPMENT, V104, P123; AWGULEWITSCH A, 1990, P NATL ACAD SCI USA, V87, P6428, DOI 10.1073/pnas.87.16.6428; AWGULEWITSCH A, 1990, DEVELOPMENT, V108, P411; AWGULEWITSCH A, 1991, METHODS NUCLEIC ACID, P359; BERGSON C, 1990, EMBO J, V9, P4287, DOI 10.1002/j.1460-2075.1990.tb07877.x; BIEBERICH CJ, 1990, P NATL ACAD SCI USA, V87, P8462, DOI 10.1073/pnas.87.21.8462; Dessain S, 1991, CURR OPIN GENET DEV, V1, P275, DOI 10.1016/S0959-437X(05)80082-6; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; FALB D, 1992, GENE DEV, V6, P454, DOI 10.1101/gad.6.3.454; GAUNT SJ, 1989, DEVELOPMENT, V107, P131; GORDON JW, 1983, METHOD ENZYMOL, V101, P411; GRAHAM A, 1991, DEVELOPMENT, V112, P255; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; Hogan B., 1986, MANIPULATING MOUSE E; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; KEYNES R, 1990, NEURON, V2, P1; LUMSDEN A, 1990, TRENDS NEUROSCI, V13, P329, DOI 10.1016/0166-2236(90)90144-Y; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; MALICKI J, 1992, NATURE, V358, P345, DOI 10.1038/358345a0; Maniatis T., 1982, MOL CLONING; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; McGinnis W, 1990, Adv Genet, V27, P363; REGULSKI M, 1987, EMBO J, V6, P767, DOI 10.1002/j.1460-2075.1987.tb04819.x; REGULSKI M, 1991, GENE DEV, V5, P278, DOI 10.1101/gad.5.2.278; RUGH R, 1990, MOUSE ITS REPRODUCTI; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TUGGLE CK, 1990, GENE DEV, V4, P180, DOI 10.1101/gad.4.2.180; WHITING J, 1991, GENE DEV, V5, P2048, DOI 10.1101/gad.5.11.2048; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0; WOLGEMUTH DJ, 1987, P NATL ACAD SCI USA, V84, P5813, DOI 10.1073/pnas.84.16.5813; WOLGEMUTH DJ, 1986, EMBO J, V5, P1229, DOI 10.1002/j.1460-2075.1986.tb04351.x; ZAKANY J, 1988, NEURON, V1, P679, DOI 10.1016/0896-6273(88)90167-5	33	71	71	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 23	1992	358	6384					341	344		10.1038/358341a0	http://dx.doi.org/10.1038/358341a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JE684	1353608				2022-12-01	WOS:A1992JE68400067
J	GETZOFF, ED; CABELLI, DE; FISHER, CL; PARGE, HE; VIEZZOLI, MS; BANCI, L; HALLEWELL, RA				GETZOFF, ED; CABELLI, DE; FISHER, CL; PARGE, HE; VIEZZOLI, MS; BANCI, L; HALLEWELL, RA			FASTER SUPEROXIDE-DISMUTASE MUTANTS DESIGNED BY ENHANCING ELECTROSTATIC GUIDANCE	NATURE			English	Article							PULSE RADIOLYSIS; COPPER; ENZYME; SIMULATION; MECHANISM; DIFFUSION; SUBSTRATE; SEQUENCE; PROTEIN; SITE	THE enzyme Cu, Zn superoxide dismutase (SOD) protects against oxidative damage by dismuting the superoxide radical O2.- to molecular oxygen and hydrogen peroxide1-3 at the active-site Cu ion4,5 in a reaction that is rate-limited by diffusion3,6 and enhanced by electrostatic guidance7-10. SOD has evolved to be one of the fastest enzymes known (V(max) approximately 2 x 10(9) M-1 s-1)6,11. The new crystal structures of human SOD12 show that amino-acid site chains that are implicated in electrostatic guidance8 (Glu 132, Glu 133 and Lys 136) form a hydrogen-bonding network. Here we show that site-specific mutants that increase local positive charge while maintaining this orienting network (Glu --> Gln) have faster reaction rates and increased ionic-strength dependence, matching brownian dynamics simulations incorporating electrostatic terms. Increased positive charge alone is insufficient: one charge reversal (Glu --> Lys) mutant is slower than the equivalent charge neutralization (Glu --> Gln) mutant, showing that the newly introduced positive charge disrupts the orienting network. Thus, electrostatically facilitated diffusion rates can be increased by design, provided the detailed structural integrity of the active-site electrostatic network is maintained.	BROOKHAVEN NATL LAB, DEPT CHEM, LONG ISL, NY 11973 USA; UNIV FLORENCE, DEPT CHEM, I-50121 FLORENCE, ITALY; CHIRON CORP, EMERYVILLE, CA 94608 USA	United States Department of Energy (DOE); Brookhaven National Laboratory; University of Florence; Novartis	GETZOFF, ED (corresponding author), SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA.			BANCI, LUCIA/0000-0003-0562-5774				ALBERTY RA, 1958, J PHYS CHEM-US, V62, P154, DOI 10.1021/j150560a005; ALLISON SA, 1988, BIOPOLYMERS, V27, P251, DOI 10.1002/bip.360270207; ARGESE E, 1987, BIOCHEMISTRY-US, V26, P3224, DOI 10.1021/bi00385a043; BANCI L, 1990, INORG CHEM, V29, P2398, DOI 10.1021/ic00338a004; BEYER WF, 1987, J BIOL CHEM, V262, P11182; BUCHEL DE, 1980, NATURE, V283, P541, DOI 10.1038/283541a0; CUDD A, 1982, J BIOL CHEM, V257, P1443; DAVIS ME, 1991, J COMPUT CHEM, V12, P909, DOI 10.1002/jcc.540120718; FRIDOVICH I, 1986, ADV ENZYMOL RAMB, V58, P61; GETZOFF ED, 1989, PROTEINS, V5, P322, DOI 10.1002/prot.340050408; GETZOFF ED, 1983, NATURE, V306, P287, DOI 10.1038/306287a0; GEYSEN HM, 1987, SCIENCE, V235, P1184, DOI 10.1126/science.3823878; HALLEWELL RA, 1991, BIOCHEM BIOPH RES CO, V181, P474, DOI 10.1016/S0006-291X(05)81443-3; HALLEWELL RA, 1989, J BIOL CHEM, V264, P5260; HALLEWELL RA, 1985, NUCLEIC ACIDS RES, V13, P2017, DOI 10.1093/nar/13.6.2017; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; KLUG D, 1972, J BIOL CHEM, V247, P4839; Koppenol W.H., 1981, OXYGEN OXYRADICALS C, P671; KOSHLAND D, 1980, CELL, V20, P749, DOI 10.1016/0092-8674(80)90321-9; LEPOCK JR, 1990, J BIOL CHEM, V265, P21612; PARGE HE, IN PRESS P NATN ACAD; ROTILIO G, 1972, BIOCHIM BIOPHYS ACTA, V268, P605, DOI 10.1016/0005-2744(72)90359-2; SCHWARZ HA, 1981, J CHEM EDUC, V58, P101, DOI 10.1021/ed058p101; SHARP K, 1987, SCIENCE, V236, P1460, DOI 10.1126/science.3589666; SHEN J, 1991, CHEM PHYS, V158, P191, DOI 10.1016/0301-0104(91)87066-5; SINES JJ, 1990, BIOCHEMISTRY-US, V29, P9403, DOI 10.1021/bi00492a014; STEINMAN HM, 1987, J BIOL CHEM, V262, P1882; TAINER JA, 1982, J MOL BIOL, V160, P181, DOI 10.1016/0022-2836(82)90174-7; TAINER JA, 1983, NATURE, V306, P284, DOI 10.1038/306284a0; TAINER JA, 1991, STUDY ENZYMES, V2, P499; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051	32	363	367	0	30	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 23	1992	358	6384					347	351		10.1038/358347a0	http://dx.doi.org/10.1038/358347a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JE684	1353610				2022-12-01	WOS:A1992JE68400069
J	HAUGHN, L; GRATTON, S; CARON, L; SEKALY, RP; VEILLETTE, A; JULIUS, M				HAUGHN, L; GRATTON, S; CARON, L; SEKALY, RP; VEILLETTE, A; JULIUS, M			ASSOCIATION OF TYROSINE KINASE P56(LCK) WITH CD4 INHIBITS THE INDUCTION OF GROWTH THROUGH THE ALPHA-BETA T-CELL RECEPTOR	NATURE			English	Article							ANTIGEN RECEPTOR; LYMPHOCYTES-T; SIGNAL TRANSDUCTION; MONOCLONAL-ANTIBODY; CROSS-LINKING; L3T4 MOLECULE; ACTIVATION; P56LCK; EXPRESSION; COMPLEX	THE membrane glycoprotein CD4 enhances antigen-mediated activation of T cells restricted by class II molecules of the major histocompatibility complex (MHC)1-3. This positive function has been attributed to the protein tyrosine kinase p56lck (ref. 4), which is noncovalently associated with the cytoplasmic portion of CD45,6, and is activated on CD4 aggregation7. Antigen presentation by MHC class II molecules coaggregates CD4 and the T-cell antigen receptor (TCR-alpha-beta-CD3)8. Thus, the mutual specificity of CD4 and TCR-alpha-beta for the MHC-antigen complex results in the juxtaposition of p56lck and TCRalpha-beta-CD39-13. In contrast, antibodies can abrogate antigen-induced14-17, as well as anti induced18-20 T-cell activation, indicating that CD4 might also transduce negative signals. The molecular basis for this opposing function remains unclear. Here we show that the CD4-p56lck complex prohibits the induction of activation signals through the TCR-CD3 complex when not specifically included in the signalling process. This negative effect does not require anti-CD4 treatment, indicating that the induction of distinct negative signals is probably not involved. Rather, the results demonstrate that the CD4-p56lck complex provides prerequisite signals for antigen-receptor-induced T-cell growth and thus characterize a molecular mechanism for functional constraints imposed on T-cell activation by the MHC.	MCGILL UNIV, DEPT MICROBIOL & IMMUNOL, 3775 UNIV ST, MONTREAL H3A 2B4, QUEBEC, CANADA; MCGILL UNIV, DEPT MED, MONTREAL H3G 1Y6, QUEBEC, CANADA; MCGILL UNIV, DEPT BIOCHEM, MONTREAL H3G 1Y6, QUEBEC, CANADA; INST RECH CLIN MONTREAL, IMMUNOL LAB, MONTREAL H2W 1R7, QUEBEC, CANADA; MCGILL UNIV, DEPT ONCOL, MONTREAL H3G 1Y6, QUEBEC, CANADA	McGill University; McGill University; McGill University; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; McGill University								ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; ANDERSON P, 1987, J IMMUNOL, V139, P678; BANK I, 1985, J EXP MED, V162, P1294, DOI 10.1084/jem.162.4.1294; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; BHATTACHARYA A, 1981, J IMMUNOL, V127, P2488; BIDDISON WE, 1982, J EXP MED, V156, P1065, DOI 10.1084/jem.156.4.1065; BURGESS KE, 1991, EUR J IMMUNOL, V21, P1663, DOI 10.1002/eji.1830210712; CAMBIER JC, 1988, SCAND J IMMUNOL, V27, P59, DOI 10.1111/j.1365-3083.1988.tb02323.x; CHUCK RS, 1990, P NATL ACAD SCI USA, V87, P5021, DOI 10.1073/pnas.87.13.5021; DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0; EMMRICH F, 1987, EUR J IMMUNOL, V17, P529, DOI 10.1002/eji.1830170415; FINKEL TH, 1989, J IMMUNOL, V142, P3006; FLEURY S, 1991, CELL, V66, P1037, DOI 10.1016/0092-8674(91)90447-7; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KUBO RT, 1989, J IMMUNOL, V142, P2736; KUPFER A, 1987, P NATL ACAD SCI USA, V84, P5888, DOI 10.1073/pnas.84.16.5888; Ledbetter J A, 1990, Semin Immunol, V2, P99; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; MARRACK P, 1983, J EXP MED, V158, P1077, DOI 10.1084/jem.158.4.1077; MOLDWIN RL, 1987, J IMMUNOL, V139, P657; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; NEWELL MK, 1990, NATURE, V347, P286, DOI 10.1038/347286a0; OWENS T, 1987, P NATL ACAD SCI USA, V84, P9209, DOI 10.1073/pnas.84.24.9209; PIERRES A, 1984, J IMMUNOL, V132, P2775; ROSOFF PM, 1987, CELL, V49, P845, DOI 10.1016/0092-8674(87)90622-2; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SLECKMAN BP, 1987, NATURE, V328, P351, DOI 10.1038/328351a0; SPRINGER TA, 1980, MONOCLONAL ANTIBODIE, P185; TEH HS, 1991, NATURE, V349, P241, DOI 10.1038/349241a0; TOMONARI K, 1990, IMMUNOGENETICS, V31, P333, DOI 10.1007/BF02115007; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VANOERS NSC, 1992, EUR J IMMUNOL, V22, P735, DOI 10.1002/eji.1830220317; VEILLETTE A, 1990, ONCOGENE, V5, P1455; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WASSMER P, 1985, J IMMUNOL, V135, P2237; WILLIAMS DA, 1984, NATURE, V310, P476, DOI 10.1038/310476a0	45	147	150	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 23	1992	358	6384					328	331		10.1038/358328a0	http://dx.doi.org/10.1038/358328a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JE684	1322497				2022-12-01	WOS:A1992JE68400063
J	KIM, SJ; WAGNER, S; LIU, F; OREILLY, MA; ROBBINS, PD; GREEN, MR				KIM, SJ; WAGNER, S; LIU, F; OREILLY, MA; ROBBINS, PD; GREEN, MR			RETINOBLASTOMA GENE-PRODUCT ACTIVATES EXPRESSION OF THE HUMAN TGF-BETA-2 GENE THROUGH TRANSCRIPTION FACTOR ATF-2	NATURE			English	Article							PROTEIN; BINDING; GROWTH; FAMILY; BETA	THE retinoblastoma susceptibility gene product (pRb) plays an important role in constraining cellular proliferation and in regulating the cell cycle1,2. The pRb inhibits transcription of genes involved in growth control (reviewed in ref. 3) and can regulate transforming growth factor beta-1 (TGF-beta-1) gene expression4,5. TGF-beta isoforms also down-regulate cellular proliferation6,7. To determine whether pRb also regulates expression of other TGF-beta isoforms, we examined the effect of pRb on the expression of the human TGF-beta-2 gene. The human TGF-beta-2 promoter contains multiple elements including an ATF site, which is essential for basal promoter activity8. Here we report that pRb activates transcription of the human TGF-beta-2 gene. The promoter element responsible for pRb-mediated transcriptional regulation is a binding site for ATF proteins, an extensive transcription factor family9. We provide evidence that implicates ATF-2 in pRb-responsiveness. First, the ATF promoter element in the TGF-beta-2 gene is a high-affinity ATF-2-binding site. Second, a GAL4-ATF2 fusion protein can support pRb-mediated transcriptional activation of a promoter containing GAL4-binding sites. Third, ATF-2 in nuclear extracts can interact with pRb. Our results reveal a new mechanism by which pRb constrains cellular proliferation: by activating ex ression of the inhibitory growth factor, TGF-beta-2.	UNIV MASSACHUSETTS,MED CTR,PROGRAM MOLEC MED,WORCESTER,MA 01605; UNIV PITTSBURGH,SCH MED,DEPT MOLEC GENET & BIOCHEM,PITTSBURGH,PA 15261	University of Massachusetts System; University of Massachusetts Worcester; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	KIM, SJ (corresponding author), NCI,CHEMOPREVENT LAB,BETHESDA,MD 20892, USA.							BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; GAUL U, 1987, CELL, V50, P639, DOI 10.1016/0092-8674(87)90037-7; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; Noma T, 1991, GROWTH FACTORS, V4, P247, DOI 10.3109/08977199109043910; RIO DC, 1986, CELL, V44, P21, DOI 10.1016/0092-8674(86)90481-2; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; RUSSELL WE, 1988, P NATL ACAD SCI USA, V85, P5126, DOI 10.1073/pnas.85.14.5126; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SILBERSTEIN GB, 1987, SCIENCE, V237, P291, DOI 10.1126/science.3474783; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; WAGNER S, 1991, NATURE, V352, P189, DOI 10.1038/352189a0	22	253	257	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 23	1992	358	6384					331	334		10.1038/358331a0	http://dx.doi.org/10.1038/358331a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JE684	1641004				2022-12-01	WOS:A1992JE68400064
J	LAU, J; ANTMAN, EM; JIMENEZSILVA, J; KUPELNICK, B; MOSTELLER, F; CHALMERS, TC				LAU, J; ANTMAN, EM; JIMENEZSILVA, J; KUPELNICK, B; MOSTELLER, F; CHALMERS, TC			CUMULATIVE METAANALYSIS OF THERAPEUTIC TRIALS FOR MYOCARDIAL-INFARCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED CLINICAL-TRIALS; CORONARY HEART-DISEASE; SCIENTIFIC DISCIPLINE; THROMBOLYTIC THERAPY; PUBLICATION BIAS; MORTALITY; STREPTOKINASE; INTRACORONARY; LONG; REHABILITATION	Background. The large volume of published randomized, controlled trials has led to a need for meta-analyses to track therapeutic advances. Performing a new meta-analysis whenever the results of a new trial of a particular therapy are published permits the study of trends in efficacy and makes it possible to determine when a new treatment appears to be significantly effective or deleterious. We describe the use of such a procedure, cumulative meta-analysis, to assess therapeutic trials among patients with myocardial infarction. Methods. We performed cumulative meta-analyses of clinical trials that evaluated 15 treatments and preventive measures for acute myocardial infarction. Results. An example of this method is its application to the use of intravenous streptokinase as thrombolytic therapy for acute infarction. Thirty-three trials evaluating this therapy were performed between 1959 and 1988. We found that a consistent, statistically significant reduction in total mortality (odds ratio, 0.74; 95 percent confidence interval, 0.59 to 0.92) was achieved in 1973, after only eight trials involving 2432 patients had been completed. The results of the 25 subsequent trials, which enrolled an additional 34,542 patients through 1988, had little or no effect on the odds ratio establishing efficacy, but simply narrowed the 95 percent confidence interval. In particular, two very large trials, the Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico trial in 1986 (11,712 patients) and the Second International Study of Infarct Survival trial in 1988 (17,187 patients) did not modify the already established evidence of efficacy. We used a similar approach to study the accumulating evidence of efficacy (or lack of efficacy) of 14 other therapies and preventive measures for myocardial infarction. Conclusions. Cumulative meta-analysis of therapeutic trials facilitates the determination of clinical efficacy and harm and may be helpful in tracking trials, planning future trials, and making clinical recommendations for therapy.	HARVARD UNIV, SCH PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, TECHNOL ASSESSMENT GRP, BOSTON, MA 02115 USA; DEPT VET AFFAIRS MED CTR, BOSTON, MA USA; BRIGHAM & WOMENS HOSP, DEPT MED, DIV CARDIOVASC, BOSTON, MA 02115 USA; NEW ENGLAND MED CTR, CTR CARDIOVASC HLTH SERV RES, BOSTON, MA 02111 USA; TUFTS UNIV, SCH MED, BOSTON, MA 02111 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Tufts Medical Center; Tufts University; Harvard University; Harvard Medical School					AHRQ HHS [P0RT-1-PO1-HS 06341-02, R01 HS-05936] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		[Anonymous], 1980, LANCET, V1, P1172; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; [Anonymous], 1988, BRIT MED J, V296, P320; ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; ARMITAGE P, 1989, J CLIN EPIDEMIOL, V42, P293, DOI 10.1016/0895-4356(89)90033-4; BABER NJ, 1982, PRIM CARDIOL S, V1, P31; BABER NS, 1983, CIRCULATION, V67, P71; BABER NS, 1982, BRIT MED J, V284, P1749, DOI 10.1136/bmj.284.6331.1749; BEGG CB, 1988, J ROY STAT SOC A STA, V151, P419, DOI 10.2307/2982993; BERLIN JA, 1989, STAT MED, V8, P141, DOI 10.1002/sim.4780080202; CANNER PL, 1987, STAT MED, V6, P255, DOI 10.1002/sim.4780060310; CANNER PL, 1983, ISRAEL J MED SCI, V19, P413; CHALMERS I, 1991, OXFORD DATABASE PERI; CHALMERS TC, 1991, STAT MED, V10, P971, DOI 10.1002/sim.4780100618; CHALMERS TC, 1987, STAT MED, V6, P733, DOI 10.1002/sim.4780060704; CHALMERS TC, 1987, STAT MED, V6, P315, DOI 10.1002/sim.4780060320; CHALMERS TC, 1977, NEW ENGL J MED, V297, P1091, DOI 10.1056/NEJM197711172972004; COLLINS R, 1988, NEW ENGL J MED, V318, P1162, DOI 10.1056/NEJM198805053181805; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DETSKY AS, 1992, J CLIN EPIDEMIOL, V45, P255, DOI 10.1016/0895-4356(92)90085-2; DICKERSIN K, 1987, CONTROL CLIN TRIALS, V8, P343, DOI 10.1016/0197-2456(87)90155-3; EMERSON JD, 1990, CONTROL CLIN TRIALS, V11, P339, DOI 10.1016/0197-2456(90)90175-2; ERKELENS DW, 1990, CARDIOLOGY, V77, P33; FURBERG CD, 1983, CIRCULATION, V67, P83; FURBERG CD, 1984, AM J CARDIOL, V53, P626, DOI 10.1016/0002-9149(84)90042-0; HELD PH, 1990, CIRCULATION, V82, P1668, DOI 10.1161/01.CIR.82.5.1668; HELD PH, 1989, BMJ-BRIT MED J, V299, P1187, DOI 10.1136/bmj.299.6709.1187; HINE LK, 1989, ARCH INTERN MED, V149, P2694, DOI 10.1001/archinte.149.12.2694; HINE LK, 1989, JAMA-J AM MED ASSOC, V262, P3037, DOI 10.1001/jama.262.21.3037; HOLME I, 1990, CIRCULATION, V82, P1916, DOI 10.1161/01.CIR.82.6.1916; HONAN MB, 1990, J AM COLL CARDIOL, V16, P359, DOI 10.1016/0735-1097(90)90586-E; KAPLAN K, 1986, ARCH INTERN MED, V146, P593, DOI 10.1001/archinte.146.3.593; LABBE KA, 1987, ANN INTERN MED, V107, P224, DOI 10.7326/0003-4819-107-2-224; LAU J, IN PRESS CONTROLLED; LEIZOROVICZ A, 1983, EUR J CLIN PHARMACOL, V24, P333, DOI 10.1007/BF00610050; LOELIGER EA, 1981, ACTA MED SCAND, P305; MACMAHON S, 1988, JAMA-J AM MED ASSOC, V260, P1910, DOI 10.1001/jama.260.13.1910; MACMAHON S, 1987, ACUTE CORONARY CARE, P51; MANTEL N, 1959, J NATL CANCER I, V22, P719; MARDER VJ, 1984, AM J MED, V77, P921, DOI 10.1016/0002-9343(84)90543-6; MAY GS, 1982, PROG CARDIOVASC DIS, V24, P331, DOI 10.1016/0033-0620(82)90010-X; NAYLOR CD, 1990, JAMA-J AM MED ASSOC, V264, P697, DOI 10.1001/jama.264.6.697; OCONNOR GT, 1989, CIRCULATION, V80, P234, DOI 10.1161/01.CIR.80.2.234; OLDRIDGE NB, 1988, JAMA-J AM MED ASSOC, V260, P945, DOI 10.1001/jama.260.7.945; PATEL B, 1987, AM J CARDIOL, V59, P501, DOI 10.1016/0002-9149(87)91156-8; ROBINS J, 1986, AM J EPIDEMIOL, V124, P719, DOI 10.1093/oxfordjournals.aje.a114447; ROSENTHAL R, 1979, PSYCHOL BULL, V86, P638, DOI 10.1037/0033-2909.86.3.638; ROSSOUW JE, 1990, NEW ENGL J MED, V323, P1112, DOI 10.1056/NEJM199010183231606; SACKS HS, 1987, NEW ENGL J MED, V316, P450, DOI 10.1056/NEJM198702193160806; STAMPFER MJ, 1982, NEW ENGL J MED, V307, P1180, DOI 10.1056/NEJM198211043071904; TEO KK, 1991, BMJ-BRIT MED J, V303, P1499, DOI 10.1136/bmj.303.6816.1499; THACKER SB, 1988, JAMA-J AM MED ASSOC, V259, P1685, DOI 10.1001/jama.259.11.1685; The Aspirin Myocardial Infarction Study: final results, 1980, CIRCULATION S5, V62, pV79; Topol E J, 1989, Cardiol Clin, V7, P827; YUSUF S, 1985, EUR HEART J, V6, P556, DOI 10.1093/oxfordjournals.eurheartj.a061905; YUSUF S, 1988, JAMA-J AM MED ASSOC, V260, P2088, DOI 10.1001/jama.260.14.2088; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; YUSUF S, 1991, AM J CARDIOL, V67, P1295, DOI 10.1016/0002-9149(91)90944-G; YUSUF S, 1988, LANCET, V1, P1088; YUSUF S, 1985, ACUTE CORONARY CARE, P73; 1982, LANCET, V1, P1159	62	896	910	0	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 23	1992	327	4					248	254		10.1056/NEJM199207233270406	http://dx.doi.org/10.1056/NEJM199207233270406			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JE381	1614465				2022-12-01	WOS:A1992JE38100006
J	PYZDROWSKI, KL; KENDALL, DM; HALTER, JB; NAKHLEH, RE; SUTHERLAND, DER; ROBERTSON, RP				PYZDROWSKI, KL; KENDALL, DM; HALTER, JB; NAKHLEH, RE; SUTHERLAND, DER; ROBERTSON, RP			PRESERVED INSULIN-SECRETION AND INSULIN INDEPENDENCE IN RECIPIENTS OF ISLET AUTOGRAFTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							I DIABETIC RECIPIENTS; PANCREATIC-POLYPEPTIDE; AUTO-TRANSPLANTATION; INDUCED HYPOGLYCEMIA; ADRENERGIC-BLOCKADE; GLUCAGON-RELEASE; CANINE PANCREAS; NERVOUS-SYSTEM; CYCLOSPORIN; PLASMA	Background. Transplantation of pancreatic islets, rather than whole pancreas, has been introduced as a treatment for diabetes mellitus. We studied five patients ranging in age from 12 to 37 years who had severe chronic pancreatitis for which they underwent total pancreatectomy followed by isolation and hepatic transplantation of their own islets. Methods. All patients had remained insulin-independent for 1 to 7 1/2 years after transplantation. The numbers of islets transplanted ranged from 110,000 to 412,000. Islet function was assessed by measuring the plasma insulin responses to intravenous glucose and arginine and the plasma glucagon responses to hypoglycemia and arginine. In one patient, islet function was studied during catheterization of the hepatic vein, portal vein, and splenic artery and by analysis of a liver-biopsy specimen. Results. After transplantation, the mean (+/-SD)fasting plasma glucose concentration was 122+/-47 mg per deciliter (6.8+/-2.6 mmol per liter) and the hemoglobin A1c concentration was 6.0+/-0.8 percent in the five patients. The values were most abnormal - 214 mg per deciliter (11.9 mmol per liter) and 7.3 percent, respectively - in the patient who received only 110,000 islets. The acute plasma insulin responses to glucose and to arginine in the five patients were 23+/-13 and 26+/-10-mu-U per milliliter (168+/-94 and 184+/-70 pmol per liter), respectively, as compared with 58+/-6 and 37+/-8-mu-U per milliliter (416+/-44 and 267+/-61 pmol per liter) in the normal subjects. The peak plasma glucagon responses to insulin and arginine were 21+/-4 and 65+/-36 pg per millilter, respectively, as compared with 125+/-28 and 156+/-99 pg per milliliter in the normal subjects. All five patients had plasma epinephrine but not pancreatic polypeptide responses to hypoglycemia. The results of the hepatic-vein catheterization in one patient indicated that the transplanted islets released insulin and glucagon in response to arginine. Immunoperoxidase staining of this patient's liver-biopsy specimen showed that the islets contained insulin, glucagon, and somatostatin but not pancreatic polypeptide. Conclusions. Intrahepatic transplantation of as few as 265,000 islets can result in the release of insulin and glucagon at appropriate times and in prolonged periods of insulin independence.	UNIV MINNESOTA, CTR DIABET, BOX 101 UMHC, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, DEPT MED, DIV ENDOCRINOL & METAB, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, DEPT SURG, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, DEPT LAB MED & PATHOL, MINNEAPOLIS, MN 55455 USA; UNIV MICHIGAN, DEPT MED, ANN ARBOR, MI 48109 USA; VET AFFAIRS MED CTR, ANN ARBOR, MI USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA)			Roberston, R Paul/AAX-5613-2021		NCRR NIH HHS [M01 RR 00400] Funding Source: Medline; NIDDK NIH HHS [R01 DK 39994, 5T32 DK 07203] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000400] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007203, R01DK039994] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CAMERON JL, 1980, SURGERY, V87, P397; CHESNEY TMC, 1969, DIABETES, V18, P627, DOI 10.2337/diab.18.9.627; DIEM P, 1990, J CLIN INVEST, V86, P2008, DOI 10.1172/JCI114936; DIEM P, 1990, DIABETES, V39, P534, DOI 10.2337/diabetes.39.5.534; DUNNING BE, 1990, AM J PHYSIOL, V258, pE436, DOI 10.1152/ajpendo.1990.258.3.E436; FARNEY AC, 1991, SURGERY, V110, P427; GERSELL DJ, 1979, DIABETES, V28, P11, DOI 10.2337/diabetes.28.1.11; GILLISON SL, 1989, DIABETES, V38, P465, DOI 10.2337/diabetes.38.4.465; GLASER B, 1983, METABOLISM, V32, P57, DOI 10.1016/0026-0495(83)90156-7; GUNNARSSON R, 1983, LANCET, V2, P571; HARRIS M, 1979, DIABETES, V28, P1039; HAVEL PJ, 1989, ENDOCR REV, V10, P332, DOI 10.1210/edrv-10-3-332; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; IVERSEN J, 1971, J CLIN INVEST, V50, P2123, DOI 10.1172/JCI106706; LARGIADER F, 1980, TRANSPLANTATION, V29, P76, DOI 10.1097/00007890-198001000-00017; LYGREN I, 1983, SCAND J GASTROENTERO, V18, P155, DOI 10.3109/00365528309181576; MARLISS EB, 1973, EUR J CLIN INVEST, V3, P16; MIRALLES P, 1990, DIABETES, V39, P996, DOI 10.2337/diabetes.39.8.996; MORGAN CR, 1963, DIABETES, V12, P115, DOI 10.2337/diab.12.2.115; NAJARIAN JS, 1980, ANN SURG, V192, P526, DOI 10.1097/00000658-198010000-00011; NIELSEN JH, 1986, DIABETES, V35, P1049, DOI 10.2337/diabetes.35.9.1049; PALMER JP, 1979, METABOLISM, V28, P549, DOI 10.1016/0026-0495(79)90196-3; PALMER JP, 1976, J CLIN INVEST, V57, P522, DOI 10.1172/JCI108305; RIZZA RA, 1979, J CLIN INVEST, V64, P62, DOI 10.1172/JCI109464; RIZZA RA, 1982, J CLIN ENDOCR METAB, V54, P131, DOI 10.1210/jcem-54-1-131; ROBERTSON RP, 1986, DIABETES, V35, P1016, DOI 10.2337/diabetes.35.9.1016; RUSSELL AE, 1989, J AUTONOM NERV SYST, V26, P85, DOI 10.1016/0165-1838(89)90111-2; SCHARP DW, 1990, DIABETES, V39, P515, DOI 10.2337/diabetes.39.4.515; SCHARP DW, 1991, TRANSPLANTATION, V51, P76, DOI 10.1097/00007890-199101000-00012; SUTHERLAND DER, 1981, DIABETOLOGIA, V20, P435; TRIMBLE ER, 1980, DIABETES, V29, P341, DOI 10.2337/diabetes.29.5.341; TZAKIS AG, 1990, LANCET, V336, P402, DOI 10.1016/0140-6736(90)91946-8; WALTER RM, 1974, J CLIN INVEST, V54, P1214, DOI 10.1172/JCI107864; WARNOCK GL, 1992, DIABETOLOGIA, V35, P89, DOI 10.1007/BF00400857; WEIR GC, 1990, DIABETES, V39, P401, DOI 10.2337/diabetes.39.4.401	35	133	139	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 23	1992	327	4					220	226		10.1056/NEJM199207233270402	http://dx.doi.org/10.1056/NEJM199207233270402			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JE381	1614463				2022-12-01	WOS:A1992JE38100002
J	RADFORD, SE; DOBSON, CM; EVANS, PA				RADFORD, SE; DOBSON, CM; EVANS, PA			THE FOLDING OF HEN LYSOZYME INVOLVES PARTIALLY STRUCTURED INTERMEDIATES AND MULTIPLE PATHWAYS	NATURE			English	Article							NUCLEAR MAGNETIC-RESONANCE; EGG-WHITE LYSOZYME; RIBONUCLEASE-A; ALPHA-LACTALBUMIN; CIRCULAR-DICHROISM; PROTEIN; NMR; EXCHANGE; KINETICS	Analysis of the folding of hen lysozyme shows that the protein does not become organized in a single cooperative event but that different parts of the structure become stabilized with very different kinetics. In particular, in most molecules the alpha-helical domain folds faster than the beta-sheet domain. Furthermore, different populations of molecules fold by kinetically distinct pathways. Thus, folding is not a simple sequential assembly process but involves parallel alternative pathways, some of which may involve substantial reorganization steps.	UNIV OXFORD,INORGAN CHEM LAB,OXFORD OX1 3QR,ENGLAND; UNIV CAMBRIDGE,CAMBRIDGE CTR MOLEC RECOGNIT,CAMBRIDGE CB2 1QW,ENGLAND; UNIV CAMBRIDGE,DEPT BIOCHEM,CAMBRIDGE CB2 1QW,ENGLAND	University of Oxford; University of Cambridge; University of Cambridge	RADFORD, SE (corresponding author), UNIV OXFORD,OXFORD CTR MOLEC SCI,S PARKS RD,OXFORD OX1 3QR,ENGLAND.			Radford, Sheena/0000-0002-3079-8039				BAUM J, 1989, BIOCHEMISTRY-US, V28, P7, DOI 10.1021/bi00427a002; BRANDTS JF, 1975, BIOCHEMISTRY-US, V14, P4953, DOI 10.1021/bi00693a026; BRIGGS MS, 1992, P NATL ACAD SCI USA, V89, P2017, DOI 10.1073/pnas.89.6.2017; BYCROFT M, 1990, NATURE, V346, P488, DOI 10.1038/346488a0; CREIGHTON TE, 1978, PROG BIOPHYS MOL BIO, V33, P231; DOBSON CM, 1984, BIOCHEMISTRY-US, V23, P4267, DOI 10.1021/bi00314a001; ELOVE GA, 1991, ACS SYM SER, V470, P50; ELOVE GA, IN PRESS BIOCHEMISTR; ENGLANDER SW, 1984, Q REV BIOPHYS, V16, P521; EWBANK JJ, 1991, NATURE, V350, P518, DOI 10.1038/350518a0; GOUX WJ, 1980, BIOPOLYMERS, V19, P2191, DOI 10.1002/bip.1980.360191205; HARDING MM, 1991, BIOCHEMISTRY-US, V30, P3120, DOI 10.1021/bi00226a020; HUGHSON FM, 1991, BIOCHEMISTRY-US, V30, P4113, DOI 10.1021/bi00231a001; HUGHSON FM, 1990, SCIENCE, V249, P1544, DOI 10.1126/science.2218495; HVIDT AASE, 1966, ADVANCE PROTEIN CHEM, V21, P287, DOI 10.1016/S0065-3233(08)60129-1; IKEGUCHI M, 1986, BIOCHEMISTRY-US, V25, P6965, DOI 10.1021/bi00370a034; JACKSON SE, 1991, BIOCHEMISTRY-US, V30, P10436, DOI 10.1021/bi00107a011; JENG MF, 1991, J MOL BIOL, V221, P1045, DOI 10.1016/0022-2836(91)80191-V; JONG MF, 1990, BIOCHEMISTRY-US, V29, P10433; KATO S, 1982, BIOCHEMISTRY-US, V21, P38, DOI 10.1021/bi00530a007; KATO S, 1981, BIOCHEMISTRY-US, V20, P1080, DOI 10.1021/bi00508a006; KLEMM JD, 1991, BIOCHEMISTRY-US, V30, P589, DOI 10.1021/bi00216a038; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUWAJIMA K, 1991, BIOCHEMISTRY-US, V30, P7693, DOI 10.1021/bi00245a005; KUWAJIMA K, 1985, BIOCHEMISTRY-US, V24, P874, DOI 10.1021/bi00325a010; MANNING MC, 1989, BIOCHEMISTRY-US, V28, P8609, DOI 10.1021/bi00447a051; MATOUSCHEK A, 1990, NATURE, V346, P440, DOI 10.1038/346440a0; MIRANKER A, 1991, NATURE, V349, P633, DOI 10.1038/349633a0; OAS TG, 1988, NATURE, V336, P42, DOI 10.1038/336042a0; PEDERSEN TG, 1991, J MOL BIOL, V218, P413, DOI 10.1016/0022-2836(91)90722-I; RADFORD SE, IN PRESS PROTEINS ST; ROBERTSON AD, 1991, BIOCHEMISTRY-US, V30, P9907, DOI 10.1021/bi00105a014; RODER H, 1986, Proteins Structure Function and Genetics, V1, P34, DOI 10.1002/prot.340010107; RODER H, 1988, NATURE, V335, P700, DOI 10.1038/335700a0; ROPSON IJ, 1990, BIOCHEMISTRY-US, V29, P9591, DOI 10.1021/bi00493a013; SCHMID FX, 1983, BIOCHEMISTRY-US, V22, P4690, DOI 10.1021/bi00289a013; SCHMID FX, 1979, J MOL BIOL, V135, P199, DOI 10.1016/0022-2836(79)90347-4; STALEY JP, 1990, NATURE, V344, P685, DOI 10.1038/344685a0; SUGAWARA T, 1991, BIOCHEMISTRY-US, V30, P2698, DOI 10.1021/bi00224a018; Tanford C, 1970, Adv Protein Chem, V24, P1, DOI 10.1016/S0065-3233(08)60241-7; UDGAONKAR JB, 1990, P NATL ACAD SCI USA, V87, P8197, DOI 10.1073/pnas.87.21.8197; UDGAONKAR JB, 1988, NATURE, V335, P694, DOI 10.1038/335694a0; WEDIN RE, 1982, BIOCHEMISTRY-US, V21, P1098, DOI 10.1021/bi00534a042; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; [No title captured]	45	746	750	0	88	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 23	1992	358	6384					302	307		10.1038/358302a0	http://dx.doi.org/10.1038/358302a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JE684	1641003				2022-12-01	WOS:A1992JE68400055
J	RIZZUTO, R; SIMPSON, AWM; BRINI, M; POZZAN, T				RIZZUTO, R; SIMPSON, AWM; BRINI, M; POZZAN, T			RAPID CHANGES OF MITOCHONDRIAL CA2+ REVEALED BY SPECIFICALLY TARGETED RECOMBINANT AEQUORIN	NATURE			English	Article							CALCIUM; CELLS; CA-2+; INVOLVEMENT; RECEPTOR; PROTEINS	INTRODUCTION of Ca2+ indicators (photoproteins, fluorescent dyes) that can be trapped in the cytosolic compartment of living cells has yielded major advances in our knowledge of Ca2+ homeostasis1,2. Ca2+ however regulates functions not only in the cytosol but also within various organelles3,4 where indicators have not yet been specifically targeted. Here we present a novel procedure by which the free Ca2+ concentration of mitochondria, [Ca2+]m, can be monitored continuously at rest and during stimulation. The complementary DNA for the Ca2+ sensitive photoprotein aequorin was fused in frame with that encoding a mitochondrial presequence. The hybrid cDNA was transfected into bovine endothelial cells and stable clones were obtained expressing variable amounts of mitochondrially targeted apoaequorin. The functional photoprotein could be reconstituted in intact cells by incubation with purified coelenterazine and [Ca2+]m could thus be monitored in situ. This allowed the unprecedented direct demonstration that agonist-stimulated elevations of cytosolic free Ca2+, [Ca2+]i, (measured in parallel with Fura-2) evoke rapid and transient increases of [Ca2+]m, which can be prevented by pretreatment with a mitochondrial uncoupler. The possibility of targeting aequorin to cellular organelles not only offers a new and powerful method for studying aspects of Ca2+ homeostasis that up to now could not be directly approached, but might also be used in the future as a tool to report in situ a variety of apparently unrelated phenomena of wide biological interest.	UNIV OXFORD, PHYSIOL LAB, OXFORD OX1 3PT, ENGLAND	University of Oxford	RIZZUTO, R (corresponding author), UNIV PADUA, DEPT BIOMED SCI, VIA TRIESTE 75, I-35121 PADUA, ITALY.		Brini, Marisa/K-5189-2016; Rizzuto, Rosario/B-6312-2008	Rizzuto, Rosario/0000-0001-7044-5097; Brini, Marisa/0000-0001-5141-0243	Telethon [126] Funding Source: Medline	Telethon(Fondazione Telethon)		ALLEN DG, 1978, NATURE, V273, P509, DOI 10.1038/273509a0; ARSLAN P, 1985, J BIOL CHEM, V260, P2719; Blinks J.R., 1978, Methods in Enzymology, V57, P292; CASADEI J, 1990, P NATL ACAD SCI USA, V87, P2047, DOI 10.1073/pnas.87.6.2047; COLLART MA, 1991, MOL CELL BIOL, V11, P2826, DOI 10.1128/MCB.11.5.2826; DEPIERRE JW, 1974, J BIOL CHEM, V249, P7111; FASOLATO C, 1990, J BIOL CHEM, V265, P20351; GAIDO ML, 1991, J BIOL CHEM, V266, P18580; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; INOUYE S, 1985, P NATL ACAD SCI USA, V82, P3154, DOI 10.1073/pnas.82.10.3154; JACOB R, 1990, BIOCHIM BIOPHYS ACTA, V1052, P427, DOI 10.1016/0167-4889(90)90152-4; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KNIGHT MR, 1991, FEBS LETT, V282, P405, DOI 10.1016/0014-5793(91)80524-7; KNIGHT MR, 1991, NATURE, V352, P524, DOI 10.1038/352524a0; MALGAROLI A, 1987, J CELL BIOL, V105, P2145, DOI 10.1083/jcb.105.5.2145; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; MELDOLESI J, 1990, BIOCHIM BIOPHYS ACTA, V1055, P130, DOI 10.1016/0167-4889(90)90113-R; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MIYATA H, 1991, AM J PHYSIOL, V261, pH1123, DOI 10.1152/ajpheart.1991.261.4.H1123; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NAKAJIMASHIMADA J, 1991, P NATL ACAD SCI USA, V88, P6878, DOI 10.1073/pnas.88.15.6878; OCONNOR SE, 1991, TRENDS PHARMACOL SCI, V12, P137, DOI 10.1016/0165-6147(91)90530-6; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; PIROTTON S, 1987, J BIOL CHEM, V262, P17461; RIZZUTO R, 1989, J BIOL CHEM, V264, P10595; RUTTER GA, 1990, BIOCHEM J, V271, P627, DOI 10.1042/bj2710627; Sambrook J, 1989, MOL CLONING; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; SHIMOMURA O, 1991, CELL CALCIUM, V12, P635, DOI 10.1016/0143-4160(91)90060-R; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TANAHASHI H, 1990, GENE, V96, P249, DOI 10.1016/0378-1119(90)90260-X; TSIEN RY, 1982, NATURE, V295, P68, DOI 10.1038/295068a0; WAYBILL MM, 1991, AM J PHYSIOL, V261, pE49, DOI 10.1152/ajpendo.1991.261.1.E49	36	781	825	3	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 23	1992	358	6384					325	327		10.1038/358325a0	http://dx.doi.org/10.1038/358325a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JE684	1322496				2022-12-01	WOS:A1992JE68400062
J	WANG, HY; WATKINS, DC; MALBON, CC				WANG, HY; WATKINS, DC; MALBON, CC			ANTISENSE OLIGODEOXYNUCLEOTIDES TO G(S) PROTEIN ALPHA-SUBUNIT SEQUENCE ACCELERATE DIFFERENTIATION OF FIBROBLASTS TO ADIPOCYTES	NATURE			English	Article							MESSENGER-RNA LEVELS; ADIPOSE CELL LINE; 3T3-L1 CELLS; ADENYLATE-CYCLASE; BETA-SUBUNITS; INHIBITION; STIMULATION; CONVERSION; EXPRESSION; RECEPTOR	FULLY-DIFFERENTIATED mouse 3T3-L1 fibroblasts accumulate large amounts of lipid at 7-10 days after induction by insulin or by dexamethasone and a methyl xanthine1-3. G proteins mediate transmembrane signalling from a diverse group of cell-surface receptors to effector units that include phospholipase C, adenylyl cyclase and ion channels4-6. They are also targets or regulation themselves7-10. 3T3-L1 fibroblasts display marked changes in levels of G protein when induced to differentiate to adipocytes11-15. Here we show that cholera toxin, which ADP-ribosylates and activates the G protein subunit G(s-alpha), blocks the induction of differentiation, whereas increasing intracellular cyclic AMP directly with the dibutyryl analogue or indirectly with pertussis toxin or forskolin does not affect differentiation. Oligodeoxynucleotides antisense to the sequence encoding G(s-alpha) accelerate differentiation markedly. The time course of adipogenesis declined from 7-10 days in controls to roughly 3 days in cultures treated with antisense-G(s-alpha) oligodeoxynucleotides, whereas oligodeoxynucleotides, antisense to G(i-alpha-1), G(i-alpha-3), and sense and missense to G(s-alpha), had no such effect. Antisense-G(s-alpha) alone induced differentiation by day 7, indicating that G(s-alpha) activity modulates differentiation in 3T3-L1 cells, acting in a new role which is independent of increased intracellular cAMP.	SUNY HLTH SCI CTR,DEPT PHARMACOL,DIABET & METAB DIS RES PROGRAM,STONY BROOK,NY 11794; NATL DEF MED CTR,DEPT BIOCHEM,TAIPEI 10764,TAIWAN	State University of New York (SUNY) System; National Defense Medical Center			malbon, craig/ABF-3604-2020					BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; GIERSCHIK P, 1986, FEBS LETT, V199, P103, DOI 10.1016/0014-5793(86)81233-9; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.biochem.56.1.615; GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; HADCOCK JR, 1990, J BIOL CHEM, V265, P14784; JASKULSKI D, 1988, SCIENCE, V240, P1544, DOI 10.1126/science.2897717; LAI E, 1981, J BIOL CHEM, V256, P2866; MAGUIRE ME, 1980, J BIOL CHEM, V255, P1030; MALBON CC, 1988, TRENDS PHARMACOL SCI, V9, P33, DOI 10.1016/0165-6147(88)90240-4; MALBON CC, 1985, J BIOL CHEM, V260, P2558; ROS M, 1989, BIOCHEM J, V260, P271, DOI 10.1042/bj2600271; ROS M, 1988, J BIOL CHEM, V263, P4632; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; RUSSELL TR, 1976, P NATL ACAD SCI USA, V73, P4516, DOI 10.1073/pnas.73.12.4516; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; WATKINS DC, 1989, BIOCHEM BIOPH RES CO, V165, P929, DOI 10.1016/0006-291X(89)92692-2; WATKINS DC, 1987, J BIOL CHEM, V262, P10651; WATKINS DC, 1989, J BIOL CHEM, V264, P4186; YATANI A, 1988, J BIOL CHEM, V263, P9887	22	148	151	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 23	1992	358	6384					334	337		10.1038/358334a0	http://dx.doi.org/10.1038/358334a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JE684	1379345				2022-12-01	WOS:A1992JE68400065
J	JOHNSON, EM				JOHNSON, EM			METHADONE AND AZT TREATMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											JOHNSON, EM (corresponding author), ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,ROCKVILLE,MD 20857, USA.							FRIEDLAND, J ACQUIRED IMMUNODEF	1	2	2	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 22	1992	268	4					447	447						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD472	1320132				2022-12-01	WOS:A1992JD47200003
J	JOHNSON, EM				JOHNSON, EM			MOUSE MODEL OF GAUCHER DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											JOHNSON, EM (corresponding author), ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,ROCKVILLE,MD 20857, USA.								0	2	2	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 22	1992	268	4					447	447						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD472	1320132				2022-12-01	WOS:A1992JD47200005
J	JOHNSON, EM				JOHNSON, EM			PRENATAL COCAINE EXPOSURE AND SIDS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											JOHNSON, EM (corresponding author), ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,ROCKVILLE,MD 20857, USA.							OLSEN GD, 1992, J PHARM EXPT THE MAY	1	2	2	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 22	1992	268	4					447	447						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD472	1320132				2022-12-01	WOS:A1992JD47200004
J	ROSENBERG, PS; LEVY, ME; BRUNDAGE, JF; PETERSEN, LR; KARON, JM; FEARS, TR; GARDNER, LI; GAIL, MH; GOEDERT, JJ; BLATTNER, WA; RYAN, CC; VERMUND, SH; BIGGAR, RJ				ROSENBERG, PS; LEVY, ME; BRUNDAGE, JF; PETERSEN, LR; KARON, JM; FEARS, TR; GARDNER, LI; GAIL, MH; GOEDERT, JJ; BLATTNER, WA; RYAN, CC; VERMUND, SH; BIGGAR, RJ			POPULATION-BASED MONITORING OF AN URBAN HIV AIDS EPIDEMIC - MAGNITUDE AND TRENDS IN THE DISTRICT-OF-COLUMBIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SHORT-TERM PROJECTIONS; UNITED-STATES; SENTINEL HOSPITALS; INFECTION; PREVALENCE; SPREAD; SIZE	Objective.-To assess the extent of the human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) epidemic in the District of Columbia and demonstrate an approach to monitoring HIV infection and projecting AIDS incidence at a community level. Design.-Backcalculation methods to reconstruct HIV incidence from AIDS incidence in subgroups. Results were compared with directly measured HIV seroprevalence in selected sentinel populations: childbearing women, civilian applicants for military service, and hospital patients admitted for conditions unrelated to HIV infection. Results.-Between the start of the epidemic in 1980 and January 1, 1991, one in 57 District of Columbia men aged 20 to 64 years was diagnosed with AIDS. Unlike the plateau projected for the nation, AIDS incidence for the District of Columbia was projected to increase by 34% between 1990 and 1994. Models of HIV infection incidence suggested two broad epidemic waves of approximately equal size. The first occurred in men who have sex with men and peaked during the period from 1982 through 1983. The second began in the mid-1980s in injecting drug users and heterosexuals. We estimated that among District of Columbia residents aged 20 to 64 years, 0.3% of white women, 2.9% of white men, 1.6% of black women, and 4.9% of black men were living with HIV infection as of January 1, 1991. These estimates are broadly consistent with survey data: among black childbearing women in their 20s, HIV prevalence doubled to 2% between the fall of 1989 and the spring of 1991; from military applicant data, we estimated that over 5% of black men born from 1951 through 1967 were HIV-positive; in the sentinel hospital, HIV prevalence rates among male patients aged 25 to 34 years were 11.3% in white men and 16.9% in black men. Conclusion.-Backcalculation and surveys yielded quantitatively consistent estimates of HIV prevalence. Many injecting drug users and heterosexuals in the District of Columbia were infected after January 1, 1986. Similar monitoring of the epidemic in other localities is needed to focus efforts to reduce the incidence of HIV transmission.	NCI, ENVIRONM EPIDEMIOL BRANCH, VIRAL EPIDEMIOL SECT, ROCKVILLE, MD 20892 USA; WALTER REED ARMY MED CTR, DIV PREVENT MED, WASHINGTON, DC 20307 USA; CTR DIS CONTROL, CTR INFECT DIS, DIV HIV AIDS, POPULAT STUDIES SECT, ATLANTA, GA 30333 USA; CTR DIS CONTROL, CTR INFECT DIS, DIV HIV AIDS, STAT & DATA MANAGEMENT BRANCH, ATLANTA, GA 30333 USA; DIST COLUMBIA COMMISS PUBL HLTH, AGCY HIV AIDS, WASHINGTON, DC USA; NIAID, DIV AIDS, VACCINE TRIALS EPIDEMIOL BRANCH, BETHESDA, MD 20892 USA; DIST COLUMBIA COMMISS PUBL HLTH, PREVENT HLTH SERV ADM, WASHINGTON, DC USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Department of Defense; United States Army; Walter Reed National Military Medical Center; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	ROSENBERG, PS (corresponding author), NCI, BIOSTAT BRANCH, EPIDEMIOL METHODS SECT, 6130 EXECUT BLVD, EPN 403, ROCKVILLE, MD 20892 USA.		Vermund, Sten/AAD-3592-2020; Brundage, John/Q-9244-2019	Vermund, Sten/0000-0001-7289-8698; 				BIGGAR RJ, 1990, AIDS, V4, P1059, DOI 10.1097/00002030-199011000-00002; BROOKMEYER R, 1991, SCIENCE, V253, P37, DOI 10.1126/science.2063206; BROOKMEYER R, 1990, BIOMETRICS, V46, P1151, DOI 10.2307/2532455; BROOKMEYER R, 1989, BIOMETRICS, V45, P325, DOI 10.2307/2532057; BROOKMEYER R, 1989, STAT MED, V8, P23, DOI 10.1002/sim.4780080105; BROOKMEYER R, 1986, LANCET, V2, P1320; BROOKMEYER R, 1988, J AM STAT ASSOC, V83, P301, DOI 10.2307/2288844; BRUNDAGE JF, 1990, J ACQ IMMUN DEF SYND, V3, P1168; CHU SY, 1992, AM J PUBLIC HEALTH, V82, P220, DOI 10.2105/AJPH.82.2.220; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; DANGELO LJ, 1991, PEDIATRICS, V88, P982; DANGELO LJ, 1991, OCT INT C ANT AG CH; DAY NE, 1989, SHORT TERM PREDICTIO; DEGRUTTOLA V, 1989, STAT MED, V8, P35, DOI 10.1002/sim.4780080106; GAIL MH, 1988, J NATL CANCER I, V80, P900, DOI 10.1093/jnci/80.12.900; GAIL MH, 1990, J ACQ IMMUN DEF SYND, V3, P296; GARDNER LI, 1989, J ACQ IMMUN DEF SYND, V2, P521; GOEDERT JJ, 1987, JAMA-J AM MED ASSOC, V257, P331, DOI 10.1001/jama.257.3.331; GRAHAM NMH, 1991, J ACQ IMMUN DEF SYND, V4, P267; GREEN TA, 1992, J ACQ IMMUN DEF SYND, V5, P547; GWINN M, 1991, JAMA-J AM MED ASSOC, V265, P1704, DOI 10.1001/jama.265.13.1704; HAHN RA, 1989, JAMA-J AM MED ASSOC, V261, P2677, DOI 10.1001/jama.261.18.2677; ISHAM V, 1989, SHORT TERM PREDICTIO; JACK N, 1992, 8TH INT C AIDS 3 STD; KARON JM, 1988, J ACQ IMMUN DEF SYND, V1, P542; KINGSLEY LA, 1991, AM J EPIDEMIOL, V134, P331, DOI 10.1093/oxfordjournals.aje.a116094; NOVICK LF, 1991, AM J PUBLIC HEALTH, V81, P15, DOI 10.2105/AJPH.81.Suppl.15; PAPPAIOANOU M, 1990, PUBLIC HEALTH REP, V105, P147; Rosenberg Philip S., 1990, Annals of Epidemiology, V1, P105; ROSENBERG PS, 1991, J ACQ IMMUN DEF SYND, V4, P392; ROSENBERG PS, 1991, AM J EPIDEMIOL, V133, P276, DOI 10.1093/oxfordjournals.aje.a115872; ROSENBERG PS, 1991, APPL STAT-J ROY ST C, V40, P269; ROSENBERG PS, IN PRESS STAT MED; SELIK RM, 1990, J ACQ IMMUN DEF SYND, V3, P73; STLOUIS ME, 1990, NEW ENGL J MED, V323, P213, DOI 10.1056/NEJM199007263230401; STLOUIS ME, 1990, PUBLIC HEALTH REP, V105, P140; TAYLOR JMG, 1989, STAT MED, V8, P45, DOI 10.1002/sim.4780080107; 1991, DIMENSION HIV AIDS E; 1991, HIV AIDS SURVEILLANC, P1; 1991, SAN FRANCISCO EPIDEM, V7, P31; 1992, COMPREHENSIVE HIV AI; 1987, MMWR S15, V36, P1; 1991, INDICES STATISTICAL, P80; 1990, MMWR, V39, P110; 1989, DISTRICT COLUMBIA CO	45	25	25	1	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 22	1992	268	4					495	503						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD472	1619741				2022-12-01	WOS:A1992JD47200024
J	SELWYN, PA; SCKELL, BM; ALCABES, P; FRIEDLAND, GH; KLEIN, RS; SCHOENBAUM, EE				SELWYN, PA; SCKELL, BM; ALCABES, P; FRIEDLAND, GH; KLEIN, RS; SCHOENBAUM, EE			HIGH-RISK OF ACTIVE TUBERCULOSIS IN HIV-INFECTED DRUG-USERS WITH CUTANEOUS ANERGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY VIRUS-INFECTION; AIDS EPIDEMIC; PROGRAM	Objectives.-To determine the incidence of active tuberculosis in human immunodeficiency virus (HIV)-seropositive and HIV-seronegative drug injectors with cutaneous anergy and to examine the effectiveness of isoniazid chemoprophylaxis in preventing tuberculosis among drug injectors with positive tuberculin test results. Design and Setting.-Prospective observational study linked to an ongoing study of HIV infection within a New York City (NY) methadone program; subjects also underwent routine intradermal tuberculin testing and multiple-antigen delayed-type hypersensitivity skin testing. The 31 -month study period ended December 31, 1990. Methods.-Anergic subjects and tuberculin reactors who were HIV seropositive were compared by HIV disease status and CD4+ T-lymphocyte levels. Tuberculosis incidence was calculated for anergics (none treated with isoniazid) and for treated and untreated tuberculin reactors, by HIV serological status. Results.-Among those seropositive for HIV, anergic subjects had more advanced HIV disease and fewer CD4+ cells (median 0.33 vs 0.56 x 10(9)/L, P<.01) compared with tuberculin reactors, although neither clinical status nor CD4+ cell counts consistently predicted anergy. Five (7.6%) of 68 anergic subjects who were HIV seropositive and none of 52 anergic subjects who were HIV seronegative (n=18) or of unknown (n=34) HIV serological status developed active tuberculosis during the study period (P<.05). The tuberculosis incidence rate among anergic subjects who were HIV seropositive was 6.6 cases per 100 person-years (95% confidence interval [CI], 2.1 to 15.3). Of 25 HIV-seropositive tuberculin reactors who did not receive or complete 12 months of isoniazid prophylaxis, tuberculosis incidence was 9.7 cases per 1 00 person-years (95% CI, 2.6 to 24.7; P=0.56, compared with the rate among anergic HIV seropositives); there were no cases of tuberculosis in 53.4 person-years of follow-up for 27 HIV-seropositive tuberculin reactors who received 12 months of prophylaxis (rate difference between treated and untreated groups, 9.7 cases per 100 person-years, 95% CI, 1.3 to 18.0). Conclusion.-Drug injectors with cutaneous anergy who are seropositive for HIV are at high risk of active tuberculosis, similar to that among untreated HIV-seropositive tuberculin reactors. A decreased incidence of active tuberculosis was seen in HIV-seropositive tuberculin reactors receiving 12 months of isoniazid chemoprophylaxis, compared with untreated or partially treated subjects. These results support the routine use of delayed-type hypersensitivity testing to accompany tuberculin testing for drug injectors with known or suspected HIV infection, and consideration of isoniazid prophylaxis for anergic as well as tuberculin-reactive subjects who are HIV seropositive, in populations with a high prevalence of coexisting HIV and Mycobacterium tuberculosis infection.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,MONTEFIORE MED CTR,DEPT EPIDEMIOL & SOCIAL MED,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,MONTEFIORE MED CTR,DEPT MED,DIV INFECT DIS,BRONX,NY 10461	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine				Schoenbaum, Ellie/0000-0002-0878-284X	NIDA NIH HHS [R01DA04347] Funding Source: Medline; PHS HHS [U62/CCU200714] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004347] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; BIRX D, 1989, 5 INT C AIDS MONTR; BLATT SP, 1991, 7TH INT C AIDS FLOR; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; CHAISSON RE, 1989, J INFECT DIS, V159, P96, DOI 10.1093/infdis/159.1.96; COHEN J, 1990, 6TH INT C AIDS SAN F; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DIPERRI G, 1989, LANCET, V2, P1502; GRAHAM NMH, 1992, JAMA-J AM MED ASSOC, V267, P369, DOI 10.1001/jama.267.3.369; JORDAN TJ, 1991, JAMA-J AM MED ASSOC, V265, P2987, DOI 10.1001/jama.265.22.2987; MARKOWITZ N, 1991, 7 INT C AIDS FLOR; NARDELL EA, 1990, AM REV RESPIR DIS, V142, P501, DOI 10.1164/ajrccm/142.3.501; PITCHENIK AE, 1990, ANN INTERN MED, V113, P89, DOI 10.7326/0003-4819-113-2-89; PITCHENIK AE, 1990, MMWR, V39, P718; RIEDER HL, 1989, JAMA-J AM MED ASSOC, V262, P385, DOI 10.1001/jama.262.3.385; ROBERT CF, 1989, NEW ENGL J MED, V321, P1268; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P214; SCHOENBAUM EE, 1989, NEW ENGL J MED, V321, P874, DOI 10.1056/NEJM198909283211306; SELWYN PA, 1988, AIDS, V2, P267, DOI 10.1097/00002030-198808000-00005; SELWYN PA, 1991, NEW YORK STATE J MED, V91, P233; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SELWYN PA, 1989, ANN INTERN MED, V111, P761, DOI 10.7326/0003-4819-111-9-761; SELWYN PA, 1989, AM J PUBLIC HEALTH, V79, P1358, DOI 10.2105/AJPH.79.10.1358; SELWYN PA, 1990, 6TH INT C AIDS SAN F; SMALL PM, 1991, NEW ENGL J MED, V324, P289, DOI 10.1056/NEJM199101313240503; SUNDERAM G, 1986, JAMA-J AM MED ASSOC, V256, P362, DOI 10.1001/jama.256.3.362; WADHAWAN D, 1990, 6TH INT C AIDS SAN F; WIERZBA TP, 1991, 7TH INT C AIDS FLOR; 1991, MMWR, V40, P649; 1990, MMWR SRR17, V39, P1; 1987, MMWR, V36, P785; 1989, MMWR, V38, P236; 1991, MMWR, V40, P585; 1990, MMWR SRR8, V39, P1; 1991, MMWR SRR5, V40, P27; 1986, MMWR, V35, P74; 1991, MMWR, V40, P129; 1990, TUBERCULOSIS NEW YOR; 1990, MMWR, V39, P638	39	261	265	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 22	1992	268	4					504	509		10.1001/jama.268.4.504	http://dx.doi.org/10.1001/jama.268.4.504			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD472	1619742				2022-12-01	WOS:A1992JD47200025
J	SHAPIRO, MF; HAYWARD, RA; GUILLEMOT, D; JAYLE, D				SHAPIRO, MF; HAYWARD, RA; GUILLEMOT, D; JAYLE, D			RESIDENTS EXPERIENCES IN, AND ATTITUDES TOWARD, THE CARE OF PERSONS WITH AIDS IN CANADA, FRANCE, AND THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHYSICIANS; RISK	Objective.-To evaluate resident physicians' experiences in, and attitudes toward, the care of persons with the acquired immunodeficiency syndrome (AIDS) in Canada, France, and the United States. Design.-Cross-sectional survey, using a self-administered, mailed questionnaire to residents in 1 0 American states, three French regions, and all 10 Canadian provinces, with follow-up surveys of nonresponders in France and the United States. Subjects.-Systematic samples of residents in the last year of internal medicine or family medicine residencies prior to subspecialization or entry into medical practice. Results.-While the majority of residents had provided inpatient and outpatient care to persons with AIDS, most believed that their training in ambulatory care of persons with AIDS had been deficient. The rate of blood-contaminated needle-sticks from human immunodeficiency virus-infected patients ranged from 4% for internal medicine residents in Canada to 14% in the United States (P<.05). The majority recognized an ethical obligation to treat AIDS, but 4% in France, 14% in Canada, and 23% in the United States indicated that they would not care for persons with AIDS if they had a choice (P<.001). A substantial minority of US physicians reported that a patient of theirs had been refused care by a medical specialist (19%) or a surgeon (39%), but less than 10% of French physicians reported such refusals (P<.001). Conclusion.-Concerns about caring for AIDS patients were common and many physicians reported that patients were refused care. While most residents acknowledged an obligation to treat human immunodeficiency virus infection, many did not, and viewpoints varied considerably across the countries studied. The lower level of reluctance to treat AIDS patients in France and Canada makes it clear that the higher rate in the United States is far from optimal and needs to be addressed.	UNIV MICHIGAN,DEPT MED,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT HLTH SERV MANAGEMENT & POLICY,ANN ARBOR,MI 48109; ASSOC PREVENT SIDA,PARIS,FRANCE; CTR REG INFORMAT & PREVENT SIDA,PARIS,FRANCE	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	SHAPIRO, MF (corresponding author), UNIV CALIF LOS ANGELES,DEPT MED,CTR GEN MED,8-552 LOUIS FACTOR BLDG,LOS ANGELES,CA 90024, USA.		Guillemot, Didier/AAN-3051-2020	Guillemot, Didier/0000-0002-8497-1765				[Anonymous], 1989, PRIVATE ACTS SOCIAL; CONNER G, 1990, PSYCHOL REP, V67, P1147; DOUGLAS CJ, 1985, HOSP COMMUNITY PSYCH, V36, P1309; EDMOND M, 1988, INFECT CONT HOSP EP, V9, P114, DOI 10.1086/645806; GERBERDING JL, 1987, J INFECT DIS, V156, P861, DOI 10.1093/infdis/156.6.861; GERBERDING JL, 1990, NEW ENGL J MED, V322, P1788, DOI 10.1056/NEJM199006213222506; GERBERT B, 1991, JAMA-J AM MED ASSOC, V266, P2837, DOI 10.1001/jama.266.20.2837; GOSTIN L, 1989, HASTINGS CENT REP, V19, P32, DOI 10.2307/3561948; HAYWARD RA, 1991, J GEN INTERN MED, V6, P18, DOI 10.1007/BF02599384; HAYWARD RA, 1991, ANN INTERN MED, V114, P23, DOI 10.7326/0003-4819-114-1-23; LINK RN, 1988, AM J PUBLIC HEALTH, V78, P455, DOI 10.2105/AJPH.78.4.455; MIZES JS, 1984, PUBLIC OPIN QUART, V48, P794, DOI 10.1086/268885; MORGAN DR, 1988, J HOSP INFECT, V12, P301, DOI 10.1016/0195-6701(88)90072-2; NORTHFELT DW, 1988, ANN INTERN MED, V109, P773, DOI 10.7326/0003-4819-109-10-773; PIOT P, 1988, SCIENCE, V239, P573, DOI 10.1126/science.3277271; POLLAK M, 1989, SCI SOC SANTE, V7, P111; Prual A, 1991, Int J STD AIDS, V2, P1; ZUGER A, 1987, JAMA-J AM MED ASSOC, V258, P1924, DOI 10.1001/jama.258.14.1924; 1989, HIV AIDS SURVEILLANC, P1; 1991, B EPIDEMIOL HEBDOMAD, V44, P187; 1991, MMWR SRR8, V40, P1	21	50	50	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 22	1992	268	4					510	515		10.1001/jama.268.4.510	http://dx.doi.org/10.1001/jama.268.4.510			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JD472	1619743				2022-12-01	WOS:A1992JD47200026
J	TOKARS, JI; CHAMBERLAND, ME; SCHABLE, CA; CULVER, DH; JONES, M; MCKIBBEN, PS; BELL, DM				TOKARS, JI; CHAMBERLAND, ME; SCHABLE, CA; CULVER, DH; JONES, M; MCKIBBEN, PS; BELL, DM			A SURVEY OF OCCUPATIONAL BLOOD CONTACT AND HIV-INFECTION AMONG ORTHOPEDIC SURGEONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RISK; TRANSMISSION	Objective.-To study the seroprevalence of human immunodeficiency virus (HIV) among orthopedic surgeons, and correlate the results with occupational and nonoccupational risk factors. Orthopedic surgeons are one of several groups of health care workers at risk for occupationally acquired HIV infection; however, few HIV seroprevalence studies in health care workers, and none in surgeons, have been performed to assist in estimating the extent of occupational risk. Design.-A voluntary, anonymous HIV serosurvey at an annual meeting. To assess the representativeness of participants, a mail survey of orthopedic surgeons was conducted 5 months prior to the annual meeting. Setting.-The 1991 annual meeting of the American Academy of Orthopaedic Surgeons held in Anaheim, Calif. Participants.-United States or Canadian orthopedic surgeons in training, in practice, or retired from practice who attended the annual meeting. Main Outcome Measures.-Participants' HIV serostatus and reporting of occupational and nonoccupational risk factors for HIV infection. Results.-Of 7147 eligible orthopedists at the annual meeting, 3420 (47.9%) participated. Compared with the 10411 orthopedic surgeons responding to the mail survey, serosurvey participants had at least as many opportunities for occupational contact with blood and with HIV-infected patients. Among participants, 87.4% reported a blood-skin contact and 39.2% reported a percutaneous blood contact in the previous month. Among 3267 participants without reported nonoccupational risk factors for HIV infection, none was positive for HIV antibody (0%; upper limit of the 95% confidence interval [CI] = 0.09%); among 108 participants with reported nonoccupational HIV risk factors, two were positive for HIV antibody (1.9%; upper limit of the 95% CI = 5.7%). Conclusion.-Although these findings may not be generalizable to all orthopedic surgeons, we found no evidence of HIV infection among serosurvey participants without nonoccupational risk factors. The high rates of self-reported blood contact underscore the importance of compliance with infection control precautions and of development of new techniques and equipment to minimize the risk of exposures to blood during surgical procedures.	CTR DIS CONTROL,NATL CTR INFECT DIS,DIV HIV AIDS,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA	TOKARS, JI (corresponding author), CTR DIS CONTROL,NATL CTR INFECT DIS,HOSP INFECT PROGRAM,MAILSTOP A-07,ATLANTA,GA 30333, USA.							BELL DM, 1991, AM J MED, V91, pS294, DOI 10.1016/0002-9343(91)90385-B; COWAN DN, 1991, JAMA-J AM MED ASSOC, V265, P2826, DOI 10.1001/jama.265.21.2826; DOCK NL, 1991, ARCH INTERN MED, V151, P525, DOI 10.1001/archinte.151.3.525; GERBERDING JL, 1990, NEW ENGL J MED, V322, P1788, DOI 10.1056/NEJM199006213222506; HENDERSON DK, 1990, ANN INTERN MED, V113, P740, DOI 10.7326/0003-4819-113-10-740; JACKSON JB, 1990, NEW ENGL J MED, V322, P217, DOI 10.1056/NEJM199001253220402; JOHNSON GK, 1991, J MED VIROL, V33, P47, DOI 10.1002/jmv.1890330110; KELLEY PW, 1990, AM J PUBLIC HEALTH, V80, P405, DOI 10.2105/AJPH.80.4.405; KLEIN RS, 1988, NEW ENGL J MED, V318, P86, DOI 10.1056/NEJM198801143180205; MARCUS R, 1989, B WORLD HEALTH ORGAN, V67, P577; MARCUS R, 1988, NEW ENGL J MED, V319, P1118, DOI 10.1056/NEJM198810273191703; MCQUILLAN GM, 1989, AM J MED, V87, pS5; PANLILIO AL, 1991, JAMA-J AM MED ASSOC, V265, P1533, DOI 10.1001/jama.265.12.1533; TOKARS JI, 1992, JAMA-J AM MED ASSOC, V267, P2899, DOI 10.1001/jama.267.21.2899; 1988, MMWR, V37, P387; 1991, MMWR, V40, P309; 1991, REDUCING RISK BLOOD; 1991, MMWR, V40, P1; 1987, MMWR S2S, V36, pS1; 1991, ADVISORY STATEMENT H; 1988, MMWR, V37, P377; 1989, RECOMMENDATIONS PREV; 1990, HIV AIDS SURVEILLANC, P1; 1989, MMWR, V38, P95; 1989, MMWR, V38, P1; 1990, MMWR, V39, P1	26	68	70	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 22	1992	268	4					489	494		10.1001/jama.268.4.489	http://dx.doi.org/10.1001/jama.268.4.489			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD472	1619740				2022-12-01	WOS:A1992JD47200023
J	ZUGER, A				ZUGER, A			MONDAY MORNING CLINIC	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 22	1992	268	4					468	468						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD472	1619737				2022-12-01	WOS:A1992JD47200009
J	CARTWRIGHT, K; REILLY, S; WHITE, D; STUART, J				CARTWRIGHT, K; REILLY, S; WHITE, D; STUART, J			EARLY TREATMENT WITH PARENTERAL PENICILLIN IN MENINGOCOCCAL DISEASE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACUTE BACTERIAL-MENINGITIS; ANTIBIOTICS; ASSOCIATION; INFECTIONS; ENDOTOXIN; CHILDHOOD; SERUM	Objective-To measure the effect of parenteral antibiotics given before admission to hospital on mortality and on bacteriological investigations in meningococcal disease. Design-Retrospective review of hospital notes and laboratory and public health medicine department records. Setting-Three health districts in south west England. Subjects-Patients with meningococcal disease in Gloucester district presenting between 1 January 1982 and 31 December 1991 (n=190); patients with meningococcal disease in Plymouth (n=118) and Bath (n=73) districts presenting between 1 January 1988 and 31 December 1991 (total=381). Main outcome measure-Number of deaths from meningococcal disease. Results-Parenteral antibiotic given by general practitioners was associated with a substantial reduction in mortality (from 9% to 5%; relative risk 0.6, 95% confidence interval 0.2 to 1.5); patients with a rash were more likely to be given parenteral antibiotics, and mortality was further reduced (from 12% to 5%; 0.5, 0.2 to 1.4). In a district where such treatment was regularly encouraged its use increased from 5% to 40% of cases over 10 years (p=0.00001). Treatment with parenteral antibiotics before admission made isolation of meningococci from blood and cerebrospinal fluid less likely but did not affect nasopharyngeal cultures. Conclusions-General practitioners should carry benzylpenicillin in their emergency bags at all times and should administer it promptly, preferably intravenously, whenever meningococcal disease is suspected, unless the patient has had an anaphylactic reaction to penicillin. Specimens for culture should include a nasopharyngeal swab.	DERRIFORD HOSP, PUBL HLTH LAB, PLYMOUTH PL6 8DH, ENGLAND; ROYAL UNITED HOSP, PUBL HLTH LAB, BATH BA1 3NG, ENGLAND; GLOUCESTER HLTH AUTHOR, COMMUNICABLE DIS CONTROL, GLOUCESTER GL1 1LY, ENGLAND	Derriford Hospital	CARTWRIGHT, K (corresponding author), GLOUCESTERSHIRE ROYAL HOSP, PUBL HLTH LAB, GLOUCESTER GL1 3NN, ENGLAND.							ABBOTT JD, 1985, J INFECTION, V11, P241, DOI 10.1016/S0163-4453(85)93294-3; ABRAMSON JS, 1985, J INFECT DIS, V151, P370, DOI 10.1093/infdis/151.2.370; ANDERSEN BM, 1980, ACTA PATH MICRO IM B, V88, P231; BANKS HS, 1948, LANCET, V252, P677, DOI 10.1016/S0140-6736(48)91113-1; BANKS HS, 1948, LANCET, V255, P635; BAXTER P, 1988, LANCET, V1, P1166; BJUNE G, 1991, LANCET, V338, P1093, DOI 10.1016/0140-6736(91)91961-S; BRANDTZAEG P, 1989, J INFECT DIS, V159, P195, DOI 10.1093/infdis/159.2.195; CARTWRIGHT KAV, 1986, LANCET, V2, P558; CARTWRIGHT KAV, 1990, J CLIN PATHOL, V43, P438, DOI 10.1136/jcp.43.5.438-a; CONVERSE GM, 1973, J PEDIATR-US, V83, P220, DOI 10.1016/S0022-3476(73)80479-2; Dean A. G., 1990, EPI INFO VERSION 5 W; DEVOE IW, 1982, MICROBIOL REV, V46, P162, DOI 10.1128/MMBR.46.2.162-190.1982; EDWARDS EA, 1977, SCAND J INFECT DIS, V9, P105, DOI 10.3109/inf.1977.9.issue-2.09; FALLON RJ, 1984, J HYG-CAMBRIDGE, V93, P167, DOI 10.1017/S0022172400064688; GEDDE-DAHL T W, 1990, NIPH (National Institute of Public Health) Annals (Oslo), V13, P45; GOLDACRE MJ, 1977, ARCH DIS CHILD, V52, P501, DOI 10.1136/adc.52.6.501; GOLDACRE MJ, 1976, BRIT MED J, V2, P501, DOI 10.1136/bmj.2.6034.501; HARVEY IM, 1989, HLTH TRENDS, V21, P73; JARVIS CW, 1972, CLIN PEDIATR, V11, P201, DOI 10.1177/000992287201100406; Jones D M, 1992, Commun Dis Rep CDR Rev, V2, pR61; Jones D M, 1991, CDR (Lond Engl Rev), V1, pR76; Lieberman J M, 1990, Infect Dis Clin North Am, V4, P703; MELLADO MC, 1991, EPIDEMIOL INFECT, V106, P283, DOI 10.1017/S0950268800048421; NIKLASSON P-M, 1971, Scandinavian Journal of Infectious Diseases, V3, P17, DOI 10.3109/inf.1971.3.issue-1.03; OAKLEY JR, 1979, BRIT MED J, V2, P468, DOI 10.1136/bmj.2.6188.468; ONG ELC, 1988, BRIT MED J, V297, P901, DOI 10.1136/bmj.297.6653.901; SIPPEL JE, 1990, J CLIN PATHOL, V43, P610, DOI 10.1136/jcp.43.7.610-c; SLACK J, 1982, J ROY COLL PHYS LOND, V16, P40; STEPHENS DS, 1991, REV INFECT DIS, V13, P22; STRANG JR, 1992, BRIT MED J, V305, P141, DOI 10.1136/bmj.305.6846.141; SURTEES SJ, 1991, BRIT MED J, V302, P1051, DOI 10.1136/bmj.302.6784.1051; TALAN DA, 1989, ANN EMERG MED, V18, P856, DOI 10.1016/S0196-0644(89)80213-6; TALAN DA, 1988, REV INFECT DIS, V10, P365; TOEWS WH, 1974, AM J DIS CHILD, V127, P173, DOI 10.1001/archpedi.1974.02110210023003; TONJUM T, 1983, NIPH (National Institute of Public Health) Annals (Oslo), V6, P175; WAAGE A, 1989, J EXP MED, V169, P333, DOI 10.1084/jem.169.1.333; WAAGE A, 1987, LANCET, V1, P355; 1990, IMMUNISATION INFECTI, P166; 1974, LANCET, V1, P55; 1988, MENINGOCOCCAL INFECT; 1989, DRUG THER B, V27, P17	42	205	207	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 18	1992	305	6846					143	147		10.1136/bmj.305.6846.143	http://dx.doi.org/10.1136/bmj.305.6846.143			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF063	1515827	Bronze, Green Submitted, Green Published			2022-12-01	WOS:A1992JF06300019
J	GORDON, RD; KLEMM, SA; TUNNY, TJ; STOWASSER, M				GORDON, RD; KLEMM, SA; TUNNY, TJ; STOWASSER, M			PRIMARY ALDOSTERONISM - HYPERTENSION WITH A GENETIC-BASIS	LANCET			English	Article							SUPPRESSIBLE HYPER-ALDOSTERONISM	Exciting developments in knowledge of primary aldosteronism include description of new subtypes and elucidation of the genetic basis of one variety. Furthermore, relatively simple biochemical screening (aldosterone/renin ratio) has disclosed that primary aldosteronism is more common than previously thought, by diagnosing patients at an earlier, normokalaemic stage. The mutant gene discovered in the glucocorticoid-suppressible variety (FHI) codes for an aldosterone biosynythetic enzyme normally controlled by angiotensin II, and now controlled by corticotropin. The zona fasciculata is hyperplastic and makes aldosterone and "hybrid steroids" 18-oxocortisol and 18-hydroxycortisol in excess, in response to ACTH but not to angiotensin II. Adrenal tumours have not yet been described in this condition. Aldosterone-producing adenomas (Conn's syndrome) are also commonly composed of zona fasciculata-like cells, make "hybrid steroids" in excess and are very sensitive to ACTH but not to angiotensin II. We have described a new variety of aldosterone-producing adenoma which is responsive to angiotensin II (AII-responsive APA), consists of at least 20% zona glomerulosa-like cells, and does not make "hybrid steroids" in excess. We have also described a new familial variety of primary aldosteronism that includes tumours and is not glucocorticoid-suppressible (FHII). We propose that primary aldosteronism is a spectrum of genetic diseases expressed as either hyperplasia or neoplasia, and that morphological and genetic diversity explains biochemical and clinical behaviour.			GORDON, RD (corresponding author), UNIV QUEENSLAND,GREENSLOPES HOSP,DEPT MED,ENDOCRINE HYPERTENS RES UNIT,BRISBANE,QLD 4120,AUSTRALIA.		Stowasser, Michael/F-4121-2010; Gordon, Richard D/K-2555-2012					AXELROD L, 1992, NEW ENGL J MED, V326, P1617, DOI 10.1056/NEJM199206113262406; GOMEZSANCHEZ CE, 1988, J CLIN ENDOCR METAB, V67, P444, DOI 10.1210/jcem-67-3-444; Gordon R D, 1987, J Hypertens Suppl, V5, pS103; GORDON RD, 1991, CLIN EXP PHARMACOL P, V18, P283, DOI 10.1111/j.1440-1681.1991.tb01446.x; GORDON RD, 1987, CLIN EXPT PHARM PHYS, V17, P175; HAMLET SM, 1985, CLIN EXP PHARMACOL P, V12, P249, DOI 10.1111/j.1440-1681.1985.tb02641.x; HIRAMATSU K, 1981, ARCH INTERN MED, V141, P1589, DOI 10.1001/archinte.141.12.1589; HOEFNAGELS WHL, 1982, NEW ENGL J MED, V306, P427; LIFTON RP, 1992, NATURE, V355, P262, DOI 10.1038/355262a0; MATSUO K, 1985, ACTA PATHOL JAPON, V35, P1511; MCKENNA TJ, 1991, J CLIN ENDOCR METAB, V73, P952, DOI 10.1210/jcem-73-5-952; MIURA K, 1968, J CLIN ENDOCR METAB, V28, P1807, DOI 10.1210/jcem-28-12-1807; STOWASSER M, 1992, CLIN EXP PHARMACOL P, V19, P319, DOI 10.1111/j.1440-1681.1992.tb00462.x; STOWASSER M, 1991, J HYPERTENS, V9, pS264; SUTHERLAND DJ, 1966, CAN MED ASSOC J, V95, P1109; TUNNY TJ, 1991, CLIN ENDOCRINOL, V34, P363, DOI 10.1111/j.1365-2265.1991.tb00306.x; WOODLAND E, 1985, CLIN EXP PHARMACOL P, V12, P245, DOI 10.1111/j.1440-1681.1985.tb02640.x	17	85	87	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 18	1992	340	8812					159	161		10.1016/0140-6736(92)93225-C	http://dx.doi.org/10.1016/0140-6736(92)93225-C			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JE382	1352575				2022-12-01	WOS:A1992JE38200013
J	KAELBLING, M; BURK, RD; ATKIN, NB; JOHNSON, AB; KLINGER, HP				KAELBLING, M; BURK, RD; ATKIN, NB; JOHNSON, AB; KLINGER, HP			LOSS OF HETEROZYGOSITY ON CHROMOSOME-17P AND MUTANT P53 IN HPV-NEGATIVE CERVICAL CARCINOMAS	LANCET			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; LUNG-CANCER; SUPPRESSION; MUTATIONS	Inactivation of the protein product of the wild-type tumour suppressor gene p53 through complexing of the protein with the E6 oncoprotein of human papillomaviruses (HPV) in HPV-infected cells is thought to be important in the aetiology of cervical carcinoma. Mutations of p53 have also been reported in HPV-negative carcinomas, and we now demonstrate loss of heterozygosity (LOH) of chromosome region 17p13 (in which p53 is located) in such tumours. Immunocytochemical staining with monoclonal antimutant-p53 antibody revealed that the carcinomas with LOH on 17p and completely lacking HPV DNA sequences had mutant p53. Thus the LOH had apparently resulted in the loss of the wild-type allele. Consequently, in both HPV-positive and HPV-negative tumours there is loss of function of wild-type p53, in the former because the protein product of the p53 gene complexes with that of the viral E6 gene, in the latter because the protein is altered, presumably as a result of a direct alteration of the p53 gene but possibly because of other posttranslational changes. That this mutant allele of the tumour suppressor gene may sometimes behave like an oncogene is suggested by the presence of more than the expected number of copies of the remaining chromosome 17 homologue in some carcinomas.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MOLEC GENET,1300 MORRIS PK AVE,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT PATHOL,BRONX,NY 10461; MT VERNON HOSP,DEPT CANC RES,NORTHWOOD HA6 2RN,MIDDX,ENGLAND; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT PEDIAT,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MICROBIOL & IMMUNOL,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT OBSTET & GYNECOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine					NATIONAL CANCER INSTITUTE [P30CA013330, R01CA051395] Funding Source: NIH RePORTER; NCI NIH HHS [CA 51395, CA13330] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATKIN NB, 1988, CYTOGENET CELL GENET, V47, P106, DOI 10.1159/000132521; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; CROOK T, 1991, ONCOGENE, V6, P873; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; KAELBLING M, 1986, CYTOGENET CELL GENET, V41, P65, DOI 10.1159/000132206; MORRISON EAB, 1991, INT J CANCER, V49, P6, DOI 10.1002/ijc.2910490103; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SMITS PHM, 1990, VIROLOGY, V176, P158, DOI 10.1016/0042-6822(90)90240-R; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WREDE D, 1991, MOL CARCINOGEN, V4, P171, DOI 10.1002/mc.2940040302	12	50	50	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 18	1992	340	8812					140	142		10.1016/0140-6736(92)93214-8	http://dx.doi.org/10.1016/0140-6736(92)93214-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JE382	1352566				2022-12-01	WOS:A1992JE38200003
J	KEE, F; WILSON, RH; GILLILAND, R; SLOAN, JM; ROWLANDS, BJ; MOOREHEAD, RJ				KEE, F; WILSON, RH; GILLILAND, R; SLOAN, JM; ROWLANDS, BJ; MOOREHEAD, RJ			CHANGING SITE DISTRIBUTION OF COLORECTAL-CANCER	BRITISH MEDICAL JOURNAL			English	Article									NO HLTH & SOCIAL SERV BOARD,DEPT PUBL HLTH MED,BALLYMENA BT42 1QB,NORTH IRELAND; QUEENS UNIV BELFAST,DEPT SURG,BELFAST BT7 1NN,ANTRIM,NORTH IRELAND; QUEENS UNIV BELFAST,DEPT SMALL ANIM MED & SURG,BELFAST BT7 1NN,ANTRIM,NORTH IRELAND	Queens University Belfast; Queens University Belfast								ARMITAGE P, 1987, STATISTICAL METHODS; BEART RW, 1983, DIS COLON RECTUM, V26, P393, DOI 10.1007/BF02553382; JASS JR, 1991, DIS COLON RECTUM, V34, P56, DOI 10.1007/BF02050208; KEE F, 1990, ULSTER MED J, V59, P155; MUIR C, 1987, CANCER INCIDENCE 5 C, V5	5	65	67	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 18	1992	305	6846					158	158		10.1136/bmj.305.6846.158	http://dx.doi.org/10.1136/bmj.305.6846.158			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF063	1515832	Green Published, Green Submitted, Bronze			2022-12-01	WOS:A1992JF06300024
J	KEENLYSIDE, RA; HAWKINS, AS; JOHNSON, AM; ADLER, MW				KEENLYSIDE, RA; HAWKINS, AS; JOHNSON, AM; ADLER, MW			FOR DEBATE - ATTITUDES TO TRACING AND NOTIFYING CONTACTS OF PEOPLE WITH HIV-INFECTION	BRITISH MEDICAL JOURNAL			English	Article							IMMUNODEFICIENCY VIRUS-INFECTION; PARTNER NOTIFICATION; AIDS				KEENLYSIDE, RA (corresponding author), UNIV COLL & MIDDLESEX SCH MED,ACAD DEPT GENITOURINARY MED,LONDON WC1 8AA,ENGLAND.			Johnson, Anne/0000-0003-1330-7100				ADLER MW, 1988, BRIT MED J, V296, P1420, DOI 10.1136/bmj.296.6634.1420; CATES W, 1988, AM J PUBLIC HEALTH, V78, P1533, DOI 10.2105/AJPH.78.12.1533; CHIN J, 1990, LANCET, V336, P221, DOI 10.1016/0140-6736(90)91743-T; DROTMAN DP, 1989, ANN INTERN MED, V110, P680, DOI 10.7326/0003-4819-110-9-680; ERON J J JR, 1990, AIDS (London), V4, pS193; FEINBERG J, 1990, AIDS (London), V4, pS209; GIESECKE J, 1990, LANCET, V336, P508, DOI 10.1016/0140-6736(90)92058-P; GIESECKE J, 1991, LANCET, V338, P1096, DOI 10.1016/0140-6736(91)91962-T; GOSTIN L, 1987, AM J PUBLIC HEALTH, V77, P361, DOI 10.2105/AJPH.77.3.361; JONES JL, 1990, JAMA-J AM MED ASSOC, V264, P1284, DOI 10.1001/jama.264.10.1284; LEEN CLS, 1989, LANCET, V2, P512; MILLER D, 1989, AIDS, V3, pS187, DOI 10.1097/00002030-198901001-00027; OSBORN JE, 1988, NEW ENGL J MED, V318, P444, DOI 10.1056/NEJM198802183180710; POTTERAT JJ, 1989, AM J PUBLIC HEALTH, V29, P874; RAMSTEDT K, 1990, SEX TRANSM DIS, V17, P37, DOI 10.1097/00007435-199017010-00008; RHAME FS, 1989, NEW ENGL J MED, V320, P1249; RUTHERFORD GW, 1988, JAMA-J AM MED ASSOC, V259, P3609, DOI 10.1001/jama.259.24.3609; SESNAN K, 1989, VENEROLOGY, V2, P75; TOOMEY KE, 1989, AIDS, V3, pS57, DOI 10.1097/00002030-198901001-00009; VERNON TM, 1988, JAMA-J AM MED ASSOC, V260, P3274; WYKOFF RF, 1988, JAMA-J AM MED ASSOC, V259, P3563, DOI 10.1001/jama.259.24.3563; 1989, REPORT CONSULTATION; 1980, HDB CONTACT TRACING; 1991, AIDS HIV QUARTERLY S; 1983, MMWR, V37, P393	25	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 18	1992	305	6846					165	168		10.1136/bmj.305.6846.165	http://dx.doi.org/10.1136/bmj.305.6846.165			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF063	1515835	Bronze, Green Published, Green Submitted			2022-12-01	WOS:A1992JF06300029
J	LIM, R; DYMOND, DS				LIM, R; DYMOND, DS			SHOULD ANTIANGINAL MEDICATION BE STOPPED FOR EXERCISE TESTING	LANCET			English	Editorial Material							CORONARY-ARTERY DISEASE				LIM, R (corresponding author), ST BARTHOLOMEWS HOSP,DEPT CARDIOL,LONDON EC1A 7BE,ENGLAND.		Lim, Richard/J-7102-2012	Lim, Richard/0000-0002-4914-7244				ELAMIN MS, 1982, BRIT HEART J, V48, P311; GOHLKE H, 1983, CIRCULATION, V68, P979, DOI 10.1161/01.CIR.68.5.979; HO WCS, 1985, AM J CARDIOL, V55, P258; JONES RH, 1981, CIRCULATION, V64, P586, DOI 10.1161/01.CIR.64.3.586; KRONE RJ, 1987, AM J CARDIOL, V60, P23, DOI 10.1016/0002-9149(87)90977-5; Lim R, 1991, Int J Card Imaging, V7, P125, DOI 10.1007/BF01798052; LIM R, 1992, AM J CARDIOL, V69, P733, DOI 10.1016/0002-9149(92)90496-L; LIM R, 1991, Journal of the American College of Cardiology, V17, p183A; STONE D, 1980, BRIT HEART J, V44, P208; WILCOX I, 1991, J AM COLL CARDIOL, V18, P677, DOI 10.1016/0735-1097(91)90789-C	10	11	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 18	1992	340	8812					161	162		10.1016/0140-6736(92)93226-D	http://dx.doi.org/10.1016/0140-6736(92)93226-D			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JE382	1352576				2022-12-01	WOS:A1992JE38200014
J	MACCHIARINI, P; FONTANINI, G; HARDIN, MJ; SQUARTINI, F; ANGELETTI, CA				MACCHIARINI, P; FONTANINI, G; HARDIN, MJ; SQUARTINI, F; ANGELETTI, CA			RELATION OF NEOVASCULARIZATION TO METASTASIS OF NON-SMALL-CELL LUNG-CANCER	LANCET			English	Note							ANGIOGENESIS; VESSELS	The growth of a tumour beyond a certain size requires angiogenesis. We assessed whether intensity of angiogenesis correlates with metastasis of non-small-cell lung cancer by counting microvessels and grading their density within the initial carcinomas in 87 T1N0M0 patients. After radical surgery, metastases developed in 22. Both microvessel count and density grades correlated significantly with metastatic disease as well as tumour size and proliferative activity. The likelihood of metastasis increased as the vessel count increased. On multivariate analysis, the microvessel density count was the only independent predictor of metastasis.	UNIV PISA,INST PATHOL ANAT & HISTOL,I-56100 PISA,ITALY; UNIV ALABAMA,DEPT BIOSTAT,BIRMINGHAM,AL 35294; UNIV PISA,SERV THORAC SURG,I-56100 PISA,ITALY	University of Pisa; University of Alabama System; University of Alabama Birmingham; University of Pisa			Fontanini, Gabriella/O-7636-2015; Macchiarini, Paolo/E-6878-2013	Fontanini, Gabriella/0000-0003-1957-2052; 				EAVES G, 1972, J PATHOL, V109, P233; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FOLKMAN J, 1980, NATURE, V288, P551, DOI 10.1038/288551a0; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; FONTANINI G, IN PRESS CANCER; Hsu S.M., 1984, ADV IMMUNOHISTOCHEMI, P31; LIOTTA LA, 1974, CANCER RES, V34, P997; NAGY J A, 1988, Biochimica et Biophysica Acta, V948, P305; SRIVASTAVA A, 1988, AM J PATHOL, V133, P19; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101	10	788	853	0	19	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 18	1992	340	8812					145	146		10.1016/0140-6736(92)93217-B	http://dx.doi.org/10.1016/0140-6736(92)93217-B			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JE382	1378165				2022-12-01	WOS:A1992JE38200005
J	MODAN, B				MODAN, B			DIET AND CANCER - CAUSAL RELATION OR JUST WISHFUL THINKING	LANCET			English	Editorial Material							BREAST-CANCER; COLON CANCER; FIBER; RISK; EPIDEMIOLOGY; ETIOLOGY				MODAN, B (corresponding author), CHAIM SHEBA MED CTR,DEPT CLIN EPIDEMIOL,IL-52621 TEL HASHOMER,ISRAEL.							Baker S. R., 1990, ADV MOD ENV TOXICOL, V18, P1; Burkitt D P, 1972, Lancet, V2, P1408; CARROLL KK, 1968, CAN MED ASSOC J, V98, P590; EIGHANY NA, 1990, EPIDEMIOLOGY, V1, P107; GRAHAM S, 1988, AM J EPIDEMIOL, V128, P490, DOI 10.1093/oxfordjournals.aje.a114997; GRAHAM S, 1979, AM J EPIDEMIOL, V109, P1; HILL MJ, 1974, CANCER, V34, P815, DOI 10.1002/1097-0142(197409)34:3+<815::AID-CNCR2820340705>3.0.CO;2-6; HOWE GR, 1990, JNCI-J NATL CANCER I, V82, P561, DOI 10.1093/jnci/82.7.561; HOWELL MA, 1974, BRIT J CANCER, V29, P328, DOI 10.1038/bjc.1974.75; HOWSON CP, 1986, EPIDEMIOL REV, V8, P1; KMET J, 1972, SCIENCE, V175, P846, DOI 10.1126/science.175.4024.846; Kritchevsky D, 1986, Prog Clin Biol Res, V222, P495; LUBIN F, 1986, JNCI-J NATL CANCER I, V77, P605, DOI 10.1093/jnci/77.3.605; MODAN B, 1975, J NATL CANCER I, V55, P15, DOI 10.1093/jnci/55.1.15; PHILLIPS RL, 1975, CANCER RES, V35, P3513; RUSSELL R, 1916, NOTES CAUSATION CANC; SLATTERY ML, 1988, J NATL CANCER I, V80, P1474, DOI 10.1093/jnci/80.18.1474; SNOW J, 1945, SNOW CHOLERA; TANNENBAUM A, 1953, ADV CANCER RES, V1, P451, DOI 10.1016/S0065-230X(08)60009-3; WYNDER EL, 1991, CANCER-AM CANCER SOC, V67, P746, DOI 10.1002/1097-0142(19910201)67:3<746::AID-CNCR2820670336>3.0.CO;2-1; 1987, REGULATING PESTICIDE	21	7	7	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 18	1992	340	8812					162	164		10.1016/0140-6736(92)93227-E	http://dx.doi.org/10.1016/0140-6736(92)93227-E			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JE382	1352577				2022-12-01	WOS:A1992JE38200015
J	NGUYENVANTAM, JS; BAKER, DM				NGUYENVANTAM, JS; BAKER, DM			GENERAL-PRACTICE AND ACCIDENT AND EMERGENCY DEPARTMENT CARE - DOES THE PATIENT KNOW BEST	BRITISH MEDICAL JOURNAL			English	Article									UNIV NOTTINGHAM HOSP,DEPT ACCID & EMERGENCY,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham			Nguyen-Van-Tam, Jonathan/I-2162-2019	Nguyen-Van-Tam, Jonathan/0000-0003-2579-4655; Baker, Daryll/0000-0002-0098-405X				DAVISON AG, 1983, J ROY SOC MED, V76, P37, DOI 10.1177/014107688307600109	1	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 18	1992	305	6846					157	158		10.1136/bmj.305.6846.157	http://dx.doi.org/10.1136/bmj.305.6846.157			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF063	1515831	Green Published, Green Submitted, Bronze			2022-12-01	WOS:A1992JF06300023
J	SHARPE, M; HAWTON, K; SEAGROATT, V; PASVOL, G				SHARPE, M; HAWTON, K; SEAGROATT, V; PASVOL, G			FOLLOW-UP OF PATIENTS PRESENTING WITH FATIGUE TO AN INFECTIOUS-DISEASES CLINIC	BRITISH MEDICAL JOURNAL			English	Article							POSTVIRAL FATIGUE; HOSPITAL ANXIETY; DEPRESSION SCALE	Objectives-To determine the symptomatic and functional status during follow up of patients referred to hospital with unexplained fatigue and to identify patient variables associated with persistent functional impairment. Design-Follow up by postal questionnaire six weeks to four years (median 1 year) after initial clinical assessment of patients referred to hospital during 1984-8. Setting-Infectious diseases outpatient clinic in a teaching hospital. Patients-200 consecutive patients with fatigue of uncertain cause for at least six weeks; 177 fulfilled the inclusion criteria. Main outcome measures-Findings at initial assessment; current symptoms, beliefs about the cause of illness, coping behaviours emotional disorder, social variables including membership of self help organisations, and degrees of recovery and functional impairment from questionnaire responses. Results-144 (81%) patients returned completed questionnaires. Initial assessment did not indicate the cause of fatigue, other than preceding infection. The proportion of patients with functional impairment was significantly smaller with longer follow up (33% (11/33) at two to four years, 73% (29/40) at six weeks to six months; chi-2 for trend = 12.5, df=1; p<0.05). Functional impairment was significantly associated with belief in a viral cause of the illness (odds ratio=3-9; 95% confidence interval 1.5 to 9.9), limiting exercise (3.2; 1.5 to 6.6), avoiding alcohol (4.5; 1.8 to 11.3), changing or leaving employment (3.1; 1.4 to 6.9), belonging to a self help organisation (7.8; 2.5 to 23.9), and current emotional disorder (4.4; 2.0 to 9.3). Conclusions-Short term prognosis for recovery of function was poor but improved with time. Most patients had made a functional recovery by two years after initial clinic attendance. Impaired functioning was more likely with certain patient characteristics. Prospective studies are required to clarify whether these associations are the consequences of a more disabling illness or indicate factors contributing to impaired function.	JOHN RADCLIFFE HOSP,NUFFIELD DEPT MED,OXFORD OX3 9DU,ENGLAND; UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,HLTH CARE EPIDEMIOL UNIT,OXFORD,ENGLAND	University of Oxford; University of Oxford	SHARPE, M (corresponding author), UNIV OXFORD,WARNEFORD HOSP,DEPT PSYCHIAT,OXFORD OX3 7JX,ENGLAND.		Pasvol, Geoffrey/B-7113-2009	sharpe, michael/0000-0002-6474-9980				BEHAN PO, 1988, CRIT REV NEUROBIOL, V4, P157; BUTLER S, 1991, J NEUROL NEUROSUR PS, V54, P153, DOI 10.1136/jnnp.54.2.153; DOWSETT EG, 1991, POSTGRAD MED J, V66, P526; HICKIE I, 1990, BRIT J PSYCHIAT, V156, P534, DOI 10.1192/bjp.156.4.534; HOLMES GP, 1988, ANN INTERN MED, V108, P387, DOI 10.7326/0003-4819-108-3-387; KROENKE K, 1988, JAMA-J AM MED ASSOC, V260, P929, DOI 10.1001/jama.260.7.929; LANDAY A, 1991, LANCET, V338, P701; LANE TJ, 1990, AM J MED SCI, V299, P313, DOI 10.1097/00000441-199005000-00005; LEWIS G, 1990, BRIT J PSYCHIAT, V157, P860, DOI 10.1192/bjp.157.6.860; MANU P, 1989, J AFFECT DISORDERS, V17, P165, DOI 10.1016/0165-0327(89)90039-6; McCullagh P., 1989, STANDARD BOOK GEN LI, DOI DOI 10.1007/978-1-4899-3242-6; Millon C, 1989, PSYCHOL HEALTH, V3, P131; Nelson E, 1987, Fam Pract Res J, V6, P175; NIXON DF, 1987, J CLIN PATHOL, V40, P673, DOI 10.1136/jcp.40.6.673; SHARPE M, 1991, BRIT MED BULL, V47, P989, DOI 10.1093/oxfordjournals.bmb.a072525; SHARPE MC, 1991, J ROY SOC MED, V84, P118, DOI 10.1177/014107689108400224; VALDINI A, 1989, FAM PRACT, V6, P286, DOI 10.1093/fampra/6.4.286; VALDINI AF, 1988, J FAM PRACTICE, V26, P33; VINCENT A, 1985, J NEUROL NEUROSUR PS, V48, P1246, DOI 10.1136/jnnp.48.12.1246; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914; WESSELY S, 1989, J NEUROL NEUROSUR PS, V52, P940, DOI 10.1136/jnnp.52.8.940; WESSELY S, 1989, J ROY COLL GEN PRACT, V39, P26; YOUSEF GE, 1988, LANCET, V1, P146; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	24	148	149	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 18	1992	305	6846					147	152		10.1136/bmj.305.6846.147	http://dx.doi.org/10.1136/bmj.305.6846.147			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF063	1515828	Green Submitted, Green Published, Bronze			2022-12-01	WOS:A1992JF06300020
J	STRANG, JR; PUGH, EJ				STRANG, JR; PUGH, EJ			MENINGOCOCCAL INFECTIONS - REDUCING THE CASE FATALITY RATE BY GIVING PENICILLIN BEFORE ADMISSION TO HOSPITAL	BRITISH MEDICAL JOURNAL			English	Article							DISEASE	Objective-To determine whether parenteral penicillin given before admission to hospital reduces the case fatality rate in patients with meningococcal disease. Design-Retrospective analysis of 46 consecutive patients admitted to hospital with meningococcal disease from january 1986 to March 1991. Setting-District general hospital. Main outcome measure-Hospital case fatality rate. Results-None of the 13 patients given parenteral penicillin by the referring doctor before admission died, compared with eight deaths (24%) in 33 patients admitted without such treatment. Conclusion-Parenteral penicillin given before admission probably contributed to a reduction in the case fatality rate from meningococcal disease, and primary care physicians should be encouraged to give such treatment immediately on suspicion of the diagnosis before transferring the patient to hospital. Public health physicians are well placed to inform and alert general practitioners of the potential benefit of this action.	MEM HOSP DARLINGTON,PUBL HLTH MED,DARLINGTON DL3 6HX,ENGLAND									BJUNE G, 1991, LANCET, V338, P1093, DOI 10.1016/0140-6736(91)91961-S; CARTWRIGHT KAV, 1986, LANCET, V2, P558; GEDDE-DAHL T W, 1990, NIPH (National Institute of Public Health) Annals (Oslo), V13, P45; HAVENS PL, 1989, PEDIATR INFECT DIS J, V8, P8, DOI 10.1097/00006454-198901000-00003; HOPKIN D A B, 1978, Lancet, V2, P1193; Jones D M, 1991, CDR (Lond Engl Rev), V1, pR76; SURTEES SJ, 1991, BRIT MED J, V302, P1051, DOI 10.1136/bmj.302.6784.1051; WELSBY PD, 1990, BRIT MED J, V300, P1150, DOI 10.1136/bmj.300.6733.1150; 1980, INFECTIONS DISEASES; 1989, COMMUNICABLE DISEASE, V8, P3; 1960, IMMUNISATION INFECTI, P166; 1988, MENINGOCOCCAL INFECT	12	117	119	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 18	1992	305	6846					141	143		10.1136/bmj.305.6846.141	http://dx.doi.org/10.1136/bmj.305.6846.141			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF063	1515826	Green Submitted, Green Published, Bronze			2022-12-01	WOS:A1992JF06300018
J	BIRREN, SJ; VERDI, JM; ANDERSON, DJ				BIRREN, SJ; VERDI, JM; ANDERSON, DJ			MEMBRANE DEPOLARIZATION INDUCES P140(TRK) AND NGF RESPONSIVENESS, BUT NOT P75(LNGFR), IN MAH CELLS	SCIENCE			English	Article							NERVE GROWTH-FACTOR; SUPERIOR CERVICAL-GANGLION; NEURONAL DIFFERENTIATION; SYMPATHETIC NEURONS; CHROMAFFIN CELLS; RECEPTOR; GLUCOCORTICOIDS; EXPRESSION; DEPENDENCE; DEATH	Nerve growth factor (NGF) is required for the maturation and survival of sympathetic neurons, but the mechanisms controlling expression of the NGF receptor in developing neuroblasts have not been defined. MAH cells, an immortalized sympathoadrenal progenitor cell line, did not respond to NGF and expressed neither low-affinity NGF receptor (p75) nor p140trk messenger RNAs. Depolarizing concentrations of potassium chloride, but none of a variety of growth factors, induced expression of p140trk but not p75 messenger RNA. A functional response to NGF was acquired by MAH cells under these conditions, suggesting that expression of p75 is not essential for this response. Depolarization also permitted a relatively high proportion of MAH cells to develop and survive as neurons in fibroblast growth factor and NGF. These data establish a relation between electrical activity and neurotrophic factor responsiveness in developing neurons, which may operate in the functioning of the mature nervous system as well.	CALTECH,HOWARD HUGHES MED INST,PASADENA,CA 91125	California Institute of Technology; Howard Hughes Medical Institute					NINDS NIH HHS [NS23476] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023476] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON DJ, 1986, CELL, V47, P1079, DOI 10.1016/0092-8674(86)90823-8; BIRREN SJ, 1990, NEURON, V4, P189, DOI 10.1016/0896-6273(90)90094-V; BIRREN SJ, UNPUB; CHANDLER CE, 1984, J BIOL CHEM, V259, P6882; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; COUGHLIN MD, 1985, DEV BIOL, V110, P392, DOI 10.1016/0012-1606(85)90098-3; DAVIES AM, 1987, NATURE, V326, P353, DOI 10.1038/326353a0; DOUPE AJ, 1985, J NEUROSCI, V5, P2119; ERNSBERGER U, 1989, DEV BIOL, V135, P250, DOI 10.1016/0012-1606(89)90177-2; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOIKE T, 1989, P NATL ACAD SCI USA, V86, P6421, DOI 10.1073/pnas.86.16.6421; KORSCHING S, 1988, DEV BIOL, V126, P40, DOI 10.1016/0012-1606(88)90236-9; LEVIMONTALCINI R, 1960, P NATL ACAD SCI USA, V46, P384, DOI 10.1073/pnas.46.3.384; LILLIEN LE, 1985, NATURE, V317, P632, DOI 10.1038/317632a0; MADERDRUT JL, 1988, BRAIN RES, V444, P189, DOI 10.1016/0006-8993(88)90928-6; NEBREDA AR, 1991, SCIENCE, V252, P558, DOI 10.1126/science.1850550; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RODRIGUEZTEBAR A, 1991, DEVELOPMENT, V112, P813; RUBIN E, 1985, J NEUROSCI, V5, P673; RUBIN E, 1985, J NEUROSCI, V5, P697; RUBIN E, 1985, J NEUROSCI, V5, P685; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; STEMPLE DL, 1988, NEURON, V1, P517, DOI 10.1016/0896-6273(88)90182-1; UNSICKER K, 1989, INT J DEV NEUROSCI, V7, P413, DOI 10.1016/0736-5748(89)90002-6; WESKAMP G, 1991, NEURON, V6, P649, DOI 10.1016/0896-6273(91)90067-A	29	128	129	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 17	1992	257	5068					395	397		10.1126/science.1321502	http://dx.doi.org/10.1126/science.1321502			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JD674	1321502				2022-12-01	WOS:A1992JD67400036
J	BURNETT, AL; LOWENSTEIN, CJ; BREDT, DS; CHANG, TSK; SNYDER, SH				BURNETT, AL; LOWENSTEIN, CJ; BREDT, DS; CHANG, TSK; SNYDER, SH			NITRIC-OXIDE - A PHYSIOLOGICAL MEDIATOR OF PENILE ERECTION	SCIENCE			English	Article							VASOACTIVE INTESTINAL POLYPEPTIDE; MONOMETHYL-L-ARGININE; RAT ANOCOCCYGEUS MUSCLE; CORPUS CAVERNOSUM; SMOOTH-MUSCLE; RELAXING FACTOR; RELAXATION; NEUROTRANSMITTER; STIMULATION; LOCALIZATION	Nitric oxide (NO) is a cytotoxic agent of macrophages, a messenger molecule of neurons, and a vasodilator produced by endothelial cells. NO synthase, the synthetic enzyme for NO, was localized to rat penile neurons innervating the corpora cavernosa and to neuronal plexuses in the adventitial layer of penile arteries. Small doses of NO synthase inhibitors abolished electrophysiologically induced penile erections. These results establish NO as a physiologic mediator of erectile function.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,725 N WOLFE ST,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOLEC SCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PSYCHIAT,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT UROL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT CARDIOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University			Bredt, David/J-4872-2012	Lowenstein, Charles/0000-0003-0485-7514	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK019300] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH018501, R01MH018501] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA000266] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-00266] Funding Source: Medline; NIDDK NIH HHS [DK-19300] Funding Source: Medline; NIMH NIH HHS [MH-18501] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BENSON GS, 1983, WORLD J UROL, V1, P209, DOI 10.1007/BF00326804; BLANCO R, 1988, AM J PHYSIOL, V254, P468; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BULT H, 1990, NATURE, V345, P346, DOI 10.1038/345346a0; COCKS TM, 1990, N-S ARCH PHARMACOL, V341, P364; DAIL WG, 1989, ANAT RECORD, V224, P94, DOI 10.1002/ar.1092240112; DESAI KM, 1991, NATURE, V351, P477, DOI 10.1038/351477a0; EMOND AM, 1980, ARCH INTERN MED, V140, P1434, DOI 10.1001/archinte.140.11.1434; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GIBSON A, 1990, BRIT J PHARMACOL, V99, P602, DOI 10.1111/j.1476-5381.1990.tb12976.x; GILLESPIE J S, 1989, British Journal of Pharmacology, V97, p453P; GILLESPIE JS, 1989, BRIT J PHARMACOL, V98, P1080, DOI 10.1111/j.1476-5381.1989.tb12650.x; HIBBS JB, 1987, J IMMUNOL, V138, P550; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; HOLMQUIST F, 1991, ACTA PHYSIOL SCAND, V143, P299, DOI 10.1111/j.1748-1716.1991.tb09236.x; HOLMQUIST F, 1991, ACTA PHYSIOL SCAND, V141, P441, DOI 10.1111/j.1748-1716.1991.tb09103.x; IGNARRO LJ, 1990, BIOCHEM BIOPH RES CO, V170, P843, DOI 10.1016/0006-291X(90)92168-Y; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; JUENEMANN KP, 1987, J UROLOGY, V138, P871, DOI 10.1016/S0022-5347(17)43406-9; KIELY EA, 1989, BRIT J UROL, V64, P191, DOI 10.1111/j.1464-410X.1989.tb05986.x; KIM N, 1991, J CLIN INVEST, V88, P112, DOI 10.1172/JCI115266; LI CG, 1990, EUR J PHARMACOL, V191, P303; MONCADA S, 1989, BIOCHEM PHARMACOL, V38, P1709, DOI 10.1016/0006-2952(89)90403-6; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; NOZAKI K, IN PRESS J CEREB BLO; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PALOMAR JM, 1980, J UROLOGY, V123, P680, DOI 10.1016/S0022-5347(17)56090-5; PICKARD RS, 1991, BRIT J PHARMACOL, V104, P755, DOI 10.1111/j.1476-5381.1991.tb12500.x; POLAK JM, 1981, LANCET, V2, P217; QUINLAN DM, 1989, J UROLOGY, V141, P656, DOI 10.1016/S0022-5347(17)40926-8; RAJFER J, 1992, NEW ENGL J MED, V326, P90, DOI 10.1056/NEJM199201093260203; RAMAGOPAL MV, 1989, EUR J PHARMACOL, V174, P297, DOI 10.1016/0014-2999(89)90325-7; ROY JB, 1990, J UROLOGY, V143, P302, DOI 10.1016/S0022-5347(17)39939-1; SJOSTRAND NO, 1990, ACTA PHYSIOL SCAND, V140, P297, DOI 10.1111/j.1748-1716.1990.tb09002.x; STEERS WD, 1984, J UROLOGY, V132, P1048, DOI 10.1016/S0022-5347(17)49997-6; TOTTRUP A, 1991, AM J PHYSIOL, V260, pG385, DOI 10.1152/ajpgi.1991.260.3.G385; WALSH PC, 1982, J UROLOGY, V128, P492, DOI 10.1016/S0022-5347(17)53012-8; WILLIS EA, 1983, LIFE SCI, V33, P383, DOI 10.1016/S0024-3205(83)80013-7	42	1009	1041	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 17	1992	257	5068					401	403		10.1126/science.1378650	http://dx.doi.org/10.1126/science.1378650			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JD674	1378650				2022-12-01	WOS:A1992JD67400038
J	CAMERON, PU; FREUDENTHAL, PS; BARKER, JM; GEZELTER, S; INABA, K; STEINMAN, RM				CAMERON, PU; FREUDENTHAL, PS; BARKER, JM; GEZELTER, S; INABA, K; STEINMAN, RM			DENDRITIC CELLS EXPOSED TO HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 TRANSMIT A VIGOROUS CYTOPATHIC INFECTION TO CD4+ T-CELLS	SCIENCE			English	Article							HUMAN PERIPHERAL-BLOOD; LYMPHOCYTES-T; LYMPH-NODES; HTLV-III/LAV; AIDS; LYMPHADENOPATHY; EXPRESSION; HIV-1; RETROVIRUS; ANTIGEN	The paucity of virus-laden CD4+ cells in individuals infected with human immunodeficiency virus type-1 (HIV-1) contrasts with the greatly reduced numbers and function of these lymphocytes. A pathway is described whereby dendritic cells carry HIV-1 to uninfected T cells, amplifying the cytopathic effects of small amounts of virus. After exposure to HIV-1, dendritic cells continue to present superantigens and antigens, forming clusters with T cells that are driven to replicate. Infection of the dendritic cells cannot be detected, but the clustered T cells form syncytia, release virions, and die. Carriage of HIV-1 by dendritic cells may facilitate the lysis and loss of antigen specific CD4+ T cells in acquired immunodeficiency syndrome.	ROCKEFELLER UNIV,CELLULAR PHYSIOL & IMMUNOL LAB,NEW YORK,NY 10021	Rockefeller University			Cameron, Paul/H-3474-2011; Steinman, Ralph/F-7729-2012	Cameron, Paul Urquhart/0000-0002-1906-6945	NCRR NIH HHS [MOI-RR00102] Funding Source: Medline; NIAID NIH HHS [AI 24775] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI024775] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; ARMSTRONG JA, 1984, LANCET, V2, P370; BHARDWAJ N, 1992, J EXP MED, V175, P267, DOI 10.1084/jem.175.1.267; BIBERFELD P, 1986, AM J PATHOL, V125, P436; CAMERON PU, 1992, CLIN EXP IMMUNOL, V88, P226, DOI 10.1111/j.1365-2249.1992.tb03066.x; CAMERON PU, 1987, CLIN EXP IMMUNOL, V68, P465; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; FLECHNER ER, 1988, CELL IMMUNOL, V111, P183, DOI 10.1016/0008-8749(88)90062-7; FREUDENTHAL PS, 1990, P NATL ACAD SCI USA, V87, P7698, DOI 10.1073/pnas.87.19.7698; GOFF S, 1981, J VIROL, V38, P239, DOI 10.1128/JVI.38.1.239-248.1981; HARPER ME, 1986, P NATL ACAD SCI USA, V83, P772, DOI 10.1073/pnas.83.3.772; INABA K, 1987, J EXP MED, V166, P182, DOI 10.1084/jem.166.1.182; INABA K, 1984, J EXP MED, V160, P1717, DOI 10.1084/jem.160.6.1717; KLATZMANN D, 1984, SCIENCE, V225, P59, DOI 10.1126/science.6328660; LANGHOFF E, 1989, J EXP MED, V169, P315, DOI 10.1084/jem.169.1.315; LANGHOFF E, 1991, P NATL ACAD SCI USA, V88, P7998, DOI 10.1073/pnas.88.18.7998; LEVY JA, 1988, NATURE, V333, P519, DOI 10.1038/333519a0; LIFSON JD, 1986, NATURE, V323, P725, DOI 10.1038/323725a0; LIFSON JD, 1986, SCIENCE, V232, P1123, DOI 10.1126/science.3010463; MACATONIA SE, 1989, IMMUNOLOGY, V67, P285; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MCDOUGAL JS, 1985, J IMMUNOL, V135, P3151; MCELRATH MJ, 1991, J CLIN INVEST, V87, P27, DOI 10.1172/JCI114981; OU CY, 1988, SCIENCE, V239, P295, DOI 10.1126/science.3336784; PANG S, 1990, NATURE, V343, P85, DOI 10.1038/343085a0; PATTERSON S, 1987, J GEN VIROL, V68, P1177, DOI 10.1099/0022-1317-68-4-1177; PATTERSON S, 1991, IMMUNOLOGY, V72, P361; SCHARF SJ, 1986, SCIENCE, V233, P1076, DOI 10.1126/science.3461561; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; TENNERRACZ K, 1988, NEW ENGL J MED, V318, P49, DOI 10.1056/NEJM198801073180113; WILLEY RL, 1988, J VIROL, V62, P139, DOI 10.1128/JVI.62.1.139-147.1988; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	34	560	572	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 17	1992	257	5068					383	386		10.1126/science.1352913	http://dx.doi.org/10.1126/science.1352913			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JD674	1352913				2022-12-01	WOS:A1992JD67400033
J	DAOPIN, S; PIEZ, KA; OGAWA, Y; DAVIES, DR				DAOPIN, S; PIEZ, KA; OGAWA, Y; DAVIES, DR			CRYSTAL-STRUCTURE OF TRANSFORMING GROWTH-FACTOR-BETA-2 - AN UNUSUAL FOLD FOR THE SUPERFAMILY	SCIENCE			English	Article							DEOXYRIBONUCLEIC-ACID CLONING; MESSENGER RIBONUCLEIC-ACID; X-RAY-DIFFRACTION; FACTOR-BETA; EMBRYO CHONDROCYTES; IDENTIFICATION; PURIFICATION	The transforming growth factors-beta (TGF-beta-1 through -beta-5) are a family of homodimeric cytokines that regulate proliferation and function in many cell types. Family members have 66 to 80% sequence identity and nine strictly conserved cysteines. A crystal structure of a member of this family, TGF-beta-2, has been determined at 2.1 angstrom (angstrom) resolution and refined to an R factor of 0.172. The monomer lacks a well-defined hydrophobic core and displays an unusual elongated nonglobular fold with dimensions of approximately 60 angstrom by 20 angstrom by 15 angstrom. Eight cysteines form four intrachain disulfide bonds, which are clustered in a core region forming a network complementary to the network of hydrogen bonds. The dimer is stabilized by the ninth cysteine, which forms an interchain disulfide bond, and by two identical hydrophobic interfaces. Sequence profile analysis of other members of the TGF-beta superfamily, including the activins, inhibins, and several developmental factors, imply that they also adopt the TGF-beta fold.	NIDDKD,MOLEC BIOL LAB,BETHESDA,MD 20892; NIH,FOGARTY INT CTR,BETHESDA,MD 20892; CELTRIX PHARMACEUT INC,SANTA CLARA,CA 95052	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH Fogarty International Center (FIC)								ARCHER S, COMMUNICATION; ASSOIAN RK, 1983, J BIOL CHEM, V258, P7155; BHAT TN, BROOKHAVEN PROTEIN D; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CHEIFETZ S, 1991, J BIOL CHEM, V266, P20767; CHEIFETZ S, 1987, CELL, V48, P409, DOI 10.1016/0092-8674(87)90192-9; CHOTHIA C, 1974, NATURE, V248, P338, DOI 10.1038/248338a0; DERYNCK R, 1988, EMBO J, V7, P3737, DOI 10.1002/j.1460-2075.1988.tb03257.x; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; FROLIK CA, 1983, P NATL ACAD SCI-BIOL, V80, P3676, DOI 10.1073/pnas.80.12.3676; HANKS SK, 1988, P NATL ACAD SCI USA, V85, P79, DOI 10.1073/pnas.85.1.79; Hendrickson W. A., 1970, Acta Crystallographica, Section B (Structural Crystallography and Crystal Chemistry), Vb26, P136, DOI 10.1107/S0567740870002078; JAKOWLEW SB, 1988, MOL ENDOCRINOL, V2, P747, DOI 10.1210/mend-2-8-747; JAKOWLEW SB, 1988, MOL ENDOCRINOL, V2, P1186, DOI 10.1210/mend-2-12-1186; JOHNSON CK, 1970, ORTEP FORTRAN THERMA; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737; KONDAIAH P, 1990, J BIOL CHEM, V265, P1089; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; LYONS RM, 1990, EUR J BIOCHEM, V187, P467, DOI 10.1111/j.1432-1033.1990.tb15327.x; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATSUMURA M, 1988, NATURE, V334, P406, DOI 10.1038/334406a0; OGAWA Y, 1992, J BIOL CHEM, V267, P2325; OGAWA Y, COMMUNICATION; PIEZ KA, 1990, TRANSFORMING GROWTH, P593; QIAN SW, IN PRESS P NATL ACAD; RICHMOND TJ, 1978, J MOL BIOL, V119, P537, DOI 10.1016/0022-2836(78)90201-2; ROBERTS AB, 1983, BIOCHEMISTRY-US, V22, P5692, DOI 10.1021/bi00294a002; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; SEYEDIN SM, 1987, J BIOL CHEM, V262, P1946; SPORN MB, 1990, CELL REGUL, V1, P875, DOI 10.1091/mbc.1.12.875; SPORN MB, 1990, PEPTIDE GROWTH FACTO, V1, pCH8; TENDIJKE P, 1988, P NATL ACAD SCI USA, V85, P4715; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WRANN M, 1987, EMBO J, V6, P1633, DOI 10.1002/j.1460-2075.1987.tb02411.x	40	394	436	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 17	1992	257	5068					369	373		10.1126/science.1631557	http://dx.doi.org/10.1126/science.1631557			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JD674	1631557	Green Submitted			2022-12-01	WOS:A1992JD67400028
J	FINKEL, MS; ODDIS, CV; JACOB, TD; WATKINS, SC; HATTLER, BG; SIMMONS, RL				FINKEL, MS; ODDIS, CV; JACOB, TD; WATKINS, SC; HATTLER, BG; SIMMONS, RL			NEGATIVE INOTROPIC EFFECTS OF CYTOKINES ON THE HEART MEDIATED BY NITRIC-OXIDE	SCIENCE			English	Article							MYOCARDIAL INJURY; REPERFUSION; DYSFUNCTION; NEUTROPHIL; ISCHEMIA; CELLS	The direct effects of pro-inflammatory cytokines on the contractility of mammalian heart were studied. Tumor necrosis factor-alpha, interleukin-6, and interleukin-2 inhibited contractility of isolated hamster papillary muscles in a concentration-dependent, reversible manner. The nitric oxide synthase inhibitor N(G)-monomethyl-L-arginine (L-NMMA) blocked these negative inotropic effectS. L-Arginine reversed the inhibition by L-NMMA. Removal of the endocardial endothelium did not alter these responses. These findings demonstrate that the direct negative inotropic effect of cytokines is mediated through a myocardial nitric oxide synthase. The regulation of pro-inflammatory cytokines and myocardial nitric oxide synthase may provide new therapeutic strategies for the treatment of cardiac disease.	UNIV PITTSBURGH, SCH MED, DEPT NEUROBIOL ANAT & CELL SCI, PITTSBURGH, PA 15213 USA; UNIV PITTSBURGH, SCH MED, DEPT PHARMACOL, PITTSBURGH, PA 15213 USA; UNIV PITTSBURGH, SCH MED, DEPT SURG, PITTSBURGH, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	FINKEL, MS (corresponding author), UNIV PITTSBURGH, SCH MED, DEPT MED, PITTSBURGH, PA 15213 USA.		Watkins, Simon/ABG-2590-2021	Watkins, Simon/0000-0003-4092-1552	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037753] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-37753] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; DEAGOSTINI AI, 1990, J CELL BIOL, V111, P1293, DOI 10.1083/jcb.111.3.1293; ENGLER R, 1987, CIRC RES, V61, P20, DOI 10.1161/01.RES.61.1.20; FINKEL MS, 1992, J CARDIOVASC PHARM, V19, P610, DOI 10.1097/00005344-199204000-00019; GARMAN RD, 1987, P NATL ACAD SCI USA, V84, P7629, DOI 10.1073/pnas.84.21.7629; GO LO, 1988, AM J PHYSIOL, V255, pH1188, DOI 10.1152/ajpheart.1988.255.5.H1188; GREEN SJ, 1991, J LEUKOCYTE BIOL, V50, P93, DOI 10.1002/jlb.50.1.93; GROSS SS, 1991, BIOCHEM BIOPH RES CO, V178, P823, DOI 10.1016/0006-291X(91)90965-A; HATTIER BG, 1991, 20TH ANN M KEYST S M; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; LI LM, 1991, CANCER RES, V51, P2531; LUCCHESI BR, 1989, J MOL CELL CARDIOL, V21, P1241, DOI 10.1016/0022-2828(89)90670-6; MONCADA S, 1991, J CARDIOVASC PHARM, V17, pS1, DOI 10.1097/00005344-199117003-00002; MULLANE KM, 1988, ANN NY ACAD SCI, V524, P103; NALDINI A, 1987, J IMMUNOL, V139, P1880; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; SHAH AM, 1991, J CARDIOVASC PHARM, V17, pS251, DOI 10.1097/00005344-199117003-00046; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; VANDAMME J, 1987, J EXP MED, V165, P914, DOI 10.1084/jem.165.3.914; WESTLIN W, 1989, CIRCULATION, V80, P1828, DOI 10.1161/01.CIR.80.6.1828	20	1420	1516	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 17	1992	257	5068					387	389		10.1126/science.1631560	http://dx.doi.org/10.1126/science.1631560			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JD674	1631560				2022-12-01	WOS:A1992JD67400034
J	HOSFORD, DA; CLARK, S; CAO, Z; WILSON, WA; LIN, FH; MORRISETT, RA; HUIN, A				HOSFORD, DA; CLARK, S; CAO, Z; WILSON, WA; LIN, FH; MORRISETT, RA; HUIN, A			THE ROLE OF GABA(B) RECEPTOR ACTIVATION IN ABSENCE SEIZURES OF LETHARGIC (IH/IH) MICE	SCIENCE			English	Article							LATERAL GENICULATE-NUCLEUS; PETIT-MAL EPILEPSY; THALAMIC NUCLEI; CALCIUM CURRENT; NEURONS; CAT; ELECTROPHYSIOLOGY; ETHOSUXIMIDE; POTENTIALS; RELEASE	Lethargic (lh/lh) mice, which function as an animal model of absence seizures, have spontaneous seizures that have behavioral and electrographic features and anticonvulsant sensitivity similar to those of human absence seizures. Antagonists of the gamma-aminobutyric acid(B) (GABA(B)) receptor suppressed these seizures in lethargic mice, whereas agonists of GABA(B) receptors exacerbated them. Furthermore, GABA(B) receptor binding and synaptically evoked GABA(B) receptor-mediated inhibition of N-methyl-D-aspartate responses were selectively increased in lh/lh mice. Therefore, enhanced GABA(B) receptor-mediated synaptic responses may underlie absence seizures in lh/lh mice, and GABA(B) receptor antagonists hold promise as anticonvulsants for absence seizures.	UNIV NEBRASKA,MED CTR,DEPT PHARMACOL,OMAHA,NE 68198; DUKE UNIV,MED CTR,DEPT PHARMACOL,DURHAM,NC 27710; VET ADM MED CTR,DURHAM,NC 27705	University of Nebraska System; University of Nebraska Medical Center; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	HOSFORD, DA (corresponding author), DUKE UNIV,MED CTR,DEPT MED NEUROL,DURHAM,NC 27710, USA.			Clark PharmBS PhD, Suzanne/0000-0002-7018-1113				BUZSAKI G, 1990, NEUROSCIENCE, V36, P1, DOI 10.1016/0306-4522(90)90345-5; CLARK S, 1991, EPILEPSIA S3, V32, P66; Cochran W.G, 1957, STAT METHODS, V6th ed; COULTER DA, 1989, ANN NEUROL, V25, P582, DOI 10.1002/ana.410250610; CRUNELLI V, 1988, J PHYSIOL-LONDON, V399, P153; CRUNELLI V, 1991, TRENDS NEUROSCI, V14, P16, DOI 10.1016/0166-2236(91)90178-W; CRUNELLI V, 1989, J PHYSIOL-LONDON, V413, P543, DOI 10.1113/jphysiol.1989.sp017668; DEISZ RA, 1989, J PHYSIOL-LONDON, V412, P513, DOI 10.1113/jphysiol.1989.sp017629; DESCHENES M, 1984, J NEUROPHYSIOL, V51, P1196, DOI 10.1152/jn.1984.51.6.1196; Dickie MM, 1964, MOUSE NEWS LETT, V30, P31; DUNG HC, 1971, TEX REP BIOL MED, V29, P273; HELLER AH, 1983, EPILEPSIA, V25, P25; HOSFORD D A, 1991, Society for Neuroscience Abstracts, V17, P170; JASPER HH, 1946, P ASS RES NERV MENT, V26, P272; KABRA PM, 1977, CLIN CHEM, V23, P1284; KARLSSON G, 1990, GABAB RECEPTORS IN MAMMALIAN FUNCTION, P349; KELLY KM, 1990, NEUROSCI LETT, V116, P233, DOI 10.1016/0304-3940(90)90416-7; KERR DIB, 1988, NEUROSCI LETT, V92, P92, DOI 10.1016/0304-3940(88)90748-3; KRALL RL, 1978, EPILEPSIA, V19, P409, DOI 10.1111/j.1528-1157.1978.tb04507.x; LIU Z, 1992, NEUROSCIENCE, V48, P87, DOI 10.1016/0306-4522(92)90340-8; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MIRSKY AF, 1986, J CLIN NEUROPHYSIOL, V3, P179; MORRISETT RA, 1991, J NEUROSCI, V11, P203; MOTT DD, 1991, SCIENCE, V252, P1718, DOI 10.1126/science.1675489; Noebels J L, 1986, Adv Neurol, V44, P97; OLPE HR, 1990, EUR J PHARMACOL, V187, P27, DOI 10.1016/0014-2999(90)90337-6; PELLEGRINI A, 1979, EXP NEUROL, V66, P285, DOI 10.1016/0014-4886(79)90081-5; ROY JP, 1984, J NEUROPHYSIOL, V51, P1220, DOI 10.1152/jn.1984.51.6.1220; SHEN C, 1985, J NEUROSCI, V5, P2696; Sidman RL, 1965, CATALOG NEUROLOGICAL, P34; SNEAD OC, 1992, EUR J PHARMACOL, V213, P343, DOI 10.1016/0014-2999(92)90623-C; SNEAD OC, 1991, SOC NEUR ABSTR, V17, P506; SNEAD OC, 1991, EPILEPSIA S3, V32, P66; STERIADE M, 1988, PHYSIOL REV, V68, P649, DOI 10.1152/physrev.1988.68.3.649; TAYLOR SM, 1985, EUR J PHARMACOL, V118, P163, DOI 10.1016/0014-2999(85)90675-2; WALDMEIER PC, 1988, N-S ARCH PHARMACOL, V337, P289; WILLIAMS D, 1953, BRAIN, V76, P50, DOI 10.1093/brain/76.1.50; YEH GC, 1989, P NATL ACAD SCI USA, V86, P8157, DOI 10.1073/pnas.86.20.8157	38	289	295	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 17	1992	257	5068					398	401		10.1126/science.1321503	http://dx.doi.org/10.1126/science.1321503			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JD674	1321503				2022-12-01	WOS:A1992JD67400037
J	TAKESHITA, T; ASAO, H; OHTANI, K; ISHII, N; KUMAKI, S; TANAKA, N; MUNAKATA, H; NAKAMURA, M; SUGAMURA, K				TAKESHITA, T; ASAO, H; OHTANI, K; ISHII, N; KUMAKI, S; TANAKA, N; MUNAKATA, H; NAKAMURA, M; SUGAMURA, K			CLONING OF THE GAMMA-CHAIN OF THE HUMAN IL-2 RECEPTOR	SCIENCE			English	Article							HUMAN INTERLEUKIN-2 RECEPTOR; COLONY-STIMULATING FACTOR; NATURAL-KILLER-CELLS; HUMAN T-CELLS; BETA-CHAIN; MOLECULAR-CLONING; SIGNAL TRANSDUCTION; LIGAND-BINDING; EXPRESSION; PROTEINS	A third subunit, the gamma-chain, of the human interleukin-2 receptor (IL-2R) was identified, and a complementary DNA clone encoding this member of the cytokine receptor family was isolated. The gamma-chain is necessary for the formation of the high- and intermediate-affinity receptors, which consist of alpha-beta-gamma-heterotrimers and beta-gamma-heterodimers, respectively. The IL-2R on murine fibroblastoid cells can be internalized after binding IL-2 only if the gamma-chain is present; alpha and beta are insufficient for internalization. Thus, the gamma-chain is an indispensable component of the functional IL-2R.	TOHOKU UNIV,SCH MED,DEPT MICROBIOL,SENDAI,MIYAGI 980,JAPAN; TOHOKU UNIV,SCH MED,DEPT BIOCHEM 2,SENDAI,MIYAGI 980,JAPAN	Tohoku University; Tohoku University			Takeshita, Toshikazu/AAL-1382-2021	Ishii, Naoto/0000-0002-0549-8245				BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BENVENISTE EN, 1986, NATURE, V321, P610, DOI 10.1038/321610a0; FUJII M, 1986, J EXP MED, V163, P550, DOI 10.1084/jem.163.3.550; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HATAKEYAMA M, 1985, NATURE, V317, P467; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HERRMANN F, 1985, J EXP MED, V162, P1111, DOI 10.1084/jem.162.3.1111; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; ISHII T, 1987, BIOCHEM J, V242, P211, DOI 10.1042/bj2420211; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; MINAMOTO S, 1990, J IMMUNOL, V145, P2177; MIURA S, 1991, MOL CELL BIOL, V11, P1313, DOI 10.1128/MCB.11.3.1313; NIKAIDO T, 1984, NATURE, V311, P631, DOI 10.1038/311631a0; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; Suzuki J, 1989, Int Immunol, V1, P373, DOI 10.1093/intimm/1.4.373; TAKAKI S, 1990, EMBO J, V9, P4367, DOI 10.1002/j.1460-2075.1990.tb07886.x; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAKESHITA T, 1989, J EXP MED, V169, P1323, DOI 10.1084/jem.169.4.1323; TAKESHITA T, 1990, INT IMMUNOL, V2, P477, DOI 10.1093/intimm/2.5.477; TAKESHITA T, 1992, J IMMUNOL, V148, P2157; TANAKA Y, 1985, MICROBIOL IMMUNOL, V29, P959, DOI 10.1111/j.1348-0421.1985.tb02960.x; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; TRINCHIERI G, 1984, J EXP MED, V160, P1147, DOI 10.1084/jem.160.4.1147; TSUDO M, 1990, J IMMUNOL, V145, P599; VOSS SD, 1990, J EXP MED, V172, P1101, DOI 10.1084/jem.172.4.1101; WALDMANN TA, 1984, J EXP MED, V160, P1450, DOI 10.1084/jem.160.5.1450; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; ZURAWSKI SM, 1990, EMBO J, V9, P3899, DOI 10.1002/j.1460-2075.1990.tb07610.x	35	876	923	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 17	1992	257	5068					379	382		10.1126/science.1631559	http://dx.doi.org/10.1126/science.1631559			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JD674	1631559				2022-12-01	WOS:A1992JD67400032
J	WILLIAMS, ME; BRUST, PF; FELDMAN, DH; PATTHI, S; SIMERSON, S; MAROUFI, A; MCCUE, AF; VELICELEBI, G; ELLIS, SB; HARPOLD, MM				WILLIAMS, ME; BRUST, PF; FELDMAN, DH; PATTHI, S; SIMERSON, S; MAROUFI, A; MCCUE, AF; VELICELEBI, G; ELLIS, SB; HARPOLD, MM			STRUCTURE AND FUNCTIONAL EXPRESSION OF AN OMEGA-CONOTOXIN SENSITIVE HUMAN N-TYPE CALCIUM-CHANNEL	SCIENCE			English	Article							CHICK SENSORY NEURONS; CURRENTS; PEPTIDES; REQUIREMENTS; BINDING; PROBES; BRAIN; GVIA	N-type calcium channels are omega-conotoxin (omega-CgTx)-sensitive, voltage-dependent ion channels involved in the control of neurotransmitter release from neurons. Multiple subtypes of voltage-dependent calcium channel complexes exist, and it is the alpha-1 subunit of the complex that forms the pore through which calcium enters the cell. The primary structures of human neuronal calcium channel alpha-1B subunits were deduced by the characterization of overlapping complementary DNAs. Two forms (alpha-1B-1 and alpha-1B-2) were identified in human neuroblastoma (IMR32) cells and in the central nervous system, but not in skeletal muscle or aorta tissues. The alpha-1B-1 subunit directs the recombinant expression of N-type calcium channel activity when it is transiently co-expressed with human neuronal beta-2 and alpha-2b subunits in mammalian HEK293 cells. The recombinant channel was irreversibly blocked by omega-CgTx but was insensitive to dihydropyridines. The alpha-1B-1-alpha-2b-beta-2-transfected cells displayed a single class of saturable, high-affinity (dissociation constant = 55 pM) omega-CgTx binding sites. Co-expression of the beta-2 subunit was necessary for N-type channel activity, whereas the alpha-2b subunit appeared to modulate the expression of the channel. The heterogeneity of alpha-1B subunits, along with the heterogeneity of alpha-2 and beta-subunits, is consistent with multiple, biophysically distinct N-type calcium channels.	SIBIA INC,505 COAST BLVD S,LA JOLLA,CA 92037									AHLIJANIAN MK, 1991, J BIOL CHEM, V266, P20192; AOSAKI T, 1989, PFLUG ARCH EUR J PHY, V414, P150, DOI 10.1007/BF00580957; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; BLOUNT P, 1990, J CELL BIOL, V111, P2601, DOI 10.1083/jcb.111.6.2601; CAMPBELL KP, 1988, TRENDS NEUROSCI, V11, P425, DOI 10.1016/0166-2236(88)90193-2; CARBONE E, 1990, PFLUG ARCH EUR J PHY, V416, P170, DOI 10.1007/BF00370239; COHEN MW, 1991, J NEUROSCI, V11, P1032; DUBEL SJ, 1992, P NATL ACAD SCI USA, V89, P5058, DOI 10.1073/pnas.89.11.5058; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; FOX AP, 1987, J PHYSIOL-LONDON, V394, P149, DOI 10.1113/jphysiol.1987.sp016864; GLASS DB, 1986, J BIOL CHEM, V261, P2987; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; JONES OT, 1989, SCIENCE, V244, P1189, DOI 10.1126/science.2543080; JONES SW, 1989, J GEN PHYSIOL, V94, P169, DOI 10.1085/jgp.94.1.169; KIM HL, 1992, P NATL ACAD SCI USA, V89, P3251, DOI 10.1073/pnas.89.8.3251; LLINAS R, 1989, P NATL ACAD SCI USA, V86, P1689, DOI 10.1073/pnas.86.5.1689; MCENERY MW, 1991, P NATL ACAD SCI USA, V88, P11095, DOI 10.1073/pnas.88.24.11095; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MILLER RJ, 1992, J BIOL CHEM, V267, P1403; MINTZ IM, 1992, NATURE, V355, P827, DOI 10.1038/355827a0; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; NOWYCKY MC, 1985, NATURE, V316, P440, DOI 10.1038/316440a0; PEREZREYES E, 1992, J BIOL CHEM, V267, P1792; PLUMMER MR, 1991, NATURE, V351, P657, DOI 10.1038/351657a0; PLUMMER MR, 1989, NEURON, V2, P1453, DOI 10.1016/0896-6273(89)90191-8; PRAGNELL M, 1991, FEBS LETT, V291, P253, DOI 10.1016/0014-5793(91)81296-K; ROBITAILLE R, 1990, NEURON, V5, P773, DOI 10.1016/0896-6273(90)90336-E; SAKAMOTO J, 1991, J BIOL CHEM, V266, P18914; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SHER E, 1988, FEBS LETT, V235, P178, DOI 10.1016/0014-5793(88)81258-4; SHER E, 1991, NEUROSCIENCE, V42, P301, DOI 10.1016/0306-4522(91)90376-Y; SMITH SJ, 1988, TRENDS NEUROSCI, V11, P458, DOI 10.1016/0166-2236(88)90199-3; SNUTCH TP, 1990, P NATL ACAD SCI USA, V87, P3391, DOI 10.1073/pnas.87.9.3391; STANLEY EF, 1991, J NEUROSCI, V11, P985; STARR TVB, 1991, P NATL ACAD SCI USA, V88, P5621, DOI 10.1073/pnas.88.13.5621; SWANDULLA D, 1991, TRENDS NEUROSCI, V14, P46, DOI 10.1016/0166-2236(91)90018-P; TARELLI FT, 1991, BRAIN RES, V547, P331, DOI 10.1016/0006-8993(91)90981-Z; TSIEN RW, 1991, TRENDS PHARMACOL SCI, V12, P349, DOI 10.1016/0165-6147(91)90595-J; WAGNER JA, 1988, J NEUROSCI, V8, P3354; WILLIAMS ME, 1992, NEURON, V8, P71, DOI 10.1016/0896-6273(92)90109-Q; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x	43	463	485	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 17	1992	257	5068					389	395		10.1126/science.1321501	http://dx.doi.org/10.1126/science.1321501			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JD674	1321501				2022-12-01	WOS:A1992JD67400035
J	EHRMANN, DA; ROSENFIELD, RL; BARNES, RB; BRIGELL, DF; SHEIKH, Z				EHRMANN, DA; ROSENFIELD, RL; BARNES, RB; BRIGELL, DF; SHEIKH, Z			DETECTION OF FUNCTIONAL OVARIAN HYPERANDROGENISM IN WOMEN WITH ANDROGEN EXCESS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GROWTH FACTOR-I; POLYCYSTIC OVARIES; IDIOPATHIC HIRSUTISM; LUTEINIZING HORMONE; DISEASE; DEXAMETHASONE; RESPONSES; PATHOGENESIS; SECRETION; CELLS	Background. Distinguishing between ovarian and adrenal causes of androgen excess may be difficult. We have found that women with the polycystic ovary syndrome have supranormal plasma 17-hydroxyprogesterone responses to the gonadotropin-releasing hormone agonist nafarelin. We determined the usefulness of testing with nafarelin to distinguish ovarian causes of hyperandrogenism in women. Methods. We studied 40 consecutive women with hyperandrogenism who had oligomenorrhea, hirsutism, or acne. All 40 underwent testing with nafarelin, dexamethasone, and corticotropin with measurement of circulating concentrations of gonadotropins and steroid hormones, and 19 underwent ovarian ultrasonography. Results. The plasma 17-hydroxyprogesterone response to nafarelin was supranormal in 23 of the 40 women (58 percent), and the plasma androgen response to corticotropin was elevated in 23; 13 women had both abnormalities. Only one woman had conclusive evidence of a steroidogenic block; she had nonclassic adrenal 21-hydroxylase deficiency. Of the 23 women with abnormal responses to nafarelin, only 11 (48 percent) had elevated base-line serum luteinizing hormone concentrations. Of the 13 women with abnormal responses to nafarelin who underwent ultrasonography, 7 (54 percent) had polycystic ovaries. Peak plasma 17-hydroxyprogesterone concentrations after nafarelin administration correlated closely with plasma free testosterone concentrations after dexamethasone administration (r = 0.75, P<0.001). Conclusions. Approximately half of women with oligomenorrhea, hirsutism, or acne have an abnormal response to the gonadotropin-releasing hormone agonist nafarelin, suggesting an ovarian cause of their androgen excess.	UNIV CHICAGO,PRITZKER SCH MED,DEPT OBSTET GYNECOL,CHICAGO,IL 60637	University of Chicago	EHRMANN, DA (corresponding author), UNIV CHICAGO,PRITZKER SCH MED,DEPT MED,ENDOCRINOL SECT,5841 S MARYLAND AVE,MC 1027,CHICAGO,IL 60637, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD006308] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007011] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00055] Funding Source: Medline; NICHD NIH HHS [HD-06308] Funding Source: Medline; NIDDK NIH HHS [DK-07011-17] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAM GE, 1976, OBSTET GYNECOL, V47, P395; ADAMS J, 1986, BRIT MED J, V293, P355, DOI 10.1136/bmj.293.6543.355; BARNES R, 1989, ANN INTERN MED, V110, P386, DOI 10.7326/0003-4819-110-5-386; BARNES RB, 1989, NEW ENGL J MED, V320, P559, DOI 10.1056/NEJM198903023200904; BERGER MJ, 1975, FERTIL STERIL, V26, P619; CARA JF, 1988, ENDOCRINOLOGY, V123, P733, DOI 10.1210/endo-123-2-733; CHANG RJ, 1983, J CLIN ENDOCR METAB, V56, P897, DOI 10.1210/jcem-56-5-897; DAVOREN JB, 1986, ENDOCRINOLOGY, V118, P888, DOI 10.1210/endo-118-2-888; ELDARGEVA T, 1990, NEW ENGL J MED, V323, P855, DOI 10.1056/NEJM199009273231302; EMANS SJ, 1988, J PEDIATR-US, V112, P821, DOI 10.1016/S0022-3476(88)83217-7; ERICKSON GF, 1985, ENDOCR REV, V6, P371, DOI 10.1210/edrv-6-3-371; FAUSER BCJM, 1991, J CLIN ENDOCR METAB, V73, P811, DOI 10.1210/jcem-73-4-811; GOLDZIEHER JW, 1962, J CLIN ENDOCR METAB, V22, P325, DOI 10.1210/jcem-22-3-325; HAGUE WM, 1989, CLIN ENDOCRINOL, V30, P355, DOI 10.1111/j.1365-2265.1989.tb00433.x; HATCH R, 1981, AM J OBSTET GYNECOL, V140, P815, DOI 10.1016/0002-9378(81)90746-8; HERNANDEZ ER, 1990, ENDOCRINOLOGY, V127, P2804, DOI 10.1210/endo-127-6-2804; HILLIER SG, 1991, MOL CELL ENDOCRINOL, V75, pR1, DOI 10.1016/0303-7207(91)90234-J; HILLIER SG, 1991, J CLIN ENDOCR METAB, V72, P1206, DOI 10.1210/jcem-72-6-1206; JIALAL I, 1987, J CLIN ENDOCR METAB, V64, P1066, DOI 10.1210/jcem-64-5-1066; JUDD HL, 1973, AM J OBSTET GYNECOL, V117, P976, DOI 10.1016/0002-9378(73)90071-9; KIRSCHNER MA, 1976, NEW ENGL J MED, V294, P637, DOI 10.1056/NEJM197603182941204; MULHERON GW, 1991, ENDOCRINOLOGY, V129, P368, DOI 10.1210/endo-129-1-368; NEW MI, 1983, J CLIN ENDOCR METAB, V57, P320, DOI 10.1210/jcem-57-2-320; POLSON DW, 1988, LANCET, V1, P870; RITTMASTER RS, 1990, J CLIN ENDOCR METAB, V70, P1096, DOI 10.1210/jcem-70-4-1096; ROSENFIELD RL, 1990, FERTIL STERIL, V53, P785; ROSENFIELD RL, 1985, J CLIN ENDOCR METAB, V60, P585, DOI 10.1210/jcem-60-3-585; Rosenfield RL, 1992, POLYCYSTIC OVARY SYN, P83; SIEGEL SF, 1990, NEW ENGL J MED, V323, P849, DOI 10.1056/NEJM199009273231301; Stein IF, 1935, AM J OBSTET GYNECOL, V29, P181, DOI 10.1016/S0002-9378(15)30642-6; STEWART PM, 1990, LANCET, V335, P431, DOI 10.1016/0140-6736(90)90664-Q; Timor-Tritsch IE, 1988, TRANSVAGINAL SONOGRA; WALDSTREICHER J, 1988, J CLIN ENDOCR METAB, V66, P165, DOI 10.1210/jcem-66-1-165; YEH HC, 1987, RADIOLOGY, V163, P111, DOI 10.1148/radiology.163.1.3547491; YEN SSC, 1970, J CLIN ENDOCR METAB, V30, P435, DOI 10.1210/jcem-30-4-435	35	268	279	2	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 16	1992	327	3					157	162		10.1056/NEJM199207163270304	http://dx.doi.org/10.1056/NEJM199207163270304			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD319	1319000				2022-12-01	WOS:A1992JD31900004
J	GRANAI, CO				GRANAI, CO			OVARIAN-CANCER - UNREALISTIC EXPECTATIONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CA-125 LEVELS; SERUM CA-125; CARCINOMA; AGENT; NEOPLASMS; TUMORS; TAXOL				GRANAI, CO (corresponding author), BROWN UNIV,WOMEN & INFANTS HOSP,SCH MED,PROVIDENCE,RI 02905, USA.							ALBERTS DS, 1988, SEMIN ONCOL, V15, P22; ANDOLF E, 1990, OBSTET GYNECOL, V75, P106; [Anonymous], 1991, J CLIN ONCOL, V9, P1668; BAKER TR, 1991, FEMALE PATIENT, V16, P49; BARBER HRK, 1990, FEMALE PATIENT, V15, P11; BELINSON JL, 1990, GYNECOL ONCOL, V37, P66, DOI 10.1016/0090-8258(90)90310-H; BOURNE T, 1989, BRIT MED J, V299, P1367, DOI 10.1136/bmj.299.6712.1367; BOURNE TH, 1991, GYNECOL ONCOL, V43, P92, DOI 10.1016/0090-8258(91)90051-6; CAMPBELL S, 1989, BMJ-BRIT MED J, V299, P1363, DOI 10.1136/bmj.299.6712.1363; Chabner B. A., 1991, TAXOL PRINCIPLES PRA, V5, P1; CHEN DX, 1990, OBSTET GYNECOL, V75, P701; CHEN DX, 1988, OBSTET GYNECOL, V72, P23; EINZIG A I, 1990, Proceedings of the American Association for Cancer Research Annual Meeting, V31, P187; HATCH KD, 1991, CANCER, V68, P269, DOI 10.1002/1097-0142(19910715)68:2<269::AID-CNCR2820680209>3.0.CO;2-O; HENAHAN JF, 1990, ONCOLOGY BIOTECH AUG, P1; HOLMES FA, 1991, J NATL CANCER I, V83, P1797, DOI 10.1093/jnci/83.24.1797-a; KREBS HB, 1986, OBSTET GYNECOL, V67, P473; MANETTA A, 1990, GYNECOL ONCOL, V36, P93, DOI 10.1016/0090-8258(90)90115-2; MARECHAL F, 1989, ANTICANCER RES, V9, P593; MCGUIRE WP, 1989, ANN INTERN MED, V111, P273, DOI 10.7326/0003-4819-111-4-273; OMURA GA, 1991, J CLIN ONCOL, V9, P1138, DOI 10.1200/JCO.1991.9.7.1138; PIVER MS, 1990, GILDA RADNER FAMILIA; PODESTA JS, 1991, PEOPLE          0603, P76; ROWINSKY EK, 1991, J NATL CANCER I, V83, P1778, DOI 10.1093/jnci/83.24.1778; ROWINSKY EK, 1990, JNCI-J NATL CANCER I, V82, P1247, DOI 10.1093/jnci/82.15.1247; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; Song J I, 1991, JAMA, V266, P1281, DOI 10.1001/jama.266.9.1281; STTLE G, 1990, CANCER MANUAL, P245; SUTTON GP, 1989, J CLIN ONCOL, V7, P1672, DOI 10.1200/JCO.1989.7.11.1672; SUTTON GP, 1989, J CLIN ONCOL, V7, P23; SWANSON RA, 1990, LAB LINE         JUL, P2; THIGPEN T, 1990, P AN M AM SOC CLIN, V9, P156; van Nagell J R Jr, 1991, Gynecol Oncol, V43, P89, DOI 10.1016/0090-8258(91)90050-F; VANNAGELL JR, 1991, CANCER, V68, P679, DOI 10.1002/1097-0142(19910815)68:4<679::AID-CNCR2820680402>3.0.CO;2-J; VANNAGELL JR, 1991, CANCER, V68, P458, DOI 10.1002/1097-0142(19910801)68:3<458::AID-CNCR2820680303>3.0.CO;2-3; VARDI JR, 1989, OBSTET GYNECOL, V74, P379; ZURAWSKI VR, 1990, 10TH ANN M NEW ENGL; 1989, CLIN GYNECOLOGIC ONC, P328; 1991, ACOG NEWSLETTER  FEB, P8; 1989, CLIN GYNECOLOGIC ONC, V335, P392; 1990, CANCER FACTS FIGURES, P11; 1991, PROVIDENCE J B, pA21; 1991, BMJ, V303, P884; 1980, TIME            0331, P60	44	31	31	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 16	1992	327	3					197	200		10.1056/NEJM199207163270313	http://dx.doi.org/10.1056/NEJM199207163270313			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD319	1351658				2022-12-01	WOS:A1992JD31900013
J	HAMM, CW; RAVKILDE, J; GERHARDT, W; JORGENSEN, P; PEHEIM, E; LJUNGDAHL, L; GOLDMANN, B; KATUS, HA				HAMM, CW; RAVKILDE, J; GERHARDT, W; JORGENSEN, P; PEHEIM, E; LJUNGDAHL, L; GOLDMANN, B; KATUS, HA			THE PROGNOSTIC VALUE OF SERUM TROPONIN-T IN UNSTABLE ANGINA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; CREATINE KINASE-MB; HIGH-RISK SUBGROUP; PLATELET ACTIVATION; SKELETAL-MUSCLE; PECTORIS; IDENTIFICATION; THROMBUS; ISCHEMIA; DEATH	Background. Cardiac troponin T is a regulatory contractile protein not normally found in blood. Its detection in the circulation has been shown to be a sensitive and specific marker for myocardial cell damage. We used a newly developed enzyme immunoassay for troponin T to determine whether its presence in the serum of patients with unstable angina was a prognostic indicator. Methods. We screened 109 patients with unstable angina (25 with accelerated or subacute angina and 84 with acute angina at rest) for serum creatine kinase activity, creatine kinase isoenzyme MB activity, and troponin T every eight hours for two days after admission to the hospital. The outcomes of interest during the hospitalization were death and myocardial infarction. Results. Troponin T was detected (range, 0.20 to 3.64-mu-g per liter; mean, 0.78; median, 0.50) in the serum of 33 of the 84 patients (39 percent) with acute angina at rest. Only three of these patients had elevated creatine kinase MB activity (two were positive for troponin T, and one was negative). Of the 33 patients who were positive for troponin T, 10 (30 percent) had myocardial infarction (3 after coronary-artery bypass surgery), and 5 of these died during hospitalization. In contrast, only 1 of the 51 patients with angina at rest who were negative for troponin T had an acute myocardial infarction (P<0.001), and this patient died (P = 0.03). Thus, 10 of the 11 patients with myocardial infarctions had detectable levels of troponin T; only 1 had elevated creatine kinase MB activity. Troponin T was not detected in any of the 25 patients with accelerated or subacute angina, and none of these patients died. Conclusions. Cardiac troponin T in serum appears to be a more sensitive indicator of myocardial-cell injury than serum creatine kinase MB activity, and its detection in the circulation may be a useful prognostic indicator in patients with unstable angina.	AARHUS UNIV HOSP,DEPT INTERNAL MED,DK-8000 AARHUS,DENMARK; UNIV HOSP HEIDELBERG,DEPT MED,HEIDELBERG,GERMANY; ODENSE UNIV HOSP,DEPT CLIN CHEM,DK-5000 ODENSE,DENMARK; UNIV BERN,INSELSPITAL,DEPT CLIN CHEM,CH-3010 BERN,SWITZERLAND; NYA LASARETTET,DEPT CLIN CHEM,HELSINGBORG,SWEDEN; NYA LASARETTET,DEPT CARDIOL,HELSINGBORG,SWEDEN	Aarhus University; Ruprecht Karls University Heidelberg; University of Southern Denmark; Odense University Hospital; University of Bern; University Hospital of Bern	HAMM, CW (corresponding author), UNIV HAMBURG,KRANKENHAUS EPPENDORF,DEPT CARDIOL,MED CLIN,MARTINISTR 52,W-2000 HAMBURG 20,GERMANY.		Hamm, Christian W./I-3155-2017	Hamm, Christian W./0000-0001-6763-4161				ARMSTRONG PW, 1982, AM J CARDIOL, V49, P1849, DOI 10.1016/0002-9149(82)90201-6; BRAUNWALD E, 1989, CIRCULATION, V80, P410, DOI 10.1161/01.CIR.80.2.410; BRESNAHAN DR, 1985, J AM COLL CARDIOL, V6, P285, DOI 10.1016/S0735-1097(85)80161-3; BRIGGS MM, 1989, J MOL BIOL, V206, P245, DOI 10.1016/0022-2836(89)90538-X; CUMMINS P, 1987, EUR J CLIN INVEST, V17, P317, DOI 10.1111/j.1365-2362.1987.tb02194.x; DAVIES MJ, 1986, CIRCULATION, V73, P418, DOI 10.1161/01.CIR.73.3.418; DONSKY MS, 1976, BRIT HEART J, V38, P257; FALK E, 1985, CIRCULATION, V71, P699, DOI 10.1161/01.CIR.71.4.699; FITZGERALD DJ, 1986, NEW ENGL J MED, V315, P983, DOI 10.1056/NEJM198610163151602; FREEMAN GH, 1951, BIOMETRIKA, V38, P141, DOI 10.2307/2332323; GAZES PC, 1973, CIRCULATION, V48, P331, DOI 10.1161/01.CIR.48.2.331; GERHARDT W, 1982, CLIN CHEM, V28, P277; GERHARDT W, 1991, CLIN CHEM, V37, P1405; GOTTLIEB SO, 1986, NEW ENGL J MED, V314, P1214, DOI 10.1056/NEJM198605083141903; HAMM CW, 1987, J AM COLL CARDIOL, V10, P998, DOI 10.1016/S0735-1097(87)80336-4; HAMM CW, 1987, DEUT MED WOCHENSCHR, V112, P1812, DOI 10.1055/s-2008-1068333; HOLMES DR, 1981, BRIT HEART J, V45, P411; HORDER M, 1979, SCAND J CLIN LAB INV, V39, P1, DOI 10.3109/00365517909104932; HORDER M, 1990, BIOCH CLIN, V14, P77; JORGENSEN PJ, 1990, CLIN CHEM, V36, P1502; JULIAN DG, 1985, UNSTABLE ANGINA CURR, P65; KATUS HA, 1991, CIRCULATION, V83, P902, DOI 10.1161/01.CIR.83.3.902; KATUS HA, 1992, CLIN CHEM, V38, P386; KATUS HA, 1991, AM J CARDIOL, V67, P1360, DOI 10.1016/0002-9149(91)90466-X; KATUS HA, 1988, J AM COLL CARDIOL, V11, P487, DOI 10.1016/0735-1097(88)91521-5; KATUS HA, 1990, UNSTABLE ANGINA /, P92; KRUSKAL JB, 1987, NEW ENGL J MED, V317, P1361, DOI 10.1056/NEJM198711263172201; MESSMER BJ, 1990, UNSTABLE ANGINA /, P245; MULCAHY R, 1981, AM J CARDIOL, V48, P525, DOI 10.1016/0002-9149(81)90083-7; NAUNHEIM KS, 1989, ANN THORAC SURG, V47, P569, DOI 10.1016/0003-4975(89)90435-9; NORDLANDER R, 1979, BRIT HEART J, V41, P647; OLSON HG, 1981, CIRCULATION, V64, P674, DOI 10.1161/01.CIR.64.4.674; PEARLSTONE JR, 1986, J BIOL CHEM, V261, P6795; SCLAROVSKY S, 1988, AM HEART J, V116, P933, DOI 10.1016/0002-8703(88)90143-3; VETROVEC GW, 1981, AM HEART J, V102, P1202, DOI 10.1016/0002-8703(81)90653-0; VONARNIM T, 1988, EUR HEART J, V9, P435; WHITE RD, 1985, AM J CARDIOL, V55, P1478, DOI 10.1016/0002-9149(85)90957-9; WILLERSON JT, 1989, CIRCULATION, V80, P198, DOI 10.1161/01.CIR.80.1.198; WURZBURG U, 1977, J CLIN CHEM CLIN BIO, V15, P131; ZACK PM, 1984, AM HEART J, V108, P1408, DOI 10.1016/0002-8703(84)90684-7; 1971, ISCHAEMIC HEART DISE	41	864	892	0	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 16	1992	327	3					146	150		10.1056/NEJM199207163270302	http://dx.doi.org/10.1056/NEJM199207163270302			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD319	1290492				2022-12-01	WOS:A1992JD31900002
J	HE, XM; CARTER, DC				HE, XM; CARTER, DC			ATOMIC-STRUCTURE AND CHEMISTRY OF HUMAN SERUM-ALBUMIN	NATURE			English	Article							AMINO-ACID SEQUENCE; DRUG-BINDING-SITES; ALPHA-FETOPROTEIN; MACROMOLECULAR CRYSTALLOGRAPHY; NUCLEOTIDE-SEQUENCE; MESSENGER-RNA; VARIANTS; GENE; POPULATIONS; EXPRESSION	The three-dimensional structure of human serum albumin has been determined crystallographically to a resolution of 2.8 angstrom. It comprises three homologous domains that assemble to form a heart-shaped molecule. Each domain is a product of two subdomains that possess common structural motifs. The principal regions of ligand binding to human serum albumin are located in hydrophobic cavities in subdomains IIA and IIIA, which exhibit similar chemistry. The structure explains numerous physical phenomena and should provide insight into future pharmacokinetic and genetically engineered therapeutic applications of serum albumin.	NASA,GEORGE C MARSHALL SPACE FLIGHT CTR,SPACE SCI LAB,ES76 BIOPHYS,HUNTSVILLE,AL 35812	National Aeronautics & Space Administration (NASA); NASA Marshall Space Flight Center								AOKI K, 1973, BIOCHIM BIOPHYS ACTA, V328, P323, DOI 10.1016/0005-2795(73)90265-1; ARAI K, 1989, P NATL ACAD SCI USA, V86, P434, DOI 10.1073/pnas.86.2.434; BOS OJM, 1988, BIOCHEM PHARMACOL, V37, P3905, DOI 10.1016/0006-2952(88)90072-X; BROWN JR, 1976, FED PROC, V35, P2141; BROWN JR, 1982, LIPID PROTEIN INTERA, V1, P25; BROWN WM, 1989, NUCLEIC ACIDS RES, V17, P10495, DOI 10.1093/nar/17.24.10495; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BYRNES L, 1990, DNA CELL BIOL, V9, P647, DOI 10.1089/dna.1990.9.647; CARTER DC, 1989, SCIENCE, V244, P1195, DOI 10.1126/science.2727704; CARTER DC, 1990, SCIENCE, V249, P302, DOI 10.1126/science.2374930; COOKE NE, 1985, J CLIN INVEST, V76, P2420, DOI 10.1172/JCI112256; Crowther R. A., 1972, MOL REPLACEMENT METH, P173; DIXON JW, 1974, J BIOL CHEM, V249, P5872; Dugiaczyk A, 1982, P NATL ACAD SCI USA, V79, P71; FEHSKE KJ, 1981, BIOCHEM PHARMACOL, V30, P687, DOI 10.1016/0006-2952(81)90151-9; FELDHOFF RC, 1983, BIOCHEM BIOPH RES CO, V114, P20, DOI 10.1016/0006-291X(83)91588-7; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GALLIANO M, 1990, P NATL ACAD SCI USA, V87, P8721, DOI 10.1073/pnas.87.22.8721; GORIN MB, 1980, P NATL ACAD SCI-BIOL, V77, P1351, DOI 10.1073/pnas.77.3.1351; GRAY JE, 1992, PROTEIN SCI, V1, P289; HAGAG N, 1983, BIOCHEMISTRY-US, V22, P2420, DOI 10.1021/bi00279a018; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; JAGDODZINSKI LL, 1981, P NATL ACAD SCI USA, V78, P3521; JONES TA, 1987, J APPL CRYSTALLOGR, V20, P383; KING TP, 1973, ARCH BIOCHEM BIOPHYS, V156, P509, DOI 10.1016/0003-9861(73)90300-7; KRAGHHANSEN U, 1981, PHARMACOL REV, V33, P17; KURONO Y, 1987, CHEM PHARM BULL, V35, P734; LUFT AJ, 1983, BIOCHEMISTRY-US, V22, P5978, DOI 10.1021/bi00294a043; MINGHETTI PP, 1985, MOL BIOL EVOL, V2, P347; MORINAGA T, 1983, P NATL ACAD SCI-BIOL, V80, P4604, DOI 10.1073/pnas.80.15.4604; MOSKAITIS JE, 1989, MOL ENDOCRINOL, V3, P464, DOI 10.1210/mend-3-3-464; OZEKI Y, 1980, CHEM PHARM BULL, V28, P535; PARDRIDGE WM, 1987, AM J PHYSIOL, V252, P157; PEDERSEN SM, 1987, BIOCHEM PHARMACOL, V35, P2661; PETERS T, 1985, ADV PROTEIN CHEM, V37, P161, DOI 10.1016/S0065-3233(08)60065-0; PUTNAM FW, 1984, PLSMA PROTEINS, V4; QUIRK AV, 1989, BIOTECHNOL APPL BIOC, V11, P273; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; SARGENT TD, 1981, P NATL ACAD SCI-BIOL, V78, P243, DOI 10.1073/pnas.78.1.243; SCHNITZER JE, 1988, P NATL ACAD SCI USA, V85, P6773, DOI 10.1073/pnas.85.18.6773; SCHOENTGEN F, 1986, BIOCHIM BIOPHYS ACTA, V871, P189, DOI 10.1016/0167-4838(86)90173-1; SOLLENE NP, 1979, MOL PHARMACOL, V14, P754; SUDLOW G, 1976, MOL PHARMACOL, V12, P1052; SUDLOW G, 1975, MOL PHARMACOL, V11, P824; TAKAHASHI N, 1987, P NATL ACAD SCI USA, V84, P8001, DOI 10.1073/pnas.84.22.8001; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WEINSTOCK J, 1988, NUCLEIC ACIDS RES, V16, P9045, DOI 10.1093/nar/16.18.9045; YANG F, 1990, GENOMICS, V7, P509, DOI 10.1016/0888-7543(90)90193-X	48	3271	3428	14	511	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 16	1992	358	6383					209	215		10.1038/358209a0	http://dx.doi.org/10.1038/358209a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JD587	1630489	Green Published			2022-12-01	WOS:A1992JD58700045
J	LAURENCE, J; HODTSEV, AS; POSNETT, DN				LAURENCE, J; HODTSEV, AS; POSNETT, DN			SUPERANTIGEN IMPLICATED IN DEPENDENCE OF HIV-1 REPLICATION IN T-CELLS ON TCR V-BETA EXPRESSION	NATURE			English	Article							MOLECULAR ANALYSIS; CLONAL ANERGY; LYMPHOCYTES-T; ENTEROTOXIN-B; INFECTION; INDUCTION; MICE	IN the pathogenesis of AIDS it is not yet understood whether the small fraction of CD4+ T cells (approximately 1%) infected with the human immunodeficiency virus (HIV) are randomly targeted or not. Here we present evidence that human CD4 T-cell lines expressing selected T-cell antigen receptor V-beta gene products can all be infected in vitro with HIV-1, but give markedly different titres of HIV-1 virion production. For example, V-beta-12 T-cell lines from several unrelated donors reproducibly yielded up to 100-fold more gag gene product (p24gag antigen) than V-beta-6.7a lines. This is consistent with a superantigen effect, because the V-beta selectivity was observed with several divergent HIV-1 isolates, was dependent on antigen-presenting cells and on major histocompatibility complex (MHC) class II but was not MHC class II-restricted. The in vivo significance of these findings is supported by the preferential stimulation of V-beta-12+ T cells by freshly obtained irradiated antigen-presenting cells from some HIV-1-seropositive but not HIV-1-negative donors. Moreover, cells from patients positive for viral antigen (gp120) were enriched in the V-beta-12 subpopulation. V-beta-12+ T cells were not deleted in AIDS patients, however, raising the possibility that a variety of mechanisms contribute to T-cell depletion. Our results indicate that a superantigen targets a subpopulation of CD4+ cells for viral replication.	CORNELL UNIV,MED CTR,COLL MED,DEPT MED,1300 YORK AVE,BOX 56,NEW YORK,NY 10021	Cornell University								ACUTO O, 1985, J EXP MED, V161, P1326, DOI 10.1084/jem.161.6.1326; BIGLER RD, 1983, J EXP MED, V158, P1000, DOI 10.1084/jem.158.3.1000; BLACKMAN MA, 1990, NATURE, V345, P540, DOI 10.1038/345540a0; BUKRINSKY MI, 1991, SCIENCE, V254, P423, DOI 10.1126/science.1925601; COFFIN JM, 1992, SCIENCE, V255, P411, DOI 10.1126/science.1310360; FRIEDMAN SM, 1991, J EXP MED, V174, P891, DOI 10.1084/jem.174.4.891; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; GOLOVKINA TV, 1992, CELL, V69, P637, DOI 10.1016/0092-8674(92)90227-4; GROUX H, 1992, J EXP MED, V175, P331, DOI 10.1084/jem.175.2.331; HAYNES BF, 1981, J IMMUNOL, V126, P1409; HERMAN A, 1991, ANNU REV IMMUNOL, V9, P745, DOI 10.1146/annurev.iy.09.040191.003525; IGNATOWICZ L, 1992, J EXP MED, V175, P917, DOI 10.1084/jem.175.4.917; IMBERTI L, 1991, SCIENCE, V254, P860, DOI 10.1126/science.1948066; JANEWAY C, 1991, NATURE, V349, P459, DOI 10.1038/349459a0; KAPPLER J, 1989, SCIENCE, V244, P811, DOI 10.1126/science.2524876; KAWABE Y, 1990, J EXP MED, V172, P1065, DOI 10.1084/jem.172.4.1065; LAURENCE J, 1991, J VIROL, V65, P213, DOI 10.1128/JVI.65.1.213-219.1991; LAURENCE J, 1989, J CLIN INVEST, V83, P1843, DOI 10.1172/JCI114090; MARRACK P, 1991, NATURE, V349, P524, DOI 10.1038/349524a0; OHEHIR RE, 1990, P NATL ACAD SCI USA, V87, P8884, DOI 10.1073/pnas.87.22.8884; ONEILL H, 1991, CELL IMMUNOL, V6136, P54; PRASHAR Y, 1991, J IMMUNOL, V147, P3441; RAMMENSEE HG, 1989, NATURE, V339, P541, DOI 10.1038/339541a0; RELLAHAN BL, 1990, J EXP MED, V172, P1091, DOI 10.1084/jem.172.4.1091; STEVENSON M, 1990, EMBO J, V9, P1551, DOI 10.1002/j.1460-2075.1990.tb08274.x; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	28	164	170	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 16	1992	358	6383					255	259		10.1038/358255a0	http://dx.doi.org/10.1038/358255a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JD587	1630494				2022-12-01	WOS:A1992JD58700060
J	MARTELLI, AM; GILMOUR, RS; BERTAGNOLO, V; NERI, LM; MANZOLI, L; COCCO, L				MARTELLI, AM; GILMOUR, RS; BERTAGNOLO, V; NERI, LM; MANZOLI, L; COCCO, L			NUCLEAR-LOCALIZATION AND SIGNALING ACTIVITY OF PHOSPHOINOSITIDASE-C-BETA IN SWISS 3T3 CELLS	NATURE			English	Article							PROTEIN-KINASE-C; PHOSPHOLIPASE-C; GROWTH-FACTOR; POLYPHOSPHOINOSITIDES; DIFFERENTIATION; PHOSPHORYLATION; INSULIN	THE hydrolysis of phosphatidylinositol 4,5-bisphosphate (PtdInsP2) is a widespread receptor-coupled signalling system at the plasma membrane of most eukaryotic cells. The existence of an entirely separate nuclear phosphoinositide signalling system is suggested from evidence that purified nuclei synthesize PtdInsP2 and phosphatidylinositol 4-phosphate (PtdInsP) in vitro1 and that a transient decrease in the mass of these lipids occurs when Swiss 3T3 cells are cultured in the presence of insulin-like growth factor-1 (IGF-1)2-4. These IGF-1-dependent changes in inositol lipids coincide with an increase in nuclear diacylglycerol4 and precede translocation to the nucleus and activation of protein kinase C (refs 5, 6). Circumstantial evidence that links these changes with mitosis comes from the isolation of a 3T3 clone that expresses the type-1 IGF receptor and binds IGF-1 peptide but does not respond mitogenically or show transient mass changes in nuclear inositol lipids7. A key question is how IGF-1 initiates the rapid breakdown of PtdInsP and PtdInsP2 in the nucleus. Here we present evidence that nuclei of 3T3 cells contain the beta-isozyme of phosphoinositidase C, whereas the gamma-isozyme is confined to the cytoplasm and that IGF-1 treatment stimulates exclusively the activity of nuclear phosphoinositidase C.	UNIV BOLOGNA, INST HUMAN ANAT, V IRNERIO 48, I-40126 BOLOGNA, ITALY; UNIV FERRARA, INST HUMAN ANAT, I-44100 FERRARA, ITALY; UNIV CHIETI, INST HUMAN ANAT, CHIETI, ITALY; IST RIZZOLI, CNR, INST CYTOMORPHOL, I-40136 BOLOGNA, ITALY; AFRC, INST ANIM PHYSIOL & GENET RES, CAMBRIDGE CB2 4AT, ENGLAND	University of Bologna; University of Ferrara; G d'Annunzio University of Chieti-Pescara; Consiglio Nazionale delle Ricerche (CNR); UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute			BERTAGNOLO, VALERIA/L-2864-2018; Neri, Luca Maria/AAU-1772-2021; Neri, Luca Maria/J-2462-2017; Cocco, Lucio/AAI-2206-2020	BERTAGNOLO, VALERIA/0000-0002-4742-2302; Neri, Luca Maria/0000-0002-7924-1477; Cocco, Lucio/0000-0002-9206-8277				BANSAL VS, 1990, ANNU REV CELL BIOL, V6, P41, DOI 10.1146/annurev.cellbio.6.1.41; BENNETT CF, 1987, J BIOL CHEM, V262, P13789; COCCO L, 1989, BIOCHEM BIOPH RES CO, V159, P720, DOI 10.1016/0006-291X(89)90054-5; COCCO L, 1987, BIOCHEM J, V248, P765, DOI 10.1042/bj2480765; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; GARLAND RC, 1972, BIOCHEMISTRY-US, V11, P4712, DOI 10.1021/bi00775a012; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HESLOP JP, 1986, CELL, V47, P703, DOI 10.1016/0092-8674(86)90513-1; KIM UH, 1991, J BIOL CHEM, V266, P1359; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANZOLI FA, 1989, ADV ENZYME REGUL, V28, P25; MARTELLI AM, 1991, BIOCHEM BIOPH RES CO, V177, P480, DOI 10.1016/0006-291X(91)92009-9; MARTELLI AM, 1991, FEBS LETT, V283, P243, DOI 10.1016/0014-5793(91)80598-W; MARTELLI AM, 1989, EXP CELL RES, V185, P191, DOI 10.1016/0014-4827(89)90048-7; MCBRIDE K, 1991, P NATL ACAD SCI USA, V88, P7111, DOI 10.1073/pnas.88.16.7111; MICHELL R H, 1992, Current Biology, V2, P200, DOI 10.1016/0960-9822(92)90533-G; PAYRASTRE B, 1992, J BIOL CHEM, V267, P5078; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RUBINS JB, 1990, P NATL ACAD SCI USA, V87, P7080, DOI 10.1073/pnas.87.18.7080; RYU SH, 1990, J BIOL CHEM, V265, P17941; SEYDEL U, 1991, J BIOL CHEM, V266, P7602; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SUH PG, 1988, J BIOL CHEM, V263, P14497; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; THORNETJOMSLAND G, 1991, BIOL CELL, V71, P33, DOI 10.1016/0248-4900(91)90049-S; TUCKER RW, 1990, EUR J CELL BIOL, V51, P120; WU DQ, 1992, J BIOL CHEM, V267, P1811	28	327	332	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 16	1992	358	6383					242	245		10.1038/358242a0	http://dx.doi.org/10.1038/358242a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JD587	1321347				2022-12-01	WOS:A1992JD58700056
J	MORGAN, BA; IZPISUABELMONTE, JC; DUBOULE, D; TABIN, CJ				MORGAN, BA; IZPISUABELMONTE, JC; DUBOULE, D; TABIN, CJ			TARGETED MISEXPRESSION OF HOX-4.6 IN THE AVIAN LIMB BUD CAUSES APPARENT HOMEOTIC TRANSFORMATIONS	NATURE			English	Article							SARCOMA; EMBRYO	IN the limb bud the 5' members of the Hox-4 gene cluster are expressed in a nested set of overlapping domains which are progressively restricted in the posterior and distal directions1. These domains arise early in limb bud development and come to approximate the primordia of the major structural elements of the limb along the anterior/posterior axis2 (Fig. 1). This pattern, and the fact that surgical manipulations which lead to mirror image duplications along the anterior/posterior axis give rise to mirror image duplications of the domains of expression of these genes, have led to the proposal that these transcription factors specify positional identity along the anterior/posterior axis3,4. Here we test this hypothesis directly using replication-competent retroviral vectors to expand the domain of expression of the Hox-4.6 gene anteriorly during limb development in vivo. We report that alteration of the domain of expression of the Hox-4.6 gene in the developing limb leads to reproducible pattern alterations consistent with a posterior homeotic transformation.	EUROPEAN MOLEC BIOL LAB,W-6900 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)	MORGAN, BA (corresponding author), HARVARD UNIV,SCH MED,DEPT GENET,25 SHATTUCK ST,BOSTON,MA 02115, USA.			duboule, denis/0000-0001-9961-2960				BOWEN J, 1989, ANAT EMBRYOL, V179, P269, DOI 10.1007/BF00326592; CEPKO C, 1989, NEUROMETHODS, V16, P177; DOLBERG DS, 1984, NATURE, V309, P552, DOI 10.1038/309552a0; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; HURLE JM, 1987, ANAT EMBRYOL, V176, P393, DOI 10.1007/BF00310193; IZPISUABELMONTE JC, 1991, EMBO J, V10, P2279, DOI 10.1002/j.1460-2075.1991.tb07764.x; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; MACLEOD M, 1980, J TERATOL, V22, P299; NOHNO T, 1991, CELL, V64, P1197, DOI 10.1016/0092-8674(91)90274-3; POTTS WM, 1987, J GEN VIROL, V68, P3177, DOI 10.1099/0022-1317-68-12-3177; ROGINA B, 1992, DEV DYNAM, V193, P92, DOI 10.1002/aja.1001930112; SUMMERBELL D, 1974, J EMBRYOL EXP MORPH, V32, P227; YOKOUCHI Y, 1991, NATURE, V353, P443, DOI 10.1038/353443a0	15	283	292	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 16	1992	358	6383					236	239		10.1038/358236a0	http://dx.doi.org/10.1038/358236a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JD587	1352858				2022-12-01	WOS:A1992JD58700054
J	OROURKE, AM; MESCHER, MF				OROURKE, AM; MESCHER, MF			CYTOTOXIC LYMPHOCYTE-T ACTIVATION INVOLVES A CASCADE OF SIGNALING AND ADHESION EVENTS	NATURE			English	Article							RECEPTOR-MEDIATED ACTIVATION; TYROSINE PHOSPHORYLATION; CLASS-I; CELLS; CD8; BINDING; RECOGNITION; LFA-1	IN addition to the antigen-specific T-cell receptor (TCR), T cells bear an array of 'accessory' molecules that can contribute to stable adhesion to the antigen-bearing cell1 and provide costimulatory signals1-7. For several of these2-7, T-cell adhesion to the ligand can be activated by TCR-dependent signalling (a signal from the TCR primes the coreceptor to bind to its ligand). It is unclear whether the individual coreceptors share common mechanisms of priming and cosignalling, and perhaps act in a redundant manner, or whether they act in a distinct way and contribute uniquely to the activation process. We report here the use of isolated alloantigen, class I proteins and fibronectin ligands to show that coreceptors on cytotoxic T lymphocytes are activated sequentially and deliver distinct biochemical signals on binding to their ligands. TCR engagement activates CD8 by a protein tyrosine kinase-dependent pathway, and CD8 then acts as a signal for initiation of polyphosphoinositide hydrolysis on binding to class I. In contrast, activated adhesion to fibronectin does not initiate polyphosphoinositide hydrolysis, but amplifies hydrolysis once it has been initiated. Thus, cytotoxic T-lymphocyte activation involves a TCR-initiated cascade of adhesion and signalling events leading to response.			OROURKE, AM (corresponding author), MED BIOL INST,DIV MEMBRANE BIOL,11077 N TORREY PINES RD,LA JOLLA,CA 92037, USA.		Mescher, Matthew/B-8068-2009					BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; DASGUPTA JD, 1992, J EXP MED, V175, P285, DOI 10.1084/jem.175.1.285; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; JUNE CH, 1990, J IMMUNOL, V144, P1591; KANE KP, 1989, J IMMUNOL, V142, P4153; KANE KP, 1990, J IMMUNOL, V144, P824; KANE KP, 1989, MOL IMMUNOL, V26, P759, DOI 10.1016/0161-5890(89)90036-9; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; NAKAUCHI H, 1985, P NATL ACAD SCI USA, V82, P5126, DOI 10.1073/pnas.82.15.5126; NOJIMA Y, 1992, J EXP MED, V175, P1045, DOI 10.1084/jem.175.4.1045; OROURKE AM, 1990, NATURE, V346, P187, DOI 10.1038/346187a0; OROURKE AM, 1988, J BIOL CHEM, V263, P18594; PANACCIO M, 1987, P NATL ACAD SCI USA, V84, P6874, DOI 10.1073/pnas.84.19.6874; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; SHIMIZU Y, 1990, J IMMUNOL, V145, P59; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; SIU G, 1989, J IMMUNOL, V143, P3813; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; VANSEVENTER GA, 1991, J EXP MED, V174, P901, DOI 10.1084/jem.174.4.901; VANSEVENTER GA, 1990, J IMMUNOL, V144, P4579; VEILLETTE A, 1989, J EXP MED, V170, P1671, DOI 10.1084/jem.170.5.1671; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484	23	103	104	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 16	1992	358	6383					253	255		10.1038/358253a0	http://dx.doi.org/10.1038/358253a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JD587	1630493				2022-12-01	WOS:A1992JD58700059
J	STAESSEN, JA; LAUWERYS, RR; BUCHET, JP; BULPITT, CJ; RONDIA, D; VANRENTERGHEM, Y; AMERY, A				STAESSEN, JA; LAUWERYS, RR; BUCHET, JP; BULPITT, CJ; RONDIA, D; VANRENTERGHEM, Y; AMERY, A			IMPAIRMENT OF RENAL-FUNCTION WITH INCREASING BLOOD LEAD CONCENTRATIONS IN THE GENERAL-POPULATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SERUM CREATININE; EXPOSURE; CADMIUM; PRESSURE; HYPERTENSION; WORKERS	Background. Nephropathy is known to occur in persons with heavy exposure to lead. Whether exposure to lead in the general population leads to impaired renal function is not known. Methods. We studied renal function and indexes ot lead exposure in a random population sample of 965 men and 1016 women (age range, 20 to 88 years). In all the subjects we measured creatinine clearance and blood concentrations of lead and zinc protoporphyrin (an indirect measure of blood lead level). Results. The mean (+/-SD) creatinine clearance rate was 99+/-30 ml per minute in the men and 80+/-25 ml per minute in the women. In the men the geometric mean blood lead concentration was 114-mu-g per liter (0.55-mu-mol per liter) (range, 23 to 725-mu-g per liter [0.11 to 3.5-mu-mol per liter]), and in the women 75-mu-g per liter (0.36-mu-mol per liter) (range, 17 to 603-mu-g per liter [0.08 to 2.9-mu-mol per liter]); the zinc protoporphyrin values in blood averaged 1.0 and 1.1-mu-g per gram ot hemoglobin, respectively. The creatinine clearance rate was inversely correlated with blood lead and zinc protoporphyrin values in the men and the women both before and after adjustments for age, body-mass index, and diuretic treatment. A 10-fold increase in blood lead concentration was associated with a reduction of 10 to 13 ml per minute in creatinine clearance. We also found a positive correlation between serum beta-2-microglobulin (which is inversely related to the glomerular filtration rate) and blood lead in men, between serum beta-2-microglobulin and zinc protoporphyrin in both sexes, and between serum creatinine and zinc protoporphyrin in men. Conclusions. Exposure to lead may impair renal function in the general population. The alternative hypothesis that renal impairment may lead to an increase in the blood lead concentration cannot be excluded. however.	CATHOLIC UNIV LEUVEN,HYPERTENS & CARDIOVASC REHABIL UNIT,B-3000 LOUVAIN,BELGIUM; CATHOLIC UNIV LEUVEN,DEPT PATHOPHYSIOL,NEPHROL UNIT,B-3000 LOUVAIN,BELGIUM; CATHOLIC UNIV LEUVEN,IND TOXICOL & OCCUPAT MED UNIT,B-3000 LOUVAIN,BELGIUM; STATE UNIV LIEGE,ENVIRONM TOXICOL UNIT,B-4000 LIEGE,BELGIUM	KU Leuven; KU Leuven; KU Leuven; University of Liege			Staessen, Jan A/A-1065-2011	Staessen, Jan A/0000-0002-3026-1637				[Anonymous], 1988, BMJ, V297, P319; BARTELS H, 1971, CLIN CHIM ACTA, V32, P81, DOI 10.1016/0009-8981(71)90467-0; BATUMAN V, 1983, NEW ENGL J MED, V309, P17, DOI 10.1056/NEJM198307073090104; BERNARD A, 1984, EXPERIENTIA, V40, P143, DOI 10.1007/BF01963577; BERNARD AM, 1983, CLIN CHEM, V29, P1007; BUCHET JP, 1980, J OCCUP ENVIRON MED, V22, P741; BUCHET JP, 1990, LANCET, V336, P699, DOI 10.1016/0140-6736(90)92201-R; CAMPBELL BC, 1981, TOXICOL LETT, V9, P121, DOI 10.1016/0378-4274(81)90027-8; CHISOLM JJ, 1962, J PEDIATR-US, V60, P1, DOI 10.1016/S0022-3476(62)80002-X; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; CRAMER K, 1974, BRIT J IND MED, V31, P113; EMMERSON BT, 1991, NEPHRON, V58, P233, DOI 10.1159/000186421; EMMERSON BT, 1963, AUSTRALAS ANN MED, V12, P139, DOI 10.1111/imj.1963.12.2.139; EMMERSON BT, 1971, AUST NZ J MED, V1, P353, DOI 10.1111/j.1445-5994.1971.tb02545.x; GERHARDSSON L, 1992, BRIT J IND MED, V49, P186; GRAZIANO JH, 1991, ARCH ENVIRON HEALTH, V46, P347, DOI 10.1080/00039896.1991.9934401; HILBRANDS LB, 1991, KIDNEY INT, V40, P1171, DOI 10.1038/ki.1991.331; KARLSSON FA, 1980, SCAND J CLIN LAB INV, V40, P27; LAUWERYS R, 1990, ENVIRON HEALTH PERSP, V87, P283, DOI 10.2307/3431036; LEVEY AS, 1988, ANNU REV MED, V39, P465, DOI 10.1146/annurev.me.39.020188.002341; PERSIJN JP, 1976, J CLIN CHEM CLIN BIO, V14, P421; POCOCK SJ, 1984, BRIT MED J, V289, P872, DOI 10.1136/bmj.289.6449.872; SHARP DS, 1987, MED TOXICOL ADV DRUG, V2, P210, DOI 10.1007/BF03259865; STAESSEN J, 1990, BRIT J IND MED, V47, P442; STAESSEN J, 1991, J HUM HYPERTENS, V5, P485; STAESSEN J, 1988, J HYPERTENS, V6, P965, DOI 10.1097/00004872-198812000-00003; WEDEEN RP, 1975, AM J MED, V59, P630, DOI 10.1016/0002-9343(75)90224-7; 1987, WORLD HLTH ORG REGIO, V23, P242; 1934, MED J AUSTRALIA, V1, P600	29	175	180	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 16	1992	327	3					151	156		10.1056/NEJM199207163270303	http://dx.doi.org/10.1056/NEJM199207163270303			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD319	1608406	Green Published			2022-12-01	WOS:A1992JD31900003
J	WEINTRAUB, SJ; PRATER, CA; DEAN, DC				WEINTRAUB, SJ; PRATER, CA; DEAN, DC			RETINOBLASTOMA PROTEIN SWITCHES THE E2F SITE FROM POSITIVE TO NEGATIVE ELEMENT	NATURE			English	Article							ADENOVIRUS E1A PROTEINS; GENE-PRODUCT; TRANSCRIPTION FACTOR; CELL-CYCLE; EXPRESSION; PROMOTER; BINDING	ORIGINALLY E2F sites were identified as elements in the promoters of adenovirus early genes that are necessary for activation of these genes by the early protein E1a (ref. 1). E2F promoter elements have been shown to be important for transcriptional activation of several genes critical for progression through the cell cycle2-4. During the G1 phase of the cell cycle, the E2F protein forms a complex with the cell-cycle protein Rb (ref. 5) and it has been suggested that this binding of Rb to E2F inactivates E2F (ref. 5). Here we show that Rb-E2F is an active complex that, when bound to the E2F site, inhibits the activity of other promoter elements and thus silences transcription. We propose that the ability of this complex to inhibit transcription is integral to the function of Rb and provide evidence that E2F is a positive element in the absence of an active form of Rb. It has been shown that binding of Rb to E2F depends on the phosphorylation state of Rb (only the underphosphorylated form binds)5 and that the phosphorylation state of Rb changes during progression through the cell cycle6,7. We therefore suggest that the E2F site alternates between a positive and negative element with the phosphorylation/dephosphorylation cycle of Rb. This cyclic activity may be responsible for activating and then inhibiting genes during the cell cycle.	WASHINGTON UNIV,SCH MED,DEPT MED,660 S EUCLID,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)								BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; HEARING P, 1983, CELL, V33, P692; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; KOVESDI I, 1987, P NATL ACAD SCI USA, V84, P2180, DOI 10.1073/pnas.84.8.2180; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; ROSEN GD, 1991, P NATL ACAD SCI USA, V88, P4094, DOI 10.1073/pnas.88.10.4094; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; WEINTRAUB SJ, 1992, MOL CELL BIOL, V12, P512, DOI 10.1128/MCB.12.2.512; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YEE AS, 1987, EMBO J, V6, P2061, DOI 10.1002/j.1460-2075.1987.tb02471.x	20	639	655	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 16	1992	358	6383					259	261		10.1038/358259a0	http://dx.doi.org/10.1038/358259a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JD587	1321348				2022-12-01	WOS:A1992JD58700061
J	YAFFE, MB; FARR, GW; MIKLOS, D; HORWICH, AL; STERNLICHT, ML; STERNLICHT, H				YAFFE, MB; FARR, GW; MIKLOS, D; HORWICH, AL; STERNLICHT, ML; STERNLICHT, H			TCP1 COMPLEX IS A MOLECULAR CHAPERONE IN TUBULIN BIOGENESIS	NATURE			English	Article							HEAT-SHOCK PROTEIN; HUMAN ALPHA-TUBULIN; BETA-TUBULIN; SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; CELLS; MICROTUBULES; EXPRESSION; COLOCALIZATION; OVEREXPRESSION	A ROLE in folding of newly translated proteins in the cytosol of eukaryotes has been proposed for t-complex polypeptide-1 (TCP1), although its molecular targets have not yet been identified1-3. Tubulin is a major cytosolic protein whose assembly into microtubules is critical to many cellular processes4-8. Although numerous studies have focused on the expression of tubulin9-20, little is known about the processes where by newly translated tubulin subunits acquire conformations that enable them to form alpha-beta-heterodimers. We examined the biogenesis of alpha- and beta-tubulin in rabbit reticulocyte lysate, and report here that newly translated tubulin subunits entered a 900K complex in a protease-sensitive conformation. Addition of Mg-ATP, but not nonhydrolysable analogues, released the tubulin subunits as assembly-competent protein with a conformation that was relatively protease-resistant. The 900K complex purified from reticulocyte lysate contained as its major constituent a 58K protein that cross-reacted with a monoclonal antiserum against mouse TCP1. We conclude that TCP1 functions as a cytosolic chaperone in the biogenesis of tubulin.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHARMACOL,CLEVELAND,OH 44106; HARVARD UNIV,NEW ENGLAND DEACONESS HOSP,SCH MED,DEPT SURG,BOSTON,MA 02146; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510	Case Western Reserve University; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Yale University; Yale University								AHMAD S, 1990, MOL CELL BIOL, V10, P5160, DOI 10.1128/MCB.10.10.5160; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BOLLAG DM, 1990, EUR J CELL BIOL, V51, P295; BROWN HR, 1983, ARCH BIOCHEM BIOPHYS, V220, P46, DOI 10.1016/0003-9861(83)90385-5; BURKE D, 1989, MOL CELL BIOL, V9, P1049, DOI 10.1128/MCB.9.3.1049; CARON JM, 1985, NATURE, V317, P648, DOI 10.1038/317648a0; CLEVELAND DW, 1978, CELL, V15, P1021, DOI 10.1016/0092-8674(78)90286-6; COIAS R, 1988, EUR J BIOCHEM, V175, P467, DOI 10.1111/j.1432-1033.1988.tb14218.x; COWAN NJ, 1983, MOL CELL BIOL, V3, P1738, DOI 10.1128/MCB.3.10.1738; Dustin P., 1984, MICROTUBULES; ELLIS RJ, 1990, SCIENCE, V250, P954, DOI 10.1126/science.250.4983.954; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GRASSO JA, 1986, ANAT REC, V156, P397; GUPTA RS, 1990, BIOCHEM INT, V20, P833; HUFFAKER TC, 1988, J CELL BIOL, V106, P1997, DOI 10.1083/jcb.106.6.1997; ISAACS WB, 1989, CELLULAR MOL BIOL MU, P137; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; LEWIS VA, 1992, NATURE, V358, P249, DOI 10.1038/358249a0; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; REDMOND T, 1989, EUR J CELL BIOL, V50, P66; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SANCHEZ ER, 1988, MOL ENDOCRINOL, V2, P756, DOI 10.1210/mend-2-8-756; SKOUFIAS DA, 1990, J CELL BIOL, V111, P1929, DOI 10.1083/jcb.111.5.1929; TRENT JD, 1991, NATURE, V354, P490, DOI 10.1038/354490a0; URSIC D, 1991, MOL CELL BIOL, V11, P2629, DOI 10.1128/MCB.11.5.2629; VALLEE R, 1991, NATURE, V352, P187; WEINSTEIN B, 1990, MOL CELL BIOL, V10, P5295, DOI 10.1128/MCB.10.10.5295; WILLISON K, 1989, CELL, V57, P621, DOI 10.1016/0092-8674(89)90131-1; WU J, 1987, GENE, V61, P51, DOI 10.1016/0378-1119(87)90364-7; YAFFE MB, 1988, J BIOL CHEM, V263, P16023; YAFFE MB, 1988, BIOCHEMISTRY-US, V27, P1869, DOI 10.1021/bi00406a012; YAFFE MB, 1989, J BIOL CHEM, V264, P19045; YEN TJ, 1988, NATURE, V334, P580, DOI 10.1038/334580a0	33	397	405	1	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 16	1992	358	6383					245	248		10.1038/358245a0	http://dx.doi.org/10.1038/358245a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JD587	1630491				2022-12-01	WOS:A1992JD58700057
J	BROUN, ER; NICHOLS, CR; KNEEBONE, P; WILLIAMS, SD; LOEHRER, PJ; EINHORN, LH; TRICOT, GJK				BROUN, ER; NICHOLS, CR; KNEEBONE, P; WILLIAMS, SD; LOEHRER, PJ; EINHORN, LH; TRICOT, GJK			LONG-TERM OUTCOME OF PATIENTS WITH RELAPSED AND REFRACTORY GERM-CELL TUMORS TREATED WITH HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS BONE-MARROW RESCUE	ANNALS OF INTERNAL MEDICINE			English	Article						BONE MARROW TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; GERM CELL NEOPLASMS; CARBOPLATIN; ETOPOSIDE	PHASE-I; TRANSPLANTATION; CARBOPLATIN; VP-16-213; CANCER	Objective: To review the long-term outcome of patients with recurrent and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. Design: Cohort study. Setting: A university hospital. Patients: Forty consecutive patients with recurrent or refractory germ cell tumors treated at Indiana University between September 1986 and June 1989. Interventions: Patients were treated with high-dose carboplatin (900 to 2000 mg/m2 body surface area) and etoposide (1200 mg/m2). Three patients also received ifosfamide (10g/m2). All patients had autologous bone marrow rescue. Of the 40 study patients, 26 received two full courses of therapy. Measurements: Patient charts were reviewed to determine the rate and duration of complete and partial remission and the number of long-term, disease-free survivors. The influence of cisplatin-refractory disease and the site of the primary tumor on the incidence of remission and survival were also investigated. Results: Of the 40 study patients, 26 (65%) responded to treatment; 12 (30%) achieved a complete response, and 14 (35%) achieved a partial response. Of the 12 complete responders, 5 relapsed, and 1 died of treatment-related acute leukemia 27.5 months after treatment without evidence of germ cell cancer. Six (15%) of the original 40 patients, of whom 3 were refractory to cisplatin, remained in complete remission after at least 24 months of follow-up. Eight of 40 patients had primary mediastinal germ cell tumors with no complete remissions and a median survival of 2 months (range, 0.5 to 9.0 months). Conclusions: Treatment with high-dose carboplatin and etoposide in conjunction with autologous bone marrow rescue in patients with relapsed or refractory germ cell tumors is a potentially curative therapeutic option, even for heavily pretreated or cisplatin-refractory patients. Some degree of disease resistance to cisplatin can be overcome with dose escalation of platinum compounds. Patients with multiple recurrences of relapsed or refractory primary mediastinal germ cell tumors were not helped by this approach.			BROUN, ER (corresponding author), INDIANA UNIV HOSP, 926 W MICHIGAN, ROOM 1730, INDIANAPOLIS, IN 46202 USA.		Nichols, Craig/ABE-1107-2020		NCI NIH HHS [R35 CA 38844-07] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R23CA038844] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATTAL M, 1991, J CLIN ONCOL, V9, P865, DOI 10.1200/JCO.1991.9.5.865; BAUME D, 1990, B CANCER, V77, P169; BROUN ER, 1991, CANCER, V68, P1513, DOI 10.1002/1097-0142(19911001)68:7<1513::AID-CNCR2820680708>3.0.CO;2-8; BROUN ER, 1991, BONE MARROW TRANSPL, V7, P53; DEPAUW BE, 1990, BONE MARROW TRANSPL, V5, P179; EINHORN LH, 1981, CANCER RES, V41, P3275; ENGLISH D, 1989, TRANSFUSION, V29, P12, DOI 10.1046/j.1537-2995.1989.29189101156.x; HAINSWORTH JD, 1983, AM J MED, V75, P817, DOI 10.1016/0002-9343(83)90413-8; HARTSTRICK A, 1991, J CLIN ONCOL, V9, P1549; HEIMDAHL A, 1989, ORAL SURG ORAL MED O, V68, P711, DOI 10.1016/0030-4220(89)90160-6; HORWITZ LJ, 1989, AUTOLOGOUS BONE MARR, P67; LINKESCH W, 1990, P AN M AM SOC CLIN, V9, P141; MOTZER RJ, 1990, CANCER, V66, P2476, DOI 10.1002/1097-0142(19901215)66:12<2476::AID-CNCR2820661206>3.0.CO;2-D; MULDER POM, 1988, EUR J CANCER CLIN ON, V24, P675, DOI 10.1016/0277-5379(88)90298-2; MUNSHI NC, 1990, P AN M AM SOC CLIN, V9, P134; NICHOLS CR, 1992, J CLIN ONCOL, V10, P558, DOI 10.1200/JCO.1992.10.4.558; NICHOLS CR, 1989, J CLIN ONCOL, V7, P932, DOI 10.1200/JCO.1989.7.7.932; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; PIZZOCARO G, 1990, P ASCO, V9, P131; SHEA TC, 1989, J CLIN ONCOL, V7, P651, DOI 10.1200/JCO.1989.7.5.651; SPINOLO JA, 1990, CANCER, V66, P619, DOI 10.1002/1097-0142(19900815)66:4<619::AID-CNCR2820660403>3.0.CO;2-Z; VALTEAU D, 1990, Bone Marrow Transplantation, V5, P133; VILLABLANCA JG, 1990, BONE MARROW TRANSPL, V5, P387; WADE JC, 1982, ANN INTERN MED, V97, P503, DOI 10.7326/0003-4819-97-4-503; WOLFF SN, 1983, J CLIN ONCOL, V1, P701, DOI 10.1200/JCO.1983.1.11.701	25	146	147	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1992	117	2					124	128		10.7326/0003-4819-117-2-124	http://dx.doi.org/10.7326/0003-4819-117-2-124			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD123	1318648				2022-12-01	WOS:A1992JD12300005
J	FRANCES, R; FRANKLIN, JE				FRANCES, R; FRANKLIN, JE			ADDICTION MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DOPAMINE-D2 RECEPTOR GENE; ALCOHOLISM; ASSOCIATION; DISORDER				FRANCES, R (corresponding author), UNIV MED & DENT NEW JERSEY,NEWARK,NJ 07103, USA.							BLUM K, 1990, JAMA-J AM MED ASSOC, V263, P2055, DOI 10.1001/jama.263.15.2055; BOLOS AM, 1990, JAMA-J AM MED ASSOC, V264, P3156; BRADY K, 1990, AM J PSYCHIAT, V147, P1164; CLONINGER CR, 1991, JAMA-J AM MED ASSOC, V266, P1833; COMINGS CE, 1991, JAMA-J AM MED ASSOC, V266, P1793; DULIT RA, 1990, AM J PSYCHIAT, V147, P1002; ELBASSEL N, 1991, PUBLIC HEALTH REP, V106, P586; GALANTER M, 1991, AM J DRUG ALCOHOL AB, V17, P1, DOI 10.3109/00952999108992805; GELERNTER J, 1991, JAMA-J AM MED ASSOC, V266, P1801, DOI 10.1001/jama.266.13.1801; GEORGE DT, 1990, ACTA PSYCHIAT SCAND, V82, P1, DOI 10.1111/j.1600-0447.1990.tb01345.x; HUGHES JR, 1991, ARCH INTERN MED, V151, P1993, DOI 10.1001/archinte.151.10.1993; KUSHNER MG, 1990, AM J PSYCHIAT, V147, P685; METZGER D, 1991, AM J PSYCHIAT, V148, P636; NOBLE EP, 1991, ARCH GEN PSYCHIAT, V48, P655; ORFORD J, 1991, BRIT J MED PSYCHOL, V64, P189, DOI 10.1111/j.2044-8341.1991.tb01656.x; PARSIAN A, 1991, ARCH GEN PSYCHIAT, V48, P653; SCHRAGER L, 1991, PUBLIC HEALTH REP, V106, P78; SCHWAB S, 1991, AM J HUM GENET, V49, P203; UHL GR, 1992, ARCH GEN PSYCHIAT, V49, P157; WALSH DC, 1991, NEW ENGL J MED, V325, P775, DOI 10.1056/NEJM199109123251105; WILSNACK SC, 1991, AM J PUBLIC HEALTH, V81, P305, DOI 10.2105/AJPH.81.3.305; YANCOVITZ SR, 1991, AM J PUBLIC HEALTH, V81, P1185, DOI 10.2105/AJPH.81.9.1185; 1991, JAMA-J AM MED ASSOC, V266, P3133; 1991, AM J PSYCHIAT, V148, P1291	24	3	3	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1992	268	3					330	332						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JC352	1613907				2022-12-01	WOS:A1992JC35200017
J	GOLDFRANK, LR				GOLDFRANK, LR			MEDICAL TOXICOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							2,3-DIMERCAPTOSUCCINIC ACID; BENZODIAZEPINES; FLUMAZENIL; ANTIBODIES; REVERSAL		NYU MED CTR,NEW YORK,NY 10016	New York University	GOLDFRANK, LR (corresponding author), BELLEVUE HOSP CTR,NEW YORK,NY 10016, USA.							BASILE AS, 1991, NEW ENGL J MED, V325, P473, DOI 10.1056/NEJM199108153250705; BOSMAN DK, 1991, GASTROENTEROLOGY, V101, P772, DOI 10.1016/0016-5085(91)90538-V; BOWYER K, 1980, CHEST, V77, P232, DOI 10.1378/chest.77.2.232; BRUNN GJ, 1991, INT J IMMUNOPHARMACO, V13, P841, DOI 10.1016/0192-0561(91)90035-6; BURR W, 1989, BRIT MED J, V298, P1713, DOI 10.1136/bmj.298.6689.1713-a; GRAZIANO JH, 1986, MED TOXICOL ADV DRUG, V1, P155, DOI 10.1007/BF03259834; GRAZIANO JH, 1988, J PEDIATR-US, V113, P751, DOI 10.1016/S0022-3476(88)80396-2; HUNKELER W, 1981, NATURE, V290, P514, DOI 10.1038/290514a0; LITOVITZ TL, 1991, AM J EMERG MED, V9, P461, DOI 10.1016/0735-6757(91)90216-7; LOPEZ A, 1990, CRIT CARE MED, V18, P1480, DOI 10.1097/00003246-199012000-00032; OBOYLE C, 1983, BRIT J ANAESTH, V55, P349, DOI 10.1093/bja/55.4.349; OSULLIVAN GF, 1987, CLIN PHARMACOL THER, V42, P254, DOI 10.1038/clpt.1987.143; PHIBBS CS, 1991, JAMA-J AM MED ASSOC, V266, P1521, DOI 10.1001/jama.266.11.1521; POLLOCK DA, 1991, JAMA-J AM MED ASSOC, V266, P2233, DOI 10.1001/jama.266.16.2233; PRISCHL F, 1988, MED TOXICOL ADV DRUG, V3, P334, DOI 10.1007/BF03259944; SCANLON JW, 1991, REPROD TOXICOL, V5, P89, DOI 10.1016/0890-6238(91)90037-G; SMITH TW, 1976, NEW ENGL J MED, V294, P797, DOI 10.1056/NEJM197604082941501; TERRIEN N, 1990, TOXICOL APPL PHARM, V104, P504, DOI 10.1016/0041-008X(90)90172-Q; WEISMAN RS, 1991, J TOXICOL-CLIN TOXIC, V29, P553, DOI 10.3109/15563659109025754; 1991, STRATEGIC PLAN ELIMI; 1988, ROLE PRIMARY CARE PH	21	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1992	268	3					375	376						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC352	1613924				2022-12-01	WOS:A1992JC35200036
J	GORE, JM; DALEN, JE				GORE, JM; DALEN, JE			CARDIOVASCULAR-DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY		UNIV ARIZONA,ARIZONA HLTH SCI CTR,TUCSON,AZ 85724	University of Arizona; University of Arizona Health Sciences	GORE, JM (corresponding author), UNIV MASSACHUSETTS,SCH MED,WORCESTER,MA 01605, USA.							BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; COOK SL, 1991, CIRCULATION, V84, P632, DOI 10.1161/01.CIR.84.2.632; DALEN JE, 1991, ARCH INTERN MED, V151, P1066, DOI 10.1001/archinte.151.6.1066; GROVER SA, 1982, JAMA-J AM MED ASSOC, V267, P816; HENNEKENS CH, 1988, NEW ENGL J MED, V318, P923; MANSON JE, 1991, JAMA-J AM MED ASSOC, V266, P521, DOI 10.1001/jama.266.4.521; OLSON RE, 1989, ARCH INTERN MED, V149, P1501, DOI 10.1001/archinte.149.7.1501; SAFIAN RD, 1990, CIRCULATION, V82, P69, DOI 10.1161/01.CIR.82.1.69; SCHULER G, 1992, J AM COLL CARDIOL, V19, P34, DOI 10.1016/0735-1097(92)90048-R; SERRUYS PW, 1991, J AM COLL CARDIOL, V17, pB143; SERRUYS PW, 1991, NEW ENGL J MED, V324, P13, DOI 10.1056/NEJM199101033240103; SLOAN MA, 1992, AM J CARDIOL, V69, pA21, DOI 10.1016/0002-9149(92)91169-5; TOPOL EJ, 1991, CIRCULATION, V84, P632; 1992, LANCET, V339, P753; 1990, LANCET, V366, P71	15	2	2	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1992	268	3					338	340						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC352	1613912				2022-12-01	WOS:A1992JC35200022
J	LACHS, MS; NACHAMKIN, I; EDELSTEIN, PH; GOLDMAN, J; FEINSTEIN, AR; SCHWARTZ, JS				LACHS, MS; NACHAMKIN, I; EDELSTEIN, PH; GOLDMAN, J; FEINSTEIN, AR; SCHWARTZ, JS			SPECTRUM BIAS IN THE EVALUATION OF DIAGNOSTIC-TESTS - LESSONS FROM THE RAPID DIPSTICK TEST FOR URINARY-TRACT INFECTION	ANNALS OF INTERNAL MEDICINE			English	Article						URINARY TRACT INFECTIONS; DIPSTICK TEST; DIAGNOSTIC TESTS, ROUTINE; URINALYSIS; SPECTRUM BIAS	FACTORS AFFECTING SENSITIVITY; SPECIFICITY; BACTERIURIA; SCREENS	Objective: To determine if the leukocyte esterase and bacterial nitrite rapid dipstick test for urinary tract infection (UTI) is susceptible to spectrum bias (when a diagnostic test has different sensitivities or specificities in patients with different clinical manifestations of the disease for which the test is intended). Design: Cross-sectional study. Patients: A total of 366 consecutive adult patients in whom clinicians performed urinalysis to diagnose or exclude UTI. Setting: An urban emergency department and walk-in clinic. Measurements: After the patient encounter, but before dipstick test or culture was done, clinicians recorded the signs and symptoms that were the basis for suspecting UTI and for performing a urinalysis and an estimate of the probability of UTI based on the clinical evaluation. For all patients who received urinalysis, dipstick tests and culture were done in the clinical microbiology laboratory by medical technologists blinded to clinical evaluation. Sensitivity for the dipstick was calculated using a positive result in either leukocyte esterase or bacterial nitrite, or both, as the criterion for a positive dipstick, and greater than 10(5) CFU/mL for a positive culture. Results: In the 107 patients with a high (>50%) prior probability of UTI, who had many characteristic UTI symptoms, the sensitivity of the test was excellent (0.92; 95% CI, 0.82 to 0.98). In the 259 patients with a low (less-than-or-equal-to 50%) prior probability of UTI, the sensitivity of the test was poor (0.56; CI, 0.03 to 0.79). Conclusions: The leukocyte esterase and bacterial nitrite dipstick test for UTI is susceptible to spectrum bias, which may be responsible for differences in the test's sensitivity reported in previous studies. As a more general principle, diagnostic tests may have different sensitivities or specificities in different parts of the clinical spectrum of the disease they purport to identify or exclude, but studies evaluating such tests rarely report sensitivity and specificity in subgroups defined by clinical symptoms. When diagnostic tests are evaluated, information about symptoms in the patients recruited for study should be included, and analyses should be done within appropriate clinical subgroups so that clinicians may decide if reported sensitivities and specificities are applicable to their patients.	UNIV PENN, SCH MED, PHILADELPHIA, PA 19104 USA	University of Pennsylvania	LACHS, MS (corresponding author), YALE UNIV, SCH MED, 333 CEDAR ST, TMP B15, NEW HAVEN, CT 06510 USA.		Nachamkin, Irving/Q-3673-2019; Edelstein, Paul/I-5527-2019	Edelstein, Paul/0000-0002-4069-5279; Nachamkin, Irving/0000-0003-4811-9716				CHERNOW B, 1984, ANN EMERG MED, V13, P150, DOI 10.1016/S0196-0644(84)80603-4; DETRANO R, 1988, AM J MED, V84, P699, DOI 10.1016/0002-9343(88)90107-6; FLETCHER RH, 1986, ANN INTERN MED, V104, P66, DOI 10.7326/0003-4819-104-1-66; GARDNER S, 1989, CONFIDENCE INTERVAL; GRINER PF, 1981, ANN INTERN MED, V94, P553, DOI 10.7326/0003-4819-94-4-571; HLATKY MA, 1984, AM J MED, V77, P64, DOI 10.1016/0002-9343(84)90437-6; HLATKY MA, 1987, AM J CARDIOL, V59, P1195, DOI 10.1016/0002-9149(87)90875-7; HURLBUT TA, 1991, AM J CLIN PATHOL, V96, P582, DOI 10.1093/ajcp/96.5.582; KELLOGG JA, 1987, AM J MED, V83, P739, DOI 10.1016/0002-9343(87)90907-7; KOMAROFF AL, 1984, NEW ENGL J MED, V310, P368, DOI 10.1056/NEJM198402093100607; LEVY D, 1990, CIRCULATION, V81, P815, DOI 10.1161/01.CIR.81.3.815; MALES BM, 1985, J CLIN MICROBIOL, V22, P531, DOI 10.1128/JCM.22.4.531-534.1985; PELS RJ, 1989, JAMA-J AM MED ASSOC, V262, P1220, DOI 10.1001/jama.1989.03430090082038; PLATT R, 1983, AM J MED, V75, P44, DOI 10.1016/0002-9343(83)90072-4; RANSOHOFF DF, 1978, NEW ENGL J MED, V299, P926, DOI 10.1056/NEJM197810262991705	15	211	211	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1992	117	2					135	140		10.7326/0003-4819-117-2-135	http://dx.doi.org/10.7326/0003-4819-117-2-135			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD123	1605428				2022-12-01	WOS:A1992JD12300008
J	LIVORNESE, LL; DIAS, S; SAMEL, C; ROMANOWSKI, B; TAYLOR, S; MAY, P; PITSAKIS, P; WOODS, G; KAYE, D; LEVISON, ME; JOHNSON, CC				LIVORNESE, LL; DIAS, S; SAMEL, C; ROMANOWSKI, B; TAYLOR, S; MAY, P; PITSAKIS, P; WOODS, G; KAYE, D; LEVISON, ME; JOHNSON, CC			HOSPITAL-ACQUIRED INFECTION WITH VANCOMYCIN-RESISTANT ENTEROCOCCUS-FAECIUM TRANSMITTED BY ELECTRONIC THERMOMETERS	ANNALS OF INTERNAL MEDICINE			English	Article						ENTEROCOCCUS-FAECIUM; GROSS INFECTION; DRUG RESISTANCE, MICROBIAL; VANCOMYCIN; THERMOMETERS	TRANSFERABLE RESISTANCE; ENDOCARDITIS; FAECALIS; INVITRO	Objectives: To describe an epidemic of vancomycin-resistant Enterococcus faecium causing bacteremia and bacteriuria, to identify the source of infection, to delineate risk factors associated with acquisition of the organism, and to determine antibiotic sensitivities for the organism. Design: Investigation of an epidemic, including a case-control study. Setting: Medical-surgical intensive care unit and ward in a university medical center. Patients: Nine patients infected or colonized with vancomycin-resistant Enterococcus faecium and 20 noninfected controls. Measurements: Clinical data, environmental surveillance cultures, and in-vitro microbiologic studies. Results: Colonization or infection by vancomycin-resistant E. faecium was associated with an increased duration of treatment with ceftazidime, 13.2 compared with 4.6 days, and a greater number of nonisolated days of hospitalization in the intensive care unit, 19.9 compared with 6.4 days for infected and noninfected patients, respectively (P < 0.05). Environmental surveillance cultures recovered the organism repeatedly from the rectal probe handles of three electronic thermometers used exclusively on nonisolated patients in the intensive care unit. Restriction endonuclease analysis of plasmid DNA showed that all clinical and environmental isolates were identical. Infection control measures, including isolation of colonized or infected patients and removal of the rectal thermometer probes suspected to be responsible for transmission, resulted in termination of the outbreak. In-vitro, time-kill studies showed that the combination of ciprofloxacin, rifampin, and gentamicin resulted in bactericidal activity against the organism. Conclusions: This nosocomial outbreak of infection due to a highly vancomycin-resistant strain of Enterococcus is the first epidemic in which an electronic thermometer has been implicated as the vehicle of transmission for an infectious agent.	DEPT VET AFFAIRS, PHILADELPHIA, PA USA; MED COLL PENN, PHILADELPHIA, PA 19129 USA	Drexel University								BENNETT PM, 1986, J ANTIMICROB CHEMOTH, V18, P421, DOI 10.1093/jac/18.3.421; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BROOKS S, 1990, INFECT CONT HOSP EP, V11, P574; BUGG TDH, 1991, BIOCHEMISTRY-US, V30, P2017, DOI 10.1021/bi00222a002; COURVALIN P, 1990, ANTIMICROB AGENTS CH, V34, P2291, DOI 10.1128/AAC.34.12.2291; ELIOPOULOS GM, 1989, REV INFECT DIS, V11, pS1210; FERNANDEZGUERRERO M, 1987, ANTIMICROB AGENTS CH, V31, P430, DOI 10.1128/AAC.31.3.430; French G L, 1981, J Hosp Infect, V2, P389, DOI 10.1016/0195-6701(81)90074-8; HERMAN DJ, 1991, ANTIMICROB AGENTS CH, V35, P215, DOI 10.1128/AAC.35.2.215; Im S W, 1981, J Hosp Infect, V2, P171, DOI 10.1016/0195-6701(81)90026-8; KAPLAN AH, 1988, J CLIN MICROBIOL, V26, P1216, DOI 10.1128/JCM.26.6.1216-1218.1988; KARANFIL LV, 1992, INFECT CONT HOSP EP, V13, P195, DOI 10.1086/646509; KREISWIRTH BN, 1991, 31ST INT C ANT AG CH, P131; LECLERCQ R, 1988, NEW ENGL J MED, V319, P157, DOI 10.1056/NEJM198807213190307; MANDELL GL, 1970, ARCH INTERN MED, V125, P258, DOI 10.1001/archinte.125.2.258; MCALLISTER TA, 1986, LANCET, V1, P1262; NICAS TI, 1989, ANTIMICROB AGENTS CH, V33, P1121, DOI 10.1128/AAC.33.7.1121; RHINEHART E, 1990, NEW ENGL J MED, V323, P1814, DOI 10.1056/NEJM199012273232606; SAHM DF, 1989, ANTIMICROB AGENTS CH, V33, P71, DOI 10.1128/AAC.33.1.71; SCHOENKNECHT FD, 1985, MANUAL CLIN MICROBIO, P1000; SHLAES DM, 1989, J ANTIMICROB CHEMOTH, V23, P503, DOI 10.1093/jac/23.4.503; SHLAES DM, 1989, ANTIMICROB AGENTS CH, V33, P198, DOI 10.1128/AAC.33.2.198; SMITH L, 1981, INFECT CONT HOSP EP, V2, P315, DOI 10.1017/S0195941700055363; SMITH SM, 1988, DIAGN MICR INFEC DIS, V9, P239, DOI 10.1016/0732-8893(88)90115-0; UTTLEY AHC, 1988, LANCET, V1, P57; WASHINGTON JA, 1985, MANUAL CLIN MICROBIO, P972; ZERVOS MJ, 1987, ANN INTERN MED, V106, P687, DOI 10.7326/0003-4819-106-5-687	27	379	387	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1992	117	2					112	116		10.7326/0003-4819-117-2-112	http://dx.doi.org/10.7326/0003-4819-117-2-112			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD123	1605425				2022-12-01	WOS:A1992JD12300003
J	PARRILLO, JE				PARRILLO, JE			CRITICAL CARE MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GRAM-NEGATIVE BACTEREMIA; SEPTIC SHOCK; ENDOTOXIN; IMPACT; UNIT				PARRILLO, JE (corresponding author), RUSH PRESBYTERIAN ST LUKES MED CTR,CHICAGO,IL 60612, USA.							COBB LA, 1980, MOD CONC CARDIOV DIS, V49, P31; DANNER RL, 1991, CHEST, V99, P169, DOI 10.1378/chest.99.1.169; GOLDBERG RJ, 1991, NEW ENGL J MED, V325, P1117, DOI 10.1056/NEJM199110173251601; GRAY WA, 1991, NEW ENGL J MED, V325, P1393, DOI 10.1056/NEJM199111143252001; GREENMAN RL, 1991, JAMA-J AM MED ASSOC, V266, P1097, DOI 10.1001/jama.266.8.1097; HOLLENBERG SM, 1991, CHEST, V100, P1133, DOI 10.1378/chest.100.4.1133; KREGER BE, 1980, AM J MED, V68, P344, DOI 10.1016/0002-9343(80)90102-3; LEE L, 1988, CIRCULATION, V78, P1345, DOI 10.1161/01.CIR.78.6.1345; LI TCM, 1984, JAMA-J AM MED ASSOC, V252, P2023, DOI 10.1001/jama.252.15.2023; MUNDTH ED, 1976, CIRCULATION, V53, P176; NATANSON C, 1989, J EXP MED, V169, P823, DOI 10.1084/jem.169.3.823; NATANSON C, 1990, AM J PHYSIOL, V259, pH1440, DOI 10.1152/ajpheart.1990.259.5.H1440; OHLSSON K, 1990, NATURE, V348, P550, DOI 10.1038/348550a0; PARRILLO JE, 1991, ANN INTERN MED, V115, P491, DOI 10.7326/0003-4819-115-6-491; PARRILLO JE, 1985, JAMA-J AM MED ASSOC, V254, P2288, DOI 10.1001/jama.1985.03360160120029; PARRILLO JE, 1990, ANN INTERN MED, V113, P27; REYNOLDS HN, 1988, JAMA-J AM MED ASSOC, V260, P3446, DOI 10.1001/jama.260.23.3446; VANDEVENTER SJH, 1988, LANCET, V1, P605; ZIEGLER EJ, 1982, NEW ENGL J MED, V307, P1225, DOI 10.1056/NEJM198211113072001; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701	20	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1992	268	3					340	342						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC352	1613913				2022-12-01	WOS:A1992JC35200023
J	REIBER, GE; PECORARO, RE; KOEPSELL, TD				REIBER, GE; PECORARO, RE; KOEPSELL, TD			RISK-FACTORS FOR AMPUTATION IN PATIENTS WITH DIABETES-MELLITUS - A CASE-CONTROL STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						DIABETES-MELLITUS; AMPUTATION; PATIENT EDUCATION; DIABETIC NEUROPATHIES; PERIPHERAL VASCULAR DISEASES	PERIPHERAL VASCULAR-DISEASE; LOWER-EXTREMITY AMPUTATIONS; FOLLOW-UP; LIMB AMPUTATION; MORTALITY; PREVENTION; FRAMINGHAM; SMOKING; HEALTH	Objective: To identify and quantify risk factors for lower extremity amputation in persons with diabetes mellitus. Design: Case-control study. Setting: A Veterans Affairs medical center. Patients: Eighty patients having amputation associated with diabetes and 236 diabetic controls without limb lesions were enrolled before surgery from the 21 167 inpatient care and outpatient surgical patients seen at the Seattle Veterans Affairs Medical Center during a 30-month period. Measurements: Selected vascular, neuropathic, environmental, health care, self care, nutritional, metabolic, lifestyle, and psychosocial risk factors were measured in all patients before surgery. Results: Statistically significant risk factors identified from analysis included insufficient mean below-knee and foot cutaneous circulation (odds ratio, 161; 95% CI, 55.1 to 469); ankle-arm blood pressure index < 0.45 (odds ratio, 55.8; CI, 14.9 to 209); absence of lower leg vibratory perception (odds ratio, 15.5; CI, 8.3 to 28.7); low levels of high-density lipoprotein (HDL) subfraction 3 less-than-or-equal-to 0.7-mu-mol/L (odds ratio, 4.9; CI, 2.9 to 8.3); and no previous outpatient diabetes education (odds ratio, 3.2; CI, 1.6 to 6.6). A logistic regression analysis done to control for the potentially confounding effects of age; race; socioeconomic status; diabetes duration, type, and severity confirmed these findings and added a statistically significant interaction between foot transcutaneous oxygen tension and peripheral vascular disease history. Clinical interventions to alter these risk factors were identified, including aggressive treatment of infection, diabetes education, protective footwear, and preventive footcare. Conclusions: Multiple risk factors exist along the continuum of conditions and events leading to lower extremity amputation in diabetes. Modification of certain risk factors by patients and health professionals may reduce the risk for amputation and thus decrease the human and dollar costs that accompany limb loss in this prevalent chronic disease.			REIBER, GE (corresponding author), VET ADM MED CTR, 1660 S COLUMBIAN WAY, SEATTLE, WA 98108 USA.							[Anonymous], 1985, DIABETOLOGIA, V28, P615, DOI 10.1007/BF00290267; Bachorik P S, 1986, Methods Enzymol, V129, P78; BAGDADE JD, 1974, DIABETES, V23, P9, DOI 10.2337/diab.23.1.9; BERKMAN LF, 1979, AM J EPIDEMIOL, V109, P186, DOI 10.1093/oxfordjournals.aje.a112674; BRESLOW NE, 1980, IARC SCI PUBL, V32, P192; BROADHEAD WE, 1983, AM J EPIDEMIOL, V117, P521, DOI 10.1093/oxfordjournals.aje.a113575; DAVIS WK, 1988, DIABETES CARE, V11, P538, DOI 10.2337/diacare.11.7.538; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; FELGAL DW, 1989, RISK FACTORS AMPUTAT; FRONEK A, 1985, NONINVASIVE DIAGNOSI, P697; GARCIA MJ, 1974, DIABETES, V23, P105, DOI 10.2337/diab.23.2.105; GOODSON WH, 1979, SURG GYNECOL OBSTET, V149, P600; GORDON T, 1972, J AMER MED ASSOC, V221, P661, DOI 10.1001/jama.221.7.661; HAUSER CJ, 1987, ARCH SURG-CHICAGO, V122, P1128; HOUSE JS, 1982, AM J EPIDEMIOL, V116, P123, DOI 10.1093/oxfordjournals.aje.a113387; HOWARD BV, 1987, J LIPID RES, V28, P613; KLEIN BEK, 1984, OPHTHALMOLOGY, V91, P10; KNIGHTON DR, 1986, ANN SURG, V204, P322, DOI 10.1097/00000658-198609000-00011; KREINES K, 1985, DIABETES CARE, V8, P235, DOI 10.2337/diacare.8.3.235; LABBE RF, 1989, SEMIN HEMATOL, V26, P40; LEVIN ME, 1988, DIABETIC FOOT, P1; LIEDBERG E, 1983, ACTA ORTHOP SCAND, V54, P383, DOI 10.3109/17453678308996589; Lipsky B A, 1990, Infect Dis Clin North Am, V4, P409; MALONE JM, 1989, AM J SURG, V158, P520, DOI 10.1016/0002-9610(89)90183-9; MANTEL N, 1959, J NATL CANCER I, V22, P719; MATTOCK MB, 1982, ATHEROSCLEROSIS, V45, P67, DOI 10.1016/0021-9150(82)90172-1; Miller A D, 1985, J Med Soc N J, V82, P723; MOST RS, 1983, DIABETES CARE, V6, P87, DOI 10.2337/diacare.6.1.87; NELSON RG, 1988, DIABETES CARE, V11, P8, DOI 10.2337/diacare.11.1.8; OGBUAWA O, 1982, SOUTHERN MED J, V75, P285, DOI 10.1097/00007611-198203000-00010; osmer D. W, 1989, APPL LOGISTIC REGRES, P38; PECORARO R, 1990, WOUNDS, V2, P65; PECORARO R E, 1988, Diabetes Research and Clinical Practice, V5, pS398; PECORARO RE, 1991, PROG CLIN BIOL RES, V365, P27; PECORARO RE, 1990, DIABETES CARE, V13, P513, DOI 10.2337/diacare.13.5.513; PECORARO RE, 1979, DIABETES, V28, P1120, DOI 10.2337/diabetes.28.12.1120; Pirart J., 1978, DIABETES CARE, V1, P168, DOI DOI 10.2337/DIACARE.1.3.168; REIBER GE, 1990, DIABETES, V39, pA18; Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010; RUTKOW IM, 1986, J BONE JOINT SURG AM, V68A, P716, DOI 10.2106/00004623-198668050-00011; Schlesselman JJ, 1982, CASE CONTROL STUDIES, P171; SHOPLAND DR, 1987, PUBLIC HEALTH REP, V102, P68; SKYLER JS, 1980, DIABETES CARE, V3, P369, DOI 10.2337/diacare.3.2.369; STEWART AL, 1980, R23742HEW RAND, P20; Warnick G R, 1986, Methods Enzymol, V129, P101; WEST KM, 1978, EPIDEMIOLOGY DIABETE, P391; WHEELOCK FC, 1984, MANAGEMENT DIABETIC, P188; WYSS CR, 1984, SURGERY, V95, P339; 1990, 1990 CTR DIS CONTR D, P24; 1980, DHEW NIH801527 PUBL, P52; 1987, DHHS NIH871587 PUBL; 1963, 15 US BUR CENS WORK, P1; 1982, DHHS PHS825017 DEP H; 1980, DHHS PHS801260 DEP H, P235	54	331	340	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1992	117	2					97	105		10.7326/0003-4819-117-2-97	http://dx.doi.org/10.7326/0003-4819-117-2-97			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD123	1605439				2022-12-01	WOS:A1992JD12300001
J	RIVLIN, RS				RIVLIN, RS			NUTRITION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CANCER		CORNELL UNIV,MED CTR,NEW YORK HOSP,NEW YORK,NY 10021	Cornell University; NewYork-Presbyterian Hospital	RIVLIN, RS (corresponding author), MEM SLOAN KETTERING CANC CTR,NEW YORK,NY 10021, USA.				NATIONAL CANCER INSTITUTE [P01CA029502, P30CA029502] Funding Source: NIH RePORTER; NCI NIH HHS [CA-29502] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BUNK MJ, 1989, P SOC EXP BIOL MED, V190, P379; COWDEN WB, 1987, T ROY SOC TROP MED H, V81, P533, DOI 10.1016/0035-9203(87)90395-6; DOWLING HJ, 1991, CLIN RES, V39, pA645; DUTTA P, 1991, J PROTOZOOL, V38, P479, DOI 10.1111/j.1550-7408.1991.tb04820.x; GOODWIN PJ, 1990, BREAST CANCER RES TR, V16, P205, DOI 10.1007/BF01806329; HOUMARD JA, 1991, INT J OBESITY, V15, P181; NEWMARK HL, 1991, AM J CLIN NUTR, V54, pS209, DOI 10.1093/ajcn/54.1.209S; RIVLIN RS, 1991, AM J CLIN NUTR, V54, pS177; SCHAPIRA DV, 1991, CANCER, V67, P2215, DOI 10.1002/1097-0142(19910415)67:8<2215::AID-CNCR2820670836>3.0.CO;2-Q; SCHAPIRA DV, 1990, ANN INTERN MED, V112, P182, DOI 10.7326/0003-4819-112-3-182; SERES DS, 1991, NUTR RES, V11, P337, DOI 10.1016/S0271-5317(05)80309-4; WEINHOUSE S, 1991, CA-CANCER J CLIN, V41, P334, DOI 10.3322/canjclin.41.6.334	12	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1992	268	3					382	383		10.1001/jama.268.3.382	http://dx.doi.org/10.1001/jama.268.3.382			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC352	1613928				2022-12-01	WOS:A1992JC35200040
J	STOECKLE, MY; DOUGLAS, RG				STOECKLE, MY; DOUGLAS, RG			INFECTIOUS-DISEASES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									MERCK & CO INC,RAHWAY,NJ 07065	Merck & Company	STOECKLE, MY (corresponding author), CORNELL UNIV,MED CTR,COLL MED,NEW YORK,NY 10021, USA.		Stoeckle, Mark/D-3729-2011	Stoeckle, Mark/0000-0002-8280-4795				BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; BONE RC, 1991, JAMA-J AM MED ASSOC, V266, P1686, DOI 10.1001/jama.266.12.1686; BONE RC, 1991, JAMA-J AM MED ASSOC, V266, P1125, DOI 10.1001/jama.266.8.1125; DOLIN R, 1991, ANN INTERN MED, V114, P119, DOI 10.7326/0003-4819-114-2-119; FERNANDEZMARTIN J, 1991, ANTIMICROB AGENTS CH, V35, P2049, DOI 10.1128/AAC.35.10.2049; GREENMAN RL, 1991, JAMA-J AM MED ASSOC, V266, P1097, DOI 10.1001/jama.266.8.1097; MENG TC, 1992, ANN INTERN MED, V116, P13, DOI 10.7326/0003-4819-116-1-13; PALESTINE AG, 1991, ANN INTERN MED, V115, P665, DOI 10.7326/0003-4819-115-9-665; REDFIELD RR, 1991, NEW ENGL J MED, V324, P1677, DOI 10.1056/NEJM199106133242401; SAFRIN S, 1991, NEW ENGL J MED, V325, P551, DOI 10.1056/NEJM199108223250805; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; STOVER CK, 1991, NATURE, V351, P456, DOI 10.1038/351456a0; YOUNG LS, 1991, LANCET, V338, P1107, DOI 10.1016/0140-6736(91)91965-W; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701; 1991, MMWR, V40, P1; 1991, MMWR, V40, P585; 1990, MMWR, V39, P1	17	0	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1992	268	3					366	368						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC352	1613922				2022-12-01	WOS:A1992JC35200034
J	JOCE, R; WOOD, D; BROWN, D; BEGG, N				JOCE, R; WOOD, D; BROWN, D; BEGG, N			PARALYTIC POLIOMYELITIS IN ENGLAND AND WALES, 1985-91	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To ascertain all cases of paralytic poliomyelitis in England and Wales during 1985-91 and to determine the source of infection in each case. Design-Descriptive study of cases reported between 1985 and 1991. Setting-All health districts in England and Wales. Subjects-Patients normally resident in England and Wales whose clinical features were consistent with paralytic poliomyelitis or with laboratory evidence of recent poliovirus infection and compatible symptoms. Main outcome measures-Clinical, epidemiological, and laboratory features in identified cases. Results-Of 54 suspected cases of poliomyelitis, 33 were excluded, leaving 21 cases, of which 13 were vaccine associated (nine recipient and four contact) cases, five were imported cases, and three were cases whose source of infection was unknown. No cases due to indigenous wild polioviruses were identified; two were imported cases due to wild viruses. One patient died during the acute phase of the illness, and two children with previously unrecognised severe congenital immune deficiency died between one and two months after the onset of paralysis after the first or second dose of oral polio vaccine. The estimated risk of vaccine associated paralysis is 1.46 per million for the first dose, 0.49 for the second, zero for the third and fourth doses, and 0.33 for the fifth. Conclusions-Indigenous wild poliovirus seems to have been eradicated, although wild virus may be imported; improved surveillance of suspected cases including immediate notification and characterisation of the virus to ensure that eradication is maintained is essential.	PUBL HLTH LAB SERV,COMMUNICABLE SURVEILLANCE CTR,LONDON NW9 5EQ,ENGLAND; E & N HERTFORDSHIRE HLTH AUTHOR,WELWYN GARDEN CIT AL8 6RD,HERTS,ENGLAND; NATL INST BIOL STAND & CONTROLS,POTTERS BAR EN6 3QG,HERTS,ENGLAND; PUBL HLTH LAB SERV,VIRUS REFERENCE LAB,LONDON NW9 5EQ,ENGLAND	Public Health England; National Institute for Biological Standards & Control; Public Health England								BEGG NT, 1987, EPIDEMIOL INFECT, V99, P97, DOI 10.1017/S0950268800066905; COLLINGHAM KE, 1978, LANCET, V1, P976; EVANS DMA, 1985, NATURE, V314, P548, DOI 10.1038/314548a0; Hall S M, 1988, Arch Dis Child, V63, P344; HOVI T, 1986, J INFECT DIS, V153, P998, DOI 10.1093/infdis/153.5.998; KUBLI D, 1987, BRIT MED J, V295, P169, DOI 10.1136/bmj.295.6591.169; VANWEZEL AL, 1978, INTERVIROLOGY, V11, P2; WHITE PMB, 1986, BRIT MED J, V293, P1153, DOI 10.1136/bmj.293.6555.1153; 1988, EVALUATION POLIOMYEL; 1982, B WORLD HEALTH ORGAN, V69, P231; 1988, WHO WEEKLY EPIDEMIOL, V63, P161; 1990, MANUAL VIROLOGICAL I; 1990, IMMUNISATION INFECTI; 1989, WHO WEEKLY EPIDEMIOL, V64, P273	14	61	63	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 11	1992	305	6845					79	82		10.1136/bmj.305.6845.79	http://dx.doi.org/10.1136/bmj.305.6845.79			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD850	1322218	Green Published, Bronze, Green Submitted			2022-12-01	WOS:A1992JD85000019
J	TAYLORROBINSON, D; GILROY, CB; THOMAS, BJ; KEAT, ACS				TAYLORROBINSON, D; GILROY, CB; THOMAS, BJ; KEAT, ACS			DETECTION OF CHLAMYDIA-TRACHOMATIS DNA IN JOINTS OF REACTIVE ARTHRITIS PATIENTS BY POLYMERASE CHAIN-REACTION	LANCET			English	Note								In 1986, Chlamydia trachomatis elementary bodies were found by direct immunofluorescence (DIF) in synovial-fluid cell deposits and synovial-membrane biopsy samples from five of eight patients with sexually acquired reactive arthritis (SARA) but in none of eight controls with other types of arthritis. Cells from the original slides (stored at 4-degrees-C) have now been examined by a polymerase chain reaction (PCR) that amplifies DNA for the major outer membrane protein of C trachomatis. Chlamydial DNA was found in samples from four DIF-positive patients, one DIF-negative patient, and one DIF-negative control. Overall, there was 80% concordance for DIF and PCR results. This study supports our previous finding of chlamydiae in joints in reactive arthritis.	ST MARYS HOSP,LONDON,ENGLAND; WESTMINSTER MED SCH & HOSP,DEPT RHEUMATOL,LONDON SW1P 2AP,ENGLAND	Imperial College London; Imperial College London	TAYLORROBINSON, D (corresponding author), CLIN RES CTR,DIV SEXUALLY TRANSMITTED DIS,WATFORD RD,HARROW HA1 3UJ,MIDDX,ENGLAND.							GILROY CB, 1992, J CLIN PATHOL, V45, P531, DOI 10.1136/jcp.45.6.531; HAMMER M, 1992, CLIN EXP RHEUMATOL, V10, P63; KEAT A, 1987, LANCET, V1, P72; KEAT AC, 1978, BRIT MED J, V1, P605, DOI 10.1136/bmj.1.6113.605; PALMER HM, 1991, J CLIN PATHOL, V44, P321, DOI 10.1136/jcp.44.4.321; RAHMAN M U, 1990, Arthritis and Rheumatism, V33, pS25; SCHUMACHER HR, 1988, ARTHRITIS RHEUM, V31, P937; TAYLORROBINSON D, 1988, ANN RHEUM DIS, V47, P295, DOI 10.1136/ard.47.4.295; WONG M L, 1986, Proceedings of the University of Otago Medical School, V64, P77; WORDSWORTH BP, 1990, BRIT J RHEUMATOL, V29, P208	10	202	205	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 11	1992	340	8811					81	82		10.1016/0140-6736(92)90399-N	http://dx.doi.org/10.1016/0140-6736(92)90399-N			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC582	1352016				2022-12-01	WOS:A1992JC58200006
J	BACKX, PH; YUE, DT; LAWRENCE, JH; MARBAN, E; TOMASELLI, GF				BACKX, PH; YUE, DT; LAWRENCE, JH; MARBAN, E; TOMASELLI, GF			MOLECULAR LOCALIZATION OF AN ION-BINDING SITE WITHIN THE PORE OF MAMMALIAN SODIUM-CHANNELS	SCIENCE			English	Article							VOLTAGE-DEPENDENT ACTION; CALF PURKINJE-FIBERS; POTASSIUM CHANNELS; NA CHANNELS; TETRODOTOXIN; BLOCK; SAXITOXIN; MYOCYTES; MUSCLE; MODEL	Sodium channels are the major proteins that underlie excitability in nerve, heart, and skeletal muscle. Chemical reaction rate theory was used to analyze the blockage of single wild-type and mutant sodium channels by cadmium ions. The affinity of cadmium for the native tetrodotoxin (TTX)-resistant cardiac channel was much higher than its affinity for the TTX-sensitive skeletal muscle isoform of the channel (mu-l). Mutation of Tyr401 to Cys, the corresponding residue in the cardiac sequence, rendered mu-l highly susceptible to cadmium blockage but resistant to TTX. The binding site was localized approximately 20% of the distance down the electrical field, thus defining the position of a critical residue within the sodium channel pore.	JOHNS HOPKINS UNIV,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,DEPT BIOMED ENGN,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University			Marban, Eduardo/GWC-8514-2022		NHLBI NIH HHS [K08 HL2421, K11 HL02639, R01 HL36957] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002421, R01HL036957, K11HL002639] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACKX PH, 1990, BIOPHYS J, V57, pA298; BAER M, 1976, NATURE, V263, P344, DOI 10.1038/263344a0; BERG JM, 1990, ANNU REV BIOPHYS BIO, V19, P405; BOWERS CW, 1985, BRAIN RES, V340, P143, DOI 10.1016/0006-8993(85)90783-8; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CHOI KL, 1991, P NATL ACAD SCI USA, V88, P5092, DOI 10.1073/pnas.88.12.5092; COHEN CJ, 1981, J GEN PHYSIOL, V78, P383, DOI 10.1085/jgp.78.4.383; DIFRANCESCO D, 1985, PROC R SOC SER B-BIO, V223, P475, DOI 10.1098/rspb.1985.0013; FRELIN C, 1986, EUR J PHARMACOL, V122, P245, DOI 10.1016/0014-2999(86)90109-3; GUY HR, 1986, P NATL ACAD SCI USA, V83, P508, DOI 10.1073/pnas.83.2.508; GUY HR, 1990, TRENDS NEUROSCI, V13, P201; HALLOWAY SF, 1989, PFLUEGERS ARCH, V414, P613; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; HILLE B, 1975, J GEN PHYSIOL, V66, P535, DOI 10.1085/jgp.66.5.535; HILLE B, 1975, BIOPHYS J, V15, P615, DOI 10.1016/S0006-3495(75)85842-5; Hille B., 1992, IONIC CHANNELS EXCIT; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MACKINNON R, 1989, SCIENCE, V245, P1382, DOI 10.1126/science.2476850; MARTELL AE, 1989, CRITICAL STABILITY C, V1, P47; MILLER C, 1991, SCIENCE, V252, P1092, DOI 10.1126/science.252.5009.1092; NODA M, 1984, NATURE, V312, P121, DOI 10.1038/312121a0; NODA M, 1989, FEBS LETT, V259, P213, DOI 10.1016/0014-5793(89)81531-5; PUSCH M, 1991, EUR BIOPHYS J, V20, P127, DOI 10.1007/BF01561134; RAVINDRAN A, 1991, J GEN PHYSIOL, V97, P89, DOI 10.1085/jgp.97.1.89; ROGART RB, 1989, P NATL ACAD SCI USA, V86, P8170, DOI 10.1073/pnas.86.20.8170; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATIN J, 1992, SCIENCE, V256, P1202, DOI 10.1126/science.256.5060.1202; SCHILD L, 1991, J GEN PHYSIOL, V97, P117, DOI 10.1085/jgp.97.1.117; SCHILD L, 1991, BIOPHYS J, V59, P523, DOI 10.1016/S0006-3495(91)82269-X; SHEETS MF, IN PRESS J PHYSL; TERLAU H, 1991, FEBS LETT, V293, P93, DOI 10.1016/0014-5793(91)81159-6; TRIMMER JS, 1989, NEURON, V3, P33, DOI 10.1016/0896-6273(89)90113-X; VASSILEV PM, 1986, AM J PHYSIOL, V251, pH475, DOI 10.1152/ajpheart.1986.251.2.H475; VISENTIN S, 1990, PFLUG ARCH EUR J PHY, V417, P213, DOI 10.1007/BF00370702; YAMAMOTO D, 1984, BIOPHYS J, V45, P337, DOI 10.1016/S0006-3495(84)84159-4; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0; YUE DT, 1990, J GEN PHYSIOL, V95, P911, DOI 10.1085/jgp.95.5.911	41	248	251	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 10	1992	257	5067					248	251		10.1126/science.1321496	http://dx.doi.org/10.1126/science.1321496			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC585	1321496				2022-12-01	WOS:A1992JC58500041
J	BARRES, BA; HART, IK; COLES, HSR; BURNE, JF; VOYYODIC, JT; RICHARDSON, WD; RAFF, MC				BARRES, BA; HART, IK; COLES, HSR; BURNE, JF; VOYYODIC, JT; RICHARDSON, WD; RAFF, MC			CELL-DEATH AND CONTROL OF CELL-SURVIVAL IN THE OLIGODENDROCYTE LINEAGE	CELL			English	Article							GROWTH FACTOR-I; RAT OPTIC-NERVE; GLIAL PROGENITOR-CELL; TYPE-2 ASTROCYTE DEVELOPMENT; FREE SUPPLEMENTED MEDIUM; MONOCLONAL-ANTIBODY; NEURONAL DEATH; CHICK-EMBRYO; NEUROTROPHIC FACTOR; PROTEIN-SYNTHESIS	Dead cells are observed in many developing animal tissues, but the causes of these normal cell deaths are mostly unknown. We show that about 50% of oligodendrocytes normally die in the developing rat optic nerve, apparently as a result of a competition for limiting amounts of survival signals. Both platelet-derived growth factor and insulin-like growth factors are survival factors for newly formed oligodendrocytes and their precursors in culture. Increasing platelet-derived growth factor in the developing optic nerve decreases normal oligodendrocyte death by up to 90% and doubles the number of oligodendrocytes in 4 days. These results suggest that a requirement for survival signals is more general than previously thought and that some normal cell deaths in nonneural tissues may also reflect competition for survival factors.			BARRES, BA (corresponding author), UNIV LONDON UNIV COLL, DEPT BIOL, MRC, DEV NEUROBIOL PROGRAMME, MEDAWAR BLDG, LONDON WC1E 6BT, ENGLAND.		Richardson, William/C-1762-2008	Richardson, William/0000-0001-7261-2485				AIZENMAN Y, 1987, BRAIN RES, V406, P32, DOI 10.1016/0006-8993(87)90766-9; ALOISI F, 1990, J NEUROSCI RES, V27, P16, DOI 10.1002/jnr.490270104; [Anonymous], [No title captured]; ARONVANEVERCOOR.A, 1991, J NEUROSCI RES, V28, P244; BALLOTTI R, 1987, EMBO J, V6, P3633, DOI 10.1002/j.1460-2075.1987.tb02695.x; BANNON MJ, 1984, BRAIN RES, V301, P184, DOI 10.1016/0006-8993(84)90421-9; BARDE YA, 1983, ANNU REV PHYSIOL, V45, P601, DOI 10.1146/annurev.ph.45.030183.003125; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BARDE YA, 1988, TRENDS NEUROSCI, V11, P343, DOI 10.1016/0166-2236(88)90055-0; BARNES D, 1980, CELL, V22, P649, DOI 10.1016/0092-8674(80)90540-1; BARRES BA, 1988, NEURON, V1, P791, DOI 10.1016/0896-6273(88)90127-4; BARTLETT PF, 1981, BRAIN RES, V204, P339, DOI 10.1016/0006-8993(81)90593-X; BEHAR T, 1988, J NEUROSCI RES, V21, P168, DOI 10.1002/jnr.490210209; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; BOGLER O, 1990, P NATL ACAD SCI USA, V87, P6368, DOI 10.1073/pnas.87.16.6368; BOTTENSTEIN JE, 1980, EXP CELL RES, V125, P183, DOI 10.1016/0014-4827(80)90202-5; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; BRUNK CF, 1979, ANAL BIOCHEM, V92, P497, DOI 10.1016/0003-2697(79)90690-0; CARSON MJ, 1990, THESIS U PENNSYLVANI; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; CLEMMONS DR, 1985, CIRC RES, V56, P418, DOI 10.1161/01.RES.56.3.418; CLEMMONS DR, 1983, J CELL PHYSIOL, V115, P137, DOI 10.1002/jcp.1041150206; COHEN JJ, 1991, ADV IMMUNOL, V50, P55; Cope FO., 1991, APOPTOSIS MOL BASIS, P47; COWAN WM, 1984, SCIENCE, V225, P1258, DOI 10.1126/science.6474175; DAVID S, 1984, J NEUROCYTOL, V13, P961, DOI 10.1007/BF01148596; DEGUCHI T, 1972, P NATL ACAD SCI USA, V69, P2208, DOI 10.1073/pnas.69.8.2208; DRAGO J, 1991, P NATL ACAD SCI USA, V88, P2199, DOI 10.1073/pnas.88.6.2199; DUKE RC, 1986, LYMPHOKINE RES, V5, P289; DUTLY F, 1991, GLIA, V4, P559, DOI 10.1002/glia.440040603; ECCLESTON PA, 1985, DEV BRAIN RES, V21, P315, DOI 10.1016/0165-3806(85)90221-4; EISENBARTH GS, 1979, P NATL ACAD SCI USA, V76, P4913, DOI 10.1073/pnas.76.10.4913; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FRIEDMAN B, 1989, GLIA, V2, P380, DOI 10.1002/glia.440020510; FULTON BP, 1992, IN PRESS J NEUROSCI; GARD AL, 1989, DEVELOPMENT, V106, P119; GLUCKSMANN A, 1951, BIOL REV, V26, P59, DOI 10.1111/j.1469-185X.1951.tb00774.x; GRATZNER HG, 1982, SCIENCE, V218, P474, DOI 10.1126/science.7123245; HABU S, 1977, EUR J IMMUNOL, V7, P451, DOI 10.1002/eji.1830070710; HAMBURGER V, 1981, J NEUROSCI, V1, P60, DOI 10.1523/JNEUROSCI.01-01-00060.1981; HAMBURGER V, 1949, J EXP ZOOL, V111, P457, DOI 10.1002/jez.1401110308; HANSSON HA, 1989, EXP EYE RES, V48, P411, DOI 10.1016/S0014-4835(89)80009-0; HART IK, 1989, J CELL BIOL, V109, P3411, DOI 10.1083/jcb.109.6.3411; HART IK, 1989, DEVELOPMENT, V105, P595; HILDEBRAND C, 1971, ACTA PHYSL SCAND S, V354, P109; HOFER MM, 1988, NATURE, V331, P261, DOI 10.1038/331261a0; HUETTNER JE, 1986, J NEUROSCI, V6, P3044; HYNES RO, 1978, CELL, V13, P151, DOI 10.1016/0092-8674(78)90146-0; JACKSON KF, 1988, J NEUROCYTOL, V17, P657, DOI 10.1007/BF01260993; Kerr J. F., 1991, APOPTOSIS MOL BASIS, V3, P5; KNAPP PE, 1986, J NEUROSCI, V6, P2813; Korr H, 1980, Adv Anat Embryol Cell Biol, V61, P1; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; KRYPIANOU N, 1988, ENDOCRINOLOGY, V122, P552; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LEVIMONTALCINI R, 1987, EMBO J, V6, P1145, DOI 10.1002/j.1460-2075.1987.tb02347.x; LIEVRE C, 1991, DEVELOPMENT, V111, P105; LILLIEN LE, 1988, NEURON, V1, P485, DOI 10.1016/0896-6273(88)90179-1; LILLIEN LE, 1990, NEURON, V4, P525, DOI 10.1016/0896-6273(90)90110-2; MAGAUD JP, 1988, J IMMUNOL METHODS, V106, P95, DOI 10.1016/0022-1759(88)90276-1; MAGE MG, 1977, J IMMUNOL METHODS, V15, P47, DOI 10.1016/0022-1759(77)90016-3; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MATHEWS LS, 1988, ENDOCRINOLOGY, V123, P2827, DOI 10.1210/endo-123-6-2827; MCKINNON RD, 1990, NEURON, V5, P603, DOI 10.1016/0896-6273(90)90215-2; MCMORRIS FA, 1988, J NEUROSCI RES, V21, P199, DOI 10.1002/jnr.490210212; MCMORRIS FA, 1986, P NATL ACAD SCI USA, V83, P822, DOI 10.1073/pnas.83.3.822; MCMORRIS FA, 1990, CELLULAR MOL BIOL MY, P281; MESSNER PW, 1991, ABST SOC NEUR, V17, P1124; MILLER RH, 1985, DEV BIOL, V111, P35, DOI 10.1016/0012-1606(85)90432-4; MORI S, 1970, J COMP NEUROL, V139, P1, DOI 10.1002/cne.901390102; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MOZELL RL, 1991, J NEUROSCI RES, V30, P382, DOI 10.1002/jnr.490300214; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NOBLE M, 1988, NATURE, V333, P560, DOI 10.1038/333560a0; NOBLE M, 1984, EMBO J, V3, P2243, DOI 10.1002/j.1460-2075.1984.tb02122.x; NOBLE M, 1991, IN PRESS ANN NY ACAD; OPPENHEIM RW, 1990, DEV BIOL, V138, P104, DOI 10.1016/0012-1606(90)90180-Q; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.neuro.14.1.453; PANNESE E, 1967, ACTA NEUROPATHOL, V8, P309, DOI 10.1007/BF00688831; PERRY VH, 1983, J COMP NEUROL, V219, P356, DOI 10.1002/cne.902190309; POTTS RA, 1982, DEV BRAIN RES, V3, P481, DOI 10.1016/0165-3806(82)90013-X; PRINGLE N, 1989, EMBO J, V8, P1049, DOI 10.1002/j.1460-2075.1989.tb03472.x; PRINGLE N, 1992, IN PRESS DEVELOPMENT; PRUSS R, 1979, NATURE, V303, P390; RAFF MC, 1985, CELL, V42, P61, DOI 10.1016/S0092-8674(85)80101-X; RAFF MC, 1988, NATURE, V333, P562, DOI 10.1038/333562a0; RAFF MC, 1983, NATURE, V303, P390, DOI 10.1038/303390a0; RAFF MC, 1983, J NEUROSCI, V3, P1289; RAFF MC, 1989, SCIENCE, V243, P1450, DOI 10.1126/science.2648568; RAFF MC, 1978, NATURE, V274, P813, DOI 10.1038/274813a0; RAFF MC, 1992, IN PRESS NATURE; RANSCHT B, 1982, P NATL ACAD SCI-BIOL, V79, P2709, DOI 10.1073/pnas.79.8.2709; RICHARDSON WD, 1988, CELL, V53, P309, DOI 10.1016/0092-8674(88)90392-3; Richardson WD, 1990, SEMIN NEUROSCI, V2, P445; RODRIGUEZTARDUCHY G, 1990, EMBO J, V9, P2997, DOI 10.1002/j.1460-2075.1990.tb07492.x; ROTWEIN P, 1988, P NATL ACAD SCI USA, V85, P265, DOI 10.1073/pnas.85.1.265; SARA VR, 1990, KAR INS NCS, P179; SARA VR, 1990, PHYSIOL REV, V70, P591, DOI 10.1152/physrev.1990.70.3.591; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; SCHWARTZ LM, 1991, ABSTR SOC NEUROSCI, V17, P228; SMALL RK, 1987, NATURE, V328, P155, DOI 10.1038/328155a0; SMART I, 1961, J COMP NEUROL, V116, P349, DOI 10.1002/cne.901160307; STALLCUP WB, 1987, J NEUROSCI, V7, P2737; STURROCK RR, 1979, NEUROPATH APPL NEURO, V5, P433, DOI 10.1111/j.1365-2990.1979.tb00642.x; SVRZIC D, 1990, BIOCHEM BIOPH RES CO, V172, P54, DOI 10.1016/S0006-291X(05)80172-X; TEMPLE S, 1986, CELL, V44, P773, DOI 10.1016/0092-8674(86)90843-3; TEMPLE S, 1985, NATURE, V313, P223, DOI 10.1038/313223a0; VAUGHN JE, 1969, Z ZELLFORSCH MIK ANA, V94, P293, DOI 10.1007/BF00319179; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; WILSON AC, 1987, TRENDS GENET, V3, P241, DOI 10.1016/0168-9525(87)90257-5; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; WYSOCKI LJ, 1978, P NATL ACAD SCI USA, V75, P2844, DOI 10.1073/pnas.75.6.2844	115	1172	1190	0	32	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 10	1992	70	1					31	46		10.1016/0092-8674(92)90531-G	http://dx.doi.org/10.1016/0092-8674(92)90531-G			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JC957	1623522				2022-12-01	WOS:A1992JC95700006
J	BICKMORE, WA; OGHENE, K; LITTLE, MH; SEAWRIGHT, A; VANHEYNINGEN, V; HASTIE, ND				BICKMORE, WA; OGHENE, K; LITTLE, MH; SEAWRIGHT, A; VANHEYNINGEN, V; HASTIE, ND			MODULATION OF DNA-BINDING SPECIFICITY BY ALTERNATIVE SPLICING OF THE WILMS-TUMOR WT1 GENE TRANSCRIPT	SCIENCE			English	Article							EARLY GROWTH-RESPONSE; FINGER; PROTEIN; SEQUENCES; DELETION; GENOME; LOCUS; EGR-1	The technique of whole-genome polymerase chain reaction was used to study the DNA binding properties of the product of the wt1 gene. The zinc finger region of this gene is alternatively spliced such that the major transcript encodes a protein with three extra amino acids between the third and fourth fingers. The minor form of the protein binds specifically to DNA. It is now shown that the major form of wt1 messenger RNA encodes a protein that binds to DNA with a specificity that differs from that of the minor form. Therefore, alternative splicing within the DNA binding domain of a transcription factor can generate proteins with distinct DNA binding specificities and probably different physiological targets.	WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of Edinburgh			van Heyningen, Veronica/B-8039-2008; VAN HEYNINGEN, Veronica/GYE-0531-2022; Little, Melissa H/A-6170-2010; Bickmore, Wendy A/C-7314-2013	van Heyningen, Veronica/0000-0003-0359-0141; Little, Melissa H/0000-0003-0380-2263; Bickmore, Wendy A/0000-0001-6660-7735	Medical Research Council [MC_U127527199] Funding Source: Medline; MRC [MC_U127527199] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BORDEREAUX D, 1990, ONCOGENE, V5, P925; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; DOWZER CEA, 1991, MOL CELL BIOL, V11, P5701, DOI 10.1128/MCB.11.11.5701; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HUFF V, 1990, AM J HUM GENET, V47, P28; KENT JF, UNPUB; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; KINZLER KW, 1989, NUCLEIC ACIDS RES, V17, P3645, DOI 10.1093/nar/17.10.3645; LITT M, 1989, AM J HUM GENET, V44, P397; LITTLE MH, IN PRESS P NATL ACAD; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MIYAGAWA K, UNPUB; NARDELLI J, 1991, NATURE, V349, P175, DOI 10.1038/349175a0; NEHLIN JO, 1990, EMBO J, V9, P2891, DOI 10.1002/j.1460-2075.1990.tb07479.x; PATWARDHAN S, 1991, ONCOGENE, V6, P917; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; SUGGS SV, 1990, NUCLEIC ACIDS RES, V18, P4283, DOI 10.1093/nar/18.14.4283	23	225	229	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 10	1992	257	5067					235	237		10.1126/science.1321494	http://dx.doi.org/10.1126/science.1321494			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC585	1321494				2022-12-01	WOS:A1992JC58500037
J	BRADLEY, DJ; KJELLBOM, P; LAMB, CJ				BRADLEY, DJ; KJELLBOM, P; LAMB, CJ			ELICITOR-INDUCED AND WOUND-INDUCED OXIDATIVE CROSS-LINKING OF A PROLINE-RICH PLANT-CELL WALL PROTEIN - A NOVEL, RAPID DEFENSE RESPONSE	CELL			English	Article							NODULIN TRANSCRIPT ENOD2; PARENCHYMA INNER CORTEX; SOYBEAN ROOT-NODULES; MONOCLONAL-ANTIBODIES; POLYACRYLAMIDE GELS; PHASEOLUS-VULGARIS; GLYCOPROTEIN GENE; SALICYLIC-ACID; EXPRESSION; PEA	Treatment of bean or soybean cells with fungal elicitor or glutathione causes a rapid insolubilization of preexisting (hydroxy)proline-rich structural proteins in the cell wall. This insolubilization, which involves H2O2-mediated oxidative cross-linking, is initiated within 2 min and is complete within 10 min under optimal conditions, and hence, precedes the expression of transcription-dependent defenses. Cross-linking is also under developmental control during hypocotyl growth and in tissues subject to mechanical stress such as the stem-petiole junction. Stimulus-dependent oxidative cross-linking of wall structural proteins is a novel site of cellular regulation with potentially important functions in cell maturation and toughening of cell walls in the initial stages of plant defense.	SALK INST BIOL STUDIES,PLANT BIOL LAB,LA JOLLA,CA 92037	Salk Institute			poinssot, benoit/B-2569-2009	poinssot, benoit/0000-0001-5890-4318				APOSTOL I, 1989, PLANT PHYSIOL, V90, P109, DOI 10.1104/pp.90.1.109; AYERS AR, 1976, PLANT PHYSIOL, V57, P760, DOI 10.1104/pp.57.5.760; BIGGS KJ, 1990, PLANT PHYSIOL, V92, P197, DOI 10.1104/pp.92.1.197; BOHLMANN H, 1988, EMBO J, V7, P1559, DOI 10.1002/j.1460-2075.1988.tb02980.x; BRADLEY DJ, 1988, PLANTA, V173, P149, DOI 10.1007/BF00403006; CASSAB GI, 1988, ANNU REV PLANT PHYS, V39, P321, DOI 10.1146/annurev.pp.39.060188.001541; CHEONG JJ, 1991, PLANT CELL, V3, P137, DOI 10.1105/tpc.3.2.137; CORBIN DR, 1987, MOL CELL BIOL, V7, P4337, DOI 10.1128/MCB.7.12.4337; COSIO EG, 1990, FEBS LETT, V271, P223, DOI 10.1016/0014-5793(90)80411-B; CRAMER CL, 1985, EMBO J, V4, P285, DOI 10.1002/j.1460-2075.1985.tb03627.x; DEOLIVEIRA DE, 1990, PLANT CELL, V2, P427, DOI 10.1105/tpc.2.5.427; Dixon R A, 1990, Adv Genet, V28, P165; DIXON RA, 1990, ANNU REV PLANT PHYS, V41, P339, DOI 10.1146/annurev.pp.41.060190.002011; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FARMER EE, 1991, J BIOL CHEM, V266, P3140; FRY SC, 1986, ANNU REV PLANT PHYS, V37, P165, DOI 10.1146/annurev.arplant.37.1.165; GUEVARA J, 1982, ELECTROPHORESIS, V3, P197, DOI 10.1002/elps.1150030404; HONG JC, 1989, PLANT CELL, V1, P937, DOI 10.1105/tpc.1.9.937; HONG JC, 1990, J BIOL CHEM, V265, P2470; Hurn B A, 1980, Methods Enzymol, V70, P104; KELLER B, 1989, P NATL ACAD SCI USA, V86, P1529, DOI 10.1073/pnas.86.5.1529; KELLER B, 1989, GENE DEV, V3, P1639, DOI 10.1101/gad.3.10.1639; KELLER B, 1988, EMBO J, V7, P3625, DOI 10.1002/j.1460-2075.1988.tb03243.x; KELLER B, 1989, EMBO J, V8, P1309, DOI 10.1002/j.1460-2075.1989.tb03510.x; KJELLBOM P, 1984, PHYSIOL PLANTARUM, V62, P501, DOI 10.1111/j.1399-3054.1984.tb02791.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB CJ, 1989, CELL, V56, P215, DOI 10.1016/0092-8674(89)90894-5; LAWTON MA, 1987, MOL CELL BIOL, V7, P335, DOI 10.1128/MCB.7.1.335; MALAMY J, 1990, SCIENCE, V250, P1002, DOI 10.1126/science.250.4983.1002; MATHIEU Y, 1991, PLANT J, V1, P333, DOI 10.1046/j.1365-313X.1991.t01-10-00999.x; METRAUX JP, 1990, SCIENCE, V250, P1004, DOI 10.1126/science.250.4983.1004; NORMAN PM, 1986, PLANTA, V167, P452, DOI 10.1007/BF00391220; Roberts K, 1990, CURR OPIN CELL BIOL, V2, P920, DOI 10.1016/0955-0674(90)90093-T; SAUER N, 1990, PLANT CELL ENVIRON, V13, P257, DOI 10.1111/j.1365-3040.1990.tb01310.x; SCHEEL D, 1991, ADV MOL GENETICS PLA, V1, P373; SEQUEIRA L, 1983, ANNU REV MICROBIOL, V37, P51, DOI 10.1146/annurev.mi.37.100183.000411; SHAPIRO BM, 1991, SCIENCE, V252, P533, DOI 10.1126/science.1850548; SHENG J, 1991, PLANT J, V3, P345; SMITH JA, 1991, PHYSIOL MOL PLANT P, V38, P232; SUTHERLAND MW, 1991, PHYSIOL MOL PLANT P, V39, P79, DOI 10.1016/0885-5765(91)90020-I; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDENBOSCH KA, 1989, EMBO J, V8, P335, DOI 10.1002/j.1460-2075.1989.tb03382.x; VANDEWIEL C, 1990, EMBO J, V9, P1; VARNER JE, 1989, CELL, V56, P231, DOI 10.1016/0092-8674(89)90896-9; WALBOT V, 1985, TRENDS GENET, V1, P165, DOI 10.1016/0168-9525(85)90071-X; WARD ER, 1991, PLANT CELL, V3, P1085, DOI 10.1105/tpc.3.10.1085; WINGATE VPM, 1988, PLANT PHYSIOL, V87, P206, DOI 10.1104/pp.87.1.206	47	981	1052	2	120	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 10	1992	70	1					21	30		10.1016/0092-8674(92)90530-P	http://dx.doi.org/10.1016/0092-8674(92)90530-P			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JC957	1623521				2022-12-01	WOS:A1992JC95700005
J	HAN, TM; RUNNEGAR, B				HAN, TM; RUNNEGAR, B			MEGASCOPIC EUKARYOTIC ALGAE FROM THE 2.1-BILLION-YEAR-OLD NEGAUNEE IRON-FORMATION, MICHIGAN	SCIENCE			English	Article							CARBONACEOUS MEGAFOSSILS; BACILLUS-SUBTILIS; RIBOSOMAL-RNA; ORIGIN; CHINA; EVOLUTION; BACTERIA	Hundreds of specimens of spirally coiled, megascopic, carbonaceous fossils resembling Grypania spiralis (Walcott), have been found in the 2.1 billion-year-old Negaunee Iron-Formation Formation at the Empire Mine, near Marquette, Michigan. This occurrence of Grypania is 700 million to 1 000 million years older than fossils from previously known sites in Montana, China, and India. As Grypania appears to have been a photosynthetic alga, this discovery places the origin of organelle-bearing eukaryotic cells prior to 2.1 billion years ago.	UNIV CALIF LOS ANGELES,INST MOLEC BIOL,DEPT EARTH & SPACE SCI,LOS ANGELES,CA 90024; CLIFFS MIN SERV CO MICHIGAN,ISHPEMING,MI 49849; UNIV CALIF LOS ANGELES,INST GEOPHYS & PLANETARY PHYS,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles								Beer EJ., 1919, REC GEOL SURV INDIA, V50, P139; CAVALIERSMITH T, 1987, ANN NY ACAD SCI, V503, P55, DOI 10.1111/j.1749-6632.1987.tb40597.x; CAVALIERSMITH T, 1987, ANN NY ACAD SCI, V503, P17, DOI 10.1111/j.1749-6632.1987.tb40596.x; CLOUD P, 1979, PRECAMBRIAN RES, V10, P73, DOI 10.1016/0301-9268(79)90020-2; CRAWFORD AR, 1971, J GEOL SOC LONDON, V125, P351; DOOLITTLE RF, 1989, HIERARCHY LIFE, P73; DU RL, 1985, PRECAMBRIAN RES, V29, P5, DOI 10.1016/0301-9268(85)90055-5; DU RL, 1986, ACTA GEOL SINICA, P115; GALLARDO VA, 1977, NATURE, V268, P331, DOI 10.1038/268331a0; Gerlach DC., 1988, EOS, V69, P1515; GOGARTEN JP, 1989, P NATL ACAD SCI USA, V86, P6661, DOI 10.1073/pnas.86.17.6661; HAN TM, 1975, 769 US GEOL SURV PRO, P76; Hayes JM., 1983, EARTHS EARLIEST BIOS, P291; HENDERSON E, 1984, SCIENCE, V225, P510, DOI 10.1126/science.6429855; HOFMANN HJ, 1981, CAN J EARTH SCI, V18, P443, DOI 10.1139/e81-038; IWABE N, 1991, J MOL EVOL, V32, P70, DOI 10.1007/BF02099931; IWABE N, 1989, P NATL ACAD SCI USA, V86, P9355, DOI 10.1073/pnas.86.23.9355; JANNASCH HW, 1989, NATURE, V342, P834, DOI 10.1038/342834a0; KABNICK S, 1991, AM SCI, V70, P34; KANDLER O, 1990, P NATL ACAD SCI USA, V87, P4576; LAKE JA, 1988, NATURE, V331, P184, DOI 10.1038/331184a0; LAKE JA, 1991, MOL BIOL EVOL, V8, P378; MENDELSON NH, 1976, P NATL ACAD SCI USA, V73, P1740, DOI 10.1073/pnas.73.5.1740; MENDELSON NH, 1989, J BACTERIOL, V171, P1055, DOI 10.1128/jb.171.2.1055-1062.1989; Peel J.S., 1988, RAPP GRPHINLANDS GEO, V137, P5; RIDING R, 1984, GEOL MAG, V121, P205, DOI 10.1017/S0016756800028260; RIVERA MC, 1992, SCIENCE, V257, P74, DOI 10.1126/science.1621096; RUNNEGAR B, UNPUB; Runnegar B, 1991, PALAEOGEOGR PALAEOCL, V97, P97, DOI 10.1016/0031-0182(91)90186-U; SCHIDLOWSKI M, 1988, NATURE, V333, P313, DOI 10.1038/333313a0; SCHOPF JW, 1992, MAJOR EVENTS IN THE HISTORY OF LIFE, P29; SMITH CR, 1989, NATURE, V341, P27, DOI 10.1038/341027a0; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; SONG XL, 1984, GEOL MAG, V121, P179; Starr M. P., 1981, PROKARYOTES; SUMMONS RE, 1988, GEOCHIM COSMOCHIM AC, V52, P1747, DOI 10.1016/0016-7037(88)90001-4; SUMMONS RE, 1990, AM J SCI, V290A, P212; TANDON K K, 1977, Geophytology, V7, P126; TANDON KK, 1977, CURR SCI INDIA, V46, P563; VIDAL G, 1989, LETHAIA, V22, P375, DOI 10.1111/j.1502-3931.1989.tb01437.x; WALTER MR, 1976, J PALEONTOL, V50, P872; WALTER MR, 1990, AM J SCI, V290A, P133; WANG F, 1981, NATURE, V294, P74; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; WOESE CR, 1977, P NATL ACAD SCI USA, V74, P5088, DOI 10.1073/pnas.74.11.5088	45	310	342	3	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 10	1992	257	5067					232	235		10.1126/science.1631544	http://dx.doi.org/10.1126/science.1631544			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC585	1631544				2022-12-01	WOS:A1992JC58500036
J	KISS, T; FILIPOWICZ, W				KISS, T; FILIPOWICZ, W			EVIDENCE AGAINST A MITOCHONDRIAL LOCATION OF THE 7-2/MRP RNA IN MAMMALIAN-CELLS	CELL			English	Editorial Material							RIBONUCLEASE-P; NUCLEAR GENE; MRP; SEQUENCES; DNA; TRANSCRIPTION; CONTAINS; ENZYME; SITE				KISS, T (corresponding author), FRIEDRICH MIESCHER INST, POB 2543, CH-4002 BASEL, SWITZERLAND.			Kiss, Tamas/0000-0003-0293-3093				ALTMAN S, 1990, J BIOL CHEM, V265, P20053; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; ATTARDI G, 1982, MITOCHONDRIAL GENES, P51; Baserga R, 1969, Int Rev Exp Pathol, V7, P1; BENNE R, 1990, TRENDS GENET, V6, P177, DOI 10.1016/0168-9525(90)90173-4; BENNETT JL, 1990, MOL CELL BIOL, V10, P2191, DOI 10.1128/MCB.10.5.2191; BROWN JW, 1990, CELL, V62, P407, DOI 10.1016/0092-8674(90)90003-W; CHANG DD, 1989, CELL, V56, P131, DOI 10.1016/0092-8674(89)90991-4; CHANG DD, 1985, EMBO J, V4, P1559, DOI 10.1002/j.1460-2075.1985.tb03817.x; CHANG DD, 1987, EMBO J, V6, P409, DOI 10.1002/j.1460-2075.1987.tb04770.x; CHANG DD, 1987, SCIENCE, V235, P1178, DOI 10.1126/science.2434997; CLAYTON DA, 1991, TRENDS BIOCHEM SCI, V16, P107, DOI 10.1016/0968-0004(91)90043-U; CREWS S, 1980, CELL, V19, P775, DOI 10.1016/S0092-8674(80)80053-5; FILIPOWICZ W, 1990, METHOD ENZYMOL, V181, P499; GELFAND R, 1981, MOL CELL BIOL, V1, P497, DOI 10.1128/MCB.1.6.497; GOLD HA, 1989, SCIENCE, V245, P1377, DOI 10.1126/science.2476849; GOODALL GJ, 1990, METHOD ENZYMOL, V181, P148; GOODALL GJ, 1989, CELL, V58, P473, DOI 10.1016/0092-8674(89)90428-5; Greenawalt J W, 1974, Methods Enzymol, V31, P310; JAMES BD, 1988, CELL, V52, P19, DOI 10.1016/0092-8674(88)90527-2; KARWAN R, 1991, GENE DEV, V5, P1264, DOI 10.1101/gad.5.7.1264; KISS T, 1991, CELL, V65, P517, DOI 10.1016/0092-8674(91)90469-F; NAGLEY P, 1989, TRENDS GENET, V5, P67, DOI 10.1016/0168-9525(89)90028-0; NELSONREES WA, 1976, SCIENCE, V191, P96, DOI 10.1126/science.1246601; PACE NR, 1990, J BIOL CHEM, V265, P3587; PARRY HD, 1989, TRENDS BIOCHEM SCI, V14, P15, DOI 10.1016/0968-0004(89)90083-2; POSAKONY JW, 1977, J CELL BIOL, V74, P468, DOI 10.1083/jcb.74.2.468; REDDY R, 1981, J BIOL CHEM, V256, P8452; Reddy R, 1988, STRUCTURE FUNCTION M, P1, DOI [10.1007/978-3-642-73020-7_1, 10.1007/978-3-642-73020-7_1.]; REIMER G, 1988, EXP CELL RES, V176, P117, DOI 10.1016/0014-4827(88)90126-7; STEELE WJ, 1965, J BIOL CHEM, V240, P1742; TAPPER DP, 1983, METHOD ENZYMOL, V97, P426; TOPPER JN, 1990, NUCLEIC ACIDS RES, V18, P793, DOI 10.1093/nar/18.4.793; YUAN Y, 1989, J BIOL CHEM, V264, P14835; YUAN Y, 1991, MOL CELL BIOL, V11, P5266, DOI 10.1128/MCB.11.10.5266	35	100	102	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 10	1992	70	1					11	16		10.1016/0092-8674(92)90528-K	http://dx.doi.org/10.1016/0092-8674(92)90528-K			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JC957	1377982				2022-12-01	WOS:A1992JC95700003
J	KUMAGAI, A; DUNPHY, WG				KUMAGAI, A; DUNPHY, WG			REGULATION OF THE CDC25 PROTEIN DURING THE CELL-CYCLE IN XENOPUS EXTRACTS	CELL			English	Article							FISSION YEAST; MITOTIC CONTROL; STEP PURIFICATION; DNA-REPLICATION; MESSENGER-RNA; M-PHASE; MITOSIS; KINASE; INVITRO; ACTIVATION	The cdc25 protein is a highly specific tyrosine phosphatase that triggers mitosis by dephosphorylating the cdc2 protein kinase. Using Xenopus extracts, we have found that the cdc25 protein is active at a low level throughout interphase. Near the onset of mitosis, the cdc25 protein undergoes a marked elevation in phosphatase activity that coincides with an extensive phosphorylation of the protein in its N-terminal region. In vitro dephosphorylation of this hyperphosphorylated form of cdc25 reduces its phosphatase activity back to the interphase level. Moreover, treatment of interphase Xenopus extracts with okadaic acid, a phosphatase inhibitor that accelerates the entry into mitosis, elicits both the premature hyperphosphorylation of cdc25 and the stimulation of its cdc2-specific tyrosine phosphatase activity. These experiments demonstrate the existence of a cdc25 regulatory system consisting of both a stimulatory kinase that phosphorylates a putative regulatory domain of the cdc25 protein and an inhibitory serine/threonine phosphatase that counteracts this kinase activity.			KUMAGAI, A (corresponding author), CALTECH, DIV BIOL, PASADENA, CA 91125 USA.							BOOHER R, 1987, EMBO J, V6, P3441, DOI 10.1002/j.1460-2075.1987.tb02667.x; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; DUNPHY WG, 1988, CELL, V55, P925, DOI 10.1016/0092-8674(88)90234-6; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; DUNPHY WG, 1988, J CELL BIOL, V106, P2047, DOI 10.1083/jcb.106.6.2047; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; FELIX MA, 1990, EMBO J, V9, P675, DOI 10.1002/j.1460-2075.1990.tb08159.x; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; Fleig U N, 1991, Semin Cell Biol, V2, P195; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HARLOW E, 1988, ANTIBODIES LABORATOR; JESSUS C, 1992, CELL, V68, P323, DOI 10.1016/0092-8674(92)90473-P; JESSUS C, 1991, DEVELOPMENT, V111, P813; Johnson B.F, 1989, MOL BIOL FISSION YEA, P243; KINOSHITA N, 1990, CELL, V63, P405, DOI 10.1016/0092-8674(90)90173-C; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LEE TH, 1991, CELL, V64, P415, DOI 10.1016/0092-8674(91)90649-J; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; LOHKA MJ, 1989, J CELL SCI, V92, P131; LOHKA MJ, 1985, J CELL BIOL, V101, P518, DOI 10.1083/jcb.101.2.518; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MORENO S, 1991, NATURE, V351, P194, DOI 10.1038/351194b0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; Nigg E A, 1991, Semin Cell Biol, V2, P261; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; PICARD A, 1991, J CELL BIOL, V115, P337, DOI 10.1083/jcb.115.2.337; PINES J, 1987, EMBO J, V6, P2987, DOI 10.1002/j.1460-2075.1987.tb02604.x; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1989, CELL, V57, P295, DOI 10.1016/0092-8674(89)90967-7; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; Sambrook J., 1989, MOL CLONING LAB MANU; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMYTHE C, 1992, CELL, V68, P787, DOI 10.1016/0092-8674(92)90153-4; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M	53	360	374	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 10	1992	70	1					139	151		10.1016/0092-8674(92)90540-S	http://dx.doi.org/10.1016/0092-8674(92)90540-S			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JC957	1623517				2022-12-01	WOS:A1992JC95700015
J	MEIER, UT; BLOBEL, G				MEIER, UT; BLOBEL, G			NOPP140 SHUTTLES ON TRACKS BETWEEN NUCLEOLUS AND CYTOPLASM	CELL			English	Article							NUCLEAR LOCATION SIGNAL; CASEIN KINASE-II; GEL-ELECTROPHORESIS; SEQUENCE REQUIREMENTS; BINDING-PROTEINS; T-ANTIGEN; SPECIFICITY DETERMINANTS; PRECURSOR PARTICLES; SYNTHETIC PEPTIDES; TRANSPORT SIGNALS	Nopp140 is a nucleolar phosphoprotein of 140 kd that we originally identified and purified as a nuclear localization signal (NLS)-binding protein. Molecular characterization revealed a 10-fold repeated motif of highly conserved acidic serine clusters that contain an abundance of phosphorylation consensus sites for casein kinase II (CK II). Indeed, Nopp140 is one of the most phosphorylated proteins in the cell, and NLS binding was dependent on phosphorylation. Nopp140 was shown to shuttle between the nucleolus and the cytoplasm. Shuttling is likely to proceed on tracks that were revealed by immunoelectron microscopy. These tracks extend from the dense fibrillar component of the nucleolus across the nucleoplasm to some nuclear pore complexes. We suggest that Nopp140 functions as a chaperone for import into and/or export from the nucleolus.			MEIER, UT (corresponding author), ROCKEFELLER UNIV, HOWARD HUGHES MED INST, CELL BIOL LAB, NEW YORK, NY 10021 USA.							ADAM SA, 1989, NATURE, V337, P276, DOI 10.1038/337276a0; ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; AHN YS, 1985, BIOCHEMISTRY-US, V24, P7296, DOI 10.1021/bi00346a041; ARIS JP, 1988, J CELL BIOL, V107, P17, DOI 10.1083/jcb.107.1.17; BACHMANN M, 1989, MOL CELL BIOCHEM, V85, P103, DOI 10.1007/BF00577106; BANVILLE D, 1982, EXP CELL RES, V137, P437, DOI 10.1016/0014-4827(82)90046-5; BENDITT JO, 1989, P NATL ACAD SCI USA, V86, P9327, DOI 10.1073/pnas.86.23.9327; BLOBEL G, 1985, P NATL ACAD SCI USA, V82, P8527, DOI 10.1073/pnas.82.24.8527; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; CLARK TG, 1977, CELL, V12, P883, DOI 10.1016/0092-8674(77)90152-0; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COCHRANE AW, 1990, J VIROL, V64, P881, DOI 10.1128/JVI.64.2.881-885.1990; COTTEN M, 1986, BIOCHEMISTRY-US, V25, P5063, DOI 10.1021/bi00366a014; DANG CV, 1989, J BIOL CHEM, V264, P18019; DWORETZKY SI, 1988, J CELL BIOL, V107, P1279, DOI 10.1083/jcb.107.4.1279; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUKUI Y, 1978, J CELL BIOL, V76, P146, DOI 10.1083/jcb.76.1.146; GOLDFARB DS, 1988, CELL BIOL INT REP, V12, P809, DOI 10.1016/0309-1651(88)90090-2; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; GOLDSTEIN L, 1981, J CELL BIOL, V88, P516, DOI 10.1083/jcb.88.3.516; GREEN N, 1982, CELL, V28, P477, DOI 10.1016/0092-8674(82)90202-1; GUIOCHONMANTEL A, 1991, EMBO J, V10, P3851, DOI 10.1002/j.1460-2075.1991.tb04954.x; HUANG S, 1991, Genes and Development, V5, P2288, DOI 10.1101/gad.5.12a.2288; HUGLE B, 1985, CELL, V41, P615, DOI 10.1016/S0092-8674(85)80034-9; IMAMOTOSONOBE N, 1990, J BIOL CHEM, V265, P16504; JOCKUSCH BM, 1974, EXP CELL RES, V89, P241, DOI 10.1016/0014-4827(74)90787-3; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KUBOTA S, 1989, BIOCHEM BIOPH RES CO, V162, P963, DOI 10.1016/0006-291X(89)90767-5; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; KUMAR A, 1972, J MOL BIOL, V63, P233, DOI 10.1016/0022-2836(72)90372-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANFORD RE, 1986, CELL, V46, P575, DOI 10.1016/0092-8674(86)90883-4; LANFORD RE, 1984, CELL, V37, P801, DOI 10.1016/0092-8674(84)90415-X; LAWRENCE JB, 1989, CELL, V57, P493, DOI 10.1016/0092-8674(89)90924-0; Le Stourgeon WM, 1978, CELL NUCLEUS, V6, P305; LEE WC, 1989, P NATL ACAD SCI USA, V86, P8808, DOI 10.1073/pnas.86.22.8808; LEE WC, 1991, J CELL BIOL, V113, P1, DOI 10.1083/jcb.113.1.1; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; MADSEN P, 1986, J CELL BIOL, V103, P2083, DOI 10.1083/jcb.103.6.2083; MANDELL RB, 1990, J CELL BIOL, V111, P1775, DOI 10.1083/jcb.111.5.1775; Maniatis T, 1989, MOL CLONING; MANSOUR SL, 1988, EMBO J, V7, P2035, DOI 10.1002/j.1460-2075.1988.tb03043.x; MARIN O, 1986, EUR J BIOCHEM, V160, P239, DOI 10.1111/j.1432-1033.1986.tb09962.x; MARSHAK DR, 1991, METHOD ENZYMOL, V200, P134; MEGGIO F, 1988, BIOCHIM BIOPHYS ACTA, V971, P227, DOI 10.1016/S0005-2728(88)80111-7; MEIER UT, 1990, J CELL BIOL, V111, P2235, DOI 10.1083/jcb.111.6.2235; NEWMEYER DD, 1986, J CELL BIOL, V103, P2091, DOI 10.1083/jcb.103.6.2091; NICCHITTA CV, 1991, CELL, V65, P587, DOI 10.1016/0092-8674(91)90091-C; NIGG EA, 1991, CELL, V66, P15, DOI 10.1016/0092-8674(91)90135-L; NIKKODEM V, 1979, ANAL BIOCHEM, V97, P382; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PFAFF M, 1988, BIOCHIM BIOPHYS ACTA, V969, P100, DOI 10.1016/0167-4889(88)90093-6; PFEIFLE J, 1981, BIOCHIM BIOPHYS ACTA, V670, P274, DOI 10.1016/0005-2795(81)90020-9; PFEIFLE J, 1984, EUR J BIOCHEM, V39, P417; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; PRESTAYKO AW, 1974, BIOCHEMISTRY-US, V13, P1945, DOI 10.1021/bi00706a026; RECHSTEINER M, 1979, CELL, V16, P901, DOI 10.1016/0092-8674(79)90105-3; ROBERTS BL, 1987, CELL, V50, P465, DOI 10.1016/0092-8674(87)90500-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEER U, 1984, P NATL ACAD SCI-BIOL, V81, P1431, DOI 10.1073/pnas.81.5.1431; SCHNELL DJ, 1990, J CELL BIOL, V111, P1825, DOI 10.1083/jcb.111.5.1825; SCHUURMAN R, 1991, BIOTECHNIQUES, V10, P185; SHELNESS GS, 1990, J BIOL CHEM, V265, P9512; SILVER P, 1989, J CELL BIOL, V109, P983, DOI 10.1083/jcb.109.3.983; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STOCHAJ U, 1991, J CELL BIOL, V113, P1243, DOI 10.1083/jcb.113.6.1243; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TOKUYASU KT, 1973, J CELL BIOL, V57, P551, DOI 10.1083/jcb.57.2.551; WANG TC, 1981, EXP CELL RES, V134, P409, DOI 10.1016/0014-4827(81)90440-7; WARNER JR, 1989, MICROBIOL REV, V53, P256, DOI 10.1128/MMBR.53.2.256-271.1989; WEHNER JM, 1977, NATURE, V266, P842, DOI 10.1038/266842a0; WICKENS M, 1984, SCIENCE, V226, P1045, DOI 10.1126/science.6208611; YAMASAKI L, 1989, MOL CELL BIOL, V9, P3028, DOI 10.1128/MCB.9.7.3028	78	349	353	0	5	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 10	1992	70	1					127	138						12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JC957	1623516				2022-12-01	WOS:A1992JC95700014
J	MELLO, CC; DRAPER, BW; KRAUSE, M; WEINTRAUB, H; PRIESS, JR				MELLO, CC; DRAPER, BW; KRAUSE, M; WEINTRAUB, H; PRIESS, JR			THE PIE-1 AND MEX-1 GENES AND MATERNAL CONTROL OF BLASTOMERE IDENTITY IN EARLY C-ELEGANS EMBRYOS	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; GERM-LINE; CELLULAR INTERACTIONS; GLP-1; SEGREGATION; GRANULES; LIN-12; MUSCLE; NOTCH; LOCUS	During C. elegans embryogenesis an 8-cell stage blastomere, called MS, undergoes a reproducible cleavage pattern, producing pharyngeal cells, body wall muscles, and cell deaths. We show here that maternal-effect mutations in the pie-1 and mex-1 genes cause additional 8-cell stage blastomeres to adopt a fate very similar to that of the wild-type MS blastomere. In pie-1 mutants one additional posterior blastomere adopts an MS-like fate, and in mex-1 mutants four additional anterior blastomeres adopt an MS-like fate. We propose that maternally provided pie-1(+) and mex-1(+) gene products may function in the early embryo to localize or regulate factors that determine the fate of the MS blastomere.	UNIV WASHINGTON,DEPT ZOOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	MELLO, CC (corresponding author), FRED HUTCHINSON CANC RES CTR,DEPT BASIC SCI,1124 COLUMBIA ST,SEATTLE,WA 98104, USA.			Draper, Bruce W/0000-0002-4397-7749; Krause, Michael/0000-0001-6127-3940				ALBERTSON DG, 1976, PHILOS T ROY SOC B, V275, P299, DOI 10.1098/rstb.1976.0085; ALBERTSON DG, 1984, DEV BIOL, V101, P61, DOI 10.1016/0012-1606(84)90117-9; AUSTIN J, 1987, CELL, V51, P589, DOI 10.1016/0092-8674(87)90128-0; AUSTIN J, 1989, CELL, V58, P565, DOI 10.1016/0092-8674(89)90437-6; AVERY L, 1989, NEURON, V3, P473, DOI 10.1016/0896-6273(89)90206-7; BOWERMAN B, 1992, CELL, V68, P1061, DOI 10.1016/0092-8674(92)90078-Q; BRENNER S, 1974, GENETICS, V77, P71; COWAN AE, 1985, CELL, V41, P923, DOI 10.1016/S0092-8674(85)80073-8; EDGAR LG, 1986, DEV BIOL, V114, P109, DOI 10.1016/0012-1606(86)90387-8; EPSTEIN HF, 1982, MUSCLE DEV MOL CELLU, P7; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; GOLDSTEIN B, 1992, NATURE, V357, P255, DOI 10.1038/357255a0; GOSSETT LA, 1982, CELL, V30, P193, DOI 10.1016/0092-8674(82)90025-3; GREENWALD IS, 1985, CELL, V45, P583; HEDGECOCK EM, 1983, SCIENCE, V220, P1277, DOI 10.1126/science.6857247; HORVITZ HR, 1982, NEUROSCI COMMENT, V1, P56; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; KRAUSE M, 1990, CELL, V63, P907, DOI 10.1016/0092-8674(90)90494-Y; LAUFER JS, 1980, CELL, V19, P569, DOI 10.1016/S0092-8674(80)80033-X; MILLER DM, 1983, CELL, V34, P477, DOI 10.1016/0092-8674(83)90381-1; PRIESS JR, 1987, CELL, V48, P241, DOI 10.1016/0092-8674(87)90427-2; PRIESS JR, 1987, CELL, V51, P601, DOI 10.1016/0092-8674(87)90129-2; SCHIERENBERG E, 1987, DEV BIOL, V122, P452, DOI 10.1016/0012-1606(87)90309-5; SCHIERENBERG E, 1984, DEV BIOL, V101, P240, DOI 10.1016/0012-1606(84)90136-2; SCHNABEL R, 1991, MECH DEVELOP, V34, P85, DOI 10.1016/0925-4773(91)90046-9; STJOHNSTON D, 1992, CELL, V68, P201; STROME S, 1982, P NATL ACAD SCI-BIOL, V79, P1558, DOI 10.1073/pnas.79.5.1558; STROME S, 1983, CELL, V35, P15, DOI 10.1016/0092-8674(83)90203-9; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; WOLF N, 1983, J EMBRYOL EXP MORPH, V73, P297; WOOD WB, 1991, NATURE, V349, P536, DOI 10.1038/349536a0; YAMAGUCHI Y, 1983, DEV GROWTH DIFFER, V25, P121; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0	36	207	217	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 10	1992	70	1					163	176		10.1016/0092-8674(92)90542-K	http://dx.doi.org/10.1016/0092-8674(92)90542-K			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JC957	1623520				2022-12-01	WOS:A1992JC95700017
J	MEYAARD, L; OTTO, SA; JONKER, RR; MIJNSTER, MJ; KEET, RPM; MIEDEMA, F				MEYAARD, L; OTTO, SA; JONKER, RR; MIJNSTER, MJ; KEET, RPM; MIEDEMA, F			PROGRAMMED DEATH OF T-CELLS IN HIV-1 INFECTION	SCIENCE			English	Article							AIDS-RELATED COMPLEX; DNA FRAGMENTATION; HOMOSEXUAL MEN; SELECTIVE LOSS; IMMUNE-SYSTEM; APOPTOSIS; LYMPHOCYTES; EXPRESSION; INDUCTION; RECEPTOR	In human immunodeficiency virus (HIV) infection, functional defects and deletion of antigen-reactive T cells are more frequent than can be explained by direct viral infection. On culturing, both CD4+ and CD8+ T cells from asymptomatic HIV-infected individuals died as a result of programmed cell death (apoptosis). Apoptosis was enhanced by activation with CD3 antibodies. Programmed cell death, associated with impaired T cell reactivity, may thus be responsible for the deletion of reactive T cells that contributes to HIV-induced immunodeficiency.	NETHERLANDS RED CROSS, BLOOD TRANSFUS SERV,CENT LAB, DEPT CLIN VIROIMMUNOL,PLESMANLAAN 125, AMSTERDAM, NETHERLANDS; UNIV AMSTERDAM, EXPTL & CLIN IMMUNOL LAB, 1066 CX AMSTERDAM, NETHERLANDS; TNO, INST APPL RADIOBIOL & IMMUNOL, DEPT MOLEC PATHOL, 2280 HV RIJSWIJK, NETHERLANDS; NETHERLANDS INST BRAIN RES, 1095 KJ AMSTERDAM, NETHERLANDS; MUNICIPAL HLTH SERV, DEPT INFECT DIS, AMSTERDAM, NETHERLANDS	University of Amsterdam; Netherlands Organization Applied Science Research; Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW)				Keet, Rene/0000-0001-9959-6032; Meyaard, Linde/0000-0003-0707-4793				AMEISEN JC, 1991, IMMUNOL TODAY, V12, P102; CEFAI D, 1990, J CLIN INVEST, V86, P2117, DOI 10.1172/JCI114950; CLERICI M, 1989, J CLIN INVEST, V84, P1892, DOI 10.1172/JCI114376; DEWOLF F, 1987, BMJ-BRIT MED J, V295, P569, DOI 10.1136/bmj.295.6598.569; DUKE RC, 1983, P NATL ACAD SCI-BIOL, V80, P6361, DOI 10.1073/pnas.80.20.6361; DUVALL E, 1986, IMMUNOL TODAY, V7, P115, DOI 10.1016/0167-5699(86)90152-0; GROUX H, 1992, J EXP MED, V175, P331, DOI 10.1084/jem.175.2.331; GRUTERS RA, 1991, AIDS, V5, P837, DOI 10.1097/00002030-199107000-00007; GRUTERS RA, 1990, EUR J IMMUNOL, V20, P1039, DOI 10.1002/eji.1830200514; JONKER RR, UNPUB; KEKOW J, 1991, J CLIN INVEST, V87, P1010, DOI 10.1172/JCI115059; MARTZ E, 1989, IMMUNOL TODAY, V10, P79, DOI 10.1016/0167-5699(89)90231-4; MEYAARD L, UNPUB; MIEDEMA F, 1990, IMMUNOL TODAY, V11, P293, DOI 10.1016/0167-5699(90)90116-Q; MIEDEMA F, 1988, J CLIN INVEST, V82, P1908, DOI 10.1172/JCI113809; NEWELL MK, 1990, NATURE, V347, P286, DOI 10.1038/347286a0; PANTALEO G, 1990, J IMMUNOL, V144, P1696; PRINCE HE, 1991, CELL IMMUNOL, V134, P276, DOI 10.1016/0008-8749(91)90302-R; ROSENBERG ZF, 1990, IMMUNOL TODAY, V11, P176, DOI 10.1016/0167-5699(90)90070-P; SALAZARGONZALEZ JF, 1985, J IMMUNOL, V135, P1778; SCHMID DS, 1986, P NATL ACAD SCI USA, V83, P1881, DOI 10.1073/pnas.83.6.1881; SCHNITTMAN SM, 1990, P NATL ACAD SCI USA, V87, P6058, DOI 10.1073/pnas.87.16.6058; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SELLINS KS, 1987, J IMMUNOL, V139, P3199; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; STITES DP, 1989, CLIN IMMUNOL IMMUNOP, V52, P96, DOI 10.1016/0090-1229(89)90196-7; TERSMETTE M, 1989, J VIROL, V63, P2118, DOI 10.1128/JVI.63.5.2118-2125.1989; TERSMETTE M, 1989, LANCET, V1, P983; VANLIER RAW, 1987, J IMMUNOL, V139, P2873; VANNOESEL CJM, 1990, J CLIN INVEST, V86, P293, DOI 10.1172/JCI114698; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112	33	905	934	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 10	1992	257	5067					217	219		10.1126/science.1352911	http://dx.doi.org/10.1126/science.1352911			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC585	1352911				2022-12-01	WOS:A1992JC58500030
J	MIYAZAKI, S; YUZAKI, M; NAKADA, K; SHIRAKAWA, H; NAKANISHI, S; NAKADE, S; MIKOSHIBA, K				MIYAZAKI, S; YUZAKI, M; NAKADA, K; SHIRAKAWA, H; NAKANISHI, S; NAKADE, S; MIKOSHIBA, K			BLOCK OF CA2+ WAVE AND CA2+ OSCILLATION BY ANTIBODY TO THE INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR IN FERTILIZED HAMSTER EGGS	SCIENCE			English	Article							SMOOTH-MUSCLE CELLS; PERIODIC INCREASE; CA-2+ RELEASE; FREE CALCIUM; GUINEA-PIG; TRISPHOSPHATE; EXPRESSION; PURIFICATION; RYANODINE; PROTEIN	The concentration of cytoplasmic free calcium (Ca2+) increases in various stimulated cells in a wave (Ca2+ wave) and in periodic transients (Ca2+ oscillations). These phenomena are explained by inositol 1,4,5-trisphosphate (IP3)-induced Ca2+ release (IICR) and Ca2+-induced Ca2+ release (CICR) from separate intracellular stores, but decisive evidence is lacking. A monoclonal antibody to the IP3 receptor inhibited both IICR and CICR upon injection of IP3 and Ca2+ into hamster eggs, respectively. The antibody completely blocked sperm-induced Ca2+ waves and Ca2+ oscillations. The results indicate that Ca2 release in fertilized hamster eggs is mediated solely by the IP3 receptor, and Ca2+-sensitized IICR, but not CICR, generates Ca2+ waves and Ca2+ oscillations.	JICHI MED SCH, DEPT BIOCHEM, MINAMI KAWACHI, TOCHIGI 32904, JAPAN; OSAKA UNIV, INST PROT RES, DIV REGULAT MACROMOLEC FUNCT, SUITA, OSAKA 565, JAPAN; UNIV TOKYO, INST MED SCI, DEPT MOLEC NEUROBIOL, MINATO KU, TOKYO 108, JAPAN	Jichi Medical University; Osaka University; University of Tokyo	MIYAZAKI, S (corresponding author), TOKYO WOMENS MED COLL, DEPT PHYSIOL, 8-1 KAWADA CHO, SHINJUKU KU, TOKYO 162, JAPAN.		Nakanishi, Setsuko/G-5871-2015; Yuzaki, Michisuke/K-5328-2013; Mikoshiba, Katsuhiko/N-7943-2015	Nakanishi, Setsuko/0000-0003-4909-2113; Yuzaki, Michisuke/0000-0002-5750-3544; 				BERRIDGE MJ, 1988, PHILOS T ROY SOC B, V320, P325, DOI 10.1098/rstb.1988.0080; BERRIDGE MJ, 1991, CELL CALCIUM, V12, P63, DOI 10.1016/0143-4160(91)90009-4; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BUSA WB, 1985, J CELL BIOL, V101, P677, DOI 10.1083/jcb.101.2.677; COBBOLD PH, 1991, CELL CALCIUM, V12, P87, DOI 10.1016/0143-4160(91)90011-3; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; HAROOTUNIAN AT, 1991, SCIENCE, V251, P75, DOI 10.1126/science.1986413; IGUSA Y, 1986, J PHYSIOL-LONDON, V377, P193, DOI 10.1113/jphysiol.1986.sp016181; IGUSA Y, 1983, J PHYSIOL-LONDON, V340, P611, DOI 10.1113/jphysiol.1983.sp014783; IINO M, 1988, BIOCHEM BIOPH RES CO, V152, P417, DOI 10.1016/S0006-291X(88)80730-7; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; Jaffe L. A., 1985, BIOL FERTILIZATION, P127; JAFFE LF, 1991, P NATL ACAD SCI USA, V88, P9883, DOI 10.1073/pnas.88.21.9883; LONGO FJ, 1974, ANAT RECORD, V179, P27, DOI 10.1002/ar.1091790104; MAEDA N, 1988, J NEUROCHEM, V51, P1724, DOI 10.1111/j.1471-4159.1988.tb01151.x; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; MIYAZAKI S, 1991, CELL CALCIUM, V12, P205, DOI 10.1016/0143-4160(91)90021-6; MIYAZAKI S, 1986, DEV BIOL, V118, P259, DOI 10.1016/0012-1606(86)90093-X; MIYAZAKI S, 1988, J CELL BIOL, V106, P345, DOI 10.1083/jcb.106.2.345; NAKADE S, 1991, BIOCHEM J, V277, P125, DOI 10.1042/bj2770125; RAKOW TL, 1990, P NATL ACAD SCI USA, V87, P9285, DOI 10.1073/pnas.87.23.9285; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; SWANN K, 1986, J CELL BIOL, V103, P2333, DOI 10.1083/jcb.103.6.2333; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; WHITAKER M, 1990, DEVELOPMENT, V108, P525; WIER WG, 1991, CELL CALCIUM, V12, P241, DOI 10.1016/0143-4160(91)90024-9; ZAIDI NF, 1989, J BIOL CHEM, V264, P21737	30	477	481	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 10	1992	257	5067					251	255		10.1126/science.1321497	http://dx.doi.org/10.1126/science.1321497			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC585	1321497				2022-12-01	WOS:A1992JC58500042
J	OROURKE, B; BACKX, PH; MARBAN, E				OROURKE, B; BACKX, PH; MARBAN, E			PHOSPHORYLATION-INDEPENDENT MODULATION OF L-TYPE CALCIUM CHANNELS BY MAGNESIUM-NUCLEOTIDE COMPLEXES	SCIENCE			English	Article							GUINEA-PIG HEART; SINGLE VENTRICULAR CELLS; ADENOSINE-TRIPHOSPHATE; INWARD RECTIFICATION; POTASSIUM CHANNELS; CARDIAC MYOCYTES; CYCLIC-AMP; INACTIVATION; CA-2+; BLOCK	Free magnesium ions and magnesium-nucleotide complexes can exert opposite effects on many fundamental cellular processes. Although increases in the intracellular concentration of magnesium ions inhibit the L-type calcium current in heart cells, magnesium-adenosine triphosphate complexes (MgATP) would be expected to increase the current by promoting channel phosphorylation. Rapid increases in the intracellular concentration of MgATP induced by flash photolysis of caged magnesium or caged ATP resulted in enhanced calcium current. The increase in calcium current was not prevented by blocking phosphorylation, revealing a previously unrecognized direct regulatory action of the magnesium-nucleotide complex.	JOHNS HOPKINS UNIV,DEPT MED,DIV CARDIOL,BALTIMORE,MD 21205	Johns Hopkins University			Marban, Eduardo/GWC-8514-2022	O'Rourke, Brian/0000-0002-5548-4853	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036957, R37HL036957, F32HL007227] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 07227, HL 36957] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGUS ZS, 1989, BELLJUU, V256, pC452; Aikawa J.K., 1981, MAGNESIUM ITS BIOL S; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ARTALEJO CR, 1990, NATURE, V348; BACKX PH, 1991, AM J HYPERTENS, V4, P416; BELLES B, 1988, PFLUG ARCH EUR J PHY, V411, P353, DOI 10.1007/BF00587713; CHENG HC, 1985, BIOCHEM J, V231, P655, DOI 10.1042/bj2310655; FABIATO A, 1975, J PHYSIOL-LONDON, V249, P497, DOI 10.1113/jphysiol.1975.sp011027; FINDLAY I, 1987, J PHYSIOL-LONDON, V391, P611, DOI 10.1113/jphysiol.1987.sp016759; GARNER PS, 1973, FEBS LETT, V34, P243, DOI 10.1016/0014-5793(73)80803-8; GOLDHABER JI, 1991, J PHYSIOL-LONDON, V443, P371, DOI 10.1113/jphysiol.1991.sp018838; GURNEY AM, 1989, NATURE, V341, P65, DOI 10.1038/341065a0; HARTZELL HC, 1989, J GEN PHYSIOL, V94, P745, DOI 10.1085/jgp.94.4.745; HARTZELL HC, 1991, NATURE, V351, P573, DOI 10.1038/351573a0; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HUME JR, 1991, P NATL ACAD SCI USA, V88, P6946; IRISAWA H, 1983, J PHYSIOL-LONDON, V338, P321, DOI 10.1113/jphysiol.1983.sp014675; ISHIHARA K, 1989, J PHYSIOL-LONDON, V419, P297, DOI 10.1113/jphysiol.1989.sp017874; KAMEYAMA M, 1985, PFLUG ARCH EUR J PHY, V405, P285, DOI 10.1007/BF00582573; KAPLAN JH, 1978, BIOCHEMISTRY-US, V17, P1929, DOI 10.1021/bi00603a020; KAPLAN JH, 1988, P NATL ACAD SCI USA, V85, P6571, DOI 10.1073/pnas.85.17.6571; LACERDA AE, 1988, NATURE, V335, P249, DOI 10.1038/335249a0; MATSUDA H, 1988, J PHYSIOL-LONDON, V397, P237, DOI 10.1113/jphysiol.1988.sp016998; MEISSNER G, 1987, J BIOL CHEM, V262, P3065; MINTA A, 1989, J BIOL CHEM, V264, P8171; MORAD M, 1988, SCIENCE, V241, P842, DOI 10.1126/science.2457253; RUBIN H, 1975, P NATL ACAD SCI USA, V72, P3551, DOI 10.1073/pnas.72.9.3551; SMITH PA, 1989, NATURE, V342, P550, DOI 10.1038/342550a0; TANIGUCHI J, 1983, CIRC RES, V53, P131, DOI 10.1161/01.RES.53.2.131; TSIEN RW, 1986, J MOL CELL CARDIOL, V18, P691, DOI 10.1016/S0022-2828(86)80941-5; TUNG RT, 1991, J PHYSIOL-LONDON, V437, P239, DOI 10.1113/jphysiol.1991.sp018593; VANDENBERG CA, 1987, P NATL ACAD SCI USA, V84, P2560, DOI 10.1073/pnas.84.8.2560; YATANI A, 1987, SCIENCE, V238, P1288, DOI 10.1126/science.2446390; YOUNT RG, 1971, BIOCHEMISTRY-US, V10, P2484, DOI 10.1021/bi00789a009; YUE DT, 1990, SCIENCE, V250, P1735, DOI 10.1126/science.2176745	35	113	113	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 10	1992	257	5067					245	248		10.1126/science.1321495	http://dx.doi.org/10.1126/science.1321495			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC585	1321495				2022-12-01	WOS:A1992JC58500040
J	PELICCI, G; LANFRANCONE, L; GRIGNANI, F; MCGLADE, J; CAVALLO, F; FORNI, G; NICOLETTI, I; GRIGNANI, F; PAWSON, T; PELICCI, PG				PELICCI, G; LANFRANCONE, L; GRIGNANI, F; MCGLADE, J; CAVALLO, F; FORNI, G; NICOLETTI, I; GRIGNANI, F; PAWSON, T; PELICCI, PG			A NOVEL TRANSFORMING PROTEIN (SHC) WITH AN SH2 DOMAIN IS IMPLICATED IN MITOGENIC SIGNAL TRANSDUCTION	CELL			English	Article							PHOSPHOLIPASE-C-GAMMA; PHOSPHOTYROSINE-CONTAINING PROTEINS; I PHOSPHATIDYLINOSITOL KINASE; TYROSINE PHOSPHORYLATION; PDGF RECEPTOR; VIRAL ONCOGENE; GROWTH; COLLAGEN; SRC; GAP	A new SH2-containing sequence, SHC, was isolated by screening cDNA libraries with SH2 representative DNA probes. The SHC cDNA is predicted to encode overlapping proteins of 46.8 and 51.7 kd that contain a single C-terminal SH2 domain, and an adjacent glycine/proline-rich motif with regions of homology with the alpha-1 chain of collagen, but no identifiable catalytic domain. Anti-SHC antibodies recognized three proteins of 46, 52, and 66 kd in a wide range of mammalian cell lines. These SHC proteins complexed with and were phosphorylated by activated epidermal growth factor receptor. The physical association of SHC proteins with activated receptors was recreated in vitro by using a bacterially expressed SHC SH2 domain. NIH 3T3 mouse fibroblasts that constitutively overexpressed SHC acquired a transformed phenotype in culture and formed tumors in nude mice. These results suggest that the SHC gene products couple activated growth factor receptors to a signaling pathway that regulates the proliferation of mammalian cells.	MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, TORONTO M5G 1X5, ONTARIO, CANADA; UNIV TURIN, IST MICROBIOL, I-10126 TURIN, ITALY	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Turin	PELICCI, G (corresponding author), UNIV PERUGIA, MONTELUCE POLICLIN, IST CLIN MED 1, I-06100 PERUGIA, ITALY.		Pawson, Tony J/E-4578-2013; Lanfrancone, Luisa/AAC-8671-2019; Pelicci, Giuliana/AAA-8921-2022; Grignani, Francesco/AAC-2565-2022; Pelicci, Pier Giuseppe/AAL-6572-2020; Cavallo, Federica/C-5666-2011	Lanfrancone, Luisa/0000-0002-4523-3815; Pelicci, Giuliana/0000-0003-0986-8255; Cavallo, Federica/0000-0003-4571-1060				ALCALAY M, 1990, ONCOGENE, V5, P267; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; ANDERSON SK, 1985, MOL CELL BIOL, V5, P1122, DOI 10.1128/MCB.5.5.1122; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BERNARD MP, 1983, BIOCHEMISTRY-US, V22, P5213, DOI 10.1021/bi00291a023; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; BLAIR DG, 1982, SCIENCE, V218, P1122, DOI 10.1126/science.6293052; BORNSTEIN P, 1980, ANNU REV BIOCHEM, V49, P957, DOI 10.1146/annurev.bi.49.070180.004521; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHU ML, 1984, NATURE, V310, P337, DOI 10.1038/310337a0; COOPER JA, 1984, J BIOL CHEM, V259, P7835; COUGHLIN SR, 1989, SCIENCE, V243, P1191; DAVIS S, 1991, SCIENCE, V252, P712, DOI 10.1126/science.1708917; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; EYRE DR, 1980, SCIENCE, V207, P1315, DOI 10.1126/science.7355290; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HAY ED, 1981, J CELL BIOL, V91, P205; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KOCH CA, 1992, MOL CELL BIOL, V12, P1366, DOI 10.1128/MCB.12.3.1366; KOCH CA, 1991, SCIENCE, V252, P669; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LETWIN K, 1988, ONCOGENE, V3, P621; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PROCKOP DJ, 1979, NEW ENGL J MED, V301, P77, DOI 10.1056/NEJM197907123010204; PROCKOP DJ, 1979, NEW ENGL J MED, V301, P13, DOI 10.1056/NEJM197907053010104; REEDIJK M, 1992, IN PRESS EMBO J, V11; Sambrook J., 1989, MOL CLONING LAB MANU; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; TAINSKY MA, 1987, MOL CELL BIOL, V7, P1280, DOI 10.1128/MCB.7.3.1280; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WHITMAN M, 1988, Biochimica et Biophysica Acta, V948, P327; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; [No title captured]	57	1254	1292	0	20	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 10	1992	70	1					93	104		10.1016/0092-8674(92)90536-L	http://dx.doi.org/10.1016/0092-8674(92)90536-L			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JC957	1623525				2022-12-01	WOS:A1992JC95700011
J	RANDALL, LL				RANDALL, LL			PEPTIDE BINDING BY CHAPERONE SECB - IMPLICATIONS FOR RECOGNITION OF NONNATIVE STRUCTURE	SCIENCE			English	Article							ESCHERICHIA-COLI; PROTEIN EXPORT; TRANSLOCATION; PREPROTEIN; MEMBRANE; INVITRO	The molecular basis for recognition of nonnative proteins by the molecular chaperone SecB was investigated with an in vitro assay based on the protection of SecB from proteolysis when a ligand is bound. The SecB tetramer has multiple binding sites for positively charged peptides. When the peptide binding sites are occupied, the complex undergoes a conformational change to expose hydrophobic sites that bind the fluorescent probe 1-anilino-naphthalene-8-sulfonate. A model is proposed for interaction of nonnative polypeptides with both hydrophilic and hydrophobic sites on SecB.			RANDALL, LL (corresponding author), WASHINGTON STATE UNIV, DEPT BIOCHEM & BIOPHYS, PULLMAN, WA 99164 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM029798, R01GM029798] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM29798] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		DAVIDSON B, 1967, BIOCHEMISTRY-US, V6, P1616, DOI 10.1021/bi00858a008; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GIERASCH LM, 1992, ANTON LEEUW INT J G, V61, P93, DOI 10.1007/BF00580613; HARDY SJS, 1991, SCIENCE, V251, P439, DOI 10.1126/science.1989077; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; ICHIMURA S, 1977, BIOPOLYMERS, V16, P1449, DOI 10.1002/bip.1977.360160706; KUMAMOTO CA, 1985, J BACTERIOL, V163, P267, DOI 10.1128/JB.163.1.267-274.1985; KUMAMOTO CA, 1989, J BIOL CHEM, V264, P2242; LYNN J, 1968, BIOCHEM BIOPH RES CO, V33, P327, DOI 10.1016/0006-291X(68)90788-2; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; Park K.- Y., UNPUB; PARK SH, 1988, SCIENCE, V239, P1033, DOI 10.1126/science.3278378; RANDALL LL, 1990, SCIENCE, V248, P860, DOI 10.1126/science.2188362; WATANABE M, 1989, P NATL ACAD SCI USA, V86, P2728, DOI 10.1073/pnas.86.8.2728; WEISS JB, 1988, P NATL ACAD SCI USA, V85, P8978, DOI 10.1073/pnas.85.23.8978	16	110	114	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 10	1992	257	5067					241	245		10.1126/science.1631545	http://dx.doi.org/10.1126/science.1631545			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC585	1631545				2022-12-01	WOS:A1992JC58500039
J	RIDDELL, SR; WATANABE, KS; GOODRICH, JM; LI, CR; AGHA, ME; GREENBERG, PD				RIDDELL, SR; WATANABE, KS; GOODRICH, JM; LI, CR; AGHA, ME; GREENBERG, PD			RESTORATION OF VIRAL IMMUNITY IN IMMUNODEFICIENT HUMANS BY THE ADOPTIVE TRANSFER OF T-CELL CLONES	SCIENCE			English	Article							TOXIC LYMPHOCYTES-T; CYTOMEGALO-VIRUS DISEASE; MARROW TRANSPLANTATION; INVIVO; REPLICATION; GENERATION; PNEUMONIA; MEMORY; DEATH; HOST	The adoptive transfer of antigen-specific T cells to establish immunity is an effective therapy for viral infections and tumors in animal models. The application of this approach to human disease would require the isolation and in vitro expansion of human antigen-specific T cells and evidence that such T cells persist and function in vivo after transfer. Cytomegalovirus-specific CD8+ cytotoxic T cell (CTL) clones could be isolated from bone marrow donors, propagated in vitro, and adoptively transferred to immunodeficient bone marrow transplant recipients. No toxicity developed and the clones provided persistent reconstitution of CD8+ cytomegalovirus-specific CTL responses.	UNIV WASHINGTON,FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104; UNIV WASHINGTON,DEPT IMMUNOL,SEATTLE,WA 98104; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98104	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	RIDDELL, SR (corresponding author), FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104, USA.		Agha, Mounzer/AAC-2520-2022; Wilson, Matthew H/K-3193-2013	Agha, Mounzer/0000-0002-2275-7544	NATIONAL CANCER INSTITUTE [P01CA018029] Funding Source: NIH RePORTER; NCI NIH HHS [CA18029] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BORYSIEWICZ LK, 1983, EUR J IMMUNOL, V13, P804, DOI 10.1002/eji.1830131005; BRACIALE TJ, 1987, IMMUNOL REV, V98, P95, DOI 10.1111/j.1600-065X.1987.tb00521.x; BRYNE JA, 1984, J VIROL, V51, P682; CHEEVER MA, 1986, J EXP MED, V163, P1100, DOI 10.1084/jem.163.5.1100; FAUCI AS, 1985, ANN INTERN MED, V102, P800, DOI 10.7326/0003-4819-102-6-800; GOTCH FM, 1990, INT IMMUNOL, V2, P707, DOI 10.1093/intimm/2.8.707; GREENBERG PD, 1991, ADV IMMUNOL, V9, P280; GREENBERG PD, 1985, J IMMUNOL, V133, P3401; HOWES EL, 1979, NATURE, V277, P67, DOI 10.1038/277067a0; LAUBSCHER A, 1988, J IMMUNOL METHODS, V110, P69, DOI 10.1016/0022-1759(88)90084-1; Li C, UNPUB; LIN YL, 1981, J EXP MED, V154, P225, DOI 10.1084/jem.154.2.225; LUKACHER AE, 1984, J EXP MED, V160, P814, DOI 10.1084/jem.160.3.814; MACHER AM, 1983, NEW ENGL J MED, V309, P1454; MEYERS JD, 1990, J INFECT DIS, V162, P373, DOI 10.1093/infdis/162.2.373; MEYERS JD, 1982, REV INFECT DIS, V4, P1119; MEYERS JD, 1987, INFECTIONS TRANSPLAN, P17; MUTTER W, 1988, J EXP MED, V167, P1645, DOI 10.1084/jem.167.5.1645; PANTALEO G, 1990, P NATL ACAD SCI USA, V87, P4818, DOI 10.1073/pnas.87.12.4818; PETERSON PK, 1980, MEDICINE, V59, P283, DOI 10.1097/00005792-198007000-00004; PLATA F, 1987, NATURE, V328, P348, DOI 10.1038/328348a0; QUINNAN GV, 1982, NEW ENGL J MED, V307, P6; REDDEHASE MJ, 1985, J VIROL, V55, P264, DOI 10.1128/JVI.55.2.264-273.1985; REUSSER P, 1991, BLOOD, V78, P1373; RIDDELL S, UNPUB; RIDDELL SR, 1990, J IMMUNOL METHODS, V128, P189, DOI 10.1016/0022-1759(90)90210-M; RIDDELL SR, 1991, J IMMUNOL, V146, P2795; SCHRIER RD, 1986, J VIROL, V59, P127, DOI 10.1128/JVI.59.1.127-131.1986; STORB R, 1986, NEW ENGL J MED, V314, P729, DOI 10.1056/NEJM198603203141201; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; WALKER BD, 1988, NATURE, V336, P484; YOSHIKAI Y, 1984, NATURE, V312, P521, DOI 10.1038/312521a0	32	1043	1151	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 10	1992	257	5067					238	241						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC585	1352912				2022-12-01	WOS:A1992JC58500038
J	SAITOH, H; TOMKIEL, J; COOKE, CA; RATRIE, H; MAURER, M; ROTHFIELD, NF; EARNSHAW, WC				SAITOH, H; TOMKIEL, J; COOKE, CA; RATRIE, H; MAURER, M; ROTHFIELD, NF; EARNSHAW, WC			CENP-C, AN AUTOANTIGEN IN SCLERODERMA, IS A COMPONENT OF THE HUMAN INNER KINETOCHORE PLATE	CELL			English	Article							MAMMALIAN KINETOCHORE; CENTROMERE PROTEINS; AUTO-ANTIGEN; ANTICENTROMERE ANTIBODIES; CHROMOSOME CONDENSATION; ELECTRON-MICROSCOPY; AUTOIMMUNE SERA; DNA; FAMILY; CELLS	We have isolated and characterized a set of overlapping cDNA clones that encode the human centromere autoantigen centromere protein C (CENP-C). The identity of these clones has been established using several criteria. First, they were shown to encode a polypeptide that migrates at the expected position for CENP-C on SDS-polyacrylamide gel electrophoresis. Second, we have demonstrated that this polypeptide shares at least two epitopes with human CENP-C. Polyclonal antibodies were raised to fusion proteins encoded by nonoverlapping regions of the cDNA clones. These antibodies were shown to recognize a protein at a position appropriate for CENP-C on immunoblots of human chromosomal proteins. In addition, we used indirect immunofluorescence to demonstrate that these antibodies recognize centromeres of HeLa chromosomes in the expected pattern for CENP-C. Localization of CENP-C by immunoelectron microscopy reveals that this protein is a component of the inner kinetochore plate.	UNIV CONNECTICUT,CTR HLTH,DEPT MED,DIV RHEUMAT DIS,FARMINGTON,CT 06032	University of Connecticut	SAITOH, H (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT CELL BIOL & ANAT,BALTIMORE,MD 21205, USA.		Earnshaw, William/AAY-7438-2020	Earnshaw, William/0000-0002-7191-0621	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR037986] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035212] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR37986] Funding Source: Medline; NIGMS NIH HHS [GM35212] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER RE, 1990, MOL CELL BIOL, V10, P2458, DOI 10.1128/MCB.10.6.2458; BERNAT RL, 1990, J CELL BIOL, V111, P1519, DOI 10.1083/jcb.111.4.1519; BISCHOFF FR, 1990, P NATL ACAD SCI USA, V87, P8617, DOI 10.1073/pnas.87.21.8617; BLOOM KS, 1982, CELL, V29, P305, DOI 10.1016/0092-8674(82)90147-7; BRINKLEY BR, 1966, CHROMOSOMA, V19, P28, DOI 10.1007/BF00332792; CAI MJ, 1990, CELL, V61, P437, DOI 10.1016/0092-8674(90)90525-J; COMINGS DE, 1971, EXP CELL RES, V67, P97, DOI 10.1016/0014-4827(71)90625-2; COOKE CA, 1990, J CELL BIOL, V110, P1475, DOI 10.1083/jcb.110.5.1475; DANSCHER G, 1981, HISTOCHEMISTRY, V71, P81, DOI 10.1007/BF00592572; DARLINGTON CD, 1936, CYTOLOGIA, V7, P242; EARNSHAW W, 1986, J CLIN INVEST, V77, P426, DOI 10.1172/JCI112320; EARNSHAW WC, 1987, P NATL ACAD SCI USA, V84, P4979, DOI 10.1073/pnas.84.14.4979; EARNSHAW WC, 1985, CHROMOSOMA, V91, P313, DOI 10.1007/BF00328227; EARNSHAW WC, 1987, J CELL BIOL, V104, P817, DOI 10.1083/jcb.104.4.817; EARNSHAW WC, 1989, CHROMOSOMA, V98, P1, DOI 10.1007/BF00293329; EARNSHAW WC, 1985, CHROMOSOMA, V92, P290, DOI 10.1007/BF00329812; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GORBSKY GJ, 1987, J CELL BIOL, V104, P9, DOI 10.1083/jcb.104.1.9; HARDIN JA, 1986, ARTHRITIS RHEUM, V29, P457, DOI 10.1002/art.1780290401; HATTORI M, 1985, NUCLEIC ACIDS RES, V13, P7813, DOI 10.1093/nar/13.21.7813; JOKELAINEN PT, 1967, J ULTRA MOL STRUCT R, V19, P19, DOI 10.1016/S0022-5320(67)80058-3; KINGWELL B, 1987, CHROMOSOMA, V95, P403, DOI 10.1007/BF00333991; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LECHNER J, 1991, CELL, V64, P717, DOI 10.1016/0092-8674(91)90501-O; LUYKX P, 1965, EXP CELL RES, V39, P643, DOI 10.1016/0014-4827(65)90068-6; MASUMOTO H, 1989, J CELL BIOL, V109, P1963, DOI 10.1083/jcb.109.5.1963; MITCHISON TJ, 1985, J CELL BIOL, V101, P776; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MOROI Y, 1980, P NATL ACAD SCI-BIOL, V77, P1627, DOI 10.1073/pnas.77.3.1627; NICKLAS RB, 1989, J CELL BIOL, V109, P2245, DOI 10.1083/jcb.109.5.2245; NISHIMOTO T, 1978, CELL, V15, P475, DOI 10.1016/0092-8674(78)90017-X; PALMER DK, 1991, P NATL ACAD SCI USA, V88, P3734, DOI 10.1073/pnas.88.9.3734; RATTNER JB, 1987, CHROMOSOMA, V95, P175, DOI 10.1007/BF00330348; REIDER CL, 1982, INT REV CYTOL, V79, P1; REIDER CL, 1990, J CELL BIOL, V110, P81; RIJHSINGHANI AG, 1988, OBSTET GYNECOL, V71, P991; RIS H, 1981, CHROMOSOMA, V82, P153, DOI 10.1007/BF00286101; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROOS UP, 1973, CHROMOSOMA, V41, P195, DOI 10.1007/BF00319696; ROTHFIELD N, 1987, ARTHRITIS RHEUM, V30, P1416, DOI 10.1002/art.1780301214; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARMA V, 1991, NUCLEIC ACIDS RES, V19, P1168, DOI 10.1093/nar/19.5.1168-a; Sharp LW., 1934, INTRO CYTOLOGY; SNYDER M, 1987, METHOD ENZYMOL, V154, P107; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; SUN L, 1984, NUCLEIC ACIDS RES, V12, P2669, DOI 10.1093/nar/12.6.2669; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAN EM, 1988, CLIN IMMUNOL IMMUNOP, V47, P121, DOI 10.1016/0090-1229(88)90066-9; WITT PL, 1980, CHROMOSOMA, V81, P483, DOI 10.1007/BF00368158; WORDEMAN L, 1991, J CELL BIOL, V114, P285, DOI 10.1083/jcb.114.2.285	50	312	322	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 10	1992	70	1					115	125		10.1016/0092-8674(92)90538-N	http://dx.doi.org/10.1016/0092-8674(92)90538-N			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JC957	1339310				2022-12-01	WOS:A1992JC95700013
J	SHI, YF; GLYNN, JM; GUILBERT, LJ; COTTER, TG; BISSONNETTE, RP; GREEN, DR				SHI, YF; GLYNN, JM; GUILBERT, LJ; COTTER, TG; BISSONNETTE, RP; GREEN, DR			ROLE FOR C-MYC IN ACTIVATION-INDUCED APOPTOTIC CELL-DEATH IN T-CELL HYBRIDOMAS	SCIENCE			English	Article							GENE-EXPRESSION; MACROMOLECULAR-SYNTHESIS; DNA FRAGMENTATION; SUICIDE PROGRAM; IL-2 ADDICTION; PROTEIN; ANTISENSE; GROWTH; THYMOCYTES; INHIBITION	Immature T cells and some T cell hybridomas undergo apoptotic cell death when activated through the T cell receptor complex, a phenomenon that is probably related to antigen induced negative selection of developing T cells. This activation-induced apoptosis depends on active protein and RNA synthesis in the dying cells, although none of the genes required for this process have previously been identified. Antisense oligonucleotides corresponding to c-myc block the constitutive expression of c-Myc protein in T cell hybridomas and interfere with all aspects of activation-induced apoptosis without affecting lymphokine production in these cells. These data indicate that c-myc expression is a necessary component of activation-induced apoptosis.	LA JOLLA INST ALLERGY & IMMUNOL,LA JOLLA,CA 92037; UNIV ALBERTA,DEPT IMMUNOL,EDMONTON T6G 2H7,ALBERTA,CANADA; ST PATRICKS COLL,DEPT BIOL,MAYNOOTH,KILDARE,IRELAND	La Jolla Institute for Immunology; University of Alberta; Maynooth University			Shi, Yufang/AAE-4431-2020; Green, Douglas R/N-8083-2018	Shi, Yufang/0000-0001-8964-319X; Green, Douglas R/0000-0002-7332-1417; Cotter, Thomas/0000-0003-4626-5613	NIAID NIH HHS [AI31591] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031591] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altman A, 1990, Adv Immunol, V48, P227, DOI 10.1016/S0065-2776(08)60756-7; ASKEW DS, 1991, ONCOGENE, V6, P1915; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BURSCH W, 1990, BIOCHEM CELL BIOL, V68, P1071, DOI 10.1139/o90-160; COHEN JJ, 1984, J IMMUNOL, V132, P38; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COTTER TG, 1992, CANCER RES, V52, P997; DEGOLS G, 1991, NUCLEIC ACIDS RES, V19, P945, DOI 10.1093/nar/19.4.945; DUKE RC, 1986, LYMPHOKINE RES, V5, P289; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FESUS L, 1987, FEBS LETT, V224, P104, DOI 10.1016/0014-5793(87)80430-1; FOTEDAR A, 1985, J IMMUNOL, V135, P3028; HARELBELLAN A, 1988, J IMMUNOL, V140, P2431; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; IWATA M, 1991, EUR J IMMUNOL, V21, P643, DOI 10.1002/eji.1830210316; KADDURAHDAOUK R, 1987, GENE DEV, V1, P347, DOI 10.1101/gad.1.4.347; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; Kerr J.F.R., 1987, P93; KERR JFR, 1980, INT REV CYTOL, V68, P251; MCCONKEY DJ, 1990, ARCH BIOCHEM BIOPHYS, V278, P284, DOI 10.1016/0003-9861(90)90261-V; MCMANAWAY ME, 1990, LANCET, V335, P808, DOI 10.1016/0140-6736(90)90934-W; MORRIS RG, 1984, AM J PATHOL, V115, P426; ODAKA C, 1990, J IMMUNOL, V144, P2096; OWENS GP, 1991, MOL CELL BIOL, V11, P4177, DOI 10.1128/MCB.11.8.4177; PALLAVICINI MG, 1990, J CELL PHYSIOL, V143, P372, DOI 10.1002/jcp.1041430223; PENDERGAST GC, 1991, CELL, V65, P395; PULLEN AM, 1989, IMMUNOL REV, V107, P125, DOI 10.1111/j.1600-065X.1989.tb00006.x; REED JC, 1990, P NATL ACAD SCI USA, V87, P3660, DOI 10.1073/pnas.87.10.3660; REIGEL JS, 1990, J IMMUNOL, V144, P3611; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SAVILL J, 1990, NATURE, V343, P170, DOI 10.1038/343170a0; Shi Y. G., UNPUB; SHI YF, 1989, NATURE, V339, P625, DOI 10.1038/339625a0; SHI YF, 1990, J IMMUNOL, V144, P3326; SHI YF, 1991, J IMMUNOL, V146, P3340; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SWAT W, 1991, J IMMUNOL METHODS, V137, P79, DOI 10.1016/0022-1759(91)90396-W; UCKER DS, 1989, J IMMUNOL, V143, P3461; VENTURELLI D, 1990, P NATL ACAD SCI USA, V87, P5963, DOI 10.1073/pnas.87.15.5963; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; WATERS CM, 1991, ONCOGENE, V6, P797; WURM FM, 1986, P NATL ACAD SCI USA, V83, P5414, DOI 10.1073/pnas.83.15.5414; WYLLIE AH, 1987, BRIT J CANCER, V56, P251, DOI 10.1038/bjc.1987.186; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YUH YS, 1989, J BIOL CHEM, V264, P10904; ZACHARCHUK CM, 1990, J IMMUNOL, V145, P4037	48	756	774	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 10	1992	257	5067					212	214		10.1126/science.1378649	http://dx.doi.org/10.1126/science.1378649			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC585	1378649				2022-12-01	WOS:A1992JC58500028
J	SHIBUYA, H; YONEYAMA, M; NINOMIYATSUJI, J; MATSUMOTO, K; TANIGUCHI, T				SHIBUYA, H; YONEYAMA, M; NINOMIYATSUJI, J; MATSUMOTO, K; TANIGUCHI, T			IL-2 AND EGF RECEPTORS STIMULATE THE HEMATOPOIETIC-CELL CYCLE VIA DIFFERENT SIGNALING PATHWAYS - DEMONSTRATION OF A NOVEL ROLE FOR C-MYC	CELL			English	Article							BETA-CHAIN; MESSENGER-RNA; ERYTHROPOIETIN RECEPTOR; GROWTH-FACTORS; T-CELLS; V-ABL; GENE; ONCOGENE; LINE; EXPRESSION	Stimulation via cytokine receptors such as IL-2 and IL-3 receptors, but not by the EGF receptor (EGFR), induces cells of the BAF-B03 hematopoietic cell line to transit the cell cycle. We demonstrate that the IL-2 receptor beta-chain (IL-2R-beta) is linked to at least two intracellular signaling pathways. One pathway may involve a protein tyrosine kinase of the src family, which leads to the induction of the c-jun and c-fos genes, among others. A second pathway, involving an as yet unknown mechanism, leads to c-myc gene induction. Stimulation of the EGFR, expressed following transfection of an appropriate recombinant construct, can activate the former, but not the latter, pathway in this cell line and cause the cells to enter S phase but not progress further. This deficiency can be rescued by ectopic expression of the c-myc gene, indicating a novel role for this proto-oncogene in the S to G2/M transition of the cell cycle.	NAGOYA UNIV,FAC SCI,DEPT MOLEC BIOL,CHIKUSA KU,NAGOYA 46401,JAPAN	Nagoya University	SHIBUYA, H (corresponding author), OSAKA UNIV,INST MOLEC & CELLULAR BIOL,SUITA,OSAKA 565,JAPAN.		Yoneyama, Mitsutoshi/D-8244-2017	Yoneyama, Mitsutoshi/0000-0001-9512-0408; Ninomiya-Tsuji, Jun/0000-0002-5584-0176				ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BLACKWOOD EM, 1992, IN PRESS CURR OPIN G; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COLLINS MKL, 1988, J CELL PHYSIOL, V137, P293, DOI 10.1002/jcp.1041370212; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DANDREA A, 1989, CELL, V58, P1023, DOI 10.1016/0092-8674(89)90499-6; DEAN M, 1987, ONCOGENE RES, V1, P279; DEAN M, 1986, J BIOL CHEM, V261, P9161; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; DOI T, 1989, EMBO J, V8, P1953, DOI 10.1002/j.1460-2075.1989.tb03600.x; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; FRANCHINI G, 1983, P NATL ACAD SCI-BIOL, V80, P7385, DOI 10.1073/pnas.80.24.7385; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GRANELLIPIPERNO A, 1986, J EXP MED, V163, P922, DOI 10.1084/jem.163.4.922; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HATAKEYAMA M, 1992, P NATL ACAD SCI USA, V89, P2022, DOI 10.1073/pnas.89.6.2022; HATAKEYAMA M, 1992, IN PRESS EUR J BIOCH; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; IMBRA RJ, 1986, NATURE, V323, P555, DOI 10.1038/323555a0; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARQUARDT H, 1984, SCIENCE, V223, P1079, DOI 10.1126/science.6320373; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MINAMOTO S, 1990, J IMMUNOL, V145, P2177; MORI H, 1991, INT IMMUNOL, V3, P149, DOI 10.1093/intimm/3.2.149; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; REED JC, 1987, ONCOGENE, V1, P223; ROUSSELMF, 1991, NATURE, V353, P361; RUDEN TV, 1988, EMBO J, V7, P2749; SATO C, 1985, J CELL BIOL, V100, P748, DOI 10.1083/jcb.100.3.748; SHERR CJ, 1991, TRENDS GENET, V7, P398, DOI 10.1016/0168-9525(91)90263-P; SHIBUYA H, 1990, NUCLEIC ACIDS RES, V18, P3697, DOI 10.1093/nar/18.13.3697; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; TANAKA T, 1991, INT IMMUNOL, V3, P105, DOI 10.1093/intimm/3.1.105; TROUCHE D, 1991, J IMMUNOL, V147, P2398; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; TSUDO M, 1989, J IMMUNOL, V143, P4039; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; WANG HM, 1989, EMBO J, V8, P3677, DOI 10.1002/j.1460-2075.1989.tb08542.x; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WANG JYJ, 1985, MOL CELL BIOL, V5, P3640, DOI 10.1128/MCB.5.12.3640; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	70	261	265	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 10	1992	70	1					57	67		10.1016/0092-8674(92)90533-I	http://dx.doi.org/10.1016/0092-8674(92)90533-I			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JC957	1535827				2022-12-01	WOS:A1992JC95700008
J	SILVA, AJ; STEVENS, CF; TONEGAWA, S; WANG, YY				SILVA, AJ; STEVENS, CF; TONEGAWA, S; WANG, YY			DEFICIENT HIPPOCAMPAL LONG-TERM POTENTIATION IN ALPHA-CALCIUM-CALMODULIN KINASE-II MUTANT MICE	SCIENCE			English	Article							DEPENDENT PROTEIN-KINASE; RAT-BRAIN; EXPRESSION; AUTOPHOSPHORYLATION; TRANSMISSION; GENE	As a first step in a program to use genetically altered mice in the study of memory mechanisms, mutant mice were produced that do not express the alpha-calcium-calmodulin-dependent kinase II (alpha-CaMKII). The alpha-CaMKII is highly enriched in postsynaptic densities of hippocampus and neocortex and may be involved in the regulation of long-term potentiation (LTP). Such mutant mice exhibited mostly normal behaviors and presented no obvious neuroanatomical defects. Whole cell recordings reveal that postsynaptic mechanisms, including N-methyl-D-aspartate (NMDA) receptor function, are intact. Despite normal postsynaptic mechanisms, these mice are deficient in their ability to produce LTP and are therefore a suitable model for studying the relation between LTP and learning processes.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; SALK INST BIOL STUDIES,HOWARD HUGHES MED INST,LA JOLLA,CA 92037	Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Salk Institute	SILVA, AJ (corresponding author), MIT,HOWARD HUGHES MED INST,CTR CANC RES,CAMBRIDGE,MA 02139, USA.		Silva, Alcino/ABD-7684-2021	Silva, Alcino/0000-0002-1587-4558; Silva, Alcino/0000-0001-5525-0494	NINDS NIH HHS [5 R01 NS 12961-17] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS012961] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; BURGIN KE, 1990, J NEUROSCI, V10, P1788; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; COLBRAN RJ, 1989, BIOCHEM J, V258, P313, DOI 10.1042/bj2580313; DAVIS M, 1992, TRENDS PHARMACOL SCI, V13, P35, DOI 10.1016/0165-6147(92)90014-W; DOUGLAS RJ, 1967, PSYCHOL BULL, V67, P416, DOI 10.1037/h0024599; ERONDU NE, 1985, J NEUROSCI, V5, P3270; FALLS WA, 1992, J NEUROSCI, V12, P854; GUTHRIE PB, 1991, NATURE, V354, P76, DOI 10.1038/354076a0; HANSON PI, 1989, NEURON, V3, P59, DOI 10.1016/0896-6273(89)90115-3; JAHR CE, 1990, J NEUROSCI, V10, P1830; JAHR CE, 1990, J NEUROSCI, V10, P3178; LIN JW, 1990, P NATL ACAD SCI USA, V87, P8257, DOI 10.1073/pnas.87.21.8257; LISMAN JE, 1988, P NATL ACAD SCI USA, V85, P5320, DOI 10.1073/pnas.85.14.5320; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MCGUINESS T, 1985, J BIOL CHEM, V260, P1969; MILLER SG, 1988, NEURON, V1, P593, DOI 10.1016/0896-6273(88)90109-2; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; MORRIS RGM, 1991, LONG TERM POTENTIATI; MULLER W, 1991, NATURE, V354, P74; SCHULMAN H, 1989, TRENDS BIOCHEM SCI, V14, P62, DOI 10.1016/0968-0004(89)90045-5; SILVA AJ, 1992, SCIENCE, V257, P209; SILVA AMS, UNPUB; THOMPSON S, 1989, CELL, V56, P313, DOI 10.1016/0092-8674(89)90905-7	29	1174	1203	2	70	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 10	1992	257	5067					201	206		10.1126/science.1378648	http://dx.doi.org/10.1126/science.1378648			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC585	1378648				2022-12-01	WOS:A1992JC58500026
J	SILVA, AJ; PAYLOR, R; WEHNER, JM; TONEGAWA, S				SILVA, AJ; PAYLOR, R; WEHNER, JM; TONEGAWA, S			IMPAIRED SPATIAL-LEARNING IN ALPHA-CALCIUM-CALMODULIN KINASE-II MUTANT MICE	SCIENCE			English	Article							DEPENDENT PROTEIN-KINASE; LONG-TERM POTENTIATION; POSTSYNAPTIC DENSITY PROTEIN; RABBIT FOLLOWING STIMULATION; HIPPOCAMPAL-LESIONS; SYNAPTIC TRANSMISSION; LASTING POTENTIATION; PERFORANT PATH; DENTATE AREA; RAT-BRAIN	Although long-term potentiation (LTP) has been studied as the mechanism for hippocampus-dependent learning and memory, evidence for this hypothesis is still incomplete. The mice with a mutation in the alpha-calcium-calmodulin-dependent kinase II (alpha-CaMKII), a synaptic protein enriched in the hippocampus, are appropriate for addressing this issue because the hippocampus of these mice is deficient in LTP but maintains intact postsynaptic mechanisms. These mutant mice exhibit specific learning impairments, an indication that alpha-CaMKII has a prominent role in spatial learning, but that it is not essential for some types of non-spatial learning. The data considerably strengthen the contention that the synaptic changes exhibited in LTP are the basis for spatial memory.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; UNIV COLORADO,INST BEHAV GENET,BOULDER,CO 80309	Massachusetts Institute of Technology (MIT); University of Colorado System; University of Colorado Boulder	SILVA, AJ (corresponding author), MIT,HOWARD HUGHES MED INST,CTR CANC RES,CAMBRIDGE,MA 02139, USA.		Silva, Alcino/ABD-7684-2021	Silva, Alcino/0000-0002-1587-4558; Silva, Alcino/0000-0001-5525-0494				BEKKERS JH, 1990, COLD SPRING HARBOR S, V50; BENSON DL, 1991, J NEUROSCI, V11, P1540; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P357, DOI 10.1113/jphysiol.1973.sp010274; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; BURGIN KE, 1990, J NEUROSCI, V10, P1788; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CASTRO CA, 1989, NATURE, V342, P545, DOI 10.1038/342545a0; COLLINGRIDGE GL, 1990, TRENDS PHARMACOL SCI, V11, P290, DOI 10.1016/0165-6147(90)90011-V; DAVIS M, 1992, TRENDS PHARMACOL SCI, V13, P35, DOI 10.1016/0165-6147(92)90014-W; DAVIS S, 1992, J NEUROSCI, V12, P21; DOUGLAS RJ, 1964, PSYCHON SCI, V1, P187, DOI 10.3758/BF03342856; Eccles, 2013, PHYSL SYNAPSES; ERONDU NE, 1985, J NEUROSCI, V5, P3270; FOREMAN NP, 1983, PHYSIOL BEHAV, V30, P711, DOI 10.1016/0031-9384(83)90167-1; HASTY P, 1991, NATURE, V350, P243, DOI 10.1038/350243a0; HEBB DO, 1949, ORG BEHAVIOR; KEITH JR, 1990, PSYCHOBIOLOGY, V18, P251; KELLY PT, 1984, P NATL ACAD SCI-BIOL, V81, P945, DOI 10.1073/pnas.81.3.945; KENNEDY MB, 1983, P NATL ACAD SCI-BIOL, V80, P7357, DOI 10.1073/pnas.80.23.7357; KIMBLE DP, 1963, J COMP PHYSIOL PSYCH, V56, P273, DOI 10.1037/h0048903; LEATON RN, 1981, J COMP PHYSIOL PSYCH, V95, P813, DOI 10.1037/h0077832; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALLINOW R, 1989, SCIENCE, V245, P862; MCNAUGHTON BL, 1978, BRAIN RES, V157, P277, DOI 10.1016/0006-8993(78)90030-6; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; OGORMAN S, 1991, SCIENCE, V251, P135; PAYLOR R, UNPUB; ROBERTS WW, 1986, J COMP PHYSIOL PSYCH, V55, P695; SCHWARTZKROIN PA, 1975, BRAIN RES, V89, P107, DOI 10.1016/0006-8993(75)90138-9; SILVA AJ, 1992, SCIENCE, V257, P204; STAUBLI U, 1989, BEHAV NEUROSCI, V103, P54, DOI 10.1037/0735-7044.103.1.54; SUTHERLAND R J, 1991, Society for Neuroscience Abstracts, V17, P483; SUTHERLAND RJ, 1982, NEUROSCI LETT, V31, P271, DOI 10.1016/0304-3940(82)90032-5; TEITELBAUM H, 1963, J COMP PHYSIOL PSYCH, V56, P284, DOI 10.1037/h0047052; UPCHURCH M, 1988, PHARMACOL BIOCHEM BE, V29, P325, DOI 10.1016/0091-3057(88)90164-5; UPCHURCH M, 1988, BEHAV GENET, V18, P55, DOI 10.1007/BF01067075; WEHNER JM, 1990, BRAIN RES, V523, P181, DOI 10.1016/0006-8993(90)91485-Y; WHISHAW IQ, 1984, BEHAV BRAIN RES, V11, P123, DOI 10.1016/0166-4328(84)90135-9	40	1045	1084	1	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 10	1992	257	5067					206	211		10.1126/science.1321493	http://dx.doi.org/10.1126/science.1321493			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	JC585	1321493				2022-12-01	WOS:A1992JC58500027
J	TAYLOR, TC; KAHN, RA; MELANCON, P				TAYLOR, TC; KAHN, RA; MELANCON, P			2 DISTINCT MEMBERS OF THE ADP-RIBOSYLATION FACTOR FAMILY OF GTP-BINDING PROTEINS REGULATE CELL-FREE INTRA-GOLGI TRANSPORT	CELL			English	Article							ADENYLATE-CYCLASE; VESICULAR TRANSPORT; MOLECULAR-WEIGHT; BOVINE BRAIN; YEAST; PURIFICATION; SECRETION; COMPARTMENTS; LOCALIZATION; EXPRESSION	We have used an intra-Golgi transport assay to identify GTP-binding proteins involved in regulation of protein traffic. Two soluble proteins of 20 kd were purified by their ability to mediate GTP-gamma-S-dependent inhibition of transport. These GTP-dependent Golgi binding factors, or GGBFs, exhibit a 3-fold difference in activity and are differentiated by their hydrophobicity, isoelectric points, and apparent size. Removal of 80% of GGBFs from cytosol abolishes GTP-gamma-S sensitivity but does not affect inhibition by aluminum fluoride. We demonstrate that GGBFs are members of the ADP-ribosylation factor (ARF) family. Recombinant ARF1 exhibits GGBF activity and myristoylation is required. The distinct biochemical properties of GGBFs indicate that members of the ARF family may have related but distinct functions in intracellular transport.	NCI, DIV CANC TREATMENT, DEV THERAPEUT PROGRAM, BIOL CHEM LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	TAYLOR, TC (corresponding author), UNIV COLORADO, DEPT CHEM & BIOCHEM, BOULDER, CO 80309 USA.		Kahn, Richard/ABD-2666-2020; Melancon, Paul/P-1304-2018	Kahn, Richard/0000-0002-0259-0601; Melancon, Paul/0000-0002-8085-3032	NIGMS NIH HHS [GM43378] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BALCH WE, 1992, IN PRESS J BIOL CHEM; BIGAY J, 1987, EMBO J, V6, P2907, DOI 10.1002/j.1460-2075.1987.tb02594.x; BOMAN AL, 1992, J CELL BIOL, V116, P281, DOI 10.1083/jcb.116.2.281; BOMAN AL, 1992, IN PRESS NATURE; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHABRE M, 1990, TRENDS BIOCHEM SCI, V15, P6, DOI 10.1016/0968-0004(90)90117-T; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHAVRIER P, 1991, NATURE, V353, P769, DOI 10.1038/353769a0; CLARY DO, 1990, J BIOL CHEM, V265, P10109; DENFERT C, 1991, J CELL BIOL, V114, P663, DOI 10.1083/jcb.114.4.663; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; ERCOLANI L, 1990, P NATL ACAD SCI USA, V87, P4635, DOI 10.1073/pnas.87.12.4635; GODA Y, 1989, FASEB J, V3, P2488, DOI 10.1096/fasebj.3.13.2680705; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1988, J BIOL CHEM, V263, P8282; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KAHN RA, 1991, J BIOL CHEM, V266, P2606; KAHN RA, 1992, IN PRESS J BIOL CHEM; KAHN RA, 1991, METHOD ENZYMOL, V195, P233; KIKUCHI A, 1988, J BIOL CHEM, V263, P2897; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG L, 1984, ANAL BIOCHEM, V140, P264, DOI 10.1016/0003-2697(84)90163-5; LAPETINA EG, 1987, P NATL ACAD SCI USA, V84, P2261, DOI 10.1073/pnas.84.8.2261; LENHARD JM, 1992, IN PRESS J BIOL CHEM; LEWIS JM, 1991, CELL REGUL, V2, P1097, DOI 10.1091/mbc.2.12.1097; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; Melancon P, 1991, Trends Cell Biol, V1, P165, DOI 10.1016/0962-8924(91)90018-5; MELANCON P, 1989, SECRETION ITS CONTRO, P175; MELMAN I, 1992, CELL, V68, P829; NAKANO A, 1989, J CELL BIOL, V109, P2677, DOI 10.1083/jcb.109.6.2677; NISHIKAWA S, 1991, BIOCHIM BIOPHYS ACTA, V1093, P135, DOI 10.1016/0167-4889(91)90114-D; OKA T, 1991, J CELL BIOL, V114, P671, DOI 10.1083/jcb.114.4.671; ORCI L, 1991, CELL, V64, P1183; Penefsky H S, 1979, Methods Enzymol, V56, P527; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; PLUTNER H, 1990, EMBO J, V9, P2375, DOI 10.1002/j.1460-2075.1990.tb07412.x; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SCHMITT HD, 1986, CELL, V47, P401, DOI 10.1016/0092-8674(86)90597-0; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SEWELL JL, 1988, P NATL ACAD SCI USA, V85, P4620, DOI 10.1073/pnas.85.13.4620; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; STERNWEIS PC, 1982, P NATL ACAD SCI-BIOL, V79, P4888, DOI 10.1073/pnas.79.16.4888; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772; WATTENBERG BW, 1986, J BIOL CHEM, V261, P2208; WEISS O, 1989, J BIOL CHEM, V264, P21066	54	124	124	0	1	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 10	1992	70	1					69	79		10.1016/0092-8674(92)90534-J	http://dx.doi.org/10.1016/0092-8674(92)90534-J			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JC957	1623523				2022-12-01	WOS:A1992JC95700009
J	BODE, W; GOMISRUTH, FX; HUBER, R; ZWILLING, R; STOCKER, W				BODE, W; GOMISRUTH, FX; HUBER, R; ZWILLING, R; STOCKER, W			STRUCTURE OF ASTACIN AND IMPLICATIONS FOR ACTIVATION OF ASTACINS AND ZINC-LIGATION OF COLLAGENASES	NATURE			English	Article							AMINO-ACID SEQUENCE; HUMAN FIBROBLAST COLLAGENASE; THERMOLYSIN; PROTEASE; PROTEINS	ASTACIN, a digestive zinc-endopeptidase from the crayfish Astacus astacus L. 1,2, is the prototype for the 'astacin family' 3-5, which includes mammalian metallo-endopeptidases 5 and developmentally regulated proteins of man 6, fruitfly 7, frog 8 and sea urchin 9,10. Here we report the X-ray crystal structure of astacin, which reveals a deep active-site cleft, with the zinc at its bottom ligated by three histidines, a water molecule and a more remote tyrosine. The third histidine (His 102) forms part of a consensus sequence, shared not only by the members of the astacin family, but also by otherwise sequentially unrelated proteinases, such as vertebrate collagenases 11. It may therefore represent the elusive 'third' zinc ligand in these enzymes. The amino terminus of astacin is buried forming an internal salt-bridge with Glu 103, adjacent to His 102. Astacin pro-forms extended at the N terminus, as observed for some 'latent' mammalian astacin homologues, did not exhibit this 'active' conformation, indicating an activation mechanism reminiscent of trypsin-like serine proteinases.	UNIV HEIDELBERG,INST ZOOL,W-6900 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg	BODE, W (corresponding author), MAX PLANCK INST BIOCHEM,W-8033 MARTINSRIED,GERMANY.		Stöcker, Walter/AAB-9704-2019	Stöcker, Walter/0000-0002-1515-6994; Gomis-Ruth, F. Xavier/0000-0002-6848-6874				BARRETT AJ, 1991, BIOCHEM SOC T, V19, P707, DOI 10.1042/bst0190707; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BRUNGER AT, 1990, XPLOR MANUAL VERSION; DUMERMUTH E, 1991, J BIOL CHEM, V266, P21381; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; JONES TA, 1978, ACTA CRYSTALLOGR A, V34, P931; KOUNNAS MZ, 1991, J BIOL CHEM, V266, P17530; LEPAGE T, 1992, DEVELOPMENT, V114, P147; Lipscomb W N, 1968, Brookhaven Symp Biol, V21, P24; MATTHEWS BW, 1972, NATURE-NEW BIOL, V238, P37, DOI 10.1038/newbio238037a0; MATTHEWS BW, 1988, ACCOUNTS CHEM RES, V21, P333, DOI 10.1021/ar00153a003; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; PAUPTIT RA, 1988, J MOL BIOL, V199, P525, DOI 10.1016/0022-2836(88)90623-7; PRIESTLE JP, 1988, J APPL CRYSTALLOGR, V21, P572, DOI 10.1107/S0021889888005746; REYNOLDS SD, 1992, DEVELOPMENT, V114, P769; SATO SM, 1990, DEV BIOL, V137, P135, DOI 10.1016/0012-1606(90)90014-A; SHANNON JD, 1989, J BIOL CHEM, V264, P11575; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; STOCKER W, 1990, BIOCHEMISTRY-US, V29, P10418; STOCKER W, 1988, BIOCHEMISTRY-US, V27, P5026; STOCKER W, 1991, BIOL CHEM H-S, V372, P385, DOI 10.1515/bchm3.1991.372.1.385; THAYER MM, 1991, J BIOL CHEM, V266, P2864; TITANI K, 1987, BIOCHEMISTRY-US, V26, P222, DOI 10.1021/bi00375a029; TITANI K, 1972, NATURE-NEW BIOL, V238, P35, DOI 10.1038/newbio238035a0; TURK D, 1992, THESIS TU MUNCHEN; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; WHITHAM SE, 1986, BIOCHEM J, V240, P913, DOI 10.1042/bj2400913; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241	30	295	304	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 9	1992	358	6382					164	167		10.1038/358164a0	http://dx.doi.org/10.1038/358164a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC583	1319561				2022-12-01	WOS:A1992JC58300057
J	CHRISTMAN, BW; MCPHERSON, CD; NEWMAN, JH; KING, GA; BERNARD, GR; GROVES, BM; LOYD, JE				CHRISTMAN, BW; MCPHERSON, CD; NEWMAN, JH; KING, GA; BERNARD, GR; GROVES, BM; LOYD, JE			AN IMBALANCE BETWEEN THE EXCRETION OF THROMBOXANE AND PROSTACYCLIN METABOLITES IN PULMONARY-HYPERTENSION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CIRCULATION; SCLERODERMA; REGRESSION; SEROTONIN; THERAPY; DISEASE; HUMANS	Background. Constriction of small pulmonary arteries and arterioles and focal vascular injury are features of pulmonary hypertension. Because thromboxane A2 is both a vasoconstrictor and a potent stimulus for platelet aggregation, it may be an important mediator of pulmonary hypertension. Its effects are antagonized by prostacyclin, which is released by vascular endothelial cells. We tested the hypothesis that there may be an imbalance between the release of thromboxane A2 and prostacyclin in pulmonary hypertension, reflecting platelet activation and an abnormal response of the pulmonary vascular endothelium. Methods. We used radioimmunoassays to measure the 24-hour urinary excretion of two stable metabolites of thromboxane A2 and a metabolite of prostacyclin in 20 patients with primary pulmonary hypertension, 14 with secondary pulmonary hypertension, 9 with severe chronic obstructive pulmonary disease (COPD) but no clinical evidence of pulmonary hypertension, and 23 normal controls. Results. The 24-hour excretion of 11-dehydro-thromboxane B2 (a stable metabolite of thromboxane A2) was increased in patients with primary pulmonary hypertension and patients with secondary pulmonary hypertension, as compared with normal controls (3224+/-482, 5392+/-1640, and 1145+/-221 pg per milligram of creatinine, respectively; P<0.05), whereas the 24-hour excretion of 2,3-dinor-6-keto-prostaglandin F1-alpha (a stable metabolite of prostacyclin) was decreased (369+/-106, 304+/-76, and 644+/-124 pg per milligram of creatinine, respectively; P<0.05). The rate of excretion of all metabolites in the patients with COPD but no clinical evidence of pulmonary hypertension was similar to that in the normal controls. Conclusions. An increase in the release of the vasoconstrictor thromboxane A2, suggesting the activation of platelets, occurs in both the primary and secondary forms of pulmonary hypertension. By contrast, the release of prostacyclin is depressed in these patients. Whether the imbalance in the release of these mediators is a cause or a result of pulmonary hypertension is unknown, but it may play a part in the development and maintenance of both forms of the disorder.	UNIV COLORADO, HLTH SCI CTR, DIV CARDIOL, DENVER, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	CHRISTMAN, BW (corresponding author), VANDERBILT UNIV, MED CTR, SCH MED, CTR LUNG RES, DIV PULM & CRIT CARE MED, NASHVILLE, TN 37232 USA.				NHLBI NIH HHS [HL 41952, HL 43167, HL 39952] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041952, R01HL043167, R01HL039952] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BADESCH DB, 1989, AM J RESP CELL MOL, V1, P489, DOI 10.1165/ajrcmb/1.6.489; BARST RJ, 1985, AM REV RESPIR DIS, V131, P171; CATELLA F, 1987, THROMB RES, V47, P647, DOI 10.1016/0049-3848(87)90103-4; CHRISTMAN BW, 1989, BIOMED ENVIRON MASS, V18, P258, DOI 10.1002/bms.1200180409; Ciabattoni G, 1987, Adv Prostaglandin Thromboxane Leukot Res, V17B, P598; COHEN M, 1986, J AM COLL CARDIOL, V7, P172, DOI 10.1016/S0735-1097(86)80277-7; DINHXUAN AT, 1991, NEW ENGL J MED, V324, P1539, DOI 10.1056/NEJM199105303242203; EDWARDS BS, 1987, J AM COLL CARDIOL, V10, P1233, DOI 10.1016/S0735-1097(87)80123-7; FITZGERALD DJ, 1986, NEW ENGL J MED, V315, P983, DOI 10.1056/NEJM198610163151602; FUSTER V, 1984, CIRCULATION, V70, P580, DOI 10.1161/01.CIR.70.4.580; Groves BM, 1990, PULMONARY CIRCULATIO, P359; HART CM, 1989, CLIN CHEST MED, V10, P59; HEATH D, 1958, CIRCULATION, V18, P533, DOI 10.1161/01.CIR.18.4.533; HENRIKSSON P, 1986, BRIT HEART J, V55, P543; HERVE P, 1990, AM J MED, V89, P117, DOI 10.1016/0002-9343(90)90111-P; KAHALEH MB, 1982, ANN INTERN MED, V96, P610, DOI 10.7326/0003-4819-96-5-610; NAIR SS, 1980, ARCH INTERN MED, V140, P109, DOI 10.1001/archinte.140.1.109; PATRONO C, 1986, J CLIN INVEST, V77, P590, DOI 10.1172/JCI112341; PIETRA GG, 1989, CIRCULATION, V80, P1198, DOI 10.1161/01.CIR.80.5.1198; REEVES JT, 1986, AM REV RESPIR DIS, V134, P342; RICH S, 1986, J AM COLL CARDIOL, V8, P1307, DOI 10.1016/S0735-1097(86)80301-1; RICH S, 1987, CHEST, V91, P356, DOI 10.1378/chest.91.3.356; RICH S, 1987, CIRCULATION, V76, P135, DOI 10.1161/01.CIR.76.1.135; RUBIN LJ, 1990, ANN INTERN MED, V112, P485, DOI 10.7326/0003-4819-112-7-485; Siegel S., 2009, NONPARAMETRIC STAT B, V2nd; STEWART DJ, 1991, ANN INTERN MED, V114, P464, DOI 10.7326/0003-4819-114-6-464; TURNERSTOKES L, 1982, CLIN RHEUM DIS, V8, P229; UNGERER RG, 1983, AM J MED, V75, P65, DOI 10.1016/0002-9343(83)91169-5; VESTERQVIST O, 1987, THROMB RES, V45, P393, DOI 10.1016/0049-3848(87)90228-3; VOELKEL NF, 1989, PULMONARY VASCULAR P, V38, P513; WAGENVOORT CA, 1970, CIRCULATION, V42, P1163, DOI 10.1161/01.CIR.42.6.1163; WEIR EK, 1989, AM REV RESPIR DIS, V140, P1623, DOI 10.1164/ajrccm/140.6.1623; YOUNG RH, 1978, AM J MED, V64, P998, DOI 10.1016/0002-9343(78)90455-2	33	890	927	2	22	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 9	1992	327	2					70	75		10.1056/NEJM199207093270202	http://dx.doi.org/10.1056/NEJM199207093270202			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC214	1603138				2022-12-01	WOS:A1992JC21400002
J	LEHMANN, PV; FORSTHUBER, T; MILLER, A; SERCARZ, EE				LEHMANN, PV; FORSTHUBER, T; MILLER, A; SERCARZ, EE			SPREADING OF T-CELL AUTOIMMUNITY TO CRYPTIC DETERMINANTS OF AN AUTOANTIGEN	NATURE			English	Article							EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; MYELIN BASIC-PROTEIN; ENCEPHALITOGENIC EPITOPES; VACCINATION; SPECIFICITY; RECEPTORS; PEPTIDES	IMMUNIZATION with myelin basic protein (MBP) induces experimental allergic encephalomyelitis (EAE), a prototype of CD4+ T-cell mediated autoimmune disease. In rodents, MBP-reactive T-cell clones are specific for a single, dominant determinant on MBP and use a highly restricted number of T-cell receptor genes 1-3. Accordingly, EAE has been prevented by various receptor-specific treatments 1-8, suggesting similar strategies may be useful for therapy of human autoimmune disease. Here we report that in (SJL x B10.PL)F1 mice, immune dominance of a single determinant, MBP: Ac1-11, is confined to the inductive phase of EAE. In mice with chronic EAE, several additional determinants of MBP in peptides 35-47, 81-100 and 121-140 recall proliferative responses. Most importantly, reactivity to the latter determinants was also detected after induction of EAE with MBP peptide Ac1-11 alone; this demonstrates priming by endogenous MBP determinants. Thus, determinants of MBP that are cryptic 9-11 after primary immunization can become immunogenic in the course of EAE. Diversification of the autoreactive T-cell repertoire due to 'determinant spreading' has major implications for the pathogenesis of, and the therapeutic approach to, T-cell driven autoimmune disease.	UNIV CALIF LOS ANGELES, DEPT MICROBIOL & MOLEC GENET, 405 HILGARD AVE, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles			Forsthuber, Thomas/AID-8080-2022	/0000-0003-0692-7125				ACHAORBEA H, 1988, CELL, V54, P263, DOI 10.1016/0092-8674(88)90558-2; BENICHOU G, 1990, J EXP MED, V172, P1341, DOI 10.1084/jem.172.5.1341; BENNUN A, 1981, NATURE, V292, P60, DOI 10.1038/292060a0; DEIBLER GE, 1972, PREP BIOCHEM, V2, P139, DOI 10.1080/00327487208061467; FRITZ RB, 1989, CHEM IMMUNOL, V46, P101; GAMMON G, 1989, NATURE, V342, P183, DOI 10.1038/342183a0; GAMMON G, 1991, IMMUNOL TODAY, V12, P193, DOI 10.1016/0167-5699(91)90052-U; HEBERKATZ E, 1989, IMMUNOL TODAY, V10, P164, DOI 10.1016/0167-5699(89)90174-6; HOOD L, 1989, COLD SPRING HARB SYM, V54, P859; HOWELL MD, 1989, SCIENCE, V246, P668, DOI 10.1126/science.2814489; KENT SBH, 1985, SYNTHETIC PEPTIDES B, P29; LINTHICUM DS, 1982, J EXP MED, V156, P31, DOI 10.1084/jem.156.1.31; MCCARRON RM, 1990, J NEUROIMMUNOL, V29, P73, DOI 10.1016/0165-5728(90)90149-H; OFFNER H, 1991, SCIENCE, V251, P430, DOI 10.1126/science.1989076; OWHASHI M, 1988, J EXP MED, V168, P2153, DOI 10.1084/jem.168.6.2153; PERRY LL, 1987, J IMMUNOL, V138, P1434; PERRY LL, 1991, J NEUROIMMUNOL, V33, P7, DOI 10.1016/0165-5728(91)90029-7; SAKAI K, 1988, J NEUROIMMUNOL, V19, P21, DOI 10.1016/0165-5728(88)90032-X; SARVETNICK N, 1990, NATURE, V346, P844, DOI 10.1038/346844a0; URBAN JL, 1988, CELL, V54, P577, DOI 10.1016/0092-8674(88)90079-7; VANDENBARK AA, 1989, NATURE, V341, P541, DOI 10.1038/341541a0; ZALLER DM, 1990, J EXP MED, V171, P1943, DOI 10.1084/jem.171.6.1943; ZAMVIL SS, 1988, J EXP MED, V168, P1181, DOI 10.1084/jem.168.3.1181	23	1056	1088	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 9	1992	358	6382					155	157		10.1038/358155a0	http://dx.doi.org/10.1038/358155a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC583	1377368				2022-12-01	WOS:A1992JC58300053
J	PYLE, AM; MURPHY, FL; CECH, TR				PYLE, AM; MURPHY, FL; CECH, TR			RNA SUBSTRATE BINDING-SITE IN THE CATALYTIC CORE OF THE TETRAHYMENA RIBOZYME	NATURE			English	Article							CIRCULARIZED INTERVENING SEQUENCE; GROUP-I INTRON; RIBOSOMAL-RNA; ACTIVE-SITE; PRE-RRNA; OLIGONUCLEOTIDE; SPECIFICITY; CLEAVAGE; ENZYME; COMPLEMENTARY	In catalysis by group I introns, the helix (P1) containing the RNA cleavage site must be positioned next to the guanosine binding site. We have identified a conserved adenine in the catalytic core that contributes to the stability of this arrangement and propose that it accepts a hydrogen bond from a specific 2'-OH in P1. Such base-backbone tertiary interactions may be generally important to the organization of RNA tertiary structure.	UNIV COLORADO, HOWARD HUGHES MED INST, BOULDER, CO 80309 USA; UNIV COLORADO, DEPT CHEM & BIOCHEM, BOULDER, CO 80309 USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder								BARFOD ET, 1989, MOL CELL BIOL, V9, P3657, DOI 10.1128/MCB.9.9.3657; BEEN MD, 1986, CELL, V47, P207, DOI 10.1016/0092-8674(86)90443-5; BEVILACQUA PC, 1991, BIOCHEMISTRY-US, V30, P10632, DOI 10.1021/bi00108a005; CELANDER DW, 1991, SCIENCE, V251, P401, DOI 10.1126/science.1989074; CURTISS LA, 1978, J AM CHEM SOC, V100, P79, DOI 10.1021/ja00469a013; DAVIES RW, 1982, NATURE, V300, P719, DOI 10.1038/300719a0; DOCKBREGEON AC, 1989, J MOL BIOL, V209, P459, DOI 10.1016/0022-2836(89)90010-7; DOUDNA JA, 1989, P NATL ACAD SCI USA, V86, P7402, DOI 10.1073/pnas.86.19.7402; DOUDNA JA, 1989, NATURE, V339, P519, DOI 10.1038/339519a0; FORSTER AC, 1990, SCIENCE, V249, P783, DOI 10.1126/science.1697102; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; GUSCHLBAUER W, 1980, NUCLEIC ACIDS RES, V8, P1421, DOI 10.1093/nar/8.6.1421; HERSCHLAG D, 1992, BIOCHEMISTRY-US, V31, P1386, DOI 10.1021/bi00120a015; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; HERSCHLAG D, 1990, NATURE, V344, P405, DOI 10.1038/344405a0; HEUS HA, 1991, SCIENCE, V253, P191, DOI 10.1126/science.1712983; HOLBROOK SR, 1991, NATURE, V353, P579, DOI 10.1038/353579a0; HUANG JF, 1989, J AM CHEM SOC, V111, P6909, DOI 10.1021/ja00200a003; INOUE T, 1985, P NATL ACAD SCI USA, V82, P648, DOI 10.1073/pnas.82.3.648; JANIK B, 1972, BIOCHEM BIOPH RES CO, V46, P1153, DOI 10.1016/S0006-291X(72)80095-0; KIM SH, 1987, P NATL ACAD SCI USA, V84, P8788, DOI 10.1073/pnas.84.24.8788; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LATHAM JA, 1989, SCIENCE, V245, P276, DOI 10.1126/science.2501870; MICHEL F, 1990, NATURE, V347, P578, DOI 10.1038/347578a0; MICHEL F, 1982, BIOCHIMIE, V64, P867, DOI 10.1016/S0300-9084(82)80349-0; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MOAZED D, 1986, J MOL BIOL, V187, P399, DOI 10.1016/0022-2836(86)90441-9; MURRAYRUST P, 1983, J AM CHEM SOC, V105, P3206, DOI 10.1021/ja00348a041; PACE NR, 1990, J BIOL CHEM, V265, P3587; PIEKEN WA, 1991, SCIENCE, V253, P314, DOI 10.1126/science.1857967; PYLE AM, 1990, P NATL ACAD SCI USA, V87, P8187, DOI 10.1073/pnas.87.21.8187; PYLE AM, 1991, NATURE, V350, P628, DOI 10.1038/350628a0; QUIGLEY GJ, 1976, SCIENCE, V194, P796, DOI 10.1126/science.790568; SUGIMOTO N, 1989, CHEM LETT, P2223, DOI 10.1246/cl.1989.2223; SUGIMOTO N, 1988, BIOCHEMISTRY-US, V27, P6384, DOI 10.1021/bi00417a029; SULLIVAN FX, 1985, CELL, V42, P639, DOI 10.1016/0092-8674(85)90121-7; TAKAHASHI LH, 1989, J AM CHEM SOC, V111, P3368, DOI 10.1021/ja00191a039; WARING RB, 1986, NATURE, V321, P133, DOI 10.1038/321133a0; WEEKS KM, 1991, CELL, V66, P577, DOI 10.1016/0092-8674(81)90020-9; WILLIAMS DM, 1992, P NATL ACAD SCI USA, V89, P918, DOI 10.1073/pnas.89.3.918; WILLIAMSON CL, 1987, J BIOL CHEM, V262, P14672; WITHERS SG, 1988, ACS SYM SER, V374, P59; ZAUG AJ, 1986, NATURE, V324, P429, DOI 10.1038/324429a0; ZAUG AJ, 1988, BIOCHEMISTRY-US, V27, P8924, DOI 10.1021/bi00425a008	45	204	209	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 9	1992	358	6382					123	131		10.1038/358123a0	http://dx.doi.org/10.1038/358123a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC583	1377367				2022-12-01	WOS:A1992JC58300042
J	REEVE, HK				REEVE, HK			QUEEN ACTIVATION OF LAZY WORKERS IN COLONIES OF THE EUSOCIAL NAKED MOLE-RAT	NATURE			English	Article							POLISTES-FUSCATUS; HYMENOPTERA; VESPIDAE; WASPS	EVOLUTIONARY ConfliCtS of interest are expected to arise in genetically diverse social groups 1. In eusocial insect societies, a potential conflict exists between the queen and her workers over how active the workers should be 2-5, and evidence exists that queen aggression increases activity levels of her lazier workers 2,3. Here I provide evidence that queen aggression (shoving) in laboratory colonies of the eusocial mammal, the naked mole-rat (Heterocephalus glaber), is a convergently evolved manifestation of queen-worker conflict over worker activity. Queen-initiated shoves activate inherently lazy workers, which tend to be larger and/or less related to the queen than are infrequently shoved, industrious workers. In addition, queen removal selectively depresses the activity of workers that are larger and less related to her. Finally, queen shoving and worker inactivity are pronounced when colonies are satiated but not when colonies are hungry, indicating that the underlying 'work-conflict' is highly context specific.	CORNELL UNIV,NEUROBIOL & BEHAV SECT,ITHACA,NY 14853	Cornell University								Braude S.H., 1991, P185; Brett R.A., 1991, P97; HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI [10.1016/0022-5193(64)90038-4, 10.1016/0022-5193(64)90039-6]; Jarvis J.U.M., 1991, P384; Jarvis J.U.M., 1991, P66; JARVIS JUM, 1981, SCIENCE, V212, P571, DOI 10.1126/science.7209555; Lacey E.A., 1991, P209; Lacey E.A., 1991, P275; REEVE HK, 1987, BEHAVIOUR, V102, P147, DOI 10.1163/156853986X00090; REEVE HK, 1983, BEHAV ECOL SOCIOBIOL, V13, P63, DOI 10.1007/BF00295077; REEVE HK, 1990, P NATL ACAD SCI USA, V87, P2496, DOI 10.1073/pnas.87.7.2496; REEVE HK, 1991, THESIS CORNELL U; Reeve HK, 1991, BIOL NAKED MOLE RAT, P337; SCHMIDHEMPEL P, 1990, AM NAT, V135, P501, DOI 10.1086/285059; West-Eberhard M.J., 1981, P3	15	136	142	2	85	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 9	1992	358	6382					147	149		10.1038/358147a0	http://dx.doi.org/10.1038/358147a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC583	1614546				2022-12-01	WOS:A1992JC58300050
J	SULLIVAN, V; TALARICO, CL; STANAT, SC; DAVIS, M; COEN, DM; BIRON, KK				SULLIVAN, V; TALARICO, CL; STANAT, SC; DAVIS, M; COEN, DM; BIRON, KK			A PROTEIN-KINASE HOMOLOG CONTROLS PHOSPHORYLATION OF GANCICLOVIR IN HUMAN CYTOMEGALOVIRUS-INFECTED CELLS	NATURE			English	Article							HERPES-SIMPLEX VIRUS; VARICELLA-ZOSTER VIRUS; COMPLETE DNA-SEQUENCE; EPSTEIN-BARR VIRUS; GENOME; PHOSPHOTRANSFERASE; HERPESVIRUSES; EXPRESSION; ACYCLOVIR	HUMAN cytomegalovirus (HCMV) is a major pathogen in immunosuppressed individuals, including patients with acquired immune deficiency syndrome. The nucleoside analogue ganciclovir (9-(1,3-dihydroxy-2-propoxymethyl)-guanine) is one of the few drugs available to treat HCMV infections, but resistant virus is a growing problem in the clinic 1 and there is a critical need for new drugs. The study of ganciclovir-resistant mutants has indicated that the selective action of ganciclovir depends largely on virus-controlled phosphorylation in HCMV-infected cells 2-5. The enzyme(s) responsible have not been identified. Here we report that the HCMV gene UL97, whose predicted product shares regions of homology with protein kinases, guanylyl cyclase and bacterial phosphotransferases 6-8, controls phosphorylation of ganciclovir in HCMV-infected cells. A four-amino-acid deletion of UL97 in a conserved region, which in cyclic AMP-dependent protein kinase participates in substrate recognition 9, causes impaired ganciclovir phosphorylation. The implications of these results for antiviral drug development and drug resistance are discussed.	BURROUGHS WELLCOME CO, DIV VIROL, RES TRIANGLE PK, NC 27709 USA	Burroughs Wellcome Fund	SULLIVAN, V (corresponding author), HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA.							AGUT H, 1989, RES VIROLOGY, V140, P219, DOI 10.1016/S0923-2516(89)80099-8; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BIRON KK, 1986, P NATL ACAD SCI USA, V83, P8769, DOI 10.1073/pnas.83.22.8769; BIRON KK, 1985, P NATL ACAD SCI USA, V82, P2473, DOI 10.1073/pnas.82.8.2473; BRENNER S, 1987, NATURE, V329, P21, DOI 10.1038/329021a0; BRITT WJ, 1986, J VIROL, V58, P185, DOI 10.1128/JVI.58.1.185-191.1986; CHEE MS, 1990, CURR TOP MICROBIOL, V154, P125; CHEE MS, 1989, J GEN VIROL, V70, P1151, DOI 10.1099/0022-1317-70-5-1151; DAVISON AJ, 1986, J GEN VIROL, V67, P1759, DOI 10.1099/0022-1317-67-9-1759; DILUCA D, 1990, VIROLOGY, V175, P199, DOI 10.1016/0042-6822(90)90200-B; DREW WL, 1991, J INFECT DIS, V163, P716, DOI 10.1093/infdis/163.4.716; FLECKENSTEIN B, 1982, GENE, V18, P39, DOI 10.1016/0378-1119(82)90054-3; FREITAS VR, 1985, ANTIMICROB AGENTS CH, V28, P240, DOI 10.1128/AAC.28.2.240; FYFE JA, 1983, MOL PHARMACOL, V24, P316; FYFE JA, 1978, J BIOL CHEM, V253, P8721; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; LAU YF, 1983, P NATL ACAD SCI-BIOL, V80, P5225, DOI 10.1073/pnas.80.17.5225; LITTLER E, 1992, NATURE, V358, P160, DOI 10.1038/358160a0; MAR EC, 1981, J GEN VIROL, V57, P149, DOI 10.1099/0022-1317-57-1-149; MCGEOCH DJ, 1988, J GEN VIROL, V69, P1531, DOI 10.1099/0022-1317-69-7-1531; MICHELSON S, 1984, VIROLOGY, V134, P259, DOI 10.1016/0042-6822(84)90295-2; ROBY C, 1986, J VIROL, V59, P714, DOI 10.1128/JVI.59.3.714-727.1986; SHOJI S, 1981, P NATL ACAD SCI-BIOL, V78, P848, DOI 10.1073/pnas.78.2.848; SINGH S, 1988, NATURE, V334, P708, DOI 10.1038/334708a0; SMITH RF, 1989, J VIROL, V63, P450, DOI 10.1128/JVI.63.1.450-455.1989; SOMOGYI T, 1990, VIROLOGY, V174, P276, DOI 10.1016/0042-6822(90)90075-3; STANAT SC, 1991, ANTIMICROB AGENTS CH, V35, P2191, DOI 10.1128/AAC.35.11.2191	28	367	372	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 9	1992	358	6382					162	164		10.1038/358162a0	http://dx.doi.org/10.1038/358162a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC583	1319560				2022-12-01	WOS:A1992JC58300056
J	WIECH, H; BUCHNER, J; ZIMMERMANN, R; JAKOB, U				WIECH, H; BUCHNER, J; ZIMMERMANN, R; JAKOB, U			HSP90 CHAPERONES PROTEIN FOLDING INVITRO	NATURE			English	Article							HEAT-SHOCK PROTEINS; LIGHT-CHAIN	THE heat-shock protein Hsp90 is the most abundant constitutively expressed stress protein in the cytosol of eukaryotic cells 1,2, where it participates in the maturation of other proteins, modulation of protein activity in the case of hormone-free steroid receptors, and intracellular transport of some newly synthesized kinases 3-5. A feature of all these processes could be their dependence on the formation of protein structure. If Hsp90 is a molecular chaperone involved in maintaining a certain subset of cellular proteins in an inactive form, it should also be able to recognize and bind non-native proteins, thereby influencing their folding to the native state. Here we investigate whether Hsp90 can influence protein folding in vitro and show that Hsp90 suppresses the formation of protein aggregates by binding to the target proteins at a stoichiometry of one Hsp90 dimer to one or two substrate molecule(s). Furthermore, the yield of correctly folded and functional protein is increased significantly. The action of Hsp90 does not depend on the presence of nucleoside triphosphates, so it may be that Hsp90 uses a novel molecular mechanism to assist protein folding in vivo.	UNIV REGENSBURG,INST BIOPHYS & PHYS BIOCHEM,UNIV STR 31,W-8400 REGENSBURG,GERMANY; UNIV GOTTINGEN,ZENTRUM BIOCHEM,BIOCHEM ABT 2,W-3400 GOTTINGEN,GERMANY	University of Regensburg; University of Gottingen			Buchner, Johannes/A-2651-2010	Buchner, Johannes/0000-0003-1282-7737				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; BUCHNER J, 1991, BIO-TECHNOL, V9, P157, DOI 10.1038/nbt0291-157; BUCKEL P, 1987, GENE, V51, P13, DOI 10.1016/0378-1119(87)90469-0; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOTO Y, 1982, J MOL BIOL, V156, P891, DOI 10.1016/0022-2836(82)90146-2; JOHNSTONE A, 1987, IMMUNOCHEMISTRY PRAC, P55; KAWATA Y, 1991, BIOCHEMISTRY-US, V30, P4367, DOI 10.1021/bi00232a001; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; SCHMIDT M, IN PRESS J BIOL CHEM; SRERE PA, 1963, ACTA CHEM SCAND, V17, pS129; TSUNENAGA M, 1987, BIOCHEMISTRY-US, V26, P4367; WELCH WJ, 1982, J BIOL CHEM, V257, P4949; Welch WJ., 1990, STRESS PROTEINS BIOL, P223; WEST SM, 1988, BIOCHEM J, V251, P135, DOI 10.1042/bj2510135; WETLAUFER DB, 1962, ADV PROTEIN CHEM, V17, P303	18	441	452	0	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 9	1992	358	6382					169	170		10.1038/358169a0	http://dx.doi.org/10.1038/358169a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC583	1614549				2022-12-01	WOS:A1992JC58300059
J	YOUNG, MP				YOUNG, MP			OBJECTIVE ANALYSIS OF THE TOPOLOGICAL ORGANIZATION OF THE PRIMATE CORTICAL VISUAL-SYSTEM	NATURE			English	Article							RHESUS-MONKEY; CORTEX; CONNECTIONS; MACAQUE; PATHWAYS; AREAS	THE primate cortical visual system is composed Of many structurally and functionally distinct areas 1-3, each receiving and sending about 10 projections from and to other cortical areas 1. The visual cortex is thus served by many cortico-cortical connections to form a network of considerable complexity. Thus the gross organization of this cortical processing system presents a formidable topological problem: although the spatial Position of the areas in the brain is reasonably well established, the gross 'processing architecture' defined by the connections, is less well understood. Here I report an optimization approach that gives both qualitative and quantitative insight into the connectional topology of the primate cortical visual system. This approach supports suggestions that the system is divided into a dorsal 'stream' and a ventral 'stream' with limited cross-talk, that these two streams reconverge in the region of the principal sulcus (area 46) and in the superior temporal polysensory areas, that the system is hierarchically organized, and that the majority of the connections are from 'nearest-neighbour' and 'next-door-but-one' areas.			YOUNG, MP (corresponding author), UNIV OXFORD,PHYSIOL LAB,PARKS RD,OXFORD OX1 3PT,ENGLAND.							BAIZER JS, 1991, J NEUROSCI, V11, P168; BOUSSAOUD D, 1990, J COMP NEUROL, V296, P462, DOI 10.1002/cne.902960311; CAVADA C, 1989, J COMP NEUROL, V287, P393, DOI 10.1002/cne.902870402; COWEY A, 1979, Q J EXP PSYCHOL, V31, P1, DOI 10.1080/14640747908400703; CROCK F, 1991, COLD SPRING HARB SYM, V55, P953; DEYOE EA, 1988, TRENDS NEUROSCI, V11, P219, DOI 10.1016/0166-2236(88)90130-0; Edgington E. S., 1980, RANDOMIZATION TESTS; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; GOWER JC, 1975, PSYCHOMETRIKA, V40, P33, DOI 10.1007/BF02291478; GROSS CG, 1972, J NEUROPHYSIOL, V35, P96, DOI 10.1152/jn.1972.35.1.96; MITCHISON G, 1991, P ROY SOC B-BIOL SCI, V245, P151, DOI 10.1098/rspb.1991.0102; MIYASHITA Y, 1988, NATURE, V335, P817, DOI 10.1038/335817a0; MOREL A, 1990, VISUAL NEUROSCI, V4, P555, DOI 10.1017/S0952523800005769; Norusis M.J., 1990, SPSS BASE SYSTEM USE; PETERS A, 1985, CEREBRAL CORTEX; SCHILLER PH, 1991, SCIENCE, V251, P1251, DOI 10.1126/science.2006413; SCHONEMAN P, 1970, PSYCHOMETRIKA, V31, P1; SELTZER B, 1978, BRAIN RES, V149, P1, DOI 10.1016/0006-8993(78)90584-X; SHEPARD RN, 1962, PSYCHOMETRIKA, V27, P125, DOI 10.1007/BF02289630; TANAKA K, 1991, J NEUROPHYSIOL, V66, P170, DOI 10.1152/jn.1991.66.1.170; Ungerleider L, 1982, ANAL VISUAL BEHAV, P549; VANESSEN DC, 1990, COLD SPRING HARB SYM, V55, P679; Young F. W., 1990, SPSS BASE SYSTEM USE, P396; YOUNG FW, 1979, MULTIDIMENSIONAL SCA; YOUNG MP, 1992, SCIENCE, V256, P1327, DOI 10.1126/science.1598577; YOUNG MP, 1990, THESIS ST ANDREWS U; YOUNG MP, 1991, SOC NEUR ABS, V17; YOUNG MP, IN PRESS J NEUROPHYS; YOUNG MP, IN PRESS BRAIN MECHA; ZEKI S, 1988, NATURE, V335, P311, DOI 10.1038/335311a0	30	337	346	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 9	1992	358	6382					152	155		10.1038/358152a0	http://dx.doi.org/10.1038/358152a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC583	1614547				2022-12-01	WOS:A1992JC58300052
J	ZYCHLINSKY, A; PREVOST, MC; SANSONETTI, PJ				ZYCHLINSKY, A; PREVOST, MC; SANSONETTI, PJ			SHIGELLA-FLEXNERI INDUCES APOPTOSIS IN INFECTED MACROPHAGES	NATURE			English	Article							LISTERIA-MONOCYTOGENES; PLASMID; SPREAD; GROWTH; CELLS; ACTIN	THE Gram-negative bacterial pathogen Shigella flexneri causes dysentery by invading the human colonic mucosa 1. Bacteria are phagocytosed by enterocytes 2, escape from the phagosome into the cytoplasm 3 and spread to adjacent cells 4. After crossing the epithelium, Shigella reaches the lamina propria of intestinal villi, the first line of defence. This tissue is densely populated with phagocytes that are killed in great numbers, resulting in abscesses 5,6. The genes required for cell invasion 7 and macrophage killing 2 are located on a 220-kilobase plasmid. We report here on the mechanism of cytotoxicity used by S. flexneri to kill macrophages. Each of four different strains was tested for its capacity to induce cell death. An invasive strain induced programmed cell death (apoptosis 8,9), whereas its non-invasive, plasmid-cured isogenic strain was not toxic; neither was a mutant in ipa B (ref. 10) (invasion protein antigen), a gene necessary for entry. A non-invasive strain expressing the haemolysin operon of Escherichia coli 11 induced accidental cell death (necrosis), demonstrating that other bacterial cytotoxic mechanisms do not lead to apoptosis. This is the first evidence that an invasive bacterial pathogen can induce suicide in its host cells.	INST PASTEUR, INSERM,U199,UNITE PATHOGENIE MICROBIENNE MOLEC, 25-28 RUE DOCTEUR ROUX, F-75724 PARIS 15, FRANCE; INST PASTEUR, CENT MICROSCOPIE ELECTR STN, F-75724 PARIS 15, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris								ANAND BS, 1986, GASTROENTEROLOGY, V90, P654, DOI 10.1016/0016-5085(86)91120-0; ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; BERNARDINI ML, 1989, P NATL ACAD SCI USA, V86, P3867, DOI 10.1073/pnas.86.10.3867; CLERC PL, 1987, INFECT IMMUN, V55, P521, DOI 10.1128/IAI.55.3.521-527.1987; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; GAILLARD JL, 1987, INFECT IMMUN, V55, P2822, DOI 10.1128/IAI.55.11.2822-2829.1987; HIGH N, 1992, EMBO J, V11, P1991, DOI 10.1002/j.1460-2075.1992.tb05253.x; LABREC EH, 1964, J BACTERIOL, V88, P1503, DOI 10.1128/JB.88.5.1503-1518.1964; MANGAN DF, 1991, J IMMUNOL, V146, P1541; MATHAN MM, 1991, REV INFECT DIS, V13, pS314; NOEGEL A, 1979, MOL GEN GENET, V175, P343, DOI 10.1007/BF00397234; SANSONETTI PJ, 1986, INFECT IMMUN, V51, P461, DOI 10.1128/IAI.51.2.461-469.1986; SANSONETTI PJ, 1982, INFECT IMMUN, V35, P852, DOI 10.1128/IAI.35.3.852-860.1982; Tanenbaum SW, 1978, CYTOCHALASINS BIOCH; TILNEY LG, 1989, J CELL BIOL, V109, P1597, DOI 10.1083/jcb.109.4.1597; WARING P, 1990, J BIOL CHEM, V265, P14476; WELCH RA, 1991, MOL MICROBIOL, V5, P521, DOI 10.1111/j.1365-2958.1991.tb00723.x; ZHENG LM, 1991, J CELL BIOL, V112, P279, DOI 10.1083/jcb.112.2.279	18	752	802	9	82	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 9	1992	358	6382					167	169		10.1038/358167a0	http://dx.doi.org/10.1038/358167a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC583	1614548				2022-12-01	WOS:A1992JC58300058
J	EISENBERG, MJ; LONDON, MJ; LEUNG, JM; BROWNER, WS; HOLLENBERG, M; TUBAU, JF; TATEO, IM; SCHILLER, NB; MANGANO, DT				EISENBERG, MJ; LONDON, MJ; LEUNG, JM; BROWNER, WS; HOLLENBERG, M; TUBAU, JF; TATEO, IM; SCHILLER, NB; MANGANO, DT			MONITORING FOR MYOCARDIAL-ISCHEMIA DURING NONCARDIAC SURGERY - A TECHNOLOGY-ASSESSMENT OF TRANSESOPHAGEAL ECHOCARDIOGRAPHY AND 12-LEAD ELECTROCARDIOGRAPHY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TRANS-ESOPHAGEAL ECHOCARDIOGRAPHY; PERIPHERAL VASCULAR-SURGERY; TWO-DIMENSIONAL ECHOCARDIOGRAPHY; WALL-MOTION ABNORMALITIES; CARDIAC SURGICAL PROCEDURES; CORONARY-ARTERY DISEASE; INTRAOPERATIVE DETECTION; RISK; INFARCTION; ANGIOPLASTY	Objective.-Transesophageal echocardiography (TEE) and 12-lead electrocardiography (ECG) are sophisticated techniques that are increasingly being used to monitor for myocardial ischemia during noncardiac surgery. We examined whether the routine use of these techniques has incremental clinical value in identifying patients at high risk for perioperative ischemic outcomes when compared with preoperative clinical data and intraoperative monitoring using continuous two-lead bipolar ECG. Design.-Cohort study. Setting.-Veterans Affairs medical center. Patients.-A total of 332 men undergoing noncardiac surgery who had or were at high risk for coronary artery disease. Interventions.-TEE, 12-lead ECG, and two-lead ECG were performed continuously during noncardiac surgery (47% vascular, 53% nonvascular). Monitoring results were not available to anesthesiologists or surgeons, and data were blindly analyzed after surgery. Main Outcome Measure.-Perioperative ischemic outcomes (cardiac death, nonfatal myocardial infarction, unstable angina). Results.-In a subset of 285 patients who were adequately studied by all three techniques, 111 patients (39%) were identified as having intraoperative myocardial ischemia (by one or more monitoring techniques). By univariate analysis, intraoperative ischemia was associated with all perioperative cardiac outcomes, including ischemic outcomes, congestive heart failure, and ventricular tachycardia (P less-than-or-equal-to .02 for each of the three monitoring techniques). However, when monitoring results for TEE and 12-lead ECG were added to a multivariate model that included preoperative clinical data and continuous two-lead ECG results, the incremental value of TEE was small (odds ratio, 2.6; 95% confidence interval [CI], 1.2 to 5.7; P=.02) and that of 12-lead ECG was not significant (odds ratio, 1.5; 95% CI, 0.6 to 3.8). Furthermore, when the multivariate analysis was repeated with only ischemic outcomes, neither TEE nor 12-lead ECG retained significant associations (odds ratio, 2.2; 95% CI, 0.5 to 9.4, and odds ratio, 1.1; 95% CI, 0.2 to 6.1, respectively). Conclusion.-When compared with preoperative clinical data and intraoperative monitoring using two-lead ECG, routine monitoring for myocardial ischemia with TEE or 12-lead ECG during noncardiac surgery has little incremental clinical value in identifying patients at high risk for perioperative ischemic outcomes.	UNIV CALIF SAN FRANCISCO, DEPT ANESTHESIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT EPIDEMIOL & BIOSTAT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT SURG, SAN FRANCISCO, CA 94143 USA; VET AFFAIRS MED CTR, SAN FRANCISCO, CA USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco				Tice, Jeffrey/0000-0002-9857-2028	NHLBI NIH HHS [HL 07192, R01-HL36744] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036744, T32HL007192] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEAUPRE PN, 1984, AM HEART J, V107, P1021, DOI 10.1016/0002-8703(84)90844-5; BLACKBURN H, 1960, CIRCULATION, V21, P1160, DOI 10.1161/01.CIR.21.6.1160; BOUCHER CA, 1985, NEW ENGL J MED, V312, P389, DOI 10.1056/NEJM198502143120701; CARLINER NH, 1985, AM J CARDIOL, V56, P51, DOI 10.1016/0002-9149(85)90565-X; CHAITMAN BR, 1978, CIRCULATION, V57, P71, DOI 10.1161/01.CIR.57.1.71; CHUNG F, 1991, CAN J ANAESTH, V38, P98, DOI 10.1007/BF03009170; CLEMENTS FM, 1987, ANESTH ANALG, V66, P249; COHEN M, 1987, J AM COLL CARDIOL, V10, P17, DOI 10.1016/S0735-1097(87)80154-7; EAGLE KA, 1989, ANN INTERN MED, V110, P859, DOI 10.7326/0003-4819-110-11-859; EAGLE KA, 1987, JAMA-J AM MED ASSOC, V257, P2185, DOI 10.1001/jama.257.16.2185; GEWERTZ BL, 1987, J VASC SURG, V5, P607, DOI 10.1067/mva.1987.avs0050607; GIANNUZZI P, 1989, EUR HEART J, V10, P880, DOI 10.1093/oxfordjournals.eurheartj.a059396; GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601; HAGGMARK S, 1989, ANESTHESIOLOGY, V70, P19; HAUSER AM, 1985, J AM COLL CARDIOL, V5, P193, DOI 10.1016/S0735-1097(85)80036-X; KREMER P, 1983, CIRCULATION, V68, P332; KREMER P, 1982, AM J CARDIOL, V49, P956, DOI 10.1016/0002-9149(82)92230-5; KRUCOFF MW, 1987, J ELECTROCARDIOL, V20, P15; LEUNG JM, 1989, ANESTHESIOLOGY, V71, P16, DOI 10.1097/00000542-198907000-00004; LONDON MJ, 1988, ANESTHESIOLOGY, V69, P232, DOI 10.1097/00000542-198808000-00013; LONDON MJ, 1990, ANESTHESIOLOGY, V73, P644, DOI 10.1097/00000542-199010000-00010; MANGANO DT, 1990, NEW ENGL J MED, V323, P1781, DOI 10.1056/NEJM199012273232601; MATSUMOTO M, 1980, AM J CARDIOL, V46, P95, DOI 10.1016/0002-9149(80)90611-6; MCCANN RL, 1989, J VASC SURG, V9, P583, DOI 10.1067/mva.1989.vs0090583; PASTERNACK PF, 1989, J VASC SURG, V10, P617, DOI 10.1067/mva.1989.15572; RABY KE, 1989, NEW ENGL J MED, V321, P1296, DOI 10.1056/NEJM198911093211904; ROIZEN MF, 1984, J VASC SURG, V1, P300, DOI 10.1067/mva.1984.avs0010300; ROY WL, 1979, ANESTHESIOLOGY, V51, P393, DOI 10.1097/00000542-197911000-00005; SHIVELY B, 1986, J AM COLL CARDIOL, V7, pA2; SLOGOFF S, 1985, ANESTHESIOLOGY, V62, P107, DOI 10.1097/00000542-198502000-00002; SMITH JS, 1985, CIRCULATION, V72, P1015, DOI 10.1161/01.CIR.72.5.1015; TOPOL EJ, 1984, J AM COLL CARDIOL, V4, P1123, DOI 10.1016/S0735-1097(84)80131-X; VONKNORRING J, 1986, SURGERY, V99, P610; WOHLGELERNTER D, 1986, J AM COLL CARDIOL, V7, P1245, DOI 10.1016/S0735-1097(86)80143-7; 1989, PHS891232 DEP HLTH H; 1978, MANUAL OPERATIONS, V2	36	102	105	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 8	1992	268	2					210	216		10.1001/jama.268.2.210	http://dx.doi.org/10.1001/jama.268.2.210			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB279	1608139				2022-12-01	WOS:A1992JB27900027
J	FISHLEDER, AJ				FISHLEDER, AJ			PRENATAL HEMOGLOBINOPATHY SCREENING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											FISHLEDER, AJ (corresponding author), CLEVELAND CLIN EDUC FDN,CLEVELAND,OH 44106, USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 8	1992	268	2					266	266						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB279	1608146				2022-12-01	WOS:A1992JB27900035
J	HOLLENBERG, M; MANGANO, DT; BROWNER, WS; LONDON, MJ; TUBAU, JF; TATEO, IM				HOLLENBERG, M; MANGANO, DT; BROWNER, WS; LONDON, MJ; TUBAU, JF; TATEO, IM			PREDICTORS OF POSTOPERATIVE MYOCARDIAL-ISCHEMIA IN PATIENTS UNDERGOING NONCARDIAC SURGERY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIABETES-MELLITUS; HEART-DISEASE; ANESTHESIA; FRAMINGHAM; RISK; REINFARCTION; INFARCTION; MORBIDITY; ONSET	Objective.-To identify predictors of postoperative myocardial ischemia in patients scheduled to undergo major noncardiac surgery. Design.-Historical, clinical, laboratory, and physiological data were obtained prospectively before and during surgery to identify potential univariate predictors of postoperative myocardial ischemia, which then were entered into multivariate logistic models. Continuous two-lead electrocardiograms before, during, and after surgery were used to identify episodes of myocardial ischemia. Setting.-Department of Veterans Affairs tertiary care hospital. Patients.-A consecutive sample of 474 men at high risk for or with coronary artery disease who were scheduled to undergo major noncardiac surgery (95% compliance rate). Main Outcome Measure.-Significant variables identified by multivariate logistic models that are associated with postoperative myocardial ischemia. Results.-Five major preoperative predictors of postoperative myocardial ischemia were identified: (1) left ventricular hypertrophy by electrocardiogram; (2) history of hypertension; (3) diabetes mellitus; (4) definite coronary artery disease; and (5) use of digoxin. The risk of postoperative myocardial ischemia increased progressively with the number of predictors present: in 22% of patients with no predictors, in 31% with one predictor, in 46% with two predictors, in 70% with three predictors, and in 77% with four predictors. Conclusion.-Patient subgroups who are at high risk for developing postoperative myocardial ischemia and who might benefit the most from intensive Holter monitoring in the postoperative period now can be identified preoperatively.	UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT ANESTHESIA, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT EPIDEMIOL & BIOSTAT, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	HOLLENBERG, M (corresponding author), DEPT VET AFFAIRS MED CTR, 4150 CLEMENT ST 111C3, SAN FRANCISCO, CA 94121 USA.			Tice, Jeffrey/0000-0002-9857-2028	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036744] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL36744] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLACKBURN H, 1960, CIRCULATION, V21, P1160, DOI 10.1161/01.CIR.21.6.1160; CAMPEAU L, 1976, CIRCULATION, V54, P522, DOI 10.1161/circ.54.3.947585; Cox DR, 2018, ANAL BINARY DATA; DORTIMER AC, 1978, CIRCULATION, V57, P133, DOI 10.1161/01.CIR.57.1.133; FOSTER ED, 1986, ANN THORAC SURG, V41, P42, DOI 10.1016/S0003-4975(10)64494-3; GARCIA MJ, 1974, DIABETES, V23, P105, DOI 10.2337/diab.23.2.105; GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601; HOLLENBERG M, 1985, AM J CARDIOL, V56, P13, DOI 10.1016/0002-9149(85)90557-0; HOLLENBERG M, 1986, J AM COLL CARDIOL, V7, pA163; KANNEL W B, 1970, Annals of Internal Medicine, V72, P813; KANNEL WB, 1979, CIRCULATION, V59, P8, DOI 10.1161/01.CIR.59.1.8; KANNEL WB, 1980, CIRCULATION, V61, P1179, DOI 10.1161/01.CIR.61.6.1179; KANNEL WB, 1985, AM HEART J, V110, P1100, DOI 10.1016/0002-8703(85)90224-8; MANGANO DT, 1990, NEW ENGL J MED, V323, P1781, DOI 10.1056/NEJM199012273232601; MANGANO DT, 1990, ANESTHESIOLOGY, V72, P153, DOI 10.1097/00000542-199001000-00025; RAO TLK, 1983, ANESTHESIOLOGY, V59, P499, DOI 10.1097/00000542-198312000-00003; ROMHILT DW, 1968, AM HEART J, V75, P752, DOI 10.1016/0002-8703(68)90035-5; SECHZER PH, 1963, ANESTHESIOLOGY, V24, P779, DOI 10.1097/00000542-196311000-00005; SOKOLOW M, 1949, AM HEART J, V37, P161, DOI 10.1016/0002-8703(49)90562-1; STEEN PA, 1978, JAMA-J AM MED ASSOC, V239, P2566, DOI 10.1001/jama.239.24.2566; STRAUER BE, 1985, J CARDIOVASC PHARM, V7, pS62, DOI 10.1097/00005344-198507002-00013; TARHAN S, 1972, J AMER MED ASSOC, V220, P1451, DOI 10.1001/jama.220.11.1451; VIGORITA VJ, 1980, AM J CARDIOL, V46, P535, DOI 10.1016/0002-9149(80)90500-7; WALLER BF, 1980, AM J MED, V69, P498, DOI 10.1016/S0149-2918(05)80002-5; 1979, NOMENCLATURE CRITERI, P94	25	122	129	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 8	1992	268	2					205	209		10.1001/jama.268.2.205	http://dx.doi.org/10.1001/jama.268.2.205			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB279	1535109				2022-12-01	WOS:A1992JB27900026
J	MANGANO, DT; BROWNER, WS; HOLLENBERG, M; LI, J; TATEO, IM				MANGANO, DT; BROWNER, WS; HOLLENBERG, M; LI, J; TATEO, IM			LONG-TERM CARDIAC PROGNOSIS FOLLOWING NONCARDIAC SURGERY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PERIPHERAL VASCULAR-DISEASE; CORONARY-ARTERY DISEASE; ISCHEMIC-HEART-DISEASE; MYOCARDIAL-INFARCTION; MORTALITY; RISK; INDEX	Objective.-To determine the long-term (2-year) cardiac prognosis of high-risk patients undergoing noncardiac surgery and to determine the predictors of long-term adverse cardiac outcome. Design.-Prospective cohort study. Historical, clinical, and laboratory data were collected during the in-hospital period, and at 6 months, 1 year, and 2 years following surgery. Data were analyzed using proportional hazards models. Setting.-University-affiliated Veterans Affairs medical center. Population.-A consecutive sample of 444 patients with or at high risk for coronary artery disease who had undergone elective noncardiac surgery and were discharged from the hospital in stable condition. Main Outcome Measures.-Cardiac death, myocardial infarction, unstable angina, progressive angina requiring coronary artery bypass graft surgery or coronary angioplasty, and new unstable angina requiring hospitalization. Results.-Forty-seven patients (11%) had major cardiovascular complications during a 728-day (median) follow-up period: 24 had cardiac death; 11, nonfatal myocardial infarction; six, progressive angina requiring coronary artery bypass graft surgery or coronary angioplasty; and six, new unstable angina requiring hospitalization. Thirty percent of outcomes occurred within 6 months of surgery and 64% within 1 year. Five independent predictors of long-term outcome were identified. Three predictors reflected the preexisting chronic disease state: (1) the presence of known vascular disease (hazard ratio, 6.1; 95% confidence interval [CI], 2.5 to 15.0; P<.0001); (2) a history of congestive heart failure (hazard ratio, 5.0; 95% CI, 2.0 to 12.0; P<.0005); and (3) known coronary artery disease (hazard ratio, 3.7; 95% CI, 1.7 to 8.0; P<.0007). Two predictors reflected acute postoperative ischemic events: (1) myocardial infarction/unstable angina (hazard ratio, 20; 95% CI, 7.5 to 53.0; P<.0001) and (2) myocardial ischemia (hazard ratio, 2.2; 95% CI, 1.1 to 4.3; P<.03). Patients surviving a postoperative in-hospital myocardial infarction had a 28-fold increase in the rate of subsequent cardiac complications within 6 months following surgery, a 15-fold increase within 1 year, and a 14-fold increase within 2 years (95% CI, 5.8 to 32; P<.00001). Seventy percent of all long-term adverse outcomes were preceded by in-hospital postoperative ischemia that occurred at least 30 days (median, 282 days) before the long-term event. The development of congestive heart failure or ventricular tachycardia (without ischemia) during hospitalization was not associated with adverse long-term outcome. Conclusions.-The incidence of long-term adverse cardiac outcomes following noncardiac surgery is substantial. At increased risk are patients with chronic cardiovascular disease; at highest risk are patients with acute perioperative ischemic events. We conclude that survivors of in-hospital perioperative ischemic events, specifically myocardial infarction, unstable angina, and postoperative ischemia, warrant more aggressive long-term follow-up and treatment than is currently practiced.	UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143; DEPT VET AFFAIRS MED CTR,SAN FRANCISCO,CA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	MANGANO, DT (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT VET AFFAIRS MED CTR 129,DEPT ANESTHESIA,4150 CLEMENT ST,SAN FRANCISCO,CA 94121, USA.			Tice, Jeffrey/0000-0002-9857-2028	NHLBI NIH HHS [R01-HL36744] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036744] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		USA Pooling Project Research Group, 1978, Journal of Chronic Diseases, V31, P201; ASHBURN WL, 1980, RADIOL CLIN N AM, V18, P467; BIGGER JT, 1984, CIRCULATION, V69, P250, DOI 10.1161/01.CIR.69.2.250; BLACKBURN H, 1960, CIRCULATION, V21, P1160, DOI 10.1161/01.CIR.21.6.1160; BRAUNWALD E, 1984, HEART FAILURE, P1; CHAITMAN BR, 1979, CIRCULATION, V59, P560, DOI 10.1161/01.CIR.59.3.560; CRAWFORD ES, 1981, SURGERY, V90, P1055; DETSKY AS, 1986, ARCH INTERN MED, V146, P2131, DOI 10.1001/archinte.146.11.2131; DIAMOND GA, 1979, NEW ENGL J MED, V300, P1350, DOI 10.1056/NEJM197906143002402; FORSTER ED, 1986, ANN THORAC SURG, V41, P42; GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601; GOTTLIEB SO, 1987, J AM COLL CARDIOL, V10, P156; HARRISON DC, 1985, AM J CARDIOL, V56, pC10, DOI 10.1016/S0002-9149(85)80003-5; HERTZER NR, 1980, ANN SURG, V192, P667; HERTZER NR, 1984, ANN SURG, V199, P223, DOI 10.1097/00000658-198402000-00016; HERTZER NR, 1982, CLEVELAND CLIN Q, V49, P1; HERTZER NR, 1981, ANN SURG, V193, P493; JAMIESON WRE, 1982, CIRCULATION, V66, P92; KANNEL WB, 1984, CIRCULATION, V70, P331, DOI 10.1161/01.CIR.70.3.331; LONDON MJ, 1988, ANESTHESIOLOGY, V69, P232, DOI 10.1097/00000542-198808000-00013; MACKEY WC, 1990, J VASC SURG, V11, P226, DOI 10.1067/mva.1990.17574; MANGANO DT, 1990, ANESTHESIOLOGY, V72, P153, DOI 10.1097/00000542-199001000-00025; MANGANO DT, 1990, NEW ENGL J MED, V323, P1171; MEHTA J, 1985, J LAB CLIN MED, V106, P661; RABY KE, 1990, AM J CARDIOL, V66, P1309, DOI 10.1016/0002-9149(90)91159-4; RABY KE, 1989, NEW ENGL J MED, V321, P1296, DOI 10.1056/NEJM198911093211904; ROCCO MB, 1988, CIRCULATION, V78, P877, DOI 10.1161/01.CIR.78.4.877; SANZ G, 1982, NEW ENGL J MED, V306, P1065, DOI 10.1056/NEJM198205063061801; SEVERI S, 1989, AM J CARDIOL, V64, P889, DOI 10.1016/0002-9149(89)90837-0; SILICIANO D, 1990, OPIOIDS ANESTHESIA, V2, P164; STONE PH, 1986, J AM COLL CARDIOL, V8, P1007, DOI 10.1016/S0735-1097(86)80374-6; TOMATIS LA, 1972, SURGERY, V71, P429; TZIVONI D, 1988, AM J CARDIOL, V62, P661, DOI 10.1016/0002-9149(88)91198-8; UDELSMAN R, 1987, J CLIN ENDOCR METAB, V64, P986, DOI 10.1210/jcem-64-5-986; YOUNIS LT, 1990, AM HEART J, V119, P1287, DOI 10.1016/S0002-8703(05)80177-2; 1989, PHS891232 US DEP HLT; 1978, MANUAL OPERATIONS, V2; 1983, NEW ENGL J MED, V309, P331	38	249	256	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 8	1992	268	2					233	239		10.1001/jama.268.2.233	http://dx.doi.org/10.1001/jama.268.2.233			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB279	1608143				2022-12-01	WOS:A1992JB27900031
J	MOSS, WT				MOSS, WT			CONSERVATIVE SURGERY AND RADIATION FOR INTRADUCTAL BREAST-CARCINOMA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											MOSS, WT (corresponding author), OREGON HLTH SCI UNIV,PORTLAND,OR 97201, USA.							SILVERSTEIN MJ, 1990, CANCER, V66, P102, DOI 10.1002/1097-0142(19900701)66:1<102::AID-CNCR2820660119>3.0.CO;2-5	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 8	1992	268	2					266	266						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB279	1318979				2022-12-01	WOS:A1992JB27900036
J	OKELLY, B; BROWNER, WS; MASSIE, B; TUBAU, J; NGO, L; MANGANO, DT				OKELLY, B; BROWNER, WS; MASSIE, B; TUBAU, J; NGO, L; MANGANO, DT			VENTRICULAR ARRHYTHMIAS IN PATIENTS UNDERGOING NONCARDIAC SURGERY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANTIARRHYTHMIC DRUG-THERAPY; NON-CARDIAC SURGERY; CIGARETTE-SMOKING; RISK; STRESS; INDEX	Objective.-To determine the incidence, clinical predictors and prognostic importance of perioperative ventricular arrhythmias. Design.-Prospective cohort study (Study of Perioperative Ischemia). Setting.-University-affiliated Department of Veterans Affairs Medical Center, San Francisco, Calif. Subjects.-A consecutive sample of 230 male patients, with known coronary artery disease (46%) or at high risk of coronary artery disease (54%), undergoing major noncardiac surgical procedures. Measurements.-We recorded cardiac rhythm throughout the preoperative (mean=21 hours), intraoperative (mean=6 hours), and postoperative (mean=38 hours) periods using continuous ambulatory electrocardiographic monitoring. Adverse cardiac outcomes were noted by physicians blinded to information about arrhythmias. Main Results.-Frequent or major ventricular arrhythmias (>30 ventricular ectopic beats per hour, ventricular tachycardia) occurred in 44% of our patients: 21% preoperatively, 16% intraoperatively, and 36% postoperatively. Compared with the preoperative baseline, the severity of arrhythmia increased in only 2% of patients intraoperatively but in 10% postoperatively. Preoperative ventricular arrhythmias were more common in smokers (odds ratio [OR], 4.1; 95% confidence interval [CI], 1.2 to 15.0), those with a history of congestive heart failure (OR, 4.1; 95% CI, 1.9 to 9.0), and those with electrocardiographic evidence of myocardial ischemia (OR, 2.2; 95% CI, 1. 1 to 4.7). Preoperative arrhythmias were associated with the occurrence of intraoperative and postoperative arrhythmias (OR, 7.3; 95% CI, 3.3 to 16.0, and OR, 6.4; 95% CI, 2.7 to 15.0, respectively). Nonfatal myocardial infarction or cardiac death occurred in nine men; these outcomes were not significantly more frequent in those with prior perioperative arrhythmias, albeit with wide CIs (OR, 1.6; 95% CI, 0.4 to 6.2). Conclusion.-Almost half of all high-risk patients undergoing noncardiac surgery have frequent ventricular ectopic beats or nonsustained ventricular tachycardia. Our results suggest that these arrhythmias, when they occur without other signs or symptoms of myocardial infarction, may not require aggressive monitoring or treatment during the perioperative period.	DEPT VET AFFAIRS MED CTR,DEPT MED,SAN FRANCISCO,CA 94121; DEPT VET AFFAIRS MED CTR,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94121; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143; DEPT VET AFFAIRS MED CTR,DEPT ANESTHESIA,SAN FRANCISCO,CA	University of California System; University of California San Francisco				Tice, Jeffrey/0000-0002-9857-2028	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036744, P01HL025847] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 25847, HL36744] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENOWITZ NL, 1988, NEW ENGL J MED, V319, P1318; BERTRAND CA, 1971, J AMER MED ASSOC, V216, P1615, DOI 10.1001/jama.216.10.1615; BLACKBURN H, 1960, CIRCULATION, V21, P1160, DOI 10.1161/01.CIR.21.6.1160; BRAUNWALD E, 1984, HEART FAILURE, P1; CAMPEAU L, 1976, CIRCULATION, V54, P522, DOI 10.1161/circ.54.3.947585; DAVIS MJE, 1984, AM J CARDIOL, V54, P282, DOI 10.1016/0002-9149(84)90183-8; DETSKY AS, 1986, J GEN INTERN MED, V1, P211, DOI 10.1007/BF02596184; DODD RB, 1962, SURGERY, V51, P440; Goldman L, 1987, J Cardiothorac Anesth, V1, P237, DOI 10.1016/S0888-6296(87)80011-X; GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601; HALLSTROM AP, 1986, NEW ENGL J MED, V314, P271, DOI 10.1056/NEJM198601303140502; HALTER JB, 1977, J CLIN ENDOCR METAB, V45, P936, DOI 10.1210/jcem-45-5-936; HENNEKENS CH, 1980, AM J EPIDEMIOL, V112, P93, DOI 10.1093/oxfordjournals.aje.a112980; HINKLE LE, 1969, AM J CARDIOL, V24, P629, DOI 10.1016/0002-9149(69)90451-2; HOLLIFIELD JW, 1989, AM J CARDIOL, V63, pG22, DOI 10.1016/0002-9149(89)90214-2; JEFFREY CC, 1983, ANESTHESIOLOGY, V58, P462, DOI 10.1097/00000542-198305000-00013; KIMBROUGH HM, 1975, J UROLOGY, V113, P846, DOI 10.1016/S0022-5347(17)59596-8; Kjekshus J, 1990, AM J CARDIOL, V65, P421, DOI DOI 10.1084/JEM.20051151; KNOEBEL SB, 1989, CIRCULATION, V79, P206, DOI 10.1161/01.CIR.79.1.206; KUNER J, 1967, DIS CHEST, V52, P580, DOI 10.1378/chest.52.5.580; LARSEN SF, 1987, EUR HEART J, V8, P179, DOI 10.1093/oxfordjournals.eurheartj.a062246; MANGANO DT, 1991, J AM COLL CARDIOL, V17, P851, DOI 10.1016/0735-1097(91)90864-6; MANGANO DT, 1990, NEW ENGL J MED, V323, P1781, DOI 10.1056/NEJM199012273232601; MANGANO DT, 1990, ANESTHESIOLOGY, V72, P153, DOI 10.1097/00000542-199001000-00025; MANGANO DT, 1991, J AM COLL CARDIOL, V17, P843, DOI 10.1016/0735-1097(91)90863-5; MASSIE B M, 1992, Journal of the American College of Cardiology, V19, p78A; MORGANROTH J, 1987, AM J CARDIOL, V59, pE32, DOI 10.1016/0002-9149(87)90199-8; MYERS MG, 1988, CHEST, V93, P14, DOI 10.1378/chest.93.1.14; NADEMANEE K, 1990, CIRCULATION, V82, P1054, DOI 10.1161/01.CIR.82.3.1054; PODRID PJ, 1989, EUR HEART J, V10, P66, DOI 10.1093/eurheartj/10.suppl_E.66; PRATT CM, 1985, NEW ENGL J MED, V313, P1444, DOI 10.1056/NEJM198512053132304; UDELSMAN R, 1987, J CLIN ENDOCR METAB, V64, P986, DOI 10.1210/jcem-64-5-986; VANIK PE, 1968, ANESTH ANAL CURR RES, V47, P299; 1978, MANUAL OPERATIONS, V2	34	75	77	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 8	1992	268	2					217	221		10.1001/jama.268.2.217	http://dx.doi.org/10.1001/jama.268.2.217			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB279	1608140				2022-12-01	WOS:A1992JB27900028
J	RABY, KE; BARRY, J; CREAGER, MA; COOK, EF; WEISBERG, MC; GOLDMAN, L				RABY, KE; BARRY, J; CREAGER, MA; COOK, EF; WEISBERG, MC; GOLDMAN, L			DETECTION AND SIGNIFICANCE OF INTRAOPERATIVE AND POSTOPERATIVE MYOCARDIAL-ISCHEMIA IN PERIPHERAL VASCULAR-SURGERY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARDIAC RISK; MORTALITY; DISEASE	Objective.-To determine the incidence and significance of intraoperative and postoperative myocardial ischemia and their relationship to preoperative ischemia and postoperative cardiac events in patients undergoing peripheral arterial surgery. Design.-Prospective cohort trial. Patients.-One hundred fifteen patients undergoing elective vascular surgery who met predefined eligibility criteria and were thought to have acceptable cardiac risk as assessed by independent cardiologists. Interventions.-Ambulatory electrocardiographic monitoring preoperatively, intraoperatively, and up to 72 hours postoperatively. Measurements.-Preoperative clinical characteristics and laboratory data were collected. Predefined adverse cardiac events were identified by an investigator who was "blinded" to monitoring results. Monitor recordings were interpreted for ST-segment depression by investigators blinded to patient information. Main Results.-Intraoperative ischemia was present in 21 patients (18%), and postoperative ischemia was present in 35 (30%). There were 16 postoperative cardiac events. The relative risk of suffering a cardiac event was 2.7 in patients with intraoperative ischemia and was 16 in patients with postoperative ischemia. Preoperative ischemia closely correlated with intraoperative and postoperative ischemia. Preoperative and postoperative ischemia preceded cardiac events in 14 of 16 patients. Conclusions.-Preoperative ischemia appears to identify high-risk patients, and subsequent perioperative monitoring detects silent ischemia that commonly precedes clinical events and that may be treatable with anti-ischemia therapy.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV CLIN EPIDEMIOL,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV VASC MED,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	RABY, KE (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV CARDIOVASC,75 FRANCIS ST,BOSTON,MA 02115, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002553, R01HL035295] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL02553-01, R01 HL35295] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARRY J, 1987, AM J CARDIOL, V60, P483, DOI 10.1016/0002-9149(87)90290-6; BOUCHER CA, 1985, NEW ENGL J MED, V312, P389, DOI 10.1056/NEJM198502143120701; DEANFIELD JE, 1983, LANCET, V2, P753; DODDS TM, 1990, 12TH ANN SOC CARD AN; EAGLE KA, 1989, ANN INTERN MED, V110, P859, DOI 10.7326/0003-4819-110-11-859; FLEISHER LA, 1991, AM HEART J, V122, P980, DOI 10.1016/0002-8703(91)90461-P; HERTZER NR, 1984, ANN SURG, V199, P223, DOI 10.1097/00000658-198402000-00016; Hosmer D, 2013, APPL LOGISTIC REGRES; JAMIESON WRE, 1982, CIRCULATION, V66, P92; KENNEDY HL, 1987, AM J CARDIOL, V59, P1190, DOI 10.1016/0002-9149(87)90874-5; LEPPO J, 1987, J AM COLL CARDIOL, V9, P269, DOI 10.1016/S0735-1097(87)80374-1; LEVIN RI, 1988, AM J CARDIOL, V61, pB13; MANGANO DT, 1991, J AM COLL CARDIOL, V17, P851, DOI 10.1016/0735-1097(91)90864-6; MANGANO DT, 1990, NEW ENGL J MED, V323, P1781, DOI 10.1056/NEJM199012273232601; MANGANO DT, 1991, J AM COLL CARDIOL, V17, P843, DOI 10.1016/0735-1097(91)90863-5; MCCANN RL, 1989, J VASC SURG, V9, P583; OUYANG P, 1989, AM J CARDIOL, V64, P1113, DOI 10.1016/0002-9149(89)90862-X; PASTERNACK PF, 1989, J VASC SURG, V10, P617; RABY KE, 1989, NEW ENGL J MED, V321, P1296, DOI 10.1056/NEJM198911093211904; SILICIANO D, 1990, ANESTH ANALG, V70, pS1; TISCHLER M D, 1991, Journal of the American College of Cardiology, V17, p264A; TISCHLER MD, 1991, AM J CARDIOL, V68, P593, DOI 10.1016/0002-9149(91)90349-P	22	166	174	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 8	1992	268	2					222	227		10.1001/jama.268.2.222	http://dx.doi.org/10.1001/jama.268.2.222			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB279	1608141				2022-12-01	WOS:A1992JB27900029
J	CAMERON, D; BISHOP, C; SIBERT, JR				CAMERON, D; BISHOP, C; SIBERT, JR			FARM ACCIDENTS IN CHILDREN	BRITISH MEDICAL JOURNAL			English	Article							INJURIES	Objective-To examine the problem of accidental injury to children on farms. Design-Prospective county based study of children presenting to accident and emergency departments over 12 months with injuries sustained in a farm setting and nationwide review of fatal childhood farm accidents over the four years April 1986 to March 1990. Setting-Accident and emergency departments in Aberystwyth, Carmarthen, Haverfordwest, and Llanelli and fatal accidents in England, Scotland, and Wales notified to the Health and Safety Executive register. Subjects-Children aged under 16. Main outcome measure-Death or injury after farm related accidents. Results-65 accidents were recorded, including 18 fractures. Nine accidents necessitated admission to hospital for a mean of two (range one to four) days. 13 incidents were related to tractors and other machinery; 24 were due to falls. None of these incidents were reported under the statutory notification scheme. 33 deaths were notified, eight related to tractors and allied machinery and 10 related to falling objects. Conclusions-Although safety is improving, the farm remains a dangerous environment for children. Enforcement of existing safety legislation with significant penalties and targeting of safety education will help reduce accident rates further.	UNIV WALES COLL CARDIFF,LANDSDOWNE HOSP,COLL MED,DEPT CHILD HLTH,COMMUNITY HLTH UNIT,CARDIFF CF1 8UL,WALES; UNIV WALES COLL MED,DEPT CHILD HLTH,CARDIFF CF4 4XN,S GLAM,WALES; HLTH & SAFETY EXECUT,EMPLOYMENT MED ADVISORY SERV,CARDIFF,WALES	Cardiff University; Cardiff University								COGBILL TH, 1985, PEDIATRICS, V76, P562; DOYLE Y, 1989, J SOC OCCUP MED, V39, P35; HALLER JA, 1983, JAMA-J AM MED ASSOC, V249, P47, DOI 10.1001/jama.249.1.47; RIVARA FP, 1985, PEDIATRICS, V76, P567; SALMI LR, 1989, PEDIATRICS, V83, P267; SWANSON JA, 1987, AM J DIS CHILD, V141, P1276, DOI 10.1001/archpedi.1987.04460120038029; 1986, LABOUR FORCE REPORT; 1986, AGR BLACK SPOT; 1988, PREVENTING ACCIDENTS; 1988, AGR SAFETY LISTINGS	10	16	16	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 4	1992	305	6844					23	25		10.1136/bmj.305.6844.23	http://dx.doi.org/10.1136/bmj.305.6844.23			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC799	1638192	Bronze, Green Published, Green Submitted			2022-12-01	WOS:A1992JC79900023
J	CAMERON, D; BISHOP, C				CAMERON, D; BISHOP, C			FARM ACCIDENTS IN ADULTS	BRITISH MEDICAL JOURNAL			English	Article											CAMERON, D (corresponding author), BRITISH COLUMBIA CHILDRENS HOSP,NEWBORN SERV,VANCOUVER V6H 3V4,BC,CANADA.							DOYLE Y, 1989, J R SOC HLTH, V4, P128; MAY JJ, 1990, AM J IND MED, V18, P121, DOI 10.1002/ajim.4700180205; 1989, CENSUS 1989; 1986, AGR BLACK SPOT; 1991, 1990 1991 HLTH SAF C	5	4	4	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 4	1992	305	6844					25	26		10.1136/bmj.305.6844.25	http://dx.doi.org/10.1136/bmj.305.6844.25			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC799	1638193	Green Published, Green Submitted, Bronze			2022-12-01	WOS:A1992JC79900024
J	FRANKLYN, JA; BETTERIDGE, J; DAYKIN, J; HOLDER, R; OATES, GD; PARLE, JV; LILLEY, J; HEATH, DA; SHEPPARD, MC				FRANKLYN, JA; BETTERIDGE, J; DAYKIN, J; HOLDER, R; OATES, GD; PARLE, JV; LILLEY, J; HEATH, DA; SHEPPARD, MC			LONG-TERM THYROXINE TREATMENT AND BONE-MINERAL DENSITY	LANCET			English	Article							THYROID-HORMONE; SUBCLINICAL HYPERTHYROIDISM; REPLACEMENT TREATMENT; THERAPY; WOMEN	Studies of the effect of thyroxine replacement therapy on bone mineral density have given conflicting results; the reductions in bone mass reported by some have prompted recommendations that prescribed doses of thyroxine should be reduced. We have examined the effect of long-term thyroxine treatment in a large homogeneous group of patients; all had undergone thyroidectomy for differentiated thyroid cancer but had no history of other thyroid disorders. The 49 patients were matched with controls for age, sex, menopausal status, body mass index, smoking history, and calcium intake score; in all subjects bone mineral density at several femoral and vertebral sites was measured by dual-energy X-ray absorptiometry. Despite long-term thyroxine therapy (mean duration 7.9 [range 1-19] years) at doses (mean 191 [SD 50]mu-g/day) that resulted in higher serum thyroxine and lower serum thyrotropin concentrations than in the controls, the patients showed no evidence of lower bone mineral density than the controls at any site. Nor was bone mineral density correlated with dose, duration of therapy, or cumulative intake, or with tests of thyroid function. There was a decrease in bone density with age in both groups. We suggest that thyroxine alone does not have a significant effect on bone mineral density and hence on risk of osteoporotic fractures.	GEN HOSP,THYROID CLIN,BIRMINGHAM B4 6NH,W MIDLANDS,ENGLAND; UNIV BIRMINGHAM,DEPT MED,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; UNIV BIRMINGHAM,DEPT STAT,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; UNIV BIRMINGHAM,DEPT NUCL MED,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Birmingham; University of Birmingham; University of Birmingham								BARAN DT, 1991, J CLIN ENDOCR METAB, V72, P1182, DOI 10.1210/jcem-72-6-1182; DIAMOND T, 1991, J CLIN ENDOCR METAB, V72, P1184, DOI 10.1210/jcem-72-6-1184; FRANKLYN JA, 1990, BRIT MED J, V300, P693, DOI 10.1136/bmj.300.6726.693; FRANKLYN JA, 1992, TRENDS ENDOCRIN MET, V3, P113, DOI 10.1016/1043-2760(92)90098-L; GREENSPAN SL, 1991, AM J MED, V91, P5, DOI 10.1016/0002-9343(91)90066-7; KROLNER B, 1983, CLIN ENDOCRINOL, V18, P439, DOI 10.1111/j.1365-2265.1983.tb02873.x; KUNG AWC, 1991, JAMA-J AM MED ASSOC, V265, P2688, DOI 10.1001/jama.265.20.2688; Lilley J, 1991, Osteoporos Int, V1, P141, DOI 10.1007/BF01625443; Meunier PJ, 1972, ORTHOPEDIA CLINICS N, V3, P745; PACINI F, 1985, CLIN ENDOCRINOL, V23, P405, DOI 10.1111/j.1365-2265.1985.tb01098.x; PARLE JV, 1991, CLIN ENDOCRINOL, V34, P77; PAUL TL, 1988, JAMA-J AM MED ASSOC, V259, P3137, DOI 10.1001/jama.259.21.3137; PEARCE CJ, 1984, BRIT MED J, V288, P693, DOI 10.1136/bmj.288.6418.693; RIBOT C, 1990, CLIN ENDOCRINOL, V33, P143, DOI 10.1111/j.1365-2265.1990.tb00477.x; ROSS DS, 1989, J CLIN ENDOCR METAB, V69, P684, DOI 10.1210/jcem-69-3-684; ROSS DS, 1987, AM J MED, V82, P1167, DOI 10.1016/0002-9343(87)90219-1; SURKS MI, 1990, JAMA-J AM MED ASSOC, V263, P1529, DOI 10.1001/jama.263.11.1529; TAELMAN P, 1990, CLIN ENDOCRINOL, V33, P107, DOI 10.1111/j.1365-2265.1990.tb00471.x; TOFT AD, 1991, CLIN ENDOCRINOL, V34, P103, DOI 10.1111/j.1365-2265.1991.tb00278.x; TOH SH, 1990, J BONE MINER RES, V5, P463, DOI 10.1002/jbmr.5650050507; TUNBRIDGE WMG, 1977, CLIN ENDOCRINOL, V7, P481, DOI 10.1111/j.1365-2265.1977.tb01340.x; UTIGER RD, 1990, NEW ENGL J MED, V323, P126; VONRECKLINGHAUS.F, 1891, R VIRCHOW FESTSCHRIF, P20; 1990, LANCET, V336, P1352	24	179	186	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 4	1992	340	8810					9	13		10.1016/0140-6736(92)92423-D	http://dx.doi.org/10.1016/0140-6736(92)92423-D			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC354	1351654				2022-12-01	WOS:A1992JC35400003
J	HALL, P; BOICE, JD; BERG, G; BJELKENGREN, G; ERICSSON, UB; HALLQUIST, A; LIDBERG, M; LUNDELL, G; MATTSSON, A; TENNVALL, J; WIKLUND, K; HOLM, LE				HALL, P; BOICE, JD; BERG, G; BJELKENGREN, G; ERICSSON, UB; HALLQUIST, A; LIDBERG, M; LUNDELL, G; MATTSSON, A; TENNVALL, J; WIKLUND, K; HOLM, LE			LEUKEMIA INCIDENCE AFTER I-131 EXPOSURE	LANCET			English	Article							CANCER; MORTALITY; LEUKEMIA; RADIOTHERAPY; I-131; RISK	Leukaemia is one of the most prominent late effects of exposure to ionising radiation. We have studied the incidence of leukaemia among 46 988 Swedish patients exposed to iodine-131 (I-131) for diagnostic reasons or to treat hyperthyroidism or thyroid cancer. The observed number of leukaemias was compared with that expected based on incidence data from the general population. The mean absorbed dose to the bone marrow was estimated as 14 mGy (range 0.01-2.226). 195 leukaemias occurred more than 2 years after exposure, and the standardised incidence ratio (SIR) was 1.09 (95% confidence interval 0.94-1.25). Similar, but again not significantly, increased risks were seen for chronic lymphocytic leukaemia (CLL) (SIR=1.08), a malignant condition not found to be increased after irradiation, and for non-CLL (SIR=1.09). The risk of leukaemia did not vary by sex, age, time, or radiation dose from I-131. One reason for the absence of a radiation effect, other than chance, includes the possible lowering of risk when exposure is protracted over time as occurs with I-131. Excess leukaemia risks of more than 25% could thus be excluded with high assurance in this population of mainly adults. These results should be reassuring to patients exposed to I-131 in medical practice and to most individuals exposed to the fall-out from the Chernobyl accident.	KAROLINSKA HOSP,RADIUM HEMMET,CTR ONCOL,S-10401 STOCKHOLM,SWEDEN; KAROLINSKA HOSP,RADIUM HEMMET,DEPT CANC EPIDEMIOL,S-10401 STOCKHOLM,SWEDEN; KAROLINSKA HOSP,RADIUM HEMMET,DEPT CANC PREVENT,S-10401 STOCKHOLM,SWEDEN; SODER SJUKHUSET,DEPT HOSP PHYS,STOCKHOLM,SWEDEN; NCI,DIV CANC ETIOL,EPIDEMIOL & BIOSTAT PROGRAM,BETHESDA,MD 20892; SAHLGRENS UNIV HOSP,DEPT GEN ONCOL,S-41345 GOTHENBURG,SWEDEN; MALMO GEN HOSP,DEPT GEN ONCOL,S-21401 MALMO,SWEDEN; MALMO GEN HOSP,DEPT INTERNAL MED,S-21401 MALMO,SWEDEN; UMEA UNIV HOSP,DEPT GEN ONCOL,S-90185 UMEA,SWEDEN; UNIV LUND HOSP,DEPT GEN ONCOL,S-22185 LUND,SWEDEN	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Sodersjukhuset Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Sahlgrenska University Hospital; Umea University; Lund University; Skane University Hospital	HALL, P (corresponding author), KAROLINSKA HOSP,RADIUM HEMMET,DEPT GEN ONCOL,S-10401 STOCKHOLM,SWEDEN.		Tennvall, Jan/F-8760-2014		DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [N01CP051034] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CP-51034] Funding Source: Medline	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AITKIN M, 1990, OXFORD STATISTICAL S, V4; [Anonymous], 1988, SOURCES EFFECTS RISK; [Anonymous], 1990, HLTH EFFECTS EXPOSUR; ANSPAUGH LR, 1988, SCIENCE, V242, P1513, DOI 10.1126/science.3201240; BOICE JD, 1987, J NATL CANCER I, V79, P1295; BRINCKER H, 1973, BRIT J CANCER, V28, P232, DOI 10.1038/bjc.1973.142; COLEMAN MP, 1989, IARC89006 INT AG RES; DARBY SC, 1987, BRIT J CANCER, V55, P179, DOI 10.1038/bjc.1987.35; EDMONDS CJ, 1986, BRIT J RADIOL, V59, P45, DOI 10.1259/0007-1285-59-697-45; HALL P, 1991, BRIT J CANCER, V64, P159, DOI 10.1038/bjc.1991.261; HOFFMAN DA, 1984, RAD CARCINOGENESIS E, P273; HOLM LE, 1991, JNCI-J NATL CANCER I, V83, P1072, DOI 10.1093/jnci/83.15.1072; HOLM LE, 1989, JNCI-J NATL CANCER I, V81, P302, DOI 10.1093/jnci/81.4.302; ICRP, 2012, COMP DOS COEFF BAS I, V60, P41; INSKIP PD, 1990, RADIAT RES, V122, P107, DOI 10.2307/3577593; International Committee on Radiological Protection Publication 53, 1988, ANN ICRP, V18; LEWIS CA, 1988, BRIT J RADIOL, V61, P212, DOI 10.1259/0007-1285-61-723-212; MATTSSON B, 1984, ACTA RADIOL ONCOL, V23, P305, DOI 10.3109/02841868409136026; RON E, 1988, AM J EPIDEMIOL, V127, P713, DOI 10.1093/oxfordjournals.aje.a114852; SAENGER EL, 1968, J AMER MED ASSOC, V205, P855, DOI 10.1001/jama.205.12.855; SHIMIZU Y, 1990, RADIAT RES, V121, P120, DOI 10.2307/3577495; SMITH PG, 1981, BRIT J RADIOL, V54, P187, DOI 10.1259/0007-1285-54-639-187; WANG JX, 1990, INT J CANCER, V45, P889, DOI 10.1002/ijc.2910450519; WING S, 1991, JAMA-J AM MED ASSOC, V265, P1397, DOI 10.1001/jama.265.11.1397; 1988, HLTH RISKS RADON OTH, V4	25	95	97	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 4	1992	340	8810					1	4						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC354	1351599				2022-12-01	WOS:A1992JC35400001
J	JUVONEN, T; NIEMELA, O				JUVONEN, T; NIEMELA, O			ABO BLOOD-GROUP AND GALL STONE DISEASE	BRITISH MEDICAL JOURNAL			English	Article									OULU UNIV HOSP,DEPT CLIN CHEM,SF-90220 OULU,FINLAND	University of Oulu	JUVONEN, T (corresponding author), OULU UNIV HOSP,DEPT SURG,SF-90220 OULU,FINLAND.							BEARDMORE JA, 1983, NATURE, V303, P522, DOI 10.1038/303522a0; BUSCH N, 1991, EUR J CLIN INVEST, V21, P453, DOI 10.1111/j.1365-2362.1991.tb01394.x; LEE JS, 1991, NEW ENGL J MED, V324, P1084, DOI 10.1056/NEJM199104183241603; MACLURE KM, 1989, NEW ENGL J MED, V321, P563, DOI 10.1056/NEJM198908313210902; WHINCUP PH, 1990, BMJ-BRIT MED J, V300, P1679, DOI 10.1136/bmj.300.6741.1679	5	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 4	1992	305	6844					26	27		10.1136/bmj.305.6844.26	http://dx.doi.org/10.1136/bmj.305.6844.26			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC799	1489401	Bronze, Green Published, Green Submitted			2022-12-01	WOS:A1992JC79900025
J	MORCOS, SK; ELNAHAS, AM; BROWN, P; HAYLOR, J				MORCOS, SK; ELNAHAS, AM; BROWN, P; HAYLOR, J			EFFECT OF IODINATED WATER-SOLUBLE CONTRAST-MEDIA ON URINARY PROTEIN ASSAYS	BRITISH MEDICAL JOURNAL			English	Letter							TESTS				MORCOS, SK (corresponding author), NO GEN HOSP,SHEFFIELD S5 7AU,S YORKSHIRE,ENGLAND.							DAWSON P, 1985, BRIT J RADIOL, V58, P785, DOI 10.1259/0007-1285-58-692-785-b; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mutzel W, 1989, Fortschr Geb Rontgenstrahlen Nuklearmed Erganzungsbd, V128, P101; SHANAHAN JC, 1985, BRIT J RADIOL, V58, P389, DOI 10.1259/0007-1285-58-688-389-b	4	13	14	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 4	1992	305	6844					29	29		10.1136/bmj.305.6844.29-a	http://dx.doi.org/10.1136/bmj.305.6844.29-a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC799	1638196	Green Published, Bronze, Green Submitted			2022-12-01	WOS:A1992JC79900029
J	OFFERHAUS, GJA; TERSMETTE, AC; GIARDIELLO, FM; HUIBREGTSE, K; VANDENBROUCKE, JP; TYTGAT, GNJ				OFFERHAUS, GJA; TERSMETTE, AC; GIARDIELLO, FM; HUIBREGTSE, K; VANDENBROUCKE, JP; TYTGAT, GNJ			EVALUATION OF ENDOSCOPY FOR EARLY DETECTION OF GASTRIC-STUMP CANCER	LANCET			English	Article							SURGERY; LESIONS; COHORT	The value of endoscopic surveillance of postgastrectomy patients for the early detection of gastric-stump cancer is controversial. Using data from an Amsterdam postgastrectomy cohort of 2633 patients, we have done a retrospective analysis of the effect on mortality from gastric cancer of endoscopic surveillance in these patients. Between 1976 and 1982, 504 symptom-free patients from the Amsterdam cohort participated in an endoscopic surveillance programme. All patients were followed up until 1988. Relative to the general Dutch population, risk of death from gastric cancer was less among patients who took part in surveillance than among those who did not participate. However, differences were small and similar differences existed for risk of death from lung and colorectal cancers, suggesting the presence of selection. Our study seems to confirm that large-scale surveillance of postgastrectomy patients is not justified.	UNIV AMSTERDAM,ACAD MED CTR,DEPT GASTROENTEROL,1105 AZ AMSTERDAM,NETHERLANDS; LEIDEN UNIV HOSP,DEPT CLIN EPIDEMIOL,2333 AA LEIDEN,NETHERLANDS; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205	University of Amsterdam; Academic Medical Center Amsterdam; Leiden University; Leiden University Medical Center (LUMC); Johns Hopkins University	OFFERHAUS, GJA (corresponding author), UNIV AMSTERDAM,ACAD MED CTR,DEPT PATHOL,MEIBERGDREEF 9,1105 AZ AMSTERDAM,NETHERLANDS.		Vandenbroucke, Jan/AAM-3928-2020	Vandenbroucke, Jan/0000-0001-5668-6716				CAYGILL CPJ, 1986, LANCET, V1, P929; COLE P, 1980, JNCI-J NATL CANCER I, V64, P1263; COLEMAN M, 1986, INT J EPIDEMIOL, V15, P134, DOI 10.1093/ije/15.1.134; CRAANEN ME, 1991, DIGEST DIS SCI, V36, P1529, DOI 10.1007/BF01296393; LOGAN RFA, 1983, LANCET, V2, P667; OFFERHAUS GJA, 1989, CANCER, V64, P698, DOI 10.1002/1097-0142(19890801)64:3<698::AID-CNCR2820640322>3.0.CO;2-D; SAVALGI RS, 1990, LANCET, V336, P413, DOI 10.1016/0140-6736(90)91954-9; SCHUMAN BM, 1986, GASTROINTEST ENDOSC, V32, P117, DOI 10.1016/S0016-5107(86)71773-2; SONNENBERG A, 1984, GASTROENTEROLOGY, V87, P489; TERSMETTE AC, 1991, AM J EPIDEMIOL, V134, P14, DOI 10.1093/oxfordjournals.aje.a115988; TERSMETTE AC, 1991, GASTROENTEROLOGY, V101, P148, DOI 10.1016/0016-5085(91)90471-V	11	29	29	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 4	1992	340	8810					33	35		10.1016/0140-6736(92)92433-G	http://dx.doi.org/10.1016/0140-6736(92)92433-G			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC354	1351609				2022-12-01	WOS:A1992JC35400013
J	PALERMO, G; JORIS, H; DEVROEY, P; VANSTEIRTEGHEM, AC				PALERMO, G; JORIS, H; DEVROEY, P; VANSTEIRTEGHEM, AC			PREGNANCIES AFTER INTRACYTOPLASMIC INJECTION OF SINGLE SPERMATOZOON INTO AN OOCYTE	LANCET			English	Note							EMBRYOS; SPERM; ZONA	Intracytoplasmic sperm injection (ICSI) is a promising assisted-fertilisation technique that may benefit women who have not become pregnant by in-vitro fertilisation (IVF) or subzonal insemination (SUZI) of oocytes. We have used ICSI to treat couples with infertility because of severely impaired sperm characteristics, and in whom IVF and SUZI had failed. Direct injection of a single spermatozoon into the ooplasm was done in 47 metaphase-II oocytes: 38 oocytes remained intact after injection, 31 became fertilised, and 15 embryos were replaced in utero. Four pregnancies occurred after eight treatment cycles-two singleton and one twin pregnancy, and a preclinical abortion. Two healthy boys have been delivered from the singleton pregnancies and a healthy boy and girl from the twin pregnancy.			PALERMO, G (corresponding author), VRIJE UNIV BRUSSELS,ACAD ZIEKENHUIS,CTR REPROD MED,LAARBEEKLAAN 101,B-1090 BRUSSELS,BELGIUM.							COHEN J, 1988, LANCET, V2, P162; IRITANI A, 1991, MOL REPROD DEV, V28, P199, DOI 10.1002/mrd.1080280214; LANZENDORF SE, 1988, FERTIL STERIL, V49, P835; NG SC, 1991, FERTIL STERIL, V56, P1117; NG SC, 1988, LANCET, V2, P790; PALERMO G, 1991, MOL REPROD DEV, V30, P339, DOI 10.1002/mrd.1080300408; PALERMO G, 1992, HUM REPROD, V7, P248, DOI 10.1093/oxfordjournals.humrep.a137626; VANSTEIRTEGHEM AC, 1987, HUM REPROD, V2, P593, DOI 10.1093/oxfordjournals.humrep.a136595; VEECK LL, 1990, 45TH P ANN M AM FERT	9	2445	2586	6	128	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 4	1992	340	8810					17	18		10.1016/0140-6736(92)92425-F	http://dx.doi.org/10.1016/0140-6736(92)92425-F			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC354	1351601				2022-12-01	WOS:A1992JC35400005
J	RAVNSKOV, U				RAVNSKOV, U			CHOLESTEROL LOWERING TRIALS IN CORONARY HEART-DISEASE - FREQUENCY OF CITATION AND OUTCOME	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MIDDLE-AGED MEN; MYOCARDIAL-INFARCTION; PRIMARY-PREVENTION; RANDOMIZED TRIALS; MORTALITY; DIET; RISK; REDUCTION	Objective-To see if the claim that lowering cholesterol values prevents coronary heart disease is true or if it is based on citation of supportive trials only. Design-Comparison of frequency of citation with outcome of all controlled cholesterol lowering trials using coronary heart disease or death, or both, as end point. Subjects-22 controlled cholesterol lowering trials. Results-Trials considered by their directors as supportive of the contention were cited almost six times more often than others, according to Science Citation Index. Apart from trials discontinued because of alleged side effects of treatment, unsupportive trials were not cited after 1970, although their number almost equalled the number considered supportive. In three supportive reviews the outcome of the selected trials was more favourable than the outcome of the excluded and ignored trials. In the 22 controlled cholesterol lowering trials studied total and coronary heart disease mortality was not changed significantly either overall or in any subgroup. A statistically significant 0-32% reduction in non-fatal coronary heart disease seemed to be due to bias as event frequencies were unrelated to trial length and to mean net reduction in cholesterol value; individual changes in cholesterol values were unsystematically or not related to outcome; and after correction for a small but significant increase in non-medical deaths in the intervention groups total mortality remained unchanged (odds ratio 1.02). Conclusion-Lowering serum cholesterol concentrations does not reduce mortality and is unlikely to prevent coronary heart disease. Claims of the opposite are based on preferential citation of supportive trials.										[Anonymous], 1965, LANCET, V2, P501; [Anonymous], 1968, LANCET, V2, P693; [Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P360; CANNER PL, 1986, J AM COLL CARDIOL, V8, P1245, DOI 10.1016/S0735-1097(86)80293-5; CARLSON LA, 1988, ACTA MED SCAND, V223, P405; DAYTON S, 1969, CIRCULATION       S2, V40, P1; DORR AE, 1978, J CHRON DIS, V31, P5, DOI 10.1016/0021-9681(78)90076-0; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; FRANTZ ID, 1989, ARTERIOSCLEROSIS, V9, P129, DOI 10.1161/01.ATV.9.1.129; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; HEADY JA, 1980, LANCET, V2, P379; HJERMANN I, 1981, LANCET, V2, P1303; HOLME I, 1990, CIRCULATION, V82, P1916, DOI 10.1161/01.CIR.82.6.1916; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; LAROSA JC, 1990, CIRCULATION, V81, P1721, DOI 10.1161/01.CIR.81.5.1721; LEREN P, 1966, ACTA MED SCAND, V446, P1; MARMORSTON J, 1962, P SOC EXP BIOL MED, V110, P400; MCCORMICK J, 1988, LANCET, V2, P839; MIETTINEN TA, 1985, JAMA-J AM MED ASSOC, V254, P2097, DOI 10.1001/jama.254.15.2097; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; OLIVER M F, 1978, British Heart Journal, V40, P1069, DOI 10.1136/hrt.40.10.1069; OLIVER MF, 1992, BMJ-BRIT MED J, V304, P393, DOI 10.1136/bmj.304.6824.393; OLIVER MF, 1961, LANCET, V2, P499; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; ROSE G, 1986, LANCET, V1, P869; ROSE GA, 1965, BMJ-BRIT MED J, V1, P1531, DOI 10.1136/bmj.1.5449.1531; ROSSOUW JE, 1990, NEW ENGL J MED, V323, P1112, DOI 10.1056/NEJM199010183231606; SMITH GD, 1992, BMJ-BRIT MED J, V304, P431, DOI 10.1136/bmj.304.6824.431; Smith RL, 1989, AM CLIN LAB, P26; STAMLER J, 1963, JAMA-J AM MED ASSOC, V183, P632; STEHBENS WE, 1989, NUTR REV, V47, P1, DOI 10.1111/j.1753-4887.1989.tb02743.x; The Coronary Drug Project, 1973, JAMA-J AM MED ASSOC, V226, P652; Woodhill J M, 1978, Adv Exp Med Biol, V109, P317; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; ZARLING EJ, 1983, JAMA-J AM MED ASSOC, V250, P1177; 1971, BMJ, V4, P775; 1971, BMJ, V4, P767; 1972, JAMA-J AM MED ASSOC, V220, P996; 1970, JAMA-J AM MED ASSOC, V214, P1303	40	253	252	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 4	1992	305	6844					15	19		10.1136/bmj.305.6844.15	http://dx.doi.org/10.1136/bmj.305.6844.15			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC799	1638188	Green Published, Bronze, Green Submitted			2022-12-01	WOS:A1992JC79900021
J	SWERDLOW, DL; MINTZ, ED; RODRIGUEZ, M; TEJADA, E; OCAMPO, C; ESPEJO, L; GREENE, KD; SALDANA, W; SEMINARIO, L; TAUXE, RV; WELLS, JG; BEAN, NH; RIES, AA; POLLACK, M; VERTIZ, B; BLAKE, PA				SWERDLOW, DL; MINTZ, ED; RODRIGUEZ, M; TEJADA, E; OCAMPO, C; ESPEJO, L; GREENE, KD; SALDANA, W; SEMINARIO, L; TAUXE, RV; WELLS, JG; BEAN, NH; RIES, AA; POLLACK, M; VERTIZ, B; BLAKE, PA			WATERBORNE TRANSMISSION OF EPIDEMIC CHOLERA IN TRUJILLO, PERU - LESSONS FOR A CONTINENT AT RISK	LANCET			English	Article							BIOTYPE EL-TOR; VIBRIO-CHOLERAE; UNITED-STATES; SLUMS	The epidemic of cholera that began in Peru in January, 1991, marked the first such epidemic in South America this century. Subsequently, over 533 000 cases and 4700 deaths have been reported from nineteen countries in that hemisphere. We investigated the epidemic in Trujillo, the second largest city in Peru. Trujillo's water supply was unchlorinated and water contamination was common. Suspect cholera cases were defined as persons presenting to a health facility with acute diarrhoea between Feb 1, and March 31, 1991. We studied a cohort of 150 patients who had been admitted to hospital and conducted a matched case-control study with 46 cases and 65 symptom-free and serologically uninfected controls; we also carried out a water quality study. By March 31, 1991, 16 400 cases of suspected cholera (attack rate 2.6%), 6673 hospital admissions, and 71 deaths (case-fatality rate 0.4%) had been reported in the province of Trujillo. 79% of stool cultures of patients with diarrhoea presenting to a single hospital yielded Vibrio cholerae O1. In the case-control study, drinking unboiled water (odds ratio [OR] 3.1, 95% confidence interval [CI] 1.3-7.3), drinking water from a household water storage container in which hands had been introduced into the water (4.2, 1.2-14.9), and going to a fiesta (social event) (3.6, 1.1-11.1) were associated with illness. The water quality study showed progressive contamination during distribution and storage in the home: faecal coliform counts were highest in water from household storage containers and lowest in city well water. V cholerae 01, biotype El Tor, serotype Inaba, was isolated from three city water samples. Cholera control measures in Trujillo should focus on treatment of water and prevention of contamination during distribution and in the home. Trujillo's water and sanitation problems are common in South America; similar control measures are needed throughout the continent to prevent spread of epidemic cholera.	CTR DIS CONTROL,EPIDEMIOL PROGRAM OFF,DIV FIELD EPIDEMIOL,ATLANTA,GA 30333; UNIDADE DEPT SALUD,TRUJILLO,PERU; NATL UNIV TRUJILLO,TRUJILLO,PERU; MINIST HLTH,GEN OFF EPIDEMIOL,LIMA,PERU; HOSP BELEN,TRUJILLO,PERU	Centers for Disease Control & Prevention - USA; Universidad Nacional de Trujillo	SWERDLOW, DL (corresponding author), CTR DIS CONTROL,NATL CTR INFECT DIS,DIV BACTERIAL & MYCOT DIS,ENTER DIS BRANCH,ATLANTA,GA 30333, USA.							[Anonymous], 1989, STANDARD METHODS EXA, V17th; BARRETT TJ, 1981, J CLIN MICROBIOL, V13, P126, DOI 10.1128/JCM.13.1.126-129.1981; BARRY AL, 1985, MANUAL CLIN MICROBIO, P878; BLAKE PA, 1980, NEW ENGL J MED, V302, P305, DOI 10.1056/NEJM198002073020601; CLEMENTS ML, 1982, J INFECT DIS, V145, P465, DOI 10.1093/infdis/145.4.465; COHEN J, 1971, LANCET, V2, P86; DEB BC, 1986, B WORLD HEALTH ORGAN, V64, P127; DEB BC, 1982, INDIAN J MED RES, V76, P814; Feachem R, 1981, Trop Dis Bull, V78, P865; GERICHTER CB, 1975, ISRAEL J MED SCI, V11, P889; HARRIS JR, 1986, AM J EPIDEMIOL, V123, P424, DOI 10.1093/oxfordjournals.aje.a114257; KOLVIN JL, 1982, J HYG-CAMBRIDGE, V89, P243, DOI 10.1017/S0022172400070777; PAVIA AT, 1987, JAMA-J AM MED ASSOC, V258, P2374, DOI 10.1001/jama.1987.03400170060012; RICE EW, 1991, LANCET, V338, P455, DOI 10.1016/0140-6736(91)91086-A; ROBINS J, 1986, AM J EPIDEMIOL, V124, P719, DOI 10.1093/oxfordjournals.aje.a114447; SACK DA, 1980, J CLIN MICROBIOL, V11, P35, DOI 10.1128/JCM.11.1.35-40.1980; SNYDER JD, 1981, J INFECT DIS, V143, P182, DOI 10.1093/infdis/143.2.182; SPIRA WM, 1981, APPL ENVIRON MICROB, V42, P730, DOI 10.1128/AEM.42.4.730-733.1981; STLOUIS ME, 1990, AM J EPIDEMIOL, V13, P719; WACHSMUTH IK, 1991, LANCET, V337, P1097; YOUNG CR, 1986, MANUAL CLIN LABORATO, P363; 1991, MMWR, V40, P108; 1991, MMWR, V40, P287; 1991, MMWR, V40, P516; 1991, MMWR, V40, P860	25	156	159	0	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 4	1992	340	8810					28	32		10.1016/0140-6736(92)92432-F	http://dx.doi.org/10.1016/0140-6736(92)92432-F			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC354	1351608				2022-12-01	WOS:A1992JC35400012
J	WALD, N; STONE, R; CUCKLE, HS; GRUDZINSKAS, JG; BARKAI, G; BRAMBATI, B; TEISNER, B; FUHRMANN, W				WALD, N; STONE, R; CUCKLE, HS; GRUDZINSKAS, JG; BARKAI, G; BRAMBATI, B; TEISNER, B; FUHRMANN, W			1ST TRIMESTER CONCENTRATIONS OF PREGNANCY ASSOCIATED PLASMA PROTEIN-A AND PLACENTAL PROTEIN-14 IN DOWNS-SYNDROME	BRITISH MEDICAL JOURNAL			English	Article									UNIV LEEDS,DEPT CLIN MED,INST EPIDEMIOL & HLTH SERV,LEEDS LS2 9LN,W YORKSHIRE,ENGLAND; ROYAL LONDON HOSP,DEPT OBSTET & GYNAECOL,LONDON,ENGLAND; CHAIM SHEBA MED CTR,INST HUMAN GENET,DEPT OBSTET & GYNECOL,IL-52621 TEL HASHOMER,ISRAEL; UNIV MILAN,IST OSTETR GINECOLOG L MANGIAGALLI,CLIN 2,PRENATAL DIAG UNIT,I-20122 MILAN,ITALY; STATENS SERUM INST,DIV IMMUNOL,DK-2300 COPENHAGEN,DENMARK; UNIV GIESSEN,INST HUMAN GENET,W-6300 GIESSEN,GERMANY	University of Leeds; Barts Health NHS Trust; Royal London Hospital; Chaim Sheba Medical Center; University of Milan; Statens Serum Institut; Justus Liebig University Giessen	WALD, N (corresponding author), ST BARTHOLOMEWS HOSP,COLL MED,WOLFSON INST PREVENT MED,DEPT ENVIRONM & PREVENT MED,LONDON EC1A 7BE,ENGLAND.		Wald, Nicholas/AAY-2814-2021; Wald, Nicholas/AAY-8924-2021					Brambati B., 1990, EMBRYO NORMAL ABNORM, P181; CUCKLE HS, 1988, LANCET, V2, P851	2	101	109	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 4	1992	305	6844					28	28		10.1136/bmj.305.6844.28	http://dx.doi.org/10.1136/bmj.305.6844.28			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC799	1379094	Bronze, Green Submitted, Green Published			2022-12-01	WOS:A1992JC79900027
J	WARKENTIN, TE; MOORE, JC; MORGAN, DG				WARKENTIN, TE; MOORE, JC; MORGAN, DG			AORTIC-STENOSIS AND BLEEDING GASTROINTESTINAL ANGIODYSPLASIA - IS ACQUIRED VONWILLEBRANDS DISEASE THE LINK	LANCET			English	Article							INDUCED PLATELET-AGGREGATION; VASCULAR ECTASIAS; PLASMA; MULTIMERS; DEFECTS	An association between aortic stenosis and haemorrhage from gastrointestinal angiodysplasia has been recognised for many years, but no explanation for this link has been found. Remarkably, aortic valve replacement, rather than bowel resection, corrects the bleeding. Aortic stenosis can be complicated by acquired von Willebrand's disease type II(A) (vWD-II(A)), which is corrected after valve replacement, and gastrointestinal angiodysplasia is a common site of bleeding in older patients with acquired or congenital vWD. Could the stenotic aortic valve lead to an acquired, reversible deficiency of the largest multimers of plasma von Willebrand factor (equivalent to vWD-II(A)) and thus explain the association with gastrointestinal haemorrhage?	HAMILTON CIVIC HOSP, HENDERSON DIV, DEPT MED, HAMILTON, ONTARIO, CANADA; MCMASTER UNIV, MED CTR, DEPT PATHOL, HAMILTON L8S 4L8, ONTARIO, CANADA	McMaster University; McMaster University	WARKENTIN, TE (corresponding author), HAMILTON CIVIC HOSP, DIV GEN, DEPT LAB MED, 237 BARTON ST E, HAMILTON L8L 2X2, ONTARIO, CANADA.							ALAM M, 1991, AM HEART J, V121, P608, DOI 10.1016/0002-8703(91)90739-5; BANERJEE AK, 1990, BRIT J CLIN PRACT, V44, P326; BOLEY SJ, 1977, GASTROENTEROLOGY, V72, P650; CAPPELL MS, 1986, ANN INTERN MED, V105, P54, DOI 10.7326/0003-4819-105-1-54; GILL JC, 1986, BLOOD, V67, P758; GOLDSMITH HL, 1986, THROMB HAEMOSTASIS, V55, P415; GRALNICK HR, 1988, AM J MED, V85, P806; GREENSTEIN RJ, 1986, AM J SURG, V151, P347, DOI 10.1016/0002-9610(86)90465-4; HEYDE EC, 1958, NEW ENGL J MED, V259, P196; KING RM, 1987, ANN THORAC SURG, V44, P514, DOI 10.1016/S0003-4975(10)62112-1; MARCUARD SP, 1988, J CLIN GASTROENTEROL, V10, P482, DOI 10.1097/00004836-198810000-00003; MATHUSVLIEGEN EMH, 1989, INT J COLORECTAL DIS, V4, P20, DOI 10.1007/BF01648545; MOAKE JL, 1986, J CLIN INVEST, V78, P1456, DOI 10.1172/JCI112736; OBRIEN JR, 1990, LANCET, V335, P711, DOI 10.1016/0140-6736(90)90815-M; RAMSAY DM, 1976, LANCET, V2, P275; ROSBOROUGH TK, 1978, AM J MED, V65, P96, DOI 10.1016/0002-9343(78)90698-8; RUGGERI ZM, 1980, J CLIN INVEST, V65, P1318, DOI 10.1172/JCI109795; STEWART AK, 1990, POSTGRAD MED J, V66, P560, DOI 10.1136/pgmj.66.777.560; WEINSTEIN M, 1988, BLOOD, V71, P1648, DOI 10.1182/blood.V71.6.1648.1648; WEISS HJ, 1989, J CLIN INVEST, V83, P288, DOI 10.1172/JCI113871; WOODLOCK TJ, 1988, AM J HEMATOL, V27, P125, DOI 10.1002/ajh.2830270211	21	208	217	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 4	1992	340	8810					35	37		10.1016/0140-6736(92)92434-H	http://dx.doi.org/10.1016/0140-6736(92)92434-H			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC354	1351610				2022-12-01	WOS:A1992JC35400014
J	AGY, MB; FRUMKIN, LR; COREY, L; COOMBS, RW; WOLINSKY, SM; KOEHLER, J; MORTON, WR; KATZE, MG				AGY, MB; FRUMKIN, LR; COREY, L; COOMBS, RW; WOLINSKY, SM; KOEHLER, J; MORTON, WR; KATZE, MG			INFECTION OF MACACA-NEMESTRINA BY HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1	SCIENCE			English	Article							PERSISTENT INFECTION; RHESUS-MONKEYS; HIV INFECTION; MOLECULAR CLONE; CD4 RECEPTOR; T-CELL; AIDS; CHIMPANZEES; MACAQUES; RETROVIRUSES	After observations that Macaca nemestrina were exceptionally susceptible to simian immunodeficiency virus and human immunodeficiency virus type-2 (HIV-2), studies of HIV-1 replication were initiated. Several strains of HIV-1, including a recent patient isolate, replicated in vitro in peripheral blood mononuclear cells (PBMCs) and in CD4-positive M. nemestrina lymphocytes in a CD4-dependent fashion. Eight animals were subsequently inoculated with either cell-associated or cell-free suspensions of HIV-1. All animals had HIV-1 isolated by cocultivation, had HIV-1 DNA in their PBMCs as shown by polymerase chain reaction, and experienced sustained seroconversion to a broad spectrum of HIV-1 proteins. Macaca nemestrina is an animal model of HIV-1 infections that provides opportunities for evaluating the pathogenesis of acute HIV-1 replication and candidate vaccines and therapies.	UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT LAB MED,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MICROBIOL,SEATTLE,WA 98195; UNIV WASHINGTON,REG PRIMATE RES CTR,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOL STRUCT,SEATTLE,WA 98195; NORTHWESTERN UNIV,DEPT MED,CHICAGO,IL 60611	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Northwestern University			Corey, Lawrence/AAE-1796-2020; Wolinsky, Steven/B-2893-2012	Corey, Lawrence/0000-0002-2179-2436; Wolinsky, Steven/0000-0002-9625-6697	NCRR NIH HHS [RR00166] Funding Source: Medline; NIAID NIH HHS [AI27757, AI26503] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000166] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027757] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; AGY MB, 1990, VIROLOGY, V177, P251, DOI 10.1016/0042-6822(90)90478-A; AGY MB, 1991, VIROLOGY, V183, P170, DOI 10.1016/0042-6822(91)90130-4; AGY MB, UNPUB; ALTER HJ, 1984, SCIENCE, V226, P549, DOI 10.1126/science.6093251; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BENVENISTE RE, 1986, J VIROL, V60, P483, DOI 10.1128/JVI.60.2.483-490.1986; BENVENISTE RE, 1988, J VIROL, V62, P2091, DOI 10.1128/JVI.62.6.2091-2101.1988; CASTRO BA, 1991, VIROLOGY, V184, P219, DOI 10.1016/0042-6822(91)90838-3; CHAFFEE S, 1988, J EXP MED, V168, P605, DOI 10.1084/jem.168.2.605; CHALIFOUX LV, 1987, AM J PATHOL, V128, P104; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; DEEN KC, 1988, NATURE, V331, P82, DOI 10.1038/331082a0; DEMATO JJ, 1988, LAB MED, V19, P753; DORMONT D, 1989, INTERVIROLOGY, V30, P59, DOI 10.1159/000150125; EHRNST A, 1988, J MED VIROL, V26, P23, DOI 10.1002/jmv.1890260105; FISHER RA, 1988, NATURE, V331, P76, DOI 10.1038/331076a0; FRANCHINI G, 1990, J VIROL, V64, P4462, DOI 10.1128/JVI.64.9.4462-4467.1990; FULTZ PN, 1986, J VIROL, V58, P116, DOI 10.1128/JVI.58.1.116-124.1986; FULTZ PN, 1989, AIDS RES HUM RETROV, V5, P397, DOI 10.1089/aid.1989.5.397; FURTADO MR, 1991, VIROLOGY, V185, P258, DOI 10.1016/0042-6822(91)90773-5; GAJDUSEK DC, 1985, LANCET, V1, P55; GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936; GARDNER MB, 1989, FASEB J, V3, P2593, DOI 10.1096/fasebj.3.14.2556312; HU SL, 1992, SCIENCE, V255, P456, DOI 10.1126/science.1531159; KESTLER H, 1990, SCIENCE, V248, P1109, DOI 10.1126/science.2160735; KINNEYTHOMAS E, 1988, AIDS, V2, P25; KOEHLER JA, UNPUB; KOYANAGI Y, 1987, SCIENCE, V236, P819, DOI 10.1126/science.3646751; Kraiselburd E N, 1990, P R Health Sci J, V9, P161; LEVY JA, 1985, VIROLOGY, V147, P441, DOI 10.1016/0042-6822(85)90146-1; LEVY JA, 1984, SCIENCE, V225, P840, DOI 10.1126/science.6206563; LINSLEY PS, 1988, J VIROL, V62, P3695, DOI 10.1128/JVI.62.10.3695-3702.1988; LUSSO P, 1988, J IMMUNOL, V141, P2467; MCCLURE MO, 1987, NATURE, V330, P487, DOI 10.1038/330487a0; MORROW WJW, 1989, AIDS RES HUM RETROV, V5, P233, DOI 10.1089/aid.1989.5.233; MORTON WR, UNPUB; NAIDU YM, 1988, J VIROL, V62, P4691, DOI 10.1128/JVI.62.12.4691-4696.1988; NARA P, 1989, J MED PRIMATOL, V18, P343; NARA PL, 1987, J VIROL, V61, P3173, DOI 10.1128/JVI.61.10.3173-3180.1987; NICOL I, 1989, INTERVIROLOGY, V30, P258, DOI 10.1159/000150101; SALAHUDDIN SZ, 1983, VIROLOGY, V129, P51, DOI 10.1016/0042-6822(83)90395-1; SCHNEIDER J, 1988, AIDS, V2, P1, DOI 10.1097/00002030-198802000-00001; STAHLHENNIG C, 1990, AIDS, V4, P611, DOI 10.1097/00002030-199007000-00001; TRAUNECKER A, 1988, NATURE, V331, P84, DOI 10.1038/331084a0; WAINHOBSON S, 1991, SCIENCE, V252, P961, DOI 10.1126/science.2035026; WHETSELL AJ, 1992, J CLIN MICROBIOL, V30, P845, DOI 10.1128/JCM.30.4.845-853.1992	47	161	172	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 3	1992	257	5066					103	106		10.1126/science.1621083	http://dx.doi.org/10.1126/science.1621083			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC165	1621083				2022-12-01	WOS:A1992JC16500041
J	JAMES, AA				JAMES, AA			MOSQUITO MOLECULAR-GENETICS - THE HANDS THAT FEED BITE BACK	SCIENCE			English	Editorial Material							ANOPHELES-GAMBIAE COMPLEX				JAMES, AA (corresponding author), UNIV CALIF IRVINE,DEPT MOLEC BIOL & BIOCHEM,IRVINE,CA 92717, USA.			James, Anthony/0000-0001-5577-3308				COLUZZI M, 1977, NATURE, V266, P832, DOI 10.1038/266832a0; CRAMPTON JM, 1990, MOL INSECT SCI; GOLIC KG, 1989, CELL, V59, P499, DOI 10.1016/0092-8674(89)90033-0; KAUFMAN PD, 1991, NUCLEIC ACIDS RES, V19, P6336, DOI 10.1093/nar/19.22.6336; MORRIS AC, 1991, NUCLEIC ACIDS RES, V19, P5895, DOI 10.1093/nar/19.21.5895; PASKEWITZ SM, 1990, MED VET ENTOMOL, V4, P367, DOI 10.1111/j.1365-2915.1990.tb00453.x; ZHENG LB, 1991, P NATL ACAD SCI USA, V88, P11187, DOI 10.1073/pnas.88.24.11187; 1991, MOSQUITO MOL GENETIC	8	114	119	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 3	1992	257	5066					37	38		10.1126/science.1352413	http://dx.doi.org/10.1126/science.1352413			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC165	1352413				2022-12-01	WOS:A1992JC16500023
J	JILKA, RL; HANGOC, G; GIRASOLE, G; PASSERI, G; WILLIAMS, DC; ABRAMS, JS; BOYCE, B; BROXMEYER, H; MANOLAGAS, SC				JILKA, RL; HANGOC, G; GIRASOLE, G; PASSERI, G; WILLIAMS, DC; ABRAMS, JS; BOYCE, B; BROXMEYER, H; MANOLAGAS, SC			INCREASED OSTEOCLAST DEVELOPMENT AFTER ESTROGEN LOSS - MEDIATION BY INTERLEUKIN-6	SCIENCE			English	Article							POSTMENOPAUSAL OSTEOPOROSIS; CALCITONIN RECEPTORS; PARATHYROID-HORMONE; OSTEOBLASTIC CELLS; MARROW CULTURES; TRABECULAR BONE; PREVENTION; RATS; MICE	Osteoclasts, the cells that resorb bone, develop from hematopoietic precursors of the bone marrow under the control of factors produced in their microenvironment. The cytokine interleukin-6 can promote hematopoiesis and osteoclastogenesis. Interleukin-6 production by bone and marrow stromal cells is suppressed by 17-beta-estradiol in vitro. In mice, estrogen loss (ovariectomy) increased the number of colony-forming units for granulocytes and macrophages, enhanced osteoclast development in ex vivo cultures of marrow, and increased the number of osteoclasts in trabecular bone. These changes were prevented by 17-beta-estradiol or an antibody to interleukin-6. Thus, estrogen loss results in an interleukin-6-mediated stimulation of osteoclastogenesis, which suggests a mechanism for the increased bone resorption in postmenopausal osteoporosis.	DEPT VET AFFAIRS MED CTR,ENDOCRINOL & METAB SECT,INDIANAPOLIS,IN 46202; ELI LILLY & CO,LILLY RES LAB,INDIANAPOLIS,IN 46285; DNAX RES INST CELLULAR & MOLEC BIOL,PALO ALTO,CA 94304; UNIV TEXAS,HLTH SCI CTR,DEPT PATHOL,SAN ANTONIO,TX 78284; INDIANA UNIV,SCH MED,DEPT MED,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT BIOCHEM,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,CTR ONCOL,INDIANAPOLIS,IN 46202	Eli Lilly; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; University of Texas System; University of Texas Health San Antonio; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis				Passeri, Giovanni/0000-0002-4039-1160	NCI NIH HHS [CA36464] Funding Source: Medline; NIAID NIH HHS [AI21761] Funding Source: Medline; NIAMS NIH HHS [AR41313] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA036464, R01CA036464] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021761] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041313] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BARZEL US, 1988, AM J MED, V85, P847; BATAILLE, 1991, J CLIN INVEST, V88, P62; BROXMEYER HE, 1991, CANCER CELL-MON REV, V3, P480; BROXMEYER HE, 1991, EXP HEMATOL, V19, P143; ERNST M, 1989, ENDOCRINOLOGY, V125, P825, DOI 10.1210/endo-125-2-825; GIRASOLE G, 1992, J CLIN INVEST, V89, P883, DOI 10.1172/JCI115668; GRAVES L, 1990, J CELL PHYSIOL, V145, P102, DOI 10.1002/jcp.1041450115; GRAY TK, 1989, BIOCHEM BIOPH RES CO, V158, P407, DOI 10.1016/S0006-291X(89)80062-2; HATTERSLEY G, 1989, ENDOCRINOLOGY, V125, P1606, DOI 10.1210/endo-125-3-1606; HATTERSLEY G, 1991, ENDOCRINOLOGY, V128, P259, DOI 10.1210/endo-128-1-259; HAWLEY TS, 1991, LEUKEMIA RES, V15, P659, DOI 10.1016/0145-2126(91)90068-5; HEANEY RP, 1978, J LAB CLIN MED, V92, P964; KALU DN, 1991, BONE MINER, V15, P175, DOI 10.1016/0169-6009(91)90124-I; KLEIN B, 1991, BLOOD, V78, P1198; KURIHARA N, 1991, J BONE MINER RES, V6, P257; KURIHARA N, 1990, ENDOCRINOLOGY, V126, P2733, DOI 10.1210/endo-126-5-2733; LINDSAY R, 1976, LANCET, V1, P1038; LIU CC, 1991, ANAT REC, V229, P240, DOI 10.1002/ar.1092290211; OTSUKA T, 1991, EXP HEMATOL, V19, P1042; PACIFICI R, 1991, P NATL ACAD SCI USA, V88, P5134, DOI 10.1073/pnas.88.12.5134; POJDA Z, 1990, EXP HEMATOL, V18, P1034; ROODMAN GD, 1992, J CLIN INVEST, V89, P46, DOI 10.1172/JCI115584; STARNES HF, 1990, J IMMUNOL, V145, P4185; TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo-123-5-2600; TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P1504, DOI 10.1210/endo-123-3-1504; TAKANOYAMAMOTO T, 1990, P NATL ACAD SCI USA, V87, P2172, DOI 10.1073/pnas.87.6.2172; TURNER RT, 1988, ENDOCRINOLOGY, V122, P1146, DOI 10.1210/endo-122-3-1146; ULICH TR, 1991, J IMMUNOL, V146, P2316; WILLIAMS D, IN PRESS CONN TISS R; WONG GG, 1988, J IMMUNOL, V140, P3040	30	1208	1290	3	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 3	1992	257	5066					88	91		10.1126/science.1621100	http://dx.doi.org/10.1126/science.1621100			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC165	1621100				2022-12-01	WOS:A1992JC16500036
J	KARLIN, S; BRENDEL, V				KARLIN, S; BRENDEL, V			CHANCE AND STATISTICAL SIGNIFICANCE IN PROTEIN AND DNA-SEQUENCE ANALYSIS	SCIENCE			English	Article							MARKOV-CHAIN ANALYSIS; EPSTEIN-BARR VIRUS; ESCHERICHIA-COLI; HUMAN CYTOMEGALOVIRUS; NUCLEOTIDE-SEQUENCES; GROWTH-FACTOR; LYTIC ORIGIN; GENOME; IDENTIFICATION; METHYLATION	Statistical approaches help in the determination of significant configurations in protein and nucleic acid sequence data. Three recent statistical methods are discussed: (i) score-based sequence analysis that provides a means for characterizing anomalies in local sequence text and for evaluating sequence comparisons; (ii) quantile distributions of amino acid usage that reveal general compositional biases in proteins and evolutionary relations; and (iii) r-scan statistics that can be applied to the analysis of spacings of sequence markers.			KARLIN, S (corresponding author), STANFORD UNIV, DEPT MATH, STANFORD, CA 94305 USA.				NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000335] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM010452] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG00335-04] Funding Source: Medline; NIGMS NIH HHS [GM10452-29] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1991, J MOL BIOL, V219, P555, DOI 10.1016/0022-2836(91)90193-A; ALTSCHUL SF, 1990, P NATL ACAD SCI USA, V87, P5509, DOI 10.1073/pnas.87.14.5509; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANDERS DG, 1991, J VIROL, V65, P931, DOI 10.1128/JVI.65.2.931-937.1991; ARRATIA R, 1989, ANN PROBAB, V17, P9, DOI 10.1214/aop/1176991491; ARRATIA R, 1985, ADV MATH, V55, P13, DOI 10.1016/0001-8708(85)90003-9; ARRATIA R, 1991, ANNU REV BIOPHYS BIO, V11, P806; Arratia R., 1990, STAT SCI, V5, P403, DOI 10.1214/ss/1177012015; ASMUSSEN S, 1982, ADV APPL PROBAB, V14, P143, DOI 10.2307/1426737; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2247, DOI 10.1093/nar/19.suppl.2247; BARILLOT E, 1991, P NATL ACAD SCI USA, V88, P3917, DOI 10.1073/pnas.88.9.3917; BELL G, 1989, COMPUTERS DNA, V7; BERNARDI G, 1985, SCIENCE, V228, P953, DOI 10.1126/science.4001930; BEUTLER E, 1989, P NATL ACAD SCI USA, V86, P192, DOI 10.1073/pnas.86.1.192; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BISHOP YMM, 1975, MULTIVARIATE ANAL TH; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BLAISDELL BE, 1985, J MOL EVOL, V21, P278, DOI 10.1007/BF02102360; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; BRENDEL V, 1992, MATH COMPUT MODEL, V16, P37, DOI 10.1016/0895-7177(92)90150-J; BRENDEL V, 1991, P NATL ACAD SCI USA, V88, P1536, DOI 10.1073/pnas.88.4.1536; BRENDEL V, 1992, P NATL ACAD SCI USA, V89, P2002, DOI 10.1073/pnas.89.6.2002; BRENDEL V, 1989, P NATL ACAD SCI USA, V86, P5698, DOI 10.1073/pnas.86.15.5698; BURGE C, 1992, P NATL ACAD SCI USA, V89, P1358, DOI 10.1073/pnas.89.4.1358; CHEE MS, 1990, CURR TOP MICROBIOL, V154, P125; CHURCHILL GA, 1990, NUCLEIC ACIDS RES, V18, P589, DOI 10.1093/nar/18.3.589; CRESSIE N, 1977, AUSTR J STATIST, V19, P132; DAVISON AJ, 1986, J GEN VIROL, V67, P1759, DOI 10.1099/0022-1317-67-9-1759; Dayhoff M., 1978, ATLAS PROTEIN SEQ S3, V5, P345; DEMBO A, 1991, ANN PROBAB, V19, P1737, DOI 10.1214/aop/1176990232; DEMBO A, 1991, ANN PROBAB, V19, P1756, DOI 10.1214/aop/1176990233; DEMBO A, 1992, ANN APPL PROBAB, V2, P304; DONOFRIO G, 1991, J MOL EVOL, V32, P504, DOI 10.1007/BF02102652; Doolittle R.F., 1990, MOL EVOLUTION COMPUT, V183; DOOLITTLE RF, 1985, TRENDS BIOCHEM SCI, V10, P233, DOI 10.1016/0968-0004(85)90140-9; DOOLITTLE RF, 1984, NATURE, V307, P558, DOI 10.1038/307558a0; DOOLITTLE RF, 1986, URFS ORFS, P55; FASMAN GD, 1990, TRENDS BIOCHEM SCI, V15, P89, DOI 10.1016/0968-0004(90)90187-G; Feller W., 1968, INTRO PROBABILITY TH, V1; Feller W., 1968, INTRO PROBABILITY TH, V2; GALAMBOS J, 1992, ASYMPTOTIC THEORY EX, V24, P113; GLAZ J, 1989, J AM STAT ASSOC, V84, P560; GRIBSKOV M, 1987, P NATL ACAD SCI USA, V84, P4355, DOI 10.1073/pnas.84.13.4355; HAMMERSCHMIDT W, 1988, CELL, V55, P427, DOI 10.1016/0092-8674(88)90028-1; HAMZEH FM, 1990, J VIROL, V64, P6184, DOI 10.1128/JVI.64.12.6184-6195.1990; HOLLANDER M, 1973, NONPARAMETRIC STATIS; HOLST L, 1980, J APPL PROBAB, V17, P284, DOI 10.2307/3212948; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; HOWARD B H, 1990, New Biologist, V2, P759; IGLEHART DL, 1972, ANN MATH STAT, V43, P627, DOI 10.1214/aoms/1177692642; IKEMURA T, 1990, GENOMICS, V8, P207, DOI 10.1016/0888-7543(90)90273-W; INMAN RB, 1966, J MOL BIOL, V18, P464, DOI 10.1016/S0022-2836(66)80037-2; JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706; JOSSE J, 1961, J BIOL CHEM, V236, P864; JUKES TH, 1986, J MOL EVOL, V24, P39, DOI 10.1007/BF02099949; JURKA J, 1991, J MOL EVOL, V32, P105, DOI 10.1007/BF02515383; KARLIN S, 1992, NUCLEIC ACIDS RES, V20, P1363, DOI 10.1093/nar/20.6.1363; KARLIN S, 1990, METHOD ENZYMOL, V183, P388; KARLIN S, 1991, NUCLEIC ACIDS RES, V19, P4241, DOI 10.1093/nar/19.15.4241; KARLIN S, 1990, P NATL ACAD SCI USA, V87, P2264, DOI 10.1073/pnas.87.6.2264; KARLIN S, 1989, J MOL BIOL, V205, P165, DOI 10.1016/0022-2836(89)90373-2; KARLIN S, 1990, ANN STAT, V18, P571, DOI 10.1214/aos/1176347616; KARLIN S, 1991, ANNU REV BIOPHYS BIO, V20, P175, DOI 10.1146/annurev.bb.20.060191.001135; KARLIN S, 1981, 2ND COURSE STOCHASTI, pCH13; KARLIN S, UNPUB; KARLIN S, 1989, MATH METHODS DNA SEQ, P133; KOBILKA BK, 1987, P NATL ACAD SCI USA, V84, P46, DOI 10.1073/pnas.84.1.46; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KOZHUKHIN CG, 1991, COMPUT APPL BIOSCI, V7, P39; KRAWIEC S, 1990, MICROBIOL REV, V54, P502, DOI 10.1128/MMBR.54.4.502-539.1990; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANDER E S, 1988, Genomics, V2, P231; LEHNINGER AL, 1975, BIOCHEMISTRY-US, P861; LEUNG MY, 1991, J MOL BIOL, V221, P1367, DOI 10.1016/0022-2836(91)90938-3; MARMUR J, 1962, J MOL BIOL, V5, P109, DOI 10.1016/S0022-2836(62)80066-7; MASSE MJO, 1992, P NATL ACAD SCI USA, V89, P5246, DOI 10.1073/pnas.89.12.5246; MCCALDON P, 1988, PROTEINS, V4, P99, DOI 10.1002/prot.340040204; MCGEOCH DJ, 1988, J GEN VIROL, V69, P1531, DOI 10.1099/0022-1317-69-7-1531; MCMACKEN R, 1987, ESCHERICHIA COLI SAL, P564; MIKOLAS GLG, 1985, MOL EVOLUTIONARY GEN, P241; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOUCHIROND D, 1988, J MOL EVOL, V28, P7; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NAKASHIMA H, 1986, J BIOCHEM-TOKYO, V99, P153, DOI 10.1093/oxfordjournals.jbchem.a135454; NAUS JI, 1979, INT STAT REV, V47, P47; NEY P, 1987, ANN PROBAB, V15, P561, DOI 10.1214/aop/1176992159; NUSSINOV R, 1987, J THEOR BIOL, V125, P219, DOI 10.1016/S0022-5193(87)80043-7; NUSSINOV R, 1981, J BIOL CHEM, V256, P8458; OHNO S, 1988, P NATL ACAD SCI USA, V85, P9630, DOI 10.1073/pnas.85.24.9630; PHILLIPS GJ, 1987, NUCLEIC ACIDS RES, V15, P2611, DOI 10.1093/nar/15.6.2611; REICH JG, 1984, NUCLEIC ACIDS RES, V12, P5529, DOI 10.1093/nar/12.13.5529; RUDD KE, 1991, NUCLEIC ACIDS RES, V19, P637, DOI 10.1093/nar/19.3.637; Sankoff D., 1983, TIME WARPS STRING ED; SCHACHTEL GA, 1991, J MOL EVOL, V33, P483, DOI 10.1007/BF02102801; SCHILDKRAUT CL, 1962, J MOL BIOL, V4, P430; SCHLEIF R, 1988, SCIENCE, V241, P1182, DOI 10.1126/science.2842864; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SHAPIRO HS, 1976, CRC HDB BIOCH MOL BI, V3, P241; SMITH HO, 1990, P NATL ACAD SCI USA, V87, P826, DOI 10.1073/pnas.87.2.826; SMITH RF, 1990, P NATL ACAD SCI USA, V87, P118, DOI 10.1073/pnas.87.1.118; STERNBERG N, 1985, J BACTERIOL, V164, P490, DOI 10.1128/JB.164.1.490-493.1985; STORMO GD, 1988, ANNU REV BIOPHYS BIO, V17, P241; STUCKLE EE, 1990, NUCLEIC ACIDS RES, V18, P6641, DOI 10.1093/nar/18.22.6641; SUEOKA N, 1961, COLD SPRING HARB SYM, V26, P35, DOI 10.1101/SQB.1961.026.01.009; VANHEEL M, 1991, J MOL BIOL, V220, P877, DOI 10.1016/0022-2836(91)90360-I; VINGRON M, 1989, COMPUT APPL BIOSCI, V5, P115; VONHEIJNE G, 1987, SEQUENCE AMA; WALLENSTEIN S, 1987, STAT MED, V6, P197, DOI 10.1002/sim.4780060212; Waterman M.S., 1989, MATH METHODS DNA SEQ; WATERMAN MS, 1987, P NATL ACAD SCI USA, V84, P1239, DOI 10.1073/pnas.84.5.1239; WATERMAN MS, 1984, B MATH BIOL, V46, P515; WILLIAMS ML, 1990, J ACQ IMMUN DEF SYND, V3, P192; ZUKER M, 1991, J MOL BIOL, V221, P403, DOI 10.1016/0022-2836(91)80062-Y; ZYSKIND JW, 1990, BACTERIAL CHROMOSOME, P269; [No title captured]	116	148	149	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 3	1992	257	5066					39	49		10.1126/science.1621093	http://dx.doi.org/10.1126/science.1621093			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC165	1621093				2022-12-01	WOS:A1992JC16500024
J	MILLER, LH				MILLER, LH			THE CHALLENGE OF MALARIA	SCIENCE			English	Editorial Material											MILLER, LH (corresponding author), NIAID,MALARIA RES LAB,BETHESDA,MD 20892, USA.							ANXOLABEHERE D, 1988, MOL BIOL EVOL, V5, P252; GREENBERG AE, 1989, B WORLD HEALTH ORGAN, V67, P189; Harrison Gordon, 1978, MOSQUITOES MALARIA M; JAROLIM P, 1991, P NATL ACAD SCI USA, V88, P11022, DOI 10.1073/pnas.88.24.11022; KROGSTAD DJ, 1987, SCIENCE, V238, P1283, DOI 10.1126/science.3317830; Macdonald G., 1957, EPIDEMIOLOGY CONTROL; MILLER LH, 1986, SCIENCE, V234, P1349, DOI 10.1126/science.2431481; Oaks SC, 1991, MALARIA OBSTACLES OP; SLATER AFG, 1992, NATURE, V355, P167, DOI 10.1038/355167a0; WARBURG A, 1991, PARASITOL TODAY, V7, P179, DOI 10.1016/0169-4758(91)90127-A; WELLEMS TE, 1991, P NATL ACAD SCI USA, V88, P3382, DOI 10.1073/pnas.88.8.3382; 1992, LANCET, V339, P649	12	38	40	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 3	1992	257	5066					36	37		10.1126/science.1621092	http://dx.doi.org/10.1126/science.1621092			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC165	1621092				2022-12-01	WOS:A1992JC16500022
J	NAKAYAMA, K; LOH, DY				NAKAYAMA, K; LOH, DY			NO REQUIREMENT FOR P56(LCK) IN THE ANTIGEN-STIMULATED CLONAL DELETION OF THYMOCYTES	SCIENCE			English	Article							T-CELL-RECEPTOR; TYROSINE PHOSPHORYLATION; KINASE-ACTIVITY; HERBIMYCIN-A; INHIBITION; ACTIVATION; CD4; IA	Activation of protein-tyrosine kinases (PTKs) is required for signal transduction during T cell activation, although the pathway used during thymic selection is unknown. An in vitro system was established in which T cell receptor transgenic thymocytes underwent clonal deletion in response to peptide antigen. The effects of two PTK-specific inhibitors, herbimycin A and genistein, on the clonal deletion of immature thymocytes and the activation of mature thymocytes were examined. Clonal deletion occurred while T cell activation was inhibited and when no p56lck activity was evident. Thus, p56lck is not required for the antigen-stimulated step of clonal deletion of immature thymocytes, and negative selection proceeds via a distinct pathway.	WASHINGTON UNIV,SCH MED,DEPT MED,HOWARD HUGHES MED INST,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT GENET,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOLEC MICROBIOL,ST LOUIS,MO 63110	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)								AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; IWABUCHI K, IN PRESS P NATL ACAD; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOH DY, 1991, NEW BIOL, V3, P924; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; NAKAYAMA K, UNPUB; NEWELL MK, 1990, NATURE, V347, P286, DOI 10.1038/347286a0; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; PARK DJ, 1991, J BIOL CHEM, V266, P16277; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; SETTE A, 1989, J IMMUNOL, V142, P35; SETTE A, 1987, NATURE, V328, P395, DOI 10.1038/328395a0; SWAT W, 1991, NATURE, V351, P150, DOI 10.1038/351150a0; TANTI JF, 1991, J BIOL CHEM, V266, P2099; UEHARA Y, 1989, CANCER RES, V49, P780; UEHARA Y, 1985, JPN J CANCER RES, V76, P672; UEHARA Y, 1989, BIOCHEM BIOPH RES CO, V163, P803, DOI 10.1016/0006-291X(89)92293-6; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484	27	50	50	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 3	1992	257	5066					94	96		10.1126/science.1621101	http://dx.doi.org/10.1126/science.1621101			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC165	1621101				2022-12-01	WOS:A1992JC16500038
J	NAKAYAMA, T; UEDA, Y; YAMADA, H; SHORES, EW; SINGER, A; JUNE, CH				NAKAYAMA, T; UEDA, Y; YAMADA, H; SHORES, EW; SINGER, A; JUNE, CH			INVIVO CALCIUM ELEVATIONS IN THYMOCYTES WITH T-CELL RECEPTORS THAT ARE SPECIFIC FOR SELF LIGANDS	SCIENCE			English	Article							TRANSGENIC MICE; CD4+8+ THYMOCYTES; ANTIGEN RECEPTOR; TOLERANCE; EXPRESSION; REACTIVITY; SELECTION; PRODUCTS; DELETION; IMMATURE	Selection of the T cell receptor (TCR) repertoire in the thymus probably involves TCR-mediated signals transduced in developing thymocytes after interaction with thymic stromal cells bearing self ligands. TCR-transduced signals should have identifiable consequences that would distinguish thymocytes whose TCRs have been engaged by self ligands from those whose TCRs have not. Among thymocytes expressing a transgenic TCR of defined specificity, a large number had elevated intracellular calcium concentrations but only when resident in a negatively selecting thymus in which their self ligand was expressed. Thus, developing thymocytes are stimulated by endogenous ligands in vivo to mobilize intracellular calcium, and increased intracellular calcium concentrations may reflect the consequences of intrathymic signaling associated with thymic negative selection.	NCI,EXPTL IMMUNOL BRANCH,BLDG 10 ROOM 4B-17,BETHESDA,MD 20892; USN,MED RES INST,IMMUNE CELL BIOL PROGRAM,BETHESDA,MD 20814	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Naval Medical Research Center (NMRC); United States Department of Defense; United States Navy			Nakayama, Toshinori/E-1067-2017	Nakayama, Toshinori/0000-0002-1434-2007				ABE R, 1988, NATURE, V335, P827, DOI 10.1038/335827a0; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; DIALYNAS DP, 1983, IMMUNOL REV, V74, P29, DOI 10.1111/j.1600-065X.1983.tb01083.x; FINKEL TH, 1987, NATURE, V330, P179, DOI 10.1038/330179a0; HAVRAN WL, 1987, NATURE, V330, P170, DOI 10.1038/330170a0; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; MACDONALD HR, 1988, NATURE, V336, P471, DOI 10.1038/336471a0; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; NAKAYAMA T, 1990, SCIENCE, V249, P1558, DOI 10.1126/science.2120773; NAKAYAMA T, 1991, P NATL ACAD SCI USA, V88, P9949, DOI 10.1073/pnas.88.22.9949; Nakayama T, UNPUB; PULLEN AM, 1988, NATURE, V335, P796, DOI 10.1038/335796a0; RABINOVITCH PS, 1986, J IMMUNOL, V137, P952; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SINGER A, 1986, PROG IMMUNOL, V6, P60; TEH HS, 1989, J EXP MED, V169, P795, DOI 10.1084/jem.169.3.795; TSIEN RY, 1990, CELL CALCIUM, V11, P93, DOI 10.1016/0143-4160(90)90063-Z	20	68	70	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 3	1992	257	5066					96	99		10.1126/science.1621102	http://dx.doi.org/10.1126/science.1621102			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC165	1621102				2022-12-01	WOS:A1992JC16500039
J	PUGLISI, JD; TAN, RY; CALNAN, BJ; FRANKEL, AD; WILLIAMSON, JR				PUGLISI, JD; TAN, RY; CALNAN, BJ; FRANKEL, AD; WILLIAMSON, JR			CONFORMATION OF THE TAR RNA-ARGININE COMPLEX BY NMR-SPECTROSCOPY	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PROTEIN; SEQUENCE; BINDING; LOOP; TRANSACTIVATION; TRANSCRIPTION; INVITRO; BULGE	The messenger RNAs of human immunodeficiency virus-1 (HIV-1) have an RNA hairpin structure, TAR, at their 5' ends that contains a six-nucleotide loop and a three-nucleotide bulge. The conformations of TAR RNA and of TAR with an arginine analog specifically bound at the binding site for the viral protein, Tat, were characterized by nuclear magnetic resonance (NMR) spectroscopy. Upon arginine binding, the bulge changes conformation, and essential nucleotides for binding, U23 and A27.U38, form a base-triple interaction that stabilizes arginine hydrogen bonding to G26 and phosphates. Specificity in the arginine-TAR interaction appears to be derived largely from the structure of the RNA.	MIT, DEPT CHEM, CAMBRIDGE, MA 02139 USA; WHITEHEAD INST BIOMED RES, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Whitehead Institute			Williamson, James/AAL-2104-2021; Williamson, James R/B-2891-2009	Williamson, James/0000-0002-8772-468X; Williamson, James R/0000-0002-8772-468X	NIAID NIH HHS [AI29135] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029135] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERKHOUT B, 1991, NUCLEIC ACIDS RES, V19, P6169, DOI 10.1093/nar/19.22.6169; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; CALNAN BJ, 1991, GENE DEV, V5, P201, DOI 10.1101/gad.5.2.201; CORDINGLEY MG, 1990, P NATL ACAD SCI USA, V87, P8985, DOI 10.1073/pnas.87.22.8985; CULLEN BR, 1990, CELL, V63, P655, DOI 10.1016/0092-8674(90)90129-3; DAVIS PW, 1990, BIOPOLYMERS, V29, P109, DOI 10.1002/bip.360290116; DELLING U, 1991, P NATL ACAD SCI USA, V88, P6234, DOI 10.1073/pnas.88.14.6234; DELLING U, 1992, J VIROL, V66, P3018, DOI 10.1128/JVI.66.5.3018-3025.1992; Denoyelle S., SYNTHESIS SAR STUDY; DINGWALL C, 1990, EMBO J, V9, P4145, DOI 10.1002/j.1460-2075.1990.tb07637.x; FENG S, 1988, NATURE, V334, P165, DOI 10.1038/334165a0; Frankel AD, 1992, CURR OPIN GENET DEV, V2, P293, DOI 10.1016/S0959-437X(05)80287-4; HEUS HA, 1991, SCIENCE, V253, P191, DOI 10.1126/science.1712983; MARCINIAK RA, 1990, CELL, V63, P791, DOI 10.1016/0092-8674(90)90145-5; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PUGLISI JD, 1990, J MOL BIOL, V214, P437, DOI 10.1016/0022-2836(90)90192-O; PUGLISI JD, 1990, BIOCHEMISTRY-US, V29, P4215, DOI 10.1021/bi00469a026; RIORDAN FA, IN PRESS J MOL BIOL; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; ROULD MA, 1991, NATURE, V352, P213, DOI 10.1038/352213a0; ROY S, 1990, GENE DEV, V4, P1365, DOI 10.1101/gad.4.8.1365; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; Saenger W., 1984, PRINCIPLES NUCLEIC A, VDM79; SUBRAMANIAN T, 1991, EMBO J, V10, P2311, DOI 10.1002/j.1460-2075.1991.tb07768.x; SUMNERSMITH M, 1991, J VIROL, V65, P5196, DOI 10.1128/JVI.65.10.5196-5202.1991; TAO JS, 1992, P NATL ACAD SCI USA, V89, P2723, DOI 10.1073/pnas.89.7.2723; VARANI G, 1989, BIOCHEMISTRY-US, V28, P7760, DOI 10.1021/bi00445a036; VARANI G, 1991, BIOCHEMISTRY-US, V30, P3280, DOI 10.1021/bi00227a016; VARANI G, 1991, Q REV BIOPHYS, V24, P479, DOI 10.1017/S0033583500003875; WEEKS KM, 1991, CELL, V66, P577, DOI 10.1016/0092-8674(81)90020-9; WEEKS KM, 1990, SCIENCE, V249, P1281, DOI 10.1126/science.2205002; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; WUTHRICH K, 1986, HNMR PROTEINS NUCLEI; YARUS M, 1988, SCIENCE, V240, P1751, DOI 10.1126/science.3381099; YARUS M, 1991, J MOL BIOL, V222, P995, DOI 10.1016/0022-2836(91)90590-3	37	559	583	1	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 3	1992	257	5066					76	80		10.1126/science.1621097	http://dx.doi.org/10.1126/science.1621097			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC165	1621097				2022-12-01	WOS:A1992JC16500033
J	SERGENT, J; ZUCK, E; TERRIAH, S; MACDONALD, B				SERGENT, J; ZUCK, E; TERRIAH, S; MACDONALD, B			DISTRIBUTED NEURAL NETWORK UNDERLYING MUSICAL SIGHT-READING AND KEYBOARD PERFORMANCE	SCIENCE			English	Article							POSITRON EMISSION TOMOGRAPHY; HUMAN-BRAIN; AGRAPHIA; ALEXIA; LOCALIZATION; ACTIVATION; COMPOSER; APHASIA	Music, like other forms of expression, requires specific skills for its production, and the organization and representation of these skills in the human brain are not well understood. With the use of positron emission tomography and magnetic resonance imaging, the functional neuroanatomy of musical sight-reading and keyboard performance was studied in ten professional pianists. Reading musical notations and translating these notations into movement patterns on a keyboard resulted in activation of cortical areas distinct from, but adjacent to, those underlying similar verbal operations. These findings help explain why brain damage in musicians may or may not affect both verbal and musical functions depending on the size and location of the damaged area.			SERGENT, J (corresponding author), MCGILL UNIV,MONTREAL NEUROL INST,COGNIT NEUROSCI LAB,MONTREAL H3A 2B4,QUEBEC,CANADA.							ALAJOUANINE T, 1948, BRAIN, V71, P229, DOI 10.1093/brain/71.3.229; [Anonymous], 1977, MUSIC BRAIN; BASSO A, 1985, J NEUROL NEUROSUR PS, V48, P407, DOI 10.1136/jnnp.48.5.407; Benton AL, 1977, MUSIC AND THE BRAIN, P378; Bernstein L., 1976, UNANSWERED QUESTION; BRUST JCM, 1980, BRAIN, V103, P367, DOI 10.1093/brain/103.2.367; Damasio H., 1989, LESION ANAL NEUROPSY; DELIEGE C, 1984, FONDEMENTS MUSIQUE T; Evans A.C., 1989, PROC SPIE, V1092, P264, DOI [10.1117/12.953267, DOI 10.1117/12.953267]; EVANS AC, 1988, J CEREBR BLOOD F MET, V8, P513, DOI 10.1038/jcbfm.1988.92; EVANS AC, 1991, IEEE T MED IMAGING, V10, P90, DOI 10.1109/42.75615; FOX PT, 1985, J COMPUT ASSIST TOMO, V9, P141, DOI 10.1097/00004728-198501000-00025; FOX PT, 1988, J CEREBR BLOOD F MET, V8, P642, DOI 10.1038/jcbfm.1988.111; FOX PT, 1991, J CEREBR BLOOD F MET, V11, pA79, DOI 10.1038/jcbfm.1991.41; GOODALE MA, 1992, TRENDS NEUROSCI, V15, P20, DOI 10.1016/0166-2236(92)90344-8; JUDD T, 1983, BRAIN, V106, P435, DOI 10.1093/brain/106.2.435; Lerdahl F., 1983, GENERATIVE GRAMMAR T; LURIA AL, 1965, J NEUROL SCI, P288; Marin O., 1982, PSYCHOL MUSIC, P453; MARIN OSM, 1980, DEEP DYSLEXIA, P407; Marnat Marcel, 1986, RAVEL; MCCARTHY RA, 1990, COGNITIVE NEUROPSYCH; MINTUN MA, 1989, J CEREBR BLOOD F MET, V9, P96, DOI 10.1038/jcbfm.1989.13; PETERSEN SE, 1988, NATURE, V331, P585, DOI 10.1038/331585a0; PETERSEN SE, 1990, SCIENCE, V249, P1041, DOI 10.1126/science.2396097; POSNER MI, 1988, SCIENCE, V240, P1627, DOI 10.1126/science.3289116; RAICHLE ME, 1983, J NUCL MED, V24, P790; ROELTGEN DP, 1984, BRAIN, V107, P811, DOI 10.1093/brain/107.3.811; ROSENTHAL M, 1987, MONDE MUS, V103, P114; SERGENT J, 1992, CEREB CORTEX, V2, P68, DOI 10.1093/cercor/2.1.68; SERGENT J, 1992, BRAIN, V115, P15, DOI 10.1093/brain/115.1.15; SERGENT J, 1989, HDB NEUROPSYCHOLOGY, P69; Shallice T, 1988, NEUROPSYCHOLOGY MENT, DOI DOI 10.1017/IPM.2020.45; SIGNORET JL, 1987, REV NEUROL-FRANCE, V143, P172; SLOBODA J, 1978, PSYCHOL MUSIC, V9, P1; Sloboda JA, 1986, MUSICAL MIND COGNITI; TAIRA M, 1990, EXP BRAIN RES, V83, P29; Talairach J., 1988, COPLANAR STEREOTAXIC, P5; TALBOT JD, 1991, SCIENCE, V251, P1355, DOI 10.1126/science.2003220; Ungerleider L, 1982, ANAL VISUAL BEHAV, P549; Weiskrantz L., 1968, ANAL BEHAV CHANGE, P400	41	196	197	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 3	1992	257	5066					106	109		10.1126/science.1621084	http://dx.doi.org/10.1126/science.1621084			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	Science & Technology - Other Topics	JC165	1621084				2022-12-01	WOS:A1992JC16500042
J	SORRENTINO, BP; BRANDT, SJ; BODINE, D; GOTTESMAN, M; PASTAN, I; CLINE, A; NIENHUIS, AW				SORRENTINO, BP; BRANDT, SJ; BODINE, D; GOTTESMAN, M; PASTAN, I; CLINE, A; NIENHUIS, AW			SELECTION OF DRUG-RESISTANT BONE-MARROW CELLS INVIVO AFTER RETROVIRAL TRANSFER OF HUMAN MDR1	SCIENCE			English	Article							HEMATOPOIETIC STEM-CELLS; GENE-TRANSFER; MULTIDRUG RESISTANCE; EXPRESSION; RECIPIENTS; LINE	Experiments were performed to determine if retroviral-mediated transfer of the human multidrug resistance 1 gene (MDR1) into murine bone marrow cells would confer drug resistance to the cells and whether the MDR1 gene could be used as a dominant selectable marker in vivo. When mice transplanted with bone marrow cells containing a transferred MDR1 gene were treated with the cytotoxic drug taxol, a substantial enrichment for transduced bone marrow cells was observed. This demonstration of positive selection establishes the ability to amplify clones of transduced hematopoietic cells in vivo and suggests possible applications in human therapy.	VANDERBILT UNIV,DEPT MED,NASHVILLE,TN 37232; VANDERBILT UNIV,DEPT CELL BIOL,NASHVILLE,TN 37232; NCI,DIV CANC BIOL & DIAG,CELL BIOL LAB,BETHESDA,MD 20892; NCI,DIV CANC BIOL & DIAG,MOLEC BIOL LAB,BETHESDA,MD 20892	Vanderbilt University; Vanderbilt University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	SORRENTINO, BP (corresponding author), NHLBI,CLIN HEMATOL BRANCH,BETHESDA,MD 20892, USA.		pastan, ira/P-9319-2019	pastan, ira/0000-0002-9223-0270				BODINE DM, 1989, P NATL ACAD SCI USA, V86, P8897, DOI 10.1073/pnas.86.22.8897; BODINE DM, 1991, EXP HEMATOL, V19, P206; BODINE DM, 1990, P NATL ACAD SCI USA, V87, P3738, DOI 10.1073/pnas.87.10.3738; COREY CA, 1990, BLOOD, V75, P337; DZIERZAK EA, 1988, NATURE, V331, P35, DOI 10.1038/331035a0; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FLETCHER FA, 1991, J EXP MED, V174, P837, DOI 10.1084/jem.174.4.837; GERMANN UA, 1989, J BIOL CHEM, V264, P7418; JORDAN CT, 1990, GENE DEV, V4, P220, DOI 10.1101/gad.4.2.220; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MCLACHLIN JR, 1990, J NATL CANCER I, V82, P1260, DOI 10.1093/jnci/82.15.1260; MICKISCH GH, 1991, CANCER RES, V51, P5417; MICKISCH GH, 1992, BLOOD, V79, P1087; MICKISCH GH, 1991, P NATL ACAD SCI USA, V88, P547, DOI 10.1073/pnas.88.2.547; PASTAN I, 1991, ANNU REV MED, V42, P277, DOI 10.1146/annurev.me.42.020191.001425; PASTAN I, 1988, P NATL ACAD SCI USA, V85, P4486, DOI 10.1073/pnas.85.12.4486; ROWINSKY EK, 1990, JNCI-J NATL CANCER I, V82, P1247, DOI 10.1093/jnci/82.15.1247	17	477	501	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 3	1992	257	5066					99	103		10.1126/science.1352414	http://dx.doi.org/10.1126/science.1352414			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC165	1352414				2022-12-01	WOS:A1992JC16500040
J	VOELKER, TA; WORRELL, AC; ANDERSON, L; BLEIBAUM, J; FAN, C; HAWKINS, DJ; RADKE, SE; DAVIES, HM				VOELKER, TA; WORRELL, AC; ANDERSON, L; BLEIBAUM, J; FAN, C; HAWKINS, DJ; RADKE, SE; DAVIES, HM			FATTY-ACID BIOSYNTHESIS REDIRECTED TO MEDIUM CHAINS IN TRANSGENIC OILSEED PLANTS	SCIENCE			English	Article							ARABIDOPSIS; TRANSFORMATION; TRANSPORT; CLONING; PROTEIN; MUTANTS	Medium-chain fatty acids (FAs), found in storage lipids of certain plants, are an important renewable resource. Seeds of undomesticated California bay accumulate laurate (12:0), and a 12:0-acyl-carrier protein thioesterase (BTE) has been purified from this tissue. Sequencing of BTE enabled the cloning of a complementary DNA coding for a plastid-targeted preprotein. Expression of the complementary DNA in the seeds of Arabidopsis thaliana resulted in BTE activity, and medium chains accumulated at the expense of long-chain (greater-than-or-equal-to 16) FAs. Laurate became the most abundant FA species and was deposited in the storage triacylglycerols. These results demonstrate a mechanism for medium-chain FA synthesis in plants.			VOELKER, TA (corresponding author), CALGENE INC,1920 5TH ST,DAVIS,CA 95616, USA.							AEBERSOLD R, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P71; ALEXANDER DC, 1987, METHOD ENZYMOL, V154, P41; BATTEY JF, 1989, TRENDS BIOTECHNOL, V7, P122, DOI 10.1016/0167-7799(89)90088-7; BROWSE J, 1986, ANAL BIOCHEM, V152, P141, DOI 10.1016/0003-2697(86)90132-6; DAVIES H, UNPUB; DAVIES HM, 1991, ARCH BIOCHEM BIOPHYS, V290, P37, DOI 10.1016/0003-9861(91)90588-A; HARWOOD JL, 1988, ANNU REV PLANT PHYS, V39, P101, DOI 10.1146/annurev.arplant.39.1.101; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; JAMES DW, 1990, THEOR APPL GENET, V80, P241, DOI 10.1007/BF00224393; KEEGSTRA K, 1989, ANNU REV PLANT PHYS, V40, P471, DOI 10.1146/annurev.pp.40.060189.002351; KNUTZON DS, 1992, P NATL ACAD SCI USA, V89, P2624, DOI 10.1073/pnas.89.7.2624; KNUTZON DS, COMMUNICATION; Kridl J. C., 1991, Seed Science Research, V1, P209, DOI 10.1017/S0960258500000921; LEE CC, 1988, SCIENCE, V239, P1288, DOI 10.1126/science.3344434; LEMIEUX B, 1990, THEOR APPL GENET, V80, P234, DOI 10.1007/BF00224392; LUTCKE HA, 1987, EMBO J, V6, P44; MCBRIDE KE, 1990, PLANT MOL BIOL, V14, P269, DOI 10.1007/BF00018567; OHLROGGE JB, 1979, P NATL ACAD SCI USA, V76, P1194, DOI 10.1073/pnas.76.3.1194; POLLARD MR, 1991, ARCH BIOCHEM BIOPHYS, V284, P1; ROSNER MR, 1982, J CELL BIOCHEM, V18, P37, DOI 10.1002/jcb.1982.240180105; SMEEKENS S, 1990, TRENDS BIOCHEM SCI, V15, P73, DOI 10.1016/0968-0004(90)90180-J; TURPEN T H, 1986, Biotechniques, V4, P14; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536	23	313	368	1	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 3	1992	257	5066					72	74		10.1126/science.1621095	http://dx.doi.org/10.1126/science.1621095			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC165	1621095				2022-12-01	WOS:A1992JC16500031
J	WEI, ZM; LABY, RJ; ZUMOFF, CH; BAUER, DW; HE, SY; COLLMER, A; BEER, SV				WEI, ZM; LABY, RJ; ZUMOFF, CH; BAUER, DW; HE, SY; COLLMER, A; BEER, SV			HARPIN, ELICITOR OF THE HYPERSENSITIVE RESPONSE PRODUCED BY THE PLANT PATHOGEN ERWINIA-AMYLOVORA	SCIENCE			English	Article							SYRINGAE PV SYRINGAE; K+/H+ EXCHANGE; TOBACCO; TN5	A proteinaceous elicitor of the plant defense reaction known as the hypersensitive response was isolated from Erwinia amylovora, the bacterium that causes fire blight of pear, apple, and other rosaceous plants. The elicitor, named harpin, is an acidic, heat-stable, cell-envelope-associated protein with an apparent molecular weight of 44 kilodaltons. Harpin caused tobacco leaf lamina to collapse and caused an increase in the pH of bathing solutions of suspension-cultured tobacco cells. The gene encoding harpin (hrpN) was located in the 40-kilobase hrp gene cluster of E. amylovora, sequenced, and mutated with Tn5tac1. The hrpN mutants were not pathogenic to pear, did not elicit the hypersensitive response, and did not produce harpin.	CORNELL UNIV, DEPT PLANT PATHOL, ITHACA, NY 14853 USA	Cornell University				He, Sheng Yang/0000-0003-1308-498X				Aldwinkle H. S., 1979, Horticultural Reviews, V1, P423; ATKINSON MM, 1985, PLANT PHYSIOL, V79, P843, DOI 10.1104/pp.79.3.843; BAKER CJ, 1987, PHYTOPATHOLOGY, V77, P1268, DOI 10.1094/Phyto-77-1268; BAUER DW, 1991, MOL PLANT MICROBE IN, V4, P493, DOI 10.1094/MPMI-4-493; Beer S. V., 1991, Advances in molecular genetics of plant-microbe interactions. Vol. 1. Proceedings of the 5th international symposium on the molecular genetics of plant-microbe interactions, Interlaken, Switzerland, September 9-14, 1990., P53; BEER SV, 1989, PLANT PATHOGENIC B B, P675; CHOW WY, 1988, P NATL ACAD SCI USA, V85, P6468, DOI 10.1073/pnas.85.17.6468; DANIELS MJ, 1988, ANNU REV PHYTOPATHOL, V26, P285, DOI 10.1146/annurev.py.26.090188.001441; HUANG HC, 1991, MOL PLANT MICROBE IN, V4, P469, DOI 10.1094/MPMI-4-469; HUANG HC, 1988, J BACTERIOL, V170, P4748, DOI 10.1128/jb.170.10.4748-4756.1988; HUYNH TV, 1989, SCIENCE, V245, P1374, DOI 10.1126/science.2781284; KLEMENT Z, 1963, NATURE, V199, P299, DOI 10.1038/199299b0; KLEMENT Z, 1964, PHYTOPATHOLOGY, V54, P474; LABY RJ, UNPUB; LABY RJ, 1991, THESIS CORNELL U; Lacy G. H., 1982, PHYTOPATHOGENIC PROK, V2, P149; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Sambrook J., 1989, MOL CLONING LAB MANU; Steinberger E. M., 1988, Molecular Plant-Microbe Interactions, V1, P135, DOI 10.1094/MPMI-1-135; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TURNER JG, 1974, PHYTOPATHOLOGY, V64, P885, DOI 10.1094/Phyto-64-885; WAY JC, 1984, GENE, V32, P369, DOI 10.1016/0378-1119(84)90012-X; WEI ZM, 1992, J BACTERIOL, V174, P1875, DOI 10.1128/jb.174.6.1875-1882.1992; WILLIS DK, 1991, MOL PLANT MICROBE IN, V4, P132, DOI 10.1094/MPMI-4-132	25	652	802	5	96	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 3	1992	257	5066					85	88		10.1126/science.1621099	http://dx.doi.org/10.1126/science.1621099			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC165	1621099				2022-12-01	WOS:A1992JC16500035
J	WILSON, DK; BOHREN, KM; GABBAY, KH; QUIOCHO, FA				WILSON, DK; BOHREN, KM; GABBAY, KH; QUIOCHO, FA			AN UNLIKELY SUGAR SUBSTRATE SITE IN THE 1.65 ANGSTROM STRUCTURE OF THE HUMAN ALDOSE REDUCTASE HOLOENZYME IMPLICATED IN DIABETIC COMPLICATIONS	SCIENCE			English	Article							HEXONATE DEHYDROGENASE; KIDNEY ALDOSE; INHIBITION; SORBINIL; ALDEHYDE; PROTEINS; NEUROPATHY; CRYSTALLIN; FEATURES; KINETICS	Aldose reductase, which catalyzes the reduced form of nicotinamide adenine dinucleotide phosphate (NADPH)-dependent reduction of a wide variety of aromatic and aliphatic carbonyl compounds, is implicated in the development of diabetic and galactosemic complications involving the lens, retina, nerves, and kidney. A 1.65 angstrom refined structure of a recombinant human placenta aldose reductase reveals that the enzyme contains a parallel beta-8/alpha-8-barrel motif and establishes a new motif for NADP-binding oxidoreductases. The substrate-binding site is located in a large, deep elliptical pocket at the COOH-terminal end of the beta-barrel with a bound NADPH in an extended conformation. The highly hydrophobic nature of the active site pocket greatly favors aromatic and apolar substrates over highly polar monosaccharides. The structure should allow for the rational design of specific inhibitors that might provide molecular understanding of the catalytic mechanism, as well as possible therapeutic agents.	BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT BIOCHEM,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT PEDIAT,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine				Bohren, Kurt/0000-0002-3183-4118	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039044] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-39,044] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON S, 1985, SCIENCE, V230, P144, DOI 10.1126/science.230.4722.144; BHATNAGAR A, 1990, BIOCHEM PHARMACOL, V39, P1115, DOI 10.1016/0006-2952(90)90292-S; BOHREN KM, 1989, J BIOL CHEM, V264, P9547; BOHREN KM, 1991, J BIOL CHEM, V266, P24031; BOLIN JT, 1982, J BIOL CHEM, V257, P13650; BOULTON AJM, 1990, DIABETOLOGIA, V33, P431, DOI 10.1007/BF00404095; Branden CI, 1991, CURR OPIN STRUC BIOL, V1, P978, DOI 10.1016/0959-440X(91)90094-A; BRUNGER AT, 1990, XPLOR SYSTEM CRYSTAL; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; DVORNIK D, 1973, SCIENCE, V182, P1146, DOI 10.1126/science.182.4117.1146; EINSPAHR HM, 1989, P S PROTEIN CARBOHYD, V25; FARBER GK, 1990, TRENDS BIOCHEM SCI, V15, P228, DOI 10.1016/0968-0004(90)90035-A; FELDMAN HB, 1977, BIOCHIM BIOPHYS ACTA, V480, P18; GABBAY KH, 1973, NEW ENGL J MED, V288, P831, DOI 10.1056/NEJM197304192881609; GRIMSHAW CE, 1990, BIOCHEMISTRY-US, V29, P9947, DOI 10.1021/bi00494a027; GRIMSHAW CE, 1989, BIOCHEMISTRY-US, V28, P5343, DOI 10.1021/bi00439a006; JOSEPH D, 1990, SCIENCE, V249, P1425, DOI 10.1126/science.2402636; KADOR PF, 1985, ANNU REV PHARMACOL, V25, P691, DOI 10.1146/annurev.pa.25.040185.003355; KADOR PF, 1988, MED RES REV, V8, P325, DOI 10.1002/med.2610080302; KURIYAN J, 1991, NATURE, V352, P172, DOI 10.1038/352172a0; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LUECKE H, 1990, NATURE, V347, P402, DOI 10.1038/347402a0; MARTYN CN, 1987, DIABETES, V36, P987, DOI 10.2337/diabetes.36.9.987; OBRIEN MM, 1982, J NEUROCHEM, V39, P810, DOI 10.1111/j.1471-4159.1982.tb07964.x; Pai EF, 1991, CURR OPIN STRUC BIOL, V1, P796, DOI 10.1016/0959-440X(91)90181-R; POULSOM R, 1986, BIOCHEM PHARMACOL, V35, P2955, DOI 10.1016/0006-2952(86)90492-2; PRIESTLE JP, 1988, J APPL CRYSTALLOGR, V21, P572, DOI 10.1107/S0021889888005746; QUIOCHO FA, 1989, PURE APPL CHEM, V61, P1293, DOI 10.1351/pac198961071293; QUIOCHO FA, 1986, ANNU REV BIOCHEM, V55, P287, DOI 10.1146/annurev.bi.55.070186.001443; QUIOCHO FA, 1987, NATURE, V329, P561, DOI 10.1038/329561a0; ROSE IA, 1980, P NATL ACAD SCI-BIOL, V77, P2439, DOI 10.1073/pnas.77.5.2439; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; SPIELBERG SP, 1991, ANN INTERN MED, V114, P720, DOI 10.7326/0003-4819-114-9-720; TOMAREV SI, 1984, FEBS LETT, V171, P297, DOI 10.1016/0014-5793(84)80508-6; Vyas NK, 1991, CURR OPIN STRUC BIOL, V1, P732, DOI 10.1016/0959-440X(91)90172-P; WATANABE K, 1988, P NATL ACAD SCI USA, V85, P11, DOI 10.1073/pnas.85.1.11; WERMUTH B, 1982, EUR J BIOCHEM, V127, P279, DOI 10.1111/j.1432-1033.1982.tb06867.x; WERMUTH B, 1992, ENZYMOLOGY CARBONYL, P261; WILSON DK, 1991, SCIENCE, V252, P1278, DOI 10.1126/science.1925539; WINTERS CJ, 1990, BIOCHEMISTRY-US, V29, P1080, DOI 10.1021/bi00456a034	40	403	413	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 3	1992	257	5066					81	84		10.1126/science.1621098	http://dx.doi.org/10.1126/science.1621098			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC165	1621098				2022-12-01	WOS:A1992JC16500034
J	ARTALEJO, CR; ROSSIE, S; PERLMAN, RL; FOX, AP				ARTALEJO, CR; ROSSIE, S; PERLMAN, RL; FOX, AP			VOLTAGE-DEPENDENT PHOSPHORYLATION MAY RECRUIT CA2+ CURRENT FACILITATION IN CHROMAFFIN CELLS	NATURE			English	Article							CARDIAC CALCIUM-CHANNEL; RABBIT SKELETAL-MUSCLE; PROTEIN KINASE-C; OKADAIC ACID; POTENT INHIBITORS; PHOSPHATASE-2A; RECEPTOR	BOVINE chromaffin cells have two components of whole-cell Ca2+ current: 'standard' Ca2+ currents that are activated by brief depolarizations, and 'facilitation' Ca2+ currents, which are normally quiescent but can be activated by large pre-depolarizations or by repetitive depolarizations to physiological potentials 1-5. The activation of protein kinase A can also stimulate Ca2+ current facilitation, indicating that phosphorylation can play a part in facilitation 6. Here we investigate the role of protein phosphorylation in the recruitment of facilitation Ca2+ currents by pre-pulses or repetitive depolarizations. We find that recruitment of facilitation by depolarization is a rapid first-order process which is suppressed by inhibitors of protein phosphorylation or by injection of phosphatase 2A into cells. Recruitment of facilitation Ca2+ current by voltage is normally reversible but phosphatase inhibitors render it irreversible. Our results indicate that recruitment of these Ca2+ currents by pre-pulses or repetitive depolarizations involves voltage-dependent phosphorylation of the facilitation Ca2+ channel or a closely associated regulatory protein. Voltage-dependent phosphorylation may therefore be a mechanism by which membrane potential can modulate ion channel activity.	UNIV CHICAGO,DEPT PHARMACOL & PHYSIOL SCI,947 E 58TH ST,CHICAGO,IL 60637; UNIV CHICAGO,DEPT PEDIAT,CHICAGO,IL 60637; UNIV CHICAGO,JOSEPH P KENNEDY JR MENTAL RETARDAT RES CTR,CHICAGO,IL 60637; UNIV AUTONOMA MADRID,FAC MED,DEPT FARMACOL,E-28029 MADRID,SPAIN; PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907	University of Chicago; University of Chicago; University of Chicago; Autonomous University of Madrid; Purdue University System; Purdue University; Purdue University West Lafayette Campus			Perlman, Robert/GZH-2102-2022					ALMERS W, 1990, ANNU REV PHYSIOL, V52, P607, DOI 10.1146/annurev.ph.52.030190.003135; AMADOR M, 1991, NEUROSCI LETT, V124, P251, DOI 10.1016/0304-3940(91)90106-4; ARTALEJO CR, 1991, J PHYSIOL-LONDON, V432, P681, DOI 10.1113/jphysiol.1991.sp018406; ARTALEJO CR, 1990, NATURE, V348, P239, DOI 10.1038/348239a0; ARTALEJO CR, 1991, J PHYSIOL-LONDON, V444, P213, DOI 10.1113/jphysiol.1991.sp018874; CHUNG S, 1991, SCIENCE, V253, P56; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COHEN P, 1988, METHOD ENZYMOL, V159, P390; FENWICK EM, 1982, J PHYSIOL-LONDON, V331, P599, DOI 10.1113/jphysiol.1982.sp014394; GRATECOS D, 1974, BIOCHEM BIOPH RES CO, V58, P960, DOI 10.1016/S0006-291X(74)80237-8; HAAVIK J, 1989, FEBS LETT, V251, P36, DOI 10.1016/0014-5793(89)81424-3; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HESCHELER J, 1988, PFLUG ARCH EUR J PHY, V412, P248, DOI 10.1007/BF00582504; HESCHELER J, 1987, EUR J BIOCHEM, V165, P261, DOI 10.1111/j.1432-1033.1987.tb11436.x; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HOSHI T, 1984, P NATL ACAD SCI-BIOL, V81, P5871, DOI 10.1073/pnas.81.18.5871; HOSHI T, 1987, J NEUROSCI, V7, P571; IMAGAWA T, 1987, J BIOL CHEM, V262, P8333; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; NESTLER EJ, 1989, BASIC NEUROCHEMISTRY; TESSMER GW, 1977, J BIOL CHEM, V252, P5666; YATANI A, 1987, SCIENCE, V238, P1288, DOI 10.1126/science.2446390; YATANI A, 1989, SCIENCE, V245, P71, DOI 10.1126/science.2544999; YOUNT RG, 1975, ADV ENZYMOL, V34, P1	24	127	128	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 2	1992	358	6381					63	66		10.1038/358063a0	http://dx.doi.org/10.1038/358063a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JB341	1319555				2022-12-01	WOS:A1992JB34100054
J	BAUER, PH; MULLER, S; PUZICHA, M; PIPPIG, S; OBERMAIER, B; HELMREICH, EJM; LOHSE, MJ				BAUER, PH; MULLER, S; PUZICHA, M; PIPPIG, S; OBERMAIER, B; HELMREICH, EJM; LOHSE, MJ			PHOSDUCIN IS A PROTEIN KINASE-A-REGULATED G-PROTEIN REGULATOR	NATURE			English	Article							BETA-ADRENERGIC-RECEPTOR; ADENYLATE-CYCLASE; PURIFICATION; BOVINE; DESENSITIZATION; PHOSPHOPROTEIN; TRANSDUCIN; COMPONENT; ARRESTIN; COMPLEX	SIGNAL transduction by G-protein-coupled receptors is regulated by various mechanisms acting at the receptor level; those studied most thoroughly are from the beta-adrenergic receptor/G(s)/adenylyl cyclase system 1-3. We report here a regulatory mechanism occurring at the level of the G proteins themselves. A protein with M(r) 33,000 that inhibits G(s)-GTPase activity was purified from bovine brain. This protein is very similar or identical to phosducin, a protein previously thought to be specific for retina and pineal gland 4-8. Recombinant phosducin inhibited the GTPase activity of several G proteins, and also inhibited G(s)-mediated adenylyl cyclase activation. Blockade of its inhibitory effects by protein kinase A suggests that phosducin may be part of a complex regulatory network controlling G-protein-mediated signalling.	UNIV WURZBURG,DEPT PHYSIOL CHEM,W-8700 WURZBURG,GERMANY	University of Wurzburg	BAUER, PH (corresponding author), UNIV MUNICH,MAX PLANCK INST BIOCHEM,MOLEC BIOL LAB,W-8033 MARTINSRIED,GERMANY.		Lohse, Martin J/A-7160-2012	Lohse, Martin J/0000-0002-0599-3510				ABE T, 1990, GENE, V91, P209, DOI 10.1016/0378-1119(90)90090-E; BENOVIC JL, 1987, J BIOL CHEM, V262, P9026; BENOVIC JL, 1987, P NATL ACAD SCI USA, V84, P8879, DOI 10.1073/pnas.84.24.8879; BENOVIC JL, 1984, BIOCHEMISTRY-US, V23, P4519; BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BOKOCH GM, 1984, J BIOL CHEM, V259, P3560; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FREISSMUTH M, 1989, J BIOL CHEM, V264, P21907; HADCOCK JR, 1991, TRENDS NEUROSCI, V14, P242, DOI 10.1016/0166-2236(91)90124-D; KUO CH, 1989, BIOCHEM BIOPH RES CO, V162, P1063, DOI 10.1016/0006-291X(89)90781-X; LEE RH, 1990, J BIOL CHEM, V265, P15867; LEE RH, 1990, J BIOL CHEM, V265, P15860; LEE RH, 1987, BIOCHEMISTRY-US, V26, P3983, DOI 10.1021/bi00387a036; LOHSE MJ, 1986, MOL PHARMACOL, V30, P403; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; LOHSE MJ, 1990, J BIOL CHEM, V265, P3210; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; LOHSE MJ, 1989, P NATL ACAD SCI USA, V86, P3011, DOI 10.1073/pnas.86.9.3011; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; LOHSE MJ, 1992, SIGNAL TRANSMISSION, P160; REIG JA, 1990, J BIOL CHEM, V265, P5816; ROTH NS, 1991, P NATL ACAD SCI USA, V88, P6201, DOI 10.1073/pnas.88.14.6201; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STERNWEIS PC, 1981, J BIOL CHEM, V256, P1517; STRITTMATTER SM, 1991, J BIOL CHEM, V266, P22465; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUGDEN PH, 1976, BIOCHEM J, V159, P409, DOI 10.1042/bj1590409; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J	30	184	185	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 2	1992	358	6381					73	76		10.1038/358073a0	http://dx.doi.org/10.1038/358073a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JB341	1319556				2022-12-01	WOS:A1992JB34100057
J	DAVIS, SJ; SCHOCKMEL, GA; SOMOZA, C; BUCK, DW; HEALEY, DG; RIEBER, EP; REITER, C; WILLIAMS, AF				DAVIS, SJ; SCHOCKMEL, GA; SOMOZA, C; BUCK, DW; HEALEY, DG; RIEBER, EP; REITER, C; WILLIAMS, AF			ANTIBODY AND HIV-1 GP120 RECOGNITION OF CD4 UNDERMINES THE CONCEPT OF MIMICRY BETWEEN ANTIBODIES AND RECEPTORS	NATURE			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; IDIOTYPIC ANTIBODIES; REOVIRUS RECEPTOR; MEMBRANE-PROTEIN; CELL-SURFACE; IDENTIFICATION; EXPRESSION; DIVERSITY; ANTIGEN; BINDING	IT has been proposed that antibodies can mimic the binding of a receptor to its ligand and that anti-idiotype antibodies raised against such antibodies can be used to identify the receptor 1-3. A large number of antibodies have been raised against CD4, the receptor on T cells for the envelope glycoprotein gp120 of the human immunodeficiency virus, and the site at which gp120 binds to CD4 has been delineated 4. It has therefore become possible to contrast the fine specificities of a natural ligand (gp120) and antibodies that interact with the receptor at the same site. Here we report that out of a panel of 225 anti-CD4 antibodies, only one showed fine binding specificity that was broadly like that of gp120, but the evidence was against this being an exact mimic. Thus the data indicate that the production of antibody mimics will occur very rarely or not at all and that the anti-idiotype approach is unlikely to be useful. This contention is supported by a review of the results of attempts to use this approach. Taking strict criteria for success, there is no example for which the anti-idiotype approach has led to the discovery of a previously undescribed receptor or other protein of interest.	BIOTECH RESOURCES INC,SAN ANTONIO,TX 78249; UNIV CAMBRIDGE,DEPT PATHOL,CAMBRIDGE CB2 1QP,ENGLAND; UNIV MUNICH,INST IMMUNOL,W-8000 MUNICH 2,GERMANY	University of Cambridge; University of Munich	DAVIS, SJ (corresponding author), UNIV OXFORD,SIR WILLIAM DUNN SCH PATHOL,MRC,CELLULAR IMMUNOL UNIT,OXFORD OX1 3RE,ENGLAND.							BENTLEY GA, 1990, NATURE, V348, P254, DOI 10.1038/348254a0; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; CHANH TC, 1987, P NATL ACAD SCI USA, V84, P3891, DOI 10.1073/pnas.84.11.3891; CHOI AHC, 1988, VIROLOGY, V163, P191, DOI 10.1016/0042-6822(88)90246-2; CO MS, 1985, P NATL ACAD SCI USA, V82, P5315, DOI 10.1073/pnas.82.16.5315; DALGLEISH AG, 1987, LANCET, V2, P1047; DAVIS SJ, 1990, J BIOL CHEM, V265, P10410; EICHMANN K, 1974, EUR J IMMUNOL, V4, P296, DOI 10.1002/eji.1830040413; Estess P, 1990, CURRENT RES PROTEIN, P499; FLUGGE UI, 1991, NATURE, V353, P364, DOI 10.1038/353364a0; GAULTON GN, 1986, ANNU REV IMMUNOL, V4, P253, DOI 10.1146/annurev.iy.04.040186.001345; GENTSCH JR, 1987, VIROLOGY, V161, P245, DOI 10.1016/0042-6822(87)90192-9; HEALEY DG, 1991, EUR J IMMUNOL, V21, P1491, DOI 10.1002/eji.1830210624; KRETH HW, 1973, EUR J IMMUNOL, V3, P141, DOI 10.1002/eji.1830030306; LEWIS MJ, 1990, NATURE, V348, P162, DOI 10.1038/348162a0; MASON DW, 1980, BIOCHEM J, V187, P1; PAIN D, 1990, NATURE, V347, P444, DOI 10.1038/347444a0; PAIN D, 1988, NATURE, V331, P232, DOI 10.1038/331232a0; PAUL RW, 1989, VIROLOGY, V172, P382, DOI 10.1016/0042-6822(89)90146-3; PAUL RW, 1987, VIROLOGY, V159, P94, DOI 10.1016/0042-6822(87)90351-5; REEVES JP, 1991, AIDS RES HUM RETROV, V7, P55, DOI 10.1089/aid.1991.7.55; SATTENTAU QJ, 1989, J EXP MED, V170, P1319, DOI 10.1084/jem.170.4.1319; SATTENTAU QJ, 1986, SCIENCE, V234, P1120, DOI 10.1126/science.2430333; SCHOCKMEL GA, 1992, J EXP MED, V175, P301, DOI 10.1084/jem.175.1.301; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SEGE K, 1978, P NATL ACAD SCI USA, V75, P2443, DOI 10.1073/pnas.75.5.2443; STAUDT LM, 1983, J EXP MED, V157, P687, DOI 10.1084/jem.157.2.687; VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0; VAUX DJT, 1988, NATURE, V336, P36, DOI 10.1038/336036a0; WILKS D, 1991, J INFECT DIS, V163, P389, DOI 10.1093/infdis/163.2.389	31	66	73	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 2	1992	358	6381					76	79		10.1038/358076a0	http://dx.doi.org/10.1038/358076a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JB341	1614536				2022-12-01	WOS:A1992JB34100058
J	FARMER, G; BARGONETTI, J; ZHU, H; FRIEDMAN, P; PRYWES, R; PRIVES, C				FARMER, G; BARGONETTI, J; ZHU, H; FRIEDMAN, P; PRYWES, R; PRIVES, C			WILD-TYPE P53 ACTIVATES TRANSCRIPTION INVITRO	NATURE			English	Article							PROTEIN; REPLICATION; ONCOGENE; ANTIGEN; MUTANT	THE p53 protein is an important determinant in human cancer and regulates the growth of cells in culture 1-3. It is known to be a sequence-specific DNA-binding protein 4,5 with a powerful activation domain 6-8, but it has not been established whether it regulates transcription directly. Here we show that intact purified wild-type human and murine p53 proteins strongly activate transcription in vitro. This activation depends on the ability of p53 to bind to a template bearing a p53-binding sequence. By contrast, tumour-derived mutant p53 proteins cannot activate transcription from the template at all, and when complexed to wild-type p53, these mutants block transcriptional activation by the wild-type protein. Moreover, the simian virus 40 large T antigen inhibits wild-type p53 from activating transcription. Our results support a model in which p53 directly activates transcription but this activity can be inhibited by mutant p53 and SV40 large T antigen through interaction with wild-type p53.			FARMER, G (corresponding author), COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027, USA.			Bargonetti, Jill/0000-0003-2692-0991				BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FRIEDMAN M, 1986, CONTEMP POLICY ISSUE, V4, P1, DOI 10.1111/j.1465-7287.1986.tb00827.x; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MURAKAMI Y, 1990, ONCOGENE, V5, P5; OROURKE RW, 1990, ONCOGENE, V5, P1829; PRYWES R, 1988, COLD SPRING HARB SYM, V53, P739, DOI 10.1101/SQB.1988.053.01.084; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SOUSSI T, 1990, ONCOGENE, V5, P945; STENGER JE, 1992, MOL CARCINOGEN, V5, P102, DOI 10.1002/mc.2940050204; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4750; ZAMBETTI GP, IN PRESS GENES DEV; ZHU H, 1991, NEW BIOL, V3, P455	31	647	662	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 2	1992	358	6381					83	86		10.1038/358083a0	http://dx.doi.org/10.1038/358083a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JB341	1614538				2022-12-01	WOS:A1992JB34100060
J	FARNAN, I; GRANDINETTI, PJ; BALTISBERGER, JH; STEBBINS, JF; WERNER, U; EASTMAN, MA; PINES, A				FARNAN, I; GRANDINETTI, PJ; BALTISBERGER, JH; STEBBINS, JF; WERNER, U; EASTMAN, MA; PINES, A			QUANTIFICATION OF THE DISORDER IN NETWORK-MODIFIED SILICATE-GLASSES	NATURE			English	Article							BOND-ANGLE DISTRIBUTION; VITREOUS SILICA; O-17 NMR; TEMPERATURE; DYNAMICS; SOLIDS; NUCLEI; TIME	Local order in silicate glasses has been observed by many experimental techniques to be similar to that in crystalline materials. Details of the intermediate-range order are more elusive, but essential for understanding the lack of long-range symmetry in glasses and the effect of composition on glass structure. Two-dimensional O-17 dynamic-angle-spinning nuclear magnetic resonance experiments reveal intermediate-range order in the distribution of inter-tetrahedral (Si-O-Si) bond angles and a high degree of order in the disposition of oxygen atoms around the network-modifying cations.	LAWRENCE BERKELEY LAB,DIV MAT SCI,BERKELEY,CA 94720; UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	FARNAN, I (corresponding author), STANFORD UNIV,DEPT GEOL,STANFORD,CA 94305, USA.		Farnan, Ian/M-3881-2014; Baltisberger, Jay/C-8340-2019; Grandinetti, Philip J/F-1084-2010	Farnan, Ian/0000-0001-7844-5112; Baltisberger, Jay/0000-0003-2305-0046; Grandinetti, Philip J/0000-0003-0102-316X; Stebbins, Jonathan/0000-0002-2384-6637				CHMELKA BF, 1989, NATURE, V339, P42, DOI 10.1038/339042a0; COHEN MH, 1957, SOLID STATE PHYS, V5, P321, DOI 10.1016/S0081-1947(08)60105-8; Dupree R, 1984, NATURE, V308, P523, DOI 10.1038/308523a0; DUPREE R, 1984, J NON-CRYST SOLIDS, V68, P399, DOI 10.1016/0022-3093(84)90020-6; EASTMAN MA, IN PRESS J MAGN RESO; ECKERSLEY MC, 1988, NATURE, V335, P525, DOI 10.1038/335525a0; ENGELHARDT G, 1984, CHEM PHYS LETT, V108, P271, DOI 10.1016/0009-2614(84)87063-3; FARNAN I, 1990, J AM CHEM SOC, V112, P32, DOI 10.1021/ja00157a008; GASKELL PH, 1991, NATURE, V350, P675, DOI 10.1038/350675a0; GEISSBERGER AE, 1983, J NON-CRYST SOLIDS, V54, P121, DOI 10.1016/0022-3093(83)90087-X; GLADDEN LF, 1986, PHILOS MAG B, V53, pL81, DOI 10.1080/01418638608244284; GREAVES GN, 1981, NATURE, V293, P611, DOI 10.1038/293611a0; GREAVES GN, 1990, GLASS SCI TECHNOLO B, V4, P1; HUANG CD, 1991, J CHEM PHYS, V95, P3634, DOI 10.1063/1.460814; Kirkpatrick R. J., 1986, STRUCTURE BONDING NO; LLOR A, 1988, CHEM PHYS LETT, V152, P248, DOI 10.1016/0009-2614(88)87362-7; MELMAN H, 1991, J NON-CRYST SOLIDS, V134, P107, DOI 10.1016/0022-3093(91)90017-Z; MOZZI RL, 1969, J APPL CRYSTALLOGR, V2, P164, DOI 10.1107/S0021889869006868; MUELLER KT, 1990, J MAGN RESON, V86, P470, DOI 10.1016/0022-2364(90)90025-5; MUELLER KT, IN PRESS J PHYS CHEM; NEWTON MD, 1980, PHYS CHEM MINER, V6, P221, DOI 10.1007/BF00309858; PETTIFER RF, 1988, J NON-CRYST SOLIDS, V106, P408, DOI 10.1016/0022-3093(88)90299-2; SAMOSON A, 1988, MOL PHYS, V65, P1013, DOI 10.1080/00268978800101571; SCHWEINSBERG H, 1974, ACTA CRYSTALLOGR B, V30, P2206, DOI 10.1107/S0567740874006753; SOULES TF, 1979, J CHEM PHYS, V71, P4570, DOI 10.1063/1.438210; SPEARING DR, IN PRESS PHYS CHEM M; STEBBINS JF, 1991, NATURE, V351, P638, DOI 10.1038/351638a0; STEBBINS JF, 1988, J NON-CRYST SOLIDS, V106, P359, DOI 10.1016/0022-3093(88)90289-X; TESAR AA, 1987, J CHEM PHYS, V87, P2986, DOI 10.1063/1.453034; TOSSELL JA, 1988, PHYS CHEM MINER, V15, P564, DOI 10.1007/BF00311027; VESSAL B, 1992, NATURE, V356, P504, DOI 10.1038/356504a0; XUE X, 1991, T AM GEOPHYS UN, V72, P572	32	231	231	0	55	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 2	1992	358	6381					31	35		10.1038/358031a0	http://dx.doi.org/10.1038/358031a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JB341	1614527				2022-12-01	WOS:A1992JB34100043
J	JONES, DT; TAYLOR, WR; THORNTON, JM				JONES, DT; TAYLOR, WR; THORNTON, JM			A NEW APPROACH TO PROTEIN FOLD RECOGNITION	NATURE			English	Article							SECONDARY STRUCTURE; MEAN FORCE; PREDICTION; POTENTIALS; FEATURES; MODELS; ENERGY	THE prediction of protein tertiary structure from sequence using molecular energy calculations has not yet been successful; an alternative strategy of recognizing known motifs 1 or folds 2-4 in sequences looks more promising. We present here a new approach to fold recognition, whereby sequences are fitted directly onto the backbone coordinates of known protein structures. Our method for protein fold recognition involves automatic modelling of protein structures using a given sequence, and is based on the frameworks of known protein folds. The plausibility of each model, and hence the degree of compatibility between the sequence and the proposed structure, is evaluated by means of a set of empirical potentials derived from proteins of known structure. The novel aspect of our approach is that the matching of sequences to backbone coordinates is performed in full three-dimensional space, incorporating specific pair interactions explicitly.	NATL INST MED RES,MATH BIOL LAB,LONDON NW7 1AA,ENGLAND	MRC National Institute for Medical Research	JONES, DT (corresponding author), UNIV LONDON UNIV COLL,DEPT BIOCHEM & MOLEC BIOL,BIOMOLEC STRUCT & MODELLING UNIT,GOWER ST,LONDON WC1E 6BT,ENGLAND.			Thornton, Janet/0000-0003-0824-4096				BASHFORD D, 1987, J MOL BIOL, V196, P199, DOI 10.1016/0022-2836(87)90521-3; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Dayhoff M., 1978, ATLAS PROTEIN SEQ S3, V5, P345; EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0; FINKELSTEIN AV, 1991, NATURE, V351, P497, DOI 10.1038/351497a0; HENDLICH M, 1990, J MOL BIOL, V216, P167, DOI 10.1016/S0022-2836(05)80068-3; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; NOVOTNY J, 1984, J MOL BIOL, V177, P787, DOI 10.1016/0022-2836(84)90049-4; ORENGO CA, 1990, J THEOR BIOL, V147, P517, DOI 10.1016/S0022-5193(05)80263-2; OVERINGTON J, 1990, P ROY SOC B-BIOL SCI, V241, P132, DOI 10.1098/rspb.1990.0077; PASTORE A, 1990, PROTEINS, V8, P133, DOI 10.1002/prot.340080204; SCHIRMER T, 1985, J MOL BIOL, V184, P257, DOI 10.1016/0022-2836(85)90379-1; SIPPL MJ, 1990, J MOL BIOL, V213, P859, DOI 10.1016/S0022-2836(05)80269-4; TAYLOR WR, 1989, J MOL BIOL, V208, P1, DOI 10.1016/0022-2836(89)90084-3; TAYLOR WR, 1991, PROTEIN ENG, V4, P853, DOI 10.1093/protein/4.8.853; TAYLOR WR, 1984, J MOL BIOL, V173, P487, DOI 10.1016/0022-2836(84)90393-0; THORNTON JM, 1991, NATURE, V354, P105, DOI 10.1038/354105a0	19	985	1017	2	51	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 2	1992	358	6381					86	89		10.1038/358086a0	http://dx.doi.org/10.1038/358086a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JB341	1614539				2022-12-01	WOS:A1992JB34100061
J	KARLHOFER, FM; RIBAUDO, RK; YOKOYAMA, WM				KARLHOFER, FM; RIBAUDO, RK; YOKOYAMA, WM			MHC CLASS-I ALLOANTIGEN SPECIFICITY OF LY-49+ IL-2-ACTIVATED NATURAL-KILLER-CELLS	NATURE			English	Article							MONOCLONAL-ANTIBODIES; EXPRESSION; ANTIGEN; IDENTIFICATION; RECEPTOR; GENE; MOLECULES; SUSCEPTIBILITY; RECOGNITION; RESISTANCE	THE molecular basis of target cell recognition by CD3- natural killer (NK) cells is poorly understood, despite the ability of NK cells to lyse specific tumour cells 1,2. In general, target cell major histocompatibility complex (MHC) class I antigen expression correlates with resistance to NK cell-mediated lysis 3-9, possibly because NK cell-surface molecules engage MHC class I antigens and consequently deliver inhibitory signals 3,4. Natural killer cell allospecificity involves the MHC class I peptide-binding cleft 10, and further understanding of this allospecificity should provide insight into the molecular mechanisms of NK cell recognition. The Ly-49 cell surface molecule is expressed by 20% of CD3- NK cells 11 in C57BL/6 mice (H-2b). Here we show that C57BL/6-derived, interleukin-2-activated NK cells expressing Ly-49 do not lyse target cells displaying H-2d or H-2k despite efficient spontaneous lysis by Ly-49- effector cells. This preferential resistance correlates with expression of target cell MHC class I antigens. Transfection and expression of H-2D(d), but not H-2K(d) or H-2L(d), renders a susceptible target (H-2b) resistant to Ly-49+ effector cells. The transfected resistance is abrogated by monoclonal antibodies directed against Ly-49 or the alpha-1/alpha-2 domains of H-2D(d), suggesting that Ly-49 specifically interacts with the peptide-binding domains of the MHC class I alloantigen, H-2D(d) Inas-much as Ly49+ effector cells cannot be stimulated to lyse H-2D(d) targets, our results indicate that NK cells may possess inhibitory receptors that specifically recognize MHC class I antigens.	SAN FRANCISCO GEN HOSP, MED SERV, SAN FRANCISCO, CA 94110 USA; NIAID, IMMUNOL LAB, BETHESDA, MD 20892 USA	San Francisco General Hospital Medical Center; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	KARLHOFER, FM (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT MED, ROSALIND RUSSELL ARTHRITIS RES LAB, SAN FRANCISCO, CA 94143 USA.		Ribaudo, Randall/AAH-7094-2021					BIX M, 1991, NATURE, V349, P329, DOI 10.1038/349329a0; CICCONE E, 1990, P NATL ACAD SCI USA, V87, P9794, DOI 10.1073/pnas.87.24.9794; COCHET M, 1986, IMMUNOGENETICS, V24, P267, DOI 10.1007/BF00364531; EVANS GA, 1982, NATURE, V300, P755, DOI 10.1038/300755a0; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HERBERMAN RB, 1982, NK CELLS OTHER NATUR; HOGLUND P, 1991, P NATL ACAD SCI USA, V88, P10332, DOI 10.1073/pnas.88.22.10332; HOUCHINS JP, 1991, J EXP MED, V173, P1017, DOI 10.1084/jem.173.4.1017; HUNZIKER W, 1990, NATURE, V345, P628, DOI 10.1038/345628a0; HYMAN R, 1976, IMMUNOGENETICS, V3, P75, DOI 10.1007/BF01576940; KARLHOFER FM, 1991, J IMMUNOL, V146, P3662; Karre K, 1985, MECHANISMS CYTOTOXIC, P81; KOO GC, 1984, HYBRIDOMA, V3, P301, DOI 10.1089/hyb.1984.3.301; KUBO RT, 1989, J IMMUNOL, V142, P2736; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; LEO O, 1986, J IMMUNOL, V137, P3874; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LIAO NS, 1991, SCIENCE, V253, P199, DOI 10.1126/science.1853205; LJUNGGREN HG, 1990, IMMUNOL TODAY, V11, P237, DOI 10.1016/0167-5699(90)90097-S; LOKEN MR, 1982, J IMMUNOL METHODS, V50, pR85, DOI 10.1016/0022-1759(82)90161-2; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; MORETTA A, 1990, J EXP MED, V172, P1589, DOI 10.1084/jem.172.6.1589; NAGASAWA R, 1987, J IMMUNOL, V138, P815; PERUSSIA B, 1989, J EXP MED, V170, P73, DOI 10.1084/jem.170.1.73; QUILLET A, 1988, J IMMUNOL, V141, P17; RUBOCKI RJ, 1991, J IMMUNOL, V146, P2352; SPRINGER TA, 1980, MONOCLONAL ANTIBODIE, P185; STORKUS WJ, 1991, P NATL ACAD SCI USA, V88, P5989, DOI 10.1073/pnas.88.14.5989; STURMHOFEL K, 1990, EUR J IMMUNOL, V20, P171, DOI 10.1002/eji.1830200125; SUZUKI N, 1990, J EXP MED, V172, P457, DOI 10.1084/jem.172.2.457; TRINCHIERI G, 1989, ADV IMMUNOL, V47, P187, DOI 10.1016/S0065-2776(08)60664-1; YOKOYAMA WM, 1990, J IMMUNOL, V145, P2353; YOKOYAMA WM, 1989, J IMMUNOL, V143, P1379; YOKOYAMA WM, 1991, J IMMUNOL, V147, P3229	34	737	747	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 2	1992	358	6381					66	70		10.1038/358066a0	http://dx.doi.org/10.1038/358066a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JB341	1614533				2022-12-01	WOS:A1992JB34100055
J	KRUMHOLZ, HM; PASTERNAK, RC; WEINSTEIN, MC; FRIESINGER, GC; RIDKER, PM; TOSTESON, ANA; GOLDMAN, L				KRUMHOLZ, HM; PASTERNAK, RC; WEINSTEIN, MC; FRIESINGER, GC; RIDKER, PM; TOSTESON, ANA; GOLDMAN, L			COST-EFFECTIVENESS OF THROMBOLYTIC THERAPY WITH STREPTOKINASE IN ELDERLY PATIENTS WITH SUSPECTED ACUTE MYOCARDIAL-INFARCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							WORCESTER HEART-ATTACK; MORTALITY; PROGNOSIS; RATES	Background. There is a lack of consensus among cardiologists about the potential benefit of thrombolytic therapy for suspected acute myocardial infarction in older patients. To investigate this issue, we constructed a decision-analytic model for patients 75 years of age or older who present with ST-segment elevation within six hours of the onset of symptoms suggesting acute myocardial infarction. Methods. The variables incorporated in this model were the probability that the patient has an acute myocardial infarction, the probability of in-hospital death among patients with acute myocardial infarction who do not receive thrombolytic therapy, the probability of a fatal or incapacitating complication resulting from thrombolytic therapy, and the expected relative reduction in the risk of death associated with thrombolytic therapy in patients with acute myocardial infarction. Our analyses were based primarily on the use of streptokinase as the thrombolytic agent. Results. Given our base-line assumptions, the probability of dying in the hospital was 21.4 percent if thrombolytic therapy was given and 24.4 percent if it was not given. In one-way sensitivity analyses, thrombolytic therapy decreased the risk of dying if the probability that the patient had an acute myocardial infarction was assumed to be greater than 9 percent, if the probability of dying in the hospital after an acute myocardial infarction without thrombolytic therapy was assumed to be greater than 3 percent, if the rate of fatal or incapacitating complications due to thrombolytic therapy was assumed to be 4 percent or less, or if the relative reduction in the risk of death associated with thrombolytic therapy was assumed to be greater than 1 percent. On the basis of our base-line assumptions, our estimate of the cost effectiveness of streptokinase therapy (the cost per year of life saved) for an 80-year-old patient with suspected acute myocardial infarction was $21,200. For a wide range of assumptions about risks, benefits, and costs, the cost per year of life saved remained less than $55,000. Conclusions. Within the limitations imposed by the assumptions used in our analysis, thrombolytic therapy with streptokinase was found to be a beneficial and cost-effective treatment for suspected acute myocardial infarction in elderly patients in a wide variety of clinical circumstances.	HARVARD UNIV, BETH ISRAEL HOSP,SCH MED,DEPT MED,DIV CARDIOVASC, BOSTON, MA 02215 USA; HARVARD UNIV, BETH ISRAEL HOSP,SCH MED,DEPT MED, DIV CLIN EPIDEMIOL, BOSTON, MA 02215 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, BOSTON, MA 02115 USA; VANDERBILT UNIV, MED CTR, DIV CARDIOVASC, NASHVILLE, TN 37240 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Vanderbilt University			, Harlan/AAI-2875-2020		AHRQ HHS [1R01HS06258, 1P01HS06341, 1R01HS06452] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		[Anonymous], 1987, Lancet, V2, P871; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; [Anonymous], 1989, NEW ENGL J MED, V320, P618; CHAMBERLAIN DA, 1988, LANCET, V1, P545; CHAMBERLAIN DA, 1990, LANCET, V335, P427; CRAGG DR, 1991, ANN INTERN MED, V115, P173, DOI 10.7326/0003-4819-115-3-173; GOLDBERG RJ, 1989, AM HEART J, V117, P543, DOI 10.1016/0002-8703(89)90727-8; GOLDBERG RJ, 1988, AM HEART J, V115, P761, DOI 10.1016/0002-8703(88)90876-9; GOLDMAN L, 1988, NEW ENGL J MED, V318, P797, DOI 10.1056/NEJM198803313181301; GRINES CL, 1990, J AM COLL CARDIOL, V16, P223, DOI 10.1016/0735-1097(90)90482-5; GUNNAR RM, 1990, J AM COLL CARDIOL, V16, P249, DOI 10.1016/0735-1097(90)90575-A; GURWITZ JH, 1991, JAMA-J AM MED ASSOC, V265, P1720, DOI 10.1001/jama.265.13.1720; Hodgson T A, 1984, Health Care Financ Rev, V5, P1; LITTENBERG B, 1990, ANN INTERN MED, V112, P192, DOI 10.7326/0003-4819-112-3-192; MULLER DWM, 1990, ANN INTERN MED, V113, P949, DOI 10.7326/0003-4819-113-12-949; OCONNOR CM, 1990, J AM COLL CARDIOL, V16, P533, DOI 10.1016/0735-1097(90)90338-P; PASTERNAK RC, 1992, HEART DISEASE TXB CA, P1232; PFEFFER MA, 1991, JAMA-J AM MED ASSOC, V266, P528, DOI 10.1001/jama.266.4.528; ROIG E, 1987, CIRCULATION, V76, P280, DOI 10.1161/01.CIR.76.2.280; SHERRY S, 1991, J AM COLL CARDIOL, V17, P1237, DOI 10.1016/0735-1097(91)90859-8; WEAVER WD, 1991, J AM COLL CARDIOL, V18, P657, DOI 10.1016/0735-1097(91)90784-7; WEINSTEIN MC, 1987, AM J PUBLIC HEALTH, V77, P1417, DOI 10.2105/AJPH.77.11.1417; WILCOX RG, 1988, LANCET, V2, P525; 1988, AGING AM TRENDS PROJ; 1991, CIRCULATION S2, V84, P230	26	160	160	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 2	1992	327	1					7	13		10.1056/NEJM199207023270102	http://dx.doi.org/10.1056/NEJM199207023270102			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA761	1598117				2022-12-01	WOS:A1992JA76100002
J	KUO, CJ; CHUNG, JK; FIORENTINO, DF; FLANAGAN, WM; BLENIS, J; CRABTREE, GR				KUO, CJ; CHUNG, JK; FIORENTINO, DF; FLANAGAN, WM; BLENIS, J; CRABTREE, GR			RAPAMYCIN SELECTIVELY INHIBITS INTERLEUKIN-2 ACTIVATION OF P70 S6 KINASE	NATURE			English	Article							PEPTIDYL-PROLYL ISOMERASE; IMMUNOSUPPRESSANT FK506; MACROLIDES FK-506; DISTINCT; PROTEIN; CLONING; ENZYME; CELLS	THE macrolide rapamycin induces cell cycle G1 arrest in yeast and in mammalian cells 1-3, which suggests that an evolutionarily conserved, rapamycin-sensitive pathway may regulate entry into S phase. In mammals, rapamycin inhibits interleukin-2 receptor-induced S phase entry and subsequent T-cell proliferation 4-6, resulting in immunosuppression. Here we show that interleukin-2 selectively stimulates the phosphorylation and activation of p70 S6 kinase but not the erk-encoded MAP kinases and rsk-encoded S6 kinases 7,8. Rapamycin completely and rapidly inhibits interleukin-2-induced phosphorylation and activation of p70 S6 kinase at concentrations comparable to those blocking S phase entry of T cells (0.05-0.2 nM). The structurally related macrolide FK506 competitively antagonizes the actions of rapamycin, indicating that these effects are mediated by FKBP, which binds the transition-state mimic structure common to both rapamycin and FK506 (refs 4, 6, 9-11). The selective blockade of the p70 S6 kinase activation cascade by the rapamycin-FKBP complex implicates this signalling pathway in the regulation of T cell entry into S phase.	HARVARD UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School	KUO, CJ (corresponding author), STANFORD UNIV,MED CTR,SCH MED,BECKMAN CTR,HOWARD HUGHES MED INST,MOLEC & GENET MED UNIT,STANFORD,CA 94305, USA.			Kuo, Calvin/0000-0002-7427-5985; Fiorentino, David/0000-0001-7951-3674				BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BLENIS J, 1991, CANCER CELL, V3, P1; CANTRELL DA, 1984, SCIENCE, V224, P1312, DOI 10.1126/science.6427923; CHEN RH, 1991, MOL CELL BIOL, V11, P1861, DOI 10.1128/MCB.11.4.1861; CHUNG J, IN PRESS CELL; CHUNG JK, 1991, MOL CELL BIOL, V11, P1868, DOI 10.1128/MCB.11.4.1868; DUMONT FJ, 1990, J IMMUNOL, V144, P1418; DUMONT FJ, 1990, J IMMUNOL, V144, P251; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; KOZMA SC, 1990, P NATL ACAD SCI USA, V87, P7365, DOI 10.1073/pnas.87.19.7365; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MIYAZAKI T, 1991, EMBO J, V10, P3191, DOI 10.1002/j.1460-2075.1991.tb04881.x; MORRIS RE, 1991, IMMUNOL TODAY, V12, P137; PELECH SL, 1986, P NATL ACAD SCI USA, V83, P5968, DOI 10.1073/pnas.83.16.5968; PRICE DJ, 1990, P NATL ACAD SCI USA, V87, P7944, DOI 10.1073/pnas.87.20.7944; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0	23	582	596	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 2	1992	358	6381					70	73		10.1038/358070a0	http://dx.doi.org/10.1038/358070a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JB341	1614535				2022-12-01	WOS:A1992JB34100056
J	MANN, GV				MANN, GV			LIPID-LEVELS AND AFFLUENT DIETS	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter																		MANN GV, 1955, NEW ENGL J MED, V253, P349, DOI 10.1056/NEJM195509012530901; MCMURRY MP, 1991, NEW ENGL J MED, V325, P1704, DOI 10.1056/NEJM199112123252405; WALKER WJ, 1953, AM J MED, V14, P654, DOI 10.1016/0002-9343(53)90383-0	3	0	0	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 2	1992	327	1					52	52						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA761	1598109				2022-12-01	WOS:A1992JA76100020
J	MIYAKE, M; TAKI, T; HITOMI, S; HAKOMORI, S				MIYAKE, M; TAKI, T; HITOMI, S; HAKOMORI, S			CORRELATION OF EXPRESSION OF H/LE(Y)/LE(B) ANTIGENS WITH SURVIVAL IN PATIENTS WITH CARCINOMA OF THE LUNG	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-EMBRYOS; CARBOHYDRATE; BLADDER; CANCERS	Background. The level of expression of H/Le(y)/Le(b) antigens is high in various histologic types of lung cancer, a feature that may be related to deletion of A and B blood-group antigens. We evaluated the possibility that expression of this antigen, which can be defined by the monoclonal antibody MIA-15-5, might be of prognostic value, as suggested by our previous observation that MIA-15-5 inhibits tumor-cell motility and metastasis. Methods. We used MIA-15-5 to stain tissue sections from 149 patients with primary lung cancer whose clinico-pathological histories were well documented. The survival curves for patients whose tumors stained positively were compared with the curves for those whose tumors stained negatively. Multivariate analyses were performed with a Cox proportional-hazards regression model. Results. Among the 149 patients studied, five-year survival in the 91 patients with MIA-positive tumors was significantly lower than survival in the 58 with MIA-negative tumors (20.9 percent vs. 58.6 percent, P<0.001). Among the 67 patients with squamous-cell carcinoma, the rates also differed significantly (10.5 percent vs. 62.1 percent, P<0.001). The difference in survival between patients with MIA-positive tumors and those with MIA-negative tumors was significant among patients with blood groups A and AB (P<0.001), but not among those with blood group B or 0 (P = 0.071 and 0.068, respectively). Multivariate analysis with the Cox regression model indicated that positivity best correlated with five-year mortality, followed by lymph-node status (N stage) and tumor size (T stage), whereas sex, age, and blood group did not correlate with mortality. Conclusions. Positivity for MIA (i.e., immunohistologic staining by MIA-15-5, which defines H/Le(y)/Le(b) antigens) is inversely correlated with survival among patients with primary lung cancer and may be of prognostic value.	KYOTO UNIV, CHEST DIS RES INST, DEPT THORAC SURG, KYOTO 606, JAPAN; UNIV WASHINGTON, INST BIOMEMBRANE, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT PATHOBIOL, SEATTLE, WA 98195 USA	Kyoto University; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	MIYAKE, M (corresponding author), KITANO HOSP, TAZUKE KOFUKAI MED RES INST, DEPT THORAC SURG, KITA KIE, OSAKA 530, JAPAN.				NCI NIH HHS [CA-42505] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042505] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1982, AM J CLIN PATHOL, V77, P123; COON JS, 1985, CANCER, V56, P797, DOI 10.1002/1097-0142(19850815)56:4<797::AID-CNCR2820560417>3.0.CO;2-H; COX DR, 1972, J R STAT SOC B, V34, P187; DABELSTEEN E, 1983, CANCER RES, V43, P1451; DABELSTEEN E, 1975, ACTA PATH MICRO IM A, VA 83, P292; DAVIDSOHN I, 1969, ARCH PATHOL, V87, P306; DAVIDSOHN I, 1966, ARCH PATHOL, V81, P381; HAKOMORI S, 1991, CURR OPIN IMMUNOL, V3, P646, DOI 10.1016/0952-7915(91)90091-E; HAKOMORI S, 1974, ANTIGENS, V2, P79; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; Hermanek P, 1987, TNM CLASSIFICATION M, P69; ITAI S, 1990, CANCER RES, V50, P7603; ITZKOWITZ SH, 1990, CANCER-AM CANCER SOC, V66, P1960, DOI 10.1002/1097-0142(19901101)66:9<1960::AID-CNCR2820660919>3.0.CO;2-X; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KAY HE, 1961, J NATL CANCER I, V26, P1349; KOVARIK S, 1968, ARCH PATHOL, V86, P12; LEE JS, 1991, NEW ENGL J MED, V324, P1084, DOI 10.1056/NEJM199104183241603; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MASAMUNE H, 1952, Tohoku J Exp Med, V56, P37; MASAMUNE H, 1958, TOHOKU J EXP MED, V8, P81; MIYAKE M, 1991, BIOCHEMISTRY-US, V30, P3328, DOI 10.1021/bi00227a023; MIYAKE M, 1988, CANCER RES, V48, P7150; ORNTOFT TF, 1989, INT J CANCER, V43, P774, DOI 10.1002/ijc.2910430505; ROSEN EM, 1989, IN VITRO CELL DEV B, V25, P1079; SILLETTI S, 1991, CANCER RES, V51, P3507; STANFORD DR, 1986, INT J CANCER, V37, P435, DOI 10.1002/ijc.2910370316; STELLNER K, 1973, BIOCHEM BIOPH RES CO, V55, P439, DOI 10.1016/0006-291X(73)91106-6	27	232	249	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 2	1992	327	1					14	18		10.1056/NEJM199207023270103	http://dx.doi.org/10.1056/NEJM199207023270103			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA761	1317941				2022-12-01	WOS:A1992JA76100003
J	ELDAR, M; SIEVNER, Z; GOLDBOURT, U; REICHERREISS, H; KAPLINSKY, E; BEHAR, S				ELDAR, M; SIEVNER, Z; GOLDBOURT, U; REICHERREISS, H; KAPLINSKY, E; BEHAR, S			PRIMARY VENTRICULAR-TACHYCARDIA IN ACUTE MYOCARDIAL-INFARCTION - CLINICAL CHARACTERISTICS AND MORTALITY	ANNALS OF INTERNAL MEDICINE			English	Article						MYOCARDIAL INFARCTION; TACHYCARDIA; HEART VENTRICLE; DEATH, SUDDEN; HEMODYNAMICS	FIBRILLATION; PROGNOSIS; ARRHYTHMIAS; REPERFUSION	Objective: To examine the immediate and long-term clinical and prognostic significance of primary ventricular tachycardia, defined as tachycardia of ventricular origin occurring within 48 hours of acute myocardial infarction in patients without hemodynamic compromise (Killip class I). Design: Prospective cohort study. Setting: Intensive coronary care units in eight regional, referral, and university hospitals. Patients: A total of 162 patients with primary ventricular tachycardia, both sustained and nonsustained (study group), and 2578 counterparts without ventricular tachycardia (reference group). Measurements: In-hospital rates of atrial fibrillation, atrioventricular block, congestive heart failure, cardiogenic shock, and cardiac arrest. In-hospital and 1-year follow-up rates of sudden death, nonsudden cardiac death, and noncardiac death. Results: The study and reference groups had similar mortality (in-hospital, 6.8% and 9.6%, P > 0.2 and at 1 year after discharge, 3.7% and 5.4%, P > 0.2, respectively) and in-hospital complication rates (atrioventricular block, 13.0% and 9.7%, P > 0.2; cardiogenic shock, 3.7% and 3.0%, P > 0.2; cardiac arrest, 1.8% and 4.4%, P > 0.2, respectively). Patients with sustained ventricular tachycardia (28 patients) compared with those with nonsustained ventricular tachycardia (134 patients) had higher rates of polymorphic tachycardia (50% compared with 6%, P = 0.001), in-hospital total cardiac mortality (21 % compared with 4%, P = 0.003) and sudden-death mortality (14% compared with 2%, P = 0.001); they also showed a trend toward a higher in-hospital mortality than the reference group (21.4% compared with 9.6%, P = 0.15) but had no increased mortality 1 year after discharge (4.6% compared with 5.4%, P > 0.2). Conclusions: As a group, patients with primary ventricular tachycardia do not differ from counterparts without primary ventricular tachycardia in their in-hospital clinical course and 1-year prognosis. Primary sustained ventricular tachycardia is often polymorphic and carries worse in-hospital prognosis than nonsustained tachycardia. However, it does not predict recurrent ventricular tachycardia or increased sudden-death rates during the next year.			ELDAR, M (corresponding author), CHAIM SHEBA MED CTR, NEUFELD CARDIAC RES CTR, NEUFELD CARDIAC RES INST, IL-52621 TEL HASHOMER, ISRAEL.							[Anonymous], 1987, Lancet, V2, P871; [Anonymous], 1989, NEW ENGL J MED, V321, P406; [Anonymous], 1977, APPL PSYCH MEAS, DOI DOI 10.1177/014662167700100218; BEHAR S, 1990, AM J CARDIOL, V66, P1208, DOI 10.1016/0002-9149(90)91101-B; BEHAR S, 1988, EUR HEART J, V9, P354; CAMPBELL RWF, 1981, BRIT HEART J, V46, P351; DUBOIS C, 1986, EUR HEART J, V7, P945, DOI 10.1093/oxfordjournals.eurheartj.a061999; GREENLAND P, 1991, CIRCULATION, V83, P484, DOI 10.1161/01.CIR.83.2.484; HINE LK, 1989, JAMA-J AM MED ASSOC, V262, P3037, DOI 10.1001/jama.262.21.3037; HOROWITZ LN, 1981, CIRCULATION, V63, P1120, DOI 10.1161/01.CIR.63.5.1120; KERSSCHOT IE, 1986, J AM COLL CARDIOL, V7, P1234, DOI 10.1016/S0735-1097(86)80141-3; LAWRIE DM, 1968, LANCET, V2, P523; LIE K I, 1974, European Journal of Cardiology, V1, P379; MILLER FC, 1986, AM HEART J, V112, P928, DOI 10.1016/0002-8703(86)90302-9; NICOD P, 1988, J AM COLL CARDIOL, V11, P464, DOI 10.1016/0735-1097(88)91518-5; TCHOU P, 1989, Journal of the American College of Cardiology, V13, p21A; TOFLER GH, 1987, AM J CARDIOL, V60, P755, DOI 10.1016/0002-9149(87)91018-6; TYE KH, 1979, AM J CARDIOL, V44, P632, DOI 10.1016/0002-9149(79)90280-7; VOLPI A, 1987, NEW ENGL J MED, V317, P257, DOI 10.1056/NEJM198707303170501; VOLPI A, 1989, AM J CARDIOL, V63, P1174, DOI 10.1016/0002-9149(89)90174-4; 1985, SAS USERS GUIDE STAT, P403; 1985, SAS USERS GUIDE STAT, P171	22	38	39	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1992	117	1					31	36		10.7326/0003-4819-117-1-31	http://dx.doi.org/10.7326/0003-4819-117-1-31			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA435	1596045				2022-12-01	WOS:A1992JA43500005
J	HEALY, B				HEALY, B			RESEARCH OFFERS NEW HOPE FOR YOUNG PERSONS WITH DIABETES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											HEALY, B (corresponding author), NIH,BETHESDA,MD 20892, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 1	1992	268	1					20	20						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA165	1608101				2022-12-01	WOS:A1992JA16500004
J	LEHMANN, KG; FRANCIS, CK; DODGE, HT				LEHMANN, KG; FRANCIS, CK; DODGE, HT			MITRAL REGURGITATION IN EARLY MYOCARDIAL-INFARCTION - INCIDENCE, CLINICAL DETECTION, AND PROGNOSTIC IMPLICATIONS	ANNALS OF INTERNAL MEDICINE			English	Article						MITRAL VALVE INSUFFICIENCY; MYOCARDIAL INFARCTION; VENTRICULAR FUNCTION, LEFT RADIONUCLEOTIDE; VENTRICULOGRAPHY	PAPILLARY-MUSCLE DYSFUNCTION; PLASMINOGEN-ACTIVATOR; VENTRICULAR-FUNCTION; LEAFLET CLOSURE; RUPTURE; ECHOCARDIOGRAPHY; THROMBOLYSIS; ADVANTAGES; MECHANISM; TRIAL	Objective: To investigate mitral regurgitation occurring early in the course of acute myocardial infarction with respect to its incidence, the impact of infarct size and location, the accuracy of clinical detection, the contribution of global and regional left ventricular performance, and its influence on prognosis. Design: Prospective observational study derived from patients entering Phase I of the Thrombolysis in Myocardial Infarction (TIMI) trial. Setting: Multicenter trial involving 13 university-affiliated medical centers. Patients: A total of 206 patients studied within 7 hours of symptom onset during their first myocardial infarction. Measurements: Contrast left ventriculography was used to document mitral regurgitation. Results: Mitral regurgitation was present in 27 patients (13%). Although the presence of regurgitation correlated with the site of infarction (20 of 27 had anterior infarctions) and the number of akinetic chords, it was not statistically related to the peak creatine kinase value or to left ventricular chamber size or filling pressure. A murmur of mitral regurgitation was heard in only 2 patients (1 incorrectly). The presence of early mitral regurgitation predicted cardiovascular mortality at 1 year by univariate (relative risk, 12.2; 95% Cl, 3.5 to 42; P < 0.0001) and multivariate (relative risk, 7.5; Cl, 2.0 to 28.6; P = 0.0008) analyses. Conclusions: Mitral regurgitation in early myocardial infarction is generally clinically "silent," is more common in anterior infarction, is associated with regional dysfunction but not early ventricular dilation or peak enzyme release, and is an important predictor of cardiovascular mortality.	YALE UNIV, SCH MED, NEW HAVEN, CT 06510 USA; UNIV WASHINGTON, SCH MED, SEATTLE, WA 98195 USA	Yale University; University of Washington; University of Washington Seattle								AHNVE S, 1986, AM J CARDIOL, V58, P872, DOI 10.1016/S0002-9149(86)80002-9; BARBOUR DJ, 1986, J AM COLL CARDIOL, V8, P558, DOI 10.1016/S0735-1097(86)80182-6; BARZILAI B, 1988, AM J CARDIOL, V61, P220, DOI 10.1016/0002-9149(88)90919-8; BARZILAI B, 1990, AM J CARDIOL, V65, P1169, DOI 10.1016/0002-9149(90)90968-7; BERGER P B, 1991, Journal of the American College of Cardiology, V17, p247A; BLUMLEIN S, 1986, CIRCULATION, V74, P306, DOI 10.1161/01.CIR.74.2.306; BRAND FR, 1967, CIRCULATION, V36, pII75; BRAUNWALD E, 1988, HEART DISEASE TXB CA, P1042; BURCH GE, 1968, AM HEART J, V75, P399, DOI 10.1016/0002-8703(68)90097-5; BURCH GE, 1985, ARCH INTERN MED, V312, P932; CHENG TO, 1969, AM J MED, V47, P924, DOI 10.1016/0002-9343(69)90206-X; FORRESTER JS, 1971, CIRCULATION, V44, P877, DOI 10.1161/01.CIR.44.5.877; GAHL K, 1977, BRIT HEART J, V39, P13; GODLEY RW, 1981, CIRCULATION, V63, P565, DOI 10.1161/01.CIR.63.3.565; Gross L., 1921, BLOOD SUPPLY HEART I; HEIKKILA J, 1967, BRIT HEART J, V29, P162; HICKEY MS, 1988, CIRCULATION, V78, P51; HIRAKAWA S, 1977, AM J PHYSIOL, V233, pH384, DOI 10.1152/ajpheart.1977.233.3.H384; IZUMI S, 1987, CIRCULATION, V76, P777, DOI 10.1161/01.CIR.76.4.777; KINNEY EL, 1985, AM HEART J, V109, P87, DOI 10.1016/0002-8703(85)90420-X; MAISEL AS, 1986, AM HEART J, V112, P705, DOI 10.1016/0002-8703(86)90464-3; MILLER GE, 1968, J THORAC CARDIOV SUR, V56, P611, DOI 10.1016/S0022-5223(19)42786-4; MITTAL AK, 1971, CIRCULATION, V44, P174, DOI 10.1161/01.CIR.44.2.174; MOSS AJ, 1983, NEW ENGL J MED, V309, P331, DOI 10.1056/nejm198308113090602; MUKHARJI J, 1984, AM J CARDIOL, V54, P31, DOI 10.1016/0002-9149(84)90299-6; NAJAFI H, 1975, ANN THORAC SURG, V20, P529, DOI 10.1016/S0003-4975(10)64252-X; NISHIMURA RA, 1983, AM J CARDIOL, V51, P373, DOI 10.1016/S0002-9149(83)80067-8; OGAWA S, 1979, AM HEART J, V97, P312, DOI 10.1016/0002-8703(79)90430-7; PASSAMANI E, 1985, NEW ENGL J MED, V312, P932; PERLOFF JK, 1972, CIRCULATION, V46, P227, DOI 10.1161/01.CIR.46.2.227; PHILLIPS JH, 1963, ANN INTERN MED, V59, P508, DOI 10.7326/0003-4819-59-4-508; PINSON CW, 1984, J THORAC CARDIOV SUR, V88, P663; RADFORD MJ, 1979, CIRCULATION, V60, pI39; REPLOGLE RL, 1989, CIRCULATION, V79, P122; ROBERTS WC, 1972, CIRCULATION, V46, P138, DOI 10.1161/01.CIR.46.1.138; SANDLER H, 1968, AM HEART J, V75, P325, DOI 10.1016/0002-8703(68)90089-6; SHEEHAN FH, 1987, CIRCULATION, V75, P817, DOI 10.1161/01.CIR.75.4.817; SHEEHAN FH, 1986, CIRCULATION, V74, P293, DOI 10.1161/01.CIR.74.2.293; SPALTEHOLZ W, 1924, ARTERIENDIE HERZWAND; TEI C, 1983, CIRCULATION, V68, P183, DOI 10.1161/01.CIR.68.1.183; TSAKIRIS AG, 1970, MAYO CLIN PROC, V45, P275; WEI JY, 1979, ANN INTERN MED, V90, P149, DOI 10.7326/0003-4819-90-2-149; WILLIAMS DO, 1986, CIRCULATION, V73, P338, DOI 10.1161/01.CIR.73.2.338; ZELDIS SM, 1980, CATHETER CARDIO DIAG, V6, P225, DOI 10.1002/ccd.1810060303	44	149	152	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1992	117	1					10	17		10.7326/0003-4819-117-1-10	http://dx.doi.org/10.7326/0003-4819-117-1-10			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA435	1596042				2022-12-01	WOS:A1992JA43500002
J	LEVINE, MN; GAFNI, A; MARKHAM, B; MACFARLANE, D				LEVINE, MN; GAFNI, A; MARKHAM, B; MACFARLANE, D			A BEDSIDE DECISION INSTRUMENT TO ELICIT A PATIENTS PREFERENCE CONCERNING ADJUVANT CHEMOTHERAPY FOR BREAST-CANCER	ANNALS OF INTERNAL MEDICINE			English	Article						DECISION MAKING; BREAST NEOPLASMS; ANTINEOPLASTIC AGENTS; QUALITY OF LIFE PATIENT SATISFACTION	THERAPY; QUALITY; LIFE	The objective of this study was to develop an instrument to help clinicians inform patients with breast cancer of risks and benefits of adjuvant chemotherapy as derived from clinical trials and to help the informed patient decide whether she prefers treatment or no treatment. The instrument consists of a visual aid (called the decision board) and written material. It provides detailed information on a patient's choices (chemotherapy or no chemotherapy), outcomes (recurrence or not), probabilities of outcomes and their meaning, and quality of life associated with treatment choice and outcome. The validity and reliability of the instrument were evaluated in 30 healthy female volunteers. It was first administered using standard estimates of recurrence for node-negative breast cancer (15% risk of recurrence without treatment, which is reduced to 10% with chemotherapy). A preference for treatment (or no treatment) was then elicited. The validity was evaluated by changing the information provided on risks and benefits and determining whether the preference changed in a predictable manner. To test for reliability, the instrument was administered 2 weeks later. Seventeen women chose chemotherapy and 13 chose no chemotherapy. In the former group, 14 women (82%) switched preference when the magnitude of benefit was reduced, and 16 (94%) switched when the toxicity of treatment was increased. For those women who chose not to receive chemotherapy, 12 (92%) switched when the benefit was increased and 100% switched when toxicity was eliminated. The reliability was excellent (kappa = 0.86). The instrument has been used to elicit treatment preferences in 37 newly presenting patients with high-risk, node-negative breast cancer and has been found to be acceptable and helpful to the patient.	MCMASTER UNIV, HAMILTON L8S 4L8, ONTARIO, CANADA	McMaster University	LEVINE, MN (corresponding author), HAMILTON REG CANC CTR, 699 CONCESS ST, HAMILTON L8V 5C3, ONTARIO, CANADA.							BONADONNA G, 1985, J CLIN ONCOL, V3, P259, DOI 10.1200/JCO.1985.3.2.259; BROCK DW, 1990, NEW ENGL J MED, V322, P1595, DOI 10.1056/NEJM199005313222209; BUDESCU DV, 1990, ORGAN BEHAV HUM DEC, V46, P240, DOI 10.1016/0749-5978(90)90031-4; CASSILETH BR, 1980, ANN INTERN MED, V92, P832, DOI 10.7326/0003-4819-92-6-832; DEVITA VT, 1989, NEW ENGL J MED, V320, P527, DOI 10.1056/NEJM198902233200812; FISHER B, 1989, NEW ENGL J MED, V320, P473, DOI 10.1056/NEJM198902233200801; GAFNI A, 1990, NEW ENGL J MED, V323, P1354; GOLDHIRSCH A, 1989, NEW ENGL J MED, V320, P491; HENDERSON IC, 1987, CURR PROB CANCER, V11, P127; HILLNER BE, 1991, NEW ENGL J MED, V324, P160, DOI 10.1056/NEJM199101173240305; HUGHES TE, 1991, MED CARE, V29, P297, DOI 10.1097/00005650-199103000-00011; LEVINE MN, 1988, J CLIN ONCOL, V6, P1798, DOI 10.1200/JCO.1988.6.12.1798; LEVINE MN, 1991, J CLIN ONCOL, V9, P348, DOI 10.1200/JCO.1991.9.2.348; LOOMES G, 1989, SOC SCI MED, V28, P299, DOI 10.1016/0277-9536(89)90030-0; MACKILLOP WJ, 1988, BRIT J CANCER, V58, P355, DOI 10.1038/bjc.1988.218; MANSOUR EG, 1989, NEW ENGL J MED, V320, P485, DOI 10.1056/NEJM198902233200803; MCGUIRE WL, 1990, J NATL CANCER I, V82, P1006, DOI 10.1093/jnci/82.12.1006; MCGUIRE WL, 1989, NEW ENGL J MED, V320, P525, DOI 10.1056/NEJM198902233200811; MEHREZ A, 1991, MED DECIS MAKING, V11, P140, DOI 10.1177/0272989X9101100212; MEHREZ A, 1989, MED DECIS MAKING, V9, P142, DOI 10.1177/0272989X8900900209; MEHREZ A, 1990, SOC SCI MED, V31, P1281, DOI 10.1016/0277-9536(90)90137-H; NORMAN GR, 1986, PDQ STATISTICS; OCONNOR AMC, 1987, J CHRON DIS, V40, P811, DOI 10.1016/0021-9681(87)90133-0; ROSE G, 1990, BRIT MED J, V301, P683, DOI 10.1136/bmj.301.6754.683; SIMINOFF LA, 1989, MED DECIS MAKING, V9, P262, DOI 10.1177/0272989X8900900406; SIMINOFF LA, 1989, J CLIN ONCOL, V7, P1192, DOI 10.1200/JCO.1989.7.9.1192	26	230	231	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1992	117	1					53	58		10.7326/0003-4819-117-1-53	http://dx.doi.org/10.7326/0003-4819-117-1-53			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA435	1596048				2022-12-01	WOS:A1992JA43500010
J	MANSON, JE; NATHAN, DM; KROLEWSKI, AS; STAMPFER, MJ; WILLETT, WC; HENNEKENS, CH				MANSON, JE; NATHAN, DM; KROLEWSKI, AS; STAMPFER, MJ; WILLETT, WC; HENNEKENS, CH			A PROSPECTIVE-STUDY OF EXERCISE AND INCIDENCE OF DIABETES AMONG UNITED-STATES MALE PHYSICIANS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GLUCOSE-TOLERANCE; POLYNESIAN POPULATION; PREVALENCE; MELLITUS; PACIFIC; RISK	Objective.-To examine prospectively the association between regular exercise and the subsequent development of non-insulin-dependent diabetes mellitus (NIDDM). Design.-Prospective cohort study including 5 years of follow-up. Participants.-21 271 US male physicians participating in the Physicians' Health Study, aged 40 to 84 years and free of diagnosed diabetes mellitus, myocardial infarction, cerebrovascular disease, and cancer at baseline. Morbidity follow-up was 99.7% complete. Main Outcome Measure.-Incidence of NIDDM. Results.-At baseline, information was obtained about frequency of vigorous exercise and other risk indicators. During 105 141 person-years of follow-up, 285 new cases of NIDDM were reported. The age-adjusted incidence of NIDDM ranged from 369 cases per 1 00 000 person-years in men who engaged in vigorous exercise less than once weekly to 214 cases per 1 00 000 person-years in those exercising at least five times per week (P, trend, <.001). Men who exercised at least once per week had an age-adjusted relative risk (RR) of NIDDM of 0.64 (95% Cl, 0.51 to 0.82; P=.0003) compared with those who exercised less frequently. The age-adjusted RR of NIDDM decreased with increasing frequency of exercise: 0.77 for once weekly, 0.62 for two to four times per week, and 0.58 for five or more times per week (P, trend, .0002). A significant reduction in risk of NIDDM persisted after adjustment for both age and body-mass index: RR, 0.71 (95% Cl, 0.56 to 0.91; P=.006) for at least once per week compared with less than once weekly, and P, trend, .009, for increasing frequency of exercise. Further control for smoking, hypertension, and other coronary risk factors did not materially alter these associations. The inverse relation of exercise to risk of NIDDM was particularly pronounced among overweight men. Conclusions.-Exercise appears to reduce the development of NIDDM even after adjusting for body-mass index. Increased physical activity may be a promising approach to the primary prevention of NIDDM.	HARVARD UNIV,SCH MED,CHANNING LAB,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PREVENT MED,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,DIABET RES CTR,BOSTON,MA 02114; BRIGHAM & WOMENS HOSP,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,JOSLIN DIABET CTR,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Joslin Diabetes Center, Inc.; Harvard University; Harvard T.H. Chan School of Public Health					NATIONAL CANCER INSTITUTE [R37CA040356, R01CA040356] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036798] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40356] Funding Source: Medline; NIDDK NIH HHS [DK 36798] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1982, EPIDEMIOLOGIC RES; [Anonymous], 1988, NEW ENGL J MED; [Anonymous], 1989, NEW ENGL J MED, V321, P129; BECKNIELSEN H, 1989, DIABETES METAB REV, V5, P487, DOI 10.1002/dmr.5610050602; BJORNTORP P, 1982, RECENT TREND DIABETE, P115; BURSTEIN R, 1985, DIABETES, V34, P756, DOI 10.2337/diabetes.34.8.756; CEDERHOLM J, 1985, ACTA MED SCAND, V217, P373; DAHM GL, 1987, AM J PHYSIOL, V252, pE170; DOWSE GK, 1991, DIABETES CARE, V14, P271, DOI 10.2337/diacare.14.4.271; FRISCH RE, 1986, DIABETES, V35, P1101, DOI 10.2337/diabetes.35.10.1101; HARRIS MI, 1985, DIABETES AM DIABETES, V6, P1; HELMRICH SP, 1991, NEW ENGL J MED, V325, P147, DOI 10.1056/NEJM199107183250302; HOLLOSZY JO, 1986, ACTA MED SCAND S, V711, P55; HUGHES T, 1987, MMWR-MORBID MORTAL W, V36, P195; JARRETT RJ, 1986, DIABETIC MED, V3, P549, DOI 10.1111/j.1464-5491.1986.tb00813.x; KING H, 1986, MED J AUSTRALIA, V145, P505, DOI 10.5694/j.1326-5377.1986.tb139452.x; KING H, 1984, AM J EPIDEMIOL, V119, P396, DOI 10.1093/oxfordjournals.aje.a113758; KOIVISTO V A, 1986, Diabetes Metabolism Reviews, V1, P445; LAPORTE RE, 1983, J GERONTOL, V38, P394, DOI 10.1093/geronj/38.4.394; MANSON JE, 1991, LANCET, V338, P774, DOI 10.1016/0140-6736(91)90664-B; MIETTINE.OS, 1974, AM J EPIDEMIOL, V99, P325, DOI 10.1093/oxfordjournals.aje.a121617; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; MONDON CE, 1980, AM J PHYSIOL, V239, pE169, DOI 10.1152/ajpendo.1980.239.3.E169; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; RUDERMAN N, 1990, DIABETES CARE, V13, P1163, DOI 10.2337/diacare.13.11.1163; SCHNEIDER SH, 1984, DIABETOLOGIA, V26, P355, DOI 10.1007/BF00266036; SICONOLFI SF, 1985, AM J EPIDEMIOL, V122, P101, DOI 10.1093/oxfordjournals.aje.a114068; STERN JS, 1987, RECENT ADV OBESITY R, P337; TAYLOR R, 1984, DIABETOLOGIA, V27, P578, DOI 10.1007/BF00276971; TAYLOR RJ, 1983, DIABETES CARE, V6, P334, DOI 10.2337/diacare.6.4.334; WASHBURN RA, 1990, AM J EPIDEMIOL, V132, P107, DOI 10.1093/oxfordjournals.aje.a115622; WASHBURN RA, 1987, PREV MED, V16, P636, DOI 10.1016/0091-7435(87)90047-8; ZIMMET P, 1981, DIABETES, V30, P45, DOI 10.2337/diabetes.30.1.45; ZIMMET P, 1990, DIABETES METAB REV, V6, P91, DOI 10.1002/dmr.5610060203; 1985, NIH851468 US DEP HLT	35	500	515	2	33	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 1	1992	268	1					63	67		10.1001/jama.268.1.63	http://dx.doi.org/10.1001/jama.268.1.63			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA165	1608115				2022-12-01	WOS:A1992JA16500024
J	MEADOR, CK				MEADOR, CK			THE PERSON WITH THE DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 1	1992	268	1					35	35						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA165	1608104				2022-12-01	WOS:A1992JA16500007
J	RAMIREZ, LC; ARAUZPACHECO, C; LACKNER, C; ALBRIGHT, G; ADAMS, BV; RASKIN, P				RAMIREZ, LC; ARAUZPACHECO, C; LACKNER, C; ALBRIGHT, G; ADAMS, BV; RASKIN, P			LIPOPROTEIN (A) LEVELS IN DIABETES-MELLITUS - RELATIONSHIP TO METABOLIC CONTROL	ANNALS OF INTERNAL MEDICINE			English	Article						DIABETES-MELLITUS; ATHEROSCLEROSIS; HEMOGLOBIN-A, GLYCOSYLATED; LIPOPROTEINS	LOW-DENSITY LIPOPROTEINS; CORONARY-ARTERY DISEASE; APOLIPOPROTEIN-B; HEART-DISEASE; LP(A); ATHEROSCLEROSIS; PLASMA; RISK; INFARCTION; LIPIDS	Objective: To determine the influence of diabetes control on serum lipoprotein (a) concentrations. Setting: Diabetes clinic of a large metropolitan public hospital, with primary- and secondary-care patients. Design: A cross-sectional study. Comparisons of lipoprotein (a) concentrations were made between a normal control group, a group of diabetic patients with glycated hemoglobin (HbA1c) less than 8.0%, and a group of diabetic patients with HbA1c of 8.0% or higher. Patients: Ninety-five normal controls and 93 diabetic subjects (49 with insulin-dependent diabetes mellitus and 44 with noninsulin-dependent diabetes mellitus). Results: Sixty diabetic subjects with HbA1c levels of 8.0% or higher had higher (25 mg/dL) median levels of lipoprotein (a) when compared with either 93 normal controls (8.8 mg/dL) or 33 diabetic patients with HbA1c less than 8.0% (7.5 mg/dL) (P = 0.008 and P = 0.012, respectively). A similar pattern of distribution of lipoprotein (a) levels according to degree of metabolic control was seen in patients with insulin-dependent diabetes mellitus and noninsulin-dependent diabetes mellitus. No difference in the lipoprotein (a) distribution was noted between diabetic men and women. No correlation was observed between lipoprotein (a) levels and total cholesterol, low-density lipoprotein cholesterol, and triglyceride levels. Conclusion. Lipoprotein (a) levels are elevated in poorly controlled diabetic patients. Increased levels of lipoprotein (a) may be a contributing factor to the high risk for atherosclerosis observed in diabetic patients.	UNIV TEXAS, SW MED CTR,DEPT INTERNAL MED, 5323 HARRY HINES BLVD,G5222, DALLAS, TX 75235 USA; GENESCREEN LAB, DALLAS, TX USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NCRR NIH HHS [M01RR006331] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALMER LO, 1980, ACTA ENDOCRINOL-COP, V94, P53; BEACH KW, 1980, DIABETES, V29, P882, DOI 10.2337/diabetes.29.11.882; BERG K, 1963, ACTA PATHOL MIC SC, V59, P369; CONOVER WJ, 1980, PRACTICAL NONPARAMET, P162; DAHLEN G, 1975, CLIN GENET, V7, P334; DAHLEN GH, 1986, CIRCULATION, V74, P758, DOI 10.1161/01.CIR.74.4.758; DAVIDOFF P, 1989, DIABETES S2, V38, pA70; DCCT Res Grp, 1987, DIABETES CARE, V10, P1; Diabetes mellitus, 1985, WHO TECHNICAL REPORT, V727; DUNN FL, 1984, METABOLISM, V33, P117, DOI 10.1016/0026-0495(84)90122-7; EATON DL, 1987, P NATL ACAD SCI USA, V84, P3224, DOI 10.1073/pnas.84.10.3224; FRICK MH, 1978, CHEST, V73, P62, DOI 10.1378/chest.73.1.62; GARCIA MJ, 1974, DIABETES, V23, P105, DOI 10.2337/diab.23.2.105; GENSINI GF, 1979, THROMB HAEMOSTASIS, V42, P983; GREENFIELD MS, 1982, ARCH INTERN MED, V142, P1498, DOI 10.1001/archinte.142.8.1498; GUYTON JR, 1985, ARTERIOSCLEROSIS, V5, P265, DOI 10.1161/01.ATV.5.3.265; HAFFNER SM, 1991, DIABETES CARE, V14, P302, DOI 10.2337/diacare.14.4.302; HOWARD BV, 1987, J LIPID RES, V28, P613; KANNEL WB, 1982, DIABETES MELLITUS OB, P735; KOSTNER GM, 1981, ATHEROSCLEROSIS, V38, P51, DOI 10.1016/0021-9150(81)90103-9; KROLEWSKI AS, 1987, AM J CARDIOL, V59, P750, DOI 10.1016/0002-9149(87)91086-1; LEVITSKY LL, 1991, DIABETES CARE, V14, P283, DOI 10.2337/diacare.14.4.283; LORENZI M, 1984, DIABETOLOGIA, V26, P218; LUFKIN EG, 1979, METABOLISM, V28, P63, DOI 10.1016/0026-0495(79)90169-0; MAEDA S, 1989, ATHEROSCLEROSIS, V78, P145, DOI 10.1016/0021-9150(89)90218-9; MILES LA, 1989, NATURE, V339, P301, DOI 10.1038/339301a0; MURAI A, 1986, ATHEROSCLEROSIS, V59, P199, DOI 10.1016/0021-9150(86)90048-1; NATHAN DM, 1984, CLIN CHEM, V30, P813; PYKE DA, 1979, DIABETOLOGIA, V17, P333, DOI 10.1007/BF01236266; RATH M, 1989, ARTERIOSCLEROSIS, V9, P579, DOI 10.1161/01.ATV.9.5.579; ROTTER JI, 1990, DIABETES MELLITUS TH, P378; SCANU AM, 1990, J CLIN INVEST, V85, P1709, DOI 10.1172/JCI114625; SCHONFELD G, 1974, DIABETES, V23, P827, DOI 10.2337/diab.23.10.827; STEINBRECHER UP, 1984, DIABETES, V33, P130, DOI 10.2337/diabetes.33.2.130; STOLAR MW, 1988, METABOLISM, V37, P1, DOI 10.1016/0026-0495(88)90180-1; UTERMANN G, 1989, P NATL ACAD SCI USA, V86, P4171, DOI 10.1073/pnas.86.11.4171; UTERMANN G, 1987, J CLIN INVEST, V80, P458, DOI 10.1172/JCI113093; 1974, NIH DHEW753628 PUBL	38	110	110	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1992	117	1					42	47		10.7326/0003-4819-117-1-42	http://dx.doi.org/10.7326/0003-4819-117-1-42			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA435	1534477				2022-12-01	WOS:A1992JA43500007
J	REDFIELD, MM; NICHOLSON, WJ; EDWARDS, WD; TAJIK, AJ				REDFIELD, MM; NICHOLSON, WJ; EDWARDS, WD; TAJIK, AJ			VALVE DISEASE ASSOCIATED WITH ERGOT ALKALOID USE - ECHOCARDIOGRAPHIC AND PATHOLOGICAL CORRELATIONS	ANNALS OF INTERNAL MEDICINE			English	Note						ERGOT ALKALOIDS; HEART VALVE DISEASES; ECHOCARDIOGRAPHY; MIGRAINE; METHYSERGIDE		Five patients had valve disease that was associated with long-term ingestion (6 to 20 years) of ergotamine (n = 3) or methysergide (n = 2). Only one patient had vascular disease suggestive of ergotism. Two patients had involvement of three or four valves, and three had mitral valve disease. Valvular lesions in the patients were both stenotic and regurgitant. Echocardiographic findings suggestive of ergot valve disease included fixed tricuspid lesions in the absence of the carcinoid syndrome. When left-sided lesions predominated, echocardiographic findings were indistinguishable from those seen in chronic rheumatic disease. All patients underwent valve replacement. Gross pathologic findings included excised valves and chordae tendineae that were thickened and retracted but not calcified; these findings were often initially reported as consistent with rheumatic disease. Microscopic findings differed from those seen in rheumatic disease and resembled those associated with carcinoid lesions. Leaflets and chordae were coated by myofibroblasts in an avascular myxoid or collagenous matrix, but underlying valve architecture was intact. The pathologic process was similar for methysergide and ergotamine.	CARDIAC DIAGNOST ASSOCIATES, YORK, PA USA		REDFIELD, MM (corresponding author), MAYO CLIN & MAYO FDN, 200 1ST ST SW, ROCHESTER, MN 55905 USA.							BANA DS, 1974, AM HEART J, V88, P640, DOI 10.1016/0002-8703(74)90251-8; GRAHAM JR, 1967, AM J MED SCI, V254, P1; HAUCK AJ, 1990, ARCH PATHOL LAB MED, V114, P62; MASON JW, 1977, CIRCULATION, V56, P889, DOI 10.1161/01.CIR.56.5.889; MISCH KA, 1974, BRIT MED J, V2, P365, DOI 10.1136/bmj.2.5915.365; MUNROE DS, 1969, CAN MED ASSOC J, V101, P536; Seiler K, 1973, Vasa, V2, P366; SPIERINGS ELH, 1988, HEADACHE, V28, P278, DOI 10.1111/j.1526-4610.1988.hed2804278.x	8	116	118	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1992	117	1					50	52		10.7326/0003-4819-117-1-50	http://dx.doi.org/10.7326/0003-4819-117-1-50			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA435	1596047				2022-12-01	WOS:A1992JA43500009
J	TCHENG, JE; JACKMAN, JD; NELSON, CL; GARDNER, LH; SMITH, LR; RANKIN, JS; CALIFF, RM; STACK, RS				TCHENG, JE; JACKMAN, JD; NELSON, CL; GARDNER, LH; SMITH, LR; RANKIN, JS; CALIFF, RM; STACK, RS			OUTCOME OF PATIENTS SUSTAINING ACUTE ISCHEMIC MITRAL REGURGITATION DURING MYOCARDIAL-INFARCTION	ANNALS OF INTERNAL MEDICINE			English	Article						MYOCARDIAL INFARCTION; MITRAL VALVE INSUFFICIENCY; HEART CATHETERIZATION; CORONARY ARTERY BYPASS; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY	CORONARY-ARTERY DISEASE; VALVE REPAIR; WALL MOTION; ANGIOPLASTY; REPLACEMENT; TRIAL; RECONSTRUCTION; STREPTOKINASE; THROMBOLYSIS; THERAPY	Objective: To describe outcomes of patients sustaining an acute myocardial infarction complicated by mitral regurgitation managed with contemporary reperfusion therapies. Design: Inception cohort case study. Long-term follow-up was obtained in 99% of all patients. Setting: University referral center. Patients: A series of 1480 consecutive patients presenting between April 1986 and March 1989 who had emergency cardiac catheterization within 6 hours of infarction. Fifty patients were found to have moderately severe or severe mitral regurgitation. Outcome Measures: Mortality; follow-up cardiac catheterization in patients with regurgitation. Results: Acute ischemic moderately severe to severe (3 + or 4 +) mitral regurgitation was associated with a mortality of 24% at 30 days (95% Cl, 12% to 36%), 42% at 6 months (Cl, 28% to 56%), and 52% at 1 year (Cl, 38% to 66%); multivariable analysis identified 3 + or 4 + mitral regurgitation as a possible independent predictor of mortality (P = 0.06). Patients with mitral regurgitation tended to be female, older, and to have cerebrovascular disease, diabetes, and pre-existing symptomatic coronary artery disease. A physical examination did not identify 50% of patients with moderately severe to severe regurgitation. Acute reperfusion with thrombolysis or angioplasty did not reliably reverse valvular incompetence. In this observational study, the greatest in-hospital and 1-year mortalities were seen in patients reperfused with emergency balloon angioplasty, whereas patients managed medically or with coronary bypass surgery had lower mortalities. Conclusions: Moderately severe to severe (3 + or 4 +) mitral regurgitation complicating acute myocardial infarction portends a grave prognosis. Acute reperfusion does not reduce mortality to levels experienced by patients with lesser degrees of mitral regurgitation nor does it reliably restore valvular competence.			TCHENG, JE (corresponding author), DUKE UNIV, MED CTR, BOX 3275, DURHAM, NC 27710 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL017670, R01HL045702, P01HL036587] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-17670, HL-36587, HL-45702] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANGELL WW, 1987, J THORAC CARDIOV SUR, V93, P665; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; BARZILAI B, 1988, AM J CARDIOL, V61, P220, DOI 10.1016/0002-9149(88)90919-8; BONCHEK LI, 1984, J THORAC CARDIOV SUR, V88, P122; BURCH GE, 1963, ARCH INTERN MED, V112, P112, DOI 10.1001/archinte.1963.03860010138015; CALIFF RM, 1989, JAMA-J AM MED ASSOC, V261, P2077, DOI 10.1001/jama.261.14.2077; CHESEBRO JH, 1987, CIRCULATION, V76, P142, DOI 10.1161/01.CIR.76.1.142; COHN LH, 1988, ANN THORAC SURG, V45, P284, DOI 10.1016/S0003-4975(10)62463-0; CONNOLLY MW, 1986, J THORAC CARDIOV SUR, V91, P379; DAVID TE, 1986, CIRCULATION, V74, P116; DESERVI S, 1988, EUR HEART J, V9, P5, DOI 10.1093/eurheartj/9.suppl_F.5; ESTES EH, 1966, AM HEART J, V71, P356, DOI 10.1016/0002-8703(66)90475-3; HEIKKILA J, 1967, BRIT HEART J, V29, P162; HEUSER RR, 1987, ANN INTERN MED, V107, P852, DOI 10.7326/0003-4819-107-6-852; HICKEY MS, 1988, CIRCULATION, V78, P51; Kay G L, 1987, Cardiovasc Clin, V17, P41; KAY GL, 1986, CIRCULATION, V74, P88; LOPERFIDO F, 1986, AM J CARDIOL, V58, P692, DOI 10.1016/0002-9149(86)90339-5; MAGOVERN JA, 1985, ANN THORAC SURG, V39, P346, DOI 10.1016/S0003-4975(10)62628-8; MAISEL AS, 1986, AM HEART J, V112, P705, DOI 10.1016/0002-8703(86)90464-3; OKEEFE JH, 1989, AM J CARDIOL, V64, P1221, DOI 10.1016/0002-9149(89)90558-4; ONEILL W, 1986, NEW ENGL J MED, V314, P812, DOI 10.1056/NEJM198603273141303; PASSAMANI E, 1985, NEW ENGL J MED, V312, P932; PHILLIPS JH, 1963, ANN INTERN MED, V59, P508, DOI 10.7326/0003-4819-59-4-508; Rankin J S, 1989, Semin Thorac Cardiovasc Surg, V1, P149; RANKIN JS, 1989, CIRCULATION, V79, P116; RANKIN JS, 1988, J THORAC CARDIOV SUR, V95, P165; RANKIN JS, 1986, TXB SURGERY, P2344; REINFELD HB, 1985, CATHETER CARDIO DIAG, V11, P273, DOI 10.1002/ccd.1810110307; ROSATI RA, 1975, ARCH INTERN MED, V135, P1017, DOI 10.1001/archinte.135.8.1017; SAND ME, 1987, J THORAC CARDIOV SUR, V94, P208; SHAWL FA, 1989, J AM COLL CARDIOL, V14, P986, DOI 10.1016/0735-1097(89)90477-4; SHEEHAN FH, 1983, CIRCULATION, V68, P756, DOI 10.1161/01.CIR.68.4.756; SHEEHAN FH, 1983, CIRCULATION, V68, P550, DOI 10.1161/01.CIR.68.3.550; SMITH LR, 1991, CIRCULATION, V84, P245; TOPOL EJ, 1987, J AM COLL CARDIOL, V10, pB65, DOI 10.1016/S0735-1097(87)80430-8	37	170	177	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1992	117	1					18	24		10.7326/0003-4819-117-1-18	http://dx.doi.org/10.7326/0003-4819-117-1-18			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA435	1596043				2022-12-01	WOS:A1992JA43500003
J	THOM, DH; GRAYSTON, JT; SISCOVICK, DS; WANG, SP; WEISS, NS; DALING, JR				THOM, DH; GRAYSTON, JT; SISCOVICK, DS; WANG, SP; WEISS, NS; DALING, JR			ASSOCIATION OF PRIOR INFECTION WITH CHLAMYDIA-PNEUMONIAE AND ANGIOGRAPHICALLY DEMONSTRATED CORONARY-ARTERY DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; ATHEROSCLEROSIS; PATHOGENESIS; TWAR; HERPESVIRUS; FINLAND; CELLS	Objective.-To evaluate the association between prior infection with Chlamydia Pneumoniae, as measured by IgG antibody, and coronary artery disease. Design.-A population-based, case-control study. Setting.-Group Health Cooperative of Puget Sound, a Seattle-based health maintenance organization. Participants.-Men 55 years of age and younger and women 65 years of age and younger. Cases (n=171) were members of Group Health Cooperative undergoing diagnostic coronary angiography who had at least one coronary artery lesion occupying 50% or more of the luminal diameter. The population controls (n=120) were Group Health Cooperative members without known coronary heart disease. Main Outcome Measure.-The adjusted odds ratio (OR) for coronary artery disease associated with prior C pneumoniae infection as measured by the presence of IgG antibody. Results.-After adjusting for age, gender, and calendar quarter of blood drawing, the OR for coronary artery disease associated with the presence of antibody was 2.6 (95% confidence interval, 1.4 to 4.8). The association was limited to cigarette smokers, in whom the OR was 3.5 (95% confidence interval, 1.7 to 7.0). Among never-smokers, the OR was 0.8 (95% confidence interval, 0.3 to 1.9). When cases and controls were restricted to those assayed concurrently, the adjusted OR (smokers and nonsmokers combined) was 4.2 (95% confidence interval, 1.8 to 10.0). Adjustment for serum cholesterol, hypertension, alcohol use, diabetes, and socioeconomic status did not change these results. Only a weak association was found when cases were compared with 63 subjects whose angiographic results were normal (OR, 1.2; 95% confidence interval, 0.6 to 2.2). Conclusions.-These results generally support the previously reported association between C pneumoniae infection and coronary heart disease. However, caution should be used in interpreting the basis for this association.	UNIV WASHINGTON,DEPT EPIDEMIOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PATHOBIOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	THOM, DH (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DIV FAMILY & COMMUNITY MED,703 WELCH RD,SUITE G-1,STANFORD,CA 94305, USA.				NHLBI NIH HHS [1-F32-HL-08194-01] Funding Source: Medline; NIAID NIH HHS [AI-21885] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL008194] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021885] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAILLIE EE, 1979, CLIN CHEM, V25, P817; BOOZE CF, 1987, AVIAT SPACE ENVIR MD, V58, P297; BRESLOW N. E., 1980, STATISTICAL METHODS; CHIRGWIN K, 1991, J INFECT DIS, V163, P757, DOI 10.1093/infdis/163.4.757; FABRICANT CG, 1978, J EXP MED, V148, P335, DOI 10.1084/jem.148.1.335; FABRICANT CG, 1985, ADV VET SCI COMP MED, V30, P39; FABRICANT CG, 1981, AM J PATHOL, V105, P176; GRAYSTON JT, 1985, REV INFECT DIS, V7, P717; GRAYSTON JT, 1990, J INFECT DIS, V161, P618, DOI 10.1093/infdis/161.4.618; HAJJAR DP, 1987, J CLIN INVEST, V80, P1317, DOI 10.1172/JCI113208; KLEEMOLA M, 1988, J INFECT DIS, V157, P230, DOI 10.1093/infdis/157.2.230; KRON J, 1983, ARCH INTERN MED, V143, P1466; LOPESVIRELLA MF, 1985, CLIN IMMUNOL IMMUNOP, V37, P377, DOI 10.1016/0090-1229(85)90107-2; MATTILA KJ, 1989, J INTERN MED, V225, P293, DOI 10.1111/j.1365-2796.1989.tb00084.x; MIKLOZEK CL, 1988, AM HEART J, V115, P768, DOI 10.1016/0002-8703(88)90877-0; Osler W, 1908, MODERN MED ITS PRACT, P429; Patnode D, 1990, CHLAMYDIAL INFECTION, P406; PATTON DL, 1987, J INFECT DIS, V155, P1292, DOI 10.1093/infdis/155.6.1292; PUOLAKKAINEN M, 1989, EPIDEMIOL INFECT, V102, P287, DOI 10.1017/S0950268800029964; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; SAIKKU P, 1992, ANN INTERN MED, V116, P273, DOI 10.7326/0003-4819-116-4-273; SAIKKU P, 1988, LANCET, V2, P983, DOI 10.1016/S0140-6736(88)90741-6; SAMMALKORPI K, 1988, METABOLISM, V37, P859, DOI 10.1016/0026-0495(88)90120-5; THOM DH, 1991, ARTERIOSCLER THROMB, V11, P547, DOI 10.1161/01.ATV.11.3.547; VISSER MR, 1988, P NATL ACAD SCI USA, V85, P8227, DOI 10.1073/pnas.85.21.8227; WAKSBERG J, 1978, J AM STAT ASSOC, V73, P40, DOI 10.2307/2286513; WANG SP, 1984, 1983 INT S MED VIR, P87; Warnick G R, 1986, Methods Enzymol, V129, P101; YAMAZAKI T, 1990, J INFECT DIS, V162, P1390, DOI 10.1093/infdis/162.6.1390	29	369	388	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 1	1992	268	1					68	72		10.1001/jama.268.1.68	http://dx.doi.org/10.1001/jama.268.1.68			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA165	1608116				2022-12-01	WOS:A1992JA16500025
J	BURNET, NG; NYMAN, J; TURESSON, I; WURM, R; YARNOLD, JR; PEACOCK, JH				BURNET, NG; NYMAN, J; TURESSON, I; WURM, R; YARNOLD, JR; PEACOCK, JH			PREDICTION OF NORMAL-TISSUE TOLERANCE TO RADIOTHERAPY FROM INVITRO CELLULAR RADIATION SENSITIVITY	LANCET			English	Note							REPAIR CAPACITY; SURVIVAL-CURVE; TUMORS	The success of radiotherapy depends on the total radiation dose, which is limited by the tolerance of surrounding normal tissues. Since there is substantial variation among patients in normal-tissue radiosensitivity, we have tested the hypothesis that in-vitro cellular radiosensitivity is correlated with in-vivo normal-tissue responses. We exposed skin fibroblast cell lines from six radiation-treated patients to various doses of radiation and measured the proportions surviving. There was a strong relation between fibroblast sensitivity in vitro and normal-tissue reactions, especially acute effects. Assessment of radiosensitivity could lead to improved tumour cure rates by enabling radiation doses to be tailored to the individual.	SAHLGRENS UNIV HOSP,DEPT ONCOL,S-41345 GOTHENBURG,SWEDEN	Sahlgrenska University Hospital	BURNET, NG (corresponding author), INST CANC RES,RADIOTHERAPY RES UNIT,15 COTSWOLD RD,SUTTON SM2 5PX,SURREY,ENGLAND.		Burnet, Neil/L-1025-2019					AGREN A, 1990, INT J RADIAT ONCOL, V19, P1077, DOI 10.1016/0360-3016(90)90037-K; DEACON J, 1984, RADIOTHER ONCOL, V2, P317, DOI 10.1016/S0167-8140(84)80074-2; FERTIL B, 1988, RADIAT RES, V116, P74, DOI 10.2307/3577479; FUKS Z, 1991, INT J RADIAT ONCOL, V21, P537, DOI 10.1016/0360-3016(91)90668-T; STEEL GG, 1991, RADIOTHER ONCOL, V20, P71; SUTTON ML, 1986, RADIOTHERAPY CLIN PR, P1; TURESSON I, 1989, RADIOTHER ONCOL, V15, P169, DOI 10.1016/0167-8140(89)90131-X; TURESSON I, 1990, INT J RADIAT ONCOL, V19, P1569, DOI 10.1016/0360-3016(90)90374-S; TURESSON I, 1989, RADIOTHER ONCOL, V15, P217, DOI 10.1016/0167-8140(89)90089-3; WEST CML, 1991, BRIT J CANCER, V64, P197, DOI 10.1038/bjc.1991.270	10	138	139	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 27	1992	339	8809					1570	1571		10.1016/0140-6736(92)91833-T	http://dx.doi.org/10.1016/0140-6736(92)91833-T			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB202	1351551				2022-12-01	WOS:A1992JB20200005
J	DEKEYSER, J; DEKLIPPEL, N; MERKX, H; VERVAECK, M; HERROELEN, L				DEKEYSER, J; DEKLIPPEL, N; MERKX, H; VERVAECK, M; HERROELEN, L			SERUM CONCENTRATIONS OF VITAMIN-A AND VITAMIN-E AND EARLY OUTCOME AFTER ISCHEMIC STROKE	LANCET			English	Article							LIPID-PEROXIDATION; CEREBRAL-ISCHEMIA; BETA-CAROTENE	Formation of free radicals and subsequent lipid peroxidation may have an important role in tissue injury and neuronal cell death after cerebral ischaemia. We conducted a prospective, controlled study to determine whether the endogenous antioxidant vitamins A and E had a protective function in acute ischaemic stroke. The study population consisted of 80 patients seen at the Free University Hospital in Brussels. Entry criteria were occurrence of sudden focal neurological deficit lasting more than 3 h; deficit due to acute ischaemia in the territory of the middle cerebral artery; and investigation within 24 h of onset of the episode. Outcome was assessed within the first 21 days. 80 controls matched for age and sex had various neurological disorders other than acute ischaemia. Serum concentrations of vitamins A and E were similar in the study and control groups. In the study population a serum vitamin A concentration higher than the mean of 2.27-mu-mol/I was associated with a higher frequency of complete recovery within the first 24 h (p<0.05), decreased mortality (p=0.038), and a better outcome as assessed by the Mathew scale of neurological deficit (p<0.03) and the Barthel index. There was no significant difference in outcome between patients with vitamin E concentrations above or below the mean of 35.3-mu-mol/l. Our results suggest a beneficial effect of a high serum vitamin A concentration on early outcome in ischaemic stroke.			DEKEYSER, J (corresponding author), VRIJE UNIV BRUSSELS, ACAD ZIEKENHUIS, DEPT NEUROL, LAARBEEKLAAN 101, B-1090 BRUSSELS, BELGIUM.		De Keyser, Jacques/D-3725-2013	De Keyser, Jacques/0000-0002-3394-7757				ALLEN CMC, 1984, J NEUROL NEUROSUR PS, V47, P475, DOI 10.1136/jnnp.47.5.475; BURTON GW, 1984, SCIENCE, V224, P569, DOI 10.1126/science.6710156; HALL ED, 1988, STROKE, V19, P997, DOI 10.1161/01.STR.19.8.997; HARPER HA, 1979, REV PHYSL CHEM, P147; JONES TH, 1981, J NEUROSURG, V54, P773, DOI 10.3171/jns.1981.54.6.0773; LINDSBERG PJ, 1991, ANN NEUROL, V30, P117, DOI 10.1002/ana.410300202; MAHONEY F I, 1965, Md State Med J, V14, P61; MATHEW NT, 1972, LANCET, V2, P1327; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; SCHMIDLEY JW, 1990, STROKE, V25, P7; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; SILVIA RC, 1987, NEUR ABST, V13, P1499; SUNDT TM, 1969, J NEUROSURG, V31, P311, DOI 10.3171/jns.1969.31.3.0311; VUILLEUMIER JP, 1983, INT J VITAM NUTR RES, V53, P265; YAMAMOTO M, 1983, STROKE, V14, P977, DOI 10.1161/01.STR.14.6.977; YOSHIDA S, 1989, ANN NY ACAD SCI, V570, P219; YOSHIDA S, 1985, J NEUROCHEM, V44, P1593, DOI 10.1111/j.1471-4159.1985.tb08800.x; 1991, LANCET, V338, P1129	18	39	40	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 27	1992	339	8809					1562	1565		10.1016/0140-6736(92)91830-2	http://dx.doi.org/10.1016/0140-6736(92)91830-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB202	1351549				2022-12-01	WOS:A1992JB20200003
J	DUNN, MJ; CRISP, SJ; ROSE, ML; TAYLOR, PM; YACOUB, MH				DUNN, MJ; CRISP, SJ; ROSE, ML; TAYLOR, PM; YACOUB, MH			ANTIENDOTHELIAL ANTIBODIES AND CORONARY-ARTERY DISEASE AFTER CARDIAC TRANSPLANTATION	LANCET			English	Article								Accelerated coronary artery disease is the most serious complication after cardiac transplantation. The disease has a multifactorial aetiology, with little agreement about the relative importance of the various risk factors. We have investigated the frequency of anti-endothelial antibodies against human umbilical vein endothelial cells by one-dimensional sodium dodecyl sulphate polyacrylamide gel electrophoresis and western blotting. Peptide-specific anti-endothelial antibodies were found in 15/21 heart transplant recipients with accelerated coronary artery disease, and 1/20 transplant patients who had not developed the disease. Positive immunofluorescence of patients' serum on frozen sections of coronary vessels confirmed the endothelial specificity of antibodies. These results provide evidence of an immune aetiology for transplant-associated coronary artery disease and could have important implications for its diagnosis and therapy.			DUNN, MJ (corresponding author), NATL HEART & LUNG INST,DEPT CARDIOTHORAC SURG,DOVEHOUSE ST,LONDON SW3 6LY,ENGLAND.							AUCHINCLOSS H, 1990, TRANSPLANT REV, V4, P14; Banner N R, 1987, Clin Transpl, P17; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DUNN MJ, 1991, TRANSPLANTATION, V51, P806, DOI 10.1097/00007890-199104000-00014; GAO S, 1990, SEMINARS THORACIC CA, P241; HEURKENS AHM, 1991, J IMMUNOL METHODS, V141, P33, DOI 10.1016/0022-1759(91)90207-V; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; PAGE C, IN PRESS AM J PATHOL; PLATT JL, 1990, TRANSPLANTATION, V50, P817, DOI 10.1097/00007890-199011000-00015; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; SALOMON RN, 1991, AM J PATHOL, V138, P791; SIMMONS J, 1991, 2D PAGE 91, P46; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; URETSKY BF, 1987, CIRCULATION, V76, P827, DOI 10.1161/01.CIR.76.4.827	15	171	174	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 27	1992	339	8809					1566	1570		10.1016/0140-6736(92)91832-S	http://dx.doi.org/10.1016/0140-6736(92)91832-S			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB202	1351550				2022-12-01	WOS:A1992JB20200004
J	JUVELA, S				JUVELA, S			ALCOHOL-CONSUMPTION AS A RISK FACTOR FOR POOR OUTCOME AFTER ANEURYSMAL SUBARACHNOID HEMORRHAGE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GAMMA-GLUTAMYL-TRANSFERASE; CEREBRAL-ISCHEMIA; CIGARETTE-SMOKING; BLOOD-PRESSURE; LIVER-DISEASE; HEMORRHAGE; STROKE; POPULATION; QUESTIONNAIRE; HEART	Objective-To evaluate the effect of factors existing before aneurysmal subarachnoid haemorrhage on outcome of haemorrhage. Design-Prospective follow up study. Setting-Helsinki University Hospital. Patients-291 consecutive patients (149 men) aged 15 to 65 years admitted within 96 hours after the bleeding. Main outcome measures-Potential risk factors (baseline characteristics, health habits, and clinical variables) for poor outcome after haemorrhage (dependent state in the activities of daily living, or death) were studied using multiple logistic regression. Results-One year after haemorrhage, 179 (62%) patients were independent in the activities of daily living and 28 (10%) dependent; 84 (29%) had died. Risk of poor outcome was predicted, after adjustment for sex and age, by clinical condition at admission according to the Glasgow coma scale (p<0.0001); occurrence of rebleeding (relative risk 7.1, 95% confidence interval 2.8 to 18.0, p<0.0001) or delayed cerebral ischaemia (10.3, 4.2 to 25.4, p<0.0001); surgery on an aneurysm (0.13, 0.05 to 0.35, p<0.0001); and heavy consumption of alcohol (4-5, 1.8 to 11.0, p=0.0014). Heavy drinking remained a significant risk factor after additional adjustment for hypertension, body mass index, and presence of intracerebral haematoma. Heavy drinkers had a more unfavourable outcome after rebleeding and delayed ischaemia than did others with rebleeding or ischaemia. Those who had salicylates in urine on admission had delayed ischaemia with fixed neurological deficits less commonly than others. Conclusions-Heavy drinking impairs outcome mainly through severe rebleeding and delayed ischaemia and to a lesser extent through a poor initial condition and presence of intracerebral haematoma.			JUVELA, S (corresponding author), HELSINKI UNIV HOSP, DEPT NEUROSURG, TOPELIUKSENKATU 5, SF-00260 HELSINKI, FINLAND.			Juvela, Seppo/0000-0003-4944-4983				ADAMS HP, 1987, NEUROLOGY, V37, P1586, DOI 10.1212/WNL.37.10.1586; BELL BA, 1979, BRIT MED J, V1, P577, DOI 10.1136/bmj.1.6163.577; BERGLUND M, 1981, ARCH GEN PSYCHIAT, V38, P351; BERNADT MW, 1982, LANCET, V1, P325; BONITA R, 1985, STROKE, V16, P591, DOI 10.1161/01.STR.16.4.591; BONITA R, 1986, STROKE, V17, P831, DOI 10.1161/01.STR.17.5.831; CAMARGO CA, 1989, STROKE, V20, P1611, DOI 10.1161/01.STR.20.12.1611; COLDITZ GA, 1988, NEW ENGL J MED, V318, P937, DOI 10.1056/NEJM198804143181501; DIXON WJ, 1988, BMDP STATISTICAL SOF; DONAHUE RP, 1986, JAMA-J AM MED ASSOC, V255, P2311, DOI 10.1001/jama.255.17.2311; ELLIOTT P, 1988, BRIT MED J, V297, P319; ETTINGER PO, 1978, AM HEART J, V95, P555, DOI 10.1016/0002-8703(78)90296-X; HASELAGER EM, 1977, LANCET, V1, P774; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; HIJDRA A, 1988, STROKE, V19, P1250, DOI 10.1161/01.STR.19.10.1250; HILLBOM M, 1988, HAEMOSTASIS, V18, P170; HILLBOM M, 1982, NEUROLOGY, V32, P706, DOI 10.1212/WNL.32.7.706; HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014; JENNETT B, 1975, LANCET, V1, P480; JUVELA S, 1990, NEUROSURGERY, V27, P929, DOI 10.1227/00006123-199012000-00011; JUVELA S, 1992, NEUROSURGERY, V30, P7, DOI 10.1227/00006123-199201000-00002; JUVELA S, 1991, J NEUROSURG, V74, P386, DOI 10.3171/jns.1991.74.3.0386; Juvela S, 1991, THESIS U HELSINKI HE; KASSELL NF, 1982, NEUROSURGERY, V10, P514, DOI 10.1227/00006123-198204000-00019; KLATSKY AL, 1977, NEW ENGL J MED, V296, P1194, DOI 10.1056/NEJM197705262962103; KRISTENSON H, 1980, PREV MED, V9, P108, DOI 10.1016/0091-7435(80)90062-6; MAYFIELD D, 1974, AM J PSYCHIAT, V131, P1121; MONTEIRO MG, 1985, DRUG ALCOHOL DEPEN, V16, P31, DOI 10.1016/0376-8716(85)90079-1; MORGAN MY, 1981, CLIN LAB HAEMATOL, V3, P35; OHMAN J, 1991, J NEUROSURG, V74, P14, DOI 10.3171/jns.1991.74.1.0014; PAPOZ L, 1981, JAMA-J AM MED ASSOC, V245, P1748; PUDDEY IB, 1985, HYPERTENSION, V7, P707, DOI 10.1161/01.HYP.7.5.707; RAGNI MV, 1982, ALCOHOL CLIN EXP RES, V6, P267, DOI 10.1111/j.1530-0277.1982.tb04973.x; SACCO RL, 1984, NEUROLOGY, V34, P847, DOI 10.1212/WNL.34.7.847; SHAPER AG, 1991, BRIT MED J, V302, P1111, DOI 10.1136/bmj.302.6785.1111; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; TEASDALE G, 1974, LANCET, V2, P81	37	49	50	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 27	1992	304	6843					1663	1667		10.1136/bmj.304.6843.1663	http://dx.doi.org/10.1136/bmj.304.6843.1663			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB939	1633519	Green Published, Bronze			2022-12-01	WOS:A1992JB93900021
J	MADDEN, BP; HODSON, ME; TSANG, V; RADLEYSMITH, R; KHAGHANI, A; YACOUB, MY				MADDEN, BP; HODSON, ME; TSANG, V; RADLEYSMITH, R; KHAGHANI, A; YACOUB, MY			INTERMEDIATE-TERM RESULTS OF HEART-LUNG TRANSPLANTATION FOR CYSTIC-FIBROSIS	LANCET			English	Article							ADULTS	Between September, 1984, and March, 1991, 79 patients underwent heart-lung transplantation for end-stage cystic fibrosis at the Harefield Hospital. Short-term outcome has already been reported, and we now present intermediate-term results. The overall actuarial patient survival was 69% at 1 year, 52% at 2 years, and 49% at 3 years. 17 patients had diabetes mellitus with a survival of 62% to 1 year and 51% to 2 years. 23 patients had one or more other possible high-risk factors, and survival of these patients was 64% at 1 year and 57% at 2 years, compared with 71% and 49%, respectively, in the low-risk group (n=56). Pseudomonas aeruginosa infection was the most common respiratory infection encountered postoperatively. 92% of patients had at least one episode of acute rejection during the first 3 postoperative months. Lung function was greatly improved after transplantation, the mean forced expiratory volume in 1 s and forced vital capacity increasing from 22% and 35% predicted, respectively, preoperatively to 68% and 70% predicted, respectively, by the sixth postoperative month. This improvement was maintained at 1, 2, and 3 years after transplantation. Lymphoproliferative disorders (4 patients) were successfully treated. Obliterative bronchiolitis developed in 17 patients and the cumulative probability of getting this complication at 1, 2, and 3 years postoperatively was 17%, 23%, and 48%, respectively. Overall, 7 patients were retransplanted. There was no coronary artery disease in the 37 patients who underwent coronary angiography at 1 year, 14 at 2 years, and 9 at 3 years after surgery. 58 patients donated their hearts for subsequent "domino" heart transplantation. Our 5 1/2-year experience with heart-lung transplantation is encouraging but the shortage of donor organs and the complication of obliterative bronchiolitis are the two main obstacles to be overcome.	HAREFIELD HOSP,UXBRIDGE UB9 6JH,MIDDX,ENGLAND; ROYAL BROMPTON HOSP,LONDON,ENGLAND; NATL HEART & LUNG INST,LONDON,ENGLAND	Royal Brompton & Harefield NHS Foundation Trust; Harefield Hospital; Royal Brompton Hospital; Imperial College London								ALAJMO F, 1989, ANN THORAC SURG, V48, P536, DOI 10.1016/S0003-4975(10)66857-9; COREY M, 1988, J CLIN EPIDEMIOL, V41, P583, DOI 10.1016/0895-4356(88)90063-7; HODSON ME, 1989, BRIT MED J, V298, P471, DOI 10.1136/bmj.298.6672.471; HODSON ME, 1991, EUR RESPIR J, V4, P524; NIELSEN OH, 1982, ACTA PAEDIATR SC   S, V301, P107; PATTERSON GA, 1989, PEDIATR PULM, V4, P56; PENKETH ARL, 1987, THORAX, V42, P526, DOI 10.1136/thx.42.7.526; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SCOTT J, 1988, LANCET, V2, P1962; SMYTH RL, 1991, THORAX, V46, P213, DOI 10.1136/thx.46.3.213; WOOD A, 1989, AM REV RESPIR DIS, V140, P1645, DOI 10.1164/ajrccm/140.6.1645; YACOUB MH, 1990, J HEART TRANSPLANT, V9, P459; YACOUB MH, 1990, TRANSPLANT REV, P1; 1988, BRIT MED J, V297, P1599; 1990, RECOMMENDATIONS CARE	15	71	71	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 27	1992	339	8809					1583	1587		10.1016/0140-6736(92)91842-V	http://dx.doi.org/10.1016/0140-6736(92)91842-V			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB202	1351559				2022-12-01	WOS:A1992JB20200013
J	MINAKAMI, H; TAKAHASHI, T; IZUMI, A; ITOI, H; TAMADA, T				MINAKAMI, H; TAKAHASHI, T; IZUMI, A; ITOI, H; TAMADA, T			ENLARGEMENT OF THE SALIVARY-GLAND AFTER RITODRINE TREATMENT IN PREGNANT-WOMEN	BRITISH MEDICAL JOURNAL			English	Article							PRETERM				MINAKAMI, H (corresponding author), JICHI MED SCH,DEPT OBSTET & GYNAECOL,MINAMI KAWACHI,TOCHIGI 32904,JAPAN.		MINAKAMI, HISANORI/D-6477-2012					BARDEN TP, 1980, OBSTET GYNECOL, V56, P1; MCPHERSON MA, 1978, BIOCHEM J, V176, P855, DOI 10.1042/bj1760855; MCPHERSON MA, 1986, LANCET, V2, P1007; RUSH RW, 1976, BRIT MED J, V2, P965, DOI 10.1136/bmj.2.6042.965; SELYE H, 1961, SCIENCE, V133, P44, DOI 10.1126/science.133.3445.44	5	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 27	1992	304	6843					1668	1668		10.1136/bmj.304.6843.1668	http://dx.doi.org/10.1136/bmj.304.6843.1668			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB939	1378771	Green Published, Bronze			2022-12-01	WOS:A1992JB93900022
J	STANLEY, FJ; WATSON, L				STANLEY, FJ; WATSON, L			TRENDS IN PERINATAL-MORTALITY AND CEREBRAL-PALSY IN WESTERN-AUSTRALIA, 1967 TO 1985	BRITISH MEDICAL JOURNAL			English	Article							BIRTH-WEIGHT INFANTS; WHITE MATTER NECROSIS; CHANGING PANORAMA; INTRAPARTUM ASPHYXIA; GESTATIONAL-AGE; SWEDEN; PERIOD; DAMAGE	Objective-To analyse the trends in stillbirths, neonatal deaths, and cerebral palsy in all infants born in Western Australia from 1967 to 1985. To relate these trends to changes in perinatal care, particularly in relation to avoidance of intrapartum asphyxia in term infants and the increased survival of low birthweight infants. Design-Descriptive epidemiological study calculating population rates for perinatal deaths and cerebral palsy according to year of birth and birth weight. Setting-Western Australia. Subjects-All infants born after 20 weeks' gestation or weighing at least 400 g (live and stillborn). Main Outcome Measures-Stillbirths, neonatal deaths (from perinatal death certificates), and cerebral palsy (from a population based register). Results-Overall stillbirth rates fell from 12.1/1000 total births in 1967-70 to 8.1 in 1983-5. Early neonatal mortality fell from 13.0/1000 live births to 4-4 over the same period whereas total cerebral palsy rates remained at around 2-2.5/1000 live births. Death rates fell in all birth weight categories, particularly in low birthweight infants between 1975 and 1985, the period when birthweight data were available. In contrast, cerebral palsy rates in infants under 1500 g rose significantly over this period (from 12.1 in 1968 to 64.9 in 1985). The rise was seen in all spastic categories, including severely and multiply handicapped children. Conclusions-Large increases in the use of interventions aimed at reducing birth asphyxia and handicaps had not (by 1985) resulted in lower rates of cerebral palsy. This suggests that birth asphyxia is not a major cause. The increased survival of low birthweight infants has resulted in more cerebral palsy in this group, due either to postnatal complications of immaturity or prenatal damage to the fetal brain. These findings have implications for planning perinatal care and for litigation for putative obstetric malpractice in cerebral palsy cases.			STANLEY, FJ (corresponding author), PRINCESS MARGARET HOSP,WESTERN AUSTRALIAN RES INST CHILD HLTH,GPO BOX D184,PERTH,WA 6001,AUSTRALIA.							ALBERMAN E, 1963, Dev Med Child Neurol, V5, P388; ARMSTRONG DL, 1987, AM J DIS CHILD, V141, P617, DOI 10.1001/archpedi.1987.04460060035027; BARTH PG, 1987, CAN J NEUROL SCI, V14, P1; BAX M C, 1964, Dev Med Child Neurol, V6, P295; BEJAR R, 1986, ANN NEUROL, V20, P436; BERNFIELD M, 1990, PEDIATR RES, V27, P21; BLAIR E, 1988, J PEDIATR-US, V112, P515, DOI 10.1016/S0022-3476(88)80161-6; BLAIR E, 1990, AM J OBSTET GYNECOL, V162, P229, DOI 10.1016/0002-9378(90)90856-3; BLAIR E, 1985, DEV MED CHILD NEUROL, V27, P615; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; COOKE RWI, 1987, ARCH DIS CHILD, V62, P931, DOI 10.1136/adc.62.9.931; DOWDING VM, 1988, IRISH MED J, V81, P25; FISHER CC, 1990, MED J AUSTRALIA, V153, P639, DOI 10.5694/j.1326-5377.1990.tb126307.x; FREEMAN JM, 1988, PEDIATRICS, V82, P240; GEE V, 1989, PERINATAL STATISTICS; HAGBERG B, 1989, ACTA PAEDIATR SCAND, V78, P283, DOI 10.1111/j.1651-2227.1989.tb11071.x; HAGBERG B, 1984, ACTA PAEDIATR SCAND, V73, P433, DOI 10.1111/j.1651-2227.1984.tb09951.x; HAGBERG B, 1989, BRAIN DEV-JPN, V11, P368, DOI 10.1016/S0387-7604(89)80018-X; HILL C, 1987, VALIDATION STUDY W A; KITCHEN WH, 1987, AM J PERINAT, V4, P29, DOI 10.1055/s-2007-999733; LARROCHE JC, 1986, BIOL NEONATE, V50, P61; LEVITON A, 1990, EARLY HUM DEV, V24, P1, DOI 10.1016/0378-3782(90)90002-Z; MCDONALD AD, 1963, ARCH DIS CHILD, V38, P579, DOI 10.1136/adc.38.202.579; MOORE DJ, 1987, PERINATAL STATISTICS; NAEYE RL, 1989, AM J DIS CHILD, V143, P1154, DOI 10.1001/archpedi.1989.02150220044018; NELSON KB, 1988, J PEDIATR-US, V112, P572, DOI 10.1016/S0022-3476(88)80169-0; NELSON KB, 1986, NEW ENGL J MED, V315, P81, DOI 10.1056/NEJM198607103150202; PANETH N, 1990, J PEDIATR-US, V116, P975, DOI 10.1016/S0022-3476(05)80664-X; PHAROAH POD, 1990, ARCH DIS CHILD, V65, P602, DOI 10.1136/adc.65.6.602; PHAROAH POD, 1971, LANCET, V1, P308; RIIKONEN R, 1989, ACTA PAEDIATR SCAND, V78, P581, DOI 10.1111/j.1651-2227.1989.tb17940.x; SARNAT HB, 1987, AM J DIS CHILD, V141, P969, DOI 10.1001/archpedi.1987.04460090046022; SHEARER MH, 1986, BIRTHS, V12, P151; STANLEY F J, 1985, Neuroepidemiology, V4, P146, DOI 10.1159/000110226; STANLEY FJ, 1991, MED J AUSTRALIA, V154, P623, DOI 10.5694/j.1326-5377.1991.tb121226.x; STANLEY FJ, 1986, AM J PUBLIC HEALTH, V76, P35, DOI 10.2105/AJPH.76.1.35; STANLEY FJ, 1988, AM J OBSTET GYNECOL, V158, P89, DOI 10.1016/0002-9378(88)90784-3; TORFS CP, 1990, J PEDIATR-US, V116, P615, DOI 10.1016/S0022-3476(05)81615-4; 1989, LANCET, V2, P1251	39	174	175	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 27	1992	304	6843					1658	1663		10.1136/bmj.304.6843.1658	http://dx.doi.org/10.1136/bmj.304.6843.1658			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB939	1633518	Bronze, Green Published			2022-12-01	WOS:A1992JB93900020
J	VIOLARIS, AG; LINNEMEIER, TJ; CAMPBELL, S; ROTHBAUM, DA; CUMBERLAND, DC				VIOLARIS, AG; LINNEMEIER, TJ; CAMPBELL, S; ROTHBAUM, DA; CUMBERLAND, DC			INTRAVASCULAR ULTRASOUND IMAGING COMBINED WITH CORONARY ANGIOPLASTY	LANCET			English	Note							INVITRO	A novel catheter combining ultrasound imaging and coronary balloon angioplasty was used in the treatment of 69 coronary-artery lesions in 51 patients. The ultrasound transducer enables real-time cross-sectional imaging and qualitative and quantitative assessment of the vessel wall before and after angioplasty. The combination catheter successfully dilated 67 lesions. There was a characteristic three-layered appearance, representing intima, media, and adventitia, in 60 cases. Intravascular imaging provided information on the vessel wall unobtainable by standard contrast angiogaphy in 28 cases and influenced our management in 6 cases.	NO GEN HOSP,CARDIAC UNIT,HERRIES RD,SHEFFIELD S5 7AU,S YORKSHIRE,ENGLAND; ST VINCENT HOSP,INDIANA HEART INST,INDIANAPOLIS,IN	Northern General Hospital								GUSSENHOVEN EJ, 1989, J AM COLL CARDIOL, V14, P947, DOI 10.1016/0735-1097(89)90471-3; NISHIMURA RA, 1990, J AM COLL CARDIOL, V16, P145, DOI 10.1016/0735-1097(90)90472-2; POTKIN BN, 1988, AM J CARDIOL, V62, P41, DOI 10.1016/0002-9149(88)91362-8; TOBIS JM, 1991, CIRCULATION, V83, P913, DOI 10.1161/01.CIR.83.3.913; Yock P G, 1989, J Am Soc Echocardiogr, V2, P296	5	6	6	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 27	1992	339	8809					1571	1572		10.1016/0140-6736(92)91834-U	http://dx.doi.org/10.1016/0140-6736(92)91834-U			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB202	1351552				2022-12-01	WOS:A1992JB20200006
J	WINQVIST, O; KARLSSON, FA; KAMPE, O				WINQVIST, O; KARLSSON, FA; KAMPE, O			21-HYDROXYLASE, A MAJOR AUTOANTIGEN IN IDIOPATHIC ADDISONS-DISEASE	LANCET			English	Article							AUTOANTIBODIES; SEQUENCE; ANTIGEN; GENE; IDENTIFICATION; EXPRESSION; PROTEINS; CLONING; P450C21	Sera from patients with idiopathic Addison's disease commonly react with the zona glomerulosa of adrenal cortex. We used high-resolution western blot analysis of an adrenal microsomal fraction to investigate the target of these antibodies. A protein with an apparent molecular weight of 54 kDa was recognised as the common and major component. Sera identifying this autoantigen (from 12 of 16 patients) also showed strong immunofluorescence staining of a steroid-producing human adrenal adrenocortical cell line, NCI-H295. On application of antisera specific for different cytochrome P450 steroidogenic enzymes (side-chain cleavage enzyme, 21-hydroxylase, 17-alpha-hydroxylase, 11-beta-hydroxylase)the mobility of the 54 kDa protein in western blots corresponded to that of 21 -hydroxylase. This parallel behaviour was confirmed by immunoprecipitation, electrophoresis, and autoradiography with the various sera and S-35-methionine-labelled NCI-H295 cell lysates. Preabsorptions of S-35-methionine-labelled cell lysates with the antiserum to 21-hydroxylase, but not with the other enzyme antisera, abolished precipitation of the 54 kDa autoantigen with the patient sera. These results indicate that 21-hydroxylase (P450c21), prominent in the zona glomerulosa of the adrenal cortex, is a major autoantigen in idiopathic Addison's disease.	UNIV HOSP UPPSALA,DEPT INTERNAL MED,S-75185 UPPSALA,SWEDEN	Uppsala University; Uppsala University Hospital				winqvist, Ola/0000-0003-0842-4441				ANDERSON J. R., 1968, CLIN EXP IMMUNOL, V3, P107; BAEKKESKOV S, 1990, NATURE, V347, P151, DOI 10.1038/347151a0; BANGA JP, 1991, AUTOIMMUNITY, V9, P177, DOI 10.3109/08916939109006755; BLIZZARD RM, 1962, LANCET, V2, P901; BLIZZARD RM, 1963, J CLIN INVEST, V42, P1653, DOI 10.1172/JCI104851; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BRIGHT GM, 1990, J CLIN ENDOCR METAB, V70, P95, DOI 10.1210/jcem-70-1-95; CHOINARD ML, 1990, MOL CELL ENDOCRINOL, V68, P29; CHUNG BC, 1986, P NATL ACAD SCI USA, V83, P4243, DOI 10.1073/pnas.83.12.4243; CZARNOCKA B, 1985, FEBS LETT, V190, P147, DOI 10.1016/0014-5793(85)80446-4; FURMANIAK J, 1988, FEBS LETT, V231, P25, DOI 10.1016/0014-5793(88)80695-1; GAZDAR AF, 1990, CANCER RES, V50, P5488; GOUDIE R. B., 1968, CLIN EXP IMMUMOL, V3, P119; GOUDIE RB, 1966, LANCET, V1, P1173; JONSSON J, 1981, OPUSC MED, V26, P1; KARLSSON FA, 1988, J CLIN INVEST, V81, P475, DOI 10.1172/JCI113344; KROHN K, 1992, LANCET, V339, P770, DOI 10.1016/0140-6736(92)91894-E; MANNS MP, 1989, J CLIN INVEST, V83, P1066, DOI 10.1172/JCI113949; MILLER WL, 1988, ENDOCR REV, V9, P295, DOI 10.1210/edrv-9-3-295; MOROHASHI K, 1984, P NATL ACAD SCI-BIOL, V81, P4647, DOI 10.1073/pnas.81.15.4647; MULLER J, 1991, ENDOCR RES, V17, P165; PICADOLEONARD J, 1987, DNA-J MOLEC CELL BIO, V6, P439, DOI 10.1089/dna.1987.6.439; SOTSIOU F, 1980, CLIN EXP IMMUNOL, V39, P97; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VOUTILAINEN R, 1986, J CLIN ENDOCR METAB, V63, P1145, DOI 10.1210/jcem-63-5-1145; WELLER TH, 1954, P SOC EXP BIOL MED, V86, P789, DOI 10.3181/00379727-86-21235; ZUBER MX, 1986, J BIOL CHEM, V261, P2475	27	304	312	0	15	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 27	1992	339	8809					1559	1562		10.1016/0140-6736(92)91829-W	http://dx.doi.org/10.1016/0140-6736(92)91829-W			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB202	1351548				2022-12-01	WOS:A1992JB20200002
J	AMIGORENA, S; BONNEROT, C; DRAKE, JR; CHOQUET, D; HUNZIKER, W; GUILLET, JG; WEBSTER, P; SAUTES, C; MELLMAN, I; FRIDMAN, WH				AMIGORENA, S; BONNEROT, C; DRAKE, JR; CHOQUET, D; HUNZIKER, W; GUILLET, JG; WEBSTER, P; SAUTES, C; MELLMAN, I; FRIDMAN, WH			CYTOPLASMIC DOMAIN HETEROGENEITY AND FUNCTIONS OF IGG FC-RECEPTORS IN LYMPHOCYTES-B	SCIENCE			English	Article							REPRESSOR CI PROTEIN; N-TERMINAL DOMAIN; LAMBDA-REPRESSOR; MONOCLONAL-ANTIBODIES; DIFFERENT HAPLOTYPES; IA MOLECULES; T RESPONSE; ANTIGEN; IMMUNOGLOBULIN; CELLS	B lymphocytes and macrophages express closely related immunoglobulin G (IgG) Fc receptors (Fc-gamma-RII) that differ only in the structures of their cytoplasmic domains. Because of cell type-specific alternative messenger RNA splicing, B-cell Fc-gamma-RII contains an insertion of 47 amino acids that participates in determining receptor function in these cells. Transfection of an Fc-gamma-RII-negative B-cell line with complementary DNA's encoding the two splice products and various receptor mutants indicated that the insertion was responsible for preventing both Fc-gamma-RII-mediated endocytosis and Fc-gamma-RII-mediated antigen presentation. The insertion was not required for Fc-gamma-RII to modulate surface immunoglobulin-triggered B-cell activation. Instead, regulation of activation involved a region of the cytoplasmic domain common to both the lymphocyte and macrophage receptor isoforms. In contrast, the insertion did contribute to the formation of caps in response to receptor cross-linking, consistent with suggestions that the lymphocyte but not macrophage form of the receptor can associate with the detergent-insoluble cytoskeleton.	YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510; INST CURIE,INSERM,U255,IMMUNOL CELLULAIRE & CLIN LAB,F-75005 PARIS,FRANCE; INST PASTEUR,INSERM,NEUROBIOL CELLULAIRE LAB,U261,F-75724 PARIS 15,FRANCE; INST COCHIN GENET MOLEC,INTERACT PROT LAB,URA 228,F-75014 PARIS,FRANCE	Yale University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Hunziker, Walter/B-3140-2010; Hunziker, Walter/GSM-8190-2022; Choquet, Daniel/K-7893-2018; Choquet, Daniel/E-4203-2013; Mellman, Ira/ABG-5896-2020	Hunziker, Walter/0000-0002-5265-4933; Choquet, Daniel/0000-0003-4726-9763; fridman, wolf herman/0000-0002-1332-0973; sautes-fridman, catherine/0000-0003-1735-8722; Amigorena, Sebastian/0000-0001-8583-8416; Webster, Paul/0000-0002-1980-6931				AMIGORENA S, 1989, EUR J IMMUNOL, V19, P1379, DOI 10.1002/eji.1830190805; BREYER RM, 1989, J BIOL CHEM, V264, P13348; CAMBIER JC, 1987, ANNU REV IMMUNOL, V5, P175, DOI 10.1146/annurev.immunol.5.1.175; DICKLER HB, 1981, J EXP MED, V153, P1329, DOI 10.1084/jem.153.5.1329; DRAKE JR, 1989, J IMMUNOL, V143, P1768; GRAZIADEI L, 1990, NATURE, V347, P396, DOI 10.1038/347396a0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HIBBS ML, 1986, P NATL ACAD SCI USA, V83, P6980, DOI 10.1073/pnas.83.18.6980; HUANG MM, 1992, J BIOL CHEM, V267, P5467; HUNZIKER W, 1990, NATURE, V345, P628, DOI 10.1038/345628a0; JONES B, 1986, J IMMUNOL, V136, P348; KEHRY MR, 1989, P NATL ACAD SCI USA, V86, P7556, DOI 10.1073/pnas.86.19.7556; KLAUS GGB, 1987, IMMUNOL REV, V99, P19, DOI 10.1111/j.1600-065X.1987.tb01170.x; LAI MZ, 1987, J IMMUNOL, V139, P3973; LANZAVECCHIA A, 1990, ANNU REV IMMUNOL, V8, P773, DOI 10.1146/annurev.immunol.8.1.773; LANZAVECCHIA A, 1985, NATURE, V314, P537, DOI 10.1038/314537a0; LEWIS VA, 1986, NATURE, V324, P372, DOI 10.1038/324372a0; MANCA F, 1991, J EXP MED, V173, P37, DOI 10.1084/jem.173.1.37; MELLMAN I, 1984, J CELL BIOL, V98, P1170, DOI 10.1083/jcb.98.4.1170; Mellman I, 1990, Semin Immunol, V2, P229; MELLMAN I, 1988, CURR OPIN IMMUNOL, V1, P16, DOI 10.1016/0952-7915(88)90046-5; MIETTINEN HM, 1989, CELL, V58, P317, DOI 10.1016/0092-8674(89)90846-5; MIETTINEN HM, 1992, J CELL BIOL, V116, P875, DOI 10.1083/jcb.116.4.875; PESANDO JM, 1989, J EXP MED, V170, P2159, DOI 10.1084/jem.170.6.2159; PHILLIPS NE, 1984, J IMMUNOL, V132, P627; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RAVETCH JV, 1986, SCIENCE, V234, P718, DOI 10.1126/science.2946078; RAVETCH JV, 1989, J EXP MED, V170, P481, DOI 10.1084/jem.170.2.481; ROOSNEK E, 1991, J EXP MED, V173, P487, DOI 10.1084/jem.173.2.487; SANAN DA, 1991, J HISTOCHEM CYTOCHEM, V39, P1017, DOI 10.1177/39.8.1906908; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; TANNER J, 1987, CELL, V50, P203, DOI 10.1016/0092-8674(87)90216-9; WILSON HA, 1989, J IMMUNOL, V138, P1712	33	413	438	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 26	1992	256	5065					1808	1812		10.1126/science.1535455	http://dx.doi.org/10.1126/science.1535455			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA434	1535455				2022-12-01	WOS:A1992JA43400033
J	ANSARI, A; JONES, CM; HENRY, ER; HOFRICHTER, J; EATON, WA				ANSARI, A; JONES, CM; HENRY, ER; HOFRICHTER, J; EATON, WA			THE ROLE OF SOLVENT VISCOSITY IN THE DYNAMICS OF PROTEIN CONFORMATIONAL-CHANGES	SCIENCE			English	Article							GEMINATE RECOMBINATION; GLASS-TRANSITION; CARBON-MONOXIDE; LIGAND-BINDING; HEME-PROTEINS; MYOGLOBIN; PHOTODISSOCIATION; SPECTROSCOPY; DIFFUSION; KINETICS	Nanosecond lasers were used to measure the rate of conformational changes ir myoglobin after ligand dissociation at ambient temperatures. At low solvent viscosities the rate is independent of viscosity, but at high viscosities it depends on approximately the inverse first power of the viscosity. Kramers theory for unimolecular rate processes can be used to explain this result if the friction term is modified to include protein as well as solvent friction. The theory and experiment suggest that the dominant factor in markedly reducing the rate of conformational changes in myoglobin at low temperatures (<200 K) is the very high viscosity (>10(7) centipoise) of the glycerol-water solvent. That is, at low temperatures conformational substates may not be "frozen" so much as "stuck."	NIDDKD,CHEM PHYS LAB,BLDG 2,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Henry, Eric R/J-3414-2013	Henry, Eric R/0000-0002-5648-8696				AGMON N, 1983, J CHEM PHYS, V79, P2042, DOI 10.1063/1.445988; ANGELL CA, 1976, ANN NY ACAD SCI, V279, P53, DOI 10.1111/j.1749-6632.1976.tb39693.x; ANSARI A, 1987, BIOPHYS CHEM, V26, P337, DOI 10.1016/0301-4622(87)80034-0; ANSARI A, 1986, BIOCHEMISTRY-US, V25, P3139, DOI 10.1021/bi00359a011; AUSTIN RH, 1975, BIOCHEMISTRY-US, V14, P5355, DOI 10.1021/bi00695a021; BEECE D, 1980, BIOCHEMISTRY-US, V19, P5147, DOI 10.1021/bi00564a001; CHRUNYK BA, 1990, BIOCHEMISTRY-US, V29, P2149, DOI 10.1021/bi00460a027; DEMCHENKO AP, 1989, BIOCHIM BIOPHYS ACTA, V998, P196, DOI 10.1016/0167-4838(89)90273-2; FRAUENFELDER H, 1991, SCIENCE, V254, P1598, DOI 10.1126/science.1749933; FRAUENFELDER H, 1990, J PHYS CHEM-US, V94, P1024, DOI 10.1021/j100366a002; GAVISH B, 1979, BIOCHEMISTRY-US, V18, P1269, DOI 10.1021/bi00574a023; GENBERG L, 1991, SCIENCE, V251, P1051, DOI 10.1126/science.1998121; HANGGI P, 1990, REV MOD PHYS, V62, P251, DOI 10.1103/RevModPhys.62.251; HASINOFF BB, 1977, ARCH BIOCHEM BIOPHYS, V183, P176, DOI 10.1016/0003-9861(77)90432-5; HENRY ER, 1992, METHOD ENZYMOL, V210, P129; HENRY ER, 1983, J MOL BIOL, V166, P443, DOI 10.1016/S0022-2836(83)80094-1; HENRY ER, 1983, BRUSSELS HEMOGLOBIN, P193; HOFRICHTER J, 1983, P NATL ACAD SCI-BIOL, V80, P2235, DOI 10.1073/pnas.80.8.2235; HOFRICHTER J, 1985, BIOCHEMISTRY-US, V24, P2667, DOI 10.1021/bi00332a012; HOFRICHTER J, 1991, BIOCHEMISTRY-US, V30, P6538; IBEN IET, 1989, PHYS REV LETT, V62, P1916, DOI 10.1103/PhysRevLett.62.1916; Kramers HA, 1940, PHYSICA, V7, P284, DOI 10.1016/S0031-8914(40)90098-2; KURIYAN J, 1986, J MOL BIOL, V192, P133, DOI 10.1016/0022-2836(86)90470-5; LAMBRIGHT DG, 1991, CHEM PHYS, V158, P249, DOI 10.1016/0301-0104(91)87069-8; MASTRO AM, 1984, J CELL BIOL, V99, pS180, DOI 10.1083/jcb.99.1.180s; MURRAY LP, 1988, BIOPHYS CHEM, V29, P63, DOI 10.1016/0301-4622(88)87025-X; NEWMAN AA, 1968, GLYCEROL; RASMUSSEN DH, 1971, J PHYS CHEM-US, V75, P967, DOI 10.1021/j100677a022; Rice S.A., 1985, DIFFUSION LTD REACTI; Smoluchowski M.V, 1918, PHYS CHEM, V92U, P129, DOI DOI 10.1515/ZPCH-1918-9209; SRAJER V, 1991, BIOCHEMISTRY-US, V30, P4886, DOI 10.1021/bi00234a008; STEINBACH PJ, 1991, BIOCHEMISTRY-US, V30, P3988, DOI 10.1021/bi00230a026; WESTRICK JA, 1987, BIOCHEMISTRY-US, V26, P8313, DOI 10.1021/bi00399a043; XIE XL, 1991, BIOCHEMISTRY-US, V30, P3682, DOI 10.1021/bi00229a013	34	489	496	0	79	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 26	1992	256	5065					1796	1798		10.1126/science.1615323	http://dx.doi.org/10.1126/science.1615323			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA434	1615323				2022-12-01	WOS:A1992JA43400029
J	CHUNG, J; KUO, CJ; CRABTREE, GR; BLENIS, J				CHUNG, J; KUO, CJ; CRABTREE, GR; BLENIS, J			RAPAMYCIN FKBP SPECIFICALLY BLOCKS GROWTH-DEPENDENT ACTIVATION OF AND SIGNALING BY THE 70 KD S6 PROTEIN-KINASES	CELL			English	Article							PEPTIDYL-PROLYL ISOMERASE; RIBOSOMAL PROTEIN-S6; IMMUNOSUPPRESSANT FK506; MACROLIDES FK-506; DISTINCT; PHOSPHORYLATION; IMMUNOPHILIN; S6-KINASE; HOMOLOGS; CHICKEN	The macrolide rapamycin blocks cell cycle progression in yeast and various animal cells by an unknown mechanism. We demonstrate that rapamycin blocks the phosphorylation and activation of the 70 kd S6 protein kinases (pp70S6K) in a variety of animal cells. The structurally related drug FK506 had no effect on pp70S6K activation but at high concentrations reversed the rapamycin-induced block, confirming the requirement for the rapamycin and FK506 receptor, FKBP. Rapamycin also interfered with signaling by these S6 kinases, blocking serum-stimulated S6 phosphorylation and delaying entry of Swiss 3T3 cells into S phase. Neither rapamycin nor FK506 blocked activation of a distinct family of S6 kinases (RSKs) or the MAP kinases. These studies identify a rapamycin-sensitive signaling pathway, argue for a ubiquitous role for FKBPs in signal transduction, indicate that FK506-FKBP-calcineurin complexes do not interfere with pp70S6K signaling, and show that in fibroblasts pp70S6K, not RSK, is the physiological S6 kinase.	STANFORD UNIV,MED CTR,SCH MED,BECKMAN CTR,MOLEC & GENET MED UNIT,STANFORD,CA 94305	Stanford University	CHUNG, J (corresponding author), HARVARD UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02115, USA.				NCI NIH HHS [CA-39612, CA-46595] Funding Source: Medline; NHLBI NIH HHS [HLB-33942] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039612, R37CA039612, R37CA046595, R01CA046595] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033942] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALCORTA DA, 1989, MOL CELL BIOL, V9, P3850, DOI 10.1128/MCB.9.9.3850; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANDRES JL, 1989, J BIOL CHEM, V264, P151; BALLOU LM, 1988, J BIOL CHEM, V263, P1188; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; BIERER BE, 1990, SCIENCE, V250, P556, DOI 10.1126/science.1700475; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BLENIS J, 1985, P NATL ACAD SCI USA, V82, P7621, DOI 10.1073/pnas.82.22.7621; BLENIS J, 1991, CELL GROWTH DIFFER, V2, P279; BLENIS J, 1991, CANCER CELL-MON REV, V3, P445; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; CHANG JY, 1991, TRENDS PHARMACOL SCI, V12, P218, DOI 10.1016/0165-6147(91)90555-7; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; CHEN RH, 1991, MOL CELL BIOL, V11, P1861, DOI 10.1128/MCB.11.4.1861; CHUNG J, 1991, P NATL ACAD SCI USA, V88, P4981, DOI 10.1073/pnas.88.11.4981; CHUNG JK, 1991, MOL CELL BIOL, V11, P1868, DOI 10.1128/MCB.11.4.1868; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; DUMONT FJ, 1990, J IMMUNOL, V144, P1418; DUMONT FJ, 1990, J IMMUNOL, V144, P251; ERIKSON E, 1989, J BIOL CHEM, V264, P13711; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; JOHNSON SP, 1987, MOL CELL BIOL, V7, P1338, DOI 10.1128/MCB.7.4.1338; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; JURIVICH DA, 1991, J CELL PHYSIOL, V148, P252, DOI 10.1002/jcp.1041480210; KOZMA SC, 1990, P NATL ACAD SCI USA, V87, P7365, DOI 10.1073/pnas.87.19.7365; KUO CJ, 1991, EMBO J, V10, P2231, DOI 10.1002/j.1460-2075.1991.tb07759.x; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MCKEON F, 1991, CELL, V66, P823, DOI 10.1016/0092-8674(91)90426-Y; MORRIS RE, 1991, IMMUNOL TODAY, V12, P137; OLIVIER AR, 1990, J BIOL CHEM, V265, P22460; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; SWEET LJ, 1990, MOL CELL BIOL, V10, P2787, DOI 10.1128/MCB.10.6.2787; TERAO K, 1970, BIOCHEM BIOPH RES CO, V38, P80, DOI 10.1016/0006-291X(70)91086-7; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	44	1069	1098	1	29	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 26	1992	69	7					1227	1236		10.1016/0092-8674(92)90643-Q	http://dx.doi.org/10.1016/0092-8674(92)90643-Q			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JA431	1377606				2022-12-01	WOS:A1992JA43100016
J	CITOVSKY, V; ZUPAN, J; WARNICK, D; ZAMBRYSKI, P				CITOVSKY, V; ZUPAN, J; WARNICK, D; ZAMBRYSKI, P			NUCLEAR-LOCALIZATION OF AGROBACTERIUM VIRE2 PROTEIN IN PLANT-CELLS	SCIENCE			English	Article							SINGLE-STRANDED-DNA; TOBACCO MOSAIC-VIRUS; BINDING-PROTEIN; T-DNA; VIRD2 PROTEIN; 5' END; TUMEFACIENS; PLASMID; COMPLEX; ASSOCIATION	The Agrobacterium single-stranded DNA (ssDNA) intermediate T-strand is likely transferred to the plant cell nucleus as a complex with a single VirD2 molecule at its 5' end and multiple VirE2 molecules along its length. VirD2 contains a nuclear localization signal (NLS); however, because the T-strand is principally coated with VirE2 molecules, VirE2 also might assist in nuclear uptake. Indeed, VirE2 fused to a reporter protein localizes to plant cell nuclei, a process mediated by two amino acid sequences with homology to the bipartite NLS of Xenopus nucleoplasmin. Moreover, tumorigenicity of an avirulent virE2 mutant is restored when inoculated on transgenic plants expressing VirE2, supporting in planta function of VirE2.	UNIV CALIF BERKELEY,DEPT PLANT BIOL,GENET & PLANT BIOL BLDG,BERKELEY,CA 94720; SANDOZ CROP PROTECT CORP,PALO ALTO,CA 94304	University of California System; University of California Berkeley; Novartis; Sandoz				Citovsky, Vitaly/0000-0003-2024-6844	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM045244, R01GM045244] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-45244-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CARRINGTON JC, 1991, PLANT CELL, V3, P953, DOI 10.1105/tpc.3.9.953; CHRISTIE PJ, 1988, J BACTERIOL, V170, P2659, DOI 10.1128/jb.170.6.2659-2667.1988; CITOVSKY V, 1990, CELL, V60, P637, DOI 10.1016/0092-8674(90)90667-4; CITOVSKY V, 1989, P NATL ACAD SCI USA, V86, P1193, DOI 10.1073/pnas.86.4.1193; CITOVSKY V, 1992, PLANT CELL, V4, P397, DOI 10.1105/tpc.4.4.397; CITOVSKY V, 1988, SCIENCE, V240, P501, DOI 10.1126/science.240.4851.501; DAS A, 1988, P NATL ACAD SCI USA, V85, P2909, DOI 10.1073/pnas.85.9.2909; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; GERACE L, 1988, ANN REV CELL BIOL, V4, P355; GIETL C, 1987, P NATL ACAD SCI USA, V84, P9006, DOI 10.1073/pnas.84.24.9006; HERRERAESTRELLA A, 1988, EMBO J, V7, P4055, DOI 10.1002/j.1460-2075.1988.tb03299.x; HIROOKA T, 1987, J BACTERIOL, V169, P1529, DOI 10.1128/jb.169.4.1529-1536.1987; HODGES LM, UNPUB; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; HOWARD E, 1990, BIOESSAYS, V12, P103, DOI 10.1002/bies.950120302; HOWARD E, 1990, UCLA SYM BI, V129, P1; HOWARD EA, 1989, P NATL ACAD SCI USA, V86, P4017, DOI 10.1073/pnas.86.11.4017; HOWARD EA, 1992, BIOESSAYS, V68, P109; KNORR DA, 1988, P NATL ACAD SCI USA, V85, P170, DOI 10.1073/pnas.85.1.170; LEHTO K, 1990, VIROLOGY, V174, P290, DOI 10.1016/0042-6822(90)90077-5; LOHMAN TM, 1986, J MOL BIOL, V187, P603, DOI 10.1016/0022-2836(86)90338-4; MCCLARY JA, 1989, BIOTECHNIQUES, V7, P282; MCDONNELL RE, 1987, PLANT MOL BIOL REP, V5, P380; MEHLIN H, 1992, CELL, V69, P605, DOI 10.1016/0092-8674(92)90224-Z; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NIGG EA, 1991, CELL, V66, P15, DOI 10.1016/0092-8674(91)90135-L; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROBERTS BL, 1987, CELL, V50, P465, DOI 10.1016/0092-8674(87)90500-9; ROGERS SG, 1987, METHOD ENZYMOL, V153, P253; STACHEL SE, 1986, EMBO J, V5, P1445, DOI 10.1002/j.1460-2075.1986.tb04381.x; WARD ER, 1988, SCIENCE, V242, P927, DOI 10.1126/science.242.4880.927; WINANS SC, 1987, NUCLEIC ACIDS RES, V15, P825, DOI 10.1093/nar/15.2.825; YOUNG C, 1988, J BACTERIOL, V170, P3367, DOI 10.1128/jb.170.8.3367-3374.1988; ZAMBRYSKI PC, 1992, ANNU REV PLANT PHYS, V43, P465, DOI 10.1146/annurev.pp.43.060192.002341	35	217	244	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 26	1992	256	5065					1802	1805		10.1126/science.1615325	http://dx.doi.org/10.1126/science.1615325			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA434	1615325				2022-12-01	WOS:A1992JA43400031
J	FURUKAWA, T; MARUYAMA, S; KAWAICHI, M; HONJO, T				FURUKAWA, T; MARUYAMA, S; KAWAICHI, M; HONJO, T			THE DROSOPHILA HOMOLOG OF THE IMMUNOGLOBULIN RECOMBINATION SIGNAL BINDING-PROTEIN REGULATES PERIPHERAL NERVOUS-SYSTEM DEVELOPMENT	CELL			English	Article							SMALL AUTOSOMAL REGION; LARGE TRANSPOSING ELEMENT; SCUTE GENE-COMPLEX; LOOP-HELIX PROTEINS; ALCOHOL-DEHYDROGENASE; STRUCTURAL GENE; NEGATIVE REGULATOR; MELANOGASTER; DNA; MUTATIONS	The J(kappa) RBP binds to the immunoglobulin recombination signal sequence flanking the kappa-type J segment. We previously isolated the highly conserved homolog of the J(kappa) RBP gene from D. melanogaster, which is not thought to have immunoglobulin molecules. Using many deficiency mutants and in situ hybridization, we mapped the Drosophila J(kappa) RBP gene in a region containing two recessive lethal mutations, i.e., br26 and br7, which shows the dominant Suppressor of Hairless (Su(H)) phenotype in heterozygotes. All six Su(H) alleles analyzed at the DNA level contained mutations in the Drosophila J(kappa) RBP gene. Since the Su(H) mutation affects peripheral nervous system development, the Drosophila J(kappa) RBP gene product is involved in gene regulation of peripheral nervous system development. The results also imply that the immunoglobulin recombination signal sequence and the target sequence of the Drosophila J(kappa) RBP protein might have a common evolutionary origin.			FURUKAWA, T (corresponding author), KYOTO UNIV,FAC MED,DEPT MED CHEM,SAKYO KU,KYOTO 606,JAPAN.		Honjo, Tasuku/N-4470-2016					AKIRA S, 1987, SCIENCE, V238, P1134, DOI 10.1126/science.3120312; ALONSO MC, 1988, EMBO J, V7, P2585, DOI 10.1002/j.1460-2075.1988.tb03108.x; ASHBURNER M, 1982, GENETICS, V102, P401; ASHBURNER M, 1990, GENETICS, V126, P679; ASHBURNER M, 1982, GENETICS, V101, P447; ASHBURNER M, 1983, GENETICS, V104, P405; ASHBURNER M, 1982, GENETICS, V102, P421; ASHBURNER M, 1989, DROSOPHILA LABORATOR; BANG AG, 1991, DEVELOPMENT, V111, P89; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; CAMPUZANO S, 1985, CELL, V40, P327, DOI 10.1016/0092-8674(85)90147-3; CAUDY M, 1988, CELL, V55, P1061, DOI 10.1016/0092-8674(88)90250-4; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CRAIG NL, 1988, ANNU REV GENET, V22, P77; DELPRADO JM, 1984, W ROUX ARCH DEV BIOL, V193, P242; EARLY P, 1980, CELL, V19, P981, DOI 10.1016/0092-8674(80)90089-6; EDGAR BA, 1986, CELL, V44, P871, DOI 10.1016/0092-8674(86)90009-7; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FURUKAWA T, 1991, J BIOL CHEM, V266, P23334; GARCIABELLIDO A, 1971, DEV BIOL, V24, P61, DOI 10.1016/0012-1606(71)90047-9; GUBB D, 1986, GENETICS, V112, P551; GUBB D, 1985, CHROMOSOMA, V92, P116, DOI 10.1007/BF00328463; GUBB D, 1984, CHROMOSOMA, V91, P54, DOI 10.1007/BF00286485; HAMAGUCHI Y, 1989, NUCLEIC ACIDS RES, V17, P9015, DOI 10.1093/nar/17.22.9015; HARTENSTEIN V, 1989, DEVELOPMENT, V107, P389; HESSE JE, 1989, GENE DEV, V3, P1053, DOI 10.1101/gad.3.7.1053; HONJO T, 1983, ANNU REV IMMUNOL, V1, P499, DOI 10.1146/annurev.iy.01.040183.002435; JAN YN, 1990, TRENDS NEUROSCI, V13, P493, DOI 10.1016/0166-2236(90)90083-M; KAWAICHI M, 1991, J BIOL CHEM, V266, P18387; LITMAN GW, 1985, P NATL ACAD SCI USA, V82, P844, DOI 10.1073/pnas.82.3.844; LITMAN GW, 1985, P NATL ACAD SCI USA, V82, P2082, DOI 10.1073/pnas.82.7.2082; MATSUNAMI N, 1989, NATURE, V342, P934, DOI 10.1038/342934a0; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MLODZIK M, 1990, GENE DEV, V4, P1848, DOI 10.1101/gad.4.11.1848; MOHLER J, 1984, GENETICS, V106, P249; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NASH D, 1990, GENETICS, V64, P471; NISHIDA Y, 1986, BIOCHEM BIOPH RES CO, V141, P474, DOI 10.1016/S0006-291X(86)80197-8; ODONNELL JD, 1977, GENETICS, V86, P533; Plunkett CR, 1926, J EXP ZOOL, V46, P181, DOI 10.1002/jez.1400460204; RUSHLOW CA, 1989, EMBO J, V8, P3095, DOI 10.1002/j.1460-2075.1989.tb08461.x; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWAGER J, 1988, EMBO J, V7, P2409, DOI 10.1002/j.1460-2075.1988.tb03086.x; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; VILLARES R, 1987, CELL, V50, P415, DOI 10.1016/0092-8674(87)90495-8; WOODRUFF RC, 1979, GENETICS, V92, P133; WOODRUFF RC, 1979, GENETICS, V92, P117	50	114	117	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 26	1992	69	7					1191	1197		10.1016/0092-8674(92)90640-X	http://dx.doi.org/10.1016/0092-8674(92)90640-X			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JA431	1617729				2022-12-01	WOS:A1992JA43100013
J	HAHN, WC; MENU, E; BOTHWELL, ALM; SIMS, PJ; BIERER, BE				HAHN, WC; MENU, E; BOTHWELL, ALM; SIMS, PJ; BIERER, BE			OVERLAPPING BUT NONIDENTICAL BINDING-SITES ON CD2 FOR CD58 AND A 2ND LIGAND CD59	SCIENCE			English	Article							T-CELL ACTIVATION; THYMIC EPITHELIAL-CELLS; MEMBRANE-PROTEIN; SURFACE LIGAND; RECEPTOR CD2; LFA-3; COMPLEMENT; ANTIGEN; EXPRESSION; MOLECULES	The interaction of the T cell glycoprotein CD2 with one ligand, CD58, contributes to T cell function. We have identified CD59, a glycoprotein with complement-inhibitory function, as a second physiological ligand for CD2. Antibodies to CD59 inhibit CD2-dependent T cell activation in murine T cell hybridomas expressing human CD2. In an in vitro binding assay with purified CD58 and CD59, CD2+ cells bind not only immobilized CD58 but also CD59. With two complementary approaches, it was demonstrated that the binding sites on CD2 for CD58 and CD59 are overlapping but nonidentical. These observations suggest that direct interactions between CD2 and both CD58 and CD59 contribute to T cell activation and adhesion.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV PEDIAT ONCOL,BOSTON,MA 02115; OKLAHOMA MED RES FDN,CARDIOVASC BIOL RES PROGRAM,OKLAHOMA CITY,OK 73104; OKLAHOMA STATE UNIV,HLTH SCI CTR,DEPT MICROBIOL & IMMUNOL,OKLAHOMA CITY,OK 73104; BRIGHAM & WOMENS HOSP,DEPT MED,DIV HEMATOL ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; YALE UNIV,SCH MED,IMMUNOBIOL SECT,NEW HAVEN,CT 06510	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Oklahoma Medical Research Foundation; Oklahoma State University System; Oklahoma State University Center for Health Sciences; Oklahoma State University - Stillwater; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Yale University			MENU, Elisabeth/B-2886-2010	MENU, Elisabeth/0000-0001-8844-9328; Bierer, Barbara/0000-0001-6448-8170	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL036061, R01HL036061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028554, R29AI028554] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36061] Funding Source: Medline; NIAID NIH HHS [AI28554] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERNARD A, 1987, J IMMUNOL, V139, P18; BIERER BE, 1988, P NATL ACAD SCI USA, V85, P1194, DOI 10.1073/pnas.85.4.1194; BIERER BE, 1989, ANNU REV IMMUNOL, V7, P579, DOI 10.1146/annurev.immunol.7.1.579; DAVIES A, 1989, J EXP MED, V170, P637, DOI 10.1084/jem.170.3.637; DECKERT M, 1992, J IMMUNOL, V148, P672; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; DRISCOLL PC, 1991, NATURE, V353, P762, DOI 10.1038/353762a0; GILLIS S, 1978, J IMMUNOL, V120, P2027; GROUX H, 1989, J IMMUNOL, V142, P3013; HAHN W, UNPUB; HAHN WC, 1991, J IMMUNOL, V147, P14; HAHN WC, IN PRESS P NATL ACAD; HARADA R, 1990, J IMMUNOL, V144, P1823; HOLGUIN MH, 1989, J CLIN INVEST, V84, P7, DOI 10.1172/JCI114172; HUNIG T, 1987, NATURE, V326, P298, DOI 10.1038/326298a0; KORTY PE, 1991, J IMMUNOL, V146, P4092; LE PT, 1990, J IMMUNOL, V144, P4541; MCMICHAEL AJ, 1987, LEUKOCYTE TYPING 3; OKADA H, 1989, BIOCHEM BIOPH RES CO, V162, P1553, DOI 10.1016/0006-291X(89)90852-8; PETERSON A, 1987, NATURE, V329, P842, DOI 10.1038/329842a0; ROLLINS SA, 1990, J IMMUNOL, V144, P3478; ROSENSTEIN Y, 1991, NATURE, V354, P233, DOI 10.1038/354233a0; SANCHEZMADRID F, 1982, P NATL ACAD SCI-BIOL, V79, P7489, DOI 10.1073/pnas.79.23.7489; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SELVARAJ P, 1987, NATURE, V326, P400, DOI 10.1038/326400a0; SHAW S, 1986, NATURE, V323, P262, DOI 10.1038/323262a0; SIMS PJ, 1982, P NATL ACAD SCI USA, V264, P19228; SLECKMAN BP, 1987, NATURE, V328, P351, DOI 10.1038/328351a0; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAMENKOVIC I, 1991, CELL, V66, P1133, DOI 10.1016/0092-8674(91)90036-X; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; TAKAI Y, 1987, P NATL ACAD SCI USA, V84, P6864, DOI 10.1073/pnas.84.19.6864; VOLLGER LW, 1987, J IMMUNOL, V138, P358; WEBB DSA, 1990, SCIENCE, V249, P1295, DOI 10.1126/science.1697984; WHITLOW MB, 1990, CELL IMMUNOL, V126, P176, DOI 10.1016/0008-8749(90)90310-N; WOLFF HL, 1990, J IMMUNOL, V144, P1215	37	178	182	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 26	1992	256	5065					1805	1807		10.1126/science.1377404	http://dx.doi.org/10.1126/science.1377404			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA434	1377404				2022-12-01	WOS:A1992JA43400032
J	HINSHAW, JE; CARRAGHER, BO; MILLIGAN, RA				HINSHAW, JE; CARRAGHER, BO; MILLIGAN, RA			ARCHITECTURE AND DESIGN OF THE NUCLEAR-PORE COMPLEX	CELL			English	Article							LINKED N-ACETYLGLUCOSAMINE; ELECTRON-MICROSCOPE; RIBOSOMAL-SUBUNITS; TRANSPORT SIGNALS; SINGLE PARTICLES; SOFTWARE SYSTEM; PROTEIN IMPORT; ENVELOPE; IDENTIFICATION; BINDING	A three-dimensional analysis of the nuclear pore complex reveals the underlying, highly symmetric framework of this supramolecular assembly, how it is anchored in the nuclear membrane, and how it is built from many distinct, interconnected subunits. The arrangement of the subunits within the membrane pore creates a large central channel, through which active nucleocytoplasmic transport is known to occur, and eight smaller peripheral channels that are probable routes for passive diffusion of ions and small molecules.	UNIV CALIF SAN DIEGO, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego	HINSHAW, JE (corresponding author), Scripps Res Inst, RES INST, DEPT CELL BIOL, LA JOLLA, CA 92037 USA.			Carragher, Bridget/0000-0002-0624-5020	NIAMS NIH HHS [AR39155] Funding Source: Medline; NIGMS NIH HHS [GM44932] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039155] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044932] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; AEBI U, 1990, EMSA B, V20, P69; AKEY CW, 1989, J CELL BIOL, V109, P971, DOI 10.1083/jcb.109.3.971; AKEY CW, 1990, BIOPHYS J, V58, P341, DOI 10.1016/S0006-3495(90)82381-X; AKEY CW, 1989, J CELL BIOL, V109, P955, DOI 10.1083/jcb.109.3.955; CROWTHER RA, 1971, J MOL BIOL, V60, P123, DOI 10.1016/0022-2836(71)90452-9; DAVIS LI, 1986, CELL, V45, P699, DOI 10.1016/0092-8674(86)90784-1; DWORETZKY SI, 1988, J CELL BIOL, V107, P1279, DOI 10.1083/jcb.107.4.1279; DWYER N, 1976, J CELL BIOL, V70, P581, DOI 10.1083/jcb.70.3.581; FELDHERR CM, 1990, ELECTRON MICROSC REV, V3, P73, DOI 10.1016/0892-0354(90)90014-J; FINCH JT, 1965, J MOL BIOL, V13, P1, DOI 10.1016/S0022-2836(65)80075-4; FINLAY DR, 1991, J CELL BIOL, V114, P169, DOI 10.1083/jcb.114.1.169; FINLAY DR, 1990, CELL, V60, P17, DOI 10.1016/0092-8674(90)90712-N; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; FRANK J, 1990, Q REV BIOPHYS, V23, P281, DOI 10.1017/S0033583500005564; FRANK J, 1981, ULTRAMICROSCOPY, V6, P343, DOI 10.1016/S0304-3991(81)80236-7; FRANK J, 1981, SCIENCE, V214, P1353, DOI 10.1126/science.7313694; FRANKE WW, 1970, J ULTRA MOL STRUCT R, V30, P288, DOI 10.1016/S0022-5320(70)80064-8; FRANKE WW, 1981, J CELL BIOL S, V91, pS39; FRANKE WW, 1974, CELL NUCLEUS, V1, P219; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; GREBER UF, 1990, EMBO J, V9, P1495, DOI 10.1002/j.1460-2075.1990.tb08267.x; GURDON JB, 1976, J EMBRYOL EXP MORPH, V36, P523; HESSLER D, 1992, MICROSCOPY KEY RES T, P73; HOLT GD, 1987, J CELL BIOL, V104, P1157, DOI 10.1083/jcb.104.5.1157; IMAMOTOSONOBE N, 1990, J BIOL CHEM, V265, P16504; KESSEL RG, 1973, PROGR SURFACE MEMBRA, V6, P243; LEE WC, 1991, J CELL BIOL, V113, P1, DOI 10.1083/jcb.113.1.1; LI RH, 1989, J CELL BIOL, V109, P2623, DOI 10.1083/jcb.109.6.2623; MILLIGAN RA, 1986, NUCLEOCYTOPLASMIC TR, P113; PAINE PL, 1975, NATURE, V254, P109, DOI 10.1038/254109a0; PANDEY S, 1991, BIOCHIM BIOPHYS ACTA, V1063, P81, DOI 10.1016/0005-2736(91)90356-D; PARK MK, 1987, P NATL ACAD SCI USA, V84, P6462, DOI 10.1073/pnas.84.18.6462; RADERMACHER M, 1988, J ELECTRON MICR TECH, V9, P359, DOI 10.1002/jemt.1060090405; REICHELT R, 1990, J CELL BIOL, V110, P883, DOI 10.1083/jcb.110.4.883; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; Ris H., 1989, I PHYS C SER, V98, P657; RIS H, 1991, EMSA B, V21, P54; SAXTON WO, 1979, ULTRAMICROSCOPY, V4, P343, DOI 10.1016/S0304-3991(79)80044-3; SILVER P, 1989, J CELL BIOL, V109, P983, DOI 10.1083/jcb.109.3.983; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SNOW CM, 1987, J CELL BIOL, V104, P1143, DOI 10.1083/jcb.104.5.1143; STEWART M, 1988, J CELL SCI, V90, P409; STOOPS JK, 1991, J STRUCT BIOL, V106, P172, DOI 10.1016/1047-8477(91)90086-C; UNWIN PNT, 1982, J CELL BIOL, V93, P63, DOI 10.1083/jcb.93.1.63; UNWIN PNT, 1980, NATURE, V283, P545, DOI 10.1038/283545a0; VANHEEL M, 1985, EMBO J, V4, P2389, DOI 10.1002/j.1460-2075.1985.tb03944.x; VANHEEL M, 1981, ULTRAMICROSCOPY, V7, P113, DOI 10.1016/0304-3991(81)90001-2; WOZNIAK RW, 1989, J CELL BIOL, V108, P2083, DOI 10.1083/jcb.108.6.2083; YAMASAKI L, 1989, MOL CELL BIOL, V9, P3028, DOI 10.1128/MCB.9.7.3028	51	373	379	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 26	1992	69	7					1133	1141		10.1016/0092-8674(92)90635-P	http://dx.doi.org/10.1016/0092-8674(92)90635-P			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JA431	1617726				2022-12-01	WOS:A1992JA43100008
J	HUNT, DF; MICHEL, H; DICKINSON, TA; SHABANOWITZ, J; COX, AL; SAKAGUCHI, K; APPELLA, E; GREY, HM; SETTE, A				HUNT, DF; MICHEL, H; DICKINSON, TA; SHABANOWITZ, J; COX, AL; SAKAGUCHI, K; APPELLA, E; GREY, HM; SETTE, A			PEPTIDES PRESENTED TO THE IMMUNE-SYSTEM BY THE MURINE CLASS-II MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULE-I-A(D)	SCIENCE			English	Article							MHC CLASS; PROTEIN ANTIGENS; BINDING PEPTIDES; SEQUENCE	Between 650 and 2000 different peptides are associated with the major histocompatibility complex class II molecule I-A(d). Sequences for nine of these were obtained by a combination of automated Edman degradation and tandem mass spectrometry. All of the peptides are derived from secretory or integral membrane proteins that are synthesized by the antigen-presenting cell itself. Peptides were 16 to 18 residues long, had ragged NH2- and COOH-termini, and contained a six-residue binding motif that was variably placed within the peptide chain. Binding data on truncated peptides suggest that the peptide binding groove on class II molecules can be open at both ends.	NCI, CELL BIOL LAB, BETHESDA, MD 20892 USA; CYTEL CORP, SAN DIEGO, CA 92121 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	HUNT, DF (corresponding author), UNIV VIRGINIA, DEPT CHEM, CHARLOTTESVILLE, VA 22901 USA.		Hunt, Donald F/I-6936-2012; Sette, Alessandro/AFO-8916-2022	Hunt, Donald F/0000-0003-2815-6368; Sakaguchi, Kazuyasu/0000-0002-8434-4171; Cox, Andrea/0000-0002-9331-2462	NIAID NIH HHS [AI18634] Funding Source: Medline; NIGMS NIH HHS [GM37357] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018634] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLEN PM, 1987, IMMUNOL REV, V98, P171, DOI 10.1111/j.1600-065X.1987.tb00524.x; BUUS S, 1987, IMMUNOL REV, V98, P115, DOI 10.1111/j.1600-065X.1987.tb00522.x; DEMOTZ S, 1989, NATURE, V342, P682, DOI 10.1038/342682a0; ESNARD F, 1990, BIOL CHEM H-S, V371, P161; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; GERMAIN RN, 1986, NATURE, V322, P687, DOI 10.1038/322687a0; HARDING CV, 1991, CELL, V64, P393, DOI 10.1016/0092-8674(91)90647-H; HUNT DF, 1986, P NATL ACAD SCI USA, V83, P6233, DOI 10.1073/pnas.83.17.6233; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; HUNT DF, 1991, TECHNIQUES PROTEIN C, V2, P441; HYLDIGNIELSEN JJ, 1983, NUCLEIC ACIDS RES, V11, P5055, DOI 10.1093/nar/11.15.5055; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; LI Z, 1989, NUCLEIC ACIDS RES, V17, P447, DOI 10.1093/nar/17.1.447; MORRISON LA, 1986, J EXP MED, V163, P903, DOI 10.1084/jem.163.4.903; RAJAVASHISTH TB, 1985, P NATL ACAD SCI USA, V82, P8085, DOI 10.1073/pnas.82.23.8085; ROBERTS KP, 1990, MOL ENDOCRINOL, V4, P531, DOI 10.1210/mend-4-4-531; ROCHE PA, 1991, P NATL ACAD SCI USA, V88, P3150, DOI 10.1073/pnas.88.8.3150; ROCHE PA, 1991, NATURE, V354, P392, DOI 10.1038/354392a0; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; RUDENSKY AY, 1991, NATURE, V353, P660, DOI 10.1038/353660a0; SETTE A, 1989, P NATL ACAD SCI USA, V86, P3296, DOI 10.1073/pnas.86.9.3296; SETTE A, 1988, J IMMUNOL, V141, P45; SETTE A, 1989, J IMMUNOL, V142, P35; SETTE A, 1992, J IMMUNOL, V148, P844; SETTE A, 1990, J IMMUNOL, V145, P1809; SWAIN SL, 1983, IMMUNOL REV, V74, P129, DOI 10.1111/j.1600-065X.1983.tb01087.x; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; VANBLEEK GM, 1990, NATURE, V348, P213	28	664	691	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 26	1992	256	5065					1817	1820		10.1126/science.1319610	http://dx.doi.org/10.1126/science.1319610			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA434	1319610				2022-12-01	WOS:A1992JA43400036
J	KESSLER, DA; TAYLOR, MR; MARYANSKI, JH; FLAMM, EL; KAHL, LS				KESSLER, DA; TAYLOR, MR; MARYANSKI, JH; FLAMM, EL; KAHL, LS			THE SAFETY OF FOODS DEVELOPED BY BIOTECHNOLOGY	SCIENCE			English	Article							ENZYMES		US FDA,CTR FOOD SAFETY & APPL NUTR,DIV FOOD & COLOR ADDIT,ROCKVILLE,MD 20857; US FDA,OFF BIOTECHNOL,ROCKVILLE,MD 20857	US Food & Drug Administration (FDA); US Food & Drug Administration (FDA)	KESSLER, DA (corresponding author), US FDA,POLICY,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.							BERKOWITZ DB, 1990, BIO-TECHNOL, V8, P819, DOI 10.1038/nbt0990-819; HOPKINS DD, 1991, MUTABLE FEAST ASSURI; JAFFE WG, 1973, TOXICANTS OCCURRING, P106; PARIZA MW, 1983, J FOOD PROTECT, V46, P453, DOI 10.4315/0362-028X-46.5.453; VIHINEN M, 1989, CRIT REV BIOCHEM MOL, V24, P329, DOI 10.3109/10409238909082556; 1992, FED REG         0529, V57, P22984; 1989, APPROACHES ASSESSING; IN PRESS REPORT FOOD; 1990, REGUL TOXICOL PHAR 2, V12; 1991, FOOD NEW BIOTECHNOLO; 1991, STRATEGIES ASSESSING	11	82	84	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 26	1992	256	5065					1747	&		10.1126/science.1615315	http://dx.doi.org/10.1126/science.1615315			0	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA434	1615315				2022-12-01	WOS:A1992JA43400011
J	LETOURNEUR, F; KLAUSNER, RD				LETOURNEUR, F; KLAUSNER, RD			A NOVEL DI-LEUCINE MOTIF AND A TYROSINE-BASED MOTIF INDEPENDENTLY MEDIATE LYSOSOMAL TARGETING AND ENDOCYTOSIS OF CD3 CHAINS	CELL			English	Article							CELL ANTIGEN RECEPTOR; ENDOPLASMIC-RETICULUM; MEMBRANE GLYCOPROTEIN; CYTOPLASMIC DOMAIN; TRANSMEMBRANE PROTEINS; INTERLEUKIN-2 RECEPTOR; MOLECULAR-CLONING; ACID-PHOSPHATASE; INTERNALIZATION; DEGRADATION	Partial complexes of the T cell antigen receptor lacking zeta-chains are delivered to lysosomes. Chimeric proteins composed of the Tac antigen fused to the cytoplasmic domains of each CD3 chain has allowed the identification of lysosomal targeting sequences. Tac-gamma and Tac-delta chimeras are retained in the endoplasmic reticulum because of the presence of basic residues reminiscent of sequences responsible for the localization of endoplasmic reticulum resident proteins. Truncation of these retention motifs revealed lysosomal targeting of both Tac-gamma and delta-chimeras. A di-leucine- and a tyrosine-based motif are individually sufficient to induce both endocytosis and delivery to lysosomes of Tac. In contrast with chimeras containing only one of these motifs, the chimera containing both was predominantly delivered directly to lysosomes without going through the cell surface. These two sequences may represent two families of targeting motifs that determine the fate of proteins within the peripheral membrane system.			LETOURNEUR, F (corresponding author), NICHHD,CELL BIOL & METAB BRANCH,BETHESDA,MD 20892, USA.			Letourneur, Francois/0000-0003-2232-6127				BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BANIYASH M, 1988, J BIOL CHEM, V263, P449; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BLOBEL G, 1975, J CELL BIOL, V67, P852, DOI 10.1083/jcb.67.3.852; BONIFACINO JS, 1991, EMBO J, V10, P2783, DOI 10.1002/j.1460-2075.1991.tb07827.x; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; BONIFACINO JS, 1988, P NATL ACAD SCI USA, V85, P6929, DOI 10.1073/pnas.85.18.6929; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; BRAUN M, 1989, EMBO J, V8, P3633, DOI 10.1002/j.1460-2075.1989.tb08537.x; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DAVIS CG, 1986, CELL, V45, P15, DOI 10.1016/0092-8674(86)90533-7; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DINGWALL C, 1982, CELL, V30, P449, DOI 10.1016/0092-8674(82)90242-2; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; FUKUDA M, 1991, J BIOL CHEM, V266, P21327; FURUNO K, 1989, J BIOCHEM-TOKYO, V106, P717, DOI 10.1093/oxfordjournals.jbchem.a122922; FURUNO K, 1989, J BIOCHEM-TOKYO, V106, P708, DOI 10.1093/oxfordjournals.jbchem.a122921; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HURTLEY SM, 1989, ANN REV CELL BIOL, V5, P227; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JOHNSON K F, 1991, Journal of Cell Biology, V115, p244A; JOHNSON KF, 1990, P NATL ACAD SCI USA, V87, P10010, DOI 10.1073/pnas.87.24.10010; KLAUSNER R D, 1989, New Biologist, V1, P3; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; KONING F, 1990, EUR J IMMUNOL, V20, P299, DOI 10.1002/eji.1830200211; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; LEBERER E, 1989, J BIOL CHEM, V264, P3484; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; LIPPINCOTTSCHWARTZ J, 1986, J CELL BIOL, V102, P1593, DOI 10.1083/jcb.102.5.1593; LIPPINCOTTSCHWARTZ J, 1987, CELL, V49, P669, DOI 10.1016/0092-8674(87)90543-5; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; MANOLIOS N, 1991, EMBO J, V10, P1643, DOI 10.1002/j.1460-2075.1991.tb07687.x; MINAMI Y, 1987, P NATL ACAD SCI USA, V84, P2688, DOI 10.1073/pnas.84.9.2688; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NABI IR, 1991, J CELL BIOL, V115, P1573, DOI 10.1083/jcb.115.6.1573; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cellbio.6.1.151; PETERS C, 1990, EMBO J, V9, P3497, DOI 10.1002/j.1460-2075.1990.tb07558.x; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; RUBIN LA, 1985, HYBRIDOMA, V4, P91, DOI 10.1089/hyb.1985.4.91; SELDIN RF, 1990, CURRENT PROTOCOLS MO, P921; SHARON M, 1986, SCIENCE, V234, P859, DOI 10.1126/science.3095922; SUZUKI CK, 1991, J CELL BIOL, V114, P189, DOI 10.1083/jcb.114.2.189; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; THIES RS, 1990, J BIOL CHEM, V265, P10132; UCHIYAMA T, 1981, J IMMUNOL, V126, P1393; VEGA MA, 1991, J BIOL CHEM, V266, P16269; WEISSMAN AM, 1986, P NATL ACAD SCI USA, V83, P1463, DOI 10.1073/pnas.83.5.1463; WHITE J, 1989, J IMMUNOL, V143, P1822; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955	59	515	528	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 26	1992	69	7					1143	1157		10.1016/0092-8674(92)90636-Q	http://dx.doi.org/10.1016/0092-8674(92)90636-Q			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JA431	1535555				2022-12-01	WOS:A1992JA43100009
J	LI, JM; SHORE, GC				LI, JM; SHORE, GC			REVERSAL OF THE ORIENTATION OF AN INTEGRAL PROTEIN OF THE MITOCHONDRIAL OUTER-MEMBRANE	SCIENCE			English	Article							INNER MEMBRANE; PRECURSOR PROTEINS; SIGNAL SEQUENCE; IMPORT; INSERTION; POLYPEPTIDE; RESIDUES; INVITRO; DOMAIN; PORIN	The NH2-terminus of the signal-anchor sequence of an integral, bitopic protein of the outer mitochondrial membrane was extended both in amino acid length (from 11 to 38 amino acids) and net charge (from +4 to +8)-changes that confer on the NH2-terminus characteristics of a strong matrix-targeting signal. The protein was inserted into the outer membrane but in an inverted orientation (N(cyto)-C(in)). These findings suggest that, in common with other membrane systems, the orientation of a protein in the outer mitochondrial membrane can be determined by a signal that causes retention of the NH2-terminus on the cytosolic side of the membrane.			LI, JM (corresponding author), MCGILL UNIV,DEPT BIOCHEM,MCINTYRE MED SCI BLDG,MONTREAL H3G 1Y6,QUEBEC,CANADA.							BAKKER EP, 1978, BIOCHEMISTRY-US, V17, P2899, DOI 10.1021/bi00607a031; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BOYD D, 1990, CELL, V62, P1031, DOI 10.1016/0092-8674(90)90378-R; FREITAG H, 1982, EUR J BIOCHEM, V126, P197, DOI 10.1111/j.1432-1033.1982.tb06766.x; FUJIKI Y, 1982, J CELL BIOL, V93, P103, DOI 10.1083/jcb.93.1.103; GILLESPIE LL, 1985, J BIOL CHEM, V260, P6045; GLICK B, 1991, ANNU REV GENET, V25, P21; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HASE T, 1984, EMBO J, V3, P3157, DOI 10.1002/j.1460-2075.1984.tb02274.x; Li J. P. H., UNPUB; MCBRIDE H, UNPUB; MIHARA K, 1982, P NATL ACAD SCI-BIOL, V79, P7102, DOI 10.1073/pnas.79.23.7102; NGUYEN M, 1987, J CELL BIOL, V104, P1193, DOI 10.1083/jcb.104.5.1193; NGUYEN M, 1986, J BIOL CHEM, V261, P800; NGUYEN M, 1988, J CELL BIOL, V106, P1499, DOI 10.1083/jcb.106.5.1499; NGUYEN M, 1987, J BIOL CHEM, V262, P3929; PARKS GD, 1991, CELL, V64, P777, DOI 10.1016/0092-8674(91)90507-U; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cellbio.6.1.247; SKERJANC IS, 1988, J BIOL CHEM, V263, P17233; SKERJANC IS, 1990, J BIOL CHEM, V265, P9444; SOLLNER T, 1990, CELL, V62, P107, DOI 10.1016/0092-8674(90)90244-9; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938	24	52	52	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 26	1992	256	5065					1815	1817		10.1126/science.1615327	http://dx.doi.org/10.1126/science.1615327			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA434	1615327				2022-12-01	WOS:A1992JA43400035
J	MENDEL, D; ELLMAN, JA; CHANG, ZY; VEENSTRA, DL; KOLLMAN, PA; SCHULTZ, PG				MENDEL, D; ELLMAN, JA; CHANG, ZY; VEENSTRA, DL; KOLLMAN, PA; SCHULTZ, PG			PROBING PROTEIN STABILITY WITH UNNATURAL AMINO-ACIDS	SCIENCE			English	Article							LYSOZYME; PACKING; HYDROPHOBICITY	Unnatural amino acid mutagenesis, in combination with molecular modeling and simulation techniques, was used to probe the effect of side chain structure on protein stability. Specific replacements at position 133 in T4 lysozyme included (i) leucine (wt), norvaline, ethyl-glycine, and alanine to measure the cost of stepwise removal of methyl groups from the hydrophobic core, (ii) norvaline and O-methyl serine to evaluate the effects of side chain solvation, and (iii) leucine, S,S-2-amino-4-methylhexanoic acid, and S-2-amino-3-cyclopentylpropanoic acid to measure the influence of packing density and side chain conformational entropy on protein stability. All of these factors (hydrophobicity, packing, conformational entropy, and cavity formation) significantly influence protein stability and must be considered when analyzing any structural change to proteins.	UNIV CALIF BERKELEY, DEPT CHEM, BERKELEY, CA 94720 USA; LAWRENCE BERKELEY LAB, CTR ADV MAT, BERKELEY, CA 94720 USA; UNIV CALIF SAN FRANCISCO, DEPT PHARMACEUT CHEM, SAN FRANCISCO, CA 94143 USA	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California San Francisco			Ellman, Jonathan A/C-7732-2013		NCRR NIH HHS [NIH-RR-1081] Funding Source: Medline; NIGMS NIH HHS [GM-29072, GM-08388-02] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001081] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008388, R01GM029072] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECKTEL WJ, 1987, BIOPOLYMERS, V26, P1859, DOI 10.1002/bip.360261104; BECKTEL WJ, 1987, BIOPOLYMERS, V26, P619, DOI 10.1002/bip.360260505; BEHE MJ, 1991, P NATL ACAD SCI USA, V88, P4195, DOI 10.1073/pnas.88.10.4195; CHOTHIA C, 1976, J MOL BIOL, V105, P1, DOI 10.1016/0022-2836(76)90191-1; DAOPIN S, 1991, ANNU REV BIOPHYS BIO, V30, P11521; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; DOERING TL, 1991, SCIENCE, V252, P1851, DOI 10.1126/science.1829548; ELLMAN J, 1991, METHOD ENZYMOL, V202, P301; ELLMAN JA, 1992, SCIENCE, V255, P197, DOI 10.1126/science.1553546; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; EVANS DA, 1990, J AM CHEM SOC, V112, P4011, DOI 10.1021/ja00166a045; FAUCHERE JL, 1983, EUR J MED CHEM, V18, P369; HEUCKROTH RO, 1986, P NATL ACAD SCI USA, V85, P8795; HUANG C, 1991, MIDAS PLUS; KARPUSAS M, 1989, P NATL ACAD SCI USA, V86, P8237, DOI 10.1073/pnas.86.21.8237; KELLIS JT, 1988, NATURE, V333, P784, DOI 10.1038/333784a0; LIM WA, 1989, NATURE, V339, P31, DOI 10.1038/339031a0; LIM WA, 1991, J MOL BIOL, V219, P359, DOI 10.1016/0022-2836(91)90570-V; LYU PC, 1991, P NATL ACAD SCI USA, V88, P5317, DOI 10.1073/pnas.88.12.5317; MATSUMURA M, 1988, NATURE, V334, P406, DOI 10.1038/334406a0; MENDEL D, 1991, J AM CHEM SOC, V113, P2758, DOI 10.1021/ja00007a063; NAEF R, 1985, HELV CHIM ACTA, V68, P135, DOI 10.1002/hlca.19850680117; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NOREN CJ, 1990, NUCLEIC ACIDS RES, V18, P83, DOI 10.1093/nar/18.1.83; NOREN CJ, 1989, SCIENCE, V244, P182, DOI 10.1126/science.2649980; SANDBERG WS, 1989, SCIENCE, V245, P54, DOI 10.1126/science.2787053; SCHAFMEISTER C, 1991, LEAP; SEIBEL G, 1991, AMBER 30 REV A; SHARP KA, 1991, SCIENCE, V252, P106, DOI 10.1126/science.2011744; SHARP KA, 1991, BIOCHEMISTRY-US, V30, P9686, DOI 10.1021/bi00104a017; SHORTLE D, 1990, BIOCHEMISTRY-US, V29, P8033, DOI 10.1021/bi00487a007; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; YUTANI K, 1987, P NATL ACAD SCI USA, V84, P4441, DOI 10.1073/pnas.84.13.4441	33	136	137	3	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 26	1992	256	5065					1798	1802		10.1126/science.1615324	http://dx.doi.org/10.1126/science.1615324			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA434	1615324				2022-12-01	WOS:A1992JA43400030
J	MOMAND, J; ZAMBETTI, GP; OLSON, DC; GEORGE, D; LEVINE, AJ				MOMAND, J; ZAMBETTI, GP; OLSON, DC; GEORGE, D; LEVINE, AJ			THE MDM-2 ONCOGENE PRODUCT FORMS A COMPLEX WITH THE P53 PROTEIN AND INHIBITS P53-MEDIATED TRANSACTIVATION	CELL			English	Article							CELLULAR TUMOR-ANTIGEN; AMINO-ACID-SEQUENCE; HEAT-SHOCK PROTEINS; TRANSFORMED-CELLS; SV40-TRANSFORMED CELLS; MONOCLONAL-ANTIBODIES; ACTIVATING MUTATIONS; MAMMALIAN-CELLS; T-ANTIGEN; GENE	A cellular phosphoprotein with an apparent molecular mass of 90 kd (p90) that forms a complex with both mutant and wild-type p53 protein has been characterized, purified, and identified. The protein was identified as a product of the murine double minute 2 gene (mdm-2). The mdm-2 gene enhances the tumorigenic potential of cells when it is overexpressed and encodes a putative transcription factor. To determine if mdm-2 could modulate p53 transactivation, a p53-responsive element from the muscle creatine kinase gene was employed. A wild-type p53-expressing plasmid enhanced the expression of the p53-responsive element when cotransfected into cells that contain no endogenous p53. When a cosmid expressing mdm-2 was transfected with this p53-expressing plasmid, the transactivation of the p53-responsive element was inhibited. Thus, a product of the mdm-2 oncogene forms a tight complex with the p53 protein, and the mdm-2 oncogene can inhibit p53-mediated transactivation.	UNIV PENN,DEPT HUMAN GENET,PHILADELPHIA,PA 19104	University of Pennsylvania	MOMAND, J (corresponding author), PRINCETON UNIV,LEWIS THOMAS LAB,DEPT MOLEC BIOL,PRINCETON,NJ 08544, USA.		Momand, Jamil/F-8154-2012; Zambetti, Gerard/N-8093-2018	Zambetti, Gerard/0000-0002-0929-5007	NATIONAL CANCER INSTITUTE [F32CA008771] Funding Source: NIH RePORTER; NCI NIH HHS [CA09258-07, 5 F32 CA08771] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHOW V, 1987, J VIROL, V61, P2777, DOI 10.1128/JVI.61.9.2777-2781.1987; CLARKE CF, 1988, MOL CELL BIOL, V8, P1206, DOI 10.1128/MCB.8.3.1206; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRONOSTAJSKI RM, 1984, MOL CELL BIOL, V4, P442, DOI 10.1128/MCB.4.3.442; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOPE IA, 1988, NATURE, V333, P635, DOI 10.1038/333635a0; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KAWASAKI E, 1989, AMPLIFICATIONS, P4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; OREN M, 1982, MOL CELL BIOL, V2, P443, DOI 10.1128/MCB.2.4.443; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PENNICA D, 1984, VIROLOGY, V134, P477, DOI 10.1016/0042-6822(84)90316-7; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; STURZBECHER HW, 1990, ONCOGENE, V5, P795; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WOLF D, 1984, MOL CELL BIOL, V4, P552, DOI 10.1128/MCB.4.3.552; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZAMBETTI GP, 1992, IN PRESS GENES DEV	53	2860	2958	4	117	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 26	1992	69	7					1237	1245		10.1016/0092-8674(92)90644-R	http://dx.doi.org/10.1016/0092-8674(92)90644-R			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JA431	1535557				2022-12-01	WOS:A1992JA43100017
J	PIMENTA, PFP; TURCO, SJ; MCCONVILLE, MJ; LAWYER, PG; PERKINS, PV; SACKS, DL				PIMENTA, PFP; TURCO, SJ; MCCONVILLE, MJ; LAWYER, PG; PERKINS, PV; SACKS, DL			STAGE-SPECIFIC ADHESION OF LEISHMANIA PROMASTIGOTES TO THE SANDFLY MIDGUT	SCIENCE			English	Article							MAJOR PROMASTIGOTES; TRYPANOSOMA-CRUZI; LIPOPHOSPHOGLYCAN; METACYCLOGENESIS; IDENTIFICATION; GLYCOCONJUGATE; ATTACHMENT; GUT	Although leishmaniasis is transmitted to humans almost exclusively by the bite of infected phlebotomine sandflies, little is known about the molecules controlling the survival and development of Leishmania parasites in their insect vectors. Adhesion of Leishmania promastigotes to the midgut epithelial cells of the sandfly was found to be an inherent property of noninfective-stage promastigotes, which was lost during their transformation to metacyclic forms, thus permitting the selective release of infective-stage parasites for subsequent transmission by bite. Midgut attachment and release was found to be controlled by specific developmental modifications in terminally exposed saccharides on lipophosphoglycan, the major surface molecule on Leishmania promastigotes.	NIAID,PARASIT DIS LAB,BLDG 4,ROOM 126,BETHESDA,MD 20892; WALTER REED ARMY MED CTR,DEPT ENTOMOL,WASHINGTON,DC 20307; UNIV KENTUCKY,MED CTR,DEPT BIOCHEM,LEXINGTON,KY 40536; UNIV DUNDEE,DEPT BIOCHEM,DUNDEE DD1 4HN,SCOTLAND	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); United States Department of Defense; United States Army; Walter Reed National Military Medical Center; University of Kentucky; University of Dundee			Pimenta, Paulo/AAH-1502-2020					BONALDO MC, 1988, J CELL BIOL, V106, P1349, DOI 10.1083/jcb.106.4.1349; COOMBS G, 1991, BIOCH PARASITIC PROT; DAVIES CR, 1990, PARASITOLOGY, V101, P337, DOI 10.1017/S0031182000060522; HANDMAN E, 1984, EMBO J, V3, P2301, DOI 10.1002/j.1460-2075.1984.tb02130.x; HENDRY KAK, 1988, PARASITOL RES, V74, P403, DOI 10.1007/BF00535138; HOWARD RJ, 1982, J PROTOZOOL, V29, P114, DOI 10.1111/j.1550-7408.1982.tb02891.x; IBRAHIM EAR, 1984, TROPENMED PARASITOL, V35, P151; KARP CL, 1991, J IMMUNOL, V147, P680; KILLICKKENDRICK R, 1979, BIOL KINETOPLASTIDA, V2, pCH8; LAWYER PG, 1990, AM J TROP MED HYG, V43, P31, DOI 10.4269/ajtmh.1990.43.31; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P19611; MCCONVILLE MJ, UNPUB; Molyneux DH, 1987, LEISHMANIASES BIOL M, V1, P121; ORLANDI P, 1987, J BIOL CHEM, V262, P10382; PEREIRA MEA, 1981, SCIENCE, V211, P597, DOI 10.1126/science.7006082; PIMENTA PFP, 1985, J SUBMICR CYTOL PATH, V17, P413; PIMENTA PFP, 1991, EXP PARASITOL, V72, P191, DOI 10.1016/0014-4894(91)90137-L; PIMENTA PFP, UNPUB; SACKS DL, 1990, MOL BIOCHEM PARASIT, V42, P225, DOI 10.1016/0166-6851(90)90165-I; SACKS DL, 1985, J IMMUNOL, V135, P564; SACKS DL, 1984, SCIENCE, V223, P1417, DOI 10.1126/science.6701528; SACKS DL, UNPUB; TURCO SJ, 1990, EXP PARASITOL, V70, P241, DOI 10.1016/0014-4894(90)90105-L; TURCO SJ, 1984, J BIOL CHEM, V259, P3883; WALLBANKS KR, 1986, TROP MED PARASITOL, V37, P409; WARBURG A, 1989, J PROTOZOOL, V36, P613, DOI 10.1111/j.1550-7408.1989.tb01104.x	26	204	207	1	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 26	1992	256	5065					1812	1815		10.1126/science.1615326	http://dx.doi.org/10.1126/science.1615326			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA434	1615326				2022-12-01	WOS:A1992JA43400034
J	RABACCHI, S; BAILLY, Y; DELHAYEBOUCHAUD, N; MARIANI, J				RABACCHI, S; BAILLY, Y; DELHAYEBOUCHAUD, N; MARIANI, J			INVOLVEMENT OF THE N-METHYL D-ASPARTATE (NMDA) RECEPTOR IN SYNAPSE ELIMINATION DURING CEREBELLAR DEVELOPMENT	SCIENCE			English	Article							EXCITATORY AMINO-ACIDS; PURKINJE-CELLS; CLIMBING FIBERS; MULTIPLE INNERVATION; RAT CEREBELLUM; OLIVOCEREBELLAR RELATIONSHIPS; POSTNATAL-DEVELOPMENT; NERVOUS-SYSTEM; STRIATE CORTEX; VISUAL-CORTEX	In many instances, the establishment of highly specific neuronal connections during development results from the rearrangement of axonal projections through the trimming of exuberant collaterals or the elimination of functional synapses or both. Although the involvement of the N-methyl D-aspartate (NMDA) subtype of the glutamate receptor has been demonstrated in the shaping of axonal arbors, its participation in the process of selective stabilization of synapses remains an open issue. In this study, the effects of chronic in vivo application of D,L-2-amino-5-phosphonovaleric acid (D,L-APV), a selective antagonist of the NMDA receptor, on the synapse elimination process that takes place in the developing cerebellum of the rat have been analyzed. D,L-APV treatment prevented the regression of supernumerary climbing fiber synapses in 49 percent of the recorded Purkinje cells, while the inactive isomer L-APV was ineffective. Thus, activation of the NMDA receptor is a critical step in the regression of functional synapses during development.	UNIV PARIS 06,F-75230 PARIS 05,FRANCE; CNRS,INST NEUROSCI,NEUROBIOL DEV LAB,F-75005 PARIS,FRANCE	UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite								ALKON DL, 1984, SCIENCE, V226, P1037, DOI 10.1126/science.6093258; ASCHER P, 1987, TRENDS NEUROSCI, V10, P284, DOI 10.1016/0166-2236(87)90174-3; AUDINAT E, 1990, J PHYSIOL-LONDON, V430, P297, DOI 10.1113/jphysiol.1990.sp018292; BEAR MF, 1990, J NEUROSCI, V10, P909; BENOIT P, 1984, DEV BRAIN RES, V14, P310, DOI 10.1016/0165-3806(84)90320-1; BENOIT P, 1987, DEV BRAIN RES, V34, P51, DOI 10.1016/0165-3806(87)90194-5; BENOIT P, 1975, BRAIN RES, V99, P354, DOI 10.1016/0006-8993(75)90036-0; BOURRAT F, 1984, DEV BRAIN RES, V16, P241, DOI 10.1016/0165-3806(84)90029-4; Cajal S.R., 1911, HISTOLOGIE SYSTEME N; CHANGEUX JP, 1976, NATURE, V264, P705, DOI 10.1038/264705a0; CLINE HT, 1989, NEURON, V3, P413, DOI 10.1016/0896-6273(89)90201-8; CLINE HT, 1987, P NATL ACAD SCI USA, V84, P4342, DOI 10.1073/pnas.84.12.4342; COLLINGRIDGE GL, 1987, TRENDS NEUROSCI, V10, P288, DOI 10.1016/0166-2236(87)90175-5; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; CREPEL F, 1982, TRENDS NEUROSCI, V5, P266, DOI 10.1016/0166-2236(82)90168-0; CREPEL F, 1976, ARCH ITAL BIOL, V114, P49; CREPEL F, 1976, J NEUROBIOL, V7, P579, DOI 10.1002/neu.480070610; CREPEL F, 1981, DEV BRAIN RES, V1, P59, DOI 10.1016/0165-3806(81)90094-8; CREPEL F, 1976, J NEUROBIOL, V7, P567, DOI 10.1002/neu.480070609; CREPEL F, 1980, NATURE, V283, P482; DAVIES J, 1982, BRAIN RES, V235, P378, DOI 10.1016/0006-8993(82)91017-4; DELHAYEBOUCHAUD N, 1985, J COMP NEUROL, V232, P299, DOI 10.1002/cne.902320303; DUPONT JL, 1987, DEV BRAIN RES, V34, P59, DOI 10.1016/0165-3806(87)90195-7; FOX K, 1989, J NEUROSCI, V9, P2443; GARTHWAITE G, 1987, DEV BRAIN RES, V36, P288, DOI 10.1016/0165-3806(87)90034-4; GARTHWAITE J, 1989, NEUROSCIENCE, V29, P401, DOI 10.1016/0306-4522(89)90067-5; HAHN J, 1991, NATURE, V351, P568; HUSSAIN S, 1991, NEUROPHARMACOLOGY, V30, P1029, DOI 10.1016/0028-3908(91)90130-4; INNOCENTI GM, 1981, TRENDS NEUROSCI, V4, P142, DOI 10.1016/0166-2236(81)90047-3; KLEINSCHMIDT A, 1987, SCIENCE, V238, P355, DOI 10.1126/science.2443978; KRUPA M, 1990, EUR J NEUROSCI, V2, P312, DOI 10.1111/j.1460-9568.1990.tb00423.x; LAI Y, 1986, P NATL ACAD SCI USA, V83, P4253, DOI 10.1073/pnas.83.12.4253; LAUFER R, 1989, MOL NEUROBIOL, V3, P1, DOI 10.1007/BF02935587; LLANO I, 1991, J PHYSIOL-LONDON, V434, P183, DOI 10.1113/jphysiol.1991.sp018465; MARIANI J, 1982, J NEUROBIOL, V13, P119, DOI 10.1002/neu.480130204; MARIANI J, 1980, J NEUROBIOL, V11, P41, DOI 10.1002/neu.480110106; MARIANI J, 1981, J NEUROSCI, V1, P696, DOI 10.1523/JNEUROSCI.01-07-00696.1981; MARIANI J, 1981, J NEUROSCI, V1, P703, DOI 10.1523/JNEUROSCI.01-07-00703.1981; MARIANI J, 1987, NEWS PHYSIOL SCI, V2, P93; MARIANI J, 1990, DEV BRAIN RES, V57, P63, DOI 10.1016/0165-3806(90)90185-2; MARIANI J, 1983, PROG BRAIN RES, V58, P383, DOI 10.1016/S0079-6123(08)60041-2; MILLER KD, 1989, P NATL ACAD SCI USA, V86, P5183, DOI 10.1073/pnas.86.13.5183; SANDOVAL ME, 1978, NEUROSCIENCE, V3, P199, DOI 10.1016/0306-4522(78)90101-X; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; SILBERSTEIN GB, 1982, DEV BIOL, V93, P272, DOI 10.1016/0012-1606(82)90259-7; WIKLUND L, 1982, SCIENCE, V216, P78, DOI 10.1126/science.6121375; WOODWARD DJ, 1974, J NEUROBIOL, V5, P283, DOI 10.1002/neu.480050402	47	290	295	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 26	1992	256	5065					1823	1825		10.1126/science.1352066	http://dx.doi.org/10.1126/science.1352066			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA434	1352066				2022-12-01	WOS:A1992JA43400038
J	REICH, CI; VANHOY, RW; PORTER, GL; WISE, JA				REICH, CI; VANHOY, RW; PORTER, GL; WISE, JA			MUTATIONS AT THE 3' SPLICE SITE CAN BE SUPPRESSED BY COMPENSATORY BASE CHANGES IN U1 SNRNA IN FISSION YEAST	CELL			English	Article							PRE-MESSENGER-RNA; SMALL NUCLEAR-RNA; SIGNAL RECOGNITION PARTICLE; SCHIZOSACCHAROMYCES-POMBE; INTRON SEQUENCES; SACCHAROMYCES-CEREVISIAE; MAMMALIAN INTRONS; LARIAT FORMATION; GENE; BINDING	U1 snRNA is an essential splicing factor known to base pair with 5' splice sites of premessenger RNAs. We demonstrate that pairing between the universally conserved CU just downstream from the 5' junction interaction region and the 3' splice site AG contributes to efficient splicing of Schizosaccharomyces pombe introns that typify the AG-dependent class described in mammals. Strains carrying mutations in the 3' AG of an artificial intron accumulate linear precursor, indicative of a first step block. Lariat formation is partially restored in these mutants by compensatory changes in nucleotides C-7 and U8 of U1 snRNA. ConsiStent with a general role in fission yeast splicing, mutations at C-7 are lethal, while U8 mutants are growth impaired and accumulate linear, unspliced precursor to U6 snRNA. U1 RNA-mediated recognition of the 3' splice site may have origins in analogous intramolecular interactions in an ancestral self-splicing RNA.			REICH, CI (corresponding author), UNIV ILLINOIS, DEPT BIOCHEM, URBANA, IL 61801 USA.							AEBI M, 1986, CELL, V47, P555, DOI 10.1016/0092-8674(86)90620-3; BACH ML, 1987, CURR GENET, V12, P527, DOI 10.1007/BF00419562; BEEN MD, 1986, CELL, V47, P207, DOI 10.1016/0092-8674(86)90443-5; BRANLANT C, 1981, NUCLEIC ACIDS RES, V9, P841, DOI 10.1093/nar/9.4.841; BRENNWALD P, 1988, MOL CELL BIOL, V8, P1580, DOI 10.1128/MCB.8.4.1580; BURKE JM, 1990, NATURE, V344, P80, DOI 10.1038/344080a0; DUCHENE M, 1988, NUCLEIC ACIDS RES, V16, P7233, DOI 10.1093/nar/16.15.7233; FOUSER LA, 1987, MOL CELL BIOL, V7, P225, DOI 10.1128/MCB.7.1.225; FRENDEWEY D, 1985, CELL, V42, P355, DOI 10.1016/S0092-8674(85)80131-8; GATERMANN KB, 1989, MOL CELL BIOL, V9, P1526, DOI 10.1128/MCB.9.4.1526; GOGUEL V, 1991, GENE DEV, V5, P1430, DOI 10.1101/gad.5.8.1430; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HANN BC, 1989, J CELL BIOL, V109, P3223, DOI 10.1083/jcb.109.6.3223; HIMMELSPACH M, 1991, MOL CELL BIOL, V11, P1258, DOI 10.1128/MCB.11.3.1258; HIRAOKA Y, 1984, CELL, V39, P349, DOI 10.1016/0092-8674(84)90013-8; JACQUIER A, 1991, J MOL BIOL, V219, P415, DOI 10.1016/0022-2836(91)90183-7; Johnson B.F, 1989, MOL BIOL FISSION YEA, P243; KROL A, 1990, NUCLEIC ACIDS RES, V18, P3803, DOI 10.1093/nar/18.13.3803; LANG KM, 1990, MOL CELL BIOL, V10, P4942, DOI 10.1128/MCB.10.9.4942; LAZAR E, 1982, NUCLEIC ACIDS RES, V10, P1193, DOI 10.1093/nar/10.4.1193; LEGRAIN P, 1988, MOL CELL BIOL, V8, P3755, DOI 10.1128/MCB.8.9.3755; LERNER MR, 1980, NATURE, V283, P220, DOI 10.1038/283220a0; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MICHAUD S, 1991, GENE DEV, V5, P2534, DOI 10.1101/gad.5.12b.2534; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MOUNT SM, 1981, NUCLEIC ACIDS RES, V9, P6351, DOI 10.1093/nar/9.23.6351; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; Parker R, 1987, MOL BIOL RNA NEW PER, P133; PATTERSON B, 1991, CELL, V64, P181, DOI 10.1016/0092-8674(91)90219-O; PORTER G, 1990, MOL CELL BIOL, V10, P2874, DOI 10.1128/MCB.10.6.2874; POTASHKIN J, 1989, NUCLEIC ACIDS RES, V17, P7821, DOI 10.1093/nar/17.19.7821; POTASHKIN J, 1989, EMBO J, V8, P551, DOI 10.1002/j.1460-2075.1989.tb03409.x; REDDY R, 1989, METHOD ENZYMOL, V180, P521; REED R, 1990, P NATL ACAD SCI USA, V87, P8031, DOI 10.1073/pnas.87.20.8031; REED R, 1989, GENE DEV, V3, P2113, DOI 10.1101/gad.3.12b.2113; REED R, 1985, CELL, V41, P95, DOI 10.1016/0092-8674(85)90064-9; REICH C, 1990, MOL CELL BIOL, V10, P5548, DOI 10.1128/MCB.10.10.5548; ROGERS J, 1980, P NATL ACAD SCI-BIOL, V77, P1877, DOI 10.1073/pnas.77.4.1877; RUBY SW, 1991, TRENDS GENET, V7, P79; RUBY SW, 1988, SCIENCE, V242, P1028, DOI 10.1126/science.2973660; RUSKIN B, 1988, CELL, V52, P207, DOI 10.1016/0092-8674(88)90509-0; RUSKIN B, 1984, CELL, V38, P317, DOI 10.1016/0092-8674(84)90553-1; RUSKIN B, 1985, NATURE, V317, P732, DOI 10.1038/317732a0; RYMOND BC, 1986, EMBO J, V5, P3517, DOI 10.1002/j.1460-2075.1986.tb04677.x; RYMOND BC, 1985, NATURE, V317, P735, DOI 10.1038/317735a0; RYMOND BC, 1987, GENE DEV, V1, P238, DOI 10.1101/gad.1.3.238; SERAPHIN B, 1989, CELL, V59, P349, DOI 10.1016/0092-8674(89)90296-1; SERAPHIN B, 1988, EMBO J, V7, P2533, DOI 10.1002/j.1460-2075.1988.tb03101.x; SERAPHIN B, 1990, CELL, V63, P619, DOI 10.1016/0092-8674(90)90457-P; SILICIANO PG, 1988, GENE DEV, V2, P1258, DOI 10.1101/gad.2.10.1258; SMITH CWJ, 1989, NATURE, V342, P243, DOI 10.1038/342243a0; SOGIN ML, 1989, INT CONGR SER, V824, P133; STEITZ JA, 1988, STRUCTURE FUNCTION M, P71; SZANKASI P, 1988, J MOL BIOL, V204, P917, DOI 10.1016/0022-2836(88)90051-4; TANI T, 1989, NATURE, V337, P87, DOI 10.1038/337087a0; TATEI K, 1987, J BIOL CHEM, V262, P11667; TODA T, 1984, CELL, V37, P233, DOI 10.1016/0092-8674(84)90319-2; TURNER DH, 1988, ANNU REV BIOPHYS BIO, V17, P167; VIJAYRAGHAVAN U, 1986, EMBO J, V5, P1683, DOI 10.1002/j.1460-2075.1986.tb04412.x; WISE JA, 1991, METHOD ENZYMOL, V194, P405; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4; ZILLMANN M, 1988, MOL CELL BIOL, V8, P814, DOI 10.1128/MCB.8.2.814; ZILLMANN M, 1987, MOL CELL BIOL, V7, P2877, DOI 10.1128/MCB.7.8.2877	65	102	102	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 26	1992	69	7					1159	1169		10.1016/0092-8674(92)90637-R	http://dx.doi.org/10.1016/0092-8674(92)90637-R			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JA431	1617727				2022-12-01	WOS:A1992JA43100010
J	ROBEY, EA; RAMSDELL, F; KIOUSSIS, D; SHA, W; LOH, D; AXEL, R; FOWLKES, BJ				ROBEY, EA; RAMSDELL, F; KIOUSSIS, D; SHA, W; LOH, D; AXEL, R; FOWLKES, BJ			THE LEVEL OF CD8 EXPRESSION CAN DETERMINE THE OUTCOME OF THYMIC SELECTION	CELL			English	Article							T-CELL-RECEPTOR; TRANSGENIC MICE; NEGATIVE SELECTION; POSITIVE SELECTION; ANTIGEN RECEPTOR; LYMPHOCYTES-T; KINASE P56LCK; TOLERANCE; DELETION; SELF	During thymic development, thymocytes that can recognize major histocompatability complex (MHC) molecules on thymic epithelial cells are selected to survive and mature (positive selection), whereas thymocytes that recognize MHC on hematopoietic cells are destroyed (negative selection). It is not known how MHC recognition can mediate both death and survival. One model to explain this paradox proposes that thymocytes whose T cell antigen receptors (TCRs) recognize MHC with high affinity are eliminated by negative selection, whereas low affinity TCR-MHC interactions are sufficient to mediate positive selection. Here we report that, while the expression of a 2C TCR transgene leads to positive selection of thymocytes in H-2b mice, expression of both a CD8 transgene and a 2C TCR transgene causes negative selection. This observation indicates that quantitative differences in TCR-MHC recognition are a critical determinant of T cell fate, a finding predicted by the affinity model for thymic selection.	WASHINGTON UNIV, DEPT IMMUNOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, HOWARD HUGHES MED INST, ST LOUIS, MO 63110 USA; NIAID, CELLULAR & MOLEC IMMUNOL LAB, BETHESDA, MD 20892 USA; NATL INST MED RES, GENE STRUCT & EXPRESS LAB, LONDON NW7 1AA, ENGLAND; COLUMBIA UNIV, DEPT BIOCHEM & MOLEC BIOPHYS, NEW YORK, NY 10032 USA; COLUMBIA UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA	Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); MRC National Institute for Medical Research; Columbia University; Columbia University; Howard Hughes Medical Institute				Axel, Richard/0000-0002-3141-4076				ALDRICH CJ, 1991, NATURE, V352, P718, DOI 10.1038/352718a0; BERG LJ, 1989, NATURE, V340, P559, DOI 10.1038/340559a0; BERG LJ, 1990, CELL, V60, P1043, DOI 10.1016/0092-8674(90)90352-F; EVAVOLD BD, 1991, SCIENCE, V252, P1308, DOI 10.1126/science.1833816; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; GAO EK, 1990, J EXP MED, V171, P1101, DOI 10.1084/jem.171.4.1101; GREAVES DR, 1989, CELL, V56, P979, DOI 10.1016/0092-8674(89)90631-4; INGOLD AL, 1991, NATURE, V352, P721, DOI 10.1038/352721a0; JANEWAY CA, 1989, IMMUNOL TODAY, V10, P234, DOI 10.1016/0167-5699(89)90260-0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; LEE NA, 1992, IN PRESS J EXP MED; LITTMAN DR, 1987, ANNU REV IMMUNOL, V5, P561, DOI 10.1146/annurev.iy.05.040187.003021; LOH DY, 1991, NEW BIOL, V3, P924; MAGE MG, 1984, METHOD ENZYMOL, V108, P118; MARRACK P, 1988, CELL, V53, P627, DOI 10.1016/0092-8674(88)90578-8; MARRACK P, 1989, NATURE, V338, P503, DOI 10.1038/338503a0; MARRACK P, 1987, SCIENCE, V238, P1073, DOI 10.1126/science.3317824; NIKOLICZUGIC J, 1990, NATURE, V344, P65, DOI 10.1038/344065a0; PARNES JR, 1989, ADV IMMUNOL, V44, P265; PIRCHER H, 1991, NATURE, V351, P482, DOI 10.1038/351482a0; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; RAHEMTULLA A, 1991, NATURE, V353, P180, DOI 10.1038/353180a0; RAMSDELL F, 1989, J IMMUNOL, V143, P1467; ROBEY EA, 1991, CELL, V64, P99, DOI 10.1016/0092-8674(91)90212-H; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; RUDENSKY AY, 1991, NATURE, V353, P660, DOI 10.1038/353660a0; RUSSELL JH, 1990, J IMMUNOL, V144, P3318; SCHWARTZ RH, 1989, CELL, V57, P1073, DOI 10.1016/0092-8674(89)90044-5; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; SHA WC, 1990, P NATL ACAD SCI USA, V87, P6186, DOI 10.1073/pnas.87.16.6186; SPRENT J, 1988, IMMUNOL REV, V101, P173, DOI 10.1111/j.1600-065X.1988.tb00737.x; TEH HS, 1991, NATURE, V349, P241, DOI 10.1038/349241a0; TEH HS, 1989, J EXP MED, V169, P795, DOI 10.1084/jem.169.3.795; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; ZUNIGAPFLUCKER JC, 1990, J EXP MED, V171, P427, DOI 10.1084/jem.171.2.427	38	146	147	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 26	1992	69	7					1089	1096		10.1016/0092-8674(92)90631-L	http://dx.doi.org/10.1016/0092-8674(92)90631-L			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JA431	1617724				2022-12-01	WOS:A1992JA43100004
J	ROSEN, GD; SANES, JR; LACHANCE, R; CUNNINGHAM, JM; ROMAN, J; DEAN, DC				ROSEN, GD; SANES, JR; LACHANCE, R; CUNNINGHAM, JM; ROMAN, J; DEAN, DC			ROLES FOR THE INTEGRIN VLA-4 AND ITS COUNTER RECEPTOR VCAM-1 IN MYOGENESIS	CELL			English	Article							CELL-ADHESION MOLECULE; ADULT SKELETAL-MUSCLE; HEPARAN-SULFATE PROTEOGLYCAN; RAT LUMBRICAL MUSCLES; N-CAM; EXTRASYNAPTIC PORTIONS; FIBRONECTIN RECEPTOR; MYOBLAST INTERACTION; SECONDARY MYOTUBES; FIBER NUMBERS	Mammalian myogenesis is biphasic: primary myoblasts fuse to form primary myotubes, then secondary myoblasts align along the primary myotubes and form secondary myotubes, which comprise most of adult muscle. We provide evidence that an integrin (VLA-4) and its counter receptor (VCAM-1) have a role in secondary myogenesis. Both receptors are synthesized by cultured muscle cells: VLA-4 is induced as myotubes form, whereas VCAM-1 is present on myoblasts and myotubes. In vivo, both molecules are expressed at sites of secondary myogenesis, VLA-4 on primary and secondary myotubes, and VCAM-1 on secondary myoblasts and on regions of secondary myotubes apposed to primary myotubes. These patterns suggest that VLA-4-VCAM-1 interactions influence alignment of secondary myoblasts along primary myotubes and/or the fusion of secondary myoblasts. In support of the latter possibility, antibodies to VLA-4 or VCAM-1 inhibit myotube formation in culture.	WASHINGTON UNIV,SCH MED,DEPT ANAT & NEUROBIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)	ROSEN, GD (corresponding author), WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110, USA.				NHLBI NIH HHS [HL 43418, HL 29594] Funding Source: Medline; NINDS NIH HHS [NS 19195] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029594, R01HL043418] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019195, R37NS019195] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; ASHMORE CR, 1972, EXP NEUROL, V37, P241, DOI 10.1016/0014-4886(72)90071-4; BIRKENMEIER TM, 1991, J BIOL CHEM, V266, P20544; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; BOZYCZKO D, 1989, EXP CELL RES, V183, P72, DOI 10.1016/0014-4827(89)90419-9; CARLOS T, 1991, BLOOD, V77, P2266; CARLSON BM, 1983, MED SCI SPORT EXER, V15, P187; CASHMAN NR, 1987, ANN NEUROL, V21, P481, DOI 10.1002/ana.410210512; CHIU AY, 1984, DEV BIOL, V103, P456, DOI 10.1016/0012-1606(84)90333-6; COSSU G, 1987, CURR TOP DEV BIOL, V23, P185; COVAULT J, 1986, J CELL BIOL, V102, P716, DOI 10.1083/jcb.102.3.716; COVAULT J, 1985, P NATL ACAD SCI USA, V82, P4544, DOI 10.1073/pnas.82.13.4544; DICKSON G, 1990, NATURE, V344, P348, DOI 10.1038/344348a0; DUXSON MJ, 1989, DEVELOPMENT, V107, P743; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FREDETTE BJ, 1991, DEV BIOL, V143, P1, DOI 10.1016/0012-1606(91)90050-D; FREEDMAN AS, 1990, SCIENCE, V249, P1030, DOI 10.1126/science.1697696; FURST DO, 1989, J CELL BIOL, V109, P517, DOI 10.1083/jcb.109.2.517; GATCHALIAN CL, 1989, J CELL BIOL, V108, P1873, DOI 10.1083/jcb.108.5.1873; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; HARRIS AJ, 1981, PHILOS T ROY SOC B, V293, P257, DOI 10.1098/rstb.1981.0076; HARRIS AJ, 1989, DEVELOPMENT, V107, P771; HARTLEY RS, 1991, DEV BIOL, V148, P249, DOI 10.1016/0012-1606(91)90334-Y; HEMLER ME, 1987, J BIOL CHEM, V262, P3300; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HOLZMANN B, 1989, IMMUNOL REV, V108, P45, DOI 10.1111/j.1600-065X.1989.tb00012.x; JAFFREDO T, 1988, DEVELOPMENT, V103, P431; KELLY AM, 1969, J CELL BIOL, V42, P135, DOI 10.1083/jcb.42.1.135; KNUDSEN KA, 1990, DEV BIOL, V138, P159, DOI 10.1016/0012-1606(90)90185-L; KNUDSEN KA, 1990, EXP CELL RES, V188, P175, DOI 10.1016/0014-4827(90)90157-6; KNUDSEN KA, 1977, DEV BIOL, V58, P328, DOI 10.1016/0012-1606(77)90095-1; KUHL U, 1986, DEV BIOL, V117, P628, DOI 10.1016/0012-1606(86)90331-3; MCLENNAN IS, 1983, DEV BIOL, V98, P287, DOI 10.1016/0012-1606(83)90359-7; MENKO AS, 1987, CELL, V51, P51, DOI 10.1016/0092-8674(87)90009-2; MILLER JB, 1990, J CELL BIOL, V111, P1149, DOI 10.1083/jcb.111.3.1149; MIYAKE K, 1991, J CELL BIOL, V114, P557, DOI 10.1083/jcb.114.3.557; MOULD AP, 1991, J BIOL CHEM, V266, P3579; NEUHAUS H, 1991, J CELL BIOL, V115, P1149, DOI 10.1083/jcb.115.4.1149; OLSON EN, 1991, MOL CELL BIOCHEM, V104, P7; ONTELL M, 1988, AM J ANAT, V181, P267, DOI 10.1002/aja.1001810305; ONTELL M, 1977, ANAT REC, V189, P669, DOI 10.1002/ar.1091890410; ONTELL M, 1984, AM J ANAT, V171, P133, DOI 10.1002/aja.1001710202; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PIERSCHBACHER MD, 1981, CELL, V26, P259, DOI 10.1016/0092-8674(81)90308-1; RICE GE, 1990, J EXP MED, V171, P1369, DOI 10.1084/jem.171.4.1369; RICE GE, 1991, AM J PATHOL, V138, P385; ROMAN J, 1989, J CELL BIOL, V108, P2529, DOI 10.1083/jcb.108.6.2529; ROSEN GD, 1991, P NATL ACAD SCI USA, V88, P4094, DOI 10.1073/pnas.88.10.4094; ROSS JJ, 1987, DEVELOPMENT, V100, P395; ROSS JJ, 1987, DEVELOPMENT, V100, P383; SANES JR, 1986, J CELL BIOL, V102, P420, DOI 10.1083/jcb.102.2.420; SCHEEREN RA, 1991, EUR J IMMUNOL, V21, P1101, DOI 10.1002/eji.1830210503; SHIMIZU Y, 1991, J CELL BIOL, V113, P1203, DOI 10.1083/jcb.113.5.1203; SOLER AP, 1991, DEV BIOL, V148, P389, DOI 10.1016/0012-1606(91)90346-5; STICKLAND NC, 1982, ANAT EMBRYOL, V164, P379, DOI 10.1007/BF00315759; STOCKDALE FE, 1987, DEV BIOL, V123, P1, DOI 10.1016/0012-1606(87)90420-9; TEIXIDO J, 1992, J BIOL CHEM, V267, P1786; TRASK RV, 1988, J BIOL CHEM, V263, P17142; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VONDERMARK H, 1991, J BIOL CHEM, V266, P23593; VONDERMARK K, 1989, DIFFERENTIATION, V40, P150, DOI 10.1111/j.1432-0436.1989.tb00823.x; WAKELAM MJO, 1985, BIOCHEM J, V228, P1; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; WHEELOCK MJ, 1991, DIFFERENTIATION, V46, P35, DOI 10.1111/j.1432-0436.1991.tb00863.x; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477	66	329	336	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 26	1992	69	7					1107	1119		10.1016/0092-8674(92)90633-N	http://dx.doi.org/10.1016/0092-8674(92)90633-N			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JA431	1377605				2022-12-01	WOS:A1992JA43100006
J	SHOJIKASAI, Y; YOSHIDA, A; SATO, K; HOSHINO, T; OGURA, A; KONDO, S; FUJIMOTO, Y; KUWAHARA, R; KATO, R; TAKAHASHI, M				SHOJIKASAI, Y; YOSHIDA, A; SATO, K; HOSHINO, T; OGURA, A; KONDO, S; FUJIMOTO, Y; KUWAHARA, R; KATO, R; TAKAHASHI, M			NEUROTRANSMITTER RELEASE FROM SYNAPTOTAGMIN-DEFICIENT CLONAL VARIANTS OF PC12 CELLS	SCIENCE			English	Article							NERVE GROWTH-FACTOR; PROTEIN-KINASE-C; PHEOCHROMOCYTOMA CELLS; AFFINITY; BINDING	Synaptotagmin (p65) is an abundant synaptic vesicle protein of neurons and contains regions similar to the regulatory domain of protein kinase C. These domains are thought to be involved in calcium-dependent interaction with membrane phospholipids during exocytosis. To assess the functional role of synaptotagmin, synaptotagmin-deficient clonal variants of PC12 cells were isolated. All of the variant cells released catecholamine and adenosine triphosphate in response to elevated intracellular concentrations of calcium, which suggests that synaptotagmin is not essential for secretion of catecholamine and adenosine triphosphate from PC12 cells.			SHOJIKASAI, Y (corresponding author), MITSUBISHI KASEI INST LIFE SCI,MACHIDA,TOKYO 194,JAPAN.							BAEGE EE, 1991, NEURON, V6, P21; BITLER CM, 1986, J NEUROCHEM, V47, P1286; Bjerrum O. J, 1986, ELECTROPHORESIS, P315; BOTHWELL MA, 1980, CELL, V21, P857, DOI 10.1016/0092-8674(80)90449-3; BURNSTOCK G, 1981, J PHYSIOL-LONDON, V313, P1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DECAMILLI P, 1990, ANNU REV PHYSIOL, V52, P625, DOI 10.1146/annurev.ph.52.030190.003205; FLETCHER TL, 1991, J NEUROSCI, V11, P1617; GEPPERT M, 1991, J BIOL CHEM, V266, P13548; GREEN SH, 1986, J CELL BIOL, V102, P830, DOI 10.1083/jcb.102.3.830; GREENE LA, 1987, METHOD ENZYMOL, V147, P207; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; HATANAKA H, 1981, BRAIN RES, V222, P225, DOI 10.1016/0006-8993(81)91029-5; Katz B., 1966, NERVE MUSCLE SYNAPSE; LEVEQUE C, 1992, P NATL ACAD SCI USA, V89, P3625, DOI 10.1073/pnas.89.8.3625; MATTHEW WD, 1981, J CELL BIOL, V91, P257, DOI 10.1083/jcb.91.1.257; OGURA A, 1984, BRAIN RES, V301, P323, DOI 10.1016/0006-8993(84)91101-6; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; OHNO Y, 1988, J BIOL CHEM, V263, P6927; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; PERIN MS, 1991, J BIOL CHEM, V266, P615; PERIN MS, 1991, J BIOL CHEM, V266, P623; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; SHOJIKASAI Y, UNPUB; SMITH SJ, 1988, TRENDS NEUROSCI, V11, P458, DOI 10.1016/0166-2236(88)90199-3; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; TAKAHASHI M, 1991, BRAIN RES, V551, P279, DOI 10.1016/0006-8993(91)90942-O; TAKAHASHI M, 1983, J BIOL CHEM, V258, P944; TRIMBLE WS, 1991, ANNU REV NEUROSCI, V14, P93, DOI 10.1146/annurev.ne.14.030191.000521; WENDLAND B, 1991, NEURON, V6, P993, DOI 10.1016/0896-6273(91)90239-V; Yoshida A, UNPUB	32	173	176	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 26	1992	256	5065					1820	1823		10.1126/science.256.5065.1820	http://dx.doi.org/10.1126/science.256.5065.1820			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA434	1352065				2022-12-01	WOS:A1992JA43400037
J	TSANEVA, IR; MULLER, B; WEST, SC				TSANEVA, IR; MULLER, B; WEST, SC			ATP-DEPENDENT BRANCH MIGRATION OF HOLLIDAY JUNCTIONS PROMOTED BY THE RUVA AND RUVB PROTEINS OF ESCHERICHIA-COLI	CELL			English	Article							STRAND EXCHANGE-REACTIONS; ESCHERICHIA-COLI; RECA PROTEIN; DNA-REPAIR; ENZYMATIC FORMATION; K-12 REVEALS; RECOMBINATION; PURIFICATION; RESOLUTION; MOLECULES	The RuvA and RuvB proteins of E. coli, which are induced as part of the cellular response to DNA damage, act together to promote the branch migration of Holliday junctions. Addition of purified RuvA and RuvB to a RecA-mediated recombination reaction stimulates the rate of strand exchange and the formation of heteroduplex DNA. Stimulation does not occur via interaction with RecA; instead, RuvA and RuvB act directly upon recombination intermediates (Holliday junctions) made by RecA. We show that RuvAB-mediated branch migration requires ATP and can bypass UV-induced DNA lesions. At high RuvB concentrations, the requirement for RuvA is overcome, indicating that the RuvB ATPase provides the motor force for branch migration. RuvA protein provides specificity by binding to the Holliday junction, thereby reducing the requirement for RuvB by 50-fold. The newly discovered biochemical properties of RuvA, RuvB, and RuvC are incorporated into a model for the postreplicational repair of DNA following UV irradiation.			TSANEVA, IR (corresponding author), IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND.			Muller, Berndt/0000-0003-1279-5421; West, Stephen/0000-0001-8848-9418				BENSON F, 1991, MOL GEN GENET, V225, P266, DOI 10.1007/BF00269858; BENSON FE, 1988, NUCLEIC ACIDS RES, V16, P1541, DOI 10.1093/nar/16.4.1541; CLARK AJ, 1988, RECOMBINATION GENETI, P155; CONNOLLY B, 1991, P NATL ACAD SCI USA, V88, P6063, DOI 10.1073/pnas.88.14.6063; CONNOLLY B, 1990, P NATL ACAD SCI USA, V87, P8476, DOI 10.1073/pnas.87.21.8476; COX MM, 1981, J BIOL CHEM, V256, P4676; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P6018, DOI 10.1073/pnas.78.10.6018; DUNDERDALE HJ, 1991, NATURE, V354, P506, DOI 10.1038/354506a0; GRIFFIN TJ, 1990, J BACTERIOL, V172, P6291, DOI 10.1128/jb.172.11.6291-6299.1990; HAHN TR, 1988, J BIOL CHEM, V263, P7431; IWASAKI H, 1989, J BACTERIOL, V171, P5276, DOI 10.1128/jb.171.10.5276-5280.1989; IWASAKI H, 1991, EMBO J, V10, P4381, DOI 10.1002/j.1460-2075.1991.tb05016.x; KAHN R, 1981, P NATL ACAD SCI-BIOL, V78, P4786, DOI 10.1073/pnas.78.8.4786; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.biophys.20.1.539; LIVNEH Z, 1982, P NATL ACAD SCI-BIOL, V79, P3171, DOI 10.1073/pnas.79.10.3171; LLOYD RG, 1991, J BACTERIOL, V173, P5414, DOI 10.1128/jb.173.17.5414-5418.1991; LLOYD RG, 1984, MOL GEN GENET, V194, P303, DOI 10.1007/BF00383532; LLOYD RG, 1987, J GEN MICROBIOL, V133, P2531; LOVETT ST, 1989, P NATL ACAD SCI USA, V86, P2627, DOI 10.1073/pnas.86.8.2627; LUISIDELUCA C, 1989, GENETICS, V122, P269; MULLER B, 1990, CELL, V60, P329, DOI 10.1016/0092-8674(90)90747-3; MULLER B, 1991, J BIOL CHEM, V266, P19028; MULLER B, 1992, IN PRESS EMBO J; OTSUJI N, 1974, J BACTERIOL, V117, P337, DOI 10.1128/JB.117.2.337-344.1974; PARSONS CA, 1992, IN PRESS P NATL ACAD; ROBINS P, 1991, EMBO J, V10, P3913, DOI 10.1002/j.1460-2075.1991.tb04961.x; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; SHARPLES GJ, 1990, MOL GEN GENET, V221, P219, DOI 10.1007/BF00261724; SHARPLES GJ, 1991, J BACTERIOL, V173, P7711, DOI 10.1128/jb.173.23.7711-7715.1991; SHIBA T, 1991, P NATL ACAD SCI USA, V88, P8445, DOI 10.1073/pnas.88.19.8445; SHINAGAWA H, 1988, J BACTERIOL, V170, P4322, DOI 10.1128/jb.170.9.4322-4329.1988; SHURVINTON CE, 1982, MOL GEN GENET, V185, P352, DOI 10.1007/BF00330811; STACEY KA, 1976, MOL GEN GENET, V143, P223, DOI 10.1007/BF00266925; TAKAHAGI M, 1991, J BACTERIOL, V173, P5747, DOI 10.1128/jb.173.18.5747-5753.1991; TAYLOR AF, 1988, GENETIC RECOMBINATIO, P231; TSANEVA IR, 1992, IN PRESS MOL GEN GEN; UMEZU K, 1990, P NATL ACAD SCI USA, V87, P5363, DOI 10.1073/pnas.87.14.5363; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; WALKER GC, 1985, ANNU REV BIOCHEM, V54, P425, DOI 10.1146/annurev.bi.54.070185.002233; WEST SC, 1982, MOL GEN GENET, V187, P209, DOI 10.1007/BF00331119; WEST SC, 1983, CELL, V32, P817, DOI 10.1016/0092-8674(83)90068-5; WEST SC, 1981, NATURE, V294, P659, DOI 10.1038/294659a0; WEST SC, 1981, P NATL ACAD SCI-BIOL, V78, P6149, DOI 10.1073/pnas.78.10.6149; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131	44	240	240	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 26	1992	69	7					1171	1180		10.1016/0092-8674(92)90638-S	http://dx.doi.org/10.1016/0092-8674(92)90638-S			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JA431	1617728				2022-12-01	WOS:A1992JA43100011
J	WLODAWER, A				WLODAWER, A			ANOTHER PIECE OF THE HIV PUZZLE FALLS INTO PLACE	SCIENCE			English	Editorial Material							PROTEASE				WLODAWER, A (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,MACROMOLEC STRUCT LAB,ABL BASIC RES PROGRAM,FREDERICK,MD 21702, USA.							APPELT K, 1991, J MED CHEM, V34, P1925, DOI 10.1021/jm00111a001; ARNOLD E, 1992, NATURE, V357, P85, DOI 10.1038/357085a0; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KROHN A, 1991, J MED CHEM, V34, P3340, DOI 10.1021/jm00115a028; MILLER M, 1989, SCIENCE, V246, P1149, DOI 10.1126/science.2686029; NAVIA MA, 1989, NATURE, V337, P615, DOI 10.1038/337615a0	7	5	6	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 26	1992	256	5065					1766	1766		10.1126/science.1377402	http://dx.doi.org/10.1126/science.1377402			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA434	1377402				2022-12-01	WOS:A1992JA43400024
J	YARNELL, WS; ROBERTS, JW				YARNELL, WS; ROBERTS, JW			THE PHAGE-LAMBDA GENE-Q TRANSCRIPTION ANTITERMINATOR BINDS DNA IN THE LATE GENE PROMOTER AS IT MODIFIES RNA-POLYMERASE	CELL			English	Article							ESCHERICHIA-COLI; TERNARY COMPLEXES; BACTERIOPHAGE-LAMBDA; Q-PROTEIN; 3' END; INITIATION; SITE; TERMINATION; ELONGATION; PRODUCT	The bacteriophage lambda-gene Q transcription antiterminator modifies RNA polymerase during an extended pause in elongation at nt +16 and +17 of the phage late gene promoter transcript. We show here that Q binds a specific DNA site between the -10 and -35 elements of the promoter as it interacts with the enzyme. We show that the pause must reflect a specialized elongation structure that is receptive to modification by Q, because Q does not bind to RNA polymerase stopped artificially after transcribing 16 nt of mutant DNA that does not encode the natural pause. Footprinting shows that RNA polymerase in the paused complex makes distinctive interactions with DNA in the region where Q binds; binding of Q, in turn, changes the footprint both at the Q-binding site and in the transcription bubble. Binding of Q to the paused transcription complex is stabilized by the transcription factor NusA, as expected from the dependence of lambda-Q-mediated antitermination on NusA.			YARNELL, WS (corresponding author), CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL SECT,BIOTECHNOL BLDG,ITHACA,NY 14853, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021941, R37GM021941] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 21941] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARIK S, 1987, CELL, V50, P885, DOI 10.1016/0092-8674(87)90515-0; CULLEN BR, 1990, CELL, V63, P655, DOI 10.1016/0092-8674(90)90129-3; DEVEGVAR HEN, 1986, CELL, V47, P259; Friedman DI., 1983, LAMBDA 2, P21; GOLIGER JA, 1989, J MOL BIOL, V210, P461, DOI 10.1016/0022-2836(89)90123-X; GRAYHACK EJ, 1982, CELL, V30, P637, DOI 10.1016/0092-8674(82)90260-4; GRAYHACK EJ, 1985, CELL, V42, P259, DOI 10.1016/S0092-8674(85)80121-5; GREENBLATT J, 1981, CELL, V24, P421, DOI 10.1016/0092-8674(81)90332-9; GUO HC, 1991, J BACTERIOL, V173, P1554, DOI 10.1128/jb.173.4.1554-1560.1991; GUO HC, 1990, THESIS CORNELL U ITH; HANSEN UM, 1980, J BIOL CHEM, V255, P9564; HATFULL GF, 1987, CELL, V49, P103, DOI 10.1016/0092-8674(87)90760-4; HERNANDEZ N, 1986, CELL, V47, P249, DOI 10.1016/0092-8674(86)90447-2; HERTZBERG RP, 1984, BIOCHEMISTRY-US, V23, P3934, DOI 10.1021/bi00312a022; HORWITZ RJ, 1987, CELL, V51, P631, DOI 10.1016/0092-8674(87)90132-2; KAINZ M, 1992, SCIENCE, V255, P838, DOI 10.1126/science.1536008; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; LANDOLFI NF, 1987, P NATL ACAD SCI USA, V84, P3851, DOI 10.1073/pnas.84.11.3851; LEVIN JR, 1987, J MOL BIOL, V196, P85, DOI 10.1016/0022-2836(87)90512-2; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MCCLURE WR, 1978, J BIOL CHEM, V253, P8941; METZGER W, 1989, EMBO J, V8, P2745, DOI 10.1002/j.1460-2075.1989.tb08416.x; PAVCO PA, 1990, J BIOL CHEM, V265, P9960; ROBERTS JW, 1988, CELL, V52, P5, DOI 10.1016/0092-8674(88)90523-5; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; SPENCER CA, 1990, ONCOGENE, V5, P777; STRANEY DC, 1987, J MOL BIOL, V193, P267, DOI 10.1016/0022-2836(87)90218-X; YANG X, 1988, THESIS CORNELL U ITH; YANG XJ, 1989, J MOL BIOL, V210, P453, DOI 10.1016/0022-2836(89)90122-8; YANG XJ, 1987, GENE DEV, V1, P217, DOI 10.1101/gad.1.3.217; YANG XJ, 1989, P NATL ACAD SCI USA, V86, P5301, DOI 10.1073/pnas.86.14.5301	32	79	79	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 26	1992	69	7					1181	1189		10.1016/0092-8674(92)90639-T	http://dx.doi.org/10.1016/0092-8674(92)90639-T			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JA431	1535556				2022-12-01	WOS:A1992JA43100012
J	CLIPSTONE, NA; CRABTREE, GR				CLIPSTONE, NA; CRABTREE, GR			IDENTIFICATION OF CALCINEURIN AS A KEY SIGNALING ENZYME IN LYMPHOCYTE-T ACTIVATION	NATURE			English	Article							CYCLOSPORINE-A; EXPRESSION; BINDING; GENE; CYCLOPHILIN; PHOSPHATASE; CALMODULIN; PROTEINS; ENHANCER; CLONING	THE immunosuppressive drugs cyclosporin A (CsA) and FK506 both interfere with a Ca2+-sensitive T-cell signal transduction pathway 1-4, thereby preventing the activation of specific transcription factors (such as NF-AT and NF-IL2A) 1,5-7 involved in lymphokine gene expression. CsA and FK506 seem to act by interaction with their cognate intracellular receptors 8-10, cyclophilin and FKBP, respectively (see ref. 11 for review). The Ca2+/calmodulin-regulated phosphatase calcineurin is a major target of drug-isomerase complexes in vitro 12. We have therefore tested the hypothesis that this interaction is responsible for the in vivo effects of CsA/FK506. We report here that overexpression of calcineurin in Jurkat cells renders them more resistant to the effects of CsA and FK506 and augments both NFAT- and NFIL2A-dependent transcription. These results identify calcineurin as a key enzyme in the T-cell signal transduction cascade and provide biological evidence to support the notion that the interaction of drug-isomerase complexes with calcineurin underlies the molecular basis of CsA/FK506-mediated immunosuppression.			CLIPSTONE, NA (corresponding author), STANFORD UNIV,MED CTR,SCH MED,HOWARD HUGHES MED INST,BECKMAN CTR MOLEC & GENET MED,STANFORD,CA 94305, USA.							BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FLANAGAN WM, 1992, J BIOL CHEM, V267, P399; GUERINI D, 1989, P NATL ACAD SCI USA, V86, P9183, DOI 10.1073/pnas.86.23.9183; GUNTER KC, 1989, J IMMUNOL, V142, P3286; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; KAY JE, 1989, CELL IMMUNOL, V124, P175, DOI 10.1016/0008-8749(89)90121-4; KINCAID RL, 1990, J BIOL CHEM, V265, P11312; KINCAID RL, 1987, NATURE, V330, P176, DOI 10.1038/330176a0; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; LIN CS, 1991, CELL IMMUNOL, V133, P269, DOI 10.1016/0008-8749(91)90103-I; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LUI J, 1992, BIOCHEMISTRY-US, V31, P3896; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MCPARTLIN AE, 1991, BIOCHIM BIOPHYS ACTA, V1088, P308, DOI 10.1016/0167-4781(91)90069-X; MERAT DL, 1985, J BIOL CHEM, V260, P1053; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; RANDAK C, 1990, EMBO J, V9, P2529, DOI 10.1002/j.1460-2075.1990.tb07433.x; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; TROPSCHUG M, 1989, NATURE, V342, P953, DOI 10.1038/342953a0	23	1497	1558	2	36	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 25	1992	357	6380					695	697		10.1038/357695a0	http://dx.doi.org/10.1038/357695a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA430	1377362				2022-12-01	WOS:A1992JA43000073
J	HESTRIN, S				HESTRIN, S			DEVELOPMENTAL REGULATION OF NMDA RECEPTOR-MEDIATED SYNAPTIC CURRENTS AT A CENTRAL SYNAPSE	NATURE			English	Article							SUPERIOR COLLICULUS; HIPPOCAMPAL SLICES; VISUAL-CORTEX; TIME COURSE; NEURONS; RAT	THE central nervous system has extraordinary plasticity in early life. This is thought to involve N-methyl-D-aspartate (NMDA) receptors 1 which, along with the non-NMDA receptors, mediate fast excitatory synaptic transmission 2. Although NMDA receptors may be transiently enhanced early in life 3-6, it has not been possible to demonstrate directly a functional change in the NMDA receptor-mediated synaptic response because of the voltage-dependence of the NMDA conductance and the overlapping inhibitory synaptic conductances. Here I report that the duration of evoked NMDA-receptor-mediated excitatory postsynaptic currents (e.p.s.cs) in the superior colliculus is several times longer at early developmental stages compared to that measured in older animals. In contrast, the amplitude of NMDA-receptor-mediated miniature e.p.s.cs does not change during development. The kinetic response of excised membrane patches to a brief activation of NMDA receptors is similar to that of the NMDA e.p.s.c, which suggests that the time course of the NMDA e.p.s.c. in the superior colliculus reflects slow NMDA channel properties as in the hippocampus 7-9. Therefore, these data indicate that the molecular properties of NMDA receptors are developmentally regulated and thus may be controlling the ability of synapses to change in early life.			HESTRIN, S (corresponding author), UNIV CALIF SAN FRANCISCO, SCH MED, DEPT PHYSIOL, BOX 0444, SAN FRANCISCO, CA 94143 USA.		Hestrin, Shaul/F-4410-2010					BENARI Y, 1988, NEUROSCI LETT, V94, P88, DOI 10.1016/0304-3940(88)90275-3; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BODEGREUEL KM, 1989, DEV BRAIN RES, V46, P197, DOI 10.1016/0165-3806(89)90283-6; COLEMAN PA, 1989, J NEUROPHYSIOL, V61, P218, DOI 10.1152/jn.1989.61.1.218; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; FISCHBACH GD, 1980, J PHYSIOL-LONDON, V303, P125, DOI 10.1113/jphysiol.1980.sp013275; FOX K, 1991, NATURE, V350, P342, DOI 10.1038/350342a0; GIBB AJ, 1991, P ROY SOC B-BIOL SCI, V243, P39, DOI 10.1098/rspb.1991.0007; HESTRIN S, 1990, NEURON, V5, P247, DOI 10.1016/0896-6273(90)90162-9; HESTRIN S, 1990, J PHYSIOL-LONDON, V422, P203, DOI 10.1113/jphysiol.1990.sp017980; KATO N, 1991, DEV BRAIN RES, V60, P43, DOI 10.1016/0165-3806(91)90153-A; KLECKNER NW, 1991, MOL BRAIN RES, V11, P151; KONNERTH A, 1990, EXP BRAIN RES, V81, P209; LESTER RAJ, 1990, NATURE, V346, P565, DOI 10.1038/346565a0; LOTURCO JJ, 1991, J NEUROSCI, V11, P792; LUND RD, 1972, BRAIN RES, V42, P1, DOI 10.1016/0006-8993(72)90038-8; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MISHINA M, 1986, NATURE, V321, P406, DOI 10.1038/321406a0; MIYAMOTO T, 1990, BRAIN RES, V518, P166, DOI 10.1016/0006-8993(90)90968-H; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; SAKMANN B, 1978, NATURE, V276, P401, DOI 10.1038/276401a0; TRUSSELL LO, 1989, NEURON, V3, P209, DOI 10.1016/0896-6273(89)90034-2; TSUMOTO T, 1987, NATURE, V327, P513, DOI 10.1038/327513a0	26	457	462	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 25	1992	357	6380					686	689		10.1038/357686a0	http://dx.doi.org/10.1038/357686a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA430	1377360				2022-12-01	WOS:A1992JA43000070
J	MALNATI, MS; MARTI, M; LAVAUTE, T; JARAQUEMADA, D; BIDDISON, W; DEMARS, R; LONG, EO				MALNATI, MS; MARTI, M; LAVAUTE, T; JARAQUEMADA, D; BIDDISON, W; DEMARS, R; LONG, EO			PROCESSING PATHWAYS FOR PRESENTATION OF CYTOSOLIC ANTIGEN TO MHC CLASS-II-RESTRICTED T-CELLS	NATURE			English	Article							TOXIC LYMPHOCYTES-T; LYMPHOBLASTOID-CELLS; EXPRESSION; REGION; HEMAGGLUTININ; TRANSPORTERS; RECOGNITION; SEQUENCES	ANTIGENS presented to CD4+ T cells derive primarily from exogenous proteins that are processed into peptides capable of binding to class II major histocompatibility complex (MHC) molecules in an endocytic compartment 1-4. In contrast, antigens presented to CD8+ T cells derive mostly from proteins processed in the cytosol, and peptide loading onto class I MHC molecules in an early exocytic compartment is dependent on a transporter for antigen presentation encoded in the class II MHC region 5-11. Endogenous cytosolic antigen can also be presented by class II molecules 12,13. Here we show that, unlike class I-restricted recognition of antigen, HLA-DR1-restricted recognition of cytosolic antigen occurs in mutant cells without a transporter for antigen presentation. In contrast, DR1-restricted recognition of a short cytosolic peptide is dependent on such a transporter. Thus helper T-cell epitopes can be generated from cytosolic antigens by several mechanisms, one of which is distinct from the classical class I pathway.	NIAID,IMMUNOGENET LAB,12441 PARKLAWN DR,ROCKVILLE,MD 20852; HOSP GERMANS TRIAS & PUJOL,IMMUNOL UNIT,E-08916 BADALONA,SPAIN; NINCDS,NEUROIMMUNOL BRANCH,BETHESDA,MD 20892; UNIV WISCONSIN,GENET LAB,MADISON,WI 53706	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Hospital Germans Trias i Pujol; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University of Wisconsin System; University of Wisconsin Madison			Malnati, Mauro/AAN-4207-2020; Long, Eric O/G-5475-2011; Martí, Mercè/I-2164-2015	Long, Eric O/0000-0002-7793-3728; Martí, Mercè/0000-0002-1846-0043; Malnati, mauro/0000-0001-5355-1680				CEMANBOGNER S, IN PRESS J IMMUN; CHAKRABARTI S, 1985, MOL CELL BIOL, V5, P3403, DOI 10.1128/MCB.5.12.3403; COX JH, 1991, J EXP MED, V174, P1629, DOI 10.1084/jem.174.6.1629; DEMARS R, 1984, HUM IMMUNOL, V11, P77, DOI 10.1016/0198-8859(84)90047-8; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; EARL PL, 1991, J VIROL, V65, P31, DOI 10.1128/JVI.65.1.31-41.1991; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; GOULD K, 1989, J EXP MED, V170, P1051, DOI 10.1084/jem.170.3.1051; GOULD KG, 1987, J EXP MED, V166, P693, DOI 10.1084/jem.166.3.693; JARAQUEMADA D, 1990, J EXP MED, V172, P947, DOI 10.1084/jem.172.3.947; KARP DR, 1992, J EXP MED, V175, P415, DOI 10.1084/jem.175.2.415; KAVATHAS P, 1980, P NATL ACAD SCI-BIOL, V77, P4251, DOI 10.1073/pnas.77.7.4251; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LONG EO, 1992, NEW BIOL, V4, P274; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MORRISON LA, 1986, J EXP MED, V163, P903, DOI 10.1084/jem.163.4.903; NUCHTERN JG, 1990, NATURE, V343, P74, DOI 10.1038/343074a0; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SMITH GL, 1987, VIROLOGY, V160, P336, DOI 10.1016/0042-6822(87)90004-3; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1992, NATURE, V355, P644, DOI 10.1038/355644a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; SWEETSER MT, 1989, NATURE, V342, P180, DOI 10.1038/342180a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TOWNSEND ARM, 1986, NATURE, V324, P575, DOI 10.1038/324575a0; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; UNANUE ER, 1987, SCIENCE, V236, P551, DOI 10.1126/science.2437650; WHITTON JL, 1989, J EXP MED, V170, P1033, DOI 10.1084/jem.170.3.1033	28	182	185	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 25	1992	357	6380					702	704		10.1038/357702a0	http://dx.doi.org/10.1038/357702a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA430	1614517				2022-12-01	WOS:A1992JA43000076
J	OKEEFE, SJ; TAMURA, J; KINCAID, RL; TOCCI, MJ; ONEILL, EA				OKEEFE, SJ; TAMURA, J; KINCAID, RL; TOCCI, MJ; ONEILL, EA			FK-506-SENSITIVE AND CSA-SENSITIVE ACTIVATION OF THE INTERLEUKIN-2 PROMOTER BY CALCINEURIN	NATURE			English	Article							EXPRESSION; CALMODULIN; DOMAIN; CELLS	ANTIGEN recognition by the T-cell receptor (TCR) initiates events including lymphokine gene transcription 1, particularly interleukin-2, that lead to T-cell activation. The immunosuppressive drugs, cyclosporin A (CsA) and FK-506, prevent T-cell proliferation by inhibiting a Ca2+-dependent event required for induction of interleukin-2 transcription 2. Complexes of FK-506 or CsA and their respective intracellular binding proteins inhibit the calmodulin-dependent protein phosphatase, calcineurin, in vitro 3. The pharmacological relevance of this observation to immunosuppression or drug toxicity is undetermined. Calcineurin, although present in lymphocytes 4, has not been implicated in TCR-mediated activation of lymphokine genes or in transcriptional regulation in general. Here we report that transfection of a calcineurin catalytic subunit increases the 50% inhibitory concentration (IC50) of the immunosuppressants FK-506 and CsA, and that a mutant subunit acts in synergy with phorbol ester alone to activate the interleukin-2 promoter in a drug-sensitive manner. These results implicate calcineurin as a component of the TCR signal transduction pathway by demonstrating its role in the drug-sensitive activation of the interleukin-2 promoter.	NIAAA,MOLEC & CELLULAR NEUROBIOL LAB,IMMUNOL SECT,ROCKVILLE,MD 20852	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	OKEEFE, SJ (corresponding author), MERCK SHARP & DOHME LTD,DEPT MOLEC IMMUNOL,RAHWAY,NJ 07065, USA.							ALTMEYER A, 1991, INT J IMMUNOPHARMACO, V13, P1187, DOI 10.1016/0192-0561(91)90170-C; BANERJI SS, 1991, MOL CELL BIOL, V11, P4074, DOI 10.1128/MCB.11.8.4074; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DUMONT FJ, 1990, J IMMUNOL, V144, P1418; FORREST MJ, 1991, BIOCHEM PHARMACOL, V42, P1221, DOI 10.1016/0006-2952(91)90257-6; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; HOLLON T, 1989, ANAL BIOCHEM, V182, P411, DOI 10.1016/0003-2697(89)90616-7; HUBBARD MJ, 1989, BIOCHEMISTRY-US, V28, P1868, DOI 10.1021/bi00430a066; KINCAID RL, 1990, J BIOL CHEM, V265, P11312; KINCAID RL, 1987, NATURE, V330, P176, DOI 10.1038/330176a0; KINCAID RL, 1988, P NATL ACAD SCI USA, V85, P8983, DOI 10.1073/pnas.85.23.8983; KINCAID RL, 1986, BIOCHEM BIOPH RES CO, V140, P320, DOI 10.1016/0006-291X(86)91093-4; KINCAID RL, 1991, ADV PROT PHOSPHATASE, V6, P73; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; SWANSON SKH, 1992, P NATL ACAD SCI USA, V89, P3741, DOI 10.1073/pnas.89.9.3741; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAMURA J, 1990, FASEB J, V4, pA2236	19	855	877	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 25	1992	357	6380					692	694		10.1038/357692a0	http://dx.doi.org/10.1038/357692a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA430	1377361				2022-12-01	WOS:A1992JA43000072
J	ROBERTS, DJ; CRAIG, AG; BERENDT, AR; PINCHES, R; NASH, G; MARSH, K; NEWBOLD, CI				ROBERTS, DJ; CRAIG, AG; BERENDT, AR; PINCHES, R; NASH, G; MARSH, K; NEWBOLD, CI			RAPID SWITCHING TO MULTIPLE ANTIGENIC AND ADHESIVE PHENOTYPES IN MALARIA	NATURE			English	Article							FALCIPARUM-INFECTED ERYTHROCYTES; HUMAN CEREBRAL MALARIA; PLASMODIUM-FALCIPARUM; PARASITIZED ERYTHROCYTES; MEMBRANE GLYCOPROTEIN; CONTINUOUS CULTURE; CYTOADHERENCE; EXPRESSION; SEQUESTRATION; RECEPTOR	ADHESION of parasitized erythrocytes to post-capillary venular endothelium 1 or uninfected red cells 2-4 is strongly implicated in the pathogenesis of severe Plasmodium falciparum malaria. Neoantigens at the infected red-cell surface adhere to a variety of host receptors 5-9, demonstrate serological diversity in field isolates 10,11 and may also be a target of the host-protective immune response 12. Here we use sequential cloning of P. falciparum by micromanipulation to investigate the ability of a parasite to switch antigenic and cytoadherence phenotypes. Our data show that antigens at the parasitized cell surface undergo clonal variation in vitro in the absence of immune pressure at the rate of 2% per generation with concomitant modulations of the adhesive phenotype. A clone has the potential to switch at high frequency to a variety of antigenic and adhesive phenotypes, including a new type of cytoadherence behaviour, 'auto-agglutination' of infected erythrocytes. This rapid appearance of antigenic and functional heterogeneity has important implications for pathogenesis and acquired immunity.	UNIV BIRMINGHAM,DEPT HAEMATOL,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Birmingham	ROBERTS, DJ (corresponding author), JOHN RADCLIFFE HOSP,INST MOLEC MED,MOLEC PARASITOL GRP,OXFORD OX3 9DU,ENGLAND.		Nash, Gerard B/E-4182-2010	Nash, Gerard B/0000-0002-5935-2831; Newbold, Chris/0000-0002-9274-3789; Craig, Alister/0000-0003-0914-6164	Wellcome Trust [061524] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAERENDT AR, 1992, CELL, V8, P71; BAIRD JK, 1991, AM J TROP MED HYG, V45, P65, DOI 10.4269/ajtmh.1991.45.65; BARNWELL JW, 1989, J CLIN INVEST, V84, P765, DOI 10.1172/JCI114234; BARNWELL JW, 1983, INFECT IMMUN, V40, P985, DOI 10.1128/IAI.40.3.985-994.1983; BERENDT AR, 1989, NATURE, V341, P57, DOI 10.1038/341057a0; BIGGS BA, 1991, P NATL ACAD SCI USA, V88, P9171, DOI 10.1073/pnas.88.20.9171; BIGGS BA, IN PRESS J IMMUN; BORST P, 1987, SCIENCE, V235, P658, DOI 10.1126/science.3544215; BROWN KN, 1965, NATURE, V208, P1286, DOI 10.1038/2081286a0; CARLSON J, 1990, LANCET, V336, P1457, DOI 10.1016/0140-6736(90)93174-N; DAVID PH, 1988, AM J TROP MED HYG, V38, P289, DOI 10.4269/ajtmh.1988.38.289; FORSYTH KP, 1989, AM J TROP MED HYG, V41, P259, DOI 10.4269/ajtmh.1989.41.259; GILKS CF, 1990, PARASITE IMMUNOL, V12, P45, DOI 10.1111/j.1365-3024.1990.tb00935.x; HANDUNNETTI SM, 1987, J EXP MED, V165, P1269, DOI 10.1084/jem.165.5.1269; HAYNES JD, 1976, NATURE, V263, P767, DOI 10.1038/263767a0; JENSEN JB, 1978, AM J TROP MED HYG, V27, P1274, DOI 10.4269/ajtmh.1978.27.1274; LEECH JH, 1984, J EXP MED, V159, P1567, DOI 10.1084/jem.159.6.1567; MACPHERSON GG, 1985, AM J PATHOL, V119, P385; MAGOWAN C, 1988, J EXP MED, V168, P1307, DOI 10.1084/jem.168.4.1307; MARSH K, 1989, T ROY SOC TROP MED H, V83, P293, DOI 10.1016/0035-9203(89)90478-1; MARSH K, 1986, SCIENCE, V231, P150, DOI 10.1126/science.2417315; MCLEAN SA, 1982, EXP PARASITOL, V54, P296, DOI 10.1016/0014-4894(82)90038-8; OCKENHOUSE CF, 1989, SCIENCE, V243, P1469, DOI 10.1126/science.2467377; OQUENDO P, 1989, CELL, V58, P95, DOI 10.1016/0092-8674(89)90406-6; ROBERTS DD, 1985, NATURE, V318, P64, DOI 10.1038/318064a0; SINNIS P, 1988, GENOMICS, V3, P287, DOI 10.1016/0888-7543(88)90117-6; TANDON NN, 1989, J BIOL CHEM, V264, P7570; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; TURNER CMR, 1989, PARASITOLOGY, V99, P67, DOI 10.1017/S0031182000061035; UDOMSANGPETCH R, 1989, J EXP MED, V169, P1835, DOI 10.1084/jem.169.5.1835	30	524	530	0	28	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 25	1992	357	6380					689	692		10.1038/357689a0	http://dx.doi.org/10.1038/357689a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA430	1614515	Green Accepted			2022-12-01	WOS:A1992JA43000071
J	HADORN, DC; MCCORMICK, K; DIOKNO, A				HADORN, DC; MCCORMICK, K; DIOKNO, A			AN ANNOTATED ALGORITHM APPROACH TO CLINICAL GUIDELINE DEVELOPMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PATIENT-CARE; MEDICINE	The Urinary Incontinence in Adults Guideline Panel facilitated the ready elucidation of its guideline's management recommendations through the use of an annotated algorithm approach. The algorithms created as part of this guideline differ from previous algorithms in two ways: (1) they employ systematic annotation to link explicitly the algorithms' recommendations to the literature, and (2) they contain patient counseling and decision nodes to depict the major preference-dependent decision or branch points in the algorithm. We believe that these two innovations can help ensure the clinical validity of guidelines' algorithms while preserving appropriate clinical flexibility and respecting patient preferences.	WILLIAM BEAUMONT HOSP, ROYAL OAK, MI 48072 USA; RAND CORP, SANTA MONICA, CA 90406 USA; NIA, GERIATR RES CTR, BETHESDA, MD 20892 USA	Beaumont Health; RAND Corporation; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)					AHRQ HHS [T32 HS 00007] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		[Anonymous], 1982, CRITERIA STANDARDS Q; Field, 1990, CLIN PRACTICE GUIDEL, DOI DOI 10.17226/1626; Gottlieb L K, 1990, QRB Qual Rev Bull, V16, P80; GREENFIELD S, 1981, MED CARE, V19, P255, DOI 10.1097/00005650-198103000-00002; GREENFIELD S, 1990, PROVIDING QUALITY CA; GRIMM RH, 1975, NEW ENGL J MED, V292, P507, DOI 10.1056/NEJM197503062921005; KASSIRER JP, 1990, HOSP PRACT, P23; KOMAROFF AL, 1982, AM J PUBLIC HEALTH, V72, P10, DOI 10.2105/AJPH.72.1.10; KOMAROFF AL, 1974, NEW ENGL J MED, V290, P307, DOI 10.1056/NEJM197402072900605; MARGOLIS CZ, 1983, JAMA-J AM MED ASSOC, V249, P627, DOI 10.1001/jama.249.5.627; PALMER RH, 1984, MED CARE, V22, P632, DOI 10.1097/00005650-198407000-00005; SOX HC, 1973, NEW ENGL J MED, V288, P818, DOI 10.1056/NEJM197304192881605; 1992, AHCPR920038 AG HLTH	13	44	44	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 24	1992	267	24					3311	3314		10.1001/jama.267.24.3311	http://dx.doi.org/10.1001/jama.267.24.3311			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY944	1597913				2022-12-01	WOS:A1992HY94400030
J	LEE, DK; MARANTZ, PR; DEVEREUX, RB; KLIGFIELD, P; ALDERMAN, MH				LEE, DK; MARANTZ, PR; DEVEREUX, RB; KLIGFIELD, P; ALDERMAN, MH			LEFT-VENTRICULAR HYPERTROPHY IN BLACK-AND-WHITE HYPERTENSIVES - STANDARD ELECTROCARDIOGRAPHIC CRITERIA OVERESTIMATE RACIAL-DIFFERENCES IN PREVALENCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; ECHOCARDIOGRAPHIC DETERMINATION; CARDIAC ANATOMY; BLOOD-PRESSURE; WORK SITE; MASS; RISK; SENSITIVITY; VALIDATION; MORTALITY	Objective.-To assess racial differences in the accuracy of standard electrocardiographic (ECG) criteria in the diagnosis of left ventricular hypertrophy (LVH). Design.-The sensitivity and specificity of standard ECG criteria were compared in blacks and whites using echocardiographic LVH as the reference standard. Setting.-Eight worksite-based hypertension clinics in New York, NY. Patients.-A sample of 122 black and 148 white hypertensive patients. Results.-The prevalence of ECG-LVH was two to six times higher in blacks than in whites, depending on the criteria used (range, 6% to 24% in blacks vs 1% to 7% in whites; P=.0005 to .19 for black-white comparisons). The difference in prevalence of ECG-LVH, however, was less striking and did not attain statistical significance (26% in blacks and 20% in whites; P >.2). The sensitivity of the ECG was low (range, 3% to 17%) and did not differ significantly between the two races for any of the conventional criteria; specificity, however, was lower in blacks for all criteria (range, 73% to 94% vs 95% to 100% for whites; P=.0001 to .09). The predictive value of a positive ECG was consistently, although not significantly, lower in the black subjects. Black race was the strongest independent predictor of decreased ECG specificity in multiple logistic regression analysis that also considered age, gender, body mass index, left ventricular mass index, and smoking. Conclusions.-Commonly used ECG criteria for the detection of LVH have a poor sensitivity in both black and white hypertensives and a lower specificity in blacks than in whites; this may lead to a greater number of false-positive diagnoses in black patients, as well as to an overestimation of black-white difference in LVH prevalence.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT EPIDEMIOL & SOCIAL MED, 1300 MORRIS PK AVE, ROOM 1301, BRONX, NY 10461 USA; CORNELL UNIV, MED CTR, NEW YORK HOSP, DEPT MED, DIV CARDIOL, NEW YORK, NY 10021 USA	Yeshiva University; Albert Einstein College of Medicine; Cornell University; NewYork-Presbyterian Hospital					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL018323] Funding Source: NIH RePORTER; NHLBI NIH HHS [2P50 HL-18323] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALDERMAN MH, 1989, JAMA-J AM MED ASSOC, V262, P920, DOI 10.1001/jama.262.7.920; ALDERMAN MH, 1975, NEW ENGL J MED, V293, P65, DOI 10.1056/NEJM197507102930203; ALDERMAN MH, 1976, J OCCUP ENVIRON MED, V18, P793, DOI 10.1097/00043764-197612000-00004; BARTEL A, 1971, ARCH INTERN MED, V128, P929, DOI 10.1001/archinte.128.6.929; BEAGLEHOLE R, 1975, J CHRON DIS, V28, P549, DOI 10.1016/0021-9681(75)90061-2; BLACKBURN H, 1970, Circulation Research Supplement, V41, P154; CARR AA, 1985, HYPERTENSION, V7, P948, DOI 10.1161/01.HYP.7.6.948; CASALE PN, 1987, CIRCULATION, V75, P565, DOI 10.1161/01.CIR.75.3.565; CASALE PN, 1986, ANN INTERN MED, V105, P173, DOI 10.7326/0003-4819-105-2-173; COOPER R, 1984, AM HEART J, V108, P715, DOI 10.1016/0002-8703(84)90662-8; COOPER RS, 1990, AM J CARDIOL, V65, P441, DOI 10.1016/0002-9149(90)90807-D; DEVEREUX RB, 1984, J AM COLL CARDIOL, V3, P82, DOI 10.1016/S0735-1097(84)80433-7; DEVEREUX RB, 1977, CIRCULATION, V55, P613, DOI 10.1161/01.CIR.55.4.613; DEVEREUX RB, 1983, CIRCULATION, V67, P907, DOI 10.1161/01.CIR.67.4.907; DEVEREUX RB, 1986, AM J CARDIOL, V57, P450, DOI 10.1016/0002-9149(86)90771-X; DEVEREUX RB, 1987, HYPERTENSION, V9, P69; DUNN FG, 1983, J AM COLL CARDIOL, V1, P1348, DOI 10.1016/S0735-1097(83)80150-8; Fleiss J. L., 1981, STAT METHODS RATES P, V2nd, DOI 10.1002/0471445428; Gubner R, 1943, ARCH INTERN MED, V72, P196, DOI 10.1001/archinte.1943.00210080052005; HAMMOND IW, 1986, J AM COLL CARDIOL, V7, P639, DOI 10.1016/S0735-1097(86)80476-4; HAMMOND IW, 1984, J NATL MED ASSOC, V76, P247; HOLT JH, 1978, CIRCULATION, V57, P1129, DOI 10.1161/01.CIR.57.6.1129; HYPERTENSION DETECTION FOLLOW-UP, 1977, AM J EPIDEMIOL, V106, P351; KANNEL W B, 1970, Annals of Internal Medicine, V72, P813; KOREN MJ, 1991, ANN INTERN MED, V114, P345, DOI 10.7326/0003-4819-114-5-345; KRAUS JF, 1980, AM J EPIDEMIOL, V111, P407, DOI 10.1093/oxfordjournals.aje.a112915; LEE DK, 1991, AM J HYPERTENS, V4, pA19; LEVY D, 1987, AM J CARDIOL, V59, P956, DOI 10.1016/0002-9149(87)91133-7; LEVY D, 1989, ANN INTERN MED, V110, P101, DOI 10.7326/0003-4819-110-2-101; LEVY D, 1990, CIRCULATION, V81, P815, DOI 10.1161/01.CIR.81.3.815; MCDONOUGH JR, 1964, ANN INTERN MED, V61, P208, DOI 10.7326/0003-4819-61-2-208; MENSAH G A, 1991, Journal of the American College of Cardiology, V17, p71A; MUNROFAURE AD, 1979, BMJ-BRIT MED J, V1, P1944; MURPHY ML, 1985, AM J CARDIOL, V55, P545, DOI 10.1016/0002-9149(85)90244-9; NEATON JD, 1984, AM HEART J, V108, P759, DOI 10.1016/0002-8703(84)90669-0; OKIN PM, 1992, J ELECTROCARDIOL, V25, P111, DOI 10.1016/0022-0736(92)90115-G; Prineas R.J., 1982, MINNESOTA CODE MANUA; RAUTAHARJU PM, 1988, AM J CARDIOL, V62, P59, DOI 10.1016/0002-9149(88)91365-3; REICHEK N, 1981, CIRCULATION, V63, P1391, DOI 10.1161/01.CIR.63.6.1391; REICHEK N, 1982, AM HEART J, V103, P202, DOI 10.1016/0002-8703(82)90493-8; ROMAN MJ, 1987, J AM COLL CARDIOL, V9, P500, DOI 10.1016/S0735-1097(87)80041-4; ROMHILT DW, 1968, AM HEART J, V75, P752, DOI 10.1016/0002-8703(68)90035-5; ROMHILT DW, 1969, CIRCULATION, V40, P185, DOI 10.1161/01.CIR.40.2.185; Savage D D, 1979, J Natl Med Assoc, V71, P709; SAVAGE DD, 1979, CIRCULATION, V59, P623, DOI 10.1161/01.CIR.59.4.623; SOKOLOW M, 1949, AM HEART J, V37, P161, DOI 10.1016/0002-8703(49)90562-1; TYROLER HA, 1984, AM HEART J, V108, P658, DOI 10.1016/0002-8703(84)90651-3; WALKER SH, 1967, BIOMETRIKA, V54, P167, DOI 10.1093/biomet/54.1-2.167; WOYTHALER JN, 1983, J AM COLL CARDIOL, V2, P305, DOI 10.1016/S0735-1097(83)80167-3; 1985, HYPERTENSION, V7, P105; [No title captured]	51	103	104	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 24	1992	267	24					3294	3299		10.1001/jama.267.24.3294	http://dx.doi.org/10.1001/jama.267.24.3294			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY944	1534587				2022-12-01	WOS:A1992HY94400027
J	NIGHTINGALE, SL				NIGHTINGALE, SL			PARALLEL TRACK POLICY ISSUED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							FED REGISTER, V57, P13250	1	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 24	1992	267	24					3262	3262		10.1001/jama.267.24.3262	http://dx.doi.org/10.1001/jama.267.24.3262			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY944	1597900				2022-12-01	WOS:A1992HY94400007
J	NIGHTINGALE, SL				NIGHTINGALE, SL			ACCELERATED APPROVAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							FED REGISTER, V57, P13234	1	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 24	1992	267	24					3262	3262		10.1001/jama.267.24.3262	http://dx.doi.org/10.1001/jama.267.24.3262			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY944	1597900				2022-12-01	WOS:A1992HY94400006
J	NIGHTINGALE, SL				NIGHTINGALE, SL			SILICONE BREAST IMPLANT DECISION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 24	1992	267	24					3262	3262		10.1001/jama.267.24.3262	http://dx.doi.org/10.1001/jama.267.24.3262			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY944	1597900				2022-12-01	WOS:A1992HY94400005
J	ALLEN, S; TICE, J; VANDEPERRE, P; SERUFILIRA, A; HUDES, E; NSENGUMUREMYI, F; BOGAERTS, J; LINDAN, C; HULLEY, S				ALLEN, S; TICE, J; VANDEPERRE, P; SERUFILIRA, A; HUDES, E; NSENGUMUREMYI, F; BOGAERTS, J; LINDAN, C; HULLEY, S			EFFECT OF SEROTESTING WITH COUNSELING ON CONDOM USE AND SEROCONVERSION AMONG HIV DISCORDANT COUPLES IN AFRICA	BRITISH MEDICAL JOURNAL			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; HETEROSEXUAL TRANSMISSION; SEXUAL PARTNERS; UNITED-STATES; RISK; INFECTION; AIDS; MEN; ALCOHOL; FEMALE	Objective-To determine whether HIV testing and counselling increased condom use and decreased heterosexual transmission of HIV in discordant couples. Design-Prospective study. Setting-Kigali, the capital of Rwanda. Subjects-Cohabiting couples with discordant HIV serology results. Main outcome measures-Condom use in the couple and HIV seroconversion in the negative partners. Results-60 HIV discordant couples were identified, of whom 53 were followed for an average of 2.2 years. The proportion of discordant couples using condoms increased from 4% to 57% after one year of follow up. During follow up two of the 23 HIV negative men and six of the 30 HIV negative women seroconverted (seroconversion rates of 4 and 9 per 100 person years). The rate among women was less than half that estimated for similar women in discordant couples whose partners had not been serotested. Condom use was less common among those who seroconverted (100% v 5%, p=0.01 in men; 67% v 25%, p=0.14 in women). Conclusions-Roughly one in seven cohabiting couples in Kigali have discordant HIV serological results. Confidential HIV serotesting with counselling caused a large increase in condom use and was associated with a lower rate of new HIV infections. HIV testing is a promising intervention for preventing the spread of HIV in African cities.	UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,DIV CLIN EPIDEMIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CTR AIDS PREVENT STUDIES,SAN FRANCISCO,CA 94143; PROJET SAN FRANCISCO,KIGALI,RWANDA; MINISTRY HLTH,KIGALI,RWANDA; NATL AIDS CONTROL PROGRAM,KIGALI,RWANDA; CTR HOSP KIGALI,KIGALI,RWANDA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Van de Perre, Philippe/B-9692-2008	Van de Perre, Philippe/0000-0002-3912-0427; Tice, Jeffrey/0000-0002-9857-2028	NIAID NIH HHS [AI-23980] Funding Source: Medline; NIMH NIH HHS [MH-42459] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023980] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALLEN S, 1991, JAMA-J AM MED ASSOC, V266, P1657, DOI 10.1001/jama.266.12.1657; ALLEN S, 1991, J INFECT DIS, V164, P67, DOI 10.1093/infdis/164.1.67; CAMERON DW, 1989, LANCET, V2, P403; CARAEL M, 1988, AIDS, V2, P201; CHIN J, 1989, B WORLD HEALTH ORGAN, V87, P1; Cochran W.G, 1957, STAT METHODS, V6th ed; FELDBLUM PJ, 1988, AM J PUBLIC HEALTH, V78, P52, DOI 10.2105/AJPH.78.1.52; FISCHL MA, 1987, JAMA-J AM MED ASSOC, V257, P640, DOI 10.1001/jama.257.5.640; HEARST N, 1988, JAMA-J AM MED ASSOC, V259, P2428, DOI 10.1001/jama.259.16.2428; HIRA SK, 1990, J ACQ IMMUN DEF SYND, V3, P83; HOLMES KK, 1990, AM J PUBLIC HEALTH, V80, P858, DOI 10.2105/AJPH.80.7.858; JOHNSON AM, 1988, AIDS, V2, pS49, DOI 10.1097/00002030-198800001-00008; JOHNSON AM, 1989, AIDS, V3, P367, DOI 10.1097/00002030-198906000-00005; Johnson NL, 1969, DISTRIBUTIONS STAT D; KAMENGA M, 1991, AIDS, V5, P61, DOI 10.1097/00002030-199101000-00009; KAMENGA M, 1989, 5 INT C AIDS MONTR; KING R, 1991, LANCET, V338, P1278, DOI 10.1016/0140-6736(91)92149-V; KREISS J, 1985, ANN INTERN MED, V102, P632; LAGA M, 1989, AIDS, V3, P361, DOI 10.1097/00002030-198906000-00004; LARSON A, 1989, REV INFECT DIS, V11, P716; LAURIAN Y, 1989, NEW ENGL J MED, V320, P183; Laurian Y., 1989, New England Journal of Medicine, V321, P268; LAWRENCE DN, 1989, AM J HEMATOL, V30, P68, DOI 10.1002/ajh.2830300204; MANN J, 1987, NEW ENGL J MED, V316, P345; MERTENS TE, 1990, AIDS, V4, P57, DOI 10.1097/00002030-199001000-00008; PADIAN N, 1987, JAMA-J AM MED ASSOC, V258, P788, DOI 10.1001/jama.258.6.788; PADIAN NS, 1990, J INFECT DIS, V161, P883, DOI 10.1093/infdis/161.5.883; PERRONI L, 1989, 5 INT C AIDS MONTR; PETERMAN TA, 1988, JAMA-J AM MED ASSOC, V259, P55, DOI 10.1001/jama.259.1.55; PETERMAN TA, 1989, JAMA-J AM MED ASSOC, V262, P502; ROBERTSON JA, 1988, DRUG ALCOHOL DEPEN, V22, P75, DOI 10.1016/0376-8716(88)90039-7; RYDER RW, 1990, AIDS, V4, P725, DOI 10.1097/00002030-199008000-00002; Sheehan A, 1990, Nursing (Lond), V4, P13; SILVESTRE AJ, 1989, AIDS, V3, P647, DOI 10.1097/00002030-198910000-00005; SMILEY ML, 1988, AM J HEMATOL, V28, P27, DOI 10.1002/ajh.2830280106; STALL R, 1986, HEALTH EDUC QUART, V13, P359, DOI 10.1177/109019818601300407; STEIN ZA, 1990, AM J PUBLIC HEALTH, V80, P460, DOI 10.2105/AJPH.80.4.460; 1989, BMJ, V298, P411	38	369	375	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 20	1992	304	6842					1605	1609		10.1136/bmj.304.6842.1605	http://dx.doi.org/10.1136/bmj.304.6842.1605			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA436	1628088	Green Published, Bronze			2022-12-01	WOS:A1992JA43600021
J	BIGGWITHER, GW; HO, KKY; GRUNSTEIN, RR; SULLIVAN, CE; DOUST, BD				BIGGWITHER, GW; HO, KKY; GRUNSTEIN, RR; SULLIVAN, CE; DOUST, BD			EFFECTS OF LONG-TERM OCTREOTIDE ON GALL STONE FORMATION AND GALL-BLADDER FUNCTION	BRITISH MEDICAL JOURNAL			English	Article							SOMATOSTATIN		ST VINCENTS HOSP,GARVAN INST MED RES,DARLINGHURST,NSW 2010,AUSTRALIA; ROYAL PRINCE ALFRED HOSP,CTR SLEEP DISORDERS,CAMPERDOWN,NSW 2050,AUSTRALIA	Garvan Institute of Medical Research; St Vincents Hospital Sydney; University of Sydney	BIGGWITHER, GW (corresponding author), ST VINCENTS HOSP,DEPT RADIOL,DARLINGHURST,NSW 2010,AUSTRALIA.		Ho, Ken/AAA-7428-2019; Ho, Ken KY/E-5832-2011	Ho, Ken/0000-0002-2508-9588; 				AHRENDT SA, 1991, AM J SURG, V161, P177, DOI 10.1016/0002-9610(91)90381-M; DODDS WJ, 1985, AM J ROENTGENOL, V145, P1009, DOI 10.2214/ajr.145.5.1009; HO KY, 1990, ANN INTERN MED, V112, P173, DOI 10.7326/0003-4819-112-3-173; LIESSUM PA, 1989, J CLIN ENDOCR METAB, V69, P557; SASSOLAS G, 1990, J CLIN ENDOCR METAB, V71, P391, DOI 10.1210/jcem-71-2-391	5	33	34	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 20	1992	304	6842					1611	1612		10.1136/bmj.304.6842.1611	http://dx.doi.org/10.1136/bmj.304.6842.1611			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA436	1628089	Green Published, Bronze			2022-12-01	WOS:A1992JA43600024
J	BOCK, T; PEDERSEN, CR; JOSEFSEN, K; BOTTAZZO, GF; PALMER, JP; BUSCHARD, K				BOCK, T; PEDERSEN, CR; JOSEFSEN, K; BOTTAZZO, GF; PALMER, JP; BUSCHARD, K			NO RISK OF DIABETES AFTER INSULIN-SHOCK TREATMENT	LANCET			English	Article							ISLET-CELL ANTIBODIES; AUTOANTIBODIES; MELLITUS	Prophylactic insulin treatment is effective in preventing diabetes in animal models of insulin-dependent diabetes mellitus (IDDM) but the safety of such preventive treatment in prediabetic human subjects remains unclear; insulin is a potential autoantigen that could accelerate beta-cell decompensation and onset of IDDM. We have investigated whether insulin treatment of non-diabetic diabetic subjects increases the risk of subsequent development of diabetes in a retrospective study of Danish patients who received insulin-shock treatment for psychiatric disorders. Mean age of the 481 patients at insulin-shock treatment was 32.6 (range 12.9-69.6) years. The patients received 59 (6-200) injections of 78 (16-261) IU bovine/porcine insulin. Hospital records provided an average of 22.0 (0.6-51.2) years' observation. During the observation time, IDDM developed in only 1 patient; 1.3 cases would be expected from Danish incidence data (p=0.75). Similarly, there was no significant difference between the observed number of cases of non-insulin-dependent diabetes mellitus (NIDDM) and the number expected from Danish prevalence data (12 vs 10.2; p=0.45). We collected blood samples from 27 of the patients. All but 2 (who had previously diagnosed NIDDM) had normal fasting blood glucose and plasma insulin concentrations, none had islet-cell antibodies, and only 2 had detectable insulin antibodies. Thus, the risk of diabetes was not increased by the use of many insulin injections in these non-diabetic subjects. We conclude that clinical trials on prevention of IDDM by prophylactic insulin treatment can be regarded as safe.	UNIV LONDON LONDON HOSP,COLL MED,DEPT IMMUNOL,LONDON E1 1BB,ENGLAND; UNIV WASHINGTON,VET AFFAIRS MED CTR,SEATTLE,WA 98195	University of London; University College London; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA)	BOCK, T (corresponding author), KOMMUNE HOSP COPENHAGEN,BARTHOLIN INST,DK-1399 COPENHAGEN K,DENMARK.			Buschard, Karsten/0000-0002-0126-7423	NIDDK NIH HHS [DK 02456] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASPLIN CM, 1981, DIABETES CARE, V4, P337, DOI 10.2337/diacare.4.3.337; ATKINSON MA, 1990, DIABETES, V39, P933, DOI 10.2337/diabetes.39.8.933; ATKINSON MA, 1986, DIABETES, V35, P894, DOI 10.2337/diabetes.35.8.894; Beck-Nielsen H, 1990, Ugeskr Laeger, V152, P2; BERRY G, 1983, BIOMETRICS, V39, P173, DOI 10.2307/2530817; BERSON SA, 1964, DIABETES, V13, P247; BONIFACIO E, 1990, LANCET, V335, P147, DOI 10.1016/0140-6736(90)90013-U; BOTTAZZO GF, 1991, ANN MED, V23, P453, DOI 10.3109/07853899109148089; BOTTAZZO GF, 1980, LANCET, V1, P668; CHRISTAU B, 1982, DIABETOLOGIA, V23, P160; Christy M, 1979, Diabetes Care, V2, P127, DOI 10.2337/diacare.2.2.127; DAMSGAARD EM, 1987, DIABETES CARE, V10, P26, DOI 10.2337/diacare.10.1.26; DEAN BM, 1986, DIABETOLOGIA, V29, P339, DOI 10.1007/BF00452073; GOTFREDSEN CF, 1985, DIABETOLOGIA, V28, P933, DOI 10.1007/BF00703140; KLOPPEL G, 1976, ACTA ENDOCRINOL-COP, V83, P107; KUHL C, 1975, ACTA ENDOCRINOL-COP, V79, P7409; KURTZ AB, 1980, DIABETOLOGIA, V18, P147, DOI 10.1007/BF00290492; LACY PE, 1965, DIABETES, V14, P634, DOI 10.2337/diab.14.10.634; LIKE AA, 1986, DIABETES, V35, pA74; MCGRATH D, 1950, J MENT SCI, V96, P285; MORGAN CR, 1965, ANAT REC, V153, P49, DOI 10.1002/ar.1091530107; PALMER JP, 1983, SCIENCE, V222, P1337, DOI 10.1126/science.6362005; SUTTON M, 1988, METABOLISM, V37, P1005, DOI 10.1016/0026-0495(88)90058-3; ZHANG ZJ, 1991, P NATL ACAD SCI USA, V88, P10252, DOI 10.1073/pnas.88.22.10252	24	8	8	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 20	1992	339	8808					1504	1506		10.1016/0140-6736(92)91264-9	http://dx.doi.org/10.1016/0140-6736(92)91264-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HZ175	1351186				2022-12-01	WOS:A1992HZ17500004
J	CHAUHAN, A; DILAWARI, JB; JAMEEL, S; KAUR, U; CHAWLA, YK; SHARMA, ML; GANGULY, NK				CHAUHAN, A; DILAWARI, JB; JAMEEL, S; KAUR, U; CHAWLA, YK; SHARMA, ML; GANGULY, NK			COMMON ETIOLOGIC AGENT FOR EPIDEMIC AND SPORADIC NON-A, NON-B HEPATITIS	LANCET			English	Note							TRANSMITTED NON-A	Enterovirus-like particles have been reported in the acute phase of both epidemic and sporadic non-A, non-B (NANB) hepatitis. To examine whether these particles were the causative agent in the two types of disease, 29 patients with acute viral hepatitis in a north Indian epidemic outbreak and 9 with sporadic acute disease were investigated. 25 (86%) of 29 patients with epidemic hepatitis and 5 (56%) of 9 with sporadic disease were diagnosed as having enterically-transmitted-NANB hepatitis by exclusion. Virus-like particles (VLP) of 30-34 nm were detected in stool of 1 patient with epidemic and 1 with sporadic hepatitis. The VLPs crossreacted serologically and a specific IgM response was seen in acute epidemic and sporadic serum samples. After inoculation with infected stool rhesus monkeys had a mild rise in liver enzymes, and bile samples contained VLPs. These results suggest that the aetiological agent in epidemic and sporadic disease is the same.	POSTGRAD INST MED EDUC & RES,DEPT HEPATOL,CHANDIGARH 160012,INDIA; POSTGRAD INST MED EDUC & RES,DEPT EXPTL MED,CHANDIGARH 160012,INDIA; INT CTR GENET ENGN & BIOTECHNOL,NEW DELHI,INDIA; PUNJAB UNIV,REG SOPHISTICATED INSTRUMENTAT CTR,CHANDIGARH,INDIA	Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh; Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh; Department of Biotechnology (DBT) India; International Center for Genetic Engineering & Biotechnology (ICGEB); International Center for Genetic Engineering & Biotechnology (ICGEB), New Delhi; Panjab University			Bambery, Upjeet/G-7593-2011					Almeida J D, 1969, Adv Virus Res, V15, P307, DOI 10.1016/S0065-3527(08)60878-7; BALAYAN MS, 1987, SOVIET MED REV E, V2, P235; BRADLEY DW, 1990, BRIT MED BULL, V46, P442, DOI 10.1093/oxfordjournals.bmb.a072409; BRADLEY DW, 1988, LANCET, V1, P819; DATTA R, 1987, J GASTROEN HEPATOL, V2, P333, DOI 10.1111/j.1440-1746.1987.tb00171.x; DOROSHENKO NV, 1989, VORP VIRUSOL, V45, P164; HUMPHREY CD, 1988, VIRAL HEPATITIS LIVE, P148; REYES GR, 1990, SCIENCE, V247, P1335, DOI 10.1126/science.2107574; SREENIVASAN MA, 1984, J GEN VIROL, V65, P1005, DOI 10.1099/0022-1317-65-5-1005	9	27	28	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 20	1992	339	8808					1509	1510		10.1016/0140-6736(92)91267-C	http://dx.doi.org/10.1016/0140-6736(92)91267-C			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HZ175	1351189				2022-12-01	WOS:A1992HZ17500007
J	DAVIES, M; RAYMAN, G; DAY, J				DAVIES, M; RAYMAN, G; DAY, J			INCREASED INCIDENCE OF CORONARY-DISEASE IN PEOPLE WITH IMPAIRED GLUCOSE-TOLERANCE - LINK WITH INCREASED LIPOPROTEIN(A) CONCENTRATIONS	BRITISH MEDICAL JOURNAL			English	Article											DAVIES, M (corresponding author), IPSWICH DIABET CTR,IPSWICH IP4 5PD,SUFFOLK,ENGLAND.			Davies, Melanie/0000-0002-9987-9371				FULLER JH, 1980, LANCET, V1, P1374; MILES LA, 1989, NATURE, V339, P301, DOI 10.1038/339301a0; SCHRIEWER H, 1984, J CLIN CHEM CLIN BIO, V22, P591; SCOTT J, 1991, BRIT MED J, V303, P663, DOI 10.1136/bmj.303.6804.663; ZIMMET P, 1989, DIABETIC MED, V6, P728, DOI 10.1111/j.1464-5491.1989.tb01266.x	5	19	19	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 20	1992	304	6842					1610	1611		10.1136/bmj.304.6842.1610	http://dx.doi.org/10.1136/bmj.304.6842.1610			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA436	1385748	Bronze, Green Published			2022-12-01	WOS:A1992JA43600023
J	HOLM, K; MAKI, M; SAVILAHTI, E; LIPSANEN, V; LAIPPALA, P; KOSKIMIES, S				HOLM, K; MAKI, M; SAVILAHTI, E; LIPSANEN, V; LAIPPALA, P; KOSKIMIES, S			INTRAEPITHELIAL GAMMA-DELTA-T-CELL-RECEPTOR LYMPHOCYTES AND GENETIC SUSCEPTIBILITY TO CELIAC-DISEASE	LANCET			English	Article							CELIAC-DISEASE; HETERODIMER	Although the proportion of gamma-delta T-cell-receptor (TCR)-bearing intraepithelial lymphocytes is increased in the jejunum of patients with active coeliac disease, an abnormality thought to be specific among those with gluten-sensitive enteropathy, the factors influencing gamma-delta TCR expression remain uncertain. We examined the relation between genetic factors associated with coeliac disease and intraepithelial gamma-delta T lymphocyte distribution in both coeliac patients and their healthy first-degree relatives. 41% (45/109) of healthy relatives had an increased density of gamma-delta T cells in their mucosa and 66% had an increased density of alpha-beta T cells. By contrast with alpha-beta T cells, the density of gamma-delta cells was significantly associated with genetic markers for coeliac disease susceptiblity (DR3, DQA, and DQB). We also found a dose effect of DQA and DQB genes on the number of intraepithelial gamma-delta T cells. An increased density of gamma-delta T cells in normal jejunal mucosa of a healthy individual with appropriate genetic determinants might be necessary for the development of the typical lesions of coeliac disease. Routine jejunal histological studies should include gamma-delta T-cell counts, thus allowing early detection of coeliac disease latency.	UNIV HELSINKI,CHILDRENS HOSP,SF-00100 HELSINKI 10,FINLAND; UNIV TAMPERE,DEPT PUBL HLTH,BIOMETRY UNIT,TAMPERE,FINLAND; FINNISH RED CROSS & BLOOD TRANSFUS SERV,BLOOD TRANSFUS SERV,HELSINKI,FINLAND	University of Helsinki; Tampere University	HOLM, K (corresponding author), UNIV TAMPERE,DEPT CLIN SCI,TEISKONTIE 35,POB 607,SF-33101 TAMPERE,FINLAND.							BAND H, 1987, SCIENCE, V238, P6824; BOSNES V, 1990, EUR J IMMUNOL, V20, P1429, DOI 10.1002/eji.1830200704; CUENOD B, 1990, GASTROENTEROLOGY, V99, P1037, DOI 10.1016/0016-5085(90)90624-A; FAURE F, 1988, J IMMUNOL, V141, P3357; HALL MA, 1991, GUT, V32, P487, DOI 10.1136/gut.32.5.487; HALSTENSEN TS, 1989, SCAND J IMMUNOL, V30, P665, DOI 10.1111/j.1365-3083.1989.tb02474.x; KOSKIMIES S, 1991, COELIAC DISEASE 40 Y, P10; MAKI M, 1990, ARCH DIS CHILD, V65, P1137, DOI 10.1136/adc.65.10.1137; MAKI M, 1991, LANCET, V337, P763, DOI 10.1016/0140-6736(91)91375-5; MAKI M, 1991, LANCET, V338, P1350, DOI 10.1016/0140-6736(91)92234-S; MAKI M, 1991, GUT, V32, P1412, DOI 10.1136/gut.32.11.1412; MAKI M, 1988, LANCET, V1, P479; PASTERNACK A, 1990, CLIN NEPHROL, V34, P56; RAJASEKAR R, 1990, P NATL ACAD SCI USA, V87, P1767, DOI 10.1073/pnas.87.5.1767; SAVILAHTI E, 1990, PEDIATR RES, V28, P579, DOI 10.1203/00006450-199012000-00005; SAVILAHTI E, 1992, GUT, V33, P206, DOI 10.1136/gut.33.2.206; SPENCER J, 1989, EUR J IMMUNOL, V19, P1335, DOI 10.1002/eji.1830190728; SPURKLAND A, 1990, HUM IMMUNOL, V29, P157, DOI 10.1016/0198-8859(90)90111-2; TRIEBEL F, 1989, IMMUNOL TODAY, V10, P186, DOI 10.1016/0167-5699(89)90321-6; WRAY D, 1981, DIGEST DIS SCI, V26, P737, DOI 10.1007/BF01316864	20	114	117	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 20	1992	339	8808					1500	1503		10.1016/0140-6736(92)91262-7	http://dx.doi.org/10.1016/0140-6736(92)91262-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HZ175	1351185				2022-12-01	WOS:A1992HZ17500003
J	JOBBINS, J; BAGG, J; FINLAY, IG; ADDY, M; NEWCOMBE, RG				JOBBINS, J; BAGG, J; FINLAY, IG; ADDY, M; NEWCOMBE, RG			ORAL AND DENTAL DISEASE IN TERMINALLY ILL CANCER-PATIENTS	BRITISH MEDICAL JOURNAL			English	Article									S GLAMORGAN HLTH AUTHOR,CARDIFF CF1 3NW,S GLAM,WALES; UNIV WALES COLL MED,ORAL MED & ORAL PATHOL,CARDIFF CF4 4XN,S GLAM,WALES; HOLME TOWER MARIE CURIE CTR,PENARTH,S GLAM,WALES; UNIV WALES COLL MED,PERIODONTOL,CARDIFF CF4 4XN,S GLAM,WALES; UNIV WALES COLL MED,MED STAT,CARDIFF CF4 4XN,S GLAM,WALES	Cardiff University; Cardiff University; Cardiff University			Newcombe, Robert G/B-4897-2009					Aldred M J, 1991, Spec Care Dentist, V11, P59; FINLAY IG, 1986, BRIT MED J, V292, P592, DOI 10.1136/bmj.292.6520.592; JANMOHAMED R, 1990, BRIT J CANCER, V61, P469, DOI 10.1038/bjc.1990.103; WALLACE TW, 1984, MICROBIOS, V41, P99; WRAY D, 1975, BRIT MED J, V2, P490, DOI 10.1136/bmj.2.5969.490	5	41	41	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 20	1992	304	6842					1612	1612		10.1136/bmj.304.6842.1612	http://dx.doi.org/10.1136/bmj.304.6842.1612			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA436	1628090	Green Published, Bronze			2022-12-01	WOS:A1992JA43600025
J	MARIOTTI, S; SANSONI, P; BARBESINO, G; CATUREGLI, P; MONTI, D; COSSARIZZA, A; GIACOMELLI, T; PASSERI, G; FAGIOLO, U; PINCHERA, A; FRANCESCHI, C				MARIOTTI, S; SANSONI, P; BARBESINO, G; CATUREGLI, P; MONTI, D; COSSARIZZA, A; GIACOMELLI, T; PASSERI, G; FAGIOLO, U; PINCHERA, A; FRANCESCHI, C			THYROID AND OTHER ORGAN-SPECIFIC AUTOANTIBODIES IN HEALTHY CENTENARIANS	LANCET			English	Note								To investigate the prevalence of thyroid autoantibodies in very old subjects, we assayed sera from 34 healthy centenarians (7 men, 27 women; age range 100-108 years) for these antibodies. There was a clear age-dependent increase in prevalence of thyroid autoantibodies in sera from 549 control subjects aged 7-85 years, prevalence in 40 subjects aged 70-85 being significantly greater (p<0.001, chi-2) than that in 436 subjects aged less than 50. By contrast, prevalence of thyroid autoantibodies in centenarians was not significantly different from that in controls aged less than 50. Cytofluorimetric analysis of peripheral blood lymphocytes showed a striking age-dependent decrease in total and CD5+ B cells (without changes in their ratio), which reached its nadir in centenarians. The age-dependent increase in prevalence of thyroid autoantibodies in the elderly is not seen after the ninth decade of life. What relation this characteristic has to derangement of circulating B cells is unknown.	UNIV MODENA,INST GEN PATHOL,I-41100 MODENA,ITALY; UNIV PARMA,INST GEN CLIN MED,I-43100 PARMA,ITALY; UNIV PADUA,INST INTERNAL MED,I-35100 PADUA,ITALY	Universita di Modena e Reggio Emilia; University of Parma; University of Padua	MARIOTTI, S (corresponding author), UNIV PISA,IST ENDOCRINOL,VIALE TIRRENO 64,I-56018 TIRRENIA,ITALY.		Franceschi, Claudio/L-4484-2017; Monti, Daniela/G-9556-2012; Mariotti, Stefano/AAN-1948-2020	Franceschi, Claudio/0000-0001-9841-6386; Monti, Daniela/0000-0001-8651-8123; Cossarizza, Andrea/0000-0002-5381-1558; Passeri, Giovanni/0000-0002-4039-1160				COSSARIZZA A, 1991, BLOOD, V77, P1263; FRANCESCHI C, 1991, ANN NY ACAD SCI, V261, P428; HACKETT E, 1960, LANCET, V2, P402; HIJMANS W, 1984, MECH AGEING DEV, V26, P83, DOI 10.1016/0047-6374(84)90167-2; HOOPER B, 1972, CLIN EXP IMMUNOL, V12, P79; KASAIAN MT, 1991, P SOC EXP BIOL MED, V197, P226; MARIOTTI S, 1990, J CLIN ENDOCR METAB, V71, P661, DOI 10.1210/jcem-71-3-661; OLSHANSKY SJ, 1990, SCIENCE, V250, P634, DOI 10.1126/science.2237414; ROBUSCHI G, 1987, ENDOCR REV, V8, P142, DOI 10.1210/edrv-8-2-142; Tomer Y, 1988, Autoimmunity, V1, P141, DOI 10.3109/08916938809001927	10	189	192	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 20	1992	339	8808					1506	1508		10.1016/0140-6736(92)91265-A	http://dx.doi.org/10.1016/0140-6736(92)91265-A			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HZ175	1351187				2022-12-01	WOS:A1992HZ17500005
J	NISHINO, T; SUGIYAMA, A; TANAKA, A; ISHIKAWA, T				NISHINO, T; SUGIYAMA, A; TANAKA, A; ISHIKAWA, T			EFFECTS OF TOPICAL NASAL ANESTHESIA ON SHIFT OF BREATHING ROUTE IN ADULTS	LANCET			English	Article							RESPIRATORY ACTIVITY; MUSCLE-ACTIVITY; ANESTHESIA; PRESSURE; OBSTRUCTION; RECEPTORS; INFANTS; HUMANS; LAMBS; SLEEP	The position of the soft palate is known to determine the breathing route, but the physiological mechanisms that bring about a shift from nasal to oral breathing are unclear. To test the hypothesis that activation of receptors in the nasal passage may be involved in reflex initiation of oral breathing after nasal obstruction, we investigated respiratory responses to nasal occlusion before and after topical lignocaine anaesthesia of the nasal passages. Eleven volunteers were fitted with custom-made partitioned face masks, which separated nasal and oral passages. Air flow through each passage was detected by changes in airway pressure and carbon dioxide concentration. Nine subjects were habitual nasal breathers both before and after topical anaesthesia with 4% lignocaine. Among these subjects, the time to initiate oral breathing in response to nasal occlusion was significantly shorter before anaesthesia than afterwards (mean 4.4 [SD 2.5] vs 10.8 [7.4] s, p<0.01). Similarly, the time to resume nasal breathing after release of nasal occlusion was significantly shorter before topical anaesthesia than afterwards (6.9 [4.9] vs 12.1 [7.8] s, p<0.01). Topical anaesthesia did not affect respiration rate, end-tidal carbon dioxide concentration, or arterial oxygen saturation. These findings suggest that in human beings sensory information from receptors in the nasal passage has an important role in controlling the shift of breathing route.			NISHINO, T (corresponding author), NATL CANC CTR,DEPT ANESTHESIOL,TSUKIJI 5-1-1,CHUO KU,TOKYO 104,JAPAN.							DEWEESE EL, 1988, J APPL PHYSIOL, V64, P1346, DOI 10.1152/jappl.1988.64.4.1346; HARDING R, 1990, RESP PHYSIOL, V80, P71, DOI 10.1016/0034-5687(90)90007-L; HARDING R, 1987, RESP PHYSIOL, V68, P177, DOI 10.1016/S0034-5687(87)80004-X; HARDING R, 1991, J APPL PHYSIOL, V71, P1574, DOI 10.1152/jappl.1991.71.4.1574; KUNA ST, 1988, AM REV RESPIR DIS, V137, P656, DOI 10.1164/ajrccm/137.3.656; MATHEW OP, 1982, J APPL PHYSIOL, V52, P438, DOI 10.1152/jappl.1982.52.2.438; MATHEW OP, 1984, RESP PHYSIOL, V58, P41, DOI 10.1016/0034-5687(84)90043-4; MATHEW OP, 1984, J APPL PHYSIOL, V56, P500, DOI 10.1152/jappl.1984.56.2.500; MCBRIDE B, 1981, J APPL PHYSIOL, V51, P1189, DOI 10.1152/jappl.1981.51.5.1189; MILLER MJ, 1985, J PEDIATR-US, V107, P465, DOI 10.1016/S0022-3476(85)80535-7; RODENSTEIN DO, 1985, AM REV RESPIR DIS, V131, P343; RODENSTEIN DO, 1984, J APPL PHYSIOL, V57, P651, DOI 10.1152/jappl.1984.57.3.651; SANTAMBROGIO FB, 1985, J APPL PHYSIOL, V58, P1298, DOI 10.1152/jappl.1985.58.4.1298; SANTAMBROGIO G, 1983, RESP PHYSIOL, V54, P317, DOI 10.1016/0034-5687(83)90075-0; SANTAMBROGIO G, 1985, RESPIR PHYSL, V59, P34; Swift DL., 1977, RESPIRATORY DEFENSE, V5, P63; WHITE DP, 1985, AM REV RESPIR DIS, V132, P972; WOLFSDORF J, 1969, PEDIATRICS, V43, P799	18	14	15	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 20	1992	339	8808					1497	1500		10.1016/0140-6736(92)91261-6	http://dx.doi.org/10.1016/0140-6736(92)91261-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HZ175	1351184				2022-12-01	WOS:A1992HZ17500002
J	RENAUD, S; DELORGERIL, M				RENAUD, S; DELORGERIL, M			WINE, ALCOHOL, PLATELETS, AND THE FRENCH PARADOX FOR CORONARY HEART-DISEASE	LANCET			English	Article							MODERATE ALCOHOL; CONSUMPTION; RISK; MEN; MORTALITY; COUNTRIES; ETHANOL; FARMERS	In most countries, high intake of saturated fat is positively related to high mortality from coronary heart disease (CHD). However, the situation in France is paradoxical in that there is high intake of saturated fat but low mortality from CHD. This paradox may be attributable in part to high wine consumption. Epidemiological studies indicate that consumption of alcohol at the level of intake in France (20-30 g per day) can reduce risk of CHD by at least 40%. Alcohol is believed to protect from CHD by preventing atherosclerosis through the action of high-density-lipoprotein cholesterol, but serum concentrations of this factor are no higher in France than in other countries. Re-examination of previous results suggests that, in the main, moderate alcohol intake does not prevent CHD through an effect on atherosclerosis, but rather through a haemostatic mechanism. Data from Caerphilly, Wales, show that platelet aggregation, which is related to CHD, is inhibited significantly by alcohol at levels of intake associated with reduced risk of CHD. Inhibition of platelet reactivity by wine (alcohol) may be one explanation for protection from CHD in France, since pilot studies have shown that platelet reactivity is lower in France than in Scotland.			RENAUD, S (corresponding author), INSERM,U63,NUTR & VASC PHYSIOPATHOL RES UNIT,22 AVE DOYEN LEPINE,CP 18,F-69675 BRON,FRANCE.							BARAONA E, 1979, J LIPID RES, V20, P289; BLACKBURN H, 1986, AM J CARDIOL, V58, P161, DOI 10.1016/0002-9149(86)90262-6; COLDITZ GA, 1985, AM HEART J, V109, P886, DOI 10.1016/0002-8703(85)90654-4; DONAHUE RP, 1986, JAMA-J AM MED ASSOC, V255, P2311, DOI 10.1001/jama.255.17.2311; DOUSTEBLAZY P, 1988, REV EPIDEMIOL SANTE, V6, P342; ELWOOD PC, 1991, CIRCULATION, V83, P38, DOI 10.1161/01.CIR.83.1.38; FRIEDMAN LA, 1986, AM J EPIDEMIOL, V124, P481, DOI 10.1093/oxfordjournals.aje.a114418; HEGSTED DM, 1988, J NUTR, V118, P1184, DOI 10.1093/jn/118.10.1184; JOST JP, 1990, REV EPIDEMIOL SANTE, V38, P517; KAGAN A, 1974, J CHRON DIS, V27, P345, DOI 10.1016/0021-9681(74)90014-9; KOZAREVIC D, 1988, INT J EPIDEMIOL, V12, P145; KROMHOUT D, 1989, AM J CLIN NUTR, V49, P889, DOI 10.1093/ajcn/49.5.889; LANGER RD, 1992, CIRCULATION, V85, P910, DOI 10.1161/01.CIR.85.3.910; LAZARUS NB, 1991, BRIT MED J, V303, P553, DOI 10.1136/bmj.303.6802.553; LITSIE AM, 1976, B WORLD HEALTH ORGAN, V53, P623; MOORE RD, 1986, MEDICINE, V65, P242, DOI 10.1097/00005792-198607000-00004; NORDOY A, 1984, EUR J CLIN INVEST, V14, P339, DOI 10.1111/j.1365-2362.1984.tb01193.x; PUCHOIS P, 1990, ARCH INTERN MED, V150, P1638, DOI 10.1001/archinte.150.8.1638; RENAUD S, 1986, ATHEROSCLEROSIS, V60, P37, DOI 10.1016/0021-9150(86)90085-7; RENAUD S, 1985, CARDIOVASC RES, V19, P155, DOI 10.1093/cvr/19.3.155; RENAUD S, 1989, J INTERN MED, V225, P39, DOI 10.1111/j.1365-2796.1989.tb01434.x; RENAUD S, 1984, DIET DIABETES ATHERO, P177; RENAUD SC, 1992, AM J CLIN NUTR, V55, P1012, DOI 10.1093/ajcn/55.5.1012; RHOADS GG, 1978, LAB INVEST, V38, P304; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; RUDEL LL, 1981, ARTERIOSCLEROSIS, V1, P144, DOI 10.1161/01.ATV.1.2.144; STLEGER AS, 1979, LANCET, V1, P1017, DOI 10.1016/S0140-6736(79)92765-X; THAULOW E, 1991, CIRCULATION, V84, P613, DOI 10.1161/01.CIR.84.2.613; ULBRICHT TLV, 1991, LANCET, V338, P985, DOI 10.1016/0140-6736(91)91846-M; YANO K, 1977, NEW ENGL J MED, V297, P405, DOI 10.1056/NEJM197708252970801; 1989, WORLD HLTH STATISTIC	31	2804	2919	6	357	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 20	1992	339	8808					1523	1526		10.1016/0140-6736(92)91277-F	http://dx.doi.org/10.1016/0140-6736(92)91277-F			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HZ175	1351198				2022-12-01	WOS:A1992HZ17500016
J	TYLER, A; BALL, D; CRAUFURD, D				TYLER, A; BALL, D; CRAUFURD, D			PRESYMPTOMATIC TESTING FOR HUNTINGTONS-DISEASE IN THE UNITED-KINGDOM	BRITISH MEDICAL JOURNAL			English	Article							LINKED DNA MARKERS; ATTITUDES; DIAGNOSIS; CHOREA	Objective-To evaluate the United Kingdom Huntington's disease presymptomatic testing programme. Design-Postal questionnaire survey to collect data on all tests performed by clinical genetics centres between 1987 and 1990. Setting-Genetic centres providing presymptomatic testing in the United Kingdom. Subjects-248 subjects at risk of Huntington's disease who had presymptomatic testing at their request. Main outcome measures-Sex, age, prior risk, and risk after testing. Results-The risk of carrying the Huntington disease gene was reduced for 151 (61%) of the applicants and raised for 97 (39%). 158 (64%) of the subjects were female and 90 (36%) male. The median age at which the results were given was 32.5 years. Conclusions-The demand for testing was lower than expected and may have reached its peak in 1990. The excess of low risk results was not fully explained by the age effect. All the genetics centres concerned have agreed a common service protocol which requires extensive pre-test counselling and post-test follow up. The worth of the procedure remains to be decided. The availability of a large body of pooled data from all the United Kingdom testing centres, which individually are likely to have only a few results, will form a valuable resource for monitoring the long term psychosocial impact of testing.	ST MARYS HOSP,MANCHESTER M13 0JH,LANCS,ENGLAND	University of Manchester	TYLER, A (corresponding author), UNIV WALES COLL MED,DEPT MED GENET,CARDIFF CF4 4XW,S GLAM,WALES.		Craufurd, David/G-5277-2013					BLOCH M, 1989, AM J MED GENET, V32, P217, DOI 10.1002/ajmg.1320320215; BRANDT J, 1989, JAMA-J AM MED ASSOC, V261, P3108, DOI 10.1001/jama.261.21.3108; CRAUFURD D, 1989, LANCET, V2, P603; CRAUFURD DIO, 1986, BRIT MED J, V293, P249, DOI 10.1136/bmj.293.6541.249; GUSELLA JF, 1983, NATURE, V306, P234, DOI 10.1038/306234a0; HARPER PS, 1992, J MED GENET, V29, P239, DOI 10.1136/jmg.29.4.239; HARPER PS, 1991, MAJOR PROBLEMS NEURO, V22, P373; HARPER PS, 1991, MAJOR PROBLEMS NEURO, V22, P251; HAYDEN MR, 1988, AM J HUM GENET, V43, P689; LAM RW, 1988, J CLIN PSYCHIAT, V49, P444; MASTROMAURO C, 1987, AM J MED GENET, V26, P271, DOI 10.1002/ajmg.1320260205; MEISSEN GJ, 1988, NEW ENGL J MED, V318, P535, DOI 10.1056/NEJM198803033180903; MORRIS M, 1988, LANCET, V2, P1069, DOI 10.1016/S0140-6736(88)90078-5; SANDKUYL L, 1989, HUM GENET, V82, P159, DOI 10.1007/BF00284050; TYLER A, 1983, J MED GENET, V20, P179, DOI 10.1136/jmg.20.3.179; TYLER A, 1990, IN PRESS BR J PSYCHI; World Federation of Neurology, 1989, J NEUROL SCI, V94, P327	17	64	64	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 20	1992	304	6842					1593	1596		10.1136/bmj.304.6842.1593	http://dx.doi.org/10.1136/bmj.304.6842.1593			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA436	1385747	Bronze, Green Published			2022-12-01	WOS:A1992JA43600018
J	ENGLANDER, SW; ENGLANDER, JJ; MCKINNIE, RE; ACKERS, GK; TURNER, GJ; WESTRICK, JA; GILL, SJ				ENGLANDER, SW; ENGLANDER, JJ; MCKINNIE, RE; ACKERS, GK; TURNER, GJ; WESTRICK, JA; GILL, SJ			HYDROGEN-EXCHANGE MEASUREMENT OF THE FREE-ENERGY OF STRUCTURAL AND ALLOSTERIC CHANGE IN HEMOGLOBIN	SCIENCE			English	Article							DIMER-TETRAMER ASSOCIATION; TEMPERATURE-DEPENDENCE; RIBONUCLEASE-S; RESOLUTION; PROTEINS; HELIX	The inability to localize and measure the free energy of protein structure and structure change severely limits protein structure-function investigations. The local unfolding model for protein hydrogen exchange quantitatively relates the free energy of local structural stability with the hydrogen exchange rate of concerted sets of structurally related protons. In tests with a number of modified hemoglobin forms, the loss in structural free energy obtained locally from hydrogen exchange results matches the loss in allosteric free energy measured globally by oxygen-binding and subunit dissociation experiments.	UNIV COLORADO,DEPT BIOCHEM,BOULDER,CO 80309; WASHINGTON UNIV,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110	University of Colorado System; University of Colorado Boulder; Washington University (WUSTL)	ENGLANDER, SW (corresponding author), UNIV PENN,JOHNSON RES FDN,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031847] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM031847] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERS GK, 1992, SCIENCE, V255, P54, DOI 10.1126/science.1553532; ALLEWELL NM, 1983, J BIOCHEM BIOPH METH, V7, P345, DOI 10.1016/0165-022X(83)90060-X; BALDWIN J, 1979, J MOL BIOL, V129, P175, DOI 10.1016/0022-2836(79)90277-8; BERGER ARIEH, 1957, ARCH BIOCHEM AND BIOPHYS, V69, P106, DOI 10.1016/0003-9861(57)90478-2; EIGEN M, 1964, ANGEW CHEM INT EDIT, V3, P1, DOI 10.1002/anie.196400011; ENGLANDER JJ, 1983, J MOL BIOL, V169, P325, DOI 10.1016/S0022-2836(83)80186-7; ENGLANDER JJ, 1985, ANAL BIOCHEM, V147, P234, DOI 10.1016/0003-2697(85)90033-8; ENGLANDER SW, 1992, ANNU REV BIOPH BIOM, V21, P243, DOI 10.1146/annurev.bb.21.060192.001331; ENGLANDER SW, 1975, ANN NY ACAD SCI, V244, P10, DOI 10.1111/j.1749-6632.1975.tb41518.x; ENGLANDER SW, 1980, BIOPHYS J, V32, P577, DOI 10.1016/S0006-3495(80)84991-5; ENGLANDER SW, 1983, STRUCTURE DYNAMICS N, P421; HVIDT AASE, 1966, ADVANCE PROTEIN CHEM, V21, P287, DOI 10.1016/S0065-3233(08)60129-1; IP SHC, 1977, J BIOL CHEM, V252, P82; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; KUWAJIMA K, 1983, J MOL BIOL, V169, P299, DOI 10.1016/S0022-2836(83)80185-5; LOUIE G, 1988, J MOL BIOL, V201, P755, DOI 10.1016/0022-2836(88)90472-X; LOUIE G, 1988, J MOL BIOL, V201, P765, DOI 10.1016/0022-2836(88)90473-1; MAIN EL, 1980, J BIOL CHEM, V255, P10695; MCKINNIE RE, 1991, CHEM PHYS, V158, P283, DOI 10.1016/0301-0104(91)87072-4; MILLS FC, 1979, J BIOL CHEM, V254, P2881; MONOD J, 1965, J MOL BIOL, V12, P33; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; RAY J, 1986, BIOCHEMISTRY-US, V25, P3000, DOI 10.1021/bi00358a040; ROGERO JR, 1986, METHOD ENZYMOL, V131, pL508; ROSA JJ, 1979, J MOL BIOL, V133, P399, DOI 10.1016/0022-2836(79)90400-5; TURNER GL, 1989, THESIS J HOPKINS U B; WAGNER G, 1982, J MOL BIOL, V160, P343, DOI 10.1016/0022-2836(82)90180-2; WAND AJ, 1986, BIOCHEMISTRY-US, V25, P1107, DOI 10.1021/bi00353a025; WYMAN J, 1964, ADV PROTEIN CHEM, V19, P223, DOI 10.1016/S0065-3233(08)60190-4	29	83	83	2	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 19	1992	256	5064					1684	1687		10.1126/science.256.5064.1684	http://dx.doi.org/10.1126/science.256.5064.1684			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HZ174	1609279	Green Accepted			2022-12-01	WOS:A1992HZ17400046
J	FUH, G; CUNNINGHAM, BC; FUKUNAGA, R; NAGATA, S; GOEDDEL, DV; WELLS, JA				FUH, G; CUNNINGHAM, BC; FUKUNAGA, R; NAGATA, S; GOEDDEL, DV; WELLS, JA			RATIONAL DESIGN OF POTENT ANTAGONISTS TO THE HUMAN GROWTH-HORMONE RECEPTOR	SCIENCE			English	Article							COLONY-STIMULATING FACTOR; PURIFICATION; MUTAGENESIS; SUPERFAMILY; EXPRESSION; PROLACTIN; CLONING; DOMAIN	A hybrid receptor was constructed that contained the extracellular binding domain of the human growth hormone (hGH) receptor linked to the transmembrane and intracellular domains of the murine granulocyte colony-stimulating factor receptor. Addition of hGH to a myeloid leukemia cell line (FDC-P1) that expressed the hybrid receptor caused proliferation of these cells. The mechanism for signal transduction of the hybrid receptor required dimerization because monoclonal antibodies to the hGH receptor were agonists whereas their monovalent fragments were not. Receptor dimerization occurs sequentially-a receptor binds to site 1 on hGH, and then a second receptor molecule binds to site 2 on hGH. On the basis of this sequential mechanism, which may occur in many other cytokine receptors, inactive hGH analogs were designed that were potent antagonists to hGH-induced cell proliferation. Such antagonists could be useful for treating clinical conditions of hGH excess, such as acromegaly.	GENENTECH INC,DEPT PROT ENGN,460 POINT SAN BRUNO BLVD,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT MOLEC BIOL,S SAN FRANCISCO,CA 94080; OSAKA BIOSCI INST,SUITA,OSAKA 565,JAPAN	Roche Holding; Genentech; Roche Holding; Genentech			Nagata, Shigekazu/AAG-3203-2019; Fukunaga, Rikiro/CAG-2891-2022; Wells, Jim A/O-9854-2016	Nagata, Shigekazu/0000-0001-9758-8426; 				BARNARD R, 1985, BIOCHEM J, V231, P459, DOI 10.1042/bj2310459; BAS SH, 1991, P NATL ACAD SCI USA, V88, P4498; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CHEN WY, 1991, MOL ENDOCRINOL, V5, P1845, DOI 10.1210/mend-5-12-1845; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; CUNNINGHAM BC, 1991, P NATL ACAD SCI USA, V88, P3407, DOI 10.1073/pnas.88.8.3407; CUNNINGHAM BC, 1990, SCIENCE, V247, P1461, DOI 10.1126/science.2321008; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FROHMAN LA, 1991, J CLIN ENDOCR METAB, V72, P1175, DOI 10.1210/jcem-72-6-1175; FUH G, 1990, J BIOL CHEM, V265, P3111; FUH G, UNPUB; FUKUNAGA R, 1990, J BIOL CHEM, V265, P14008; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; HIGUCHI R, 1989, PCR PROTOCOLS GUIDE, P177; ISHIZAKAIKEDA E, UNPUB; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; MELMED S, 1990, NEW ENGL J MED, V322, P966, DOI 10.1056/NEJM199004053221405; PATTHY L, 1990, CELL, V61, P13, DOI 10.1016/0092-8674(90)90208-V; WELLS JA, IN PRESS RECENT PROG	23	585	652	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 19	1992	256	5064					1677	1680		10.1126/science.256.5064.1677	http://dx.doi.org/10.1126/science.256.5064.1677			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HZ174	1535167				2022-12-01	WOS:A1992HZ17400044
J	GEORGOPOULOS, AP; ASHE, J; SMYRNIS, N; TAIRA, M				GEORGOPOULOS, AP; ASHE, J; SMYRNIS, N; TAIRA, M			THE MOTOR CORTEX AND THE CODING OF FORCE	SCIENCE			English	Article							FREE ARM MOVEMENTS; NEURONAL POPULATION; 3-DIMENSIONAL SPACE; VISUAL TARGETS; CELL DISCHARGE; DIRECTION; MONKEY; DYNAMICS; PATTERN; MUSCLE	The relation of cellular activity in the motor cortex to the direction of two-dimensional isometric force was investigated under dynamic conditions in monkeys. A task was designed so that three force variables were dissociated: the force exerted by the subject, the net force, and the change in force. Recordings of neuronal activity in the motor cortex revealed that the activity of single cells was directionally tuned and that this tuning was invariant across different directions of a bias force. Cell activity was not related to the direction of force exerted by the subject, which changed drastically as the bias force changed. In contrast, the direction of net force, the direction of force change, and the visually instructed direction all remained quite invariant and congruent and could be the directional variables, alone or in combination, to which cell activity might relate.	UNIV MINNESOTA,SCH MED,DEPT NEUROL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,SCH MED,DEPT PHYSIOL,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	GEORGOPOULOS, AP (corresponding author), VET AFFAIRS MED CTR,CTR BRAIN SCI,MINNEAPOLIS,MN 55455, USA.		SMYRNIS, NIKOLAOS/B-9822-2011; Smyrnis, Nikolaos/AAA-3783-2020		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS007226, R01NS017413] Funding Source: NIH RePORTER; NINDS NIH HHS [NS17413, NS07226] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALEXANDER GE, 1990, J NEUROPHYSIOL, V64, P133, DOI 10.1152/jn.1990.64.1.133; Bernshtein N. A, 1967, COORDINATION REGULAT; BIZZI E, 1991, SCIENCE, V253, P287, DOI 10.1126/science.1857964; CAMINITI R, 1990, J NEUROSCI, V10, P2039; CHENEY PD, 1980, J NEUROPHYSIOL, V44, P773, DOI 10.1152/jn.1980.44.4.773; CONRAD B, 1977, EXP BRAIN RES, V29, P85; CRUTCHER MD, 1990, J NEUROPHYSIOL, V64, P151, DOI 10.1152/jn.1990.64.1.151; Evarts E. V., 1967, NEUROPHYSIOLOGICAL B, P215; EVARTS EV, 1968, J NEUROPHYSIOL, V31, P14, DOI 10.1152/jn.1968.31.1.14; EVARTS EV, 1983, J NEUROPHYSIOL, V49, P1199, DOI 10.1152/jn.1983.49.5.1199; EVARTS EV, 1969, J NEUROPHYSIOL, V32, P375, DOI 10.1152/jn.1969.32.3.375; FLANDERS M, 1992, J NEUROPHYSIOL, V67, P931, DOI 10.1152/jn.1992.67.4.931; FROMM C, 1983, PFLUG ARCH EUR J PHY, V398, P318, DOI 10.1007/BF00657241; Georgopoulos A. P., 1984, DYNAMIC ASPECTS NEOC, P501; GEORGOPOULOS AP, 1985, BEHAV BRAIN RES, V18, P159, DOI 10.1016/0166-4328(85)90071-3; GEORGOPOULOS AP, 1991, ANNU REV NEUROSCI, V14, P361, DOI 10.1146/annurev.ne.14.030191.002045; GEORGOPOULOS AP, 1988, J NEUROSCI, V8, P2928; GEORGOPOULOS AP, 1989, SCIENCE, V243, P234, DOI 10.1126/science.2911737; GEORGOPOULOS AP, 1986, SCIENCE, V233, P1416, DOI 10.1126/science.3749885; GEORGOPOULOS AP, 1982, J NEUROSCI, V2, P1527; GHEZ C, 1979, INTEGRATION NERVOUS, P307; GIBSON AR, 1985, J PHYSIOL-LONDON, V358, P551, DOI 10.1113/jphysiol.1985.sp015566; GROBSTEIN P, 1988, BRAIN BEHAV EVOLUT, V31, P34, DOI 10.1159/000116574; HEPPREYMOND MC, 1978, J PHYSIOL-PARIS, V74, P287; HOCHERMAN S, 1991, EXP BRAIN RES, V83, P285; HOLLERBACH JM, 1982, BIOL CYBERN, V44, P67, DOI 10.1007/BF00353957; Humphrey D R, 1983, Adv Neurol, V39, P347; KALASKA JF, 1990, EXP BRAIN RES, V80, P351; KALASKA JF, 1989, J NEUROSCI, V9, P2080; KALASKA JF, 1991, MOTOR CONTROL CONCEP, P307; LURITO J T, 1991, Society for Neuroscience Abstracts, V17, P1226; LURITO J T, 1990, Society for Neuroscience Abstracts, V16, P1087; MARTIN JH, 1985, EXP BRAIN RES, V57, P427; MASINO T, 1990, NATURE, V345, P434, DOI 10.1038/345434a0; MASSEY JT, 1991, EXP BRAIN RES, V83, P439, DOI 10.1007/BF00231170; MOUNTCASTLE VB, 1991, J NEUROSCI METH, V36, P77, DOI 10.1016/0165-0270(91)90140-U; RIEHLE A, 1989, J NEUROPHYSIOL, V61, P534, DOI 10.1152/jn.1989.61.3.534; SCHWARTZ AB, 1988, J NEUROSCI, V8, P2913; SMITH AM, 1975, EXP BRAIN RES, V23, P315; SNEDECOR GW, 1980, STATISTICAL METHODS, P288; SOECHTING JF, 1987, NEUROSCIENCE, V23, P39, DOI 10.1016/0306-4522(87)90269-7; SOECHTING JF, 1992, ANNU REV NEUROSCI, V15, P167, DOI 10.1146/annurev.ne.15.030192.001123; THACH WT, 1978, J NEUROPHYSIOL, V41, P654, DOI 10.1152/jn.1978.41.3.654; VIVIANI P, 1982, NEUROSCIENCE, V7, P431, DOI 10.1016/0306-4522(82)90277-9; [No title captured]	45	281	287	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 19	1992	256	5064					1692	1695		10.1126/science.256.5064.1692	http://dx.doi.org/10.1126/science.256.5064.1692			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HZ174	1609282				2022-12-01	WOS:A1992HZ17400049
J	MERGNY, JL; DUVALVALENTIN, G; NGUYEN, CH; PERROUAULT, L; FAUCON, B; ROUGEE, M; MONTENAYGARESTIER, T; BISAGNI, E; HELENE, C				MERGNY, JL; DUVALVALENTIN, G; NGUYEN, CH; PERROUAULT, L; FAUCON, B; ROUGEE, M; MONTENAYGARESTIER, T; BISAGNI, E; HELENE, C			TRIPLE HELIX SPECIFIC LIGANDS	SCIENCE			English	Article							COLI RNA-POLYMERASE; ANTINEOPLASTIC AGENTS; DNA; OLIGONUCLEOTIDES; SEQUENCES; PROMOTER; COMPLEX	A triple helix is formed upon binding of an oligodeoxynucleotide to the major groove of duplex DNA. A benzo[e]pyridoindole derivative (BePI) strongly stabilized this structure and showed preferential binding to a triplex rather than to a duplex. Energy transfer experiments suggest that BePI intercalates within the triple helix. Sequence-specific inhibition of transcription initiation of a specific gene by Escherichia coli RNA polymerase by a triplex-forming oligodeoxynucleotide is strongly enhanced when the triplex is stabilized by BePI. Upon irradiation with ultraviolet light, BePI induces covalent modifications of the target within the triple helix structure.	MUSEUM NATL HIST NAT, BIOPHYS LAB,CNRS,UA 481,INSERM,U201,43 RUE CUVIER, F-75005 PARIS, FRANCE; INST CURIE, SYNTH LAB, CNRS, URA 1387, F-91405 ORSAY, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Museum National d'Histoire Naturelle (MNHN); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie			Nguyen, Chi/GWR-1592-2022; Mergny, Jean-Louis/E-2860-2013; Nguyen, Chi/GZG-5146-2022	Mergny, Jean-Louis/0000-0003-3043-8401; 				BISAGNI E, 1988, J MED CHEM, V31, P398, DOI 10.1021/jm00397a023; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; COLLIER DA, 1991, NUCLEIC ACIDS RES, V19, P4219, DOI 10.1093/nar/19.15.4219; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; CROTHERS DM, 1971, BIOPOLYMERS, V10, P2147, DOI 10.1002/bip.360101110; DELOSSANTOS C, 1989, BIOCHEMISTRY-US, V28, P7282, DOI 10.1021/bi00444a021; DUVALVALENTIN G, 1988, NUCLEIC ACIDS RES, V16, P2031, DOI 10.1093/nar/16.5.2031; DUVALVALENTIN G, 1992, P NATL ACAD SCI USA, V89, P504, DOI 10.1073/pnas.89.2.504; DUVALVALENTIN G, 1987, NUCLEIC ACIDS RES, V15, P575, DOI 10.1093/nar/15.2.575; GRIGORIEV M, 1992, J BIOL CHEM, V267, P3389; HELENE C, 1991, ANTI-CANCER DRUG DES, V6, P569; LEDOAN T, 1987, NUCLEIC ACIDS RES, V15, P8643, DOI 10.1093/nar/15.21.8643; LYAMICHEV VI, 1988, NUCLEIC ACIDS RES, V16, P2165, DOI 10.1093/nar/16.5.2165; MERGNY JL, 1991, NUCLEIC ACIDS RES, V19, P1521, DOI 10.1093/nar/19.7.1521; MONTENAYGARESTIER T, 1990, JERUS SYM Q, V23, P275; MORGAN JP, 1980, PHOTOCHEM PHOTOBIOL, V31, P101, DOI 10.1111/j.1751-1097.1980.tb03692.x; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; NGUYEN CH, 1990, J MED CHEM, V33, P1519, DOI 10.1021/jm00167a037; NGUYEN CH, 1987, J MED CHEM, V30, P1642, DOI 10.1021/jm00392a021; PERROUAULT L, 1990, NATURE, V344, P358, DOI 10.1038/344358a0; POSTEL EH, 1991, P NATL ACAD SCI USA, V88, P8227, DOI 10.1073/pnas.88.18.8227; POVSIC TJ, 1989, J AM CHEM SOC, V111, P3059, DOI 10.1021/ja00190a047; RAJAGOPAL P, 1989, BIOCHEMISTRY-US, V28, P7859, DOI 10.1021/bi00445a048; ROUGEE M, UNPUB; SARI MA, 1986, BIOCHEM BIOPH RES CO, V141, P643, DOI 10.1016/S0006-291X(86)80221-2; SCARIA PV, 1991, J BIOL CHEM, V266, P5417; SUN JS, 1989, P NATL ACAD SCI USA, V86, P9198, DOI 10.1073/pnas.86.23.9198	27	309	312	0	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 19	1992	256	5064					1681	1684		10.1126/science.256.5064.1681	http://dx.doi.org/10.1126/science.256.5064.1681			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HZ174	1609278				2022-12-01	WOS:A1992HZ17400045
J	POTTS, M; ANGELONI, SV; EBEL, RE; BASSAM, D				POTTS, M; ANGELONI, SV; EBEL, RE; BASSAM, D			MYOGLOBIN IN A CYANOBACTERIUM	SCIENCE			English	Article							AMINO-ACID-SEQUENCE; NITROGEN-FIXATION; PROTEINS	Myoglobin was found in the nitrogen-fixing cyanobacterium Nostoc commune. This cyanobacterial myoglobin, referred to as cyanoglobin, was shown to be a soluble hemoprotein of 12.5 kilodaltons with an amino acid sequence that is related to that of myoglobins from two lower eukaryotes, the ciliated protozoa Paramecium caudatum and Tetrahymena pyriformis. Cyanoglobin is encoded by the glbNgene, which is positioned between nifU and nifH-two genes essential for nitrogen fixation-in the genome of Nostoc. Cyanoglobin was detected in Nostoc cells only when they were starved for nitrogen and incubated microaerobically.			POTTS, M (corresponding author), VIRGINIA POLYTECH INST & STATE UNIV,DEPT BIOCHEM,BLACKSBURG,VA 24061, USA.							Bothe H., 1982, biology of cyanobacteria [edited by Carr, N.G.; Whitton, B.A.], P87; CARPENTER EJ, 1976, SCIENCE, V191, P1278, DOI 10.1126/science.1257749; DEFRANCESCO N, 1988, J BACTERIOL, V170, P3297, DOI 10.1128/jb.170.7.3297-3300.1988; GALLON JR, 1974, CAN J MICROBIOL, V20, P1633, DOI 10.1139/m74-254; Haselkorn R, 1992, BIOL NITROGEN FIXATI, P166; IWAASA H, 1990, J BIOL CHEM, V265, P8603; IWAASA H, 1989, J MOL BIOL, V208, P355, DOI 10.1016/0022-2836(89)90395-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MULLIGAN ME, 1989, J BIOL CHEM, V264, P19200; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2441; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; Schopf JW, 1982, BIOL CYANOBACTERIA, P543; STEWART WDP, 1978, ENDEAVOUR, V2, P170, DOI 10.1016/0160-9327(78)90097-2; WAKABAYASHI S, 1986, NATURE, V322, P481, DOI 10.1038/322481a0; Wolk C. P., 1982, biology of cyanobacteria [edited by Carr, N.G.; Whitton, B.A.], P359	18	98	103	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 19	1992	256	5064					1690	1692		10.1126/science.256.5064.1690	http://dx.doi.org/10.1126/science.256.5064.1690			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HZ174	1609281				2022-12-01	WOS:A1992HZ17400048
J	POWERS, R; GARRETT, DS; MARCH, CJ; FRIEDEN, EA; GRONENBORN, AM; CLORE, GM				POWERS, R; GARRETT, DS; MARCH, CJ; FRIEDEN, EA; GRONENBORN, AM; CLORE, GM			3-DIMENSIONAL SOLUTION STRUCTURE OF HUMAN INTERLEUKIN-4 BY MULTIDIMENSIONAL HETERONUCLEAR MAGNETIC-RESONANCE SPECTROSCOPY	SCIENCE			English	Article							RESTRAINED MOLECULAR-DYNAMICS; CYTOKINE RECEPTOR SUPERFAMILY; CELL-STIMULATING FACTOR; 2D NMR-SPECTRA; DISTANCE GEOMETRY; FACTOR-I; COUPLING-CONSTANTS; HYDROGEN-EXCHANGE; PROTEINS; ASSIGNMENT	The three-dimensional solution structure of recombinant human interleukin-4, a protein of 133 residues and 15.4 kilodaltons that plays a key role in the immune and inflammatory systems, has been solved by multidimensional heteronuclear magnetic resonance spectroscopy. The structure is dominated by a left-handed four-helix bundle with an unusual topology comprising two overhand connections. The linker elements between the helices are formed by either long loops, small helical turns, or short strands. The overall topology is remarkably similar to that of growth hormone and granulocyte-macrophage colony stimulating factor, despite the absence of any sequence homology, and substantial differences in the relative lengths of the helices, the length and nature of the various connecting elements, and the pattern of disulfide bridges. These three proteins, however, bind to cell surface receptors belonging to the same hematopoietic superfamily, which suggests that interleukin-4 may interact with its receptor in an analogous manner to that observed in the crystal structure of the growth hormone-extracellular receptor complex.	NIDDKD, CHEM PHYS LAB, BETHESDA, MD 20892 USA; IMMUNEX CORP, SEATTLE, WA 98101 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Immunex Corporation			Powers, Robert/AAK-3431-2020; Clore, G. Marius/A-3511-2008; Clore, G Marius/L-2546-2018	Powers, Robert/0000-0001-9948-6837; Clore, G. Marius/0000-0003-3809-1027; Clore, G Marius/0000-0003-3809-1027; Gronenborn, Angela M/0000-0001-9072-3525				ABDELMEGUID SS, 1987, P NATL ACAD SCI USA, V84, P6434, DOI 10.1073/pnas.84.18.6434; ARAI KI, 1990, ANNU REV BIOCHEM, V59, P7983; BAX A, 1990, J MAGN RESON, V86, P304, DOI 10.1016/0022-2364(90)90262-8; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1986, P NATL ACAD SCI USA, V83, P3801, DOI 10.1073/pnas.83.11.3801; BRUNGER AT, 1992, XPLOR VERSION 3 MANU; CARR C, 1991, BIOCHEMISTRY-US, V30, P1515, DOI 10.1021/bi00220a011; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CHICHE L, 1990, P NATL ACAD SCI USA, V87, P3240, DOI 10.1073/pnas.87.8.3240; CLORE GM, 1986, EMBO J, V5, P2729, DOI 10.1002/j.1460-2075.1986.tb04557.x; CLORE GM, 1991, SCIENCE, V252, P1390, DOI 10.1126/science.2047852; CLORE GM, 1987, BIOCHEMISTRY-US, V26, P8012, DOI 10.1021/bi00398a069; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; CURTIS BM, 1991, PROTEINS, V11, P111, DOI 10.1002/prot.340110204; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DIEDERICHS K, 1991, SCIENCE, V254, P1779, DOI 10.1126/science.1837174; DIEDERICHS K, 1991, J MOL BIOL, V221, P55, DOI 10.1016/0022-2836(91)90803-E; EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; FORMANKAY JD, 1990, BIOCHEMISTRY-US, V29, P1566, DOI 10.1021/bi00458a030; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; GARRETT DS, 1992, BIOCHEMISTRY-US, V31, P4347, DOI 10.1021/bi00132a027; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GOLUMBEK PT, 1991, SCIENCE, V254, P713, DOI 10.1126/science.1948050; GRABSTEIN K, 1986, J EXP MED, V163, P1405, DOI 10.1084/jem.163.6.1405; IKURA M, 1990, J MAGN RESON, V86, P204, DOI 10.1016/0022-2364(90)90227-Z; IKURA M, 1990, J AM CHEM SOC, V112, P9020, DOI 10.1021/ja00180a080; KAY LE, 1989, J MAGN RESON, V84, P72, DOI 10.1016/0022-2364(89)90006-1; KAY LE, 1990, J MAGN RESON, V86, P110, DOI 10.1016/0022-2364(90)90215-U; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; KUSZEWSKI J, 1992, J BIOMOL NMR, V2, P33, DOI 10.1007/BF02192799; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MARION D, 1989, J MAGN RESON, V85, P393, DOI 10.1016/0022-2364(89)90152-2; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; PARDI A, 1984, J MOL BIOL, V180, P741, DOI 10.1016/0022-2836(84)90035-4; PARK LS, 1987, P NATL ACAD SCI USA, V84, P1669, DOI 10.1073/pnas.84.6.1669; PARK LS, 1987, J EXP MED, V166, P476, DOI 10.1084/jem.166.2.476; PAUL WE, 1987, ANNU REV IMMUNOL, V5, P429, DOI 10.1146/annurev.iy.05.040187.002241; POWERS R, 1992, BIOCHEMISTRY-US, V31, P4334, DOI 10.1021/bi00132a026; REDFIELD C, 1991, BIOCHEMISTRY-US, V30, P11029, DOI 10.1021/bi00110a004; SPERA S, 1991, J AM CHEM SOC, V113, P5490, DOI 10.1021/ja00014a071; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; Wuthrich K., 1986, NMR PROTEINS NUCL AC; YOKOTA T, 1986, P NATL ACAD SCI USA, V83, P5894, DOI 10.1073/pnas.83.16.5894; YOKOTA T, 1988, IMMUNOL REV, V102, P137, DOI 10.1111/j.1600-065X.1988.tb00744.x; ZUIDERWEG ERP, 1989, BIOCHEMISTRY-US, V28, P2387, DOI 10.1021/bi00432a008; ZUIDERWEG ERP, 1990, J MAGN RESON, V86, P210, DOI 10.1016/0022-2364(90)90228-2	50	150	164	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 19	1992	256	5064					1673	1677		10.1126/science.256.5064.1673	http://dx.doi.org/10.1126/science.256.5064.1673			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HZ174	1609277	Green Published			2022-12-01	WOS:A1992HZ17400043
J	SENGUPTA, DJ; BOROWIEC, JA				SENGUPTA, DJ; BOROWIEC, JA			STRAND-SPECIFIC RECOGNITION OF A SYNTHETIC DNA-REPLICATION FORK BY THE SV40 LARGE TUMOR-ANTIGEN	SCIENCE			English	Article							LARGE T-ANTIGEN; SIMIAN VIRUS-40 DNA; TERMINATION FACTOR-RHO; COLI RNA-POLYMERASE; ESCHERICHIA-COLI; UNWINDING ACTIVITY; HELICASE ACTIVITY; ORIGIN; INVITRO; BINDING	The mechanism by which DNA helicases unwind DNA was tested; an "unwinding complex" between the SV40 large tumor antigen (T antigen) and a DNA molecule designed to resemble a replication fork was probed. In an adenosine triphosphate (ATP)-dependent reaction, T antigen quantitatively recognized this synthetic replication fork and bound the DNA primarily as a hexamer. The T antigen bound only one of the two strands at the fork, an asymmetric interaction consistent with the 3' --> 5' directionality of the DNA helicase activity of T antigen. Binding to chemically modified DNA substrates indicated that the DNA helicase recognized the DNA primarily through the sugar-phosphate backbone. Ethylation of six top strand phosphates at the junction of single-stranded and double-stranded DNA inhibited the DNA helicase activity of T antigen. Neither a 3' single-stranded end on the DNA substrate nor ATP hydrolysis was required for T antigen to bind the replication fork. These data suggest that T antigen can directly bind the replication fork through recognition of a fork-specific structure.			SENGUPTA, DJ (corresponding author), NYU MED CTR,DEPT BIOCHEM,NEW YORK,NY 10016, USA.				NATIONAL CANCER INSTITUTE [P30CA016087] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029963] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA 16087] Funding Source: Medline; NIAID NIH HHS [AI29963] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARAI K, 1981, J BIOL CHEM, V256, P5247; AUBORN KJ, 1988, J VIROL, V62, P2204, DOI 10.1128/JVI.62.6.2204-2208.1988; BOROWIEC JA, 1988, EMBO J, V7, P3149, DOI 10.1002/j.1460-2075.1988.tb03182.x; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BOROWIEC JA, 1988, P NATL ACAD SCI USA, V85, P64, DOI 10.1073/pnas.85.1.64; BOROWIEC JA, 1991, J VIROL, V65, P1228, DOI 10.1128/JVI.65.3.1228-1235.1991; BOROWIEC JA, 1987, J MOL BIOL, V196, P101, DOI 10.1016/0022-2836(87)90513-4; BRENNAN CA, 1987, CELL, V48, P945, DOI 10.1016/0092-8674(87)90703-3; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P8267, DOI 10.1073/pnas.84.23.8267; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P8981, DOI 10.1073/pnas.84.24.8981; DEAN FB, 1989, UCLA S MOL CELL BIOL, V127, P315; DEB SP, 1987, J VIROL, V61, P3649, DOI 10.1128/JVI.61.12.3649-3654.1987; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; FINGER LR, 1982, J MOL BIOL, V156, P203, DOI 10.1016/0022-2836(82)90467-3; GOETZ GS, 1988, J BIOL CHEM, V263, P383; JOHNSTON BH, 1985, CELL, V42, P713, DOI 10.1016/0092-8674(85)90268-5; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Maniatis T., 1982, MOL CLONING; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.biochem.59.1.289; ODA T, 1972, J MOL BIOL, V71, P799; PARSONS R, 1990, J VIROL, V64, P509, DOI 10.1128/JVI.64.2.509-518.1990; PARSONS RE, 1991, J VIROL, V65, P2798, DOI 10.1128/JVI.65.6.2798-2806.1991; REHAKRANTZ LJ, 1978, J BIOL CHEM, V253, P4051; SCHEFFNER M, 1989, CELL, V57, P955, DOI 10.1016/0092-8674(89)90334-6; SIEBENLIST U, 1980, CELL, V20, P269, DOI 10.1016/0092-8674(80)90613-3; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; STAHL H, 1986, EMBO J, V5, P1939, DOI 10.1002/j.1460-2075.1986.tb04447.x; STAHL H, 1983, J VIROL, V47, P65, DOI 10.1128/JVI.47.1.65-76.1983; STAHL H, 1985, J VIROL, V54, P473, DOI 10.1128/JVI.54.2.473-482.1985; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; TJIAN R, 1981, CELL, V26, P1, DOI 10.1016/0092-8674(81)90026-X; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WIEKOWSKI M, 1987, J VIROL, V61, P411, DOI 10.1128/JVI.61.2.411-418.1987; WIEKOWSKI M, 1988, J BIOL CHEM, V263, P436; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOLD MS, 1987, P NATL ACAD SCI USA, V84, P3643, DOI 10.1073/pnas.84.11.3643; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; WONG I, 1992, SCIENCE, V256, P350, DOI 10.1126/science.256.5055.350; YARRANTON GT, 1979, P NATL ACAD SCI USA, V76, P1658, DOI 10.1073/pnas.76.4.1658; ZHU JY, 1989, J VIROL, V63, P4777, DOI 10.1128/JVI.63.11.4777-4786.1989	46	64	65	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 19	1992	256	5064					1656	1661		10.1126/science.256.5064.1656	http://dx.doi.org/10.1126/science.256.5064.1656			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HZ174	1319087				2022-12-01	WOS:A1992HZ17400038
J	BERKEL, H; BIRDSELL, DC; JENKINS, H				BERKEL, H; BIRDSELL, DC; JENKINS, H			BREAST AUGMENTATION - A RISK FACTOR FOR BREAST-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CARCINOGENICITY; 2,4-TOLUENEDIAMINE; RATS	Background. A relation between breast augmentation and the subsequent risk of breast cancer has been postulated. Since an estimated 2 million women in the United States alone have received breast implants, even a small increase in the risk of breast cancer could have considerable public health consequences. Methods. We performed a population-based nonconcurrent cohort-linkage study. All women in Alberta, Canada, who underwent cosmetic breast augmentation from 1973 through 1986 were included in the implant cohort (n = 11,676). This cohort was compared with the cohort of all women in Alberta in whom a first primary breast cancer was diagnosed (n = 13,557). The expected number of breast-cancer cases in the implant cohort was estimated by applying age-specific and calendar year-specific incidence rates of breast cancer (obtained from the Alberta Cancer Registry) to the implant cohort, Standardized incidence ratios were calculated by dividing the observed by the expected number of breast-cancer cases in the implant cohort. Results. Forty-one patients with implants were subsequently found to have breast cancer. The expected number was 86.2. The standardized incidence ratio was thus 47.6 percent, significantly lower than expected (P<0.01). The average length of follow-up in the implant cohort was 10.2 years, and the average length of time from breast augmentation to the diagnosis of breast cancer was 7.5 years. Conclusions. Women who undergo breast augmentation with silicone implants have a lower risk of breast cancer than the general population. This finding suggests that these women are drawn from a population already at low risk and that the implants do not substantially increase the risk.	UNIV CALGARY, FOOTHILLS HOSP,SCH MED,DEPT SURG, DIV PLAST & RECONSTRUCT SURG, CALGARY T2N 1N4, ALBERTA, CANADA	University of Calgary	BERKEL, H (corresponding author), ALBERTA CANC BOARD, DIV EPIDEMIOL & PREVENT ONCOL, 9707 110 ST, 6TH FL, EDMONTON T5K 2L9, ALBERTA, CANADA.							BAILAR JC, 1964, BIOMETRICS, V20, P639; BENAVENT WJ, 1973, PLAST RECONSTR SURG, V51, P588, DOI 10.1097/00006534-197305000-00026; BERKEL J, 1990, INCIDENCE SURVIVAL D; BINGHAM HG, 1988, ANN PLAS SURG, V20, P236, DOI 10.1097/00000637-198803000-00007; BLAKESLEE S, 1991, GLAMOUR          AUG; BOWERS DG, 1969, PLAST RECONSTR SURG, V44, P541, DOI 10.1097/00006534-196912000-00003; BOYES DC, 1991, CAN MED ASSOC J, V145, P1125; CARDY RH, 1979, J NATL CANCER I, V62, P1107; CHAN SC, 1991, CLIN CHEM, V37, P756; CHOLNOKY TD, 1970, PLAST RECONSTR SURG, V45, P573, DOI 10.1097/00006534-197006000-00007; DEAPEN DM, 1986, PLAST RECONSTR SURG, V77, P361, DOI 10.1097/00006534-198603000-00001; GILES AL, 1976, J TOXICOL ENV HEALTH, V1, P433, DOI 10.1080/15287397609529342; HARRIS HI, 1961, PLAST RECONSTR SURG, V28, P81, DOI 10.1097/00006534-196107000-00007; HIROHATA T, 1977, BRIT MED J, V2, P641, DOI 10.1136/bmj.2.6087.641-c; HOOPES JE, 1967, PLAST RECONSTR SURG, V39, P263, DOI 10.1097/00006534-196703000-00005; HSIEH CC, 1991, EUR J CANCER, V27, P131, DOI 10.1016/0277-5379(91)90469-T; ITO N, 1969, CANCER RES, V29, P1137; KOCH M, 1985, CHRONIC DIS CAN, V5, P74; LILIENFELD AM, 1976, F EIDEMIOLOGY; ROHLFING C, 1991, LONGEVITY        JUL; SNYDERMAN R K, 1960, Plast Reconstr Surg Transplant Bull, V25, P253, DOI 10.1097/00006534-196003000-00006; SONTAG JM, 1981, JNCI-J NATL CANCER I, V66, P591; UMEDA M, 1955, Gan, V46, P597; VALAORAS VG, 1969, INT J CANCER, V4, P350, DOI 10.1002/ijc.2910040312; WYNDER EL, 1969, CANCER, V24, P1235, DOI 10.1002/1097-0142(196912)24:6<1235::AID-CNCR2820240629>3.0.CO;2-G	25	163	165	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 18	1992	326	25					1649	1653		10.1056/NEJM199206183262501	http://dx.doi.org/10.1056/NEJM199206183262501			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY628	1588977	Bronze			2022-12-01	WOS:A1992HY62800001
J	DEVRIESSMITS, AMM; BURGERING, BMT; LEEVERS, SJ; MARSHALL, CJ; BOS, JL				DEVRIESSMITS, AMM; BURGERING, BMT; LEEVERS, SJ; MARSHALL, CJ; BOS, JL			INVOLVEMENT OF P21RAS IN ACTIVATION OF EXTRACELLULAR SIGNAL-REGULATED KINASE-2	NATURE			English	Article							INSULIN; PHOSPHORYLATES; STIMULATION	MANY growth factors upon stimulation of their receptors induce the activity of extracellular signal-regulated kinases, ERKs, also known as MAP kinases 1,2. Several of these growth factors also activate the ras proto-oncogene product, p21ras (Ras), by stimulating the conversion of the inactive GDP-bound form of Ras to the active GTP-bound form 3-6. We have shown that direct introduction of p21ras oncoprotein into cells in the absence of growth factors activates ERKs within five minutes 7, which indicates that normal p21ras may be involved in the activation of ERKs by growth factors. Here we use a recombinant vaccinia virus expressing an interfering mutant of p21ras, Ras(Asn17), to investigate this question. In NIH3T3 cells that overexpress the insulin receptor, this recombinant virus inhibits insulin-induced activation of ERK2 completely, but there is no inhibition of insulin-induced activation of phosphatidyl-inositol-3-kinase. In rat-1 cells the recombinant virus inhibited ERK2 activity induced by platelet-derived growth factor (PDGF) but not by phorbol ester. We conclude that p21ras mediates insulin- and PDGF-induced activation of ERK2.	CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND	University of London; Institute of Cancer Research - UK	DEVRIESSMITS, AMM (corresponding author), UNIV UTRECHT,PHYSIOL CHEM LAB,VONDELLAAN 24A,3521 GG UTRECHT,NETHERLANDS.							ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BLACKSHEAR PJ, 1991, J BIOL CHEM, V266, P10946; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; DAVISON AJ, 1989, J MOL BIOL, V210, P749, DOI 10.1016/0022-2836(89)90107-1; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; Mackett M., 1985, DNA CLONING PRACTICA, P191; MEDEMA RH, 1991, J BIOL CHEM, V266, P21186; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; OSTEROP APR, IN PRESS J BIOL CHEM; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SJOLANDER A, 1991, P NATL ACAD SCI USA, V88, P7908, DOI 10.1073/pnas.88.18.7908; STACEY DW, 1991, ONCOGENE, V6, P2297; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0	23	387	388	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 18	1992	357	6379					602	604		10.1038/357602a0	http://dx.doi.org/10.1038/357602a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HZ112	1608472				2022-12-01	WOS:A1992HZ11200058
J	FEUTREN, G; MIHATSCH, MJ				FEUTREN, G; MIHATSCH, MJ			RISK-FACTORS FOR CYCLOSPORINE-INDUCED NEPHROPATHY IN PATIENTS WITH AUTOIMMUNE-DISEASES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEPHROTOXICITY; TRANSPLANTS; CREATININE; CHILDREN; THERAPY; RATS	Background. Cyclosporine is an immunosuppressive drug that is used to treat patients with autoimmune disease as well a's patients who have received allografts. The drug can cause renal damage, but the incidence of and risk factors for nephropathy in patients treated with cyclosporine for autoimmune or inflammatory diseases are not known. Methods. We analyzed data from renal biopsies performed in 192 patients (129 adults and 63 children) who had been treated with cyclosporine for insulin-dependent diabetes mellitus of recent onset, uveitis, psoriasis, Sjogren's syndrome, or polychondritis. The mean (+/-SD) initial dose of cyclosporine was 8.2+/-2.8 mg per kilogram of body weight per day, and the duration of treatment was 4 to 39 months (median, 13). Results. Forty-one patients (37 adults and 4 children) had cyclosporine-induced nephropathy, defined as at least moderate focal interstitial fibrosis with tubular atrophy, arteriolar alterations, or both. As compared with patients in whom nephropathy did not develop, these patients received a larger initial dose of cyclosporine (9.3+/-2.8 vs. 8.0+/-2.8 mg per kilogram per day), had a larger maximal increase in the serum creatinine concentration above base-line values (101+/-77 percent vs. 50+/-33 percent), and were older (31+/-13 vs. 23+/-12 years). These three variables were shown by multivariate logistic-regression analysis to be significant risk factors. The duration of the elevation in the serum creatinine concentration and the occurrence of elevated blood pressure were not additional risk factors. Conclusions. Nephropathy is an important potential effect of cyclosporine therapy. The risk of its development in patients with autoimmune diseases who are treated with cyclosporine can be minimized by allowing a dose no higher than 5 mg per kilogram per day and avoiding increases in serum creatinine of more than 30 percent above the patient's base-line value.	UNIV BASEL,INST PATHOL,CH-4051 BASEL,SWITZERLAND	University of Basel	FEUTREN, G (corresponding author), SANDOZ PHARMA LTD,DEPT CLIN RES IMMUNOL,CH-4002 BASEL,SWITZERLAND.							[Anonymous], 1988, DIABETES, V37, P1574, DOI 10.2337/diabetes.37.11.15742903105; ANTIGNAC C, 1989, KIDNEY INT, V35, P1336, DOI 10.1038/ki.1989.132; ASSAN R, 1990, DIABETES, V39, P768, DOI 10.2337/diabetes.39.7.768; BERTANI T, 1991, KIDNEY INT, V40, P243, DOI 10.1038/ki.1991.206; BOUGNERES PF, 1988, NEW ENGL J MED, V318, P663, DOI 10.1056/NEJM198803173181103; DIETERLE A, 1990, TRANSPLANTATION, V49, P1093, DOI 10.1097/00007890-199006000-00013; Donatsch P, 1981, J Immunoassay, V2, P19, DOI 10.1080/01971528108062989; EKNOYAN G, 1988, DISEASES KIDNEY, P2191; FEUTREN G, 1988, TRANSPLANT P, V20, P356; FEUTREN G, 1991, LANCET, V38, P1017; GILBERT SC, 1989, J AM ACAD DERMATOL, V21, P470, DOI 10.1016/S0190-9622(89)70209-7; HOYER PF, 1984, CLIN NEPHROL, V22, P68; KLAHR S, 1988, NEW ENGL J MED, V318, P1657; MIESCHER PA, 1987, KLIN WOCHENSCHR, V65, P727, DOI 10.1007/BF01736809; MIHATSCH MJ, 1986, PROG ALLERGY, V38, P447; MIHATSCH MJ, 1983, TRANSPLANT P, V15, P2821; MIHATSCH MJ, 1988, KLIN WOCHENSCHR, V66, P43, DOI 10.1007/BF01713009; MOSS NG, 1985, P NATL ACAD SCI USA, V82, P8222, DOI 10.1073/pnas.82.23.8222; MYERS BD, 1988, TRANSPLANTATION, V46, P694, DOI 10.1097/00007890-198811000-00014; MYERS BD, 1984, NEW ENGL J MED, V311, P699, DOI 10.1056/NEJM198409133111103; PALESTINE AG, 1986, NEW ENGL J MED, V314, P1293, DOI 10.1056/NEJM198605153142005; SVENSON K, 1986, ARCH INTERN MED, V146, P2007, DOI 10.1001/archinte.146.10.2007; THOMSON SC, 1989, J CLIN INVEST, V83, P960, DOI 10.1172/JCI113982; TOMLANOVICH S, 1986, AM J KIDNEY DIS, V8, P332, DOI 10.1016/S0272-6386(86)80107-X; 1988, SAS USERS GUIDE STAT; 1990, BR J DERMATOL S36, V122, P95	26	417	426	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 18	1992	326	25					1654	1660		10.1056/NEJM199206183262502	http://dx.doi.org/10.1056/NEJM199206183262502			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY628	1588978	Bronze			2022-12-01	WOS:A1992HY62800002
J	FISHER, JC				FISHER, JC			THE SILICONE CONTROVERSY - WHEN WILL SCIENCE PREVAIL	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CONNECTIVE-TISSUE DISEASE; BREAST IMPLANTS; AUGMENTATION; MAMMOPLASTY; CANCER				FISHER, JC (corresponding author), UNIV CALIF SAN DIEGO,MED CTR,SAN DIEGO,CA 92103, USA.							ANDERSON N, 1988, 1988 M FDA ADV PAN G; BALCH CM, 1991, 1991 FDA ADV PAN GEN; BERKEL H, 1992, NEW ENGL J MED, V326, P1649, DOI 10.1056/NEJM199206183262501; CALNAN KC, 1992, SILICONE GELE BREAST; DEAPEN DM, 1986, PLAST RECONSTR SURG, V77, P361, DOI 10.1097/00006534-198603000-00001; GAYOU RM, 1979, PLAST RECONSTR SURG, V63, P700, DOI 10.1097/00006534-197905000-00015; HAUSNER RJ, 1978, PLAST RECONSTR SURG, V62, P381, DOI 10.1097/00006534-197809000-00007; HEGGERS JP, 1992, FEB TOX FOR  WASH; IVERSON R, 1990, PATIENT SURVEY COMMI; JENNINGS DA, 1991, ANN PLAS SURG, V27, P553, DOI 10.1097/00000637-199112000-00007; OPPENHEIMER BS, 1955, CANCER RES, V15, P333; RUDOLPH R, 1978, PLAST RECONSTR SURG, V62, P185, DOI 10.1097/00006534-197808000-00006; SERGENT JS, 1992, SILICONE GEL BREAST; SILVERSTEIN MJ, 1988, ARCH SURG-CHICAGO, V123, P681; STAHL DL, 1992, 1992 FDA ADV PAN GEN; VANNUNEN SA, 1982, ARTHRITIS RHEUM, V25, P694, DOI 10.1002/art.1780250613; WEISMAN MH, 1988, PLAST RECONSTR SURG, V82, P626, DOI 10.1097/00006534-198810000-00011; 1991, REPORT BREAST IMPLAN	18	67	67	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 18	1992	326	25					1696	1698		10.1056/NEJM199206183262511	http://dx.doi.org/10.1056/NEJM199206183262511			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY628	1588986				2022-12-01	WOS:A1992HY62800011
J	GALAN, JE; PACE, J; HAYMAN, MJ				GALAN, JE; PACE, J; HAYMAN, MJ			INVOLVEMENT OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR IN THE INVASION OF CULTURED-MAMMALIAN-CELLS BY SALMONELLA-TYPHIMURIUM	NATURE			English	Article							ESCHERICHIA-COLI; IDENTIFICATION; INFECTION; CLONING	SALMONELLA infection continues to be a major world-wide health problem 1. One essential pathogenic feature common to all Salmonella is their ability to penetrate the cells of the intestinal epithelium which are normally non-phagocytic 2. The internalization of Salmonella into mammalian cells is thought to be a receptor-mediated phenomenon and the invasion of cultured epithelial cells depends on several Salmonella genes, but nothing is known about the host determinants participating in this interaction 3-6. Protein tyrosine phosphorylation follows stimulation of many cell-surface receptors to initiate signal transduction pathways that stimulate cellular responses 7. We report here that invasion of cultured Henle-407 cells by Salmonella typhimurium induces the tyrosine phosphorylation of the epidermal growth factor (EGF) receptor. In contrast, an isogenic strain of S. typhimurium that is defective in invasion owing to a mutation in the invA gene is unable to induce such phosphorylation. Addition of EGF to cultured Henle-407 cells allowed the internalization of the invasion-defective S. typhimurium invA mutant although it did not cause the internalization of an adherent, but non-invasive, strain of Escherichia coli. This result indicates that stimulation of the EGF receptor is involved in the invasion of cultured Henle-407 cells by S. typhimurium.			GALAN, JE (corresponding author), SUNY STONY BROOK,SCH MED,DEPT MICROBIOL,STONY BROOK,NY 11794, USA.							CHALKER RB, 1988, REV INFECT DIS, V10, P111; CHENEY CP, 1980, INFECT IMMUN, V28, P1019; ELSINGHORST EA, 1989, P NATL ACAD SCI USA, V86, P5173, DOI 10.1073/pnas.86.13.5173; EPPSTEIN DA, 1985, NATURE, V318, P663, DOI 10.1038/318663a0; FINLAY BB, 1988, MOL MICROBIOL, V2, P757, DOI 10.1111/j.1365-2958.1988.tb00087.x; GALAN JE, 1989, P NATL ACAD SCI USA, V86, P6383, DOI 10.1073/pnas.86.16.6383; GALAN JE, IN PRESS J BACT; GINOCCHIO C, IN PRESS P NATN ACAD; HOISETH SK, 1981, NATURE, V291, P238, DOI 10.1038/291238a0; ISBERG RR, 1991, SCIENCE, V252, P934, DOI 10.1126/science.1674624; KADOWAKI T, 1986, J BIOL CHEM, V261, P6141; KAMPS MP, 1988, ONCOGENE, V2, P305; LEE EB, 1990, ONCOGENE, V5, P1165; MOOLENAAR WH, 1984, J BIOL CHEM, V259, P8066; NAIR N, 1992, MOL CELL BIOL, V12, P2010, DOI 10.1128/MCB.12.5.2010; RIJKEN PJ, 1991, J CELL SCI, V100, P491; TAKEUCHI A, 1967, AM J PATHOL, V50, P109; Todaro G J, 1990, Semin Cancer Biol, V1, P257; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K	19	182	186	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 18	1992	357	6379					588	589		10.1038/357588a0	http://dx.doi.org/10.1038/357588a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HZ112	1608468				2022-12-01	WOS:A1992HZ11200053
J	HOLMVANG, G				HOLMVANG, G			USEFULNESS OF MRI IN AORTIC DISSECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Note																			0	0	0	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 18	1992	326	25					1670	1670						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY628	1588980				2022-12-01	WOS:A1992HY62800005
J	KESSLER, DA				KESSLER, DA			THE BASIS OF THE FDAS DECISION ON BREAST IMPLANTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											KESSLER, DA (corresponding author), US FDA,ROCKVILLE,MD 20857, USA.								0	251	254	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 18	1992	326	25					1713	1715		10.1056/NEJM199206183262525	http://dx.doi.org/10.1056/NEJM199206183262525			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY628	1309171				2022-12-01	WOS:A1992HY62800032
J	LOMAS, DA; EVANS, DL; FINCH, JT; CARRELL, RW				LOMAS, DA; EVANS, DL; FINCH, JT; CARRELL, RW			THE MECHANISM OF Z-ALPHA-1-ANTITRYPSIN ACCUMULATION IN THE LIVER	NATURE			English	Article							ALPHA-1-ANTITRYPSIN; PURIFICATION; DEFICIENCY; DAMAGE; PLASMA	MOST northern Europeans have only the normal M form of the plasma protease inhibitor alpha-1-antitrypsin, but some 4% are heterozygotes for the Z deficiency variant 1. For reasons that have not been well-understood, the Z mutation results in a blockage in the final stage of processing of antitrypsin in the liver 2 such that in the Z homozygote only 15% of the protein is secreted into the plasma.The 85% of the alpha-1-antitrypsin that is not secreted accumulates in the endoplasmic reticulum of the hepatocyte; much of it is degraded but the remainder aggregates to form insoluble intracellular inclusions. These inclusions are associated with hepatocellular damage, and 10% of newborn Z homozygotes develop liver disease which often leads to a fatal childhood cirrhosis. Here we demonstrate the molecular pathology underlying this accumulation and describe how the Z mutation in antitrypsin results in a unique molecular interaction between the reactive centre loop of one molecule and the gap in the A-sheet of another. This loop-sheet polymerization of Z antitrypsin occurs spontaneously at 37-degrees-C and is completely blocked by the insertion of a specific peptide into the A-sheet of the antitrypsin molecule. Z antitrypsin polymerized in vitro has identical properties and ultrastructure to the inclusions isolated from hepatocytes of a Z homozygote. The concentration and temperature dependence of this loop-sheet polymerization has implications for the management of the liver disease of the newborn Z homozygote.	MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	MRC Laboratory Molecular Biology	LOMAS, DA (corresponding author), UNIV CAMBRIDGE,DEPT HAEMATOL,CAMBRIDGE,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BATHURST IC, 1984, FEBS LETT, V177, P179, DOI 10.1016/0014-5793(84)81279-X; CARLSON JA, 1989, J CLIN INVEST, V83, P1183, DOI 10.1172/JCI113999; CARRELL RW, 1991, NATURE, V353, P576, DOI 10.1038/353576a0; CARRELL RW, 1986, J CLIN INVEST, V78, P1427, DOI 10.1172/JCI112731; COX DW, 1986, FEBS LETT, V205, P255, DOI 10.1016/0014-5793(86)80908-5; CURIEL DT, 1989, J BIOL CHEM, V264, P13939; ERIKSSON S, 1975, NEW ENGL J MED, V292, P176, DOI 10.1056/NEJM197501232920403; EVANS DLI, 1991, THESIS U CAMBRIDGE; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; LAURELL CB, 1975, EUR J BIOCHEM, V57, P107, DOI 10.1111/j.1432-1033.1975.tb02281.x; LAURELL CB, 1963, SCAND J CLIN LAB INV, V15, P132, DOI 10.3109/00365516309051324; LE AQ, 1992, J BIOL CHEM, V267, P1072; SCHULZE AJ, 1990, EUR J BIOCHEM, V194, P51, DOI 10.1111/j.1432-1033.1990.tb19425.x; SEYAMA K, 1991, J BIOL CHEM, V266, P12627; STEIN P, 1991, J MOL BIOL, V221, P615, DOI 10.1016/0022-2836(91)80076-7	15	839	882	0	41	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 18	1992	357	6379					605	607		10.1038/357605a0	http://dx.doi.org/10.1038/357605a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HZ112	1608473				2022-12-01	WOS:A1992HZ11200059
J	MALLABIABARRENA, A; FRESNO, M; ALARCON, B				MALLABIABARRENA, A; FRESNO, M; ALARCON, B			AN ENDOPLASMIC-RETICULUM RETENTION SIGNAL IN THE CD3-EPSILON CHAIN OF THE T-CELL RECEPTOR	NATURE			English	Article							ANTIGEN RECEPTOR; CD3 COMPLEX; EPSILON-SUBUNITS; DEGRADATION; PROTEINS; LOCALIZATION	ISOLATED polypeptide chains of the T-cell antigen receptor complex are degraded or retained in the endoplasmic reticulum (ER) 1-4. Assembly of the multisubunit complex allows the individual chains to escape retention in the ER and to be expressed on the cell surface. We engineered a series of deletions in the CD3-epsilon subunit of the human T-cell receptor in order to find the sequences responsible for its retention in the ER. Deletion of amino acids 171 to 180 in the cytosolic tail resulted in the cell-surface expression of the isolated chain. This sequence also promotes retention when it is appended to CD4, a plasma membrane protein. Mutagenesis of the 10-amino-acid CD3-epsilon sequence established that the tyrosine and serine residues are important for ER retention. This and other ER retention signals must be hidden when a complete T-cell receptor complex is assembled in order to allow its expression on the cell surface.	UNIV AUTONOMA MADRID, CSIC, CTR BIOL MOLEC, CANTOBLANCO, E-28049 MADRID, SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)			Alarcon, Balbino/N-9648-2016; SANZ, MAGDALENA/L-4825-2013	Alarcon, Balbino/0000-0001-7820-1070; SANZ, MAGDALENA/0000-0002-3106-2680; Fresno Escudero, Manuel/0000-0002-9223-5477				ALARCON B, 1988, J BIOL CHEM, V263, P2953; ALARCON B, 1991, EMBO J, V10, P903, DOI 10.1002/j.1460-2075.1991.tb08023.x; ASHWELL JD, 1990, ANNU REV IMMUNOL, V8, P139, DOI 10.1146/annurev.immunol.8.1.139; BLUMBERG RS, 1990, P NATL ACAD SCI USA, V87, P7220, DOI 10.1073/pnas.87.18.7220; BONIFACINO JS, 1991, EMBO J, V10, P2783, DOI 10.1002/j.1460-2075.1991.tb07827.x; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; CARRERA AC, 1987, EUR J IMMUNOL, V17, P179, DOI 10.1002/eji.1830170205; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; HALL C, 1991, INT IMMUNOL, V3, P359, DOI 10.1093/intimm/3.4.359; INOUYE S, 1991, DIRECTED MUTAGENESIS, P71; KAPPES DJ, 1991, P NATL ACAD SCI USA, V88, P10619, DOI 10.1073/pnas.88.23.10619; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NASH RA, 1991, IMMUNOGENETICS, V33, P396, DOI 10.1007/BF00216700; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; PAGANO RE, 1989, METHOD CELL BIOL, V29, P75; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; SALMERON A, 1991, J IMMUNOL, V147, P3047; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TERASAKI M, 1984, CELL, V38, P101, DOI 10.1016/0092-8674(84)90530-0; WEISSMAN AM, 1988, P NATL ACAD SCI USA, V85, P9709, DOI 10.1073/pnas.85.24.9709; WILEMAN T, 1990, J CELL BIOL, V110, P973, DOI 10.1083/jcb.110.4.973	24	66	66	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 18	1992	357	6379					593	596		10.1038/357593a0	http://dx.doi.org/10.1038/357593a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HZ112	1535117				2022-12-01	WOS:A1992HZ11200055
J	MCLAUGHLIN, SK; MCKINNON, PJ; MARGOLSKEE, RF				MCLAUGHLIN, SK; MCKINNON, PJ; MARGOLSKEE, RF			GUSTDUCIN IS A TASTE-CELL-SPECIFIC G-PROTEIN CLOSELY RELATED TO THE TRANSDUCINS	NATURE			English	Article							AMINO-ACID SEQUENCE; CYCLIC-GMP PHOSPHODIESTERASE; GTP-BINDING PROTEIN; ROD OUTER SEGMENTS; ALPHA-SUBUNIT; ADENYLATE-CYCLASE; INHIBITORY SUBUNIT; ADENOSINE RECEPTOR; ELONGATION-FACTORS; PERTUSSIS TOXIN	A novel G protein alpha-subunit (alpha-gustducin) has been identified and cloned from taste tissue. Alpha-gustducin messenger RNA is expressed in taste buds of all taste papillae (circumvallate, foliate and fungiform); it is not expressed in non-sensory portions of the tongue, nor is it expressed in the other tissues examined. Alpha-gustducin most closely resembles the transducins (the rod and cone photoreceptor G proteins), suggesting that gustducin's role in taste transduction is analogous to that of transducin in light transduction.	ROCHE RES CTR, ROCHE INST MOLEC BIOL, NUTLEY, NJ 07110 USA	Roche Holding				Margolskee, Robert/0000-0002-9572-2887				AKABAS MH, 1988, SCIENCE, V242, P1047, DOI 10.1126/science.3194756; Ausubel F.M., 1989, SHORT PROTOCOLS MOL; AVENET P, 1987, J MEMBRANE BIOL, V97, P223, DOI 10.1007/BF01869225; AVENET P, 1989, J MEMBRANE BIOL, V112, P1, DOI 10.1007/BF01871158; AVENET P, 1988, NATURE, V331, P351, DOI 10.1038/331351a0; BEIDLER LM, 1970, CIBA F S, P51; BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; FINDLAY JBC, 1986, BIOCHEM J, V238, P625, DOI 10.1042/bj2380625; FUNG BKK, 1989, BIOCHEMISTRY-US, V28, P3133, DOI 10.1021/bi00434a003; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.biochem.56.1.615; GRAZIADEI PPC, 1970, 2ND S OR SENS PERC, P5; GROVERJOHNSON N, 1976, CELL TISSUE RES, V169, P395; GUTH L, 1963, EXP NEUROL, V8, P336, DOI 10.1016/0014-4886(63)90085-2; HALLIDAY KR, 1984, J CYCLIC NUCL PROT, V9, P435; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HECK GL, 1984, SCIENCE, V223, P403, DOI 10.1126/science.6691151; JONES DT, 1989, SCIENCE, V244, P790, DOI 10.1126/science.2499043; JONES DT, 1987, J BIOL CHEM, V262, P14241; KINNAMON SC, 1988, P NATL ACAD SCI USA, V85, P7023, DOI 10.1073/pnas.85.18.7023; KINNAMON SC, 1988, J GEN PHYSIOL, V91, P351, DOI 10.1085/jgp.91.3.351; KINNAMON SC, 1988, TRENDS NEUROSCI, V11, P491, DOI 10.1016/0166-2236(88)90010-0; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; Kuhn H, 1984, PROGR RETINAL RES, V3, P123; KURIHARA K, 1972, BIOCHEM BIOPH RES CO, V48, P30, DOI 10.1016/0006-291X(72)90339-7; LAW JS, 1982, RES COMMUN CHEM PATH, V38, P439; LEREA CL, 1986, SCIENCE, V234, P77, DOI 10.1126/science.3529395; LOCHRIE MA, 1985, SCIENCE, V228, P96, DOI 10.1126/science.3856323; LUGO DI, 1989, MOL ENDOCRINOL, V3, P1313, DOI 10.1210/mend-3-8-1313; MEDYNSKI DC, 1985, P NATL ACAD SCI USA, V82, P4311, DOI 10.1073/pnas.82.13.4311; NATHANS J, 1983, CELL, V34, P807, DOI 10.1016/0092-8674(83)90537-8; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; NAVON SE, 1988, J BIOL CHEM, V263, P489; OVCHINNIKOV YA, 1987, FEBS LETT, V223, P169, DOI 10.1016/0014-5793(87)80530-6; OVCHINNIKOV YA, 1986, FEBS LETT, V201, P237, DOI 10.1016/0014-5793(86)80616-0; PANG IH, 1990, J BIOL CHEM, V265, P18707; PRICE S, 1973, NATURE, V241, P54, DOI 10.1038/241054a0; RAPORT CJ, 1989, J BIOL CHEM, V264, P7122; REUTTER K, 1971, Z ZELLFORSCH MIK ANA, V120, P280, DOI 10.1007/BF00335540; ROPER SD, 1989, ANNU REV NEUROSCI, V12, P329, DOI 10.1146/annurev.ne.12.030189.001553; Sambrook J, 1989, MOL CLONING; SCHIFFMAN SS, 1983, P NATL ACAD SCI-BIOL, V80, P6136, DOI 10.1073/pnas.80.19.6136; SCHIFFMAN SS, 1985, PHARMACOL BIOCHEM BE, V22, P195, DOI 10.1016/0091-3057(85)90377-6; SCHIFFMAN SS, 1986, PHARMACOL BIOCHEM BE, V24, P429, DOI 10.1016/0091-3057(86)90536-8; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SPICKOFSKY N, 1992, ASS CHEMORECEPTION S, V14, P192; SPIELMAN AI, 1989, CHEM SENSES, V14, P841, DOI 10.1093/chemse/14.6.841; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; STRATHMANN M, 1989, P NATL ACAD SCI USA, V86, P7407, DOI 10.1073/pnas.86.19.7407; STRIEM BJ, 1989, BIOCHEM J, V260, P121, DOI 10.1042/bj2600121; STRIEM BJ, 1990, CHEM SENSES, V15, P529, DOI 10.1093/chemse/15.5.529; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; TANABE T, 1985, NATURE, V315, P242, DOI 10.1038/315242a0; TONOSAKI K, 1988, NATURE, V331, P354, DOI 10.1038/331354a0; UI M, 1984, ADV CYCLIC NUCL PROT, V17, P145; VANDOP C, 1984, J BIOL CHEM, V259, P23; WENSEL TG, 1990, BIOCHEMISTRY-US, V29, P2155, DOI 10.1021/bi00460a028; Whiteside B, 1926, J COMP NEUROL, V40, P33, DOI 10.1002/cne.900400105; YATSUNAMI K, 1985, P NATL ACAD SCI USA, V82, P4316, DOI 10.1073/pnas.82.13.4316	60	536	563	2	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 18	1992	357	6379					563	569		10.1038/357563a0	http://dx.doi.org/10.1038/357563a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HZ112	1608467				2022-12-01	WOS:A1992HZ11200044
J	MILLER, DJ; MACEK, MB; SHUR, BD				MILLER, DJ; MACEK, MB; SHUR, BD			COMPLEMENTARITY BETWEEN SPERM SURFACE BETA-1,4-GALACTOSYL-TRANSFERASE AND EGG-COAT ZP3 MEDIATES SPERM EGG BINDING	NATURE			English	Article							O-LINKED OLIGOSACCHARIDES; ZONA PELLUCIDA; MOUSE SPERM; ACROSOME REACTION; RECEPTOR ACTIVITY; GALACTOSYLTRANSFERASE; IDENTIFICATION; PROTEIN; FERTILIZATION; GLYCOPROTEINS	DESPITE its importance, the molecular basis of mammalian gamete recognition has remained unclear. The enzyme beta-1,4-galactosyltransferase (Gal-transferase) has been viewed traditionally as a biosynthetic component of the Golgi complex, but is also found on the surface of many cells where it can bind its specific glycoside substrate on adjacent cell surfaces or in the extracellular matrix 1-3. In mouse it has been suggested that Gal-transferase on the sperm head mediates fertilization by binding oligosaccharide residues in the egg coat, or zona pellucida 4-9, and that the ability of the zona pellucida to bind sperm is conferred by oligosaccharides of the ZP3 glycoprotein 10,13. However, it has not been confirmed that Gal-transferase and ZP3 are in fact complementary gamete receptors whose interaction mediates sperm-eg binding. Here we show that mouse sperm Gal-transferase specifically recognizes those oligosaccharides on ZP3 that have sperm-binding activity, but does not interact with other zona pellucida glycoproteins. In contrast, all zona pellucida glycoproteins are recognized by non-sperm Gal-transferase, demonstrating a more stringent substrate specificity for the sperm enzyme. This interaction is required for sperm-egg binding because blocking or removing the binding site for Gal-transferase on ZP3 inhibits its ability to bind sperm. After the release of the sperm acrosome, the transferase relocalizes to a new membrane domain where it can no longer bind to ZP3, which is consistent with the inability of acrosome-reacted sperm to bind ZP3 or to initiate binding to the zona pellucida. Following fertilization, ZP3 is modified by egg cortical granule secretions so that it loses sperm receptor activity, which can be accounted for by a selective loss of its binding site for sperm Gal-transferase. These results show that sperm surface beta-1,4-galactosyltransferase and the egg-coat glycoprotein ZP3 are complementary adhesion molecules that mediate primary gamete binding in the mouse.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,1515 HOLCOMBE BLVD,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center			Miller, David J/ABC-2156-2020	Miller, David J/0000-0001-7147-5546				BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; BEER D, 1985, HELV CHIM ACTA, V68, P2254, DOI 10.1002/hlca.19850680821; BEGOVAC PC, 1991, J CELL BIOL, V113, P637, DOI 10.1083/jcb.113.3.637; BENAU DA, 1988, BIOL REPROD, V39, P235, DOI 10.1095/biolreprod39.2.235; BERGER T, 1989, J REPROD FERTIL, V86, P559, DOI 10.1530/jrf.0.0860559; BLEIL JD, 1988, DEV BIOL, V128, P376, DOI 10.1016/0012-1606(88)90299-0; BLEIL JD, 1990, P NATL ACAD SCI USA, V87, P5563, DOI 10.1073/pnas.87.14.5563; BLEIL JD, 1988, P NATL ACAD SCI USA, V85, P6778, DOI 10.1073/pnas.85.18.6778; BLEIL JD, 1980, CELL, V20, P873, DOI 10.1016/0092-8674(80)90334-7; BLEIL JD, 1986, J CELL BIOL, V102, P1363, DOI 10.1083/jcb.102.4.1363; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; ENDO Y, 1987, DEV BIOL, V119, P210, DOI 10.1016/0012-1606(87)90222-3; FAYRER-HOSKEN R A, 1987, Biology of Reproduction, V36, P53; FAYRERHOSKEN RA, 1991, MOL REPROD DEV, V28, P74, DOI 10.1002/mrd.1080280112; FLORMAN HM, 1984, DEV BIOL, V106, P243, DOI 10.1016/0012-1606(84)90079-4; FLORMAN HM, 1985, CELL, V41, P313, DOI 10.1016/0092-8674(85)90084-4; HUMPHREYSBEHER MG, 1990, FERTIL STERIL, V54, P133; JONES R, 1988, DEVELOPMENT, V102, P781; LAMBERT CC, 1989, DEVELOPMENT, V105, P415; LEYTON L, 1989, J CELL BIOL, V108, P2163, DOI 10.1083/jcb.108.6.2163; LEYTON L, 1989, CELL, V57, P1123, DOI 10.1016/0092-8674(89)90049-4; LOPEZ LC, 1985, J CELL BIOL, V101, P1501, DOI 10.1083/jcb.101.4.1501; LOPEZ LC, 1987, J CELL BIOL, V105, P1663, DOI 10.1083/jcb.105.4.1663; MACEK MB, 1991, DEV BIOL, V147, P440, DOI 10.1016/0012-1606(91)90301-I; MILLER DJ, 1992, COMP SPERMATOLOGY 20, P569; MORI E, 1991, BIOCHEMISTRY-US, V30, P2078, DOI 10.1021/bi00222a012; NEILL JM, 1988, GAMETE RES, V20, P459, DOI 10.1002/mrd.1120200407; NETER J, 1974, APPLIED LINEAR STATI; PASSANITI A, 1990, CANCER RES, V50, P7261; PRODY GA, 1985, J EXP ZOOL, V235, P335, DOI 10.1002/jez.1402350304; ROSEMAN S, 1970, CHEM PHYS LIPIDS, V5, P270, DOI 10.1016/0009-3084(70)90024-1; ROTH S, 1973, Q REV BIOL, V48, P541, DOI 10.1086/407816; RUIZBRAVO N, 1986, DEV BIOL, V118, P202, DOI 10.1016/0012-1606(86)90088-6; SCHACHTER H, 1986, BIOCHEM CELL BIOL, V64, P163, DOI 10.1139/o86-026; SHUR B D, 1991, Glycobiology, V1, P563, DOI 10.1093/glycob/1.6.563; SHUR BD, 1982, J CELL BIOL, V95, P574, DOI 10.1083/jcb.95.2.574; SHUR BD, 1988, J BIOL CHEM, V263, P17706; SULLIVAN R, 1989, BIOCHEM BIOPH RES CO, V162, P184, DOI 10.1016/0006-291X(89)91979-7; WASSARMAN PM, 1988, ANNU REV BIOCHEM, V57, P415, DOI 10.1146/annurev.bi.57.070188.002215	39	417	429	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 18	1992	357	6379					589	593		10.1038/357589a0	http://dx.doi.org/10.1038/357589a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HZ112	1608469	Bronze			2022-12-01	WOS:A1992HZ11200054
J	MISSIAEN, L; DESMEDT, H; DROOGMANS, G; CASTEELS, R				MISSIAEN, L; DESMEDT, H; DROOGMANS, G; CASTEELS, R			CA2+ RELEASE INDUCED BY INOSITOL 1,4,5-TRISPHOSPHATE IS A STEADY-STATE PHENOMENON CONTROLLED BY LUMINAL CA2+ IN PERMEABILIZED CELLS	NATURE			English	Article							SMOOTH-MUSCLE CELLS; CALCIUM RELEASE; CA-2+ RELEASE; RAT; STORES; TRISPHOSPHATE; PHOSPHATES; KINETICS; ENTRY	Low concentrations of inositol 1,4,5-trisphosphate (InsP3) evoke a very rapid mobilization of intracellular Ca2+ stores in many cell types, which can be followed by a further, much slower efflux 1-8. Two explanations have been suggested for this biphasic release. The first proposes that the Ca2+ stores vary in their sensitivity to InsP3, and each store releases either its entire contents or nothing 2,5,7 (all-or-none release); the second proposes instead that the stores are uniformly sensitive to the effects of InsP3, but that they can release only a fraction of their Ca2+ before their sensitivity is somehow attenuated 6,8-11 (steady-state release). Experiments using purified InsP3 receptor molecules reconstituted into lipid vesicles have shown heterogeneity of the receptors in their response to InsP3 under conditions in which the total Ca2+ level at both sides of the receptor is held constant 7. We now report that in permeabilized A7r5 smooth-muscle cells incubated in Ca2+-free medium, the amount of Ca-45(2+) remaining in the stores after the rapid transient phase of release is independent of their initial Ca2+ levels, indicating that partially depleted stores are less sensitive to InsP3. Moreover, if the stores are reloaded with Ca-40(2+) after the first stimulus, reapplication of the same low concentration of InsP3 will release further Ca-45(2+). This recovery of InsP3 sensitivity is almost complete. Under these conditions, Ca2+ release must thus occur by a steady-state mechanism, in which the decreasing Ca2+ content of the stores slows down further release.			MISSIAEN, L (corresponding author), CATHOLIC UNIV LEUVEN, FYSIOL LAB, CAMPUS GASTHUISBERG, HERESTR 49, B-3000 LOUVAIN, BELGIUM.							BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; CHAMPEIL P, 1989, J BIOL CHEM, V264, P17665; DANOFF SK, 1991, P NATL ACAD SCI USA, V88, P2951, DOI 10.1073/pnas.88.7.2951; FERRIS CD, 1992, NATURE, V356, P350, DOI 10.1038/356350a0; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; GHOSH TK, 1989, NATURE, V340, P236, DOI 10.1038/340236a0; HILL TD, 1988, SCIENCE, V242, P1176, DOI 10.1126/science.2847317; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; IRVINE RF, 1991, BIOESSAYS, V13, P419, DOI 10.1002/bies.950130810; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; MAEDA N, 1991, J BIOL CHEM, V266, P1109; MENNITI FS, 1991, J BIOL CHEM, V266, P13646; MEYER T, 1990, BIOCHEMISTRY-US, V29, P32, DOI 10.1021/bi00453a004; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; MISSIAEN L, 1990, J PHYSIOL-LONDON, V427, P171, DOI 10.1113/jphysiol.1990.sp018166; MORRIS AJ, 1988, BIOCHEM J, V251, P157, DOI 10.1042/bj2510157; MUALLEM S, 1989, J BIOL CHEM, V264, P205; NAKAGAWA T, 1991, P NATL ACAD SCI USA, V88, P6244, DOI 10.1073/pnas.88.14.6244; NUNN DL, 1992, MOL PHARMACOL, V41, P115; OLDERSHAW KA, 1991, BIOCHEM J, V278, P705, DOI 10.1042/bj2780705; PARKER I, 1990, SCIENCE, V250, P977, DOI 10.1126/science.2237441; PARKER I, 1991, P ROY SOC B-BIOL SCI, V246, P269, DOI 10.1098/rspb.1991.0154; PERES A, 1990, FEBS LETT, V275, P213, DOI 10.1016/0014-5793(90)81474-3; SATOH T, 1990, J CELL BIOL, V111, P615, DOI 10.1083/jcb.111.2.615; STERN MD, 1992, CELL CALCIUM, V13, P183, DOI 10.1016/0143-4160(92)90046-U; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; TAYLOR CW, 1990, BIOCHEM J, V266, P189, DOI 10.1042/bj2660189; TREGEAR RT, 1991, P ROY SOC B-BIOL SCI, V243, P263, DOI 10.1098/rspb.1991.0040	32	250	252	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 18	1992	357	6379					599	602		10.1038/357599a0	http://dx.doi.org/10.1038/357599a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HZ112	1608471				2022-12-01	WOS:A1992HZ11200057
J	PETERSON, M; MILLER, J				PETERSON, M; MILLER, J			ANTIGEN PRESENTATION ENHANCED BY THE ALTERNATIVELY SPLICED INVARIANT CHAIN GENE-PRODUCT P41	NATURE			English	Article							H-2-RESTRICTED T-CELLS; II MHC MOLECULES; B-CELL; RECOGNITION; HYBRIDOMAS; TRANSPORT; PEPTIDE; BINDING; ENCODES; REGIONS	DURING biosynthesis, class II molecules of the major histocompatibility complex are associated with a nonpolymorphic protein called invariant chain, Ii, which facilitates folding of class II molecules and their exit from the endoplasmic reticulum 1-4, interferes with their association with peptide 5,6 and directs their post-Golgi transport (refs 7-9). If Ii blocks class II loading with endogenous antigens in the endoplasmic reticulum and/or directs class II molecules to the exogenous antigen-loading compartment, then the co-expression of Ii should enhance the ability of class II molecules to present exogenous antigens to T cells. But data supporting a role for Ii in class II-restricted antigen presentation are controversial 1,10-13. Here we show that Ii can facilitate exogenous antigen presentation for a subset of antigens. Although all known functions of li have been ascribed to the principal form of Ii, p31, we find that in most cases antigen presentation is facilitated only by the alternatively spliced, minor form of Ii, p41.			PETERSON, M (corresponding author), UNIV CHICAGO, DEPT MOLEC GENET & CELL BIOL, 920 E 58TH ST, CHICAGO, IL 60637 USA.							ALLEN PM, 1984, P NATL ACAD SCI-BIOL, V81, P2489, DOI 10.1073/pnas.81.8.2489; ANDERSON MS, 1992, P NATL ACAD SCI USA, V89, P2282, DOI 10.1073/pnas.89.6.2282; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BERTOLINO P, 1991, INT IMMUNOL, V3, P435, DOI 10.1093/intimm/3.5.435; BLUM JS, 1988, P NATL ACAD SCI USA, V85, P3975, DOI 10.1073/pnas.85.11.3975; BRAUNSTEIN NS, 1990, J IMMUNOL, V145, P1635; EKHOLM R, 1990, INT REV CYTOL, V120, P243; HARDING CV, 1991, P NATL ACAD SCI USA, V88, P2740, DOI 10.1073/pnas.88.7.2740; HASKINS K, 1984, J EXP MED, V160, P452, DOI 10.1084/jem.160.2.452; JENSEN PE, 1988, J IMMUNOL, V141, P2545; JENSEN PE, 1990, J EXP MED, V171, P1779, DOI 10.1084/jem.171.5.1779; KAPPLER J, 1982, P NATL ACAD SCI-BIOL, V79, P3604, DOI 10.1073/pnas.79.11.3604; KOCH N, 1987, EMBO J, V6, P1677, DOI 10.1002/j.1460-2075.1987.tb02417.x; LAMB CA, 1991, P NATL ACAD SCI USA, V88, P5998, DOI 10.1073/pnas.88.14.5998; LAYET C, 1991, P NATL ACAD SCI USA, V88, P2346, DOI 10.1073/pnas.88.6.2346; LORENZ RG, 1988, J IMMUNOL, V141, P4124; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; MILLER J, 1988, P NATL ACAD SCI USA, V85, P1359, DOI 10.1073/pnas.85.5.1359; NADIMI F, 1991, EUR J IMMUNOL, V21, P1255, DOI 10.1002/eji.1830210524; OZAKI S, 1988, J IMMUNOL, V141, P71; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; PETERSON M, 1990, NATURE, V345, P172, DOI 10.1038/345172a0; PIERRES M, 1981, IMMUNOGENETICS, V14, P481, DOI 10.1007/BF00350120; PIETERS J, 1991, J CELL BIOL, V115, P1213, DOI 10.1083/jcb.115.5.1213; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; ROCHE PA, 1991, NATURE, V354, P392, DOI 10.1038/354392a0; ROSIONIEC E, 1989, J IMMUNOL, V143, P50; SCHAIFF WT, 1991, J IMMUNOL, V147, P603; SEKALY RP, 1988, P NATL ACAD SCI USA, V85, P1209, DOI 10.1073/pnas.85.4.1209; SETTE A, 1992, J IMMUNOL, V148, P844; SHIMONKEVITZ R, 1983, J EXP MED, V158, P303, DOI 10.1084/jem.158.2.303; SHIMONKEVITZ R, 1984, J IMMUNOL, V133, P2067; STOCKINGER B, 1989, CELL, V56, P683, DOI 10.1016/0092-8674(89)90590-4; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; YAMAMOTO K, 1985, J IMMUNOL, V134, P3461	35	124	125	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 18	1992	357	6379					596	598		10.1038/357596a0	http://dx.doi.org/10.1038/357596a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HZ112	1608470				2022-12-01	WOS:A1992HZ11200056
J	WALLACE, A; SALUZ, H				WALLACE, A; SALUZ, H			BEYOND SILVER STAINING	NATURE			English	Article							POLYACRYLAMIDE GELS; PROTEINS; DNA				WALLACE, A (corresponding author), IST RIC BIOL MOLEC,VIA PONTINA KM 30600,I-00040 POMEZIA,ITALY.							ANSORGE W, 1985, J BIOCHEM BIOPH METH, V11, P13, DOI 10.1016/0165-022X(85)90037-5; ASKINS BS, 1976, APPL OPTICS, V15, P2860, DOI 10.1364/AO.15.002860; DEMPSTER DT, 1978, THESIS ROCHESTER I T; FYSON JR, 1980, J PHOTOGR SCI, V28, P194; GLAFKIDES P, 1987, CHIMIE PHYSIQUE PHOT, V2; GLAFKIDES P, 1987, CHIMIE PHYSIQUE PHOT, V1; IRIE S, 1982, ANAL BIOCHEM, V126, P350, DOI 10.1016/0003-2697(82)90526-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; MERRIL CR, 1990, NATURE, V343, P779, DOI 10.1038/343779a0; OWUNWANNE A, 1982, J APPL PHOTOGR ENG, V8, P104; SMITH AG, 1985, J IMAGING TECHNOL, V11, P27; SMITHYMAN K, 1985, LANDFALL, V39, P8; SUZUKI S, 1952, J SOC SCI PHOTO 1109; THACKRAY M, 1974, AUTORADIOGRAPHY RADI; VACHON D, 1980, J APPL PHOTOGR ENG, V6, P141; WALLACE A, 1992, ANAL BIOCHEM, V203, P27, DOI 10.1016/0003-2697(92)90038-9	17	4	4	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 18	1992	357	6379					608	609		10.1038/357608a0	http://dx.doi.org/10.1038/357608a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HZ112	1608474				2022-12-01	WOS:A1992HZ11200064
J	BIJUR, PE; KURZON, M; OVERPECK, MD; SCHEIDT, PC				BIJUR, PE; KURZON, M; OVERPECK, MD; SCHEIDT, PC			PARENTAL ALCOHOL-USE, PROBLEM DRINKING, AND CHILDRENS INJURIES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective. - Millions of US children are exposed to parents who are problem drinkers, yet there is little evidence about the effect of parental alcohol consumption on children's health. The aim of this study was to assess the association between children's injuries and parental drinking. Design. - Survey of a nationally representative sample of the US population by household interview. Participants. - 12360 children and parents from single-family households, with data from the Alcohol and Child Health supplements to the 1988 National Health Interview Survey. Main Outcome Measure. - Serious injuries-injuries resulting in hospitalization, surgical treatment, missed school, one half day or more in bed. Results. - Children of mothers categorized as problem drinkers had 2.1 times the risk of serious injury as children of mothers who were nondrinkers (95% CI, 1.3 to 3.5). Other measures of mothers' alcohol consumption (ie, average, maximum, and self-rated consumption) were unrelated to child injuries, as were all measures of fathers' drinking. Children of women who were problem drinkers married to men rated as moderate or heavy drinkers had a relative risk of serious injury of 2.7 (95% CI, 0.8 to 8.6) compared with children of nondrinkers. Conclusion. - Children of women who are problem drinkers have an elevated injury risk; children with two parents who are problem drinkers are at higher risk. Further research is needed on potential mechanisms and interventions. Primary prevention might be enhanced if physicians elicited information about parental drinking, helped secure appropriate treatment, and participated in public health efforts to reduce the deleterious effects of alcohol.	NICHHD, ROCKVILLE, MD USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	BIJUR, PE (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT PEDIAT, ROOM 920, ROSE F KENNEDY CTR, BRONX, NY 10461 USA.				NICHD NIH HHS [R01-HD25416-02] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD025416] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADAMS PF, 1989, VITAL HLTH STAT, V10, P173; BEYER JM, 1981, J DRUG ISSUES, V11, P233, DOI 10.1177/002204268101100205; BIJUR P, 1988, AM J DIS CHILD, V142, P1307, DOI 10.1001/archpedi.1988.02150120061041; CHAFETZ ME, 1971, Q J STUD ALCOHOL, V32, P687; CLAIR D, 1987, J STUD ALCOHOL, V48, P345, DOI 10.15288/jsa.1987.48.345; DAWSON DA, 1991, J MARRIAGE FAM, V53, P573, DOI 10.2307/352734; ELGUEBALY N, 1977, AM J PSYCHIAT, V134, P357; FAMULARO R, 1986, AM J ORTHOPSYCHIAT, V56, P481, DOI 10.1111/j.1939-0025.1986.tb03480.x; KAMMEIER SM, 1971, Q J STUD ALCOHOL, V32, P364; KAPLAN SJ, 1983, J AM ACAD CHILD PSY, V22, P238, DOI 10.1016/S0002-7138(09)60371-X; KATZ D, 1978, BIOMETRICS, V34, P469, DOI 10.2307/2530610; Kleinbaum DG, 1982, EPIDEMIOLOGIC RES PR, P298; LINDEN W, 1986, J CONSULT CLIN PSYCH, V54, P309, DOI 10.1037/0022-006X.54.3.309; LOWENFELS AB, 1984, ANN EMERG MED, V13, P1056, DOI 10.1016/S0196-0644(84)80070-0; MARGOLIS LH, 1986, PEDIATRICS, V77, P870; Obuchowska I., 1974, INT MENTAL HLTH RES, V16, P2; ORFORD J, 1990, RES ADV ALCOHOL DRUG, V10, P81; PUTNAM S, 1987, NOV AM MED C UN INJ; Reilly E L, 1986, Adv Psychosom Med, V16, P17; RIVARA FP, 1982, AM J DIS CHILD, V136, P502, DOI 10.1001/archpedi.1982.03970420026004; SCHOENBORN CA, 1991, ADV DATA, V205; SHAH BV, 1989, SUDAAN PROCEDURES DE; WALLER JA, 1985, INJURY CONTROL GUIDE, P467; WILLIAMS GD, 1986, PUBLIC HEALTH REP, V101, P593; 1987, DIAGNOSTIC STATISTIC; 1972, US DHEW HSM721050 NA; [No title captured]; 1984, ALCOHOL HLTH RES WOR, V8, P1	28	77	77	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 17	1992	267	23					3166	3171		10.1001/jama.267.23.3166	http://dx.doi.org/10.1001/jama.267.23.3166			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX918	1593737				2022-12-01	WOS:A1992HX91800025
J	MCFARLANE, J; PARKER, B; SOEKEN, K; BULLOCK, L				MCFARLANE, J; PARKER, B; SOEKEN, K; BULLOCK, L			ASSESSING FOR ABUSE DURING PREGNANCY - SEVERITY AND FREQUENCY OF INJURIES AND ASSOCIATED ENTRY INTO PRENATAL-CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							PHYSICAL ABUSE; VIOLENCE; CONFLICT; WOMEN	Objective. - To assess the occurrence, frequency, and severity of physical abuse during pregnancy and associated initiation of prenatal care. Design. - Stratified, prospective cohort analysis. Setting. - Public prenatal clinics in Houston, Tex, and Baltimore, Md. Participants. - Total population-based sample of 691 black, Hispanic, and white pregnant women. All of the women were urban residents and most of the Hispanic women were Mexican American. All participants were invited into the study at the first prenatal visit and were followed up until delivery. Main Outcome Measure. - Identification of abuse status. Results. - A three-question Abuse Assessment Screen detected a 17% (1/6) prevalence of physical or sexual abuse during pregnancy, which is more than double all previous published reports. When evaluated against nationally tested research instruments, the three-question screen that was asked at the first prenatal visit was sensitive and specific to abuse status. Abuse was recurrent, with 60% of abused women reporting two or more episodes of assault. Location of abuse focused on the head. Frequency and severity of abuse and potential danger of homicide was appreciably worse for white women. Abused women were twice as likely as nonabused women to begin prenatal care during the third trimester. Conclusions. - A simple clinical assessment screen completed by the health care provider in a private setting and with the male partner absent is as effective as research instruments in identifying abused women. Straightforward, routine clinical assessment is recommended as essential in preventing potential trauma, interrupting existing abuse, and protecting health.	UNIV MARYLAND,BALTIMORE,MD 21201; UNIV OTAGO,DUNEDIN,NEW ZEALAND	University System of Maryland; University of Maryland Baltimore; University of Otago	MCFARLANE, J (corresponding author), TEXAS WOMANS UNIV,1130 MD ANDERSON BLVD,HOUSTON,TX 77030, USA.				PHS HHS [R49/CCR603514-01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AMARO H, 1990, AM J PUBLIC HEALTH, V80, P575, DOI 10.2105/AJPH.80.5.575; BERENSON A, 1991, AM J OBSTET GYNECOL, V164, P491; CAMPBELL J, IN PRESS RES NURS HL; CAMPBELL JC, 1986, ADV NURS SCI, V8, P36, DOI 10.1097/00012272-198607000-00006; HELTON AS, 1987, AM J PUBLIC HEALTH, V77, P1337, DOI 10.2105/AJPH.77.10.1337; HILLARD PJA, 1985, OBSTET GYNECOL, V66, P185; HUDSON WW, 1981, J MARRIAGE FAM, V43, P873, DOI 10.2307/351344; JORGENSEN SR, 1977, J MARRIAGE FAM, V39, P653, DOI 10.2307/350472; LAZARRO M, 1991, J NURS ADMIN, V21, P24; MCFARLANE J, 1989, WOMEN HEALTH, V15, P69, DOI 10.1300/J013v15n03_06; MCFARLANE J, 1991, PUBLIC HEALTH NURS, V8, P245, DOI 10.1111/j.1525-1446.1991.tb00664.x; MCFARLANE J, 1991, VIOLENCE WOMEN NURSI; MCFARLANE J, 1991, DATING VIOLENCE YOUN; Parker B, 1991, MCN Am J Matern Child Nurs, V16, P161, DOI 10.1097/00005721-199105000-00013; SCHEI B, 1989, BRIT J OBSTET GYNAEC, V96, P1379, DOI 10.1111/j.1471-0528.1989.tb06298.x; Steinmetz S., 1977, CYCLE VIOLENCE ASSER; STRAUS MA, 1979, J MARRIAGE FAM, V41, P75, DOI 10.2307/351733; STRAUS MA, 1986, J MARRIAGE FAM, V48, P465, DOI 10.2307/352033; STRAUS MA, 1981, CLOSED DOORS VIOLENC; 1988, ABUSED WOMAN; 1986, SURGEON GENERALS WOR; 1989, BATTERED WOMAN	22	713	725	0	22	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 17	1992	267	23					3176	3178		10.1001/jama.267.23.3176	http://dx.doi.org/10.1001/jama.267.23.3176			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HX918	1593739				2022-12-01	WOS:A1992HX91800027
J	CALVERLEY, DC; JONES, GW; KELTON, JG				CALVERLEY, DC; JONES, GW; KELTON, JG			SPLENIC RADIATION FOR CORTICOSTEROID-RESISTANT IMMUNE THROMBOCYTOPENIA	ANNALS OF INTERNAL MEDICINE			English	Article						SPLEEN; RADIOTHERAPY; THROMBOCYTOPENIA; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; PREDNISONE	CHRONIC LYMPHOCYTIC-LEUKEMIA; PURPURA; SPLENECTOMY; IRRADIATION	Objective: To determine the role of splenic radiation as a treatment for immune thrombocytopenia. Design: Retrospective analysis of an open, nonrandomized investigation. Setting: A regional cancer center, referred care, and primary care settings. Patients: Eleven older patients with idiopathic thrombocytopenic purpura (ITP) and 8 patients with secondary immune thrombocytopenia refractory to corticosteroid treatment for whom surgery would have posed a high risk. Intervention: A short course (1 to 6 weeks) of radiation therapy to the spleen (total dose, 75 to 1370 cGy) with or without concurrent and postradiation corticosteroid administration. Measurements: Efficacy was assessed by measuring any increase in the platelet count and by monitoring the duration of response and side effects. Results: Of 11 patients with ITP, 8 patients responded. Three patients had a sustained (> 52 weeks) increase in the platelet count to safe levels after therapy was discontinued. An additional patient had a sustained response but required intermittent, low-dose corticosteroids. Four other patients had increases in their platelet counts that lasted from 8 to 25 weeks. Two of the eight patients without ITP had a positive response, whereas four did not respond, and two were not evaluable. Patients had no adverse reactions to the radiation treatment. Conclusion: Splenic radiation can be a safe and effective method to raise the platelet count in older patients with ITP that is refractory to corticosteroids and in whom the risks associated with splenectomy are high.	MCMASTER UNIV, MED CTR, DEPT MED, ROOM 2N34, 1200 MAIN ST W, HAMILTON L8N 3Z5, ONTARIO, CANADA; MCMASTER UNIV, MED CTR, DEPT PATHOL, HAMILTON L8N 3Z5, ONTARIO, CANADA; HAMILTON REG CANC CTR, DEPT RADIAT ONCOL, HAMILTON L8V 1C3, ONTARIO, CANADA; CANADIAN RED CROSS, BLOOD TRANSFUS SERV, HAMILTON, ONTARIO, CANADA	McMaster University; McMaster University; McMaster University								AKWARI OE, 1987, ANN SURG, V206, P529, DOI 10.1097/00000658-198710000-00014; BRENNAN MF, 1975, AM J SURG, V129, P490, DOI 10.1016/0002-9610(75)90197-X; BYHARDT RW, 1975, CANCER, V35, P1621, DOI 10.1002/1097-0142(197506)35:6<1621::AID-CNCR2820350622>3.0.CO;2-U; COLA B, 1986, INT SURG, V71, P195; COMAS FV, 1968, AMER J ROENTGENOL RA, V104, P668, DOI 10.2214/ajr.104.3.668; COON WW, 1987, SURG GYNECOL OBSTET, V164, P225; DAILEY MO, 1980, NEW ENGL J MED, V302, P215, DOI 10.1056/NEJM198001243020406; GUINEY MJ, 1989, INT J RADIAT ONCOL, V16, P225, DOI 10.1016/0360-3016(89)90035-7; JACOBS P, 1986, Q J MED, V58, P153; PIZZUTO J, 1984, BLOOD, V64, P1179; RUSSO D, 1987, HAEMATOLOGICA, V72, P445; SCHWARTZ SI, 1980, SURGERY, V88, P497; STRATTON JR, 1989, J NUCL MED, V30, P629; TERSTAPPEN LWMM, 1988, EUR J HAEMATOL, V41, P496; WARKENTIN TE, 1990, DRUGS, V40, P531, DOI 10.2165/00003495-199040040-00004; WILLIAMS WJ, 1990, HEMATOLOGY, P1381	16	32	34	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1992	116	12	1				977	981		10.7326/0003-4819-116-12-977	http://dx.doi.org/10.7326/0003-4819-116-12-977			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY793	1586107				2022-12-01	WOS:A1992HY79300004
J	OKEEFFE, ST; TSAPATSARIS, NP; BEETHAM, WP				OKEEFFE, ST; TSAPATSARIS, NP; BEETHAM, WP			INCREASED PREVALENCE OF MIGRAINE AND CHEST PAIN IN PATIENTS WITH PRIMARY RAYNAUD DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article						RAYNAUDS DISEASE; MIGRAINE; CHEST PAIN; VASOCONSTRICTION; HEADACHE	VARIANT ANGINA; FIBROMYALGIA; POPULATION; HEADACHES; DISORDER; SPASM	Objective: To investigate the prevalence of headaches and recurrent chest pain in patients with primary Raynaud disease. Design: Postal survey. Setting: Raynaud disease clinic at the Lahey Clinic Medical Center, a tertiary care hospital. Participants: A consecutive series of 120 patients with primary Raynaud disease who had been observed for at least 2 years, 97 of whom received and 93 of whom completed the questionnaire, and a control group of 93 age- and sex-matched hospital employees with Raynaud phenomenon. Results: Migraine was diagnosed in 57 (61%) patients with primary Raynaud disease and in 21 (23%) of the control group (odds ratio, 5.4; 95% Cl, 2.8 to 10.3). Migraine with aura and migraine without aura were more common in patients with Raynaud disease than in the control subjects (27% compared with 5%; P < 0.001 and 34% compared with 17%; P = 0.008, respectively). Nonmigrainous headaches were more common in the control group (51% compared with 25%; P = 0.003). Chest pains were reported by 44 (47%) of the patients with Raynaud disease and by 15 (16%) of the control group (odds ratio, 4.4; Cl, 2.4 to 9.3). Chest pains were more frequently reported by patients with Raynaud disease who had migraine (34 of 57, 60%) than by patients without migraine (10 of 36, 28%; P = 0.003). Conclusions: An increased prevalence of migraine was found in patients with primary Raynaud disease. Chest pain, often diagnosed as musculoskeletal or nonspecific, was common in patients with primary Raynaud phenomenon, especially in patients who had coexisting migraine.	LAHEY CLIN MED CTR, VASC MED & HYPERTENS SECT, 41 MALL RD, BURLINGTON, MA 01805 USA	Lahey Hospital & Medical Center				O'Keeffe, Shaun/0000-0002-7682-5004				APPENZELLER O, 1963, J NEUROL NEUROSUR PS, V26, P447, DOI 10.1136/jnnp.26.5.447; COFFMAN JD, 1975, PROG CARDIOVASC DIS, V18, P123, DOI 10.1016/0033-0620(75)90002-X; COFFMAN JD, 1989, RAYNAUDS PHENOMENON, P3; DALESSANDRO R, 1988, J NEUROL NEUROSUR PS, V51, P21, DOI 10.1136/jnnp.51.1.21; FAM AG, 1985, CAN MED ASSOC J, V133, P379; HEUPLER FA, 1980, AM J CARDIOL, V45, P873, DOI 10.1016/0002-9149(80)90134-4; ISENBERG DA, 1982, ANN RHEUM DIS, V41, P30, DOI 10.1136/ard.41.1.30; LEPPERT J, 1987, ANGIOLOGY, V38, P871, DOI 10.1177/000331978703801201; LEVINE PR, 1989, SOUTHERN MED J, V82, P580, DOI 10.1097/00007611-198905000-00010; MARICQ HR, 1986, J CHRON DIS, V39, P423, DOI 10.1016/0021-9681(86)90109-8; MARKUS HS, 1992, J NEUROL, V239, P39, DOI 10.1007/BF00839210; MASERI A, 1987, J AM COLL CARDIOL, V9, P249, DOI 10.1016/S0735-1097(87)80372-8; MILLER D, 1981, NEW ENGL J MED, V304, P763, DOI 10.1056/NEJM198103263041306; OLESEN J, 1987, ARCH NEUROL-CHICAGO, V44, P321, DOI 10.1001/archneur.1987.00520150061023; PAL B, 1989, ANN RHEUM DIS, V48, P312, DOI 10.1136/ard.48.4.312; PELLEGRINO MJ, 1990, ARCH PHYS MED REHAB, V71, P526; PRIOLLET P, 1987, AM J MED, V83, P494, DOI 10.1016/0002-9343(87)90760-1; RASKIN NH, 1988, HEADACHE, P99; ROBERTSON D, 1978, LANCET, V1, P452; ROSE GA, 1962, B WORLD HEALTH ORGAN, V27, P645; Rothman KJ., 1982, EPIDEMIOLOGIC ANAL P; SILMAN A, 1990, BMJ-BRIT MED J, V301, P590, DOI 10.1136/bmj.301.6752.590; TAYLOR PJ, 1970, BRIT J IND MED, V27, P364; WATERS WE, 1975, J NEUROL NEUROSUR PS, V38, P613, DOI 10.1136/jnnp.38.6.613; WELCH KMA, 1987, ARCH NEUROL-CHICAGO, V44, P323, DOI 10.1001/archneur.1987.00520150063024; WOLFE F, 1990, ARTHRITIS RHEUM-US, V33, P160, DOI 10.1002/art.1780330203; ZAHAVI I, 1984, ARCH INTERN MED, V144, P742, DOI 10.1001/archinte.144.4.742	27	53	53	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1992	116	12	1				985	989		10.7326/0003-4819-116-12-985	http://dx.doi.org/10.7326/0003-4819-116-12-985			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY793	1586109				2022-12-01	WOS:A1992HY79300006
J	RUBIN, SM; CUMMINGS, SR				RUBIN, SM; CUMMINGS, SR			RESULTS OF BONE DENSITOMETRY AFFECT WOMENS DECISIONS ABOUT TAKING MEASURES TO PREVENT FRACTURES	ANNALS OF INTERNAL MEDICINE			English	Article						BONE DENSITY; ESTROGEN REPLACEMENT THERAPY; OSTEOPOROSIS; DENSITOMETRY; HEALTH BEHAVIOR; WOMENS HEALTH	HIP FRACTURE; POSTMENOPAUSAL OSTEOPOROSIS; PRIMARY HYPERPARATHYROIDISM; CALCIUM SUPPLEMENTATION; REPLACEMENT THERAPY; DIETARY CALCIUM; ESTROGEN; RISK; CALCITONIN; DENSITY	Objective: To describe how the results of bone densitometry affect women's decisions about measures to prevent fractures and to determine whether labeling women as having below-normal bone density has adverse effects. Design: Mail survey of a random sample of women. Setting: Four community hospitals in the San Francisco Bay area. Patients: A total of 261 women (response rate, 81.3%) who had undergone bone densitometry. Measurements: Bone densitometry and self-report of changes in attitude and behaviors. Results: Fifty-three percent of the women reported that their first bone density measurements were below normal, and 44% said that they were diagnosed as having osteoporosis on the basis of their test results. Women who reported that their bone density measurements were below normal were much more likely than women with normal results to begin some type of measure to prevent fractures (94% compared with 56%; P < 0.01), to start hormone therapy (38% compared with 8%; P < 0.01), and to take precautions to avoid falling (50% compared with 9%; P < 0.01). Women reporting low bone density, however, also became more fearful of falling (38% compared with 2%; P < 0.01) and limited their activities to avoid falling (24% compared with 2%; P < 0.01). Conclusions: The results of bone densitometry substantially influence women's decisions about beginning estrogen replacement therapy and other preventive measures for osteoporotic fractures. The potential effects of labeling a women as having below-normal bone density need to be considered before densitometry is widely used for unselective screening of women.			RUBIN, SM (corresponding author), UNIV CALIF SAN FRANCISCO, PREVENT SCI GRP, BOX 0886, SAN FRANCISCO, CA 94143 USA.							ALDERMAN MH, 1990, J CLIN EPIDEMIOL, V43, P195, DOI 10.1016/0895-4356(90)90185-R; ALOIA JF, 1978, ANN INTERN MED, V89, P356, DOI 10.7326/0003-4819-89-3-356; BARRETTCONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1861, DOI 10.1001/jama.265.14.1861; BUSH TL, 1990, MENOPAUSE BIOL CLIN, P211; Canadian Task Force on the Periodic Health Examination, 1979, CAN MED ASSOC J, V121, P1193; CHESTNUT CH, 1988, OSTEOPOROSIS ETIOLOG, P403; CUMMINGS SR, 1990, ANN INTERN MED, V113, P565, DOI 10.7326/0003-4819-113-8-565; CUMMINGS SR, 1985, EPIDEMIOL REV, V7, P178, DOI 10.1093/oxfordjournals.epirev.a036281; CUMMINGS SR, 1990, JAMA-J AM MED ASSOC, V263, P665, DOI 10.1001/jama.263.5.665; CUMMINGS SR, 1986, ANN INTERN MED, V104, P817, DOI 10.7326/0003-4819-104-6-817; DAWSONHUGHES B, 1990, NEW ENGL J MED, V323, P878, DOI 10.1056/NEJM199009273231305; DUPONT WD, 1991, ARCH INTERN MED, V151, P67, DOI 10.1001/archinte.151.1.67; EASTELL R, 1988, OSTEOPOROSIS ETIOLOG, P373; ERNSTER VL, 1988, PREV MED, V17, P201, DOI 10.1016/0091-7435(88)90064-3; ETTINGER B, 1985, ANN INTERN MED, V102, P319, DOI 10.7326/0003-4819-102-3-319; ETTINGER B, 1987, ANN INTERN MED, V106, P40, DOI 10.7326/0003-4819-106-1-40; ETTINGER B, 1987, AM J OBSTET GYNECOL, V156, P1298, DOI 10.1016/0002-9378(87)90168-2; FATOURECHI V, 1987, ANN INTERN MED, V107, P923, DOI 10.7326/0003-4819-107-6-923; FELDMAN W, 1990, Journal of General Internal Medicine, V5, pS50, DOI 10.1007/BF02600842; Frame P S, 1975, J Fam Pract, V2, P29; GENANT HK, 1989, RADIOLOGY, V170, P817, DOI 10.1148/radiology.170.3.2916037; HILLNER BE, 1986, AM J MED, V80, P1115, DOI 10.1016/0002-9343(86)90674-1; HOLBROOK TL, 1988, LANCET, V2, P1046, DOI 10.1016/S0140-6736(88)90065-7; HUI SL, 1989, ANN INTERN MED, V111, P355, DOI 10.7326/0003-4819-111-5-355; HUTCHINSON TA, 1979, LANCET, V2, P705; JOHNSON RE, 1981, AM J PUBLIC HEALTH, V71, P138, DOI 10.2105/AJPH.71.2.138; JOHNSTON CC, 1989, J BONE MINER RES S2, V4, P1; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; KOCHERSBERGER G, 1987, ARCH INTERN MED, V147, P1951, DOI 10.1001/archinte.147.11.1951; KREIGER N, 1982, AM J EPIDEMIOL, V116, P141, DOI 10.1093/oxfordjournals.aje.a113388; LEFEBVRE RC, 1988, ARCH INTERN MED, V148, P1993, DOI 10.1001/archinte.148.9.1993; LERMAN C, 1991, ANN INTERN MED, V114, P657, DOI 10.7326/0003-4819-114-8-657; LINDSAY R, 1980, LANCET, V2, P1151; MACDONALD LA, 1984, J CHRON DIS, V37, P933, DOI 10.1016/0021-9681(84)90070-5; MACINTYRE I, 1988, LANCET, V1, P900; MELTON LJ, 1990, ANN INTERN MED, V112, P516, DOI 10.7326/0003-4819-112-7-516; MELTON LJ, 1988, OSTEOPOROSIS ETIOLOG, P155; MeltonIII L. J., 1988, OSTEOPOROSIS ETIOLOG, P133; MICHEL BA, 1989, ARCH INTERN MED, V149, P2325, DOI 10.1001/archinte.149.10.2325; Morrison AS., 1985, SCREENING CHRONIC DI; PAGANINIHILL A, 1981, ANN INTERN MED, V95, P28, DOI 10.7326/0003-4819-95-1-28; PARISIEN M, 1990, ENDOCRIN METAB CLIN, V19, P19, DOI 10.1016/S0889-8529(18)30337-2; REGINSTER JY, 1987, LANCET, V2, P1481; RICHARDSON ML, 1986, SKELETAL RADIOL, V15, P85, DOI 10.1007/BF00350200; RIGGS BL, 1988, ANN INTERN MED, V108, P293, DOI 10.7326/0003-4819-108-2-293; RIIS B, 1987, NEW ENGL J MED, V316, P173, DOI 10.1056/NEJM198701223160401; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; STEINBERG KK, 1991, JAMA-J AM MED ASSOC, V265, P1985, DOI 10.1001/jama.265.15.1985; STORM T, 1990, NEW ENGL J MED, V322, P1265, DOI 10.1056/NEJM199005033221803; THOMAS DB, 1990, MENOPAUSE BIOL CLIN, P101; WASNICH RD, 1985, AM J OBSTET GYNECOL, V153, P745, DOI 10.1016/0002-9378(85)90338-2; WASNICH RD, 1987, OSTEOPOROSIS UPDATE, P123; WATTS NB, 1990, NEW ENGL J MED, V323, P73, DOI 10.1056/NEJM199007123230201; WEISS NS, 1980, NEW ENGL J MED, V303, P1195, DOI 10.1056/NEJM198011203032102; WHITE LJ, 1987, ANN INTERN MED, V107, P932, DOI 10.7326/0003-4819-107-6-932; WICKHAM CAC, 1989, BMJ-BRIT MED J, V299, P889, DOI 10.1136/bmj.299.6704.889; 1989, GUIDE CLIN PREVENTIV, P239; 1984, JAMA-J AM MED ASSOC, P799	58	146	147	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1992	116	12	1				990	995		10.7326/0003-4819-116-12-990	http://dx.doi.org/10.7326/0003-4819-116-12-990			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY793	1586110				2022-12-01	WOS:A1992HY79300007
J	SELLICK, JA; LONGBINE, D; SCHIFELING, R; MYLOTTE, JM				SELLICK, JA; LONGBINE, D; SCHIFELING, R; MYLOTTE, JM			SCREENING HOSPITAL EMPLOYEES FOR MEASLES IMMUNITY IS MORE COST-EFFECTIVE THAN BLIND IMMUNIZATION	ANNALS OF INTERNAL MEDICINE			English	Article						MEASLES; COST-BENEFIT ANALYSIS; HEALTH PERSONNEL; IMMUNIZATION	TRANSMISSION	Objective: To examine alternative strategies in developing a cost-effective program to assure measles immunity among hospital employees. Design: Observational. Setting: Referral teaching hospital. Participants: Eighteen hundred "established" hospital employees with potential patient contact and 630 newly hired hospital employees. Interventions: Established employees born after 1 January 1957 and all newly hired employees were screened for serologic evidence of measles immunity and immunized if necessary. Measurements: Cost analysis. Results: The cost of screening and directed immunization of established employees was $3.98 per employee compared with a potential cost $10.03 to $42.80 per employee if all employees were "blindly" immunized with monovalent measles vaccine or trivalent mumps-measles-rubella vaccine. The cost of the screening and directed immunization of new employees was $2.42 per employee compared with potential costs $8.30 to $39.34 per employee for blind immunization. These analyses assumed that varying percentages of employees would be able to produce documentation of having received a previous dose of vaccine or of having had measles. Conclusions: In a large referral hospital, screening for measles immunity followed by directed immunization was considerably less expensive than immunizing all potentially susceptible employees.	BUFFALO GEN HOSP, DEPT EMPLOYEE HLTH, BUFFALO, NY 14203 USA; SUNY BUFFALO, BUFFALO, NY 14260 USA	Buffalo General Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	SELLICK, JA (corresponding author), BUFFALO GEN HOSP, DEPT MED, 100 HIGH ST, BUFFALO, NY 14203 USA.							ATKINSON WL, 1991, AM J MED, V91, pS320, DOI 10.1016/0002-9343(91)90389-F; BART KJ, 1991, JAMA-J AM MED ASSOC, V266, P1547; BRAUNSTEIN H, 1990, AM J DIS CHILD, V144, P296, DOI 10.1001/archpedi.1990.02150270046024; CHEN RT, 1990, J INFECT DIS, V162, P1036, DOI 10.1093/infdis/162.5.1036; DAVIS RM, 1986, JAMA-J AM MED ASSOC, V255, P1295, DOI 10.1001/jama.255.10.1295; MATHIAS RG, 1989, AM J PUBLIC HEALTH, V79, P475, DOI 10.2105/AJPH.79.4.475; NEUMANN PW, 1985, J CLIN MICROBIOL, V22, P296, DOI 10.1128/JCM.22.2.296-298.1985; SUBBARAO EK, 1991, J INFECT DIS, V163, P876, DOI 10.1093/infdis/163.4.876; WEBER DJ, 1991, J PEDIATR-US, V119, P322, DOI 10.1016/S0022-3476(05)80753-X; WHARTON M, 1990, ARCH INTERN MED, V150, P47, DOI 10.1001/archinte.150.1.47; 1991, MMWR, V40, P369; 1989, MMWR, V38, P1	12	17	18	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1992	116	12	1				982	984		10.7326/0003-4819-116-12-982	http://dx.doi.org/10.7326/0003-4819-116-12-982			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY793	1586108				2022-12-01	WOS:A1992HY79300005
J	BEWLEY, S				BEWLEY, S			THE LAW, MEDICAL-STUDENTS, AND ASSAULT	BRITISH MEDICAL JOURNAL			English	Article											BEWLEY, S (corresponding author), UNIV COLL HOSP LONDON,DEPT OBSTET & GYNAECOL,LONDON WC1E 6AU,ENGLAND.			bewley, susan/0000-0001-8064-652X				BEWLEY S, 1992, IN PRESS 26TH P BRIT; BRAZIER M, 1987, MED PATIENTS LAW, P55; CHAMBERLAIN G, 1990, AVOID MEDICOLEGAL PR, P16; Corbett J., 1990, METRO            JUL, p54e71; CORBETT J, 1990, METRO            SEP, P124; Dyer C, 1991, GUARDIAN        0916, P2; PHILLIPS A, 1991, GUARDIAN        0122, P34; ROBINSON J, 1985, J MED ETHICS, V11, P15; SKEGG PDG, 1984, LAW ETHICS MED, P95; WINKLER F, 1988, NEEDLE           JUN, P10; 1981, LAW SOC GAZETTE, V78, P1341; 1986, WOMEN MED        MAY, P8	12	20	20	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 13	1992	304	6841					1551	1553		10.1136/bmj.304.6841.1551	http://dx.doi.org/10.1136/bmj.304.6841.1551			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HZ178	1628058	Green Published, Bronze			2022-12-01	WOS:A1992HZ17800029
J	BRAHAMS, D				BRAHAMS, D			LIFE-SUSTAINING TREATMENT FOR BRAIN-DAMAGED CHILD	LANCET			English	Editorial Material																			0	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 13	1992	339	8807					1472	1473		10.1016/0140-6736(92)92052-H	http://dx.doi.org/10.1016/0140-6736(92)92052-H			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY317	1351139				2022-12-01	WOS:A1992HY31700017
J	BRYNDORF, T; CHRISTENSEN, B; PHILIP, J; HANSEN, W; YOKOBATA, K; BUI, N; GAISER, C				BRYNDORF, T; CHRISTENSEN, B; PHILIP, J; HANSEN, W; YOKOBATA, K; BUI, N; GAISER, C			NEW RAPID TEST FOR PRENATAL DETECTION OF TRISOMY-21 (DOWNS-SYNDROME) - PRELIMINARY-REPORT	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INSITU HYBRIDIZATION; CHROMOSOME; INTERPHASE; GENE	Objective - To devise and evaluate a rapid screening method for detecting trisomy 21 (Down's syndrome) in samples of uncultured amniotic fluid cells. Design - Non-radioactive in situ hybridisation with HY128, a 500 000 base pair yeast artificial chromosome probe specific for chromosome 21. Blinded study of 12 karyotypically normal amniotic fluid samples and eight samples trisomic for chromosome 21. Setting - Cytogenetic and obstetric services at a tertiary referral centre, Copenhagen. Main outcome measures - Time necessary to complete the test. Proportion of cell nuclei containing two and three hybridisation signals in karyotypically normal and abnormal amniotic fluid samples. Results - The test could be completed within three to four days after amniocentesis. In the normal samples a mean of 73% (range 61-82%) of the amniotic cell nuclei showed two hybridisation signals and 6% (0-18%) showed three signals. By contrast, among the trisomic samples 29% (19-38%) of the nuclei exhibited two signals and 48% (31-60%) showed three signals. Conclusion - The technique clearly distinguished between normal and trisomic samples. Prenatal diagnosis with in situ hybridisation with chromosome specific probes was fast and may make it possible to screen for selected, aneuploidies. However, the technique is still at a preliminary stage and needs further evaluation and refinement.	BECTON DICKINSON IMMUNOCYTOMETRY SYST, SAN JOSE, CA 95131 USA	Becton Dickinson	BRYNDORF, T (corresponding author), UNIV COPENHAGEN HOSP, RIGSHOSP, DEPT OBSTET & GYNAECOL, CLIN GENET SECT, CHROMOSOME LAB, DK-2100 COPENHAGEN, DENMARK.							BURKE DT, 1991, METHOD ENZYMOL, V194, P251; CHRISTENSEN B, 1992, PRENAT DIAGN, V12, P251; CREMER T, 1986, HUM GENET, V74, P346, DOI 10.1007/BF00280484; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GOSDEN CM, 1983, BRIT MED BULL, V39, P348, DOI 10.1093/oxfordjournals.bmb.a071847; GUYOT B, 1988, PRENATAL DIAG, V8, P485, DOI 10.1002/pd.1970080703; HOPMAN AHN, 1990, IN SITU HYBRIDIZATIO, P165; KLINGER KW, 1991, AM J HUM GENET, V49, P23; KUO W, 1991, AM J HUM GENET, V49, P382; KUO WL, 1991, AM J HUM GENET, V49, P112; LAWRENCE JB, 1990, SCIENCE, V249, P928, DOI 10.1126/science.2203143; LAWRENCE JB, 1989, CELL, V57, P493, DOI 10.1016/0092-8674(89)90924-0; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; PINKEL D, 1988, P NATL ACAD SCI USA, V85, P9138, DOI 10.1073/pnas.85.23.9138; WHITEMAN DAH, 1991, AM J HUM GENET, V49, P234; WILLARD HF, 1983, NUCLEIC ACIDS RES, V11, P2017, DOI 10.1093/nar/11.7.2017; YU LC, 1991, AM J HUM GENET, V49, P235	17	14	15	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 13	1992	304	6841					1536	1539		10.1136/bmj.304.6841.1536	http://dx.doi.org/10.1136/bmj.304.6841.1536			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HZ178	1385745	Green Published, Bronze			2022-12-01	WOS:A1992HZ17800022
J	DICK, PH; CROMBIE, IK; DURHAM, T; MCFEE, C; PRIMROSE, M; MITCHELL, S				DICK, PH; CROMBIE, IK; DURHAM, T; MCFEE, C; PRIMROSE, M; MITCHELL, S			UNNECESSARY HOSPITALIZATION IN A PSYCHIATRIC REHABILITATION UNIT	BRITISH MEDICAL JOURNAL			English	Article									UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT EPIDEMIOL & PUBL HLTH,DUNDEE DD1 9SY,SCOTLAND	University of Dundee	DICK, PH (corresponding author), ROYAL LIFF HOSP,DUNDEE PSYCHIAT REHABIL SERV,DUNDEE DD2 5NF,SCOTLAND.							AFFLECK JW, 1984, BRIT J PSYCHIAT, V145, P517, DOI 10.1192/bjp.145.5.517; Dick P H, 1990, Int J Rehabil Res, V13, P119, DOI 10.1097/00004356-199006000-00003; MCCREADIE RG, 1983, BRIT J PSYCHIAT, V143, P564, DOI 10.1192/bjp.143.6.564; MCCREADIE RG, 1991, BRIT J PSYCHIAT, V158, P398, DOI 10.1192/bjp.158.3.398; 1989, CARING PEOPLE COMMUN	5	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 13	1992	304	6841					1544	1544		10.1136/bmj.304.6841.1544	http://dx.doi.org/10.1136/bmj.304.6841.1544			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HZ178	1628055	Green Published, Bronze			2022-12-01	WOS:A1992HZ17800026
J	FROST, P; LEVIN, B				FROST, P; LEVIN, B			CLINICAL IMPLICATIONS OF METASTATIC PROCESS	LANCET			English	Article							CLONAL ORIGIN; HUMAN-TUMORS; CANCER; CHROMOSOME-1; CELLS		UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CELL BIOL,HOUSTON,TX 77025; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MED ONCOL,GI ONCOL & DIGEST DIS SECT,HOUSTON,TX 77025	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center								ATKIN NB, 1986, CANCER GENET CYTOGEN, V21, P279, DOI 10.1016/0165-4608(86)90206-2; BELL C, 1991, CANCER GENET CYTOGEN, V54, P153, DOI 10.1016/0165-4608(91)90203-7; BELL C, 1990, INT J CANCER, V645, P968; DUFFY MJ, 1987, EUR J CANCER CLIN ON, V23, P583, DOI 10.1016/0277-5379(87)90326-9; DVORAK HF, 1987, HUM PATHOL, V18, P275, DOI 10.1016/S0046-8177(87)80010-2; FEARON ER, 1986, NEW ENGL J MED, V315, P15, DOI 10.1056/NEJM198607033150103; FIALKOW PJ, 1979, ANNU REV MED, V30, P135, DOI 10.1146/annurev.me.30.020179.001031; FOULDS L, 1954, CANCER RES, V14, P327; FOULDS L, 1975, NEOPLASTIC DEV, P675; FROST P, 1989, Cancer Bulletin (Houston), V41, P139; FROST P, 1990, CANCER METAST REV, V9, P93, DOI 10.1007/BF00047591; Garrido F, 1991, Semin Cancer Biol, V2, P3; GIAVAZZI R, 1991, CANCER RES, V266, P14869; GORELIK E, 1988, BIOCHEM CELL BIOL, V66, P617, DOI 10.1139/o88-071; GRANT SGN, 1991, CANCER RES, V51, P4917; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HANNA N, 1983, CIBA S FUND CANC RES, V36, P309; KELLY SA, 1991, CANCER RES, V51, P4020; KENDAL WS, 1986, PATHOL IMMUNOPATH R, V5, P455, DOI 10.1159/000157032; Linehan W.M., 1989, CANCER PRINCIPLES PR, P979; Liotta L A, 1988, Prog Clin Biol Res, V256, P3; Liotta LA, 1989, CANCER PRINCIPLES PR, P98; McCarthy J B, 1991, Semin Cancer Biol, V2, P155; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Paget S., 1889, LANCET, V133, P571, DOI DOI 10.1016/S0140-6736(00)49915-0; REICHMANN A, 1984, CANCER GENET CYTOGEN, V12, P295, DOI 10.1016/0165-4608(84)90062-1; ROWLEY JD, 1978, VIRCHOWS ARCH B, V29, P129; SIRDANSKY D, 1992, NEW ENGL J MED, V326, P737; STAROSELSKY AN, IN PRESS INT J CANCE; TARIN D, 1984, CANCER RES, V44, P3584; TARIN D, 1984, INVAS METAST, V4, P1; VOGELSTEIN B, 1985, SCIENCE, V227, P642, DOI 10.1126/science.2982210; VOGELSTEIN B, 1987, CANCER RES, V47, P4806; WAGHORNE C, 1988, CANCER RES, V48, P6109; WEISS L, 1988, INT J CANCER, V41, P450, DOI 10.1002/ijc.2910410323	35	55	56	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 13	1992	339	8807					1458	1461		10.1016/0140-6736(92)92040-M	http://dx.doi.org/10.1016/0140-6736(92)92040-M			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY317	1351135				2022-12-01	WOS:A1992HY31700013
J	HART, IR; SAINI, A				HART, IR; SAINI, A			BIOLOGY OF TUMOR-METASTASIS	LANCET			English	Article							ANGIOGENESIS; RECEPTORS; MELANOMA; CELLS; GENE				HART, IR (corresponding author), IMPERIAL CANC RES FUND,LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND.							ALBELDA SM, 1990, CANCER RES, V50, P6757; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FIDLER IJ, 1977, SCIENCE, V197, P893, DOI 10.1126/science.887927; FOLKMAN J, 1983, SCIENCE, V221, P719, DOI 10.1126/science.6192498; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FOULDS L, 1954, CANCER RES, V14, P327; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HART IR, 1989, BIOCHIM BIOPHYS ACTA, V989, P65, DOI 10.1016/0304-419X(89)90035-8; HART IR, 1989, CURR OPIN IMMUNOL, V1, P900, DOI 10.1016/0952-7915(89)90068-X; HUMPHRIES MJ, 1986, SCIENCE, V233, P467, DOI 10.1126/science.3726541; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LLOTA LA, 1991, CELL, V64, P327; MAHADEVAN V, 1991, BRIT J CANCER, V63, P889, DOI 10.1038/bjc.1991.195; MAHADEVAN V, 1990, ACTA ONCOL, V29, P97, DOI 10.3109/02841869009089997; MATSUSHITA Y, 1991, CLIN EXP METASTAS, V9, P283, DOI 10.1007/BF01753731; ROSEN EM, 1991, CELL GROWTH DIFFER, V2, P603; SHIMOYAMA Y, 1991, CANCER LETT, V57, P131, DOI 10.1016/0304-3835(91)90206-W; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; STOKER M, 1991, BICHIM BIOPHYS ACTA, V1072, P88; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101	26	339	351	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 13	1992	339	8807					1453	1457		10.1016/0140-6736(92)92039-I	http://dx.doi.org/10.1016/0140-6736(92)92039-I			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY317	1376386				2022-12-01	WOS:A1992HY31700012
J	HENDRICKSE, MT; THULUVATH, PJ; TRIGER, DR				HENDRICKSE, MT; THULUVATH, PJ; TRIGER, DR			NATURAL-HISTORY OF AUTONOMIC NEUROPATHY IN CHRONIC LIVER-DISEASE	LANCET			English	Article							CIRRHOSIS; PROGNOSIS; PRESSURE	To determine the natural history of autonomic neuropathy in chronic liver disease we used standard cardiovascular autonomic tests to evaluate prospectively 60 patients (33 male, 27 female) with initially well-preserved hepatic function. On initial testing, 27 patients (45%, median [range] age 56 [32-67] years) had vagal neuropathy. Autonomic dysfunction was equally common in patients with alcohol-related and non-alcoholic-related liver disease. The cumulative 4-year mortality rate in patients with vagal neuropathy was 30% compared with 6% in those with normal autonomic function. Multiple logistic regression analysis showed that presence of vagal neuropathy and severity of hepatic damage were independent predictors of mortality. Serial testing showed that whereas disease progression occurred in some patients, in others mild abnormalities in autonomic function were reversible. Vagal dysfunction is common in well-compensated chronic liver disease and its presence identifies a subgroup of patients with a substantially worse outlook.	ROYAL HALLAMSHIRE HOSP,DEPT MED & PHARMACOL,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND	University of Sheffield								DALY LE, 1991, INTERPRETATION USES, P258; EWING DJ, 1986, CLIN ENDOCRINOL META, V15, P855, DOI 10.1016/S0300-595X(86)80078-0; EWING DJ, 1980, Q J MED, V49, P95; EWING DJ, 1985, DIABETES CARE, V8, P491, DOI 10.2337/diacare.8.5.491; HENDRICKSE MT, 1990, GUT, V31, pA1164; JOHNSON RH, 1988, J NEUROL NEUROSUR PS, V51, P476, DOI 10.1136/jnnp.51.4.476; LLACH J, 1988, GASTROENTEROLOGY, V94, P482, DOI 10.1016/0016-5085(88)90441-6; LUNZER M, 1973, GUT, V14, P354, DOI 10.1136/gut.14.5.354; LUNZER MR, 1975, LANCET, V2, P382; MACGILCHRIST AJ, 1990, AM J GASTROENTEROL, V85, P288; O'Brien IA, 1991, Q J MED, V79, P495; PAGE MM, 1978, LANCET, V1, P14; PUGH RWH, 1983, BRIT J SURG, V60, P646; SATCHELL PM, 1988, AUTONOMIC FAILURE, P159; SCHUMER M, 1988, AM J MED, V85, P144, DOI 10.1016/0002-9343(88)90407-X; TAGEJENSEN U, 1988, J HEPATOL, V6, P350, DOI 10.1016/S0168-8278(88)80053-9; TAN ETH, 1984, J NEUROL NEUROSUR PS, V47, P1335, DOI 10.1136/jnnp.47.12.1335; THULUVATH PJ, 1989, Q J MED, V72, P737; 1985, WHO TECH REP SER, V727, P10; 1989, LANCET, V2, P721	20	154	158	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 13	1992	339	8807					1462	1464		10.1016/0140-6736(92)92042-E	http://dx.doi.org/10.1016/0140-6736(92)92042-E			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY317	1351136				2022-12-01	WOS:A1992HY31700014
J	JONES, MH; JENKINS, D; CUZICK, J; WOLFENDALE, MR; JONES, JJ; BALOGUNLYNCH, C; USHERWOOD, MM; SINGER, A				JONES, MH; JENKINS, D; CUZICK, J; WOLFENDALE, MR; JONES, JJ; BALOGUNLYNCH, C; USHERWOOD, MM; SINGER, A			MILD CERVICAL DYSKARYOSIS - SAFETY OF CYTOLOGICAL SURVEILLANCE	LANCET			English	Article							INTRAEPITHELIAL NEOPLASIA; ATYPIA; COLPOSCOPY; EXPERIENCE; DIAGNOSIS; SMEARS	How best to manage women who are found on cervical screening to have mild dyskaryosis remains controversial. Cytological surveillance misses some lesions picked up by colposcopy, but colposcopy is emotionally traumatic for women, the majority of whom will have a normal result. To determine what proportion of lesions are missed by cytological surveillance, and whether any abnormalities persist after colposcopy, we studied, by means of colposcopy and biopsy, the prevalence of cervical intraepithelial neoplasia (CIN) and subclinical human papillomavirus infection (HPVI) in two groups of patients who had had a first smear showing mild dyskaryosis at least 24 months earlier. One group was recruited from a centre practising cytological surveillance, with colposcopy for patients showing persistent or progressive cytological abnormality. The other group all had early colposcopy and treatment. Of 214 patients recruited into the cytological surveillance group, 70 (33%) had been referred for colposcopy within 24 months. Colposcopy of the remaining 144 (after a mean interval of 27 months from presentation) revealed that 54 (38%) were disease free, 64 (44%) had HPVI/CIN1, 8 (6%) had CIN2, and 18 (12%) had CIN3. A smear at that time identified 12 of the 18 (67%) with CIN3 as needing close cytological follow-up (1 patient) or prompt referral for colposcopy (11 patients). 137 women in the early colposcopy group attended for the study colposcopy (after a mean interval of 32 months from presentation). 37% were found to have some abnormality persisting after an earlier colposcopy, but none had CIN3. Cytological surveillance of mild dyskaryosis resulted in a 12% risk of patients having a small CIN3 lesion after 2 years, but this risk was reduced to 4% by the addition of a third repeat smear 12 months after the second. With such a policy only about a third of women would require colposcopy, and the risk of missing serious underlying precancerous changes would be low.	LEICESTER DIST HLTH AUTHOR,20-28 PRINCESS RD W,LEICESTER LE1 6TY,ENGLAND; ROYAL NO HOSP,DEPT COLPOSCOPY,LONDON N7 6LD,ENGLAND; ROYAL NO HOSP,DEPT OBSTET & GYNAECOL,LONDON N7 6LD,ENGLAND; WHITTINGTON HOSP,DEPT HISTOPATHOL,LONDON N19 5NF,ENGLAND; IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND; STOKE MANDEVILLE HOSP,DEPT CYTOL,AYLESBURY,BUCKS,ENGLAND; STOKE MANDEVILLE HOSP,DEPT OBSTET & GYNAECOL,AYLESBURY,BUCKS,ENGLAND; MILTON KEYNES DIST GEN HOSP,DEPT OBSTET & GYNAECOL,MILTON KEYNES,BUCKS,ENGLAND	University of London; University College London; Cancer Research UK								BIGRIGG MA, 1990, LANCET, V336, P229, DOI 10.1016/0140-6736(90)91746-W; BUCKLEY CH, 1982, J CLIN PATHOL, V35, P1, DOI 10.1136/jcp.35.1.1; CAMPION MJ, 1986, LANCET, V2, P237; CAMPION MJ, 1988, BRIT J OBSTET GYNAEC, V95, P175, DOI 10.1111/j.1471-0528.1988.tb06848.x; EVANS DMD, 1986, J CLIN PATHOL, V39, P933, DOI 10.1136/jcp.39.9.933; GILES JA, 1988, BRIT MED J, V296, P1099, DOI 10.1136/bmj.296.6629.1099; JARMULOWICZ MR, 1989, BRIT J OBSTET GYNAEC, V96, P1061, DOI 10.1111/j.1471-0528.1989.tb03381.x; JENKINS D, 1988, BRIT MED J, V297, P918, DOI 10.1136/bmj.297.6653.918-a; Jenkinson E J, 1990, Semin Immunol, V2, P51; JORDAN JA, 1988, BRIT MED J, V297, P6, DOI 10.1136/bmj.297.6640.6; MCCORMICK JS, 1989, LANCET, V2, P207; MCDONALD TW, 1989, GYNECOL ONCOL, V34, P345, DOI 10.1016/0090-8258(89)90170-4; MCINDOE WA, 1984, OBSTET GYNECOL, V64, P451; Posner T, 1988, PREVENTION CERVICAL; ROBERTSON JH, 1988, BRIT MED J, V297, P18, DOI 10.1136/bmj.297.6640.18; SANDMIRE HF, 1976, OBSTET GYNECOL, V48, P56; SMITH A, 1988, BRIT MED J, V296, P1670, DOI 10.1136/bmj.296.6637.1670; SOUTTER WP, 1986, BRIT J OBSTET GYNAEC, V93, P70, DOI 10.1111/j.1471-0528.1986.tb07816.x; TAY SK, 1987, AUST NZ J OBSTET GYN, V27, P140; 1987, REPORT INTERCOLLEGIA	20	57	57	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 13	1992	339	8807					1440	1443		10.1016/0140-6736(92)92031-A	http://dx.doi.org/10.1016/0140-6736(92)92031-A			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY317	1351129				2022-12-01	WOS:A1992HY31700004
J	KEMP, IW; CLARKE, K; KINLEN, LJ				KEMP, IW; CLARKE, K; KINLEN, LJ			ESOPHAGEAL CANCER AND DISTILLERIES IN SCOTLAND	BRITISH MEDICAL JOURNAL			English	Article									UNIV OXFORD,RADCLIFFE INFIRM,DEPT PUBL HLTH & PRIMARY CARE,CANC RES CAMPAIGN EPIDEMIOL GRP,OXFORD OX2 6HE,ENGLAND	Radcliffe Infirmary; University of Oxford	KEMP, IW (corresponding author), UNIV EDINBURGH,SCH MED,DEPT PUBL HLTH SCI,EDINBURGH EH8 9AJ,SCOTLAND.							BRESLOW NE, 1987, IARC SCI PUBL, V82, P96; KEMP JW, 1985, ATLAS CANCER SCOTLAN; MUIR C, 1987, IARC SCI PUBLICATION, V88; PATHAN AH, 1985, ABERDEEN POSTGRADUAT, V19, P8	4	2	2	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 13	1992	304	6841					1543	1544		10.1136/bmj.304.6841.1543	http://dx.doi.org/10.1136/bmj.304.6841.1543			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HZ178	1628054	Green Published, Bronze			2022-12-01	WOS:A1992HZ17800025
J	KOURI, YH; BASCH, RS; KARPATKIN, S				KOURI, YH; BASCH, RS; KARPATKIN, S			B-CELL SUBSETS AND PLATELET COUNTS IN HIV-1 SEROPOSITIVE SUBJECTS	LANCET			English	Note								A subset of B lymphocytes positive for the CD5 antigen have been implicated in several autoimmune disorders. To investigate their role in human immunodeficiency virus type 1 (HIV-1) infection, we studied peripheral-blood B and T lymphocytes from HIV-1-positive patients with (n = 13) and without (n = 18) thrombocytopenia, 8 patients with classic autoimmune thrombocytopenia, and 16 healthy controls. The proportion of CD5-positive B cells was significantly higher in the HIV-1-positive thrombocytopenic patients than in the healthy controls, as a result of both higher numbers of CD5-positive B cells and lower numbers of CD5-negative B cells. Platelet count was positively correlated with CD5-negative B-cell count (r = 0.6, P < 0.001) and negatively correlated with proportion of B cells that were CD5 positive (r = -0.5, p < 0.01) among the HIV-1-positive patients. The high concentrations of IgM-containing immune complexes in HIV-1-positive patients with autoimmune disorders may be due to changes in the CD5-positive B-cell subset.	NYU MED CTR, DEPT MED, 550 1ST AVE, NEW YORK, NY 10016 USA; NYU MED CTR, DEPT PATHOL, NEW YORK, NY 10016 USA; NYU MED CTR, KAPLAN CANC CTR, NEW YORK, NY 10016 USA	New York University; New York University; New York University				Basch, Ross/0000-0001-6666-2718	NHLBI NIH HHS [HL133336] Funding Source: Medline; NIA NIH HHS [AGO48660] Funding Source: Medline; NIDA NIH HHS [DADA04315] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R56HL133336, R01HL133336] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004315] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ARAUJO PMF, 1987, SCAND J IMMUNOL, V25, P497, DOI 10.1111/j.1365-3083.1987.tb02221.x; BOUMSELL L, 1980, J EXP MED, V152, P229, DOI 10.1084/jem.152.1.229; Burastero S E, 1989, Contrib Microbiol Immunol, V11, P231; HARDY RR, 1987, SCIENCE, V236, P81, DOI 10.1126/science.3105057; KARPATKIN S, 1988, P NATL ACAD SCI USA, V85, P9763, DOI 10.1073/pnas.85.24.9763; KARPATKIN S, 1992, J CLIN INVEST, V89, P356, DOI 10.1172/JCI115593; KIPPS TJ, 1989, ADV IMMUNOL, V47, P117, DOI 10.1016/S0065-2776(08)60663-X; KOPELMAN RG, 1988, AM J MED, V84, P82, DOI 10.1016/0002-9343(88)90012-5; PAINTER CJ, 1988, J EXP MED, V167, P1137, DOI 10.1084/jem.167.3.1137; ZAULI G, 1991, J ACQ IMMUN DEF SYND, V4, P1251	10	19	19	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 13	1992	339	8807					1445	1446		10.1016/0140-6736(92)92033-C	http://dx.doi.org/10.1016/0140-6736(92)92033-C			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY317	1376384				2022-12-01	WOS:A1992HY31700006
J	LIFSON, AR; HESSOL, NA; BUCHBINDER, SP; OMALLEY, PM; BARNHART, L; SEGAL, M; KATZ, MH; HOLMBERG, SD				LIFSON, AR; HESSOL, NA; BUCHBINDER, SP; OMALLEY, PM; BARNHART, L; SEGAL, M; KATZ, MH; HOLMBERG, SD			SERUM BETA-2-MICROGLOBULIN AND PREDICTION OF PROGRESSION TO AIDS IN HIV-INFECTION	LANCET			English	Article							IMMUNODEFICIENCY-VIRUS-INFECTION; BISEXUAL MEN; ACTIVATION; MARKERS; ANTIGEN; FOLLOW; COHORT; TYPE-1; COUNT; LEVEL	Identification of laboratory tests that can help predict progression to acquired immunodeficiency syndrome (AIDS) in people infected with human immunodeficiency virus (HIV) is important for clinical management and counselling. We have assessed the usefulness of CD4 lymphocyte count, serum beta-2-microglobulin concentration, and the presence of p24 antigen as predictors of AIDS. We studied 214 homosexual and bisexual men with well-defined dates of HIV seroconversion. For each participant we defined the baseline date as the earliest date before the development of AIDS on which the three laboratory tests were done. beta-2-microglobulin concentration at baseline was in all analyses an independent predictor of AIDS, even after stratification by baseline CD4 count, duration of HIV infection, or use of zidovudine before or at baseline. For example, among men with at least 0.5 x 10(9)/l CD4 cells who were negative for p24 antigen, the risks of AIDS at 12 months and 24 months were 1% and 5%, respectively, for those whose beta-2-microglobulin concentrations were below 4.0 mg/l, compared with 17% and 27%, respectively for those with beta-2-microglobulin concentrations above that cut-off point (p<0.001). Among men with an estimated duration of infection of 5 years or less, beta-2-microglobulin concentration was the strongest independent predictor of AIDS. Measurement of serum beta-2-microglobulin adds important prognostic information to CD4 count in determining the risk of progression to AIDS in HIV-infected subjects, including those whose CD4 cell count has not yet fallen.	DEPT PUBL HLTH,AIDS PROGRAM,SAN FRANCISCO,CA; CTR DIS CONTROL,CTR INFECT DIS,DIV HIV AIDS,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA	LIFSON, AR (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,DEPT EPIDEMIOL & BIOSTAT,BOX 0560,SAN FRANCISCO,CA 94143, USA.				PHS HHS [U62/CCU900523-03-5] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDERSON RE, 1990, ARCH INTERN MED, V150, P73, DOI 10.1001/archinte.150.1.73; ASCHER MS, 1990, J ACQ IMMUN DEF SYND, V3, P177; BASS HZ, 1992, J ACQ IMMUN DEF SYND, V5, P215; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; EYSTER ME, 1989, ANN INTERN MED, V110, P963, DOI 10.7326/0003-4819-110-12-963; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; FLEGG PJ, 1991, AIDS, V5, P1021, DOI 10.1097/00002030-199108000-00015; GALLO D, 1986, J CLIN MICROBIOL, V23, P1049, DOI 10.1128/JCM.23.6.1049-1051.1986; HESSOL NA, 1989, AM J EPIDEMIOL, V130, P1167, DOI 10.1093/oxfordjournals.aje.a115445; HESSOL NA, 1992, AM J PUBLIC HEALTH, V82, P561, DOI 10.2105/AJPH.82.4.561; HOFMANN B, 1990, AIDS, V4, P207, DOI 10.1097/00002030-199003000-00005; JACOBSON MA, 1989, J INFECT DIS, V159, P1029, DOI 10.1093/infdis/159.6.1029; JACOBSON MA, 1991, BRIT MED J, V302, P73, DOI 10.1136/bmj.302.6768.73; JORGENSEN AF, 1990, AIDS, V4, P1168; KIN K, 1979, IMMUNOLOGY, V36, P47; LAURENCE J, 1990, J INFECT DIS, V162, P338, DOI 10.1093/infdis/162.2.338; MCDOUGAL JS, 1985, J IMMUNOL, V135, P3151; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; OSMOND DH, 1991, AIDS, V5, P505, DOI 10.1097/00002030-199105000-00005; PEDERSEN C, 1987, BRIT MED J, V295, P567, DOI 10.1136/bmj.295.6598.567; PHAIR J, 1990, NEW ENGL J MED, V322, P161, DOI 10.1056/NEJM199001183220304; RUTHERFORD GW, 1990, BRIT MED J, V301, P1183, DOI 10.1136/bmj.301.6762.1183; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; ZANGERLE R, 1991, AIDS, V5, P985, DOI 10.1097/00002030-199108000-00010; 1989, MMWR, V38, P1	25	83	88	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 13	1992	339	8807					1436	1440		10.1016/0140-6736(92)92030-J	http://dx.doi.org/10.1016/0140-6736(92)92030-J			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY317	1351128				2022-12-01	WOS:A1992HY31700003
J	REGNERY, RL; OLSON, JG; PERKINS, BA; BIBB, W				REGNERY, RL; OLSON, JG; PERKINS, BA; BIBB, W			SEROLOGICAL RESPONSE TO ROCHALIMAEA-HENSELAE ANTIGEN IN SUSPECTED CAT-SCRATCH DISEASE	LANCET			English	Note							ANGIOMATOSIS; AGENT	There are no generally accepted diagnostic tests for cat-scratch disease (CSD), the cause of which is unknown. During the development of an indirect fluorescence antibody (IFA) test for detection of antibodies to "Rochalimaea henselae", sera from patients with CSD were found to have high titres to R henselae antigens. Further tests with this assay showed that 36 (88%) of 41 patients with suspected CSD had serum titres of 64 or more to R henselae antigen, that there was a low prevalence (3%) of substantial titres to R henselae in healthy controls (n = 107), and that the immune responses to R henselae antigens were specific. These data suggest that the R henselae IFA test, or other serological assays based on R henselae, may be useful for diagnosis of CSD.	CTR DIS CONTROL,NATL CTR INFECT DIS,DIV BACTERIAL & MYCOT DIS,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA	REGNERY, RL (corresponding author), CTR DIS CONTROL,NATL CTR INFECT DIS,DIV VIRAL & RICKETTSIAL DIS,ATLANTA,GA 30333, USA.							BRENNER DJ, 1991, J CLIN MICROBIOL, V29, P2450, DOI 10.1128/JCM.29.11.2450-2460.1991; CARITHERS HA, 1985, AM J DIS CHILD, V139, P1124, DOI 10.1001/archpedi.1985.02140130062031; ENGLISH CK, 1988, JAMA-J AM MED ASSOC, V259, P1347, DOI 10.1001/jama.259.9.1347; KEMPER CA, 1990, AM J MED, V89, P216, DOI 10.1016/0002-9343(90)90301-S; LEBOIT PE, 1988, LANCET, V1, P960; REGNERY RL, 1992, J CLIN MICROBIOL, V30, P265, DOI 10.1128/JCM.30.2.265-274.1992; RELMAN DA, 1991, NEW ENGL J MED, V324, P1514; RELMAN DA, 1990, NEW ENGL J MED, V323, P1573, DOI 10.1056/NEJM199012063232301; TEPPERO JW, 1991, 7 INT C AIDS FLOR, P340; WELCH DF, 1992, J CLIN MICROBIOL, V30, P275, DOI 10.1128/JCM.30.2.275-280.1992	10	470	487	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 13	1992	339	8807					1443	1445		10.1016/0140-6736(92)92032-B	http://dx.doi.org/10.1016/0140-6736(92)92032-B			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY317	1351130				2022-12-01	WOS:A1992HY31700005
J	SUTHERLAND, VJ; COOPER, CL				SUTHERLAND, VJ; COOPER, CL			JOB STRESS, SATISFACTION, AND MENTAL-HEALTH AMONG GENERAL-PRACTITIONERS BEFORE AND AFTER INTRODUCTION OF NEW CONTRACT	BMJ-BRITISH MEDICAL JOURNAL			English	Article							WORK; CONSULTATION; QUALITY; DOCTORS; TIME	Objective - To compare measures of job stress, job satisfaction, and mental health among general practitioners before and after the introduction of the new contract in April 1990. Design - Cross sectional postal questionnaire survey in July 1990. Comparison of results with those obtained in previous survey in November 1987. Setting - General practice in United Kingdom. Subjects - 1500 general practitioners randomly selected from general medical services lists, 917 of whom (61%) returned questionnaires usable for statistical analysis. Main outcome measures - Aspects of job causing stress, job satisfaction (Warr, Cook, and Wall scale), and mental health (Crown-Crisp experiential index). Results - Compared with 1987, in 1990 doctors experienced more stress from night calls (mean score 3.83 in 1990 v 3.45 in 1987), emergencies during surgery hours (3.72 v 3.48), and interruption of family life by telephone (3.58 v 2.73; p<0.001 for all three variables). Scores for somatic anxiety and depression were higher in both men and women in 1990 (men: somatic anxiety 3.12 v 2.36; depression 3.80 v 2.94; women: somatic anxiety 3.56 v 2.65; depression 4.02 v 3.37; p<0.001). Job satisfaction had also decreased in 1990 (5.23 v 4.26; p<0.001). Conclusions - Doctors experienced more stress, less job satisfaction, and poorer mental health in 1990 than in 1987. These changes may have resulted from the introduction of the new contract.			SUTHERLAND, VJ (corresponding author), UNIV MANCHESTER, INST SCI & TECHNOL, MANCHESTER SCH MANAGEMENT, DEPT ORG PSYCHOL, POB 88, MANCHESTER M60 1QD, LANCS, ENGLAND.							ABROOK M, 1990, PRACTITIONER, V234, P992; COOPER CL, 1989, BRIT MED J, V298, P366, DOI 10.1136/bmj.298.6670.366; Crown S, 1979, MANUAL CROWN CRISP E; FRENCH JRP, 1973, FAILURE SUCCESS, P30; GROL R, 1985, FAM PRACT, V2, P128, DOI 10.1093/fampra/2.3.128; HOWIE JGR, 1989, BMJ-BRIT MED J, V298, P1008, DOI 10.1136/bmj.298.6679.1008; KARASEK RA, 1979, ADMIN SCI QUART, V24, P285, DOI 10.2307/2392498; KEELEY D, 1991, BMJ-BRIT MED J, V302, P1514, DOI 10.1136/bmj.302.6791.1514; LLOYD G, 1990, BRIT MED J, V300, P728, DOI 10.1136/bmj.300.6726.728; MACPHERSON G, 1989, BRIT MED J, V298, P1406, DOI 10.1136/bmj.298.6685.1406; MARSH G, 1976, TEAM CARE GENERAL PR; MORRELL D, 1989, BRIT MED J, V298, P1005, DOI 10.1136/bmj.298.6679.1005; MORRELL DC, 1986, BMJ-BRIT MED J, V292, P870, DOI 10.1136/bmj.292.6524.870; MYERSON S, 1990, PRACTITIONER, V234, P973; PORTER AMD, 1985, FAM PRACT, V2, P136, DOI 10.1093/fampra/2.3.136; PORTER AMD, 1987, STRESS HLTH PROFESSI, P45; SALES SM, 1971, J CHRON DIS, V23, P861, DOI 10.1016/0021-9681(71)90015-4; SCHEIBER SC, 1987, STRESS HLTH PROFESSI, P23; Selye H., 1979, STRESS DISTRESS; SMITH T, 1989, BRIT MED J, V298, P1405, DOI 10.1136/bmj.298.6685.1405; SUTHERLAND VJ, 1990, UNDERSTANDING STRESS, P165; VANSELL M, 1981, HUM RELAT, V34, P43, DOI 10.1177/001872678103400104; WARR P, 1979, J OCCUP PSYCHOL, V52, P129, DOI 10.1111/j.2044-8325.1979.tb00448.x	23	162	162	0	17	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 13	1992	304	6841					1545	1548		10.1136/bmj.304.6841.1545	http://dx.doi.org/10.1136/bmj.304.6841.1545			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HZ178	1628056	Green Published, Bronze			2022-12-01	WOS:A1992HZ17800027
J	BURNASHEV, N; KHODOROVA, A; JONAS, P; HELM, PJ; WISDEN, W; MONYER, H; SEEBURG, PH; SAKMANN, B				BURNASHEV, N; KHODOROVA, A; JONAS, P; HELM, PJ; WISDEN, W; MONYER, H; SEEBURG, PH; SAKMANN, B			CALCIUM-PERMEABLE AMPA-KAINATE RECEPTORS IN FUSIFORM CEREBELLAR GLIAL-CELLS	SCIENCE			English	Article							FUNCTIONAL EXPRESSION; GLUTAMATE; ASTROCYTES; CHANNELS; CULTURES; MORPHOLOGY; <H-3>GABA; CLONING; FAMILY	Glutamate-operated ion channels (GluR channels) of the L-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-kainate subtype are found in both neurons and glial cells of the central nervous system. These channels are assembled from the GluR-A, -B, -C, and -D subunits; channels containing a GluR-B subunit show an outwardly rectifying current-voltage relation and low calcium permeability, whereas channels lacking the GluR-B subunit are characterized by a doubly rectifying current-voltage relation and high calcium permeability. Most cell types in the central nervous system coexpress several subunits, including GluR-B. However, Bergmann glia in rat cerebellum do not express GluR-B subunit genes. In a subset of cultured cerebellar glial cells, likely derived from Bergmann glial cells, GluR channels exhibit doubly rectifying current-voltage relations and high calcium permeability, whereas GluR channels of cerebellar neurons have low calcium permeability. Thus, differential expression of the GluR-B subunit gene in neurons and glia is one mechanism by which functional properties of native GluR channels are regulated.	MAX PLANCK INST MED RES, ZELLPHYSIOL ABT, JAHNSTR 29, W-6900 HEIDELBERG 1, GERMANY; ALL UNION BIOTECHNOL RES INST, MOSCOW 117246, USSR; UNIV HEIDELBERG, CTR MOLEC BIOL, W-6900 HEIDELBERG, GERMANY	Max Planck Society; Ruprecht Karls University Heidelberg			Burnashev, Nail/G-4056-2013; Wisden, William/A-4071-2011	Wisden, William/0000-0003-4743-0334; Jonas, Peter/0000-0001-5001-4804; Monyer, Hannah/0000-0002-9332-5749				BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; BURNASHEV N, 1992, NEURON, V8, P189, DOI 10.1016/0896-6273(92)90120-3; DEBUS E, 1983, DIFFERENTIATION, V25, P193, DOI 10.1111/j.1432-0436.1984.tb01355.x; GRANDES P, 1991, EUR J NEUROSCI, V3, P1370, DOI 10.1111/j.1460-9568.1991.tb00070.x; HATTEN ME, 1990, TRENDS NEUROSCI, V13, P179, DOI 10.1016/0166-2236(90)90044-B; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; IINO M, 1990, J PHYSIOL-LONDON, V424, P151, DOI 10.1113/jphysiol.1990.sp018060; JOHNSTONE SR, 1986, DEV BRAIN RES, V24, P63, DOI 10.1016/0165-3806(86)90173-2; JONAS P, IN PRESS J PHYSL LON; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; LEVI G, 1983, DEV BRAIN RES, V10, P227, DOI 10.1016/0165-3806(83)90139-6; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MONYER H, 1991, NEURON, V6, P799, DOI 10.1016/0896-6273(91)90176-Z; NOVELLI A, 1988, BRAIN RES, V451, P205, DOI 10.1016/0006-8993(88)90765-2; ORTEGA A, 1991, NEUROSCIENCE, V41, P335, DOI 10.1016/0306-4522(91)90331-H; OZAWA S, 1991, J NEUROPHYSIOL, V66, P2, DOI 10.1152/jn.1991.66.1.2; RAFF MC, 1983, J NEUROSCI, V3, P1289; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; SOMOGYI P, 1990, NEUROSCIENCE, V35, P9, DOI 10.1016/0306-4522(90)90116-L; SONTHEIMER H, 1988, GLIA, V1, P328, DOI 10.1002/glia.440010505; TEICHBERG VI, 1991, FASEB J, V5, P3086, DOI 10.1096/fasebj.5.15.1660422; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; WYLLIE DJA, 1991, J PHYSIOL-LONDON, V432, P235, DOI 10.1113/jphysiol.1991.sp018383; WYLLIE DJA, 1992, J PHYSIOL-LONDON, V446, pP598	27	383	386	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 12	1992	256	5063					1566	1570		10.1126/science.1317970	http://dx.doi.org/10.1126/science.1317970			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY075	1317970				2022-12-01	WOS:A1992HY07500032
J	CULVER, KW; RAM, Z; WALLBRIDGE, S; ISHII, H; OLDFIELD, EH; BLAESE, RM				CULVER, KW; RAM, Z; WALLBRIDGE, S; ISHII, H; OLDFIELD, EH; BLAESE, RM			INVIVO GENE-TRANSFER WITH RETROVIRAL VECTOR PRODUCER CELLS FOR TREATMENT OF EXPERIMENTAL BRAIN-TUMORS	SCIENCE			English	Article							THYMIDINE KINASE GENES; RAT-BRAIN; INTERLEUKIN-2; POTENT	Direct in situ introduction of exogenous genes into proliferating tumors could provide an effective therapeutic approach for treatment of localized tumors. Rats with a cerebral glioma were given an intratumoral stereotaxic injection of murine fibroblasts that were producing a retroviral vector in which the herpes simplex thymidine kinase (HS-tk) gene had been inserted. After 5 days during which the HS-tk retroviral vectors that were produced in situ transduced the neighboring proliferating glioma cells, the rats were treated with the anti-herpes drug ganciclovir. Gliomas in the ganciclovir- and vector-treated rats regressed completely both macroscopically and microscopically. This technique exploits what was previously considered to be a disadvantage of retroviral vectors-that is, their inability to transfer genes into nondividing cells. Instead, this feature of retroviruses is used to target gene delivery to dividing tumor cells and to spare nondividing neural tissue.	NINCDS,SURG NEUROL BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	CULVER, KW (corresponding author), NCI,METAB BRANCH,CELLULAR IMMUNOL SECT,BETHESDA,MD 20892, USA.							BORRELLI E, 1988, P NATL ACAD SCI USA, V85, P7572, DOI 10.1073/pnas.85.20.7572; CULVER KW, UNPUB; EZZEDDINE ZD, 1991, NEW BIOL, V3, P608; FEARON ER, 1990, CELL, V60, P397, DOI 10.1016/0092-8674(90)90591-2; GANSBACHER B, 1990, CANCER RES, V50, P7820; ISHII H, UNPUB; ITAYA T, 1987, CANCER RES, V47, P3136; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MILLER DG, 1990, MOL CELL BIOL, V10, P4239, DOI 10.1128/MCB.10.8.4239; MOOLTEN FL, 1986, CANCER RES, V46, P5276; MOOLTEN FL, 1990, J NATL CANCER I, V82, P297, DOI 10.1093/jnci/82.4.297; MULLEN CA, 1992, P NATL ACAD SCI USA, V89, P33, DOI 10.1073/pnas.89.1.33; SHORT MP, 1990, J NEUROSCI RES, V27, P427, DOI 10.1002/jnr.490270322; SPIESS PJ, 1987, JNCI-J NATL CANCER I, V79, P1067; TEPPER RI, 1989, CELL, V57, P503, DOI 10.1016/0092-8674(89)90925-2; WEIZSAECKER M, 1981, J NEUROL, V224, P183, DOI 10.1007/BF00313280; WIDNER H, 1988, BRAIN RES REV, V13, P287, DOI 10.1016/0165-0173(88)90010-0	17	1486	1680	1	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 12	1992	256	5063					1550	1552		10.1126/science.1317968	http://dx.doi.org/10.1126/science.1317968			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY075	1317968				2022-12-01	WOS:A1992HY07500027
J	DAN, Y; POO, MM				DAN, Y; POO, MM			HEBBIAN DEPRESSION OF ISOLATED NEUROMUSCULAR SYNAPSES INVITRO	SCIENCE			English	Article							LONG-TERM POTENTIATION; SYNAPTIC TRANSMISSION; EMBRYONIC NEURON; EVOKED RELEASE; HIPPOCAMPUS; ACETYLCHOLINE; MECHANISM; TRANSMITTER; ENHANCEMENT; INDUCTION	Modulation of synaptic efficacy may depend on the temporal correlation between pre- and postsynaptic activities. At isolated neuromuscular synapses in culture, repetitive postsynaptic application of acetylcholine pulses alone or in the presence of asynchronous presynaptic activity resulted in immediate and persistent synaptic depression, whereas synchronous pre- and postsynaptic coactivation had no effect. This synaptic depression was a result of a reduction of evoked transmitter release, but induction of the depression requires a rise in postsynaptic cytosolic calcium concentration. Thus, Hebbian modulation operates at isolated peripheral synapses in vitro, and transsynaptic retrograde interaction appears to be an underlying mechanism.	COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027	Columbia University				Dan, Yang/0000-0002-3818-877X	NINDS NIH HHS [NS 22764] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022764] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADLER EM, 1991, J NEUROSCI, V11, P1496; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BETZ WJ, 1989, J PHYSIOL-LONDON, V418, P25, DOI 10.1113/jphysiol.1989.sp017827; BROWN TH, 1990, ANNU REV NEUROSCI, V13, P475, DOI 10.1146/annurev.ne.13.030190.002355; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; DAN Y, UNPUB; DECKER ER, 1990, J NEUROSCI, V10, P3413; DOLPHIN AC, 1982, NATURE, V297, P496, DOI 10.1038/297496a0; GIOVANELLI A, 1991, P NATL ACAD SCI USA, V88, P10069, DOI 10.1073/pnas.88.22.10069; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HEBB DO, 1949, ORG BEHAVIOR; LEVY WB, 1979, BRAIN RES, V175, P233, DOI 10.1016/0006-8993(79)91003-5; LEVY WB, 1983, NEUROSCIENCE, V8, P791, DOI 10.1016/0306-4522(83)90010-6; LO YJ, 1991, SCIENCE, V254, P1019, DOI 10.1126/science.1658939; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; LYNCH GS, 1977, NATURE, V266, P737, DOI 10.1038/266737a0; MALENKA RC, 1988, SCIENCE, V242, P81, DOI 10.1126/science.2845577; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; POO MM, 1982, NATURE, V295, P332, DOI 10.1038/295332a0; POPOV S, 1992, J NEUROSCI, V12, P77; PURVES D, 1985, PRINCIPLES NEURAL DE; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SEJNOWSKI T J, 1991, Current Biology, V1, P38, DOI 10.1016/0960-9822(91)90122-D; Sejnowski T.J., 1989, NEURAL MODELS PLASTI, P94; SKREDE KK, 1981, BRAIN RES, V208, P436, DOI 10.1016/0006-8993(81)90573-4; SPITZER NC, 1976, P NATL ACAD SCI USA, V73, P1641, DOI 10.1073/pnas.73.5.1641; STENT GS, 1973, P NATL ACAD SCI USA, V70, P997, DOI 10.1073/pnas.70.4.997; SUN YA, 1987, P NATL ACAD SCI USA, V84, P2540, DOI 10.1073/pnas.84.8.2540; Tabti N., 1991, CULTURING NERVE CELL, P137; WILLIAMS JH, 1989, NATURE, V341, P739, DOI 10.1038/341739a0; XIE ZP, 1986, P NATL ACAD SCI USA, V83, P7069, DOI 10.1073/pnas.83.18.7069; YOUNG SH, 1983, NATURE, V305, P634, DOI 10.1038/305634a0	33	107	107	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 12	1992	256	5063					1570	1573		10.1126/science.1317971	http://dx.doi.org/10.1126/science.1317971			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY075	1317971				2022-12-01	WOS:A1992HY07500033
J	ERICSON, J; THOR, S; EDLUND, T; JESSELL, TM; YAMADA, T				ERICSON, J; THOR, S; EDLUND, T; JESSELL, TM; YAMADA, T			EARLY STAGES OF MOTOR-NEURON DIFFERENTIATION REVEALED BY EXPRESSION OF HOMEOBOX GENE ISLET-1	SCIENCE			English	Article							CHICK-EMBRYO; SPINAL-CORD; NEUROBLASTS; HOMEODOMAIN; ORGANIZATION; MOTONEURONS; INDUCTION; MIGRATION; LINEAGE; ELEGANS	Motor neurons in the embryonic chick spinal cord express a homeobox gene, islet-1, soon after their final mitotic division and before the appearance of other differentiated motor neuron properties. The expression of islet-1 by neural cells is regulated by inductive signals from the floor plate and notochord. These results establish islet-1 as the earliest marker of developing motor neurons. The molecular nature of the Islet-1 protein suggests that it may be involved in the establishment of motor neuron fate.	COLUMBIA UNIV, HAMMER HLTH SCI CTR, CTR NEUROBIOL & BEHAV, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA; UMEA UNIV, DEPT MICROBIOL, S-90187 UMEA, SWEDEN	Columbia University; Howard Hughes Medical Institute; Umea University			Thor, Stefan/Y-5804-2019	Thor, Stefan/0000-0001-5095-541X; Ericson, Johan/0000-0002-8019-7127				BLOCHGALLEGO E, 1991, DEVELOPMENT, V111, P221; CARPENTER EM, 1992, DEV BIOL, V150, P144, DOI 10.1016/0012-1606(92)90014-8; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; EISEN JS, 1991, SCIENCE, V252, P569, DOI 10.1126/science.1708527; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; FRANK E, 1979, J CELL BIOL, V83, P143, DOI 10.1083/jcb.83.1.143; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HAMBURGER V, 1982, NEUROSCI COMMENT, V1, P39; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; HOLLYDAY M, 1977, BRAIN RES, V132, P197, DOI 10.1016/0006-8993(77)90416-4; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; LANCEJONES C, 1981, PROC R SOC SER B-BIO, V214, P1, DOI 10.1098/rspb.1981.0079; LANGMAN J, 1966, J COMP NEUROL, V127, P399, DOI 10.1002/cne.901270308; LANGMAN J, 1970, J COMP NEUROL, V138, P419, DOI 10.1002/cne.901380403; LEBER SM, 1990, J NEUROSCI, V10, P2451; LEVIMONTALCINI R, 1950, J MORPHOL, V86, P253, DOI 10.1002/jmor.1050860203; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; MCCONNELL SK, 1991, SCIENCE, V254, P282, DOI 10.1126/science.1925583; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MCMAHAN UJ, 1990, COLD SH Q B, V55, P407; OPPENHEIM R, 1950, J COMP NEUROL, V210, P174; OPPENHEIM RW, 1988, J COMP NEUROL, V275, P159, DOI 10.1002/cne.902750202; PLACZEK M, 1990, SCIENCE, V250, P985, DOI 10.1126/science.2237443; PLACZEK M, 1991, DEVELOPMENT, P105; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SMITH JL, 1988, CELL TISSUE RES, V252, P491, DOI 10.1007/BF00216636; TANAKA H, 1991, NEURON, V7, P535, DOI 10.1016/0896-6273(91)90366-8; TANAKA H, 1984, DEV BIOL, V106, P26, DOI 10.1016/0012-1606(84)90057-5; THOR S, 1991, NEURON, V7, P881, DOI 10.1016/0896-6273(91)90334-V; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; VANSTRAATEN HWM, 1985, DEV BIOL, V110, P247, DOI 10.1016/0012-1606(85)90081-8; WALTHER C, 1991, DEVELOPMENT, V113, P1435; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V	39	573	592	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 12	1992	256	5063					1555	1560		10.1126/science.1350865	http://dx.doi.org/10.1126/science.1350865			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY075	1350865				2022-12-01	WOS:A1992HY07500029
J	FREEMAN, M; KLAMBT, C; GOODMAN, CS; RUBIN, GM				FREEMAN, M; KLAMBT, C; GOODMAN, CS; RUBIN, GM			THE ARGOS GENE ENCODES A DIFFUSIBLE FACTOR THAT REGULATES CELL FATE DECISIONS IN THE DROSOPHILA EYE	CELL			English	Article							SEGMENT POLARITY GENE; NERVOUS-SYSTEM; RECEPTOR; HOMOLOG; MELANOGASTER; WINGLESS; CLONING; EMBRYOS; PROTEIN; DIFFERENTIATION	The argos gene encodes a protein that is required for viability and that regulates the determination of cells in the Drosophila eye. A developmental analysis of argos mutant eyes indicates that the mystery cells, which are usually nonneuronal, are transformed into extra photoreceptors, and that supernumerary cone cells and pigment cells are also recruited. Clonal analysis indicates that argos acts nonautonomously and can diffuse over the range of several cell diameters. Conceptual translation of the argos gene suggests that it encodes a secreted protein.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley				Rubin, Gerald/0000-0001-8762-8703; Freeman, Matthew/0000-0003-0410-5451				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARMAYA E, 1991, CELL, V66, P257; ARTAVANISTSAKONAS S, 1991, TRENDS GENET, V7, P403, DOI 10.1016/0168-9525(91)90264-Q; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; BAKER NE, 1990, SCIENCE, V250, P1370, DOI 10.1126/science.2175046; BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; BAKER NE, 1989, NATURE, V340, P150, DOI 10.1038/340150a0; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BIER E, 1988, SCIENCE, V240, P913, DOI 10.1126/science.3129785; CAGAN RL, 1989, GENE DEV, V3, P1099, DOI 10.1101/gad.3.8.1099; CAMPOS AR, 1992, DEVELOPMENT, V114, P355; COHEN B, 1991, MECH DEVELOP, V33, P229, DOI 10.1016/0925-4773(91)90030-A; DANIELS SB, 1985, GENETICS, V109, P95; FISCHERVIZE JA, 1992, IN PRESS DEVELOPMENT; FORTINI ME, 1990, GENE DEV, V4, P444, DOI 10.1101/gad.4.3.444; FUJITA SC, 1982, P NATL ACAD SCI-BIOL, V79, P7929, DOI 10.1073/pnas.79.24.7929; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GELBART WM, 1989, DEVELOPMENT, V107, P65; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HEBERLEIN U, 1991, DEVELOPMENT, V112, P703; HERMAN RK, 1990, NATURE, V348, P169, DOI 10.1038/348169a0; HORTSCH M, 1990, NEURON, V4, P697, DOI 10.1016/0896-6273(90)90196-M; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; HULTMARK D, 1986, CELL, V44, P429, DOI 10.1016/0092-8674(86)90464-2; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; LAWRENCE PA, 1979, DEV BIOL, V71, P142, DOI 10.1016/0012-1606(79)90088-5; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MELAMED J, 1975, J ULTRA MOL STRUCT R, V51, P79, DOI 10.1016/S0022-5320(75)80010-4; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; MLODZIK M, 1990, GENE DEV, V4, P1848, DOI 10.1101/gad.4.11.1848; MLODZIK M, 1992, METHODS NEUROSCIENCE, V9, P397; OKANE CJ, 1987, P NATL ACAD SCI USA, V84, P9123, DOI 10.1073/pnas.84.24.9123; PALAZZOLO MJ, 1990, GENE, V88, P25, DOI 10.1016/0378-1119(90)90056-W; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; POSAKONY LG, 1990, MECH DEVELOP, V33, P69, DOI 10.1016/0925-4773(90)90136-A; RAY RP, 1991, DEVELOPMENT, V113, P35; READY DF, 1989, TRENDS NEUROSCI, V12, P102, DOI 10.1016/0166-2236(89)90166-5; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; ROBERTSON HM, 1988, GENETICS, V118, P461; ROBINOW S, 1991, J NEUROBIOL, V22, P443, DOI 10.1002/neu.480220503; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TOMLINSON A, 1988, DEVELOPMENT, V104, P183; TOMLINSON A, 1988, CELL, V55, P771, DOI 10.1016/0092-8674(88)90133-X; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; VANDENEIJNDENVANRAAIJ AJM, 1990, NATURE, V345, P732, DOI 10.1038/345732a0; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; Wieschaus E., 1986, P199; WOLFF T, 1991, DEVELOPMENT, V113, P825	59	218	222	0	3	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 12	1992	69	6					963	975		10.1016/0092-8674(92)90615-J	http://dx.doi.org/10.1016/0092-8674(92)90615-J			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HY792	1606617				2022-12-01	WOS:A1992HY79200008
J	GAO, YJ; THOMAS, JO; CHOW, RL; LEE, GH; COWAN, NJ				GAO, YJ; THOMAS, JO; CHOW, RL; LEE, GH; COWAN, NJ			A CYTOPLASMIC CHAPERONIN THAT CATALYZES BETA-ACTIN FOLDING	CELL			English	Article							RIBULOSE BISPHOSPHATE CARBOXYLASE; T-COMPLEX POLYPEPTIDE-1; HEAT-SHOCK PROTEINS; MOLECULAR CHAPERONES; TCP-1; CELLS; GROE; ARCHAEBACTERIA; MITOCHONDRIA; PURIFICATION	We have isolated a cytoplasmic chaperonin based on its ability to catalyze the folding of denatured beta-actin. The cytoplasmic chaperonin is organized as a multisubunit toroid and requires Mg2+ and ATP for activity. The folding reaction proceeds via the rapid ATP-independent formation of a binary complex, followed by a slower ATP-dependent release of the native product. Electron microscopic observations reveal a striking structural change that occurs upon addition of Mg2+ and ATP. The eukaryotic cytoplasm thus contains a chaperonin that is functionally analagous to its prokaryotic, mitochondrial, and chloroplastic counter parts.			GAO, YJ (corresponding author), NYU MED CTR,DEPT BIOCHEM,NEW YORK,NY 10016, USA.							AHMAD S, 1990, BIOCHIM BIOPHYS ACTA, V1087, P253, DOI 10.1016/0167-4781(90)90214-M; AUER J, 1989, CAN J MICROBIOL, V35, P200, DOI 10.1139/m89-031; BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; CAVALIERSMITH T, 1987, ANN NY ACAD SCI, V503, P17, DOI 10.1111/j.1749-6632.1987.tb40596.x; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CHENG MY, 1990, NATURE, V348, P455, DOI 10.1038/348455a0; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; ELLIS RJ, 1990, SCIENCE, V250, P954, DOI 10.1126/science.250.4983.954; GETHING M J, 1991, Current Opinion in Cell Biology, V3, P610, DOI 10.1016/0955-0674(91)90030-3; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GUPTA RS, 1990, BIOCHEM INT, V20, P833; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOHN T, 1979, J MOL BIOL, V129, P359, DOI 10.1016/0022-2836(79)90501-1; HUTCHISON EG, 1989, EMBO J, V8, P1484; IWABE N, 1989, P NATL ACAD SCI USA, V86, P9355, DOI 10.1073/pnas.86.23.9355; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KORN ED, 1982, PHYSIOL REV, V62, P672, DOI 10.1152/physrev.1982.62.2.672; LAZARIDES E, 1974, P NATL ACAD SCI USA, V71, P4742, DOI 10.1073/pnas.71.12.4742; LEVILLIERS N, 1984, BIOCHIMIE, V66, P531, DOI 10.1016/0300-9084(84)90147-0; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MILLER SG, 1990, J MOL BIOL, V214, P407, DOI 10.1016/0022-2836(90)90190-W; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PHIPPS BM, 1991, EMBO J, V10, P1711, DOI 10.1002/j.1460-2075.1991.tb07695.x; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SHI Y, 1992, IN PRESS MOL CELL BI; SILVER LM, 1979, P NATL ACAD SCI USA, V77, P6077; SPUDICH JA, 1971, J BIOL CHEM, V246, P4865; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TRENT JT, 1992, NATURE, V354, P490; VIITANEN PV, 1992, J BIOL CHEM, V267, P695; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WILLISON K, 1989, CELL, V57, P621, DOI 10.1016/0092-8674(89)90131-1; WILLISON KR, 1986, CELL, V44, P727, DOI 10.1016/0092-8674(86)90839-1; ZILLIG W, 1987, ANN NY ACAD SCI, V503, P78, DOI 10.1111/j.1749-6632.1987.tb40599.x	40	427	439	1	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 12	1992	69	6					1043	1050		10.1016/0092-8674(92)90622-J	http://dx.doi.org/10.1016/0092-8674(92)90622-J			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HY792	1351421				2022-12-01	WOS:A1992HY79200015
J	GLASS, RI; LIBEL, M; BRANDLINGBENNETT, AD				GLASS, RI; LIBEL, M; BRANDLINGBENNETT, AD			EPIDEMIC CHOLERA IN THE AMERICA	SCIENCE			English	Editorial Material									PAN AMER HLTH ORG,HLTH SITUAT & TREND ASSESSMENT PROGRAM,WASHINGTON,DC	Pan American Health Organization	GLASS, RI (corresponding author), CTR DIS CONTROL,NATL CTR INFECT DIS,VIRAL GASTROENTERITIS UNIT,ATLANTA,GA 30333, USA.							[Anonymous], 1991, Epidemiol Bull, V12, P1; CLEMENS JD, 1990, LANCET, V335, P270, DOI 10.1016/0140-6736(90)90080-O; GOODGAME RW, 1975, ANN INTERN MED, V82, P101, DOI 10.7326/0003-4819-82-1-101; KAMAL AM, 1974, CHOLERA, P1; KOBLAVI S, 1990, RES MICROBIOL, V141, P645, DOI 10.1016/0923-2508(90)90059-Y; KOLVIN JL, 1982, J HYG-CAMBRIDGE, V89, P243, DOI 10.1017/S0022172400070777; LEVINE MM, 1988, LANCET, V2, P468, DOI 10.1016/S0140-6736(88)90120-1; MAKUKUTU CA, 1986, APPL ENVIRON MICROB, V52, P824, DOI 10.1128/AEM.52.4.824-831.1986; MEKALANOS JJ, 1983, NATURE, V306, P551, DOI 10.1038/306551a0; Pollitzer R., 1959, WHO MONOGRAPH SERIES, V43; WACHSMUTH IK, 1991, LANCET, V337, P1097	11	42	44	2	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 12	1992	256	5063					1524	1525		10.1126/science.1598586	http://dx.doi.org/10.1126/science.1598586			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY075	1598586				2022-12-01	WOS:A1992HY07500019
J	HONG, SC; CHELOUCHE, A; LIN, RH; SHAYWITZ, D; BRAUNSTEIN, NS; GLIMCHER, L; JANEWAY, CA				HONG, SC; CHELOUCHE, A; LIN, RH; SHAYWITZ, D; BRAUNSTEIN, NS; GLIMCHER, L; JANEWAY, CA			AN MHC INTERACTION SITE MAPS TO THE AMINO-TERMINAL HALF OF THE T-CELL RECEPTOR ALPHA-CHAIN VARIABLE DOMAIN	CELL			English	Article							CLASS-II MHC; ANTIGEN-BINDING SITE; BETA-CHAIN; MONOCLONAL-ANTIBODY; FOREIGN ANTIGEN; DIRECTED MUTAGENESIS; JUNCTIONAL REGIONS; RECOGNITION; SPECIFICITY; MOLECULES	We have used cloned T cell receptor (TCR) genes from closely related CD4 T cell lines to probe the interaction of the TCR with several specific major histocompatibility complex (MHC) class II ligands. Complementarity determining region 3 (CDR3) equivalents of both alpha and beta-TCR chains are required for antigen-MHC recognition. Our data provide novel information about the rotational orientation of TCR-MHC contacts in that exchange of the amino terminal portion of the TCR alpha-chain containing the putative CDR1 and CDR2 regions results in both gain and loss of MHC class II specificity by the resulting receptor. These two TCRs differ primarily in recognition of polymorphisms in the second hypervariable region of the MHC class II alpha-chain. These results document the involvement of CDR1 and/or CDR2 of the TCR alpha-chain in MHC recognition and suggest a rotational orientation of this TCR to its MHC ligand.	COLUMBIA UNIV COLL PHYS & SURG, DEPT MED, DIV RHEUMATOL, NEW YORK, NY 10032 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT CANC BIOL, BOSTON, MA 02115 USA	Columbia University; Harvard University; Harvard T.H. Chan School of Public Health	HONG, SC (corresponding author), YALE UNIV, SCH MED, HOWARD HUGHES MED INST, IMMUNOBIOL SECT, NEW HAVEN, CT 06510 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI014579, R37AI014579] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-14579] Funding Source: Medline; NIGMS NIH HHS [GM39275] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHAORBEA H, 1988, CELL, V54, P263, DOI 10.1016/0092-8674(88)90558-2; AJITKUMAR P, 1988, CELL, V54, P47, DOI 10.1016/0092-8674(88)90178-X; AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; ASHWELL JD, 1986, J IMMUNOL, V136, P389; BARBER LD, 1991, J IMMUNOL, V147, P2346; BERKOWITZ N, 1992, J IMMUNOL, V148, P309; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BRAUNSTEIN NS, 1987, P NATL ACAD SCI USA, V84, P2921, DOI 10.1073/pnas.84.9.2921; BRAUNSTEIN NS, 1990, J IMMUNOL, V145, P1635; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; BUERSTEDDE JM, 1989, J EXP MED, V169, P1645, DOI 10.1084/jem.169.5.1645; BUERSTEDDE JM, 1988, J EXP MED, V167, P473, DOI 10.1084/jem.167.2.473; CHOTHIA C, 1988, EMBO J, V7, P3745, DOI 10.1002/j.1460-2075.1988.tb03258.x; CLAVERIE JM, 1989, IMMUNOL TODAY, V10, P10, DOI 10.1016/0167-5699(89)90058-3; COHN LE, 1986, P NATL ACAD SCI USA, V83, P747, DOI 10.1073/pnas.83.3.747; DANSKA JS, 1990, J EXP MED, V172, P27, DOI 10.1084/jem.172.1.27; DAVIS CB, 1989, J EXP MED, V169, P2239, DOI 10.1084/jem.169.6.2239; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DELLABONA P, 1991, EUR J IMMUNOL, V21, P209, DOI 10.1002/eji.1830210131; DEMOTZ S, 1991, P NATL ACAD SCI USA, V88, P8730, DOI 10.1073/pnas.88.19.8730; DIALYNAS DP, 1983, IMMUNOL REV, V74, P29, DOI 10.1111/j.1600-065X.1983.tb01083.x; ECKELS DD, 1990, HUM IMMUNOL, V27, P240, DOI 10.1016/0198-8859(90)90054-S; ENGEL I, 1988, CELL, V54, P473, DOI 10.1016/0092-8674(88)90068-2; ESCH TR, 1989, CELL IMMUNOL, V123, P226, DOI 10.1016/0008-8749(89)90282-7; FINK PJ, 1986, NATURE, V321, P219, DOI 10.1038/321219a0; GERMAIN RN, 1986, NATURE, V322, P687, DOI 10.1038/322687a0; GLIMCHER LH, 1987, IMMUNOL TODAY, V8, P274, DOI 10.1016/0167-5699(87)90188-5; HASKINS K, 1984, J EXP MED, V160, P452, DOI 10.1084/jem.160.2.452; HEATH WR, 1989, NATURE, V341, P749, DOI 10.1038/341749a0; HEDRICK SM, 1988, ADV IMMUNOL, V43, P193; HEDRICK SM, 1988, SCIENCE, V239, P1541, DOI 10.1126/science.2832942; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; JANEWAY CA, 1982, BEHRING I MITT, V70, P200; JORGENSEN JL, 1992, NATURE, V355, P224, DOI 10.1038/355224a0; KARR RW, 1990, J EXP MED, V172, P273, DOI 10.1084/jem.172.1.273; KAYE J, 1988, NATURE, V336, P580, DOI 10.1038/336580a0; KAYE J, 1984, J EXP MED, V159, P1397, DOI 10.1084/jem.159.5.1397; KAYE J, 1983, J EXP MED, V158, P836, DOI 10.1084/jem.158.3.836; Klein J., 1986, NATURAL HIST MAJOR H; KUBO RT, 1989, J IMMUNOL, V142, P2736; LAI MZ, 1990, J IMMUNOL, V144, P4851; LANG B, 1990, HUM IMMUNOL, V27, P378, DOI 10.1016/0198-8859(90)90088-7; LECHLER RI, 1990, IMMUNOL TODAY, V11, P83, DOI 10.1016/0167-5699(90)90033-6; LEE JM, 1991, J IMMUNOL, V146, P2952; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LOMBARDI G, 1991, J IMMUNOL, V147, P2034; MALISSEN M, 1988, CELL, V55, P49, DOI 10.1016/0092-8674(88)90008-6; MELLINS E, 1990, P NATL ACAD SCI USA, V87, P4785, DOI 10.1073/pnas.87.12.4785; NAKAGAWA TY, 1991, EUR J IMMUNOL, V21, P2851, DOI 10.1002/eji.1830211129; NALEFSKI EA, 1990, J BIOL CHEM, V265, P8842; PANINABORDIGNON P, 1989, COLD SH Q B, V54, P445; PANINABORDIGNON P, 1991, SCIENCE, V252, P1548, DOI 10.1126/science.1710827; PECCOUD J, 1990, EMBO J, V9, P4215, DOI 10.1002/j.1460-2075.1990.tb07869.x; PORTOLES P, 1989, J MOL CELL IMMUNOL, V4, P129; PORTOLES P, 1989, J IMMUNOL, V142, P4169; PORTOLES P, 1989, EUR J IMMUNOL, V19, P83, DOI 10.1002/eji.1830190114; ROJO JM, 1988, J IMMUNOL, V140, P1081; ROJO JM, 1989, EUR J IMMUNOL, V19, P2061, DOI 10.1002/eji.1830191114; ROSLONIEC EF, 1989, J IMMUNOL, V143, P50; ROTZSCHKE O, 1991, J EXP MED, V174, P1059, DOI 10.1084/jem.174.5.1059; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; RUDENSKY AY, 1991, NATURE, V353, P660, DOI 10.1038/353660a0; SAITO T, 1987, NATURE, V329, P256, DOI 10.1038/329256a0; SORGER SB, 1990, IMMUNOGENETICS, V31, P118, DOI 10.1007/BF00661222; STAERZ UD, 1985, J IMMUNOL, V134, P3994; VONBOEHMER H, 1989, IMMUNOL TODAY, V10, P57, DOI 10.1016/0167-5699(89)90307-1; VONBOEHMER H, 1979, EUR J IMMUNOL, V9, P592, DOI 10.1002/eji.1830090804; WEI BY, 1991, INT IMMUNOL, V3, P833, DOI 10.1093/intimm/3.8.833; WILSON DB, 1968, J EXP MED, V128, P1157, DOI 10.1084/jem.128.5.1157; WINOTO A, 1986, NATURE, V324, P679, DOI 10.1038/324679a0; YAGI JJ, 1990, J IMMUNOL, V144, P892; Zinkernagel R.M., 1979, ADV IMMUNOL, V27, P52	73	96	96	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 12	1992	69	6					999	1009		10.1016/0092-8674(92)90618-M	http://dx.doi.org/10.1016/0092-8674(92)90618-M			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HY792	1318787				2022-12-01	WOS:A1992HY79200011
J	HUARTE, J; STUTZ, A; OCONNELL, ML; GUBLER, P; BELIN, D; DARROW, AL; STRICKLAND, S; VASSALLI, JD				HUARTE, J; STUTZ, A; OCONNELL, ML; GUBLER, P; BELIN, D; DARROW, AL; STRICKLAND, S; VASSALLI, JD			TRANSIENT TRANSLATIONAL SILENCING BY REVERSIBLE MESSENGER-RNA DEADENYLATION	CELL			English	Article							XENOPUS OOCYTE MATURATION; MOUSE OOCYTES; PLASMINOGEN-ACTIVATOR; MEIOTIC MATURATION; POLY(A) ADDITION; RICH SEQUENCES; CYTOPLASMIC POLYADENYLATION; SPISULA OOCYTES; DEGRADATION; FERTILIZATION	Tissue-type plasminogen activator (tPA) mRNA is stored, stable and untranslated, in the cytoplasm of fully grown primary mouse oocytes. Dormancy is associated with an unusually short poly(A) tail, and poly(A) tail elongation controls tPA mRNA translational activation during meiotic maturation. Here we show that the nuclear transcript of this mRNA is extensively polyadenylated and that primary oocytes contain a deadenylating activity capable of silencing the cytoplasmic message. The sequence determinants that control deadenylation and polyadenylation overlap; this AU-rich region thus serves as an adenylation control element (ACE). The translation of a reporter mRNA in primary oocytes is prevented upon inclusion of an ACE in its 3' untranslated region. Therefore, the stage-specific regulation of poly(A) tail length accounts for the regulated synthesis of tPA in oocytes, and reversible deadenylation provides a mechanism for the translational control of dormant mRNAs.	SUNY STONY BROOK, DEPT PHARMACOL, STONY BROOK, NY 11794 USA; UNIV GENEVA, SCH MED, DEPT PATHOL, CH-1211 GENEVA 4, SWITZERLAND	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Geneva	HUARTE, J (corresponding author), UNIV GENEVA, SCH MED, INST HISTOL & EMBRYOL, CH-1211 GENEVA 4, SWITZERLAND.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017875, R01HD025922] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-25922, HD-17875] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALTABA AR, 1987, EMBO J, V6, P3065, DOI 10.1002/j.1460-2075.1987.tb02613.x; BACHVAROVA R, 1985, DEV BIOL, V108, P325, DOI 10.1016/0012-1606(85)90036-3; BAER BW, 1980, P NATL ACAD SCI-BIOL, V77, P1890, DOI 10.1073/pnas.77.4.1890; BRAUN RE, 1989, GENE DEV, V3, P793, DOI 10.1101/gad.3.6.793; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; Davidson E. H., 1986, GENE ACTIVITY EARLY; DELEON V, 1983, DEV BIOL, V98, P400, DOI 10.1016/0012-1606(83)90369-X; FENG P, 1990, J BIOL CHEM, V265, P2022; FOX CA, 1989, GENE DEV, V3, P2151, DOI 10.1101/gad.3.12b.2151; FOX CA, 1990, GENE DEV, V4, P2287, DOI 10.1101/gad.4.12b.2287; HAN J, 1991, J IMMUNOL, V146, P1843; HUARTE J, 1985, CELL, V43, P551, DOI 10.1016/0092-8674(85)90184-9; HUARTE J, 1987, GENE DEV, V1, P1201, DOI 10.1101/gad.1.10.1201; KONECKI DS, 1982, NUCLEIC ACIDS RES, V10, P6763, DOI 10.1093/nar/10.21.6763; KRUYS V, 1989, SCIENCE, V245, P852, DOI 10.1126/science.2672333; MCGREW LL, 1989, GENE DEV, V3, P803, DOI 10.1101/gad.3.6.803; MCGREW LL, 1990, EMBO J, V9, P3743, DOI 10.1002/j.1460-2075.1990.tb07587.x; NEVINS JR, 1983, ANNU REV BIOCHEM, V52, P441, DOI 10.1146/annurev.bi.52.070183.002301; NEVINS JR, 1978, CELL, V15, P1477, DOI 10.1016/0092-8674(78)90071-5; PARIS J, 1990, MOL CELL BIOL, V10, P5634, DOI 10.1128/MCB.10.11.5634; PAYNTON BV, 1988, DEV BIOL, V129, P304, DOI 10.1016/0012-1606(88)90377-6; RICHTER JD, 1991, BIOESSAYS, V13, P179, DOI 10.1002/bies.950130406; RICKLES RJ, 1988, J BIOL CHEM, V263, P1563; ROSENTHAL ET, 1983, J MOL BIOL, V166, P309, DOI 10.1016/S0022-2836(83)80087-4; ROSENTHAL ET, 1987, DEV BIOL, V121, P237, DOI 10.1016/0012-1606(87)90155-2; SALES FJ, 1992, IN PRESS GENES DEV; Sambrook J., 1989, MOL CLONING LAB MANU; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; STRICKLAND S, 1988, SCIENCE, V241, P680, DOI 10.1126/science.2456615; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; VARNUM SM, 1990, GENE DEV, V4, P2278, DOI 10.1101/gad.4.12b.2278; VASSALLI JD, 1989, GENE DEV, V3, P2163, DOI 10.1101/gad.3.12b.2163; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P320, DOI 10.1016/0968-0004(90)90022-4; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0	35	208	209	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 12	1992	69	6					1021	1030		10.1016/0092-8674(92)90620-R	http://dx.doi.org/10.1016/0092-8674(92)90620-R			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HY792	1606611				2022-12-01	WOS:A1992HY79200013
J	LASKY, LA; SINGER, MS; DOWBENKO, D; IMAI, Y; HENZEL, WJ; GRIMLEY, C; FENNIE, C; GILLETT, N; WATSON, SR; ROSEN, SD				LASKY, LA; SINGER, MS; DOWBENKO, D; IMAI, Y; HENZEL, WJ; GRIMLEY, C; FENNIE, C; GILLETT, N; WATSON, SR; ROSEN, SD			AN ENDOTHELIAL LIGAND FOR L-SELECTIN IS A NOVEL MUCIN-LIKE MOLECULE	CELL			English	Article							NODE HOMING RECEPTOR; CELL-ADHESION; LYMPH-NODES; VASCULAR ADDRESSIN; SPERM RECEPTOR; MEL-14 ANTIGEN; LECTIN DOMAIN; SIALIC-ACID; CARBOHYDRATE; LYMPHOCYTES	The adhesive interaction between circulating lymphocytes and the high endothelial venules (HEV) of lymph nodes (LN) is mediated by lymphocyte L-selectin, a member of the selectin family of cell adhesion proteins. Previous work has identified a sulfated 50 kd glycoprotein (Sgp50) as an HEV ligand for L-selectin. We now report the purification of this glycoprotein and the utilization of the derived N-terminal amino acid sequence to clone a cDNA. The predicted sequence reveals a novel, mucin-like molecule containing two serine/threonine-rich domains. The mRNA encoding this glycoprotein is preferentially expressed in LN. Antibodies against predicted peptides immunoprecipitate Sgp50 and stain the apical surface of LN HEV. These results thus define a tissue-specific mucin-like endothelial glycoprotein that appears to function as a scaffold that presents carbohydrates to the L-selectin lectin domain.	GENENTECH INC, DEPT SAFETY EVALUAT, San Francisco, CA 94080 USA; GENENTECH INC, DEPT PROT CHEM, San Francisco, CA 94080 USA; UNIV CALIF SAN FRANCISCO, DEPT ANAT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, PROGRAM IMMUNOL, SAN FRANCISCO, CA 94143 USA	Roche Holding; Genentech; Roche Holding; Genentech; University of California System; University of California San Francisco; University of California System; University of California San Francisco	LASKY, LA (corresponding author), GENENTECH INC, DEPT IMMUNOBIOL, 460 POINT SAN BRUNO BLVD, San Francisco, CA 94080 USA.		Imai, Yasuyuki/E-8701-2010	Imai, Yasuyuki/0000-0002-8937-0221; Henzel, William/0000-0003-2940-3797	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023547, R01GM023547] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM23547] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARGATZE RF, 1987, J EXP MED, V166, P1125, DOI 10.1084/jem.166.4.1125; BARGATZE RF, 1990, J CELL BIOCHEM, V42, P219, DOI 10.1002/jcb.240420405; BERG EL, 1991, J CELL BIOL, V114, P343, DOI 10.1083/jcb.114.2.343; BERG EL, 1989, IMMUNOL REV, V108, P5, DOI 10.1111/j.1600-065X.1989.tb00010.x; BEVILACQUA M, 1991, CELL, V67, P233, DOI 10.1016/0092-8674(91)90174-W; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BOWEN BR, 1990, J CELL BIOL, V110, P147, DOI 10.1083/jcb.110.1.147; BOWEN BR, 1989, J CELL BIOL, V109, P421, DOI 10.1083/jcb.109.1.421; BUTCHER EC, 1980, EUR J IMMUNOL, V10, P556, DOI 10.1002/eji.1830100713; BUTCHER EC, 1986, CURR TOP MICROBIOL, V128, P85; BUTCHER EC, 1990, AM J PATHOL, V136, P3; CAMERINI D, 1989, NATURE, V342, P78, DOI 10.1038/342078a0; CARAS IW, 1991, CELL BIOL INT REP, V15, P815, DOI 10.1016/0309-1651(91)90035-H; CARRAWAY K L, 1991, Glycobiology, V1, P131, DOI 10.1093/glycob/1.2.131; CORRAL L, 1990, BIOCHEM BIOPH RES CO, V172, P1349, DOI 10.1016/0006-291X(90)91598-M; CUMMING D A, 1991, Glycobiology, V1, P115, DOI 10.1093/glycob/1.2.115; CYSTER J, 1990, EUR J IMMUNOL, V20, P875, DOI 10.1002/eji.1830200424; CYSTER JG, 1991, EMBO J, V10, P893, DOI 10.1002/j.1460-2075.1991.tb08022.x; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FINERMOORE J, 1984, P NATL ACAD SCI-BIOL, V81, P155, DOI 10.1073/pnas.81.1.155; FLORMAN HM, 1985, CELL, V41, P313, DOI 10.1016/0092-8674(85)90084-4; FUKUDA M, 1991, Glycobiology, V1, P347, DOI 10.1093/glycob/1.4.347; GALLATIN M, 1986, CELL, V44, P673, DOI 10.1016/0092-8674(86)90832-9; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; GENDLER SJ, 1991, AM REV RESPIR DIS, V144, pS42, DOI 10.1164/ajrccm/144.3_pt_2.S42; GEOFFROY JS, 1989, J CELL BIOL, V109, P2463, DOI 10.1083/jcb.109.5.2463; GUM JR, 1991, J BIOL CHEM, V266, P22733; HAFFAR OK, 1988, J CELL BIOL, V107, P1677, DOI 10.1083/jcb.107.5.1677; HALLMANN R, 1991, BIOCHEM BIOPH RES CO, V174, P236, DOI 10.1016/0006-291X(91)90511-5; HAMANN A, 1991, EUR J IMMUNOL, V21, P2925, DOI 10.1002/eji.1830211205; HARDING SE, 1989, ADV CARBOHYD CHEM BI, V47, P345; HARLOW E, 1988, ANTIBODIES LABORATOR; HENDRIKS HR, 1987, EUR J IMMUNOL, V17, P1691, DOI 10.1002/eji.1830171203; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; IMAI Y, 1990, J CELL BIOL, V111, P1225, DOI 10.1083/jcb.111.3.1225; IMAI Y, 1991, J CELL BIOL, V113, P1213, DOI 10.1083/jcb.113.5.1213; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; JUTILA MA, 1989, J IMMUNOL, V143, P3318; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LARSEN E, 1990, CELL, V63, P467, DOI 10.1016/0092-8674(90)90443-I; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LEE YC, 1989, CIBA F S, V145, P80; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LEWINSOHN DM, 1987, J IMMUNOL, V138, P4313; LEY K, 1991, BLOOD, V77, P2553; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MEBIUS RE, 1991, J CELL BIOL, V115, P85, DOI 10.1083/jcb.115.1.85; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MOORE KL, 1991, J CELL BIOL, V112, P491, DOI 10.1083/jcb.112.3.491; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; PORCHET N, 1991, AM REV RESPIR DIS, V144, pS15, DOI 10.1164/ajrccm/144.3_pt_2.S15; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; Rosen SD, 1989, CURR OPIN CELL BIOL, V1, P913, DOI 10.1016/0955-0674(89)90058-6; ROSEN SD, 1985, SCIENCE, V228, P1005, DOI 10.1126/science.4001928; ROSEN SD, 1989, J IMMUNOL, V142, P1895; ROTHLEIN R, 1991, J IMMUNOL, V147, P3788; Sambrook J., 1989, MOL CLONING LAB MANU; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SHARON N, 1989, LECTINS; SHER BT, 1988, ADV CANCER RES, V51, P361, DOI 10.1016/S0065-230X(08)60226-2; SHERBLOM AP, 1980, J BIOL CHEM, V255, P2051; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; SIEGELMAN MH, 1990, CELL, V61, P611, DOI 10.1016/0092-8674(90)90473-R; SIMMONS DL, 1992, J IMMUNOL, V148, P267; SPERTINI O, 1991, J IMMUNOL, V147, P2565; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STOOLMAN LM, 1989, J CLIN INVEST, V84, P1196, DOI 10.1172/JCI114285; STOOLMAN LM, 1983, J CELL BIOL, V96, P722, DOI 10.1083/jcb.96.3.722; STOOLMAN LM, 1989, CELL, V56, P907, DOI 10.1016/0092-8674(89)90620-X; STOOLMAN LM, 1987, BLOOD, V70, P1842; STOOLMAN LM, 1984, J CELL BIOL, V99, P1535, DOI 10.1083/jcb.99.4.1535; STREETER PR, 1988, J CELL BIOL, V107, P1853, DOI 10.1083/jcb.107.5.1853; STREETER PR, 1988, NATURE, V331, P41, DOI 10.1038/331041a0; TEDDER TF, 1989, J EXP MED, V170, P123, DOI 10.1084/jem.170.1.123; TIEMEYER M, 1991, P NATL ACAD SCI USA, V88, P1138, DOI 10.1073/pnas.88.4.1138; TRUE DD, 1990, J CELL BIOL, V111, P2757, DOI 10.1083/jcb.111.6.2757; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WASSARMAN PM, 1990, DEVELOPMENT, V108, P1; WATSON SR, 1990, J CELL BIOL, V110, P2221, DOI 10.1083/jcb.110.6.2221; WATSON SR, 1991, NATURE, V349, P164, DOI 10.1038/349164a0; WILCOX JN, 1989, P NATL ACAD SCI USA, V86, P2839, DOI 10.1073/pnas.86.8.2839; WILLIAMS AF, 1991, NATURE, V352, P473, DOI 10.1038/352473a0; WOODRUFF JJ, 1987, ANNU REV IMMUNOL, V5, P201, DOI 10.1146/annurev.immunol.5.1.201; YEDNOCK TA, 1987, J CELL BIOL, V104, P713, DOI 10.1083/jcb.104.3.713; YEDNOCK TA, 1989, ADV IMMUNOL, V44, P313, DOI 10.1016/S0065-2776(08)60645-8; YEDNOCK TA, 1987, J CELL BIOL, V104, P725, DOI 10.1083/jcb.104.3.725; ZHOU Q, 1991, J CELL BIOL, V115, P557, DOI 10.1083/jcb.115.2.557	93	634	662	1	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 12	1992	69	6					927	938		10.1016/0092-8674(92)90612-G	http://dx.doi.org/10.1016/0092-8674(92)90612-G			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HY792	1376638				2022-12-01	WOS:A1992HY79200005
J	LEFEBVRE, DL; GIAID, A; BENNETT, H; LARIVIERE, R; ZINGG, HH				LEFEBVRE, DL; GIAID, A; BENNETT, H; LARIVIERE, R; ZINGG, HH			OXYTOCIN GENE-EXPRESSION IN RAT UTERUS	SCIENCE			English	Article							HUMAN PARTURITION; LOCALIZATION; INITIATION; LACTATION; RECEPTORS; ELEMENT; LABOR	The neurohypophyseal hormone oxytocin (OT) is the most potent uterotonic agent known and is used to induce labor. Yet, endogenous circulating OT appears not to participate in the induction of labor. As shown here, the finding of OT messenger RNA and peptide in the uterus suggests a solution for this paradox. During gestation, rat uterus OT messenger RNA increased more than 150-fold and, at term, exceeded hypothalamic OT messenger RNA by 70-fold. Thus, during parturition, OT may act primarily as a local mediator and not as a circulating hormone.	MCGILL UNIV,ROYAL VICTORIA HOSP,MOLEC ENDOCRINOL LAB,MONTREAL H3A 1A1,QUEBEC,CANADA; MCGILL UNIV,MONTREAL GEN HOSP,MONTREAL H3A 1A1,QUEBEC,CANADA; MCGILL UNIV,ROYAL VICTORIA HOSP,ENDOCRINE LAB,MONTREAL H3A 1A1,QUEBEC,CANADA	McGill University; Royal Victoria Hospital; McGill University; McGill University; Royal Victoria Hospital			Zingg, Hans/GPS-9984-2022					AKERLUND M, 1987, BRIT J OBSTET GYNAEC, V94, P1040, DOI 10.1111/j.1471-0528.1987.tb02287.x; ALE CC, 1961, J ENDOCRINOL, V22, P107; AYAD VJ, 1991, J ENDOCRINOL, V128, P187, DOI 10.1677/joe.0.1280187; BARASH I, 1988, ENDOCRINOLOGY, V122, P1151, DOI 10.1210/endo-122-3-1151; CHARD T, 1989, AM J PERINAT, V6, P145, DOI 10.1055/s-2007-999566; CIAROCHI FF, 1985, PEPTIDES, V6, P903, DOI 10.1016/0196-9781(85)90321-3; COLLINS S, 1990, J BIOL CHEM, V265, P19330; DEGEEST K, 1985, J PERINAT MED, V13, P3, DOI 10.1515/jpme.1985.13.1.3; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; FUCHS AR, 1982, SCIENCE, V215, P1396, DOI 10.1126/science.6278592; FUCHS AR, 1984, BRIT J OBSTET GYNAEC, V91, P948, DOI 10.1111/j.1471-0528.1984.tb03671.x; GIRALDI A, 1990, DAN MED BULL, V37, P377; GOEDERT M, 1987, EMBO J, V6, P3627, DOI 10.1002/j.1460-2075.1987.tb02694.x; GOREWIT RC, 1979, P SOC EXP BIOL MED, V160, P80, DOI 10.3181/00379727-160-40394; GRAHAM RC, 1966, J HISTOCHEM CYTOCHEM, V14, P291, DOI 10.1177/14.4.291; HCIBBAR R, 1992, 39TH P ANN M SOC GYN, P251; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; IVELL R, 1984, P NATL ACAD SCI-BIOL, V81, P2006, DOI 10.1073/pnas.81.7.2006; KUMARESAN P, 1979, J ENDOCRINOL INVEST, V2, P65, DOI 10.1007/BF03349277; LEFEBVRE D, UNPUB; LEFEBVRE DL, 1991, MOL ENDOCRINOL, V5, P645, DOI 10.1210/mend-5-5-645; LEFEBVRE DL, 1992, ENDOCRINOLOGY, V130, P1185, DOI 10.1210/en.130.3.1185; MARTINI L, 1977, CLIN NEUROENDOCRINOL, P569; PHELAN JP, 1978, AM J OBSTET GYNECOL, V130, P365; SELLERS SM, 1981, BRIT J OBSTET GYNAEC, V88, P725, DOI 10.1111/j.1471-0528.1981.tb01273.x; SHUKOVSKI L, 1991, J ENDOCRINOL, V128, P305, DOI 10.1677/joe.0.1280305; SILVERMAN AJ, 1983, ANNU REV NEUROSCI, V6, P357, DOI 10.1146/annurev.ne.06.030183.002041; SOLOFF MS, 1979, SCIENCE, V204, P1313, DOI 10.1126/science.221972; WALLACE JM, 1991, J ENDOCRINOL, V128, P253, DOI 10.1677/joe.0.1280253; WILSON L, 1990, AM J OBSTET GYNECOL, V163, P1875, DOI 10.1016/0002-9378(90)90767-2; ZINGG HH, 1988, MOL BRAIN RES, V4, P1, DOI 10.1016/0169-328X(88)90011-3; ZINGG HH, 1984, ENDOCRINOLOGY, V115, P90, DOI 10.1210/endo-115-1-90; ZINGG HH, 1986, J BIOL CHEM, V261, P2956	33	181	182	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 12	1992	256	5063					1553	1555		10.1126/science.1598587	http://dx.doi.org/10.1126/science.1598587			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY075	1598587				2022-12-01	WOS:A1992HY07500028
J	LEWIS, JD; MEEHAN, RR; HENZEL, WJ; MAURERFOGY, I; JEPPESEN, P; KLEIN, F; BIRD, A				LEWIS, JD; MEEHAN, RR; HENZEL, WJ; MAURERFOGY, I; JEPPESEN, P; KLEIN, F; BIRD, A			PURIFICATION, SEQUENCE, AND CELLULAR-LOCALIZATION OF A NOVEL CHROMOSOMAL PROTEIN THAT BINDS TO METHYLATED DNA	CELL			English	Article							MOUSE SATELLITE DNA; GENE-EXPRESSION; CHROMATIN STRUCTURE; DENOVO METHYLATION; PROMOTER; CELLS; 5-METHYLCYTOSINE; IDENTIFICATION; DEMETHYLATION; ORGANIZATION	Methylation of mammalian DNA can lead to repression of transcription and alteration of chromatin structure. Recent evidence suggests that both effects are the result of an interaction between the methylated sites and methyl-CpG-binding proteins (MeCPs). MeCP1 has previously been detected in crude nuclear extracts. Here we report the identification, purification, and cDNA cloning of a novel MeCP called MeCP2. Unlike MeCP1, the new protein is able to bind to DNA that contains a single methyl-CpG pair. By staining with an antibody, we show that the distribution of MeCP2 along the chromosomes parallels that of methyl-CpG. In mouse, for example, MeCP2 is concentrated in pericentromeric heterochromatin, which contains a large fraction (about 40%) of all genomic 5-methylcytosine.	RES INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA; GENENTECH INC,S SAN FRANCISCO,CA 94080; ERNST BOEHRINGER INST ARZNEIMITTELFORSCH,A-1121 VIENNA,AUSTRIA; WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; UNIV VIENNA,INST BOT,A-1010 VIENNA,AUSTRIA	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Roche Holding; Genentech; University of Edinburgh; University of Vienna	LEWIS, JD (corresponding author), UNIV EDINBURGH,INST CELL & MOLEC BIOL,KINGS BLDG,EDINBURGH EH9 3JR,MIDLOTHIAN,SCOTLAND.			Bird, Adrian/0000-0002-8600-0372; Meehan, Richard/0000-0001-6471-6882; Henzel, William/0000-0003-2940-3797	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANTEQUERA F, 1989, CELL, V58, P509, DOI 10.1016/0092-8674(89)90431-5; ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; ASHLEY CT, 1989, J BIOL CHEM, V264, P8394; BELL MV, 1991, CELL, V64, P861, DOI 10.1016/0092-8674(91)90514-Y; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; BOYES J, 1992, EMBO J, V11, P327, DOI 10.1002/j.1460-2075.1992.tb05055.x; BUSCHHAUSEN G, 1985, NUCLEIC ACIDS RES, V13, P5503, DOI 10.1093/nar/13.15.5503; CHURCHILL MEA, 1989, EMBO J, V8, P4189, DOI 10.1002/j.1460-2075.1989.tb08604.x; COMINGS DE, 1973, EXP CELL RES, V77, P469, DOI 10.1016/0014-4827(73)90601-0; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GROUDINE M, 1981, NATURE, V292, P311, DOI 10.1038/292311a0; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOJOH H, 1990, NUCLEIC ACIDS RES, V18, P4099; HORZ W, 1981, NUCLEIC ACIDS RES, V9, P683, DOI 10.1093/nar/9.3.683; HUBSCHER U, 1987, NUCLEIC ACIDS RES, V15, P5486, DOI 10.1093/nar/15.13.5486; JEPPESEN PN, 1991, CHROMOSOMA, V101, P322; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; JONES KW, 1970, NATURE, V225, P912, DOI 10.1038/225912a0; JOSEPH A, 1989, EXP CELL RES, V183, P494, DOI 10.1016/0014-4827(89)90408-4; KESHET I, 1985, P NATL ACAD SCI USA, V82, P2560, DOI 10.1073/pnas.82.9.2560; KIT S, 1961, J MOL BIOL, V3, P711, DOI 10.1016/S0022-2836(61)80075-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE A, 1991, P NATL ACAD SCI USA, V88, P6515, DOI 10.1073/pnas.88.15.6515; MANSON MM, 1981, CARCINOGENESIS, V2, P661, DOI 10.1093/carcin/2.7.661; MANUELIDIS L, 1981, FEBS LETT, V129, P25, DOI 10.1016/0014-5793(81)80746-6; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; MILLER OJ, 1974, NATURE, V251, P636, DOI 10.1038/251636a0; MISKIMINS WK, 1985, P NATL ACAD SCI USA, V82, P6741, DOI 10.1073/pnas.82.20.6741; MURRAY EJ, 1987, EMBO J, V6, P2329, DOI 10.1002/j.1460-2075.1987.tb02508.x; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; PARDUE ML, 1970, SCIENCE, V168, P1356, DOI 10.1126/science.168.3937.1356; PAWLAK A, 1991, NUCLEIC ACIDS RES, V19, P1029; PFEIFER GP, 1990, GENE DEV, V4, P1277, DOI 10.1101/gad.4.8.1277; REEVES R, 1990, J BIOL CHEM, V265, P8573; RENBAUM P, 1990, NUCLEIC ACIDS RES, V18, P1145, DOI 10.1093/nar/18.5.1145; RICKWOOD D, 1975, EUR J BIOCHEM, V51, P593, DOI 10.1111/j.1432-1033.1975.tb03961.x; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMID M, 1984, HUM GENET, V67, P257, DOI 10.1007/BF00291352; SOLAGE A, 1978, BIOCHEMISTRY-US, V17, P2934, DOI 10.1021/bi00607a036; STANLEY KK, 1984, EMBO J, V3, P1429, DOI 10.1002/j.1460-2075.1984.tb01988.x; STEIN R, 1982, P NATL ACAD SCI USA, V79, P4418; STEWART CL, 1982, P NATL ACAD SCI-BIOL, V79, P4098, DOI 10.1073/pnas.79.13.4098; SUTTER D, 1980, P NATL ACAD SCI-BIOL, V77, P253, DOI 10.1073/pnas.77.1.253; VANDERPLOEG LHT, 1980, CELL, V19, P947, DOI 10.1016/0092-8674(80)90086-0; VIEGASPEQUIGNOT E, 1976, HUM GENET, V34, P247, DOI 10.1007/BF00295287; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WANG RYH, 1986, NUCLEIC ACIDS RES, V14, P9843, DOI 10.1093/nar/14.24.9843; WEIH F, 1991, EMBO J, V10, P2559, DOI 10.1002/j.1460-2075.1991.tb07796.x; WILKS AF, 1982, P NATL ACAD SCI-BIOL, V79, P4252, DOI 10.1073/pnas.79.14.4252	52	1039	1076	2	47	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 12	1992	69	6					905	914		10.1016/0092-8674(92)90610-O	http://dx.doi.org/10.1016/0092-8674(92)90610-O			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HY792	1606614				2022-12-01	WOS:A1992HY79200003
J	LI, E; BESTOR, TH; JAENISCH, R				LI, E; BESTOR, TH; JAENISCH, R			TARGETED MUTATION OF THE DNA METHYLTRANSFERASE GENE RESULTS IN EMBRYONIC LETHALITY	CELL			English	Article							MURINE ERYTHROLEUKEMIA-CELLS; DENOVO METHYLATION; RETROVIRAL GENOMES; STEM-CELLS; HOMOLOGOUS RECOMBINATION; DETERMINES METHYLATION; SEQUENCE SPECIFICITY; TRANSGENIC MICE; EXPRESSION; MOUSE	Gene targeting in embryonic stem (ES) cells has been used to mutate the murine DNA methyltransferase gene. ES cell lines homozygous for the mutation were generated by consecutive targeting of both wild-type alleles; the mutant cells were viable and showed no obvious abnormalities with respect to growth rate or morphology, and had only trace levels of DNA methyltransferase activity. A quantitative end-labeling assay showed that the level of m5C in the DNA of homozygous mutant cells was about one-third that of wild-type cells, and Southern blot analysis after cleavage of the DNA with a methylation-sensitive restriction endonuclease revealed substantial demethylation of endogenous retroviral DNA. The mutation was introduced into the germline of mice and found to cause a recessive lethal phenotype. Homozygous embryos were stunted, delayed in development, and did not survive past midgestation. The DNA of homozygous embryos showed a reduction of the level of m5C similar to that of homozygous ES cells. These results indicate that while a 3-fold reduction in levels of genomic m5C has no detectable effect on the viability or proliferation of ES cells in culture, a similar reduction of DNA methylation in embryos causes abnormal development and embryonic lethality.	MIT,DEPT BIOL,CAMBRIDGE,MA 02142; HARVARD UNIV,SCH MED,DEPT ANAT & CELLULAR BIOL,HUMAN REPROD & REPROD BIOL LAB,BOSTON,MA 02115	Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School	LI, E (corresponding author), WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142, USA.				NATIONAL CANCER INSTITUTE [R35CA044339] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043565] Funding Source: NIH RePORTER; NCI NIH HHS [R35 CA 44339-05] Funding Source: Medline; NIGMS NIH HHS [GM43565] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; BENHATTAR J, 1988, GENE, V65, P219, DOI 10.1016/0378-1119(88)90458-1; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; BESTOR TH, 1985, P NATL ACAD SCI USA, V82, P2674, DOI 10.1073/pnas.82.9.2674; BESTOR TH, 1990, PHILOS T ROY SOC B, V326, P179, DOI 10.1098/rstb.1990.0002; BESTOR TH, 1983, P NATL ACAD SCI-BIOL, V80, P5559, DOI 10.1073/pnas.80.18.5559; BESTOR TH, 1984, MOL CELL BIOL, V4, P1800, DOI 10.1128/MCB.4.9.1800; BRADLEY A, 1987, TERATOCARCINOMAS EMB, P113; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; CHAILLET JR, 1991, CELL, V66, P77, DOI 10.1016/0092-8674(91)90140-T; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; GILLESPIE PG, 1991, P NATL ACAD SCI USA, V88, P2536; GRANT SG, 1988, ANNU REV GENET, V22, P199, DOI 10.1146/annurev.ge.22.120188.001215; GRUENBAUM Y, 1982, NATURE, V295, P620, DOI 10.1038/295620a0; HADCHOUEL M, 1987, NATURE, V329, P454, DOI 10.1038/329454a0; HARLOW E, 1988, ANTIBODIES LABORATOR; HOWLETT SK, 1991, DEVELOPMENT, V113, P119; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; JAENISCH R, 1985, P NATL ACAD SCI USA, V82, P1451, DOI 10.1073/pnas.82.5.1451; JAHNER D, 1982, NATURE, V298, P623, DOI 10.1038/298623a0; Jahner D., 1984, DNA METHYLATION BIOC, P189; JONES PA, 1990, P NATL ACAD SCI USA, V87, P6117, DOI 10.1073/pnas.87.16.6117; JONES PA, 1985, CELL, V40, P485, DOI 10.1016/0092-8674(85)90192-8; JONES PA, 1983, RECENT RES CANCER, V84, P202; Kaufman M. H, 1990, POSTIMPLANTATION MAM, P81; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LAUSTER R, 1989, J MOL BIOL, V206, P305, DOI 10.1016/0022-2836(89)90480-4; MANN JR, 1988, DEVELOPMENT, V103, P129; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MONK M, 1991, DEVELOPMENT, V112, P189; MONK M, 1987, DEVELOPMENT, V99, P371; PEDRALINOY G, 1986, J BIOL CHEM, V261, P7600; PFEIFER GP, 1986, BIOCHIM BIOPHYS ACTA, V868, P238, DOI 10.1016/0167-4781(86)90059-X; POSFAI J, 1989, NUCLEIC ACIDS RES, V17, P2421, DOI 10.1093/nar/17.7.2421; REIK W, 1987, NATURE, V328, P248, DOI 10.1038/328248a0; RIELE HT, 1990, NATURE, V348, P649, DOI 10.1038/348649a0; RIGGS AD, 1975, CYTOGENET CELL GENET, V14, P9, DOI 10.1159/000130315; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; SAPIENZA C, 1987, NATURE, V328, P251, DOI 10.1038/328251a0; SASAKI H, 1991, DEVELOPMENT, V111, P573; SCHWARZ MB, 1962, J BIOL CHEM, V237, P1961; SHEMER R, 1991, P NATL ACAD SCI USA, V88, P11300, DOI 10.1073/pnas.88.24.11300; SIMPSON VJ, 1986, NUCLEIC ACIDS RES, V14, P6711, DOI 10.1093/nar/14.16.6711; STEVENS LC, 1973, J NATL CANCER I, V50, P235, DOI 10.1093/jnci/50.1.235; STEWART CL, 1982, P NATL ACAD SCI-BIOL, V79, P4098, DOI 10.1073/pnas.79.13.4098; STUHLMANN H, 1981, CELL, V26, P221, DOI 10.1016/0092-8674(81)90305-6; SWAIN JL, 1987, CELL, V50, P719, DOI 10.1016/0092-8674(87)90330-8; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; URIELISHOVAL S, 1982, FEBS LETT, V146, P148, DOI 10.1016/0014-5793(82)80723-0; WATT F, 1988, GENE DEV, V2, P1136, DOI 10.1101/gad.2.9.1136; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WIGLER M, 1981, CELL, V24, P33, DOI 10.1016/0092-8674(81)90498-0; ZIJLSTRA M, 1989, NATURE, V342, P435, DOI 10.1038/342435a0	58	3116	3353	8	211	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 12	1992	69	6					915	926		10.1016/0092-8674(92)90611-F	http://dx.doi.org/10.1016/0092-8674(92)90611-F			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HY792	1606615				2022-12-01	WOS:A1992HY79200004
J	MOORE, MS; BLOBEL, G				MOORE, MS; BLOBEL, G			THE 2 STEPS OF NUCLEAR IMPORT, TARGETING TO THE NUCLEAR-ENVELOPE AND TRANSLOCATION THROUGH THE NUCLEAR-PORE, REQUIRE DIFFERENT CYTOSOLIC FACTORS	CELL			English	Article							SIGNAL-BINDING PROTEINS; COMPLEX GLYCOPROTEINS; LOCALIZATION SIGNALS; TRANSPORT SIGNAL; LOCATION SIGNAL; T-ANTIGEN; IDENTIFICATION; SEQUENCE; INHIBITION; MIGRATION	We have isolated two cytosolic fractions from Xenopus oocytes that contain all of the activity necessary to support both steps of nuclear import in digitonin-permeabilized mammalian cells: binding at the nuclear envelope and translocation through the nuclear pore. The first cytosolic fraction (fraction A) interacts with an import-competent, but not a mutant, nuclear localization sequence-bearing conjugate and stimulates its accumulation at the nuclear envelope in an ATP-independent fashion. The second cytosolic fraction (fraction B) gives no discernible effect when added alone; but when added either together with fraction A, or after fraction A, stimulates the passage of the conjugate from the outer nuclear envelope to the interior of the nucleus in an ATP-dependent fashion.			MOORE, MS (corresponding author), ROCKEFELLER UNIV,HOWARD HUGHES MED INST,CELL BIOL LAB,NEW YORK,NY 10021, USA.				PHS HHS [1F326M137585-02] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADAM SA, 1989, NATURE, V337, P276, DOI 10.1038/337276a0; ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; AKEY CW, 1989, J CELL BIOL, V109, P955, DOI 10.1083/jcb.109.3.955; BENDITT JO, 1989, P NATL ACAD SCI USA, V86, P9327, DOI 10.1073/pnas.86.23.9327; BREEUWER M, 1990, CELL, V60, P999, DOI 10.1016/0092-8674(90)90348-I; DAVIS LI, 1987, P NATL ACAD SCI USA, V84, P7552, DOI 10.1073/pnas.84.21.7552; DAVIS LI, 1986, CELL, V45, P699, DOI 10.1016/0092-8674(86)90784-1; DINGWALL C, 1982, CELL, V30, P449, DOI 10.1016/0092-8674(82)90242-2; DINGWALL C, 1986, ANNU REV CELL BIOL, V2, P367, DOI 10.1146/annurev.cellbio.2.1.367; DWORETZKY SI, 1988, J CELL BIOL, V107, P1279, DOI 10.1083/jcb.107.4.1279; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; FISCHER U, 1991, J CELL BIOL, V113, P705, DOI 10.1083/jcb.113.4.705; FISCHER U, 1990, SCIENCE, V249, P786, DOI 10.1126/science.2143847; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; HAMM J, 1990, CELL, V62, P569, DOI 10.1016/0092-8674(90)90021-6; HOLT GD, 1987, J CELL BIOL, V104, P1157, DOI 10.1083/jcb.104.5.1157; JANS DA, 1991, J CELL BIOL, V115, P1203, DOI 10.1083/jcb.115.5.1203; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KROHNE G, 1980, P NATL ACAD SCI-BIOL, V77, P1034, DOI 10.1073/pnas.77.2.1034; LANFORD RE, 1986, CELL, V46, P575, DOI 10.1016/0092-8674(86)90883-4; LANFORD RE, 1984, CELL, V37, P801, DOI 10.1016/0092-8674(84)90415-X; LEE WC, 1989, P NATL ACAD SCI USA, V86, P8808, DOI 10.1073/pnas.86.22.8808; LI RH, 1989, J CELL BIOL, V109, P2623, DOI 10.1083/jcb.109.6.2623; LOEWINGER L, 1988, EMBO J, V7, P2301, DOI 10.1002/j.1460-2075.1988.tb03073.x; MATTAJ IW, 1985, CELL, V40, P111, DOI 10.1016/0092-8674(85)90314-9; MEIER UT, 1990, J CELL BIOL, V111, P2235, DOI 10.1083/jcb.111.6.2235; MICHAUD N, 1991, J CELL BIOL, V112, P215, DOI 10.1083/jcb.112.2.215; MICHAUD N, 1992, J CELL BIOL, V116, P851, DOI 10.1083/jcb.116.4.851; NEWMEYER DD, 1990, J CELL BIOL, V110, P547, DOI 10.1083/jcb.110.3.547; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; PAINE PL, 1975, NATURE, V254, P109, DOI 10.1038/254109a0; REICHELT R, 1990, J CELL BIOL, V110, P883, DOI 10.1083/jcb.110.4.883; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; RIHS HP, 1989, EMBO J, V8, P1479, DOI 10.1002/j.1460-2075.1989.tb03531.x; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROBERTS BL, 1987, CELL, V50, P465, DOI 10.1016/0092-8674(87)90500-9; SILVER P, 1989, J CELL BIOL, V109, P983, DOI 10.1083/jcb.109.3.983; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SNOW CM, 1987, J CELL BIOL, V104, P1143, DOI 10.1083/jcb.104.5.1143; WALTER P, 1980, P NATL ACAD SCI-BIOL, V77, P7112, DOI 10.1073/pnas.77.12.7112; YAMASAKI L, 1989, MOL CELL BIOL, V9, P3028, DOI 10.1128/MCB.9.7.3028; YONEDA Y, 1987, EXP CELL RES, V173, P586, DOI 10.1016/0014-4827(87)90297-7; ZHAO LJ, 1988, CELL, V55, P1005, DOI 10.1016/0092-8674(88)90245-0	46	259	259	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 12	1992	69	6					939	950		10.1016/0092-8674(92)90613-H	http://dx.doi.org/10.1016/0092-8674(92)90613-H			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HY792	1606616				2022-12-01	WOS:A1992HY79200006
J	MULLER, T; MOLLER, T; BERGER, T; SCHNITZER, J; KETTENMANN, H				MULLER, T; MOLLER, T; BERGER, T; SCHNITZER, J; KETTENMANN, H			CALCIUM ENTRY THROUGH KAINATE RECEPTORS AND RESULTING POTASSIUM-CHANNEL BLOCKADE IN BERGMANN GLIAL-CELLS	SCIENCE			English	Article							BRAIN	Glutamate receptors, the most abundant excitatory transmitter receptors in the brain, are not restricted to neurons; they have also been detected on glial cells. Bergmann glial cells in mouse cerebellar slices revealed a kainate-type glutamate receptor with a sigmoid current-to-voltage relation, as demonstrated with the patch-clamp technique. Calcium was imaged with fura-2, and a kainate-induced increase in intracellular calcium concentration was observed, which was blocked by the non-N-methyl-D-aspartate (NMDA) glutamate receptor antagonist 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) and by low concentrations of external calcium, indicating that there was an influx of calcium through the kainate receptor itself. The entry of calcium led to a marked reduction in the resting (passive) potassium conductance of the cell. Purkinje cells, which have glutamatergic synapses, are closely associated with Bergmann glial cells and therefore may provide a functionally important stimulus.	UNIV HEIDELBERG,DEPT NEUROBIOL,NEUENHEIMER FELD 345,W-6900 HEIDELBERG,GERMANY; MAX PLANCK INST BRAIN RES,W-6000 FRANKFURT,GERMANY	Ruprecht Karls University Heidelberg; Max Planck Society			Möller, Thomas/W-8974-2019; Kettenmann, Helmut/AAJ-5142-2021	Kettenmann, Helmut/0000-0001-8208-0291				BLANKENFELD G, 1992, MOL NEUROBIOL, V5, P31; BURNASHEV N, 1992, SCIENCE, V256, P1566, DOI 10.1126/science.1317970; DEBUS E, 1983, DIFFERENTIATION, V25, P193, DOI 10.1111/j.1432-0436.1984.tb01355.x; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; FINDLAY I, 1987, PFLUG ARCH EUR J PHY, V410, P313, DOI 10.1007/BF00580282; GREGOR P, 1989, NATURE, V342, P689, DOI 10.1038/342689a0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HATTEN ME, 1990, TRENDS NEUROSCI, V13, P179, DOI 10.1016/0166-2236(90)90044-B; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; Ito M., 1984, CEREBELLUM NEURAL CO; MONYER H, 1991, NEURON, V6, P799, DOI 10.1016/0896-6273(91)90176-Z; RAKIC P, 1981, TRENDS NEUROSCI, V4, P184, DOI 10.1016/0166-2236(81)90060-6; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829	14	312	316	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 12	1992	256	5063					1563	1566		10.1126/science.1317969	http://dx.doi.org/10.1126/science.1317969			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY075	1317969				2022-12-01	WOS:A1992HY07500031
J	NAGLICH, JG; METHERALL, JE; RUSSELL, DW; EIDELS, L				NAGLICH, JG; METHERALL, JE; RUSSELL, DW; EIDELS, L			EXPRESSION CLONING OF A DIPHTHERIA-TOXIN RECEPTOR - IDENTITY WITH A HEPARIN-BINDING EGF-LIKE GROWTH-FACTOR PRECURSOR	CELL			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; CYTOPLASMIC DOMAIN; MOLECULAR-CLONING; BACTERIAL TOXINS; SIGNAL SEQUENCE; FACTOR-ALPHA; B-FRAGMENT; ZETA-CHAIN; LOW PH; CELLS	A monkey cDNA (pDTS) encoding a diphtheria toxin (DT) sensitivity determinant was isolated by expression cloning in mouse L-M cells. Mouse cells are naturally resistant to DT, because they lack functional cell surface receptors for the toxin. Unlike wild-type L-M cells, pDTS-transfected mouse cells are extremely toxin sensitive and specifically bind radioiodinated DT. Intoxication of the transfected cells requires receptor-mediated endocytosis of the bound toxin. The cDNA is predicted to encode an integral membrane protein that is identical to the precursor of a heparin-binding EGF-like growth factor. The DT sensitivity protein is thus a growth factor precursor that DT exploits as a receptor.	UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	NAGLICH, JG (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MICROBIOL,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.		Ibrahim, Essam Hassan/G-1960-2018	Ibrahim, Essam Hassan/0000-0003-0130-2257; Russell, David/0000-0002-0277-403X	NCI NIH HHS [CA 08398] Funding Source: Medline; NIAID NIH HHS [AI-16805] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA008398] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI016805] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BELL GI, 1986, NUCLEIC ACIDS RES, V14, P8427, DOI 10.1093/nar/14.21.8427; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; BREITFELD PP, 1990, J BIOL CHEM, V265, P13750; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CIEPLAK W, 1987, J BIOL CHEM, V262, P13246; COLLIER RJ, 1975, BACTERIOL REV, V39, P54, DOI 10.1128/MMBR.39.1.54-85.1975; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DAVIS JA, 1989, MOL ENDOCRINOL, V3, P674, DOI 10.1210/mend-3-4-674; DAWSON PA, 1991, J BIOL CHEM, V266, P9128; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOOLITTLE RF, 1985, TRENDS BIOCHEM SCI, V10, P233, DOI 10.1016/0968-0004(85)90140-9; DRAPER RK, 1980, J CELL BIOL, V87, P849, DOI 10.1083/jcb.87.3.849; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; EIDELS L, 1982, INFECT IMMUN, V37, P1054, DOI 10.1128/IAI.37.3.1054-1058.1982; EIDELS L, 1983, MICROBIOL REV, V47, P596, DOI 10.1128/MMBR.47.4.596-620.1983; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GRAHAM FL, 1980, INTRO MACROMOLECULES, V1, P3; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; HOBBS HH, 1990, ANNU REV GENET, V24, P133, DOI 10.1146/annurev.ge.24.120190.001025; IWAMOTO R, 1991, J BIOL CHEM, V266, P20463; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; KAUFMAN JF, 1984, J BIOL CHEM, V259, P7230; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; Kornfeld R., 1980, BIOCH GLYCOPROTEINS, P1; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; MARGOLSKEE RF, 1988, MOL CELL BIOL, V8, P2837, DOI 10.1128/MCB.8.7.2837; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MATTHEWS LS, 1991, CELL, V65, P973; MEKADA E, 1991, J BIOL CHEM, V266, P20457; MEKADA E, 1985, J BIOL CHEM, V260, P2148; MIDDLEBROOK JL, 1978, J BIOL CHEM, V253, P7325; MIDDLEBROOK JL, 1984, MICROBIOL REV, V48, P199, DOI 10.1128/MMBR.48.3.199-221.1984; MIDDLEBROOK JL, 1977, CAN J MICROBIOL, V23, P183, DOI 10.1139/m77-026; MOEHRING TJ, 1974, BIOCHEM BIOPH RES CO, V60, P1446, DOI 10.1016/0006-291X(74)90360-X; MOSKAUG JO, 1987, J BIOL CHEM, V262, P10339; MROCZKOWSKI B, 1989, MOL CELL BIOL, V9, P2771, DOI 10.1128/MCB.9.7.2771; NAGLICH JG, 1990, P NATL ACAD SCI USA, V87, P7250, DOI 10.1073/pnas.87.18.7250; NAGLICH JG, 1992, P NATL ACAD SCI USA, V89, P2170, DOI 10.1073/pnas.89.6.2170; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; NEF P, 1988, EMBO J, V7, P595, DOI 10.1002/j.1460-2075.1988.tb02852.x; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P69, DOI 10.1146/annurev.bi.46.070177.000441; PLOWMAN GD, 1990, MOL CELL BIOL, V10, P1969, DOI 10.1128/MCB.10.5.1969; PROIA RL, 1981, J BIOL CHEM, V256, P4991; PROIA RL, 1980, J BIOL CHEM, V255, P2025; RAETZ CRH, 1982, P NATL ACAD SCI-BIOL, V79, P3223, DOI 10.1073/pnas.79.10.3223; ROBBINS AR, 1987, METHOD ENZYMOL, V138, P458; ROLF JM, 1990, J BIOL CHEM, V265, P7331; ROLF JM, 1989, P NATL ACAD SCI USA, V86, P2036, DOI 10.1073/pnas.86.6.2036; RYSER HJP, 1991, J BIOL CHEM, V266, P18439; SABATINI DD, 1982, J CELL BIOL, V92, P1, DOI 10.1083/jcb.92.1.1; Sambrook J., 1989, MOL CLONING LAB MANU; SANDVIG K, 1980, J CELL BIOL, V87, P828, DOI 10.1083/jcb.87.3.828; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; STENMARK H, 1988, J BIOL CHEM, V263, P13449; THOMSEN DR, 1984, P NATL ACAD SCI-BIOL, V81, P659, DOI 10.1073/pnas.81.3.659; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377; WEISSMAN AM, 1988, P NATL ACAD SCI USA, V85, P9709, DOI 10.1073/pnas.85.24.9709; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; WRIGHT HT, 1984, J BIOL CHEM, V259, P1649	67	470	492	1	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 12	1992	69	6					1051	1061		10.1016/0092-8674(92)90623-K	http://dx.doi.org/10.1016/0092-8674(92)90623-K			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HY792	1606612				2022-12-01	WOS:A1992HY79200016
J	PATTNAIK, AK; BALL, LA; LEGRONE, AW; WERTZ, GW				PATTNAIK, AK; BALL, LA; LEGRONE, AW; WERTZ, GW			INFECTIOUS DEFECTIVE INTERFERING PARTICLES OF VSV FROM TRANSCRIPTS OF A CDNA CLONE	CELL			English	Article							VESICULAR STOMATITIS-VIRUS; RNA-POLYMERASE; INFLUENZA-VIRUS; VACCINIA VIRUS; REPLICATION; EXPRESSION; AMPLIFICATION; MUTATIONS; PROTEINS; VECTORS	The generation of infectious defective interfering (DI) particles of vesicular stomatitis virus (VSV) entirely from cDNA clones is reported. Bacteriophage T7 RNA polymerase was used to direct the transcription of a complete negative-stranded genomic RNA from a cDNA clone of a VSV DI RNA in cells simultaneously expressing the five VSV proteins from separately transfected cDNA clones. The negative-stranded transcript was encapsidated with N protein, replicated by the VSV polymerase, and the replicated RNAs were assembled and budded to yield infectious DI virions. No helper VSV was required. Replication occurred at high levels and was assayed by direct biochemical means. An exact 3' terminus of the initial transcript, which was generated by autolytic cleavage using a ribozyme from hepatitis delta virus, was critical for replication.			PATTNAIK, AK (corresponding author), UNIV ALABAMA, SCH MED, DEPT MICROBIOL, BIRMINGHAM, AL 35294 USA.		Pattnaik, Asit K./X-1531-2019	Pattnaik, Asit K./0000-0002-9581-6787	NIAID NIH HHS [AI20181, R37 AI18270, R37-AI12464] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI018270, R37AI012464, R01AI020181] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLISON RF, 1988, J VIROL, V62, P3581, DOI 10.1128/JVI.62.10.3581-3588.1988; BALL LA, 1992, J VIROL, V66, P2335, DOI 10.1128/JVI.66.4.2335-2345.1992; COLLINS PL, 1991, P NATL ACAD SCI USA, V88, P9663, DOI 10.1073/pnas.88.21.9663; DAVISON AJ, 1989, J MOL BIOL, V210, P749, DOI 10.1016/0022-2836(89)90107-1; DZIANOTT AM, 1988, NUCLEIC ACIDS RES, V16, P10940, DOI 10.1093/nar/16.22.10940; EMERSON SU, 1972, J VIROL, V10, P297, DOI 10.1128/JVI.10.2.297-309.1972; EMERSON SU, 1975, J VIROL, V15, P1348, DOI 10.1128/JVI.15.6.1348-1356.1975; ENAMI M, 1990, P NATL ACAD SCI USA, V87, P3802, DOI 10.1073/pnas.87.10.3802; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; HALTINER M, 1985, NUCLEIC ACIDS RES, V13, P1015, DOI 10.1093/nar/13.3.1015; KEENE JD, 1978, P NATL ACAD SCI USA, V75, P3225, DOI 10.1073/pnas.75.7.3225; KONARSKA MM, 1989, CELL, V57, P423, DOI 10.1016/0092-8674(89)90917-3; LUYTJES W, 1989, CELL, V59, P1107, DOI 10.1016/0092-8674(89)90766-6; MEIER E, 1984, J VIROL, V51, P515, DOI 10.1128/JVI.51.2.515-521.1984; MOYER SA, 1991, J VIROL, V65, P2170, DOI 10.1128/JVI.65.5.2170-2178.1991; PARK KH, 1991, P NATL ACAD SCI USA, V88, P5537, DOI 10.1073/pnas.88.13.5537; PATTNAIK AK, 1990, J VIROL, V64, P2948, DOI 10.1128/JVI.64.6.2948-2957.1990; PATTNAIK AK, 1991, P NATL ACAD SCI USA, V88, P1379, DOI 10.1073/pnas.88.4.1379; PATTON JT, 1984, J VIROL, V49, P303, DOI 10.1128/JVI.49.2.303-309.1984; PERROTTA AT, 1991, NATURE, V350, P434, DOI 10.1038/350434a0; PRODY GA, 1986, SCIENCE, V231, P1577, DOI 10.1126/science.231.4745.1577; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; Sambrook J., 1989, MOL CLONING LAB MANU; SORIA M, 1974, VIROLOGY, V61, P270, DOI 10.1016/0042-6822(74)90261-X; SULLENDER WM, 1991, J VIROL, V65, P5425, DOI 10.1128/JVI.65.10.5425-5434.1991; WERTZ GW, 1981, NUCLEIC ACIDS RES, V9, P6487, DOI 10.1093/nar/9.23.6487	26	246	270	1	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 12	1992	69	6					1011	1020		10.1016/0092-8674(92)90619-N	http://dx.doi.org/10.1016/0092-8674(92)90619-N			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HY792	1318785				2022-12-01	WOS:A1992HY79200012
J	POLLENZ, RS; CHEN, TLL; TRIVINOSLAGOS, L; CHISHOLM, RL				POLLENZ, RS; CHEN, TLL; TRIVINOSLAGOS, L; CHISHOLM, RL			THE DICTYOSTELIUM ESSENTIAL LIGHT CHAIN IS REQUIRED FOR MYOSIN FUNCTION	CELL			English	Article							SMOOTH-MUSCLE MYOSIN; HEAVY-CHAIN; SCALLOP MYOSIN; HOMOLOGOUS RECOMBINATION; ACANTHAMOEBA MYOSIN; ELECTRON-MICROSCOPY; ESCHERICHIA-COLI; THICK FILAMENTS; ANTISENSE RNA; BINDING-SITES	A Dictyostelium mutant (7-11) that expresses less than 0.5% of wild-type levels of the myosin essential light chain (EMLC) has been created by overexpression of antisense RNA. Cells from 7-11 contain wild-type levels of the myosin heavy chain (MHC) and regulatory light chain (RMLC). Myosin isolated from 7-11 cells consists of the MHC with the RMLC associated in reduced stoichiometry, and binds to purified actin in an ATP-sensitive fashion. Purified 7-11 myosin displays calcium-activated ATPase activity with a V(max) about 15%-25% of that of wild type, and a K(m) for ATP of 27 +/- 5-mu-M versus 83 +/- 30-mu-M for wild type. At actin concentrations as high as 17-mu-M, 7-11 myosin displays greatly reduced actin-activated ATPase activity. Phenotypically, 7-11 cells resemble MHC mutants, growing poorly in suspension and becoming large and multinucleate. When starved for multicellular development, 7-11 cells take several hours longer than wild-type cells to aggregate. Although multicellular aggregates eventually form, they fail to develop further. The cells are also unable to cap receptors in response to Con A treatment. Since cells expressing the EMLC are phenotypically similar to MHC null mutants, the EMLC appears necessary for myosin function, at least in part because it is required for normal actin-activated ATPase activity.			POLLENZ, RS (corresponding author), NORTHWESTERN UNIV,SCH MED,DEPT CELL MOLEC & STRUCT BIOL,CHICAGO,IL 60611, USA.		Chisholm, Rex L/B-3418-2009	Chisholm, Rex L/0000-0002-5638-3990	NIGMS NIH HHS [GM39264] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039264] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADELSTEIN RS, 1980, ANNU REV BIOCHEM, V49, P921, DOI 10.1146/annurev.bi.49.070180.004421; BEALL CJ, 1989, GENE DEV, V3, P131, DOI 10.1101/gad.3.2.131; BURKE D, 1989, MOL CELL BIOL, V9, P1049, DOI 10.1128/MCB.9.3.1049; CHISHOLM RL, 1988, MOL CELL BIOL, V8, P794, DOI 10.1128/MCB.8.2.794; CLARKE M, 1974, J MOL BIOL, V86, P209, DOI 10.1016/0022-2836(74)90013-8; COLLINS JH, 1980, J BIOL CHEM, V255, P8011; CROWLEY TE, 1985, CELL, V43, P633, DOI 10.1016/0092-8674(85)90235-1; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; DELOZANNE A, 1987, J CELL BIOL, V105, P2999, DOI 10.1083/jcb.105.6.2999; DREIZEN P, 1970, BIOCHEMISTRY-US, V9, P1688, DOI 10.1021/bi00810a006; EGELHOFF TT, 1991, J CELL BIOL, V112, P677, DOI 10.1083/jcb.112.4.677; EISENBERG E, 1985, SCIENCE, V227, P999, DOI 10.1126/science.3156404; FLICKER PF, 1983, J MOL BIOL, V169, P723, DOI 10.1016/S0022-2836(83)80167-3; FREDERIKSEN DW, 1968, BIOCHEMISTRY-US, V7, P3935, DOI 10.1021/bi00851a022; FUJIWARA K, 1976, J CELL BIOL, V71, P848, DOI 10.1083/jcb.71.3.848; FUKUI Y, 1991, CELL MOTIL CYTOSKEL, V18, P41, DOI 10.1002/cm.970180105; FUKUI Y, 1990, J CELL BIOL, V110, P367, DOI 10.1083/jcb.110.2.367; FUKUI Y, 1989, NATURE, V341, P328, DOI 10.1038/341328a0; FUKUI Y, 1987, METHOD CELL BIOL, P347; GERSHMAN LC, 1970, BIOCHEMISTRY-US, V9, P1677, DOI 10.1021/bi00810a005; GERSHMAN LC, 1969, J MOL BIOL, V44, P2726; GOODWIN EB, 1990, J MOL BIOL, V216, P85, DOI 10.1016/S0022-2836(05)80062-2; GRIFFITH LM, 1987, J CELL BIOL, V104, P1309, DOI 10.1083/jcb.104.5.1309; HARDWICKE PMD, 1983, NATURE, V301, P478, DOI 10.1038/301478a0; HARDWICKE PMD, 1982, J MOL BIOL, V156, P141, DOI 10.1016/0022-2836(82)90463-6; HASEGAWA Y, 1990, J BIOCHEM-TOKYO, V108, P909, DOI 10.1093/oxfordjournals.jbchem.a123313; HOPKINSON SB, 1989, MOL CELL BIOL, V9, P4170, DOI 10.1128/MCB.9.10.4170; HUXLEY HE, 1963, J MOL BIOL, V7, P281, DOI 10.1016/S0022-2836(63)80008-X; IZANT JG, 1989, CELL MOTIL CYTOSKEL, V14, P81, DOI 10.1002/cm.970140117; JACKSON AP, 1986, FEBS LETT, V197, P154, DOI 10.1016/0014-5793(86)80317-9; JUNG G, 1990, J CELL BIOL, V110, P1955, DOI 10.1083/jcb.110.6.1955; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; KARESS RE, 1991, CELL, V65, P1177, DOI 10.1016/0092-8674(91)90013-O; KATOH T, 1989, J CELL BIOL, V109, P1549, DOI 10.1083/jcb.109.4.1549; KIEHART DP, 1984, J CELL BIOL, V99, P1024, DOI 10.1083/jcb.99.3.1024; KIEHART DP, 1986, J CELL BIOL, V103, P1517, DOI 10.1083/jcb.103.4.1517; KNECHT DA, 1986, MOL CELL BIOL, V6, P3973, DOI 10.1128/MCB.6.11.3973; KNECHT DA, 1987, SCIENCE, V236, P1081, DOI 10.1126/science.3576221; KUCZMARSKI ER, 1980, P NATL ACAD SCI-BIOL, V77, P7292, DOI 10.1073/pnas.77.12.7292; KULESH DA, 1989, MOL CELL BIOL, V9, P1553, DOI 10.1128/MCB.9.4.1553; LYMN RW, 1971, BIOCHEMISTRY-US, V10, P4617, DOI 10.1021/bi00801a004; MABUCHI I, 1977, J CELL BIOL, V74, P251, DOI 10.1083/jcb.74.1.251; MANSTEIN DJ, 1989, EMBO J, V8, P923, DOI 10.1002/j.1460-2075.1989.tb03453.x; MCNALLY EM, 1991, J CELL BIOL, V113, P585, DOI 10.1083/jcb.113.3.585; MITCHELL EJ, 1989, J MOL BIOL, V208, P199, DOI 10.1016/0022-2836(89)90096-X; MITCHELL EJ, 1986, EUR J BIOCHEM, V161, P25, DOI 10.1111/j.1432-1033.1986.tb10120.x; NACHMIAS VT, 1989, CELL MOTIL CYTOSKEL, V13, P158, DOI 10.1002/cm.970130304; OHALLORAN TJ, 1990, J CELL BIOL, V110, P63, DOI 10.1083/jcb.110.1.63; OKAMOTO Y, 1980, J BIOCHEM-TOKYO, V87, P167, DOI 10.1093/oxfordjournals.jbchem.a132722; OKAMOTO Y, 1986, NATURE, V324, P78, DOI 10.1038/324078a0; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PASTERNAK C, 1989, J CELL BIOL, V109, P203, DOI 10.1083/jcb.109.1.203; PASTERNAK C, 1989, NATURE, V341, P549, DOI 10.1038/341549a0; POLLARD TD, 1973, J BIOL CHEM, V248, P4682; POLLENZ RS, 1991, CELL MOTIL CYTOSKEL, V20, P83, DOI 10.1002/cm.970200202; REES DD, 1981, J BIOL CHEM, V256, P357; REINES D, 1985, J BIOL CHEM, V260, P4248; SELLERS JR, 1984, J BIOL CHEM, V259, P4203; SELLERS JR, 1980, J MOL BIOL, V144, P223, DOI 10.1016/0022-2836(80)90088-1; SIVARAMAKRISHNAN M, 1982, J BIOL CHEM, V257, P1102; SPUDICH JA, 1989, CELL REGUL, V1, P1; STAFFORD WF, 1979, BIOCHEMISTRY-US, V18, P5273, DOI 10.1021/bi00591a002; SUN TJ, 1991, GENE DEV, V5, P572, DOI 10.1101/gad.5.4.572; SUSSMAN M, 1987, METHOD CELL BIOL, V28, P9; SZENTKIRALYI EM, 1984, J MUSCLE RES CELL M, V5, P147, DOI 10.1007/BF00712153; TAKAYAMA KM, 1990, CRIT REV BIOCHEM MOL, V25, P155, DOI 10.3109/10409239009090608; Taylor D L, 1979, Int Rev Cytol, V56, P57, DOI 10.1016/S0074-7696(08)61821-5; TOKUNAGA M, 1987, J MOL BIOL, V194, P245, DOI 10.1016/0022-2836(87)90372-X; TRYBUS KM, 1991, CELL MOTIL CYTOSKEL, V18, P81, DOI 10.1002/cm.970180202; VARNUM B, 1984, J CELL BIOL, V99, P1151, DOI 10.1083/jcb.99.3.1151; VIBERT P, 1988, J MUSCLE RES CELL M, V9, P296, DOI 10.1007/BF01773873; WAGNER PD, 1981, NATURE, V292, P560, DOI 10.1038/292560a0; WAGNER PD, 1977, J MOL BIOL, V109, P455, DOI 10.1016/S0022-2836(77)80023-5; WEEDS AG, 1971, J MOL BIOL, V61, P701, DOI 10.1016/0022-2836(71)90074-X; WEEDS AG, 1967, BIOCHEM J, V105, pC25, DOI 10.1042/bj1050025C; WEEDS AG, 1969, NATURE, V322, P1362; WESSELS D, 1988, DEV BIOL, V128, P164, DOI 10.1016/0012-1606(88)90279-5; WITKE W, 1987, EMBO J, V6, P4143, DOI 10.1002/j.1460-2075.1987.tb02760.x; YUMURA S, 1985, NATURE, V314, P194, DOI 10.1038/314194a0; YUMURA S, 1984, J CELL BIOL, V99, P894, DOI 10.1083/jcb.99.3.894	80	68	68	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 12	1992	69	6					951	962		10.1016/0092-8674(92)90614-I	http://dx.doi.org/10.1016/0092-8674(92)90614-I			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HY792	1535025				2022-12-01	WOS:A1992HY79200007
J	UDAKA, K; TSOMIDES, TJ; EISEN, HN				UDAKA, K; TSOMIDES, TJ; EISEN, HN			A NATURALLY-OCCURRING PEPTIDE RECOGNIZED BY ALLOREACTIVE CD8+ CYTOTOXIC LYMPHOCYTES-T IN ASSOCIATION WITH A CLASS-I MHC PROTEIN	CELL			English	Article							CELL RECEPTOR; MONOCLONAL-ANTIBODY; ANTIGEN RECEPTOR; HISTOCOMPATIBILITY ANTIGENS; TRANSGENIC MICE; VIRAL PEPTIDES; CLONE; GENE; DETERMINANT; EXPRESSION	The antigenic structures that initiate T cell responses to foreign (allogeneic) cells have long attracted considerable interest. We have purified and sequenced a peptide from mouse spleen that is recognized in association with the class I MHC protein H-2L(d) by 2C, an alloreactive CD8+ T cell clone. The peptide (LSP-FPFDL) greatly enhances the susceptibility of L(d+) cells to lysis by 2C, and this activity is completely blocked by a clonotypic antibody against the 2C T cell receptor. Thus, this study characterizes the naturally occurring peptide moiety of an MHC-I/peptide complex recognized by alloreactive CD8+ T cells. The peptide, which occurs in the thymus of MHC-disparate mice, can be used to study T cell development in mice expressing transgenes for the 2C T cell receptor.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; MIT, CTR CANC RES, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)					NCI NIH HHS [R35-CA42504, CA14051, CA09255] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042504, P30CA014051] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEVAN MJ, 1984, IMMUNOL TODAY, V5, P128, DOI 10.1016/0167-5699(84)90233-0; BEVAN MJ, 1977, P NATL ACAD SCI USA, V74, P2094, DOI 10.1073/pnas.74.5.2094; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; CARBONE FR, 1990, J EXP MED, V171, P377, DOI 10.1084/jem.171.2.377; ERARD F, 1985, EUR J IMMUNOL, V15, P798, DOI 10.1002/eji.1830150811; EVANS GA, 1982, P NATL ACAD SCI-BIOL, V79, P1994, DOI 10.1073/pnas.79.6.1994; FALK K, 1991, J EXP MED, V174, P425, DOI 10.1084/jem.174.2.425; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; GOVERMAN J, 1990, CELL, V60, P929, DOI 10.1016/0092-8674(90)90341-B; HANSEN TH, 1988, J IMMUNOL, V140, P3522; HEATH WR, 1991, P NATL ACAD SCI USA, V88, P5101, DOI 10.1073/pnas.88.12.5101; HEATH WR, 1989, NATURE, V341, P749, DOI 10.1038/341749a0; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; KAYE J, 1984, J EXP MED, V159, P1397, DOI 10.1084/jem.159.5.1397; KISHI H, 1991, EMBO J, V10, P93, DOI 10.1002/j.1460-2075.1991.tb07924.x; KOURILSKY P, 1989, ADV IMMUNOL, V45, P107, DOI 10.1016/S0065-2776(08)60693-8; KRANZ DM, 1984, P NATL ACAD SCI-BIOL, V81, P7922, DOI 10.1073/pnas.81.24.7922; KRANZ DM, 1984, P NATL ACAD SCI-BIOL, V81, P573, DOI 10.1073/pnas.81.2.573; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LURQUIN C, 1989, CELL, V58, P293, DOI 10.1016/0092-8674(89)90844-1; MARYANSKI JL, 1982, EUR J IMMUNOL, V12, P401, DOI 10.1002/eji.1830120508; MATZINGER P, 1977, CELL IMMUNOL, V29, P1, DOI 10.1016/0008-8749(77)90269-6; MESCHER MF, 1983, METHOD ENZYMOL, V92, P86; MOORE KW, 1982, SCIENCE, V215, P679, DOI 10.1126/science.7058332; MULLBACHER A, 1991, J IMMUNOL, V147, P1765; NIKOLICZUGIC J, 1990, NATURE, V344, P65, DOI 10.1038/344065a0; OZATO K, 1982, TRANSPLANTATION, V34, P113, DOI 10.1097/00007890-198209000-00001; PANINABORDIGNON P, 1991, SCIENCE, V252, P1548, DOI 10.1126/science.1710827; PORTOLES P, 1989, J MOL CELL IMMUNOL, V4, P129; PUNT JA, 1991, J EXP MED, V174, P775, DOI 10.1084/jem.174.4.775; REDDEHASE MJ, 1989, NATURE, V337, P651, DOI 10.1038/337651a0; ROTZSCHKE O, 1991, J EXP MED, V174, P1059, DOI 10.1084/jem.174.5.1059; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; ROTZSCHKE O, 1991, IMMUNOL TODAY, V12, P447, DOI 10.1016/0167-5699(91)90018-O; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; RUDENSKY AY, 1991, NATURE, V353, P660, DOI 10.1038/353660a0; SAITO H, 1984, NATURE, V309, P757, DOI 10.1038/309757a0; SAITO H, 1984, NATURE, V312, P36, DOI 10.1038/312036a0; SCHULZ M, 1991, EUR J IMMUNOL, V21, P1181, DOI 10.1002/eji.1830210513; SCHUMACHER TNM, 1991, NATURE, V350, P703, DOI 10.1038/350703a0; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; SHA WC, 1990, P NATL ACAD SCI USA, V87, P6186, DOI 10.1073/pnas.87.16.6186; STAERZ UD, 1985, J IMMUNOL, V134, P3994; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TSOMIDES TJ, 1991, J BIOL CHEM, V266, P3357; TSOMIDES TJ, 1991, P NATL ACAD SCI USA, V88, P11276, DOI 10.1073/pnas.88.24.11276; VANBLEEK GM, 1990, NATURE, V348, P213; VANMEERWIJK JPM, 1991, J EXP MED, V174, P815, DOI 10.1084/jem.174.4.815	51	287	296	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 12	1992	69	6					989	998		10.1016/0092-8674(92)90617-L	http://dx.doi.org/10.1016/0092-8674(92)90617-L			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HY792	1606619				2022-12-01	WOS:A1992HY79200010
J	ZHENG, B; BRETT, SJ; TITE, JP; LIFELY, MR; BRODIE, TA; RHODES, J				ZHENG, B; BRETT, SJ; TITE, JP; LIFELY, MR; BRODIE, TA; RHODES, J			GALACTOSE OXIDATION IN THE DESIGN OF IMMUNOGENIC VACCINES	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; T-CELL ACTIVATION; INFLUENZA-A VIRUS; IMMUNE-RESPONSE; ANTIGEN; RECOGNITION; VACCINATION; ANTIBODIES; RETROVIRUS; INDUCTION	Potent immunological adjuvants are urgently required to complement recombinant and synthetic vaccines. However, it has not been possible to derive new principles for the design of vaccine adjuvants from knowledge of the mechanism of immunogenicity. Carbonyl-amino condensations, which are essential to the inductive interaction between antigen-presenting cells and T helper cells, were tested as a target for the enhancement of immune responses. Enzymic oxidation of cell-surface galactose to increase amine-reactive carbonyl groups on murine lymphocytes and antigen-presenting cells provided a potent, noninflammatory method of enhancing the immunogenicity of viral, bacterial, and protozoal subunit vaccines in mice.	WELLCOME RES LABS,DEPT PHARMACOL,LANGLEY COURT,S EDEN PK RD,BECKENHAM BR3 3BS,KENT,ENGLAND; WELLCOME RES LABS,DEPT CELL BIOL,BECKENHAM BR3 3BS,KENT,ENGLAND; WELLCOME RES LABS,DEPT DRUG SAFETY EVALUAT,BECKENHAM BR3 3BS,KENT,ENGLAND	GlaxoSmithKline; Wellcome Research Laboratories; GlaxoSmithKline; Wellcome Research Laboratories; GlaxoSmithKline; Wellcome Research Laboratories								ADA GL, 1990, LANCET, V335, P523, DOI 10.1016/0140-6736(90)90748-T; BUUS S, 1987, IMMUNOL REV, V98, P115, DOI 10.1111/j.1600-065X.1987.tb00522.x; CHARLES IG, 1989, P NATL ACAD SCI USA, V86, P3554, DOI 10.1073/pnas.86.10.3554; CHEDID L, 1976, P NATL ACAD SCI USA, V73, P2472, DOI 10.1073/pnas.73.7.2472; FURUKAWA KS, 1989, J EXP MED, V169, P583; GAO XM, 1990, J IMMUNOL, V144, P2883; GAO XM, 1991, J IMMUNOL, V147, P3268; GAO XM, 1989, J IMMUNOL, V143, P3007; GLENNY AT, 1926, CHEM IND         JUN, P415; GREGORIADIS G, 1989, IMMUNOLOGICAL ADJUVA; HART MK, 1990, J IMMUNOL, V145, P2677; KOFF WC, 1989, AIDS, V3, pS125, DOI 10.1097/00002030-198901001-00018; LASKY LA, 1986, SCIENCE, V233, P209, DOI 10.1126/science.3014647; LIFELY MR, 1991, VACCINE, V9, P60, DOI 10.1016/0264-410X(91)90318-Z; LIN YL, 1981, J EXP MED, V154, P225, DOI 10.1084/jem.154.2.225; MURPHY VF, 1990, PARASITOLOGY, V100, P177, DOI 10.1017/S0031182000061175; NOVOGRODSKY A, 1973, P NATL ACAD SCI USA, V70, P1824, DOI 10.1073/pnas.70.6.1824; PLAYFAIR JHL, 1990, LANCET, V335, P1263, DOI 10.1016/0140-6736(90)91316-3; RHODES J, 1990, J IMMUNOL, V145, P463; RHODES J, 1989, J IMMUNOL, V143, P1482; RUPRECHT RM, 1990, P NATL ACAD SCI USA, V87, P5558, DOI 10.1073/pnas.87.14.5558; SCHILD GC, 1990, LANCET, V335, P1081, DOI 10.1016/0140-6736(90)92645-X; SCHWARTZ RH, 1985, ANNU REV IMMUNOL, V3, P237, DOI 10.1146/annurev.iy.03.040185.001321; SPRINGER TA, 1990, NATURE, V345, P426; STOVER CK, 1991, NATURE, V351, P456, DOI 10.1038/351456a0; TAYLOR PM, 1987, IMMUNOGENETICS, V26, P267, DOI 10.1007/BF00346521; YAP KL, 1978, NATURE, V273, P238, DOI 10.1038/273238a0; ZHENG B, UNPUB	28	54	59	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 12	1992	256	5063					1560	1563		10.1126/science.1598588	http://dx.doi.org/10.1126/science.1598588			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY075	1598588				2022-12-01	WOS:A1992HY07500030
J	BORN, RT; TOOTELL, RBH				BORN, RT; TOOTELL, RBH			SEGREGATION OF GLOBAL AND LOCAL MOTION PROCESSING IN PRIMATE MIDDLE TEMPORAL VISUAL AREA	NATURE			English	Article							MACAQUE MONKEY; CORTEX; NEURONS; DIRECTION; ANATOMY; FIELD; MT	THE early stages Of primate visual processing appear to be divided up into several component parts so that, for example, colour, form and motion are analysed by anatomically distinct streams 1-3. We have found that further subspecialization occurs within the motion processing stream. Neurons representing two different kinds of information about visual motion are segregated in columnar fashion within the middle temporal area of the owl monkey. These columns can be distinguished by labelling with 2-deoxyglucose in response to large-field random-dot patterns. Neurons in lightly labelled interbands have receptive fields with antagonistic surrounds: the response to a centrally placed moving stimulus is suppressed by motion in the surround. Neurons in more densely labelled bands have surrounds that reinforce the centre response so that they integrate motion cues over large areas of the visual field. Interband cells carry information about local motion contrast that may be used to detect motion boundaries or to indicate retinal slip during visual tracking. Band cells encode information about global motion that might be useful for orienting the animal in its environment.			BORN, RT (corresponding author), HARVARD UNIV,SCH MED,DEPT NEUROBIOL,220 LONGWOOD AVE,BOSTON,MA 02115, USA.		Born, Richard/M-6454-2019	Born, Richard/0000-0003-4360-427X				ALLMAN J, 1985, PERCEPTION, V14, P105, DOI 10.1068/p140105; BAKER JF, 1981, J NEUROPHYSIOL, V45, P397, DOI 10.1152/jn.1981.45.3.397; BORN RT, 1991, P NATL ACAD SCI USA, V88, P7066, DOI 10.1073/pnas.88.16.7066; DEYOE EA, 1988, TRENDS NEUROSCI, V11, P219, DOI 10.1016/0166-2236(88)90130-0; FROST BJ, 1981, EXP BRAIN RES, V43, P173; FROST BJ, 1983, SCIENCE, V220, P744, DOI 10.1126/science.6836313; HUBEL DH, 1968, J PHYSIOL-LONDON, V195, P215, DOI 10.1113/jphysiol.1968.sp008455; KAAS JH, 1992, INVEST OPHTH VIS SCI, V33, P1219; Krauzlis RJ, 1989, NEURAL COMPUT, V1, P116, DOI 10.1162/neco.1989.1.1.116; KUFFLER SW, 1953, J NEUROPHYSIOL, V16, P37, DOI 10.1152/jn.1953.16.1.37; LAGAE L, 1989, BRAIN RES, V496, P361, DOI 10.1016/0006-8993(89)91089-5; LIVINGSTONE M, 1988, SCIENCE, V240, P740, DOI 10.1126/science.3283936; MAUNSELL JHR, 1987, ANNU REV NEUROSCI, V10, P363, DOI 10.1146/annurev.ne.10.030187.002051; ROCKLAND KS, 1989, VISUAL NEUROSCI, V3, P155, DOI 10.1017/S0952523800004466; STERLING P, 1969, J NEUROPHYSIOL, V32, P1, DOI 10.1152/jn.1969.32.1.1; TANAKA K, 1986, J NEUROSCI, V6, P134; TOOTELL R B H, 1990, Investigative Ophthalmology and Visual Science, V31, P238; TOOTELL RBH, 1988, J NEUROSCI, V8, P1500; TOOTELL RBH, 1985, J NEUROSCI, V5, P2786; Treisman A, 1986, SCI AM, V255, P106; WONGRILEY M, 1979, BRAIN RES, V171, P11, DOI 10.1016/0006-8993(79)90728-5; WURTZ RH, 1990, COLD SPRING HARB SYM, V55, P45	22	287	287	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 11	1992	357	6378					497	499		10.1038/357497a0	http://dx.doi.org/10.1038/357497a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY052	1608448				2022-12-01	WOS:A1992HY05200063
J	DHANARAJ, V; DEALWIS, CG; FRAZAO, C; BADASSO, M; SIBANDA, BL; TICKLE, IJ; COOPER, JB; DRIESSEN, HPC; NEWMAN, M; AGUILAR, C; WOOD, SP; BLUNDELL, TL; HOBART, PM; GEOGHEGAN, KF; AMMIRATI, MJ; DANLEY, DE; OCONNOR, BA; HOOVER, DJ				DHANARAJ, V; DEALWIS, CG; FRAZAO, C; BADASSO, M; SIBANDA, BL; TICKLE, IJ; COOPER, JB; DRIESSEN, HPC; NEWMAN, M; AGUILAR, C; WOOD, SP; BLUNDELL, TL; HOBART, PM; GEOGHEGAN, KF; AMMIRATI, MJ; DANLEY, DE; OCONNOR, BA; HOOVER, DJ			X-RAY ANALYSES OF PEPTIDE-INHIBITOR COMPLEXES DEFINE THE STRUCTURAL BASIS OF SPECIFICITY FOR HUMAN AND MOUSE RENINS	NATURE			English	Article							HUMAN RENAL RENIN; 3-DIMENSIONAL STRUCTURE; SEQUENCE-ANALYSIS; GLAND RENIN; RESOLUTION	X-ray analyses have defined the three-dimensional structures of crystals of mouse and human renins complexed with peptide inhibitors at resolutions of 1.9 and 2.8 angstrom, respectively. The exquisite specificity of renin arises partly from ordered loop regions at the periphery of the binding cleft. Although the pattern of main-chain hydrogen bonding in other aspartic proteinase inhibitor complexes is conserved in renins, differences in the positions of secondary structure elements (particularly helices) also lead to improved specificity in renins for angiotensinogen substrates.	UNIV LONDON BIRKBECK COLL,MOLEC BIOL LAB,LONDON WC1E 7HX,ENGLAND; UNIV LONDON BIRKBECK COLL,DEPT CRYSTALLOG,IMPERIAL CANC RES FUND,STRUCT MOLEC BIOL UNIT,LONDON WC1E 7HX,ENGLAND; PFIZER INC,DEPT MOLEC GENET & PROT CHEM,GROTON,CT 06340; PFIZER INC,DEPT MED CHEM,DIV CENT RES,GROTON,CT 06340	University of London; Birkbeck University London; Cancer Research UK; University of London; Birkbeck University London; Pfizer; Pfizer			Wood, Stephen P/B-1438-2009; Frazao, Carlos/C-1965-2008	Tickle, Ian/0000-0003-2977-0650; Frazao, Carlos/0000-0002-7725-1671				AKAHANE K, 1985, HYPERTENSION, V7, P3, DOI 10.1161/01.HYP.7.1.3; BADASSO M, 1992, J MOL BIOL, V223, P447, DOI 10.1016/0022-2836(92)90663-5; BLUNDELL T, 1983, NATURE, V304, P273, DOI 10.1038/304273a0; CARLSON W, 1985, HYPERTENSION, V7, P13, DOI 10.1161/01.HYP.7.1.13; COOPER JB, 1990, J MOL BIOL, V214, P199, DOI 10.1016/0022-2836(90)90156-G; Crowther R. A., 1972, MOL REPLACEMENT METH, P173; CROWTHER RA, 1967, ACTA CRYSTALLOGR, V23, P544, DOI 10.1107/S0365110X67003172; CUMIN F, 1987, BIOCHIM BIOPHYS ACTA, V913, P10, DOI 10.1016/0167-4838(87)90226-3; DODSON EJ, 1985, MOL REPLACEMENT, P33; DRIESSEN H, 1989, J APPL CRYSTALLOGR, V22, P510, DOI 10.1107/S0021889889004097; DRIESSEN HPC, 1992, ACTA CRYSTALLOGR B, V47, P987; GREEN DW, 1990, BIOCHEMISTRY-US, V29, P3126, DOI 10.1021/bi00464a032; GREENLEE WJ, 1990, MED RES REV, V10, P173, DOI 10.1002/med.2610100203; HOBART PM, 1984, P NATL ACAD SCI-BIOL, V81, P5026, DOI 10.1073/pnas.81.16.5026; HOLZMAN TF, 1991, J PROTEIN CHEM, V10, P553, DOI 10.1007/BF01025483; HUTCHINS C, 1991, CRIT REV BIOCHEM MOL, V26, P77, DOI 10.3109/10409239109081721; IMAI T, 1983, P NATL ACAD SCI-BIOL, V80, P7405, DOI 10.1073/pnas.80.24.7405; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; LIM LW, 1989, J MOL BIOL, V210, P239, DOI 10.1016/0022-2836(89)90305-7; MORNON JP, 1982, J MOL BIOL, V155, P539, DOI 10.1016/0022-2836(82)90487-9; NAVIA MA, 1984, J BIOL CHEM, V259, P2714; NEWMAN M, 1991, J MOL BIOL, V221, P1295, DOI 10.1016/0022-2836(91)80127-G; POE M, 1984, ANAL BIOCHEM, V140, P459, DOI 10.1016/0003-2697(84)90194-5; RAHUEL J, 1991, J STRUCT BIOL, V107, P227, DOI 10.1016/1047-8477(91)90048-2; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SALI A, 1989, EMBO J, V8, P2179, DOI 10.1002/j.1460-2075.1989.tb08340.x; SALI A, 1992, PROTEINS, V12, P158, DOI 10.1002/prot.340120209; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SIBANDA BL, 1984, FEBS LETT, V174, P102, DOI 10.1016/0014-5793(84)81086-8; SIBANDA BL, 1986, THESIS U LONDON; SIELECKI AR, 1989, SCIENCE, V243, P1346, DOI 10.1126/science.2493678; SKEGGS LT, 1968, J EXP MED, V120, P13; Tigerstedt R., 1898, SKAND ARCH PHYSIOL, V8, P223, DOI [10.1111/j.1748-1716.1898.tb00272.x, DOI 10.1111/J.1748-1716.1898.TB00272.X]; VEERAPANDIAN B, 1990, J MOL BIOL, V216, P1017, DOI 10.1016/S0022-2836(99)80017-5; VEERAPANDIAN B, 1992, PROTEIN SCI, V1, P322	36	131	134	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 11	1992	357	6378					466	472		10.1038/357466a0	http://dx.doi.org/10.1038/357466a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY052	1608447				2022-12-01	WOS:A1992HY05200052
J	DIRICK, L; MOLL, T; AUER, H; NASMYTH, K				DIRICK, L; MOLL, T; AUER, H; NASMYTH, K			A CENTRAL ROLE FOR SWI6 IN MODULATING CELL-CYCLE START-SPECIFIC TRANSCRIPTION IN YEAST	NATURE			English	Article							HO GENE; CEREVISIAE; SEQUENCE	MOST genes involved in DNA replication in the yeast Saccharomyces cerevisiae are transcribed transiently during late G1 as cells become committed to a new cell cycle at Start 1. Their promoters all contain one or more versions of an 8-base-pair motif (ACGCGTNA) containing an MluI restriction enzyme site and called the MluI cell-cycle box (MCB) 2. MCBs are both necessary and sufficient for the late G1-specific transcription of the TMP1 thymidylate synthase and POL1 DNA polymerase genes 3,4. A different late G1-specific 8-base-pair transcription element called the SCB (CACGAAAA; ref. 5) is bound by a factor containing the Swi4 and Swi6 proteins 6,7. We describe here the formation in vitro of complexes on TMP1 MCBs that contain the Swi6 protein and, we suggest, a protein of relative molecular mass 120,000 (p120) that is distinct from Swi4. Transcription due to SCBs and MCBs occurs in the absence of Swi6 but it is no longer correctly regulated in the cell cycle. We suggest that Swi6 is an essential regulatory subunit of two different Start-dependent transcription factors. One factor (SBF) contains Swi4 and binds to SCBs, whereas the other (MBF) contains the protein p120 and binds MCBs.	INST MOLEC PATHOL,DR BOHR GASSE 7,A-1030 VIENNA,AUSTRIA	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)			Auer, Herbert/AAV-2332-2020	Nasmyth, Kim/0000-0001-7030-4403				AMMERER G, 1990, GENE DEV, V4, P299, DOI 10.1101/gad.4.2.299; ANDREWS BJ, 1990, J BIOL CHEM, V265, P14057; ANDREWS BJ, 1989, NATURE, V342, P803; BARBERIS A, 1990, GENE DEV, V4, P849, DOI 10.1101/gad.4.5.849; BREEDEN L, 1987, NATURE, V329, P651, DOI 10.1038/329651a0; CROSS FR, 1991, CELL, V65, P875, DOI 10.1016/0092-8674(91)90394-E; DIRICK L, 1991, NATURE, V351, P754, DOI 10.1038/351754a0; ELLEDGE SJ, 1990, GENE DEV, V4, P740, DOI 10.1101/gad.4.5.740; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GORDON CB, 1991, P NATL ACAD SCI USA, V88, P6058, DOI 10.1073/pnas.88.14.6058; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; KUWABARA MD, 1987, BIOCHEMISTRY-US, V26, P7234, DOI 10.1021/bi00397a006; LOWNDES NF, 1992, NATURE, V355, P449, DOI 10.1038/355449a0; LYDALL D, 1991, GENE DEV, V5, P2405, DOI 10.1101/gad.5.12b.2405; Maxam A M, 1980, Methods Enzymol, V65, P499; MCINTOSH EM, 1991, MOL CELL BIOL, V11, P329, DOI 10.1128/MCB.11.1.329; MOLL T, IN PRESS J CELL SCI; NASMYTH K, 1985, CELL, V42, P225, DOI 10.1016/S0092-8674(85)80118-5; NASMYTH K, 1991, CELL, V66, P995, DOI 10.1016/0092-8674(91)90444-4; OGAS J, 1991, CELL, V66, P1015, DOI 10.1016/0092-8674(91)90445-5; PIZZAGALLI A, 1988, P NATL ACAD SCI USA, V85, P3772, DOI 10.1073/pnas.85.11.3772; PRICE C, 1991, J MOL BIOL, V218, P543, DOI 10.1016/0022-2836(91)90700-G; STILLMAN DJ, 1988, EMBO J, V7, P485, DOI 10.1002/j.1460-2075.1988.tb02836.x; STURM R, 1987, GENE DEV, V1, P1147, DOI 10.1101/gad.1.10.1147; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; TABA MRM, 1991, GENE DEV, V5, P2000, DOI 10.1101/gad.5.11.2000	26	163	165	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 11	1992	357	6378					508	513		10.1038/357508a0	http://dx.doi.org/10.1038/357508a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY052	1608451				2022-12-01	WOS:A1992HY05200067
J	EVANS, RJ; DERKACH, V; SURPRENANT, A				EVANS, RJ; DERKACH, V; SURPRENANT, A			ATP MEDIATES FAST SYNAPTIC TRANSMISSION IN MAMMALIAN NEURONS	NATURE			English	Article							MOUSE VAS-DEFERENS; AUTONOMIC NEUROTRANSMISSION; SURAMIN; CELLS; RAT; AUTORECEPTORS; VESICLES; SINGLE	IN addition to its diverse functions inside cells, ATP can act at several types of cell-surface receptor 1-3. One of these (P2X-purinoceptor) is believed to be a ligand-gated cation channel 1-6. The presence of P2X receptors on autonomic, sensory and central neurons suggests that ATP might be released to act as a fast excitatory synaptic transmitter. Here we record excitatory synaptic potentials and currents from cultured coeliac ganglion neurons which are mimicked by ATP, blocked by the P2-purinoceptor antagonist suramin, desensitized by alpha,beta-methylene-ATP and unaffected by antagonists acting at nicotine, 5-hydroxytryptamine, N-methyl-D-aspartate (NMDA), non-NMDA glutamate, gamma-aminobutyric acid (GABA), noradrenaline or adenosine receptors. We conclude that ATP is the neurotransmitter at this neuroneuronal synapse.			EVANS, RJ (corresponding author), OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201, USA.							ALM P, 1979, NEUROSCIENCE, V4, P145, DOI 10.1016/0306-4522(79)90224-0; BEAN BP, 1990, J NEUROSCI, V10, P11; BEAN BP, 1990, J NEUROSCI, V10, P1; BENHAM CD, 1987, J PHYSIOL-LONDON, V387, P473, DOI 10.1113/jphysiol.1987.sp016585; BURNSTOCK G, 1991, NUCLEOS NUCLEOT NUCL, V10, P917, DOI 10.1080/07328319108047230; BURNSTOCK G, 1986, ACTA PHYSIOL SCAND, V126, P67, DOI 10.1111/j.1748-1716.1986.tb07790.x; BURNSTOCK G, 1990, NEUROCHEM INT, V17, P357, DOI 10.1016/0197-0186(90)90158-P; COGGAN JS, 1991, J AUTONOM NERV SYST, V34, P147, DOI 10.1016/0165-1838(91)90081-D; DUNN PM, 1988, BRIT J PHARMACOL, V93, P243, DOI 10.1111/j.1476-5381.1988.tb11427.x; EVANS RJ, IN PRESS BR J PHARM; FIEBER LA, 1991, J PHYSIOL-LONDON, V434, P239, DOI 10.1113/jphysiol.1991.sp018467; FRIED G, 1980, ACTA PHYSL SCAND, V493, P546; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOYLE CHV, 1990, BRIT J PHARMACOL, V99, P617, DOI 10.1111/j.1476-5381.1990.tb12979.x; JAHR CE, 1983, NATURE, V304, P730, DOI 10.1038/304730a0; LAGERCRANTZ H, 1976, NEUROSCIENCE, V1, P81, DOI 10.1016/0306-4522(76)90002-6; NAKAZAWA K, 1990, BRIT J PHARMACOL, V101, P224, DOI 10.1111/j.1476-5381.1990.tb12117.x; SHEN KZ, 1990, J PHYSL, V431, P585; STARKE K, 1987, REV PHYSIOL BIOCH P, V107, P73, DOI 10.1007/BFb0027645; STARKE K, 1989, PHYSIOL REV, V69, P864, DOI 10.1152/physrev.1989.69.3.864; VOLKNANDT W, 1986, J NEUROCHEM, V47, P1449, DOI 10.1111/j.1471-4159.1986.tb00778.x; VONKUGELGEN I, 1990, N-S ARCH PHARMACOL, V342, P198, DOI 10.1007/BF00166965; VONKUGELGEN I, 1989, N-S ARCH PHARMACOL, V340, P760, DOI 10.1007/BF00169686; WHITE TD, 1988, PHARMACOL THERAPEUT, V38, P129, DOI 10.1016/0163-7258(88)90095-2	24	508	515	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 11	1992	357	6378					503	505		10.1038/357503a0	http://dx.doi.org/10.1038/357503a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY052	1351659				2022-12-01	WOS:A1992HY05200065
J	FORSCHER, P; LIN, CH; THOMPSON, C				FORSCHER, P; LIN, CH; THOMPSON, C			NOVEL FORM OF GROWTH CONE MOTILITY INVOLVING SITE-DIRECTED ACTIN FILAMENT ASSEMBLY	NATURE			English	Article							LATEX BEADS; LIPID FLOW; MOVEMENTS; NEURONS	REGULATION of cytoskeletal structure and motility by extracellular signals is essential for all directed forms of cell movement and underlies the developmental process of axonal guidance in neuronal growth cones. Interaction with polycationic microbeads can trigger morphogenic changes in neurons and muscle cells normally associated with formation of pre- and postsynaptic specializations 1,2. Furthermore, when various types of microscopic particles are applied to the lamellar surface of a neuronal growth cone or motile cell they often exhibit retrograde movement at rates of 1-6-mu-m min-1 (refs 3-6). There is strong evidence that this form of particle movement results from translocation of membrane proteins associated with cortical F-actin networks, not from bulk retrograde lipid flow 4,5,7 and may be a mechanism behind processes such as cell locomotion, growth cone migration and capping of cell-surface antigens 6,8,9. Here we report a new form of motility stimulated by polycationic bead interactions with the growth-cone membrane surface. Bead binding rapidly induces intracellular actin filament assembly, coincident with a production of force sufficient to drive bead movements. These extracellular bead movements resemble intracellular movements of bacterial parasites known to redirect host cell F-actin assembly for propulsion. Our results suggest that site-directed actin filament assembly may be a widespread cellular mechanism for generating force at membrane-cytoskeletal interfaces.	YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510	Yale University	FORSCHER, P (corresponding author), YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06511, USA.			Smith, Peter/0000-0003-4400-6853; Forscher, Paul/0000-0003-1988-5155				BRAY D, 1988, SCIENCE, V239, P883, DOI 10.1126/science.3277283; BRAY D, 1970, P NATL ACAD SCI USA, V65, P905, DOI 10.1073/pnas.65.4.905; DABIRI GA, 1990, P NATL ACAD SCI USA, V87, P6068, DOI 10.1073/pnas.87.16.6068; FORSCHER P, 1987, J NEUROSCI, V7, P3600; FORSCHER P, 1990, OPTICAL MICROSCOPY FOR BIOLOGY, P459; FORSCHER P, 1988, J CELL BIOL, V107, P1505, DOI 10.1083/jcb.107.4.1505; LEE J, 1990, SCIENCE, V247, P1229, DOI 10.1126/science.2315695; MITCHISON T, 1988, NEURON, V1, P761, DOI 10.1016/0896-6273(88)90124-9; PENG HB, 1981, NATURE, V292, P831, DOI 10.1038/292831a0; PENG HB, 1987, SYNAPSE, V1, P10, DOI 10.1002/syn.890010104; SHEETZ MP, 1989, NATURE, V340, P284, DOI 10.1038/340284a0; SMITH SJ, 1988, SCIENCE, V242, P708, DOI 10.1126/science.3055292; TILNEY LG, 1990, J CELL BIOL, V111, P2979, DOI 10.1083/jcb.111.6.2979	13	132	132	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 11	1992	357	6378					515	518		10.1038/357515a0	http://dx.doi.org/10.1038/357515a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY052	1608453				2022-12-01	WOS:A1992HY05200069
J	HAASS, C; KOO, EH; MELLON, A; HUNG, AY; SELKOE, DJ				HAASS, C; KOO, EH; MELLON, A; HUNG, AY; SELKOE, DJ			TARGETING OF CELL-SURFACE BETA-AMYLOID PRECURSOR PROTEIN TO LYSOSOMES - ALTERNATIVE PROCESSING INTO AMYLOID-BEARING FRAGMENTS	NATURE			English	Article							ALZHEIMERS-DISEASE; IDENTIFICATION; RECEPTOR	PROGRESSIVE cerebral deposition of the amyloid beta-peptide is an early and invariant feature of Alzheimer's disease. The beta-peptide is released by proteolytic cleavages from the beta-amyloid precursor protein (beta-APP) 1, a membrane-spanning glycoprotein expressed in most mammalian cells. Normal secretion of beta-APP involves a cleavage in the beta-peptide region 2,3, releasing the soluble extramembranous portion 4,5 and retaining a 10K C-terminal fragment in the membrane 6. Because this secretory pathway precludes beta-amyloid formation, we searched for an alternative proteolytic processing pathway that can generate beta-peptide-bearing fragments from full-length beta-APP. Incubation of living human endothelial cells with a beta-APP antibody revealed reinternalization of mature PAPP from the cell surface and its targeting to endosomes/lysosomes. After cell-surface biotinylation, full-length biotinylated beta-APP was recovered inside the cells. Purification of lysosomes directly demonstrated the presence of mature beta-APP and an extensive array of beta-peptide-containing proteolytic products. Our results define a second processing pathway for beta-APP and suggest that it may be responsible for generating amyloid-bearing fragments in Alzheimer's disease.	HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, NEUROSCI PROGRAM, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, DIV NEUROL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	HAASS, C (corresponding author), HARVARD UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02115 USA.							BASKIN F, 1991, J NEUROSCI RES, V29, P127, DOI 10.1002/jnr.490290115; BENOWITZ LI, 1989, EXP NEUROL, V106, P237, DOI 10.1016/0014-4886(89)90156-8; BUKTENICA S, 1987, J BIOL CHEM, V262, P9469; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COLE GM, 1989, NEUROCHEM RES, V14, P933, DOI 10.1007/BF00965926; DICE JF, 1990, CRIT REV THER DRUG, V7, P211; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; GIMBRONE MA, 1974, J CELL BIOL, V60, P673, DOI 10.1083/jcb.60.3.673; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; HAASS C, 1991, J NEUROSCI, V11, P3783; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; PARTON RG, 1991, J CELL BIOL, V113, P261, DOI 10.1083/jcb.113.2.261; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; TAMAOKA A, 1992, P NATL ACAD SCI USA, V89, P1345, DOI 10.1073/pnas.89.4.1345; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; WEIBEL ER, 1964, J CELL BIOL, V23, P101, DOI 10.1083/jcb.23.1.101; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3	26	824	842	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 11	1992	357	6378					500	503		10.1038/357500a0	http://dx.doi.org/10.1038/357500a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY052	1608449				2022-12-01	WOS:A1992HY05200064
J	LOWNDES, NF; JOHNSON, AL; BREEDEN, L; JOHNSTON, LH				LOWNDES, NF; JOHNSON, AL; BREEDEN, L; JOHNSTON, LH			SWI6 PROTEIN IS REQUIRED FOR TRANSCRIPTION OF THE PERIODICALLY EXPRESSED DNA-SYNTHESIS GENES IN BUDDING YEAST	NATURE			English	Article							CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; FISSION YEAST; REGULATORS	IN budding yeast many genes are expressed under cell-cycle control in late G1. These include a large group of DNA synthesis genes 1, the HO gene 2 involved in mating-type switching, CTS1 (chitinase) 3 and also CLN1 and CLN2 (ref. 4) encoding G1 cyclins. Two factors, encoded by the SWI4 and SWI6 genes, are required for HO (ref. 5), CLN (refs 6, 7) and CTS1 (ref. 3) gene expression and, at least in the HO promoter, bind to CACGA4 upstream sequences 5,7-9 (CCBs). This motif is not found upstream of the DNA synthesis genes, which instead have a hexamer element, ACGCGT 1 (MCB), an MluI restriction site, that is recognized by a cell-cycle regulated transcription complex DSC1 (ref. 1). This MluI-activation system consisting of the MCBs and DSC1 is conserved in fission yeast where a DSC1-like complex controls the cdc22+ ribonucleotide reductase gene 10. The Schizosaccharomyces pombe cdc10+ gene encodes a component of DSC1 (ref. 10) and, significantly, this has homology with both the Swi4 and Swi6 proteins 8,11. Here we show that Swi6 is an essential component of DSC1 and that deletion of SWI6 impairs the cell-cycle regulation of the DNA synthesis genes, as well as CLN1 and CLN2. Thus Swi6 is the common factor in regulation of all the above genes and may therefore be responsible for the timing of their expression in late G1.	NATL INST MED RES,YEAST GENET LAB,RIDGEWAY,MILL HILL,LONDON NW7 1AA,ENGLAND; FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104	MRC National Institute for Medical Research; Fred Hutchinson Cancer Center			Lowndes, Noel F/B-9084-2008	Lowndes, Noel F/0000-0002-3216-4427; Breeden, Linda/0000-0001-7337-5434				ANDREWS BJ, 1989, NATURE, V342, P830, DOI 10.1038/342830a0; BARKER DG, 1985, NUCLEIC ACIDS RES, V13, P8323, DOI 10.1093/nar/13.23.8323; BREEDEN L, 1987, NATURE, V329, P651, DOI 10.1038/329651a0; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; BREEDEN L, 1991, GENE DEV, V5, P1183, DOI 10.1101/gad.5.7.1183; DOHRMANN PR, IN PRESS GENES DEV; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; JOHNSTON LH, 1990, MOL CELL BIOL, V10, P1358, DOI 10.1128/MCB.10.4.1358; JOHNSTON LH, IN PRESS COLD SPRING; LOWNDES NF, 1992, NATURE, V355, P449, DOI 10.1038/355449a0; LOWNDES NF, 1992, TRENDS GENET, V8, P79, DOI 10.1016/0168-9525(92)90183-5; LOWNDES NF, 1991, NATURE, V350, P247, DOI 10.1038/350247a0; MCINTOSH EM, 1991, MOL CELL BIOL, V11, P329, DOI 10.1128/MCB.11.1.329; NASMYTH K, 1987, CELL, V49, P549, DOI 10.1016/0092-8674(87)90457-0; NASMYTH K, 1983, NATURE, V302, P670, DOI 10.1038/302670a0; NASMYTH K, 1991, CELL, V66, P995, DOI 10.1016/0092-8674(91)90444-4; OGAS J, 1991, CELL, V66, P1015, DOI 10.1016/0092-8674(91)90445-5; SIMANIS V, 1989, J CELL SCI, V92, P51; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; TABA MRM, 1991, GENE DEV, V5, P2000, DOI 10.1101/gad.5.11.2000; WHITE JHM, 1986, EMBO J, V5, P1705, DOI 10.1002/j.1460-2075.1986.tb04414.x; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H	23	148	148	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 11	1992	357	6378					505	508		10.1038/357505a0	http://dx.doi.org/10.1038/357505a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY052	1608450				2022-12-01	WOS:A1992HY05200066
J	MASCARI, MJ; GOTTLIEB, W; ROGAN, PK; BUTLER, MG; WALLER, DA; ARMOUR, JAL; JEFFREYS, AJ; LADDA, RL; NICHOLIS, RD				MASCARI, MJ; GOTTLIEB, W; ROGAN, PK; BUTLER, MG; WALLER, DA; ARMOUR, JAL; JEFFREYS, AJ; LADDA, RL; NICHOLIS, RD			THE FREQUENCY OF UNIPARENTAL DISOMY IN PRADER-WILLI SYNDROME - IMPLICATIONS FOR MOLECULAR DIAGNOSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PARENTAL ORIGIN; ANGELMAN SYNDROME; CHROMOSOME-ABNORMALITIES; 15Q DELETIONS; X-CHROMOSOME; HUMAN DNA; LOCUS; POLYMORPHISMS; TRISOMY; PROBES	Background. Prader-Willi syndrome is a genetic disorder characterized by infantile hypotonia, obesity, hypogonadism, and mental retardation, but it is difficult to diagnose clinically in infants and young children. In about two thirds of patients, a cytogenetically visible deletion can be detected in the paternally derived chromosome 15(15q11q13). Recently, patients with Prader-Willi syndrome have been described who do not have the cytogenetic deletion but instead have two copies of the 15q11q13 region that are inherited from the mother (with none inherited from the father). This unusual form of inheritance is known as maternal uniparental disomy. Using molecular genetic techniques, we sought to determine the frequency of uniparental disomy in Prader-Willi syndrome. Methods. We performed molecular analyses using DNA markers within 15q11ql3 and elsewhere on chromosome 15 in 30 patients with Prader-Willi syndrome who had no cytogenetically visible deletion. We also studied their parents. Three patients with Prader-Willi syndrome who had a cytogenetic deletion served as controls. Results. In 18 of the 30 patients without a cytogenetic deletion (60 percent), we demonstrated the presence of maternal uniparental disomy for chromosome 15 and its association with advanced maternal age. In another eight patients (27 percent), we identified large molecular deletions. The remaining four patients (13 percent) had evidence of normal biparental inheritance for chromosome 15; three of these patients were the only ones in the study who had some atypical clinical features. Conclusions. In about 20 percent of all cases, Prader-Willi syndrome results from the inheritance of both copies of chromosome 15 from the mother (maternal uniparental disomy). With the combined use of cytogenetic and molecular techniques, the genetic basis of Prader-Willi syndrome can be identified in up to 95 percent of patients.	UNIV FLORIDA, INST BRAIN, DEPT NEUROSCI, GAINESVILLE, FL 32611 USA; UNIV FLORIDA, COLL MED, CTR MAMMALIAN GENET, GAINESVILLE, FL 32611 USA; UNIV FLORIDA, COLL MED, DEPT PEDIAT, DIV GENET, GAINESVILLE, FL 32611 USA; VANDERBILT UNIV, MED CTR, SCH MED, DEPT PEDIAT, DIV GENET, NASHVILLE, TN 37232 USA; UNIV TEXAS, SW MED CTR, DEPT PSYCHIAT, DIV CHILD & ADOLESCENT PSYCHIAT, DALLAS, TX 75230 USA; UNIV LEICESTER, DEPT GENET, LEICESTER LE1 7RH, ENGLAND	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; Vanderbilt University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Leicester	MASCARI, MJ (corresponding author), PENN STATE UNIV, MILTON S HERSHEY MED CTR, DEPT PEDIAT, DIV GENET, 500 UNIV DR, HERSHEY, PA 17033 USA.		Rogan, Peter/B-9845-2017	Rogan, Peter/0000-0003-2070-5254; Armour, John/0000-0002-8558-8506	NICHD NIH HHS [P01 HD030329] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Wellcome Trust(Wellcome TrustEuropean Commission)		ALDRIDGE J, 1984, AM J HUM GENET, V36, P546; ANGELMAN H, 1965, DEV MED CHILD NEUROL, V7, P681; ANTONARAKIS SE, 1991, NEW ENGL J MED, V324, P872, DOI 10.1056/NEJM199103283241302; ARMOUR JAL, 1990, GENOMICS, V8, P501, DOI 10.1016/0888-7543(90)90037-U; AUGHTON DJ, 1990, AM J DIS CHILD, V144, P1251, DOI 10.1001/archpedi.1990.02150350083032; BARKER D, 1984, CELL, V36, P131, DOI 10.1016/0092-8674(84)90081-3; BRISSENDEN JE, 1986, GENET EPIDEMIOL, V3, P231, DOI 10.1002/gepi.1370030404; BUTLER MG, 1983, LANCET, V1, P1285; BUTLER MG, 1986, AM J MED GENET, V23, P793, DOI 10.1002/ajmg.1320230307; BUTLER MG, 1989, AM J HUM GENET, V45, P140; BUTLER MG, 1990, AM J MED GENET, V35, P319, DOI 10.1002/ajmg.1320350306; Cassidy S B, 1984, Curr Probl Pediatr, V14, P1; CASSIDY SB, IN PRESS AM J HUM GE; DONLON TA, 1986, P NATL ACAD SCI USA, V83, P6964; DONLON TA, 1988, HUM GENET, V80, P322, DOI 10.1007/BF00273644; DONLON TA, 1986, P NATL ACAD SCI USA, V83, P4408, DOI 10.1073/pnas.83.12.4408; DRISCOLL DJ, IN PRESS GENOMICS; ENGEL E, 1980, AM J MED GENET, V6, P137, DOI 10.1002/ajmg.1320060207; FRYBURG JS, 1991, AM J MED GENET, V38, P58, DOI 10.1002/ajmg.1320380114; GREENBERG F, 1987, AM J MED GENET, V28, P845, DOI 10.1002/ajmg.1320280409; HALL JG, 1990, AM J HUM GENET, V46, P857; HALL JG, 1992, NEW ENGL J MED, V326, P827, DOI 10.1056/NEJM199203193261210; HAMABE J, 1990, NUCLEIC ACIDS RES, V18, P5579, DOI 10.1093/nar/18.18.5579; HASSOLD T, 1985, HUM GENET, V70, P11, DOI 10.1007/BF00389450; HASSOLD TJ, 1984, ANNU REV GENET, V18, P69, DOI 10.1146/annurev.genet.18.1.69; HAWKEY CJ, 1976, J MED GENET, V13, P152, DOI 10.1136/jmg.13.2.152; HIGGS DR, 1986, P NATL ACAD SCI USA, V83, P5165, DOI 10.1073/pnas.83.14.5165; Holm V. A., 1981, PRADERWILLI SYNDROME, P27; KAPLAN LC, 1987, AM J MED GENET, V28, P45, DOI 10.1002/ajmg.1320280107; KNOLL JHM, 1991, AM J HUM GENET, V48, P16; KNOLL JHM, 1990, AM J HUM GENET, V47, P149; KNOLL JHM, 1989, AM J MED GENET, V32, P285, DOI 10.1002/ajmg.1320320235; KUPKE KG, 1989, AM J HUM GENET, V45, P599; LEDBETTER DH, 1987, AM J MED GENET, V28, P779, DOI 10.1002/ajmg.1320280402; LEDBETTER DH, 1981, NEW ENGL J MED, V304, P325, DOI 10.1056/NEJM198102053040604; MAGENIS RE, 1990, AM J MED GENET, V35, P333, DOI 10.1002/ajmg.1320350307; MALCOLM S, 1991, LANCET, V337, P694, DOI 10.1016/0140-6736(91)90278-W; MASCARI MJW, 1991, THESIS PENNSYLVANIA; MAY KM, 1990, AM J HUM GENET, V46, P754; NICHOLLS RD, 1989, AM J MED GENET, V33, P66, DOI 10.1002/ajmg.1320330109; NICHOLLS RD, 1989, NATURE, V342, P281, DOI 10.1038/342281a0; NICHOLLS RD, 1991, AM J HUM GENET, V49, P334; NICHOLLS RD, IN PRESS SEMINARS DE; NICHOLLS RD, IN PRESS ANN NEUROL; NICHOLLS RD, IN PRESS AM J MED GE; RICH DC, 1988, NUCLEIC ACIDS RES, V16, P8740, DOI 10.1093/nar/16.17.8740; ROBINSON WP, 1991, AM J HUM GENET, V49, P1219; SAITOH S, 1992, LANCET, V339, P366, DOI 10.1016/0140-6736(92)91686-3; SAPIENZA C, 1990, SCI AM, V263, P52, DOI 10.1038/scientificamerican1090-52; SEABRIGH.M, 1971, LANCET, V2, P971; SMEETS DFCM, 1992, NEW ENGL J MED, V326, P807, DOI 10.1056/NEJM199203193261206; SOLTER D, 1988, ANNU REV GENET, V22, P127; SPENCE JE, 1988, AM J HUM GENET, V42, P217; TANTRAVAHI U, 1989, AM J MED GENET, V33, P78, DOI 10.1002/ajmg.1320330110; WARBURTON D, 1988, AM J HUM GENET, V42, P215; WEBER JL, 1989, AM J HUM GENET, V44, P388; WILLIAMS CA, 1990, AM J MED GENET, V35, P350, DOI 10.1002/ajmg.1320350308; WILLIAMS CA, 1989, AM J MED GENET, V32, P339, DOI 10.1002/ajmg.1320320313; YU RL, 1981, CYTOGENET CELL GENET, V31, P111, DOI 10.1159/000131634; ZACKOWSKI JL, IN PRESS AM J MED GE	60	227	229	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 11	1992	326	24					1599	1607		10.1056/NEJM199206113262404	http://dx.doi.org/10.1056/NEJM199206113262404			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX633	1584261	Green Accepted			2022-12-01	WOS:A1992HX63300005
J	MITSUHASHI, M; KELLER, C; AKITAYA, T				MITSUHASHI, M; KELLER, C; AKITAYA, T			GENE MANIPULATION ON PLASTIC PLATES	NATURE			English	Article							HYBRIDIZATION	Oligonucleotide-immobilized plastic plates provide a rapid and easy-to-use tool for use in mRNA research, including the long-term storage, amplification and detection of the specific message, in vitro synthesis of both strands of sense and antisense mRNA, and ligation of cDNA to other DNA molecules.			MITSUHASHI, M (corresponding author), HITACHI CHEM RES CTR,DIV MED SCI,1003 HLTH SCI RD W,IRVINE,CA 92715, USA.							ALWINE JC, 1977, P NATL ACAD SCI USA, V74, P5350, DOI 10.1073/pnas.74.12.5350; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; KAWASAKI ES, 1989, PCR TECHNOLOGY PRINC, P89; Melton D. A., 1984, NUCLEIC ACIDS RES, V7, P1175; Sambrook J., 1989, MOL CLONING LAB MANU; WHITE BA, 1982, J BIOL CHEM, V257, P8569	6	27	60	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 11	1992	357	6378					519	520		10.1038/357519a0	http://dx.doi.org/10.1038/357519a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY052	1608454				2022-12-01	WOS:A1992HY05200070
J	MUSIERFORSYTH, K; SCHIMMEL, P				MUSIERFORSYTH, K; SCHIMMEL, P			FUNCTIONAL CONTACTS OF A TRANSFER-RNA SYNTHETASE WITH 2'-HYDROXYL GROUPS IN THE RNA MINOR GROOVE	NATURE			English	Article							IDENTITY	THE functional analysis of determinants on RNA has been largely limited to molecules that contain naturally occurring ribonucleotides, so little is known about the role of 2'-hydroxyl groups in protein-RNA recognition. A single base pair (G3.U70) in the acceptor stem of tRNA(Ala) is the principal element for specific recognition by Escherichia coli alanine-tRNA synthetase 1,2. This tRNA synthetase aminoacylates small RNA helices that contain the G3.U70 base pair. Furthermore, removal of the G3 exocyclic 2-amino group that projects into the minor groove eliminates aminoacylation 3. This 2-amino group is flanked on either side by ribose 2'-hydroxyl groups that line the minor groove. Here we use chemical synthesis to construct 32 helices that make deoxy and O-methyl substitutions of individual and multiple 2'-hydroxyl groups near and beyond the G3.U70 base pair and find that functional 2'-hydroxyl contacts are clustered within a few angstroms of the critical 2-amino group. These contacts are highly specific and make a thermodynamically significant contribution to RNA recognition.			MUSIERFORSYTH, K (corresponding author), MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA.							BEVILACQUA PC, 1991, BIOCHEMISTRY-US, V30, P10632, DOI 10.1021/bi00108a005; CHOWRIRA BM, 1991, BIOCHEMISTRY-US, V30, P8518, DOI 10.1021/bi00099a003; DOCKBREGEON AC, 1988, NATURE, V335, P375, DOI 10.1038/335375a0; FRANCKLYN C, 1992, SCIENCE, V255, P1121, DOI 10.1126/science.1546312; HALL KB, 1991, BIOCHEMISTRY-US, V30, P10606, DOI 10.1021/bi00108a002; HOU YM, 1988, NATURE, V333, P140, DOI 10.1038/333140a0; JASIN M, 1985, J BIOL CHEM, V260, P2226; MCCLAIN WH, 1988, SCIENCE, V240, P793, DOI 10.1126/science.2452483; MUSIERFORSYTH K, 1991, P NATL ACAD SCI USA, V88, P209, DOI 10.1073/pnas.88.1.209; MUSIERFORSYTH K, 1991, SCIENCE, V253, P784, DOI 10.1126/science.1876835; PERREAULT JP, 1991, BIOCHEMISTRY-US, V30, P4020, DOI 10.1021/bi00230a029; PYLE AM, 1991, NATURE, V350, P628, DOI 10.1038/350628a0; SCARINGE SA, 1990, NUCLEIC ACIDS RES, V18, P5433, DOI 10.1093/nar/18.18.5433; SCHREIER AA, 1972, BIOCHEMISTRY-US, V11, P1582, DOI 10.1021/bi00759a006; WANG AHJ, 1982, NATURE, V299, P601, DOI 10.1038/299601a0	15	113	113	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 11	1992	357	6378					513	515		10.1038/357513a0	http://dx.doi.org/10.1038/357513a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY052	1608452				2022-12-01	WOS:A1992HY05200068
J	SALTZMAN, LE; MERCY, JA; OCARROLL, PW; ROSENBERG, ML; RHODES, PH				SALTZMAN, LE; MERCY, JA; OCARROLL, PW; ROSENBERG, ML; RHODES, PH			WEAPON INVOLVEMENT AND INJURY OUTCOMES IN FAMILY AND INTIMATE ASSAULTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DOMESTIC VIOLENCE; HOMICIDE; WOMEN; GUNS	Objective. - To compare the risk of death and the risk of nonfatal injury during firearm-associated family and intimate assaults (FIAs) with the risks during non-firearm-associated FiAs. Design. - Records review of police incident reports of FIAs that occurred in 1984. Victim outcomes (death, nonfatal injury, no injury) and weapon involvement were examined for incidents involving only one perpetrator. Setting. - City of Atlanta, Ga, within Fulton County. Participants. - Stratified sample (n = 142) of victims of nonfatal FIAs, drawn from seven nonfatal crime categories, plus all fatal victims (n = 23) of FIAs. Main Outcome Measures.-Risk of death (vs nonfatal injury or no injury) during FIAs involving firearms, relative to other types of weapons; risk of nonfatal injury (vs all other outcomes, including death) during FIAs involving firearms, relative to other types of weapons. Results. - Firearm-associated FIAs were 3.O times (95% confidence interval, 0.9 to 10.0) more likely to result in death than FIAs involving knives or other cutting instruments and 23.4 times (95% confidence interval, 7.0 to 78.6) more likely to result in death than FIAs involving other weapons or bodily force. Overall, firearm-associated FIAs were 12.0 times (95% confidence interval, 4.6 to 31.5) more likely to result in death than non-firearm-associated FIAs. Conclusions. - Strategies for limiting the number of deaths and injuries resulting from FIAs include reducing the access of potential FIA assailants to firearms, modifying firearm lethality through redesign, and establishing programs for primary prevention of violence among intimates.			SALTZMAN, LE (corresponding author), CTR DIS CONTROL,NATL CTR ENVIRONM HLTH & INJURY CONTROL,DIV INJURY CONTROL,ATLANTA,GA 30333, USA.				PHS HHS [U50/CCU400931-01-1] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADAMS D, 1982, ABUSIVE PARTNER ANAL, P170; [Anonymous], 1968, U CHICAGO LAW REV; BAKER SP, 1985, AM J PUBLIC HEALTH, V75, P587, DOI 10.2105/AJPH.75.6.587; BILLINGHAM RE, 1987, FAM RELAT, V36, P283, DOI 10.2307/583541; Campbell J, 1981, ANS Adv Nurs Sci, V3, P67; Conklin JE, 1972, ROBBERY CRIMINAL JUS; Cook P., 1991, CRIME JUSTICE REV RE, P1; COOK PJ, 1981, ANN AM ACAD POLIT SS, V455, P63, DOI 10.1177/000271628145500107; COOK PJ, 1987, J CRIM LAW CRIM, V78, P357, DOI 10.2307/1143453; Cox DR, 1974, THEORETICAL STATISTI; FOLLINGSTAD DR, 1988, CLIN PSYCHOL REV, V8, P373, DOI 10.1016/0272-7358(88)90065-7; Gelles R., 1990, INTIMATE VIOLENCE FA, V2nd ed.; Goetting A., 1989, J FAM VIOLENCE, V4, P285, DOI [10.1007/bf00980429Goetting, DOI 10.1007/BF00980429GOETTING]; HABER JD, 1985, AM J NURS, V85, P1010, DOI 10.2307/3425176; HEDEBOE J, 1985, AM J PUBLIC HEALTH, V75, P651, DOI 10.2105/AJPH.75.6.651; Hotaling G T, 1986, Violence Vict, V1, P101; KELLERMANN AL, 1986, NEW ENGL J MED, V314, P1557, DOI 10.1056/NEJM198606123142406; KOSS MP, 1991, ARCH INTERN MED, V151, P342, DOI 10.1001/archinte.151.2.342; Levy B., 1984, SKILLS VIOLENCE FREE; MCLEER SV, 1987, ANN EMERG MED, V16, P1155, DOI 10.1016/S0196-0644(87)80476-6; Mercy J A, 1988, Violence Vict, V3, P285; PARROT A, 1986, ACQUAINTANCE RAPE SE; Rand M., 1986, USE WEAPONS COMMITTI; RAND MR, 1990, HANDGUN CRIME VICTIM; SALTZMAN L, 1977, IN PRESS AM J PUBLIC; Saltzman L E, 1990, Violence Vict, V5, P3; SAUNDERS DG, 1991, EMERG CARE Q, V7, P51; Schulman Mark, 1979, SURVEY SPOUSAL VIOLE; SLOAN JH, 1988, NEW ENGL J MED, V319, P1256, DOI 10.1056/NEJM198811103191905; SPROULE CF, 1989, CAN J CRIMINOL, V31, P245; STARK E, 1981, OFFICE DOMESTIC VIOL, V7; Stets J.E., 1989, PHYSICAL VIOLENCE AM, P151; STRAUS MA, 1986, B NEW YORK ACAD MED, V62, P446; SWEETMAN S, 1987, REPORT ATTORNEY GENE; TESKE R, 1983, SPOUSE ABUSE TEXAS S; WEBSTER DE, 1991, ISSUES SCI TECHN SPR, P73; WIDOM CS, 1989, SCIENCE, V244, P160, DOI 10.1126/science.2704995; Wolfgang M. E., 1958, PATTERNS CRIMINAL HO; 1958, VITAL STATISTICS MOR; 1989, INJURY PREVENTION M; 1991, HLTH PEOPLE 2000 NAT; 1991, NATIONAL CRIME SURVE; 1989, MMWR, V38, P17; 1984, PREVENTING FAMILY VI; 1990, CRIMINAL VICTIMIZATI	45	88	88	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 10	1992	267	22					3043	3047		10.1001/jama.267.22.3043	http://dx.doi.org/10.1001/jama.267.22.3043			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HW970	1588718				2022-12-01	WOS:A1992HW97000024
J	TERET, SP; WINTEMUTE, GJ; BEILENSON, PL				TERET, SP; WINTEMUTE, GJ; BEILENSON, PL			THE FIREARM FATALITY REPORTING SYSTEM - A PROPOSAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CHILD RESTRAINT LAWS; COVERAGE; DEATHS; STATES; GAPS		UNIV CALIF DAVIS,SACRAMENTO MED CTR,SCH MED,SACRAMENTO,CA 95817	University of California System; University of California Davis	TERET, SP (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,JOHNS HOPKINS INJURY PREVENT CTR,624 N BROADWAY,BALTIMORE,MD 21205, USA.				PHS HHS [R49CCR302484-05] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BAKER S, 1991, INJURY FACT BOOK; BAUM HM, 1990, J SAFETY RES, V21, P1, DOI 10.1016/0022-4375(90)90042-A; BOYD JH, 1986, AM J PUBLIC HEALTH, V76, P1240, DOI 10.2105/AJPH.76.10.1240; FELL JC, 860038 SOC AUT ENG I; FINGERHUT LA, 1991, MONTHLY VITAL STAT R, V39, P1; KELLERMANN AL, 1986, NEW ENGL J MED, V314, P1557, DOI 10.1056/NEJM198606123142406; KELLERMANN AL, 1991, ANNU REV PUBL HEALTH, V12, P17; Rice DP, 1989, COST INJURY US REPOR; ROBERTSON LS, 1989, AM J PUBLIC HEALTH, V79, P300, DOI 10.2105/AJPH.79.3.300; ROBERTSON LS, 1981, AM J PUBLIC HEALTH, V71, P818, DOI 10.2105/AJPH.71.8.818; ROKAW WM, 1990, PUBLIC HEALTH REP, V105, P447; TERET SP, 1986, AM J PUBLIC HEALTH, V76, P31, DOI 10.2105/AJPH.76.1.31; WAGENAAR AC, 1987, J TRAUMA, V27, P726, DOI 10.1097/00005373-198707000-00006; WELLS JK, 1989, AM J PUBLIC HEALTH, V79, P332, DOI 10.2105/AJPH.79.3.332; WINTEMUTE GJ, 1987, JAMA-J AM MED ASSOC, V257, P3107, DOI 10.1001/jama.257.22.3107; WRIGHT J, 1989, INJURY PREVENTION M; 1977, INT STATISTICAL CLAS; 1988, CRIME US 1987	18	45	45	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 10	1992	267	22					3073	3074		10.1001/jama.267.22.3073	http://dx.doi.org/10.1001/jama.267.22.3073			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HW970	1588724				2022-12-01	WOS:A1992HW97000031
J	COHN, M; STEWART, P				COHN, M; STEWART, P			PREVALENCE OF POTENTIAL PATHOGENS IN CERVICAL CANAL BEFORE TERMINATION OF PREGNANCY	BRITISH MEDICAL JOURNAL			English	Article							THERAPEUTIC-ABORTION; INFECTION		NO GEN HOSP,DEPT OBSTET & GYNAECOL,SHEFFIELD S5 7AU,S YORKSHIRE,ENGLAND	Northern General Hospital								AGRESTI A, 1990, CATEGORICAL DATA ANA, P332; FRANK PI, 1985, J ROY COLL GEN PRACT, V35, P175; HEISTERBERG L, 1988, DAN MED BULL, V35, P64; QVIGSTAD E, 1983, BRIT J VENER DIS, V59, P189; RIDGWAY GL, 1983, BRIT MED J, V286, P1478, DOI 10.1136/bmj.286.6376.1478-a	5	14	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 6	1992	304	6840					1479	1479		10.1136/bmj.304.6840.1479	http://dx.doi.org/10.1136/bmj.304.6840.1479			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY553	1611371	Green Published, Bronze			2022-12-01	WOS:A1992HY55300024
J	ELLIS, JS; SEYMOUR, RA; MONKMAN, SC; IDLE, JR				ELLIS, JS; SEYMOUR, RA; MONKMAN, SC; IDLE, JR			GINGIVAL SEQUESTRATION OF NIFEDIPINE IN NIFEDIPINE-INDUCED GINGIVAL OVERGROWTH	LANCET			English	Note								The mechanism of gingival overgrowth associated with long-term use of nifedipine and of other drugs that affect calcium homoeostasis, such as cyclosporin and phenytoin, is unknown. With an ultrasensitive assay, we measured the pharmacokinetics of nifedipine in plasma and gingival crevicular fluid (GCF) of nine patients receiving this drug for angina and hypertension. In seven patients, the maximum nifedipine concentration was in the range 15-316 (mean 84 [SD 105]) times greater in GCF than in plasma. The two patients with low (undetectable) GCF nifedipine did not have overgrowth. We propose that gingival tissues sequester nifedipine and that the very high nifedipine concentrations predispose the tissues to overgrowth.	UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT PHARMACOL SCI,PHARMACOGENET RES UNIT,FRAMLINGTON PL,NEWCASTLE TYNE NE2 4HH,ENGLAND; UNIV NEWCASTLE UPON TYNE,SCH DENT,DEPT OPERAT DENT,NEWCASTLE TYNE NE2 4HH,ENGLAND	Newcastle University - UK; Newcastle University - UK			Ellis, Janice/R-5300-2018	Ellis, Janice/0000-0002-4602-6674	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARCLAY S, 1992, J CLIN PERIODONTOL, V19, P311, DOI 10.1111/j.1600-051X.1992.tb00650.x; FERNER RE, 1990, HUM EXP TOXICOL, V9, P309, DOI 10.1177/096032719000900507; GELFAND EW, 1987, J IMMUNOL, V138, P1115; KAPUR RN, 1973, DEV MED CHILD NEUROL, V15, P483; MCGAW T, 1987, ORAL SURG ORAL MED O, V64, P293, DOI 10.1016/0030-4220(87)90007-7; SCHMID BJ, 1988, J CHROMATOGR-BIOMED, V425, P107, DOI 10.1016/0378-4347(88)80011-2; SEYMOUR RA, 1988, J CLIN PERIODONTOL, V15, P1, DOI 10.1111/j.1600-051X.1988.tb01549.x; SEYMOUR RA, 1991, BRIT DENT J, V170, P376, DOI 10.1038/sj.bdj.4807564; VATER W, 1972, ARZNEI-FORSCHUNG, V22, P1	9	39	40	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 6	1992	339	8806					1382	1383		10.1016/0140-6736(92)91199-I	http://dx.doi.org/10.1016/0140-6736(92)91199-I			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX636	1350808				2022-12-01	WOS:A1992HX63600006
J	HULL, MGR; EDDOWES, HA; FAHY, U; ABUZEID, MI; MILLS, MS; CAHILL, DJ; FLEMING, CF; WARDLE, PG; FORD, WCL; MCDERMOTT, A				HULL, MGR; EDDOWES, HA; FAHY, U; ABUZEID, MI; MILLS, MS; CAHILL, DJ; FLEMING, CF; WARDLE, PG; FORD, WCL; MCDERMOTT, A			EXPECTATIONS OF ASSISTED CONCEPTION FOR INFERTILITY	BRITISH MEDICAL JOURNAL			English	Article							INVITRO FERTILIZATION; PREGNANCY; RATES	Objective - To provide reliable prognostic information for couples seeking assisted conception. Design - Analysis of four years' practice (1988-91). Setting - Private university service finked with NHS reproductive medicine services. Patients - 804 couples with various causes of subfertility, median duration five years, median age of women 34 years. Interventions - 1280 completed cycles: 950 in vitro fertilisation, 144 gamete intrafallopian transfer, and 186 intrauterine insemination and superovulation. Main outcome measures - Pregnancy and birth rates per cycle and cumulative pregnancy and take home baby rates per couple. Results - In women under 40 years and men with normal sperm, whatever the cause of infertility, results with in vitro fertilisation improved steadily reaching a pregnancy rate per cycle of 30% (95% confidence interval 26% to 35%) during 1990-1 and birth rate per cycle of 29% (23% to 35%) in 1990. Pregnancy and birth rates for gamete intrafallopian transfer were 36% (28% to 44%) and 26% (17% to 37%) and for intrauterine insemination 18% (12% to 24%) and 16% (10% to 22%). After six cycles cumulative probability of pregnancy was 82% and cumulative take home baby rate 70%. Considering only in vitro fertilisation and gamete intrafallopian transfer after four cycles the pregnancy rate was 78% (66% to 91%). Conclusions - Conception is less likely in women over 40 and men with sperm dysfunction. For other couples the prognosis for a live birth is at least as good as for fertile couples if they persist with treatment.	UNIV BRISTOL,BUPA HOSP,IVF UNIT,BRISTOL BS8 1TH,AVON,ENGLAND	University of Bristol			Cahilll, David/AAQ-6724-2020; Cahill, David/AAE-9893-2019					CHAFFKIN LM, 1991, FERTIL STERIL, V55, P252; CROSIGNANI PG, 1991, HUM REPROD, V6, P953, DOI 10.1093/oxfordjournals.humrep.a137468; DEMOUZON J, 1990, CONTRACEPT FERTIL S, V18, P589; DODSON WC, 1991, FERTIL STERIL, V55, P457; GUZICK DS, 1986, FERTIL STERIL, V46, P663; HAAN G, 1991, HUM REPROD, V6, P939, DOI 10.1093/oxfordjournals.humrep.a137465; HULL MGR, 1990, BRIT MED BULL, V46, P580, DOI 10.1093/oxfordjournals.bmb.a072418; KOVACS GT, 1986, MED J AUSTRALIA, V144, P682, DOI 10.5694/j.1326-5377.1986.tb113694.x; MATTHEWS DE, 1988, USING UNDERSTANDING, P75; MILLS MS, IN PRESS HUM REPROD; NICE L, 1991, J REPR FERT ABSTR SE, V7, P48; TAN SL, 1990, LANCET, V335, P299, DOI 10.1016/0140-6736(90)90126-P; TIETZE C, 1956, FERTIL STERIL, V7, P88; TIETZE C, 1986, FERTIL STERIL, V13, P385; VESSEY MP, 1978, BRIT MED J, V1, P265, DOI 10.1136/bmj.1.6108.265; WARDLE PG, 1985, LANCET, V2, P236; 1990, WHO EURICPMCH122S RE	17	91	91	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 6	1992	304	6840					1465	1469		10.1136/bmj.304.6840.1465	http://dx.doi.org/10.1136/bmj.304.6840.1465			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY553	1611367	Green Published, Bronze			2022-12-01	WOS:A1992HY55300019
J	JONES, DRE; HOPKINSON, ND; POWELL, RJ				JONES, DRE; HOPKINSON, ND; POWELL, RJ			AUTOANTIBODIES IN PET DOGS OWNED BY PATIENTS WITH SYSTEMIC LUPUS-ERYTHEMATOSUS	LANCET			English	Article							ANTIBODIES; HOUSEHOLD	Systemic lupus erythematosus (SLE) occurs in human beings and in dogs. There is evidence to suggest that the disease is caused by a transmissible factor that may cross the species barrier. We investigated this possibility by looking for autoantibodies and serum protein abnormalities in serum samples from 15 pet dogs owned by patients with SLE and comparing results with those obtained with serum from 10 healthy dogs kept in a controlled environment and 9 dogs with autoimmune diseases. We used standard immunological assays modified for use with canine samples. Compared with the normal dogs, increased amounts of antibody to double-stranded DNA were found in serum from the SLE patients' dogs (median optical density [405 nm] = 0.117 vs 0.299; p = 0.0001), this latter amount being similar to that found in serum from the autoimmune group (0.201; p = 0.6). Abnormal serum protein electrophoresis patterns were found in samples from the autoimmune and SLE patients' dogs but not the normal dogs. These findings support the idea that exposure to common environmental factors or transmissible agents may have a role in causing SLE.			JONES, DRE (corresponding author), UNIV NOTTINGHAM HOSP,QUEENS MED CTR,DEPT IMMUNOL,NOTTINGHAM NG7 2UH,ENGLAND.							BEAUCHER WN, 1977, NEW ENGL J MED, V296, P982, DOI 10.1056/NEJM197704282961707; Bennett D., 1987, Veterinary Annual, V27, P350; CLAIR D, 1980, ARTHRITIS RHEUM, V23, P251, DOI 10.1002/art.1780230219; COSTA O, 1984, VET IMMUNOL IMMUNOP, V7, P369, DOI 10.1016/0165-2427(84)90094-1; DEAPEN D M, 1986, Arthritis and Rheumatism, V29, pS26; FESSEL WJ, 1988, RHEUM DIS CLIN N AM, V14, P15; FRYE F L, 1976, Theriogenology, V6, P127; JONES DRE, 1987, VET IMMUNOL IMMUNOP, V16, P11, DOI 10.1016/0165-2427(87)90170-X; KALLICK CA, 1972, NATURE-NEW BIOL, V236, P145, DOI 10.1038/newbio236145a0; KRISTENSEN S, 1979, VET REC, V105, P422, DOI 10.1136/vr.105.18.422; LEWIS RM, 1974, NATURE, V252, P78, DOI 10.1038/252078a0; LEWIS RM, 1972, AM J PATHOL, V69, P537; LEWIS RM, 1971, J EXP MED, V134, P417, DOI 10.1084/jem.134.2.417; LEWIS RM, 1973, J CLIN INVEST, V52, P1893, DOI 10.1172/JCI107373; MAYR A, 1989, ZBL HYG UMWELTMED, V187, P508; MONIER JC, 1980, ARTHRITIS RHEUM, V23, P294, DOI 10.1002/art.1780230305; REINERTSEN JL, 1980, ARTHRITIS RHEUM-US, V23, P564, DOI 10.1002/art.1780230507; Shanley K J, 1985, Clin Dermatol, V3, P131, DOI 10.1016/0738-081X(85)90086-0; SHARP J T, 1971, Hospital Practice, V6, P142; SILMAN AJ, 1990, BRIT J RHEUMATOL, V29, P494; THOBURN R, 1972, P NATL ACAD SCI USA, V69, P3327, DOI 10.1073/pnas.69.11.3327; WALLACE DJ, 1987, DUBOIS LUPUS ERYTHEM; WALLINGTON TB, 1990, CLIN IMMUNOLOGY PRAC, P212; ZAMBINSKI M, 1989, 53RD P ANN GEN M CIN, pS25	24	20	20	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 6	1992	339	8806					1378	1380		10.1016/0140-6736(92)91197-G	http://dx.doi.org/10.1016/0140-6736(92)91197-G			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX636	1350806				2022-12-01	WOS:A1992HX63600004
J	LUCK, CA				LUCK, CA			VALUE OF ROUTINE ULTRASOUND SCANNING AT 19 WEEKS - A 4 YEAR STUDY OF 8849 DELIVERIES	BRITISH MEDICAL JOURNAL			English	Article							DIAGNOSIS	Objective - To evaluate the effectiveness of routine ultrasound scanning at 19 weeks' gestation in an unselected population in terms of accuracy of detection of fetal structural abnormality and the effect on obstetric and neonatal care. Design - Prospective study over four years. Scans performed by radiographers with overall supervision by a radiologist. Setting - Ultrasound department of district general hospital. Subjects - All pregnant women were offered scans; 8523 of 8849 (96%) accepted. Main outcome measures - Information obtained from hospital records, genetic analysis, and post-mortem findings. Results - 166 fetal anomalies occurred; 140 were detected at 19 weeks (sensitivity 85%; specificity 99.9%). In 27 cases fetuses were shown to have severely crippling or lethal abnormalities; termination of pregnancy was requested in 25. Early diagnosis influenced timing and place of delivery in babies with severe cardiac or gastrointestinal anomalies. Conclusion - Scanning at 19 weeks with availability of termination can reduce perinatal morbidity and mortality. Scanning can be performed in a general ultrasound department with adequate counselling facilities and close cooperation between radiographers, midwives, obstetricians, paediatricians, and the radiologist.			LUCK, CA (corresponding author), HEATHERWOOD HOSP,ASCOT SL5 8AA,BERKS,ENGLAND.							BENACERRAF BR, 1987, AM J OBSTET GYNECOL, V156, P573, DOI 10.1016/0002-9378(87)90053-6; CAMPBELL S, 1983, CLIN OBSTET GYNAECOL, V10, P475; CAMPBELL S, 1984, PRENATAL DIAGNOSIS, P325; CHERVENAK FA, 1991, ULTRASOUND OBST GYN, V1, P18, DOI 10.1046/j.1469-0705.1991.01010018.x; CHITTY LS, 1991, BRIT MED J, V303, P1165, DOI 10.1136/bmj.303.6811.1165; CRAWFORD DC, 1988, AM J OBSTET GYNECOL, V159, P352, DOI 10.1016/S0002-9378(88)80083-8; HANSMANN M, 1991, ULTRASOUND OBST GYN, V1, P305, DOI 10.1046/j.1469-0705.1991.01050305.x; HECHER K, 1991, ULTRASOUND OBST GYN, V1, P426, DOI 10.1046/j.1469-0705.1991.01060426.x; MCNAY M, 1991, BRIT MED SOC ULTRASO, V63, P23; THOMSON P, 1991, TIMES           1202, P15; 1984, WORKING PARTY REPORT, P10; 1989, REPORT PRENATAL DIAG, P14	12	157	160	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 6	1992	304	6840					1474	1478		10.1136/bmj.304.6840.1474	http://dx.doi.org/10.1136/bmj.304.6840.1474			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY553	1611369	Green Published			2022-12-01	WOS:A1992HY55300022
J	PRYLE, BJ; GRECH, H; STODDART, PA; CARSON, R; OMAHONEY, T; REYNOLDS, F				PRYLE, BJ; GRECH, H; STODDART, PA; CARSON, R; OMAHONEY, T; REYNOLDS, F			TOXICITY OF NORPETHIDINE IN SICKLE-CELL CRISIS	BRITISH MEDICAL JOURNAL			English	Article							MEPERIDINE; CANCER		ST THOMAS HOSP,DEPT ANAESTHESIA,LONDON SE1 7EH,ENGLAND; ST THOMAS HOSP,DEPT HAEMATOL,LONDON SE1 7EH,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust								KAIKO RF, 1983, ANN NEUROL, V13, P180, DOI 10.1002/ana.410130213; MITCHELL A, 1991, BRIT MED J, V303, P249, DOI 10.1136/bmj.303.6796.249-a; REYNOLDS F, 1968, BRIT J PHARMACOL, V20, P704; SZETO HH, 1977, ANN INTERN MED, V86, P738, DOI 10.7326/0003-4819-86-6-738; Tang R, 1980, HOSP FORMUL, V15, P764	5	26	26	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 6	1992	304	6840					1478	1479		10.1136/bmj.304.6840.1478	http://dx.doi.org/10.1136/bmj.304.6840.1478			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY553	1611370	Green Published, Bronze			2022-12-01	WOS:A1992HY55300023
J	REIBNEGGER, G; FUCHS, D; JUDMAIER, G; WEISS, G; WERNERFELMAYER, G; WACHTER, H				REIBNEGGER, G; FUCHS, D; JUDMAIER, G; WEISS, G; WERNERFELMAYER, G; WACHTER, H			CRITICAL-STUDY OF CONSENSUS ANALYSIS	LANCET			English	Article							RHEUMATOID-ARTHRITIS; CROHNS-DISEASE; NEOPTERIN; TESTS	Consensus analysis has been proposed as a statistical method by which the efficacy of clinical and laboratory tests of inflammatory activity can be assessed. This technique is claimed to overcome the need for an external "gold standard" as a reference method; instead, the consensus of all tests is used as the gold standard. We have evaluated the reliability of consensus analysis using data collected from patients with Crohn's disease. Our results demonstrate that the technique depends strongly on the correlation structure underlying the set of measures of disease used for analysis. This observation was supported by a series of conventional cluster analyses of the same set of variables. Furthermore, slight modifications of the algorithm had profound effects on the final result. We conclude that for the evaluation of tests of inflammatory activity, an external reference method, albeit an imperfect one, remains indispensable.	UNIV INNSBRUCK,DEPT INTERNAL MED,A-6020 INNSBRUCK,AUSTRIA	University of Innsbruck	REIBNEGGER, G (corresponding author), UNIV INNSBRUCK,INST MED CHEM & BIOCHEM,FRITZ PREGL STR 3,A-6020 INNSBRUCK,AUSTRIA.		Reibnegger, Gilbert/H-5742-2012; Fuchs, Dietmar/AAL-8011-2021	Reibnegger, Gilbert/0000-0001-7202-2426; Fuchs, Dietmar/0000-0003-1627-9563; Werner-Felmayer, Gabriele/0000-0002-2340-8063; Weiss, Guenter/0000-0003-0709-2158				BEST WR, 1976, GASTROENTEROLOGY, V70, P439; BULL BS, 1986, LANCET, V2, P377; BULL BS, 1989, LANCET, V2, P965; DAWES PT, 1989, LANCET, V2, P1219; DUCLOS B, 1990, GASTROEN CLIN BIOL, V14, P22; LOBO AJ, 1991, EUR J GASTROEN HEPAT, V3, P663; PAWLOTSKY Y, 1989, LANCET, V2, P1532; PRIOR C, 1986, CLIN CHIM ACTA, V155, P11, DOI 10.1016/0009-8981(86)90094-X; PULLAR T, 1989, LANCET, V2, P1532; SCOTT DL, 1989, LANCET, V2, P1531	10	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 6	1992	339	8806					1394	1397		10.1016/0140-6736(92)91206-N	http://dx.doi.org/10.1016/0140-6736(92)91206-N			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX636	1350814				2022-12-01	WOS:A1992HX63600013
J	SMITH, CAD; GOUGH, AC; LEIGH, PN; SUMMERS, BA; HARDING, AE; MARANGANORE, DM; STURMAN, SG; SCHAPIRA, AHV; WILLIAMS, AC; SPURR, NK; WOLF, CR				SMITH, CAD; GOUGH, AC; LEIGH, PN; SUMMERS, BA; HARDING, AE; MARANGANORE, DM; STURMAN, SG; SCHAPIRA, AHV; WILLIAMS, AC; SPURR, NK; WOLF, CR			DEBRISOQUINE HYDROXYLASE GENE POLYMORPHISM AND SUSCEPTIBILITY TO PARKINSONS-DISEASE	LANCET			English	Article							COMPLEX-I DEFICIENCY; POOR METABOLIZERS; CYP2D LOCUS; 4-HYDROXYLATION; PHENOTYPES; NEUROTOXIN; OXIDATION; DEFECT	The pathogenesis of Parkinson's disease may be influenced by genetic and environmental factors. Cytochrome P450 mono-oxygenases help to protect against toxic environmental compounds and individual variations in cytochrome P450 expression might, therefore, influence susceptibility to environmentally linked diseases. The frequency of mutant CYP2D6 alleles was studied in 229 patients with Parkinson's disease and 720 controls. Individuals with a metabolic defect in the cytochrome P450 CYP2D6-debrisoquine hydroxylase gene with the poor metaboliser phenotype had a 2.54-fold (95% CI 1.51-4.28) increased risk of Parkinson's disease. Determination of CYP2D6 phenotype and genotype may help to identify those at greatest risk of Parkinson's disease and may also help to identify the environmental or metabolic agents involved in the pathogenesis of this disease.	IMPERIAL CANC RES FUND, MOLEC PHARMACOL GRP, GEORGE SQ, EDINBURGH EH8 9XD, SCOTLAND; IMPERIAL CANC RES FUND, HUMAN GENET RESOURCES, CLARE HALL LABS, S MIMMS, ENGLAND; UNIV LONDON, INST PSYCHIAT, DEPT NEUROL, LONDON, ENGLAND; UNIV LONDON KINGS COLL, SCH MED & DENT, LONDON WC2R 2LS, ENGLAND; UNIV LONDON, INST NEUROL, DEPT CLIN NEUROL, LONDON, ENGLAND; UNIV BIRMINGHAM, QUEEN ELIZABETH HOSP, DEPT NEUROL, BIRMINGHAM B15 2TH, W MIDLANDS, ENGLAND; ROYAL FREE HOSP, SCH MED, DEPT NEUROSCI, LONDON, ENGLAND	University of London; King's College London; University of London; King's College London; University of London; University College London; University of Birmingham; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School			Leigh, Peter/AAD-5638-2019; Schapira, Anthony H V/A-1245-2010	Schapira, Anthony H V/0000-0002-3018-3966				BARBEAU A, 1985, LANCET, V2, P1213; BENITEZ J, 1990, J NEUROL NEUROSUR PS, V53, P289, DOI 10.1136/jnnp.53.4.289; CALNE DB, 1983, LANCET, V2, P1457, DOI 10.1016/S0140-6736(83)90802-4; CHIBA Z, 1987, BIOCHEM BIOPH RES CO, V120, P574; COMELLA C L, 1987, Neurology, V37, P261; EICHELBAUM M, 1990, PHARMACOL THERAPEUT, V46, P377, DOI 10.1016/0163-7258(90)90025-W; FONNEPFISTER R, 1987, BIOCHEM BIOPH RES CO, V148, P1144, DOI 10.1016/S0006-291X(87)80252-8; GAEDIGK A, 1991, AM J HUM GENET, V48, P943; GIBB WRG, 1989, NEUROPATH APPL NEURO, V15, P27, DOI 10.1111/j.1365-2990.1989.tb01147.x; GOLBE LI, 1990, NEUROLOGY, V40, P7; GOUGH AC, 1990, NATURE, V347, P773, DOI 10.1038/347773a0; GUDJONSSON O, 1990, BRIT J CLIN PHARMACO, V30, P301, DOI 10.1111/j.1365-2125.1990.tb03780.x; HANIOKA N, 1990, AM J HUM GENET, V47, P994; HEIM M, 1990, LANCET, V336, P529, DOI 10.1016/0140-6736(90)92086-W; ISLAM SA, 1991, CARCINOGENESIS, V12, P2211, DOI 10.1093/carcin/12.12.2211; JOHNSON WG, 1991, NEUROLOGY, V41, P82, DOI 10.1212/WNL.41.5_Suppl_2.82; KAGIMOTO M, 1990, J BIOL CHEM, V265, P17209; KALLIO J, 1991, ACTA NEUROL SCAND, V83, P194, DOI 10.1111/j.1600-0404.1991.tb04676.x; Langdon J.S., 1985, RECENT ADV AQUACULTU, P79, DOI [10.4324/9780429303937-3, DOI 10.4324/9780429303937-3]; MARAGANORE DM, 1991, MOVEMENT DISORD, V6, P205, DOI 10.1002/mds.870060303; NICKLAS WJ, 1985, LIFE SCI, V36, P2503, DOI 10.1016/0024-3205(85)90146-8; NIZNIK HB, 1990, ARCH BIOCHEM BIOPHYS, V276, P424, DOI 10.1016/0003-9861(90)90741-G; POIRIER J, 1987, LANCET, V2, P386; PRICEEVANS DA, 1980, J MED GENET, V17, P102; SASAHARA M, 1991, CELL, V64, P217, DOI 10.1016/0092-8674(91)90223-L; SCHAPIRA AHV, 1990, J NEUROCHEM, V55, P2142, DOI 10.1111/j.1471-4159.1990.tb05809.x; SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x; SPURR NK, 1991, METHOD ENZYMOL, V206, P149; STEIGER MJ, IN PRESS ACTA NEUROL; STEVENTON G B, 1989, Medical Science Research, V17, P163; WOLF CR, 1990, CANCER SURV, V9, P437; WOLF CR, 1990, LANCET, V336, P1452, DOI 10.1016/0140-6736(90)93163-J; WOLF CR, IN PRESS CARCINOGENE; YOUNGSTER SK, 1990, BIOCHEM BIOPH RES CO, V169, P758, DOI 10.1016/0006-291X(90)90396-5	34	455	460	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 6	1992	339	8806					1375	1377		10.1016/0140-6736(92)91196-F	http://dx.doi.org/10.1016/0140-6736(92)91196-F			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX636	1350805				2022-12-01	WOS:A1992HX63600003
J	TAN, SL; ROYSTON, P; CAMPBELL, S; JACOBS, HS; BETTS, J; MASON, B; EDWARDS, RG				TAN, SL; ROYSTON, P; CAMPBELL, S; JACOBS, HS; BETTS, J; MASON, B; EDWARDS, RG			CUMULATIVE CONCEPTION AND LIVEBIRTH RATES AFTER INVITRO FERTILIZATION	LANCET			English	Article							MATERNAL AGE; FERTILIZATION; PREGNANCY; PROSPECTS; PROGRAM; EMBRYO	Cumulative conception and livebirth rates related to age and cause of infertility provide the most useful estimate of success after in-vitro fertilisation (IVF), but limited data are available. It is also uncertain whether the probability of pregnancy, livebirth, and pregnancy failure changes with repeated treatment cycles. To assess the effects of patients' age and cause of infertility on these outcomes, we studied the results of 5055 consecutive IVF cycles (773 clinical pregnancies, 518 livebirths) undertaken on 2735 patients in a single IVF unit. Cumulative conception and livebirth rates were analysed by the life-table approach and differences in rates between age-groups and between causes of infertility were measured by the log-rank test and logistic regression modelling. Both conception and livebirth rates per cycle declined with age (p < 0.001), and cumulative conception and livebirth rates after five treatment cycles were about 54% and 45%, respectively, at 20-34 years, compared with 38.7% and 28.9% at 35-39 years and 20.2% and 14.4% at greater-than-or-equal-to 40 years. The two rates were significantly different between causal groups (p < 0.001 and p = 0.02, respectively) and were lowest in patients with male infertility or multiple infertility factors. The pregnancy failure rate was higher (p = 0.006) in women over the age of 34 years and there was a significant decline in the chances of pregnancy and livebirth per cycle with successive treatment cycles. The success of IVF compares favourably with that of spontaneous conception in the natural menstrual cycle. For women up to the age of 34 years, almost 55% will become pregnant and 45% will have a livebirth within five cycles of treatment.	HALLAM MED CTR,LONDON,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT MED PHYS,LONDON W12 0HS,ENGLAND; MIDDLESEX HOSP,COBBOLD LABS,LONDON W1,ENGLAND	Imperial College London; University of London; University College London	TAN, SL (corresponding author), KINGS COLL,SCH MED & DENT,DEPT OBSTET & GYNAECOL,DENMARK HILL,LONDON SE5 8RX,ENGLAND.		Jacobs, Howard/A-9845-2009; Tan, Seang Lin/I-7710-2012					COOKE ID, 1981, CLIN OBSTET GYNAECOL, V8, P531; COX DR, 1972, J R STAT SOC B, V34, P187; CRAMER DW, 1979, FERTIL STERIL, V32, P80; DEMOUZON J, 1987, CONTRACEPT FERTIL S, V15, P740; GOSDEN RG, 1985, ANN NY ACAD SCI, V442, P45, DOI 10.1111/j.1749-6632.1985.tb37504.x; GUZICK DS, 1986, FERTIL STERIL, V46, P663; HUGHES EG, 1990, J CLIN ENDOCR METAB, V70, P358, DOI 10.1210/jcem-70-2-358; Kalbfleisch JD, 1980, STATISTICAL ANAL FAI, P14; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KOVACS GT, 1986, MED J AUSTRALIA, V144, P682, DOI 10.5694/j.1326-5377.1986.tb113694.x; NAVOT D, 1991, LANCET, V337, P1375, DOI 10.1016/0140-6736(91)93060-M; PADILLA SL, 1989, FERTIL STERIL, V52, P270; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; SCHWARTZ D, 1982, NEW ENGL J MED, V306, P404, DOI 10.1056/NEJM198202183060706; SHARMA V, 1988, FERTIL STERIL, V49, P468; STEPTOE PC, 1986, HUM REPROD, V1, P89, DOI 10.1093/oxfordjournals.humrep.a136366; STEPTOE PC, 1978, LANCET, V2, P366; TAN SL, IN PRESS AM J OBSTET; VANNOORDZAADSTRA BM, 1991, BMJ-BRIT MED J, V302, P1361, DOI 10.1136/bmj.302.6789.1361; 1991, 6TH REPORT INTERIM L; 1991, FERTIL STERIL, V55, P14	21	232	235	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 6	1992	339	8806					1390	1394		10.1016/0140-6736(92)91205-M	http://dx.doi.org/10.1016/0140-6736(92)91205-M			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX636	1350813				2022-12-01	WOS:A1992HX63600012
J	WALLER, PC; WOOD, SM; LANGMAN, MJS; BRECKENRIDGE, AM; RAWLINS, MD				WALLER, PC; WOOD, SM; LANGMAN, MJS; BRECKENRIDGE, AM; RAWLINS, MD			REVIEW OF COMPANY POSTMARKETING SURVEILLANCE STUDIES	BRITISH MEDICAL JOURNAL			English	Article								Objectives - To review postmarketing surveillance studies sponsored by the pharmaceutical industry since the introduction of voluntary guidelines in 1987 and to evaluate their contribution to monitoring drug safety. Design - Retrospective analysis of the information submitted to the Medicines Control Agency on postmarketing surveillance studies. Setting - United Kingdom. Main outcome measures - Study designs, projected and actual sample sizes, provision of interim and final reports, number of suspected serious adverse reactions reported, identification of new drug safety hazards. Results - 31 studies had been conducted under the guidelines, of which 27 were prospective and four retrospective. Nine studies had at least one comparator group, the remainder were uncontrolled. The median projected sample size for the studies was 5600 patients. Only five studies had achieved at least 75% of the projected sample size. 11 studies had been abandoned, predominantly because of difficulties in recruitment, and 15 were ongoing. One study had identified an important new safety hazard. Conclusions - Company postmarketing surveillance studies have made only a limited contribution to the assessment of drug safety, principally because of weak study designs and difficulties in recruitment. The guidelines require modification to take this experience into account.	COMM SAFETY MED,ADVERSE REACT GRP,LONDON SW8 5BR,ENGLAND; COMM SAFETY MED,SUBCOMM SAFETY EFFICACY & ADVERSE REACT,LONDON SW8 5BR,ENGLAND		WALLER, PC (corresponding author), MED CONTROL AGCY,PHARMACOVIGILANCE UNIT,MARKET TOWERS,LONDON SW8 5NQ,ENGLAND.							RAWLINS MD, 1991, BRIT MED J, V302, P223, DOI 10.1136/bmj.302.6770.223; 1987, ADVERSE DRUG REACT, P62; 1988, BMJ, V296, P399	3	62	62	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 6	1992	304	6840					1470	1472		10.1136/bmj.304.6840.1470	http://dx.doi.org/10.1136/bmj.304.6840.1470			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY553	1611368	Bronze, Green Published			2022-12-01	WOS:A1992HY55300020
J	KANG, SM; TRAN, AC; GRILLI, M; LENARDO, MJ				KANG, SM; TRAN, AC; GRILLI, M; LENARDO, MJ			NF-KAPPA-B SUBUNIT REGULATION IN NONTRANSFORMED CD4+ LYMPHOCYTES-T	SCIENCE			English	Article							ANTIGEN-PRESENTING CELLS; HUMAN INTERLEUKIN-2 GENE; DNA-BINDING SUBUNIT; PROTEIN-BINDING; REL ONCOGENE; EXPRESSION; ENHANCER; ACTIVATION; IDENTIFICATION; TRANSCRIPTION	Regulation of interleukin-2 (IL-2) gene expression by the p50 and p65 subunits of the DNA binding protein NF-kappa-B was studied in nontransformed CD4+ T lymphocyte clones. A homodimeric complex of the NF-kappa-B p50 subunit was found in resting T cells. The amount of p50-p50 complex decreased after full antigenic stimulation, whereas the amount of the NF-kappa-B p50-p65 heterodimer was increased. Increased expression of the IL-2 gene and activity of the IL-2 kappa-B DNA binding site correlated with a decrease in the p50-p50 complex. Overexpression of p50 repressed IL-2 promoter expression. The switch from p50-p50 to p50-p65 complexes depended on a protein that caused sequestration of the p50-p50 complex in the nucleus.	NIAID,IMMUNOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			grilli, mariagrazia/ABF-1542-2020	grilli, mariagrazia/0000-0001-9165-5827				BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAUERLE PA, 1988, SCIENCE, V242, P540; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BOURS V, 1992, MOL CELL BIOL, V12, P682; BRABLETZ T, 1991, NUCLEIC ACIDS RES, V19, P61, DOI 10.1093/nar/19.1.61; BRORSON KA, 1991, J IMMUNOL, V147, P3601; CHIU JJS, UNPUB; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DURAND DB, 1987, J EXP MED, V165, P395, DOI 10.1084/jem.165.2.395; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; EMMEL EA, 1989, SCIENCE, V246, P617; FATHMAN CG, 1989, FUNDAMENTAL IMMUNOLO, P803; FIERING S, 1990, GENE DEV, V4, P1823, DOI 10.1101/gad.4.10.1823; FUJITA T, 1986, CELL, V46, P401, DOI 10.1016/0092-8674(86)90660-4; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRILLI M, IN PRESS INT REV CYT; GRILLI MG, 1991, CYTOKINE, V3, P372; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HAZAN U, 1990, P NATL ACAD SCI USA, V87, P7861, DOI 10.1073/pnas.87.20.7861; HECHT TT, 1983, J IMMUNOL, V131, P1049; HOYOS B, 1989, SCIENCE, V244, P457, DOI 10.1126/science.2497518; JAMIESON C, 1991, J IMMUNOL, V147, P416; JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302; Kang S.-G., UNPUB; KANG SM, IN PRESS MOL CELL BI; KAWAKAMI K, 1988, P NATL ACAD SCI USA, V85, P4700, DOI 10.1073/pnas.85.13.4700; KAYE J, 1983, J EXP MED, V158, P836, DOI 10.1084/jem.158.3.836; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KRONKE M, 1984, P NATL ACAD SCI-BIOL, V81, P5214, DOI 10.1073/pnas.81.16.5214; LAMB JR, 1983, J EXP MED, V157, P1434, DOI 10.1084/jem.157.5.1434; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; LENARDO M, UNPUB; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LENARDO MJ, 1988, P NATL ACAD SCI USA, V85, P8825, DOI 10.1073/pnas.85.23.8825; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; MUELLER DL, 1990, J IMMUNOL, V144, P3701; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; PIERCE JW, 1988, P NATL ACAD SCI USA, V85, P1482, DOI 10.1073/pnas.85.5.1482; RADLER-POHL A, 1990, New Biologist, V2, P566; RANDAK C, 1990, EMBO J, V9, P2529, DOI 10.1002/j.1460-2075.1990.tb07433.x; RONCHESE F, 1987, NATURE, V329, P254, DOI 10.1038/329254a0; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P675; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SHIBUYA H, 1989, NUCLEIC ACIDS RES, V17, P9173, DOI 10.1093/nar/17.22.9173; SHIBUYA H, 1989, INT IMMUNOL, V1, P143; STAUDT LM, 1988, SCIENCE, V241, P577, DOI 10.1126/science.3399892; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; THOMPSON CC, 1991, SCIENCE, V253, P672; URBAN MB, 1991, NEW BIOL, V3, P279; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x; WEAVER CT, 1988, P NATL ACAD SCI USA, V85, P8181, DOI 10.1073/pnas.85.21.8181; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; YANO O, 1987, EMBO J, V6, P3317, DOI 10.1002/j.1460-2075.1987.tb02652.x	66	313	330	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 5	1992	256	5062					1452	1456		10.1126/science.1604322	http://dx.doi.org/10.1126/science.1604322			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HX337	1604322				2022-12-01	WOS:A1992HX33700038
J	LI, BQ; KAPLAN, D; KUNG, HF; KAMATA, T				LI, BQ; KAPLAN, D; KUNG, HF; KAMATA, T			NERVE GROWTH-FACTOR STIMULATION OF THE RAS-GUANINE NUCLEOTIDE EXCHANGE FACTOR AND GAP ACTIVITIES	SCIENCE			English	Article							GTPASE ACTIVATING PROTEIN; PC12 CELLS; TYROSINE PHOSPHORYLATION; BOVINE BRAIN; DIFFERENTIATION; MICROINJECTION; PURIFICATION; P21RAS; ONCOGENES; INDUCTION	The biological activity of Ras proteins is thought to be controlled by the guanine nucleotide exchange factor and the guanosine triphosphatase activating protein (GAP). Treatment of rat pheochromocytoma PC-12 cells with nerve growth factor (NGF) increased the amount of active Ras guanosine triphosphate complex and stimulated the activities of both the guanine nucleotide exchange factor and GAP. In PC-12 cells that overexpressed the tyrosine kinase encoded by the trk proto-oncogene (a component of the high-affinity NGF receptor), the NGF-induced activation of the regulatory proteins was potentiated. These results suggest that the NGF receptor system enhances the activities of both the guanine nucleotide exchange factor and GAP and that the activation of Ras might be controlled by the balance in activity between these two regulatory proteins.	NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC DYNCORP,BIOL CARCINOGENESIS & DEV PROGRAM,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,BASIC RES PROGRAM,ADV BIOSCI LAB,EUKARYOT SIGNAL TRANSDUCT GRP,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,BIOCHEM PHYSIOL LAB,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick					OFFICE OF THE DIRECTOR, NCI [N01CO074101, N01CO074102] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101, N01-CO-74102] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; DECLUE JE, 1991, P NATL ACAD SCI USA, V88, P9914, DOI 10.1073/pnas.88.22.9914; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DOWNWARD J, 1990, P NATL ACAD SCI USA, V87, P5998, DOI 10.1073/pnas.87.15.5998; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEMPSTEAD BL, UNPUB; HUANG YK, 1990, P NATL ACAD SCI USA, V87, P8008, DOI 10.1073/pnas.87.20.8008; KAMATA T, 1987, BIOCHEM BIOPH RES CO, V144, P19, DOI 10.1016/S0006-291X(87)80469-2; KAMATA T, 1984, NATURE, V310, P147, DOI 10.1038/310147a0; Kamata T., UNPUB; KAPLAN DE, UNPUB; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; Li B. A., UNPUB; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MUROYA K, 1992, ONCOGENE, V7, P277; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SATOH T, 1987, MOL CELL BIOL, V7, P4553, DOI 10.1128/MCB.7.12.4553; SUBULESKI MJ, UNPUB; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; WEST M, 1990, FEBS LETT, V259, P245, DOI 10.1016/0014-5793(90)80019-F; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626	37	121	124	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 5	1992	256	5062					1456	1459		10.1126/science.1604323	http://dx.doi.org/10.1126/science.1604323			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HX337	1604323				2022-12-01	WOS:A1992HX33700039
J	MILTON, RCD; MILTON, SCF; KENT, SBH				MILTON, RCD; MILTON, SCF; KENT, SBH			TOTAL CHEMICAL SYNTHESIS OF A D-ENZYME - THE ENANTIOMERS OF HIV-1 PROTEASE SHOW DEMONSTRATION OF RECIPROCAL CHIRAL SUBSTRATE-SPECIFICITY	SCIENCE			English	Article							PROTEINASE; PEPTIDES	The D and L forms of the enzyme HIV-1 protease have been prepared by total chemical synthesis. The two proteins had identical covalent structures. However, the folded protein-enzyme enantiomers showed reciprocal chiral specificity on peptide substrates. That is, each enzyme enantiomer cut only the corresponding substrate enantiomer. Reciprocal chiral specificity was also evident in the effect of enantiomeric inhibitors. These data imply that the folded forms of the chemically synthesized D- and L-enzyme molecules are mirror images of one another in all elements of the three-dimensional structure. Enantiomeric proteins are expected to display reciprocal chiral specificity in all aspects of their biochemical interactions.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute								ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BERGMAN DA, 1992, FEB LORN C VICT; BRUINS AP, 1987, ANAL CHEM, V59, P2642, DOI 10.1021/ac00149a003; CHAIT BT, UNPUB; ELLMAN JA, 1992, SCIENCE, V255, P197, DOI 10.1126/science.1553546; FERSHT A, 1977, ENZYME STRUCTURE MEC, P75; FRUTON JS, 1972, MOL LIFE, P53; HENKLEIN P, IN PRESS SOLID PHASE; KENT SBH, 1988, ANNU REV BIOCHEM, V57, P957, DOI 10.1146/annurev.bi.57.070188.004521; KENT SBH, 1989, VIRAL PROTEINASES TH, P223; KENT SBH, IN PRESS INNOVATION; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRAUSSLICH HG, 1989, P NATL ACAD SCI USA, V86, P807, DOI 10.1073/pnas.86.3.807; MACKAY AL, 1989, NATURE, V342, P133, DOI 10.1038/342133a0; MASON SF, 1991, CHIRALITY, V3, P223, DOI 10.1002/chir.530030403; MILLER M, 1989, SCIENCE, V246, P1149, DOI 10.1126/science.2686029; MIRSKY AE, 1936, P NATL ACAD SCI USA, V22, P438; PASTEUR L, 1960, SOC CHIM PARIS, P1; RICHARDS AD, 1989, FEBS LETT, V247, P113, DOI 10.1016/0014-5793(89)81251-7; RICHARDSON JS, 1990, PROTEIN FOLDING : DECIPHERING THE SECOND HALF OF THE GENETIC CODE, P5; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SCHNOLZER M, 1992, SCIENCE, V256, P221, DOI 10.1126/science.1566069; SCHNOLZER M, IN PRESS INT J PEPT; TOTH MV, 1990, INT J PEPT PROT RES, V36, P544; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279	25	319	356	2	98	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 5	1992	256	5062					1445	1448		10.1126/science.1604320	http://dx.doi.org/10.1126/science.1604320			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HX337	1604320				2022-12-01	WOS:A1992HX33700036
J	NOLLER, HF; HOFFARTH, V; ZIMNIAK, L				NOLLER, HF; HOFFARTH, V; ZIMNIAK, L			UNUSUAL RESISTANCE OF PEPTIDYL TRANSFERASE TO PROTEIN EXTRACTION PROCEDURES	SCIENCE			English	Article							23S RIBOSOMAL-RNA; ESCHERICHIA-COLI RIBOSOMES; PEPTIDYLTRANSFERASE ACTIVITY; A-SITES; P-SITES; SUBUNITS; CHLORAMPHENICOL; RECONSTITUTION; IDENTIFICATION; NUCLEOTIDES	Peptidyl transferase, the ribosomal activity responsible for catalysis of peptide bond formation, is resistant to vigorous procedures that are conventionally employed to remove proteins from protein-nucleic acid complexes. When the "fragment reaction" was used as a model assay for peptide bond formation, Escherichia coli ribosomes or 50S subunits retained 20 to 40 percent activity after extensive treatment with proteinase K and SDS, but lost activity after extraction with phenol or exposure to EDTA. Ribosomes from the thermophilic eubacterium Thermus aquaticus remained more than 80 percent active after treatment with proteinase K and SDS, which was followed by vigorous extraction with phenol. This activity is attributable to peptidyl transferase, as judged by specific inhibition by the peptidyl transferase-specific antibiotics chloramphenicol and carbomycin. In contrast, activity is abolished by treatment with ribonuclease T1. These findings support the possibility that 23S ribosomal RNA participates in the peptidyl transferase function.			NOLLER, HF (corresponding author), UNIV CALIF SANTA CRUZ, SINSHEIMER LABS, SANTA CRUZ, CA 95064 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM017129, R37GM017129] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM17129] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATCHISON RE, UNPUB; BARTA A, 1984, P NATL ACAD SCI-BIOL, V81, P3607, DOI 10.1073/pnas.81.12.3607; BURMA DP, 1985, ARCH BIOCHEM BIOPHYS, V239, P427, DOI 10.1016/0003-9861(85)90708-8; CECH TR, 1981, CELL, V27, P487, DOI 10.1016/0092-8674(81)90390-1; CERNA J, 1973, EUR J BIOCHEM, V34, P551, DOI 10.1111/j.1432-1033.1973.tb02794.x; Chambliss G., 1980, RIBOSOMES STRUCTURE, P357; DAHLBERG AE, 1989, CELL, V57, P525, DOI 10.1016/0092-8674(89)90122-0; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; HAMPL H, 1981, J BIOL CHEM, V256, P2284; HELD WA, 1973, J BIOL CHEM, V248, P5720; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MADEN BEH, 1968, J MOL BIOL, V35, P333, DOI 10.1016/S0022-2836(68)80028-2; MOAZED D, 1991, P NATL ACAD SCI USA, V88, P3725, DOI 10.1073/pnas.88.9.3725; MOAZED D, 1989, CELL, V57, P585, DOI 10.1016/0092-8674(89)90128-1; MOAZED D, 1986, J MOL BIOL, V187, P399, DOI 10.1016/0022-2836(86)90441-9; MOAZED D, 1987, BIOCHIMIE, V69, P879, DOI 10.1016/0300-9084(87)90215-X; MOAZED D, 1986, CELL, V47, P985, DOI 10.1016/0092-8674(86)90813-5; MONRO RE, 1967, J MOL BIOL, V25, P347, DOI 10.1016/0022-2836(67)90146-5; MONRO RE, 1967, J MOL BIOL, V28, P161, DOI 10.1016/S0022-2836(67)80085-8; MOORE VG, 1975, P NATL ACAD SCI USA, V72, P844, DOI 10.1073/pnas.72.3.844; NIERHAUS KH, 1973, P NATL ACAD SCI USA, V70, P1931, DOI 10.1073/pnas.70.7.1931; NIERHAUS KH, 1982, CURR TOP MICROBIOL, V97, P81; NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.biochem.60.1.191; NOLLER HF, 1981, SCIENCE, V212, P403, DOI 10.1126/science.6163215; PARISH JH, 1966, BIOCHIM BIOPHYS ACTA, V129, P554, DOI 10.1016/0005-2787(66)90070-0; ROHL R, 1982, P NATL ACAD SCI-BIOL, V79, P729, DOI 10.1073/pnas.79.3.729; SIEGMANN M, 1987, METHOD ENZYMOL, V146, P362; STAEHELIN T, 1969, COLD SPRING HARB SYM, V34, P39, DOI 10.1101/SQB.1969.034.01.008; STEINER G, 1988, EMBO J, V7, P3949, DOI 10.1002/j.1460-2075.1988.tb03281.x; STERN S, 1989, SCIENCE, V244, P783, DOI 10.1126/science.2658053; TERAOKA H, 1978, FEBS LETT, V88, P223, DOI 10.1016/0014-5793(78)80179-3; VESTER B, 1988, EMBO J, V7, P3577, DOI 10.1002/j.1460-2075.1988.tb03235.x; 1989, CATALOGUE BACTERIA B	33	608	629	1	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 5	1992	256	5062					1416	1419		10.1126/science.1604315	http://dx.doi.org/10.1126/science.1604315			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HX337	1604315				2022-12-01	WOS:A1992HX33700026
J	PHILPOTT, KL; VINEY, JL; KAY, G; RASTAN, S; GARDINER, EM; CHAE, S; HAYDAY, AC; OWEN, MJ				PHILPOTT, KL; VINEY, JL; KAY, G; RASTAN, S; GARDINER, EM; CHAE, S; HAYDAY, AC; OWEN, MJ			LYMPHOID DEVELOPMENT IN MICE CONGENITALLY LACKING T-CELL RECEPTOR-ALPHA-BETA EXPRESSING CELLS	SCIENCE			English	Article							DENDRITIC EPIDERMAL-CELLS; MONOCLONAL-ANTIBODIES; LYMPHOCYTES-T; GAMMA-CHAIN; ANTIGEN; COMPLEX; DIFFERENTIATION; RECOGNITION; SPECIFICITY; COMMITMENT	Vertebrate T cells express either an alpha-beta or gamma-delta T cell receptor (TCR). The developmental relatedness of the two cell types is unresolved. Alpha-beta+ T cells respond to specific pathogens by collaborating with immunoglobulin-producing B cells in distinct lymphoid organs such as the spleen and Peyer's patches. The precise influence of alpha-beta+ T cells on B cell development is poorly understood. To investigate the developmental effects of alpha-beta+ T cells on B cells and gamma-delta+ T cells, mice homozygous for a disrupted TCR-alpha gene were generated. The homozygotes showed elimination of alpha-beta+ T cells and the loss of thymic medullae. Despite this, gamma-delta+ T cells developed in normal numbers, and there was an increase in splenic B cells.	IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND; MRC,CLIN RES CTR,COMPARAT BIOL SECT,HARROW HA1 3UJ,MIDDX,ENGLAND; YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06511	Cancer Research UK; Medical Research Council Clinical Trials Unit; Yale University			Kay, Graham F/A-4130-2011		NIGMS NIH HHS [GM37759] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037759] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BONNEVILLE M, 1989, NATURE, V342, P931, DOI 10.1038/342931a0; BORN W, 1990, SCIENCE, V249, P67, DOI 10.1126/science.1695022; BRENNER MB, 1986, NATURE, V322, P145, DOI 10.1038/322145a0; BUTCHER EC, 1989, FUNDAMENTAL IMMUNOLO, P117; CARBONE A, 1991, IMMUNOL REV, V120, P35; CARDING SR, 1990, GENE DEV, V4, P1304, DOI 10.1101/gad.4.8.1304; CEBRA JJ, 1983, ANN NY ACAD SCI, V409, P25, DOI 10.1111/j.1749-6632.1983.tb26857.x; CEBRA JJ, 1982, RECENT ADV MUCOSAL I, P155; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; Cobbold S P, 1983, Mol Biol Med, V1, P285; DIALYNAS DP, 1983, IMMUNOL REV, V74, P29, DOI 10.1111/j.1600-065X.1983.tb01083.x; GLICK B, 1956, POULTRY SCI, V35, P224, DOI 10.3382/ps.0350224; GOODMAN T, 1989, J EXP MED, V170, P1569, DOI 10.1084/jem.170.5.1569; GUIDOS CJ, 1990, J EXP MED, V172, P835, DOI 10.1084/jem.172.3.835; HAVRAN WL, 1990, NATURE, V344, P68, DOI 10.1038/344068a0; HAVRAN WL, 1988, NATURE, V335, P443, DOI 10.1038/335443a0; HAYDAY AC, 1985, NATURE, V316, P828, DOI 10.1038/316828a0; HAYDAY AC, UNPUB; HAYDAY AC, IN PRESS ENCY IMMUNO; HOCHSTENBACH F, 1989, NATURE, V340, P562, DOI 10.1038/340562a0; IKEDA RM, 1978, ANIMAL MODELS COMP D, P201; ITOHARA S, 1990, NATURE, V343, P754, DOI 10.1038/343754a0; JANEWAY CA, 1988, IMMUNOL TODAY, V9, P73, DOI 10.1016/0167-5699(88)91267-4; JANIS EM, 1989, SCIENCE, V244, P713, DOI 10.1126/science.2524098; KAWANISHI H, 1983, J EXP MED, V157, P433, DOI 10.1084/jem.157.2.433; Kay G., UNPUB; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; KUBO RT, 1989, J IMMUNOL, V142, P2736; KUZIEL WA, 1987, NATURE, V328, P263, DOI 10.1038/328263a0; LEDBETTER JA, 1980, J EXP MED, V152, P280, DOI 10.1084/jem.152.2.280; MACKAY CR, 1990, RES IMMUNOL, V141, P611, DOI 10.1016/0923-2494(90)90067-9; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MATIS LA, 1987, NATURE, V330, P262, DOI 10.1038/330262a0; MILLER JF, 1961, LANCET, V2, P748; MIXTER PF, 1991, J IMMUNOL, V147, P4109; MONGINI PKA, 1983, J EXP MED, V157, P69, DOI 10.1084/jem.157.1.69; PHILPOTT KL, UNPUB; PORTOLES P, 1989, J IMMUNOL, V142, P4169; RAFF MC, 1985, CELL, V42, P61, DOI 10.1016/S0092-8674(85)80101-X; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SAITO H, 1984, NATURE, V309, P757, DOI 10.1038/309757a0; STINGL G, 1987, P NATL ACAD SCI USA, V84, P4586, DOI 10.1073/pnas.84.13.4586; STROBER W, 1985, ADV HOST DEFENSE MEC, V4, P1; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; VIDOVIC D, 1989, NATURE, V340, P646, DOI 10.1038/340646a0	46	344	353	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 5	1992	256	5062					1448	1452		10.1126/science.1604321	http://dx.doi.org/10.1126/science.1604321			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HX337	1604321				2022-12-01	WOS:A1992HX33700037
J	PICCIRILLI, JA; MCCONNELL, TS; ZAUG, AJ; NOLLER, HF; CECH, TR				PICCIRILLI, JA; MCCONNELL, TS; ZAUG, AJ; NOLLER, HF; CECH, TR			AMINOACYL ESTERASE-ACTIVITY OF THE TETRAHYMENA RIBOZYME	SCIENCE			English	Article							SELF-SPLICING RNA; GROUP-I INTRON; BINDING-SITE; ENDORIBONUCLEASE ACTIVITY; THERMOPHILA RIBOZYME; KINETIC DESCRIPTION; RIBONUCLEASE-P; CATALYSIS; CLEAVAGE; SUBSTRATE	Several classes of ribozymes (catalytic RNA's) catalyze reactions at phosphorus centers, but apparently no reaction at a carbon center has been demonstrated. The active site of the Tetrahymena ribozyme was engineered to bind an oligonucleotide derived from the 3' end of N-formyl-methionyl-tRNA(fMet). This ribozyme catalyzes the hydrolysis of the aminoacyl ester bond to a modest extent, 5 to 15 times greater than the uncatalyzed rate. Catalysis involves binding of the oligonucleotide to the internal guide sequence of the ribozyme and requires Mg2+ and sequence elements of the catalytic core. The ability of RNA to catalyze reactions with aminoacyl esters expands the catalytic versatility of RNA and suggests that the first aminoacyl tRNA synthetase could have been an RNA molecule.	UNIV COLORADO,HOWARD HUGHES MED INST,DEPT CHEM & BIOCHEM,BOULDER,CO 80309; UNIV CALIF SANTA CRUZ,SINSHEIMER LABS,SANTA CRUZ,CA 95064	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; University of California System; University of California Santa Cruz								ALTMAN S, 1990, J BIOL CHEM, V265, P20053; BARFOD ET, 1989, MOL CELL BIOL, V9, P3657, DOI 10.1128/MCB.9.9.3657; BASS BL, 1984, NATURE, V308, P820, DOI 10.1038/308820a0; BEEN MD, 1986, CELL, V47, P207, DOI 10.1016/0092-8674(86)90443-5; Benkovic S. J, 1973, ENZYMES, P201; Benkovic S. J., 1978, TRANSITION STATES BI, P493; BENNER SA, 1989, P NATL ACAD SCI USA, V86, P7054, DOI 10.1073/pnas.86.18.7054; BUERGI HB, 1973, J AM CHEM SOC, V95, P5605; CECH TR, 1986, P NATL ACAD SCI USA, V83, P4360, DOI 10.1073/pnas.83.12.4360; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; CELANDER DW, 1991, SCIENCE, V251, P401, DOI 10.1126/science.1989074; CRICK FHC, 1968, J MOL BIOL, V38, P367, DOI 10.1016/0022-2836(68)90392-6; DAVIES RW, 1982, NATURE, V300, P719, DOI 10.1038/300719a0; DESLONGC.P, 1972, CAN J CHEMISTRY, V50, P3405, DOI 10.1139/v72-549; DOUDNA JA, 1989, P NATL ACAD SCI USA, V86, P7402, DOI 10.1073/pnas.86.19.7402; DOWNS WD, 1990, BIOCHEMISTRY-US, V29, P5605, DOI 10.1021/bi00475a027; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; FORSTER AC, 1990, SCIENCE, V249, P784; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; GILBERT W, 1986, NATURE, V319, P618, DOI 10.1038/319618a0; GROSSHANS CA, 1991, NUCLEIC ACIDS RES, V19, P3875, DOI 10.1093/nar/19.14.3875; GROSSHANS CA, 1989, BIOCHEMISTRY-US, V28, P6888, DOI 10.1021/bi00443a017; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10172, DOI 10.1021/bi00496a004; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; HERSCHLAG D, 1990, NATURE, V344, P405, DOI 10.1038/344405a0; HERSCHLAG D, UNPUB; Jencks W.P., 1987, CATALYSIS CHEM ENZYM; JOYCE GF, 1989, NATURE, V338, P217, DOI 10.1038/338217a0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LERNER RA, 1988, BIOESSAYS, V9, P107, DOI 10.1002/bies.950090402; MCSWIGGEN JA, 1989, SCIENCE, V244, P679, DOI 10.1126/science.2470150; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; Monro RE., 1971, METHOD ENZYMOL, V20, P472; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; ORGEL LE, 1968, J MOL BIOL, V38, P381, DOI 10.1016/0022-2836(68)90393-8; ORGEL LE, 1986, J THEOR BIOL, V123, P127, DOI 10.1016/S0022-5193(86)80149-7; PACE NR, 1985, ORIGINS LIFE EVOL B, V16, P97, DOI 10.1007/BF01809465; PACE NR, 1990, J BIOL CHEM, V265, P3587; PICCIRILLI JA, UNPUB; PYLE AM, 1990, P NATL ACAD SCI USA, V87, P8187, DOI 10.1073/pnas.87.21.8187; RAJAGOPAL J, 1989, SCIENCE, V244, P692, DOI 10.1126/science.2470151; ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULTZ PG, 1990, CHEM ENG NEWS, V68, P26, DOI 10.1021/cen-v068n022.p026; SYMONS RH, 1991, CRIT REV PLANT SCI, V10, P189, DOI 10.1080/07352689109382312; SZOSTAK JW, 1986, NATURE, V322, P83, DOI 10.1038/322083a0; TAIJI M, 1985, BIOCHEMISTRY-US, V24, P5776, DOI 10.1021/bi00342a013; VISSER CM, 1984, ORIGINS LIFE EVOL B, V14, P291, DOI 10.1007/BF00933670; VISSER CM, 1978, J MOL EVOL, V11, P171, DOI 10.1007/BF01733892; WARING RB, 1986, NATURE, V321, P133, DOI 10.1038/321133a0; WEINER AM, 1987, P NATL ACAD SCI USA, V84, P7383, DOI 10.1073/pnas.84.21.7383; WESTHEIMER FH, 1986, NATURE, V319, P534, DOI 10.1038/319534a0; White H. I., 1982, PYRIDINE NUCLEOTIDE; WHITE HB, 1976, J MOL EVOL, V7, P101, DOI 10.1007/BF01732468; Woese C.R., 1967, MOL BASIS GENETIC EX, P186; WOLFENDEN R, 1963, BIOCHEMISTRY-US, V2, P1090, DOI 10.1021/bi00905a031; YARUS M, 1988, SCIENCE, V240, P1751, DOI 10.1126/science.3381099; ZAUG AJ, 1986, NATURE, V324, P429, DOI 10.1038/324429a0; ZAUG AJ, 1988, BIOCHEMISTRY-US, V27, P8924, DOI 10.1021/bi00425a008	61	165	176	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 5	1992	256	5062					1420	1424		10.1126/science.1604316	http://dx.doi.org/10.1126/science.1604316			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HX337	1604316				2022-12-01	WOS:A1992HX33700027
J	RICE, WR				RICE, WR			SEXUALLY ANTAGONISTIC GENES - EXPERIMENTAL-EVIDENCE	SCIENCE			English	Article								When selection differs between the sexes, a mutation beneficial to one sex may be harmful to the other (sexually antagonistic). Because the sexes share a common gene pool, selection in one sex can interfere with the other's adaptive evolution. Theory predicts that sexually antagonistic mutations should accumulate in tight linkage with a new sex-determining gene, even when the harm to benefit ratio is high. Genetic markers and artificial selection were used to make a pair of autosomal genes segregate like a new pair of sex-determining genes in a Drosophila melanogaster model system. A 29-generation study provides experimental evidence that sexually antagonistic genes may be common in nature and will accumulate in response to a new sex-determining gene.			RICE, WR (corresponding author), UNIV CALIF SANTA CRUZ,BIOL BOARD STUDIES,SANTA CRUZ,CA 95064, USA.							Bull J.J., 1983, EVOLUTION SEX DETERM; CHARLESWORTH B, 1991, SCIENCE, V251, P1030, DOI 10.1126/science.1998119; CHARLESWORTH B, 1987, AM NAT, V130, P113, DOI 10.1086/284701; CHARLESWORTH D, 1980, GENET RES, V35, P205, DOI 10.1017/S0016672300014051; Fisher RA, 1931, BIOL REV BIOL P CAMB, V6, P345, DOI 10.1111/j.1469-185X.1931.tb01030.x; KIDWELL JF, 1973, GENETICS, V85, P171; Lindsley D.L., 1968, GENETIC VARIATIONS D; MANDEL SPH, 1971, HEREDITY, V26, P49, DOI 10.1038/hdy.1971.5; RICE WR, 1984, EVOLUTION, V38, P735, DOI [10.1111/j.1558-5646.1984.tb00346.x, 10.2307/2408385]; SPEITH HT, 1983, GENETICS BIOL DROSOP, V3, pCH23	10	239	240	1	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 5	1992	256	5062					1436	1439		10.1126/science.1604317	http://dx.doi.org/10.1126/science.1604317			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HX337	1604317				2022-12-01	WOS:A1992HX33700033
J	ARSHAVSKY, VY; BOWNDS, MD				ARSHAVSKY, VY; BOWNDS, MD			REGULATION OF DEACTIVATION OF PHOTORECEPTOR G-PROTEIN BY ITS TARGET ENZYME AND CGMP	NATURE			English	Article							ROD OUTER SEGMENTS; CYCLIC-GMP PHOSPHODIESTERASE; MOLECULAR MECHANISM; VISUAL EXCITATION; TRANSDUCIN GTPASE; CASCADE; ACTIVATION; MEMBRANES; TURNOVER; SUBUNIT	THE photoreceptor G protein, transducin, is One of the class of heterotrimeric G proteins that mediates between membrane receptors and intracellular enzymes or ion channels. Light-activated rhodopsin catalyses the exchange of GDP for GTP on multiple transducin molecules. Activated transducin then stimulates cyclic GMP phosphodiesterase by releasing an inhibitory action of the phosphodiesterase gamma-subunits. This leads to a decrease in cGMP levels in the rod, and closure of plasma membrane cationic channels gated by cGMP 1-4. In this and other systems, turn-off of the response requires the GTP bound to G protein to be hydrolysed by an intrinsic GTPase activity 5-7. Here we report that the interaction of transducin with cGMP phosphodiesterase, specifically with its gamma-subunits, accelerates GTPase activity by several fold. Thus the gamma-subunits of the phosphodiesterase serve a function analogous to the GTPase-activating proteins that regulate the class of small GTP-binding proteins. The acceleration can be partially suppressed by cGMP, most probably through the non-catalytic cGMP-binding sites of phosphodiesterase alpha and beta-subunits. This cGMP regulation may function in light-adaptation of the photoresponse as a negative feedback that decreases the lifetime of activated cGMP phosphodiesterase as light causes decreases in cytoplasmic cGMP.	UNIV WISCONSIN,DEPT ZOOL,NEUROSCI TRAINING PROGRAM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison	ARSHAVSKY, VY (corresponding author), UNIV WISCONSIN,DEPT ZOOL,MOLEC BIOL LAB,MADISON,WI 53706, USA.							ARSHAVSKY VY, 1989, FEBS LETT, V250, P353, DOI 10.1016/0014-5793(89)80754-9; ARSHAVSKY VY, 1991, J BIOL CHEM, V266, P18530; BAEHR W, 1982, J BIOL CHEM, V257, P6452; BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P589; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BREER H, 1990, NATURE, V345, P65, DOI 10.1038/345065a0; BREITWIESER GE, 1988, J GEN PHYSIOL, V91, P469, DOI 10.1085/jgp.91.4.469; BROWN RL, 1989, P NATL ACAD SCI USA, V86, P4922, DOI 10.1073/pnas.86.13.4922; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; CHARBONNEAU H, 1990, P NATL ACAD SCI USA, V87, P288, DOI 10.1073/pnas.87.1.288; DETERRE P, 1988, P NATL ACAD SCI USA, V85, P2424, DOI 10.1073/pnas.85.8.2424; DRATZ EA, 1987, BIOCHEM BIOPH RES CO, V146, P379, DOI 10.1016/0006-291X(87)90540-7; FAIN GL, 1976, J PHYSIOL-LONDON, V261, P71, DOI 10.1113/jphysiol.1976.sp011549; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; HURLEY JB, 1982, J BIOL CHEM, V257, P1094; IYENGAR R, 1990, G PROTEINS; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; LI T, 1990, P NATL ACAD SCI USA, V87, P293, DOI 10.1073/pnas.87.1.293; LIEBMAN PA, 1987, ANNU REV PHYSIOL, V49, P765, DOI 10.1146/annurev.ph.49.030187.004001; PUGH EN, 1990, VISION RES, V30, P1923, DOI 10.1016/0042-6989(90)90013-B; ROBINSON PR, 1980, J GEN PHYSIOL, V76, P631, DOI 10.1085/jgp.76.5.631; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SITARAMAYYA A, 1983, J BIOL CHEM, V258, P2106; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; TAYLOR CW, 1990, BIOCHEM J, V272, P1; VUONG TM, 1991, P NATL ACAD SCI USA, V88, P9813, DOI 10.1073/pnas.88.21.9813; WAGNER R, 1988, FEBS LETT, V234, P44, DOI 10.1016/0014-5793(88)81299-7; WITT PL, 1984, J GEN PHYSIOL, V84, P251, DOI 10.1085/jgp.84.2.251; YAMAZAKI A, 1980, J BIOL CHEM, V255, P1619	30	239	241	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 4	1992	357	6377					416	417		10.1038/357416a0	http://dx.doi.org/10.1038/357416a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HX172	1317509	Green Published, Bronze			2022-12-01	WOS:A1992HX17200067
J	DELMAS, B; GELFI, J; LHARIDON, R; VOGEL, LK; SJOSTROM, H; NOREN, O; LAUDE, H				DELMAS, B; GELFI, J; LHARIDON, R; VOGEL, LK; SJOSTROM, H; NOREN, O; LAUDE, H			AMINOPEPTIDASE-N IS A MAJOR RECEPTOR FOR THE ENTEROPATHOGENIC CORONAVIRUS TGEV	NATURE			English	Article							INTESTINAL BRUSH-BORDER; TRANSMISSIBLE GASTROENTERITIS; VIRUS; EXPRESSION; SEQUENCE; CLONING; KIDNEY; GENE	CORONAVIRUSES, like many animal viruses, are characterized by a restricted host range and tissue tropism 1. Transmissible gastroenteritis virus (TGEV), a major pathogen causing a fatal diarrhoea in newborn pig, replicates selectively in the differentiated enterocytes covering the villi of the small intestine 2. To investigate the molecular determinants of the infection, we characterized the surface molecule used by the virus for binding and entry into host cells. Here we report that aminopeptidase N, an ectoenzyme abundantly expressed at the apical membrane of the enterocytes, serves as a receptor for TGEV. Monoclonal antibodies were selected for their ability to block infection by TGEV of porcine cell lines. They recognized a brush-border membrane protein of M(r) 150K, which was identified as aminopeptidase N by amino-terminal sequencing. Two lines of evidence supported the view that the peptidase itself acts as a receptor. First, virions bound specifically to aminopeptidase N that was purified to homogeneity. Second, recombinant expression of aminopeptidase N conferred infectivity by TGEV to an otherwise non-permissive cell line.	INRA,UNITE VIROL & IMMUNOL MOLEC,DOMAINE VILVERT,F-78350 JOUY EN JOSAS,FRANCE; PANUM INST,DEPT BIOCHEM,DK-2200 COPENHAGEN N,DENMARK	INRAE; UDICE-French Research Universities; Universite Paris Saclay				Vogel, Lotte K./0000-0001-9920-0982				DVEKSLER GS, 1991, J VIROL, V65, P6881, DOI 10.1128/JVI.65.12.6881-6891.1991; GORVEL JP, 1989, J CELL BIOL, V108, P2193, DOI 10.1083/jcb.108.6.2193; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; HAELTERMAN EO, 1972, J AM VET MED ASSOC, V160, P534; HAUSER H, 1980, BIOCHIM BIOPHYS ACTA, V602, P567, DOI 10.1016/0005-2736(80)90335-1; JOHANSEN TE, 1990, FEBS LETT, V267, P289, DOI 10.1016/0014-5793(90)80947-H; KENNY AJ, 1982, PHYSIOL REV, V62, P91, DOI 10.1152/physrev.1982.62.1.91; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; KRAMERS MTC, 1979, EUR J BIOCHEM, V99, P345, DOI 10.1111/j.1432-1033.1979.tb13262.x; KUENG W, 1989, ANAL BIOCHEM, V182, P16, DOI 10.1016/0003-2697(89)90710-0; LAUDE H, 1986, J GEN VIROL, V67, P119, DOI 10.1099/0022-1317-67-1-119; LOOK AT, 1989, J CLIN INVEST, V83, P1299, DOI 10.1172/JCI114015; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MAROUX S, 1973, BIOCHIM BIOPHYS ACTA, V321, P282, DOI 10.1016/0005-2744(73)90083-1; MENDELSOHN CL, 1989, CELL, V56, P855, DOI 10.1016/0092-8674(89)90690-9; OLSEN J, 1988, FEBS LETT, V238, P307, DOI 10.1016/0014-5793(88)80502-7; OLSEN J, 1989, FEBS LETT, V251, P275, DOI 10.1016/0014-5793(89)81470-X; PENSAERT M, 1970, ARCH GES VIRUSFORSCH, V31, P321, DOI 10.1007/BF01253767; SIDDELL S, 1983, J GEN VIROL, V64, P761, DOI 10.1099/0022-1317-64-4-761; SJOSTROM H, 1978, EUR J BIOCHEM, V88, P503, DOI 10.1111/j.1432-1033.1978.tb12476.x; SJOSTROM H, 1982, EUR J BIOCHEM, V122, P245, DOI 10.1111/j.1432-1033.1982.tb05873.x	21	504	549	2	40	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 4	1992	357	6377					417	420		10.1038/357417a0	http://dx.doi.org/10.1038/357417a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HX172	1350661	Bronze, Green Published			2022-12-01	WOS:A1992HX17200068
J	EDLIN, BR; TOKARS, JI; GRIECO, MH; CRAWFORD, JT; WILLIAMS, J; SORDILLO, EM; ONG, KR; KILBURN, JO; DOOLEY, SW; CASTRO, KG; JARVIS, WR; HOLMBERG, SD				EDLIN, BR; TOKARS, JI; GRIECO, MH; CRAWFORD, JT; WILLIAMS, J; SORDILLO, EM; ONG, KR; KILBURN, JO; DOOLEY, SW; CASTRO, KG; JARVIS, WR; HOLMBERG, SD			AN OUTBREAK OF MULTIDRUG-RESISTANT TUBERCULOSIS AMONG HOSPITALIZED-PATIENTS WITH THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VIRUS-INFECTION; ASSOCIATION; SHELTER	Background. Since 1990 several clusters of multidrug-resistant tuberculosis have been identified among hospitalized patients with the acquired immunodeficiency syndrome (AIDS). We investigated one such cluster in a voluntary hospital in New York. Methods. We compared exposures among 18 patients with AIDS in whom tuberculosis resistant to isoniazid and streptomycin was diagnosed from January 1989 through April 1990 (the case patients) with exposures among 30 control patients who had AIDS and tuberculosis susceptible to isoniazid, streptomycin, or both. We also compared exposures among the 14 case patients hospitalized during the six months before the diagnosis of tuberculosis (the exposure period) with those among 44 control patients with AIDS matched for duration of hospitalization. Mycobacterium tuberculosis isolates were typed with analysis of restriction-fragment-length polymorphism (RFLP). Results. Case patients with drug-resistant tuberculosis were significantly more likely than controls with drug-susceptible tuberculosis to have been hospitalized during their exposure periods (14 of 18 vs. 10 of 30) (odds ratio, 7.0; 95 percent confidence interval, 1.6 to 36; P = 0.006). Case patients hospitalized during their exposure periods were significantly more likely to have been hospitalized on the same ward as a patient with infectious drug-resistant tuberculosis than were either controls with drug-susceptible tuberculosis hospitalized during their exposure periods or controls matched for duration of hospitalization (13 of 14 vs. 2 of 10 and 23 of 44) (odds ratio, 52; 95 percent confidence interval, 3.1 to 2474; P < 0.001; and odds ratio, infinity; 95 percent confidence interval, 2.4 to infinity; P = 0.005, respectively). Among those hospitalized on the same ward, the rooms of case patients were closer to that of the nearest patient with infectious tuberculosis than were the rooms of controls matched for duration of hospitalization. M. tuberculosis isolates from 15 of 16 case patients had identical patterns on RFLP analysis. Of 16 patients' rooms tested with air-flow studies, only 1 had the recommended negative-pressure ventilation. Conclusions. Multidrug-resistant tuberculosis is readily transmitted among hospitalized patients with AIDS. Physicians must be alert to this danger and must enforce adherence to the measures recommended to prevent nosocomial transmission of tuberculosis.	CTR DIS CONTROL,HOSP INFECT PROGRAM,ATLANTA,GA 30333; CTR DIS CONTROL,NATL CTR INFECT DIS DIV BACTERIAL & MYCOT DIS,ATLANTA,GA 30333; CTR DIS CONTROL,NATL CTR PREVENT SERV,DIV TB ELIMINAT,ATLANTA,GA 30333; COLUMBIA UNIV COLL PHYS & SURG,ST LUKES ROOSEVELT HOSP CTR,NEW YORK,NY 10032	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Columbia University; Mount Sinai St. Luke's; Mount Sinai West	EDLIN, BR (corresponding author), CTR DIS CONTROL,DIV HIV AIDS,MAILSTOP E-45,ATLANTA,GA 30333, USA.		Sordillo, Emilia Mia/AAF-3012-2021; Castro, Kenneth G/P-1882-2018; Edlin, Brian R/F-2966-2018	Sordillo, Emilia Mia/0000-0001-7787-3051; Castro, Kenneth G/0000-0001-7964-6354; Edlin, Brian R/0000-0001-8172-8797				BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; BRAUN MM, 1989, JAMA-J AM MED ASSOC, V261, P393, DOI 10.1001/jama.261.3.393; CAVE MD, 1991, MOL CELL PROBE, V5, P73, DOI 10.1016/0890-8508(91)90040-Q; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DESPREZ RM, 1990, PRINCIPLES PRACTICE, P1881; DIPERRI G, 1989, LANCET, V2, P1502; ISEMAN MD, 1989, CLIN CHEST MED, V10, P341; Kent PT, 1985, PUBLIC HLTH MYCOBACT, P159; LUBIN JH, 1981, COMPUT BIOMED RES, V14, P138, DOI 10.1016/0010-4809(81)90031-8; MCADAM JM, 1991, CHEST, V99, P792, DOI 10.1378/chest.99.3.792-c; MCADAM JM, 1990, CHEST, V97, P798, DOI 10.1378/chest.97.4.798; MONNO L, 1991, LANCET, V337, P852, DOI 10.1016/0140-6736(91)92559-K; PELLETIER AR, 1991, 40TH ANN C EP INT SE, P43; SALOMON N, 1991, 31ST INT C ANT AG CH, P152; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SHAFER RW, 1991, AIDS, V5, P399, DOI 10.1097/00002030-199104000-00007; TORRES RA, 1990, ARCH INTERN MED, V150, P2030, DOI 10.1001/archinte.150.10.2030; VALWAY SE, 1992, 41ST ANN C EP INT SE, P30; 1985, MMWR, V34, P429; 1991, MMWR, V40, P585; [No title captured]; 1991, MMWR, V40, P129; 1990, MMWR S, V39, pRR17	23	743	762	0	14	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 4	1992	326	23					1514	1521		10.1056/NEJM199206043262302	http://dx.doi.org/10.1056/NEJM199206043262302			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW972	1304721				2022-12-01	WOS:A1992HW97200002
J	KOUTSKY, LA; STEVENS, CE; HOLMES, KK; ASHLEY, RL; KIVIAT, NB; CRITCHLOW, CW; COREY, L				KOUTSKY, LA; STEVENS, CE; HOLMES, KK; ASHLEY, RL; KIVIAT, NB; CRITCHLOW, CW; COREY, L			UNDERDIAGNOSIS OF GENITAL HERPES BY CURRENT CLINICAL AND VIRAL-ISOLATION PROCEDURES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SIMPLEX VIRUS-INFECTION; TYPE-2 INFECTION; IMMUNE-RESPONSE; NATURAL-HISTORY; WESTERN BLOT; WOMEN; PREVALENCE; DIAGNOSIS; IMMUNOFLUORESCENCE; MANIFESTATIONS	Background. The current clinical strategy for diagnosing genital herpes simplex virus (HSV) infection in women relies on clinical findings plus the selective use of viral culture. The effectiveness of this approach for identifying women with genital herpes is unknown. Methods. We performed physical examinations, colposcopy, Pap smears, viral cultures, and HSV type-specific serologic assays of 779 randomly selected women attending a sexually transmitted disease clinic. Results. Evidence of HSV type 2 infection was detected in 363 women (47 percent), and 9 others (1 percent) had positive cultures indicative of urogenital or anal infection with HSV type 1. Of these 372 women, only 82 (22 percent) had symptoms. Fourteen women (4 percent) had viral shedding without symptoms, 60 (16 percent) had formerly had symptomatic episodes, and 216 (58 percent) had antibodies to HSV-2 with neither viral shedding nor a history of clinical episodes. Characteristic ulcerations of the external genitalia were present in only two thirds of the 66 women with positive HSV cultures; the others had atypical genital lesions or asymptomatic viral shedding. Isolation of HSV from a genitourinary tract specimen was the most sensitive (77 percent) test for confirming a first episode of infection. The detection of HSV-2-specific antibodies was the most sensitive (97 percent) way to confirm symptomatic reactivations of HSV-2 infection. HSV-2 serologic testing also identified the 290 women with asymptomatic HSV-2 infections (37 percent), including 14 (5 percent) who were shedding virus asymptomatically on the day of the examination. Conclusions. The current strategy for diagnosing genital HSV infection in women misses many cases. Newly developed type-specific serologic methods can identify women with recurrent genital HSV-2 infection, as well as those with unrecognized or subclinical infection.	UNIV WASHINGTON,SCH PUBL HLTH,DEPT EPIDEMIOL,SEATTLE,WA 98195; UNIV WASHINGTON,SCH PUBL HLTH,DEPT BIOSTAT,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT LAB MED,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT MED,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT MICROBIOL,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT PATHOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle			, Holmes/K-6215-2019; Corey, Lawrence/AAE-1796-2020	Corey, Lawrence/0000-0002-2179-2436	NATIONAL CANCER INSTITUTE [R01CA034493] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020381, P01AI012192] Funding Source: NIH RePORTER; NCI NIH HHS [CA-34493] Funding Source: Medline; NIAID NIH HHS [AI-20381, AI-12192] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASHLEY R, 1985, J MED VIROL, V17, P153, DOI 10.1002/jmv.1890170208; ASHLEY R, 1991, ANN INTERN MED, V115, P520, DOI 10.7326/0003-4819-115-7-520; ASHLEY RL, 1988, J CLIN MICROBIOL, V26, P662, DOI 10.1128/JCM.26.4.662-667.1988; ASHLEY RL, 1987, J VIROL METHODS, V18, P159, DOI 10.1016/0166-0934(87)90121-2; BADER C, 1978, J INFECT DIS, V138, P897, DOI 10.1093/infdis/138.6.897; BRESLOW NE, 1980, IARC SCI PUBL, V32, P192; BROWN ZA, 1991, NEW ENGL J MED, V324, P1247, DOI 10.1056/NEJM199105023241804; BRYSON YJ, 1983, NEW ENGL J MED, V308, P916, DOI 10.1056/NEJM198304213081602; CONE RW, 1991, J INFECT DIS, V164, P757, DOI 10.1093/infdis/164.4.757; COREY L, 1983, ANN INTERN MED, V98, P958, DOI 10.7326/0003-4819-98-6-958; COREY L, 1983, ANN INTERN MED, V98, P973, DOI 10.7326/0003-4819-98-6-973; DORSKY DI, 1987, ANN INTERN MED, V107, P859, DOI 10.7326/0003-4819-107-6-859; ESCHENBACH DA, 1988, AM J OBSTET GYNECOL, V158, P819, DOI 10.1016/0002-9378(88)90078-6; FLEISS JL, 1981, STATISTICAL METHODS, P51; GUINAN ME, 1985, EPIDEMIOL REV, V7, P127, DOI 10.1093/oxfordjournals.epirev.a036279; GUINAN ME, 1981, NEW ENGL J MED, V304, P759, DOI 10.1056/NEJM198103263041305; HARDY DA, 1990, J INFECT DIS, V162, P1031, DOI 10.1093/infdis/162.5.1031; HOLMBERG SD, 1988, JAMA-J AM MED ASSOC, V259, P1048, DOI 10.1001/jama.259.7.1048; JOHNSON RE, 1989, NEW ENGL J MED, V321, P7, DOI 10.1056/NEJM198907063210102; KAUFMAN RH, 1973, CANCER RES, V33, P1446; KOUTSKY LA, 1990, SEX TRANSM DIS, V17, P90, DOI 10.1097/00007435-199004000-00009; LAFFERTY WE, 1987, NEW ENGL J MED, V316, P1444, DOI 10.1056/NEJM198706043162304; LAFFERTY WE, 1987, J CLIN MICROBIOL, V25, P323, DOI 10.1128/JCM.25.2.323-326.1987; LANGENBERG A, 1989, ANN INTERN MED, V110, P882, DOI 10.7326/0003-4819-110-11-882; LIPSON SM, 1987, J CLIN MICROBIOL, V25, P391, DOI 10.1128/JCM.25.2.391-394.1987; LYNCH PJ, 1970, CUTIS, V6, P79; MANN SL, 1984, J INFECT DIS, V149, P1026, DOI 10.1093/infdis/149.6.1026; MERTZ GJ, 1988, J INFECT DIS, V157, P1169, DOI 10.1093/infdis/157.6.1169; MERTZ GJ, 1992, ANN INTERN MED, V116, P197, DOI 10.7326/0003-4819-116-3-197; MERTZ GJ, 1985, SEX TRANSM DIS, V12, P33, DOI 10.1097/00007435-198501000-00007; MERTZ GL, 1984, JAMA-J AM MED ASSOC, V242, P1147; Nahmias A J, 1990, Scand J Infect Dis Suppl, V69, P19; PAPANICOLAOU GN, 1963, ATLAS EXFOLIATIVE CY, P3; PETERSON E, 1983, J CLIN MICROBIOL, V17, P92, DOI 10.1128/JCM.17.1.92-96.1983; ROONEY JF, 1986, NEW ENGL J MED, V314, P1561, DOI 10.1056/NEJM198606123142407; WADE JC, 1984, J INFECT DIS, V149, P750, DOI 10.1093/infdis/149.5.750; WHITLEY RJ, 1980, PEDIATRICS, V66, P489; 1991, HIV AIDS Q EPIDEMIOL	38	229	233	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 4	1992	326	23					1533	1539		10.1056/NEJM199206043262305	http://dx.doi.org/10.1056/NEJM199206043262305			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW972	1315930				2022-12-01	WOS:A1992HW97200005
J	LI, TY; ETLER, DA				LI, TY; ETLER, DA			NEW MIDDLE PLEISTOCENE HOMINID CRANIA FROM YUNXIAN IN CHINA	NATURE			English	Article							HOMO-SAPIENS; ORIGIN; SKULL	Two fossil human crania have been found in Middle Pleistocene terrace deposits of the Han River in Yun county (Yunxian), Hubei province, China (Figs 1 and 2) 1. These damaged but relatively complete adult specimens show a mixture of features associated both with Homo erectus and with 'archaic H. sapiens'. The Yunxian crania (Figs 3 and 4), although crushed and distorted to varying degrees, are unusual in having major elements of the basicranium, palate, face and cranial vault preserved together. The specimens reveal many details of facial and basicranial anatomy rarely seen in hominid crania of comparable antiquity. Moreover, they are the most complete crania of such great age discovered on the Asian mainland. They consequently throw new light on Middle Pleistocene hominid diversity and the relationships among regionally disparate Middle Pleistocene hominids.	UNIV CALIF BERKELEY,DEPT ANTHROPOL,HUMAN EVOLUT STUDIES LAB,BERKELEY,CA 94720	University of California System; University of California Berkeley	LI, TY (corresponding author), HUBEI INST ARCHEOL,67 DONGHU RD,WUHAN 430077,PEOPLES R CHINA.							Aiello L., 1990, INTRO HUMAN EVOLUTIO; BLACK DAVIDSON, 1931, PALAEONTOLOGIA SINICA SER D, V7, P1; Brauer G., 1990, Acta Anthropologica Sinica, V9, P350; CLARKE RJ, 1990, J HUM EVOL, V19, P699, DOI 10.1016/0047-2484(90)90004-U; CONTROY GC, 1978, NATURE, V276, P67; DAY MH, 1980, NATURE, V284, P55, DOI 10.1038/284055a0; Dong X., 1989, EARLY HUMANKIND CHIN, P9; Howell F.C., 1978, P154; HUBLIN JJ, 1984, ANTHROPOS BRNO, V23, P175; KENNEDY GE, 1991, J HUM EVOL, V20, P375, DOI 10.1016/0047-2484(91)90006-H; Maier W., 1984, Courier Forschungsinstitut Senckenberg, V69, P123; Murrill R.I., 1975, Zeitschrift Morph Anthrop, V66, P176; POPE GG, 1991, J HUM EVOL, V21, P189, DOI 10.1016/0047-2484(91)90061-Y; RAK Y, 1986, J HUM EVOL, V15, P151, DOI 10.1016/S0047-2484(86)80042-2; RIGHTMIRE GP, 1990, EVOLUTION H ERECTUS; Sartono S., 1975, P327; SOHN S, 1990, ACTA ANTHR SINICA, V9, P359; Stringer C.B., 1984, Courier Forschungsinstitut Senckenberg, V69, P131; STRINGER CB, 1979, J ARCHAEOL SCI, V6, P235, DOI 10.1016/0305-4403(79)90002-5; STRINGER CB, 1988, SCIENCE, V239, P1263, DOI 10.1126/science.3125610; Wang Z., 1991, JIANGHAN KAOGU, V39, P1; Weidenreich F., 1943, Palaeontologia Sinica, VD 10, P1; WEIDENREICH F, 1937, PALAEONTOL SINICA D, V1, P1; WEIDENREICH F, 1936, PALAEONTOLOGICA SI D, V7, P1; Weidenreich F., 1951, ANTHROPOLOGICAL PAPE, V43, P205; Woo J., 1959, PALEOVERTEBR PALEOAN, V1, P159; WOO JK, 1965, SCI SINICA, V14, P1032; Wu, 1990, ACTA ANTHR SINICA, V9, P312; Wu RK., 1988, ACTA ANTHROPOL SIN, V7, P97; Wu RK, 1982, ACTA ANTHR SIN, V1, P2; WU XZ, 1981, SCI SINICA, V24, P530; Xinzhi W., 1988, ACTA ANTHROPOL SIN, V7, P287	32	80	97	2	28	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 4	1992	357	6377					404	407						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HX172	1594044				2022-12-01	WOS:A1992HX17200063
J	MARSH, RL; OLSON, JM; GUZIK, SK				MARSH, RL; OLSON, JM; GUZIK, SK			MECHANICAL PERFORMANCE OF SCALLOP ADDUCTOR MUSCLE DURING SWIMMING	NATURE			English	Article								MECHANICAL performance of skeletal muscle has long been the subject of intense interest 1, but the details of in vivo performance of individual skeletal muscles during normal locomotion remain largely unknown. Performance in vitro has been described with considerable precision under simplified loading conditions 2. The force production and shortening velocity of most muscles, however, probably change continuously during natural movements. Therefore, modelling in vivo performance on the basis of in vitro contractile properties 3 is subject to large degrees of uncertainty. Designing in vitro experiments that effectively examine the limits of mechanical performance requires increasing knowledge of precisely how muscles are used during normal movements. We report here measurements of the mechanical performance of the adductor muscle in scallops during jet-propulsion swimming. Swimming in scallops is powered solely by the striated portion of the single adductor muscle. Exploiting this simple locomotor morphology with simultaneous high-resolution measurements of pressure and flow rate, we have recorded nearly instantaneous measurements of the performance of a single skeletal muscle during normal locomotion.			MARSH, RL (corresponding author), NORTHEASTERN UNIV,DEPT BIOL,360 HUNTINGTON AVE,BOSTON,MA 02115, USA.			Marsh, Richard/0000-0002-4264-9890				BENNETCLARK HC, 1975, J EXP BIOL, V63, P53; DANIEL TL, 1984, AM ZOOL, V24, P121; DAVIES CTM, 1989, EUR J APPL PHYSIOL O, V58, P838, DOI 10.1007/BF02332216; GADE G, 1978, J COMP PHYSIOL, V124, P121; HILL AV, 1920, J PHYSIOL-LONDON, V53, pR88; LOWY J, 1954, J PHYSIOL-LONDON, V124, P100, DOI 10.1113/jphysiol.1954.sp005088; MELLON D, 1969, Z VERGL PHYSIOL, V62, P318; MOORE J D, 1971, Journal of Experimental Marine Biology and Ecology, V6, P179, DOI 10.1016/0022-0981(71)90017-7; TRUEMAN ER, 1953, J EXP BIOL, V30, P453; VANLEEUWEN JL, 1991, J THEOR BIOL, V149, P229, DOI 10.1016/S0022-5193(05)80279-6; WANG CY, 1979, J BIOMECH, V12, P9, DOI 10.1016/0021-9290(79)90003-4; WILKENS LA, 1981, PROC R SOC SER B-BIO, V211, P341, DOI 10.1098/rspb.1981.0011; Woledge RC., 1985, ENERGETIC ASPECTS MU; Yonge C. M., 1936, Mem Mus Hist Nat Belg (2), V3, P77; [No title captured]	15	81	81	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 4	1992	357	6377					411	413		10.1038/357411a0	http://dx.doi.org/10.1038/357411a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HX172	1594046				2022-12-01	WOS:A1992HX17200065
J	PRAS, E; AKSENTIJEVICH, I; GRUBERG, L; BALOW, JE; PROSEN, L; DEAN, M; STEINBERG, AD; PRAS, M; KASTNER, DL				PRAS, E; AKSENTIJEVICH, I; GRUBERG, L; BALOW, JE; PROSEN, L; DEAN, M; STEINBERG, AD; PRAS, M; KASTNER, DL			MAPPING OF A GENE CAUSING FAMILIAL MEDITERRANEAN FEVER TO THE SHORT ARM OF CHROMOSOME-16	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LINKAGE ANALYSIS; DNA; AMYLOIDOSIS; IDENTIFICATION; POLYSEROSITIS; C5A-INHIBITOR; LOCALIZATION; ARMENIANS; FREQUENCY; COMMITTEE	Background. Familial Mediterranean fever is an autosomal-recessive disease characterized by acute attacks of fever with sterile peritonitis, pleurisy, or synovitis. The biochemical basis of the disease is unknown, but determining the chromosomal location of the gene for the disorder should be a first step toward defining the biochemical events. Methods and Results. As part of a systematic genome-wide search, we sought evidence of linkage between familial Mediterranean fever and chromosome 16 DNA markers in 27 affected non-Ashkenazi Jewish families from Israel. Two loci from the subtelomeric region of the short arm of chromosome 16 (16p) had lod scores sufficient to establish linkage (a score greater-than-or-equal-to 3). One DNA marker (D16S84) gave a maximal lod score of 9.17 (odds of 10(9.17) to 1 in favor of linkage) at a recombination frequency (theta) of 0.04. A probe associated with the hemoglobin-alpha complex (5'HVR) gave a maximal lod score of 14.47 at a theta of 0.06. Multipoint linkage analysis indicated that the following was the most likely gene order: the centromere, the gene for familial Mediterranean fever, D16S84, hemoglobin-alpha, and the telomere. The maximal multipoint lod score was 19.86. There was a striking degree of homozygosity at chromosome 16p loci in the affected offspring of eight consanguineous couples. Conclusions. The gene that causes familial Mediterranean fever in non-Ashkenazi Jews maps to the short arm of chromosome 16.	NIAMSD,ARTHRITIS & RHEUMATISM BRANCH,BLDG 6,RM 112,BETHESDA,MD 20892; CHAIM SHEBA MED CTR,DEPT MED,IL-52621 TEL HASHOMER,ISRAEL; CHAIM SHEBA MED CTR,HELLER INST MED RES,IL-52621 TEL HASHOMER,ISRAEL; NCI,FREDERICK CANC RES & DEV CTR,FREDERICK,MD 21701	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Chaim Sheba Medical Center; Chaim Sheba Medical Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Aksentijevich, Ivona/AAF-1335-2019; Dean, Michael/R-7501-2019; Dean, Michael C/G-8172-2012	Dean, Michael C/0000-0003-2234-0631				AKSENTIJEVICH I, 1991, AM J HUM GENET, V49, P335; ANDERSON MA, 1984, IN VITRO CELL DEV B, V20, P856; AYESH SK, 1990, J IMMUNOL, V144, P3066; BARAKAT MH, 1986, Q J MED, V60, P837; Battey, 1986, BASIC METHODS MOL BI; CAVENEE W, 1984, AM J HUM GENET, V36, P10; COLLINS FS, 1992, NAT GENET, V1, P3, DOI 10.1038/ng0492-3; CONNEALLY PM, 1985, CYTOGENET CELL GENET, V40, P356, DOI 10.1159/000132186; CORBI AL, 1988, J EXP MED, V167, P1597, DOI 10.1084/jem.167.5.1597; DIAMOND JM, 1987, NATURE, V329, P105, DOI 10.1038/329105a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRADKIN A, 1985, ISRAEL J MED SCI, V21, P757; GERMINO GG, 1990, AM J HUM GENET, V46, P925; GRUBERG L, 1991, CYTOGENET CELL GENET, V58, P2113; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; JARMAN AP, 1988, AM J HUM GENET, V43, P249; JULIER C, 1990, GENOMICS, V6, P419, DOI 10.1016/0888-7543(90)90471-6; KASTNER DL, 1991, CYTOGENET CELL GENET, V58, P2115; Kosambi D. D., 1944, ANN EUGENICS, V12, P172; LANDER ES, 1987, SCIENCE, V236, P1567, DOI 10.1126/science.2884728; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; MATZNER Y, 1984, NEW ENGL J MED, V311, P287, DOI 10.1056/NEJM198408023110503; MATZNER Y, 1984, BLOOD, V63, P629; MEYERHOFF J, 1980, MEDICINE, V59, P66, DOI 10.1097/00005792-198001000-00004; MULLEY JC, 1990, CYTOGENET CELL GENET, V53, P175, DOI 10.1159/000132923; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P3122, DOI 10.1093/nar/16.7.3122; OTT J, 1985, ANAL HUMAN GENETIC L, P27; OZDEMIR A I, 1969, American Journal of Gastroenterology, V51, P311; PRAS M, 1982, JOHNS HOPKINS MED J, V150, P22; PRITCHARD MA, 1991, GENOMICS, V10, P801, DOI 10.1016/0888-7543(91)90466-R; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; REEDERS S T, 1988, Genomics, V3, P150, DOI 10.1016/0888-7543(88)90146-2; REEDERS ST, 1989, CYTOGENET CELL GENET, V51, P299, DOI 10.1159/000132796; REEDERS ST, 1991, CYTOGENET CELL GENET, V58, P643, DOI 10.1159/000133176; REIMANN HA, 1954, JAMA-J AM MED ASSOC, V154, P1254, DOI 10.1001/jama.1954.02940490018005; ROGERS DB, 1989, AM J MED GENET, V34, P168, DOI 10.1002/ajmg.1320340206; SCHLESINGER M, 1984, TISSUE ANTIGENS, V24, P65; SCHWABE AD, 1974, MEDICINE, V53, P453, DOI 10.1097/00005792-197411000-00005; SCHWABE AD, 1987, JPN J MED, V26, P370, DOI 10.2169/internalmedicine1962.26.370; SOHAR E, 1967, AM J MED, V43, P227, DOI 10.1016/0002-9343(67)90167-2; WILSON D E, 1989, American Journal of Human Genetics, V45, pA168	41	228	236	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 4	1992	326	23					1509	1513		10.1056/NEJM199206043262301	http://dx.doi.org/10.1056/NEJM199206043262301			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW972	1579134				2022-12-01	WOS:A1992HW97200001
J	RASMUSSEN, BF; STOCK, AM; RINGE, D; PETSKO, GA				RASMUSSEN, BF; STOCK, AM; RINGE, D; PETSKO, GA			CRYSTALLINE RIBONUCLEASE-A LOSES FUNCTION BELOW THE DYNAMIC TRANSITION AT 220-K	NATURE			English	Article							TEMPERATURE-DEPENDENCE; NEUTRON-SCATTERING; MYOGLOBIN	WHEN the dynamic properties of many different proteins are plotted as a function of temperature, biphasic behaviour is observed, with a broad transition centred around 220 K. Atomic mean-square displacements from X-ray crystallography 1 and Mossbauer scattering 2-3 show this behaviour, as do electron transfer rates 4 and dynamic information from inelastic neutron scattering 5. Molecular dynamics simulations over a range of temperatures also exhibit a transition at about 220 K: high-temperature atomic fluctuations are dominated by anharmonic collective motions of bonded and nonbonded groups of atoms, but below 220 K the predominant dynamic behaviour is harmonic vibration of individual atoms 6. Here we show by high-resolution X-ray diffraction that crystalline ribonuclease A does not bind substrate or inhibitor at 212 K but will bind either rapidly at 228 K. Once bound at the higher temperature, inhibitor cannot be washed off after the enzyme is cooled to below the transition temperature. These results suggest that enzyme flexibility is required for catalytic function.	BRANDEIS UNIV,DEPT BIOCHEM,WALTHAM,MA 02254; BRANDEIS UNIV,DEPT CHEM,WALTHAM,MA 02254	Brandeis University; Brandeis University	RASMUSSEN, BF (corresponding author), BRANDEIS UNIV,ROSENSTIEL BASIC MED SCI RES CTR,STRUCT BIOL LAB,WALTHAM,MA 02254, USA.		Petsko, Gregory/AAO-7962-2020					CARLISLE CH, 1974, J MOL BIOL, V85, P1, DOI 10.1016/0022-2836(74)90125-9; DOSTER W, 1986, BIOPHYS J, V50, P213, DOI 10.1016/S0006-3495(86)83455-5; DOSTER W, 1989, NATURE, V337, P754, DOI 10.1038/337754a0; Douzou P, 1977, CRYOBIOCHEMISTRY; FINK AL, 1987, BIOCHEMISTRY-US, V26, P8571, DOI 10.1021/bi00400a012; GILBERT WA, 1982, J RAMAN SPECTROSC, V12, P173, DOI 10.1002/jrs.1250120217; HOWLIN B, 1987, J MOL BIOL, V196, P159, DOI 10.1016/0022-2836(87)90518-3; KARTHA G, 1973, SCIENCE, V179, P495, DOI 10.1126/science.179.4072.495; KELLER H, 1980, PHYS REV LETT, V45, P68, DOI 10.1103/PhysRevLett.45.68; LONCHARICH RJ, 1990, J MOL BIOL, V215, P439, DOI 10.1016/S0022-2836(05)80363-8; NOCEK JM, 1991, J AM CHEM SOC, V113, P6822, DOI 10.1021/ja00018a017; PARAK F, 1980, FEBS LETT, V117, P368, DOI 10.1016/0014-5793(80)80982-3; PETSKO GA, 1985, METHOD ENZYMOL, V114, P141; RASMUSSEN BF, UNPUB J APPL CRYSTAL; RICHARDS FM, 1971, ENZYMES, V4, P647; STEINBACH PJ, 1991, BIOCHEMISTRY-US, V30, P3988, DOI 10.1021/bi00230a026; TILTON RF, 1992, BIOCHEMISTRY-US, V31, P2469, DOI 10.1021/bi00124a006	17	507	511	0	29	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 4	1992	357	6377					423	424		10.1038/357423a0	http://dx.doi.org/10.1038/357423a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HX172	1463484				2022-12-01	WOS:A1992HX17200070
J	TORPEY, N; WYLIE, CC; HEASMAN, J				TORPEY, N; WYLIE, CC; HEASMAN, J			FUNCTION OF MATERNAL CYTOKERATIN IN XENOPUS DEVELOPMENT	NATURE			English	Article							HUMAN KERATIN-18; OOCYTES; EMBRYOS; CELLS; EXPRESSION; LAEVIS; ORGANIZATION; DEGRADATION; CLONING; MOUSE	INTERMEDIATE filaments are ubiquitous in eukaryotic cells, but their functions are poorly understood. The Xenopus oocyte contains both messenger RNA and protein products of cytokeratin and vimentin genes 1-5 in non-overlapping arrays. The cytokeratin filaments contain dimers of the type I (acidic) subunit XLK3a(19), and the type II (basic) subunit XCK1(8), polymerized to form a cortical network. These are homologues of the human simple epithelial keratins 19 and 8, respectively. After the first few cell cycles following fertilization these filaments become restricted to the superficial cells of the blastula. We have depleted the oocyte's store of the type II cytokeratin mRNA by injecting antisense oligodeoxynucleotides (oligos) and studied the effect on embryonic development. As zygotic transcription does not commence until the late blastula stage 6, there are at least 9 hours in which to see the effect of loss of function of this mRNA. We report here that the cytokeratin filaments become depleted in the cortical cells of the embryo. As a result, there is a loss of the 'compacted' epithelial surface of the blastula, an inability to close a wounded surface and defective gastrulation.	WELLCOME CANC RES CAMPAIGN,INST CANC & DEV BIOL,TENNIS COURT RD,CAMBRIDGE CB2 1QR,ENGLAND; DEPT ZOOL,CAMBRIDGE CB2 3ED,ENGLAND						Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		COULOMBE PA, 1991, CELL, V66, P1301, DOI 10.1016/0092-8674(91)90051-Y; DAGLE JM, 1990, NUCLEIC ACIDS RES, V18, P4751, DOI 10.1093/nar/18.16.4751; DOMENJOUD L, 1988, EXP CELL RES, V179, P352, DOI 10.1016/0014-4827(88)90274-1; FRANZ JK, 1986, P NATL ACAD SCI USA, V83, P6475, DOI 10.1073/pnas.83.17.6475; GURDON JB, 1985, CELL, V41, P913, DOI 10.1016/S0092-8674(85)80072-6; HERMANN H, 1989, DEVELOPMENT, V105, P279; HOLWILL S, 1987, DEVELOPMENT, V100, P735; KLYMKOWSKY MW, 1987, DEVELOPMENT, V100, P543; KLYMKOWSKY MW, 1989, DEV BIOL, V134, P479, DOI 10.1016/0012-1606(89)90121-8; KNAPP AC, 1989, CELL, V59, P67, DOI 10.1016/0092-8674(89)90870-2; KULESH DA, 1988, MOL CELL BIOL, V8, P1540, DOI 10.1128/MCB.8.4.1540; KULESH DA, 1989, MOL CELL BIOL, V9, P1553, DOI 10.1128/MCB.9.4.1553; LANE EB, 1992, NATURE, V356, P244, DOI 10.1038/356244a0; LU X, 1990, CELL, V62, P681, DOI 10.1016/0092-8674(90)90114-T; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; Sambrook J., 1989, MOL CLONING LAB MANU; TANG P, 1988, DEVELOPMENT, V103, P279; TORPEY NP, 1992, J CELL SCI, V101, P151; TORPEY NP, 1990, DEVELOPMENT, V110, P1185; VASSAR R, 1991, CELL, V64, P365, DOI 10.1016/0092-8674(91)90645-F	20	71	71	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 4	1992	357	6377					413	415		10.1038/357413a0	http://dx.doi.org/10.1038/357413a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HX172	1375708				2022-12-01	WOS:A1992HX17200066
J	TRUOG, RD; BRETT, AS; FRADER, J				TRUOG, RD; BRETT, AS; FRADER, J			THE PROBLEM WITH FUTILITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MEDICAL INTENSIVE-CARE; FAMILY; RESUSCITATE; PATIENT; ORDERS; POLICY; ETHICS		UNIV PITTSBURGH,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	TRUOG, RD (corresponding author), HARVARD UNIV,SCH MED,BOSTON,MA 02115, USA.		Frader, Joel/A-8610-2010					AARON H, 1990, SCIENCE, V247, P418, DOI 10.1126/science.2300804; ANNAS GJ, 1990, NEW ENGL J MED, V323, P670, DOI 10.1056/NEJM199009063231010; [Anonymous], 1990, CRIT CARE MED, V18, P1435; BEDELL SE, 1983, NEW ENGL J MED, V309, P569, DOI 10.1056/NEJM198309083091001; BLACKHALL LJ, 1987, NEW ENGL J MED, V317, P1281, DOI 10.1056/NEJM198711123172009; BRAITHWAITE S, 1986, ANN INTERN MED, V104, P711, DOI 10.7326/0003-4819-104-5-711; BRENNAN TA, 1988, JAMA-J AM MED ASSOC, V260, P803, DOI 10.1001/jama.260.6.803; CALLAHAN D, 1991, HASTINGS CENT REP, V21, P30, DOI 10.2307/3562999; CAPRON AM, 1991, HASTINGS CENT REP, V21, P26, DOI 10.2307/3562887; DANIS M, 1988, CRIT CARE MED, V16, P594, DOI 10.1097/00003246-198806000-00006; DANIS M, 1988, JAMA-J AM MED ASSOC, V260, P797, DOI 10.1001/jama.260.6.797; DANIS M, 1987, CRIT CARE MED, V15, P138, DOI 10.1097/00003246-198702000-00012; EDDY DM, 1991, JAMA-J AM MED ASSOC, V266, P417, DOI 10.1001/jama.266.3.417; ELSTEIN AS, 1976, SCIENCE, V194, P696, DOI 10.1126/science.982034; HACKLER JC, 1990, JAMA-J AM MED ASSOC, V264, P1281, DOI 10.1001/jama.264.10.1281; HIPPOCRATES, 1977, ETHICS MED HIST PERS, P6; LANTOS JD, 1989, AM J MED, V87, P81; LAPUMA J, 1987, WESTERN J MED, V146, P633; MEISEL A, 1989, RIGHT DIE, P104; MILES SH, 1991, NEW ENGL J MED, V325, P512, DOI 10.1056/NEJM199108153250713; MISBIN RI, 1991, NEW ENGL J MED, V325, P1307, DOI 10.1056/NEJM199110313251811; MURPHY DJ, 1988, JAMA-J AM MED ASSOC, V260, P2098, DOI 10.1001/jama.260.14.2098; PARIS JJ, 1990, NEW ENGL J MED, V322, P1012, DOI 10.1056/NEJM199004053221420; POSES RM, 1989, CRIT CARE MED, V17, P827, DOI 10.1097/00003246-198908000-00021; POSES RM, 1985, JAMA-J AM MED ASSOC, V254, P925, DOI 10.1001/jama.254.7.925; SCHNEIDERMAN LJ, 1990, ANN INTERN MED, V112, P949, DOI 10.7326/0003-4819-112-12-949; TVERSKY A, 1974, SCIENCE, V185, P1124, DOI 10.1126/science.185.4157.1124; YOUNGER SJ, 1988, JAMA-J AM MED ASSOC, V260, P2094, DOI 10.1001/jama.260.14.2094; 1983, PRESIDENTS COMMISSIO, P188; 1991, NY TIMES        0705, pA8; 1986, DO NOT RESISCIATE OR, P96; 1986, DO NOT RESUSCITATE O, P83; 1987, GUIDELINES TERMINATI, P112; 1974, JAMA-J AM MED ASSOC, V227, P864; 1987, GUIDELINES TERMINATI, P32; 1991, JAMA-J AM MED ASSOC, V265, P1868	36	302	305	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 4	1992	326	23					1560	1564		10.1056/NEJM199206043262310	http://dx.doi.org/10.1056/NEJM199206043262310			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW972	1285741				2022-12-01	WOS:A1992HW97200010
J	TYBULEWICZ, VLJ; TREMBLAY, ML; LAMARCA, ME; WILLEMSEN, R; STUBBLEFIELD, BK; WINFIELD, S; ZABLOCKA, B; SIDRANSKY, E; MARTIN, BM; HUANG, SP; MINTZER, KA; WESTPHAL, H; MULLIGAN, RC; GINNS, EI				TYBULEWICZ, VLJ; TREMBLAY, ML; LAMARCA, ME; WILLEMSEN, R; STUBBLEFIELD, BK; WINFIELD, S; ZABLOCKA, B; SIDRANSKY, E; MARTIN, BM; HUANG, SP; MINTZER, KA; WESTPHAL, H; MULLIGAN, RC; GINNS, EI			ANIMAL-MODEL OF GAUCHERS-DISEASE FROM TARGETED DISRUPTION OF THE MOUSE GLUCOCEREBROSIDASE GENE	NATURE			English	Article							CELLS; MUTATIONS	GAUCHER's disease is the most prevalent lysosomal storage disorder in humans and results from an autosomally inherited deficiency of the enzyme glucocerebrosidase (beta-D-glucosyl-N-acylsphingosine glucohydrolase) 1-6, which is responsible for degrading the sphingolipid glucocerebroside. An animal model for Gaucher's disease would be important for investigating its phenotypic diversity and pathogenesis and for evaluating therapeutic approaches. A naturally occurring canine model has been reported but not propagated 7. Attempts to mimic the disease in animals by inhibiting glucocerebrosidase have been inadequate 8. Here we generate an animal model for Gaucher's disease by creating a null allele in embryonic stem cells through gene targeting and using these genetically modified cells to establish a mouse strain carrying the mutation 9,10. Mice homozygous for this mutation have < 4% Of normal glucocerebrosidase activity, die within twenty-four hours of birth and store glucocerebroside in lysosomes of cells of the reticuloendothelial system.	NIMH,ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,CLIN NEUROSCI BRANCH,BETHESDA,MD 20892; MIT,WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139; NICHHD,MAMMALIAN GENES & DEV LAB,BETHESDA,MD 20892; ERASMUS UNIV,DEPT CELL BIOL & GENET,3000 DR ROTTERDAM,NETHERLANDS	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Erasmus University Rotterdam				Zablocka, Barbara/0000-0003-3116-7295				Barranger J. A., 1989, METABOLIC BASIS INHE, P1677; BEUTLER E, 1970, LANCET, V1, P612; BEUTLER E, 1991, P NATL ACAD SCI USA, V88, P10544, DOI 10.1073/pnas.88.23.10544; BRADLEY A, 1987, TERATOCARCINOMAS EMB, P113; CAPECCHI MR, 1989, TRENDS GENET, V5, P70, DOI 10.1016/0168-9525(89)90029-2; DEBRUIJN WC, 1976, HISTOCHEM J, V8, P121, DOI 10.1007/BF01007164; FREDRICKSON DS, 1978, METABOLIC BASIS INHE, P731; GRABOWSKI GA, 1990, CRIT REV BIOCHEM MOL, V25, P385, DOI 10.3109/10409239009090616; HARTLEY WJ, 1982, HDB ANIMAL MODELS HU; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; Kanfer J N, 1982, Prog Clin Biol Res, V95, P627; KUEHN MR, 1987, NATURE, V326, P295, DOI 10.1038/326295a0; Kundu S K, 1981, Methods Enzymol, V72, P185, DOI 10.1016/S0076-6879(81)72012-3; Lee R E, 1982, Prog Clin Biol Res, V95, P177; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; Martin B M, 1989, Adv Pediatr, V36, P277; ONEILL RR, 1989, P NATL ACAD SCI USA, V86, P5049, DOI 10.1073/pnas.86.13.5049; ROBERTSON E, 1986, NATURE, V323, P445, DOI 10.1038/323445a0; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; SUN CC, 1984, PATHOL RES PRACT, V179, P101, DOI 10.1016/S0344-0338(84)80069-2; SVENNERHOLM L, 1982, GAUCHER DIS CENTURY, P231; TSUJI S, 1988, P NATL ACAD SCI USA, V85, P2349, DOI 10.1073/pnas.85.7.2349; TSUJI S, 1987, NEW ENGL J MED, V316, P570, DOI 10.1056/NEJM198703053161002; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WILLEMSEN R, 1988, ULTRASTRUCT PATHOL, V12, P471, DOI 10.3109/01913128809032232	25	245	250	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 4	1992	357	6377					407	410		10.1038/357407a0	http://dx.doi.org/10.1038/357407a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HX172	1594045				2022-12-01	WOS:A1992HX17200064
J	YEAGER, CL; ASHMUN, RA; WILLIAMS, RK; CARDELLICHIO, CB; SHAPIRO, LH; LOOK, AT; HOLMES, KV				YEAGER, CL; ASHMUN, RA; WILLIAMS, RK; CARDELLICHIO, CB; SHAPIRO, LH; LOOK, AT; HOLMES, KV			HUMAN AMINOPEPTIDASE-N IS A RECEPTOR FOR HUMAN CORONAVIRUS-229E	NATURE			English	Article							AMINO-ACID SEQUENCE; ENDOPEPTIDASE 24.11 ENKEPHALINASE; MEMBRANE ANTIGEN GP150; NEUTRAL ENDOPEPTIDASE; MOLECULAR-CLONING; LEUKEMIA ANTIGEN; GENE; KIDNEY; IDENTIFICATION; EXPRESSION	HUMAN coronaviruses (HCV) in two serogroups represented by HCV-229E and HCV-OC43 are an important cause of upper respiratory tract infections 1. Here we report that human aminopeptidase N, a cell-surface metalloprotease on intestinal, lung and kidney epithelial cells 2-5, is a receptor for human coronavirus strain HCV-229E, but not for HCV-OC43. A monoclonal antibody, RBS, blocked HCV-229E virus infection of human lung fibroblasts, immunoprecipitated aminopeptidase N and inhibited its enzymatic activity. HCV-229E-resistant murine fibroblasts became susceptible after transfection with complementary DNA encoding human aminopeptidase N. By contrast, infection of human cells with HCV-OC43 was not inhibited by antibody RBS and expression of aminopeptidase N did not enhance HCV-OC43 replication in mouse cells. A mutant aminopeptidase lacking the catalytic site of the enzyme did not bind HCV-229E or RBS and did not render murine cells susceptible to HCV-229E infection, suggesting that the virus-binding site may lie at or near the active site of the human aminopeptidase molecule.	UNIFORMED SERV UNIV HLTH SCI, DEPT PATHOL, 4301 JONES BRIDGE RD, BETHESDA, MD 20814 USA; ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38105 USA; UNIV TENNESSEE, CTR HLTH SCI, COLL MED, DEPT PEDIAT, MEMPHIS, TN 38163 USA	Uniformed Services University of the Health Sciences - USA; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center								ASHMUN RA, 1990, BLOOD, V75, P462; ASHMUN RA, IN PRESS BLOOD; DELMAS B, 1992, NATURE, V357, P417, DOI 10.1038/357417a0; DEVAULT A, 1987, EMBO J, V6, P1317, DOI 10.1002/j.1460-2075.1987.tb02370.x; DVEKSLER GS, 1991, J VIROL, V65, P6881, DOI 10.1128/JVI.65.12.6881-6891.1991; KENNY AJ, 1982, PHYSIOL REV, V62, P91, DOI 10.1152/physrev.1982.62.1.91; LETARTE M, 1988, J EXP MED, V168, P1247, DOI 10.1084/jem.168.4.1247; LOOK AT, 1985, J CLIN INVEST, V75, P569, DOI 10.1172/JCI111733; LOOK AT, 1986, J CLIN INVEST, V78, P914, DOI 10.1172/JCI112680; LOOK AT, 1989, J CLIN INVEST, V83, P1299, DOI 10.1172/JCI114015; LOOK AT, 1989, LEUCOCYTE TYPING, V4, P784; MALFROY B, 1988, FEBS LETT, V229, P206, DOI 10.1016/0014-5793(88)80828-7; MATSAS R, 1985, BIOCHEM J, V231, P445, DOI 10.1042/bj2310445; MCINTOSH K, 1990, VIROLOGY, P857; NOREN O, 1989, FEBS LETT, V259, P107, DOI 10.1016/0014-5793(89)81506-6; OLSEN J, 1989, FEBS LETT, V251, P275, DOI 10.1016/0014-5793(89)81470-X; RICH DH, 1984, J MED CHEM, V27, P417, DOI 10.1021/jm00370a001; SAKAGUCHI AY, 1982, SOMAT CELL GENET, V8, P83, DOI 10.1007/BF01538652; SEMENZA G, 1986, ANNU REV CELL BIOL, V2, P255, DOI 10.1146/annurev.cellbio.2.1.255; SHIPP MA, 1989, P NATL ACAD SCI USA, V86, P297, DOI 10.1073/pnas.86.1.297; TURNER AJ, 1987, MAMMALIAN ECTOENZYME, P211; UMEZAWA H, 1985, J ANTIBIOT, V38, P1629, DOI 10.7164/antibiotics.38.1629; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; WATT VM, 1989, J BIOL CHEM, V264, P5480; WILKES SH, 1985, J BIOL CHEM, V260, P3154; WILLIAMS RK, 1990, J VIROL, V64, P3817, DOI 10.1128/JVI.64.8.3817-3823.1990; WILLIAMS RK, 1991, P NATL ACAD SCI USA, V88, P5533, DOI 10.1073/pnas.88.13.5533; WU Q, 1991, P NATL ACAD SCI USA, V88, P676, DOI 10.1073/pnas.88.2.676; WU Q, 1990, P NATL ACAD SCI USA, V87, P993, DOI 10.1073/pnas.87.3.993; [No title captured]	30	645	709	2	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 4	1992	357	6377					420	422		10.1038/357420a0	http://dx.doi.org/10.1038/357420a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HX172	1350662	Bronze, Green Published			2022-12-01	WOS:A1992HX17200069
J	LEVINE, RL; PEPE, PE; FROMM, RE; CURKA, PA; CLARK, PA				LEVINE, RL; PEPE, PE; FROMM, RE; CURKA, PA; CLARK, PA			PROSPECTIVE EVIDENCE OF A CIRCADIAN-RHYTHM FOR OUT-OF-HOSPITAL CARDIAC ARRESTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; BLOOD-PRESSURE; FREQUENCY; DEATH	Objectives. --Published studies have indicated a circadian rhythm in the occurrence of sudden cardiac death. However, these studies have involved either retrospective analyses of death certificates or analyses of data collected during studies of pharmacologic agents in selected populations. Purpose. --To determine whether a circadian pattern could be clearly demonstrated in a prospective study of out-of-hospital sudden cardiac death in a large, unselected population. Design. --All adult cases of sudden death of presumed primary cardiac cause from a large urban population were prospectively evaluated over a 12-month period. The incidence of sudden cardiac death was analyzed using harmonic regression of the data tabulated by hour of the day. Results. --During the year of study, 1019 consecutive primary cardiac arrests were analyzed. A significant circadian pattern was found (P < .0001) with the frequency of cardiac arrests increasing dramatically from 6 AM until noon. Conclusions. --This prospective study of out-of-hospital cardiac arrest confirms the existence of a circadian rhythm. These data have important implications for future investigations concerning the pathophysiology of sudden cardiac deaths.	CITY HOUSTON CTR RESUSCITAT & EMERGENCY MED SERV,410 BAGBY,SUITE 300,HOUSTON,TX 77002; BAYLOR COLL MED,PULM & CRIT CARE SECT,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030; BAYLOR COLL MED,CARDIOL SECT,HOUSTON,TX 77030; METHODIST HOSP,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston								ARGENTINO C, 1990, STROKE, V21, P387, DOI 10.1161/01.STR.21.3.387; COUCH RD, 1990, AM J FOREN MED PATH, V11, P106, DOI 10.1097/00000433-199006000-00003; LAMBERT CR, 1989, AM J CARDIOL, V64, P835, DOI 10.1016/0002-9149(89)90827-8; LUCENTE M, 1988, AM J CARDIOL, V62, P670, DOI 10.1016/0002-9149(88)91200-3; MANCIA G, 1988, J CARDIOVASC PHARM, V12, pS11, DOI 10.1097/00005344-198812007-00003; MILLARCRAIG MW, 1978, LANCET, V1, P795; MULCAHY D, 1988, LANCET, V2, P755; MULLER JE, 1985, NEW ENGL J MED, V313, P1315, DOI 10.1056/NEJM198511213132103; Nademanee K, 1988, CIRCULATION S2, V78, P610; NESTO RW, 1991, AM J CARDIOL, V67, P128, DOI 10.1016/0002-9149(91)90433-L; PEPINE CJ, 1991, JAMA-J AM MED ASSOC, V265, P386, DOI 10.1001/jama.265.3.386; TOFLER GH, 1987, NEW ENGL J MED, V316, P1514, DOI 10.1056/NEJM198706113162405; 1987, TXB ADV CARDIAC LIFE, P1	13	109	110	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 3	1992	267	21					2935	2937		10.1001/jama.267.21.2935	http://dx.doi.org/10.1001/jama.267.21.2935			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW133	1583765				2022-12-01	WOS:A1992HW13300033
J	TOKARS, JI; BELL, DM; CULVER, DH; MARCUS, R; MENDELSON, MH; SLOAN, EP; FARBER, BF; FLIGNER, D; CHAMBERLAND, ME; MCKIBBEN, PS; MARTONE, WJ				TOKARS, JI; BELL, DM; CULVER, DH; MARCUS, R; MENDELSON, MH; SLOAN, EP; FARBER, BF; FLIGNER, D; CHAMBERLAND, ME; MCKIBBEN, PS; MARTONE, WJ			PERCUTANEOUS INJURIES DURING SURGICAL-PROCEDURES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEPATITIS-B; RISK; TRANSMISSION; OPERATIONS; INFECTION; SURGEONS	Objective. --To study the numbers and circumstances of percutaneous injuries (eg, needle sticks, cuts) that occur during surgical procedures. Surgical personnel risk infection with blood-borne pathogens from percutaneous injuries; some injuries might also place patients at risk by exposing them to a health care worker's blood. Design. --Observers present at 1382 surgical procedures recorded information about the procedure, the personnel present, and percutaneous injuries that occurred. Setting. --Four US teaching hospitals during 1990. Participants. --Operating room personnel in five surgical specialties. Main Outcome Measures. --Numbers and circumstances of percutaneous injuries among surgical personnel and instances in which surgical instruments that had injured a worker recontacted the patient's surgical wound. Results. --Ninety-nine injuries occurred during 95 (6.9%) of the 1382 procedures. Seventy-six injuries (77%) were caused by suture needles and affected the nondominant hand (62 injuries [63%]), especially the distal forefinger. The risk of injury adjusted for confounding variables by logistic regression was higher during vaginal hysterectomy (odds ratio [OR], 3.5; 95% confidence interval [Cl], 1.6 to 7.5) and lower during certain orthopedic procedures (OR, 0.2; Cl, 0.1 to 0.7) than during 11 other types of procedures (reference group; OR, 1.0). Use of fingers rather than an instrument to hold the tissue being sutured was associated with 35 injuries (35%). Eighty-eight injuries (89%) were sustained by resident or attending surgeons; in 28 (32%) of the 88 injuries in surgeons, the sharp object that caused the injury recontacted the patient. Conclusion. --Percutaneous injuries occur regularly during surgery, placing surgical personnel and, to a lesser extent, patients at risk for infection with blood-borne pathogens. Many such injuries may be preventable with changes in devices, techniques, or protective equipment; all such measures require careful evaluation to determine their efficacy in reducing injury and their effect on patient care.	N SHORE UNIV HOSP,CORNELL UNIV MED COLL,DEPT MED,DIV INFECT DIS,MANHASSET,NY 11030; CHRIST HOSP,DEPT EMERGENCY MED,OAK LAWN,IL; CUNY MT SINAI SCH MED,DEPT MED,DIV INFECT DIS,NEW YORK,NY 10029; COOK CTY HOSP,DEPT EMERGENCY MED,CHICAGO,IL 60612	Cornell University; Northwell Health; North Shore University Hospital; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; John H Stroger Junior Hospital Cook County	TOKARS, JI (corresponding author), CTR DIS CONTROL,NATL CTR INFECT DIS,HOSP INFECT PROGRAM,MAILSTOP A-07,ATLANTA,GA 30333, USA.			Marcus, Ruthanne/0000-0002-9094-0674				Bell DM, 1991, AM J MED S3B, V91, P294; BESSINGER CD, 1988, SURG GYNECOL OBSTET, V167, P287; BICKEL JT, 1990, J FORENSIC SCI, V35, P12; DIAZBUXO JA, 1991, SURG GYNECOL OBSTET, V172, P312; GERBERDING JL, 1990, NEW ENGL J MED, V322, P1788, DOI 10.1056/NEJM199006213222506; HUSSAIN SA, 1988, BRIT J SURG, V75, P314, DOI 10.1002/bjs.1800750407; LETTAU LA, 1986, JAMA-J AM MED ASSOC, V255, P934, DOI 10.1001/jama.255.7.934; LOWENFELS AB, 1989, ARCH SURG-CHICAGO, V124, P1284; LYNCH P, 1990, AM J INFECT CONTROL, V18, P1, DOI 10.1016/0196-6553(90)90204-6; PANLILIO AL, 1991, JAMA-J AM MED ASSOC, V265, P1533, DOI 10.1001/jama.265.12.1533; POPEJOY SL, 1991, SURG GYNECOL OBSTET, V172, P480; QUEBBEMAN EJ, 1991, ANN SURG, V214, P614, DOI 10.1097/00000658-199111000-00012; SERRANO CW, 1991, OBSTET GYNECOL, V77, P525; TELFORD GL, 1987, SURG ROUNDS, V10, P30; WELCH J, 1989, LANCET, V1, P205; WRIGHT JG, 1991, JAMA-J AM MED ASSOC, V266, P1668, DOI 10.1001/jama.266.12.1668; 1991, MMWR, V40, P309; 1991, MMWR, V40, P1; 1987, MMWR S2S, V36, pS3	19	196	199	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 3	1992	267	21					2899	2904		10.1001/jama.267.21.2899	http://dx.doi.org/10.1001/jama.267.21.2899			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW133	1583758				2022-12-01	WOS:A1992HW13300026
J	WECHSLER, H; ISAAC, N				WECHSLER, H; ISAAC, N			BINGE DRINKERS AT MASSACHUSETTS COLLEGES - PREVALENCE, DRINKING STYLE, TIME TRENDS, AND ASSOCIATED PROBLEMS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							CONSUMPTION	Objective. --To compare drinking patterns among college freshmen with those found among students at similar schools 12 years ago, and to describe in detail the differences between "binge" drinkers and "nonbinge" drinkers. Design. --Mailed survey. Setting. --Fourteen 4-year colleges in Massachusetts. Participants. --A total of 1669 first-year college students. Main Outcome Measures. --The survey instrument contains a variety of self-report measures of drinking behaviors, attitudes, and consequences. "Binge" drinking is defined as the consumption of five or more drinks on one or more occasions in the past 2 weeks. Main Results. --The proportion of "frequent-heavy" drinkers remained constant between the 1977 and 1989 surveys (30% vs 31% of men; 13% vs 14% of women), but today's students get intoxicated more often and are more motivated to drink to get drunk. The proportion of students who said "to get drunk" was a "somewhat" or "very important" reason for drinking was two to three times as high in 1989 as in 1977. Among students surveyed in 1989, binge drinkers drank greater quantities, with greater regularity, and experienced more intoxication and alcohol-associated problems than did nonbinge drinkers. Close to half of the binge drinkers (46.5% of men, 48.3% of women) were drunk twice or more in the past month, compared with 5% or fewer of the nonbinge drinkers. Conclusions. --The stability over time of the prevalence of frequent heavy drinking among college students indicates an apparent failure of both social and institutional policies to alter this behavior. Binge drinkers in particular appear to be a population whose drinking patterns and attitudes place them and those around them at increased risk for adverse consequences.	HARVARD UNIV,SCH PUBL HLTH,CTR INJURY CONTROL,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health	WECHSLER, H (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH & SOCIAL BEHAV,677 HUNTINGTON AVE,BOSTON,MA 02115, USA.							ENGS RC, 1988, PUBLIC HEALTH REP, V103, P667; JOHNSTON LD, 1991, DRUG USE AM HIGH SCH, V2; MEILMAN PW, 1990, J STUD ALCOHOL, V51, P389, DOI 10.15288/jsa.1990.51.389; OHARE TM, 1990, J STUD ALCOHOL, V51, P536, DOI 10.15288/jsa.1990.51.536; REINISCH OJ, 1991, N3189CHF RAND CORP P; ROOM R, 1971, DRINKING DRUG PRACTI, V3, P15; Straus R, 1953, DRINKING IN COLLEGE; WECHSLER H, 1979, J STUD ALCOHOL, V40, P969, DOI 10.15288/jsa.1979.40.969; WECHSLER H, 1991, ALCOHOL COLLEGE FRES; 1990, ALCOHOL HLTH; 1990, CAMPUS LIFE SEARCH C	11	212	212	1	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 3	1992	267	21					2929	2931						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HW133	1583763				2022-12-01	WOS:A1992HW13300031
J	ABRAMSON, SV; BURKE, JF; KELLY, JJ; KITCHEN, JG; DOUGHERTY, MJ; YIH, DF; MCGEEHIN, FC; SHUCK, JW; PHIAMBOLIS, TP				ABRAMSON, SV; BURKE, JF; KELLY, JJ; KITCHEN, JG; DOUGHERTY, MJ; YIH, DF; MCGEEHIN, FC; SHUCK, JW; PHIAMBOLIS, TP			PULMONARY-HYPERTENSION PREDICTS MORTALITY AND MORBIDITY IN PATIENTS WITH DILATED CARDIOMYOPATHY	ANNALS OF INTERNAL MEDICINE			English	Article						HYPERTENSION; TRICUSPID VALVE INSUFFICIENCY; CARDIOMYOPATHY, CONGESTIVE; ECHOCARDIOGRAPHY; HEART FAILURE, CONGESTIVE	CONGESTIVE HEART-FAILURE; TRICUSPID REGURGITATION; NONINVASIVE ESTIMATION; DOPPLER ULTRASOUND; SYSTOLIC PRESSURE; PULSED DOPPLER; PROGNOSIS; ECHOCARDIOGRAPHY; SURVIVAL; DETERMINANTS	Objective: To ascertain whether pulmonary hypertension, as assessed noninvasively by continuous-wave Doppler of tricuspid regurgitation, can be an important independent factor in the prognosis of patients with ischemic or idiopathic dilated cardiomyopathy. Design: Cohort study of consecutive patients with dilated cardiomyopathy in whom follow-up was obtained on all survivors for 28 months. Setting: Outpatient cardiology private practice office in a tertiary care center. Patients: Consecutive sample of 108 patients who presented for a scheduled office visit during a 15-month period. Measurements: M-mode, two-dimensional, and Doppler echocardiographic examinations were done on all patients at entry into the study and on survivors 1 year later. All examinations included extensive pulsed- and continuous-wave Doppler evaluation for tricuspid regurgitation. Main Outcome Measures: Overall mortality, mortality due to myocardial failure, and hospitalization for congestive heart failure. Results: Twenty-eight patients had a high velocity of tricuspid regurgitation (> 2.5 m/s), and 80 patients had a low velocity (less-than-or-equal-to 2.5 m/s). After 28 months of follow-up, the mortality rate was 57% in patients with a high velocity compared with 17% in patients with a low velocity (difference of 40%, 95% Cl, 20% to 60%). Hospitalization for congestive heart failure occurred in 75% and 26% of patients, respectively (difference of 49%, Cl, 30% to 68%). Eighty-nine percent of patients with a high velocity either died or were hospitalized compared with only 32% of patients with a low velocity (difference of 57%, Cl, 42% to 72%). The peak velocity of tricuspid regurgitation was the only prognostic variable selected using stepwise logistic regression models for the three outcome events. Conclusion: Noninvasive assessment of pulmonary hypertension using continuous-wave Doppler of tricuspid regurgitation can predict morbidity and mortality in patients with ischemic or idiopathic dilated cardiomyopathy.	LANKENAU HOSP, ECHOCARDIOG LAB, SUITE 356 LANKENAU MED BLDG E, 100 LANCASTER AVE W CITY LINE, WYNNEWOOD, PA 19096 USA; THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, PHILADELPHIA, PA 19107 USA	Lankenau Medical Center; Jefferson University								ABBASI AS, 1980, CIRCULATION, V61, P143, DOI 10.1161/01.CIR.61.1.143; BERGER M, 1985, J AM COLL CARDIOL, V6, P359, DOI 10.1016/S0735-1097(85)80172-8; CLELAND JGF, 1987, BRIT HEART J, V58, P572; COHN JN, 1986, NEW ENGL J MED, V314, P1547, DOI 10.1056/NEJM198606123142404; COHN JN, 1984, NEW ENGL J MED, V311, P819, DOI 10.1056/NEJM198409273111303; COHN JN, 1988, AM J CARDIOL, V62, pA25, DOI 10.1016/S0002-9149(88)80081-X; CURRIE PJ, 1985, J AM COLL CARDIOL, V6, P750, DOI 10.1016/S0735-1097(85)80477-0; DIAZ RA, 1987, BRIT HEART J, V58, P393; DOUGLAS PS, 1989, J AM COLL CARDIOL, V13, P311, DOI 10.1016/0735-1097(89)90504-4; FUSTER V, 1981, AM J CARDIOL, V47, P525, DOI 10.1016/0002-9149(81)90534-8; GRADMAN A, 1989, J AM COLL CARDIOL, V14, P564, DOI 10.1016/0735-1097(89)90093-4; HATLE L, 1981, BRIT HEART J, V45, P157; IKRAM H, 1987, BRIT HEART J, V57, P521; Kannel W B, 1989, Cardiol Clin, V7, P1; KATZ AM, 1990, NEW ENGL J MED, V322, P100; KELLY TL, 1990, AM HEART J, V119, P1111, DOI 10.1016/S0002-8703(05)80242-X; LEE WH, 1986, CIRCULATION, V73, P257, DOI 10.1161/01.CIR.73.2.257; LIKOFF MJ, 1987, AM J CARDIOL, V59, P634; MASSIE BM, 1987, CIRCULATION, V75, P11; MIKAMI T, 1984, AM J CARDIOL, V53, P160, DOI 10.1016/0002-9149(84)90702-1; Newman T J, 1988, Am J Med, V84, P140, DOI 10.1016/0002-9343(88)90221-5; PACKER M, 1987, CIRCULATION, V75, P55; POLAK JF, 1983, J AM COLL CARDIOL, V2, P217, DOI 10.1016/S0735-1097(83)80156-9; ROMEO F, 1989, CLIN CARDIOL, V12, P387, DOI 10.1002/clc.4960120708; SIMONSON JS, 1988, J AM COLL CARDIOL, V11, P557, DOI 10.1016/0735-1097(88)91531-8; STEWART RAH, 1990, Q J MED, V74, P309; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; UNVERFERTH DV, 1984, AM J CARDIOL, V54, P147, DOI 10.1016/0002-9149(84)90320-5; WILSON JR, 1987, CIRCULATION, V75, P64; WYATT HL, 1980, CIRCULATION, V61, P1119, DOI 10.1161/01.CIR.61.6.1119; YOCK PG, 1984, CIRCULATION, V70, P657, DOI 10.1161/01.CIR.70.4.657; YOSHIDA K, 1988, CIRCULATION, V78, P840, DOI 10.1161/01.CIR.78.4.840	32	249	257	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1992	116	11					888	895		10.7326/0003-4819-116-11-888	http://dx.doi.org/10.7326/0003-4819-116-11-888			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW137	1580444				2022-12-01	WOS:A1992HW13700002
J	COLEMAN, RA; WINTER, HS; WOLF, B; GILCHRIST, JM; CHEN, YT				COLEMAN, RA; WINTER, HS; WOLF, B; GILCHRIST, JM; CHEN, YT			GLYCOGEN-STORAGE-DISEASE TYPE-III (GLYCOGEN DEBRANCHING ENZYME DEFICIENCY) - CORRELATION OF BIOCHEMICAL DEFECTS WITH MYOPATHY AND CARDIOMYOPATHY	ANNALS OF INTERNAL MEDICINE			English	Article						GLYCOGEN STORAGE DISEASE TYPE-III; GLYCOGEN DEBRANCHING ENZYME SYSTEM; MUSCULAR DISEASES; MYOCARDIAL DISEASES; LIVER DISEASES; GROWTH DISORDERS	IMMUNOBLOT ANALYSES; INVOLVEMENT; ADULTS	Objective: To determine whether a specific subtype of glycogen storage disease type III is associated with myopathy and cardiomyopathy. Design: Case series. Setting: Three referral medical centers. Patients: All patients with glycogen storage disease type III who were followed in 1990 and for whom both immunoblot analysis and clinical data were available. Main Outcome Measures: Evaluation for myopathy and cardiomyopathy included determinations of serum creatine kinase activity; muscle strength testing; ischemic exercise testing; nerve conduction studies; and electromyographic, electrocardiographic, and echocardiographic studies. Results: Three patients with deficient debranching enzyme activity and deficient immunoreactive material in liver but normal debranching enzyme activity in muscle (glycogen storage disease IIIb) had no clinical evidence of myopathy or cardiomyopathy. Serum creatine kinase activity, muscle strength, ischemic exercise testing, electrocardiograms, and echocardiograms were normal in these patients. These studies and electromyograms were abnormal in seven patients with total debranching enzyme deficiency and an absence of immunoreactive material in both liver and muscle (glycogen storage disease IIIa) and in three patients who had debranching enzyme transferase deficiency but normal glucosidase activity in both liver and muscle (glycogen storage disease IIId). All 10 of these patients had progressive myopathy, and 6 had progressive cardiomyopathy. Conclusion: Clinical features of glycogen storage disease type III correlate with the particular biochemical defect seen with the disorder. Assessments of debranching enzyme or debranching enzyme transferase activity in muscle can be used to predict whether patients with glycogen storage disease type III will develop myopathy and cardiomyopathy.	DUKE UNIV, MED CTR, DEPT PEDIAT, DURHAM, NC 27710 USA; HARVARD UNIV, CHILDRENS HOSP, SCH MED, DEPT PEDIAT, BOSTON, MA 02115 USA; VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT HUMAN GENET, RICHMOND, VA 23298 USA; VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT PEDIAT, RICHMOND, VA 23298 USA; RHODE ISL HOSP, DEPT NEUROL, PROVIDENCE, RI 02902 USA; BROWN UNIV, PROVIDENCE, RI 02912 USA	Duke University; Harvard University; Boston Children's Hospital; Harvard Medical School; Virginia Commonwealth University; Virginia Commonwealth University; Lifespan Health Rhode Island; Rhode Island Hospital; Brown University					NCRR NIH HHS [M01-RR30] Funding Source: Medline; NIDDK NIH HHS [DK 39078] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039078] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BATES EJ, 1975, FEBS LETT, V58, P181, DOI 10.1016/0014-5793(75)80254-7; BROWN BI, 1968, CARBOHYD METABOL, P123; Brown D.H., 1966, METHOD ENZYMOL, P515, DOI 10.1016/0076-6879(66)08093-5; BRUNBERG JA, 1971, ARCH NEUROL-CHICAGO, V25, P171, DOI 10.1001/archneur.1971.00490020089011; CHEN YT, 1987, AM J HUM GENET, V41, P1002; COLEMAN RA, 1986, MUSCLE NERVE, V9, P216, DOI 10.1002/mus.880090305; CORNELIO F, 1984, ARCH NEUROL-CHICAGO, V41, P1027, DOI 10.1001/archneur.1984.04050210025008; DAESCHEL IE, 1983, J AM DIET ASSOC, V83, P135; DIMAURO S, 1979, ANN NEUROL, V5, P422, DOI 10.1002/ana.410050504; DING JH, 1990, J PEDIATR-US, V116, P95, DOI 10.1016/S0022-3476(05)81652-X; FORBES GB, 1953, J PEDIATR-US, V42, P645, DOI 10.1016/S0022-3476(53)80420-8; HERS HG, 1967, EUR J BIOCHEM, V2, P257, DOI 10.1111/j.1432-1033.1967.tb00133.x; Hers HG, 1989, METABOLIC BASIS INHE, P425; ILLINGWORTH B, 1956, J BIOL CHEM, V218, P123; MOSES SW, 1986, ACTA PAEDIATR SCAND, V75, P289, DOI 10.1111/j.1651-2227.1986.tb10201.x; MURASE T, 1973, J NEUROL SCI, V20, P287, DOI 10.1016/0022-510X(73)90190-1; NELSON TE, 1970, ANAL BIOCHEM, V33, P87, DOI 10.1016/0003-2697(70)90442-2; PERNOT C, 1978, ARCH MAL COEUR VAISS, V71, P428; POWELL HC, 1985, MUSCLE NERVE, V8, P667, DOI 10.1002/mus.880080808; SLONIM AE, 1983, METABOLISM, V32, P70, DOI 10.1016/0026-0495(83)90159-2; SLONIM AE, 1982, ANN NEUROL, V11, P420, DOI 10.1002/ana.410110417; VANHOOF F, 1967, EUR J BIOCHEM, V2, P265; YANG BZ, 1990, AM J HUM GENET, V47, P735	23	64	68	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1992	116	11					896	900		10.7326/0003-4819-116-11-896	http://dx.doi.org/10.7326/0003-4819-116-11-896			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW137	1580445				2022-12-01	WOS:A1992HW13700003
J	GURWITZ, JH; AVORN, J; ROSSDEGNAN, D; CHOODNOVSKIY, I; ANSELL, J				GURWITZ, JH; AVORN, J; ROSSDEGNAN, D; CHOODNOVSKIY, I; ANSELL, J			AGING AND THE ANTICOAGULANT RESPONSE TO WARFARIN THERAPY	ANNALS OF INTERNAL MEDICINE			English	Article						AGING; ANTICOAGULANTS; WARFARIN; PROTHROMBIN TIME; DRUG MONITORING	PROTHROMBIN TIME; DRUG-THERAPY; VITAMIN-K; AGE; REQUIREMENTS; DETERMINANTS; WEIGHT	Objective: To assess the effect of aging on the anticoagulant response to warfarin. Design: Retrospective cohort study. Setting: A university hospital outpatient anticoagulation clinic. Patients: All patients (n = 530) monitored in the anticoagulation clinic over a 10-year period (1980 to 1990). The 530 study patients had a mean age of 61.5 (+/- 14.7) years (age range, 12 to 90 years). The patients were stratified into four age groups: younger than 50 years (n = 97); 50 to 59 years (n = 107); 60 to 69 years (n = 149); and 70 years or older (n = 177). Measurements: For each patient, a dose-adjusted mean prothrombin time ratio was calculated by dividing the mean prothrombin time ratio by the mean daily warfarin dose. Results: Older patients were more likely to be female (P < 0.001), to have more medical problems (P < 0.001), to be taking more medications (P < 0.001), and to weigh less than younger patients (P < 0.001). Across age groups, there were no significant differences in the use of medications that potentiated or inhibited the anticoagulant effects of warfarin. The prothrombin time ratio, when adjusted for dose, was significantly increased in older patients (P < 0.001). The increased anticoagulant response to warfarin seen with increasing patient age persisted even after simultaneously controlling for relevant demographic and clinical variables in a multivariate model. Other factors significantly associated with an increased sensitivity to warfarin included use of a medication with a potentiating interactive effect with warfarin, female gender, and overall medication use. Increased body weight and duration of warfarin use exceeding 6 months were found to be inversely related to anticoagulant response. Conclusion: The anticoagulant response to warfarin is exaggerated with advancing age. This finding emphasizes the need for close monitoring of older patients treated with warfarin therapy.	BETH ISRAEL HOSP, BOSTON, MA 02215 USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; HEBREW REHABIL CTR AGED, BOSTON, MA USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; UNIV MASSACHUSETTS, SCH MED, DEPT MED, WORCESTER, MA 01655 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Massachusetts System; University of Massachusetts Worcester					NIA NIH HHS [K08 AG00510-01] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [K08AG000510] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BELL RG, 1978, FED PROC, V37, P2599; CAMPION EW, 1988, J GERONTOL, V43, pM18, DOI 10.1093/geronj/43.1.M18; COON WW, 1977, ANN SURG, V186, P149, DOI 10.1097/00000658-197708000-00006; DOBRZANSKI S, 1983, J CLIN HOSP PHARM, V8, P75, DOI 10.1111/j.1365-2710.1983.tb00899.x; ECCLES J T, 1975, Age and Ageing, V4, P161, DOI 10.1093/ageing/4.3.161; GILMAN AG, 1990, GOODMAN GILMANS PHAR, P1317; GREENBLATT DJ, 1982, NEW ENGL J MED, V306, P1081; GREENBLATT DJ, 1985, PHARMACOKINETICS CLI, P84; GURWITZ JH, 1988, ARCH INTERN MED, V148, P1733, DOI 10.1001/archinte.148.8.1733; HALLAK HO, 1991, DRUG METAB DISPOS, V19, P278; HAYES MJ, 1975, BRIT J CLIN PHARMACO, V2, P69, DOI 10.1111/j.1365-2125.1975.tb00474.x; HIRSH J, 1991, NEW ENGL J MED, V324, P1865; HIRSH J, 1986, CHEST, V89, pS11, DOI 10.1378/chest.89.2_Supplement.11S; HIRSH J, 1989, CHEST, V95, pS5, DOI 10.1378/chest.95.2.5S; HOTRAPHINYO K, 1978, CLIN EXP PHARMACOL P, V5, P143, DOI 10.1111/j.1440-1681.1978.tb00664.x; HUSTED S, 1977, BRIT J CLIN PHARMACO, V4, P559, DOI 10.1111/j.1365-2125.1977.tb00786.x; JONES BR, 1980, J AM GERIATR SOC, V28, P10, DOI 10.1111/j.1532-5415.1980.tb00116.x; KANNEL WB, 1982, NEW ENGL J MED, V306, P1018, DOI 10.1056/NEJM198204293061703; KIRKING DM, 1985, J CLIN HOSP PHARM, V10, P101; LANDEFELD CS, 1989, AM J MED, V87, P144; LANDEFELD CS, 1989, AM J MED, V87, P153; LIPPINCOTT JB, 1990, DRUG INTERACTION FAC; LOELIGER EA, 1964, THROMB DIATH HAEMOST, V10, P267; MACLENNAN WJ, 1977, GERONTOLOGY, V23, P360, DOI 10.1159/000212209; MANSON A, 1991, AM J PUBLIC HEALTH, V81, P1195, DOI 10.2105/AJPH.81.9.1195; MONTAMAT SC, 1989, NEW ENGL J MED, V321, P303; OMALLEY K, 1977, BRIT J CLIN PHARMACO, V4, P309, DOI 10.1111/j.1365-2125.1977.tb00718.x; OREILLY RA, 1980, NEW ENGL J MED, V303, P160; PETITTI DB, 1989, J CLIN EPIDEMIOL, V42, P759, DOI 10.1016/0895-4356(89)90073-5; ROUTLEDGE PA, 1979, EUR J CLIN PHARMACOL, V15, P319, DOI 10.1007/BF00558434; Sackett DL, 1979, COMPLIANCE HLTH CARE; SHEPHERD AMM, 1977, BRIT J CLIN PHARMACO, V4, P315, DOI 10.1111/j.1365-2125.1977.tb00719.x; SHEPHERD AMM, 1978, POSTGRAD MED J, V54, P784, DOI 10.1136/pgmj.54.638.784; TOOHEY M, 1953, BRIT MED J, V1, P650, DOI 10.1136/bmj.1.4811.650; 1987, SADSTAT GUIDE PERSON	35	199	203	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1992	116	11					901	904		10.7326/0003-4819-116-11-901	http://dx.doi.org/10.7326/0003-4819-116-11-901			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW137	1580446				2022-12-01	WOS:A1992HW13700004
J	SESSO, R; SANTOS, AP; NISHIDA, SK; KLAG, MJ; CARVALHAES, JT; AJZEN, H; RAMOS, OL; PEREIRA, AB				SESSO, R; SANTOS, AP; NISHIDA, SK; KLAG, MJ; CARVALHAES, JT; AJZEN, H; RAMOS, OL; PEREIRA, AB			PREDICTION OF STEROID RESPONSIVENESS IN THE IDIOPATHIC NEPHROTIC SYNDROME USING URINARY RETINOL-BINDING PROTEIN AND BETA-2-MICROGLOBULIN	ANNALS OF INTERNAL MEDICINE			English	Article						RETINOL-BINDING PROTEINS; BETA 2 MICROGLOBULIN; NEPHROTIC SYNDROME; NEPHROSIS, LIPOID	RENAL-FUNCTION	Objectives: To determine the prevalence of early proximal tubular dysfunction, measured by urinary excretion of retinol-binding protein (RBP) and beta-2-microglobulin (B2M), in patients with the idiopathic nephrotic syndrome and to investigate the value of these tests in predicting steroid responsiveness. Design: Before-after trial with 8-week treatment period. Setting: Tertiary referral center. Patients: Sequential sample of 37 patients with the idiopathic nephrotic syndrome caused by minimal change disease, focal segmental glomerulosclerosis, or mesangial proliferative glomerulonephritis. Intervention: All patients were treated with prednisone as one dose of 1 to 1.5 mg/kg body weight per day for 8 weeks. Measurements: Urinary RBP was measured by an immunoenzymometric assay and B2M, by an enzyme-linked immunosorbent assay. Remission of the nephrotic syndrome after steroid treatment was the main outcome variable. Results: Elevated levels of urinary RBP and B2M before treatment were detected in 65% and 75% of the patients, respectively. Median urinary RBP and B2M, before treatment, were significantly higher in the steroid-unresponsive group than in the responsive group (P < 0.01). In the steroid-responsive group, urinary RBP and B2M levels decreased significantly after remission (P < 0.01). In the steroid-unresponsive group, the likelihood ratios for urinary RBP greater than 4000-mu-g/g creatinine and for B2M greater than 3000-mu-g/g creatinine were 3.8 and 3.0, respectively. The probability was 100% that values of RBP of less than 1300-mu-g/g creatinine and B2M of less than 130-mu-g/g creatinine were from steroid-responsive patients. Multivariate analysis confirmed that higher urinary levels of RBP and B2M were associated with a lower likelihood of steroid responsiveness, independent of age and histologic diagnosis. Conclusions: Proximal tubular dysfunction is frequent in patients with the idiopathic nephrotic syndrome. Pretreatment urinary RBP and B2M levels may be helpful in identifying nephrotic patients who are more likely to be responsive to steroids.	ESCOLA PAULISTA MED SCH, DIV NEPHROL, BR-04023 SAO PAULO, BRAZIL; ESCOLA PAULISTA MED SCH, DEPT PEDIAT, BR-04023 SAO PAULO, BRAZIL	Universidade Federal de Sao Paulo (UNIFESP); Universidade Federal de Sao Paulo (UNIFESP)	SESSO, R (corresponding author), JOHNS HOPKINS MED INST, WELCH CTR PREVENT EPIDEMIOL & CLIN RES, 600 N WOLFE ST, CARNEGIE 292, BALTIMORE, MD 21205 USA.		Sesso, Ricardo C C/B-4767-2013	Tavares, Alze/0000-0003-0783-0106; Sesso, Ricardo/0000-0002-1062-0073				BERNARD AM, 1987, CLIN CHEM, V33, P775; BOHLE A, 1990, PATHOL RES PRACT, V186, P135, DOI 10.1016/S0344-0338(11)81021-6; BOUISSOU F, 1980, CLIN NEPHROL, V14, P135; CAMERON JS, 1990, AM J NEPHROL, V10, P81; EDDY AA, 1989, AM J PATHOL, V135, P719; ERDREICH LS, 1981, AM J EPIDEMIOL, V114, P649, DOI 10.1093/oxfordjournals.aje.a113236; FERRUA B, 1980, J IMMUNOL METHODS, V36, P149, DOI 10.1016/0022-1759(80)90039-3; MCVICAR M, 1980, J PEDIATR-US, V97, P918, DOI 10.1016/S0022-3476(80)80420-3; PEREIRA A B, 1991, Clinical Chemistry, V37, P1062; PORTMAN RJ, 1986, KIDNEY INT, V30, P91, DOI 10.1038/ki.1986.156; Sackett D.L., 1985, CLIN EPIDEMIOLOGY BA; SCHARDIJN GHC, 1987, KIDNEY INT, V32, P635, DOI 10.1038/ki.1987.255; SHIOJI R, 1974, CLIN NEPHROL, V2, P76; STICKLER GB, 1960, PEDIATRICS, V26, P75; TEGLAERS WH, 1955, HELV PAEDIATR ACTA, V10, P269	15	30	30	1	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1992	116	11					905	909		10.7326/0003-4819-116-11-905	http://dx.doi.org/10.7326/0003-4819-116-11-905			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW137	1580447				2022-12-01	WOS:A1992HW13700005
J	SUH, I; SHATEN, BJ; CUTLER, JA; KULLER, LH				SUH, I; SHATEN, BJ; CUTLER, JA; KULLER, LH			ALCOHOL-USE AND MORTALITY FROM CORONARY HEART-DISEASE - THE ROLE OF HIGH-DENSITY-LIPOPROTEIN CHOLESTEROL	ANNALS OF INTERNAL MEDICINE			English	Article						CORONARY DISEASE; ALCOHOL DRINKING; LIPOPROTEINS, HDL CHOLESTEROL; MORTALITY; DOSE-RESPONSE RELATIONSHIP, DRUG	CARDIOVASCULAR MORTALITY; CONSUMPTION; MEN; SUBFRACTIONS; FRAMINGHAM; DRINKING	Objective: To study the association between alcohol consumption and death from coronary heart disease and to determine the extent to which the association can be explained by the high-density lipoprotein (HDL) cholesterol level. Design: A cohort study involving men enrolled in the Multiple Risk Factor Intervention Trial (MRFIT). Setting: Community-based study. Participants: Men (n = 11 688) at high risk for developing coronary heart disease but without clinical evidence of it. More than 90% of the men were white, and the average age was 46 years. Five percent of the men abstained from alcohol during the trial, 81% consumed fewer than 21 alcoholic drinks per week, and 14% consumed more than 21 alcoholic drinks per week. Measurements: Average alcohol intake over 7 years was calculated for MRFIT participants who were alive at the end of the trial and who had at least three follow-up records of alcohol consumption. Post-trial mortality during a 3.8-year period was assessed. Results: The adjusted relative risk for death from coronary heart disease for each increase of 7 drinks per week was 0.89 (95% Cl, 0.80 to 1.00), with an apparent dose-response relationship. The average HDL level was associated with the average alcohol intake in a least-squares regression model (beta = -0.0074; P < 0.01). When the average HDL level was included in the proportional hazards model for mortality from coronary heart disease, the absolute value of the coefficient for average drinks per week declined 45%, yielding an adjusted relative risk for each additional 7 drinks per week of 0.94 (Cl, 0.84 to 1.05). Conclusion: In middle-aged men who are light to moderate drinkers, the inverse association between alcohol consumption and death from coronary heart disease can be explained, in large part, by the HDL cholesterol level, which increases with alcohol consumption. However, alcohol consumption cannot be recommended because of the known adverse effects of excess alcohol use.	UNIV MINNESOTA, SCH PUBL HLTH,DIV BIOSTAT, COORDINATING CTR BIOMETR RES,2221 UNIV AVE SE, SUITE 200, MINNEAPOLIS, MN 55414 USA; NHLBI, DIV EPIDEMIOL & CLIN APPLICAT, BETHESDA, MD 20814 USA; UNIV PITTSBURGH, GRAD SCH PUBL HLTH, PITTSBURGH, PA 15261 USA	University of Minnesota System; University of Minnesota Twin Cities; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NHLBI NIH HHS [HC22971] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC022971] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		COLDITZ GA, 1985, AM HEART J, V109, P886, DOI 10.1016/0002-8703(85)90654-4; CRIQUI MH, 1987, AM J EPIDEMIOL, V126, P629, DOI 10.1093/oxfordjournals.aje.a114702; CRIQUI MH, 1987, ACTA MED SCAND, P73; DAVIDSON DM, 1989, WESTERN J MED, V151, P430; DYER AR, 1980, PREV MED, V9, P78, DOI 10.1016/0091-7435(80)90060-2; FERRENCE RG, 1986, J STUD ALCOHOL, V47, P394, DOI 10.15288/jsa.1986.47.394; FRIEDMAN LA, 1986, AM J EPIDEMIOL, V124, P481, DOI 10.1093/oxfordjournals.aje.a114418; GORDON T, 1983, AM HEART J, V105, P667, DOI 10.1016/0002-8703(83)90492-1; GORDON T, 1981, CIRCULATION, V64, P63; HARTUNG GH, 1990, METABOLISM, V39, P81, DOI 10.1016/0026-0495(90)90152-3; HULLEY SB, 1981, CIRCULATION, V64, P57; KJELSBERG MO, 1990, JAMA-J AM MED ASSOC, V263, P1795; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; KLATSKY AL, 1981, ANN INTERN MED, V95, P139, DOI 10.7326/0003-4819-95-2-139; KLATSKY AL, 1990, AM J CARDIOL, V66, P1237, DOI 10.1016/0002-9149(90)91107-H; KULLER LH, 1983, AM J EPIDEMIOL, V117, P406, DOI 10.1093/oxfordjournals.aje.a113559; LANGER RD, 1988, AM J EPIDEMIOL, V128, P916; LUPIEN PJ, 1988, CAN J CARDIOL, V4, P102; MACMAHON S, 1987, HYPERTENSION, V9, P111, DOI 10.1161/01.HYP.9.2.111; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MILLER NE, 1988, J EPIDEMIOL COMMUN H, V42, P220, DOI 10.1136/jech.42.3.220; PETERSSON B, 1982, BRIT MED J, V285, P1457, DOI 10.1136/bmj.285.6353.1457; REGAN TJ, 1990, JAMA-J AM MED ASSOC, V264, P377, DOI 10.1001/jama.264.3.377; SHAPER AG, 1988, LANCET, V2, P1267; SHATEN BJ, 1991, PREV MED, V20, P655, DOI 10.1016/0091-7435(91)90061-8; STEINBERG D, 1991, ANN INTERN MED, V114, P967, DOI 10.7326/0003-4819-114-11-967; WANNAMETHEE G, 1988, INT J EPIDEMIOL, V17, P307, DOI 10.1093/ije/17.2.307; 1974, DHEW2ND REP, P68; 1989, J AM COLL CARDIOL, V13, pA11	29	270	272	0	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1992	116	11					881	887		10.7326/0003-4819-116-11-881	http://dx.doi.org/10.7326/0003-4819-116-11-881			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW137	1580443				2022-12-01	WOS:A1992HW13700001
J	WILKES, MS; DOBLIN, BH; SHAPIRO, MF				WILKES, MS; DOBLIN, BH; SHAPIRO, MF			PHARMACEUTICAL ADVERTISEMENTS IN LEADING MEDICAL JOURNALS - EXPERTS ASSESSMENTS	ANNALS OF INTERNAL MEDICINE			English	Article						ADVERTISING; DRUG INFORMATION SERVICES; DRUG INDUSTRY; UNITED-STATES-FOOD-AND-DRUG-ADMINISTRATION	DRUG COMPANIES; PHYSICIANS; INFORMATION; DOCTORS; GIFTS	Objective: To assess both the accuracy of scientific data presented in print pharmaceutical advertisements and the compliance of these advertisements with current Food and Drug Administration (FDA) standards. Design: Cross-sectional survey. Measurements: Each full-page pharmaceutical advertisement (n = 109) appearing in 10 leading medical journals, along with all available references cited in the advertisement (82% of the references cited were available) were sent to three reviewers: two physicians in the relevant clinical area who were experienced in peer review and one academic clinical pharmacist. Reviewers, 95% of whom responded, were asked to evaluate the advertisements using criteria based on FDA guidelines, to judge the educational value and overall quality of the advertisements, and to make a recommendation regarding publication. Results: In 30% of cases, two or more reviewers disagreed with the advertisers' claim that the drug was the "drug of choice." Reviewers felt that information on efficacy was balanced with that on side effects and contraindications in 49% of advertisements but was not balanced in 40%. Reviewers agreed with advertisements' claims that the drug was safe in 86% of the cases but judged that headlines in 32% of the advertisements containing headlines misled the reader about efficacy. In 44% of cases, reviewers felt that the advertisement would lead to improper prescribing if a physician had no other information about the drug other than that contained in the advertisement. Fifty-seven percent of advertisements were judged by two or more reviewers to have little or no educational value. Overall, reviewers would not have recommended publication of 28% of the advertisements and would have required major revisions in 34% before publication. Conclusion: In the opinion of the reviewers, many advertisements contained deficiencies in areas in which the FDA has established explicit standards of quality. New strategies are needed to ensure that advertisements comply with standards intended to promote proper use of the products and to protect the consumer.			WILKES, MS (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, DIV GEN INTERNAL MED, LOS ANGELES, CA 90024 USA.				PHS HHS [R01-90-1088] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AHMAD SR, 1991, LANCET, V338, P1384; AVORN J, 1982, AM J MED, V73, P4, DOI 10.1016/0002-9343(82)90911-1; CHREN MM, 1989, JAMA-J AM MED ASSOC, V262, P3448, DOI 10.1001/jama.262.24.3448; CHRISTENSEN DB, 1979, SOC SCI MED-MED SOC, V13, P313, DOI 10.1016/0160-7979(79)90066-3; FASSOLD RW, 1968, CAN MED ASSOC J, V98, P701; GARFUNKEL JM, 1990, JAMA-J AM MED ASSOC, V263, P1369, DOI 10.1001/jama.263.10.1369; GORSKI TN, 1990, JAMA-J AM MED ASSOC, V263, P2177, DOI 10.1001/jama.1990.03440160039016; JACOBY J, 1975, J MARKETING, V39, P65, DOI 10.2307/1250601; LINN LS, 1972, SOC SCI MED, V6, P199, DOI 10.1016/0037-7856(72)90025-X; LIPTON HL, 1988, DRUGS ELDERLY CLIN S; LOCK S, 1986, DIFFICULT BALANCE, P24; MILLSTEIN LG, 1983, AM PHARM, V23, P54, DOI 10.1016/S0160-3450(16)32075-X; MOSER M, 1991, JAMA-J AM MED ASSOC, V265, P498, DOI 10.1001/jama.265.4.498; MOSER RH, 1977, ANN INTERN MED, V87, P114, DOI 10.7326/0003-4819-87-1-114; RELMAN AS, 1979, NEW ENGL J MED, V301, P999, DOI 10.1056/NEJM197911013011811; SCHIFF G, 1990, JAMA-J AM MED ASSOC, V263, P658, DOI 10.1001/jama.1990.03440050052019; ZELLMER WA, 1987, AM J HOSP PHARM, V44, P1651, DOI 10.1093/ajhp/44.7.1651; ZUCKERMAN H, 1971, MINERVA, V9, P66, DOI 10.1007/BF01553188; 1991, OEI01900000000482 DE; 1989, HLTH CARE COMMUNICAT	20	206	212	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1992	116	11					912	919		10.7326/0003-4819-116-11-912	http://dx.doi.org/10.7326/0003-4819-116-11-912			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW137	1580449				2022-12-01	WOS:A1992HW13700007
J	BLACK, RJ; URQUHART, JD; KENDRICK, SW; BUNCH, KJ; WARNER, J; JONES, DA				BLACK, RJ; URQUHART, JD; KENDRICK, SW; BUNCH, KJ; WARNER, J; JONES, DA			INCIDENCE OF LEUKEMIA AND OTHER CANCERS IN BIRTH AND SCHOOLS COHORTS IN THE DOUNREAY AREA	BRITISH MEDICAL JOURNAL			English	Article							WEST CUMBRIA; CHILDHOOD LEUKEMIA; CHILDREN BORN; YOUNG-PEOPLE; SEASCALE; FOLLOW	Objective - To determine whether a raised incidence of leukaemia in the Dounreay area occurred in children born to local mothers (birth cohort) or in those who moved to the area after birth (schools cohort) and also whether any cases of cancer have occurred in children born near Dounreay who may have moved elsewhere. Design - Follow up study. Setting - Dounreay area of Caithness, Scotland. Subjects - 4144 children born in the area in the period 1969-88 and 1641 children who attended local schools in the same period but who had been born elsewhere. Main outcome measures - Cancer registration records linked to birth and schools records with computerised probability matching methods. Results - Five cancer registrations were traced from the birth cohort compared with 5.8 expected on the basis of national rates (observed to expected ratio 0.9, 95% confidence interval 0.3 to 2.0). Atl five cases were of leukaemia (2.3, 0.7 to 5.4). In the schools cohort three cases were found (2.1, 0.4 to 6.2), all of which were of leukaemia (6.7, 1.4 to 19.5). All eight children were resident in the Dounreay area at the time of diagnosis; thus no cases were found in children who were born in or had attended school in the study area but who subsequently moved away. Conclusion - The raised incidence of leukaemia in both the birth and schools cohorts suggests that place of birth is not a more important factor than place of residence in the series of cases of leukaemia observed near Dounreay area.	UNIV OXFORD,CHILDHOOD CANC RES GRP,OXFORD OX2 6HJ,ENGLAND	University of Oxford	BLACK, RJ (corresponding author), SCOTTISH HLTH SERV,COMMON SERV AGCY,DIV INFORMAT & STAT,EDINBURGH EH5 3SQ,SCOTLAND.							Baldwin JA, 1987, TXB MED RECORD LINKA; BELL AG, 1989, REPORT DOUNREAY EDRP; BLACK D, 1984, INVESTIGATION POSSIB; Breslow NE, 1987, SCI PUBLICATIONS, VII; DRAPER GJ, 1988, SCI PUBLICATION, V87; GARDNER MJ, 1984, LANCET, V1, P216; GARDNER MJ, 1987, BRIT MED J, V295, P819, DOI 10.1136/bmj.295.6602.819; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; GARDNER MJ, 1987, BRIT MED J, V295, P822, DOI 10.1136/bmj.295.6602.822; GLASS S, 1987, LEUKEMIA RES, V2, P881; HEASMAN M A, 1987, Health Bulletin (Edinburgh), V45, P147; HEASMAN MA, 1986, LANCET, V1, P266; KINLEN L, 1988, LANCET, V2, P1323; Newcombe H. B., 1988, HDB RECORD LINKAGE; STILLER CA, 1988, SCI PUBLICATION, V87; URQUHART JD, 1991, BRIT MED J, V302, P687, DOI 10.1136/bmj.302.6778.687; 1988, COMARE2ND COMM MED A	17	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 30	1992	304	6839					1401	1405		10.1136/bmj.304.6839.1401	http://dx.doi.org/10.1136/bmj.304.6839.1401			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX082	1628012	Green Published, Bronze			2022-12-01	WOS:A1992HX08200015
J	CHAPLIN, JE; LASSO, RY; SHORVON, SD; FLOYD, M				CHAPLIN, JE; LASSO, RY; SHORVON, SD; FLOYD, M			NATIONAL GENERAL-PRACTICE STUDY OF EPILEPSY - THE SOCIAL AND PSYCHOLOGICAL EFFECTS OF A RECENT DIAGNOSIS OF EPILEPSY	BRITISH MEDICAL JOURNAL			English	Article							PROGNOSIS; SEIZURES	Objectives - To determine the nature and extent of psychosocial problems in epilepsy and their associations. Design - A postal survey was used drawing data from prospective consecutive cases. Data on demographic, medical, and social backgrounds were collected. A specially designed, validated attitude questionnaire examined 14 areas of psychosocial adjustment to epilepsy. Setting - 124 primary care general practices. Subjects - Adults (aged over 17) with a recent diagnosis of epilepsy (within previous 36 months). They were registered with the national general practice study of epilepsy and had a confirmed diagnosis according to the usual criteria. 216 subjects were approached for the survey by their general practitioners; 192 returned questionnaires. Results - Problems in at least one area were experienced by 175 (91%) of the 192 subjects. Problems were generally mild, which contrasts strongly with findings in chronic cases. The areas of greatest concern were fear of seizures (80% of cases; 72% moderate or severe) and fear of stigma in employment (69% of cases; 40% moderate or severe). A highly significant relation was found between psychosocial effects and the frequency and recency of seizures. Conclusions-In the early stages of epilepsy psychosocial effects are closely related to the severity of the medical condition, suggesting that the argument for the stigmatising effect of the diagnosis by itself is less important than previously thought. The findings also suggest that problems may evolve as the condition becomes chronic.	INST NEUROL,LONDON WC1N 3BG,ENGLAND	University of London; University College London	CHAPLIN, JE (corresponding author), CITY UNIV LONDON,CTR REHABIL RESOURCE,DEPT SYST SCI,LONDON EC1V 0HB,ENGLAND.		Shorvon, Simon D/A-2019-2009; Chaplin, John/AAI-8584-2020	Chaplin, John/0000-0001-8128-4225				CHAPLIN JE, 1990, NEUROEPIDEMIOLOGY, V9, P151, DOI 10.1159/000110765; DODRILL CB, 1984, EPILEPSIA, V25, P168, DOI 10.1111/j.1528-1157.1984.tb04173.x; HART YM, 1989, NEUROEPIDEMIOLOGY, V8, P221; HART YM, 1990, LANCET, V336, P1271, DOI 10.1016/0140-6736(90)92960-P; LEVIN R, 1988, EPILEPSIA, V29, P805, DOI 10.1111/j.1528-1157.1988.tb04238.x; Nunnally J. C, 1981, PSYCHOMETRIC THEORY; RODIN EA, 1972, EPILEPSIA, V13, P121, DOI 10.1111/j.1528-1157.1972.tb04559.x; SANDER JWAS, 1990, LANCET, V336, P1267, DOI 10.1016/0140-6736(90)92959-L; SHORVON SD, 1984, J NEUROL NEUROSUR PS, V47, P1157, DOI 10.1136/jnnp.47.11.1157; WRIGHT GN, 1978, NEW DIMENSIONS REHAB, P492	10	61	61	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 30	1992	304	6839					1416	1418		10.1136/bmj.304.6839.1416	http://dx.doi.org/10.1136/bmj.304.6839.1416			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HX082	1628019	Green Published, Bronze			2022-12-01	WOS:A1992HX08200023
J	CHENG, KK; DAY, NE; DUFFY, SW; LAM, TH; FOK, M; WONG, J				CHENG, KK; DAY, NE; DUFFY, SW; LAM, TH; FOK, M; WONG, J			PICKLED VEGETABLES IN THE ETIOLOGY OF ESOPHAGEAL CANCER IN HONG-KONG CHINESE	LANCET			English	Article							HIGH-RISK POPULATION; ESOPHAGEAL CANCER; PRECURSOR LESIONS; IRAN	Oesophageal cancer is common in Chinese populations, but individual-based epidemiological studies have provided little explanation. A case control study with 400 cases and 1598 controls (800 hospital and 798 general practice) was conducted among Hong Kong Chinese. In multivariate analyses, statistically significant effects on risk were detected for several potentially preventable exposures with high attributable risks (ARs). These included preference for consuming drinks or soups at high temperature (AR = 14%), infrequent consumption of green leafy vegetables (AR = 15%) and citrus fruits (AR = 26%), ingestion of pickled vegetables (AR = 29%), tobacco smoking (AR = 44%), and alcohol drinking (AR = 48%). On the assumption of multiplicative risk, the combined AR due to these exposures was 89%. This is the first case control study to show an association between pickled vegetable consumption and oesophageal cancer risk. The finding considerably strengthens the evidence for carcinogenicity of N-nitroso compounds in man and helps to explain the very high risk among Chinese.	ADDENBROOKES HOSP,DEPT COMMUNITY MED,LEVEL 5,HILLS RD,CAMBRIDGE CB2 2QQ,ENGLAND; UNIV HONG KONG,DEPT COMMUNITY MED,HONG KONG,HONG KONG; UNIV CAMBRIDGE,DEPT COMMUNITY MED,CAMBRIDGE,ENGLAND; MRC,BIOSTAT UNIT,CAMBRIDGE,ENGLAND; UNIV HONG KONG,QUEEN MARY HOSP,DEPT SURG,HONG KONG,HONG KONG	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Hong Kong; University of Cambridge; MRC Biostatistics Unit; University of Hong Kong			Lam, Tai Hing/C-4317-2009	Lam, Tai Hing/0000-0002-2033-9971				BENICHOU J, 1991, STAT MED, V10, P1753, DOI 10.1002/sim.4780101113; BRESLOW N. E., 1980, STATISTICAL METHODS; BRUZZI P, 1985, AM J EPIDEMIOL, V122, P904, DOI 10.1093/oxfordjournals.aje.a114174; CHANGCLAUDE JC, 1990, CANCER RES, V50, P2268; CHEN J, 1987, IARC SCI PUBL, V84, P503; COOKMOZAFFARI PJ, 1979, BRIT J CANCER, V39, P293, DOI 10.1038/bjc.1979.54; DEJONG UW, 1974, INT J CANCER, V13, P291, DOI 10.1002/ijc.2910130304; LEE HP, 1988, IARC SCI PUBL, V91; LI JY, 1989, INT J CANCER, V43, P755, DOI 10.1002/ijc.2910430502; Li M H, 1986, Nutr Cancer, V8, P63, DOI 10.1080/01635588609513877; Lu S H, 1991, IARC Sci Publ, P11; Lu S H, 1987, IARC Sci Publ, P538; LU SH, 1986, CANCER RES, V46, P1485; MARTINEZ I, 1969, J NATL CANCER I, V42, P1069; MUIR C, 1987, CANCER INCIDENCE 5 C, V5; MUNOZ N, 1982, LANCET, V1, P876; MUNOZ N, IN PRESS CANCER EPID; PARKIN DM, 1988, INT J CANCER, V41, P184, DOI 10.1002/ijc.2910410205; STEINMETZ KA, 1991, CANCER CAUSE CONTROL, V2, P325, DOI 10.1007/BF00051672; VASSALLO A, 1985, J NATL CANCER I, V75, P1005; VICTORA CG, 1987, INT J CANCER, V39, P710, DOI 10.1002/ijc.2910390610; WAHRENDORF J, 1989, LANCET, V2, P1239, DOI 10.1016/S0140-6736(89)91850-3; YANG CS, 1980, CANCER RES, V40, P2633; Yu M C, 1991, IARC Sci Publ, P39	24	112	119	3	22	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 30	1992	339	8805					1314	1318		10.1016/0140-6736(92)91960-G	http://dx.doi.org/10.1016/0140-6736(92)91960-G			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW837	1349991				2022-12-01	WOS:A1992HW83700003
J	DUJARDIN, B; DESCHAMPHELEIRE, I; SENE, H; NDIAYE, F				DUJARDIN, B; DESCHAMPHELEIRE, I; SENE, H; NDIAYE, F			VALUE OF THE ALERT AND ACTION LINES ON THE PARTOGRAM	LANCET			English	Article								A partogram based on a World Health Organisation model has been used for many years in the peripheral maternity clinics of Pikine, Senegal, to monitor labour. We have assessed the value of the partogram and efficacy of the alert and action lines. 1022 pregnant women were monitored by partogram during 4 months. The alert line was crossed in 100 (9.8%) of these cases and the frequency of neonatal resuscitation was higher for this group (relative risk 4.0, 95% confidence interval 2.3-7.1; p < 0.0001), as was the number of "fresh" stillbirths (5.3, 1.8-15.6; p < 0.01) (recent death may have occurred during labour). Among the women who crossed the alert but not the action line, neonatal resuscitation was also four times more likely than for the normal labour group (4.0, 2.1-7.6; p < 0.001), and the fresh stillbirth rate was higher but not significantly so. For women who crossed both lines, the fresh stillbirth rate was ten times higher than for women in the normal labour group (9.9, 2.8-34.7; p < 0001). Crossing the alert line had a sensitivity of 27%, a specificity of 93%, and a positive predictive value of 17% for neonatal resuscitation. If the action line was chosen as the decision level, the positive predictive value remained the same but the sensitivity was only 8%. Health workers intervened (eg, artificial rupture of the membranes, administration of oxytocics) in half the dystocic cases. Of the women who did not receive any such treatment 44% crossed the action line compared with only 26% of those who did receive treatment (p = 0.06) The results show the usefulness and efficacy of the partogram and underscore the value of medical intervention as soon as the alert line is crossed.	BELGIUM MED COOPERAT PRIMARY HLTH CARE,PIKINE,SENEGAMBIA; YEMBEUL HLTH CTR,PIKINE,SENEGAMBIA; DEGGO HLTH CTR,DAKAR,SENEGAMBIA		DUJARDIN, B (corresponding author), INST TROP MED PRINCE LEOPOLD,PUBL HLTH RES & TRAINING UNIT,NATINALESTR 155,B-2000 ANTWERP,BELGIUM.							BIRD GC, 1978, TROP DOCT, V8, P78, DOI 10.1177/004947557800800213; DROUIN P, 1979, OBSTET GYNECOL, V53, P741; MAHLER H, 1987, LANCET, V1, P668; PHILPOTT RH, 1972, J OBSTET GYN BR COMM, V79, P592; STUDD J, 1973, BRIT MED J, V4, P451, DOI 10.1136/bmj.4.5890.451; 1988, WHOMCH883; 1988, WHOMCH891; 1986, CHRONIQUE OMS, V40, P193; 1988, WHOMCH884; 1988, WHOMCH892	10	36	37	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 30	1992	339	8805					1336	1338		10.1016/0140-6736(92)91969-F	http://dx.doi.org/10.1016/0140-6736(92)91969-F			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW837	1350000				2022-12-01	WOS:A1992HW83700012
J	DUSTAN, HP				DUSTAN, HP			GROWTH-FACTORS AND RACIAL-DIFFERENCES IN SEVERITY OF HYPERTENSION AND RENAL DISEASES	LANCET			English	Note							WHITE PATIENTS; BLACK; FIBROBLASTS		UNIV ALABAMA, SCH MED, BIRMINGHAM, AL 35233 USA	University of Alabama System; University of Alabama Birmingham								[Anonymous], 1992, LANCET, V339, P28; BABU M, 1989, MOL CELL BIOL, V9, P1642, DOI 10.1128/MCB.9.4.1642; BERK BC, 1989, BIOCHEM PHARMACOL, V38, P219, DOI 10.1016/0006-2952(89)90030-0; CHOBANIAN AV, 1990, HYPERTENSION, V15, P666, DOI 10.1161/01.HYP.15.6.666; DATUBOBROWN DD, 1990, BRIT J PLAST SURG, V43, P70, DOI 10.1016/0007-1226(90)90047-4; DUNN FG, 1983, J AM COLL CARDIOL, V1, P1348, DOI 10.1016/S0735-1097(83)80150-8; DUSTAN HP, 1958, CIRCULATION, V18, P644, DOI 10.1161/01.CIR.18.4.644; FROHLICH ED, 1984, MINER ELECTROL METAB, V10, P173; HAMMOND IW, 1984, J NATL MED ASSOC, V76, P247; MESSERLI FH, 1979, AM J MED, V67, P27, DOI 10.1016/0002-9343(79)90065-2; MUIRHEAD EE, 1989, CLIN CARDIOL, V12, P58; PITCOCK JA, 1976, HUM PATHOL, V7, P333, DOI 10.1016/S0046-8177(76)80043-3; PITCOCK JA, 1975, CIRC RES, V36, P133, DOI 10.1161/01.RES.36.6.133; ROCCELLA EJ, 1985, HYPERTENSION, V7, P457; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; ROSTAND SG, 1989, NEW ENGL J MED, V320, P684, DOI 10.1056/NEJM198903163201102; RUSSELL SB, 1988, P NATL ACAD SCI USA, V85, P587, DOI 10.1073/pnas.85.2.587; SAOUAF R, 1991, J CLIN INVEST, V88, P1182, DOI 10.1172/JCI115420; SHULMAN N B, 1989, Hypertension (Dallas), V13, pI80; SMITH SR, 1991, KIDNEY INT, V40, P815, DOI 10.1038/ki.1991.281; 1990, USRDS1990 NIH US REN	21	22	23	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 30	1992	339	8805					1339	1340		10.1016/0140-6736(92)91971-A	http://dx.doi.org/10.1016/0140-6736(92)91971-A			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW837	1350001				2022-12-01	WOS:A1992HW83700013
J	HATTERSLEY, AT; TURNER, RC; PERMUTT, MA; PATEL, P; TANIZAWA, Y; CHIU, KC; ORAHILLY, S; WATKINS, PJ; WAINSCOAT, JS				HATTERSLEY, AT; TURNER, RC; PERMUTT, MA; PATEL, P; TANIZAWA, Y; CHIU, KC; ORAHILLY, S; WATKINS, PJ; WAINSCOAT, JS			LINKAGE OF TYPE-2 DIABETES TO THE GLUCOKINASE GENE	LANCET			English	Article							INSULIN GENE; BETA-CELL; ONSET; YOUNG; MELLITUS; FAMILIES; GLUCOSE; TWINS	Maturity-onset diabetes of the young (MODY) is a subtype of type 2 diabetes that presents from the second decade and has an autosomal dominant mode of inheritance. We have investigated the glucokinase gene, a candidate gene for diabetes, in two MODY pedigrees. In a large 5-generation pedigree (BX) with 15 diabetic members, use of a microsatellite polymorphism revealed linkage of diabetes to the glucokinase locus on chromosome 7p. A peak lod score of 4.60 was obtained at a recombination fraction (theta) of zero. This finding suggests that a defective glucokinase gene contributes to the diabetes phenotype in this pedigree. This is not universal in MODY since linkage to the glucokinase locus was excluded in a second pedigree M (lod score= -7.36 at theta = 0). The affected members in pedigree BX were diagnosed either when young (in pregnancy or on screening) or when they presented symptomatically in middle and old age; most of them were treated by diet alone. Defects in the glucokinase gene may play an important part in the pathogenesis of type 2 diabetes.	JOHN RADCLIFFE HOSP,DEPT HAEMATOL,OXFORD OX3 9DU,ENGLAND; WASHINGTON UNIV,SCH MED,DIV METAB,ST LOUIS,MO 63110; UNIV LONDON KINGS COLL HOSP,DIABET UNIT,LONDON SE5 8RX,ENGLAND	University of Oxford; Washington University (WUSTL); King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London	HATTERSLEY, AT (corresponding author), RADCLIFFE INFIRM,NUFFIELD DEPT CLIN MED,DIABET RES LABS,OXFORD OX2 6HE,ENGLAND.		O'Rahilly, Stephen/ABF-6509-2020; Chiu, Ken/M-6473-2013	O'Rahilly, Stephen/0000-0003-2199-4449; Chiu, Ken/0000-0002-2226-1039; Hattersley, Andrew/0000-0001-5620-473X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016746, R37DK016746] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 16746] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREONE T, 1985, DIABETES, V34, P108, DOI 10.2337/diabetes.34.2.108; BARNETT AH, 1981, DIABETOLOGIA, V20, P87, DOI 10.1007/BF00262007; BELL GI, 1991, P NATL ACAD SCI USA, V88, P1484, DOI 10.1073/pnas.88.4.1484; BELL JI, 1983, BRIT MED J, V286, P590, DOI 10.1136/bmj.286.6365.590; BOWDEN DW, 1992, DIABETES, V41, P88, DOI 10.2337/diabetes.41.1.88; COOK JTE, 1991, DIABETES S1, V40, pA296; ELBIN SC, 1987, DIABETOLOGIA, V30, P641; FAJANS SS, 1989, DIABETES METAB REV, V5, P579, DOI 10.1002/dmr.5610050705; FROGUEL P, 1992, NATURE, V356, P162, DOI 10.1038/356162a0; FROGUEL P, 1991, Diabetologia, V34, pA71; LATHROP GM, 1984, AM J HUM GENET, V36, P460; LEVY JC, 1991, DIABETOLOGIA, V34, P488, DOI 10.1007/BF00403285; MAGNUSON MA, 1989, J BIOL CHEM, V264, P15936; MAGNUSON MA, 1990, DIABETES, V39, P523, DOI 10.2337/diabetes.39.5.523; Maniatis T., 1982, MOL CLONING; MATSCHINSKY FM, 1990, DIABETES, V39, P647, DOI 10.2337/diabetes.39.6.647; MATSUTANI A, 1992, GENOMICS, V12, P319, DOI 10.1016/0888-7543(92)90380-B; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MEGLASSON MD, 1984, AM J PHYSIOL, V246, pE1, DOI 10.1152/ajpendo.1984.246.1.E1; NEWMAN B, 1987, DIABETOLOGIA, V30, P763; ORAHILLY S, 1988, DIABETOLOGIA, V31, P792; ORAHILLY S, 1988, DIABETOLOGIA, V31, P407, DOI 10.1007/BF00271584; ORAHILLY S, 1989, DIABETES RES CLIN EX, V10, P125; PATEL P, IN PRESS DIABETES; TATTERSALL RB, 1975, DIABETES, V24, P44, DOI 10.2337/diabetes.24.1.44; TATTERSALL RB, 1974, Q J MED, V43, P339; VINIK AJ, 1988, DIABETOLOGIA, V31, P778, DOI 10.1007/BF00274785; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0; 1985, WHO TECH REP SER, V727	30	313	322	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 30	1992	339	8805					1307	1310		10.1016/0140-6736(92)91958-B	http://dx.doi.org/10.1016/0140-6736(92)91958-B			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW837	1349989				2022-12-01	WOS:A1992HW83700001
J	HAWTON, K; FAGG, J				HAWTON, K; FAGG, J			TRENDS IN DELIBERATE SELF POISONING AND SELF INJURY IN OXFORD, 1976-90	BRITISH MEDICAL JOURNAL			English	Article							MANAGEMENT; PARASUICIDE; EDINBURGH	Objective - To review trends in deliberate self poisoning and self injury (attempted suicide) over 15 years (1976-90) on the basis of general hospital referrals. Design - Prospective data collection by computerised monitoring system. Setting - Teaching general hospital. Subjects - All patients aged 15 and over (n = 9605) referred to the hospital after episodes (n = 13 340) of deliberate self poisoning or self injury. Main outcome measures - Rates based on population of Oxford city; changes in substances used for self poisoning; history and repetition of attempts; and rates of admission to the hospital and of referral to the psychiatric service. Results - Attempted suicide rates for women declined during the late 1970s and early 1980s but increased again during the late 1980s. Those for men remained relatively steady throughout the period. Highest mean annual rates occurred in women aged 15-19 (711/100 000) and in 20-34 year old men (334/100 000). The proportion of overdoses with paracetamol increased from 14.3% (125/873) in 1976 to 42% (365/869) in 1990 (chi-2 for trend = 481, p < 0.01). Throughout the period the proportions of referred patients admitted to hospital and of those attempting suicide for the first time (over two thirds) did not decrease. Annual rates of repetition of attempts by women declined from 15.1% (257/1700) in 1976-8 to 11.9% (161/1356) in 1987-9 (chi-2 for trend = 7.8, p < 0.01). Lower repetition rates occurred in women admitted to hospital and referred to the psychiatric service (431/4585, 9.4%) than in those not referred (42/235, 17.9%; chi-2 = 17.2, p < 0.0001). Conclusions - Rates of attempted suicide declined in the 1970s and early 1980s, in women, but there are probably at least 100 000 hospital referrals a year in England and Wales because of this problem. Prevention of paracetamol self poisoning requires urgent attention, and psychosocial assessment should be conducted with as many of those who attempt suicide as possible.			HAWTON, K (corresponding author), UNIV OXFORD,WARNEFORD HOSP,DEPT PSYCHIAT,OXFORD OX3 7JX,ENGLAND.							ALDERSON MR, 1974, LANCET, V1, P1040; [Anonymous], 1984, MANAGEMENT DELIBERAT; BANCROFT JHJ, 1975, BRIT J PREV SOC MED, V29, P170; BLACK D, 1988, J ROY SOC MED, V81, P97, DOI 10.1177/014107688808100216; BLAKE DR, 1978, BRIT MED J, V1, P1032, DOI 10.1136/bmj.1.6119.1032; BREWER C, 1985, BRIT MED J, V290, P391, DOI 10.1136/bmj.290.6465.391; FORSTER DP, 1985, ACTA PSYCHIAT SCAND, V71, P657; HAWTON K, 1979, BRIT MED J, V2, P1040, DOI 10.1136/bmj.2.6197.1040; HAWTON K, 1987, ATTEMPTED SUICIDE; HAWTON K, 1989, CURRENT RES SUICIDE, P180; KREITMAN N, 1979, PSYCHOL MED, V9, P469, DOI 10.1017/S0033291700032013; OWENS DW, 1988, BRIT J PSYCHIAT, V152, P830, DOI 10.1192/bjp.152.6.830; PLATT S, 1988, PSYCHOL MED, V18, P405, DOI 10.1017/S0033291700007959; SKRIMSHIRE AM, 1976, J BIOSOC SCI, V8, P85, DOI 10.1017/S0021932000010531	14	130	131	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 30	1992	304	6839					1409	1411		10.1136/bmj.304.6839.1409	http://dx.doi.org/10.1136/bmj.304.6839.1409			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HX082	1628014	Bronze, Green Published			2022-12-01	WOS:A1992HX08200017
J	IRO, H; SCHNEIDER, HT; FODRA, C; WAITZ, G; NITSCHE, N; HEINRITZ, HH; BENNINGER, J; ELL, C				IRO, H; SCHNEIDER, HT; FODRA, C; WAITZ, G; NITSCHE, N; HEINRITZ, HH; BENNINGER, J; ELL, C			SHOCKWAVE LITHOTRIPSY OF SALIVARY DUCT STONES	LANCET			English	Article								Surgical extirpation of the affected gland has been necessary for cases of sialolithiasis in which the stone cannot be removed by dilatation or dissection of the salivary duct. The ability of the piezoelectric lithotripter to deliver shockwaves to a small focus makes extracorporeal shockwave lithotripsy of salivary gland stones potentially safe. Its safety and efficacy have been assessed in 51 patients with symptomatic solitary salivary stones that could not be removed by conservative measures. The stones had a median diameter of 8 (range 4-18) mm and were located in the submandibular gland in 69% of patients and in the parotid gland in 31%. A total of 72 shockwave treatment sessions (maximum 3 per patient) were given under continuous sonographic monitoring. In 45 patients (88%) complete fragmentation (fragments less-than-or-equal-to 3 mm) of the concrements was achieved. No patient needed anaesthesia, sedatives, or analgesics. The only untoward effects were localised petechial haemorrhages after 10 (13%) out of 72 treatments and transient swelling of the gland immediately after delivery of shockwave in 2/72 (3%) sessions. 20 weeks after the first session 90% (46/51) of patients were free of discomfort, and 53% (27/51) were stone free. Stone-clearance rate was higher among patients with stones in the parotid gland (81%) than among those with stones of the submandibular gland (40%). Auxiliary measures such as dilatation or dissection of the salivary duct were required only in patients with stones in the submandibular gland (20%). No long-term damage to the treated salivary gland or to adjacent tissue structures was noted during the median follow-up of 9 (1-24) months. Extracorporeal piezoelectric shockwave therapy seems likely to be a safe, comfortable, and effective minimally-invasive, non-surgical treatment for salivary stones.	UNIV ERLANGEN NURNBERG, DEPT MED, W-8520 ERLANGEN, GERMANY	University of Erlangen Nuremberg	IRO, H (corresponding author), UNIV ERLANGEN NURNBERG, DEPT OTORHINOLARYNGOL HEAD & NECK SURG, W-8520 ERLANGEN, GERMANY.							COLEMAN AJ, 1989, ULTRASOUND MED BIOL, V15, P213, DOI 10.1016/0301-5629(89)90066-5; EPKER BN, 1972, ORAL SURG ORAL MED O, V33, P2, DOI 10.1016/0030-4220(72)90203-4; IRO H, 1989, LANCET, V2, P114; IRO H, 1991, J LITHOTR STONE DIS, V3, P211; IRO H, 1990, LARYNGO RHINO OTOL, V69, P102, DOI 10.1055/s-2007-998153; KENEFICK JS, 1961, BRIT J SURG, V48, P435; PATEY DAVID H., 1961, BRIT JOUR SURG, V48, P435, DOI 10.1002/bjs.18004821015; PATEY DH, 1981, OPERATIVE SURGERY HE, P835; Rauch S, 1970, THOMAS ORAL PATHOLOG, P962; SEIFERT G, 1986, DIS SALIVARY GLANDS, P91; SELDIN HM, 1953, ORAL SURG ORAL MED O, V6, P579, DOI 10.1016/0030-4220(53)90160-1; SEWARD GR, 1968, ORAL SURG ORAL MED O, V26, P137, DOI 10.1016/0030-4220(68)90242-9	12	101	103	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 30	1992	339	8805					1333	1336		10.1016/0140-6736(92)91968-E	http://dx.doi.org/10.1016/0140-6736(92)91968-E			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW837	1349999				2022-12-01	WOS:A1992HW83700011
J	JEANRENAUD, X; GOY, JJ; KAPPENBERGER, L				JEANRENAUD, X; GOY, JJ; KAPPENBERGER, L			EFFECTS OF DUAL-CHAMBER PACING IN HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY	LANCET			English	Article							ECHOCARDIOGRAPHY; VERAPAMIL; MOTION	Although attempts have been made to treat hypertrophic obstructive cardiomyopathy with right ventricular pacing, the usual treatment for those refractory to medical therapy is open heart surgery. To assess in detail the value of non-surgical therapy the effects of acute and long-term dual-chamber pacing were investigated in 13 patients with hypertrophic obstructive cardiomyopathy refractory to medical treatment. In the first part of the study, atrioventricular (AV) sequential pacing was found to reduce peak subaortic pressure gradient in 12 of the 13 patients, from 82 (SD 42) to 47 (34) mm Hg (p < 0.002), without concomitantly reducing aortic blood pressure or cardiac output. This effect was related to AV interval. In the second part of the study, a dual-chamber pacemaker was implanted in 8 patients and programmed to the optimum AV interval for the individual (50-90 ms). Patients were followed up for up to 62 months. Pacing resulted in a significant and long-lasting reduction in severity of angina pectoris (from NYHA class 3 to 1) and dyspnoea (from NYHA class 3 to 2). Echocardiography showed no significant change in septal thickness or left ventricular contractility but there was a trend to a spontaneous decrease in obstruction. In patients with hypertrophic obstructive cardiomyopathy, synchronised and ventricular pacing at optimum AV interval for the individual reduces the intraventricular pressure gradient and improves functional tolerance. Since the effect is longlasting, such pacing should be deemed an alternative therapy to surgery in selected cases.			JEANRENAUD, X (corresponding author), CHU VAUDOIS,DEPT INTERNAL MED,DIV CARDIOL,CH-1011 LAUSANNE,SWITZERLAND.							ASKENAZI J, 1984, AM J CARDIOL, V53, P99, DOI 10.1016/0002-9149(84)90691-X; BONOW RO, 1983, AM J CARDIOL, V51, P1386, DOI 10.1016/0002-9149(83)90317-X; CANNON RO, 1987, J AM COLL CARDIOL, V10, P53, DOI 10.1016/S0735-1097(87)80159-6; COHEN LS, 1967, CIRCULATION, V35, P847, DOI 10.1161/01.CIR.35.5.847; Duck H J, 1984, Z Gesamte Inn Med, V39, P437; GOMES JAC, 1977, AM J CARDIOL, V39, P641, DOI 10.1016/S0002-9149(77)80123-9; Hassenstein P, 1967, Verh Dtsch Ges Kreislaufforsch, V33, P242; Hassenstein P, 1975, Thoraxchir Vask Chir, V23, P496; IWASE M, 1986, AM J CARDIOL, V58, P104, DOI 10.1016/0002-9149(86)90251-1; JANOSIK DL, 1989, J AM COLL CARDIOL, V14, P499, DOI 10.1016/0735-1097(89)90208-8; KALTENBACH M, 1979, BRIT HEART J, V42, P35; KRACJER Z, 1988, CIRCULATION S1, V78, P35; LEVINE RA, 1989, CIRCULATION S2, V80, P662; MARON BJ, 1981, AM J CARDIOL, V48, P418, DOI 10.1016/0002-9149(81)90068-0; MCDONALD K, 1988, EUR HEART J, V9, P893, DOI 10.1093/oxfordjournals.eurheartj.a062584; MCINTOSH CL, 1988, CIRCULATION, V78, P487, DOI 10.1161/01.CIR.78.3.487; POLLICK C, 1988, AM J CARDIOL, V62, P1252, DOI 10.1016/0002-9149(88)90269-X; POLLICK C, 1984, CIRCULATION, V69, P43, DOI 10.1161/01.CIR.69.1.43; Rothlin M, 1971, Verh Dtsch Ges Kreislaufforsch, V37, P411; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; SPIRITO P, 1987, AM J CARDIOL, V60, P123, DOI 10.1016/0002-9149(87)90998-2; WIGLE ED, 1985, PROG CARDIOVASC DIS, V28, P1, DOI 10.1016/0033-0620(85)90024-6; ZILE MR, 1987, J AM COLL CARDIOL, V10, P702, DOI 10.1016/S0735-1097(87)80215-2; 1989, J AM SOC ECHO, V2, P358	24	238	251	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 30	1992	339	8805					1318	1323		10.1016/0140-6736(92)91961-7	http://dx.doi.org/10.1016/0140-6736(92)91961-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW837	1349992				2022-12-01	WOS:A1992HW83700004
J	KENNY, N; HILL, J				KENNY, N; HILL, J			GONAD PROTECTION IN YOUNG ORTHOPEDIC PATIENTS	BRITISH MEDICAL JOURNAL			English	Article								Objective - To determine whether gonad shields are correctly positioned on the pelvic radiographs of children with slipped capital femoral epiphysis. Design - Retrospective study of radiographs taken of children treated by in situ pinning of slipped capital femoral epiphysis between 1 january 1983 and 31 December 1988. Setting - Three teaching hospitals in north west England. Patients - 32 patients with complete set of radiographs. Results - An average of 10.8 anteroposterior pelvic radiographs plus 8.9 lateral hip radiographs had been performed per patient. Gonad shields had been completely omitted in 137 (40%) anteroposterior pelvic radiographs performed on the 32 patients at the time of completion of the study. In 100 (29%) the gonad shields were adequately protecting the gonads, but in 109(31%) the gonad shields were not protecting the gonads due to incorrect positioning of the shield. The incorrect positioning of the gonad shields was more commonly found in girls than boys (64 v 45; p < 0.012), presumably because of the difficulty in determining gonadal position in relation to surface landmarks. Absence of gonad shields was also more commonly seen in girls (82 v 55; p < 0.005), but this is not easily explained. Conclusions - Gonad shields are not protecting the gonads in a large percentage of anteroposterior pelvic radiographs (71%) because they have been omitted or inadequately placed. This avoidable excess radiation exposure to the gonads, combined with the inability to shield the gonads in lateral hip radiographs and the large number of radiographs performed, results in the gonads receiving a higher dose of radiation than may otherwise be the case, and may increase the potential for disease in the future offspring of these patients.	ROYAL PRESTON HOSP,RADIOL & NUCL MED,PRESTON PR2 4HT,LANCS,ENGLAND	Royal Preston Hospital	KENNY, N (corresponding author), ANCOATS HOSP,MANCHESTER M4 6EB,ENGLAND.							[Anonymous], 1988, SOURCES EFFECTS RISK; [Anonymous], 1977, ANN ICRP, V1, P228; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; KENDALL GM, 1980, NRPBR104; MCKINNEY PA, 1991, BRIT MED J, V302, P681, DOI 10.1136/bmj.302.6778.681; RICHARDSON RB, 1990, BRIT J RADIOL, V63, P235, DOI 10.1259/0007-1285-63-748-235; RUSSELL JGB, 1986, BRIT J RADIOL, V59, P630, DOI 10.1259/0007-1285-59-702-630; WALL BF, 1980, NRPBR105; 1990, PATIENT DOSE REDUCTI; 1989, WORKING PATIENTS; 1991, BRIT J RADIOL, V64, P53; 1991, WHICH            JAN, P40; 1991, ANN ICRP, V21, P1	13	23	23	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 30	1992	304	6839					1411	1413		10.1136/bmj.304.6839.1411	http://dx.doi.org/10.1136/bmj.304.6839.1411			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX082	1628015	Green Published, Bronze			2022-12-01	WOS:A1992HX08200018
J	MISHRA, M; CHAMBERS, JB; JACKSON, G				MISHRA, M; CHAMBERS, JB; JACKSON, G			MURMURS IN PREGNANCY - AN AUDIT OF ECHOCARDIOGRAPHY	BRITISH MEDICAL JOURNAL			English	Article									LEWISHAM HOSP,CARDIOL,LONDON SE13 6LH,ENGLAND									ELKAYAM U, 1985, PRINCIPLES MED TREAT; MCFAUL PB, 1988, BRIT J OBSTET GYNAEC, V95, P861, DOI 10.1111/j.1471-0528.1988.tb06570.x; SUGRUE D, 1980, BRIT HEART J, V44, P499, DOI 10.1136/hrt.44.5.499; 1990, LANCET, V335, P88; 1990, DRUG THER B, V28, P90	5	23	24	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 30	1992	304	6839					1413	1414		10.1136/bmj.304.6839.1413	http://dx.doi.org/10.1136/bmj.304.6839.1413			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX082	1628016	Green Published, Bronze			2022-12-01	WOS:A1992HX08200019
J	BLACK, DL				BLACK, DL			ACTIVATION OF C-SRC NEURON-SPECIFIC SPLICING BY AN UNUSUAL RNA ELEMENT INVIVO AND INVITRO	CELL			English	Article							PRE-MESSENGER-RNA; GENE-EXPRESSION; RIBONUCLEOPROTEIN-PARTICLES; BINDING PROTEINS; POLYMERASE-II; SEX-LETHAL; INTRON; SITE; INITIATION; CONTAINS	A conserved positive-acting RNA sequence was found to be required for the neuron-specific splicing of the mouse c-src N1 exon. The sequence lies in the intron between exons N1 and 4, close to the N1 donor site. Normally, only the neural-specific splicing of exon N1 required this sequence. When the intron downstream of N1 was shortened, splicing at the constitutive exon 4 acceptor also became dependent on the activating sequence. The neuronal and nonneuronal patterns of src splicing were reconstituted in vitro. HeLa cell extracts spliced exon 4 to exon 3, skipping exon N1. Weri-1 retinoblastoma cell extracts spliced exon 4 to exon N1 as well as to exon 3. Both patterns of splicing were dependent on the activating sequence. A 123 nt RNA containing just the activating sequence specifically inhibited both patterns of src splicing, indicating that factors bound to the activator were required for its effects.			BLACK, DL (corresponding author), WHITEHEAD INST BIOMED RES,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.				NICHD NIH HHS [HD28063-1] Funding Source: Medline; NIGMS NIH HHS [GM39458] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028063] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039458] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel M., 1989, MOL REPROD DEV, V1, P146, DOI [10.1002/mrd.1080010210, DOI 10.1002/MRD.1080010210]; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BINGHAM PM, 1988, TRENDS GENET, V4, P134, DOI 10.1016/0168-9525(88)90136-9; BISHOP JM, 1985, RNA TUMOR VIRUSES S, V2, P249; BLACK DL, 1991, GENE DEV, V5, P389, DOI 10.1101/gad.5.3.389; CHEBLI K, 1989, MOL CELL BIOL, V9, P4852, DOI 10.1128/MCB.9.11.4852; COTE GJ, 1991, NUCLEIC ACIDS RES, V19, P3601, DOI 10.1093/nar/19.13.3601; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORVAL BC, 1991, SCIENCE, V252, P1823, DOI 10.1126/science.2063195; DREYFUSS G, 1986, ANNU REV CELL BIOL, V2, P459, DOI 10.1146/annurev.cb.02.110186.002331; EMESON RB, 1989, NATURE, V341, P76, DOI 10.1038/341076a0; ENG FJ, 1991, CELL, V65, P797, DOI 10.1016/0092-8674(91)90387-E; Erlich H.A., 1989, PCR TECHNOLOGY; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUO W, 1991, GENE DEV, V5, P2096, DOI 10.1101/gad.5.11.2096; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HEDLEY ML, 1991, CELL, V65, P579, DOI 10.1016/0092-8674(91)90090-L; HELFMAN DM, 1988, GENE DEV, V2, P1627, DOI 10.1101/gad.2.12a.1627; HOSHIJIMA K, 1991, SCIENCE, V252, P833, DOI 10.1126/science.1902987; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; KUO HC, 1991, SCIENCE, V251, P1045, DOI 10.1126/science.1825520; LASKI FA, 1989, GENE DEV, V3, P720, DOI 10.1101/gad.3.5.720; LEVY JB, 1987, MOL CELL BIOL, V7, P4142, DOI 10.1128/MCB.7.11.4142; LIBRI D, 1991, SCIENCE, V252, P1842, DOI 10.1126/science.2063196; LUE NF, 1987, P NATL ACAD SCI USA, V84, P8839, DOI 10.1073/pnas.84.24.8839; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; Maniatis T, 1989, DECONTAMINATION DILU; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MICHAUD S, 1991, GENE DEV, V5, P2534, DOI 10.1101/gad.5.12b.2534; PAWSON T, 1988, ONCOGENE, V3, P491; PINOLROMA S, 1988, GENE DEV, V2, P215, DOI 10.1101/gad.2.2.215; PYPER JM, 1990, MOL CELL BIOL, V10, P2035, DOI 10.1128/MCB.10.5.2035; ROSBASH M, 1991, TRENDS BIOCHEM SCI, V16, P187, DOI 10.1016/0968-0004(91)90073-5; RUSKIN B, 1985, SCIENCE, V229, P135, DOI 10.1126/science.2990042; RYNER LC, 1991, GENE DEV, V5, P2071, DOI 10.1101/gad.5.11.2071; SIEBEL CW, 1990, SCIENCE, V248, P1200, DOI 10.1126/science.2161558; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SOLNICK D, 1985, CELL, V42, P157, DOI 10.1016/S0092-8674(85)80111-2; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; STREULI M, 1989, EMBO J, V8, P787, DOI 10.1002/j.1460-2075.1989.tb03439.x; TIAN M, 1992, SCIENCE, V256, P237, DOI 10.1126/science.1566072; TSENG JC, 1991, MECH DEVELOP, V35, P65, DOI 10.1016/0925-4773(91)90042-5	51	150	152	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 29	1992	69	5					795	807		10.1016/0092-8674(92)90291-J	http://dx.doi.org/10.1016/0092-8674(92)90291-J			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HW838	1591778				2022-12-01	WOS:A1992HW83800010
J	DIKSTEIN, R; HEFFETZ, D; BEN-NERIAH, Y; SHAUL, Y				DIKSTEIN, R; HEFFETZ, D; BEN-NERIAH, Y; SHAUL, Y			C-ABL HAS A SEQUENCE-SPECIFIC ENHANCER BINDING-ACTIVITY	CELL			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; B VIRUS ENHANCER; ACUTE LYMPHOBLASTIC-LEUKEMIA; PHILADELPHIA-CHROMOSOME; MOLECULAR-CLONING; GENE-PRODUCT; PROTEIN; KINASE; REGION; BCR	The enhancers of several distinct viruses contain a common functional element, termed EP. This element binds ubiquitous cellular proteins and generates specific complexes in gel retardation analysis. Ultraviolet cross-linking and Southwestern analysis showed that a 140 kd polypeptide is the major EP DNA-binding protein. Using a combination of DNA binding and immunological techniques, we have identified the c-abl protein in a nuclear complex that binds to the EP element. abl was found to have both a specific and high affinity DNA binding activity. The ability to bind DNA is abolished in the mutant abl protein, p210bcr-abl, consistent with its cytoplasmic localization in chronic myelogenous leukemia.	HEBREW UNIV JERUSALEM, HADASSAH MED SCH, LAUTENBERG CTR GEN & TUMOR IMMUNOL, IL-91010 JERUSALEM, ISRAEL	Hebrew University of Jerusalem	DIKSTEIN, R (corresponding author), WEIZMANN INST SCI, DEPT MOLEC GENET & VIROL, IL-76100 REHOVOT, ISRAEL.		Ben-Neriah, Yinon/L-6285-2019					ANAFI M, 1992, IN PRESS J BIOL CHEM, V267; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; BEN-NERIAH Y, 1986, CURR TOP MICROBIOL, V132, P81; BENLEVY R, 1989, MOL CELL BIOL, V9, P1804, DOI 10.1128/MCB.9.4.1804; CHAN LC, 1987, NATURE, V325, P635, DOI 10.1038/325635a0; CLARK SS, 1987, SCIENCE, V235, P85, DOI 10.1126/science.3541203; CLEVELAND DW, 1983, METHOD ENZYMOL, V96, P222; DALEY GQ, 1991, ADV CANCER RES, V57, P151; DIKSTEIN R, 1990, MOL CELL BIOL, V10, P3683, DOI 10.1128/MCB.10.7.3683; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; HENKEMEYER M, 1990, CELL, V63, P949, DOI 10.1016/0092-8674(90)90498-4; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KURZROCK R, 1987, NATURE, V325, P631, DOI 10.1038/325631a0; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MESMASSON AM, 1986, P NATL ACAD SCI USA, V83, P9768, DOI 10.1073/pnas.83.24.9768; OSTAPCHUK P, 1989, MOL CELL BIOL, V9, P2787, DOI 10.1128/MCB.9.7.2787; PAWSON T, 1988, ONCOGENE, V3, P491; PENDERGAST AM, 1987, MOL CELL BIOL, V7, P4280, DOI 10.1128/MCB.7.12.4280; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WANG JYJ, 1984, CELL, V36, P349; WESTBROOK CA, 1988, BLOOD, V71, P697	29	70	71	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 29	1992	69	5					751	757		10.1016/0092-8674(92)90287-M	http://dx.doi.org/10.1016/0092-8674(92)90287-M			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HW838	1591775				2022-12-01	WOS:A1992HW83800006
J	ENGEL, I; OTTENHOFF, THM; KLAUSNER, RD				ENGEL, I; OTTENHOFF, THM; KLAUSNER, RD			HIGH-EFFICIENCY EXPRESSION AND SOLUBILIZATION OF FUNCTIONAL T-CELL ANTIGEN RECEPTOR HETERODIMERS	SCIENCE			English	Article							ENDOPLASMIC-RETICULUM; CYTOCHROME-C; DEGRADATION; RECOGNITION; IA; COMPLEX; CHAINS; GENE; ZETA; BETA	The T cell receptor (TCR) zeta-chain was attached to the TCR-alpha and beta-extracellular domains to induce efficient expression of alpha-beta-heterodimers that can recognize complexes of antigen with major histocompatibility complex (MHC) molecules. Chimeric constructs expressed in RBL-2H3 cells were efficiently transported to the cell surface uniquely as disulfide-linked heterodimers. Transfectants were activated by specific antigen-MHC complexes, which demonstrated that the expressed-alpha-beta was functional and that CD3 was not required for antigen-MHC binding. Constructs with thrombin cleavage sites were efficiently cleaved to soluble disulfide-linked heterodimers. Thus, attachment of TCR-zeta-domains and protease cleavage sites to TCR-alpha and beta induces expression of demonstrably functional heterodimers that can be solubilized.			ENGEL, I (corresponding author), NICHHD,CELL BIOL & METAB BRANCH,BETHESDA,MD 20892, USA.							BECKER DM, 1985, NATURE, V317, P430, DOI 10.1038/317430a0; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; BUUS S, 1987, SCIENCE, V235, P1353, DOI 10.1126/science.2435001; CHEN C, 1988, J CELL BIOL, V107, P2149, DOI 10.1083/jcb.107.6.2149; CHIEN YH, 1984, NATURE, V309, P322, DOI 10.1038/309322a0; GREGOIRE C, 1991, P NATL ACAD SCI USA, V88, P8077, DOI 10.1073/pnas.88.18.8077; HANSBURG D, 1983, J IMMUNOL, V131, P319; HEDRICK SM, 1982, CELL, V30, P141, DOI 10.1016/0092-8674(82)90020-4; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; KRONENBERG M, 1986, ANNU REV IMMUNOL, V4, P529, DOI 10.1146/annurev.iy.04.040186.002525; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; LIN AY, 1990, SCIENCE, V249, P677, DOI 10.1126/science.1696397; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; NOVOTNY J, 1991, P NATL ACAD SCI USA, V88, P8646, DOI 10.1073/pnas.88.19.8646; ORLOFF DG, 1989, J BIOL CHEM, V264, P14812; RACIOPPI L, 1991, J IMMUNOL, V147, P3718; SAITO T, 1987, NATURE, V325, P125, DOI 10.1038/325125a0; SAMELSON LE, 1985, CELL, V43, P223, DOI 10.1016/0092-8674(85)90027-3; SAMELSON LE, 1983, P NATL ACAD SCI-BIOL, V80, P6972, DOI 10.1073/pnas.80.22.6972; SLANETZ AE, 1991, EUR J IMMUNOL, V21, P179, DOI 10.1002/eji.1830210127; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUZUKI C, UNPUB; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377; WILEMAN T, 1990, INT IMMUNOL, V2, P743, DOI 10.1093/intimm/2.8.743	30	76	94	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 29	1992	256	5061					1318	1321		10.1126/science.1598575	http://dx.doi.org/10.1126/science.1598575			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HW135	1598575				2022-12-01	WOS:A1992HW13500033
J	GAMER, J; BUJARD, H; BUKAU, B				GAMER, J; BUJARD, H; BUKAU, B			PHYSICAL INTERACTION BETWEEN HEAT-SHOCK PROTEINS DNAK, DNAJ, AND GRPE AND THE BACTERIAL HEAT-SHOCK TRANSCRIPTION FACTOR-SIGMA(32)	CELL			English	Article							ESCHERICHIA-COLI DNAK; METAL CHELATE ADSORBENT; BACTERIOPHAGE-LAMBDA; RNA-POLYMERASE; CELLULAR DEFECTS; REGULATORY GENE; SIGMA-32; REPLICATION; MUTANTS; INITIATION	Genetic evidence indicates central roles for Hsp70 chaperones in the regulation of heat shock gene expression. This regulatory function has been postulated for Escherichia coli to rely on the direct association of DnaK (Hsp70) with the heat shock transcription factor sigma-32. This report presents evidence for the physical association of DnaK, DnaJ, and GrpE chaperones with sigma-32 in vivo. Surprisingly, an interaction of DnaJ with sigma-32 exists that is distinguishable from an interaction of DnaK and GrpE with sigma-32: addition of ATP disrupts the association of DnaK and GrpE with sigma-32, but not the association of DnaJ with sigma-32. Furthermore, DnaJ-sigma-32 and DnaK-sigma-32 associations occur independent of DnaK and DnaJ, respectively. These results suggest distinct regulatory functions of DnaJ and DnaK/GrpE.			GAMER, J (corresponding author), UNIV HEIDELBERG,ZENTRUM MOLEK BIOL,INF 282,W-6900 HEIDELBERG,GERMANY.			Bukau, Bernd/0000-0003-0521-7199				ALFANO C, 1989, J BIOL CHEM, V264, P10699; ANATHAN J, 1986, SCIENCE, V232, P252; BUJARD H, 1987, METHOD ENZYMOL, V155, P416; BUKAU B, 1989, J BACTERIOL, V171, P6030, DOI 10.1128/jb.171.11.6030-6038.1989; BUKAU B, 1989, J BACTERIOL, V171, P2337, DOI 10.1128/jb.171.5.2337-2346.1989; BUKAU B, 1990, EMBO J, V9, P4027, DOI 10.1002/j.1460-2075.1990.tb07624.x; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; COWING DW, 1985, P NATL ACAD SCI USA, V82, P2679, DOI 10.1073/pnas.82.9.2679; CRAIG EA, 1984, CELL, V38, P841, DOI 10.1016/0092-8674(84)90279-4; CRAIG EA, 1991, TRENDS BIOCHEM SCI, V16, P135, DOI 10.1016/0968-0004(91)90055-Z; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; ERICKSON JW, 1987, GENE DEV, V1, P419, DOI 10.1101/gad.1.5.419; GAITANARIS GA, 1990, CELL, V61, P1013, DOI 10.1016/0092-8674(90)90066-N; GEORGOPOULOS C, 1990, STRESS PROTEINS BIOL, P191; GOFF SA, 1985, CELL, V41, P587, DOI 10.1016/S0092-8674(85)80031-3; GOTTESMAN S, 1981, J BACTERIOL, V148, P265, DOI 10.1128/JB.148.1.265-273.1981; GROSSMAN AD, 1987, GENE DEV, V1, P179, DOI 10.1101/gad.1.2.179; GROSSMAN AD, 1984, CELL, V38, P383, DOI 10.1016/0092-8674(84)90493-8; HARLOW E, 1988, ANTIBODIES LABORATOR; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; JOHNSON C, 1989, J BACTERIOL, V171, P1590, DOI 10.1128/jb.171.3.1590-1596.1989; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; KRUGER JH, 1984, P NATL ACAD SCI USA, V81, P1499; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZER M, 1988, THESIS U HEIDELBERG; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIBEREK K, 1990, J BIOL CHEM, V265, P3022; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; Maniatis T, 1989, DECONTAMINATION DILU; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; Miller JH., 1972, EXPT MOL GENETICS; Morimoto RI, 1990, STRESS PROTEINS BIOL; NAGAI H, 1990, J BACTERIOL, V172, P2710, DOI 10.1128/jb.172.5.2710-2715.1990; NEIDHARDT FC, 1987, CELLULAR MOL BIOL, V2, P1334; PARSELL DA, 1989, GENE DEV, V3, P1226, DOI 10.1101/gad.3.8.1226; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SELL SM, 1990, J BACTERIOL, V172, P4827, DOI 10.1128/jb.172.9.4827-4835.1990; Silhavy T.J., 1984, EXPT GENE FUSIONS; SKELLY S, 1988, P NATL ACAD SCI USA, V85, P5497, DOI 10.1073/pnas.85.15.5497; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; STRAUS D, 1990, GENE DEV, V4, P2202, DOI 10.1101/gad.4.12a.2202; STRAUS DB, 1987, NATURE, V329, P348, DOI 10.1038/329348a0; STRAUS DB, 1989, GENE DEV, V3, P2003, DOI 10.1101/gad.3.12a.2003; STUBER D, 1990, IMMUNOLOGICAL METHOD, V4, P121; TILLY K, 1983, CELL, V34, P641, DOI 10.1016/0092-8674(83)90396-3; TILLY K, 1989, J BACTERIOL, V171, P1585, DOI 10.1128/jb.171.3.1585-1589.1989; WICKNER SH, 1990, P NATL ACAD SCI USA, V87, P2690, DOI 10.1073/pnas.87.7.2690; WOLD MS, 1982, P NATL ACAD SCI-BIOL, V79, P6176, DOI 10.1073/pnas.79.20.6176; YAMAMORI T, 1982, P NATL ACAD SCI-BIOL, V79, P860, DOI 10.1073/pnas.79.3.860	50	278	281	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 29	1992	69	5					833	842		10.1016/0092-8674(92)90294-M	http://dx.doi.org/10.1016/0092-8674(92)90294-M			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HW838	1534276				2022-12-01	WOS:A1992HW83800013
J	GLENN, JS; WATSON, JA; HAVEL, CM; WHITE, JM				GLENN, JS; WATSON, JA; HAVEL, CM; WHITE, JM			IDENTIFICATION OF A PRENYLATION SITE IN DELTA-VIRUS LARGE ANTIGEN	SCIENCE			English	Article							GENOME REPLICATION; MOLECULAR-CLONING; HEPATITIS; RNA; PROTEINS; AGENT; SERUM; LIVER; CELLS; HETEROGENEITY	During replication, hepatitis delta virus (HDV) switches from production of small to large delta antigen. Both antigen isoforms have an HDV genome binding domain and are packaged into hepatitis B virus (HBV)-derived envelopes but differ at their carboxyl termini. The large antigen was shown to contain a terminal CXXX box and undergo prenylation. The large, but not the small, antigen formed secreted particles when expressed singly with HBV surface antigen. Mutation of Cys211 in the CXXX box of the large antigen abolished both prenylation and particle formation, suggesting that this site is important for virion morphogenesis.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	GLENN, JS (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA.							BECK LA, 1988, J CELL BIOL, V107, P1307, DOI 10.1083/jcb.107.4.1307; BERGMANN KF, 1986, J INFECT DIS, V154, P702, DOI 10.1093/infdis/154.4.702; BONINO F, 1986, J VIROL, V58, P945, DOI 10.1128/JVI.58.3.945-950.1986; BONINO F, 1984, INFECT IMMUN, V43, P1000, DOI 10.1128/IAI.43.3.1000-1005.1984; BRUSS V, 1991, J VIROL, V65, P3813, DOI 10.1128/JVI.65.7.3813-3820.1991; CHAO M, 1990, J VIROL, V64, P5066, DOI 10.1128/JVI.64.10.5066-5069.1990; CHAO YC, 1991, HEPATOLOGY, V13, P345, DOI 10.1016/0270-9139(91)92451-D; DENY P, 1991, J GEN VIROL, V72, P735, DOI 10.1099/0022-1317-72-3-735; ELLENS H, 1989, METHOD CELL BIOL, V31, P155; GIBBS JB, 1991, CELL, V65, P1, DOI 10.1016/0092-8674(91)90352-Y; GLENN J, UNPUB; GLENN JS, 1991, J VIROL, V65, P2357, DOI 10.1128/JVI.65.5.2357-2361.1991; GLENN JS, 1990, J VIROL, V64, P3104, DOI 10.1128/JVI.64.6.3104-3107.1990; GLENN JS, 1992, THESIS U CALIFORNIA; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HOOFNAGLE JH, 1989, JAMA-J AM MED ASSOC, V261, P1321, DOI 10.1001/jama.261.9.1321; IMAZEKI F, 1990, J VIROL, V64, P5594, DOI 10.1128/JVI.64.11.5594-5599.1990; KELLER RK, 1986, J BIOL CHEM, V261, P2053; KUO MYP, 1989, J VIROL, V63, P1945, DOI 10.1128/JVI.63.5.1945-1950.1989; KUO MYP, 1988, J VIROL, V62, P1855, DOI 10.1128/JVI.62.6.1855-1861.1988; LIN JH, 1990, J VIROL, V64, P4051, DOI 10.1128/JVI.64.9.4051-4058.1990; LUO GX, 1990, J VIROL, V64, P1021, DOI 10.1128/JVI.64.3.1021-1027.1990; MAKINO S, 1987, NATURE, V329, P343, DOI 10.1038/329343a0; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MOORES SL, 1991, J BIOL CHEM, V266, P14603; RAMIG RF, 1990, VIROLOGY, P112; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; RIZZETTO M, 1983, HEPATOLOGY, V3, P729; RIZZETTO M, 1980, J INFECT DIS, V141, P590, DOI 10.1093/infdis/141.5.590; RIZZETTO M, 1980, P NATL ACAD SCI-BIOL, V77, P6124, DOI 10.1073/pnas.77.10.6124; RYU WS, IN PRESS J VIROL; RYU WS, UNPUB; SALDANHA JA, 1990, J GEN VIROL, V71, P1603, DOI 10.1099/0022-1317-71-7-1603; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SUREAU C, COMMUNICATION; WANG CJ, 1991, J VIROL, V65, P6630, DOI 10.1128/JVI.65.12.6630-6636.1991; WANG KS, 1986, NATURE, V323, P508, DOI 10.1038/323508a0; XIA YP, 1990, VIROLOGY, V178, P331, DOI 10.1016/0042-6822(90)90415-N	39	229	244	2	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 29	1992	256	5061					1331	1333		10.1126/science.1598578	http://dx.doi.org/10.1126/science.1598578			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HW135	1598578				2022-12-01	WOS:A1992HW13500037
J	GLICK, BS; BRANDT, A; CUNNINGHAM, K; MULLER, S; HALLBERG, RL; SCHATZ, G				GLICK, BS; BRANDT, A; CUNNINGHAM, K; MULLER, S; HALLBERG, RL; SCHATZ, G			CYTOCHROMES-C1 AND CYTOCHROMES-B2 ARE SORTED TO THE INTERMEMBRANE SPACE OF YEAST MITOCHONDRIA BY A STOP-TRANSFER MECHANISM	CELL			English	Article							PRECURSOR PROTEINS; INNER MEMBRANE; C PEROXIDASE; NUCLEAR GENE; ENDOPLASMIC-RETICULUM; OUTER-MEMBRANE; CONTACT SITES; 2 STEPS; IMPORT; TRANSLOCATION	The pathway by which cytochromes c1 and b2 reach the mitochondrial intermembrane space has been controversial. According to the "conservative sorting" hypothesis, these proteins are first imported across both outer and inner membranes into the matrix, and then are retranslocated across the inner membrane. Our data argue against this model: import intermediates of cytochromes c1 and b2 were found only outside the inner membrane; maturation of these proteins was independent of the matrix-localized hsp60 chaperone; and dihydrofolate reductase linked to the presequence of either cytochrome was imported to the intermembrane space in the absence of ATP. We conclude that cytochromes c1 and b2 are sorted by a mechanism in which translocation through the inner membrane is arrested by a "stop-transfer" signal in the presequence. The arrested intermediates may be associated with a proteinaceous channel in the inner membrane.			GLICK, BS (corresponding author), UNIV BASEL, BIOCTR, CH-4056 BASEL, SWITZERLAND.			Muller, Sabina/0000-0002-4580-2758	NIGMS NIH HHS [2R01 GM 37803, GM 43885] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037803] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEHRENS M, 1991, MOL GEN GENET, V228, P167, DOI 10.1007/BF00282462; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BRANDT A, 1991, METHOD CELL BIOL, V34, P369; CASTELLOT JJ, 1980, INTRO MACROMOLECULES, P297; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; DAUM G, 1982, J BIOL CHEM, V257, P3075; DAUM G, 1982, J BIOL CHEM, V257, P3028; EILERS M, 1987, EMBO J, V6, P1073, DOI 10.1002/j.1460-2075.1987.tb04860.x; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GASSER SM, 1982, P NATL ACAD SCI-BIOL, V79, P267, DOI 10.1073/pnas.79.2.267; GLICK B, 1991, ANNU REV GENET, V25, P21; GLICK BS, 1991, METHOD CELL BIOL, V34, P389; GUIARD B, 1985, EMBO J, V4, P3265, DOI 10.1002/j.1460-2075.1985.tb04076.x; HAAS RC, 1990, J BIOL CHEM, V265, P6921; HAID A, 1983, METHOD ENZYMOL, V96, P192; HARTL FU, 1987, CELL, V51, P1027, DOI 10.1016/0092-8674(87)90589-7; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HARTL FU, 1986, CELL, V47, P939, DOI 10.1016/0092-8674(86)90809-3; HIGH S, 1991, J CELL BIOL, V113, P35, DOI 10.1083/jcb.113.1.35; HINES V, 1990, EMBO J, V9, P3191, DOI 10.1002/j.1460-2075.1990.tb07517.x; HURT EC, 1986, TRENDS BIOCHEM SCI, V11, P204, DOI 10.1016/0968-0004(86)90007-1; HURT EC, 1984, EMBO J, V3, P3149, DOI 10.1002/j.1460-2075.1984.tb02272.x; HWANG ST, 1991, J BIOL CHEM, V266, P21083; HWANG ST, 1989, P NATL ACAD SCI USA, V86, P8432, DOI 10.1073/pnas.86.21.8432; KAPUT J, 1982, J BIOL CHEM, V257, P5054; KOZLOWSKI M, 1988, ANAL BIOCHEM, V172, P382; KUROIWA T, 1990, J BIOCHEM, V108, P829, DOI 10.1093/oxfordjournals.jbchem.a123288; LEWIN AS, 1990, MOL CELL BIOL, V10, P1399, DOI 10.1128/MCB.10.4.1399; LINGAPPA VR, 1991, CELL, V65, P527, DOI 10.1016/0092-8674(91)90081-9; MANNINGKRIEG UC, 1991, EMBO J, V10, P3273, DOI 10.1002/j.1460-2075.1991.tb04891.x; Margulis L., 1993, SYMBIOSIS CELL EVOLU; NEUPERT W, 1990, CELL, V63, P447, DOI 10.1016/0092-8674(90)90437-J; NGUYEN M, 1988, J CELL BIOL, V106, P1499, DOI 10.1083/jcb.106.5.1499; NICHOLSON DW, 1989, J BIOL CHEM, V264, P10156; NICHOLSON DW, 1988, PROTEIN TRANSFER ORG, P677; OHASHI A, 1982, J BIOL CHEM, V257, P3042; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PFANNER N, 1990, J BIOL CHEM, V265, P16324; PFANNER N, 1987, EUR J BIOCHEM, V169, P289, DOI 10.1111/j.1432-1033.1987.tb13610.x; PRATJE E, 1986, EMBO J, V5, P1312; RASSOW J, 1989, J CELL BIOL, V109, P1421, DOI 10.1083/jcb.109.4.1421; REID GA, 1982, J BIOL CHEM, V257, P3068; SADLER I, 1984, EMBO J, V3, P2137, DOI 10.1002/j.1460-2075.1984.tb02103.x; SCHERER P, 1988, THESIS U BASEL BASEL; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; SCHNAITMAN C, 1968, J CELL BIOL, V38, P158, DOI 10.1083/jcb.38.1.158; SCHNEIDER A, 1991, EMBO J, V10, P247, DOI 10.1002/j.1460-2075.1991.tb07944.x; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; SOMLO M, 1965, BIOCHIM BIOPHYS ACTA, V97, P183, DOI 10.1016/0304-4165(65)90083-8; STUEBER D, 1984, EMBO J, V3, P3143, DOI 10.1002/j.1460-2075.1984.tb02271.x; TEINTZE M, 1982, J BIOL CHEM, V257, P364; THRIFT RN, 1991, J CELL BIOL, V112, P809, DOI 10.1083/jcb.112.5.809; VANLOON APG, 1987, EMBO J, V8, P2433; VANLOON APGM, 1986, CELL, V44, P801, DOI 10.1016/0092-8674(86)90846-9; VANLOON APGM, 1987, EMBO J, V6, P2441, DOI 10.1002/j.1460-2075.1987.tb02523.x; VESTWEBER D, 1988, J CELL BIOL, V107, P2037, DOI 10.1083/jcb.107.6.2037; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819; ZIMMERMAN DL, 1990, J BIOL CHEM, V265, P4048	59	315	315	0	13	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 29	1992	69	5					809	822		10.1016/0092-8674(92)90292-K	http://dx.doi.org/10.1016/0092-8674(92)90292-K			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HW838	1350514				2022-12-01	WOS:A1992HW83800011
J	HANSSON, BS; LJUNGBERG, H; HALLBERG, E; LOFSTEDT, C				HANSSON, BS; LJUNGBERG, H; HALLBERG, E; LOFSTEDT, C			FUNCTIONAL SPECIALIZATION OF OLFACTORY GLOMERULI IN A MOTH	SCIENCE			English	Article							PHEROMONE-SENSITIVE NEURONS; DROSOPHILA-MELANOGASTER; ANTENNAL LOBE; BULB; DEUTOCEREBRUM; PROJECTION; BRAIN	The specific function of the glomerular structures present in the antennal lobes or olfactory bulbs of organisms ranging from insects to humans has been obscure because of limitations in neuronal marking methods. By tracing individual neurons in the moth Agrotis segetum, it was determined that physiologically distinct types of pheromone receptor neurons project axons to different regions of the macroglomerular complex (MGC). Each glomerulus making up the MGC has a specific functional identity, initially processing information about one specific pheromone component. This indicates that, at least through the first stage of synapses, olfactory information moves through labeled lines.	UNIV LUND,DEPT ZOOL,S-22362 LUND,SWEDEN	Lund University	HANSSON, BS (corresponding author), UNIV LUND,DEPT ECOL,S-22362 LUND,SWEDEN.		Hansson, Bill S/G-2774-2013; Löfstedt, Christer/G-2016-2014	Hansson, Bill S/0000-0002-4811-1223; Löfstedt, Christer/0000-0002-3116-6922				ARNOLD G, 1987, CR ACAD SCI III-VIE, V305, P271; ASTIC L, 1987, BRAIN RES, V424, P144, DOI 10.1016/0006-8993(87)91204-2; BOECKH J, 1979, J COMP PHYSIOL, V132, P235, DOI 10.1007/BF00614495; BURROWS M, 1982, J COMP PHYSIOL A, V15, P447; Christensen T.A., 1987, P457; CHRISTENSEN TA, 1991, J COMP PHYSIOL A, V169, P259; HANSSON BS, 1991, J COMP NEUROL, V312, P264, DOI 10.1002/cne.903120209; HOSL M, 1990, J COMP PHYSIOL A, V167, P321, DOI 10.1007/BF00192567; JASTREBOFF PJ, 1984, P NATL ACAD SCI-BIOL, V81, P5250, DOI 10.1073/pnas.81.16.5250; Kaissling KE, 1974, BIOCH SENSORY FUNCTI, P243; LOFSTEDT C, 1982, J CHEM ECOL, V8, P1305, DOI 10.1007/BF00987764; MATSUMOTO SG, 1981, PROC R SOC SER B-BIO, V213, P249, DOI 10.1098/rspb.1981.0066; MELLON D, 1990, J COMP NEUROL, V296, P253, DOI 10.1002/cne.902960205; OBERMAYER M, 1980, NEUROANATOMICAL TECH, P406; PEDERSEN PE, 1986, J COMP NEUROL, V250, P93, DOI 10.1002/cne.902500109; RODRIGUES V, 1988, BRAIN RES, V453, P299, DOI 10.1016/0006-8993(88)90170-9; ROWELL CHF, 1963, Q J MICROSC SCI, V104, P81; SCHNEIDERMAN AM, 1982, NATURE, V298, P844, DOI 10.1038/298844a0; SHANBHAG SR, 1992, CELL TISSUE RES, V267, P273, DOI 10.1007/BF00302965; STOCKER RF, 1983, CELL TISSUE RES, V232, P237, DOI 10.1007/BF00213783; VANDERPERS JNC, 1978, J INSECT PHYSIOL, V24, P337, DOI 10.1016/0022-1910(78)90033-1	21	187	197	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 29	1992	256	5061					1313	1315		10.1126/science.1598574	http://dx.doi.org/10.1126/science.1598574			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HW135	1598574				2022-12-01	WOS:A1992HW13500031
J	HERENDEEN, DR; KASSAVETIS, GA; GEIDUSCHEK, EP				HERENDEEN, DR; KASSAVETIS, GA; GEIDUSCHEK, EP			A TRANSCRIPTIONAL ENHANCER WHOSE FUNCTION IMPOSES A REQUIREMENT THAT PROTEINS TRACK ALONG DNA	SCIENCE			English	Article							COLI RNA-POLYMERASE; ESCHERICHIA-COLI; BINDING PROTEIN; REPLICATION APPARATUS; PROMOTER SEARCH; GENE; EXPRESSION; ACTIVATOR; DISTANCE; SITE	Transcriptional regulation of the bacteriophage T4 late genes requires the participation of three DNA polymerase accessory proteins that are encoded by T4 genes 44, 62, and 45, and that act at an enhancer-like site. Transcriptional activation by these DNA replication proteins also requires the function of an RNA polymerase-bound coactivator protein that is encoded by T4 gene 33 and a promoter recognition protein that is encoded by T4 gene 55. Transcriptional activation in DNA constructs, in which the enhancer and a T4 late promoter can be segregated on two rings of a DNA catenane, has now been analyzed. The ability of an interposed DNA-binding protein to affect communication between the enhancer and the promoter was also examined. Together, these experiments demonstrate that this transcription-activating signal is conveyed between its enhancer and a T4 late promoter by a DNA-tracking mechanism. Alternative activation mechanisms relying entirely on through-space interactions of enhancer-bound and promoter-bound proteins are excluded.	UNIV CALIF SAN DIEGO,DEPT BIOL,9500 GILMAN DR,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR MOLEC GENET,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego								ADHYA S, 1989, ANNU REV GENET, V23, P207; ADZUMA K, 1989, CELL, V57, P41, DOI 10.1016/0092-8674(89)90170-0; ALBERTS BM, 1982, COLD SPRING HARB SYM, V47, P655, DOI 10.1101/SQB.1983.047.01.077; BEDINGER P, 1983, J BIOL CHEM, V258, P9649; BEDINGER P, 1983, CELL, V34, P115, DOI 10.1016/0092-8674(83)90141-1; CAPSON TL, 1991, CELL, V65, P249, DOI 10.1016/0092-8674(91)90159-V; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; DUNAWAY M, 1989, NATURE, V341, P657, DOI 10.1038/341657a0; ECHOLS H, 1990, J BIOL CHEM, V265, P14697; ELLIOTT T, 1984, CELL, V36, P211, DOI 10.1016/0092-8674(84)90091-6; GEIDUSCHEK EP, 1983, BACTERIOPHAGE T, V4, P189; GOGOL EP, 1992, J MOL BIOL, V224, P395, DOI 10.1016/0022-2836(92)91003-8; GREENSTEIN D, 1908, J MOL BIOL, V197, P157; GRUIDL ME, 1991, VIROLOGY, V184, P359, DOI 10.1016/0042-6822(91)90852-3; HERENDEEN DR, 1989, SCIENCE, V245, P952, DOI 10.1126/science.2672335; HERENDEEN DR, 1990, SCIENCE, V248, P573, DOI 10.1126/science.2185541; Hochschild A., 1990, DNA TOPOLOGY ITS BIO, P107; JARVIS TC, 1991, J BIOL CHEM, V266, P1830; JARVIS TC, 1989, J BIOL CHEM, V264, P12717; KASSAVETIS GA, 1986, J BIOL CHEM, V261, P14256; KUSTU S, 1989, MICROBIOL REV, V53, P367, DOI 10.1128/MMBR.53.3.367-376.1989; KUSTU S, 1991, TRENDS BIOCHEM SCI, V16, P3977; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; MACE DC, 1984, J MOL BIOL, V177, P313, DOI 10.1016/0022-2836(84)90459-5; MAGASANIK B, 1989, New Biologist, V1, P247; Maniatis T., 1982, MOL CLONING; MCPHEETERS DS, 1986, NUCLEIC ACIDS RES, V14, P5813, DOI 10.1093/nar/14.14.5813; MULLER HP, 1989, CELL, V58, P767, DOI 10.1016/0092-8674(89)90110-4; MUNN MM, 1991, J BIOL CHEM, V266, P20034; NOSSAL NG, 1983, BACTERIOPHAGE T, V4, P71; PAVCO PA, 1990, J BIOL CHEM, V265, P9960; PEEBLES CL, 1979, CELL, V18, P27, DOI 10.1016/0092-8674(79)90350-7; PIPERNO JR, 1978, J BIOL CHEM, V253, P5174; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PTASHNE M, 1986, NATURE, V322, P697, DOI 10.1038/322697a0; REED RR, 1981, P NATL ACAD SCI-BIOL, V78, P3428, DOI 10.1073/pnas.78.6.3428; REED RR, 1981, CELL, V25, P713, DOI 10.1016/0092-8674(81)90178-1; REITZER LJ, 1986, CELL, V45, P785, DOI 10.1016/0092-8674(86)90553-2; SCARLATO V, 1989, VIROLOGY, V171, P475, DOI 10.1016/0042-6822(89)90617-X; SCHNEIDER GJ, 1990, J BIOL CHEM, V265, P10198; SELICK HE, 1987, UCLA S MOL CELL BIOL, V26, P183; SINGER P, 1987, J BIOL CHEM, V262, P14178; SINGER PT, 1988, J BIOL CHEM, V263, P4208; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; SU W, 1990, P NATL ACAD SCI USA, V87, P5504, DOI 10.1073/pnas.87.14.5504; VENKATESAN M, 1982, J BIOL CHEM, V257, P2435; VONHIPPEL PH, 1989, J BIOL CHEM, V264, P675; WANG JC, 1988, SCIENCE, V240, P300, DOI 10.1126/science.3281259; WEDEL A, 1990, SCIENCE, V248, P486, DOI 10.1126/science.1970441; WILLIAMS KJ, 1991, THESIS U CALIFORNIA; WRIGHT DJ, 1989, J BIOL CHEM, V264, P11816	51	116	117	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 29	1992	256	5061					1298	1303		10.1126/science.1598572	http://dx.doi.org/10.1126/science.1598572			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HW135	1598572				2022-12-01	WOS:A1992HW13500026
J	KITAMURA, D; KUDO, A; SCHAAL, S; MULLER, W; MELCHERS, F; RAJEWSKY, K				KITAMURA, D; KUDO, A; SCHAAL, S; MULLER, W; MELCHERS, F; RAJEWSKY, K			A CRITICAL ROLE OF LAMBDA-5 PROTEIN IN B-CELL DEVELOPMENT	CELL			English	Article							IMMUNOGLOBULIN GENE REARRANGEMENT; LIGHT CHAIN GENES; LYMPHOCYTES-PRE-B; HEAVY-CHAINS; TRANSGENIC MICE; STEM-CELLS; MU; ANTIBODIES; MOUSE; VPREB	The lambda-5 gene is a homolog of immunoglobulin J(lambda)-C(lambda) genes, expressed specifically in immature B-lineage cells. Lambda-5-encoded molecules form membrane complexes with mu or D(mu) proteins in association with an additional protein specifically expressed in immature B cells that is encoded by the V(pre-B) gene. We have generated mice in which the lambda-5 gene is inactivated by targeted gene disruption in embryonic stem cells. In these mice, B cell development in the bone marrow is blocked at the pre-B cell stage. However, the blockade is leaky, allowing B cells to populate the peripheral immune system at a low rate. These cells are allelically excluded and able to respond to antigen.	UNIV COLOGNE, INST GENET, W-5000 COLOGNE 41, GERMANY; BASEL INST IMMUNOL, CH-4058 BASEL, SWITZERLAND	University of Cologne			Muller, Werner/B-9044-2008; Kudo, Akira/C-7340-2015	Muller, Werner/0000-0002-1297-9725; Kudo, Akira/0000-0001-6289-3391				ALT F, 1981, CELL, V27, P381, DOI 10.1016/0092-8674(81)90421-9; BLACKWELL TK, 1989, EMBO J, V8, P735, DOI 10.1002/j.1460-2075.1989.tb03433.x; BRADLEY A, 1987, TERATOCARCINOMAS EMB, P113; CHERAYIL BJ, 1991, J EXP MED, V173, P111, DOI 10.1084/jem.173.1.111; CHESNUT RW, 1981, J IMMUNOL, V126, P1075; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COFFMAN RL, 1983, IMMUNOL REV, V69, P5, DOI 10.1111/j.1600-065X.1983.tb00446.x; COFFMAN RL, 1983, J MOL CELL IMMUNOL, V1, P31; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; FORSTER I, 1987, EUR J IMMUNOL, V17, P521, DOI 10.1002/eji.1830170414; FORSTER I, 1990, P NATL ACAD SCI USA, V87, P4781, DOI 10.1073/pnas.87.12.4781; Forster I, 1989, Int Immunol, V1, P321, DOI 10.1093/intimm/1.4.321; Grutzmann R., 1981, THESIS U COLOGNE COL; GU H, 1991, CELL, V65, P47, DOI 10.1016/0092-8674(91)90406-O; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HERZENBERG LA, 1986, IMMUNOL REV, V93, P81, DOI 10.1111/j.1600-065X.1986.tb01503.x; IMANISHI T, 1973, EUR J IMMUNOL, V3, P323, DOI 10.1002/eji.1830030602; ISCOVE NN, 1978, J EXP MED, V147, P923, DOI 10.1084/jem.147.3.923; KANTOR AB, 1991, IMMUNOL TODAY, V12, P389, DOI 10.1016/0167-5699(91)90136-H; KARASUYAMA H, 1990, J EXP MED, V172, P969, DOI 10.1084/jem.172.3.969; KENDALL C, 1983, J IMMUNOL METHODS, V56, P329, DOI 10.1016/S0022-1759(83)80022-2; Kerr W G, 1989, Int Immunol, V1, P355, DOI 10.1093/intimm/1.4.355; KITAMURA D, 1992, NATURE, V356, P154, DOI 10.1038/356154a0; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KUBAGAWA H, 1989, P NATL ACAD SCI USA, V86, P2356, DOI 10.1073/pnas.86.7.2356; KUDO A, 1987, EMBO J, V6, P103, DOI 10.1002/j.1460-2075.1987.tb04725.x; KUDO A, 1987, EMBO J, V6, P2267, DOI 10.1002/j.1460-2075.1987.tb02500.x; KUDO A, 1989, PROGR IMMUNOLOGY, V7, P339; MANZ J, 1988, J EXP MED, V168, P1363, DOI 10.1084/jem.168.4.1363; MULLER CE, 1983, THESIS U COLOGNE COL; MULLER W, 1989, EUR J IMMUNOL, V19, P923, DOI 10.1002/eji.1830190520; MULLER W, 1991, EUR J IMMUNOL, V21, P921, DOI 10.1002/eji.1830210410; NISHIKAWA SI, 1986, IMMUNOGENETICS, V23, P137, DOI 10.1007/BF00377976; NISHIMOTO N, 1991, P NATL ACAD SCI USA, V88, P6284, DOI 10.1073/pnas.88.14.6284; NUSSENZWEIG MC, 1987, SCIENCE, V236, P816, DOI 10.1126/science.3107126; OI VT, 1979, MOL IMMUNOL, V16, P1005, DOI 10.1016/0161-5890(79)90034-8; OPITZ HG, 1982, IMMUNOBIOLOGY, V160, P438, DOI 10.1016/S0171-2985(82)80007-7; OSMOND DG, 1991, CURR OPIN IMMUNOL, V3, P179, DOI 10.1016/0952-7915(91)90047-5; PILLAI S, 1987, NATURE, V329, P172, DOI 10.1038/329172a0; PILLAI S, 1988, CURR TOP MICROBIOL, V137, P136; RETH M, 1987, EMBO J, V6, P3299, DOI 10.1002/j.1460-2075.1987.tb02649.x; RETH M, 1979, EUR J IMMUNOL, V9, P1004, DOI 10.1002/eji.1830091216; RETH MG, 1984, NATURE, V312, P418, DOI 10.1038/312418a0; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROEHM NW, 1984, J EXP MED, V160, P679, DOI 10.1084/jem.160.3.679; ROLINK A, 1991, EMBO J, V10, P327, DOI 10.1002/j.1460-2075.1991.tb07953.x; SAKAGUCHI N, 1986, NATURE, V324, P579, DOI 10.1038/324579a0; SAKAGUCHI N, 1986, EMBO J, V5, P2139, DOI 10.1002/j.1460-2075.1986.tb04477.x; SCHUPPEL R, 1987, EUR J IMMUNOL, V17, P739, DOI 10.1002/eji.1830170527; SEEMANN G, 1981, THESIS U COLOGNE COL; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TSUBATA T, 1991, EUR J IMMUNOL, V21, P1359, DOI 10.1002/eji.1830210605; TSUBATA T, 1990, J EXP MED, V172, P973, DOI 10.1084/jem.172.3.973; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0	54	543	547	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 29	1992	69	5					823	831		10.1016/0092-8674(92)90293-L	http://dx.doi.org/10.1016/0092-8674(92)90293-L			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HW838	1591779				2022-12-01	WOS:A1992HW83800012
J	KOLESKE, AJ; BURATOWSKI, S; NONET, M; YOUNG, RA				KOLESKE, AJ; BURATOWSKI, S; NONET, M; YOUNG, RA			A NOVEL TRANSCRIPTION FACTOR REVEALS A FUNCTIONAL LINK BETWEEN THE RNA POLYMERASE-II CTD AND TFIID	CELL			English	Article							C-TERMINAL DOMAIN; LARGEST SUBUNIT; REPEAT DOMAIN; SACCHAROMYCES-CEREVISIAE; HEPTAPEPTIDE REPEAT; INITIATION; YEAST; PHOSPHORYLATION; PROMOTER; PROTEIN	The RNA polymerase II large subunit carboxy-terminal domain (CTD) plays a role in transcription initiation, but its mechanism of action is not well understood. We have investigated the function of the SRB2 gene, which was isolated as a dominant suppressor of CTD truncation mutations. The allele specificity of this suppressor indicates that SRB2 and the CTD are involved in the same function. Indeed, cells lacking SRB2 and cells lacking a large portion of the CTD exhibit the same set of conditional growth phenotypes and exhibit very similar defects in gene expression in vivo. The SRB2 protein is a novel transcription factor that has an important role in basal and activated transcription in vitro and is essential for efficient establishment of the transcription initiation apparatus. Template commitment experiments suggest that SRB2 becomes physically associated with the transcription initiation complex. We f ind that SRB2 binds specifically to TFIID. As SRB2 and the RNA polymerase II CTD are involved in the same function, these results reveal a functional link between the CTD and the TATA-binding factor. This study implicates the CTD in recruitment of RNA polymerase II to the transcription initiation complex.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)	KOLESKE, AJ (corresponding author), WHITEHEAD INST BIOMED RES,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.		Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647				ALLISON LA, 1988, MOL CELL BIOL, V8, P321, DOI 10.1128/MCB.8.1.321; ALLISON LA, 1989, P NATL ACAD SCI USA, V86, P2794, DOI 10.1073/pnas.86.8.2794; ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; ARIAS JA, 1991, J BIOL CHEM, V266, P8055; ARNDT KT, 1989, CELL, V56, P527, DOI 10.1016/0092-8674(89)90576-X; BARTOLOMEI MS, 1988, MOL CELL BIOL, V8, P330, DOI 10.1128/MCB.8.1.330; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BUERMEYER AB, 1992, MOL CELL BIOL, V12, P2250, DOI 10.1128/MCB.12.5.2250; BURATOWSKI S, 1991, P NATL ACAD SCI USA, V88, P7509, DOI 10.1073/pnas.88.17.7509; BURATOWSKI S, 1990, MOL CELL BIOL, V10, P5562, DOI 10.1128/MCB.10.10.5562; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CONAWAY RC, 1992, J BIOL CHEM, V267, P8464; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P383, DOI 10.1016/0968-0004(90)90236-5; CORDEN JL, 1985, P NATL ACAD SCI USA, V82, P7934, DOI 10.1073/pnas.82.23.7934; DAHMUS ME, 1992, IN PRESS TRANSCRIPTI; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; EDLER RT, 1983, P NATL ACAD SCI USA, V80, P2432; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P7410, DOI 10.1073/pnas.79.23.7410; HARLOW E, 1988, ANTIBODIES LABORATOR; KIM WY, 1989, J BIOL CHEM, V264, P3169; KOLODZIEJ PA, 1990, MOL CELL BIOL, V10, P1915, DOI 10.1128/MCB.10.5.1915; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGFORD CJ, 1984, CELL, V36, P645, DOI 10.1016/0092-8674(84)90344-1; LANGFORD CJ, 1983, CELL, V33, P519, DOI 10.1016/0092-8674(83)90433-6; LAYBOURN PJ, 1989, J BIOL CHEM, V264, P6693; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LEE JM, 1991, GENE EXPRESSION, V1, P149; LEE JM, 1989, P NATL ACAD SCI USA, V86, P3624, DOI 10.1073/pnas.86.10.3624; LIAO SM, 1991, GENE DEV, V5, P2431, DOI 10.1101/gad.5.12b.2431; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; LUE NF, 1987, P NATL ACAD SCI USA, V84, P8839, DOI 10.1073/pnas.84.24.8839; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MOYLE M, 1989, MOL CELL BIOL, V9, P5750, DOI 10.1128/MCB.9.12.5750; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; NONET ML, 1989, GENETICS, V123, P715; Parker R, 1987, MOL BIOL RNA NEW PER, P133; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; PETERSON CL, 1991, CELL, V64, P1135, DOI 10.1016/0092-8674(91)90268-4; PIKIELNY CW, 1983, CELL, V34, P395, DOI 10.1016/0092-8674(83)90373-2; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; ROSBASH M, 1981, CELL, V24, P679, DOI 10.1016/0092-8674(81)90094-5; Sambrook J., 1989, MOL CLONING LAB MANU; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; THOMPSON NE, 1989, J BIOL CHEM, V264, P11511; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WOONTNER M, 1991, MOL CELL BIOL, V11, P4555, DOI 10.1128/MCB.11.9.4555; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.bi.60.070191.003353; ZAWEL L, 1992, IN PRESS PROG NUCL A; ZEHRING WA, 1990, J BIOL CHEM, V265, P8351; ZEHRING WA, 1988, P NATL ACAD SCI USA, V85, P3698, DOI 10.1073/pnas.85.11.3698	65	153	155	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 29	1992	69	5					883	894		10.1016/0092-8674(92)90298-Q	http://dx.doi.org/10.1016/0092-8674(92)90298-Q			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HW838	1591782				2022-12-01	WOS:A1992HW83800017
J	LEE, KF; LI, E; HUBER, LJ; LANDIS, SC; SHARPE, AH; CHAO, MV; JAENISCH, R				LEE, KF; LI, E; HUBER, LJ; LANDIS, SC; SHARPE, AH; CHAO, MV; JAENISCH, R			TARGETED MUTATION OF THE GENE ENCODING THE LOW AFFINITY NGF RECEPTOR P75 LEADS TO DEFICITS IN THE PERIPHERAL SENSORY NERVOUS-SYSTEM	CELL			English	Article							GROWTH-FACTOR RECEPTORS; NEUROTROPHIC FACTOR; MOLECULAR-CLONING; SYMPATHETIC NEURONS; FACTOR FAMILY; CHICK-EMBRYO; SUBSTANCE-P; EXPRESSION; CELLS; BRAIN	We have generated mice carrying a mutation of the gene encoding the low affinity NGF receptor p75NGFR by targeted mutation in embryonic stem cells. Mice homozygous for the mutation were viable and fertile. Immunohistochemical analyses of the footpad skin of mutant mice revealed markedly decreased sensory innervation by calcitonin gene-related peptide- and substance P-immunoreactive fibers. The defective innervation was correlated with loss of heat sensitivity and associated with the development of ulcers in the distal extremities. Complicated by secondary bacterial infection, the ulcers progressed to toenail and hair loss. Crossing a human transgene encoding p75NGFR into the mutant animals rescued the absent heat sensitivity and the occurrence of skin ulcers and increased the density of neuropeptide-immunoreactive sensory innervation of footpad skin. The mutation in the gene encoding p75NGFR did not decrease the size of sympathetic ganglia or the density of sympathetic innervation of the iris or salivary gland. Our results suggest that p75NGFR has an important role in the development and function of sensory neurons.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; CORNELL UNIV, MED CTR, COLL MED, DEPT CELL BIOL & ANAT, NEW YORK, NY 10021 USA; CASE WESTERN RESERVE UNIV, SCH MED, DEPT NEUROSCI, CLEVELAND, OH 44106 USA	Massachusetts Institute of Technology (MIT); Cornell University; Case Western Reserve University	LEE, KF (corresponding author), WHITEHEAD INST BIOMED RES, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA.			Chao, Moses/0000-0002-6969-3744	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD023315] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023678, R01NS021072] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 23315] Funding Source: Medline; NINDS NIH HHS [NS 023678, NS 21072] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACHESON A, 1991, NEURON, V7, P265, DOI 10.1016/0896-6273(91)90265-2; ADAMS RD, 1989, PRINCIPLES NEUROLOGY, P1028; ALOE L, 1981, NATURE, V291, P413, DOI 10.1038/291413a0; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; BERG MM, 1991, P NATL ACAD SCI USA, V88, P7106, DOI 10.1073/pnas.88.16.7106; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; BOTHWELL M, 1991, CURR TOP MICROBIOL, V165, P55; BOTHWELL M, 1991, CELL, V65, P915, DOI 10.1016/0092-8674(91)90540-F; BRADLEY A, 1987, TERATOCARCINOMAS EMB, P113; BYERS MR, 1990, DEVELOPMENT, V109, P461; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; DAVIES AM, 1986, J NEUROSCI, V6, P1897; DELATORRE JC, 1980, J NEUROSCI METH, V3, P1, DOI 10.1016/0165-0270(80)90029-1; DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K; ERNFORS P, 1990, P NATL ACAD SCI USA, V87, P5454, DOI 10.1073/pnas.87.14.5454; FABRICANT RN, 1977, P NATL ACAD SCI USA, V74, P565, DOI 10.1073/pnas.74.2.565; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; GREEN SH, 1986, J CELL BIOL, V102, P830, DOI 10.1083/jcb.102.3.830; HAEGERSTRAND A, 1990, P NATL ACAD SCI USA, V87, P3299, DOI 10.1073/pnas.87.9.3299; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; HAMBURGER V, 1981, J NEUROSCI, V1, P60, DOI 10.1523/JNEUROSCI.01-01-00060.1981; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEMPSTEAD BL, 1989, SCIENCE, V243, P373, DOI 10.1126/science.2536190; HEUER JG, 1990, DEV BIOL, V137, P287, DOI 10.1016/0012-1606(90)90255-H; HOFER MM, 1988, NATURE, V331, P261, DOI 10.1038/331261a0; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HOLZER P, 1988, NEUROSCIENCE, V24, P739, DOI 10.1016/0306-4522(88)90064-4; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; JOHNSON EM, 1983, NEUROSCIENCE, V8, P631, DOI 10.1016/0306-4522(83)90204-X; JOHNSON EM, 1980, SCIENCE, V210, P916, DOI 10.1126/science.7192014; JOHNSON EM, 1988, TRENDS NEUROSCI, V11, P299, DOI 10.1016/0166-2236(88)90090-2; JONES KR, 1990, P NATL ACAD SCI USA, V87, P8060, DOI 10.1073/pnas.87.20.8060; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KOIKE T, 1991, P NATL ACAD SCI USA, V88, P3892, DOI 10.1073/pnas.88.9.3892; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; Levi-Montalcini R, 1990, PROG NEUROENDOCRINOL, V3, P1; LEVIMONTALCINI R, 1963, DEV BIOL, V7, P653, DOI 10.1016/0012-1606(63)90149-0; LEVIMONTALCINI R, 1987, EMBO J, V6, P1145, DOI 10.1002/j.1460-2075.1987.tb02347.x; LEVIMONTALCINI R, 1968, PHYSIOL REV, V48, P534, DOI 10.1152/physrev.1968.48.3.534; LINDBERGER M, 1989, J NEUROL SCI, V93, P289, DOI 10.1016/0022-510X(89)90198-6; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MALLETT S, 1991, IMMUNOL TODAY, V12, P220, DOI 10.1016/0167-5699(91)90033-P; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; NILSSON J, 1985, NATURE, V315, P61, DOI 10.1038/315061a0; PATIL N, 1990, NEURON, V4, P437, DOI 10.1016/0896-6273(90)90056-L; PEARSON J, 1982, NATURE, V295, P61, DOI 10.1038/295061a0; PERSSON H, 1990, SCIENCE, V247, P704, DOI 10.1126/science.2154035; PLEASURE SJ, 1990, P NATL ACAD SCI USA, V87, P8496, DOI 10.1073/pnas.87.21.8496; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RITTER AM, 1991, NATURE, V350, P500, DOI 10.1038/350500a0; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; ROHRER H, 1988, DEVELOPMENT, V103, P545; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; SARIOLA H, 1991, SCIENCE, V254, P571, DOI 10.1126/science.1658930; SCHOTZINGER RJ, 1990, NEURON, V5, P91, DOI 10.1016/0896-6273(90)90037-G; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SEHESTED M, 1981, VIRCHOWS ARCH A, V391, P217, DOI 10.1007/BF00437598; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; STEVENS LC, 1973, J NATL CANCER I, V50, P235, DOI 10.1093/jnci/50.1.235; SUTTER A, 1979, J BIOL CHEM, V254, P5972; TANIUCHI M, 1986, P NATL ACAD SCI USA, V83, P1950, DOI 10.1073/pnas.83.6.1950; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VONBARTHELD CS, 1991, DEVELOPMENT, V113, P455; WAKADE AR, 1984, NEUROSCI LETT, V45, P71, DOI 10.1016/0304-3940(84)90331-8; WEIHER H, 1990, CELL, V62, P425, DOI 10.1016/0092-8674(90)90008-3; WELCHER AA, 1991, P NATL ACAD SCI USA, V88, P159, DOI 10.1073/pnas.88.1.159; WESKAMP G, 1991, NEURON, V6, P649, DOI 10.1016/0896-6273(91)90067-A; WYATT S, 1990, NEURON, V4, P421, DOI 10.1016/0896-6273(90)90054-J; YAN H, 1991, J BIOL CHEM, V266, P12099; YAN Q, 1988, J NEUROSCI, V8, P3481; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	85	863	880	1	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 29	1992	69	5					737	749		10.1016/0092-8674(92)90286-L	http://dx.doi.org/10.1016/0092-8674(92)90286-L			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HW838	1317267				2022-12-01	WOS:A1992HW83800005
J	LEUTHER, KK; JOHNSTON, SA				LEUTHER, KK; JOHNSTON, SA			NONDISSOCIATION OF GAL4 AND GAL80 INVIVO AFTER GALACTOSE INDUCTION	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; DNA-BINDING; YEAST; GENE; ACTIVATOR; TRANSCRIPTION; INVITRO; PROTEIN; VP16	Transcription of galactose-inducible genes in yeast is regulated by interaction between the activator protein GAL4 and the negative regulatory protein GAL80. It has been suggested that GAL80 binds to and represses GAL4 under uninduced conditions and dissociates from GAL4 on induction. However, the possibility that GAL80 remains associated with GAL4 after induction has not been ruled out. Experiments to discriminate between these two models were performed and revealed that GAL80 stays bound after induction.	UNIV TEXAS,SW MED CTR,DEPT MED,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; JOHNSTON SA, 1982, P NATL ACAD SCI-BIOL, V79, P6971, DOI 10.1073/pnas.79.22.6971; LANGDON SD, UNPUB; LEUTHER KK, UNPUB; LUE NF, 1987, MOL CELL BIOL, V7, P3446, DOI 10.1128/MCB.7.10.3446; MA J, 1988, CELL, V55, P443, DOI 10.1016/0092-8674(88)90030-X; MA J, 1987, CELL, V50, P137, DOI 10.1016/0092-8674(87)90670-2; MATSUMOTO K, 1980, J BACTERIOL, V141, P509; PARTHUN MR, 1990, J BIOL CHEM, V265, P209; SELLECK SB, 1987, MOL CELL BIOL, V7, P3260, DOI 10.1128/MCB.7.9.3260; TORCHIA TE, 1984, MOL CELL BIOL, V4, P1521, DOI 10.1128/MCB.4.8.1521; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; YOCUM RR, 1984, GENE, V32, P75, DOI 10.1016/0378-1119(84)90034-9	14	128	132	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 29	1992	256	5061					1333	1335		10.1126/science.1598579	http://dx.doi.org/10.1126/science.1598579			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HW135	1598579				2022-12-01	WOS:A1992HW13500038
J	PHILPOTT, A; LENO, GH				PHILPOTT, A; LENO, GH			NUCLEOPLASMIN REMODELS SPERM CHROMATIN IN XENOPUS EGG EXTRACTS	CELL			English	Article							NUCLEOSOME ASSEMBLY INVITRO; HISTONE COMPLEXES; LAEVIS OOCYTES; ACIDIC PROTEIN; NUCLEI; FERTILIZATION; DNA; REPLICATION; TRANSITIONS; CLEAVAGE	Nucleoplasmin is necessary and sufficient for the initial stage of Xenopus sperm decondensation in egg extracts. In this article we show that sperm decondensation is accompanied by loss of two sperm-specific basic proteins (X and Y) and gain of histones H2A and H2B, resulting in nucleosome formation. Purified nucleoplasmin alone removes X and Y and assembles purified H2A and H2B on decondensing sperm chromatin, forming nucleosome cores. Immunodepletion of nucleoplasmin from extract prevents removal of X and Y and addition of H2A and H2B, while adding back nucleoplasmin restores decondensation and X and Y removal. Thus, nucleoplasmin acts as both an assembly and a disassembly factor for remodeling sperm chromatin at fertilization.	UNIV CAMBRIDGE,WELLCOME CANC RES CAMPAIGN INST CANC & DEV BIOL,CAMBRIDGE CB2 1QR,ENGLAND	University of Cambridge				Philpott, Anna/0000-0003-3789-2463	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; BOLS NC, 1972, CAN J ZOOLOG, V50, P171, DOI 10.1139/z72-026; BOLS NC, 1973, CAN J ZOOL, V51, P203, DOI 10.1139/z73-029; DEAN J, 1983, DEV BIOL, V99, P210, DOI 10.1016/0012-1606(83)90269-5; DILWORTH SM, 1987, CELL, V51, P1009, DOI 10.1016/0092-8674(87)90587-3; EARNSHAW WC, 1980, CELL, V21, P373, DOI 10.1016/0092-8674(80)90474-2; GORDON K, 1985, EXP CELL RES, V157, P409, DOI 10.1016/0014-4827(85)90126-0; KLEINSCHMIDT JA, 1990, EMBO J, V9, P1309, DOI 10.1002/j.1460-2075.1990.tb08240.x; KLEINSCHMIDT JA, 1985, J BIOL CHEM, V260, P1166; KLEINSCHMIDT JA, 1991, EMBO J, V10, P3043, DOI 10.1002/j.1460-2075.1991.tb07855.x; KLEINSCHMIDT JA, 1983, J CELL BIOL, V97, P838, DOI 10.1083/jcb.97.3.838; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1978, NATURE, V275, P416, DOI 10.1038/275416a0; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; LOHKA MJ, 1983, EXP CELL RES, V148, P481, DOI 10.1016/0014-4827(83)90169-6; Longo F.J., 1978, Current Topics in Developmental Biology, V12, P149, DOI 10.1016/S0070-2153(08)60596-7; MANN M, 1982, J EXP ZOOL, V222, P173, DOI 10.1002/jez.1402220209; MILLS AD, 1980, J MOL BIOL, V139, P561, DOI 10.1016/0022-2836(80)90148-5; NOLL M, 1974, NATURE, V251, P249, DOI 10.1038/251249a0; OHSUMI K, 1991, DEV BIOL, V147, P110, DOI 10.1016/S0012-1606(05)80011-9; PHILPOTT A, 1991, CELL, V65, P569, DOI 10.1016/0092-8674(91)90089-H; POCCIA D, 1986, INT REV CYTOL, V105, P1, DOI 10.1016/S0074-7696(08)61061-X; POCCIA D, 1984, DEV BIOL, V104, P274, DOI 10.1016/0012-1606(84)90083-6; POCCIA D, 1981, DEV BIOL, V82, P287, DOI 10.1016/0012-1606(81)90452-8; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; RISLEY MS, 1981, DEV BIOL, V84, P79, DOI 10.1016/0012-1606(81)90372-9; SHEEHAN MA, 1988, J CELL BIOL, V106, P1, DOI 10.1083/jcb.106.1.1; SMITH RC, 1988, GENE DEV, V2, P1284, DOI 10.1101/gad.2.10.1284; STICK R, 1985, CELL, V41, P191, DOI 10.1016/0092-8674(85)90073-X; WEST MHP, 1980, BIOCHEMISTRY-US, V19, P3238, DOI 10.1021/bi00555a022; WOLFFE AP, 1989, NUCLEIC ACIDS RES, V17, P769; Zweidler A, 1978, Methods Cell Biol, V17, P223, DOI 10.1016/S0091-679X(08)61145-0	32	202	210	1	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 29	1992	69	5					759	767		10.1016/0092-8674(92)90288-N	http://dx.doi.org/10.1016/0092-8674(92)90288-N			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HW838	1591776				2022-12-01	WOS:A1992HW83800007
J	POSSELT, AM; BARKER, CF; FRIEDMAN, AL; NAJI, A				POSSELT, AM; BARKER, CF; FRIEDMAN, AL; NAJI, A			PREVENTION OF AUTOIMMUNE DIABETES IN THE BB RAT BY INTRATHYMIC ISLET TRANSPLANTATION AT BIRTH	SCIENCE			English	Article							LYMPHOCYTES-T; MONOCLONAL-ANTIBODIES; SELF-TOLERANCE; CELLS; EXPRESSION; RECEPTOR; SUBSETS	Spontaneous diabetes in the BioBreeding (BB) rat, like human type I diabetes, results from the destruction of pancreatic islets by autoreactive T lymphocytes recognizing beta-cell-specific antigens. T cell tolerance is in part mediated by interactions of maturing thymocytes with antigens expressed in the thymic microenvironment; islets were therefore implanted into the thymus of neonatal diabetes-prone BB rats to determine whether exposure of T cell precursors to beta-cell antigens could influence the development of diabetes. This treatment completely prevented diabetes and insulitis in the native pancreas. The effect may be the result of specific modulation of diabetogenic T cells maturing in an islet-bearing thymus.	HOSP UNIV PENN,DEPT SURG,4 SILVERSTEIN,3400 SPRUCE ST,PHILADELPHIA,PA 19104	University of Pennsylvania; Pennsylvania Medicine					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034878, R01DK026007, R37DK026007, R01DK034878] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK34878, DK26007] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APPEL MC, 1989, DIABETOLOGIA, V32, pA461; DEAN BM, 1985, DIABETOLOGIA, V28, P464, DOI 10.1007/BF00280892; GEORGIOU HM, 1988, J EXP MED, V167, P132, DOI 10.1084/jem.167.1.132; GOTFREDSEN CF, 1985, DIABETOLOGIA, V28, P933, DOI 10.1007/BF00703140; HUNIG T, 1989, J EXP MED, V169, P73, DOI 10.1084/jem.169.1.73; JAWORSKI MA, 1986, DIABETES RES CLIN EX, V3, P1; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; LIKE AA, 1986, DIABETES, V35, pA74; LIKE AA, 1986, J EXP MED, V164, P1145, DOI 10.1084/jem.164.4.1145; LIKE AA, 1979, SCIENCE, V206, P1421, DOI 10.1126/science.388619; MASON DW, 1983, IMMUNOL REV, V74, P57, DOI 10.1111/j.1600-065X.1983.tb01084.x; MCKEEVER U, 1990, P NATL ACAD SCI USA, V87, P7618, DOI 10.1073/pnas.87.19.7618; MORDES JP, 1987, DIABETES METAB REV, V3, P725, DOI 10.1002/dmr.5610030307; MORDES JP, 1987, DIABETOLOGIA, V30, P22, DOI 10.1007/BF01788902; MURASE N, 1990, DIABETES, V39, P1584, DOI 10.2337/diabetes.39.12.1584; NAJI A, 1983, J IMMUNOL, V130, P2168; NAJI A, 1981, SCIENCE, V213, P1390, DOI 10.1126/science.6791286; NAKHOODA AF, 1977, DIABETES, V26, P100, DOI 10.2337/diabetes.26.2.100; PARFREY NA, 1989, CRIT REV IMMUNOL, V9, P45; POSSELT AM, 1990, SCIENCE, V249, P1293, DOI 10.1126/science.2119056; POSSELT AM, 1991, ANN SURG, V214, P363, DOI 10.1097/00000658-199110000-00001; RAMSDELL F, 1989, SCIENCE, V246, P1038, DOI 10.1126/science.2511629; ROSSINI AA, 1984, J CLIN INVEST, V74, P36; SCHWARTZ RH, 1989, CELL, V57, P1073, DOI 10.1016/0092-8674(89)90044-5	24	133	136	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 29	1992	256	5061					1321	1324		10.1126/science.1598576	http://dx.doi.org/10.1126/science.1598576			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HW135	1598576				2022-12-01	WOS:A1992HW13500034
J	PRYCIAK, PM; VARMUS, HE				PRYCIAK, PM; VARMUS, HE			NUCLEOSOMES, DNA-BINDING PROTEINS, AND DNA-SEQUENCE MODULATE RETROVIRAL INTEGRATION TARGET SITE SELECTION	CELL			English	Article							I-HYPERSENSITIVE SITES; CHROMATIN STRUCTURE; PREFERRED TARGETS; CORE PARTICLE; INVITRO; REGIONS; MAP; PROMOTER; OPERATOR; COMPLEX	Integration of retroviral DNA can serve as a paradigm for cellular functions that are affected by the packaging of DNA into chromatin. We have used a novel polymerase chain reaction-based assay to survey DNA and chromatin for the precise distribution of many integration sites. Integration into naked DNA targets is non-uniform, implying a nucleotide sequence bias. In chromatin, integration occurs preferentially at positions where the major groove is on the exposed face of the nucleosomal DNA helix, generating a 10 bp periodic spacing of preferred sites. Chromatin assembly enhances the reactivity of many sites, so that integration occurs most frequently at sites in nucleosomal, rather than nucleosome-free, regions of minichromosomes. In contrast, integration is prevented in a region occupied by a site-specific DNA-binding protein. Comparisons of integration events mediated by viral nucleoprotein complexes or by two different retroviral integrases show that the integration machinery also affects target site selection.	UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	PRYCIAK, PM (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.		Pryciak, Peter/P-7205-2019	Pryciak, Peter/0000-0001-9142-1369				BOWERMAN B, 1989, GENE DEV, V3, P469, DOI 10.1101/gad.3.4.469; BROWN PO, 1989, P NATL ACAD SCI USA, V86, P2525, DOI 10.1073/pnas.86.8.2525; BROWN PO, 1987, CELL, V49, P347, DOI 10.1016/0092-8674(87)90287-X; BUSHMAN FD, 1990, SCIENCE, V249, P1555, DOI 10.1126/science.2171144; CRAIGIE R, 1990, CELL, V62, P829, DOI 10.1016/0092-8674(90)90126-Y; DREW HR, 1984, J MOL BIOL, V176, P535, DOI 10.1016/0022-2836(84)90176-1; DREW HR, 1985, J MOL BIOL, V186, P773, DOI 10.1016/0022-2836(85)90396-1; DREW HR, 1984, CELL, V37, P491, DOI 10.1016/0092-8674(84)90379-9; DREW HR, 1990, DNA TOPOLOGY ITS BIO, P1; ELLISON V, 1990, J VIROL, V64, P2711, DOI 10.1128/JVI.64.6.2711-2715.1990; FARNET CM, 1990, P NATL ACAD SCI USA, V87, P4164, DOI 10.1073/pnas.87.11.4164; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FUJIWARA T, 1988, CELL, V54, P497, DOI 10.1016/0092-8674(88)90071-2; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; HIRANO T, 1991, J CELL BIOL, V115, P1479, DOI 10.1083/jcb.115.6.1479; JOHNSON AD, 1985, CELL, V42, P237, DOI 10.1016/S0092-8674(85)80119-7; KATZ RA, 1990, CELL, V63, P87, DOI 10.1016/0092-8674(90)90290-U; KING W, 1985, SCIENCE, V228, P554, DOI 10.1126/science.3838595; KORNBERG RD, 1991, CELL, V67, P833, DOI 10.1016/0092-8674(91)90354-2; KORNBERG RD, 1977, ANNU REV BIOCHEM, V46, P931, DOI 10.1146/annurev.bi.46.070177.004435; LEAVITT AD, 1992, J VIROL, V66, P2359, DOI 10.1128/JVI.66.4.2359-2368.1992; LEE YMH, 1990, J VIROL, V64, P5958, DOI 10.1128/JVI.64.12.5958-5965.1990; MOOSLEHNER K, 1990, J VIROL, V64, P3056, DOI 10.1128/JVI.64.6.3056-3058.1990; PEDERSON DS, 1986, ANNU REV CELL BIOL, V2, P117, DOI 10.1146/annurev.cellbio.2.1.117; PERLMANN T, 1988, EMBO J, V7, P3073, DOI 10.1002/j.1460-2075.1988.tb03172.x; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; PRYCIAK PM, 1992, EMBO J, V11, P291, DOI 10.1002/j.1460-2075.1992.tb05052.x; ROHDEWOHLD H, 1987, J VIROL, V61, P336, DOI 10.1128/JVI.61.2.336-343.1987; SAUER RT, 1988, GENE DEV, V2, P807, DOI 10.1101/gad.2.7.807; SCHERDIN U, 1990, J VIROL, V64, P907, DOI 10.1128/JVI.64.2.907-912.1990; SHIH CC, 1988, CELL, V53, P531, DOI 10.1016/0092-8674(88)90569-7; SHIMIZU M, 1991, EMBO J, V10, P3033, DOI 10.1002/j.1460-2075.1991.tb07854.x; SIMPSON RT, 1983, P NATL ACAD SCI-BIOL, V80, P51, DOI 10.1073/pnas.80.1.51; SMITH DL, 1992, CELL, V68, P133, DOI 10.1016/0092-8674(92)90212-U; SUCK D, 1988, NATURE, V332, P464, DOI 10.1038/332464a0; SUCK D, 1984, EMBO J, V3, P2423, DOI 10.1002/j.1460-2075.1984.tb02149.x; TAYLOR ICA, 1991, GENE DEV, V5, P1285, DOI 10.1101/gad.5.7.1285; THOMA F, 1985, NATURE, V315, P250, DOI 10.1038/315250a0; THOMA F, 1984, J MOL BIOL, V177, P715, DOI 10.1016/0022-2836(84)90046-9; Travers A. A., 1990, DNA TOPOLOGY ITS BIO, P57; VARMUS H, 1989, MOBILE DNA, P53; VIJAYA S, 1986, J VIROL, V60, P683, DOI 10.1128/JVI.60.2.683-692.1986; WOLFFE A P, 1991, Current Biology, V1, P366, DOI 10.1016/0960-9822(91)90195-3	44	240	247	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 29	1992	69	5					769	780		10.1016/0092-8674(92)90289-O	http://dx.doi.org/10.1016/0092-8674(92)90289-O			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HW838	1317268				2022-12-01	WOS:A1992HW83800008
J	SANSOM, IJ; SMITH, MP; ARMSTRONG, HA; SMITH, MM				SANSOM, IJ; SMITH, MP; ARMSTRONG, HA; SMITH, MM			PRESENCE OF THE EARLIEST VERTEBRATE HARD TISSUES IN CONODONTS	SCIENCE			English	Article								From histological investigations into the microstructure of conodont elements, a number of tissue types characteristic of the phosphatic skeleton of vertebrates have been identified. These include cellular bone, two forms of hypermineralized enamel homologs, and globular calcified cartilage. The presence of cellular bone in conodont elements provides unequivocal evidence for their vertebrate affinities. Furthermore, the identification of vertebrate hard tissues in the oral elements of conodonts extends the earliest occurrence of vertebrate hard tissues back by around 40 million years, from the Middle Ordovician (475 million years ago) to the Late Cambrian (515 million years ago).	UNIV BIRMINGHAM,SCH EARTH SCI,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,DIV ANAT & CELL BIOL,LONDON SE1 9RT,ENGLAND	University of Birmingham; University of London; King's College London	SANSOM, IJ (corresponding author), UNIV DURHAM,DEPT GEOL SCI,SOUTH RD,DURHAM DH1 3LE,ENGLAND.		Sansom, Ivan/B-4078-2009	Smith, Paul/0000-0002-5141-1577				ALDRIDGE RJ, 1986, LETHAIA, V19, P279, DOI 10.1111/j.1502-3931.1986.tb00741.x; ANDRES D, 1988, Palaeontographica Abteilung A Palaeozoologie-Stratigraphie, V200, P105; Barnes C.R., 1973, Life Sci Contr R Ont Mus, VNo. 90, P1; BARSKOV IS, 1982, PALEONTOL J, P82; BENGTSON S, 1976, Lethaia, V9, P185, DOI 10.1111/j.1502-3931.1976.tb00966.x; BRIGGS DEG, 1987, LETHAIA, V20, P381, DOI 10.1111/j.1502-3931.1987.tb00799.x; BRIGGS DEG, 1983, LETHAIA, V16, P1, DOI 10.1111/j.1502-3931.1983.tb01139.x; Denison R H, 1963, Clin Orthop Relat Res, V31, P141; Dzik J., 1986, PROBLEMATIC FOSSIL T, P240; Fahraeus L.E., 1987, P105; Gross W., 1954, Senckenbergiana Lethaea, V35, P73; HALSTEAD LB, 1982, PROBLEMS PHYLOGENETI, P159; JANVIER P, 1981, Journal of Vertebrate Paleontology, V1, P121; JEPPSSON L, 1979, LETHAIA, V12, P153, DOI 10.1111/j.1502-3931.1979.tb00994.x; KREJSA RJ, 1990, LETHAIA, V23, P359, DOI 10.1111/j.1502-3931.1990.tb01369.x; Lindstrom M, 1964, CONODONTS; MULLER KJ, 1981, TREATISE INVERTE W S, V2, pW78; ORVIG T, 1989, ZOOL SCR, V18, P427, DOI 10.1111/j.1463-6409.1989.tb00138.x; ORVIG T, 1968, CURRENT PROBLEMS LOW, P374; Pander C. H., 1856, AKAD WISS, V10, P1; Pietzner H., 1968, Palaeontographica A, V128, P115; Schmidt H., 1964, Palaeontologische Zeitschrift, V38, P105; Smith M.M., 1989, Historical Biology, V3, P97; SMITH MM, 1990, BIOL REV, V65, P277, DOI 10.1111/j.1469-185X.1990.tb01427.x; SMITH MM, 1991, SCIENCE, V251, P301, DOI 10.1126/science.251.4991.301; STEWART GA, 1956, J PALEONTOL, V30, P261; Sweet, 1988, CONODONTA MORPHOLOGY; Szaniawski H., 1987, P35; TILLIER S, 1986, RECHERCHE, V17, P1574; TILLIER S, 1986, CR ACAD SCI II, V303, P627; 1968, ODONT REVY S13, V19, P1	31	135	145	0	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 29	1992	256	5061					1308	1311		10.1126/science.1598573	http://dx.doi.org/10.1126/science.1598573			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HW135	1598573				2022-12-01	WOS:A1992HW13500029
J	USHEVA, A; MALDONADO, E; GOLDRING, A; LU, H; HOUBAVI, C; REINBERG, D; ALONI, Y				USHEVA, A; MALDONADO, E; GOLDRING, A; LU, H; HOUBAVI, C; REINBERG, D; ALONI, Y			SPECIFIC INTERACTION BETWEEN THE NONPHOSPHORYLATED FORM OF RNA POLYMERASE-II AND THE TATA-BINDING PROTEIN	CELL			English	Article							MAJOR LATE PROMOTER; C-TERMINAL DOMAIN; LARGEST SUBUNIT; TRANSCRIPTION INITIATION; ACCURATE TRANSCRIPTION; INVITRO TRANSCRIPTION; COMPLEXES; INVIVO; GENE; ADENOVIRUS-2	Fractionation of a transcription-competent HeLa cell extract on a column containing one copy of the heptamer repeat (YSPTSPS) present in the carboxy-terminal domain (CTD) of the largest subunit of RNA polymerase II resulted in the loss of transcriptional activity. Fractionation of the extracts on columns containing mutations of the heptamer repeat was without effect. Such transcriptionally inactive extracts regained their ability to specifically transcribe different class II promoters upon the addition of human TFIID, recombinant yeast TATA-binding protein (TBP), or proteins bound to the column. Fractionation of RNA polymerase II on columns containing human or yeast TBP resulted in the specific retention of the nonphosphorylated form of RNA polymerase II. The phosphorylated form of the enzyme was unable to interact with TBP. The specific interaction of RNA polymerase II with TBP was mediated by the CTD of RNA polymerase II.	WEIZMANN INST SCI,DEPT MOLEC GENET & VIROL,IL-76100 REHOVOT,ISRAEL; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854	Weizmann Institute of Science; Rutgers State University New Brunswick; Rutgers State University Medical Center				Reinberg, Danny/0000-0003-4288-2016	NCI NIH HHS [CA 14995] Funding Source: Medline; NIGMS NIH HHS [GM 37120] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA014995] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM037120, R01GM037120] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHEARN JM, 1987, J BIOL CHEM, V265, P425; ALLISON LA, 1988, MOL CELL BIOL, V8, P321, DOI 10.1128/MCB.8.1.321; ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; BARTHOLOMEW B, 1986, J BIOL CHEM, V261, P14226; BARTOLOMEI MS, 1988, MOL CELL BIOL, V8, P330, DOI 10.1128/MCB.8.1.330; BIGGS J, 1985, CELL, V42, P611, DOI 10.1016/0092-8674(85)90118-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CARCAMO J, 1989, J BIOL CHEM, V264, P7704; CARCAMO J, 1991, P NATL ACAD SCI USA, V88, P8052, DOI 10.1073/pnas.88.18.8052; CARCAMO J, 1990, GENE DEV, V4, P1611, DOI 10.1101/gad.4.9.1611; CHO KWY, 1985, J BIOL CHEM, V260, P5204; CHRISTMANN JL, 1981, J BIOL CHEM, V256, P1798; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CORDEN JL, 1985, P NATL ACAD SCI USA, V82, P7934, DOI 10.1073/pnas.82.23.7934; CORTES P, 1992, MOL CELL BIOL, V12, P413, DOI 10.1128/MCB.12.1.413; DAHMUS ME, 1983, J BIOL CHEM, V258, P2303; DAVISON BL, 1983, NATURE, V301, P680, DOI 10.1038/301680a0; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; FIRE A, 1984, J BIOL CHEM, V259, P2509; FLORES O, 1992, J BIOL CHEM, V267, P2786; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KIM WY, 1986, J BIOL CHEM, V261, P14219; KIM WY, 1989, J BIOL CHEM, V264, P3169; KOLESKE A, 1992, IN PRESS CELL, V69; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MANLEY JL, 1983, METHOD ENZYMOL, V101, P568; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MOYLE M, 1989, MOL CELL BIOL, V9, P5750, DOI 10.1128/MCB.9.12.5750; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; REINBERG D, 1987, J BIOL CHEM, V262, P3322; Roeder R.G., 1976, RNA POLYMERASE, P285; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; SCHWARTZ LB, 1975, J BIOL CHEM, V250, P3221; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; THOMPSON NE, 1989, J BIOL CHEM, V264, P11511; TIMMERS HTM, 1991, GENE DEV, V5, P1946, DOI 10.1101/gad.5.11.1946; ZEHRING WA, 1988, P NATL ACAD SCI USA, V85, P3698, DOI 10.1073/pnas.85.11.3698	49	215	217	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 29	1992	69	5					871	881		10.1016/0092-8674(92)90297-P	http://dx.doi.org/10.1016/0092-8674(92)90297-P			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HW838	1591781				2022-12-01	WOS:A1992HW83800016
J	VYAS, P; VICKERS, MA; SIMMONS, DL; AYYUB, H; CRADDOCK, CF; HIGGS, DR				VYAS, P; VICKERS, MA; SIMMONS, DL; AYYUB, H; CRADDOCK, CF; HIGGS, DR			CIS-ACTING SEQUENCES REGULATING EXPRESSION OF THE HUMAN ALPHA-GLOBIN CLUSTER LIE WITHIN CONSTITUTIVELY OPEN CHROMATIN	CELL			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; LOCUS ACTIVATION REGION; CPG-RICH ISLANDS; CELL-SPECIFIC ENHANCER; I SENSITIVE DOMAIN; GENE-CLUSTER; TRANSGENIC MICE; HYPERSENSITIVE SITES; CHICKEN LYSOZYME; MESSENGER-RNAS	Current models suggest that tissue-specific genes are arranged in discrete, independently controlled segments of chromatin referred to as regulatory domains. Transition from a closed to open chromatin structure may be an important step in the regulation of gene expression. To determine whether the human alpha-globin cluster, like the beta-globin cluster, lies within a discrete, erythroid-specific domain, we have examined the long-range genomic organization and chromatin structure around this region. The alpha-genes lie adjacent to at least four widely expressed genes. The major alpha-globin regulatory element lies 40 kb away from the cluster within an intron of one of these genes. Therefore, unlike the beta-cluster, cis-acting sequences controlling alpha-gene expression are dispersed within a region of chromatin that is open in both erythroid and nonerythroid cells. This implies a difference in the hierarchical control of alpha- and beta-globin expression.	JOHN RADCLIFFE HOSP,IMPERIAL CANC RES FUND,INST MOLEC MED,OXFORD OX3 9DU,ENGLAND	University of Oxford	VYAS, P (corresponding author), JOHN RADCLIFFE HOSP,MRC,MOLEC HAEMATOL UNIT,OXFORD OX3 9DU,ENGLAND.		Vyas, Paresh/B-5708-2009	Vyas, Paresh/0000-0003-3931-0914	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; ALBITAR M, 1989, BLOOD, V74, P629; ALEVY MC, 1984, BIOCHEMISTRY-US, V23, P2309, DOI 10.1021/bi00305a034; BARSH GS, 1984, J BIOL CHEM, V259, P4906; BICKMORE WA, 1989, TRENDS GENET, V5, P144, DOI 10.1016/0168-9525(89)90055-3; BIRD AP, 1987, EMBO J, V6, P999, DOI 10.1002/j.1460-2075.1987.tb04851.x; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BODNAR JW, 1988, J THEOR BIOL, V132, P479, DOI 10.1016/S0022-5193(88)80086-9; BONIFER C, 1990, EMBO J, V9, P2843, DOI 10.1002/j.1460-2075.1990.tb07473.x; BOSSY B, 1984, EMBO J, V3, P2537, DOI 10.1002/j.1460-2075.1984.tb02169.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COHENSOLAL MM, 1982, DNA-J MOLEC CELL BIO, V1, P355, DOI 10.1089/dna.1982.1.355; COMINGS DE, 1978, ANNU REV GENET, V12, P25, DOI 10.1146/annurev.ge.12.120178.000325; DHAR V, 1989, MOL CELL BIOL, V9, P3524, DOI 10.1128/MCB.9.8.3524; ECCLES S, 1990, New Biologist, V2, P801; EISSENBERG JC, 1991, TRENDS GENET, V7, P335, DOI 10.1016/0168-9525(91)90424-O; Elgin SCR, 1990, CURR OPIN CELL BIOL, V2, P437, DOI 10.1016/0955-0674(90)90125-X; EPNER E, 1988, P NATL ACAD SCI USA, V85, P8081, DOI 10.1073/pnas.85.21.8081; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISCHELGHODSIAN N, 1987, NUCLEIC ACIDS RES, V15, P6197, DOI 10.1093/nar/15.15.6197; FISCHELGHODSIAN N, 1987, NUCLEIC ACIDS RES, V15, P9215, DOI 10.1093/nar/15.22.9215; FOGH J, 1975, HUMAN TUMOR CELLS IN, P115, DOI DOI 10.1007/978-1-4757-1647-4_5; FORRESTER WC, 1987, NUCLEIC ACIDS RES, V15, P10159, DOI 10.1093/nar/15.24.10159; FORRESTER WC, 1986, P NATL ACAD SCI USA, V83, P1359, DOI 10.1073/pnas.83.5.1359; FORRESTER WC, 1990, GENE DEV, V4, P1637, DOI 10.1101/gad.4.10.1637; FRAME MC, 1984, BRIT J CANCER, V49, P269, DOI 10.1038/bjc.1984.44; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GASSER SM, 1987, TRENDS GENET, V3, P16, DOI 10.1016/0168-9525(87)90156-9; GEY GO, 1952, CANCER RES, V12, P264; GOLDMAN MA, 1984, SCIENCE, V224, P686, DOI 10.1126/science.6719109; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GREAVES DR, 1989, CELL, V56, P979, DOI 10.1016/0092-8674(89)90631-4; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HAGMAN J, 1990, GENE DEV, V4, P978, DOI 10.1101/gad.4.6.978; HALL LMC, 1983, J MOL BIOL, V169, P83, DOI 10.1016/S0022-2836(83)80176-4; HANSCOMBE O, 1991, GENE DEV, V5, P1387, DOI 10.1101/gad.5.8.1387; HANSON IM, 1991, GENOMICS, V10, P417, DOI 10.1016/0888-7543(91)90327-B; HATTON CSR, 1990, BLOOD, V76, P221; HENIKOFF S, 1986, CELL, V44, P33, DOI 10.1016/0092-8674(86)90482-4; HIGGS DR, 1989, BLOOD, V73, P1081; HIGGS DR, 1990, GENE DEV, V4, P1588, DOI 10.1101/gad.4.9.1588; HOLMQUIST G, 1982, CELL, V31, P121, DOI 10.1016/0092-8674(82)90411-1; HOLMQUIST GP, 1987, AM J HUM GENET, V40, P151; HSU SL, 1988, NATURE, V331, P94, DOI 10.1038/331094a0; HUXLEY C, 1990, MOL CELL BIOL, V10, P605, DOI 10.1128/MCB.10.2.605; JACKSON DA, 1991, BIOESSAYS, V13, P1, DOI 10.1002/bies.950130102; JANTZEN K, 1986, NUCLEIC ACIDS RES, V14, P6085, DOI 10.1093/nar/14.15.6085; JARMAN AP, 1991, MOL CELL BIOL, V11, P4679, DOI 10.1128/MCB.11.9.4679; JARMAN AP, 1988, EMBO J, V7, P3337, DOI 10.1002/j.1460-2075.1988.tb03205.x; JARMAN AP, 1988, AM J HUM GENET, V43, P249; JARMAN AP, 1989, HEMOGLOBIN SWITCHI B, P33; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; KIOUSSIS D, 1983, NATURE, V306, P662, DOI 10.1038/306662a0; KLEIN E, 1967, LANCET, V2, P1068; LAUER J, 1980, CELL, V20, P119, DOI 10.1016/0092-8674(80)90240-8; LAWSON GM, 1982, J BIOL CHEM, V257, P1501; LAWSON GM, 1980, BIOCHEMISTRY-US, V19, P4403, DOI 10.1021/bi00560a004; LEIBOVITZ A, 1973, JNCI-J NATL CANCER I, V51, P691; LEUNG SO, 1989, NUCLEIC ACIDS RES, V17, P8283, DOI 10.1093/nar/17.20.8283; LEVINSON B, 1990, GENOMICS, V7, P1, DOI 10.1016/0888-7543(90)90512-S; LIEBHABER SA, 1990, P NATL ACAD SCI USA, V87, P9431, DOI 10.1073/pnas.87.23.9431; LINDSAY S, 1987, NATURE, V327, P336, DOI 10.1038/327336a0; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MCCORMICK D, 1983, BRIT J EXP PATHOL, V64, P103; MEYER KB, 1989, EMBO J, V8, P1959, DOI 10.1002/j.1460-2075.1989.tb03601.x; MIRKOVITCH J, 1986, J MOL BIOL, V190, P255, DOI 10.1016/0022-2836(86)90296-2; NICHOLLS RD, 1987, CELL, V49, P369, DOI 10.1016/0092-8674(87)90289-3; Old JM., 1983, METHODS HEMATOLOGY T, V6, P74; PESCHLE C, 1985, NATURE, V313, P235, DOI 10.1038/313235a0; PETTERSSON S, 1990, NATURE, V344, P165, DOI 10.1038/344165a0; ROMAO L, 1991, BLOOD, V78, P1589; Sambrook J., 1989, MOL CLONING LAB MANU; SARGENT CA, 1989, EMBO J, V8, P2305, DOI 10.1002/j.1460-2075.1989.tb08357.x; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SEED B, 1987, P NATL ACAD SCI USA, V84, P8573; SPIES T, 1989, P NATL ACAD SCI USA, V86, P8955, DOI 10.1073/pnas.86.22.8955; SPIES T, 1989, SCIENCE, V243, P214, DOI 10.1126/science.2911734; STIEF A, 1989, NATURE, V341, P343, DOI 10.1038/341343a0; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; THOMPSON S, 1984, J CELL SCI, V72, P37; TOWNES TM, 1990, TRENDS GENET, V6, P219, DOI 10.1016/0168-9525(90)90182-6; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; VANASSENDELFT GB, 1989, CELL, V56, P969, DOI 10.1016/0092-8674(89)90630-2; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WILKIE AOM, 1991, CELL, V64, P595, DOI 10.1016/0092-8674(91)90243-R; WILKIE AOM, 1990, NATURE, V346, P868, DOI 10.1038/346868a0; WILLIAMS T, 1986, NATURE, V322, P275, DOI 10.1038/322275a0; WILSON JT, 1980, J BIOL CHEM, V255, P2807; YAGI M, 1986, MOL CELL BIOL, V6, P1108, DOI 10.1128/MCB.6.4.1108	92	155	155	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 29	1992	69	5					781	793		10.1016/0092-8674(92)90290-S	http://dx.doi.org/10.1016/0092-8674(92)90290-S			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HW838	1591777				2022-12-01	WOS:A1992HW83800009
J	WEIGEL, D; ALVAREZ, J; SMYTH, DR; YANOFSKY, MF; MEYEROWITZ, EM				WEIGEL, D; ALVAREZ, J; SMYTH, DR; YANOFSKY, MF; MEYEROWITZ, EM			LEAFY CONTROLS FLORAL MERISTEM IDENTITY IN ARABIDOPSIS	CELL			English	Article							POLYMORPHISM LINKAGE MAP; FLOWER DEVELOPMENT; ANTIRRHINUM-MAJUS; TRANSCRIPTION FACTORS; GENETIC-CONTROL; THALIANA; AMPLIFICATION; MORPHOGENESIS; PRIMER; DNA	The first step in flower development is the generation of a floral meristem by the inflorescence meristem. We have analyzed how this process is affected by mutant alleles of the Arabidopsis gene LEAFY. We show that LEAFY interacts with another floral control gene, APETALA1, to promote the transition from inflorescence to floral meristem. We have cloned the LEAFY gene, and, consistent with the mutant phenotype, we find that LEAFY RNA is expressed strongly in young flower primordia. LEAFY expression precedes expression of the homeotic genes AGAMOUS and APETALA3, which specify organ identity within the flower. Furthermore, we demonstrate that LEAFY is the Arabidopsis homolog of the FLORICAULA gene, which controls floral meristem identity in the distantly related species Antirrhinum majus.	MONASH UNIV,DEPT GENET & DEV BIOL,CLAYTON,VIC 3168,AUSTRALIA	Monash University	WEIGEL, D (corresponding author), CALTECH,DIV BIOL 15629,PASADENA,CA 91125, USA.		Meyerowitz, Elliot M/A-7118-2009; Smyth, David R/K-5993-2012; Weigel, Detlef/C-1418-2008; Weigel, Detlef/GSJ-0799-2022; Weigel, Detlef/AAR-3312-2021	Smyth, David R/0000-0003-0455-9699; Weigel, Detlef/0000-0002-2114-7963; Weigel, Detlef/0000-0002-2114-7963; 				ALVAREZ J, 1992, PLANT J, V2, P103, DOI 10.1111/j.1365-313X.1992.00103.x; BATTEY NH, 1990, BOT REV, V56, P163; BOWMAN JL, 1991, DEVELOPMENT, V112, P1; BOWMAN JL, 1989, PLANT CELL, V1, P37, DOI 10.1105/tpc.1.1.37; BOWMAN JL, 1991, THESIS CALTECH PASAD; CARPENTER R, 1990, GENE DEV, V4, P1483, DOI 10.1101/gad.4.9.1483; CHANG C, 1988, P NATL ACAD SCI USA, V85, P6856, DOI 10.1073/pnas.85.18.6856; COEN ES, 1991, NATURE, V353, P31, DOI 10.1038/353031a0; COEN ES, 1990, CELL, V63, P1311, DOI 10.1016/0092-8674(90)90426-F; CRAWFORD NM, 1986, P NATL ACAD SCI USA, V83, P8073, DOI 10.1073/pnas.83.21.8073; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; FELDMANN KA, 1991, PLANT J, V1, P71, DOI 10.1111/j.1365-313X.1991.00071.x; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Gifford EM., 1988, MORPHOLOGY EVOLUTION; GRILL E, 1991, MOL GEN GENET, V226, P484, DOI 10.1007/BF00260662; HAUGHN GW, 1988, DEV GENET, V9, P73, DOI 10.1002/dvg.1020090202; HILL JP, 1989, CAN J BOT, V67, P2922, DOI 10.1139/b89-375; IRISH VF, 1990, PLANT CELL, V2, P741, DOI 10.1105/tpc.2.8.741; JACK T, 1992, CELL, V68, P683, DOI 10.1016/0092-8674(92)90144-2; KLEMM M., 1927, BOT ARCH, V20, P423; KOORNNEEF M, 1990, GENETIC MAPS; KUNST L, 1989, PLANT CELL, V1, P1195, DOI 10.1105/tpc.1.12.1195; Muller A., 1961, KULTURPFLANZE, V9, P364, DOI [10.1007/BF02095757, DOI 10.1007/BF02095757]; NAM HG, 1989, PLANT CELL, V1, P699, DOI 10.1105/tpc.1.7.699; OCHMAN H, 1990, PCR PROTOCOLS; POETHIG RS, 1988, GENETICS, V119, P959; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHULTZ EA, 1991, PLANT CELL, V3, P771, DOI 10.1105/tpc.3.8.771; SCHWARZSOMMER Z, 1992, EMBO J, V11, P251, DOI 10.1002/j.1460-2075.1992.tb05048.x; SCHWARZSOMMER Z, 1990, SCIENCE, V250, P931, DOI 10.1126/science.250.4983.931; SHANNON S, 1991, PLANT CELL, V3, P877, DOI 10.1105/tpc.3.9.877; SMYTH DR, 1990, PLANT CELL, V2, P755, DOI 10.1105/tpc.2.8.755; SOMMER H, 1990, EMBO J, V9, P605, DOI 10.1002/j.1460-2075.1990.tb08152.x; Stevens WL, 1939, J GENET, V39, P171, DOI 10.1007/BF02982823; WARD ER, 1990, PLANT MOL BIOL, V14, P561, DOI 10.1007/BF00027501; Weberling F., 1981, MORPHOLOGIE BLUTEN B; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0	38	1150	1307	0	137	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 29	1992	69	5					843	859		10.1016/0092-8674(92)90295-N	http://dx.doi.org/10.1016/0092-8674(92)90295-N			17	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HW838	1350515	Green Accepted, hybrid			2022-12-01	WOS:A1992HW83800014
J	YOUNG, MP; YAMANE, S				YOUNG, MP; YAMANE, S			SPARSE POPULATION CODING OF FACES IN THE INFEROTEMPORAL CORTEX	SCIENCE			English	Article							TEMPORAL CORTEX; NEURONS; MONKEY; PERCEPTION; RESPONSES; DIRECTION; IDENTITY; FEATURES	How does the brain represent objects in the world? A proportion of cells in the temporal cortex of monkeys responds specifically to objects, such as faces, but the type of coding used by these cells is not known. Population analysis of two sets of such cells showed that information is carried at the level of the population and that this information relates, in the anterior inferotemporal cortex, to the physical properties of face stimuli and, in the superior temporal polysensory area, to other aspects of the faces, such as their familiarity. There was often sufficient information in small populations of neurons to identify particular faces. These results suggest that representations of complex stimuli in the higher visual areas may take the form of a sparse population code.	INST PHYS & CHEM RES,FRONTIER RES PROGRAM,NEURAL INFORMAT PROC LAB,WAKO,SAITAMA 351,JAPAN; ELECTROTECH LAB,DIV NEUROSCI,TSUKUBA,IBARAKI 305,JAPAN	RIKEN; National Institute of Advanced Industrial Science & Technology (AIST)	YOUNG, MP (corresponding author), UNIV OXFORD,PHYSIOL LAB,PARKS RD,OXFORD OX1 3PT,ENGLAND.							Barlow H B, 1972, Perception, V1, P371, DOI 10.1068/p010371; BARLOW HB, 1985, Q J EXP PSYCHOL-A, V37, P121, DOI 10.1080/14640748508400927; BAYLIS GC, 1985, BRAIN RES, V342, P91, DOI 10.1016/0006-8993(85)91356-3; Dasser V., 1988, MACHIAVELLIAN INTELL, P85; Edgington E. S., 1980, RANDOMIZATION TESTS; FREE WJ, 1975, MASS ACTION NERVOUS; GEORGOPOULOS AP, 1989, SCIENCE, V243, P234, DOI 10.1126/science.2911737; GEORGOPOULOS AP, 1986, SCIENCE, V233, P1416, DOI 10.1126/science.3749885; GEORGOPOULOS AP, 1982, J NEUROSCI, V2, P1527; GEORGOPOULOS AP, 1984, DYNAMIC ASPECTS NEOC; Gower, 1971, MATH ARCHAEOLOGICAL, P138; HASSELMO ME, 1989, BEHAV BRAIN RES, V32, P203, DOI 10.1016/S0166-4328(89)80054-3; Konorski J, 1967, INTEGRATIVE ACTIVITY; LEHKY SR, 1990, J NEUROSCI, V10, P2281; PERRETT DI, 1984, HUM NEUROBIOL, V3, P197; PERRETT DI, 1987, TRENDS NEUROSCI, V10, P358, DOI 10.1016/0166-2236(87)90071-3; PERRETT DI, 1982, EXP BRAIN RES, V47, P329; RHODES G, 1988, PERCEPTION, V17, P43, DOI 10.1068/p170043; SCHONEMANN PH, 1970, PSYCHOMETRIKA, V35, P245, DOI 10.1007/BF02291266; SHEPARD RN, 1980, SCIENCE, V210, P390, DOI 10.1126/science.210.4468.390; YAMANE S, 1988, EXP BRAIN RES, V73, P209, DOI 10.1007/BF00279674; YOUNG MP, 1990, THESIS U ST ANDREWS	22	418	421	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 29	1992	256	5061					1327	1331		10.1126/science.1598577	http://dx.doi.org/10.1126/science.1598577			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HW135	1598577				2022-12-01	WOS:A1992HW13500036
J	ZHANG, JP; STEPHENS, RS				ZHANG, JP; STEPHENS, RS			MECHANISM OF C-TRACHOMATIS ATTACHMENT TO EUKARYOTIC HOST-CELLS	CELL			English	Article							CHLAMYDIA-TRACHOMATIS; HEPARAN-SULFATE; LEISHMANIA-DONOVANI; BINDING PROTEINS; MCCOY CELLS; PSITTACI; GLYCOSAMINOGLYCAN; BIOSYNTHESIS; SEQUENCE; HELA	A novel trimolecular mechanism of microbial attachment to mammalian host cells was characterized for the obligate intracellular pathogen Chlamydia trachomatis. Using purified glycosaminoglycans (GAGs) and specific GAG lyases, we demonstrated that a heparan sulfate-like GAG present on the surface of chlamydia organisms is required for attachment to host cells. These observations were supported by inhibition of attachment following binding of heparan sulfate receptor analogs to chlamydiae and by demonstrating that chlamydiae synthesize a unique heparan sulfate-like GAG. Furthermore, exogenous heparan sulfate, as an adhesin analog, restored attachment and infectivity to organisms that had lost these attributes following treatment with heparan sulfate lyase. These data suggest that a GAG adhesin ligand mediates attachment by bridging mutual GAG receptors on the host cell surface and on the chlamydial outer membrane surface.	UNIV CALIF SAN FRANCISCO,FRANCIS I PROCTOR FDN,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT LAB MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	ZHANG, JP (corresponding author), UNIV CALIF BERKELEY,DEPT BIOMED & ENVIRONM HLTH SCI,BERKELEY,CA 94720, USA.				NATIONAL EYE INSTITUTE [R01EY007757] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029432] Funding Source: NIH RePORTER; NEI NIH HHS [EY07757] Funding Source: Medline; NIAID NIH HHS [AI29432] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLEN J, 1988, J BACTERIOL, V171, P285; BARZU T, 1985, BIOCHIM BIOPHYS ACTA, V845, P196, DOI 10.1016/0167-4889(85)90177-6; BEACHEY EH, 1981, J INFECT DIS, V143, P325, DOI 10.1093/infdis/143.3.325; BECKER Y, 1969, ISRAEL J MED SCI, V5, P121; BILOZUR ME, 1990, J BIOL CHEM, V265, P19697; BUTCHER BA, 1990, EXP PARASITOL, V71, P49, DOI 10.1016/0014-4894(90)90007-Y; BYRNE GI, 1976, INFECT IMMUN, V14, P645, DOI 10.1128/IAI.14.3.645-651.1976; BYRNE GI, 1978, INFECT IMMUN, V19, P598, DOI 10.1128/IAI.19.2.598-606.1978; CARDIN AD, 1984, ANAL BIOCHEM, V137, P368, DOI 10.1016/0003-2697(84)90099-X; CERI H, 1986, INFECT IMMUN, V51, P1; DAWSON CR, 1985, REV INFECT DIS, V7, P768; EISSENBERG LG, 1983, INFECT IMMUN, V40, P741, DOI 10.1128/IAI.40.2.741-751.1983; ESKO JD, 1986, J BIOL CHEM, V261, P5725; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; FALKOW S, 1991, CELL, V65, P1099, DOI 10.1016/0092-8674(91)90003-H; GRAYSTON JT, 1986, NEW ENGL J MED, V315, P161, DOI 10.1056/NEJM198607173150305; HATCH TP, 1981, J GEN MICROBIOL, V125, P273; HODINKA RL, 1986, INFECT IMMUN, V54, P885; ISBERG RR, 1991, SCIENCE, V252, P934, DOI 10.1126/science.1674624; ISHIHARA M, 1986, J BIOL CHEM, V261, P3575; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JOHNSON AP, 1983, BRIT J VENER DIS, V59, P369; KIELIAN MC, 1982, J CELL BIOL, V93, P875, DOI 10.1083/jcb.93.3.875; KOEHLER JE, 1990, J BIOL CHEM, V265, P13206; KOHNKEGODT B, 1991, BIOCHEMISTRY-US, V30, P55, DOI 10.1021/bi00215a009; KUO CC, 1976, INFECT IMMUN, V13, P1103, DOI 10.1128/IAI.13.4.1103-1109.1976; KURE S, 1986, J IMMUNOL, V137, P3900; LINDAHL U, 1986, TRENDS BIOCHEM SCI, V11, P221, DOI 10.1016/0968-0004(86)90011-3; LINHARDT RJ, 1990, BIOCHEMISTRY-US, V29, P2611, DOI 10.1021/bi00462a026; MENOZZI FD, 1991, FEMS MICROBIOL LETT, V78, P59; METTENLEITER TC, 1990, J VIROL, V64, P278, DOI 10.1128/JVI.64.1.278-286.1990; MOULDER JW, 1988, MICROBIOLOGY CHLAMYD, P3; MUKHOPADHYAY NK, 1989, BIOCHEM J, V264, P517, DOI 10.1042/bj2640517; OFEK I, 1982, J BACTERIOL, V149, P426, DOI 10.1128/JB.149.2.426-433.1982; OKAZAKI K, 1991, VIROLOGY, V181, P666, DOI 10.1016/0042-6822(91)90900-V; ORTEGABARRIA E, 1991, CELL, V67, P411, DOI 10.1016/0092-8674(91)90192-2; PANGBURN MK, 1991, J BIOL CHEM, V266, P16847; PAUL G, 1987, J BIOL CHEM, V262, P9587; SCHACHTER J, 1988, MICROBIOLOGY CHLAMYD, P153; SODERLUND G, 1983, INFECT IMMUN, V40, P534; STEPHENS RS, 1986, J BACTERIOL, V168, P1277, DOI 10.1128/jb.168.3.1277-1282.1986; STEPHENS RS, 1982, J CLIN MICROBIOL, V16, P4, DOI 10.1128/JCM.16.1.4-7.1982; STEPHENS RS, 1989, INTRACELLULAR PARASI, P51; STORZ J, 1989, MICROBIOLOGY CHLAMYD, P167; TROY FA, 1979, ANNU REV MICROBIOL, V33, P519, DOI 10.1146/annurev.mi.33.100179.002511; TURNBULL JE, 1990, BIOCHEM J, V265, P715, DOI 10.1042/bj2650715; VANN WF, 1981, EUR J BIOCHEM, V116, P359, DOI 10.1111/j.1432-1033.1981.tb05343.x; VRETOU E, 1989, J GEN MICROBIOL, V135, P3229; WIELAND F, 1980, FEBS LETT, V120, P110, DOI 10.1016/0014-5793(80)81058-1; WINER MA, 1989, J REPROD FERTIL, V87, P337, DOI 10.1530/jrf.0.0870337; WUDUNN D, 1989, J VIROL, V63, P52, DOI 10.1128/JVI.63.1.52-58.1989; WYRICK PB, 1989, INFECT IMMUN, V57, P2378, DOI 10.1128/IAI.57.8.2378-2389.1989	52	206	211	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 29	1992	69	5					861	869		10.1016/0092-8674(92)90296-O	http://dx.doi.org/10.1016/0092-8674(92)90296-O			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HW838	1591780				2022-12-01	WOS:A1992HW83800015
J	BIRNBAUMER, M; SEIBOLD, A; GILBERT, S; ISHIDO, M; BARBERIS, C; ANTARAMIAN, A; BRABET, P; ROSENTHAL, W				BIRNBAUMER, M; SEIBOLD, A; GILBERT, S; ISHIDO, M; BARBERIS, C; ANTARAMIAN, A; BRABET, P; ROSENTHAL, W			MOLECULAR-CLONING OF THE RECEPTOR FOR HUMAN ANTIDIURETIC-HORMONE	NATURE			English	Article							EXPRESSION; DNA; PROTEIN; PROBES; GENE; CDNA	ANTIDIURESIS, the recovery of water from the lumen of the renal collecting tubule, is regulated by the hypothalamic release of antidiuretic hormone (ADH), which binds to specific receptors on renal collecting tubule cells, stimulates adenylyl cyclase and promotes the cyclic AMP-mediated incorporation of water pores into the luminal surface of these cells 1-3. We report here the isolation of the human ADH receptor gene using a genomic expression cloning approach 4. The gene was used to clone the complementary DNA from a human renal library. The deduced amino-acid sequence of the receptor yields a hydropathy profile characteristic of receptors with seven putative transmembrane regions. This and the comparison with other cloned receptors indicates that the ADH receptor is a member of the superfamily of G-protein-coupled receptors.			BIRNBAUMER, M (corresponding author), BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030, USA.		Brabet, Philippe/AAO-8522-2020	Brabet, Philippe/0000-0003-2739-1622				BIRNBAUMER L, 1974, J BIOL CHEM, V249, P7857; BIRNBAUMER M, 1990, MOL ENDOCRINOL, V4, P245, DOI 10.1210/mend-4-2-245; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRIELLE T, 1987, P NATL ACAD SCI USA, V84, P7920, DOI 10.1073/pnas.84.22.7920; GUDERMANN T, 1992, J BIOL CHEM, V267, P4479; HARRIS HW, 1990, AM J PHYSIOL, V258, P237; JARD S, 1983, CURR TOP MEMBR TRANS, V18, P255; JARD S, 1987, AM J PHYSIOL, V253, P41; KAISER K, 1985, DNA CLONING PRACTICA, V1, P1; KENNELLY PJ, 1991, J BIOL CHEM, V266, P1555; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAWRENCE CB, 1989, MOL BIOL INFORM RESO; LEVY FO, IN PRESS J BIOL CHEM; LIAO CF, 1989, J BIOL CHEM, V264, P7328; LICHTER P, 1990, P NATL ACAD SCI USA, V87, P6634, DOI 10.1073/pnas.87.17.6634; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MASU Y, 1987, NATURE, V329, P836, DOI 10.1038/329836a0; Michell R H, 1979, Biochem Soc Trans, V7, P861; ORLOFF J, 1967, AM J MED, V42, P757, DOI 10.1016/0002-9343(67)90093-9; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; WAHL GM, 1987, P NATL ACAD SCI USA, V84, P2160, DOI 10.1073/pnas.84.8.2160; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x	23	480	486	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 28	1992	357	6376					333	335		10.1038/357333a0	http://dx.doi.org/10.1038/357333a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HW132	1534149				2022-12-01	WOS:A1992HW13200049
J	GEIST, V				GEIST, V			ENDANGERED SPECIES AND THE LAW	NATURE			English	Editorial Material											GEIST, V (corresponding author), UNIV CALGARY,FAC ENVIRONM DESIGN,CALGARY T2N 1N4,ALBERTA,CANADA.							BARTOS L, 1981, ZOOL ANZ, V207, P260; BARTOS L, 1981, ZOOL ANZEIGER JENA, V208, P30; BARTOS L, 1981, ZOOL ANZEIGER JENA, V207, P217; GEIST V, 1991, CAN J ZOOL, V69, P706, DOI 10.1139/z91-103; GEIST V, 1991, ARCTIC, V44, P287; GITTLEMAN JL, 1991, NATURE, V351, P524, DOI 10.1038/351524a0; HALTENORTH T, 1963, HDB ZOOLOGIE, V1, P1; HARRINGTON S, 1982, I FOREST, V30, P64; HIRSCH J, 1976, SAG RAC REL ABSTR, V6, P1; LEHMAN N, 1991, EVOLUTION, V45, P104, DOI 10.1111/j.1558-5646.1991.tb05270.x; NADLER C F, 1973, Zeitschrift fuer Saeugetierkunde, V38, P109; OBRIEN SJ, 1991, SCIENCE, V251, P1187, DOI 10.1126/science.251.4998.1187; RENNIE J, 1991, SCI AM, V256, P18; SMITH MH, 1986, J MAMMAL, V67, P103, DOI 10.2307/1381006; SMITH MH, 1985, WHITE TAILED DEER, P119; WAYNE RK, 1991, NATURE, V351, P565, DOI 10.1038/351565a0	16	32	40	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 28	1992	357	6376					274	276		10.1038/357274a0	http://dx.doi.org/10.1038/357274a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HW132	1589032				2022-12-01	WOS:A1992HW13200018
J	GIMBLE, FS; THORNER, J				GIMBLE, FS; THORNER, J			HOMING OF A DNA ENDONUCLEASE GENE BY MEIOTIC GENE CONVERSION IN SACCHAROMYCES-CEREVISIAE	NATURE			English	Article							SITE-SPECIFIC ENDONUCLEASE; INTRON-ENCODED PROTEINS; DOUBLE-STRAND-BREAK; RIBOSOMAL-RNA GENE; ADENOSINE-TRIPHOSPHATASE; YEAST; SUBUNIT; RECOMBINATION; TRANSCRIPTION; PURIFICATION	An unusual protein splicing reaction joins the N-terminal segment (A) and the C-terminal segment (C) of the 119K primary translation product (ABC) of the yeast VMA1 gene to yield a 69K vacuolar H+-ATPase subunit (AC) and an internal 50K polypeptide (B). This 50K protein is a site-specific DNA endonuclease that shares 34% identity with the homothallic switching endonuclease. The site cleaved by the VMA1-derived endonuclease exists in a VMA1 allele that lacks the derived endonuclease segment of the open reading frame. Cleavage at this site only occurs during meiosis and initiates 'homing', a genetic event that converts a VMA1 allele lacking the endonuclease coding sequence into one that contains it.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, DIV BIOCHEM & MOLEC BIOL, ROOM 401, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley			THORNER, Jeremy/O-6132-2019; Wood, David W/B-2992-2012	THORNER, Jeremy/0000-0002-2583-500X; 				BALLESTER R, 1989, CELL, V59, P681, DOI 10.1016/0092-8674(89)90014-7; BELFORT M, 1990, ANNU REV GENET, V24, P363; BOWMAN EJ, 1988, J BIOL CHEM, V263, P13994; COLLEAUX L, 1988, P NATL ACAD SCI USA, V85, P6022, DOI 10.1073/pnas.85.16.6022; DELAHODDE A, 1989, CELL, V56, P431, DOI 10.1016/0092-8674(89)90246-8; DREYFUSS G, 1984, MOL CELL BIOL, V4, P415, DOI 10.1128/MCB.4.3.415; DUJON B, 1980, CELL, V20, P185, DOI 10.1016/0092-8674(80)90246-9; FOGEL S, 1981, MOL BIOL YEAST SACCH, P289; HENIGENS LAM, 1980, CELL, P185; HERSKOWITZ I, 1991, METHOD ENZYMOL, V194, P132; HIRATA R, 1990, J BIOL CHEM, V265, P6726; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HSU MT, 1978, BIOCHEMISTRY-US, V17, P131, DOI 10.1021/bi00594a019; JACQUIER A, 1985, CELL, V41, P383, DOI 10.1016/S0092-8674(85)80011-8; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; KASSIR Y, 1991, METHOD ENZYMOL, V194, P94; KAWASAKI K, 1991, J BIOL CHEM, V266, P5342; KLAR AJS, 1984, COLD SPRING HARB SYM, V49, P77, DOI 10.1101/SQB.1984.049.01.011; KOSTRIKEN R, 1984, COLD SPRING HARB SYM, V49, P89, DOI 10.1101/SQB.1984.049.01.012; KOSTRIKEN R, 1983, CELL, V35, P167, DOI 10.1016/0092-8674(83)90219-2; KRONSTAD JW, 1987, CELL, V50, P369, DOI 10.1016/0092-8674(87)90491-0; LEMIEUX B, 1988, MOL GEN GENET, V212, P48, DOI 10.1007/BF00322443; MICHEL F, 1982, BIOCHIMIE, V64, P867, DOI 10.1016/S0300-9084(82)80349-0; MURRAY JAH, 1986, EMBO J, V5, P3391, DOI 10.1002/j.1460-2075.1986.tb04655.x; MUSCARELLA DE, 1989, CELL, V56, P443, DOI 10.1016/0092-8674(89)90247-X; NAKAGAWA K, 1988, EUR J BIOCHEM, V171, P23, DOI 10.1111/j.1432-1033.1988.tb13753.x; NASMYTH K, 1983, NATURE, V302, P670, DOI 10.1038/302670a0; PAUSCH MH, 1991, EMBO J, V10, P1511, DOI 10.1002/j.1460-2075.1991.tb07671.x; PERLMAN PS, 1989, SCIENCE, V246, P1106, DOI 10.1126/science.2479980; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sambrook J., 1989, MOL CLONING LAB MANU; SARWAR G, 1985, J FOOD SCI, V50, P353, DOI 10.1111/j.1365-2621.1985.tb13400.x; SCHERER S, 1979, P NATL ACAD SCI USA, V76, P4951, DOI 10.1073/pnas.76.10.4951; Sherman F., 1986, METHODS YEAST GENETI; SHIBATA T, 1984, J BIOL CHEM, V259, P499; SHIH CK, 1988, MOL CELL BIOL, V8, P3094, DOI 10.1128/MCB.8.8.3094; SIKORSKI RS, 1989, GENETICS, V122, P19; SILICIANO PG, 1984, CELL, V37, P969, DOI 10.1016/0092-8674(84)90431-8; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; VANARSDELL SW, 1987, TRANSCRIPTIONAL CONT, P325; WARING RB, 1982, P NATL ACAD SCI-BIOL, V79, P6332, DOI 10.1073/pnas.79.20.6332; WATABE H, 1983, J BIOL CHEM, V258, P4663; WENZLAU JM, 1989, CELL, V56, P421, DOI 10.1016/0092-8674(89)90245-6; WERNETTE C, 1992, MOL CELL BIOL, V12, P716, DOI 10.1128/MCB.12.2.716; WERNETTE CM, 1990, J BIOL CHEM, V265, P18976; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x; ZINN AR, 1985, CELL, V40, P887, DOI 10.1016/0092-8674(85)90348-4	50	245	252	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 28	1992	357	6376					301	306		10.1038/357301a0	http://dx.doi.org/10.1038/357301a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HW132	1534148				2022-12-01	WOS:A1992HW13200037
J	KLEIJMEER, MJ; KELLY, A; GEUZE, HJ; SLOT, JW; TOWNSEND, A; TROWSDALE, J				KLEIJMEER, MJ; KELLY, A; GEUZE, HJ; SLOT, JW; TOWNSEND, A; TROWSDALE, J			LOCATION OF MHC-ENCODED TRANSPORTERS IN THE ENDOPLASMIC-RETICULUM AND CIS-GOLGI	NATURE			English	Article							CLASS-I MOLECULES; HLA-B ANTIGENS; MAJOR HISTOCOMPATIBILITY COMPLEX; T-CELLS; INFLUENZA NUCLEOPROTEIN; REGION; BIOSYNTHESIS; RECOGNITION; ASSOCIATION; PEPTIDES	IMMUNE recognition of intracellular proteins is mediated by major histocompatibility complex (MHC) class I molecules that present short peptides to cytotoxic T cells 1-4. Evidence suggests that peptides arise by cleavage of proteins in the cytoplasm and are transported by a signal-independent mechanism into a pre-Golgi region of the cell, where they take part in the assembly of class I heavy chains with beta-2-microglobulin (reviewed in refs 5-7). Analysis of cells that have defects in class I molecule assembly and antigen presentation 8-14 has shown that this phenotype can result from mutations in either of the two ABC transporter genes located in the class II region of the MHC 15-22. This suggested that the protein complex encoded by these two genes 20,22 transports peptides from the cytosol into the endoplasmic reticulum. Here we report additional evidence by showing that the transporter complex is located in the endoplasmic reticulum membrane and is probably oriented with its ATP-binding domains in the cytosol.	IMPERIAL CANC RES FUND,HUMAN IMMUNOGENET LAB,LONDON WC2A 3PX,ENGLAND; JOHN RADCLIFFE HOSP,INST MOLEC MED,OXFORD OX3 9DU,ENGLAND	Cancer Research UK; University of Oxford	KLEIJMEER, MJ (corresponding author), UNIV UTRECHT,SCH MED,DEPT CELL BIOL,UTRECHT,NETHERLANDS.			Townsend, Alain/0000-0002-3702-0107				ANDERSON K, 1991, J EXP MED, V174, P489, DOI 10.1084/jem.174.2.489; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BRACIALE TJ, 1991, IMMUNOL TODAY, V12, P124, DOI 10.1016/0167-5699(91)90096-C; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; DEMARS R, 1985, P NATL ACAD SCI USA, V82, P8183, DOI 10.1073/pnas.82.23.8183; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; DOBBERSTEIN B, 1992, NATURE, V355, P109, DOI 10.1038/355109a0; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; GLYNNE R, 1991, NATURE, V353, P357, DOI 10.1038/353357a0; HOSKEN NA, 1990, SCIENCE, V248, P367, DOI 10.1126/science.2326647; HSU VW, 1991, NATURE, V352, P441, DOI 10.1038/352441a0; KELLY A, 1991, NATURE, V353, P667, DOI 10.1038/353667a0; KELLY A, 1992, NATURE, V355, P641, DOI 10.1038/355641a0; LEVY F, 1991, CELL, V67, P265, DOI 10.1016/0092-8674(91)90178-2; LJUNGGREN HG, 1989, J IMMUNOL, V142, P2911; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; NUCHTERN JG, 1989, NATURE, V339, P223, DOI 10.1038/339223a0; OWEN MJ, 1980, J BIOL CHEM, V255, P9678; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; POWIS SH, 1992, P NATL ACAD SCI USA, V89, P1463, DOI 10.1073/pnas.89.4.1463; POWIS SJ, 1991, NATURE, V354, P528, DOI 10.1038/354528a0; SALTER RD, 1986, EMBO J, V5, P943, DOI 10.1002/j.1460-2075.1986.tb04307.x; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SCHWEIZER A, 1991, J CELL BIOL, V113, P45, DOI 10.1083/jcb.113.1.45; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; SLOT JW, 1988, METHOD MICROBIOL, V20, P211, DOI 10.1016/S0580-9517(08)70053-9; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1992, NATURE, V355, P644, DOI 10.1038/355644a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; TOWNSEND ARM, 1985, CELL, V42, P457, DOI 10.1016/0092-8674(85)90103-5; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; YEWDELL JW, 1990, CELL, V62, P203, DOI 10.1016/0092-8674(90)90356-J; YEWDELL JW, 1989, SCIENCE, V244, P1072, DOI 10.1126/science.2471266; Zinkernagel R M, 1979, Adv Immunol, V27, P51, DOI 10.1016/S0065-2776(08)60262-X	41	197	198	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 28	1992	357	6376					342	344		10.1038/357342a0	http://dx.doi.org/10.1038/357342a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HW132	1589036				2022-12-01	WOS:A1992HW13200052
J	LOLAIT, SJ; OCARROLL, AM; MCBRIDE, OW; KONIG, M; MOREL, A; BROWNSTEIN, MJ				LOLAIT, SJ; OCARROLL, AM; MCBRIDE, OW; KONIG, M; MOREL, A; BROWNSTEIN, MJ			CLONING AND CHARACTERIZATION OF A VASOPRESSIN V2 RECEPTOR AND POSSIBLE LINK TO NEPHROGENIC DIABETES-INSIPIDUS	NATURE			English	Article							ARGININE-VASOPRESSIN; MESSENGER-RNAS; BINDING-SITES; LOCALIZATION; DNA; AMPLIFICATION; ANTAGONISTS; EXPRESSION; PRIMER; POTENT	THE antidiuretic effect of arginine vasopressin (AVP) is mediated by renal-type (V2) receptors linked to adenylyl cyclase 1. We report here the cloning of the rat kidney V2 AVP receptor complementary DNA that encodes a 370-amino-acid protein with a transmembrane topography characteristic of G protein-coupled receptors, and with similarity to the V1a (hepatic) AVP receptor 2 in its seven membrane-spanning domains. Expression of the cloned cDNA in mammalian cells showed specific ligand binding and activity characteristic of the native V2 AVP receptor. The receptor messenger RNA is detected only in the kidney. The human V2 receptor gene has been localized to the long arm of the X chromosome close to the locus for nephrogenic diabetes insipidus, an X-linked recessive disorder characterized by renal resistance to the antidiuretic action of AVP 3-6.	NIMH,CELL BIOL LAB,BLDG 36,ROOM 3A-17,BETHESDA,MD 20892; GRP NEUROBIOCHIM CELLULAIRE & MOLEC,F-75006 PARIS,FRANCE; NCI,CHEM LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Lolait, Stephen/AAG-4483-2020; Brownstein, Michael/B-8609-2009; Morel, Alain/AAU-7496-2021	morel, alain/0000-0003-0125-1883				ANTONI FA, 1984, NEUROPEPTIDES, V4, P413, DOI 10.1016/0143-4179(84)90116-1; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; BICHET DG, 1989, KIDNEY INT, V36, P859, DOI 10.1038/ki.1989.272; BODE HH, 1969, NEW ENGL J MED, V280, P750, DOI 10.1056/NEJM196904032801404; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DORSA DM, 1983, PEPTIDES, V4, P699, DOI 10.1016/0196-9781(83)90021-9; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HOLMES MC, 1985, NEUROENDOCRINOLOGY, V117, P421; JANS DA, 1990, J BIOL CHEM, V265, P15379; JARD S, 1983, CURR TOP MEMBR TRANS, V18, P255; Jard S, 1987, PROG BRAIN RES <D>, V72, P173; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; KIRK CJ, 1977, FEBS LETT, V83, P267, DOI 10.1016/0014-5793(77)81020-X; KNOERS N, 1988, NEPHRON, V50, P187, DOI 10.1159/000185155; KNOERS N, 1988, HUM GENET, V80, P31, DOI 10.1007/BF00451451; KONIG M, 1991, Molecular and Cellular Neuroscience, V2, P331, DOI 10.1016/1044-7431(91)90063-T; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KRUSZYNSKI M, 1980, J MED CHEM, V23, P364, DOI 10.1021/jm00178a003; LIN HY, 1991, SCIENCE, V254, P1022, DOI 10.1126/science.1658940; MANNING M, 1984, J MED CHEM, V27, P423, DOI 10.1021/jm00370a002; MCBRIDE OW, 1982, NUCLEIC ACIDS RES, V10, P8155, DOI 10.1093/nar/10.24.8155; MOREL A, 1992, NATURE, V356, P523, DOI 10.1038/356523a0; OLSEN AS, 1981, MOL CELL BIOL, V1, P439, DOI 10.1128/MCB.1.5.439; PHILLIPS PA, 1990, ENDOCRINOLOGY, V126, P1478, DOI 10.1210/endo-126-3-1478; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; YAMADA Y, 1992, P NATL ACAD SCI USA, V89, P251, DOI 10.1073/pnas.89.1.251; YOUNG WS, 1986, P NATL ACAD SCI USA, V83, P9827, DOI 10.1073/pnas.83.24.9827; YOUNG WS, 1987, NEUROENDOCRINOLOGY, V46, P439	28	487	493	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 28	1992	357	6376					336	339		10.1038/357336a0	http://dx.doi.org/10.1038/357336a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HW132	1534150				2022-12-01	WOS:A1992HW13200050
J	PRUKSANANONDA, P; HALL, CB; INSEL, RA; MCINTYRE, K; PELLETT, PE; LONG, CE; SCHNABEL, KC; PINCUS, PH; STAMEY, FR; DAMBAUGH, TR; STEWART, JA				PRUKSANANONDA, P; HALL, CB; INSEL, RA; MCINTYRE, K; PELLETT, PE; LONG, CE; SCHNABEL, KC; PINCUS, PH; STAMEY, FR; DAMBAUGH, TR; STEWART, JA			PRIMARY HUMAN HERPESVIRUS-6 INFECTION IN YOUNG-CHILDREN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EXANTHEM-SUBITUM; ANTIBODY; PREVALENCE; DNA; IDENTIFICATION; AMPLIFICATION; SEQUENCES; INFANTS; HBLV; RASH	Background. Human herpesvirus 6 (HHV-6) is a recently discovered virus that, on the basis of serologic evidence, appears to infect most children by the age of three years. However, the clinical manifestations of primary HHV-6 infection have not been well defined. Methods. We studied consecutive children two years old or younger who presented to an emergency ward with febrile illnesses. Our evaluation included the isolation of HHV-6 from peripheral-blood mononuclear cells, an immunofluorescent-antibody assay, the detection of HHV-6 by the polymerase chain reaction (PCR), and restriction-endonuclease-fragment profiles of HHV-6 isolates. Results. HHV-6 was isolated from 34 of 243 acutely ill children (14 percent). The children with viremia had irritability, high temperatures (mean, 39.7-degrees-C), and inflammation of tympanic membranes (in 21), but few other localizing signs. Two children were hospitalized, but all 34 recovered after an average of four days of fever. The rash characteristic of roseola, which has been associated with HHV-6 infection, was noted in only three children. In 29 children (85 percent), serum samples obtained during convalescence had at least a fourfold increase in IgG antibody titers; 4 infants less than three months old who presumably had maternal antibody did not have this increase. HHV-6 was isolated from blood obtained during convalescence in only one child, but in two thirds of the children the virus could be detected by PCR. The isolates had genomic heterogeneity, indicating the presence of multiple strains. Conclusions. Primary infection with HHV-6 is a major cause of acute febrile illness in young children. Such infection is associated with varied clinical manifestations, viremia, and the frequent persistence of the viral genome in mononuclear cells.	UNIV ROCHESTER,SCH MED,DEPT PEDIAT,601 ELMWOOD AVE,BOX 689,ROCHESTER,NY 14642; CTR DIS CONTROL,NATL CTR INFECT DIS,DIV VIRAL & RICKETTSIAL DIS,ATLANTA,GA 30333; DUPONT MERCK PHARMACEUT,WILMINGTON,DE	University of Rochester; Centers for Disease Control & Prevention - USA				Pellett, Philip/0000-0002-8536-8343				ABLASHI DV, 1991, VIROLOGY, V184, P545, DOI 10.1016/0042-6822(91)90424-A; AGUT H, 1988, LANCET, V1, P712; ASANO Y, 1991, J PEDIATR-US, V118, P891, DOI 10.1016/S0022-3476(05)82200-0; ASANO Y, 1989, J PEDIATR-US, V114, P535, DOI 10.1016/S0022-3476(89)80689-4; ASANO Y, 1989, J PEDIATR-US, V115, P264, DOI 10.1016/S0022-3476(89)80078-2; AUBIN JT, 1991, J CLIN MICROBIOL, V29, P367, DOI 10.1128/JCM.29.2.367-372.1991; Breese Jr. BB., 1941, NEW YORK J MED, V41, P1854; BRIGGS M, 1988, LANCET, V1, P1058; BROWN NA, 1988, LANCET, V2, P396; DOWNING RG, 1987, LANCET, V2, P390; JARRETT RF, 1988, LEUKEMIA, V2, P496; KIKUTA H, 1989, J INFECT DIS, V160, P550, DOI 10.1093/infdis/160.3.550; KNOWLES WA, 1988, LANCET, V2, P912; KONDO K, 1990, J CLIN MICROBIOL, V28, P970, DOI 10.1128/JCM.28.5.970-974.1990; KRUEGER GRF, 1988, J VIROL METHODS, V21, P125, DOI 10.1016/0166-0934(88)90059-6; LINDQUESTER GJ, 1991, VIROLOGY, V182, P102, DOI 10.1016/0042-6822(91)90653-S; PELLETT PE, 1990, ADV EXP MED BIOL, V278, P9; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SALAHUDDIN SZ, 1986, SCIENCE, V234, P596, DOI 10.1126/science.2876520; SCHIRMER EC, 1991, P NATL ACAD SCI USA, V88, P5922, DOI 10.1073/pnas.88.13.5922; SUGA S, 1989, PEDIATRICS, V83, P1003; TAKAHASHI K, 1988, LANCET, V1, P1463; UEDA K, 1989, J INFECT DIS, V159, P750, DOI 10.1093/infdis/159.4.750; YAMANISHI K, 1988, LANCET, V1, P1065	24	213	218	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 28	1992	326	22					1445	1450		10.1056/NEJM199205283262201	http://dx.doi.org/10.1056/NEJM199205283262201			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV469	1315416				2022-12-01	WOS:A1992HV46900001
J	ROTHSTEIN, JD; MARTIN, LJ; KUNCL, RW				ROTHSTEIN, JD; MARTIN, LJ; KUNCL, RW			DECREASED GLUTAMATE TRANSPORT BY THE BRAIN AND SPINAL-CORD IN AMYOTROPHIC-LATERAL-SCLEROSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EXCITATORY AMINO-ACIDS; HUNTINGTONS-DISEASE; RAT STRIATUM; D-ASPARTATE; NEUROTOXICITY; INHIBITION; RECEPTORS; DEHYDROGENASE; SYNAPTOSOMES; QUISQUALATE	Background. Amyotrophic lateral sclerosis (ALS) is a chronic degenerative neurologic disorder characterized by the death of motor neurons in the cerebral cortex and spinal cord. Recent studies have suggested that the metabolism of glutamate, a potentially neurotoxic amino acid, is abnormal in patients with ALS. We hypothesized that the high-affinity glutamate transporter is the site of the defect. Methods. We measured high-affinity, sodium-dependent glutamate transport in synaptosomes from neural tissue obtained from 13 patients with ALS, 17 patients with no neurologic disease, and 27 patients with other neurodegenerative diseases (Alzheimer's disease in 15 patients and Huntington's disease in 12 patients). The groups were comparable with respect to age and the interval between death and autopsy. Synaptosomes were prepared from spinal cord, motor cortex, sensory cortex, visual cortex, striatum, and hippocampus. We also measured sodium-dependent transport of gamma-aminobutyric acid and phenylalanine in the synaptosomal preparations. Results. In patients with ALS, there was a marked decrease in the maximal velocity of transport for high-affinity glutamate uptake in synaptosomes from spinal cord (-59 percent, P < 0.001), motor cortex (-70 percent, P < 0.001), and somatosensory cortex (-39 percent, P < 0.05), but not in those from visual cortex, striatum, or hippocampus. The affinity of the transporter for glutamate was not altered. No abnormalities in glutamate transport were found in synaptosomes from patients with other chronic neurodegenerative disorders. The transport of gamma-aminobutyric acid and phenylalanine was normal in patients with ALS. Conclusions. ALS is associated with a defect in high-affinity glutamate transport that has disease, region, and chemical specificity. Defects in the clearance of extracellular glutamate because of a faulty transporter could lead to neurotoxic levels of extracellular glutamate and thus be pathogenic in ALS.	JOHNS HOPKINS UNIV,DEPT NEUROPATHOL,BALTIMORE,MD 21205	Johns Hopkins University	ROTHSTEIN, JD (corresponding author), JOHNS HOPKINS UNIV,DEPT NEUROL,MEYER 5-119,600 N WOLFE ST,BALTIMORE,MD 21205, USA.		rothstein, jeffrey d/C-9470-2013		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001355, R01NS030086] Funding Source: NIH RePORTER; NINDS NIH HHS [NS30086, NS01355] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALCAR VJ, 1977, J NEUROCHEM, V28, P1145, DOI 10.1111/j.1471-4159.1977.tb10682.x; BEBIN EM, 1990, ARCH NEUROL-CHICAGO, V47, P188, DOI 10.1001/archneur.1990.00530020094021; BENJAMIN AM, 1980, J NEUROCHEM, V35, P67, DOI 10.1111/j.1471-4159.1980.tb12490.x; CHASE RA, 1985, NEUROSCI LETT, V55, P89, DOI 10.1016/0304-3940(85)90317-9; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; DEBELLEROCHE J, 1984, NEUROCHEM PATHOL, V2, P1; ERECINSKA M, 1990, J NEUROCHEM, V54, P1335, DOI 10.1111/j.1471-4159.1990.tb01967.x; FLETCHER EJ, 1988, BRIT J PHARMACOL, V95, P585, DOI 10.1111/j.1476-5381.1988.tb11680.x; FONNUM F, 1984, J NEUROCHEM, V42, P1, DOI 10.1111/j.1471-4159.1984.tb09689.x; HARDY JA, 1986, J NEUROCHEM, V47, P460; Hughes J T, 1982, Adv Neurol, V36, P61; MANEV H, 1990, FASEB J, V4, P2789, DOI 10.1096/fasebj.4.10.2165013; MCBEAN GJ, 1985, J NEUROCHEM, V44, P247, DOI 10.1111/j.1471-4159.1985.tb07137.x; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; PERRY TL, 1990, NEUROLOGY, V40, P20, DOI 10.1212/WNL.40.1.20; PERRY TL, 1987, NEUROLOGY, V37, P1845, DOI 10.1212/WNL.37.12.1845; PLAITAKIS A, 1980, ANN NEUROL, V7, P297, DOI 10.1002/ana.410070403; PLAITAKIS A, 1988, LANCET, V1, P1015; PLAITAKIS A, 1988, ANN NEUROL, V24, P446, DOI 10.1002/ana.410240314; ROBINSON MB, 1991, BRAIN RES, V544, P196, DOI 10.1016/0006-8993(91)90054-Y; ROTHSTEIN JD, 1985, BIOCHEM PHARMACOL, V34, P73, DOI 10.1016/0006-2952(85)90102-9; ROTHSTEIN JD, 1991, ANN NEUROL, V30, P224, DOI 10.1002/ana.410300223; ROTHSTEIN JD, 1990, ANN NEUROL, V28, P18, DOI 10.1002/ana.410280106; SCHWARCZ R, 1982, NEUROSCIENCE, V7, P1771, DOI 10.1016/0306-4522(82)90034-3; SHAW PJ, 1991, BRAIN RES, V539, P164, DOI 10.1016/0006-8993(91)90701-V; SIMPSON MDC, 1988, BRAIN RES, V462, P76, DOI 10.1016/0006-8993(88)90587-2; SPINK DC, 1986, ANAL BIOCHEM, V158, P79, DOI 10.1016/0003-2697(86)90592-0; STEVENS TJ, 1983, IBRO HDB SERIES METH, V2, P171; TALLARIDA RJ, 1987, MANUAL PHARM CALCULA; TESTA D, 1989, J NEUROL, V236, P445, DOI 10.1007/BF00328503; TSAI GC, 1991, BRAIN RES, V556, P151, DOI 10.1016/0006-8993(91)90560-I; URCA G, 1990, BRAIN RES, V529, P7, DOI 10.1016/0006-8993(90)90805-L; VINCENT SR, 1980, BRAIN RES, V184, P99, DOI 10.1016/0006-8993(80)90589-2; WEISS JH, 1989, BRAIN RES, V497, P64, DOI 10.1016/0006-8993(89)90970-0; YOUNG AB, 1988, SCIENCE, V241, P981, DOI 10.1126/science.2841762; ZISKINDCONHAIM L, 1990, J NEUROSCI, V10, P125	38	1020	1039	0	25	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 28	1992	326	22					1464	1468		10.1056/NEJM199205283262204	http://dx.doi.org/10.1056/NEJM199205283262204			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV469	1349424	Bronze			2022-12-01	WOS:A1992HV46900004
J	ALDERMAN, MH				ALDERMAN, MH			WHICH ANTIHYPERTENSIVE DRUGS 1ST - AND WHY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HYPERTENSION				ALDERMAN, MH (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED, MONTEFIORE MED CTR, DEPT EPIDEMIOL & SOCIAL MED, BRONX, NY 10461 USA.							[Anonymous], 1970, JAMA, V213, P1143; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; DOLLERY CT, 1987, J HYPERTENS, V5, pS75; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; GOLDSTEIN G, 1990, HYPERTENSION, V15, P361, DOI 10.1161/01.HYP.15.4.361; HUNT D, 1992, LANCET, V339, P753; KAPLAN NM, 1991, AM J HYPERTENS, V4, P970, DOI 10.1093/ajh/4.12.970; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MANGANO DT, 1991, CIRCULATION, V84, P1879, DOI 10.1161/01.CIR.84.4.1879; PACKER M, 1991, NEW ENGL J MED, V325, P1468, DOI 10.1056/NEJM199111213252103; PEART S, 1985, British Medical Journal, V291, P97; POLLARE T, 1989, NEW ENGL J MED, V321, P868, DOI 10.1056/NEJM198909283211305; SCHULMAN SP, 1990, NEW ENGL J MED, V322, P1350, DOI 10.1056/NEJM199005103221904; SHEKELLE RB, 1984, ATHER REV, V12, P113; STASON WB, 1989, HYPERTENSION S, V13, P45; Wassertheilsmoller S, 1991, ANN INTERN MED, V114, P613, DOI 10.7326/0003-4819-114-8-613; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; 1971, CIRCULATION, V44, pA263; 1991, JAMA-J AM MED ASSOC, V266, P3255; 1990, NATIONAL DISEASE THE, V1; 1991, BIRTHS MARRIAGE DIVO, V39	22	37	37	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 27	1992	267	20					2786	2787		10.1001/jama.267.20.2786	http://dx.doi.org/10.1001/jama.267.20.2786			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV265	1349655				2022-12-01	WOS:A1992HV26500028
J	ANDERSON, DJ; OBRIEN, TR; POLITCH, JA; MARTINEZ, A; SEAGE, GR; PADIAN, N; HORSBURGH, CR; MAYER, KH				ANDERSON, DJ; OBRIEN, TR; POLITCH, JA; MARTINEZ, A; SEAGE, GR; PADIAN, N; HORSBURGH, CR; MAYER, KH			EFFECTS OF DISEASE STAGE AND ZIDOVUDINE THERAPY ON THE DETECTION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 IN SEMEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HIV INFECTION; RISK-FACTORS; TRANSMISSION; AIDS; QUANTITATION; ANTIBODY; CELLS; BLOOD; MEN	Objective.-To determine the prevalence and temporal expression of infectious human immunodeficiency virus type 1 (HIV-1) in the semen of HIV-1 seropositive men and to determine whether the detection of HIV-1 in semen is associated with disease stage, zidovudine treatment status, or other clinical factors. Design.-A microculture technique was used to detect infectious HIV-1 in semen from a cohort of 95 seropositive men. In addition, semen cultures were performed monthly for at least 6 months for 14 of the men. information was obtained by interview and extracted from medical records to identify clinical variables associated with HIV-1 in semen. Patients.-Sixty HIV-1 seropositive homosexual men participating in clinical studies at the Fenway Community Health Center, Boston, Mass, and 35 HIV seropositive bisexual or heterosexual men participating in the California Partner Study of the University of California, San Francisco. Main Outcome Measures.-Semen HIV-1 culture results, seminal leukocyte counts, Centers for Disease Control (CDC) disease stage, peripheral CD4+ cell counts, zidovudine therapy, HIV risk category. Results.-In the cross-sectional study, HIV-1 was cultured from the semen of nine (9%) of 95 men. Factors associated with detection of HIV-1 in semen were peripheral CD4+ cell counts of 0.20 X 10(9)/L (200/mu-L) or less (adjusted odds ratio [OR], 23.33; 95% confidence interval [CI], 2.89 to 175.63); symptomatic (CDC class IV) disease (adjusted OR, 6.56; 95% CI, 1.02 to 66.76); and seminal leukocytosis (> 1 x 10(9) white blood cells per liter of semen) (adjusted OR, 7.02; 95% CI, 1.28 to 39.29). Zidovudine therapy was associated with decreased detection of HIV-1 in semen (adjusted OR, 0.04; 95% Cl, 0.00 to 0.63). In the longitudinal study of 14 men who had neither peripheral CD4+ cells counts of 0.20 X 10(9)/L or less nor seminal leukocytosis, seminal HIV-1 was detected in at least one sample from six men (43%). Conclusion.-HIV-1 is more commonly found in semen from men with advanced HIV-1 infection and seminal leukocytosis but can also be cultured from semen of men with neither of these conditions. Zidovudine therapy may decrease the prevalence and/or titer of seminal HIV-1. However, all HIV-1-infected persons should continue to assume that they are potentially infectious through sexual contact.	CTR DIS CONTROL,CTR INFECT DIS,DIV HIV AIDS,ATLANTA,GA 30333; BOSTON DEPT HLTH & HOSP,INST URBAN HLTH RES,BOSTON,MA; BOSTON UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL & BIOSTAT,BOSTON,MA 02215; UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143; MEM HOSP,INFECT DIS BRANCH,PAWTUCKET,RI 02860; FENWAY COMMUNITY HLTH CTR,BOSTON,MA	Centers for Disease Control & Prevention - USA; Boston University; University of California System; University of California San Francisco	ANDERSON, DJ (corresponding author), HARVARD UNIV,SCH MED,DEPT OBSTET GYNECOL & REPROD BIOL,FEARING RES LAB,ROOM 204,BOSTON,MA 02115, USA.			Anderson, Deborah/0000-0002-2848-7290; Horsburgh, C./0000-0001-6838-7895; Politch, Joseph/0000-0002-7022-0135	NIAID NIH HHS [AI25305] Funding Source: Medline; PHS HHS [U62/CCU100607, CCR903266] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025305] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALEXANDER NJ, 1987, FERTIL STERIL, V47, P192; ANDERESON DJ, 1990, 6TH P C AIDS, V1, P263; ANDERSON DJ, 1990, HETEROSEXUAL TRANSMI, P167; ANDERSON RM, 1991, NATURE, V350, P356, DOI 10.1038/350356a0; [Anonymous], 1982, EPIDEMIOLOGIC RES; CASTRO BA, 1988, J CLIN MICROBIOL, V26, P2371, DOI 10.1128/JCM.26.11.2371-2376.1988; CLUMECK N, 1989, NEW ENGL J MED, V321, P1460, DOI 10.1056/NEJM198911233212107; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; DEVINCENZI I, 1989, 5TH INT C ACQ IMM SY, P115; GOEDERT JJ, 1987, AIDS RES HUM RETROV, V3, P355, DOI 10.1089/aid.1987.3.355; GUPTA P, 1989, J VIROL, V63, P2361, DOI 10.1128/JVI.63.5.2361-2365.1989; HENRY K, 1988, JAMA-J AM MED ASSOC, V259, P3023, DOI 10.1001/jama.259.20.3023; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HOLMBERG SD, 1989, J INFECT DIS, V160, P116, DOI 10.1093/infdis/160.1.116; KRIEGER JN, 1991, J INFECT DIS, V163, P386, DOI 10.1093/infdis/163.2.386; LEVY JA, 1988, JAMA-J AM MED ASSOC, V259, P3037, DOI 10.1001/jama.259.20.3037; MCCUSKER J, 1988, AM J PUBLIC HEALTH, V78, P68, DOI 10.2105/AJPH.78.1.68; MEHTA CR, 1985, J AM STAT ASSOC, V80, P969, DOI 10.2307/2288562; MERMIN JH, 1991, J INFECT DIS, V164, P769, DOI 10.1093/infdis/164.4.769; MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096; OSHEA S, 1990, J MED VIROL, V31, P291, DOI 10.1002/jmv.1890310409; OSMOND D, 1988, AM J PUBLIC HEALTH, V78, P944, DOI 10.2105/AJPH.78.8.944; PADIAN N, 1987, JAMA-J AM MED ASSOC, V258, P788, DOI 10.1001/jama.258.6.788; PUDNEY J, 1991, AM J PATHOL, V39, P149; SEAGE GR, 1989, AM J PUBLIC HEALTH, V79, P1638, DOI 10.2105/AJPH.79.12.1638; VANVOORHIS BJ, 1991, FERTIL STERIL, V55, P588; WOLFF H, 1992, J ACQ IMMUN DEF SYND, V5, P65; WOLFF H, 1988, FERTIL STERIL, V49, P497; ZAGURY D, 1984, SCIENCE, V226, P449, DOI 10.1126/science.6208607; 1987, WHO LABORATORY MANUA, P27; [No title captured]	31	183	185	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 27	1992	267	20					2769	2774		10.1001/jama.267.20.2769	http://dx.doi.org/10.1001/jama.267.20.2769			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV265	1349654				2022-12-01	WOS:A1992HV26500025
J	ONORATO, IM; WASSILAK, SG; MEADE, B				ONORATO, IM; WASSILAK, SG; MEADE, B			EFFICACY OF WHOLE-CELL PERTUSSIS-VACCINE IN PRESCHOOL-CHILDREN IN THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROTECTIVE EFFICACY; HOUSEHOLD EXPOSURE; DIPHTHERIA; ANTIBODY; DTP	Objective.-To evaluate the efficacy of currently used whole-cell pertussis vaccines. Design.-Active surveillance to detect pertussis cases in Baltimore, Md, Denver, Colo, and Milwaukee, Wis, and investigation of secondary attack rates in 347 household contacts, aged 1 through 4 years, to estimate vaccine efficacy. Outcome Measure.-Vaccine efficacy was estimated using different case definitions for pertussis. Results.-Vaccine efficacy was 64%, 81%, and 95% for case definitions of mild cough, paroxysmal cough, and severe clinical illness, respectively. Requiring laboratory confirmation increased efficacy to 95% to 98% for culture-positive children and to 77% to 95% for culture- or serology-confirmed cases, depending on disease severity. Vaccine efficacy for typical paroxysmal cough increased from 44% for one diphtheria, tetanus, and pertussis vaccine dose to 80% for four or more doses. Conclusions.-The trend toward increasing vaccine efficacy with different case definitions may be due to improved efficacy in preventing severe illness and to case definitions that are more specific for pertussis. Whole-cell pertussis vaccine was highly effective in preventing pertussis in preschool children exposed to infection within their households. Direct side-by-side efficacy studies of whole-cell vaccine and the recently licensed acellular vaccine will be necessary to assure that comparable protection is afforded by the new vaccines if they are to be used for immunization of infants.	US FDA,CTR BIOL EVALUAT & RES,BETHESDA,MD 20014	US Food & Drug Administration (FDA)	ONORATO, IM (corresponding author), CTR DIS CONTROL,NATL CTR PREVENT SERV,TECH INFORMAT SERV,DIV IMMUNIZAT,ATLANTA,GA 30333, USA.							[Anonymous], 1988, LANCET, Vi, P955; BEGG RC, 1984, NEW ZEAL MED J, V97, P408; BLACKWELDER WC, 1991, AM J DIS CHILD, V145, P1285, DOI 10.1001/archpedi.1991.02160110077024; BLENNOW M, 1988, BRIT MED J, V296, P1570, DOI 10.1136/bmj.296.6636.1570; BLUMBERG DA, 1990, J PEDIATR-US, V117, P46, DOI 10.1016/S0022-3476(05)82442-4; CODY CL, 1981, PEDIATRICS, V68, P650; COUTLER HL, 1985, SHOT DARK; FINE PEM, 1987, REV INFECT DIS, V9, P866; FINE PEM, 1988, INT J EPIDEMIOL, V17, P635, DOI 10.1093/ije/17.3.635; HINMAN AR, 1984, PUBLIC HEALTH REP, V99, P255; HOLLANDER HO, 1991, J INFECT DIS, V163, P1046; Howson CP, 1991, ADVERSE EFFECTS PERT; KULENKAMPFF M, 1974, ARCH DIS CHILD, V49, P46, DOI 10.1136/adc.49.1.46; LONG SS, 1990, J INFECT DIS, V161, P480, DOI 10.1093/infdis/161.3.480; Manclark CR, 1986, MANUAL CLIN LAB IMMU, V3rd, P388; MEADE BD, 1990, DHHS PUBLICATION, P322; MORTIMER EA, 1990, AM J DIS CHILD, V144, P899, DOI 10.1001/archpedi.1990.02150320063029; ONORATO IM, 1987, PEDIATR INFECT DIS J, V6, P145, DOI 10.1097/00006454-198702000-00002; REGAN J, 1977, J CLIN MICROBIOL, V6, P303; STORSAETER J, 1990, VACCINE, V8, P457, DOI 10.1016/0264-410X(90)90246-I; WENTZ KR, 1991, PEDIATRICS, V87, P287; 1992, MMWR, V41, P1; 1984, WEEKLY EPIDEMIOL REC, V59, P26; 1984, MMWR, V33, P573; 1991, MMWR, V40, P1; 1991, ANN NEUROL, V29, P458	26	79	83	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 27	1992	267	20					2745	2749		10.1001/jama.267.20.2745	http://dx.doi.org/10.1001/jama.267.20.2745			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV265	1578592				2022-12-01	WOS:A1992HV26500020
J	SODERSTROM, CA; DISCHINGER, PC; SMITH, GS; MCDUFF, DR; HEBEL, JR; GORELICK, DA				SODERSTROM, CA; DISCHINGER, PC; SMITH, GS; MCDUFF, DR; HEBEL, JR; GORELICK, DA			PSYCHOACTIVE SUBSTANCE DEPENDENCE AMONG TRAUMA CENTER PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ALCOHOL; RECOGNITION; PREVALENCE; ABUSE; SEVERITY	Introduction.-The practice of assessing only trauma patients with elevated blood alcohol concentrations (BACs) or positive drug screens for psychoactive substance use disorders (PSUDs) was evaluated. Methods.-Twenty-four BAC-negative (BAC-) (BAC, 0) and 21 BAC-positive (BAC+) (BAC, greater-than-or-equal-to 22 mmol/L or 100 mg/dL; mean, 41 mmol/L; range, 24.3 to 79 mmol/L) adult trauma patients were evaluated for alcoholism and other PSUDs using the Structured Clinical Interview (SCI) from the Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition (DSM-III-R). Approximately half were vehicular crash victims and 78% were men. Results.-A total of 64 PSUDs were diagnosed in 31 (68.9%) of the 45 patients; all but one was for dependence (vs abuse). Of the BAC+ patients, 14 (66.7%) met DSM-III-R criteria for alcohol dependence, 11 (78.6%) of whom also had other PSUDs not related to alcohol. Two other BAC+ patients had nonalcohol PSUDs. Of the BAC- patients, 11 (45.8%) had alcohol dependence, six (54.5%) of whom also had nonalcohol PSUDs. Another four BAC- patients had nonalcohol PSUDs. Overall, 76.2% of the BAC+ patients and 62.5% of the BAC- patients had a diagnosis of psychoactive substance dependence. Conclusion.-All patients admitted to trauma centers should be assessed for alcoholism and other PSUDs.	CHARLES MATHIAS NATL STUDY CTR TRAUMA & EMERGENCY, BALTIMORE, MD USA; JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, CTR INJURY PREVENT, BALTIMORE, MD 21218 USA; UNIV MARYLAND, SCH MED, DEPT PSYCHIAT, BALTIMORE, MD 21201 USA; UNIV MARYLAND, SCH MED, DEPT EPIDEMIOL & PREVENT MED, BALTIMORE, MD 21201 USA; NIDA, BETHESDA, MD USA	Johns Hopkins University; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA)	SODERSTROM, CA (corresponding author), MARYLAND INST EMERGENCY MED SERV SYST, R ADAMS COWLEY SHOCK TRAUMA CTR, DEPT SURG, 22 S GREENE ST, BALTIMORE, MD 21201 USA.		Gorelick, David/ABF-4941-2021	Smith, Gordon/0000-0002-2911-3071	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R29AA007700] Funding Source: NIH RePORTER; NIAAA NIH HHS [R29AA07700] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BUCHSBAUM DG, 1991, ANN INTERN MED, V115, P774, DOI 10.7326/0003-4819-115-10-774; CLARK DE, 1985, ANN EMERG MED, V14, P274, DOI 10.1016/S0196-0644(85)80456-X; CLEARY PD, 1988, AM J MED, V85, P466; COULEHAN JL, 1987, ARCH INTERN MED, V147, P349, DOI 10.1001/archinte.147.2.349; CYR MG, 1988, JAMA-J AM MED ASSOC, V259, P51, DOI 10.1001/jama.259.1.51; GENTILELLO LM, 1988, AM J SURG, V156, P558, DOI 10.1016/S0002-9610(88)80553-1; HOFFMANN N G, 1989, Advances in Alcohol and Substance Abuse, V8, P119; LINDENBAUM GA, 1989, J TRAUMA, V29, P1654, DOI 10.1097/00005373-198912000-00012; MACKENZIE EJ, 1989, J TRAUMA, V29, P757, DOI 10.1097/00005373-198906000-00011; MOORE RD, 1989, JAMA-J AM MED ASSOC, V261, P403, DOI 10.1001/jama.261.3.403; Ramzy A I, 1988, Md Med J, V37, P517; REDMOND AD, 1987, ALCOHOL ALCOHOLISM, V22, P341; REGIER DA, 1988, ARCH GEN PSYCHIAT, V45, P977; RIVARA FP, 1989, J TRAUMA, V29, P462, DOI 10.1097/00005373-198904000-00008; SHERIN KM, 1982, J FAM PRACTICE, V15, P1091; SILVERMAN JJ, 1985, J TRAUMA, V25, P544, DOI 10.1097/00005373-198506000-00014; SLOAN EP, 1989, J TRAUMA, V29, P1647, DOI 10.1097/00005373-198912000-00011; SMITH GS, 1988, ANNU REV PUBL HEALTH, V9, P99; SODERSTROM CA, 1987, ARCH SURG-CHICAGO, V122, P1067; SODERSTROM CA, 1988, ARCH SURG-CHICAGO, V123, P733; SOLOMON J, 1980, J STUD ALCOHOL, V41, P583, DOI 10.15288/jsa.1980.41.583; Spitzer R. L., 1987, STRUCTURED CLIN INTE; THAL ER, 1985, ARCH SURG-CHICAGO, V120, P708; WARD RE, 1982, AM J SURG, V144, P153, DOI 10.1016/0002-9610(82)90617-1; WEISBESKI D, 1989, J TRAUMA, V29, P940, DOI 10.1097/00005373-198907000-00006; YERSIN B, 1989, ARCH INTERN MED, V149, P2071, DOI 10.1001/archinte.149.9.2071; 1990, US DHHS901656 PUBL; 1987, DIAGNOSTIC STATISTIC; 1989, INJURY PREVENTION M; 1991, ALCOHOL ALERT, P1; [No title captured]; 1990, MMWR, V39, P173; 1986, JAMA-J AM MED ASSOC, V255, P522; 1991, HS807693 US DEP TRAN; 1988, MMWR, V37, P753; 1991, ALCOHOL ALERT, V12, P1; 1990, RESOURCES OPTIMAL CA; 1987, MMWR, V36, P437	38	103	105	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 27	1992	267	20					2756	2759		10.1001/jama.267.20.2756	http://dx.doi.org/10.1001/jama.267.20.2756			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV265	1578594				2022-12-01	WOS:A1992HV26500022
J	TIESZEN, ME; GRUENBERG, JC				TIESZEN, ME; GRUENBERG, JC			A QUANTITATIVE, QUALITATIVE, AND CRITICAL-ASSESSMENT OF SURGICAL WASTE - SURGEONS VENTURE THROUGH THE TRASH CAN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objectives.-To quantitatively and qualitatively evaluate the surgical waste produced from several common surgical procedures, define categories of waste that might be readily separated for alternative disposal practices or substitution, and determine the change in surgical waste output that elimination or alternative handling methods may effect. Design.-A case series evaluating the surgical waste from five types of surgical procedures including operations of the back, heart, abdomen, hip and knee, and herniorrhaphies, prospectively identified and allocated at the availability of the investigator. Setting.-A single tertiary community teaching hospital. Outcome Measures.-Weight, volume, and percentage of disposable linen, paper, and plastic plus miscellaneous material from surgical waste with a later subset separating plastics from miscellaneous items to completely identify all categories Results.-Surgical waste weighing 610.5 lb (274.7 kg) and occupying 171.6 cu ft (5.1 m3) from 27 cases was examined. Disposable linens accounted for 39% of the weight; paper, 7%; plastic, 26%; and miscellaneous waste, 27%. By volume, disposable linen and paper accounted for 69%; plastic, 23%; and miscellaneous waste, 7%. Disposable linen, paper, and recyclable plastic accounted for 73% +/- 7% (mean +/- SD) by weight and 93% +/- 4% by volume of total surgical waste. Conclusion.-Nationally, annual surgical waste from these five procedures weighs 5.1 X 10(7) lb (2.3 X 10(7) kg) and occupies 1.4 X 10(7) cu ft (4.0 X 10(5) m3). By using reusable linen products and engaging in recycling methods currently available and feasible, we estimate that weight reductions of 73% and volume reductions of 93% in surgical waste are possible.	SAGINAW COOPERAT HOSP INC, DEPT SURG, 1000 HOUGHTON, SAGINAW, MI 48602 USA									Burks J, 1988, Hosp Mater Manage Q, V9, P17; CHADZYNSKI L, 1990, MICH MED, V89, P17; DANCER JW, 1991, MICHIGAN HOSP, V27, P4; Dutlinger B, 1987, J Healthc Mater Manage, V5, P61; Fay M F, 1990, AORN J, V51, P1493, DOI 10.1016/S0001-2092(07)66899-9; GRAVES EJ, 1991, VITAL HLTH STAT 13, V107; GROSSMAN D, 1990, DISCOVER        0411, P36; KUNES E, 1988, OMNI             FEB, P40; KUNES E, 1988, OMNI             FEB, P92; MATHIAS JM, 1990, OR MANAGER, V6, P9; Patterson P, 1990, OR Manager, V6, P8; PATTERSON P, 1990, OR MANAGER, V6, P8; PATTERSON P, 1990, OR MANAGER, V6, P6; RATHJE WL, 1991, NATIONAL GEOGRAP MAY, P117; RUTALA WA, 1989, JAMA-J AM MED ASSOC, V262, P1635, DOI 10.1001/jama.262.12.1635; WAGNER M, 1990, MOD HEALTHCARE, V20, P46; 1985, HOSP PURCHASING NEWS, V9, P14; 1989, JAMA-J AM MED ASSOC, V262, P1669; 1987, MMWR S, V36, pS2; 1985, HOSP PURCHASING NEWS, V9, P26; 1988, INVESTIGATION SOURCE	21	46	47	2	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 27	1992	267	20					2765	2768		10.1001/jama.267.20.2765	http://dx.doi.org/10.1001/jama.267.20.2765			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV265	1578596				2022-12-01	WOS:A1992HV26500024
J	BRADA, M; FORD, D; ASHLEY, S; BLISS, JM; CROWLEY, S; MASON, M; RAJAN, B; TRAISH, D				BRADA, M; FORD, D; ASHLEY, S; BLISS, JM; CROWLEY, S; MASON, M; RAJAN, B; TRAISH, D			RISK OF 2ND BRAIN-TUMOR AFTER CONSERVATIVE SURGERY AND RADIOTHERAPY FOR PITUITARY-ADENOMA	BRITISH MEDICAL JOURNAL			English	Article							NERVOUS-SYSTEM; IRRADIATION; CANCER; CHILDHOOD; COMPLICATIONS	Objective-To assess the risk of second brain tumour in patients with pituitary adenoma treated with conservative surgery and external beam radiotherapy. Design-Long term follow up of a cohort of patients with pituitary adenoma and comparison of tumour occurrence with population incidence rates. Setting-The Royal Marsden Hospital. Subjects-334 patients with pituitary adenoma treated with conservative surgery and radiotherapy (median dose 45 Gy) and followed up for 3760 person years. Main outcome measures-Second intracranial tumour and systemic malignancy. Results-Five patients developed a second brain tumour: two had astrocytoma, two meningioma, and one meningeal sarcoma. The cumulative risk of developing a second brain tumour over the first 10 years after treatment was 1.3% (95% confidence interval 0.4% to 3.9%) and over 20 years 1.9% (0.7% to 5.0%). The relative risk of a second brain tumour compared with the incidence in the normal population was 9.38 (3.05 to 21.89). There was no excess risk of any other type of second primary malignancy. Conclusions-There is an increased risk of second intracranial tumour in patients with pituitary adenoma treated with surgery and radiotherapy. Although radiation is likely to be the most important factor contributing to the excess risk, further study is required in a cohort of similar patients not receiving radiation.	INST CANC RES,ACAD UNIT RADIOTHERAPY & ONCOL,SUTTON SM2 5PX,SURREY,ENGLAND; INST CANC RES,EPIDEMIOL SECT,SUTTON SM2 5PX,SURREY,ENGLAND; ROYAL MARSDEN HOSP,SUTTON SM2 5PT,SURREY,ENGLAND	University of London; Institute of Cancer Research - UK; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust	BRADA, M (corresponding author), INST CANC RES,NEUROONCOL UNIT,SUTTON SM2 5PX,SURREY,ENGLAND.			Bliss, Judith/0000-0001-7957-7424				Albo V, 1985, P AN M AM SOC CLIN, V4, P172; AMENDOLA BE, 1985, CANCER INVEST, V3, P507, DOI 10.3109/07357908509039812; ARISTIZABAL S, 1977, INT J RADIAT ONCOL, V2, P667, DOI 10.1016/0360-3016(77)90046-3; BERNSTEIN M, 1991, RAD INJURY NERVOUS, P480; BRESLOW NE, 1987, DESIGN ANAL COHORT S, V2, P69; COLEMAN MP, 1989, PERSON YEARS USER MA; DOWSETT RJ, 1990, INT J RADIAT ONCOL, V19, P453, DOI 10.1016/0360-3016(90)90557-Z; EBERSOLD MJ, 1986, J NEUROSURG, V64, P713, DOI 10.3171/jns.1986.64.5.0713; FARWELL J, 1984, NEW ENGL J MED, V311, P749, DOI 10.1056/NEJM198409203111201; FEEK CM, 1984, CLIN ENDOCRINOL, V20, P401, DOI 10.1111/j.1365-2265.1984.tb03435.x; FLICKINGER JC, 1989, CANCER, V63, P2409, DOI 10.1002/1097-0142(19890615)63:12<2409::AID-CNCR2820631206>3.0.CO;2-M; GRIGSBY PW, 1989, INT J RADIAT ONCOL, V16, P1411, DOI 10.1016/0360-3016(89)90942-5; HALBERG FE, 1987, ENDOCRIN METAB CLIN, V16, P667, DOI 10.1016/S0889-8529(18)30468-7; HARRIS JR, 1976, RADIOLOGY, V120, P167, DOI 10.1148/120.1.167; HAWKINS MM, 1987, BRIT J CANCER, V56, P339, DOI 10.1038/bjc.1987.200; KAPLAN EL, 1978, J AM STAT ASSOC, V54, P457; KINGSTON JE, 1987, BRIT J CANCER, V56, P331, DOI 10.1038/bjc.1987.199; KLIBANSKI A, 1991, NEW ENGL J MED, V324, P822; PARKER RG, 1990, INT J RADIAT ONCOL, V18, P993, DOI 10.1016/0360-3016(90)90432-J; RIMM IJ, 1987, CANCER, V59, P1506, DOI 10.1002/1097-0142(19870415)59:8<1506::AID-CNCR2820590819>3.0.CO;2-P; RON E, 1988, NEW ENGL J MED, V319, P1033, DOI 10.1056/NEJM198810203191601; ROSS DA, 1988, J NEUROSURG, V68, P854, DOI 10.3171/jns.1988.68.6.0854; SOFFER D, 1983, J NEUROSURG, V59, P1048, DOI 10.3171/jns.1983.59.6.1048; TUCKER MA, 1988, NEW ENGL J MED, V318, P76, DOI 10.1056/NEJM198801143180203	24	329	332	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 23	1992	304	6838					1343	1346		10.1136/bmj.304.6838.1343	http://dx.doi.org/10.1136/bmj.304.6838.1343			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW417	1611331	Bronze, Green Published			2022-12-01	WOS:A1992HW41700021
J	HALL, A; ANWAR, KS; TOMKINS, AM				HALL, A; ANWAR, KS; TOMKINS, AM			INTENSITY OF REINFECTION WITH ASCARIS-LUMBRICOIDES AND ITS IMPLICATIONS FOR PARASITE CONTROL	LANCET			English	Article							HELMINTH INFECTIONS; SCHISTOSOMA-MANSONI; PREDISPOSITION; HEALTH; HUMANS	Intestinal helminths are among the most common and widespread of human infections. Because it is typical to find that most worms are aggregated in a few potential hosts it has been suggested that some individuals are predisposed to heavy infections and that morbidity could be controlled by the treatment of heavily infected individuals only. We have studied the prevalence and intensity of reinfection with the intestinal nematode Ascaris lumbricoides among people living in Dhaka, Bangladesh. 880 people were treated with pyrantel pamoate three times at six month intervals, and on each occasion they collected all their stools for 48 h after treatment. Worms expelled by each subject were counted and weighed. The prevalence of infection at round 1 of treatment was 89% and the mean burden was 18.5 worms. Reinfection was rapid and at rounds 2 and 3 the prevalence was 82% and 80%, respectively, with mean burdens of 14.0 and 11.5 worms. The intensity of reinfection was not random more subjects than expected became heavily reinfected (greater-than-or-equal-to 15 worms) and more subjects than expected remained lightly infected (less-than-or-equal-to 14 worms) (p < 0.001). Worms were highly aggregated at each round of treatment but although just over 10% of all subjects were heavily infected at each and every round of treatment, over 60% of all subjects were heavily infected at least once. The findings show that some individuals seem to be susceptible to heavy infection whereas others are not, that deworming has a greater effect on the intensity of infection than on the prevalence, and that mass chemotherapy is likely to be a more effective means to control morbidity than is selective treatment of heavily infected individuals only.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, DEPT BIOL,PRINCE CONSORT RD, LONDON SW7 2BB, ENGLAND; INT CTR DIARRHOEL DIS RES, DHAKA 1000, BANGLADESH; INST PUBL HLTH, DHAKA 1212, BANGLADESH; INST CHILD HLTH, CTR INT CHILD HLTH, LONDON WC1N 1EH, ENGLAND	Imperial College London; International Centre for Diarrhoeal Disease Research (ICDDR); University of London; University College London				Anwar, Kazi Selim/0000-0002-6001-6616; Selim Anwar, Kazi/0000-0002-3437-4014				Anderson R.M., 1982, P204; ANDERSON R M, 1991; ANDERSON RM, 1985, PARASITOLOGY, V90, P629, DOI 10.1017/S0031182000052288; ANDERSON RM, 1982, NATURE, V297, P557, DOI 10.1038/297557a0; BENSTEDSMITH R, 1987, T ROY SOC TROP MED H, V81, P651, DOI 10.1016/0035-9203(87)90442-1; Gustafsson LL, 1987, HDB DRUGS TROPICAL P; HALL A, 1981, T ROY SOC TROP MED H, V75, P682, DOI 10.1016/0035-9203(81)90148-6; HASWELLELKINS MR, 1987, PARASITOLOGY, V95, P323, DOI 10.1017/S0031182000057772; James DM, 1985, HUMAN ANTIPARASITIC; KEYMER A, 1990, HOOKWORM DISEASE : CURRENT STATUS AND NEW DIRECTIONS, P177; Pawlowski Z. S., 1990, Tropical and Geographical Medicine., P369; SINNIAH B, 1981, ANN TROP MED PARASIT, V75, P315, DOI 10.1080/00034983.1981.11687445; THIENHLAING, 1985, ASCARIASIS ITS PUBLI, P83; TINGLEY GA, 1988, T ROY SOC TROP MED H, V82, P448, DOI 10.1016/0035-9203(88)90159-9; WAKELIN D, 1984, IMMUNITY PARASITES; WALSH JA, 1979, NEW ENGL J MED, V301, P967, DOI 10.1056/NEJM197911013011804; Warren K. S., 1990, Tropical and Geographical Medicine., P110; WARREN KS, 1991, LANCET, V338, P686, DOI 10.1016/0140-6736(91)91251-O; 1990, WHO MODEL PRESCRIBIN	19	68	72	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 23	1992	339	8804					1253	1257		10.1016/0140-6736(92)91593-W	http://dx.doi.org/10.1016/0140-6736(92)91593-W			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV191	1349668				2022-12-01	WOS:A1992HV19100003
J	JONES, KP; CHARLTON, IH; MIDDLETON, M; PREECE, WJ; HILL, AP				JONES, KP; CHARLTON, IH; MIDDLETON, M; PREECE, WJ; HILL, AP			TARGETING ASTHMA CARE IN GENERAL-PRACTICE USING A MORBIDITY INDEX	BRITISH MEDICAL JOURNAL			English	Article							PRESSURIZED AEROSOL INHALERS; MANAGEMENT; MORTALITY; PATIENT; TRENDS; RATES; AUDIT	Objectives-To evaluate a morbidity index as a postal surveillance tool in defining previously diagnosed asthmatic patients needing extra education or management; to determine the accuracy of a computerised asthma register in general practice. Design-Postal questionnaire survey of asthmatic patients identified from a computer register. Questionnaire comprised three morbidity questions, two questions about current asthma status, and one about treatments. Setting-Urban general practice of 8400 patients linked to academic unit. Subjects-853 asthmatic patients of all ages. Main outcome measures-Numbers of patients with low, medium, and high morbidity; associations of these groups with age, asthma status, and drugs taken. Results-Two mailings yielded 621 replies (73%); 28 patients (5%) had moved away, leaving 593 for analysis. Attempts were subsequently made to contact 20% sample of non-respondents. 234 respondents (40%) were in the "low morbidity" group, 149 (25%) in the "medium morbidity" group, and 210 (35%) in the "high morbidity" category. 53% of patients perceiving themselves as currently asthmatic (193/362) were in the high morbidity group, but 7% (11/153) who said they were no longer asthmatic and 8% (6/78) who did not believe they had ever been asthmatic were also in that group. High morbidity was also found in 10% (18/185) of those on no treatment, 38% (59/154) of those on bronchodilators alone, and 54% (119/220) of those on inhaled corticosteroids. 25 patients (4%) were wrongly identified as asthmatic; when combined with returns marked "gone away" this gave a disease register accuracy of 91%. Conclusions-This exercise identified subgroups of previously diagnosed asthmatic patients with high morbidity in general practice who might benefit from extra education and management and revealed some misclassification on the asthma disease register.			JONES, KP (corresponding author), UNIV SOUTHAMPTON,FAC MED,ALDERMOOR HLTH CTR,PRIMARY MED CARE GRP,SOUTHAMPTON SO1 6ST,ENGLAND.							ALLEN SC, 1986, BRIT J DIS CHEST, V80, P45, DOI 10.1016/0007-0971(86)90008-2; ANDERSON HR, 1990, THORAX, V45, P431, DOI 10.1136/thx.45.6.431; [Anonymous], 1990, BMJ, V301, P651; ASTHMA, 1992, ARCH DIS CHILD, V67, P240; BEASLEY R, 1989, THORAX, V44, P200, DOI 10.1136/thx.44.3.200; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BURNEY PGJ, 1986, LANCET, V2, P323; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; BURNEY PGJ, 1991, THORAX, V46, P574, DOI 10.1136/thx.46.8.574; CHARLTON I, 1991, BRIT J GEN PRACT, V41, P227; CHARLTON I, 1990, BRIT MED J, V301, P1355, DOI 10.1136/bmj.301.6765.1355; CHARLTON I, 1991, BRIT J GEN PRACT, V41, P256; CROMPTON GK, 1982, EUR J RESPIR DIS, V63, P101; EVANS R, 1987, CHEST S, V91, P65; HILTON S, 1990, BRIT J GEN PRACT, V40, P505; HILTON S, 1986, LANCET, V1, P26; HORN CR, 1990, RESP MED, V84, P67, DOI 10.1016/S0954-6111(08)80097-2; HORN CR, 1989, RESP MED, V83, P71, DOI 10.1016/S0954-6111(89)80063-0; HORSLEY MG, 1988, J CLIN PHARM THER, V13, P139, DOI 10.1111/j.1365-2710.1988.tb00170.x; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; JOHNSON N, 1991, BRIT MED J, V302, P763, DOI 10.1136/bmj.302.6779.763; JONES K, 1991, BRIT J GEN PRACT, V41, P224; JONES K, 1989, J ROY COLL GEN PRACT, V39, P254; JONES KP, 1992, BRIT MED J, V304, P361, DOI 10.1136/bmj.304.6823.361; JONES KP, 1991, THORAX, V46; MAO Y, 1987, CAN MED ASSOC J, V137, P620; MITCHELL EA, 1985, ARCH DIS CHILD, V60, P376, DOI 10.1136/adc.60.4.376; SLY RM, 1988, J ALLERGY CLIN IMMUN, V82, P705, DOI 10.1016/0091-6749(88)90069-3; STANLEY PH, 1991, BRIT MED J, V303, P971, DOI 10.1136/bmj.303.6808.971; TURNERWARWICK M, 1989, J ROY COLL GEN PRACT, V39, P239; WARNER JO, 1989, ARCH DIS CHILD, V64, P1065, DOI 10.1136/adc.64.7.1065; WHITE PT, 1989, J ROY COLL GEN PRACT, V39, P182; 1989, LANCET, V2, P199; 1990, BMJ, V301, P797	34	24	24	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 23	1992	304	6838					1353	1356		10.1136/bmj.304.6838.1353	http://dx.doi.org/10.1136/bmj.304.6838.1353			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW417	1611335	Green Published, Bronze			2022-12-01	WOS:A1992HW41700026
J	LARON, Z; ANIN, S; KLIPPERAURBACH, Y; KLINGER, B				LARON, Z; ANIN, S; KLIPPERAURBACH, Y; KLINGER, B			EFFECTS OF INSULIN-LIKE GROWTH-FACTOR ON LINEAR GROWTH, HEAD CIRCUMFERENCE, AND BODY-FAT IN PATIENTS WITH LARON-TYPE DWARFISM	LANCET			English	Article							HORMONE-RECEPTOR GENE; FACTOR-I; BINDING-PROTEIN; IGF-I; DEFICIENCY; THERAPY	Patients with Laron-type dwarfism are clinically indistinguishable from those with isolated growth hormone (GH) deficiency, yet have high circulating GH concentrations associated with an inability to generate endogenous insulin-like growth factor I (IGF-I). Biosynthetic IGF-I was administered subcutaneously once daily for 3 to 10 months to 5 children with Laron-type dwarfism aged 3.3 to 14.5 years. There was a rapid stimulation of linear growth in body limbs, with a striking increase in head circumference, increased body weight, and a reduction in subcutaneous fat. Administration of IGF-I to patients with Laron-type dwarfism seems to have a beneficial effect on growth similar to that observed with long-term administration of GH in children with GH deficiency.			LARON, Z (corresponding author), TEL AVIV UNIV,SACKLER FAC MED,CHILDRENS MED CTR,INST PAEDIAT & ADOLESCENT ENDOCRINOL,IL-49100 PETAH TIQWA,ISRAEL.							ACETO T, 1972, J CLIN ENDOCR METAB, V35, P483, DOI 10.1210/jcem-35-4-483; AMSELEM S, 1989, NEW ENGL J MED, V321, P989, DOI 10.1056/NEJM198910123211501; BAUMANN G, 1987, J CLIN ENDOCR METAB, V65, P814, DOI 10.1210/jcem-65-4-814; ESHET R, 1984, ISRAEL J MED SCI, V20, P8; GODOWSKI PJ, 1989, P NATL ACAD SCI USA, V86, P8083, DOI 10.1073/pnas.86.20.8083; HEDING LG, 1972, DIABETOLOGIA, V8, P260, DOI 10.1007/BF01225569; JORGENSEN JOL, 1989, LANCET, V1, P1221; JOSEFSBERG Z, 1987, HORM RES, V27, P126, DOI 10.1159/000180800; LARON Z, 1990, ACTA ENDOCRINOL-COP, V123, P378, DOI 10.1530/acta.0.1230378; LARON Z, 1991, CLIN ENDOCRINOL, V35, P145, DOI 10.1111/j.1365-2265.1991.tb03513.x; LARON Z, 1988, LANCET, V2, P1170; LARON Z, 1966, ISRAEL J MED SCI, V2, P152; LARON Z, 1968, HELV PAEDIATR ACTA, V23, P37; LARON Z, 1979, CLIN ENDOCRINOL, V10, P393, DOI 10.1111/j.1365-2265.1979.tb02094.x; LARON Z, 1971, J CLIN ENDOCR METAB, V33, P332, DOI 10.1210/jcem-33-2-332; LARON Z, 1989, ACTA ENDOCRINOL-COP, V121, P603, DOI 10.1530/acta.0.1210603; LARON Z, 1974, HORM METAB RES S, V5, P162; LARON Z, 1972, GROWTH GROWTH HORMON, P458; Laron Z, 1984, ADV INTERNAL MED PED, P117; MEACHAM LR, 1990, 72ND P ANN M AM END, P373; NELLHAUS G, 1968, PEDIATRICS, V41, P106; NIWA M, 1986, ANN NY ACAD SCI, V469, P31, DOI 10.1111/j.1749-6632.1986.tb26482.x; TAKANO K, 1990, ENDOCRINOL JAPON, V37, P309; TANNER JM, 1966, ARCH DIS CHILD, V41, P454, DOI 10.1136/adc.41.219.454	24	172	173	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 23	1992	339	8804					1258	1261		10.1016/0140-6736(92)91594-X	http://dx.doi.org/10.1016/0140-6736(92)91594-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV191	1349669				2022-12-01	WOS:A1992HV19100004
J	LESOUEF, PN				LESOUEF, PN			VALIDITY OF METHODS USED TO TEST AIRWAY RESPONSIVENESS IN CHILDREN	LANCET			English	Editorial Material							BRONCHIAL HYPERRESPONSIVENESS; AUSTRALIAN SCHOOLCHILDREN; INHALATION CHALLENGE; RESPIRATORY SYMPTOMS; INHALED HISTAMINE; NORMAL INFANTS; METHACHOLINE; REACTIVITY; STANDARDIZATION; PREVALENCE	Methods to test airway responsiveness to inhaled agonists in children were originally developed for use in adults, and agonist dosage regimens do not adequately correct for the size of the child. Because small children receive a higher dose relative to their body size than do large children, the age-related decline in airway responsiveness reported in many recent studies might reflect failure to adequately size-correct test dosages rather than a genuine physiological event. Until the administered doses of inhaled agonists can be satisfactorily size-corrected, tests of airway responsiveness in children should be regarded as qualitative rather than quantitative.			LESOUEF, PN (corresponding author), PRINCESS MARGARET HOSP,DEPT RESP MED,GPO BOX D184,PERTH,WA 6001,AUSTRALIA.		Le Souef, Peter N/H-5256-2014	Le Souef, Peter/0000-0003-0930-1654				AVITAL A, 1991, AM REV RESPIR DIS, V144, P36, DOI 10.1164/ajrccm/144.1.36; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHUA H L, 1991, American Review of Respiratory Disease, V143, pA706; CLIFFORD RD, 1989, ARCH DIS CHILD, V64, P1126, DOI 10.1136/adc.64.8.1126; CLOUGH JB, 1991, AM REV RESPIR DIS, V143, P755, DOI 10.1164/ajrccm/143.4_Pt_1.755; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COLLIS GG, 1990, LANCET, V336, P341, DOI 10.1016/0140-6736(90)91880-J; DUNNILL M. S., 1962, THORAX, V17, P329, DOI 10.1136/thx.17.4.329; GERRITSEN J, 1989, AM REV RESPIR DIS, V140, P1325, DOI 10.1164/ajrccm/140.5.1325; GODFREY S, 1979, CLIN PAEDIATRIC PHYS; HOPP RJ, 1986, AM REV RESPIR DIS, V134, P994, DOI 10.1164/arrd.1986.134.5.994; HOPP RJ, 1985, J ALLERGY CLIN IMMUN, V76, P609, DOI 10.1016/0091-6749(85)90783-3; LESOUEF PN, 1989, AM REV RESPIR DIS, V139, P62, DOI 10.1164/ajrccm/139.1.62; MONTGOMERY GL, 1990, AM REV RESPIR DIS, V142, P1372, DOI 10.1164/ajrccm/142.6_Pt_1.1372; PEAT JK, 1991, AM REV RESPIR DIS, V144, P663, DOI 10.1164/ajrccm/144.3_Pt_1.663; PEAT JK, 1989, CLIN EXP ALLERGY, V19, P299, DOI 10.1111/j.1365-2222.1989.tb02387.x; RUFFIN RE, 1978, AM REV RESPIR DIS, V117, P485; RYAN G, 1981, J ALLERGY CLIN IMMUN, V67, P156, DOI 10.1016/0091-6749(81)90012-9; SALOME CM, 1987, CLIN ALLERGY, V17, P271, DOI 10.1111/j.1365-2222.1987.tb02015.x; SEARS MR, 1986, THORAX, V41, P283, DOI 10.1136/thx.41.4.283; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; STICK SM, 1991, AM REV RESPIR DIS, V144, P1012, DOI 10.1164/ajrccm/144.5.1012; STICK SM, 1990, AM REV RESPIR DIS, V142, P1143, DOI 10.1164/ajrccm/142.5.1143; TANNER JM, 1976, ARCH DIS CHILD, V51, P170, DOI 10.1136/adc.51.3.170; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760; YOUNG S, 1991, NEW ENGL J MED, V324, P1168, DOI 10.1056/NEJM199104253241704; YOUNG S, 1991, American Review of Respiratory Disease, V143, pA23	27	53	53	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 23	1992	339	8804					1282	1284		10.1016/0140-6736(92)91602-5	http://dx.doi.org/10.1016/0140-6736(92)91602-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV191	1349677				2022-12-01	WOS:A1992HV19100012
J	MCCULLOCH, P				MCCULLOCH, P			GASTRIC-CANCER	BRITISH MEDICAL JOURNAL			English	Article											MCCULLOCH, P (corresponding author), NATL CANC CTR,5-1-1 TSUKIJI,CHUO KU,TOKYO 104,JAPAN.			McCulloch, Peter/0000-0002-3210-8273					0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 23	1992	304	6838					1372	1373		10.1136/bmj.304.6838.1372	http://dx.doi.org/10.1136/bmj.304.6838.1372			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW417	1611340	Green Published, Bronze			2022-12-01	WOS:A1992HW41700033
J	TOVO, PA; DEMARTINO, M; GABIANO, C; CAPPELLO, N; DELIA, R; LOY, A; PLEBANI, A; ZUCCOTTI, GV; DALLACASA, P; FERRARIS, G; CASELLI, D; FUNDARO, C; DARGENIO, P; GALLI, L; PRINCIPI, N; STEGAGNO, M; RUGA, E; PALOMBA, E				TOVO, PA; DEMARTINO, M; GABIANO, C; CAPPELLO, N; DELIA, R; LOY, A; PLEBANI, A; ZUCCOTTI, GV; DALLACASA, P; FERRARIS, G; CASELLI, D; FUNDARO, C; DARGENIO, P; GALLI, L; PRINCIPI, N; STEGAGNO, M; RUGA, E; PALOMBA, E			PROGNOSTIC FACTORS AND SURVIVAL IN CHILDREN WITH PERINATAL HIV-1 INFECTION	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; POLYMERASE CHAIN-REACTION; REGRESSION-MODELS; INFANTS; MOTHERS; TYPE-1; EXPRESSION; BLOOD; BORN	The signs that may arise after perinatal infection with human immunodeficiency virus type 1 (HIV-1) have been classified by the Centers for Disease Control, but the clinical usefulness of the classification system and the prognostic importance of each disease pattern have not been established. We sought to address these issues by analysing data from the italian Register for HIV infection in children. We studied 1887 children born to HIV-1-seropositive mothers. 1045 were identified at birth and the others were registered later (median age 4.8 [range 0.4-72] months). HIV-1-associated signs developed in 433 (81.8%) of 529 seropositive infected children at a median age of 5 (0.03-84) months. These signs appeared significantly earlier in the 102 children who died of HIV-1-related illness than in those who are still alive (median 3 [0.03-55] vs 6 [0.03-84] months; p < 0.001). The cumulative proportion surviving at age 9 years was 49.5% (95% confidence interval 27-65%) and the median survival time was 96.2 months. Separate analysis of the 112 seropositive infected children followed from birth and older than 15 months gave similar results. Hepatomegaly, splenomegaly, lymphadenopathy, parotitis, skin diseases, and recurrent respiratory tract infections formed the mildest disease pattern. Lymphoid interstitial pneumonitis and thrombocytopenia were signs of intermediate disease. By contrast, in multivariate analysis specific secondary infectious diseases, severe bacterial infections, progressive neurological disease, anaemia, and fever were significant and independent negative predictors of survival. Growth failure, persistent oral candidosis, hepatitis, and cardiopathy were associated in univariate analysis with significantly shorter survival. Our findings suggest that the outlook for children with perinatal HIV-1 infection is better than previously thought and that a new clinical staging system of single disease patterns is needed.	UNIV FLORENCE, DEPT PAEDIAT, I-50121 FLORENCE, ITALY; UNIV TURIN, DEPT GENET BIOL & MED CHEM, I-10124 TURIN, ITALY; UNIV PADUA, DEPT PAEDIAT, I-35100 PADUA, ITALY; UNIV GENOA, G GASLINI INST, DEPT INFECT DIS 1, I-16126 GENOA, ITALY; UNIV MILAN, DEPT PEDIAT 1, I-20122 MILAN, ITALY; UNIV MILAN, DEPT PAEDIAT 5, I-20122 MILAN, ITALY; UNIV BOLOGNA, INST CHILD HLTH & NEONATOL, I-40126 BOLOGNA, ITALY; INFANT & MATERNAL CTR DRUG DEPENDENT RELATED ILLNE, MILAN, ITALY; UNIV PAVIA, DEPT PAEDIAT, I-27100 PAVIA, ITALY; UNIV CATTOLICA SACRO CUORE, DEPT PAEDIAT, I-00168 ROME, ITALY; BAMBINO GESU PEDIAT HOSP, ROME, ITALY; UNIV MILAN, DEPT PAEDIAT 4, I-20122 MILAN, ITALY; UNIV ROME LA SAPIENZA, DEPT CHILD HLTH, I-00185 ROME, ITALY	University of Florence; University of Turin; University of Padua; University of Genoa; IRCCS Istituto Giannina Gaslini; University of Milan; University of Milan; University of Bologna; University of Pavia; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; IRCCS Bambino Gesu; University of Milan; Sapienza University Rome	TOVO, PA (corresponding author), UNIV TURIN, DEPT PAEDIAT, PIAZZA POLONIA 94, I-10126 TURIN, ITALY.		Cappello, Nazario/D-9530-2012; D'Argenio, Patrizia/ABA-3852-2021; Plebani, Alessandro/C-8593-2011; Zuccotti, Gianvincenzo/H-8572-2017	Guarino, Alfredo/0000-0003-0199-0336; Tovo, Pier Angelo/0000-0002-0192-3240; Zuccotti, Gianvincenzo/0000-0002-2795-9874				ARICO M, 1991, CANCER, V68, P2473, DOI 10.1002/1097-0142(19911201)68:11<2473::AID-CNCR2820681125>3.0.CO;2-L; BLANCHE S, 1990, AM J DIS CHILD, V144, P1210, DOI 10.1001/archpedi.1990.02150350042021; BRESLOW N, 1974, BIOMETRICS, V30, P89, DOI 10.2307/2529620; COX DR, 1972, J R STAT SOC B, V34, P187; DEMARTINO M, 1991, J PEDIATR-US, V119, P702, DOI 10.1016/S0022-3476(05)80283-5; DEMARTINO M, 1991, ARCH DIS CHILD, V66, P1235, DOI 10.1136/adc.66.10.1235; FALLOON J, 1989, J PEDIATR-US, V114, P1, DOI 10.1016/S0022-3476(89)80596-7; FERRIS S, 1990, 6TH INT C AIDS SAN F, V1, P261; GABIANO C, IN PRESS PEDIATRICS; HAUGER S B, 1991, Journal of Pediatrics, V119, pS25, DOI 10.1016/S0022-3476(05)81450-7; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KRASINSKI K, 1989, PEDIATR INFECT DIS J, V8, P216; KRIVINE A, 1990, J PEDIATR-US, V116, P372, DOI 10.1016/S0022-3476(05)82823-9; LAMPERT R, 1986, PEDIATR INFECT DIS J, V5, P374, DOI 10.1097/00006454-198605000-00020; LAURE F, 1988, LANCET, V2, P538; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; PAWHA S, 1986, JAMA-J AM MED ASSOC, V225, P2299; PECKHAM CS, 1991, LANCET, V337, P253; PEDUZZI PN, 1980, BIOMETRICS, V36, P511, DOI 10.2307/2530219; ROGERS MF, 1987, PEDIATRICS, V79, P1008; ROGERS MF, 1989, NEW ENGL J MED, V320, P1649, DOI 10.1056/NEJM198906223202503; RYDER RW, 1989, NEW ENGL J MED, V320, P1637, DOI 10.1056/NEJM198906223202501; SCOTT GB, 1989, NEW ENGL J MED, V321, P1791, DOI 10.1056/NEJM198912283212604; TOVO PA, 1987, LANCET, V1, P1201; TOVO PA, 1988, LANCET, V2, P1043; TOVO PA, 1985, RIV ITAL PED, V11, P885; WAHN V, 1990, EUR J PEDIATR, V149, P330, DOI 10.1007/BF02171559; 1987, MMWR, V36, P225; 1987, MMWR, V36, P1	30	300	304	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 23	1992	339	8804					1249	1253		10.1016/0140-6736(92)91592-V	http://dx.doi.org/10.1016/0140-6736(92)91592-V			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV191	1349667				2022-12-01	WOS:A1992HV19100002
J	TUNSTALLPEDOE, H; BAILEY, L; CHAMBERLAIN, DA; MARSDEN, AK; WARD, ME; ZIDEMAN, DA				TUNSTALLPEDOE, H; BAILEY, L; CHAMBERLAIN, DA; MARSDEN, AK; WARD, ME; ZIDEMAN, DA			SURVEY OF 3765 CARDIOPULMONARY RESUSCITATIONS IN BRITISH HOSPITALS (THE BRESUS STUDY) - METHODS AND OVERALL RESULTS	BRITISH MEDICAL JOURNAL			English	Article							BASIC LIFE SUPPORT; CARDIAC-ARREST; INTENSIVE-CARE; EMERGENCY; SURVIVAL; ACCIDENT; GUIDELINES	Objective-To determine the circumstances, incidence, and outcome of cardiopulmonary resuscitation in British hospitals. Design-Hospitals registered all cardiopulmonary resuscitation attempts for 12 months or longer and followed survival to one year. Setting-12 metropolitan, provincial, teaching, and non-teaching hospitals across Britain. Subjects-3765 patients in whom a resuscitation attempt was performed, including 927 in whom the onset of arrest was outside the hospital. Main outcome measure-Survival after initial resuscitation, at 24 hours, at discharge from hospital, and at one year, calculated by the life table method. Results-There were 417 known survivors at one year, with 214 lost to follow up. By life table analysis for every eight attempted resuscitations there were three immediate survivors, two at 24 hours, 1.5 leaving hospital alive, and one alive at one year. Survival at one year was 12.5% including out of hospital cases and 15.0% not including these cases. Each hospital year averaged 30 survivors at one year: three who had an arrest outside hospital, seven who had one in the accident and emergency department, seven in the cardiac care unit, 10 in the general wards, and three in other, non-ward areas. Within the hospitals survival rates were best in those who had an arrest in the accident and emergency department, the cardiac care unit, or other specialised units. Outcome varied 12-fold in subgroups defined by age, type of arrest, and place of arrest. Conclusion-71% of the mortality at one year in patients undergoing attempted resuscitation occurred during the initial arrest. Hospital resuscitation is life saving and cost effective and warrants appropriate attention, training, coordination, and equipment.	UNIV SUSSEX,BRIGHTON BN1 9RH,E SUSSEX,ENGLAND; ROYAL SUSSEX CTY HOSP,BRIGHTON BN2 5BE,E SUSSEX,ENGLAND; PINDERFIELDS HOSP,ACCID & EMERGENCY MED,WAKEFIELD,ENGLAND; JOHN RADCLIFFE HOSP,OXFORD OX3 9DU,ENGLAND; HAMMERSMITH HOSP,LONDON W12 0HS,ENGLAND	University of Sussex; University of Brighton; Pinderfields Hospital; University of Oxford; Imperial College London	TUNSTALLPEDOE, H (corresponding author), UNIV DUNDEE,NINEWELLS HOSP & MED SCH,CARDIOVASC EPIDEMIOL UNIT,DUNDEE DD1 9SY,SCOTLAND.							BEDELL SE, 1983, NEW ENGL J MED, V309, P569, DOI 10.1056/NEJM198309083091001; CASEY WF, 1984, J ROY SOC MED, V77, P921, DOI 10.1177/014107688407701105; CHAMBERLAIN DA, 1989, BRIT MED J, V299, P446, DOI 10.1136/bmj.299.6696.446; COBBE SM, 1991, BRIT MED J, V302, P1517, DOI 10.1136/bmj.302.6791.1517; COPE AR, 1987, J ROY SOC MED, V80, P746, DOI 10.1177/014107688708001207; CUMMINS RO, 1991, CIRCULATION, V84, P960, DOI 10.1161/01.CIR.84.2.960; DEBARD ML, 1981, ANN EMERG MED, V10, P408, DOI 10.1016/S0196-0644(81)80307-1; DELOOZ HH, 1989, RESUSCITATION, V17, pS1, DOI 10.1016/0300-9572(89)90085-3; EVANS TR, 1990, ABC RESUSCITATION; GEORGE AL, 1989, AM J MED, V87, P28; GRAY WA, 1991, NEW ENGL J MED, V325, P1393, DOI 10.1056/NEJM199111143252001; HERSHEY CO, 1982, LANCET, V1, P31, DOI 10.1016/S0140-6736(82)92567-3; KAYE W, 1981, HEART LUNG, V10, P860; MARSDEN AK, 1989, BRIT MED J, V299, P442, DOI 10.1136/bmj.299.6696.442; MCGRATH RB, 1987, ANN EMERG MED, V16, P1365, DOI 10.1016/S0196-0644(87)80420-1; ROBERTSON CE, 1984, ARCH EMERG MED, V1, P17; ROSER LA, 1967, ARCH SURG-CHICAGO, V95, P658; SCOTT RPF, 1981, ANAESTHESIA, V36, P526, DOI 10.1111/j.1365-2044.1981.tb10290.x; SKINNER DV, 1985, BRIT MED J, V290, P1549, DOI 10.1136/bmj.290.6481.1549; SMITH GB, 1987, INTENS CARE MED, V13, P260, DOI 10.1007/BF00265115; SULJAGAPECHTEL K, 1984, RESUSCITATION, V12, P77, DOI 10.1016/0300-9572(84)90061-3; TAFFET GE, 1988, JAMA-J AM MED ASSOC, V260, P2069, DOI 10.1001/jama.260.14.2069; WARDROPE J, 1986, ARCH EMERG MED, V3, P183; WILDSMITH JA, 1972, BRIT J ANAESTH, V44, P716; WYNNE G, 1987, BRIT MED J, V294, P1198, DOI 10.1136/bmj.294.6581.1198; ZIDEMAN DA, 1985, J WORLD ASS EMERGENC, V1, P291; 1980, JAMA-J AM MED ASSOC, V244, P453; 1987, J R COLL PHYSICIANS, V21, P1	28	233	237	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 23	1992	304	6838					1347	1351		10.1136/bmj.304.6838.1347	http://dx.doi.org/10.1136/bmj.304.6838.1347			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW417	1611332	Green Published, Bronze			2022-12-01	WOS:A1992HW41700022
J	BUSTELO, XR; BARBACID, M				BUSTELO, XR; BARBACID, M			TYROSINE PHOSPHORYLATION OF THE VAV PROTOONCOGENE PRODUCT IN ACTIVATED B-CELLS	SCIENCE			English	Article							ANTI-IGM; STIMULATION	Activation of B lymphocytes by engagement of their immunoglobulin M antigen receptors results in phosphorylation of a number of proteins on tyrosine residues. One such protein is p95vav, the product of the vav proto-oncogene. Tyrosine phosphorylation of p95-vav occurred within seconds of immunoglobulin M cross-linking and was independent of other events induced during stimulation of B cells, such as protein kinase C activation, guanosine triphosphate-binding protein signaling, and calcium mobilization. Moreover, engagement of antigen receptors induced the rapid (approximately 5 seconds) and transient (approximately 60 seconds) association of p95vav with a 70-kilodalton tyrosine-phosphorylated protein, Vap-1, an interaction mediated by the Src homology 2 domain of p95vav. These results suggest that the vav proto-oncogene participates in the signaling processes that mediate the antigen-induced activation of B lymphocytes.			BUSTELO, XR (corresponding author), BRISTOL MYERS SQUIBB,PHARMACEUT RES INST,DEPT MOLEC BIOL,PRINCETON,NJ 08543, USA.		Bustelo, Xose R./A-9526-2010; Bustelo, Xose R./AAD-2081-2022	Bustelo, Xose R./0000-0001-9398-6072; Bustelo, Xose R./0000-0001-9398-6072				ADAMS JM, IN PRESS ONCOGENE; BRUNSWICK M, 1991, P NATL ACAD SCI USA, V88, P1311, DOI 10.1073/pnas.88.4.1311; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; COLIGAN JE, 1991, CURRENT PROTOCOLS IM, pCH3; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; GALLAND F, 1992, ONCOGENE, V7, P585; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MIZUGUCHI J, 1986, J IMMUNOL, V137, P2162; MIZUGUCHI J, 1988, J IMMUNOL, V140, P2495; MIZUGUCHI J, 1986, P NATL ACAD SCI USA, V83, P4474, DOI 10.1073/pnas.83.12.4474; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903	18	211	220	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 22	1992	256	5060					1196	1199		10.1126/science.256.5060.1196	http://dx.doi.org/10.1126/science.256.5060.1196			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV192	1375396				2022-12-01	WOS:A1992HV19200034
J	HANSMA, HG; VESENKA, J; SIEGERIST, C; KELDERMAN, G; MORRETT, H; SINSHEIMER, RL; ELINGS, V; BUSTAMANTE, C; HANSMA, PK				HANSMA, HG; VESENKA, J; SIEGERIST, C; KELDERMAN, G; MORRETT, H; SINSHEIMER, RL; ELINGS, V; BUSTAMANTE, C; HANSMA, PK			REPRODUCIBLE IMAGING AND DISSECTION OF PLASMID DNA UNDER LIQUID WITH THE ATOMIC FORCE MICROSCOPE	SCIENCE			English	Article							SCANNING TUNNELING MICROSCOPY; NUCLEIC-ACIDS; WATER; RESOLUTION; SURFACE; IMAGES; AIR	Reproducible images of uncoated DNA in the atomic force microscope (AFM) have been obtained by imaging plasmid DNA on mica in n-propanol. Specially sharpened AFM tips give images with reproducible features several nanometers in size along the DNA. Plasmids can be dissected in propanol by increasing the force applied by the AFM tip at selected locations.	UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403; DIGITAL INSTRUMENTS INC,SANTA BARBARA,CA 93117	University of Oregon	HANSMA, HG (corresponding author), UNIV CALIF SANTA BARBARA,DEPT PHYS,SANTA BARBARA,CA 93106, USA.			Bustamante, Carlos/0000-0002-2970-0073	NIGMS NIH HHS [GM32543] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032543, R37GM032543] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKAMA Y, 1990, J VAC SCI TECHNOL A, V8, P429, DOI 10.1116/1.576413; ALBRECHT TR, 1988, J VAC SCI TECHNOL A, V6, P271, DOI 10.1116/1.575441; ALLEN MJ, IN PRESS ULTRAMICROS; BEEBE TP, 1989, SCIENCE, V243, P370, DOI 10.1126/science.2911747; BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; BINNIG G, 1987, EUROPHYS LETT, V3, P1281, DOI 10.1209/0295-5075/3/12/006; BUSTAMANTE C, 1992, BIOCHEMISTRY-US, V31, P22, DOI 10.1021/bi00116a005; CLEMMER CR, 1991, SCIENCE, V251, P640, DOI 10.1126/science.1992517; DRAKE B, 1989, SCIENCE, V243, P1586, DOI 10.1126/science.2928794; DRISCOLL RJ, 1990, NATURE, V346, P294, DOI 10.1038/346294a0; DUNLAP DD, 1989, NATURE, V342, P204, DOI 10.1038/342204a0; HANSMA HG, 1991, J VAC SCI TECHNOL B, V9, P1282, DOI 10.1116/1.585221; HECKL WM, 1991, P NATL ACAD SCI USA, V88, P8003, DOI 10.1073/pnas.88.18.8003; HECKL WM, IN PRESS ULTRAMICROS; HECKL WM, 1992, NONLINEAR OPTICS, V1, P53; HENDERSON E, IN PRESS NUCLEIC ACI; HOH JH, 1991, SCIENCE, V253, P1405, DOI 10.1126/science.1910206; Israelachvili J.N., 1985, INTERMOLECULAR SURFA; JEFFREY GA, 1991, HYDROGEN BONDONG BIO; KELLER D, IN PRESS SURF SCI; KOLLER T, 1974, BIOPOLYMERS, V13, P995, DOI 10.1002/bip.1974.360130514; KUNISADA T, 1983, PLASMID, V9, P8, DOI 10.1016/0147-619X(83)90027-6; LEE G, 1989, SCIENCE, V244, P475, DOI 10.1126/science.2470146; LEE KL, 1989, J VAC SCI TECHNOL B, V7, P1941, DOI 10.1116/1.584652; LINDSAY SM, 1989, SCIENCE, V244, P1063, DOI 10.1126/science.2727694; LIU CY, 1991, LANGMUIR, V7, P1138, DOI 10.1021/la00054a020; RUGAR D, 1990, PHYS TODAY, V43, P23, DOI 10.1063/1.881238; SAENGER W, 1984, PRINCIPLES NUCLEIC A; SCHNEIR J, 1986, PHYS REV B, V34, P4979, DOI 10.1103/PhysRevB.34.4979; VASILE MJ, 1991, REV SCI INSTRUM, V62, P2167, DOI 10.1063/1.1142334; VESENKA J, IN PRESS ULTRAMICROS; WEISENHORN AL, 1989, APPL PHYS LETT, V54, P2651, DOI 10.1063/1.101024; WEISENHORN AL, 1991, LANGMUIR, V7, P8, DOI 10.1021/la00049a003	33	483	496	0	100	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 22	1992	256	5060					1180	1184		10.1126/science.256.5060.1180	http://dx.doi.org/10.1126/science.256.5060.1180			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV192	1589799				2022-12-01	WOS:A1992HV19200028
J	JIANG, H; ZHANG, SL; PERNIS, B				JIANG, H; ZHANG, SL; PERNIS, B			ROLE OF CD8+ T-CELLS IN MURINE EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS	SCIENCE			English	Article							MYELIN BASIC-PROTEIN; AUTOIMMUNE ENCEPHALOMYELITIS; IMMUNOREGULATION; SUPPRESSION; CLONES; INVIVO	The course of experimental allergic encephalomyelitis (EAE), an animal model for multiple sclerosis, is affected by immunoregulatory T lymphocytes. When animals are immunized with encephalitogenic peptide of myelin basic protein and recover from the first episode of EAE, they become resistant to a second induction of this disease. Animals depleted of CD8+ T cells by antibody-mediated clearance were used to examine the role of CD8+ T cells in EAE. These cells were found to be major participants in the resistance to a second induction of EAE but were not essential for spontaneous recovery from the first episode of the disease.			JIANG, H (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT MICROBIOL,NEW YORK,NY 10032, USA.							ANDO DG, 1989, CELL IMMUNOL, V124, P132, DOI 10.1016/0008-8749(89)90117-2; EICHELBERGER M, 1991, J EXP MED, V174, P857; ELLERMAN KE, 1988, NATURE, V331, P265, DOI 10.1038/331265a0; KARPUS WJ, 1989, J IMMUNOL, V143, P3942; KOH DR, 1992, SCIENCE, V256, P1210, DOI 10.1126/science.256.5060.1210; LECLERC C, 1990, J IMMUNOL, V145, P1343; SAKAI K, 1986, J IMMUNOL, V137, P1527; SEDGWICK JD, 1988, EUR J IMMUNOL, V18, P495, DOI 10.1002/eji.1830180402; SUN D, 1988, NATURE, V332, P843, DOI 10.1038/332843a0; SUN DM, 1991, CELL IMMUNOL, V137, P292, DOI 10.1016/0008-8749(91)90080-U; WILLENBORG DO, 1986, J IMMUNOL, V136, P1676; ZAMVIL SS, 1985, J EXP MED, V162, P2107, DOI 10.1084/jem.162.6.2107; ZAMVIL SS, 1986, NATURE, V324, P258, DOI 10.1038/324258a0	13	312	324	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 22	1992	256	5060					1213	1215		10.1126/science.256.5060.1213	http://dx.doi.org/10.1126/science.256.5060.1213			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV192	1375398				2022-12-01	WOS:A1992HV19200039
J	KOH, DR; FUNGLEUNG, WP; HO, A; GRAY, D; ACHAORBEA, H; MAK, TW				KOH, DR; FUNGLEUNG, WP; HO, A; GRAY, D; ACHAORBEA, H; MAK, TW			LESS MORTALITY BUT MORE RELAPSES IN EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS IN CD8-/- MICE	SCIENCE			English	Article							MYELIN BASIC-PROTEIN; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; SUPPRESSOR CELLS; T-CELLS; INVIVO; DEPLETION; ANTIBODY; INVITRO; EAE	Mice lacking in CD8 were generated from homologous recombination in embryonal stem cells at the CD8 locus and bred with the experimental allergic encephalomyelitis (EAE)-susceptible PL/J H-2u through four backcross generations to investigate the role of CD8+ T cells in this model of multiple sclerosis. The disease onset and susceptibility were similar to those of wild-type mice. However, the mutant mice had a milder acute EAE, reflected by fewer deaths, but more chronic EAE, reflected by a higher frequency of relapse. This suggests that CD8+ T lymphocytes may participate as both effectors and regulators in this animal model.	UNIV TORONTO,PRINCESS MARGARET HOSP,ONTARIO CANC INST,DEPT IMMUNOL,TORONTO M4X 1K9,ONTARIO,CANADA; LUDWIG INST CANC RES,LAUSANNE BRANCH,CH-1066 EPALINGES,SWITZERLAND	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Ludwig Institute for Cancer Research	KOH, DR (corresponding author), UNIV TORONTO,PRINCESS MARGARET HOSP,ONTARIO CANC INST,DEPT MED BIOPHYS,500 SHERBOURNE ST,TORONTO M4X 1K9,ONTARIO,CANADA.			Fung-Leung, Wai-Ping/0000-0001-7013-8855				ACHAORBEA H, 1989, ANNU REV IMMUNOL, V7, P371, DOI 10.1146/annurev.iy.07.040189.002103; ANDO DG, 1989, CELL IMMUNOL, V124, P132, DOI 10.1016/0008-8749(89)90117-2; ARNASON BG, 1962, J EXP MED, V116, P177, DOI 10.1084/jem.116.2.177; ARNON R, 1981, IMMUNOL REV, V55, P5, DOI 10.1111/j.1600-065X.1981.tb00337.x; BITAR DM, 1988, CELL IMMUNOL, V112, P364, DOI 10.1016/0008-8749(88)90305-X; BROSTOFF SW, 1984, J IMMUNOL, V133, P1938; BROWN A, 1982, LAB INVEST, V46, P171; ELLERMAN KE, 1988, NATURE, V331, P265, DOI 10.1038/331265a0; FUNGLEUNG WP, 1991, J EXP MED, V174, P1425, DOI 10.1084/jem.174.6.1425; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; FUNGLEUNG WP, UNPUB; HIGGINS PJ, 1988, J IMMUNOL, V140, P440; JIANG H, 1992, SCIENCE, V256, P1213, DOI 10.1126/science.256.5060.1213; KARPUS WJ, 1989, J IMMUNOL, V143, P3492; KARPUS WJ, 1991, J IMMUNOL, V146, P1163; LEMIRE JM, 1986, J IMMUNOL, V137, P3169; LIDER O, 1989, J IMMUNOL, V142, P748; MASON D, 1991, IMMUNOL TODAY, V12, P57, DOI 10.1016/0167-5699(91)90158-P; MATHIESON PW, 1991, EUR J IMMUNOL, V21, P2105, DOI 10.1002/eji.1830210919; MILLER A, 1992, P NATL ACAD SCI USA, V89, P421, DOI 10.1073/pnas.89.1.421; MOSSMANN TR, 1989, ADV IMMUNOL, V46, P111; PETTINELLI CB, 1981, J IMMUNOL, V127, P1420; POWELL MB, 1990, INT IMMUNOL, V2, P539, DOI 10.1093/intimm/2.6.539; RACKE MK, 1991, J IMMUNOL, V146, P3012; SAKAI K, 1986, J IMMUNOL, V137, P1527; SAMBHARA SR, 1991, SCIENCE, V252, P1424; SEDGWICK JD, 1988, EUR J IMMUNOL, V18, P495, DOI 10.1002/eji.1830180402; SEDGWICK JD, 1990, J IMMUNOL, V145, P2474; SRIRAM S, 1988, J NEUROIMMUNOL, V17, P147, DOI 10.1016/0165-5728(88)90022-7; SRIRAM S, 1988, J IMMUNOL, V141, P464; SUN D, 1988, NATURE, V332, P843, DOI 10.1038/332843a0; ZAMVIL S, 1985, NATURE, V317, P355, DOI 10.1038/317355a0; ZAMVIL SS, 1986, NATURE, V324, P258, DOI 10.1038/324258a0	33	319	332	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 22	1992	256	5060					1210	1213		10.1126/science.256.5060.1210	http://dx.doi.org/10.1126/science.256.5060.1210			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV192	1589800				2022-12-01	WOS:A1992HV19200038
J	NICOLAOU, KC; DAI, WM; TSAY, SC; ESTEVEZ, VA; WRASIDLO, W				NICOLAOU, KC; DAI, WM; TSAY, SC; ESTEVEZ, VA; WRASIDLO, W			DESIGNED ENEDIYNES - A NEW CLASS OF DNA-CLEAVING MOLECULES WITH POTENT AND SELECTIVE ANTICANCER ACTIVITY	SCIENCE			English	Article							NEOCARZINOSTATIN CHROMOPHORE ANALOGS; ESPERAMICIN-CALICHEMICIN CLASS; CHROMIUM-MEDIATED CLOSURES; 10-MEMBERED RING ANALOGS; DIELS-ALDER ROUTE; ANTITUMOR ANTIBIOTICS; CALICHEAMICIN-ESPERAMICIN; BICYCLIC CORE; DYNEMICIN-A; GENERAL METHODOLOGY	The rational design and biological actions of a new class of DNA-cleaving molecules with potent and selective anticancer activity are reported. These relatively simple enediyne-type compounds were designed from basic chemical principles to mimic the actions of the rather complex naturally occurring enediyne anticancer antibiotics, particularly dynemicin A. Equipped with locking and triggering devices, these compounds damage DNA in vitro and in vivo on activation by chemical or biological means. Their damaging effects are manifested in potent anticancer activity with remarkable selectivities. Their mechanism of action involves intracellular unlocking and triggering of a Bergman reaction, leading to highly reactive benzenoid diradicals that cause severe DNA damage. The results of these studies demonstrate the potential of these de novo designed molecules as biotechnology tools and anticancer agents.	UNIV CALIF SAN DIEGO, DEPT CHEM, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego	NICOLAOU, KC (corresponding author), Scripps Res Inst, RES INST, DEPT CHEM, LA JOLLA, CA 92037 USA.		Dai, Wei-Min/B-6981-2008	Dai, Wei-Min/0000-0001-5688-7606				BERGMAN RG, 1973, ACCOUNTS CHEM RES, V6, P25, DOI 10.1021/ar50061a004; BIRNBOIM HC, 1981, CANCER RES, V41, P1889; BORMAN S, 1991, CHEM ENG NEWS, V69, P11, DOI 10.1021/cen-v069n035.p011; CABAL MP, 1990, J AM CHEM SOC, V112, P3253, DOI 10.1021/ja00164a079; CHIKASHITA H, 1991, J ORG CHEM, V56, P1962; DANISHEFSKY SJ, 1988, TETRAHEDRON LETT, V29, P4681, DOI 10.1016/S0040-4039(00)80579-1; DANISHEFSKY SJ, 1988, J AM CHEM SOC, V110, P6890, DOI 10.1021/ja00228a051; DARBY N, 1971, J CHEM SOC CHEM COMM, P1516, DOI 10.1039/c29710001516; DOI T, 1991, J ORG CHEM, V56, P3465, DOI 10.1021/jo00011a002; DOYLE TW, 22ND P ANN CANC S AN, V1; DRAK J, 1991, P NATL ACAD SCI USA, V88, P7464, DOI 10.1073/pnas.88.17.7464; EDO K, 1985, TETRAHEDRON LETT, V26, P331, DOI 10.1016/S0040-4039(01)80810-8; GOLIK J, 1987, J AM CHEM SOC, V109, P3462, DOI 10.1021/ja00245a049; HASELTINE JN, 1989, J AM CHEM SOC, V111, P7638, DOI 10.1021/ja00201a068; HASELTINE JN, 1991, J AM CHEM SOC, V113, P3850, DOI 10.1021/ja00010a030; HASELTINE JN, 1990, J ORG CHEM, V55, P2576, DOI 10.1021/jo00296a007; HIRAMA M, 1989, J AM CHEM SOC, V111, P4120, DOI 10.1021/ja00193a065; HIRAMA M, 1991, J AM CHEM SOC, V113, P9851, DOI 10.1021/ja00026a022; JONES RR, 1972, J AM CHEM SOC, V94, P660, DOI 10.1021/ja00757a071; KONISHI M, 1990, J AM CHEM SOC, V112, P3715, DOI 10.1021/ja00165a097; KREBS A, 1990, TETRAHEDRON LETT, V31, P3533, DOI 10.1016/S0040-4039(00)94435-6; LEE MD, 1987, J AM CHEM SOC, V109, P3464, DOI 10.1021/ja00245a050; LEE MD, 1991, ACCOUNTS CHEM RES, V24, P235, DOI 10.1021/ar00008a003; LEE MD, 1987, J AM CHEM SOC, V109, P3466, DOI 10.1021/ja00245a051; LOCKHART TP, 1981, J AM CHEM SOC, V103, P4082, DOI 10.1021/ja00404a018; LOCKHART TP, 1981, J AM CHEM SOC, V103, P4091, DOI 10.1021/ja00404a019; MAGNUS P, 1989, J CHEM SOC CHEM COMM, P916, DOI 10.1039/c39890000916; MAGNUS P, 1989, TETRAHEDRON LETT, V30, P1905, DOI 10.1016/S0040-4039(00)99609-6; MAGNUS P, 1990, J ORG CHEM, V55, P1709, DOI 10.1021/jo00293a009; MAGNUS P, 1988, J AM CHEM SOC, V110, P6921, DOI 10.1021/ja00228a071; MAGNUS P, 1990, J AM CHEM SOC, V112, P4986, DOI 10.1021/ja00168a068; MAGNUS P, 1991, J CHEM SOC CHEM COMM, P544, DOI 10.1039/c39910000544; MAGNUS P, 1991, J CHEM SOC CHEM COMM, P541, DOI 10.1039/c39910000541; MANTLO NB, 1989, J ORG CHEM, V54, P2781, DOI 10.1021/jo00273a002; MCGUIRE WP, 1989, ANN INTERN MED, V111, P273, DOI 10.7326/0003-4819-111-4-273; MYERS AG, 1989, J AM CHEM SOC, V111, P9130, DOI 10.1021/ja00207a036; MYERS AG, 1991, J AM CHEM SOC, V113, P694, DOI 10.1021/ja00002a059; MYERS AG, 1989, J AM CHEM SOC, V111, P8057, DOI 10.1021/ja00202a079; NAGATA R, 1989, TETRAHEDRON LETT, V30, P4995, DOI 10.1016/S0040-4039(01)80564-5; NAGATA R, 1990, TETRAHEDRON LETT, V31, P2907, DOI 10.1016/0040-4039(90)80181-K; NICOLAOU KC, 1992, ANGEW CHEM INT EDIT, V31, P340, DOI 10.1002/anie.199203401; NICOLAOU KC, 1990, ANGEW CHEM INT EDIT, V29, P1064, DOI 10.1002/anie.199010641; NICOLAOU KC, 1988, J AM CHEM SOC, V110, P7247, DOI 10.1021/ja00229a068; NICOLAOU KC, 1991, ANGEW CHEM INT EDIT, V30, P1032, DOI 10.1002/anie.199110321; NICOLAOU KC, 1991, J AM CHEM SOC, V113, P3106, DOI 10.1021/ja00008a045; NICOLAOU KC, 1988, J AM CHEM SOC, V110, P4866, DOI 10.1021/ja00222a077; NICOLAOU KC, 1990, J AM CHEM SOC, V112, P7416, DOI 10.1021/ja00176a064; NICOLAOU KC, 1991, J AM CHEM SOC, V113, P9878, DOI 10.1021/ja00026a039; NICOLAOU KC, 1991, ANGEW CHEM INT EDIT, V30, P1387, DOI 10.1002/anie.199113873; NICOLAOU KC, 1989, ANGEW CHEM INT EDIT, V28, P1272, DOI 10.1002/anie.198912721; NICOLAOU KC, 1990, J AM CHEM SOC, V112, P7825, DOI 10.1021/ja00177a070; NICOLAOU KC, IN PRESS ANGEW CHEM; NICOLAOU KC, UNPUB; NISHIKAWA T, 1991, CHEM LETT, P1271, DOI 10.1246/cl.1991.1271; NISHIKAWA T, 1991, SYNLETT, P393; PORCO JA, 1990, J AM CHEM SOC, V112, P7410, DOI 10.1021/ja00176a060; ROWINSKY EK, 1990, JNCI-J NATL CANCER I, V82, P1247, DOI 10.1093/jnci/82.15.1247; SAKAI Y, 1991, TETRAHEDRON LETT, V32, P4363, DOI 10.1016/S0040-4039(00)92171-3; SCHOENEN FJ, 1989, TETRAHEDRON LETT, V30, P3765, DOI 10.1016/S0040-4039(01)80649-3; SCHREIBER SL, 1988, J AM CHEM SOC, V110, P631, DOI 10.1021/ja00210a071; SCHREIBER SL, 1989, TETRAHEDRON LETT, V30, P433, DOI 10.1016/S0040-4039(00)95220-1; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; SMITH AL, 1992, J AM CHEM SOC, V114, P3134, DOI 10.1021/ja00034a068; TOMIOKA K, 1989, TETRAHEDRON LETT, V30, P851, DOI 10.1016/S0040-4039(01)80634-1; TOSHIMA K, 1991, TETRAHEDRON LETT, V32, P391, DOI 10.1016/S0040-4039(00)92636-4; WEHLAGE T, 1990, TETRAHEDRON LETT, V31, P6625, DOI 10.1016/S0040-4039(00)97131-4; WENDER PA, 1990, J AM CHEM SOC, V112, P5369, DOI 10.1021/ja00169a065; WENDER PA, 1988, TETRAHEDRON LETT, V29, P909, DOI 10.1016/S0040-4039(00)82479-X; WENDER PA, 1991, J AM CHEM SOC, V113, P2311, DOI 10.1021/ja00006a065	69	330	347	1	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 22	1992	256	5060					1172	1178		10.1126/science.256.5060.1172	http://dx.doi.org/10.1126/science.256.5060.1172			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV192	1589797				2022-12-01	WOS:A1992HV19200026
J	PAN, MG; FLORIO, T; STORK, PJS				PAN, MG; FLORIO, T; STORK, PJS			G-PROTEIN ACTIVATION OF A HORMONE-STIMULATED PHOSPHATASE IN HUMAN TUMOR-CELLS	SCIENCE			English	Article							GROWTH-FACTOR RECEPTOR; MIA PACA-2; DEPHOSPHORYLATION	The growth-inhibiting peptide hormone somatostatin stimulates phosphotyrosine phosphatase activity in the human pancreatic cell line MIA PaCa-2. This hormonal activation was mediated by a pertussis toxin-sensitive guanosine 5'-triphosphate-binding protein (G protein) in the membranes of these cells. Activation of this G protein by somatostatin stimulated the dephosphorylation of exogenous epidermal growth factor receptor prepared from A-431 cells in vitro. This pathway may mediate the antineoplastic action of somatostatin in these cells and in human tumors and could represent a general mechanism of G protein coupling Mat is utilized by normal cells in the hormonal control of cell growth.	OREGON HLTH SCI UNIV, VOLLUM INST ADV BIOMED RES, L474, 3181 SW SAM JACKSON PK RD, PORTLAND, OR 97201 USA; OREGON HLTH SCI UNIV, DEPT CELL BIOL & ANAT, PORTLAND, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University			Florio, Tullio/A-2211-2012; FLORIO, TULLIO/ABG-3182-2020	Florio, Tullio/0000-0002-2394-996X; 				BLUMENTHAL DK, 1986, J BIOL CHEM, V261, P8140; CICIRELLI MF, 1990, P NATL ACAD SCI USA, V87, P5514, DOI 10.1073/pnas.87.14.5514; CIRILLO D, 1988, MOL CELL BIOL, V6, P4641; COHEN S, 1982, J BIOL CHEM, V257, P1523; CUI Z, 1991, J BIOL CHEM, V266, P20276; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; HERMOUET S, 1991, P NATL ACAD SCI USA, V88, P10455, DOI 10.1073/pnas.88.23.10455; HIEROWSKI MT, 1985, FEBS LETT, V179, P252, DOI 10.1016/0014-5793(85)80529-9; INGEBRITSEN TS, 1989, J BIOL CHEM, V264, P7754; JARVIS MF, 1991, 21ST ANN M SOC NEUR, P45; KARLUND JK, 1985, CELL, V41, P707; LIEBOW C, 1991, P NATL ACAD SCI USA, V88, P2244, DOI 10.1073/pnas.88.6.2244; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MACKINTOSH C, 1990, FEBS LETT, V264, P187, DOI 10.1016/0014-5793(90)80245-E; Pan M.-L., UNPUB; STORK PJS, UNPUB; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; TEITELBAUM I, 1990, J BIOL CHEM, V265, P4218; TONKS NK, 1991, METHOD ENZYMOL, V201, P427; YUNIS AA, 1977, INT J CANCER, V19, P128, DOI 10.1002/ijc.2910190118; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577	21	232	235	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 22	1992	256	5060					1215	1217		10.1126/science.256.5060.1215	http://dx.doi.org/10.1126/science.256.5060.1215			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV192	1350382				2022-12-01	WOS:A1992HV19200040
J	REYES, H; REISZPORSZASZ, S; HANKINSON, O				REYES, H; REISZPORSZASZ, S; HANKINSON, O			IDENTIFICATION OF THE AH RECEPTOR NUCLEAR TRANSLOCATOR PROTEIN (ARNT) AS A COMPONENT OF THE DNA-BINDING FORM OF THE AH RECEPTOR	SCIENCE			English	Article							XENOBIOTIC RESPONSIVE ELEMENTS; HEAT-SHOCK PROTEIN; DIOXIN RECEPTOR; GLUCOCORTICOID RECEPTOR; MUTAGENIC ACTIVATION; CARCINOGENIC ARYLAMINES; AROMATIC-AMINES; MOUSE-LIVER; P-450C GENE; RAT-LIVER	The Ah (dioxin) receptor binds a number of widely disseminated environmental pollutants, including 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and polycyclic aromatic hydrocarbons, and mediates their carcinogenic effects. The ligand-bound receptor activates Cyp1a1 gene transcription through interaction with specific DNA sequences, termed xenobiotic responsive elements (XREs). The Ah receptor nuclear translocator protein (Arnt) is required for Ah receptor function. Arnt is now shown to be a structural component of the XRE binding form of the Ah receptor. Furthermore, Arnt and the ligand-binding subunit of the receptor were extracted as a complex from the nuclei of cells treated with ligand. Arnt contains a basic helix-loop-helix motif, which may be responsible for interacting with both the XRE and the ligand-binding subunit.	UNIV CALIF LOS ANGELES,DEPT PATHOL LAB MED,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,BIOMED & ENVIRONM SCI LAB,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NATIONAL CANCER INSTITUTE [R01CA028868] Funding Source: NIH RePORTER; NCI NIH HHS [CA 28868] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AOYAMA T, 1990, CANCER RES, V50, P2060; BUTLER MA, 1989, P NATL ACAD SCI USA, V86, P7696, DOI 10.1073/pnas.86.20.7696; COON MJ, 1983, SOMATIC CELL GENET, V9, P497; COON MJ, 1980, MICROSOMES DRUG OXID, P1149; COON MJ, 1981, SOMATIC CELL GENET, V7, P373; CULLITON BJ, 1991, NATURE, V352, P753, DOI 10.1038/352753a0; CUTHILL S, 1987, J BIOL CHEM, V262, P3477; CUTHILL S, 1991, MOL CELL BIOL, V11, P401, DOI 10.1128/MCB.11.1.401; DEGAWA M, 1989, CARCINOGENESIS, V10, P1119, DOI 10.1093/carcin/10.6.1119; DENIS M, 1988, BIOCHEM BIOPH RES CO, V155, P801, DOI 10.1016/S0006-291X(88)80566-7; DENISON MS, 1986, J BIOL CHEM, V261, P3987; DENISON MS, 1988, P NATL ACAD SCI USA, V85, P2528, DOI 10.1073/pnas.85.8.2528; DENISON MS, 1986, EUR J BIOCHEM, V155, P223, DOI 10.1111/j.1432-1033.1986.tb09480.x; DENISON MS, 1988, J BIOL CHEM, V263, P17221; ELFERINK CJ, 1990, J BIOL CHEM, V265, P20708; FUJISAWASEHARA A, 1988, P NATL ACAD SCI USA, V85, P5859, DOI 10.1073/pnas.85.16.5859; FUJISAWASEHARA A, 1987, NUCLEIC ACIDS RES, V15, P4179, DOI 10.1093/nar/15.10.4179; GUSTAFSSON JA, 1987, ENDOCR REV, V8, P185, DOI 10.1210/edrv-8-2-185; HANKINSON O, 1979, P NATL ACAD SCI USA, V76, P373, DOI 10.1073/pnas.76.1.373; HANKINSON O, UNPUB; HAPGOOD J, 1989, P NATL ACAD SCI USA, V86, P60, DOI 10.1073/pnas.86.1.60; HENRY EC, 1989, BIOCHEMISTRY-US, V28, P6430, DOI 10.1021/bi00441a041; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; KARENLAMPI SO, 1988, J BIOL CHEM, V263, P10111; LEGRAVEREND C, 1982, J BIOL CHEM, V257, P6402; MCMANUS ME, 1989, CARCINOGENESIS, V10, P357, DOI 10.1093/carcin/10.2.357; MILLER AG, 1983, J BIOL CHEM, V258, P3523; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; NEUHOLD LA, 1989, MOL CELL BIOL, V9, P2378, DOI 10.1128/MCB.9.6.2378; OKEY AB, 1980, J BIOL CHEM, V255, P1415; PERDEW GH, 1988, J BIOL CHEM, V263, P9848; PERDEW GH, 1987, J BIOL CHEM, V262, P13802; POLAND A, 1991, MOL PHARMACOL, V39, P20; POLAND A, 1984, BANBURY REPORT, V18, P109; PROKIPCAK RD, 1988, ARCH BIOCHEM BIOPHYS, V267, P811, DOI 10.1016/0003-9861(88)90091-4; REYES H, UNPUB; ROBERTS L, 1991, SCIENCE, V251, P624, DOI 10.1126/science.1846976; ROBERTS L, 1991, SCIENCE, V251, P866, DOI 10.1126/science.2000488; SAATCIOGLU F, 1990, J BIOL CHEM, V265, P9251; SAATCIOGLU F, 1990, MOL CELL BIOL, V10, P6408, DOI 10.1128/MCB.10.12.6408; SAFE SH, 1986, ANNU REV PHARMACOL, V26, P371, DOI 10.1146/annurev.pa.26.040186.002103; SNYDERWINE EG, 1989, J NATL CANCER I, V81, P223, DOI 10.1093/jnci/81.3.223; WATSON AJ, 1992, J BIOL CHEM, V267, P6874; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WILHELMSSON A, 1990, EMBO J, V9, P69, DOI 10.1002/j.1460-2075.1990.tb08081.x	45	725	748	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 22	1992	256	5060					1193	1195		10.1126/science.256.5060.1193	http://dx.doi.org/10.1126/science.256.5060.1193			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV192	1317062				2022-12-01	WOS:A1992HV19200033
J	SMITH, TF; WATERMAN, MS				SMITH, TF; WATERMAN, MS			THE CONTINUING CASE OF THE FLORIDA DENTIST	SCIENCE			English	Editorial Material									UNIV SO CALIF,DEPT MATH,LOS ANGELES,CA 90089	University of Southern California	SMITH, TF (corresponding author), BOSTON UNIV,BIOMOLEC ENGN RES CTR,BOSTON,MA 02215, USA.							[Anonymous], 1992, DNA TECHNOLOGY FOREN; BARINAGA M, 1992, SCIENCE, V255, P686, DOI 10.1126/science.1738842; HWANG SS, 1991, SCIENCE, V253, P71, DOI 10.1126/science.1905842; LANDER ES, 1989, NATURE, V339, P501, DOI 10.1038/339501a0; MCCABE ERB, 1992, J PEDIATR-US, V120, P499, DOI 10.1016/S0022-3476(05)82475-8; OU CY, 1992, SCIENCE, V256, P1165, DOI 10.1126/science.256.5060.1165; PALCA J, 1992, SCIENCE, V255, P392, DOI 10.1126/science.1734515; WOLINSKY SM, 1992, SCIENCE, V255, P1134, DOI 10.1126/science.1546316; 1990, MORB MORTAL WKLY REP, V39, P489	9	32	32	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 22	1992	256	5060					1155	1156		10.1126/science.256.5060.1155	http://dx.doi.org/10.1126/science.256.5060.1155			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV192	1589795				2022-12-01	WOS:A1992HV19200023
J	THOMPSON, AM				THOMPSON, AM			THE OXIDIZING CAPACITY OF THE EARTHS ATMOSPHERE - PROBABLE PAST AND FUTURE CHANGES	SCIENCE			English	Article							ACID DEPOSITION MODEL; TROPOSPHERIC OZONE PRODUCTION; CLIMATE CHANGE; HYDROGEN-PEROXIDE; SULFUR-DIOXIDE; SURFACE OZONE; METHANE; CHEMISTRY; OXIDANTS; MECHANISMS	The principal oxidants in the lower atmosphere are ozone (O3) and two by-products of O3 photodissociation, the hydroxyl radical (OH) and hydrogen peroxide (H2O2). A number of critical atmospheric chemical problems depend on the earth's "oxidizing capacity," which is essentially the global burden of these oxidants. There is limited direct evidence for changes in the earth's oxidizing capacity since recent preindustrial times when, because of industrial and population growth, increasing amounts of O3 precursor trace gases (carbon monoxide, nitrogen oxides, and hydrocarbons) have been released into the atmosphere. The concentrations of O3 and possibly H2O2 have increased over large regions. Models predict that tropospheric O3 will increase approximately 0.3 to 1% per year over the next 50 years with both positive and negative trends possible for OH and H2O2. Models and the observational network for oxidants are improving, but validation of global models is still at an early stage.			THOMPSON, AM (corresponding author), NASA, GODDARD SPACE FLIGHT CTR, ATMOSPHERES LAB, GREENBELT, MD 20771 USA.		Thompson, Anne Mee/V-5862-2019; Thompson, Anne M/C-3649-2014	Thompson, Anne Mee/0000-0002-7829-0920; Thompson, Anne M/0000-0002-7829-0920				ATHERTON CS, 1990, J GEOPHYS RES-ATMOS, V95, P14027, DOI 10.1029/JD095iD09p14027; ATKINSON R, 1989, MONOGRAPH AM I PHYSI, V1; BECK JP, 1992, ATMOS ENVIRON A-GEN, V26, P17, DOI 10.1016/0960-1686(92)90257-L; BLAKE DR, 1986, J ATMOS CHEM, V4, P43, DOI 10.1007/BF00053772; BOJKOV RD, 1986, J CLIM APPL METEOROL, V25, P343, DOI 10.1175/1520-0450(1986)025<0343:SODTSH>2.0.CO;2; BRUHL C, 1989, GEOPHYS RES LETT, V16, P703, DOI 10.1029/GL016i007p00703; BRUHL C, 1991, JUN UN ENV PROGR WOR; Bruhl C., 1988, CLIM DYNAM, V2, P173, DOI 10.1007/BF01053474; BRUNE WH, 1992, SCIENCE, V256, P1154, DOI 10.1126/science.256.5060.1154; BUTLER JH, 1991, J GEOPHYS RES-ATMOS, V96, P22347, DOI 10.1029/91JD02126; CHAMEIDES WL, 1982, J GEOPHYS RES-OCEANS, V87, P4863, DOI 10.1029/JC087iC07p04863; CHAMEIDES WL, 1977, J GEOPHYS RES-OC ATM, V82, P1795, DOI 10.1029/JC082i012p01795; CHANG JS, 1987, J GEOPHYS RES-ATMOS, V92, P14681, DOI 10.1029/JD092iD12p14681; CHATFIELD RB, 1984, J GEOPHYS RES-ATMOS, V89, P7111, DOI 10.1029/JD089iD05p07111; CRAIG H, 1982, GEOPHYS RES LETT, V9, P1221, DOI 10.1029/GL009i011p01221; CRUTZEN P, 1973, PURE APPL GEOPHYS, V106, P1385, DOI 10.1007/BF00881092; CRUTZEN PJ, 1979, NATURE, V282, P253, DOI 10.1038/282253a0; CRUTZEN PJ, 1983, J GEOPHYS RES-OCEANS, V88, P6641, DOI 10.1029/JC088iC11p06641; CRUTZEN PJ, 1991, TELLUS A, V43, P136, DOI 10.1034/j.1600-0870.1991.00012.x; CRUTZEN PJ, 1992, NATURE, V356, P104, DOI 10.1038/356104a0; CUNNOID DM, 1992, J GEOPHYS RES, V96, P17392; DEMORE WB, 1990, NASA JPL PUBL, V901; DERWENT RG, 1982, ATMOS ENVIRON, V16, P1997, DOI 10.1016/0004-6981(82)90470-X; DICKERSON RR, 1987, SCIENCE, V235, P460, DOI 10.1126/science.235.4787.460; DODGE MC, 1989, J GEOPHYS RES-ATMOS, V94, P5121, DOI 10.1029/JD094iD04p05121; DORN H-P, 1988, Tellus Series B Chemical and Physical Meteorology, V40, P437; EHHALT DH, 1988, CHANGING ATMOSPHERE, P25; Finlayson-Pitts B.J., 1986, ATMOSPHERIC CHEM FUN; FISHMAN J, 1990, J GEOPHYS RES-ATMOS, V95, P3599, DOI 10.1029/JD095iD04p03599; FISHMAN J, 1991, SCIENCE, V252, P1693, DOI 10.1126/science.252.5013.1693; FISHMAN J, COMMUNICATION; GERY MW, 1989, J GEOPHYS RES-ATMOS, V94, P12925, DOI 10.1029/JD094iD10p12925; GERY MW, 1991, ENV EFFECTS OZONE DE; GERY MW, 1986, J GEOPHYS RES, V91, P10905; Graedel T. E., 1978, CHEM COMPOUNDS ATMOS; GRAEDEL TE, 1981, REV GEOPHYS, V19, P505, DOI 10.1029/RG019i004p00505; GUNZ DW, 1990, ATMOS ENVIRON A-GEN, V24, P1601, DOI 10.1016/0960-1686(90)90496-A; Guthrie PD, 1989, GLOBAL BIOGEOCHEM CY, V3, P287, DOI 10.1029/GB003i004p00287; HAMEED S, 1979, J GEOPHYS RES-OCEANS, V84, P763, DOI 10.1029/JC084iC02p00763; HOFZUMAHAUS A, 1991, ATMOS ENVIRON A-GEN, V25, P2017, DOI 10.1016/0960-1686(91)90281-B; HOGAN KB, 1991, NATURE, V354, P181, DOI 10.1038/354181a0; HOUGH AM, 1990, NATURE, V344, P645, DOI 10.1038/344645a0; HOUGH AM, 1988, J GEOPHYS RES-ATMOS, V93, P3789, DOI 10.1029/JD093iD04p03789; ISAKSEN I S A, 1987, Tellus Series B Chemical and Physical Meteorology, V39, P271, DOI 10.1111/j.1600-0889.1987.tb00099.x; Isaksen I. S. A., 1988, CHANGING ATMOSPHERE, P141; ISAKSEN ISA, 1992, SCI ASSESSMENT OZONE, pCH5; ISAKSEN ISA, 1989, OZONE ATMOSPHERE, P576; Jackman C., 1989, NASA C PUBLICATION, V3042; JOHNSON C, 1992, NATURE, V355, P69, DOI 10.1038/355069a0; KANAKIDOU M, 1991, J GEOPHYS RES-ATMOS, V96, P15395, DOI 10.1029/91JD01345; KANAKIDOU M, IN PRESS CHEMOSPHERE; KHALIL MAK, 1985, ATMOS ENVIRON, V19, P397, DOI 10.1016/0004-6981(85)90161-1; KLEY D, 1989, GLOBAL REGIONAL ENV, P9; LACIS AA, 1990, J GEOPHYS RES-ATMOS, V95, P9971, DOI 10.1029/JD095iD07p09971; LASHOF DA, 1990, USEPA21P20031 REP; LAW KS, 1991, ATMOS ENVIRON A-GEN, V25, P1863, DOI 10.1016/0960-1686(91)90269-D; LEIFER IS, 1991, EOS, V72, P99; LELIEVELD J, 1990, NATURE, V343, P227, DOI 10.1038/343227a0; LEONE JA, 1985, ATMOS ENVIRON, V19, P437, DOI 10.1016/0004-6981(85)90166-0; LEVINE JS, 1985, NATURE, V318, P254, DOI 10.1038/318254a0; LEVY H, 1972, PLANET SPACE SCI, V20, P919, DOI 10.1016/0032-0633(72)90177-8; LIN X, 1988, J GEOPHYS RES-ATMOS, V93, P15879, DOI 10.1029/JD093iD12p15879; LIU SC, 1988, J ATMOS CHEM, V6, P221, DOI 10.1007/BF00053857; LIU SC, 1980, J GEOPHYS RES-OCEANS, V85, P7546, DOI 10.1029/JC085iC12p07546; LIU SC, 1987, J GEOPHYS RES-ATMOS, V92, P4191, DOI 10.1029/JD092iD04p04191; LOGAN JA, 1985, J GEOPHYS RES-ATMOS, V90, P10463, DOI 10.1029/JD090iD06p10463; LOGAN JA, 1988, TROPOSPHERIC OZONE, P327; LU Y, 1991, CHEMOSPHERE, V23, P397, DOI 10.1016/0045-6535(91)90194-I; Lu Y.R., UNPUB; LUBIN D, 1989, J GEOPHYS RES-ATMOS, V94, P8491, DOI 10.1029/JD094iD06p08491; MADRONICH S, 1987, J GEOPHYS RES-ATMOS, V92, P9740, DOI 10.1029/JD092iD08p09740; MADRONICH S, 1992, GEOPHYS RES LETT, V19, P465, DOI 10.1029/92GL00378; MADRONICH S, 1992, GEOPHYS RES LETT, V19, P37, DOI 10.1029/91GL02954; MCELROY MB, 1989, PHYS CH EAR, V8, P363; MOUNT GH, 1992, J GEOPHYS RES-ATMOS, V97, P2427, DOI 10.1029/91JD02971; MOUNT GH, 1992, SCIENCE, V256, P1187, DOI 10.1126/science.256.5060.1187; NEFTEL A, 1984, NATURE, V311, P43, DOI 10.1038/311043a0; OLTMANS SJ, 1986, J GEOPHYS RES-ATMOS, V91, P5229, DOI 10.1029/JD091iD04p05229; PENKETT SA, 1979, ATMOS ENVIRON, V13, P123, DOI 10.1016/0004-6981(79)90251-8; PENKETT SA, 1986, NATURE, V319, P655, DOI 10.1038/319655a0; PICKERING KE, 1990, J GEOPHYS RES-ATMOS, V95, P14049, DOI 10.1029/JD095iD09p14049; PINTO JP, 1991, TELLUS B, V43, P347, DOI 10.1034/j.1600-0889.1991.t01-2-00001.x; PRATHER M, 1990, J GEOPHYS RES-ATMOS, V95, P18723, DOI 10.1029/JD095iD11p18723; PRATHER MJ, 1989, NASA C PUBL, V3023; PRINN R, 1987, SCIENCE, V238, P945, DOI 10.1126/science.238.4829.945; PRINN R, 1992, J GEOPHYS RES-ATMOS, V97, P2445, DOI 10.1029/91JD02755; RASMUSSEN RA, 1981, J GEOPHYS RES-OCEANS, V86, P9826, DOI 10.1029/JC086iC10p09826; RASMUSSEN RA, 1984, J GEOPHYS RES-ATMOS, V89, P1599, DOI 10.1029/JD089iD07p11599; RAYNAUD D, 1988, NATURE, V333, P655, DOI 10.1038/333655a0; RIND D, 1990, J ATMOS SCI, V47, P475, DOI 10.1175/1520-0469(1990)047<0475:CCATMA>2.0.CO;2; SANDRONI S, 1992, J GEOPHYS RES-ATMOS, V97, P2535, DOI 10.1029/91JD02660; SCHNELL RC, 1991, NATURE, V351, P726, DOI 10.1038/351726a0; SIGG A, 1991, NATURE, V351, P557, DOI 10.1038/351557a0; SIGG A, 1992, J ATMOS CHEM, V14, P223, DOI 10.1007/BF00115235; Sigg A., 1988, ANN GLACIOL, V10, P157; SOLBERG S, 1989, OZONE ATMOSPHERE, P548; SPIVAKOVSKY CM, 1991, J GEOPHYS RES-ATMOS, V96, P17395, DOI 10.1029/91JD01669; STAUFFER B, 1985, SCIENCE, V229, P1386, DOI 10.1126/science.229.4720.1386; STAUFFER B, 1988, NATURE, V332, P812, DOI 10.1038/332812a0; STOCKWELL WR, 1986, ATMOS ENVIRON, V20, P1615, DOI 10.1016/0004-6981(86)90251-9; STOCKWELL WR, 1990, J GEOPHYS RES-ATMOS, V95, P16343, DOI 10.1029/JD095iD10p16343; STOLARSKI RS, 1991, GEOPHYS RES LETT, V18, P1015, DOI 10.1029/91GL01302; SZE N D, 1977, Science (Washington D C), V195, P673, DOI 10.1126/science.195.4279.673; Thompson AD, UNPUB; THOMPSON AM, 1986, J GEOPHYS RES-ATMOS, V91, P853, DOI 10.1029/JD091iD10p10853; THOMPSON AM, 1990, J GEOPHYS RES-ATMOS, V95, P9829, DOI 10.1029/JD095iD07p09829; THOMPSON AM, 1989, ATMOS ENVIRON, V23, P519, DOI 10.1016/0004-6981(89)90001-2; THOMPSON AM, 1991, ATMOS ENVIRON A-GEN, V25, P1837, DOI 10.1016/0960-1686(91)90267-B; THOMPSON AM, 1991, J GEOPHYS RES-ATMOS, V96, P13089, DOI 10.1029/91JD01056; THOMPSON AM, 1984, J GEOPHYS RES-ATMOS, V89, P1341, DOI 10.1029/JD089iD01p01341; THOMPSON AM, 1991, NATURE, V352, P282, DOI 10.1038/352282a0; THOMPSON AM, IN PRESS ATMOS ENV; VALENTIN KM, 1990, THESIS JOHANNESGUTEN; VOLZ A, 1988, NATURE, V332, P240, DOI 10.1038/332240a0; WANG WC, 1980, J ATMOS SCI, V37, P333, DOI 10.1175/1520-0469(1980)037<0333:CEDTHC>2.0.CO;2; WATSON RT, 1990, CLIMATE CHANGE IPCC, pCH1; WUEBBLES DJ, 1989, JAPCA J AIR WASTE MA, V39, P22, DOI 10.1080/08940630.1989.10466502; WUEBBLES DJ, 1989, 1988 SENS URB REG CH; WUEBBLES DJ, 1987, UCRL21178 LAWR LIV N; ZIMMERMANN PH, 1988, AIR POLLUTION MODELI, V6, P593; 1990, NOAACMDL18 SUMM REP, P40	121	611	642	11	213	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 22	1992	256	5060					1157	1165		10.1126/science.256.5060.1157	http://dx.doi.org/10.1126/science.256.5060.1157			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV192	1317061				2022-12-01	WOS:A1992HV19200024
J	BAGASRA, O; HAUPTMAN, SP; LISCHNER, HW; SACHS, M; POMERANTZ, RJ				BAGASRA, O; HAUPTMAN, SP; LISCHNER, HW; SACHS, M; POMERANTZ, RJ			DETECTION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 PROVIRUS IN MONONUCLEAR-CELLS BY INSITU POLYMERASE CHAIN-REACTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN GLIAL-CELLS; PERIPHERAL-BLOOD; HTLV-III; T-CELL; INFECTED INDIVIDUALS; HIV INFECTION; SYNDROME AIDS; DNA; EXPRESSION; HYBRIDIZATION	Background. Studies of human immunodeficiency virus type 1 (HIV-1) infection have attempted to quantitate the viral load and correlate it with the degree of immune deficiency. In one study, only about 1 in 10,000 peripheral-blood mononuclear cells (PBMC) expressed HIV-1, but in other studies, at least 1 in 100 CD4-positive cells was infected and harbored the HIV-1 provirus. Methods. We developed a new, highly sensitive in situ polymerase-chain-reaction (PCR) method that amplifies selected genetic regions within intact single cells. We used this technique to determine the proportion of PBMC carrying HIV-1 provirus in infected patients in different stages of disease. Results. None of the PBMC from 11 HIV-1-seronegative patients were found to be positive for HIV-1 provirus by the in situ PCR method. In 56 patients infected with HIV-1, the percentage of PBMC with HIV-1 ranged from 0.1 percent to 13.5 percent. The mean percentage of infected mononuclear cells was greater in 13 patients with persistent generalized adenopathy (mean, 6.6 percent) and 19 with the acquired immunodeficiency syndrome (Stages IV-A to IV-C) (4.6 percent) than in 19 patients with asymptomatic HIV-1 infection (0.9 percent) (P < 0.001). However, in five patients with Kaposi's sarcoma (Stage IV-D), an average of only 1.6 percent of mononuclear cells were infected Conclusions. In HIV-1 infection, the proportion of PBMC that are infected appears to be at least 10 times higher than previously described. It is likely that most infected cells contain HIV-1 provirus in a latent or defective form that was not detected in some earlier studies.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,CARDEZA FDN HEMATOL RES,PHILADELPHIA,PA 19107; ST CHRISTOPHERS HOSP CHILDREN,DEPT PEDIAT,PHILADELPHIA,PA 19133; TEMPLE UNIV,PHILADELPHIA,PA 19122	Jefferson University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	BAGASRA, O (corresponding author), THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT MED,DIV INFECT DIS,1025 WALNUT ST,SUITE 813,PHILADELPHIA,PA 19107, USA.				NIAID NIH HHS [AI-00930] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K11AI000930] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BORKOWSKY W, 1987, LANCET, V1, P1168; BRINCHMANN JE, 1991, J VIROL, V65, P2019, DOI 10.1128/JVI.65.4.2019-2023.1991; BUKRINSKY MI, 1991, SCIENCE, V254, P423, DOI 10.1126/science.1925601; CHENGMAYER C, 1987, P NATL ACAD SCI USA, V84, P3526, DOI 10.1073/pnas.84.10.3526; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; CLEWLEY JP, 1989, J VIROL METHODS, V25, P179, DOI 10.1016/0166-0934(89)90031-1; CLOUSE KA, 1989, J IMMUNOL, V142, P431; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; DEFRANCHIS R, 1988, NUCLEIC ACIDS RES, V16, P10355, DOI 10.1093/nar/16.21.10355; DEWHURST S, 1987, J VIROL, V61, P3774, DOI 10.1128/JVI.61.12.3774-3782.1987; DICKOVER RE, 1990, J CLIN MICROBIOL, V28, P2130, DOI 10.1128/JCM.28.9.2130-2133.1990; DUESBERG PH, 1991, P NATL ACAD SCI USA, V88, P1575, DOI 10.1073/pnas.88.4.1575; FARZADEGAN H, 1988, ANN INTERN MED, V108, P785, DOI 10.7326/0003-4819-108-6-785; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; FOLKS TM, 1987, SCIENCE, V238, P800, DOI 10.1126/science.3313729; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; GENESCA J, 1990, J INFECT DIS, V162, P1025, DOI 10.1093/infdis/162.5.1025; HAASE AT, 1990, P NATL ACAD SCI USA, V87, P4971, DOI 10.1073/pnas.87.13.4971; HARPER ME, 1986, P NATL ACAD SCI USA, V83, P772, DOI 10.1073/pnas.83.3.772; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HO DD, 1986, J CLIN INVEST, V77, P1712, DOI 10.1172/JCI112491; HO DD, 1987, NEW ENGL J MED, V317, P278; HORSBURGH RC, 1990, J INFECT DIS, V152, P542; HSIA K, 1991, J INFECT DIS, V164, P470, DOI 10.1093/infdis/164.3.470; IKEUCHI K, 1990, J VIROL, V64, P4226, DOI 10.1128/JVI.64.9.4226-4231.1990; JACKSON JB, 1988, JAMA-J AM MED ASSOC, V260, P2236; JACKSON JB, 1990, J CLIN MICROBIOL, V28, P16, DOI 10.1128/JCM.28.1.16-19.1990; KELLER GH, 1989, ANAL BIOCHEM, V177, P27, DOI 10.1016/0003-2697(89)90007-9; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; KWOK S, 1989, NATURE, V339, P490; KWOK S, 1989, PCR PROTOCOLS GUIDE, P142; LEWIS DE, 1990, J INFECT DIS, V162, P1373, DOI 10.1093/infdis/162.6.1373; LIFSON AR, 1990, J INFECT DIS, V161, P436, DOI 10.1093/infdis/161.3.436; LOCHE M, 1988, LANCET, V2, P418; MEYERHANS A, 1989, CELL, V58, P901, DOI 10.1016/0092-8674(89)90942-2; MONTAGNIER L, 1984, SCIENCE, V225, P63, DOI 10.1126/science.6328661; OU CY, 1988, SCIENCE, V239, P295, DOI 10.1126/science.3336784; POMERANTZ RJ, 1987, NEW ENGL J MED, V317, P1643, DOI 10.1056/NEJM198712243172607; POMERANTZ RJ, 1988, ANN INTERN MED, V108, P321, DOI 10.7326/0003-4819-108-3-321; POMERANTZ RJ, 1990, CELL, V61, P1271, DOI 10.1016/0092-8674(90)90691-7; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; POZNANSKY MC, 1991, J ACQ IMMUN DEF SYND, V4, P368; PYUN KH, 1987, NEW ENGL J MED, V317, P611, DOI 10.1056/NEJM198709033171006; ROTHENBERG R, 1987, NEW ENGL J MED, V317, P1297, DOI 10.1056/NEJM198711193172101; SALAHUDDIN SZ, 1985, P NATL ACAD SCI USA, V82, P5530, DOI 10.1073/pnas.82.16.5530; SALAHUDDIN SZ, 1986, BLOOD, V68, P281; SCHNITTMAN SM, 1990, ANN INTERN MED, V113, P438, DOI 10.7326/0003-4819-113-6-438; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; SIMMONDS P, 1990, J VIROL, V64, P864, DOI 10.1128/JVI.64.2.864-872.1990; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; TATENO M, 1989, P NATL ACAD SCI USA, V86, P4287, DOI 10.1073/pnas.86.11.4287; TSUBOTA H, 1989, J IMMUNOL, V143, P858; WATKINS BA, 1990, SCIENCE, V249, P549, DOI 10.1126/science.2200125; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; [No title captured]	56	276	293	2	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 21	1992	326	21					1385	1391		10.1056/NEJM199205213262103	http://dx.doi.org/10.1056/NEJM199205213262103			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HU890	1569974				2022-12-01	WOS:A1992HU89000003
J	GOLDSTEIN, B				GOLDSTEIN, B			INDUCTION OF GUT IN CAENORHABDITIS-ELEGANS EMBRYOS	NATURE			English	Article								Two types of developmental events can cause an embryonic cell to adopt a fate different from that of its neighbours: during a cell division particular contents may be segregated to only one daughter cell and cells may experience different external cues, commonly in the form of inductive cell interactions. Work on development in the nematode Caenorhabditis elegans suggests that most cell fates are specified without a need for cell interactions. In particular, the gut cell lineage of C. elegans has been used as a primary example of specification by differential segregation of determinants 1. Here I re-examine the role of induction in gut specification by isolating early blastomeres. In C. elegans, the gut derives from all the progeny of a single blastomere (E) of the eight-cell stage 2. When a gut precursor cell (EMS) is isolated during the first half of the four-cell stage, gut does not differentiate. Gut differentiation is rescued by recombining EMS with its posterior neighbour (P2), but not by recombining EMS with one or both of the other two cells of the four-cell stage. These results demonstrate that P2 induces EMS to form gut in C. elegans.			GOLDSTEIN, B (corresponding author), UNIV TEXAS,DEPT ZOOL,CTR DEV BIOL,AUSTIN,TX 78712, USA.			Goldstein, Bob/0000-0001-6961-675X				Chitwood, 1974, INTRO NEMATOLOGY; Davidson E. H., 1986, GENE ACTIVITY EARLY; EDGAR LG, 1986, DEV BIOL, V114, P109, DOI 10.1016/0012-1606(86)90387-8; LAUFER JS, 1981, SCIENCE, V211, P402, DOI 10.1126/science.7194506; LAUFER JS, 1980, CELL, V19, P569, DOI 10.1016/S0092-8674(80)80033-X; MAINE EM, 1990, BIOESSAYS, V12, P265, DOI 10.1002/bies.950120604; PRIESS JR, 1987, CELL, V48, P241, DOI 10.1016/0092-8674(87)90427-2; SCHIERENBERG E, 1987, DEV BIOL, V122, P452, DOI 10.1016/0012-1606(87)90309-5; SCHNABEL R, 1991, MECH DEVELOP, V34, P85, DOI 10.1016/0925-4773(91)90046-9; Sulston J.E., 1988, NEMATODE CAENORHABDI, P587; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; WOOD WB, 1991, NATURE, V349, P536, DOI 10.1038/349536a0	12	183	183	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 21	1992	357	6375					255	257		10.1038/357255a0	http://dx.doi.org/10.1038/357255a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV195	1589023				2022-12-01	WOS:A1992HV19500059
J	JAFFE, DB; JOHNSTON, D; LASSERROSS, N; LISMAN, JE; MIYAKAWA, H; ROSS, WN				JAFFE, DB; JOHNSTON, D; LASSERROSS, N; LISMAN, JE; MIYAKAWA, H; ROSS, WN			THE SPREAD OF NA+ SPIKES DETERMINES THE PATTERN OF DENDRITIC CA2+ ENTRY INTO HIPPOCAMPAL-NEURONS	NATURE			English	Article							LONG-TERM POTENTIATION; PYRAMIDAL CELLS; RAT HIPPOCAMPUS; CALCIUM; EXCITABILITY; ORGANIZATION; INDICATORS; ACTIVATION; INDUCTION; SYNAPSES	THE dendrites of many types of neurons contain voltage-dependent Na+ and Ca2+ conductances that generate action potentials (see ref. 1 for review). The function of these spikes is not well understood, but the Ca2+ entry stimulated by spikes probably affects Ca2+-dependent processes in dendrites. These include synaptic plasticity 2,3, cytotoxicity 4 and exocytosis 5. Several lines of evidence suggest that dendritic spikes occur within subregions of the dendrites 6-8. To study the mechanism that govern the spread of spikes in the dendrites of hippocampal pyramidal cells, we imaged Ca2+ entry with Fura-2 (ref. 9) and Na+ entry with a newly developed Na+-sensitive dye 10). Our results indicate that Ca2+ entry into dendrites is triggered by Na+ spikes that actively invade the dendrites. The restricted spatial distribution of Ca2+ entry seems to depend on the spread of Na+ spikes in the dendrites, rather than on a limited distribution of Ca2+ channels. In addition, we have observed an activity-dependent process that modulates the invasion of spikes into the dendrites and progressively restricts Ca2+ entry to more proximal dendritic regions.	NEW YORK MED COLL,DEPT PHYSIOL,VALHALLA,NY 10595; BAYLOR COLL MED,DIV NEUROSCI,HOUSTON,TX 77030; BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254; YAMAGATA UNIV,SCH MED,DEPT PHYSIOL,YAMAGATA 99023,JAPAN; MARINE BIOL LAB,WOODS HOLE,MA 02543	New York Medical College; Baylor College of Medicine; Brandeis University; Yamagata University; Marine Biological Laboratory - Woods Hole					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016295] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS016295] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMARAL DG, 1989, NEUROSCIENCE, V31, P571, DOI 10.1016/0306-4522(89)90424-7; ANDERSEN P, 1987, J PHYSIOL-LONDON, V383, P509; BLAUSTEIN MP, 1988, TRENDS NEUROSCI, V11, P438, DOI 10.1016/0166-2236(88)90195-6; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; JAFFE D, 1990, J NEUROPHYSIOL, V64, P948, DOI 10.1152/jn.1990.64.3.948; JOHNSTON D, 1983, J NEUROPHYSIOL, V50, P464, DOI 10.1152/jn.1983.50.2.464; LANCASTER B, 1986, J NEUROPHYSIOL, V55, P1268, DOI 10.1152/jn.1986.55.6.1268; LASSERROSS N, 1992, P ROY SOC B-BIOL SCI, V247, P35, DOI 10.1098/rspb.1992.0006; LASSERROSS N, 1991, J NEUROSCI METH, V36, P253, DOI 10.1016/0165-0270(91)90051-Z; LEV-RAM V, 1990, Society for Neuroscience Abstracts, V16, P894; LISMAN J, 1989, P NATL ACAD SCI USA, V86, P9574, DOI 10.1073/pnas.86.23.9574; LLINAS RR, 1988, SCIENCE, V242, P1654, DOI 10.1126/science.3059497; LLINAS RR, 1987, P NATL ACAD SCI USA, V84, P3047, DOI 10.1073/pnas.84.9.3047; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; MALENKA RC, 1988, SCIENCE, V242, P81, DOI 10.1126/science.2845577; MASUKAWA LM, 1984, J NEUROSCI, V4, P217; MINTA A, 1989, J BIOL CHEM, V264, P19449; MIYAKAWA H, 1986, BRAIN RES, V5399, P303; REGEHR WG, 1989, NATURE, V341, P533, DOI 10.1038/341533a0; ROSS W N, 1991, Society for Neuroscience Abstracts, V17, P581; ROSS WN, 1990, PROC R SOC SER B-BIO, V240, P173, DOI 10.1098/rspb.1990.0032; SAH P, 1989, SCIENCE, V246, P815, DOI 10.1126/science.2573153; STEWARD O, 1976, J COMP NEUROL, V167, P285, DOI 10.1002/cne.901670303; TURNER RW, 1989, J NEUROPHYSIOL, V62, P1375, DOI 10.1152/jn.1989.62.6.1375; TURNER RW, 1991, J NEUROSCI, V11, P2270; WESTENBROEK RE, 1990, NATURE, V347, P281, DOI 10.1038/347281a0; WONG RKS, 1979, SCIENCE, V204, P1228, DOI 10.1126/science.451569	28	376	378	1	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 21	1992	357	6375					244	246		10.1038/357244a0	http://dx.doi.org/10.1038/357244a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV195	1350327				2022-12-01	WOS:A1992HV19500055
J	KELEN, GD; GREEN, GB; PURCELL, RH; CHAN, DW; QAQISH, BF; SIVERTSON, KT; QUINN, TC				KELEN, GD; GREEN, GB; PURCELL, RH; CHAN, DW; QAQISH, BF; SIVERTSON, KT; QUINN, TC			HEPATITIS-B AND HEPATITIS-C IN EMERGENCY DEPARTMENT PATIENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; NON-A; HEPATOCELLULAR-CARCINOMA; SEXUAL TRANSMISSION; UNITED-STATES; CIRCULATING ANTIBODIES; RISK; INFECTION; EPIDEMIOLOGY; PREVALENCE	Background. Infections with hepatitis B virus (HBV), hepatitis C virus (HCV), and the human immunodeficiency virus type 1 (HIV-1) are common in inner-city populations, but their frequency and interrelations are not well established. Methods. During a six-week period, excess serum samples were collected, along with information on risk factors, from all adult patients presenting to an inner-city emergency department. The samples were assayed for hepatitis B surface antigen (HBsAg) and antibodies to HCV and HIV-1. Results. Of the 2523 patients tested, 612 (24 percent) were infected with at least one of the three viruses. Five percent were seropositive for HBV, 18 percent for HCV, and 6 percent for HIV-1. HCV was found in 145 of the 175 intravenous drug users (83 percent), 36 of the 171 transfusion recipients (21 percent), and 5 of the 24 homosexual men (21 percent). Among black men 35 to 44 years of age, the seroprevalence of HCV was 51 percent. HBsAg was present in 9 percent of those whose only identifiable risk was possible heterosexual exposure. At least one viral marker was found in about 30 percent of the patients who were actively bleeding or in whom procedures were performed. Testing for HIV-1 alone would have failed to identify 87 percent of the patients infected with HBV and 80 percent of those infected with HCV. Conclusions. In a population of patients in an inner-city emergency room, HBV, HCV, and HIV-1 are all highly prevalent. However, routine screening for HIV-1 alone would identify only a small fraction of the patients who pose risks of severe viral infections, including HBV and HCV, to providers.	JOHNS HOPKINS UNIV,SCH MED,DIV EMERGENCY MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DIV INFECT DIS,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV HOSP,DEPT LAB MED,BALTIMORE,MD 21205; UNIV N CAROLINA,DEPT BIOSTAT,CHAPEL HILL,NC 27514; NIAID,INFECT DIS LAB,BETHESDA,MD 20892; NIAID,IMMUNOREGULAT LAB,BETHESDA,MD 20892	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Quinn, Thomas/A-2494-2010	Kelen, Gabor/0000-0002-3236-8286				AHTONE J, 1980, LANCET, V1, P1142; ALEXANDER PG, 1990, PUBLIC HEALTH REP, V105, P610; ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER MJ, 1982, J INFECT DIS, V145, P886, DOI 10.1093/infdis/145.6.886; ALTER MJ, 1990, JAMA-J AM MED ASSOC, V264, P2231, DOI 10.1001/jama.264.17.2231; ALTER MJ, 1989, JAMA-J AM MED ASSOC, V262, P1201, DOI 10.1001/jama.262.9.1201; ANGELL M, 1991, NEW ENGL J MED, V324, P1498, DOI 10.1056/NEJM199105233242110; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; COLOMBO M, 1989, LANCET, V2, P1006; DIENSTAG JL, 1983, GASTROENTEROLOGY, V85, P439; DIENSTAG JL, 1982, AM J EPIDEMIOL, V115, P26, DOI 10.1093/oxfordjournals.aje.a113277; DONAHUE JG, 1991, AM J EPIDEMIOL, V134, P1206, DOI 10.1093/oxfordjournals.aje.a116023; ESTEBAN JI, 1990, NEW ENGL J MED, V323, P1107, DOI 10.1056/NEJM199010183231605; ESTEBAN JI, 1989, LANCET, V2, P294; EVATT BL, 1985, NEW ENGL J MED, V312, P483, DOI 10.1056/NEJM198502213120805; EVERHART JE, 1990, ANN INTERN MED, V112, P544, DOI 10.7326/0003-4819-112-7-544; FARCI P, 1991, NEW ENGL J MED, V325, P98, DOI 10.1056/NEJM199107113250205; GORDIN FM, 1990, J INFECT DIS, V161, P14, DOI 10.1093/infdis/161.1.14; HANDSFIELD HH, 1987, JAMA-J AM MED ASSOC, V258, P3395, DOI 10.1001/jama.258.23.3395; HESS G, 1989, LANCET, V2, P987; HOPF U, 1990, J HEPATOL, V10, P69, DOI 10.1016/0168-8278(90)90075-3; JOHNSON RE, 1985, AM J EPIDEMIOL, V121, P797, DOI 10.1093/oxfordjournals.aje.a114051; JOVANOVICH JF, 1983, JAMA-J AM MED ASSOC, V250, P1893; KELEN GD, 1989, JAMA-J AM MED ASSOC, V262, P516, DOI 10.1001/jama.262.4.516; KELEN GD, 1988, NEW ENGL J MED, V318, P1645, DOI 10.1056/NEJM198806233182503; KEW MC, 1990, LANCET, V335, P873, DOI 10.1016/0140-6736(90)90474-J; KIYOSAWA K, 1991, ANN INTERN MED, V115, P367, DOI 10.7326/0003-4819-115-5-367; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LIANG KY, IN PRESS J R STAT B; LIDDLE C, 1990, MED J AUSTRALIA, V153, P265, DOI 10.5694/j.1326-5377.1990.tb136898.x; MARCUS R, 1990, MAY ANN M SOC AC EM; MAYOSMITH MF, 1987, AM J INFECT CONTROL, V15, P266, DOI 10.1016/0196-6553(87)90120-9; MELBYE M, 1990, BRIT MED J, V301, P210, DOI 10.1136/bmj.301.6745.210; MOSLEY JW, 1990, JAMA-J AM MED ASSOC, V263, P77, DOI 10.1001/jama.263.1.77; NALPAS B, 1991, J HEPATOL, V12, P70, DOI 10.1016/0168-8278(91)90912-U; PARES A, 1990, HEPATOLOGY, V12, P1295, DOI 10.1002/hep.1840120608; RHAME FS, 1989, NEW ENGL J MED, V320, P1248, DOI 10.1056/NEJM198905113201905; SAKAMOTO M, 1988, CANCER RES, V48, P7294; SCHLIPKOTER U, 1990, SCAND J INFECT DIS, V22, P757, DOI 10.3109/00365549009027136; SEEFF LB, 1991, ANN INTERN MED, V115, P411, DOI 10.7326/0003-4819-115-5-411_1; STEVENS CE, 1990, JAMA-J AM MED ASSOC, V263, P49, DOI 10.1001/jama.263.1.49; TOR J, 1990, BRIT MED J, V301, P1130, DOI 10.1136/bmj.301.6761.1130; VALLARI DS, 1992, J CLIN MICROBIOL, V30, P552, DOI 10.1128/JCM.30.3.552-556.1992; Watson G.S., 1964, SANKHYA A, V26, P359, DOI DOI 10.2307/25049340; WEARS RL, 1991, ANN EMERG MED, V20, P749, DOI 10.1016/S0196-0644(05)80836-4; WEINER AJ, 1990, LANCET, V336, P695, DOI 10.1016/0140-6736(90)92194-M; WERNER AJ, 1990, LANCET, V335, P1; WILLIAMS AE, 1990, ANN CLIN LAB SCI, V20, P192; 1989, MMWR SS6, V38; 1991, MMWR SRR13, V40, P1; 1990, MMWR SRR2, V39, P5; 1991, MMWR SRR8, V40, P1; 1989, 1ST P INT S HEP C VI, pCH2; 1987, MMWR, V36, P353	54	246	248	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 21	1992	326	21					1399	1404		10.1056/NEJM199205213262105	http://dx.doi.org/10.1056/NEJM199205213262105			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HU890	1373867				2022-12-01	WOS:A1992HU89000005
J	KULLMANN, DM; NICOLL, RA				KULLMANN, DM; NICOLL, RA			LONG-TERM POTENTIATION IS ASSOCIATED WITH INCREASES IN QUANTAL CONTENT AND QUANTAL AMPLITUDE	NATURE			English	Article							PRESYNAPTIC MECHANISM; HIPPOCAMPAL SLICES; PERFORANT PATH; NEURONS; INDUCTION; ALGORITHM; RELEASE	LONG-TERM potentiation (LTP) of synaptic transmission in CA1 neurons of the hippocampus, elicited by the conjunction of presynaptic firing and postsynaptic depolarization, is an important model of plasticity, which may underlie memory storage 1-3. Although induction of LTP takes place in the postsynaptic cell 4-7, it is not clear whether it is expressed through an enhancement of transmitter release 8-12 or through an increased postsynaptic response to the same amount of transmitter 13-16. Analysis of the trial-to-trial amplitude fluctuations of synaptic signals, that is quantal analysis, gives an important insight into the probabilistic mechanisms of transmission, although attempts to apply it to the mode of expression of LTP have so far yielded inconsistent results 9-12,15, at least in part because they have relied on models of transmitter release that have not been confirmed experimentally 17-19. Here we report clear evidence for quantal fluctuation in a subset of cells. Induction of LTP in these cells causes abrupt increases in either quantal content or quantal amplitude, or both. This shows that two different mechanisms can underlie the maintenance of LTP.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco			Kullmann, Dimitri M/A-3162-2009	Kullmann, Dimitri M/0000-0001-6696-3545				BEKKERS JM, 1990, P NATL ACAD SCI USA, V87, P5359, DOI 10.1073/pnas.87.14.5359; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BLISS T V P, 1988, P3; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; CLEMENTS J, 1991, NATURE, V353, P396, DOI 10.1038/353396a0; COLEMAN PA, 1989, J NEUROPHYSIOL, V61, P218, DOI 10.1152/jn.1989.61.1.218; DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1, DOI 10.1111/j.2517-6161.1977.tb01600.x; DOLPHIN AC, 1982, NATURE, V297, P496, DOI 10.1038/297496a0; EDWARDS F, 1991, NATURE, V350, P271, DOI 10.1038/350271a0; Foster T C, 1991, Hippocampus, V1, P79, DOI 10.1002/hipo.450010108; GULL SF, 1978, NATURE, V272, P686, DOI 10.1038/272686a0; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; KAUER JA, 1988, NEURON, V1, P911, DOI 10.1016/0896-6273(88)90148-1; KELSO SR, 1986, P NATL ACAD SCI USA, V83, P5326, DOI 10.1073/pnas.83.14.5326; KORN H, 1991, TRENDS NEUROSCI, V14, P439, DOI 10.1016/0166-2236(91)90042-S; KULLMANN DM, 1989, J NEUROSCI METH, V30, P231, DOI 10.1016/0165-0270(89)90134-9; LARKMAN A, 1991, NATURE, V350, P344, DOI 10.1038/350344a0; MALINOW R, 1986, NATURE, V320, P529, DOI 10.1038/320529a0; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MALINOW R, 1991, SCIENCE, V252, P722, DOI 10.1126/science.1850871; MALINOW R, 1991, NATURE, V252, P722; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; MULLER D, 1988, SCIENCE, V242, P1694, DOI 10.1126/science.2904701; NICOLL RA, 1988, NEURON, V1, P97, DOI 10.1016/0896-6273(88)90193-6; NICOLL RA, 1981, J NEUROSCI METH, V4, P153, DOI 10.1016/0165-0270(81)90049-2; REDMAN S, 1990, PHYSIOL REV, V70, P165, DOI 10.1152/physrev.1990.70.1.165; SASTRY BR, 1986, SCIENCE, V232, P988, DOI 10.1126/science.3010459; VORONIN LL, 1990, NEUROPHYSIOLOGY+, V22, P341; WIGSTROM H, 1986, ACTA PHYSIOL SCAND, V126, P317, DOI 10.1111/j.1748-1716.1986.tb07822.x; ZUCKER RS, 1973, J PHYSIOL-LONDON, V229, P787, DOI 10.1113/jphysiol.1973.sp010167	31	232	234	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 21	1992	357	6375					240	244		10.1038/357240a0	http://dx.doi.org/10.1038/357240a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV195	1317014				2022-12-01	WOS:A1992HV19500054
J	LANZAVECCHIA, A; REID, PA; WATTS, C				LANZAVECCHIA, A; REID, PA; WATTS, C			IRREVERSIBLE ASSOCIATION OF PEPTIDES WITH CLASS-II MHC MOLECULES IN LIVING CELLS	NATURE			English	Article							INVARIANT CHAIN; T-CELLS; B-CELLS; HLA-DR; ANTIGEN PRESENTATION; PROTEIN ANTIGENS; LYMPHOCYTE-B; BREFELDIN-A; BINDING; IA	FUNCTIONAL, morphological and biochemical evidence indicates that class II major histocompatibility complex (MHC) molecules associate with processed peptides during biosynthesis 1-9. Peptide/MHC complexes in living cells have been reported to be less stable than similar complexes generated in vitro, which has led to the suggestion that there may be a peptide exchange mechanism operating in vivo 10-12. Although this could increase the capacity for binding incoming antigens, it would reduce the efficacy of processed antigenic peptides by exchanging these for self peptides. Here we measure the half-life of peptide/class II complexes in human antigen-presenting cells and find that it is very similar to the half-life of class II molecules themselves, indicating that peptides are bound irreversibly under physiological conditions. Thus class II MHC retains long-term 'memory' of past encounters with antigen to maximize the opportunity for T cell/antigen-presenting cell interaction.	UNIV DUNDEE,INST MED SCI,DEPT BIOCHEM,DUNDEE DD1 4HN,SCOTLAND	University of Dundee	LANZAVECCHIA, A (corresponding author), BASEL INST IMMUNOL,GRENZACHERSTR 487,CH-4005 BASEL,SWITZERLAND.			Watts, Colin/0000-0001-6183-2087	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADORINI L, 1990, NATURE, V346, P63, DOI 10.1038/346063a0; ADORINI L, 1989, NATURE, V342, P800, DOI 10.1038/342800a0; BRETSCHER MS, 1988, EMBO J, V7, P4087, DOI 10.1002/j.1460-2075.1988.tb03302.x; BUSCH R, 1990, INT IMMUNOL, V2, P443, DOI 10.1093/intimm/2.5.443; DAVIDSON HW, 1989, J CELL BIOL, V109, P85, DOI 10.1083/jcb.109.1.85; DAVIDSON HW, 1991, CELL, V67, P105, DOI 10.1016/0092-8674(91)90575-J; DAVIS JE, 1990, J IMMUNOL, V144, P990; FLAJNIK MF, 1991, P NATL ACAD SCI USA, V88, P537, DOI 10.1073/pnas.88.2.537; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; GUY K, 1982, EUR J IMMUNOL, V12, P942, DOI 10.1002/eji.1830121109; HARDING CV, 1989, P NATL ACAD SCI USA, V86, P4230, DOI 10.1073/pnas.86.11.4230; HARDING CV, 1989, J IMMUNOL, V142, P12; JENSEN PE, 1990, J EXP MED, V171, P1779, DOI 10.1084/jem.171.5.1779; JENSEN PE, 1989, J IMMUNOL, V143, P420; KAMPGEN E, 1991, P NATL ACAD SCI USA, V88, P3014, DOI 10.1073/pnas.88.8.3014; LANZAVECCHIA A, 1985, NATURE, V314, P537, DOI 10.1038/314537a0; LANZAVECCHIA A, 1987, IMMUNOL REV, V99, P39, DOI 10.1111/j.1600-065X.1987.tb01171.x; LEE JM, 1990, J IMMUNOL, V144, P1829; MATHIS L, 1983, P NATL ACAD SCI USA, V80, P6019; NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3; NEEFJES JJ, 1992, EMBO J, V11, P411, DOI 10.1002/j.1460-2075.1992.tb05069.x; NYGARD NR, 1991, J EXP MED, V174, P243, DOI 10.1084/jem.174.1.243; PANINABORDIGNON P, 1991, SCIENCE, V252, P1548, DOI 10.1126/science.1710827; PANINABORDIGNON P, 1989, EUR J IMMUNOL, V19, P2237, DOI 10.1002/eji.1830191209; PEDRAZZINI T, 1991, J IMMUNOL, V146, P3496; PERNIS B, 1985, IMMUNOL TODAY, V6, P45, DOI 10.1016/0167-5699(85)90046-5; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; PURE E, 1990, J EXP MED, V172, P1459, DOI 10.1084/jem.172.5.1459; REID PA, 1990, NATURE, V346, P655, DOI 10.1038/346655a0; RIPPMANN F, 1991, EMBO J, V10, P1053, DOI 10.1002/j.1460-2075.1991.tb08044.x; ROCHE PA, 1990, J IMMUNOL, V144, P1849; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; ROTHBARD JB, 1991, ANNU REV IMMUNOL, V9, P527, DOI 10.1146/annurev.iy.09.040191.002523; SADEGHNASSERI S, 1991, NATURE, V353, P167, DOI 10.1038/353167a0; STERN LJ, 1992, CELL, V68, P465, DOI 10.1016/0092-8674(92)90184-E; STPIERRE Y, 1990, J IMMUNOL, V145, P812; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; THOMPSON JA, 1987, BIOCHEMISTRY-US, V26, P743, DOI 10.1021/bi00377a014	40	175	181	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 21	1992	357	6375					249	252		10.1038/357249a0	http://dx.doi.org/10.1038/357249a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV195	1375347				2022-12-01	WOS:A1992HV19500057
J	MOLLER, AP				MOLLER, AP			FEMALE SWALLOW PREFERENCE FOR SYMMETRICAL MALE SEXUAL ORNAMENTS	NATURE			English	Article							FLUCTUATING ASYMMETRY; TAIL LENGTH; CHOICE	MANY secondary sexual characters are supposed to have evolved as a response to female choice of the most extravagantly ornamented males 1, a hypothesis supported by studies demonstrating female preferences for the most ornamented males 2-5. Comparative studies of elaborate feather ornaments in birds have shown that (1) ornaments have larger degrees of fluctuating asymmetry 6 (small, random deviations from bilateral symmetry caused by an inability of individuals to cope with environmental and genetic stress during development of a character 7) than other morphological traits, and (2) the degree of fluctuating asymmetry is often negatively related to the size of the ornament 6. The negative relationship between ornament asymmetry and size suggests that ornament size reliably reflects male quality because the largest secondary sex traits demonstrate the least degree of fluctuating asymmetry. I manipulated tail length and tail asymmetry independently in male swallows (Hirundo rustica) to determine whether ornament size or asymmetry were used as cues in mate choice. Male swallows with elongated, symmetric tails mated earlier, and enjoyed larger annual reproductive success than did males with shortened tails and increased asymmetry. Females therefore prefer large as well as symmetric ornaments, which suggests that females in their mate choice use ornament asymmetry and size as reliable indicators of male quality.	UNIV UPPSALA,DEPT ZOOL,S-75122 UPPSALA,SWEDEN	Uppsala University			Moller, Anders/O-6665-2016	Moller, Anders/0000-0003-3739-4675				ANDERSSON M, 1982, NATURE, V299, P818, DOI 10.1038/299818a0; Darwin C., 1871, P423; KIRKPATRICK M, 1991, NATURE, V350, P33, DOI 10.1038/350033a0; LUDWIG W, 1932, RECHTS LINK PROBLEM; MOLLER AP, 1990, ANIM BEHAV, V39, P458, DOI 10.1016/S0003-3472(05)80409-9; MOLLER AP, 1988, NATURE, V332, P640, DOI 10.1038/332640a0; MOLLER AP, 1991, P ROY SOC B-BIOL SCI, V245, P1, DOI 10.1098/rspb.1991.0080; MOLLER AP, 1991, P ROY SOC B-BIOL SCI, V243, P59, DOI 10.1098/rspb.1991.0010; MOLLER AP, 1990, ANIM BEHAV, V40, P1185, DOI 10.1016/S0003-3472(05)80187-3; PALMER AR, 1986, ANNU REV ECOL SYST, V17, P391, DOI 10.1146/annurev.es.17.110186.002135; PARSONS PA, 1990, BIOL REV, V65, P131, DOI 10.1111/j.1469-185X.1990.tb01186.x; PETRIE M, 1991, ANIM BEHAV, V41, P323, DOI 10.1016/S0003-3472(05)80484-1; SMITH HG, 1990, BEHAV ECOL SOCIOBIOL, V28, P195; Trivers R.L., 1972, SEXUAL SELECTION DES, P136, DOI DOI 10.1002/AJPA.1330400226; ZAHAVI A, 1975, J THEOR BIOL, V53, P205, DOI 10.1016/0022-5193(75)90111-3	15	397	400	0	95	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 21	1992	357	6375					238	240		10.1038/357238a0	http://dx.doi.org/10.1038/357238a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV195	1589021				2022-12-01	WOS:A1992HV19500053
J	STACEY, GN; BOLTON, BJ; DOYLE, A				STACEY, GN; BOLTON, BJ; DOYLE, A			DNA FINGERPRINTING TRANSFORMS THE ART OF CELL AUTHENTICATION	NATURE			English	Article							QUALITY-CONTROL; MARKERS; LINES	The increasing diversity of new cell cultures is seriously stretching the capabilities of traditional methods of identification. DNA fingerprinting is set to play an important role in increasing confidence in the authenticity of cultures in research and industry.			STACEY, GN (corresponding author), PUBL HLTH LAB SERV APPL MICROBIOL & RES,EUROPEAN COLLECT ANIM CELL CULTURES,DIV BIOL,SALISBURY SP4 0JG,WILTS,ENGLAND.							HALTON DM, 1983, IN VITRO CELL DEV B, V19, P16, DOI 10.1007/BF02617989; HANLAN CR, 1989, CYTOGENETICS ANIMALS, pR11; HAY RJ, 1988, ANAL BIOCHEM, V171, P225, DOI 10.1016/0003-2697(88)90480-0; JEFFREYS AJ, 1991, NATURE, V354, P204, DOI 10.1038/354204a0; JEFFREYS AJ, 1985, NATURE, V316, P76, DOI 10.1038/316076a0; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; MOWLES JM, 1990, CYTOTECHNOLOGY, V3, P107, DOI 10.1007/BF00143670; NAKAMURA Y, 1987, SCIENCE, V235, P1616, DOI 10.1126/science.3029872; NELSONRE.WA, 1974, SCIENCE, V184, P1093, DOI 10.1126/science.184.4141.1093; NELSONREES WA, 1976, SCIENCE, V195, P1343; OBRIEN SJ, 1980, IN VITRO CELL DEV B, V16, P119; STACEY GN, 1991, DNA FINGERPRINTING A; STACEY GN, IN PRESS CYTOTECHNOL; TAUTZ D, 1989, NUCLEIC ACIDS RES, V17, P6463, DOI 10.1093/nar/17.16.6463; THACKER J, 1988, SOMAT CELL MOLEC GEN, V14, P519, DOI 10.1007/BF01535307	15	39	40	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 21	1992	357	6375					261	262		10.1038/357261a0	http://dx.doi.org/10.1038/357261a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV195	1589025				2022-12-01	WOS:A1992HV19500061
J	THERIOT, JA; MITCHISON, TJ; TILNEY, LG; PORTNOY, DA				THERIOT, JA; MITCHISON, TJ; TILNEY, LG; PORTNOY, DA			THE RATE OF ACTIN-BASED MOTILITY OF INTRACELLULAR LISTERIA-MONOCYTOGENES EQUALS THE RATE OF ACTIN POLYMERIZATION	NATURE			English	Article							FILAMENTS	THE Gram-positive bacterium Listeria monocytogenes is a facultative intracellular pathogen capable of rapid movement through the host cell cytoplasm 1. The biophysical basis of the motility of L. monocytogenes is an interesting question in its own right, the answer to which may shed light on the general processes of actin-based motility in cells. Moving intracellular bacteria display phase-dense 'comet tails' made of actin filaments, the formation of which is required for bacterial Motility 2,3. We have investigated the dynamics of the actin filaments in the comet tails using the technique of photoactivation of fluorescence, which allows monitoring of the movement and turnover of labelled actin filaments after activation by illumination with ultraviolet light. We find that the actin filaments remain stationary in the cytoplasm as the bacterium moves forward, and that length of the comet tails is linearly proportional to the rate of movement. Our results imply that the motile mechanism involves continuous polymerization and release of actin filaments at the bacterial surface and that the rate of filament generation is related to the rate of movement. We suggest that actin polymerization provides the driving force for bacterial propulsion.	UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA; UNIV PENN, DEPT BIOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT MICROBIOL, PHILADELPHIA, PA 19104 USA	University of California System; University of California San Francisco; University of Pennsylvania; University of Pennsylvania	THERIOT, JA (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA.			Theriot, Julie/0000-0002-2334-2535	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI036929] Funding Source: NIH RePORTER; NIAID NIH HHS [R37 AI036929] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		DABIRI GA, 1990, P NATL ACAD SCI USA, V87, P6068, DOI 10.1073/pnas.87.16.6068; EGELMAN EH, 1982, NATURE, V298, P131, DOI 10.1038/298131a0; HILL TL, 1982, P NATL ACAD SCI-BIOL, V79, P490, DOI 10.1073/pnas.79.2.490; KOCKS C, 1992, CELL, V68, P521, DOI 10.1016/0092-8674(92)90188-I; MITCHISON TJ, 1989, J CELL BIOL, V109, P637, DOI 10.1083/jcb.109.2.637; OSTER GF, 1987, J CELL SCI, P35; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; SANDERS MC, 1990, J CELL BIOL, V110, P359, DOI 10.1083/jcb.110.2.359; SANGER J M, 1990, Journal of Cell Biology, V111, p415A; THERIOT JA, 1991, NATURE, V352, P126, DOI 10.1038/352126a0; TILNEY LG, 1990, J CELL BIOL, V111, P2979, DOI 10.1083/jcb.111.6.2979; TILNEY LG, 1989, J CELL BIOL, V109, P1597, DOI 10.1083/jcb.109.4.1597; TILNEY LG, IN PRESS J CELL BIOL	13	431	437	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 21	1992	357	6375					257	260		10.1038/357257a0	http://dx.doi.org/10.1038/357257a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV195	1589024				2022-12-01	WOS:A1992HV19500060
J	WHEELER, CJ; VONHOEGEN, P; PARNES, JR				WHEELER, CJ; VONHOEGEN, P; PARNES, JR			AN IMMUNOLOGICAL ROLE FOR THE CD8 BETA-CHAIN	NATURE			English	Article							TYROSINE-PROTEIN-KINASE; MAJOR HISTOCOMPATIBILITY COMPLEX; T-CELL RECEPTOR; MHC CLASS; MONOCLONAL-ANTIBODIES; ALPHA-3 DOMAIN; LYMPHOCYTES-T; EXPRESSION; MOLECULES; P56LCK	MATURE T cells can be functionally divided into two categories distinguished by surface expression of either CD4 or CD8, which in turn corresponds to restriction by and binding to class II or class I major histocompatibility complex proteins, respectively 1-8. CD8 can be expressed as a homodimer of the alpha-chain, or as a heterodimer of alpha- and beta-chains on human and mouse T cells, although most peripheral T cells seem to express CD8-alpha-beta heterodimers exclusively (reviewed in ref. 9). Functional characterization of CD8 has focused primarily on the effect of the alpha-chain, which enhances or reconstitutes T-cell responses in homodimeric form 10,11 and may play a specific role in thymic selection 12-14. In contrast, no role has been ascribed to CD8-beta or alpha-beta heterodimers specifically. Here we show that CD8-alpha-beta transfectants produce more interleukin-2 than CD8-alpha transfectants in response to specific stimuli. Increased interleukin-2 is also observed in cells expressing hybrid CD8-beta-alpha molecules (extracellular CD8-beta plus CD8-alpha transmembrane and cytoplasmic regions) on their surface. These results indicate that external portions of CD8-beta could be critical and that they may act independently of CD8-alpha in mediating their augmentation effect.	STANFORD UNIV, MED CTR, DEPT MED, DIV IMMUNOL & RHEUMATOL, STANFORD, CA 94305 USA	Stanford University								BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BLUESTONE JA, 1984, J IMMUNOGENET, V11, P197; DEMBIC Z, 1987, NATURE, V326, P510, DOI 10.1038/326510a0; DIALYNAS DP, 1983, IMMUNOL REV, V74, P29, DOI 10.1111/j.1600-065X.1983.tb01083.x; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; GABERT J, 1987, CELL, V50, P545, DOI 10.1016/0092-8674(87)90027-4; GELIEBTER J, 1988, MOL CELL BIOL, V8, P4342, DOI 10.1128/MCB.8.10.4342; GORMAN SD, 1988, J IMMUNOL, V140, P3646; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LETOURNEUR F, 1990, P NATL ACAD SCI USA, V87, P2339, DOI 10.1073/pnas.87.6.2339; LEWIS J, 1988, J IMMUNOL, V141, P728; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; MACDONALD HR, 1982, IMMUNOL REV, V68, P89, DOI 10.1111/j.1600-065X.1982.tb01061.x; MICELI MC, 1991, P NATL ACAD SCI USA, V88, P2623, DOI 10.1073/pnas.88.7.2623; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NORMENT AM, 1988, EMBO J, V7, P3433, DOI 10.1002/j.1460-2075.1988.tb03217.x; NORMENT AM, 1988, NATURE, V336, P79, DOI 10.1038/336079a0; PARNES JR, 1989, ADV IMMUNOL, V44, P265; PORTOLES P, 1989, J IMMUNOL, V142, P4169; ROBEY EA, 1991, CELL, V64, P99, DOI 10.1016/0092-8674(91)90212-H; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SALTER RD, 1989, NATURE, V338, P345, DOI 10.1038/338345a0; SARMIENTO M, 1980, J IMMUNOL, V125, P2665; SCHNECK J, 1989, CELL, V56, P47, DOI 10.1016/0092-8674(89)90982-3; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; SWAIN SL, 1981, P NATL ACAD SCI-BIOL, V78, P7101, DOI 10.1073/pnas.78.11.7101; SWAIN SL, 1983, IMMUNOL REV, V74, P129, DOI 10.1111/j.1600-065X.1983.tb01087.x; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; ZAMOYSKA R, 1989, NATURE, V342, P278, DOI 10.1038/342278a0	33	79	80	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 21	1992	357	6375					247	249		10.1038/357247a0	http://dx.doi.org/10.1038/357247a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV195	1534146				2022-12-01	WOS:A1992HV19500056
J	WHITMAN, M; MELTON, DA				WHITMAN, M; MELTON, DA			INVOLVEMENT OF P21RAS IN XENOPUS MESODERM INDUCTION	NATURE			English	Article							HA-RAS MUTATION; GROWTH-FACTORS; ACTIVIN-A; EMBRYOS; CELLS; DIFFERENTIATION; EMBRYOGENESIS; GASTRULATION; LAEVIS; GENES	DURING early vertebrate embryogenesis, mesoderm is specified by a signal emanating from prospective endoderm. This signal can respecify Xenopus prospective ectoderm as mesoderm, and can be mimicked by members of the fibroblast growth factor and transforming growth factor-beta families 1,2. In other systems, the p21c-ras proto-oncogene product has been implicated in signal transduction for various polypeptide growth factors. We report here that a dominant inhibitory ras mutant blocks the mesoderm-inducing activity of fibroblast growth factor and activin, as well as the endogenous inducing activity of prospective endoderm. A constitutively active ras mutant partially mimics these activities. These results indicate that p21ras may have a central role in the transduction of the mesoderm inductive signal. Basic fibroblast growth factor 3,4 and activin 5-8 have emerged as candidates for endogenous mesoderm-inducing molecules. The character of the mesoderm induced by these two factors is overlapping but distinct when assessed both by histological and molecular criteria 9,10. The signal transduction pathways used during induction by these factors are unknown. We used messenger RNA microinjection of Xenopus eggs to express a dominant inhibitory mutant ras, p21(Asn 17)Ha-ras, in cells competent to respond to inducing factors to examine the role of p21ras in this response. This mutant, which has a reduced affinity for GTP relative to GDP 11, blocks a variety of mitogenic signals in 3T3 fibroblasts 12 as well as the differentiation of pheochromocytoma cells in response to nerve growth factor 13.	DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138				Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647				ASASHIMA M, 1990, ROUX ARCH DEV BIOL, V198, P330, DOI 10.1007/BF00383771; Barbacid M., 1987, REV BIOCH, V56, P779; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; DAAR I, 1991, SCIENCE, V253, P74, DOI 10.1126/science.1829549; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GODSAVE SF, 1988, DEVELOPMENT, V102, P555; GURDON JB, 1985, CELL, V41, P913, DOI 10.1016/S0092-8674(85)80072-6; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; JAMRICH M, 1987, GENE DEV, V1, P124, DOI 10.1101/gad.1.2.124; KIMELMAN D, 1988, SCIENCE, V242, P1053, DOI 10.1126/science.3194757; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MITRANI E, 1990, CELL, V63, P495, DOI 10.1016/0092-8674(90)90446-L; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; NIEUWKOOP P D, 1969, Wilhelm Roux' Archiv fuer Entwicklungsmechanik der Organismen, V162, P341, DOI 10.1007/BF00578701; Ruiz i Altaba A, 1989, Nature, V341, P33; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH JC, 1989, DEVELOPMENT, V105, P665; SOKOL S, 1990, SCIENCE, V249, P561, DOI 10.1126/science.2382134; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; SYMES K, 1987, DEVELOPMENT, V101, P339; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; WHITMAN M, 1989, ANNU REV CELL BIOL, V5, P93; WHITMAN M, 1989, SCIENCE, V244, P803, DOI 10.1126/science.2658054	29	181	182	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 21	1992	357	6375					252	254		10.1038/357252a0	http://dx.doi.org/10.1038/357252a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV195	1589022				2022-12-01	WOS:A1992HV19500058
J	BLENDON, RJ; SZALAY, US; KNOX, RA				BLENDON, RJ; SZALAY, US; KNOX, RA			SHOULD PHYSICIANS AID THEIR PATIENTS IN DYING - THE PUBLIC PERSPECTIVE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									BOSTON GLOBE,BOSTON,MA		BLENDON, RJ (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,PROGRAM PUBL OPIN & HLTH CARE,BOSTON,MA 02115, USA.							KENT C, 1991, MED HLTH        1202, V45, pA2; OUSLANDER JG, 1989, ARCH INTERN MED, V149, P1367, DOI 10.1001/archinte.149.6.1367; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; UHLMANN RF, 1988, J GERONTOL, V43, pM115, DOI 10.1093/geronj/43.5.M115; WOOD F, 1990, AM PROFILE OPINIONS, P627; 1991, AM VIEW ANGING RESUL; 1989, PHYSICIAN PUBLIC ATT; 1991, NY TIMES        1107, pB14; 1990, GENERAL SOCIAL SURVE	9	181	182	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 20	1992	267	19					2658	2662		10.1001/jama.267.19.2658	http://dx.doi.org/10.1001/jama.267.19.2658			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT823	1573758				2022-12-01	WOS:A1992HT82300038
J	CLINTON, JJ				CLINTON, JJ			ACUTE PAIN MANAGEMENT CAN BE IMPROVED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											CLINTON, JJ (corresponding author), AGCY HLTH CARE POLICY & RES,OFF FORUM,SUITE 401,2101 E JEFFERSON ST,ROCKVILLE,MD 20852, USA.							1987, PAIN, V30, P69; 1989, ANESTHESIOL CLIN N A, V7, P1	2	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 20	1992	267	19					2580	2580		10.1001/jama.267.19.2580	http://dx.doi.org/10.1001/jama.267.19.2580			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT823	1573734				2022-12-01	WOS:A1992HT82300004
J	DOOLEY, SW; VILLARINO, ME; LAWRENCE, M; SALINAS, L; AMIL, S; RULLAN, JV; JARVIS, WR; BLOCH, AB; CAUTHEN, GM				DOOLEY, SW; VILLARINO, ME; LAWRENCE, M; SALINAS, L; AMIL, S; RULLAN, JV; JARVIS, WR; BLOCH, AB; CAUTHEN, GM			NOSOCOMIAL TRANSMISSION OF TUBERCULOSIS IN A HOSPITAL UNIT FOR HIV-INFECTED PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							EPIDEMIC	Objective. - To assess nosocomial transmission of tuberculosis (TB). Design. - A historical cohort study of hospitalized patients with the human immunodeficiency virus (HIV) and a purified protein derivative (PPD) tuberculin skin test survey of health care workers (HCWs). Setting. - A large public teaching hospital in San Juan, Puerto Rico. Patients. - For the cohort study, a case patient was defined as any patient in the HIV unit at the hospital who developed culture-positive TB from 31 days or more after admission through December 31, 1989. For the PPD survey, of 1420 HCWs from the hospital, 908 agreed to participate and had sufficient data for analysis. Main Outcome Measures. - For the cohort study, to compare the risk of developing active TB among patients who were exposed to hospital roommates with infectious TB and the risk among nonexposed patients. For the HCW PPD survey, to determine the prevalence of and risk factors for tuberculous infection. Results. - Eight of 48 (9.7/10 000 person-days) exposed case patients vs four of 192 (0.8/10 000 person-days) nonexposed case patients developed active TB (relative risk [RR] = 11; 95% confidence interval [Cl], 2.3, 50.3). Positive PPDs (greater-than-or-equal-to 10 mm of induration) in HCWs were associated with older age (P = .0001) and with history of community TB exposure (P = .0002). In a multivariable logistic model that adjusted for these variables, HIV unit nurses (nine of 19) and nurses in the internal medicine ward (45 of 90) had a higher proportion of positive PPDs than the reference group (clerical personnel on other floors: 35 of 188, P = .0005). Conclusions. - These data suggest that patient-to-patient transmission of TB in HIV units can occur and that HCWs are at risk of acquiring TB infection.	HOSPITAL MUNICIPAL,SAN JUAN,PR; CTR DIS CONTROL,NATL CTR INFECT DIS,HOSP INFECT PROGRAM,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA	DOOLEY, SW (corresponding author), CTR DIS CONTROL,NATL CTR PREVENT SERV,DIV TB ELIMINAT,MAILSTOP E-10,ATLANTA,GA 30333, USA.							CATANZARO A, 1982, AM REV RESPIR DIS, V125, P559, DOI 10.1164/arrd.1982.125.5.559; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DIPERRI G, 1989, LANCET, V2, P1502; EHRENKRA.NJ, 1972, ANN INTERN MED, V77, P377, DOI 10.7326/0003-4819-77-3-377; HALEY CE, 1989, INFECT CONT HOSP EP, V10, P204, DOI 10.1086/646003; KANTOR HS, 1988, AM J MED, V84, P833, DOI 10.1016/0002-9343(88)90060-5; Kent PT, 1985, GUIDE LEVEL 3 LAB; 1985, SAS USERS GUIDE STAT; 1991, MMWR, V40, P585; 1990, MMWR, V39, P1	10	197	203	1	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 20	1992	267	19					2632	2634		10.1001/jama.267.19.2632	http://dx.doi.org/10.1001/jama.267.19.2632			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT823	1573751				2022-12-01	WOS:A1992HT82300031
J	LEE, SH; EWERT, DP; FREDERICK, PD; MASCOLA, L				LEE, SH; EWERT, DP; FREDERICK, PD; MASCOLA, L			RESURGENCE OF CONGENITAL-RUBELLA SYNDROME IN THE 1990S - REPORT ON MISSED OPPORTUNITIES AND FAILED PREVENTION POLICIES AMONG WOMEN OF CHILDBEARING AGE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; IMMUNIZATION; PROGRAM; VACCINATION	Objective. - To assess previous missed opportunities for rubella screening and vaccination of women delivering infants with congenital rubella syndrome and to discuss prevention strategies. Design. - Descriptive analysis of data collected through interviews and review of medical records. Population Studied. - Twenty-one women who delivered infants with congenital rubella syndrome in four Southern California counties from January 1, 1990, through January 8, 1991. Results. - Twelve (57%) of the women had a total of 22 known missed opportunities for rubella screening or vaccination. Of the 22 missed opportunities, three (14%) were missed screenings at the time of marriage, two (9%) were missed screenings during previous pregnancies, five (23%) were missed screenings during induced abortions, and 12 (55%) were missed opportunities for vaccination postpartum or after induced abortions. Nine (43%) of the women had no known missed opportunities for rubella screening or vaccination. Of 12 women educated in California, only four (33%) were subject to the 1982 California school rubella immunization requirement. Conclusions. - Congenital rubella syndrome could have been prevented in more than half of the infants born to these women if missed opportunities for rubella testing and/or vaccination had not occurred. Because premarital rubella testing and school immunization requirements do not ensure that all women of childbearing age are immune to rubella, physicians and hospitals should establish procedures for postpartum rubella vaccination of susceptible women. Family planning and abortion clinics should implement routine rubella testing and follow-up vaccination of susceptible women.	LOS ANGELES CTY DEPT HLTH SERV,ACUTE COMMUNICABLE DIS CONTROL UNIT,ROOM 231,313 N FIGUEROA ST,LOS ANGELES,CA 90012; CTR DIS CONTROL,EPIDEMIOL PROGRAM OFF,DIV FIELD EPIDEMIOL,LOS ANGELES,CA					Frederick, Paul/0000-0002-7936-5488				ANTHONY N, 1977, AM J PUBLIC HEALTH, V67, P763, DOI 10.2105/AJPH.67.8.763; COCHI SL, 1989, AM J EPIDEMIOL, V129, P349, DOI 10.1093/oxfordjournals.aje.a115138; DALES LG, 1981, WESTERN J MED, V135, P266; GRILLNER L, 1973, SCAND J INFECT DIS, V5, P237, DOI 10.3109/inf.1973.5.issue-4.01; KAPLAN KM, 1990, AM J DIS CHILD, V144, P118, DOI 10.1001/archpedi.1990.02150250130050; KLEIN EB, 1980, J PEDIATR-US, V97, P774, DOI 10.1016/S0022-3476(80)80264-2; LANDES RD, 1980, J PEDIATR-US, V97, P465, DOI 10.1016/S0022-3476(80)80207-1; LOSONSKY GA, 1982, J INFECT DIS, V145, P661, DOI 10.1093/infdis/145.2.661; NELSON DB, 1982, AM J PUBLIC HEALTH, V72, P710, DOI 10.2105/AJPH.72.7.710; ORENSTEIN WA, 1984, JAMA-J AM MED ASSOC, V251, P1988, DOI 10.1001/jama.251.15.1988; POLK BF, 1982, AM J EPIDEMIOL, V115, P19, DOI 10.1093/oxfordjournals.aje.a113276; PREBLUD SR, 1986, J INFECT DIS, V154, P367, DOI 10.1093/infdis/154.2.367; ROBERTSON SE, 1987, AM J PUBLIC HEALTH, V77, P1347, DOI 10.2105/AJPH.77.10.1347; SERDULA MK, 1986, PUBLIC HEALTH REP, V101, P329; SEWELL CM, 1986, AM J PUBLIC HEALTH, V76, P1250, DOI 10.2105/AJPH.76.10.1250; SHLIAN DM, 1978, JAMA-J AM MED ASSOC, V240, P662, DOI 10.1001/jama.240.7.662; TINGLE AJ, 1985, J INFECT DIS, V152, P606, DOI 10.1093/infdis/152.3.606; TINGLE AJ, 1986, J INFECT DIS, V154, P368, DOI 10.1093/infdis/154.2.368; VOGT RL, 1985, AM J PUBLIC HEALTH, V75, P1088, DOI 10.2105/AJPH.75.9.1088; 1985, MMWR, V34, P228; 1985, MMWR, V34, P65; 1986, MMWR, V35, P779; 1986, MMWR, V35, P770; 1990, MMWR, V39, P32; 1990, MMWR, V39, P1; 1991, MMWR, V40, P93	26	41	41	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 20	1992	267	19					2616	2620		10.1001/jama.267.19.2616	http://dx.doi.org/10.1001/jama.267.19.2616			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HT823	1573748				2022-12-01	WOS:A1992HT82300027
J	MARZUK, PM; TARDIFF, K; SMYTH, D; STAJIC, M; LEON, AC				MARZUK, PM; TARDIFF, K; SMYTH, D; STAJIC, M; LEON, AC			COCAINE USE, RISK-TAKING, AND FATAL RUSSIAN ROULETTE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							BEHAVIOR	Objective. - To examine the association between recent cocaine use and risk taking, particularly in the form of playing Russian roulette, a paradigm for extreme risk-taking behavior. Design. - A case-control study. Cases and Controls. - The prevalence of cocaine use among all Russian roulette fatalities (N = l4) was compared with a demographically similar, randomly selected sample (N = 54) of all suicides by handgun during a contemporaneous 4-year period in New York City, NY. Results. - Recent use of cocaine, the most common drug found at autopsy, was detected in 64% of Russian roulette fatalities and in 35% of the control group (P < .05). All Russian roulette fatalities were male and usually young and unemployed. Blacks and Hispanics accounted for 80% of all cases and were overrepresented compared with their numbers in the general population. Conclusion. - In some populations cocaine may be associated with life-threatening risk-taking behaviors.	CORNELL UNIV,MED CTR,COLL MED,DEPT AFRC,NEW YORK,NY 10021; NYU,SCH MED,DEPT FORENS MED,NEW YORK,NY 10003; NEW YORK OFF CHIEF MED EXAMINER,NEW YORK,NY	Cornell University; New York University	MARZUK, PM (corresponding author), CORNELL UNIV,MED CTR,COLL MED,DEPT PSYCHIAT,1300 YORK AVE,NEW YORK,NY 10021, USA.							ADLAF EM, 1983, DRUG ALCOHOL DEPEN, V11, P287, DOI 10.1016/0376-8716(83)90020-0; AMBRE J, 1988, J ANAL TOXICOL, V34, P53; Brown G L, 1986, Ann N Y Acad Sci, V487, P175, DOI 10.1111/j.1749-6632.1986.tb27897.x; COHEN PA, 1977, PERS SOC PSYCHOL B, V11, P119; COLE P, 1980, STATISTICAL METHODS; DACKIS CA, 1985, NEUROSCI BIOBEHAV RE, V9, P447; FISHBAIN DA, 1987, AM J PSYCHIAT, V144, P563; KOGAN N, 1967, NEW DIR PSYCH, V3, P111; MARZUK PM, 1990, JAMA-J AM MED ASSOC, V263, P250, DOI 10.1001/jama.263.2.250; TARDIFF K, 1989, J FORENSIC SCI, V34, P53; TEGER AI, 1969, J PERS SOC PSYCHOL, V11, P170, DOI 10.1037/h0027054; WEISS JMA, 1957, PSYCHIATR, V20, P17	12	10	11	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 20	1992	267	19					2635	2637						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HT823	1573752				2022-12-01	WOS:A1992HT82300032
J	SIMON, TL; STEHLING, L				SIMON, TL; STEHLING, L			INDICATIONS FOR AUTOLOGOUS TRANSFUSIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											SIMON, TL (corresponding author), UNITED BLOOD SERV,SCOTTSDALE,AZ, USA.							AuBuchon J P, 1989, Transfus Med Rev, V3, P290, DOI 10.1016/S0887-7963(89)70089-4; CREGAN P, 1991, TRANSFUSION, V31, P172, DOI 10.1046/j.1537-2995.1991.31291142950.x; 1988, JAMA-J AM MED ASSOC, V260, P2700	3	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 20	1992	267	19					2669	2669						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT823	1573760				2022-12-01	WOS:A1992HT82300039
J	BERNERSEN, B; JOHNSEN, R; BOSTAD, L; STRAUME, B; SOMMER, AI; BURHOL, PG				BERNERSEN, B; JOHNSEN, R; BOSTAD, L; STRAUME, B; SOMMER, AI; BURHOL, PG			IS HELICOBACTER-PYLORI THE CAUSE OF DYSPEPSIA	BRITISH MEDICAL JOURNAL			English	Article							CAMPYLOBACTER-LIKE ORGANISMS; UPPER GASTROINTESTINAL SYMPTOMS; FOLLOW-UP EXAMINATIONS; NON-ULCER DYSPEPSIA; CHRONIC GASTRITIS; MUCOSAL HISTOLOGY; BIOPSY SPECIMENS; PREVALENCE; INFECTION; DIAGNOSIS	Objective-To determine the association between infection with Helicobacter pylori and dyspepsia. Design-Cross sectional study of dyspeptic subjects and age and sex matched controls identified by a questionnaire survey of all inhabitants aged 20-69. (Endoscopy, histological examination, and microbiological examinations of biopsies from the gastric mucosa were performed blind.) Setting-Population based survey in Sorreisa, Norway. Subjects-All 782 dyspeptic subjects (excluding those with a previous history of peptic ulcer, gall stones or kidney stones, and coronary heart disease) and controls were offered an endoscopy, of whom 309 dyspeptic subjects and 310 controls attended. Main outcome measures-Prevalences of endoscopic and histological diagnoses and of cultures positive for H pylori. Results-A high prevalence of positive cultures, increasing with age, was found in both dyspeptic subjects (48%) and non-dyspeptic controls (36%) (p = 0.004). Positive cultures in both dyspeptic subjects and controls were strongly associated with histological gastritis (70%, 95% confidence interval 65.5 to 85.3; 60%, 52.7 to 67.7, respectively) and peptic ulcer (92%, 61.5 to 99.8; 64.1, 9.4 to 99.2, respectively). Only 3% of subjects with a histologically non-inflamed gastric mucosa had this infection (dyspeptic subjects 2%, 0.2 to 7.0; controls 4%; 1.2 to 8.8). Conclusions-The relation between dyspeptic symptoms and H pylori is dubious; H pylori seems to have a pathogenetic role in gastritis and may be a contributing factor but not a cause of peptic ulcer.	UNIV TROMSO,INST COMMUNITY MED,N-9001 TROMSO,NORWAY; UNIV TROMSO HOSP,GASTROENTEROL,N-9012 TROMSO,NORWAY	UiT The Arctic University of Tromso; UiT The Arctic University of Tromso; University Hospital of North Norway								ALMOAGEL MA, 1990, AM J GASTROENTEROL, V85, P944; BARTHEL JS, 1988, ARCH INTERN MED, V148, P1149, DOI 10.1001/archinte.148.5.1149; BARTLETT JG, 1988, GASTROENTEROLOGY, V94, P229, DOI 10.1016/0016-5085(88)90634-8; BERNERSEN B, 1990, GUT, V31, P989, DOI 10.1136/gut.31.9.989; COGHLAN JG, 1987, LANCET, V2, P1109; COLINJONES DG, 1988, LANCET, V1, P576; Doenges JL, 1938, P SOC EXP BIOL MED, V38, P536; DOOLEY CP, 1988, ANN INTERN MED, V108, P70, DOI 10.7326/0003-4819-108-1-70; DOOLEY CP, 1989, NEW ENGL J MED, V321, P1562, DOI 10.1056/NEJM198912073212302; Fleiss J. L., 1981, STAT METHODS RATES P, V2nd, DOI 10.1002/0471445428; Freedberg A. S., 1940, AM J DIG DIS, V7, P443, DOI DOI 10.1007/BF02997393; GOODWIN CS, 1986, J CLIN PATHOL, V39, P353, DOI 10.1136/jcp.39.4.353; HEATLEY RV, 1987, LANCET, V2, P779; JOHNSEN R, 1991, BRIT MED J, V302, P749, DOI 10.1136/bmj.302.6779.749; JOHNSSON F, 1987, SCAND J GASTROENTERO, V22, P714, DOI 10.3109/00365528709011148; JONES DM, 1984, J CLIN PATHOL, V37, P1002, DOI 10.1136/jcp.37.9.1002; LANGENBERG ML, 1984, LANCET, V1, P1348; LAWSON HH, 1964, LANCET, V1, P469; LOFFELD RJLF, 1989, GUT, V30, P1206, DOI 10.1136/gut.30.9.1206; MARSHALL BJ, 1985, MED J AUSTRALIA, V142, P439, DOI 10.5694/j.1326-5377.1985.tb113444.x; MARSHALL BJ, 1985, MED J AUSTRALIA, V142, P436, DOI 10.5694/j.1326-5377.1985.tb113443.x; MORRIS A, 1987, AM J GASTROENTEROL, V82, P192; MYREN J, 1974, SCAND J GASTROENTERO, V9, P457; NESLAND AA, 1985, SCAND J GASTROENTERO, V20, P222, DOI 10.3109/00365528509089661; OWEN DA, 1979, PATHOL ANNU, V1, P247; PETERSON WL, 1986, GASTROENTEROLOGY, V90, P1585; PETTROSS CW, 1988, DIGEST DIS SCI, V33, P649, DOI 10.1007/BF01540425; RAUWS EA, 1988, GASTROENTEROLOGY, V94, P33, DOI 10.1016/0016-5085(88)90606-3; SAVARY M, 1977, OESOPHAGUS LEHRBUCH; SIURALA M, 1988, GUT, V29, P909, DOI 10.1136/gut.29.7.909; TALLEY NJ, 1988, ANN INTERN MED, V108, P865, DOI 10.7326/0003-4819-108-6-865; TATSUTA M, 1986, DIGEST DIS SCI, V31, P7, DOI 10.1007/BF01347902; VENABLES CW, 1985, SCAND J GASTROENTERO, V20, P91, DOI 10.3109/00365528509103941; VILLAKO K, 1990, ENDOSCOPY, V22, P114, DOI 10.1055/s-2007-1012814; WARREN JR, 1983, LANCET, V1, P1273; WHITEHEAD R, 1972, J CLIN PATHOL, V25, P1, DOI 10.1136/jcp.25.1.1; WHITEHEAD R, 1975, DIGESTION, V13, P129, DOI 10.1159/000197701	37	141	141	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 16	1992	304	6837					1276	1279		10.1136/bmj.304.6837.1276	http://dx.doi.org/10.1136/bmj.304.6837.1276			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV086	1606428	Green Published			2022-12-01	WOS:A1992HV08600019
J	BLAU, JN				BLAU, JN			MIGRAINE - THEORIES OF PATHOGENESIS	LANCET			English	Article							CEREBRAL BLOOD-FLOW; XE-133 INHALATION; DOUBLE-BLIND; DURA MATER; HEADACHES; ATTACKS; EXTRAVASATION; PAIN				BLAU, JN (corresponding author), UCL NATL HOSP NEUROL & NEUROSURG, LONDON WC1N 3BG, ENGLAND.							ANTHONY M, 1969, RESEARCH CLINICAL ST, V2, P29; BICKERSTAFF ER, 1975, NEUROLOGICAL COMPLIC, P81; BILLE B, 1962, ACTA PAEDIATR S S136, V51, P3; BLAU JN, 1981, CEPHALALGIA, V1, P143, DOI 10.1046/j.1468-2982.1981.0103143.x; BLAU JN, 1991, CEPHALALGIA, V11, P229; BLAU JN, 1970, LANCET, V2, P241; BLAU JN, 1985, J ROY COLL PHYS LOND, V19, P166; Blau JN, 1987, MIGRAINE CLIN THERAP, P3; BLAU JN, IN PRESS PATHOL BIOL; Blau Joseph N., 1987, MIGRAINE CLIN RES AS, P241; BRUYN GW, 1984, PHARM BASIS MIGRAINE, P267; BUZZI MG, 1990, BRIT J PHARMACOL, V99, P202, DOI 10.1111/j.1476-5381.1990.tb14679.x; COUCH JR, 1983, HEADACHE, V23, P94; DALESSIO DJ, 1982, CEREBRAL HYPOXIA PAT, P28; EADIE MJ, 1985, BIOCH MIGRAINE, P1; EKBOM K, 1991, NEW ENGL J MED, V325, P322, DOI 10.1056/nejm199108013250505; FEATHERSTONE HJ, 1986, HEADACHE, V26, P39, DOI 10.1111/j.1526-4610.1986.hed2601039.x; FERRARI MD, 1991, NEW ENGL J MED, V325, P316; Fisher C M, 1971, Clin Neurosurg, V18, P267; GLOOR P, 1986, TRENDS NEUROSCI, V9, P21, DOI 10.1016/0166-2236(86)90008-1; GOWERS WR, 1988, MANUAL DISEASES NERV, P776; HANINGTON E, 1967, BMJ-BRIT MED J, V2, P550; HAWKING SW, 1988, BRIEF HIST TIME, P9; LAURITZEN M, 1984, BRAIN, V107, P447, DOI 10.1093/brain/107.2.447; Leao AAP, 1944, J NEUROPHYSIOL, V7, P391, DOI 10.1152/jn.1944.7.6.391; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359, DOI 10.1152/jn.1944.7.6.359; LIVEING E, 1873, MEGRIM SICK HEADACHE, P26; MACGREGOR EA, 1990, CEPHALALGIA, V10, P305, DOI 10.1046/j.1468-2982.1990.1006305.x; MARTINS I, 1989, HEADACHE, V29, P660, DOI 10.1111/j.1526-4610.1989.hed2910660.x; MOFFETT A, 1972, J NEUROL NEUROSUR PS, V35, P496, DOI 10.1136/jnnp.35.4.496; MOFFETT AM, 1974, J NEUROL NEUROSUR PS, V37, P445, DOI 10.1136/jnnp.37.4.445; MOSKOWITZ MA, 1984, ANN NEUROL, V16, P157, DOI 10.1002/ana.410160202; MRSULJA BB, 1973, SLEEP PHYSL BIOCH PS, P271; OLESEN J, 1990, ANN NEUROL, V28, P791, DOI 10.1002/ana.410280610; OSTFELD AM, 1960, JAMA-J AM MED ASSOC, V174, P1188, DOI 10.1001/jama.1960.63030090011010; POINCARE H, 1952, SCI HYPOTHESIS, P142; SAITO K, 1988, ANN NEUROL, V24, P732, DOI 10.1002/ana.410240607; SAKAI F, 1978, HEADACHE, V18, P122, DOI 10.1111/j.1526-4610.1978.hed1803122.x; SOKOLOFF L, 1983, HDB NEUROCHEMISTRY, V3, P225; SOMERVILLE BW, 1972, NEUROLOGY, V22, P824, DOI 10.1212/WNL.22.8.824; WAELKENS J, 1982, BRIT MED J, V284, P944, DOI 10.1136/bmj.284.6320.944; WATERS WE, 1983, BRIT MED J, V287, P1442, DOI 10.1136/bmj.287.6403.1442; WOLFF HG, 1963, HEADACHE OTHER HEAD, P269	43	127	129	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 16	1992	339	8803					1202	1207		10.1016/0140-6736(92)91140-4	http://dx.doi.org/10.1016/0140-6736(92)91140-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HU684	1349944				2022-12-01	WOS:A1992HU68400010
J	CORAZZA, GR; FRISONI, M; FILIPPONI, C; GULLO, L; POGGI, VM; GASBARRINI, G				CORAZZA, GR; FRISONI, M; FILIPPONI, C; GULLO, L; POGGI, VM; GASBARRINI, G			INVESTIGATION OF QT INTERVAL IN ADULT CELIAC-DISEASE	BRITISH MEDICAL JOURNAL			English	Article									S ORSOLA UNIV HOSP,DEPT MED PATHOL & CLIN MED 1,I-40138 BOLOGNA,ITALY	IRCCS Azienda Ospedaliero-Universitaria di Bologna	CORAZZA, GR (corresponding author), UNIV LAQUILA,DEPT MED,I-67100 LAQUILA,ITALY.		Corazza, Gino Roberto/K-8500-2016	Corazza, Gino Roberto/0000-0001-9532-0573				CHAMBERS JB, 1985, LANCET, V2, P1308; GREEN PA, 1960, GASTROENTEROLOGY, V38, P399; ISNER JM, 1985, ANN INTERN MED, V102, P49, DOI 10.7326/0003-4819-102-1-49; MOSS AJ, 1986, JAMA-J AM MED ASSOC, V256, P2985; VINCENT G M, 1974, Progress in Cardiovascular Diseases, V16, P523	5	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 16	1992	304	6837					1285	1285		10.1136/bmj.304.6837.1285	http://dx.doi.org/10.1136/bmj.304.6837.1285			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV086	1606432	Bronze, Green Published			2022-12-01	WOS:A1992HV08600024
J	CROFT, P; COGGON, D; CRUDDAS, M; COOPER, C				CROFT, P; COGGON, D; CRUDDAS, M; COOPER, C			OSTEOARTHRITIS OF THE HIP - AN OCCUPATIONAL-DISEASE IN FARMERS	BRITISH MEDICAL JOURNAL			English	Article								Objective-To test the hypothesis that farmers are at high risk of hip osteoarthritis and to investigate possible causes for such a hazard. Design-Cross sectional survey. Setting-Five rural general practices. Subjects-167 male farmers aged 60-76 and 83 controls from mainly sedentary jobs. All those without previous hip replacement underwent radiography of the hip. Main outcome measures-Hip replacement for osteoarthritis or radiological evidence of hip osteoarthritis. Results-Prevalence of hip osteoarthritis was higher in farmers than controls and especially in those who had farmed for over 10 years (odds ratio 9.3, 95% confidence interval 1.9 to 44.5). The excess could not be attributed to any one type of farming, and heavy lifting seems the likely explanation. Conclusions-Manual handling in agriculture should be limited where possible. Consideration should be given to making hip osteoarthritis a prescribed industrial disease in farmers. There may be wider implications for the prevention of hip osteoarthritis in the general population.	UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON S09 4XY,ENGLAND; UNIV MANCHESTER,AFRC,EPIDEMIOL RES UNIT,MANCHESTER M13 9PT,LANCS,ENGLAND; BRISTOL ROYAL INFIRM & GEN HOSP,DEPT MED,RHEUMATOL UNIT,BRISTOL BS2 8HW,AVON,ENGLAND	University of Southampton; University of Manchester; Bristol Royal Infirmary					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AXMACHER B, 1988, PROGR OCCUPATIONAL E, P203; CROFT P, 1990, AM J EPIDEMIOL, V132, P514, DOI 10.1093/oxfordjournals.aje.a115687; CROFT P, 1992, SCAND J WORK ENV HEA, V18, P59, DOI 10.5271/sjweh.1608; CROFT P, IN PRESS BR J RHEUMA; FRANK O, 1968, Z RHEUMAFORSCH, V27, P371; FRANKEL S, 1990, EPIDEMIOLOGICALLY BA; HAGGLUND G, 1984, CLIN ORTHOPAEDICS, V191, P81; JACOBSSON B, 1987, INT ORTHOP, V11, P311, DOI 10.1007/BF00271306; LINDBERG H, 1984, CLIN ORTHOP RELAT R, V191, P159; LOUYOT P, 1966, REV RHUM, V33, P625; ORDEBERG G, 1984, CLIN ORTHOPAEDICS, V191, P95; THELIN A, 1990, AM J IND MED, V18, P339, DOI 10.1002/ajim.4700180316; Typpti T., 1985, ANN CHIR GYNAEC S201, V74, P1; VANSAASE JLCM, 1989, ANN RHEUM DIS, V48, P271, DOI 10.1136/ard.48.4.271; VINGARD E, 1991, SCAND J WORK ENV HEA, V17, P104, DOI 10.5271/sjweh.1727; VINGARD E, 1991, WORK SPORTS OVERWEIG; WALSH K, 1991, SCAND J WORK ENV HEA, V17, P420, DOI 10.5271/sjweh.1680; WILCOCK GK, 1979, INT J EPIDEMIOL, V8, P247, DOI 10.1093/ije/8.3.247; 1986, OCCUPATIONAL MORTALI; 1979, DHEW PHS791161 PUBL	20	157	158	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 16	1992	304	6837					1269	1272		10.1136/bmj.304.6837.1269	http://dx.doi.org/10.1136/bmj.304.6837.1269			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV086	1606427	Green Published, Bronze			2022-12-01	WOS:A1992HV08600017
J	FALINI, B; BOLOGNESI, A; FLENGHI, L; TAZZARI, PL; BROE, MK; STEIN, H; DURKOP, H; AVERSA, F; CORNELI, P; PIZZOLO, G; BARBABIETOLA, G; SABATTINI, E; PILERI, S; MARTELLI, MF; STIRPE, F				FALINI, B; BOLOGNESI, A; FLENGHI, L; TAZZARI, PL; BROE, MK; STEIN, H; DURKOP, H; AVERSA, F; CORNELI, P; PIZZOLO, G; BARBABIETOLA, G; SABATTINI, E; PILERI, S; MARTELLI, MF; STIRPE, F			RESPONSE OF REFRACTORY HODGKINS-DISEASE TO MONOCLONAL ANTI-CD30 IMMUNOTOXIN	LANCET			English	Note							ANTIGEN	In Hodgkin's disease, Hodgkin and Reed-Sternberg cells consistently express the antigen CD30. We investigated the possible therapeutic role of an immunotoxin prepared by covalent linking of an anti-CD30 monoclonal antibody (Ber-H2) to saporin (SO6), a type-1 ribosome-inactivating protein. The immunotoxin (0.8 mg/kg in one or two doses) was given to four patients with advanced refractory Hodgkin's disease. In three, there was rapid and substantial reduction in tumour mass (50% to > 75%). Clinical responses were transient (6-10 weeks). In-vivo binding of the immunotoxin to tumour cells was shown by immunohistology in two patients. Antibodies to both parts of the immunotoxin developed in all patients.	FREE UNIV BERLIN,INST PATHOL,W-1000 BERLIN 33,GERMANY; UNIV VERONA,DEPT HAEMATOL,I-37100 VERONA,ITALY; UNIV BOLOGNA,DEPT EXPTL PATHOL,I-40126 BOLOGNA,ITALY; UNIV BOLOGNA,INST HAEMATOL,I-40126 BOLOGNA,ITALY; NATL INST CANC RES,GENOA,ITALY; UNIV PERUGIA,INST HAEMATOL,I-06100 PERUGIA,ITALY; UNIV PERUGIA,INST RADIOL,I-06100 PERUGIA,ITALY	Free University of Berlin; University of Verona; University of Bologna; University of Bologna; University of Genoa; IRCCS AOU San Martino IST; University of Perugia; University of Perugia			Bolognesi, Andrea/Q-6526-2017	FALINI, Brunangelo/0000-0002-7198-5965; Aversa, Franco/0000-0002-8871-6817; Bolognesi, Andrea/0000-0001-7497-4586				ENGERT A, 1990, CANCER RES, V50, P84; ENGERT A, 1990, CANCER RES, V50, P2929; FALINI B, 1991, EXP HEMATOL, V19, P545; PIZZOLO G, 1990, BRIT J HAEMATOL, V75, P282, DOI 10.1111/j.1365-2141.1990.tb02664.x; SCHWARTING R, 1989, BLOOD, V74, P1678; STEIN H, 1985, BLOOD, V66, P848; STIRPE F, 1986, FEBS LETT, V195, P1, DOI 10.1016/0014-5793(86)80118-1; STIRPE F, 1987, VIRCHOWS ARCH B, V53, P259, DOI 10.1007/BF02890252; TAZZARI PL, IN PRESS BR J HAEMAT; VITETTA ES, 1991, CANCER RES, V51, P4052	10	192	213	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 16	1992	339	8803					1195	1196		10.1016/0140-6736(92)91135-U	http://dx.doi.org/10.1016/0140-6736(92)91135-U			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HU684	1349939				2022-12-01	WOS:A1992HU68400005
J	GREAVES, I; GRANT, AJ; HEATH, DA; MICHAEL, J; ADU, D				GREAVES, I; GRANT, AJ; HEATH, DA; MICHAEL, J; ADU, D			HYPERCALCEMIA - CHANGING CAUSES OVER THE PAST 10 YEARS	BRITISH MEDICAL JOURNAL			English	Article									QUEEN ELIZABETH HOSP,DEPT MED,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND	University of Birmingham								FISKEN R A, 1980, QJM, V196, P405; FISKEN RA, 1981, LANCET, V1, P202; HEATH D, 1991, CLIN ENDOCRINOL, V34, P155, DOI 10.1111/j.1365-2265.1991.tb00286.x; MALLUCHE H, 1990, KIDNEY INT, V38, P193, DOI 10.1038/ki.1990.187	4	16	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 16	1992	304	6837					1284	1284		10.1136/bmj.304.6837.1284	http://dx.doi.org/10.1136/bmj.304.6837.1284			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV086	1606431	Green Published, Bronze			2022-12-01	WOS:A1992HV08600023
J	HJORTDAHL, P; LAERUM, E				HJORTDAHL, P; LAERUM, E			CONTINUITY OF CARE IN GENERAL-PRACTICE - EFFECT ON PATIENT SATISFACTION	BRITISH MEDICAL JOURNAL			English	Article							MEDICAL-CARE; META-ANALYSIS; DIMENSIONS	Objective-To evaluate the influence of continuity of care on patient satisfaction with consultations. Design-Directed and episodic specific evaluation of patient satisfaction with recent consultation. Setting and subjects-A representative sample of 3918 Norwegian primary care patients were asked to evaluate their consultations by filling in a questionnaire. The response rate was 78%. Main outcome measures-The patient's overall satisfaction with the consultation was rated on a six point scale. Continuity of care was recorded as the duration and intensity of the present patient-doctor relationship and as patients' perception of the present doctor being their personal doctor or not. Results-The multivariate analysis indicated that an overall personal patient-doctor relationship increased the odds of the patient being satisfied with the consultation sevenfold (95% confidence interval 4.9 to 9.9) as compared with consultations where no such relationships existed. The duration of the patient-doctor relationship had a weak but significant association with patient satisfaction, while the intensity of contacts showed no such association. Conclusion-Personal, continuous care is linked with patient satisfaction. If patient satisfaction is accepted as an integral part of quality health care, reinforcing personal care may be one way of increasing this quality.			HJORTDAHL, P (corresponding author), UNIV OSLO,DEPT GEN PRACTICE,N-0264 OSLO,NORWAY.							[Anonymous], 1970, EXIT VOICE LOYALTY R, DOI DOI 10.3917/RCE.002.0244; BANAHAN BF, 1981, J FAM PRACTICE, V12, P767; FITZPATRICK R, 1991, BMJ-BRIT MED J, V302, P1129, DOI 10.1136/bmj.302.6785.1129; FITZPATRICK R, 1991, BRIT MED J, V302, P887, DOI 10.1136/bmj.302.6781.887; FITZPATRICK RM, 1983, SOC SCI MED, V17, P501, DOI 10.1016/0277-9536(83)90057-6; FREEMAN G, 1984, FAM PRACT, V1, P245, DOI 10.1093/fampra/1.4.245; HALL JA, 1988, SOC SCI MED, V27, P637, DOI 10.1016/0277-9536(88)90012-3; HALL JA, 1988, SOC SCI MED, V27, P935, DOI 10.1016/0277-9536(88)90284-5; HARRIS RT, 1978, J APPL BEHAV SCI, V14, P382, DOI 10.1177/002188637801400313; HJORTDAHL P, 1991, BRIT MED J, V303, P1181, DOI 10.1136/bmj.303.6811.1181; HJORTDAHL P, 1989, FAM PRACT, V6, P292, DOI 10.1093/fampra/6.4.292; Hosmer D, 2013, APPL LOGISTIC REGRES; KEELEY D, 1991, BMJ-BRIT MED J, V302, P1514, DOI 10.1136/bmj.302.6791.1514; MARQUIS MS, 1983, MED CARE, V21, P821, DOI 10.1097/00005650-198308000-00006; McWhinney IR, 1989, TXB FAMILY MED; MURPHY M, 1989, BRIT MED J, V298, P1331, DOI 10.1136/bmj.298.6684.1331; Pascoe G C, 1983, Eval Program Plann, V6, P185, DOI 10.1016/0149-7189(83)90002-2; PENDLETON D, 1984, CONSULTATON APPROACH; ROTER DL, 1987, MED CARE, V25, P437, DOI 10.1097/00005650-198705000-00007; RUTLE O, 1983, 11983 STAT I FOLK RE; WARE JE, 1975, MED CARE, V13, P669, DOI 10.1097/00005650-197508000-00006; Wood M, 1987, ICPC INT CLASSIFICAT	22	263	268	0	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 16	1992	304	6837					1287	1290		10.1136/bmj.304.6837.1287	http://dx.doi.org/10.1136/bmj.304.6837.1287			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HV086	1606434	Green Published, Bronze			2022-12-01	WOS:A1992HV08600026
J	KRIVINE, A; FIRTION, G; CAO, L; FRANCOUAL, C; HENRION, R; LEBON, P				KRIVINE, A; FIRTION, G; CAO, L; FRANCOUAL, C; HENRION, R; LEBON, P			HIV REPLICATION DURING THE 1ST WEEKS OF LIFE	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; POLYMERASE CHAIN-REACTION; INFANTS BORN; TRANSMISSION; CHILDREN; TYPE-1; DNA; AMPLIFICATION; RETROVIRUS; INFECTION	Diagnosis of HIV infection among children born to HIV-positive mothers can be made in the first 12 months, but few studies have examined HIV status during the first weeks of life. In a prospective longitudinal study of 50 infants born to HIV-1 seropositive women, blood samples were obtained at birth and at 4-9 weeks and 5-9 months of age, and were tested for HIV-1 by the polymerase chain reaction (PCR), viral culture, and p24 antigen measurements. 16 were diagnosed as HIV-infected by the age of 4-9 weeks according to both PCR and culture; by contrast, infection could be detected in only 5 children at birth. No changes in HIV status were observed between 4-9 weeks and 5-9 months in the 44 children who could be retested. Perinatal HIV-1 infection can therefore be diagnosed in the first 2 months of life, either by PCR or viral culture. Our inability to detect HIV-1 infection at birth in almost 70% of babies subsequently found infected suggests an active replication of HIV during the first weeks of life. Our results might favour the hypothesis that transmission of HIV-1 takes place either at the end of pregnancy or at delivery.	UNIV PARIS 05,HOP ST VINCENT DE PAUL,DEPT GYNAECOL & OBSTET,F-75014 PARIS,FRANCE; CLIN UNIV PORT ROYAL,DEPT GYNAECOL & OBSTET,PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite	KRIVINE, A (corresponding author), UNIV PARIS 05,HOP ST VINCENT DE PAUL,DEPT VIROL,82 AVE DENFERT ROCHEREAU,F-75014 PARIS,FRANCE.							BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502; COURGNAUD V, 1991, AIDS RES HUM RETROV, V7, P337, DOI 10.1089/aid.1991.7.337; DEROSSI A, 1991, AIDS, V5, P15, DOI 10.1097/00002030-199101000-00002; EDWARDS JR, 1989, J PEDIATR-US, V115, P200, DOI 10.1016/S0022-3476(89)80065-4; EHRNST A, 1991, LANCET, V338, P203, DOI 10.1016/0140-6736(91)90347-R; FOLKS TM, 1986, J EXP MED, V164, P280, DOI 10.1084/jem.164.1.280; GOEDERT JJ, 1991, LANCET, V338, P1471, DOI 10.1016/0140-6736(91)92297-F; HOLODNIY M, 1991, J INFECT DIS, V163, P862, DOI 10.1093/infdis/163.4.862; JACKSON JB, 1988, J CLIN MICROBIOL, V26, P1416, DOI 10.1128/JCM.26.7.1416-1418.1988; JOVAISAS E, 1985, LANCET, V2, P1129; KRIVINE A, 1990, J PEDIATR-US, V116, P372, DOI 10.1016/S0022-3476(05)82823-9; LAURE F, 1988, LANCET, V2, P538; MCCUNE JM, 1991, CELL, V64, P351, DOI 10.1016/0092-8674(91)90644-E; OTTMANN M, 1991, J VIROL METHODS, V31, P273, DOI 10.1016/0166-0934(91)90165-V; OU CY, 1988, SCIENCE, V239, P295, DOI 10.1126/science.3336784; ROGERS MF, 1989, NEW ENGL J MED, V320, P1649, DOI 10.1056/NEJM198906223202503; RUBINSTEIN A, 1983, JAMA-J AM MED ASSOC, V249, P2345; RYDER RW, 1989, NEW ENGL J MED, V320, P1637, DOI 10.1056/NEJM198906223202501; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SPRECHER S, 1986, LANCET, V2, P288; WEINBRECK P, 1988, LANCET, V1, P482; ZIEGLER JB, 1985, LANCET, V1, P896; 1991, LANCET, V337, P253	23	170	173	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 16	1992	339	8803					1187	1189		10.1016/0140-6736(92)91131-Q	http://dx.doi.org/10.1016/0140-6736(92)91131-Q			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HU684	1349936				2022-12-01	WOS:A1992HU68400002
J	LANCE, JW				LANCE, JW			TREATMENT OF MIGRAINE	LANCET			English	Article							MENSTRUAL MIGRAINE; NAPROXEN SODIUM; AMITRIPTYLINE; PROPHYLAXIS; ESTRADIOL; ATTACKS; THERAPY; DRUG				LANCE, JW (corresponding author), PRINCE WALES HOSP, INST NEUROL SCI, RANDWICK, NSW 2031, AUSTRALIA.							ADLER CS, 1987, PSYCHIATRIC ASPECTS; AMERY WK, 1983, HEADACHE, V23, P70, DOI 10.1111/j.1526-4610.1983.hed2302070.x; [Anonymous], 1991, Eur Neurol, V31, P314; ANTHONY M, 1969, ARCH NEUROL-CHICAGO, V21, P263, DOI 10.1001/archneur.1969.00480150053007; ANTHONY M, 1967, ARCH NEUROL-CHICAGO, V16, P544, DOI 10.1001/archneur.1967.00470230096013; BLAU JN, 1980, BRIT MED J, V281, P658, DOI 10.1136/bmj.281.6241.658; BROWN EG, 1991, EUR NEUROL, V31, P339, DOI 10.1159/000116762; CLEAL A, 1991, EUR NEUROL, V31, P323; COPPEN A, 1978, LANCET, V1, P63; Curran D.A., 1967, RESEARCH CLINICAL ST, V1, P74; DELIGNIERES B, 1986, BMJ-BRIT MED J, V293, P1540, DOI 10.1136/bmj.293.6561.1540; GOADSBY PJ, 1991, LANCET, V338, P782, DOI 10.1016/0140-6736(91)90666-D; GOMERSALL JD, 1973, J NEUROL NEUROSUR PS, V36, P684, DOI 10.1136/jnnp.36.4.684; GRAHAM AN, 1984, PROGR MIGRAINE RES, V2, P283; HIRT D, 1989, CEPHALALGIA S10, V9, P410; JOHNSON ES, 1985, CEPHALALGIA, V5, P5, DOI 10.1046/j.1468-2982.1985.0501005.x; KIMBALL RW, 1960, NEUROLOGY, V10, P107, DOI 10.1212/WNL.10.2.107; Lance J. W, 1986, MIGRAINE OTHER HEADA; LANCE JW, 1964, LANCET, V1, P1236; LITTLEWOOD JT, 1987, CURR PROBLEMS NEUROL, V4, P123; MAGOS AL, 1983, J NEUROL NEUROSUR PS, V46, P1044, DOI 10.1136/jnnp.46.11.1044; MCQUEEN J, 1989, ADV HEADACHE RES, P235; MELLOR C, 1991, EUR NEUROL, V31, P306; MEYER JS, 1983, HEADACHE, V23, P266, DOI 10.1111/j.1526-4610.1983.hed2306266.x; PRADALIER A, 1985, CEPHALALGIA, V5, P107, DOI 10.1046/j.1468-2982.1985.0502107.x; RASKIN NH, 1986, NEUROLOGY, V36, P995, DOI 10.1212/WNL.36.7.995; RASKIN NH, 1988, HEADACHE, P176; SORENSEN KV, 1988, ACTA NEUROL SCAND, V78, P346, DOI 10.1111/j.1600-0404.1988.tb03667.x; TFELTHANSEN P, 1980, J NEUROL NEUROSUR PS, V43, P369, DOI 10.1136/jnnp.43.4.369; 1988, CEPHALALGIA S7, V8, P13	30	20	20	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 16	1992	339	8803					1207	1209		10.1016/0140-6736(92)91141-T	http://dx.doi.org/10.1016/0140-6736(92)91141-T			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HU684	1349945				2022-12-01	WOS:A1992HU68400011
J	LEFF, RL; LOVE, LA; MILLER, FW; GREENBERG, SJ; KLEIN, EA; DALAKAS, MC; PLOTZ, PH				LEFF, RL; LOVE, LA; MILLER, FW; GREENBERG, SJ; KLEIN, EA; DALAKAS, MC; PLOTZ, PH			VIRUSES IN IDIOPATHIC INFLAMMATORY MYOPATHIES - ABSENCE OF CANDIDATE VIRAL GENOMES IN MUSCLE	LANCET			English	Article							INCLUSION-BODY MYOSITIS; POLYMYOSITIS; DERMATOMYOSITIS; RNA; AMPLIFICATION; PICORNAVIRUS; MYOCARDITIS; POLYMERASE; RETROVIRUS; MODEL	There is indirect evidence that various viruses have aetiological roles in the idiopathic inflammatory myopathies. By means of a sensitive and specific method based on the polymerase chain reaction (PCR), we sought direct evidence for the presence in affected muscle of nucleic acid sequences from Coxsackie virus, mumps virus, encephalomyocarditis virus, adenovirus, human T-lymphotropic virus types I and II, and human immunodeficiency virus. RNA was extracted from muscle biopsy samples obtained from 44 patients with idiopathic inflammatory myopathies a mean of 45 (range 0-216) months after disease onset. All the subjects were older than 16 years at disease onset. The integrity of the mRNA extracted was confirmed by the successful PCR amplification of insulin receptor mRNA in all samples. The PCR method was able to detect between 1 and 20 molecules of added viral nucleic acid for the picornaviruses sought. No detectable virus sequences were found, however, in any of the patients' muscle samples or in samples from 13 controls. We tested for retroviral DNA in 22 samples (17 patients, 5 controls) that met our criterion for adequate DNA extraction (detectable beta-actin DNA by PCR); again no virus sequences were found. Persistence in muscle of these or closely related viruses is unlikely to be a continuing stimulus for disease in the idiopathic inflammatory myopathies.	ROSWELL PK CANC INST,DEPT NEUROL,BUFFALO,NY; SUNY BUFFALO,BUFFALO,NY 14260; NINCDS,BETHESDA,MD 20892	Roswell Park Cancer Institute; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	LEFF, RL (corresponding author), NIAMS,ARTHRIT & RHEUMATISM BRANCH,BLDG 10,ROOM 9N228,BETHESDA,MD 20892, USA.		Miller, Frederick/D-2431-2019	Miller, Frederick/0000-0003-2831-9593				BOWLES NE, 1987, LANCET, V1, P1004; CHOU SM, 1970, NEUROLOGY, V20, P205, DOI 10.1212/WNL.20.3.205; CHOU SM, 1986, HUM PATHOL, V17, P765, DOI 10.1016/S0046-8177(86)80197-6; CHRISTENSEN ML, 1986, ARTHRITIS RHEUM, V29, P1365, DOI 10.1002/art.1780291109; CRENNAN JM, 1986, AM J MED, V81, P35, DOI 10.1016/0002-9343(86)90179-8; CRONIN ME, 1988, J EXP MED, V168, P1639, DOI 10.1084/jem.168.5.1639; DALAKAS MC, 1986, JAMA-J AM MED ASSOC, V256, P2381, DOI 10.1001/jama.256.17.2381; DALAKAS MC, 1986, NEUROLOGY, V36, P569, DOI 10.1212/WNL.36.4.569; DENMAN AM, 1988, POLYMYOSITIS DERMATO, P97; EHRLICH GD, 1991, NEUROLOGY, V41, P335, DOI 10.1212/WNL.41.3.335; EHRLICH GD, 1990, PCR PROTOCOLS GUIDE, P325; JIN O, 1990, CIRCULATION, V82, P8, DOI 10.1161/01.CIR.82.1.8; KALLAJOKI M, 1991, HUM PATHOL, V22, P29, DOI 10.1016/0046-8177(91)90057-V; LEFF RL, 1991, ARTHRITIS RHEUM, V11, P1391; LINDLEY IJD, 1977, J GEN VIROL, V34, P177, DOI 10.1099/0022-1317-34-1-177; LOVE LA, 1991, MEDICINE, V70, P360, DOI 10.1097/00005792-199111000-00002; MATHEWS MB, 1983, NATURE, V304, P177, DOI 10.1038/304177a0; MIKOL J, 1982, ANN NEUROL, V11, P576, DOI 10.1002/ana.410110605; MURPHY BR, 1990, VIROLOGY, P1109; NISHINO H, 1989, ANN NEUROL, V25, P260, DOI 10.1002/ana.410250309; PLOTZ PH, 1989, ANN INTERN MED, V111, P143, DOI 10.7326/0003-4819-111-2-143; ROSENBERG NL, 1989, ANN NEUROL, V26, P204, DOI 10.1002/ana.410260204; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SALOMON R, 1974, NATURE, V249, P32, DOI 10.1038/249032a0; STRONGWATER SL, 1984, ARTHRITIS RHEUM, V27, P433, DOI 10.1002/art.1780270411; TANG TT, 1975, NEW ENGL J MED, V292, P608, DOI 10.1056/NEJM197503202921203; WILEY CA, 1989, NEW ENGL J MED, V320, P992, DOI 10.1056/NEJM198904133201507; YOUSEF GE, 1990, ANN RHEUM DIS, V49, P310, DOI 10.1136/ard.49.5.310	28	107	107	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 16	1992	339	8803					1192	1195		10.1016/0140-6736(92)91134-T	http://dx.doi.org/10.1016/0140-6736(92)91134-T			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HU684	1349938				2022-12-01	WOS:A1992HU68400004
J	LIU, J; LISSENS, W; DEVROEY, P; VANSTEIRTEGHEM, A; LIEBAERS, I				LIU, J; LISSENS, W; DEVROEY, P; VANSTEIRTEGHEM, A; LIEBAERS, I			EFFICIENCY AND ACCURACY OF POLYMERASE-CHAIN-REACTION ASSAY FOR CYSTIC-FIBROSIS ALLELE DELTA-F508 IN SINGLE CELL	LANCET			English	Article							HUMAN PREIMPLANTATION EMBRYOS; ENZYMATIC AMPLIFICATION; DNA AMPLIFICATION; IDENTIFICATION; DIAGNOSIS; INVITRO; BIOPSY; GENE; PCR	Diagnosis of genetic disorders in the embryo before implantation, though possible by removal of one or two blastomeres at the eight-cell stage, is still experimental because the procedures of gene analysis of DNA from a single cell are not yet reliable enough for clinical application. We have evaluated the efficiency and accuracy of polymerase-chain-reaction (PCR) amplification of a single-copy gene, wild-type or cystic fibrosis DELTA-F508 allele, on single sperm cells from a donor known to be a heterozygous carrier of the DELTA-F508 mutation. DNA from single spermatozoa was decontaminated by restriction-enzyme treatment, then the region around the DELTA-F508 site was amplified by nested PCR. The distribution of the wild-type and mutant alleles (59 [55%] and 48 [45%, respectively]) in the 107 single spermatozoa did not differ from that expected (50% each). 1 sample did not provide an amplified signal. To check that the two alleles would be amplified with equal efficiency when they were both present within a cell, we did PCR for 51 two-sperm samples. Again the distribution did not deviate from that expected (17 [33%] both wild-type; 21 [41 %] one wild-type, one DELTA-F508; 13 [26%] both DELTA-F508 vs 25%; 50%; 25% expected). None of the 74 blanks in these experiments was contaminated. We conclude that our DELTA-F508 single-cell assay is efficient and accurate and can be used for analysis of blastomere DNA to diagnose cystic fibrosis before embryo implantation.	VRIJE UNIV BRUSSELS HOSP,DEPT MED GENET,LAARBEEKLAAN 101,B-1090 BRUSSELS,BELGIUM; FREE UNIV BRUSSELS,CTR REPROD MED,B-1050 BRUSSELS,BELGIUM; FREE UNIV BRUSSELS,DEPT MED GENET,B-1050 BRUSSELS,BELGIUM	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel			Lissens, Willy/B-2892-2013	Lissens, Willy/0000-0003-3875-9955				GYLLENSTEN U, 1990, PCR PROTOCOLS GUIDE, P300; HANDYSIDE AH, 1989, LANCET, V1, P347; HANDYSIDE AH, 1990, NATURE, V344, P768, DOI 10.1038/344768a0; HARDY K, 1990, HUM REPROD, V5, P708, DOI 10.1093/oxfordjournals.humrep.a137173; JINNO Y, 1990, NUCLEIC ACIDS RES, V18, P6739, DOI 10.1093/nar/18.22.6739; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; LI HH, 1988, NATURE, V335, P414, DOI 10.1038/335414a0; NAVIDI W, 1991, HUM REPROD, V6, P836, DOI 10.1093/oxfordjournals.humrep.a137438; QUINN P, 1985, ANN NY ACAD SCI, V442, P195, DOI 10.1111/j.1749-6632.1985.tb37520.x; RIORDAN JR, 1989, SCIENCE, V245, P1066; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SARKAR G, 1990, NATURE, V343, P27, DOI 10.1038/343027a0; STROM CM, 1990, LANCET, V336, P306, DOI 10.1016/0140-6736(90)91835-X; VARAWALLA NY, 1991, PRENATAL DIAG, V11, P775, DOI 10.1002/pd.1970111006	15	44	44	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 16	1992	339	8803					1190	1192		10.1016/0140-6736(92)91133-S	http://dx.doi.org/10.1016/0140-6736(92)91133-S			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HU684	1349937				2022-12-01	WOS:A1992HU68400003
J	MACARTHUR, C; LEWIS, M; KNOX, EG				MACARTHUR, C; LEWIS, M; KNOX, EG			INVESTIGATION OF LONG-TERM PROBLEMS AFTER OBSTETRIC EPIDURAL-ANESTHESIA	BRITISH MEDICAL JOURNAL			English	Article							INTRAMUSCULAR PETHIDINE; MATERNAL OPINION; ANALGESIA; LABOR; ANESTHESIA; BLOCK	Objective-To examine the association between obstetric epidural anaesthesia and subsequent long term problems. Design -Postal questionnaire on heath problems after childbirth linked to maternity case note data. Setting-Maternity hospital in Birmingham. Subjects-11 701 women who delivered their most recent child during 1978-85 and who returned completed questionnaires. Main outcome measures-Frequencies of long term symptoms after childbirth. Results-Compared with the 6935 women who did Dot have epidural anaesthesia the 4766 women who did more commonly experienced backache (903 (18.9%) with epidural v 731 (10.5%) without epidural), frequent headaches 220 (4.6%) v 199 (2.9%)), migraine (92 (1.9%) v 73 (1.1%)), neckache (116 (2.4%) v 112 (1-6%)), and tingling in hands or fingers (143 (3.0%) v 150 (2.2%)). The results could not be explained by correlated social or obstetric factors. The associations with head, neck, and hand symptoms were found only in women who reported backache. An excess of visual disturbances among women who had epidural anaesthesia (83 (1.7%) v 91 (1.3%); was present only in association with migraine, but excess of dizziness or fainting (102 (2.1%) v 109 (1.6%)) was independent of other symptoms. 26 women had numbness or tingling in the lower back, buttocks, and leg, of whom 23 had had epidural anaesthesia. Of 34 women with spinal headache, nine (five after accidental dural puncture; four after spinal block) reported long term headaches. Conclusions-These associations may indicate a causal sequence, although this cannot be proved from this type of study. Randomised trials of epidural anaesthesia are required to determine whether causal relations exist.	BIRMINGHAM MATERN HOSP,DEPT ANAESTHET,BIRMINGHAM B15 2TG,W MIDLANDS,ENGLAND		MACARTHUR, C (corresponding author), UNIV BIRMINGHAM,SCH MED,DEPT PUBL HLTH & EPIDEMIOL,BIRMINGHAM B15 2TJ,W MIDLANDS,ENGLAND.		MacArthur, Christine/ABA-8601-2021	MacArthur, Christine/0000-0003-0434-2158				BROWNRIDGE P, 1983, ANAESTH INTENS CARE, V11, P4, DOI 10.1177/0310057X8301100102; CRAWFORD JS, 1972, BRIT J ANAESTH, V44, P66, DOI 10.1093/bja/44.1.66; CRAWFORD JS, 1985, ANAESTHESIA, V40, P1219, DOI 10.1111/j.1365-2044.1985.tb10664.x; Crawford JS, 1985, PRINCIPLES PRACTICE; HIBBARD BM, 1990, BRIT J OBSTET GYNAEC, V97, P402, DOI 10.1111/j.1471-0528.1990.tb01826.x; KITZINGER S, 1987, SOME WOMENS EXPERIEN; MACARTHUR C, 1990, BRIT MED J, V301, P9, DOI 10.1136/bmj.301.6742.9; MACARTHUR C, 1991, HLTH AFTER CHILDBIRT; MOORE J, 1974, ANAESTHESIA, V29, P537, DOI 10.1111/j.1365-2044.1974.tb00716.x; MORGAN BM, 1982, LANCET, V2, P808; PHILIPSEN T, 1990, EUR J OBSTET GYN R B, V34, P205, DOI 10.1016/0028-2243(90)90072-9; RAMANATHAN S, 1988, OBSTETRIC ANAESTHESI; ROBINSON JO, 1980, ANAESTHESIA, V35, P1173, DOI 10.1111/j.1365-2044.1980.tb05074.x	13	46	46	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 16	1992	304	6837					1279	1282		10.1136/bmj.304.6837.1279	http://dx.doi.org/10.1136/bmj.304.6837.1279			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV086	1535010	Bronze, Green Published			2022-12-01	WOS:A1992HV08600020
J	PELOSI, AJ; APPLEBY, L				PELOSI, AJ; APPLEBY, L			PSYCHOLOGICAL INFLUENCES ON CANCER AND ISCHEMIC-HEART-DISEASE	BRITISH MEDICAL JOURNAL			English	Article							PERSONALITY; PREDICTORS		UNIV HOSP S MANCHESTER,MANCHESTER M20 8LR,LANCS,ENGLAND	Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital	PELOSI, AJ (corresponding author), HAIRMYRES HOSP,E KILBRIDE G75 8RG,SCOTLAND.			Pelosi, Anthony/0000-0002-5501-2661				BINIK YM, 1991, BEHAV RES THER, V29, P33, DOI 10.1016/S0005-7967(09)80004-1; Eysenck H.J., 1991, SMOKING PERSONALITY; EYSENCK HJ, 1989, J SOC POLIT ECON ST, V14, P25; EYSENCK HJ, 1985, PERS INDIV DIFFER, V6, P535, DOI 10.1016/0191-8869(85)90003-0; EYSENCK HJ, 1991, BEHAV RES THER, V29, P17, DOI 10.1016/S0005-7967(09)80003-X; EYSENCK HJ, 1986, SMOKING SOC MORE BAL; FOX BH, 1988, TOPICS HLTH PSYCHOL, P37; GROSSARTHMATICE.R, 1988, PRIMARY PREVENTION C, P199; GROSSARTHMATICE.R, 1980, PSYCHOTHER PSYCHOSOM, V33, P120; GROSSARTHMATICE.R, 1988, TOPICS HLTH PSYCHOL, P57; GROSSARTHMATICEK R, 1984, CANCER DETECT PREV, V7, P201; GROSSARTHMATICEK R, 1990, J BEHAV THER EXP PSY, V21, P91, DOI 10.1016/0005-7916(90)90014-C; GROSSARTHMATICEK R, 1983, PSYCHOTHER PSYCHOSOM, V40, P191, DOI 10.1159/000287767; GROSSARTHMATICEK R, 1985, J PSYCHOSOM RES, V29, P167, DOI 10.1016/0022-3999(85)90038-8; GROSSARTHMATICEK R, 1982, SOC SCI MED, V16, P493, DOI 10.1016/0277-9536(82)90058-2; GROSSARTHMATICEK R, 1991, BEHAV RES THER, V29, P1; GROSSARTHMATICEK R, 1980, PSYCHOTHER PSYCHOSOM, V33, P129, DOI 10.1159/000287423; GROSSARTHMATICEK R, 1988, PERS INDIV DIFFER, V9, P479, DOI 10.1016/0191-8869(88)90125-0; GROSSARTHMATICEK R, 1990, PSYCHOL REP, V66, P355, DOI 10.2466/PR0.66.2.355-373; GROSSARTHMATICEK R, 1989, PSYCHOL REP, V65, P177, DOI 10.2466/pr0.1989.65.1.177; GROSSARTHMATICK R, 1985, PERS INDIV DIFFER, V6, P313, DOI 10.1016/0191-8869(85)90055-8	21	28	28	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 16	1992	304	6837					1295	1298		10.1136/bmj.304.6837.1295	http://dx.doi.org/10.1136/bmj.304.6837.1295			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HV086	1606436	Green Published, Bronze			2022-12-01	WOS:A1992HV08600029
J	PRYCE, D; BEHRENS, R; DAVIDSON, R; CHIODINI, P; BRYCESON, A; MCLEOD, J				PRYCE, D; BEHRENS, R; DAVIDSON, R; CHIODINI, P; BRYCESON, A; MCLEOD, J			ONCHOCERCIASIS IN MEMBERS OF AN EXPEDITION TO CAMEROON - ROLE OF ADVICE BEFORE TRAVEL AND LONG-TERM FOLLOW-UP	BRITISH MEDICAL JOURNAL			English	Article											PRYCE, D (corresponding author), HOSP TROP DIS,1ST FLOOR,QUEENS HOUSE,LONDON W1P 9LE,ENGLAND.							GILLES HM, 1984, RECENT ADV TROPICAL; MANSONBAHR PEC, 1987, MANSONS TROPICAL DIS; 1987, WHO TECH REP SER, P752	3	13	13	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 16	1992	304	6837					1285	1286		10.1136/bmj.304.6837.1285-a	http://dx.doi.org/10.1136/bmj.304.6837.1285-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV086	1606433	Green Published, Bronze			2022-12-01	WOS:A1992HV08600025
J	REGNSTROM, J; NILSSON, J; TORNVALL, P; LANDOU, C; HAMSTEN, A				REGNSTROM, J; NILSSON, J; TORNVALL, P; LANDOU, C; HAMSTEN, A			SUSCEPTIBILITY TO LOW-DENSITY-LIPOPROTEIN OXIDATION AND CORONARY ATHEROSCLEROSIS IN MAN	LANCET			English	Article							HERITABLE HYPERLIPIDEMIC RABBIT; GRADIENT ULTRACENTRIFUGATION; DEGRADATION; PROGRESSION; PLASMA; INVIVO	Animal studies indicate a possible role for lipid oxidation in the development of atherosclerosis. We set out to investigate whether there was a relation between the ability of low-density lipoprotein (LDL) to resist oxidation in vitro and the severity of coronary atherosclerosis in man. 35 unselected young (mean [SD] age 39.9 [4.2] years) male survivors of myocardial infarction underwent angiography, and LDL was isolate from their plasma by density gradient ultracentrifugation. In-vitro LDL susceptibility to oxidation was assessed by determination of the lag phase for the formation of conjugated dienes in the presence of copper ions. An inverse relation was found between lag phase and quantitative estimates of global coronary atherosclerosis (r = - 0.45; p < 0.02). Multivariate analysis indicated that the lag phase for oxidative modification of LDL and LDL cholesterol concentration correlated independently with seversity of coronary atherosclerosis. The lag phase for oxidation of LDL was also related to the triglyceride content of the LDL fraction (r = - 0.55; p < 0.002). The finding that susceptibility of LDL oxidation is associated with severity of coronary atherosclerosis may indicate that lipid oxidation promotes premature coronary atherosclerosis and that individuals with an LDL enriched in triglycerides are at particular risk.	KAROLINSKA INST,KAROLINSKA HOSP,DEPT MED,S-10401 STOCKHOLM 60,SWEDEN; KAROLINSKA INST,KAROLINSKA HOSP,DEPT THORAC RADIOL,S-10401 STOCKHOLM 60,SWEDEN	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital	REGNSTROM, J (corresponding author), KAROLINSKA INST,KAROLINSKA HOSP,KING GUSTAF VTH RES INST,BOX 60004,S-10401 STOCKHOLM 60,SWEDEN.							AVOGARO P, 1988, ARTERIOSCLEROSIS, V8, P79, DOI 10.1161/01.ATV.8.1.79; BERLINER JA, 1990, J CLIN INVEST, V85, P1260, DOI 10.1172/JCI114562; CAREW TE, 1987, P NATL ACAD SCI USA, V84, P7725, DOI 10.1073/pnas.84.21.7725; Carlson K, 1973, J Clin Pathol Suppl (Assoc Clin Pathol), V5, P32; CATHCART MK, 1985, J LEUKOCYTE BIOL, V38, P341, DOI 10.1002/jlb.38.2.341; CHAPMAN MJ, 1988, J LIPID RES, V29, P442; ESTERBAUER H, 1989, FREE RADICAL RES COM, V6, P67, DOI 10.3109/10715768909073429; FROSTEGARD J, 1990, P NATL ACAD SCI USA, V87, P904, DOI 10.1073/pnas.87.3.904; HAMSTEN A, 1986, CIRCULATION, V73, P1097, DOI 10.1161/01.CIR.73.6.1097; HENRIKSEN T, 1981, P NATL ACAD SCI-BIOL, V78, P6499, DOI 10.1073/pnas.78.10.6499; KITA T, 1987, P NATL ACAD SCI USA, V84, P5928, DOI 10.1073/pnas.84.16.5928; LOWRY OH, 1951, J BIOL CHEM, V193, P265; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; REDGRAVE TG, 1975, ANAL BIOCHEM, V65, P42, DOI 10.1016/0003-2697(75)90488-1; RIEMERSMA RA, 1991, LANCET, V337, P1, DOI 10.1016/0140-6736(91)93327-6; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STRINGER MD, 1989, BRIT MED J, V298, P281, DOI 10.1136/bmj.298.6669.281; TORNVALL P, 1991, ATHEROSCLEROSIS, V90, P67, DOI 10.1016/0021-9150(91)90245-X	19	507	519	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 16	1992	339	8803					1183	1186		10.1016/0140-6736(92)91129-V	http://dx.doi.org/10.1016/0140-6736(92)91129-V			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HU684	1349935				2022-12-01	WOS:A1992HU68400001
J	STEEL, JM; ALLWINKLE, J; MOFFAT, R; CARRINGTON, DJ				STEEL, JM; ALLWINKLE, J; MOFFAT, R; CARRINGTON, DJ			USE OF LUCOZADE AND GLUCAGON BY AMBULANCE STAFF FOR TREATING HYPOGLYCEMIA	BMJ-BRITISH MEDICAL JOURNAL			English	Article									SCOTTISH AMBULANCE SERV, EDINBURGH EH10 5SA, SCOTLAND		STEEL, JM (corresponding author), ROYAL INFIRM, DEPT DIABET, EDINBURGH EH3 9YW, MIDLOTHIAN, SCOTLAND.							COLLIER A, 1987, DIABETES CARE, V10, P712, DOI 10.2337/diacare.10.6.712; DCCT Res Grp, 1991, AM J MED, V90, P450, DOI 10.1016/0002-9343(91)80085-Z; MULHAUSER I, 1985, DIABETES CARE S1, V8, P39; WESTON C, 1990, BRIT MED J, V300, P908, DOI 10.1136/bmj.300.6729.908-a; YAXLEY L, 1991, DIABETIC MED S1, V8, P71	5	10	10	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 16	1992	304	6837					1283	1284		10.1136/bmj.304.6837.1283	http://dx.doi.org/10.1136/bmj.304.6837.1283			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV086	1606430	Green Published, Bronze			2022-12-01	WOS:A1992HV08600022
J	TOOLE, MJ				TOOLE, MJ			MICRONUTRIENT DEFICIENCIES IN REFUGEES	LANCET			English	Editorial Material											TOOLE, MJ (corresponding author), CTR DIS CONTROL,ATLANTA,GA 30333, USA.							DESENCLOS JC, 1989, B WORLD HEALTH ORGAN, V67, P309; IRWIN MI, 1976, J NUTR, V106, P824; LEVINE M, 1986, NEW ENGL J MED, V314, P892, DOI 10.1056/NEJM198604033141407; MAGAN AM, 1982, DISASTERS, V7, P93; MOREN A, 1990, LANCET, V335, P1403, DOI 10.1016/0140-6736(90)91283-G; NIEBURG P, 1988, B WORLD HEALTH ORGAN, V66, P698; ROE DA, 1973, PLAGUE CORN, P1; SOMMER A, 1983, LANCET, V2, P585; TOOLE MJ, 1990, JAMA-J AM MED ASSOC, V263, P3269; YIP R, 1987, OCT ANN M AM PUBL HL; 1989, NUTRITION TIMES DISA; 1967, WHO TECH REP SER, V362, P45; 1989, MMWR, V38, P455; 1989, MMWR, V38, P461; 1991, 1991 INT S RESP NUTR; 1991, MMWR, V40, P209	16	24	24	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 16	1992	339	8803					1214	1216		10.1016/0140-6736(92)91143-V	http://dx.doi.org/10.1016/0140-6736(92)91143-V			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HU684	1349947				2022-12-01	WOS:A1992HU68400013
J	TURNER, G; ROBINSON, H; LAING, S; VANDENBERK, M; COLLEY, A; GODDARD, A; SHERMAN, S; PARTINGTON, M				TURNER, G; ROBINSON, H; LAING, S; VANDENBERK, M; COLLEY, A; GODDARD, A; SHERMAN, S; PARTINGTON, M			POPULATION SCREENING FOR FRAGILE-X	LANCET			English	Article							LINKED MENTAL-RETARDATION; LOCALIZATION	A screening programme to detect fragile X syndrome has been operating in New South Wales, Australia, since 1984. The aim of this programme is to find previously unidentified individuals with the syndrome so that their extended families can be properly informed of the risks before making decisions about childbearing. 14 225 individuals attending adult and child facilities for the intellectually handicapped have been screened, of whom 8172 have been offered testing for the fragile X syndrome with a 79% uptake of the service. 253 probands were found, and in the extended families 818 females at 25-100% risk of being carriers were interviewed and counselled. Continuing contact was maintained and prenatal diagnosis was offered. The effect of the programme was assessed in a subgroup of 90 individuals, most of whom were appreciative of the service and felt that they had been adequately informed. The influence of knowing the diagnosis and its genetic implications were also assessed, the main consequences being a 26% reduction in births and a 61% uptake of prenatal diagnosis. Improved techniques for diagnosis of fragile X have benefited the families identified and counselled, suggesting that systematic screening for fragile X should be an essential component of community genetic services.	EMORY UNIV,DEPT PEDIAT,DIV MED GENET,ATLANTA,GA 30322; WESTERN SUBURBS HOSP,NEWCASTLE & NO NEW S WALES GENET SERV,NEWCASTLE,NSW,AUSTRALIA	Emory University	TURNER, G (corresponding author), PRINCE WALES CHILDRENS HOSP,FRAGILE X PROGRAMME,SYDNEY,NSW 2031,AUSTRALIA.							COLLINS FA, 1990, CLIN GENET, V37, P18; FISHBURN J, 1983, AM J MED GENET, V14, P713, DOI 10.1002/ajmg.1320140413; GEDEON A, 1991, J MED GENET, V28, P372, DOI 10.1136/jmg.28.6.372; HEITZ D, IN PRESS AM J MED GE; LAING S, 1991, AM J MED GENET, V38, P256, DOI 10.1002/ajmg.1320380219; MODELL B, 1991, 8TH INT C HUM GEN WA; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; PARTINGTON MW, 1988, AM J MED GENET, V30, P509, DOI 10.1002/ajmg.1320300153; PARTINGTON MW, 1988, AM J MED GENET, V30, P251, DOI 10.1002/ajmg.1320300127; PARTINGTON MW, 1988, AM J MED GENET, V29, P633, DOI 10.1002/ajmg.1320290322; PARTINGTON MW, IN PRESS AM J MED GE; PURVISSMITH SG, 1988, AM J MED GENET, V30, P337, DOI 10.1002/ajmg.1320300134; SHERMAN SL, 1984, ANN HUM GENET, V48, P21, DOI 10.1111/j.1469-1809.1984.tb00830.x; SHERMAN SL, 1988, AM J MED GENET, V30, P633, DOI 10.1002/ajmg.1320300164; SUTHERS GK, 1988, AM J MED GENET, V30, P485, DOI 10.1002/ajmg.1320300151; THODE A, 1988, AM J MED GENET, V30, P239, DOI 10.1002/ajmg.1320300125; TURNER G, 1989, AM J MED GENET, V34, P463, DOI 10.1002/ajmg.1320340402; TURNER G, 1986, NEW ENGL J MED, V315, P607, DOI 10.1056/NEJM198609043151002; TURNER G, 1980, NEW ENGL J MED, V303, P662, DOI 10.1056/NEJM198009183031202; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; WILSON M, 1991, AM J MED GENET, V40, P406, DOI 10.1002/ajmg.1320400405; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179	22	57	58	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 16	1992	339	8803					1210	1213		10.1016/0140-6736(92)91142-U	http://dx.doi.org/10.1016/0140-6736(92)91142-U			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HU684	1349946				2022-12-01	WOS:A1992HU68400012
J	VETTER, NJ; LEWIS, PA; LLEWELLYN, L				VETTER, NJ; LEWIS, PA; LLEWELLYN, L			SUPPORTING ELDERLY DEPENDENT PEOPLE AT HOME	BRITISH MEDICAL JOURNAL			English	Article							CARE	Objective-To clarify the relation between the dependency of elderly people and the assistance they receive from others by using a detailed but simple measure of dependency. Design - Secondary analysis of data from a survey of people aged 70 and over. Setting-Two general practices in south Wales. Subjects - 1280 people aged 70 and over. Main outcome measures-Dependency on others to perform essential functions; detailed data on who assists with those functions. Results-Increasing dependency was associated with increased use of more than one member of the family or friends and an increase in the provision of statutory services. Conclusion-The complexity of the relation between dependency and those who care for dependent people has previously been underestimated. The presence of providers of statutory services at the household of elderly dependent people suggests that these services can be developed further to help those caring for elderly people at home.	UNIV WALES COLL MED,DEPT PUBL HLTH MED,CARDIFF CF4 4XN,S GLAM,WALES; UNIV WALES COLL MED,DEPT MED COMP,CARDIFF CF4 4XN,S GLAM,WALES	Cardiff University; Cardiff University	VETTER, NJ (corresponding author), UNIV WALES COLL MED,DEPT EPIDEMIOL & COMMUNITY MED,CARDIFF CF4 4XN,S GLAM,WALES.							BOYDEN PGK, 1979, NZ MED J, V89, P265; BRODY EM, 1981, GERONTOLOGIST, V21, P471, DOI 10.1093/geront/21.5.471; ISAACS B, 1971, BRIT MED J, V4, P282, DOI 10.1136/bmj.4.5782.282; JONES DA, 1984, SOC SCI MED, V19, P511, DOI 10.1016/0277-9536(84)90046-7; NISSEL M, 1984, AGEING SOC, V4, P185; SALVAGE AV, 1988, AGE AGEING, V17, P270, DOI 10.1093/ageing/17.4.270; Vetter N J, 1990, Int Disabil Stud, V12, P22; VETTER NJ, 1984, BRIT MED J, V288, P369, DOI 10.1136/bmj.288.6414.369; 1980, EXPERIENCE CARING EL	9	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 16	1992	304	6837					1290	1292		10.1136/bmj.304.6837.1290	http://dx.doi.org/10.1136/bmj.304.6837.1290			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HV086	1606435	Green Published, Bronze			2022-12-01	WOS:A1992HV08600027
J	BICKELL, NA; PIEPER, KS; LEE, KL; MARK, DB; GLOWER, DD; PRYOR, DB; CALIFF, RM				BICKELL, NA; PIEPER, KS; LEE, KL; MARK, DB; GLOWER, DD; PRYOR, DB; CALIFF, RM			REFERRAL PATTERNS FOR CORONARY-ARTERY DISEASE TREATMENT - GENDER BIAS OR GOOD CLINICAL JUDGMENT	ANNALS OF INTERNAL MEDICINE			English	Article						CORONARY DISEASE; SELECTION BIAS; SEX FACTORS; CORONARY ARTERY BYPASS; REFERRAL AND CONSULTATION; WOMENS HEALTH	ACUTE MYOCARDIAL-INFARCTION; SEX-DIFFERENCES; BYPASS-SURGERY; PROGNOSTIC PREDICTION; MEDICAL COMPLAINTS; REGRESSION-MODELS; FEMALE PATIENTS; WOMEN; MORTALITY; SURVIVAL	Objective: To determine whether a gender bias exists in referral for coronary bypass graft surgery among patients with catheterization-documented coronary artery disease. Design: Historical cohort study (1969 to 1984). Setting: A referral medical center. Patients: A total of 5795 patients with catheterization-documented coronary artery disease. Measurements: Surgical referral patterns of men and women grouped by risk for cardiac death and by treatment effectiveness. Time trends were evaluated for three periods: 1969 to 1974, 1975 to 1979, and 1980 to 1984. Results: Overall, when no adjustment was made for baseline risk for cardiac death, no statistical difference was found between men and women regarding referral for surgery (46% compared with 44%, respectively). When an adjustment was made for such risk, the male-to-female odds ratio for surgical referral was 1.28 (95% Cl, 1.05 to 1.58) among patients with a low risk for cardiac death. This effect was most evident in the 1980 to 1984 period (odds ratio, 1.73; Cl, 1.29 to 2.31). In the high-risk group, the odds ratio was 0.84 (Cl, 0.68 to 1.04), with little change occurring during the study. Men were more likely to be referred for surgery when surgery offered the least survival benefit relative to medical therapy (odds ratio, 1.29; Cl, 1.08 to 1.54). This effect was most pronounced in the 1980 to 1984 period (odds ratio, 1.63; Cl, 1.27 to 2.10). Conclusions: Women are less likely than men to be referred for coronary bypass graft surgery among patients with a low risk for cardiac death, in whom surgery offers little or no survival benefit over medical treatment. Women are at least as likely as men to be referred for bypass surgery among more symptomatic and more severely diseased patients, in whom surgery offers the greatest survival benefits. These trends were most prominent in the recent years of the study. Based on surgical survival benefits, these referral patterns may represent more appropriate treatment referral for women than men.	UNIV N CAROLINA, CHAPEL HILL, NC 27514 USA; DUKE UNIV, MED CTR, DEPT COMMUNITY & FAMILY MED, DIV BIOMETRY, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT MED, DIV CARDIOL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT SURG, DURHAM, NC 27710 USA	University of North Carolina; University of North Carolina Chapel Hill; Duke University; Duke University; Duke University				Mark, Daniel/0000-0001-6340-8087	AHRQ HHS [HS-06503, HS-05635] Funding Source: Medline; NHLBI NIH HHS [HL-36587] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R18HS005635] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036587] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMITAGE KJ, 1979, JAMA-J AM MED ASSOC, V241, P2186, DOI 10.1001/jama.241.20.2186; AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; BERNSTEIN B, 1981, MED CARE, V19, P600, DOI 10.1097/00005650-198106000-00004; BOLOOKI H, 1975, J THORAC CARDIOV SUR, V69, P271; CALIFF RM, 1988, CIRCULATION, V78, P185; CALIFF RM, 1972, JR STAT SOC B, V34, P187; COLAMECO S, 1983, J FAM PRACTICE, V16, P1117; COSGROVE DM, 1984, J THORAC CARDIOV SUR, V88, P673; COWLEY MJ, 1985, CIRCULATION, V71, P90, DOI 10.1161/01.CIR.71.1.90; DEVLIN TF, 1986, 11TH P ANN SAS US GR, P646; DOLISZNY KM, 1989, CIRCULATION, V80, P410; EAKER ED, 1987, CORONARY HEART DISEA, P122; EISENBERG JM, 1979, ANN INTERN MED, V90, P957, DOI 10.7326/0003-4819-90-6-957; FISHER LD, 1982, J THORAC CARDIOV SUR, V84, P334; GREER S, 1986, J FAM PRACTICE, V23, P49; HARLAN WR, 1987, CORONARY HEART DISEA, P131; HARRELL FE, 1984, STAT MED, V3, P143, DOI 10.1002/sim.4780030207; HARRELL FE, 1985, CANCER TREAT REP, V69, P1071; HARRELL FE, 1988, J NATL CANCER I, V80, P1198, DOI 10.1093/jnci/80.15.1198; HIBARD JH, 1984, INT Q COMMUNITY HLTH, V4, P95; HLATKY MA, 1988, J AM COLL CARDIOL, V11, P237, DOI 10.1016/0735-1097(88)90086-1; JOHANSSON S, 1984, AM J EPIDEMIOL, V119, P610, DOI 10.1093/oxfordjournals.aje.a113778; JONES RH, 1981, CIRCULATION, V64, P586, DOI 10.1161/01.CIR.64.3.586; KHAN SS, 1990, ANN INTERN MED, V112, P561, DOI 10.7326/0003-4819-112-8-561; KIRKLIN JW, 1991, CIRCULATION, V83, P1125; KOSKENVUO M, 1986, SOC SCI MED, V23, P605, DOI 10.1016/0277-9536(86)90154-1; LOOP FD, 1983, J AM COLL CARDIOL, V1, P383, DOI 10.1016/S0735-1097(83)80064-3; MCCRANIE EW, 1978, SOC SCI MED-MED SOC, V12, P111, DOI 10.1016/0160-7979(78)90032-2; NATHANSON CA, 1977, SOC SCI MED, V11, P13, DOI 10.1016/0037-7856(77)90141-X; ORENTLICHER D, 1991, JAMA-J AM MED ASSOC, V266, P559; PRYOR DB, 1984, J CHRON DIS, V37, P521, DOI 10.1016/0021-9681(84)90003-1; PRYOR DB, 1987, CIRCULATION, V76, P13; PRYOR DB, 1988, TRENDS CORONARY HEAR, P76; PRYOR DB, 1989, CIRCULATION S2, V80, P409; PULETTI M, 1984, AM HEART J, V108, P63, DOI 10.1016/0002-8703(84)90545-3; SKETCH MH, 1975, AM J CARDIOL, V36, P169, DOI 10.1016/0002-9149(75)90521-4; SMITH PL, 1979, AM STAT, V33, P57, DOI 10.2307/2683222; STACK RS, 1988, J AM COLL CARDIOL, V11, P1141, DOI 10.1016/0735-1097(88)90274-4; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402; Stone CJ., 1985, P STAT COMP SECT AM, V1, P45; TOBIN JN, 1987, ANN INTERN MED, V107, P19, DOI 10.7326/0003-4819-107-1-19; TOFLER GH, 1987, J AM COLL CARDIOL, V9, P473, DOI 10.1016/S0735-1097(87)80038-4; VERBRUGGE LM, 1981, MED CARE, V19, P609, DOI 10.1097/00005650-198106000-00005; VERBRUGGE LM, 1987, WOMEN HEALTH, V12, P103, DOI 10.1300/J013v12n02_07; WAGNER PJ, 1988, BEHAVIORAL MED, V6, P9; WALKER SH, 1967, BIOMETRIKA, V54, P167, DOI 10.1093/biomet/54.1-2.167; Wallen J, 1979, Women Health, V4, P135, DOI 10.1300/J013v04n02_03; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; Wingard DL, 1987, CORONARY HEART DISEA, P99	49	174	174	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1992	116	10					791	797		10.7326/0003-4819-116-10-791	http://dx.doi.org/10.7326/0003-4819-116-10-791			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT802	1567093				2022-12-01	WOS:A1992HT80200002
J	BROSE, N; PETRENKO, AG; SUDHOF, TC; JAHN, R				BROSE, N; PETRENKO, AG; SUDHOF, TC; JAHN, R			SYNAPTOTAGMIN - A CALCIUM SENSOR ON THE SYNAPTIC VESICLE SURFACE	SCIENCE			English	Article							PROTEIN-KINASE-C; MEMBRANE-PROTEIN; PHASE-SEPARATION; BINDING PROTEIN; POLYLYSINE; CELLS	Neurons release neurotransmitters by calcium-dependent exocytosis of synaptic vesicles. However, the molecular steps transducing the calcium signal into membrane fusion are still an enigma. It is reported here that synaptotagmin, a highly conserved synaptic vesicle protein, binds calcium at physiological concentrations in a complex with negatively charged phospholipids. This binding is specific for calcium and involves the cytoplasmic domain of synaptotagmin. Calcium binding is dependent on the intact oligomeric structure of synaptotagmin (it is abolished by proteolytic cleavage at a single site). These results suggest that synaptotagmin acts as a cooperative calcium receptor in exocytosis.	MAX PLANCK INST PSYCHIAT,DEPT NEUROCHEM,W-8033 MARTINSRIED,GERMANY; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235	Max Planck Society; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Jahn, Reinhard/0000-0003-1542-3498; Petrenko, Alexander/0000-0002-6689-6546				AUGUSTINE GJ, 1987, ANNU REV NEUROSCI, V10, P633, DOI 10.1146/annurev.ne.10.030187.003221; BAZZI MD, 1991, BIOCHEMISTRY-US, V30, P7961, DOI 10.1021/bi00246a013; BAZZI MD, 1990, BIOCHEMISTRY-US, V29, P7624, DOI 10.1021/bi00485a012; BIRRELL GB, 1976, BIOCHEMISTRY-US, V15, P2925, DOI 10.1021/bi00658a035; BOGGS JM, 1976, BIOCHEMISTRY-US, V15, P5420; CARRIER D, 1986, BIOCHEMISTRY-US, V25, P4167, DOI 10.1021/bi00362a027; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; FOHR KJ, IN PRESS METHODS ENZ; GEPPERT M, 1991, J BIOL CHEM, V266, P13548; HARTMANN W, 1978, BIOCHIM BIOPHYS ACTA, V509, P474, DOI 10.1016/0005-2736(78)90241-9; IKEDA T, 1990, BIOCHIM BIOPHYS ACTA, V1026, P105, DOI 10.1016/0005-2736(90)90339-P; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LLINAS R, 1981, BIOPHYS J, V33, P289, DOI 10.1016/S0006-3495(81)84898-9; MATTHEW WD, 1981, J CELL BIOL, V91, P257, DOI 10.1083/jcb.91.1.257; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; NAVONE F, 1986, J CELL BIOL, V103, P2511, DOI 10.1083/jcb.103.6.2511; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PERIN MS, 1991, J BIOL CHEM, V266, P615; PERIN MS, 1991, J BIOL CHEM, V266, P623; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; PETRENKO AG, 1991, NATURE, V353, P65, DOI 10.1038/353065a0; REHM H, 1986, EMBO J, V5, P535, DOI 10.1002/j.1460-2075.1986.tb04243.x; REICHARDT LF, 1983, ANNU REV BIOCHEM, V52, P871, DOI 10.1146/annurev.bi.52.070183.004255; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; TRIFARO JM, 1989, NEUROSCIENCE, V29, P1, DOI 10.1016/0306-4522(89)90327-8; WENDLAND B, 1991, NEURON, V6, P993, DOI 10.1016/0896-6273(91)90239-V	27	794	801	2	73	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 15	1992	256	5059					1021	1025		10.1126/science.1589771	http://dx.doi.org/10.1126/science.1589771			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU224	1589771				2022-12-01	WOS:A1992HU22400039
J	BUZSAKI, G; HORVATH, Z; URIOSTE, R; HETKE, J; WISE, K				BUZSAKI, G; HORVATH, Z; URIOSTE, R; HETKE, J; WISE, K			HIGH-FREQUENCY NETWORK OSCILLATION IN THE HIPPOCAMPUS	SCIENCE			English	Article							LONG-TERM POTENTIATION; RAT HIPPOCAMPUS; SYNAPTIC TRANSMISSION; PATTERNED STIMULATION; THETA-RHYTHM; CA1 REGION; NEURONS; INTERNEURONS; INDUCTION; ORIGIN	Pyramidal cells in the CA1 hippocampal region displayed transient network oscillations (200 hertz) during behavioral immobility, consummatory behaviors, and slow-wave sleep. Simultaneous, multisite recordings revealed temporal and spatial coherence of neuronal activity during population oscillations. Participating pyramidal cells discharged at a rate lower than the frequency of the population oscillation, and their action potentials were phase locked to the negative phase of the simultaneously recorded oscillatory field potentials. In contrast, interneurons discharged at population frequency during the field oscillations. Thus, synchronous output of cooperating CA1 pyramidal cells may serve to induce synaptic enhancement in target structures of the hippocampus.	UNIV MICHIGAN,CTR INTEGRATED SENSORS & CIRCUITS,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan	BUZSAKI, G (corresponding author), RUTGERS STATE UNIV,CTR MOLEC & BEHAV NEUROSCI,197 UNIV AVE,NEWARK,NJ 07102, USA.			Buzsaki, Gyorgy/0000-0002-3100-4800	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027058] Funding Source: NIH RePORTER; NINDS NIH HHS [NS27058, NS02383] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAUDRY M, 1991, LONG TERM POTENTIATI; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; Bush PC, 1991, NEURAL COMPUT, V3, P19, DOI 10.1162/neco.1991.3.1.19; BUZSAKI G, 1986, BRAIN RES, V398, P242, DOI 10.1016/0006-8993(86)91483-6; BUZSAKI G, 1989, J NEUROSCI METH, V28, P209, DOI 10.1016/0165-0270(89)90038-1; BUZSAKI G, 1983, BRAIN RES REV, V6, P139, DOI 10.1016/0165-0173(83)90037-1; BUZSAKI G, 1982, J NEUROPHYSIOL, V48, P597, DOI 10.1152/jn.1982.48.3.597; BUZSAKI G, 1989, NEUROSCIENCE, V31, P551, DOI 10.1016/0306-4522(89)90423-5; CHRISTIAN EP, 1988, J NEUROPHYSIOL, V59, P110, DOI 10.1152/jn.1988.59.1.110; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; FINCH DM, 1983, BRAIN RES, V271, P201, DOI 10.1016/0006-8993(83)90283-4; FOX SE, 1981, EXP BRAIN RES, V41, P299; GERSTEIN GL, 1985, J NEUROSCI, V5, P881; JEFFERYS JGR, 1982, NATURE, V300, P448, DOI 10.1038/300448a0; KATSUMARU H, 1988, EXP BRAIN RES, V72, P363; KRUGER GJ, 1991, TRENDS NEUROSCI, V7, P1001; KUPERSTEIN M, 1986, EXP BRAIN RES, V61, P438; LACAILLE JC, 1990, NEUROSCIENCE, V36, P349, DOI 10.1016/0306-4522(90)90431-3; LARSON J, 1986, SCIENCE, V232, P985, DOI 10.1126/science.3704635; LLINAS RR, 1988, SCIENCE, V242, P1654, DOI 10.1126/science.3059497; LYTTON WW, 1991, J NEUROPHYSIOL, V66, P1059, DOI 10.1152/jn.1991.66.3.1059; MICHELSON HB, 1991, SCIENCE, V253, P1420, DOI 10.1126/science.1654594; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; Otto T, 1991, Hippocampus, V1, P181, DOI 10.1002/hipo.450010206; PAVLIDES C, 1988, BRAIN RES, V439, P383, DOI 10.1016/0006-8993(88)91499-0; PERKEL DH, 1967, BIOPHYS J, V7, P327; ROSE GM, 1986, NEUROSCI LETT, V69, P244, DOI 10.1016/0304-3940(86)90487-8; SEJNOWSKI TJ, 1988, SCIENCE, V241, P1299, DOI 10.1126/science.3045969; SUZUKI SS, 1987, ELECTROENCEPHALOGR C, V67, P438; TAMAMAKI N, 1988, BRAIN RES, V452, P255, DOI 10.1016/0006-8993(88)90030-3; TAYLOR CP, 1982, SCIENCE, V218, P810, DOI 10.1126/science.7134978; TRAUB RD, 1989, SCIENCE, V243, P1319, DOI 10.1126/science.2646715; TRAUB RD, 1985, NEUROSCIENCE, V15, P947, DOI 10.1016/0306-4522(85)90245-3; WISE KD, 1991, SCIENCE, V254, P1335, DOI 10.1126/science.1962192	34	842	857	2	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 15	1992	256	5059					1025	1027		10.1126/science.1589772	http://dx.doi.org/10.1126/science.1589772			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU224	1589772				2022-12-01	WOS:A1992HU22400040
J	CHEN, JW; LEE, J; JAYARAM, M				CHEN, JW; LEE, J; JAYARAM, M			DNA CLEAVAGE IN TRANS BY THE ACTIVE-SITE TYROSINE DURING FLP RECOMBINATION - SWITCHING PROTEIN PARTNERS BEFORE EXCHANGING STRANDS	CELL			English	Article							CEREVISIAE 2-MU-M PLASMID; CIRCLE PLASMID; MECHANISM; MUTANTS; TARGET; IDENTIFICATION; RECOGNITION; RESOLVASE; SUBSTRATE; BENDS	Each recombination event mediated by the Flp recombinase is the sum of four strand breakage and reunion reactions executed in two steps of two-strand exchanges. The reaction requires four Flp monomers. The key catalytic residue in Flp is Tyr-343. Arg-191, His-305, and Arg-308 appear to facilitate the cleavage and exchange steps of recombination. These four residues constitute the invariant tetrad of the Int family site-specific recombinases. Complementation tests between "step-arrest" mutants of Flp suggest that each Flp protomer harbors a "fractional active site." Hybrid "half site-recombinase" complexes reveal that efficient catalysis occurs when the Arg-His-Arg triad is present on one Flp monomer and the active site Tyr on a second monomer. Strand cleavage by an Flp monomer occurs virtually exclusively on the half site to which its partner protein is bound (cleavage in trans), and almost never on the half site to which it is bound (cleavage in cis). Trans-cleavage by Flp can provide a means for functionally exchanging Flp monomers between two DNA partners. Such a mechanism would be germane to recombination, since cleavage and rejoining in cis can only restore the parental substrate configuration and cannot yield recombinants.			CHEN, JW (corresponding author), UNIV TEXAS,DEPT MICROBIOL,AUSTIN,TX 78712, USA.		Lee, Jehee/AAS-3229-2021	Lee, Jehee/0000-0001-9144-3648				AMIN A, 1991, MOL CELL BIOL, V11, P4497, DOI 10.1128/MCB.11.9.4497; ANDREWS BJ, 1986, MOL CELL BIOL, V6, P2482, DOI 10.1128/MCB.6.7.2482; ARGOS P, 1986, EMBO J, V5, P433, DOI 10.1002/j.1460-2075.1986.tb04229.x; BEAUCAGE SL, 1981, TETRAHEDRON LETT, V22, P1859, DOI 10.1016/S0040-4039(01)90461-7; CHEN JW, 1991, J MOL BIOL, V218, P107, DOI 10.1016/0022-2836(91)90877-9; CHEN JW, 1991, P NATL ACAD SCI USA, V88, P5944, DOI 10.1073/pnas.88.14.5944; DROGE P, 1990, P NATL ACAD SCI USA, V87, P5336, DOI 10.1073/pnas.87.14.5336; EVANS BR, 1990, J BIOL CHEM, V265, P18504; GRONOSTAJSKI RM, 1985, MOL CELL BIOL, V5, P3274, DOI 10.1128/MCB.5.11.3274; HOESS RH, 1985, J MOL BIOL, V181, P351, DOI 10.1016/0022-2836(85)90224-4; KIM SH, 1990, CELL, V63, P773, DOI 10.1016/0092-8674(90)90143-3; Maniatis T., 1982, MOL CLONING; PAN H, 1991, J BIOL CHEM, V266, P11347; PARGELLIS CA, 1988, J BIOL CHEM, V263, P7678; PARSONS RL, 1988, MOL CELL BIOL, V8, P3303, DOI 10.1128/MCB.8.8.3303; PARSONS RL, 1990, J BIOL CHEM, V265, P4527; PRASAD PV, 1986, MOL CELL BIOL, V6, P4329, DOI 10.1128/MCB.6.12.4329; QIAN XH, 1990, J BIOL CHEM, V265, P21779; QIAN XH, 1992, IN PRESS J BIOL CHEM; SCHWARTZ CJE, 1989, J MOL BIOL, V205, P647, DOI 10.1016/0022-2836(89)90310-0; SCHWARTZ CJE, 1990, J MOL BIOL, V216, P289, DOI 10.1016/S0022-2836(05)80320-1; SERRE MC, 1992, IN PRESS J MOL BIOL; STARK WM, 1989, CELL, V58, P779, DOI 10.1016/0092-8674(89)90111-6; WENTE SR, 1987, P NATL ACAD SCI USA, V84, P31, DOI 10.1073/pnas.84.1.31	24	152	156	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 15	1992	69	4					647	658		10.1016/0092-8674(92)90228-5	http://dx.doi.org/10.1016/0092-8674(92)90228-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HV089	1586945				2022-12-01	WOS:A1992HV08900009
J	CIESIELSKI, C; MARIANOS, D; OU, CY; DUMBAUGH, R; WITTE, J; BERKELMAN, R; GOOCH, B; MYERS, G; LUO, CC; SCHOCHETMAN, G; HOWELL, J; LASCH, A; BELL, K; ECONOMOU, N; SCOTT, B; FURMAN, L; CURRAN, J; JAFFE, H				CIESIELSKI, C; MARIANOS, D; OU, CY; DUMBAUGH, R; WITTE, J; BERKELMAN, R; GOOCH, B; MYERS, G; LUO, CC; SCHOCHETMAN, G; HOWELL, J; LASCH, A; BELL, K; ECONOMOU, N; SCOTT, B; FURMAN, L; CURRAN, J; JAFFE, H			TRANSMISSION OF HUMAN-IMMUNODEFICIENCY-VIRUS IN A DENTAL PRACTICE	ANNALS OF INTERNAL MEDICINE			English	Article						HUMAN IMMUNODEFICIENCY VIRUS; HEALTH PERSONNEL; INFECTION CONTROL; DENTISTS; ACQUIRED IMMUNODEFICIENCY SYNDROME	HEPATITIS-B TRANSMISSION; ORAL SURGEON; OUTBREAK; TYPE-1; AIDS; PROFESSIONALS; INFECTION; BLOOD; RISK	Objective: To determine if patients of a dentist with the acquired immunodeficiency syndrome (AIDS) became infected with human immunodeficiency virus (HIV) during their dental care and, if so, to identify possible mechanisms of transmission. Design: Retrospective epidemiologic follow-up of the dentist, his office practice, and his former patients. Setting: The practice of a dentist with AIDS in Florida. Participants: A dentist with AIDS, his health care providers and employees, and former patients of the dentist, including eight HIV-infected patients. Measurements: Identification of risks for HIV transmission (if present), degree of genetic relatedness of the viruses, and identification of infection control and other office practices. Results: Five of the eight HIV-infected patients had no confirmed exposures to HIV other than the dental practice and were infected with HIV strains that were closely related to those of the dentist. Each of the five had invasive dental procedures, done by the dentist after he was diagnosed with AIDS. Four of these five patients shared visit days (P > 0.2). Breaches in infection control and other dental office practices to explain these transmissions could not be identified. Conclusion: Although the specific incident that resulted in HIV transmission to these patients remains uncertain, the epidemiologic evidence supports direct dentist-to-patient transmission rather than a patient-to-patient route.	CTR DIS CONTROL, NATL CTR PREVENT SERV, DIV ORAL HLTH, ATLANTA, GA 30333 USA; FLORIDA DEPT HLTH & REHAB SERV, W PALM BEACH, FL 33401 USA; FLORIDA DEPT HLTH & REHAB SERV, TALLAHASSEE, FL 32301 USA; UNIV CALIF LOS ALAMOS SCI LAB, LOS ALAMOS, NM 87545 USA	Centers for Disease Control & Prevention - USA; Florida Department of Health; Florida Department of Health; United States Department of Energy (DOE); Los Alamos National Laboratory	CIESIELSKI, C (corresponding author), CTR DIS CONTROL, DIV HIV AIDS, 1600 CLIFTON RD NE, ATLANTA, GA 30333 USA.							AHTONE J, 1983, J AM DENT ASSOC, V106, P219, DOI 10.14219/jada.archive.1983.0416; ALTER MJ, 1983, ANN INTERN MED, V99, P330, DOI 10.7326/0003-4819-99-3-330; ARMSTRONG FP, 1987, MIL MED, V152, P414; BALFE P, 1990, J VIROL, V64, P6221, DOI 10.1128/JVI.64.12.6221-6233.1990; BURGER H, 1990, VACCINES 90, P255; CANTER J, 1990, ARCH INTERN MED, V150, P1923, DOI 10.1001/archinte.150.9.1923; CARL M, 1982, LANCET, V1, P731; CHAMBERLAND ME, 1991, JAMA-J AM MED ASSOC, V266, P3459, DOI 10.1001/jama.266.24.3459; Comer R W, 1991, J Dent Educ, V55, P187; COUTINHO RA, 1982, LANCET, V1, P345; DANILA RN, 1991, NEW ENGL J MED, V325, P1406, DOI 10.1056/NEJM199111143252003; FLOWER AJE, 1990, 1990 INT S VIR HEP L, P94; FLYNN NM, 1987, WESTERN J MED, V146, P439; GOODMAN RA, 1982, ANN INTERN MED, V96, P119, DOI 10.7326/0003-4819-96-1-119_1; GROB PJ, 1981, LANCET, V2, P1218; HADLER SC, 1981, ANN INTERN MED, V95, P133, DOI 10.7326/0003-4819-95-2-133; HAEREM JW, 1981, ACTA MED SCAND, V210, P389; HENDERSON DK, 1990, ANN INTERN MED, V113, P740, DOI 10.7326/0003-4819-113-10-740; Heptonstall J, 1991, CDR (Lond Engl Rev), V1, pR81; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; KLEIN RS, 1988, NEW ENGL J MED, V318, P86, DOI 10.1056/NEJM198801143180205; LETTAU LA, 1986, JAMA-J AM MED ASSOC, V255, P934, DOI 10.1001/jama.255.7.934; LEVIN ML, 1974, JAMA-J AM MED ASSOC, V228, P1139, DOI 10.1001/jama.228.9.1139; LEVY RM, 1985, J NEUROSURG, V62, P475, DOI 10.3171/jns.1985.62.4.0475; MARCUS R, 1988, NEW ENGL J MED, V319, P1118, DOI 10.1056/NEJM198810273191703; MATHE AA, 1980, LANCET, V1, P16; MILLER RG, 1988, AIDS NERVOUS SYSTEM, P65; MISHU B, 1990, JAMA-J AM MED ASSOC, V264, P467, DOI 10.1001/jama.264.4.467; MYERS G, 1990, HUMAN RETROVIRUSES A; OREN I, 1989, ANN INTERN MED, V110, P691, DOI 10.7326/0003-4819-110-9-691; OU CY, 1992, IN PRESS SCIENCE, P255; POLISH LB, 1992, NEW ENGL J MED, V326, P721, DOI 10.1056/NEJM199203123261101; PORTER JD, 1990, LANCET, V335, P113, DOI 10.1016/0140-6736(90)90582-P; REINGOLD AL, 1982, J INFECT DIS, V145, P262, DOI 10.1093/infdis/145.2.262; RIMLAND D, 1977, NEW ENGL J MED, V296, P953, DOI 10.1056/NEJM197704282961701; SACKS JJ, 1985, NEW ENGL J MED, V313, P1017, DOI 10.1056/NEJM198510173131610; SHAW FE, 1986, JAMA-J AM MED ASSOC, V255, P3260, DOI 10.1001/jama.255.23.3260; SNIDER WD, 1983, ANN NEUROL, V14, P403, DOI 10.1002/ana.410140404; SNYDMAN DR, 1976, ANN INTERN MED, V85, P573, DOI 10.7326/0003-4819-85-5-573; SO YT, 1988, ARCH NEUROL-CHICAGO, V45, P945, DOI 10.1001/archneur.1988.00520330023005; WELCH J, 1989, LANCET, V1, P205; 1987, J HOSP INFECT, V9, P34; 1988, REPORT PRESIDENTIAL, P33; 1987, MMWR, V36, P132; 1987, MMWR, V36, P1; 1986, MMWR, V35, P221; 1990, MMWR, V39, P489; 1991, MMWR, V40, P377; 1991, MMWR, V40, P21	49	183	187	0	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1992	116	10					798	805		10.7326/0003-4819-116-10-798	http://dx.doi.org/10.7326/0003-4819-116-10-798			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT802	1567094				2022-12-01	WOS:A1992HT80200003
J	CORMACK, BP; STRUHL, K				CORMACK, BP; STRUHL, K			THE TATA-BINDING PROTEIN IS REQUIRED FOR TRANSCRIPTION BY ALL 3 NUCLEAR-RNA POLYMERASES IN YEAST-CELLS	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; RIBOSOMAL-RNA; PROMOTER ELEMENT; MOLECULAR MECHANISMS; ACTIVATOR PROTEIN; ESCHERICHIA-COLI; DNA-SEQUENCES; GENE; INVITRO; INITIATION	Using temperature- and proteolytically sensitive derivatives to inactivate the function of the yeast TATA-binding protein (TBP) in vivo, we investigated the requirement of TBP for transcription by the three nuclear RNA polymerases in yeast cells. TBP is required for RNA polymerase II (pol II) transcription from promoters containing conventional TATA elements as well as functionally distinct promoters that lack TATA-like sequences. TBP is also required for transcription of the U6 snRNA and two different tRNA genes mediated by RNA pol III as well as transcription of ribosomal RNA mediated by RNA pol I. For all promoters tested, transcription decreases rapidly and specifically upon inactivation of TBP, strongly suggesting that TBP is directly involved in the transcription process. These observations suggest that TBP is required for transcription of all nuclearly encoded genes in yeast, although distinct molecular mechanisms are probably involved for the three RNA polymerase transcription machineries.			CORMACK, BP (corresponding author), HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030186, R01GM030186] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30186] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BELL SP, 1989, CELL, V59, P489, DOI 10.1016/0092-8674(89)90032-9; BELL SP, 1988, SCIENCE, V241, P1192, DOI 10.1126/science.3413483; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BRANDL CJ, 1990, MOL CELL BIOL, V10, P4256, DOI 10.1128/MCB.10.8.4256; BROW DA, 1990, GENE DEV, V4, P1345, DOI 10.1101/gad.4.8.1345; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; BURATOWSKI S, 1992, SCIENCE, V255, P1130, DOI 10.1126/science.1546314; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; BUTT TR, 1988, J BIOL CHEM, V263, P16364; CARCAMO J, 1990, GENE DEV, V4, P1611, DOI 10.1101/gad.4.9.1611; CASHEL M, 1975, ANNU REV MICROBIOL, V29, P301, DOI 10.1146/annurev.mi.29.100175.001505; CAVALLINI B, 1988, NATURE, V334, P77, DOI 10.1038/334077a0; CHEN W, 1989, EMBO J, V8, P261, DOI 10.1002/j.1460-2075.1989.tb03372.x; CHEN W, 1988, P NATL ACAD SCI USA, V85, P2691, DOI 10.1073/pnas.85.8.2691; CHEN W, 1987, CELL, V50, P1047, DOI 10.1016/0092-8674(87)90171-1; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CORMACK BP, 1991, CELL, V65, P341, DOI 10.1016/0092-8674(91)90167-W; DAHLBERG JE, 1991, SCIENCE, V254, P1462, DOI 10.1126/science.1962205; DAVISON BL, 1983, NATURE, V301, P680, DOI 10.1038/301680a0; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; ELION EA, 1986, MOL CELL BIOL, V6, P2089, DOI 10.1128/MCB.6.6.2089; FEDOR MJ, 1988, J MOL BIOL, V204, P109, DOI 10.1016/0022-2836(88)90603-1; FIRE A, 1984, J BIOL CHEM, V259, P2509; GALLANT JA, 1979, ANNU REV GENET, V13, P393, DOI 10.1146/annurev.ge.13.120179.002141; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GILL G, 1991, CELL, V65, P333, DOI 10.1016/0092-8674(91)90166-V; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; GRUMMT I, 1982, NATURE, V296, P173, DOI 10.1038/296173a0; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; HOMA FL, 1988, GENE DEV, V2, P40, DOI 10.1101/gad.2.1.40; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; HORIKOSHI M, 1990, CELL, V61, P1171, DOI 10.1016/0092-8674(90)90681-4; KAMBADUR R, 1990, P NATL ACAD SCI USA, V87, P9168, DOI 10.1073/pnas.87.23.9168; KELLEHER RJ, 1992, GENE DEV, V6, P296, DOI 10.1101/gad.6.2.296; KEMPERSVEENSTRA AE, 1986, EMBO J, V5, P2703, DOI 10.1002/j.1460-2075.1986.tb04554.x; KNAPP G, 1978, CELL, V14, P221, DOI 10.1016/0092-8674(78)90109-5; LOBO SM, 1991, GENE DEV, V5, P1477, DOI 10.1101/gad.5.8.1477; MAHADEVAN S, 1990, MOL CELL BIOL, V10, P4447, DOI 10.1128/MCB.10.9.4447; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; MEISTERERNST M, 1990, P NATL ACAD SCI USA, V87, P9153, DOI 10.1073/pnas.87.23.9153; MEMET S, 1988, J BIOL CHEM, V263, P10048; MOENNE A, 1990, EMBO J, V9, P271, DOI 10.1002/j.1460-2075.1990.tb08105.x; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NICOLET CM, 1991, METHOD ENZYMOL, V194, P710; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; PARK EC, 1992, P NATL ACAD SCI USA, V89, P1249, DOI 10.1073/pnas.89.4.1249; PARKER CS, 1984, CELL, V36, P357, DOI 10.1016/0092-8674(84)90229-0; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PONTICELLI AS, 1990, MOL CELL BIOL, V10, P2832, DOI 10.1128/MCB.10.6.2832; POON D, 1991, MOL CELL BIOL, V11, P4809, DOI 10.1128/MCB.11.10.4809; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REDDY P, 1991, CELL, V65, P349, DOI 10.1016/0092-8674(91)90168-X; REINBERG D, 1987, J BIOL CHEM, V262, P3310; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SENTENAC A, 1985, CRC CR REV BIOCH MOL, V18, P31, DOI 10.3109/10409238509082539; SIMMEN KA, 1991, EMBO J, V10, P1853, DOI 10.1002/j.1460-2075.1991.tb07711.x; SIMON MC, 1988, CELL, V52, P723, DOI 10.1016/0092-8674(88)90410-2; SINGER VL, 1990, GENE DEV, V4, P636, DOI 10.1101/gad.4.4.636; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; SOLLNERWEBB B, 1986, ANNU REV BIOCHEM, V55, P801, DOI 10.1146/annurev.bi.55.070186.004101; STRUBIN M, 1992, CELL, V68, P721, DOI 10.1016/0092-8674(92)90147-5; STRUHL K, 1986, MOL CELL BIOL, V6, P3847, DOI 10.1128/MCB.6.11.3847; TIMMERS HTM, 1991, GENE DEV, V5, P1946, DOI 10.1101/gad.5.11.1946; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; WEFALD FC, 1990, NATURE, V344, P260, DOI 10.1038/344260a0; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; WOYCHIK NA, 1990, GENE DEV, V4, P313, DOI 10.1101/gad.4.3.313	74	325	328	1	11	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 15	1992	69	4					685	696		10.1016/0092-8674(92)90232-2	http://dx.doi.org/10.1016/0092-8674(92)90232-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HV089	1586947				2022-12-01	WOS:A1992HV08900013
J	DAVIS, RL; WEINTRAUB, H				DAVIS, RL; WEINTRAUB, H			ACQUISITION OF MYOGENIC SPECIFICITY BY REPLACEMENT OF 3 AMINO-ACID-RESIDUES FROM MYOD INTO E12	SCIENCE			English	Article							DISTINCT TRANSCRIPTION FACTORS; ENHANCER MU-E5/KE2 MOTIF; DNA-BINDING DOMAIN; DROSOPHILA-MELANOGASTER; MYC HOMOLOGY; MUSCLE; FIBROBLASTS; EXPRESSION; MYOBLASTS; PROTEIN	The basic helix-loop-helix (bHLH) protein MyoD is a transcription factor that is important for the induction of the myogenic phenotype. The DNA binding basic region (13 amino acids) is necessary for recognition of the consensus MyoD binding site, for transcriptional activation, and for conversion of fibroblasts to muscle. In contrast, the non-tissue-specific bHLH protein E12 can bind to the MyoD binding site but does not induce myogenesis. Here, it is shown that only two amino acids in the MyoD basic region and a single amino acid from the junction, which separates the basic region and helix 1, are sufficient for myogenic specificity when substituted into the corresponding region of E12. These findings suggest that the recognition of particular determinants in the basic region is required for conversion of fibroblasts to muscle.	FRED HUTCHINSON CANC RES CTR,HOWARD HUGHES MED INST LAB,SEATTLE,WA 98104	Fred Hutchinson Cancer Center								BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BRAUN T, 1989, EMBO J, V8, P3617, DOI 10.1002/j.1460-2075.1989.tb08535.x; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P5675, DOI 10.1073/pnas.88.13.5675; CABRERA CV, 1987, CELL, V50, P425, DOI 10.1016/0092-8674(87)90496-X; CAMPOSORTEGA JA, 1990, EUR J BIOCHEM, V190, P1, DOI 10.1111/j.1432-1033.1990.tb15538.x; CAUDY M, 1988, CELL, V55, P1061, DOI 10.1016/0092-8674(88)90250-4; CHAKRABORTY T, 1991, MOL CELL BIOL, V11, P3633, DOI 10.1128/MCB.11.7.3633; CHOI J, 1990, P NATL ACAD SCI USA, V87, P7988, DOI 10.1073/pnas.87.20.7988; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; GARCIABELLIDO A, 1979, GENETICS, V91, P491; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; JOHNSON JP, IN PRESS P NATL ACAD; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1986, CELL, V47, P649, DOI 10.1016/0092-8674(86)90507-6; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MULLER HJ, 1955, BROOKHAVEN SYM BIOL, V8, P126; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; RUPP RAW, 1991, CELL, V65, P927, DOI 10.1016/0092-8674(91)90545-A; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WENTWORTH BM, 1991, P NATL ACAD SCI USA, V88, P1242, DOI 10.1073/pnas.88.4.1242	31	135	135	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 15	1992	256	5059					1027	1030		10.1126/science.1317057	http://dx.doi.org/10.1126/science.1317057			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU224	1317057				2022-12-01	WOS:A1992HU22400041
J	FARLEY, MM; STEPHENS, DS; BRACHMAN, PS; HARVEY, RC; SMITH, JD; WENGER, JD				FARLEY, MM; STEPHENS, DS; BRACHMAN, PS; HARVEY, RC; SMITH, JD; WENGER, JD			INVASIVE HAEMOPHILUS-INFLUENZAE DISEASE IN ADULTS - A PROSPECTIVE, POPULATION-BASED SURVEILLANCE	ANNALS OF INTERNAL MEDICINE			English	Article						HAEMOPHILUS-INFLUENZAE; PNEUMONIA; LUNG DISEASES; PREGNANCY; DRUG RESISTANCE, MICROBIAL; AMPICILLIN	NONTYPABLE HEMOPHILUS-INFLUENZAE; GENITOURINARY TRACT INFECTIONS; ANTIMICROBIAL RESISTANCE; OLIGOSACCHARIDE PORTION; PNEUMONIA; AMPICILLIN; SPECTRUM; LIPOOLIGOSACCHARIDE; EPIGLOTTITIS; MENINGITIS	Objective: To define the incidence of and possible risk factors for invasive Haemophilus influenzae disease in adults. Design: Prospective, population-based surveillance of hospital and referral bacteriology laboratories. Setting: Metropolitan Atlanta, Georgia community. Patients: All patients with H. influenzae isolated from normally sterile sites (blood, cerebrospinal fluid, joint, pleura) from 1 December 1988 through 31 May 1990. Measurements: Isolates of H. influenzae were analyzed for serotype and biotype status, outer membrane proteins, lipooligosaccharide phenotypes, ribotyping patterns and 13-lactamase production. Results: A total of 194 cases of invasive H. influenzae occurred (annual incidence of 5.6 cases/100 000 population), of which 47 (24%) were in adults 18 years old or older (annual incidence 1.7 cases/100 000 adults). Adults with invasive H. influenzae ranged from 18 to 96 years; 79% were women. Bacteremic pneumonia accounted for 70% of the adult cases. Other sources for invasive H. influenzae in adults were obstetric infections, epiglottitis, and tracheobronchitis; one patient had meningitis. Underlying conditions were noted in 92% of the patients. Chronic lung disease was the most common risk factor, but pregnancy (annual incidence, 4.9/100 000 pregnant women), HIV infection (annual incidence, 41/100 000 known HIV-infected adults), and malignancy were also important. Overall mortality was 28% in adults, and over half of pregnancy-related infections resulted in fetal death. Fifty percent of the 40 isolates available for testing were serotype b; 47.5%, nontypable; and 2.5%, serotype f. Sixteen of the 45 isolates (36%) were ampicillin-resistant. Based on biotypes, outer membrane protein profiles, lipooligosaccharide phenotypes, and ribotyping patterns, the type b isolates showed less heterogeneity than the nontypable isolates but were distinguishable from one another. Conclusions: Adult cases currently represent one quarter of all cases of invasive H. influenzae disease. Half of the reported adult cases were caused by type b H. influenzae, and the rate of ampicillin resistance in H. influenzae isolates from adults was higher than previously reported. Haemophilus influenzae is an important cause of bacteremia in compromised adults.	OFF EPIDEMIOL, DEPT HUMAN RESOURCES, ATLANTA, GA 30309 USA; CTR DIS CONTROL, CTR INFECT DIS, DIV BACTERIAL & MYCOT DIS, MENINGITIS & SPECIAL PATHOGENS BRANCH, ATLANTA, GA 30333 USA	Centers for Disease Control & Prevention - USA	FARLEY, MM (corresponding author), ATLANTA DEPT VET AFFAIRS MED CTR, RES SERV 151, 1670 CLAIRMONT RD, DECATUR, GA 30033 USA.		Stephens, David S/A-8788-2012					ALBRITTON WL, 1978, ARCH INTERN MED, V138, P1819, DOI 10.1001/archinte.138.12.1819; BARENKAMP SJ, 1981, J INFECT DIS, V143, P668, DOI 10.1093/infdis/143.5.668; BERCZY J, 1973, LANCET, V1, P1197; BERK SL, 1982, ARCH INTERN MED, V142, P537, DOI 10.1001/archinte.142.3.537; BRUNHAM RC, 1988, J INFECT DIS, V158, P510, DOI 10.1093/infdis/158.3.510; CROWE HM, 1987, ARCH INTERN MED, V147, P241, DOI 10.1001/archinte.147.2.241; DOERN GV, 1986, DIAGN MICR INFEC DIS, V4, P95, DOI 10.1016/0732-8893(86)90143-4; DOERN GV, 1988, ANTIMICROB AGENTS CH, V32, P180, DOI 10.1128/AAC.32.2.180; GLODE MP, 1984, PEDIATR INFECT DIS J, V3, P548, DOI 10.1097/00006454-198411000-00013; GULIG PA, 1987, INFECT IMMUN, V55, P513, DOI 10.1128/IAI.55.3.513-520.1987; HALL GD, 1983, DIAGN MICR INFEC DIS, V1, P65, DOI 10.1016/0732-8893(83)90034-2; HIRSCHMANN JV, 1979, MEDICINE, V58, P80, DOI 10.1097/00005792-197901000-00005; JAKACKI R, 1990, ANN INTERN MED, V112, P143, DOI 10.7326/0003-4819-112-2-143; JANOFF EN, 1990, 30TH INT C ANT AG CH; KHAN W, 1974, JAMA-J AM MED ASSOC, V229, P298, DOI 10.1001/jama.229.3.298; KILIAN M, 1976, J GEN MICROBIOL, V93, P9, DOI 10.1099/00221287-93-1-9; KRISTENSEN K, 1989, SCAND J INFECT DIS, V21, P651, DOI 10.3109/00365548909021693; LEVIN DC, 1977, AM J MED, V62, P219, DOI 10.1016/0002-9343(77)90317-5; MAYOSMITH MF, 1986, NEW ENGL J MED, V314, P1133, DOI 10.1056/NEJM198605013141801; MENDELMAN PM, 1984, ANTIMICROB AGENTS CH, V26, P235, DOI 10.1128/AAC.26.2.235; MOXON ER, 1990, PRINCIPLES PRACTICE, P1722; MURPHY TF, 1983, J INFECT DIS, V147, P838, DOI 10.1093/infdis/147.5.838; MUSHER DM, 1983, ANN INTERN MED, V99, P444, DOI 10.7326/0003-4819-99-4-444; NORDEN CW, 1978, MED CLIN N AM, V62, P1037, DOI 10.1016/S0025-7125(16)31753-9; PATRICK CC, 1987, INFECT IMMUN, V55, P2902, DOI 10.1128/IAI.55.12.2902-2911.1987; QUENTIN R, 1989, J CLIN MICROBIOL, V27, P2286, DOI 10.1128/JCM.27.10.2286-2294.1989; Quinones C A, 1989, Semin Respir Infect, V4, P12; QUINTILIANI R, 1971, AM J MED, V50, P781, DOI 10.1016/0002-9343(71)90186-0; SCHLAMM HT, 1989, AM J MED, V86, P11, DOI 10.1016/0002-9343(89)90222-2; SIMON HB, 1980, AM J MED, V69, P219, DOI 10.1016/0002-9343(80)90381-2; SPAGNUOLO PJ, 1982, MEDICINE, V61, P74, DOI 10.1097/00005792-198203000-00002; STEINHOFF MC, 1991, NEW ENGL J MED, V325, P1837, DOI 10.1056/NEJM199112263252603; STULL TL, 1988, J INFECT DIS, V157, P280, DOI 10.1093/infdis/157.2.280; TAKALA AK, 1990, ARCH INTERN MED, V150, P2573, DOI 10.1001/archinte.150.12.2573; TOMEH MO, 1974, JAMA-J AM MED ASSOC, V229, P295; TROLLFORS B, 1984, EUR J CLIN MICROBIOL, V3, P180, DOI 10.1007/BF02014874; WALLACE RJ, 1983, REV INFECT DIS, V5, P123; WALLACE RJ, 1981, J INFECT DIS, V144, P101, DOI 10.1093/infdis/144.2.101; WALLACE RJ, 1978, AM J MED, V64, P87, DOI 10.1016/0002-9343(78)90182-1; WENGER JD, 1990, J INFECT DIS, V162, P1316, DOI 10.1093/infdis/162.6.1316; WILLIAMS JD, 1986, REV INFECT DIS, V8, pS555; 1988, NCCLS M7T2 NAT COMM	42	125	127	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1992	116	10					806	812		10.7326/0003-4819-116-10-806	http://dx.doi.org/10.7326/0003-4819-116-10-806			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT802	1314530				2022-12-01	WOS:A1992HT80200004
J	FLANIGAN, T; WHALEN, C; TURNER, J; SOAVE, R; TOERNER, J; HAVLIR, D; KOTLER, D				FLANIGAN, T; WHALEN, C; TURNER, J; SOAVE, R; TOERNER, J; HAVLIR, D; KOTLER, D			CRYPTOSPORIDIUM INFECTION AND CD4 COUNTS	ANNALS OF INTERNAL MEDICINE			English	Note						CRYPTOSPORIDIOSIS; ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIGENS, CD4; CD4-CD8 RATIO; HUMAN IMMUNODEFICIENCY VIRUS		Cryptosporidium infection in immunocompetent persons is associated with self-limited diarrhea. In contrast, in persons with the acquired immunodeficiency syndrome (AIDS), cryptosporidiosis causes persistent enteritis that is refractory to treatment. In our clinical practices, we observed men infected with the human immunodeficiency virus (HIV) who had self-limited diarrhea due to Cryptosporidium infection. To better define the characteristics associated with self-limited disease, we did a retrospective chart review of HIV-seropositive patients with Cryptosporidium infection. We compared 13 HIV-positive persons with self-limited cryptosporidiosis with 34 persons with AIDS who had persistent Cryptosporidium infection. The mean CD4 count was significantly greater in patients with self-limited infection (312 cells/mm3, range, 14 to 651 cells/mm3) than in patient with persistent infection (57 cells/mm3, range 4 to 150 cells/mm3, P < 0.001). A similar relationship was found for the mean CD8 count, the mean ratio of CD4 to CD8 count, and the mean hematocrit. All patients with CD4 counts of 180 cells/mm3 or greater (n = 8) cleared the infection spontaneously over a period of 7 days to 1 month. This observation is important both in predicting the natural history of Cryptosporidium infection and in designing therapeutic trials.	UNIV HOSP CLEVELAND, CLEVELAND, OH 44106 USA; GRAD HOSP PHILADELPHIA, PHILADELPHIA, PA 19146 USA; CORNELL UNIV, MED CTR, NEW YORK HOSP, NEW YORK, NY 10021 USA; WHITMAN WALKER CLIN, WASHINGTON, DC 20009 USA; UNIV CALIF SAN DIEGO, CTR TREATMENT, SAN DIEGO, CA 92103 USA; ST LUKES ROOSEVELT HOSP, NEW YORK, NY 10025 USA	University Hospitals of Cleveland; University of Pennsylvania; Pennsylvania Medicine; Cornell University; NewYork-Presbyterian Hospital; University of California System; University of California San Diego; Mount Sinai St. Luke's; Mount Sinai West	FLANIGAN, T (corresponding author), MIRIAM HOSP, DEPT GEOG MED, 164 SUMMIT AVE, PROVIDENCE, RI 02906 USA.				NIAID NIH HHS [AI-01038, AI-25879] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI025879] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CONNOLLY GM, 1988, GUT, V29, P593, DOI 10.1136/gut.29.5.593; FAYER R, 1986, MICROBIOL REV, V50, P458, DOI 10.1128/MMBR.50.4.458-483.1986; GREENBERG RE, 1989, GASTROENTEROLOGY, V97, P1327, DOI 10.1016/0016-5085(89)91708-3; HOJLYNG N, 1990, 6 INT C AIDS SAN FRA; JACOBSON MA, 1991, J INFECT DIS, V164, P994, DOI 10.1093/infdis/164.5.994; SOAVE R, 1988, J INFECT DIS, V157, P225, DOI 10.1093/infdis/157.2.225; 1987, MMWR, V36, pS3; 1986, SUGI SUPPLEMENTAL LI, P270	8	197	204	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1992	116	10					840	842		10.7326/0003-4819-116-10-840	http://dx.doi.org/10.7326/0003-4819-116-10-840			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT802	1348918				2022-12-01	WOS:A1992HT80200009
J	GOLOVKINA, TV; CHERVONSKY, A; DUDLEY, JP; ROSS, SR				GOLOVKINA, TV; CHERVONSKY, A; DUDLEY, JP; ROSS, SR			TRANSGENIC MOUSE MAMMARY-TUMOR VIRUS SUPERANTIGEN EXPRESSION PREVENTS VIRAL-INFECTION	CELL			English	Article							T-CELLS; DNA; TOLERANCE; TRANSMISSION; SEQUENCES; RECEPTOR; GLAND; GENES; MICE; RNA	Endogenous mouse mammary tumor virus (MMTV) proviruses have recently been shown to cosegregate genetically with the minor lymphocyte-stimulating loci, also termed self-superantigens. The antigenic activity has been localized to the open reading frame (ORF) protein encoded in the long terminal repeat of MMTV. We show here that unlike their nontransgenic littermates, transgenic mice expressing high levels of an ORF protein derived from the C3H exogenous MMTV specifically delete their V-beta-14+ T cells and do not become infected with this virus when it is present in their mother's milk. Thus, it appears that MMTV utilizes cells of the immune system in its infection pathway, and mice that retain endogenous MMTVs should be immune to infection by exogenous virus. These results offer possible new approaches to anti-viral therapy or immunization.	UNIV CHICAGO,DEPT PATHOL,CHICAGO,IL 60637; UNIV TEXAS,DEPT MICROBIOL,AUSTIN,TX 78712	University of Chicago; University of Texas System; University of Texas Austin	GOLOVKINA, TV (corresponding author), UNIV ILLINOIS,COLL MED,DEPT BIOCHEM,CHICAGO,IL 60612, USA.			Chervonsky, Alexander/0000-0001-7547-871X; Ross, Susan R/0000-0002-3094-3769	NCI NIH HHS [R01 CA45954, R01 CA34780] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA034780, R01CA045954] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACHAORBEA H, 1991, NATURE, V350, P207, DOI 10.1038/350207a0; BLACKMAN M, 1990, SCIENCE, V248, P1335, DOI 10.1126/science.1972592; BLACKMAN MA, 1990, NATURE, V345, P540, DOI 10.1038/345540a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOI YW, 1987, J VIROL, V61, P3013, DOI 10.1128/JVI.61.10.3013-3019.1987; CHOI YW, 1991, NATURE, V350, P203, DOI 10.1038/350203a0; DYSON PJ, 1991, NATURE, V349, P531, DOI 10.1038/349531a0; FESTENSTEIN H, 1973, TRANSPLANT REV-DENMA, V15, P62; FRANKEL WN, 1991, NATURE, V349, P526, DOI 10.1038/349526a0; FRITSCH EF, 1977, J VIROL, V24, P461, DOI 10.1128/JVI.24.2.461-469.1977; GUDKOV AV, 1989, INT J CANCER, V44, P1052, DOI 10.1002/ijc.2910440619; HAREL J, 1981, VIROLOGY, V110, P202, DOI 10.1016/0042-6822(81)90022-2; HENRARD D, 1988, J VIROL, V62, P3046, DOI 10.1128/JVI.62.8.3046-3049.1988; HESTON WE, 1945, J NATL CANCER I, V5, P289; HUANG AL, 1981, CELL, V27, P245, DOI 10.1016/0092-8674(81)90408-6; HUGIN AW, 1991, SCIENCE, V252, P424, DOI 10.1126/science.1850169; ICHIMARU M, 1991, CANCER DETECT PREV, V15, P177; IMBERTI L, 1991, SCIENCE, V254, P860, DOI 10.1126/science.1948066; JANEWAY CA, 1990, CELL, V63, P659, DOI 10.1016/0092-8674(90)90130-7; KOZAK C, 1987, J VIROL, V61, P1651, DOI 10.1128/JVI.61.5.1651-1654.1987; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; MARRACK P, 1991, NATURE, V349, P524, DOI 10.1038/349524a0; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Moore D H, 1979, Adv Cancer Res, V29, P347, DOI 10.1016/S0065-230X(08)60850-7; NANDI S, 1973, ADV CANCER RES, V17, P353; NUSSE R, 1988, TRENDS GENET, V4, P291, DOI 10.1016/0168-9525(88)90172-2; PAYVAR F, 1983, CELL, V35, P381, DOI 10.1016/0092-8674(83)90171-X; PULLEN AM, 1992, J EXP MED, V175, P41, DOI 10.1084/jem.175.1.41; PULLEN AM, 1988, NATURE, V335, P796, DOI 10.1038/335796a0; RAMSDELL F, 1990, SCIENCE, V248, P1342, DOI 10.1126/science.1972593; SAJI F, 1990, CANCER, V66, P1933, DOI 10.1002/1097-0142(19901101)66:9<1933::AID-CNCR2820660914>3.0.CO;2-5; SALMONS B, 1987, VIRUS RES, V8, P81, DOI 10.1016/0168-1702(87)90022-0; SELTZER V, 1990, OBSTET GYNECOL, V75, P713; SPRENT J, 1990, SCIENCE, V248, P1357, DOI 10.1126/science.1694041; SQUARTINI F, 1970, CANCER RES, V30, P2069; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; TSUBURA A, 1988, CANCER RES, V48, P6555; VARMUS HE, 1973, J MOL BIOL, V79, P663, DOI 10.1016/0022-2836(73)90070-3; VARMUS HE, 1977, CELL, V11, P307, DOI 10.1016/0092-8674(77)90047-2; WOODLAND DL, 1991, NATURE, V349, P529, DOI 10.1038/349529a0; WOODLAND DL, 1992, IN PRESS J EXP MED; ZIEGLER JB, 1985, LANCET, V1, P896	43	226	229	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 15	1992	69	4					637	645		10.1016/0092-8674(92)90227-4	http://dx.doi.org/10.1016/0092-8674(92)90227-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HV089	1316806				2022-12-01	WOS:A1992HV08900008
J	HARWOOD, AJ; HOPPER, NA; SIMON, MN; DRISCOLL, DM; VERON, M; WILLIAMS, JG				HARWOOD, AJ; HOPPER, NA; SIMON, MN; DRISCOLL, DM; VERON, M; WILLIAMS, JG			CULMINATION IN DICTYOSTELIUM IS REGULATED BY THE CAMP-DEPENDENT PROTEIN-KINASE	CELL			English	Article							DIFFERENTIATION INDUCING FACTOR; PRESTALK GENE-EXPRESSION; CELLULAR SLIME-MOLD; ANTERIOR-LIKE CELLS; STALK CELLS; CYCLIC-AMP; DISCOIDEUM; MORPHOGEN; DIF; TRANSFORMATION	We placed a specific inhibitor of cyclic AMP-dependent protein kinase (PKA) under the control of a prestalk-specific promoter. Cells containing this construct form normally patterned slugs, but under environmental conditions that normally trigger immediate culmination, the slugs undergo prolonged migration. Slugs that eventually enter culmination do so normally but arrest as elongated, hairlike structures that contain neither stalk nor spore cells. Mutant cells do not migrate to the stalk entrance when codeveloped with wild-type cells and show greatly reduced inducibility by DIF, the stalk cell morphogen. These results suggest that the activity of PKA is necessary for the altered pattern of movement of prestalk cells at culmination and their differentiation into stalk cells. We propose a model whereby a protein repressor, under the control of PKA, inhibits precocious induction of stalk cell differentiation by DIF and so regulates the choice between slug migration and culmination.	INST PASTEUR,UNITE BIOCHIM CELLULAIRE,F-75724 PARIS 15,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	HARWOOD, AJ (corresponding author), IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND.		Harwood, Adrian/A-4350-2010	Harwood, Adrian/0000-0003-3124-5169				ABE K, 1983, DEV BIOL, V95, P200, DOI 10.1016/0012-1606(83)90018-0; BERKS M, 1990, DEVELOPMENT, V110, P977; BERKS M, 1988, DEV BIOL, V125, P108; BONNER JT, 1952, AM NAT, V86, P79, DOI 10.1086/281707; BONNER JT, 1985, J EMBRYOL EXP MORPH, V87, P207; CECCARELLI A, 1991, CELL, V65, P983, DOI 10.1016/0092-8674(91)90550-I; DEGUNZBURG J, 1982, EMBO J, V1, P1063, DOI 10.1002/j.1460-2075.1982.tb01297.x; DINGERMANN T, 1989, GENE, V85, P353, DOI 10.1016/0378-1119(89)90428-9; EARLY AE, 1987, GENE, V59, P99, DOI 10.1016/0378-1119(87)90270-8; EARLY AE, 1988, MOL CELL BIOL, V8, P3458, DOI 10.1128/MCB.8.8.3458; FIRTEL RA, 1990, GENE DEV, V4, P18, DOI 10.1101/gad.4.1.18; GEORGE RP, 1972, J GEN MICROBIOL, V70, P477, DOI 10.1099/00221287-70-3-477; GROSS JD, 1983, NATURE, V303, P244, DOI 10.1038/303244a0; HARWOOD AJ, 1991, DIFFERENTIATION, V46, P7, DOI 10.1111/j.1432-0436.1991.tb00860.x; HARWOOD AJ, 1991, IN PRESS DEV BIOL; INOUYE K, 1988, DEVELOPMENT, V104, P669; JERMYN KA, 1991, DEVELOPMENT, V111, P779; JERMYN KA, 1989, NATURE, V340, P144, DOI 10.1038/340144a0; JERMYN KA, 1987, DEVELOPMENT, V100, P745; KAKUTANI T, 1986, DEV BIOL, V115, P439, DOI 10.1016/0012-1606(86)90264-2; KAY RR, 1982, P NATL ACAD SCI-BIOL, V79, P3228, DOI 10.1073/pnas.79.10.3228; KAY RR, 1983, NATURE, V303, P242, DOI 10.1038/303242a0; KNECHT DA, 1986, MOL CELL BIOL, V6, P3973, DOI 10.1128/MCB.6.11.3973; KREFFT M, 1983, EXP CELL RES, V147, P235, DOI 10.1016/0014-4827(83)90291-4; KWONG L, 1988, DIFFERENTIATION, V37, P1, DOI 10.1111/j.1432-0436.1988.tb00789.x; KWONG L, 1990, DEVELOPMENT, V110, P303; MAEDA M, 1988, DEV GROWTH DIFFER, V30, P573; MCROBBIE SJ, 1988, DEV BIOL, V125, P59, DOI 10.1016/0012-1606(88)90058-9; MCROBBIE SJ, 1988, DEVELOPMENT, V104, P275; MERKLE RK, 1984, CELL DIFFER DEV, V14, P257, DOI 10.1016/0045-6039(84)90014-9; MORRIS HR, 1987, NATURE, V328, P811, DOI 10.1038/328811a0; MUTZEL R, 1987, P NATL ACAD SCI USA, V84, P6, DOI 10.1073/pnas.84.1.6; NELLEN W, 1984, MOL CELL BIOL, V4, P2890, DOI 10.1128/MCB.4.12.2890; NEWELL PC, 1982, J GEN MICROBIOL, V128, P1639; RAPER K, 1940, J E MITCHELL SCI SOC, V59, P241; RAPER KENNETH B., 1952, BULL TORREY BOT CLUB, V79, P25, DOI 10.2307/2482103; RILEY BB, 1990, DEVELOPMENT, V109, P715; SCHAAP P, 1985, DEV BIOL, V111, P51, DOI 10.1016/0012-1606(85)90434-8; SCHINDLER J, 1977, J MOL BIOL, V116, P161, DOI 10.1016/0022-2836(77)90124-3; SIEGERT F, 1991, PHYSICA D, V49, P224, DOI 10.1016/0167-2789(91)90210-Z; SIMON MN, 1989, EMBO J, V8, P2039, DOI 10.1002/j.1460-2075.1989.tb03612.x; STERNFELD J, 1981, DIFFERENTIATION, V20, P10, DOI 10.1111/j.1432-0436.1981.tb01150.x; STERNFELD J, 1982, DEV BIOL, V93, P111, DOI 10.1016/0012-1606(82)90244-5; SUSSMAN M, 1978, EXP CELL RES, V116, P217, DOI 10.1016/0014-4827(78)90078-2; SUSSMAN M, 1977, FRB FIGGRTRNYISYION, P31; TAKEUCHI I, 1977, DEV DIFFERENTIATION, P1; TOWN CD, 1976, NATURE, V262, P717, DOI 10.1038/262717a0; WANG M, 1989, DEVELOPMENT, V105, P569; WANG M, 1990, DEV BIOL, V140, P182, DOI 10.1016/0012-1606(90)90065-Q; WILLIAMS JG, 1987, CELL, V49, P185, DOI 10.1016/0092-8674(87)90559-9; WILLIAMS JG, 1989, DEVELOPMENT, V7, P91	51	129	130	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 15	1992	69	4					615	624		10.1016/0092-8674(92)90225-2	http://dx.doi.org/10.1016/0092-8674(92)90225-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HV089	1586944				2022-12-01	WOS:A1992HV08900006
J	KOCH, C; ZADOR, A; BROWN, TH				KOCH, C; ZADOR, A; BROWN, TH			DENDRITIC SPINES - CONVERGENCE OF THEORY AND EXPERIMENT	SCIENCE			English	Article							LONG-TERM POTENTIATION; RAT HIPPOCAMPUS; SYNAPTIC TRANSMISSION; PYRAMIDAL CELLS; CALCIUM; STIMULATION; ENHANCEMENT; MECHANISM; NEURONS		YALE UNIV,NEUROSCI PROGRAM,NEW HAVEN,CT 06520; YALE UNIV,DEPT PSYCHOL,NEW HAVEN,CT 06520	Yale University; Yale University	KOCH, C (corresponding author), CALTECH,COMP & NEURAL SYST PROGRAM,PASADENA,CA 91125, USA.			Zador, Anthony/0000-0002-8431-9136; Koch, Christof/0000-0001-6482-8067				BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BRADLEY P, 1979, BRAIN RES, V162, P148, DOI 10.1016/0006-8993(79)90764-9; BROWN T H, 1988, P201; BROWN TH, 1988, SCIENCE, V242, P724, DOI 10.1126/science.2903551; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; COSS RG, 1985, BEHAV NEURAL BIOL, V44, P151, DOI 10.1016/S0163-1047(85)90170-0; COSS RG, 1978, SCIENCE, V200, P787, DOI 10.1126/science.644322; CRICK F, 1982, TRENDS NEUROSCI, V5, P44, DOI 10.1016/0166-2236(82)90020-0; DESMOND N L, 1988, P265; GAMBLE E, 1987, SCIENCE, V236, P1311, DOI 10.1126/science.3495885; GREENOUGH WT, 1985, SYNAPTIC PLASTICITY, P335; GUTHRIE PB, 1991, NATURE, V354, P76, DOI 10.1038/354076a0; HARRIS KM, 1989, J NEUROSCI, V9, P2982; HARRIS KM, 1989, HIPPOCAMPUS NEW VIST, P32; HOLMES WR, 1990, J NEUROPHYSIOL, V63, P1148, DOI 10.1152/jn.1990.63.5.1148; KOCH C, 1983, PROC R SOC SER B-BIO, V218, P455, DOI 10.1098/rspb.1983.0051; LARKMAN AU, 1991, J COMP NEUROL, V306, P320, DOI 10.1002/cne.903060208; LEE KS, 1980, J NEUROPHYSIOL, V44, P247, DOI 10.1152/jn.1980.44.2.247; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; MALENKA RC, 1988, SCIENCE, V242, P81, DOI 10.1126/science.2845577; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MULLER W, 1991, NATURE, V354, P73, DOI 10.1038/354073a0; PERKEL DH, 1985, BRAIN RES, V325, P331, DOI 10.1016/0006-8993(85)90334-8; PURPURA DP, 1974, SCIENCE, V186, P1126, DOI 10.1126/science.186.4169.1126; Rall W., 1974, CELLULAR MECH SUBSER, P13; Rall W., 1978, STUDIES NEUROPHYSIOL, P203; REGEHR WG, 1989, NATURE, V341, P533, DOI 10.1038/341533a0; RINZEL J, 1982, SOME MATH QUESTIONS, P7; SEGEV I, 1988, J NEUROPHYSIOL, V60, P499, DOI 10.1152/jn.1988.60.2.499; SHEPHERD GM, 1985, P NATL ACAD SCI USA, V82, P2192, DOI 10.1073/pnas.82.7.2192; VANHARREVELD A, 1975, EXP NEUROL, V49, P736, DOI 10.1016/0014-4886(75)90055-2; WILSON CJ, 1984, J NEUROSCI, V4, P281; WILSON CJ, 1983, J NEUROSCI, V3, P383; XIANG Z, 1991, Society for Neuroscience Abstracts, V17, P1330; ZADOR A, 1990, P NATL ACAD SCI USA, V87, P6718, DOI 10.1073/pnas.87.17.6718	35	80	81	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 15	1992	256	5059					973	974		10.1126/science.1589781	http://dx.doi.org/10.1126/science.1589781			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU224	1589781				2022-12-01	WOS:A1992HU22400025
J	KRUMHOLZ, HM; DOUGLAS, PS; LAUER, MS; PASTERNAK, RC				KRUMHOLZ, HM; DOUGLAS, PS; LAUER, MS; PASTERNAK, RC			SELECTION OF PATIENTS FOR CORONARY ANGIOGRAPHY AND CORONARY REVASCULARIZATION EARLY AFTER MYOCARDIAL-INFARCTION - IS THERE EVIDENCE FOR A GENDER BIAS	ANNALS OF INTERNAL MEDICINE			English	Article						MYOCARDIAL INFARCTION; CORONARY ANGIOGRAPHY; CORONARY ARTERY BYPASS; SEX FACTORS; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; WOMENS HEALTH; SELECTION BIAS	ARTERY BYPASS-SURGERY; WOMEN; MORTALITY; SEX; DISEASE; MEN	Objective: To determine whether a gender bias exists in the selection of patients for diagnostic and therapeutic cardiovascular procedures early after myocardial infarction. Design: A retrospective cohort study. Setting: A community-based tertiary care teaching hospital. Patients: A total of 2473 consecutive patients with a principal discharge diagnosis of acute myocardial infarction and a peak creatine kinase MB fraction of at least 4%. Measurements: Comparison of men and women regarding the frequency with which they underwent various cardiac procedures. Results: Women had coronary angiography during hospitalization for myocardial infarction much less frequently than men (odds ratio, 0.55; 95% Cl, 0.46 to 0.65), but the age-adjusted rates were similar in women and men (odds ratio, 0.91; Cl, 0.75 to 1.12). An abnormal ejection fraction (< 50%) was equally frequent in women and men who underwent left ventriculography (odds ratio, 0.85; Cl, 0.56 to 1.30). Among patients who had coronary angiography, women had a significantly lower rate of severe coronary artery disease, defined as either a left main stenosis of more than 50%, three-vessel disease, or two-vessel disease with a proximal left anterior descending stenosis of more than 70% (odds ratio, 0.67; Cl, 0.48 to 0.93). When adjustments were made for age, women had percutaneous transluminal coronary angioplasty as often as men (odds ratio, 1.16; Cl, 0.83 to 1.62) but had coronary artery bypass graft surgery significantly less frequently (odds ratio, 0.58; Cl, 0.37 to 0.91). When adjustments were made for age and the severity of coronary artery disease, the difference in rates was of borderline significance (odds ratio, 0.65; Cl, 0.41 to 1.01). Conclusions: No evidence of a difference in the rate of coronary angiography early after myocardial infarction between women and men was found after age adjustment. Among patients who have cardiac catheterization early after myocardial infarction, women and men are equally likely to have angioplasty, but women are less likely than men to have coronary artery bypass surgery.	MASSACHUSETTS GEN HOSP, CELL BIOL UNIT, 32 FRUIT ST, BOSTON, MA 02114 USA; BETH ISRAEL HOSP, DIV CARDIOVASC, BOSTON, MA 02215 USA; LAHEY CLIN FDN, MED CTR, CARDIOL SECT, BURLINGTON, MA 01805 USA	Harvard University; Massachusetts General Hospital; Harvard University; Beth Israel Deaconess Medical Center; Lahey Hospital & Medical Center			, Harlan/AAI-2875-2020; Lauer, Michael S/L-9656-2013	Lauer, Michael S/0000-0002-9217-8177; Douglas, Pamela/0000-0001-9876-4049	NHLBI NIH HHS [HL-07374] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007374] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; BOLOOKI H, 1975, J THORAC CARDIOV SUR, V69, P271; DITTRICH H, 1988, AM J CARDIOL, V62, P1, DOI 10.1016/0002-9149(88)91356-2; FIEBACH NH, 1990, JAMA-J AM MED ASSOC, V263, P1092, DOI 10.1001/jama.263.8.1092; FISHER LD, 1982, J THORAC CARDIOV SUR, V84, P334; GILLUM RF, 1987, AM HEART J, V113, P1255, DOI 10.1016/0002-8703(87)90952-5; GREENLAND P, 1991, CIRCULATION, V83, P484, DOI 10.1161/01.CIR.83.2.484; HEALY B, 1991, NEW ENGL J MED, V325, P274, DOI 10.1056/NEJM199107253250408; IEZZONI LI, 1988, ANN INTERN MED, V109, P745, DOI 10.7326/0003-4819-109-9-745; JOHANSSON S, 1984, EUR HEART J, V5, P374, DOI 10.1093/oxfordjournals.eurheartj.a061671; KENNEDY RH, 1982, NEW ENGL J MED, V307, P986, DOI 10.1056/NEJM198210143071605; KHAN SS, 1990, ANN INTERN MED, V112, P561, DOI 10.7326/0003-4819-112-8-561; LERNER DJ, 1986, AM HEART J, V111, P383, DOI 10.1016/0002-8703(86)90155-9; LOOP FD, 1983, J AM COLL CARDIOL, V1, P383, DOI 10.1016/S0735-1097(83)80064-3; MERRILEES MA, 1984, BRIT MED J, V288, P356, DOI 10.1136/bmj.288.6414.356; Rosner B., 1986, FUNDAMENTALS BIOSTAT, V2nd, P442; SAFRAN C, 1989, ANN INTERN MED, V111, P751, DOI 10.7326/0003-4819-111-9-751; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402; TOBIN JN, 1987, ANN INTERN MED, V107, P19, DOI 10.7326/0003-4819-107-1-19; TOFLER GH, 1987, J AM COLL CARDIOL, V9, P473, DOI 10.1016/S0735-1097(87)80038-4; WENGER NK, 1990, ANN INTERN MED, V112, P557, DOI 10.7326/0003-4819-112-8-557; ZIR LM, 1976, CIRCULATION, V53, P627, DOI 10.1161/01.CIR.53.4.627	22	252	256	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1992	116	10					785	790		10.7326/0003-4819-116-10-785	http://dx.doi.org/10.7326/0003-4819-116-10-785			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT802	1567092				2022-12-01	WOS:A1992HT80200001
J	MCMAHON, AP; JOYNER, AL; BRADLEY, A; MCMAHON, JA				MCMAHON, AP; JOYNER, AL; BRADLEY, A; MCMAHON, JA			THE MIDBRAIN HINDBRAIN PHENOTYPE OF WNT-1--WNT-1- MICE RESULTS FROM STEPWISE DELETION OF ENGRAILED-EXPRESSING CELLS BY 9.5 DAYS POSTCOITUM	CELL			English	Article							SEGMENT-POLARITY GENE; MAMMARY ONCOGENE INT-1; NUCLEOTIDE-SEQUENCE; MOLECULAR ANALYSIS; MOUSE DEVELOPMENT; TUMOR VIRUS; STEM-CELLS; HOMEO BOX; DROSOPHILA; PROTEIN	Mice homozygous for null alleles of the putative signaling molecule Wnt-1 have a reproducible phenotype: loss of the midbrain and adjacent cerebellar component of the metencephalon. By examining embryonic expression of the mouse engrailed (En) genes, from 8.0 to 9.5 days postcoitum, we demonstrate that Wnt-1 primarily regulates midbrain development. The midbrain itself is required for normal development of the metencephalon. Thus, the observed neonatal phenotype is explained by a series of early events, within 48 hr of neural plate induction, that leads to a complete loss of En domains in the anterior central nervous system. Wnt-1 and a related gene, Wnt-3a, are coexpressed from early somite stages in dorsal aspects of the myelencephalon and spinal cord. We suggest that functional redundancy between these two genes accounts for the lack of a caudal central nervous system phenotype.	MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, TORONTO M5G 1X5, ONTARIO, CANADA; BAYLOR COLL MED, INST MOLEC GENET, HOUSTON, TX 77030 USA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Baylor College of Medicine	MCMAHON, AP (corresponding author), ROCHE INST MOLEC BIOL, ROCHE RES CTR, DEPT CELL & DEV BIOL, NUTLEY, NJ 07110 USA.			Bradley, Allan/0000-0002-2349-8839				ALVARADOMALLART RM, 1990, DEV BIOL, V139, P75, DOI 10.1016/0012-1606(90)90280-V; ALVARADOMALLART RM, 1984, DEV BIOL, V103, P378, DOI 10.1016/0012-1606(84)90326-9; ARIAS AM, 1988, DEVELOPMENT, V103, P157; BAKER NE, 1988, DEV BIOL, V125, P96, DOI 10.1016/0012-1606(88)90062-0; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; BROWN AMC, 1986, CELL, V46, P1001, DOI 10.1016/0092-8674(86)90699-9; Cowan W.M., 1982, NEURONAL DEV, P377; DAVIDSON D, 1988, DEVELOPMENT, V104, P305; DAVIS CA, 1988, GENE DEV, V2, P1736, DOI 10.1101/gad.2.12b.1736; DAVIS CA, 1991, DEVELOPMENT, V111, P287; DAVIS CA, 1988, GENE DEV, V2, P361, DOI 10.1101/gad.2.3.361; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; DiNardo S, 1990, Semin Cell Biol, V1, P173; FUNG YKT, 1985, MOL CELL BIOL, V5, P3337, DOI 10.1128/MCB.5.12.3337; GARDNER CA, 1991, DEVELOPMENT, V113, P1037; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; HALLONET MER, 1990, DEVELOPMENT, V108, P19; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; ICHIJO H, 1990, DEVELOPMENT, V110, P331; Ingham PW, 1991, CURR OPIN GENET DEV, V1, P261, DOI 10.1016/S0959-437X(05)80080-2; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; JOYNER AL, 1987, GENE DEV, V1, P29, DOI 10.1101/gad.1.1.29; JOYNER AL, 1989, NATURE, V338, P153, DOI 10.1038/338153a0; JOYNER AL, 1985, CELL, V43, P29, DOI 10.1016/0092-8674(85)90009-1; JOYNER AL, 1991, SCIENCE, V251, P1239, DOI 10.1126/science.1672471; KLINGENSMITH J, 1989, DEV BIOL, V134, P130, DOI 10.1016/0012-1606(89)90084-5; KORNBERG T, 1981, P NATL ACAD SCI-BIOL, V78, P1095, DOI 10.1073/pnas.78.2.1095; Lane P. W., 1967, MOUSE NEWS LETT, V36, P40; MARTINEZ S, 1990, DEV BIOL, V139, P432, DOI 10.1016/0012-1606(90)90312-7; MARTINEZ S, 1991, NEURON, V6, P971, DOI 10.1016/0896-6273(91)90237-T; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MCMAHON AP, 1992, ADV DEV BIOL, V1, P31; MCMAHON JA, 1989, DEVELOPMENT, V107, P643; NAKAMURA H, 1990, BRAIN RES, V511, P122, DOI 10.1016/0006-8993(90)90231-Y; NUSSE R, 1990, MOL CELL BIOL, V10, P4170, DOI 10.1128/MCB.10.8.4170; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PAPKOFF J, 1989, MOL CELL BIOL, V9, P3377, DOI 10.1128/MCB.9.8.3377; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; RIGGLEMAN B, 1990, CELL, V63, P549, DOI 10.1016/0092-8674(90)90451-J; RIGGLEMAN B, 1989, GENE DEV, V3, P96, DOI 10.1101/gad.3.1.96; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; ROELINK H, 1991, GENE DEV, V5, P381, DOI 10.1101/gad.5.3.381; TAM PPL, 1986, J EMBRYOL EXP MORPH, V92, P269; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; THOMAS KR, 1991, CELL, V67, P969, DOI 10.1016/0092-8674(91)90369-A; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VANOOYEN A, 1984, CELL, V39, P233, DOI 10.1016/0092-8674(84)90209-5; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WILKINSON DG, 1987, DEVELOPMENT, V99, P493	56	518	527	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 15	1992	69	4					581	595		10.1016/0092-8674(92)90222-X	http://dx.doi.org/10.1016/0092-8674(92)90222-X			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HV089	1534034				2022-12-01	WOS:A1992HV08900003
J	MEHLIN, H; DANEHOLT, B; SKOGLUND, U				MEHLIN, H; DANEHOLT, B; SKOGLUND, U			TRANSLOCATION OF A SPECIFIC PREMESSENGER RIBONUCLEOPROTEIN PARTICLE THROUGH THE NUCLEAR-PORE STUDIED WITH ELECTRON-MICROSCOPE TOMOGRAPHY	CELL			English	Article							CHIRONOMUS-TENTANS; BALBIANI RINGS; PROTEIN IMPORT; RNA TRANSPORT; COMPLEX; ENVELOPE; OOCYTES; BINDING; GENES; CELL	A specific premessenger ribonucleoprotein (RNP) particle in the salivary glands of the dipteran Chironomus tentans was studied with electron microscope tomography during translocation from the cell nucleus to the cytoplasm. The RNP particle consists of a thin RNP fiber tightly folded into a ribbon, which is bent into a ring-like structure. Upon translocation through the pore, the particle is first orientated in a specific manner at the pore entrance, and subsequently the bent ribbon is gradually straightened and transported through the pore with the 5' end of the RNA in the lead. Concomitantly, the elementary RNP fiber constituting the ribbon is gradually unpacked and will appear more or less extended on the cytoplasmic side of the pore complex. The ordered nature of the process suggests a specific recognition of the RNP particle at the nuclear pore.			MEHLIN, H (corresponding author), KAROLINSKA INST,MED NOBEL INST,DEPT MOLEC GENET,S-10401 STOCKHOLM 60,SWEDEN.		Skoglund, Ulf/B-5829-2015	Skoglund, Ulf/0000-0002-3407-0053				AGUTTE PS, 1976, NATURE, V263, P165, DOI 10.1038/263165a0; Agutter P S, 1984, Subcell Biochem, V10, P281; AKEY CW, 1989, J CELL BIOL, V109, P971, DOI 10.1083/jcb.109.3.971; AKEY CW, 1989, J CELL BIOL, V109, P955, DOI 10.1083/jcb.109.3.955; ANDERSSON K, 1980, EXP CELL RES, V130, P313, DOI 10.1016/0014-4827(80)90008-7; BEERMANN W, 1962, MAI C GES SCHAFT PHY, P64; CASE ST, 1983, J BIOL CHEM, V258, P7793; CLAWSON GA, 1985, MOL CELL BIOCHEM, V67, P87, DOI 10.1007/BF02370167; Daneholt B, 1976, Prog Nucleic Acid Res Mol Biol, V19, P319; DANEHOLT B, 1977, J CELL BIOL, V3, P149; DAVIS LI, 1987, P NATL ACAD SCI USA, V84, P7552, DOI 10.1073/pnas.84.21.7552; DAVIS LI, 1986, CELL, V45, P699, DOI 10.1016/0092-8674(86)90784-1; DINGWALL C, 1986, ANNU REV CELL BIOL, V2, P367, DOI 10.1146/annurev.cellbio.2.1.367; DREYFUSS G, 1986, ANNU REV CELL BIOL, V2, P459, DOI 10.1146/annurev.cb.02.110186.002331; DWORETZKY SI, 1988, J CELL BIOL, V106, P575, DOI 10.1083/jcb.106.3.575; FELDHERR CM, 1984, J CELL BIOL, V99, P2216, DOI 10.1083/jcb.99.6.2216; FETHERSTONE C, 1988, J CELL BIOL, V107, P1289; FRANKE WW, 1970, J ULTRA MOL STRUCT R, V30, P317, DOI 10.1016/S0022-5320(70)80065-X; FRANKE WW, 1981, J CELL BIOL, V91, P39; GALLER R, 1985, EMBO J, V4, P2977, DOI 10.1002/j.1460-2075.1985.tb04032.x; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; HOLCOMB ER, 1984, J BIOL CHEM, V259, P31; JONES RE, 1980, J CELL BIOL, V86, P235, DOI 10.1083/jcb.86.1.235; LAMB MM, 1979, CELL, V17, P835, DOI 10.1016/0092-8674(79)90324-6; LONN U, 1977, NATURE, V270, P630, DOI 10.1038/270630a0; MAUL GR, 1977, INT REV CYTOL      S, V6, P75; MCDONALD JR, 1980, FEBS LETT, V116, P145, DOI 10.1016/0014-5793(80)80629-6; MEHLIN H, 1991, EXP CELL RES, V193, P72, DOI 10.1016/0014-4827(91)90539-7; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; NEWPORT JW, 1987, ANNU REV BIOCHEM, V56, P535; OLINS AL, 1980, EUR J CELL BIOL, V22, P714; PAINE PL, 1975, NATURE, V254, P109, DOI 10.1038/254109a0; PARK MK, 1987, P NATL ACAD SCI USA, V84, P6462, DOI 10.1073/pnas.84.18.6462; PETERS R, 1984, EMBO J, V3, P1831, DOI 10.1002/j.1460-2075.1984.tb02055.x; Preobrazhensky A A, 1978, Prog Nucleic Acid Res Mol Biol, V21, P1, DOI 10.1016/S0079-6603(08)60265-2; REICHELT R, 1990, J CELL BIOL, V110, P883, DOI 10.1083/jcb.110.4.883; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; RIS H, 1989, Journal of Cell Biology, V109, p134A; ROWLAND SW, 1979, TOP APPL PHYS, V32, P9; SCHEER U, 1988, CELL BIOL INT REP, V12, P669, DOI 10.1016/0309-1651(88)90083-5; SCHRODER HC, 1987, PROG NUCLEIC ACID RE, V34, P89, DOI 10.1016/S0079-6603(08)60494-8; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SKOGLUND U, 1986, TRENDS BIOCHEM SCI, V11, P499, DOI 10.1016/0968-0004(86)90077-0; SKOGLUND U, 1986, NATURE, V319, P560, DOI 10.1038/319560a0; SNOW CM, 1987, J CELL BIOL, V104, P1143, DOI 10.1083/jcb.104.5.1143; STEVENS BJ, 1966, J CELL BIOL, V31, P55, DOI 10.1083/jcb.31.1.55; UNWIN PNT, 1982, J CELL BIOL, V93, P63, DOI 10.1083/jcb.93.1.63; WIESLANDER L, 1984, J MOL EVOL, V20, P304, DOI 10.1007/BF02104736; WURTZ T, 1990, P NATL ACAD SCI USA, V87, P831, DOI 10.1073/pnas.87.2.831; ZASLOFF M, 1983, P NATL ACAD SCI-BIOL, V80, P6436, DOI 10.1073/pnas.80.21.6436; [No title captured]	52	224	227	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 15	1992	69	4					605	613		10.1016/0092-8674(92)90224-Z	http://dx.doi.org/10.1016/0092-8674(92)90224-Z			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HV089	1586943				2022-12-01	WOS:A1992HV08900005
J	MOORE, MJ; SHARP, PA				MOORE, MJ; SHARP, PA			SITE-SPECIFIC MODIFICATION OF PRE-MESSENGER-RNA - THE 2'-HYDROXYL GROUPS AT THE SPLICE SITES	SCIENCE			English	Article							POLYNUCLEOTIDE LIGASE; LARIAT FORMATION; GROUP-II; TETRAHYMENA; SEQUENCE; RIBOZYME; INTRONS; CLEAVAGE; INVITRO; DNA	A simple and efficient method for synthesizing long, site-specifically modified RNA molecules was developed whereby segments of RNA were joined with the use of bacteriophage T4 DNA ligase. A single hydrogen or O-methyl group was substituted for the 2'-hydroxyl group at either splice site of a nuclear pre-messenger RNA substrate. Splicing of the modified pre-messenger RNA's in vitro revealed that, although a 2'-hydroxyl is not absolutely required at either splice site, the 2'-hydroxyl at the 3' splice site is important for the second step of splicing. These results are compared to previous studies of analogous 2'-hydroxyl groups in the self-splicing Tetrahymena group I intron.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)	MOORE, MJ (corresponding author), MIT, CTR CANC RES, CAMBRIDGE, MA 02139 USA.				NATIONAL CANCER INSTITUTE [P30CA014051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034277] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA14051] Funding Source: Medline; NIGMS NIH HHS [R01 GM34277] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBI M, 1986, CELL, V47, P555, DOI 10.1016/0092-8674(86)90620-3; BASS BL, 1984, NATURE, V308, P820, DOI 10.1038/308820a0; BASS BL, 1986, BIOCHEMISTRY-US, V25, P4473, DOI 10.1021/bi00364a001; BEEN MD, 1991, SCIENCE, V252, P434, DOI 10.1126/science.2017681; Blackburn P, 1982, ENZYMES, VXV, P317; CECH TR, 1986, CELL, V44, P207, DOI 10.1016/0092-8674(86)90751-8; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOCKBREGEON AC, 1988, NATURE, V335, P375, DOI 10.1038/335375a0; ENGLAND TE, 1978, BIOCHEMISTRY-US, V17, P2069, DOI 10.1021/bi00604a008; ENGLAND TE, 1977, P NATL ACAD SCI USA, V74, P4839, DOI 10.1073/pnas.74.11.4839; Engler M.J., 1982, ENZYMES, V15, P3, DOI [10.1016/S1874-6047(08)60273-5, DOI 10.1016/S1874-6047(08)60273-5]; FAREED GC, 1971, J BIOL CHEM, V246, P925; GARCIABLANCO MA, 1989, GENE DEV, V3, P1874, DOI 10.1101/gad.3.12a.1874; GRABOWSKI PJ, 1984, CELL, V37, P415, DOI 10.1016/0092-8674(84)90372-6; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HERSCHLAG D, 1990, NATURE, V344, P405, DOI 10.1038/344405a0; INOUE T, 1985, CELL, V43, P431, DOI 10.1016/0092-8674(85)90173-4; INOUE T, 1986, J MOL BIOL, V189, P143, DOI 10.1016/0022-2836(86)90387-6; JACQUIER A, 1990, TRENDS BIOCHEM SCI, V15, P351, DOI 10.1016/0968-0004(90)90075-M; JOYCE GF, 1989, NATURE, V338, P217, DOI 10.1038/338217a0; KAY PS, 1987, NATURE, V327, P343, DOI 10.1038/327343a0; KLEPPE K, 1970, P NATL ACAD SCI USA, V67, P68, DOI 10.1073/pnas.67.1.68; KONARSKA MM, 1985, NATURE, V313, P552, DOI 10.1038/313552a0; MANIATIS T, 1987, NATURE, V325, P673, DOI 10.1038/325673a0; MEI HY, 1989, P NATL ACAD SCI USA, V86, P9727, DOI 10.1073/pnas.86.24.9727; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; NOBLE JCS, 1986, NUCLEIC ACIDS RES, V14, P1219; PERREAULT JP, 1990, NATURE, V344, P565, DOI 10.1038/344565a0; QUIGLEY GJ, 1976, SCIENCE, V194, P796, DOI 10.1126/science.790568; RICHARDS FM, 1971, ENZYMES, V4, P647; ROMANIUK E, 1982, EUR J BIOCHEM, V125, P639, DOI 10.1111/j.1432-1033.1982.tb06730.x; ROMANIUK PJ, 1983, METHOD ENZYMOL, V100, P52; RUBY SW, 1991, TRENDS GENET, V7, P79; RYMOND BC, 1985, NATURE, V317, P735, DOI 10.1038/317735a0; Saenger W., 1984, PRINCIPLES NUCLEIC A, VDM79; SANO H, 1974, BIOCHEMISTRY-US, V13, P5110, DOI 10.1021/bi00722a009; SGARAMELLA V, 1972, J MOL BIOL, V72, P427, DOI 10.1016/0022-2836(72)90155-6; SHABAROVA ZA, 1988, BIOCHIMIE, V70, P1323, DOI 10.1016/0300-9084(88)90003-X; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; SHARP PA, 1991, SCIENCE, V254, P663, DOI 10.1126/science.1948046; SHARP PA, 1987, SCIENCE, V235, P766, DOI 10.1126/science.3544217; SMITH CWJ, 1989, NATURE, V342, P243, DOI 10.1038/342243a0; SUGINO A, 1977, J BIOL CHEM, V252, P3987; Takahashi K., 1982, ENZYMES, V15, p435 468; TSIAPALIS CM, 1970, BIOCHEM BIOPH RES CO, V39, P631, DOI 10.1016/0006-291X(70)90251-2; Uhlenbeck O.C., 1982, ENZYMES, V15, P31, DOI [10.1016/s1874-6047(08)60274-7, DOI 10.1016/S1874-6047(08)60274-7]; UHLENBECK OC, 1977, NUCLEIC ACIDS RES, V4, P85, DOI 10.1093/nar/4.1.85; USHER DA, 1970, NATURE, V228, P663, DOI 10.1038/228663a0; VANDERVEEN R, 1987, EMBO J, V6, P3827, DOI 10.1002/j.1460-2075.1987.tb02719.x; WANG XD, 1989, P NATL ACAD SCI USA, V86, P7795, DOI 10.1073/pnas.86.20.7795; WEISS B, 1968, J BIOL CHEM, V243, P4543; WEISS B, 1976, J MOL BIOL, V103, P669, DOI 10.1016/0022-2836(76)90226-6; WITTENBERG WL, 1985, BIOCHEMISTRY-US, V24, P2705, DOI 10.1021/bi00332a017; YISRAELI JK, 1989, METHOD ENZYMOL, V180, P42	56	434	508	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 15	1992	256	5059					992	997		10.1126/science.1589782	http://dx.doi.org/10.1126/science.1589782			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU224	1589782				2022-12-01	WOS:A1992HU22400029
J	PAPPAS, PG; POTTAGE, JC; POWDERLY, WG; FRASER, VJ; STRATTON, CW; MCKENZIE, S; TAPPER, ML; CHMEL, H; BONEBRAKE, FC; BLUM, R; SHAFER, RW; KING, C; DISMUKES, WE				PAPPAS, PG; POTTAGE, JC; POWDERLY, WG; FRASER, VJ; STRATTON, CW; MCKENZIE, S; TAPPER, ML; CHMEL, H; BONEBRAKE, FC; BLUM, R; SHAFER, RW; KING, C; DISMUKES, WE			BLASTOMYCOSIS IN PATIENTS WITH THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME	ANNALS OF INTERNAL MEDICINE			English	Article						BLASTOMYCOSIS; ACQUIRED IMMUNODEFICIENCY SYNDROME; CENTRAL NERVOUS SYSTEM INFECTIONS; AMPHOTERICIN-B; KETOCONAZOLE; HUMAN IMMUNODEFICIENCY VIRUS	DERMATITIDIS; KETOCONAZOLE; ITRACONAZOLE; INFECTIONS; PULMONARY	Objective: To describe the clinical, demographic, radiographic, diagnostic, and therapeutic aspects of blastomycosis in patients with the acquired immunodeficiency syndrome (AIDS). Design: A retrospective survey. Setting: Ten university medical centers and community hospitals, six in geographic areas endemic for Blastomyces dermatitidis, and four outside the endemic area. Patients: We identified 15 patients with blastomycosis and positive serologic test results for human immunodeficiency virus (HIV). Measurements: A diagnosis of blastomycosis was based on a positive culture (14 patients) or typical histopathologic features (one patient) for B. dermatitidis in clinical specimens. Results: Twelve of 15 patients had a previous or concomitant AIDS-defining illness at the time of diagnosis of blastomycosis, and only one patient had a CD4 lymphocyte count of greater than 200 cells/mm3. Two patterns of disease emerged: localized pulmonary involvement (seven patients), and disseminated or extrapulmonary blastomycosis (eight patients). Central nervous system involvement was common (40%). Six patients died within 21 days of presentation with blastomycosis, including four patients with disseminated and two with fulminant pulmonary disease. Among the nine patients who survived longer than 1 month, all received amphotericin B as initial antifungal therapy, and most received subsequent therapy with ketoconazole. Only two of these nine patients died with evidence of progressive blastomycosis. Conclusions: Blastomycosis is a late and frequently fatal infectious complication in a few patients with AIDS. In these patients, overwhelming disseminated disease including involvement of the central nervous system is common, and it is associated with a high early mortality. Initial therapy with amphotericin B is appropriate in patients with AIDS and presumptive blastomycosis.			PAPPAS, PG (corresponding author), UNIV ALABAMA, DIV INFECT DIS, 229 TINSLEY HARRISON TOWER, UNIV STN, BIRMINGHAM, AL 35294 USA.			Powderly, William/0000-0001-7808-3086; Fraser, Victoria/0000-0001-6251-0733	NIAID NIH HHS [N01-AI-15082] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI015082] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARATHOON EG, 1989, MYCOSES, V32, P109, DOI 10.1111/j.1439-0507.1989.tb02300.x; BRADSHER RW, 1984, AM REV RESPIR DIS, V129, P430; BRADSHER RW, 1985, ANN INTERN MED, V103, P872, DOI 10.7326/0003-4819-103-6-872; BROWN LR, 1991, MAYO CLIN PROC, V66, P29, DOI 10.1016/S0025-6196(12)61172-0; CHERNISS EI, 1956, ANN INTERN MED, V44, P105, DOI 10.7326/0003-4819-44-1-105; CHIU J, 1988, 4 INT C AIDS STOCKH; CHUCK SL, 1989, NEW ENGL J MED, V321, P794, DOI 10.1056/NEJM198909213211205; DISMUKES WE, 1985, ANN INTERN MED, V103, P861, DOI 10.7326/0003-4819-103-6-861; DUTTERA J, 1969, SOUTHERN MED J, V62, P295; EHNI W, 1989, AM J MED, V86, P831, DOI 10.1016/0002-9343(89)90483-X; ENG RHK, 1986, AM J MED, V81, P19, DOI 10.1016/0002-9343(86)90176-2; ESPINELINGROFF A, 1984, ANTIMICROB AGENTS CH, V26, P5, DOI 10.1128/AAC.26.1.5; EVANS ME, 1982, AM REV RESPIR DIS, V126, P1099; FRASER VJ, 1991, J INFECT DIS, V163, P1378, DOI 10.1093/infdis/163.6.1378; GRIFFITH JE, 1979, CHEST, V75, P630, DOI 10.1378/chest.75.5.630; HERD AM, 1990, CAN MED ASSOC J, V143, P1329; KITCHEN LW, 1989, J INFECT DIS, V160, P911, DOI 10.1093/infdis/160.5.911; KLEIN BS, 1986, NEW ENGL J MED, V314, P529, DOI 10.1056/NEJM198602273140901; KOVACS JA, 1985, ANN INTERN MED, V103, P533, DOI 10.7326/0003-4819-103-4-533; LAKEBAKAAR G, 1988, ANN INTERN MED, V109, P471, DOI 10.7326/0003-4819-109-6-471; LASKEY W, 1978, ANN INTERN MED, V88, P50, DOI 10.7326/0003-4819-88-1-50; ONAL E, 1976, AM REV RESPIR DIS, V113, P83; PETERSON PK, 1982, MEDICINE, V61, P360, DOI 10.1097/00005792-198211000-00002; RECHT LD, 1982, AM REV RESPIR DIS, V125, P359; ROOS KL, 1987, MEDICINE, V66, P224, DOI 10.1097/00005792-198705000-00006; SAROSI GA, 1979, AM REV RESPIR DIS, V120, P911; STEVENS DA, 1990, REV INFECT DIS, V12, pS304; Turner S, 1986, Semin Respir Infect, V1, P22; WINSTON DJ, 1979, MEDICINE, V58, P1, DOI 10.1097/00005792-197901000-00001; WITORSCH P, 1968, MEDICINE, V47, P169, DOI 10.1097/00005792-196805000-00001; 1987, MMWR S, V36, P1	31	158	159	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1992	116	10					847	853		10.7326/0003-4819-116-10-847	http://dx.doi.org/10.7326/0003-4819-116-10-847			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT802	1567099				2022-12-01	WOS:A1992HT80200011
J	POGGIO, T; FAHLE, M; EDELMAN, S				POGGIO, T; FAHLE, M; EDELMAN, S			FAST PERCEPTUAL-LEARNING IN VISUAL HYPERACUITY	SCIENCE			English	Article							ORIENTATION; IMPROVEMENT	In many different spatial discrimination tasks, such as in determining the sign of the offset in a vernier stimulus, the human visual system exhibits hyperacuity by evaluating spatial relations with the precision of a fraction of a photoreceptor's diameter. It is proposed that this impressive performance depends in part on a fast learning process that uses relatively few examples and that occurs at an early processing stage in the visual pathway. This hypothesis is given support by the demonstration that it is possible to synthesize, from a small number of examples of a given task, a simple network that attains the required performance level. Psychophysical experiments agree with some of the key predictions of the model. In particular, fast stimulus-specific learning is found to take place in the human visual system, and this learning does not transfer between two slightly different hyperacuity tasks.	WEIZMANN INST SCI, DEPT APPL MATH & COMP SCI, IL-76100 REHOVOT, ISRAEL; UNIV TUBINGEN, EYE CLIN, DEPT NEUROOPHTHALMOL, W-7400 TUBINGEN 1, GERMANY	Weizmann Institute of Science; Eberhard Karls University of Tubingen	POGGIO, T (corresponding author), MIT, CTR BIOL INFORMAT PROC, ARTIFICIAL INTELLIGENCE LAB, CAMBRIDGE, MA 02139 USA.							BALL K, 1982, SCIENCE, V218, P697, DOI 10.1126/science.7134968; BARLOW HB, 1979, NATURE, V279, P189, DOI 10.1038/279189a0; BENNETT RG, 1991, PERCEPT PSYCHOPHYS, V49, P541, DOI 10.3758/BF03212188; Black H. S., 1953, MODULATION THEORY; BRUNELLI R, 1991, IRST9111004 I RIC SC; BRUNELLI R, 1991, 12TH P INT JOINT C A; CRICK FHC, 1980, ORG CEREBRAL CORTEX, P505; Duda R.O., 1973, PATTERN CLASSIFICATI, VXVII, P482; EDELMAN S, 1991, BIOL CYBERN, V64, P209, DOI 10.1007/BF00201981; EDELMAN S, IN PRESS INT J PATTE; EDELMAN S, 1990, AI MEMO MIT ARTIFICI, V1181; EDELMAN S, IN PRESS IMAGE PRO B; EDELMAN S, 1991, CSTR9120 WEIZM I DEP; FAHLE M, UNPUB; FIORENTINI A, 1980, NATURE, V287, P43, DOI 10.1038/287043a0; FREGNAC Y, 1988, NATURE, V333, P367, DOI 10.1038/333367a0; KARNI A, 1991, P NATL ACAD SCI USA, V88, P4966, DOI 10.1073/pnas.88.11.4966; MARUYAMA M, 1992, AI MEMO MIT ARTIFICI, V1291; MCKEE SP, 1978, PERCEPT PSYCHOPHYS, V24, P258, DOI 10.3758/BF03206097; Omohundro S. M., 1987, Complex Systems, V1, P273; POGGIO T, 1990, P IEEE, V78, P1481, DOI 10.1109/5.58326; POGGIO T, 1990, COLD SPRING HARB SYM, V55, P899; POGGIO T, 1990, NATURE, V343, P263, DOI 10.1038/343263a0; POGGIO T, 1989, AI MEMO MIT ARTIFICI, V1140; RAMACHANDRAN VS, 1973, PERCEPTION, V2, P371, DOI 10.1068/p020371; RUMELHART DE, 1986, NATURE, V323, P533, DOI 10.1038/323533a0; WATT R J, 1985, Spatial Vision, V1, P31, DOI 10.1163/156856885X00053; WEISS Y, 1991, CSTR9121 WEIZM I DEP; WESTHEIMER G, 1977, VISION RES, V17, P941, DOI 10.1016/0042-6989(77)90069-4	29	438	444	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 15	1992	256	5059					1018	1021		10.1126/science.1589770	http://dx.doi.org/10.1126/science.1589770			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU224	1589770	Green Submitted			2022-12-01	WOS:A1992HU22400038
J	RARICK, HM; ARTEMYEV, NO; HAMM, HE				RARICK, HM; ARTEMYEV, NO; HAMM, HE			A SITE ON ROD G-PROTEIN ALPHA-SUBUNIT THAT MEDIATES EFFECTOR ACTIVATION	SCIENCE			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; CGMP PHOSPHODIESTERASE; OUTER SEGMENTS; INHIBITORY SUBUNIT; TRANSDUCTION; CYCLASE; CASCADE; VISION; CHAIN	The heterotrimeric guanine nucleotide binding proteins (G proteins) are activated by sensory or hormone receptors. In turn, the G proteins activate effector proteins such as adenylyl cyclase, cyclic guanosine 3',5'-monophosphate phosphodiesterase (cGMP PDE), phospholipase C, and potassium and calcium ion channels by mechanisms that are poorly understood. A site on the alpha-subunit of the G protein transducin (alpha(t)) has been identified that interacts with and activates cGMP phosphodiesterase, the effector enzyme in rod photoreceptors. A 22-amino acid peptide, corresponding to residues 293 to 314 from the COOH-terminal region of alpha(t), fully mimicked alpha(t) and potently activated PDE. This region is adjacent to the receptor activation domain; thus, the alpha-subunit of this G protein has a site for interaction with both its effector and receptor that maps near the COOH-terminus.	UNIV ILLINOIS, COLL MED, DEPT PHYSIOL & BIOPHYS, BOX 6998, CHICAGO, IL 60680 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital			Hamm, Heidi E/G-2374-2014	Artemyev, Nikolai/0000-0002-5266-6854	NATIONAL EYE INSTITUTE [R01EY006062] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007692] Funding Source: NIH RePORTER; NEI NIH HHS [EY 06062] Funding Source: Medline; NHLBI NIH HHS [T32 HL 07692-02] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARTEMYEV NO, 1992, BIOCHEM J, V283, P273, DOI 10.1042/bj2830273; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; BROWN RL, 1989, P NATL ACAD SCI USA, V86, P4922, DOI 10.1073/pnas.86.13.4922; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; CHEE WW, 1989, J BIOL CHEM, V264, P5687; DETERRE P, 1986, Proteins Structure Function and Genetics, V1, P188, DOI 10.1002/prot.340010210; DETERRE P, 1988, P NATL ACAD SCI USA, V85, P2424, DOI 10.1073/pnas.85.8.2424; FUNG BKK, 1983, J BIOL CHEM, V258, P503; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; GILLESPIE PG, 1989, MOL PHARMACOL, V36, P773; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.biochem.56.1.615; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P752; HURLEY JB, 1982, J BIOL CHEM, V257, P1094; ITOH H, 1991, J BIOL CHEM, V266, P16226; KROLL S, 1989, J BIOL CHEM, V264, P4490; LAURSEN RA, 1981, J BIOL CHEM, V256, P8102; LIEBMAN PA, 1982, METHOD ENZYMOL, V81, P532; MASTERS SB, 1988, SCIENCE, V241, P448, DOI 10.1126/science.2899356; MAY DC, 1985, J BIOL CHEM, V260, P5829; MAZZONI MR, 1991, J BIOL CHEM, V266, P14072; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; OSAWA S, 1990, CELL, V63, P697, DOI 10.1016/0092-8674(90)90136-3; RARICK HM, UNPUB; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SPIEGEL AM, 1988, VITAM HORM, V44, P47; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; TAKEMOTO DJ, 1990, CELL SIGNAL, V2, P99, DOI 10.1016/0898-6568(90)90013-Z; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; WENSEL T G, 1986, Proteins Structure Function and Genetics, V1, P90, DOI 10.1002/prot.340010114; WENSEL TG, 1990, BIOCHEMISTRY-US, V29, P2155, DOI 10.1021/bi00460a028	31	98	111	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 15	1992	256	5059					1031	1033		10.1126/science.1317058	http://dx.doi.org/10.1126/science.1317058			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU224	1317058				2022-12-01	WOS:A1992HU22400042
J	RAY, CA; BLACK, RA; KRONHEIM, SR; GREENSTREET, TA; SLEATH, PR; SALVESEN, GS; PICKUP, DJ				RAY, CA; BLACK, RA; KRONHEIM, SR; GREENSTREET, TA; SLEATH, PR; SALVESEN, GS; PICKUP, DJ			VIRAL INHIBITION OF INFLAMMATION - COWPOX VIRUS ENCODES AN INHIBITOR OF THE INTERLEUKIN-1-BETA CONVERTING ENZYME	CELL			English	Article							VACCINIA VIRUS; REACTIVE SITE; STRUCTURAL EVIDENCE; EXPRESSION SYSTEM; MESSENGER-RNA; CLEAVAGE SITE; DNA-SEQUENCE; PROTEASE; PURIFICATION; GENERATION	Cowpox virus effectively inhibits inflammatory responses against viral infection in the chick embryo. This study demonstrates that one of the viral genes necessary for this inhibition, the crmA gene (a cytokine response modifier gene), encodes a serpin that is a specific inhibitor of the interleukin-1-beta converting enzyme. This serpin can prevent the proteolytic activation of interleukin-1-beta, thereby suppressing an interleukin-1-beta response to infection. However, the modification of this single cytokine response is not sufficient to inhibit inflammatory responses. This suggests that cowpox virus encodes several cytokine response modifiers that act together to inhibit the release of pro-inflammatory cytokines in response to infection. These viral counter measures to host defenses against infection may contribute significantly to the pathology associated with poxvirus infections.	DUKE UNIV, MED CTR, DEPT PATHOL, DURHAM, NC 27710 USA; IMMUNEX CORP, DEPT PROT CHEM, SEATTLE, WA 98101 USA	Duke University; Immunex Corporation	RAY, CA (corresponding author), DUKE UNIV, MED CTR, DEPT MICROBIOL & IMMUNOL, DURHAM, NC 27710 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023886] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI23886] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDREASEN PA, 1986, FEBS LETT, V209, P213, DOI 10.1016/0014-5793(86)81113-9; BLACK RA, 1989, FEBS LETT, V247, P386, DOI 10.1016/0014-5793(89)81376-6; BLACK RA, 1988, J BIOL CHEM, V263, P9437; CARRELL RW, 1987, COLD SPRING HARB SYM, V52, P527, DOI 10.1101/SQB.1987.052.01.060; CERRETTI DP, 1992, IN PRESS SCIENCE; CHUA TP, 1990, IMMUNOLOGY, V69, P202; DINARELLO CA, 1991, BLOOD, V77, P1627; DINARELLO CA, 1988, INFLAMMATION BASIC P, P195; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; ENSOLI B, 1989, SCIENCE, V243, P223, DOI 10.1126/science.2643161; Fenner F., 1989, MONKEYPOX VIRUS ORTH, P227; FLAMAND L, 1991, J VIROL, V65, P5105, DOI 10.1128/JVI.65.9.5105-5110.1991; FREDRICKSON TN, 1992, IN PRESS VIROLOGY; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Goebel S.J., 1990, VIROLOGY, V179, P517; GOEBEL SJ, 1990, VIROLOGY, V179, P247, DOI 10.1016/0042-6822(90)90294-2; GRIFFITH MJ, 1985, BIOCHEMISTRY-US, V24, P6777, DOI 10.1021/bi00345a008; HAZUDA D, 1989, J BIOL CHEM, V264, P1689; HAZUDA DJ, 1988, J BIOL CHEM, V263, P8473; HOWARD AD, 1991, J IMMUNOL, V147, P2964; HOWARD ST, 1991, VIROLOGY, V180, P633, DOI 10.1016/0042-6822(91)90077-O; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; JOHNSON D, 1978, J BIOL CHEM, V253, P7142; JORNVALL H, 1979, FEBS LETT, V106, P358, DOI 10.1016/0014-5793(79)80532-3; KISO U, 1988, FEBS LETT, V230, P51, DOI 10.1016/0014-5793(88)80640-9; KOSTURA MJ, 1989, P NATL ACAD SCI USA, V86, P5227, DOI 10.1073/pnas.86.14.5227; KOTWAL GJ, 1989, J VIROL, V63, P600, DOI 10.1128/JVI.63.2.600-606.1989; MACKETT M, 1984, J VIROL, V49, P857, DOI 10.1128/JVI.49.3.857-864.1984; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MORII M, 1983, J BIOL CHEM, V258, P2749; MOSLEY B, 1987, P NATL ACAD SCI USA, V84, P4572, DOI 10.1073/pnas.84.13.4572; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; PALUMBO GJ, 1989, VIROLOGY, V172, P262, DOI 10.1016/0042-6822(89)90128-1; PATEL DD, 1988, P NATL ACAD SCI USA, V85, P9431, DOI 10.1073/pnas.85.24.9431; PICKUP DJ, 1986, P NATL ACAD SCI USA, V83, P7698, DOI 10.1073/pnas.83.20.7698; PICKUP DJ, 1984, P NATL ACAD SCI-BIOL, V81, P6817, DOI 10.1073/pnas.81.21.6817; Salvesen G, 1989, PROTEOLYTIC ENZYMES, P83; SALVESEN GS, 1985, J BIOL CHEM, V260, P2432; SAMBHI SK, 1991, P NATL ACAD SCI USA, V88, P4025, DOI 10.1073/pnas.88.9.4025; SCHINDLER R, 1990, J BIOL CHEM, V265, P10232; SHIEH BH, 1987, J BIOL CHEM, V262, P6055; SLEATH PR, 1990, J BIOL CHEM, V265, P14526; SMITH CA, 1991, BIOCHEM BIOPH RES CO, V176, P335, DOI 10.1016/0006-291X(91)90929-2; SMITH CA, 1991, SCIENCE, V72, P1349; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH GL, 1991, J GEN VIROL, V72, P511, DOI 10.1099/0022-1317-72-3-511; TABOR S, 1990, J BIOL CHEM, V265, P8322; UPTON C, 1991, VIROLOGY, V184, P370, DOI 10.1016/0042-6822(91)90853-4; WANO Y, 1987, J CLIN INVEST, V80, P911, DOI 10.1172/JCI113152; [No title captured]	50	921	976	2	30	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 15	1992	69	4					597	604		10.1016/0092-8674(92)90223-Y	http://dx.doi.org/10.1016/0092-8674(92)90223-Y			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HV089	1339309				2022-12-01	WOS:A1992HV08900004
J	SCHULTZ, MC; REEDER, RH; HAHN, S				SCHULTZ, MC; REEDER, RH; HAHN, S			VARIANTS OF THE TATA-BINDING PROTEIN CAN DISTINGUISH SUBSETS OF RNA POLYMERASE-I, POLYMERASE-II, AND POLYMERASE-III PROMOTERS	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION; GENES	Transcription extracts prepared from yeast that are deficient in the TATA-binding protein (TBP or TFIID) are also impaired in specific promoter recognition by all three nuclear RNA polymerases (pol I, II, and III). Specific initiation can be rescued by the addition of purified recombinant TBP, demonstrating that pol I, II, and III all require this factor, A mutation of TBP has been identified that will function with pol I but not with pol II or III. Conversely, another mutation, which inactivates TATA element binding in vitro, will function with pol I and III promoters but is inactive for a pol II promoter. Thus, it is possible to identify TBP variants that will only function on different subsets of all nuclear promoters.			SCHULTZ, MC (corresponding author), HUTCHINSON CANC RES CTR,1124 COLUMBIA ST,SEATTLE,WA 98104, USA.							BAKER RE, 1984, EMBO J, V3, P2793, DOI 10.1002/j.1460-2075.1984.tb02211.x; BELL GI, 1977, J BIOL CHEM, V252, P8118; BURATOWSKI S, 1992, SCIENCE, V255, P1130, DOI 10.1126/science.1546314; CHOE SY, 1992, NUCLEIC ACIDS RES, V20, P279, DOI 10.1093/nar/20.2.279; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CORMACK BP, 1991, CELL, V65, P341, DOI 10.1016/0092-8674(91)90167-W; DAHLBERG JE, 1991, SCIENCE, V254, P1462, DOI 10.1126/science.1962205; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; GEIDUSCHEK P, 1992, IN PRESS TRANSCRIPTI; GILL G, 1991, CELL, V65, P333, DOI 10.1016/0092-8674(91)90166-V; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HAHN S, 1985, P NATL ACAD SCI USA, V82, P8562, DOI 10.1073/pnas.82.24.8562; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HORIKOSHI M, 1990, CELL, V61, P1171, DOI 10.1016/0092-8674(90)90681-4; KLEKAMP MS, 1982, J BIOL CHEM, V257, P8432; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LUE NF, 1989, P NATL ACAD SCI USA, V86, P486, DOI 10.1073/pnas.86.2.486; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; POON D, 1991, MOL CELL BIOL, V11, P4809, DOI 10.1128/MCB.11.10.4809; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; REDDY P, 1991, CELL, V65, P349, DOI 10.1016/0092-8674(91)90168-X; REEDER RH, 1992, IN PRESS TRANSCRIPTI; SCHULTZ MC, 1991, P NATL ACAD SCI USA, V88, P1004, DOI 10.1073/pnas.88.3.1004; SENTENAC A, 1985, CRC CR REV BIOCH MOL, V18, P31, DOI 10.3109/10409238509082539; SIKORSKI RS, 1989, GENETICS, V122, P19; SIMMEN KA, 1991, EMBO J, V10, P1853, DOI 10.1002/j.1460-2075.1991.tb07711.x; STRUBIN M, 1992, CELL, V68, P721, DOI 10.1016/0092-8674(92)90147-5; ZAWEL L, 1992, IN PRESS PROGR NUCLE; ZHOU Q, 1991, EMBO J, V10, P1843, DOI 10.1002/j.1460-2075.1991.tb07710.x	30	198	199	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 15	1992	69	4					697	702		10.1016/0092-8674(92)90233-3	http://dx.doi.org/10.1016/0092-8674(92)90233-3			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HV089	1586948				2022-12-01	WOS:A1992HV08900014
J	SIMON, SM; BLOBEL, G				SIMON, SM; BLOBEL, G			SIGNAL PEPTIDES OPEN PROTEIN-CONDUCTING CHANNELS IN ESCHERICHIA-COLI	CELL			English	Article							SYNTHESIZING SECRETORY PROTEIN; ENDOPLASMIC-RETICULUM; ESCHERICHIA-COLI; RECOGNITION PARTICLE; PHOSPHOLIPID-VESICLES; NASCENT PREPROLACTIN; MICROSOMAL-MEMBRANES; PLANAR MEMBRANE; PLASMA-MEMBRANE; TRANSLOCATION	Plasma membrane vesicles and protoplasts of Escherichia coli were fused to planar lipid bilayers and studied with electrophysiological techniques. Large transmembrane aqueous channels were opened when 0.2 nM LamB signal peptide was added to the cytoplasmic side of the membrane. These aqueous pores are similar in conductance to those previously observed in mammalian endoplasmic reticulum when puromycin is used to release and thus unplug nascent translocating chains. Signal sequences have been previously shown to be necessary and sufficient for targeting proteins to cellular membranes. These results demonstrate that signal peptides are sufficient for opening the protein-conducting channels. We suggest that they are the physiological ligands that open protein-conducting channels at the initiation of protein translocation across prokaryotic plasma membrane and mammalian endoplasmic reticulum.	ROCKEFELLER UNIV, CELL BIOL LAB, NEW YORK, NY 10021 USA	Rockefeller University	SIMON, SM (corresponding author), ROCKEFELLER UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA.			Simon, Sanford/0000-0002-8615-4224	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047005] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM47005-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON K, 1991, J EXP MED, V174, P489, DOI 10.1084/jem.174.2.489; BIRDSELL DC, 1967, J BACTERIOL, V93, P427, DOI 10.1128/JB.93.1.427-437.1967; BLIGHT MA, 1990, MOL MICROBIOL, V4, P873, DOI 10.1111/j.1365-2958.1990.tb00660.x; BRIGGS MS, 1986, SCIENCE, V233, P206, DOI 10.1126/science.2941862; COBET WWE, 1989, J BIOL CHEM, V264, P10169; COHEN FS, 1989, J GEN PHYSIOL, V93, P201, DOI 10.1085/jgp.93.2.201; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; DIERSTEIN R, 1985, J BIOL CHEM, V260, P5919; EMR SD, 1983, P NATL ACAD SCI-BIOL, V80, P4599, DOI 10.1073/pnas.80.15.4599; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; FRANK G, 1978, FEBS LETT, V96, P183, DOI 10.1016/0014-5793(78)81090-4; FRIEDLANDER M, 1985, NATURE, V318, P338, DOI 10.1038/318338a0; GAROFF H, 1978, J MOL BIOL, V124, P587, DOI 10.1016/0022-2836(78)90173-0; GILMORE R, 1982, J CELL BIOL, V95, P463, DOI 10.1083/jcb.95.2.463; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GILSON L, 1990, EMBO J, V9, P3875, DOI 10.1002/j.1460-2075.1990.tb07606.x; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; JOSEFSSON LG, 1983, METHOD ENZYMOL, V97, P77; Kaback H., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; KILLIAN JA, 1990, EMBO J, V9, P815, DOI 10.1002/j.1460-2075.1990.tb08178.x; KORONAKIS V, 1989, EMBO J, V8, P595, DOI 10.1002/j.1460-2075.1989.tb03414.x; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; KURZCHALIA TV, 1986, NATURE, V320, P634, DOI 10.1038/320634a0; LUBBEN TH, 1987, SCIENCE, V238, P1112, DOI 10.1126/science.238.4830.1112; MEYER DI, 1980, J CELL BIOL, V87, P498, DOI 10.1083/jcb.87.2.498; MILLER C, 1976, J MEMBRANE BIOL, V30, P283, DOI 10.1007/BF01869673; MOSTOV KE, 1981, NATURE, V292, P87, DOI 10.1038/292087a0; MUELLER P, 1962, NATURE, V194, P979, DOI 10.1038/194979a0; MULLER M, 1984, P NATL ACAD SCI-BIOL, V81, P7421, DOI 10.1073/pnas.81.23.7421; NGUYEN M, 1987, J BIOL CHEM, V262, P3929; PARK SH, 1988, SCIENCE, V239, P1033, DOI 10.1126/science.3278378; RANDALL LL, 1989, SCIENCE, V243, P1156, DOI 10.1126/science.2646712; ROBERTS RB, 1963, STUDIES BIOSYNTHESIS; SHAW AS, 1988, P NATL ACAD SCI USA, V85, P7592, DOI 10.1073/pnas.85.20.7592; SIMON SM, 1989, P NATL ACAD SCI USA, V86, P6176, DOI 10.1073/pnas.86.16.6176; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; VONHEIJNE G, 1979, EUR J BIOCHEM, V97, P175; WALTER P, 1979, P NATL ACAD SCI USA, V76, P1795, DOI 10.1073/pnas.76.4.1795; WALTER P, 1981, J CELL BIOL, V91, P551, DOI 10.1083/jcb.91.2.551; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; WATANABE M, 1989, CELL, V58, P695, DOI 10.1016/0092-8674(89)90104-9; ZIMMERBERG J, 1980, J GEN PHYSIOL, V75, P241, DOI 10.1085/jgp.75.3.241; ZIMMERMANN R, 1990, BIOCHIMIE, V72, P95, DOI 10.1016/0300-9084(90)90134-3	43	199	201	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 15	1992	69	4					677	684		10.1016/0092-8674(92)90231-Z	http://dx.doi.org/10.1016/0092-8674(92)90231-Z			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HV089	1375130				2022-12-01	WOS:A1992HV08900012
J	VEGETO, E; ALLAN, GF; SCHRADER, WT; TSAI, MJ; MCDONNELL, DP; OMALLEY, BW				VEGETO, E; ALLAN, GF; SCHRADER, WT; TSAI, MJ; MCDONNELL, DP; OMALLEY, BW			THE MECHANISM OF RU486 ANTAGONISM IS DEPENDENT ON THE CONFORMATION OF THE CARBOXY-TERMINAL TAIL OF THE HUMAN PROGESTERONE-RECEPTOR	CELL			English	Article							HUMAN GLUCOCORTICOID RECEPTOR; TRANSCRIPTIONAL ACTIVATION FUNCTIONS; CELL-FREE TRANSCRIPTION; HUMAN ESTROGEN-RECEPTOR; STEROID BINDING DOMAIN; DNA-BINDING; SACCHAROMYCES-CEREVISIAE; MONOCLONAL-ANTIBODIES; RESPONSIVE ELEMENT; HORMONE RECEPTORS	The human progesterone receptor form B (hPR-B) was expressed in Saccharomyces cerevisiae together with a specific reporter plasmid. To understand the mechanism underlying antagonist ligand activity, libraries of hormone binding domain (HBD)-mutated hPR-B molecules were prepared. A mutant receptor was identified that had lost the ability to bind either progesterone or R5020; it could still bind RU486 and, surprisingly, fully activated transcription in the presence of this "antagonist" and other antiprogestins. When this receptor mutant was assayed in mammalian cells, RU486 again demonstrated agonistic activity. Sequence analysis indicated that the mutant phenotype was due to truncation of the carboxy (C)-terminal 42 aa. We conclude that amino acids in the extreme C-terminal region are required for the receptor to bind progesterone, while antagonists bind to a site located more N-terminal of the HBD. Our results suggest that the extreme C-terminal region of the receptor contains an inhibitory function that silences receptor transactivation in the absence of agonist and in the presence of antagonist.			VEGETO, E (corresponding author), BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030, USA.							BAGCHI MK, 1990, NATURE, V345, P547, DOI 10.1038/345547a0; BAGCHI MK, 1988, MOL ENDOCRINOL, V2, P1221, DOI 10.1210/mend-2-12-1221; BAGCHI MK, 1991, MOL CELL BIOL, V11, P4998, DOI 10.1128/MCB.11.10.4998; BAGCHI MK, 1992, IN PRESS P NATL ACAD; BAKKER GH, 1990, J STEROID BIOCHEM, V37, P789, DOI 10.1016/0960-0760(90)90421-G; BAULIEU EE, 1987, J CELL BIOCHEM, V35, P161, DOI 10.1002/jcb.240350209; BAULIEU EE, 1989, SCIENCE, V245, P1351, DOI 10.1126/science.2781282; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BECKER PB, 1986, NATURE, V324, P686, DOI 10.1038/324686a0; BENHAMOU B, 1992, SCIENCE, V255, P206, DOI 10.1126/science.1372753; BOCQUEL MT, 1989, NUCLEIC ACIDS RES, V17, P2581, DOI 10.1093/nar/17.7.2581; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARSON MA, 1987, MOL ENDOCRINOL, V1, P791, DOI 10.1210/mend-1-11-791; CARSONJURICA MA, 1990, ENDOCR REV, V11, P201, DOI 10.1210/edrv-11-2-201; CATO ACB, 1986, EMBO J, V5, P2237, DOI 10.1002/j.1460-2075.1986.tb04490.x; CHAO CC, 1991, CANCER RES, V51, P3938; CHRISTENSEN K, 1991, MOL ENDOCRINOL, V5, P1755, DOI 10.1210/mend-5-11-1755; DALMAN FC, 1991, J BIOL CHEM, V266, P3482; DENIS M, 1988, NATURE, V333, P686, DOI 10.1038/333686a0; DENNER LA, 1990, SCIENCE, V250, P1740, DOI 10.1126/science.2176746; DOBSON ADW, 1989, J BIOL CHEM, V264, P4207; ECKERT KA, 1990, NUCLEIC ACIDS RES, V18, P3739, DOI 10.1093/nar/18.13.3739; ELASHRY D, 1989, MOL ENDOCRINOL, V3, P1545, DOI 10.1210/mend-3-10-1545; ESTES PA, 1987, BIOCHEMISTRY-US, V26, P6250, DOI 10.1021/bi00393a045; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GREEN S, 1987, NATURE, V325, P75, DOI 10.1038/325075a0; GROYER A, 1987, NATURE, V328, P624, DOI 10.1038/328624a0; GUIOCHONMANTEL A, 1988, NATURE, V336, P695, DOI 10.1038/336695a0; GUIOCHONMANTEL A, 1989, CELL, V57, P1147, DOI 10.1016/0092-8674(89)90052-4; HOLLENBERG SM, 1987, CELL, V49, P39, DOI 10.1016/0092-8674(87)90753-7; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; HORWITZ KB, 1985, ENDOCRINOLOGY, V116, P2236, DOI 10.1210/endo-116-6-2236; HOWARD KJ, 1990, J BIOL CHEM, V265, P11928; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KLEINHITPASS L, 1990, CELL, V60, P247, DOI 10.1016/0092-8674(90)90740-6; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LECH K, 1988, CELL, V52, P179, DOI 10.1016/0092-8674(88)90506-5; LERNER CG, 1990, J BIOL CHEM, V265, P20085; MAK P, 1989, J BIOL CHEM, V264, P21613; MARTINEZ E, 1987, EMBO J, V6, P3719, DOI 10.1002/j.1460-2075.1987.tb02706.x; MCDONNELL DP, 1991, J STEROID BIOCHEM, V39, P291, DOI 10.1016/0960-0760(91)90038-7; MCDONNELL DP, 1989, MOL ENDOCRINOL, V3, P635, DOI 10.1210/mend-3-4-635; MCDONNELL DP, 1989, MOL CELL BIOL, V9, P3517, DOI 10.1128/MCB.9.8.3517; MCDONNELL DP, 1991, MOL CELL BIOL, V11, P4350, DOI 10.1128/MCB.11.9.4350; METZGER D, 1988, NATURE, V334, P31, DOI 10.1038/334031a0; MEYER ME, 1990, EMBO J, V9, P3923, DOI 10.1002/j.1460-2075.1990.tb07613.x; Miller, 1972, EXPT MOL GENETICS; MISRAHI M, 1987, BIOCHEM BIOPH RES CO, V143, P740, DOI 10.1016/0006-291X(87)91416-1; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; PHILIBERT D, 1984, ADRENAL STEROID ANTA, P77; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; PRATT WB, 1988, J BIOL CHEM, V263, P267; PRIVALSKY ML, 1990, CELL, V63, P1277, DOI 10.1016/0092-8674(90)90423-C; SCHENA M, 1989, GENE DEV, V3, P1590, DOI 10.1101/gad.3.10.1590; SCHENA M, 1988, SCIENCE, V241, P965, DOI 10.1126/science.3043665; SCHNEIDER MR, 1990, J STEROID BIOCHEM, V37, P783, DOI 10.1016/0960-0760(90)90420-P; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; STRAHLE U, 1987, P NATL ACAD SCI USA, V84, P7871, DOI 10.1073/pnas.84.22.7871; SULLIVAN WP, 1986, ENDOCRINOLOGY, V119, P1549, DOI 10.1210/endo-119-4-1549; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TSAI SY, 1989, CELL, V57, P443, DOI 10.1016/0092-8674(89)90919-7; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; WARD AC, 1990, NUCLEIC ACIDS RES, V18, P5319, DOI 10.1093/nar/18.17.5319; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WILLMANN T, 1986, NATURE, V324, P688, DOI 10.1038/324688a0	68	352	371	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 15	1992	69	4					703	713		10.1016/0092-8674(92)90234-4	http://dx.doi.org/10.1016/0092-8674(92)90234-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HV089	1586949				2022-12-01	WOS:A1992HV08900015
J	WANG, L; HELMANN, JD; WINANS, SC				WANG, L; HELMANN, JD; WINANS, SC			THE A-TUMEFACIENS TRANSCRIPTIONAL ACTIVATOR OCCR CAUSES A BEND AT A TARGET PROMOTER, WHICH IS PARTIALLY RELAXED BY A PLANT TUMOR METABOLITE	CELL			English	Article							AGROBACTERIUM TI-PLASMID; ESCHERICHIA-COLI; RNA-POLYMERASE; REGULATORY PROTEINS; BINDING-SPECIFICITY; INDUCIBLE GENES; DNA; SEQUENCE; ORGANIZATION; FAMILY	Octopine is released from crown gall tumors as a nutrient source and a signal molecule for the plant pathogen Agrobacterium tumefaciens. Some or all octopine-inducible genes are regulated by a protein called OccR. Primer extension analysis showed that OccR protein represses the occR gene and both represses and activates the occQ operon, which is divergently transcribed from occR. These promoters initiate transcription 46 bp apart. This regulatory system was reconstituted in vitro using purified OccR protein and Escherichia coli RNA polymerase. OccR binds with high affinity to a single site overlapping these promoters. Octopine shortens the DNAase I footprint of OccR and increases the gel mobility of OccR-DNA complexes by relaxing an OccR-incited DNA bend.			WANG, L (corresponding author), CORNELL UNIV,MICROBIOL SECT,ITHACA,NY 14853, USA.			Helmann, John/0000-0002-3832-3249	NIGMS NIH HHS [1 R29 GM2893-01] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANSARI AZ, 1992, NATURE, V355, P87, DOI 10.1038/355087a0; BERG OG, 1988, J MOL BIOL, V200, P709, DOI 10.1016/0022-2836(88)90482-2; BINNS AN, 1988, ANNU REV MICROBIOL, V42, P575, DOI 10.1146/annurev.mi.42.100188.003043; BRACCO L, 1989, EMBO J, V8, P4289, DOI 10.1002/j.1460-2075.1989.tb08615.x; BRENNAN RG, 1989, J BIOL CHEM, V264, P903; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; CHANG M, 1991, J BACTERIOL, V173, P1590, DOI 10.1128/jb.173.5.1590-1597.1991; CHRISTMAN MF, 1989, P NATL ACAD SCI USA, V86, P3484, DOI 10.1073/pnas.86.10.3484; CHUNG YT, 1990, MOL CELL BIOL, V10, P206, DOI 10.1128/MCB.10.1.206; DEGREVE H, 1981, PLASMID, V6, P235, DOI 10.1016/0147-619X(81)90069-X; DESSAUX Y, 1987, MOL GEN GENET, V208, P301, DOI 10.1007/BF00330457; DEVOS G, 1981, PLASMID, V6, P249, DOI 10.1016/0147-619X(81)90070-6; ECKERT RL, 1987, CURRENT PROTOCOLS MO; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GARTENBERG MR, 1990, P NATL ACAD SCI USA, V87, P6034, DOI 10.1073/pnas.87.16.6034; GONZALEZ N, 1977, ARCH BIOCHEM BIOPHYS, V182, P404, DOI 10.1016/0003-9861(77)90521-5; GRAYHACK EJ, 1985, CELL, V42, P259, DOI 10.1016/S0092-8674(85)80121-5; HABEEB LF, 1991, MOL PLANT MICROBE IN, V4, P379, DOI 10.1094/MPMI-4-379; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.biochem.59.1.933; HELMANN JD, 1989, J BACTERIOL, V171, P222, DOI 10.1128/jb.171.1.222-229.1989; HENIKOFF S, 1988, P NATL ACAD SCI USA, V85, P6602, DOI 10.1073/pnas.85.18.6602; HO YS, 1983, NATURE, V304, P703, DOI 10.1038/304703a0; HONG GF, 1987, NUCLEIC ACIDS RES, V15, P9677, DOI 10.1093/nar/15.23.9677; HRYNIEWICZ MM, 1991, J BACTERIOL, V173, P5876, DOI 10.1128/jb.173.18.5876-5886.1991; HUANG MW, 1990, J BACTERIOL, V172, P1814, DOI 10.1128/jb.172.4.1814-1822.1990; Innis M. A., 1990, PCR PROTOCOLS GUIDE, P3; JIN SG, 1990, J BACTERIOL, V172, P531, DOI 10.1128/jb.172.2.531-537.1990; KADO CI, 1991, CRIT REV PLANT SCI, V10, P1, DOI 10.1080/07352680490273310; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; KERPPOLA TK, 1991, NATURE, V254, P1210; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; KINGSTON RE, 1987, CURRENT PROTOCOLS MO; KLAPWIJK PM, 1979, J BACTERIOL, V141, P424; KNAUF VC, 1982, PLASMID, V8, P45, DOI 10.1016/0147-619X(82)90040-3; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEROUX B, 1987, EMBO J, V6, P849, DOI 10.1002/j.1460-2075.1987.tb04830.x; LOBELL RB, 1990, SCIENCE, V250, P528, DOI 10.1126/science.2237403; MAXON ME, 1990, P NATL ACAD SCI USA, V87, P7076, DOI 10.1073/pnas.87.18.7076; OHALLORAN TV, 1989, CELL, V56, P119, DOI 10.1016/0092-8674(89)90990-2; REAM W, 1989, ANNU REV PHYTOPATHOL, V27, P583, DOI 10.1146/annurev.py.27.090189.003055; ROJO F, 1990, J MOL BIOL, V211, P713, DOI 10.1016/0022-2836(90)90072-T; ROTHMEL RK, 1991, J BACTERIOL, V173, P4717, DOI 10.1128/jb.173.15.4717-4724.1991; SCHELL MA, 1989, J BACTERIOL, V171, P1952, DOI 10.1128/jb.171.4.1952-1959.1989; SCHINDLER U, 1989, J BACTERIOL, V171, P847, DOI 10.1128/jb.171.2.847-854.1989; SCHRODER J, 1990, 5TH INT S MOL GEN PL, P52; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; STACHEL SE, 1986, EMBO J, V5, P1445, DOI 10.1002/j.1460-2075.1986.tb04381.x; STACHEL SE, 1985, EMBO J, V4, P891, DOI 10.1002/j.1460-2075.1985.tb03715.x; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; STRAGIER P, 1983, J MOL BIOL, V168, P333, DOI 10.1016/S0022-2836(83)80022-9; SUMMERS WC, 1970, ANAL BIOCHEM, V33, P459; TABATA S, 1989, J BACTERIOL, V171, P1665, DOI 10.1128/jb.171.3.1665-1672.1989; TEMPE J, 1982, MOL BIOL PLANT TUMOR, P00451, DOI DOI 10.1016/B978-0-12-394380-4.50022-0; Tempe J, 1982, MOL BIOL PLANT TUMOR, P427, DOI [10.1016/B978-0-12-394380-4.50021-9, DOI 10.1016/B978-0-12-394380-4.50021-9]; THOMASHOW MF, 1980, CELL, V19, P729, DOI 10.1016/S0092-8674(80)80049-3; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; VALDIVIA RH, 1991, J BACTERIOL, V173, P6398, DOI 10.1128/jb.173.20.6398-6405.1991; VONBODMAN SB, 1992, P NATL ACAD SCI USA, V89, P643, DOI 10.1073/pnas.89.2.643; VONLINTIG J, 1991, MOL PLANT MICROBE IN, V4, P370, DOI 10.1094/MPMI-4-370; WINANS SC, 1986, P NATL ACAD SCI USA, V83, P8278, DOI 10.1073/pnas.83.21.8278; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; ZAMBRYSKI P, 1989, CELL, V56, P193, DOI 10.1016/0092-8674(89)90892-1; ZAMBRYSKI P, 1988, ANNU REV GENET, V22, P1, DOI 10.1146/annurev.ge.22.120188.000245; ZAMBRYSKI P, 1989, MOBILE DNA, P309; ZWEIB C, 1989, GENE DEV, V3, P606; ZWIEB C, 1990, NUCLEIC ACIDS RES, V18, P583, DOI 10.1093/nar/18.3.583	69	118	122	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 15	1992	69	4					659	667		10.1016/0092-8674(92)90229-6	http://dx.doi.org/10.1016/0092-8674(92)90229-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HV089	1586946				2022-12-01	WOS:A1992HV08900010
J	BELL, SP; STILLMAN, B				BELL, SP; STILLMAN, B			ATP-DEPENDENT RECOGNITION OF EUKARYOTIC ORIGINS OF DNA-REPLICATION BY A MULTIPROTEIN COMPLEX	NATURE			English	Article							ESCHERICHIA-COLI CHROMOSOME; SACCHAROMYCES-CEREVISIAE; BINDING-PROTEINS; T-ANTIGEN; YEAST; INVITRO; PURIFICATION; INITIATION; SEQUENCE; PLASMIDS	A multiprotein complex that specifically recognizes cellular origins of DNA replication has been identified and purified from the yeast Saccharomyces cerevisiae. We observe a strong correlation between origin function and origin recognition by this activity. Interestingly, specific DNA binding by the origin recognition complex is dependent upon the addition of ATP. We propose that the origin recognition complex acts as the initiator protein for S. cerevisiae origins of DNA replication.			BELL, SP (corresponding author), COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA.			Stillman, Bruce/0000-0002-9453-4091; Bell, Stephen/0000-0002-2876-610X				BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BOUTON AH, 1986, MOL CELL BIOL, V6, P2354, DOI 10.1128/MCB.6.7.2354; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BROACH JR, 1982, COLD SPRING HARB SYM, V47, P1165, DOI 10.1101/SQB.1983.047.01.132; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P210, DOI 10.1128/MCB.8.1.210; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P8981, DOI 10.1073/pnas.84.24.8981; DEB SP, 1987, J VIROL, V61, P3649, DOI 10.1128/JVI.61.12.3649-3654.1987; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DIFFLEY JFX, 1988, P NATL ACAD SCI USA, V85, P2120, DOI 10.1073/pnas.85.7.2120; DODSON M, 1985, P NATL ACAD SCI USA, V82, P4678, DOI 10.1073/pnas.82.14.4678; DUBEY DD, 1991, MOL CELL BIOL, V11, P5346, DOI 10.1128/MCB.11.10.5346; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; FUNNELL BE, 1987, J BIOL CHEM, V262, P10327; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; HOFMANN JFX, 1991, CELL, V64, P951, DOI 10.1016/0092-8674(91)90319-T; HOLMES SG, 1989, MOL CELL BIOL, V9, P5464, DOI 10.1128/MCB.9.12.5464; HUBERMAN JA, 1988, NUCLEIC ACIDS RES, V16, P6373, DOI 10.1093/nar/16.14.6373; HUBERMAN JA, 1987, CELL, V51, P473, DOI 10.1016/0092-8674(87)90643-X; JACOB F, 1963, COLD SPRING HARB SYM, V28, P329, DOI 10.1101/SQB.1963.028.01.048; JAZWINSKI SM, 1982, P NATL ACAD SCI-BIOL, V79, P3428, DOI 10.1073/pnas.79.11.3428; JAZWINSKI SM, 1984, J BIOL CHEM, V259, P6852; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KORNBERG A, 1992, DNA REPLICATION, P1; KUNO K, 1990, GENE, V95, P73, DOI 10.1016/0378-1119(90)90415-N; KUSTU S, 1989, MICROBIOL REV, V53, P367, DOI 10.1128/MMBR.53.3.367-376.1989; LINSKENS MHK, 1990, CELL, V62, P845, DOI 10.1016/0092-8674(90)90258-G; LORIMER HE, 1991, J VIROL, V65, P687, DOI 10.1128/JVI.65.2.687-699.1991; LUE NF, 1987, P NATL ACAD SCI USA, V84, P8839, DOI 10.1073/pnas.84.24.8839; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; NEWLON CS, 1988, MICROBIOL REV, V52, P568, DOI 10.1128/MMBR.52.4.568-601.1988; PALZKILL TG, 1988, CELL, V37, P299; SCHMIDT AMA, 1991, EMBO J, V10, P981, DOI 10.1002/j.1460-2075.1991.tb08032.x; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7136; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7124; SHORE D, 1987, EMBO J, V6, P461, DOI 10.1002/j.1460-2075.1987.tb04776.x; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; STINCHCOMB DT, 1979, NATURE, V282, P39, DOI 10.1038/282039a0; SWEDER KS, 1988, J BIOL CHEM, V263, P17270; TRAVERS AA, 1987, PHILOS T ROY SOC B, V317, P537, DOI 10.1098/rstb.1987.0080; WALKER SS, 1991, NUCLEIC ACIDS RES, V19, P6255, DOI 10.1093/nar/19.22.6255; WALKER SS, 1990, P NATL ACAD SCI USA, V87, P4665, DOI 10.1073/pnas.87.12.4665; WEISS DS, 1991, CELL, V67, P155, DOI 10.1016/0092-8674(91)90579-N; YANG L, 1991, NATURE, V353, P628, DOI 10.1038/353628a0	46	1019	1037	2	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 14	1992	357	6374					128	134		10.1038/357128a0	http://dx.doi.org/10.1038/357128a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU122	1579162				2022-12-01	WOS:A1992HU12200048
J	DIFFLEY, JFX; COCKER, JH				DIFFLEY, JFX; COCKER, JH			PROTEIN DNA INTERACTIONS AT A YEAST REPLICATION ORIGIN	NATURE			English	Article							NUCLEASE-SENSITIVE REGIONS; SACCHAROMYCES-CEREVISIAE; CHROMATIN; ARS1; PURIFICATION; INITIATION; SEQUENCES; SILENCER	AN understanding of the protein-DNA interactions in vivo at origins of DNA replication in eukaryotes is essential to delineate the mechanism of initiation of DNA synthesis and its control in the cell cycle 1,2. In the yeast Saccharomyces cerevisiae, a family of sequences known as autonomously replicating sequences (ARSs) function as origins of bidirectional DNA replication on plasmids and, in several instances, also in their normal chromosomal location 3. Here we use nucleotide resolution genomic footprinting to investigate the association of proteins with ARS1. Nuclease protection patterns indicate that at least two different cellular factors interact with functional elements in ARS1. The first seems to be ARS-binding factor 1. The second seems to be a novel protein that generates extensive protection over the essential ARS consensus sequence and phased DNaseI-sensitive sites across a functionally important flanking sequence. Hypersensitivity of this region to cleavage by copper phenanthroline indicates that it is under torsional strain, analogous to that produced at transcriptional start sites by assembly of an initiation complex. The protection in situ is similar to that generated by the origin recognition complex (ORC) protein.			DIFFLEY, JFX (corresponding author), IMPERIAL CANC RES FUND, BLANCHE LANE, POTTERS BAR EN6 3LD, HERTS, ENGLAND.			Diffley, John/0000-0001-5184-7680				BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BOROWIEC JA, 1988, EMBO J, V7, P3149, DOI 10.1002/j.1460-2075.1988.tb03182.x; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P210, DOI 10.1128/MCB.8.1.210; BURATOWSKI S, 1991, P NATL ACAD SCI USA, V88, P7509, DOI 10.1073/pnas.88.17.7509; CAMPBELL JL, IN PRESS MOL BIOL YE; CELNIKER SE, 1984, MOL CELL BIOL, V4, P2455, DOI 10.1128/MCB.4.11.2455; DIFFLEY JFX, 1991, P NATL ACAD SCI USA, V88, P7864, DOI 10.1073/pnas.88.17.7864; DIFFLEY JFX, 1988, P NATL ACAD SCI USA, V85, P2120, DOI 10.1073/pnas.85.7.2120; DIFFLEY JFX, 1990, TRENDS GENET, V6, P426; FANGMAN WL, 1991, ANNU REV CELL BIOL, V7, P375, DOI 10.1146/annurev.cb.07.110191.002111; HOFMANN JFX, 1991, CELL, V64, P951, DOI 10.1016/0092-8674(91)90319-T; HUIBREGTSE JM, 1991, METHOD ENZYMOL, V194, P550; KATAOKA T, 1984, CELL, V37, P437, DOI 10.1016/0092-8674(84)90374-X; KUNO K, 1990, GENE, V95, P73, DOI 10.1016/0378-1119(90)90415-N; LOHR D, 1988, BIOCHEMISTRY-US, V27, P3961, DOI 10.1021/bi00411a011; LONG CM, 1985, MOL CELL BIOL, V5, P3124, DOI 10.1128/MCB.5.11.3124; LOWNDES NF, 1991, NATURE, V350, P247, DOI 10.1038/350247a0; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; Sambrook J., 1989, MOL CLONING LAB MANU; SAWODOGO M, 1985, R G CELL, V43, P165; SCHMIDT AMA, 1991, EMBO J, V10, P981, DOI 10.1002/j.1460-2075.1991.tb08032.x; SCHNOS M, 1988, CELL, V52, P385, DOI 10.1016/S0092-8674(88)80031-X; SHORE D, 1987, EMBO J, V6, P461, DOI 10.1002/j.1460-2075.1987.tb04776.x; SIGMAN DS, 1990, BIOCHEMISTRY-US, V29, P9097, DOI 10.1021/bi00491a001; SIMPSON RT, 1990, NATURE, V343, P387, DOI 10.1038/343387a0; STINCHCOMB DT, 1979, NATURE, V282, P39, DOI 10.1038/282039a0; SWEDER KS, 1988, J BIOL CHEM, V263, P17270; THOMA F, 1986, J MOL BIOL, V190, P177, DOI 10.1016/0022-2836(86)90291-3; THOMA F, 1984, J MOL BIOL, V177, P715, DOI 10.1016/0022-2836(84)90046-9; van Holde K.E., 1989, CHROMATIN; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; [No title captured]	33	321	324	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 14	1992	357	6374					169	172		10.1038/357169a0	http://dx.doi.org/10.1038/357169a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU122	1579168				2022-12-01	WOS:A1992HU12200062
J	GUTNIAK, M; ORSKOV, C; HOLST, JJ; AHREN, B; EFENDIC, S				GUTNIAK, M; ORSKOV, C; HOLST, JJ; AHREN, B; EFENDIC, S			ANTIDIABETOGENIC EFFECT OF GLUCAGON-LIKE PEPTIDE-1 (7-36)AMIDE IN NORMAL SUBJECTS AND PATIENTS WITH DIABETES-MELLITUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PERFUSED RAT PANCREAS; SECONDARY FAILURE; INCRETIN CONCEPT; HUMAN-PLASMA; INSULIN; GLUCOSE; SOMATOSTATIN; RELEASE; RADIOIMMUNOASSAY; PROGLUCAGON	Background. Glucagon-like peptide-1 (7-36) amide (glucagon-like insulinotropic peptide, or GLIP) is a gastrointestinal peptide that potentiates the release of insulin in physiologic concentrations. Its effects in patients with diabetes mellitus are not known. Methods. We compared the effect of an infusion of GLIP that raised plasma concentrations of GLIP twofold with the effect of an infusion of saline, on the meal-related release of insulin, glucagon, and somatostatin in eight normal subjects, nine obese patients with non-insulin-dependent diabetes mellitus (NIDDM), and eight patients with insulin-dependent diabetes mellitus (IDDM). The blood glucose concentrations in the patients with diabetes were controlled by a closed-loop insulin-infusion system (artificial pancreas) during the infusion of each agent, allowing measurement of the meal-related requirement for exogenous insulin. In the patients with IDDM, normoglycemic-clamp studies were performed during the infusions of GLIP and saline to determine the effect of GLIP on insulin sensitivity. Results. In the normal subjects, the infusion of GLIP significantly lowered the meal-related increases in the blood glucose concentration (P < 0.01) and the plasma concentrations of insulin and glucagon (P < 0.05 for both comparisons). The insulinogenic index (the ratio of insulin to glucose) increased almost 10-fold, indicating that GLIP had an insulinotropic effect. In the patients with NIDDM, the infusion of GLIP reduced the mean (+/- SE) calculated isoglycemic meal-related requirement for insulin from 17.4 +/- 2.8 to 2.0 +/- 0.5 U (P < 0.001), so that the integrated area under the curve for plasma free insulin was decreased (P < 0.05) in spite of the stimulation of insulin release. In the patients with IDDM, the GLIP infusion decreased the calculated isoglycemic meal-related insulin requirement from 9.4 +/- 1.5 to 4.7 +/- 1.4 U. The peptide decreased glucagon and somatostatin release in both groups of patients. In the normoglycemic-clamp studies in the patients with IDDM, the GLIP infusion significantly increased glucose utilization (saline vs. GLIP, 7.2 +/- 0.5 vs. 8.6 +/- 0.4 mg per kilogram of body weight per minute; P < 0.01). Conclusions. GLIP has an antidiabetogenic effect, and it may therefore be useful in the treatment of patients with NIDDM.	UNIV COPENHAGEN,PANUM INST,INST MED PHYSIOL C,DEPT ENDOCRINOL,DK-2200 COPENHAGEN,DENMARK; UNIV LUND,DEPT PHARMACOL,S-22101 LUND,SWEDEN	University of Copenhagen; Lund University	GUTNIAK, M (corresponding author), KAROLINSKA INST,KAROLINSKA SJUKHUSET,DEPT ENDOCRINOL,BOX 60500,S-10401 STOCKHOLM 60,SWEDEN.		Holst, Jens/AAA-8022-2022	Holst, Jens Juul/0000-0001-6853-3805; Orskov, Cathrine/0000-0002-7762-2372				ARIMURA A, 1978, METABOLISM, V27, P1139, DOI 10.1016/0026-0495(78)90032-X; BROWN JC, 1979, CLIN ENDOCRINOL META, V8, P365, DOI 10.1016/S0300-595X(79)80047-X; CONLON JM, 1988, DIABETOLOGIA, V31, P563, DOI 10.1007/BF00264761; CREUTZFELDT W, 1985, DIABETOLOGIA, V28, P565, DOI 10.1007/BF00281990; CREUTZFELDT W, 1979, DIABETOLOGIA, V16, P75, DOI 10.1007/BF01225454; DEFRONZO RA, 1982, DIABETOLOGIA, V23, P313; DRUCKER DJ, 1990, PANCREAS, V5, P484, DOI 10.1097/00006676-199007000-00018; EBERT R, 1979, GASTROENTEROLOGY, V76, P515; EFENDIC S, 1978, FEBS LETT, V92, P33, DOI 10.1016/0014-5793(78)80715-7; EFENDIC S, 1980, FRONTIERS HORMONE RE, V7, P41; FALOONA GR, 1974, METHOD HORM RADIOIMM, P317; FEHMANN HC, 1991, FEBS LETT, V279, P335, DOI 10.1016/0014-5793(91)80182-3; FINEGOOD DT, 1988, DIABETES, V37, P1025, DOI 10.2337/diabetes.37.8.1025; GENNARO WD, 1975, CLIN CHEM, V21, P873; GUTNIAK M, 1987, DIABETES, V36, P802, DOI 10.2337/diabetes.36.7.802; GUTNIAK M, 1987, DIABETES CARE, V10, P545, DOI 10.2337/diacare.10.5.545; GUTNIAK M, 1990, AM J PHYSIOL, V258, pE805, DOI 10.1152/ajpendo.1990.258.5.E805; HANSEN IL, 1985, DIABETES, V34, P751, DOI 10.2337/diabetes.34.8.751; HOLST JJ, 1987, FEBS LETT, V211, P169, DOI 10.1016/0014-5793(87)81430-8; HUGGETT ASG, 1957, LANCET, V2, P368; JOHANSSON C, 1981, DIGESTION, V22, P126, DOI 10.1159/000198619; KREJS GJ, 1980, GASTROENTEROLOGY, V78, P26; KREYMANN B, 1987, LANCET, V2, P1300; LABARRE J, 1930, AM J PHYSIOL, V91, P649; Lebovitz H E, 1978, Diabetes Care, V1, P189; MILLER LL, 1960, NATURE, V185, P248, DOI 10.1038/185248a0; MOJSOV S, 1987, J CLIN INVEST, V79, P616, DOI 10.1172/JCI112855; Moore B, 1906, BIOCHEM J, V1, P28, DOI 10.1042/bj0010028; ORSKOV C, 1987, DIABETOLOGIA, V30, P874; ORSKOV C, 1989, J BIOL CHEM, V264, P12826; ORSKOV C, 1988, ENDOCRINOLOGY, V123, P2009, DOI 10.1210/endo-123-4-2009; ORSKOV C, 1991, J CLIN INVEST, V87, P415, DOI 10.1172/JCI115012; PENMAN E, 1979, ANN CLIN BIOCHEM, V16, P15, DOI 10.1177/000456327901600103; POLONSKY KS, 1984, DIABETES, V33, P486, DOI 10.2337/diabetes.33.5.486; ROBERTSON DA, 1988, BAILLIERE CLIN ENDOC, V2, P407, DOI 10.1016/S0950-351X(88)80040-5; SARSON DL, 1984, DIABETES, V33, P389, DOI 10.2337/diabetes.33.4.389; SCHEEN AJ, 1989, DIABETES RES CLIN PR, V6, pS33, DOI 10.1016/0168-8227(89)90076-4; SIMON M, 1982, CLIN CHEM, V28, P9; SUTHERLAND EW, 1960, PHARMACOL REV, V12, P265; SUZUKI S, 1989, ENDOCRINOLOGY, V125, P3109, DOI 10.1210/endo-125-6-3109; TAKAHASHI H, 1990, BIOMED RES-TOKYO, V11, P99, DOI 10.2220/biomedres.11.99; VERDONK CA, 1980, HORM METAB RES, V12, P133, DOI 10.1055/s-2007-996224; WETTERGREN A, 1990, Digestion, V46, P120; 1979, DIABETES, V28, P1039	44	799	950	1	24	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 14	1992	326	20					1316	1322		10.1056/NEJM199205143262003	http://dx.doi.org/10.1056/NEJM199205143262003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT803	1348845				2022-12-01	WOS:A1992HT80300003
J	IRVING, M; LOMBARDI, V; PIAZZESI, G; FERENCZI, MA				IRVING, M; LOMBARDI, V; PIAZZESI, G; FERENCZI, MA			MYOSIN HEAD MOVEMENTS ARE SYNCHRONOUS WITH THE ELEMENTARY FORCE-GENERATING PROCESS IN MUSCLE	NATURE			English	Article							STRIATED-MUSCLE; MECHANISM; FIBERS; HYDROLYSIS; ACTOMYOSIN; LENGTH; ACTIN	MOTOR proteins such as myosin, dynein and kinesin use the free energy of ATP hydrolysis to produce force or motion, but despite recent progress 1-4 their molecular mechanism is unknown. The best characterized system is the myosin motor which moves actin filaments in muscle 5-12. When an active muscle fibre is rapidly shortened the force first decreases, then partially recovers over the next few milliseconds 5. This elementary force-generating process is thought to be due to a structural 'working stroke' in the myosin head domain 5-9, although structural studies have not provided definitive support for this 10-12. X-ray diffraction has shown that shortening steps produce a large decrease in the intensity of the 14.5 nm reflection arising from the axial repeat of the myosin heads along the filaments 13,14 . This was interpreted as a structural change at the end of the working stroke, but the techniques then available did not allow temporal resolution of the elementary force-generating process itself. Using improved measurement techniques, we show here that myosin heads move by about 10 nm with the same time course as the elementary force-generating process.	UNIV FLORENCE,DIPARTIMENTO SCI FISIOL,I-50134 FLORENCE,ITALY; NATL INST MED RES,LONDON NW7 1AA,ENGLAND	University of Florence; MRC National Institute for Medical Research	IRVING, M (corresponding author), UNIV LONDON KINGS COLL,DEPT BIOPHYS CELL & MOLEC BIOL,26-29 DRURY LANE,LONDON WC2B 5RL,ENGLAND.		Ferenczi, Michael/F-9510-2015	Ferenczi, Michael/0000-0002-0349-331X				BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; Cecchi G, 1976, Boll Soc Ital Biol Sper, V52, P733; COOKE R, 1986, CRIT REV BIOCHEM MOL, V21, P53, DOI 10.3109/10409238609113609; FORD LE, 1977, J PHYSIOL-LONDON, V269, P441, DOI 10.1113/jphysiol.1977.sp011911; FORD LE, 1981, J PHYSIOL-LONDON, V311, P219, DOI 10.1113/jphysiol.1981.sp013582; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; HUXLEY AF, 1957, PROG BIOPHYS MOL BIO, V7, P255, DOI 10.1016/S0096-4174(18)30128-8; HUXLEY AF, 1981, J PHYSIOL-LONDON, V317, pP12; HUXLEY AF, 1980, J PHYSIOL-LONDON, V305, pP15; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HUXLEY HE, 1990, J BIOL CHEM, V265, P8347; HUXLEY HE, 1983, J MOL BIOL, V169, P469, DOI 10.1016/S0022-2836(83)80062-X; HUXLEY HE, 1982, J MOL BIOL, V158, P637, DOI 10.1016/0022-2836(82)90253-4; HUXLEY HE, 1969, SCIENCE, V164, P1356, DOI 10.1126/science.164.3886.1356; IRVING M, 1991, NATURE, V352, P284, DOI 10.1038/352284a0; IRVING M, 1987, FIBROUS PROTEIN STRU, P495; ISHIJIMA A, 1991, NATURE, V352, P301, DOI 10.1038/352301a0; KUSHMERICK MJ, 1969, PROC R SOC SER B-BIO, V174, P315, DOI 10.1098/rspb.1969.0096; LOMBARDI V, 1990, J PHYSIOL-LONDON, V431, P141, DOI 10.1113/jphysiol.1990.sp018324; LOMBARDI V, 1992, NATURE, V355, P638, DOI 10.1038/355638a0; LYMN RW, 1971, BIOCHEMISTRY-US, V10, P4617, DOI 10.1021/bi00801a004; MATSUBARA I, 1985, J PHYSIOL-LONDON, V361, P151, DOI 10.1113/jphysiol.1985.sp015638; PIAZZESI G, 1992, J PHYSIOL-LONDON, V445, P659, DOI 10.1113/jphysiol.1992.sp018945; REEDY MK, 1965, NATURE, V207, P1276, DOI 10.1038/2071276a0; SCHROER TA, 1989, CELL, V56, P937, DOI 10.1016/0092-8674(89)90627-2; THOMAS DD, 1987, ANNU REV PHYSIOL, V49, P691, DOI 10.1146/annurev.ph.49.030187.003355; TOWNSANDREWS E, 1989, REV SCI INSTRUM, V60, P2346, DOI 10.1063/1.1140765; UYEDA TQP, 1991, NATURE, V352, P307, DOI 10.1038/352307a0; UYEDA TQP, 1990, J MOL BIOL, V214, P699, DOI 10.1016/0022-2836(90)90287-V; YANAGIDA T, 1985, NATURE, V316, P366, DOI 10.1038/316366a0	30	184	187	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 14	1992	357	6374					156	158		10.1038/357156a0	http://dx.doi.org/10.1038/357156a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU122	1579164				2022-12-01	WOS:A1992HU12200057
J	KRISHNA, S; BENAROCH, P; PILLAI, S				KRISHNA, S; BENAROCH, P; PILLAI, S			TETRAMERIC CELL-SURFACE MHC CLASS-I MOLECULES	NATURE			English	Article							MONOCLONAL-ANTIBODIES; ANTIGEN; COMPLEX; MOUSE	PURIFIED major histocompatibility complex (MHC) class I molecules have been studied at high resolution by X-ray crystallography 1; the structure is a complex of a single heavy chain, a beta-2-microglobulin light chain and a tightly bound peptide moiety. We show here that complete MHC class I molecules are post-translationally assembled into tetramers (made up of four heavy chains and four beta-2-microglobulin units) and that this tetrameric species is expressed on the cell surface. The multivalent tetrameric structure of class I molecules can be reconciled with models of T-cell activation that invoke antigen-receptor crosslinking, as opposed to models that depend on an allosteric change.	HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	KRISHNA, S (corresponding author), MASSACHUSETTS GEN HOSP,CTR CANC,MOLEC GENET GRP,MOLEC IMMUNOL LAB,BLDG 149,13TH ST,BOSTON,MA 02129, USA.			Benaroch, Philippe/0000-0002-2655-0129				BERNARDS A, 1990, EMBO J, V9, P2279, DOI 10.1002/j.1460-2075.1990.tb07399.x; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BRAUN J, 1983, J IMMUNOL, V130, P2113; CHERAYIL BJ, 1991, J EXP MED, V173, P111, DOI 10.1084/jem.173.1.111; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; KRANGEL MS, 1979, CELL, V18, P979, DOI 10.1016/0092-8674(79)90210-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANIER LL, 1981, J IMMUNOL, V127, P1691; MICHAELSON J, 1983, IMMUNOGENETICS, V17, P219, DOI 10.1007/BF00364409; NEEFJES J J, 1991, Current Opinion in Cell Biology, V3, P601, DOI 10.1016/0955-0674(91)90029-X; OZATO K, 1980, J IMMUNOL, V125, P2473; PILLAI S, 1987, NATURE, V329, P172, DOI 10.1038/329172a0; ROCHE PA, 1991, NATURE, V354, P392, DOI 10.1038/354392a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125	15	33	34	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 14	1992	357	6374					164	167		10.1038/357164a0	http://dx.doi.org/10.1038/357164a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU122	1579167				2022-12-01	WOS:A1992HU12200060
J	MALGAROLI, A; TSIEN, RW				MALGAROLI, A; TSIEN, RW			GLUTAMATE-INDUCED LONG-TERM POTENTIATION OF THE FREQUENCY OF MINIATURE SYNAPTIC CURRENTS IN CULTURED HIPPOCAMPAL-NEURONS	NATURE			English	Article							PROTEIN KINASE-C; FROG NEUROMUSCULAR-JUNCTION; EXCITATORY AMINO-ACIDS; CENTRAL NERVOUS-SYSTEM; PRESYNAPTIC ENHANCEMENT; TRANSMITTER RELEASE; QUANTAL ANALYSIS; RAT HIPPOCAMPUS; PERFORANT PATH; TRANSMISSION	Glutamate application at synapses between hippocampal neurons in culture produces long-term potentiation of the frequency of spontaneous miniature synaptic currents, together with long-term potentiation of evoked synaptic currents. The mini frequency potentiation is initiated postsynaptically and requires activity of NMDA receptors. Although the frequency of unitary quantal responses increases strongly, their amplitude remains little changed with potentiation. Tests of postsynaptic responsiveness rule out recruitment of latent glutamate receptor clusters. Thus, postsynaptic induction can lead to enhancement of presynaptic transmitter release. The sustained potentiation of mini frequency is expressed even in the absence of Ca2+ entry into presynaptic terminals.	STANFORD UNIV, MED CTR, BECKMAN CTR, DEPT MOLEC & CELLULAR PHYSIOL, STANFORD, CA 94305 USA	Stanford University			Malgaroli, Antonio/I-5090-2013	Malgaroli, Antonio/0000-0003-3758-7477				AMARAL DG, 1990, PROG BRAIN RES, V83, P1; ASCHER P, 1987, TRENDS NEUROSCI, V10, P284, DOI 10.1016/0166-2236(87)90174-3; BAXTER D, 1985, P NATL ACAD SCI USA, V80, P7347; BEKKERS JM, 1989, NATURE, V341, P230, DOI 10.1038/341230a0; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BLISS T V P, 1988, P3; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; BROWN TH, 1979, BRAIN RES, V177, P194, DOI 10.1016/0006-8993(79)90931-4; BROWN TH, 1988, SCIENCE, V242, P724, DOI 10.1126/science.2903551; CHERNEVSKAYA NI, 1991, NATURE, V349, P418, DOI 10.1038/349418a0; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; CLEMENTS J, 1991, NATURE, V353, P396, DOI 10.1038/353396a0; COLLINGRIDGE GL, 1990, TRENDS PHARMACOL SCI, V11, P290, DOI 10.1016/0165-6147(90)90011-V; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; DALE N, 1990, J PHYSIOL-LONDON, V421, P203, DOI 10.1113/jphysiol.1990.sp017941; DAVIES SN, 1989, NATURE, V338, P500, DOI 10.1038/338500a0; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V124, P560, DOI 10.1113/jphysiol.1954.sp005129; DOLPHIN AC, 1982, NATURE, V297, P496, DOI 10.1038/297496a0; EDWARDS F, 1991, NATURE, V350, P271, DOI 10.1038/350271a0; EDWARDS FA, 1990, J PHYSIOL-LONDON, V430, P213, DOI 10.1113/jphysiol.1990.sp018289; FATT P, 1952, J PHYSIOL-LONDON, V117, P109; FINCH DM, 1990, BRAIN RES, V518, P269, DOI 10.1016/0006-8993(90)90979-L; FORSYTHE ID, 1990, J PHYSIOL-LONDON, V429, P1; Foster T C, 1991, Hippocampus, V1, P79, DOI 10.1002/hipo.450010108; GALLY JA, 1990, P NATL ACAD SCI USA, V87, P3547, DOI 10.1073/pnas.87.9.3547; HARTLEY DM, 1989, J PHARMACOL EXP THER, V250, P752; HU GY, 1987, NATURE, V328, P426, DOI 10.1038/328426a0; HUBBARD JI, 1968, J PHYSIOL-LONDON, V197, P639, DOI 10.1113/jphysiol.1968.sp008579; KORN H, 1991, TRENDS NEUROSCI, V14, P439, DOI 10.1016/0166-2236(91)90042-S; KORN H, 1991, NATURE, V350, P282, DOI 10.1038/350282a0; LARKMAN A, 1991, NATURE, V350, P344, DOI 10.1038/350344a0; LESTER RAJ, 1990, NEURON, V4, P741, DOI 10.1016/0896-6273(90)90200-Y; LEVTOV A, 1980, J PHYSIOL-LONDON, V309, P247, DOI 10.1113/jphysiol.1980.sp013507; LIN JW, 1990, P NATL ACAD SCI USA, V87, P8257, DOI 10.1073/pnas.87.21.8257; LONGENEC.HE, 1970, NATURE, V225, P701, DOI 10.1038/225701a0; Lynch G, 1991, Hippocampus, V1, P9, DOI 10.1002/hipo.450010103; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; MALENKA RC, 1991, NEURON, V6, P53, DOI 10.1016/0896-6273(91)90121-F; MALENKA RC, 1988, SCIENCE, V242, P81, DOI 10.1126/science.2845577; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MALINOW R, 1991, SCIENCE, V252, P722, DOI 10.1126/science.1850871; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; MARTIN AR, 1977, HDB PHYSL          1, V1, P329; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MULLER W, 1991, NATURE, V354, P73, DOI 10.1038/354073a0; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; REDMAN S, 1990, PHYSIOL REV, V70, P165, DOI 10.1152/physrev.1990.70.1.165; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SEGAL M, 1989, NEUROSCI LETT, V101, P169, DOI 10.1016/0304-3940(89)90525-9; SHAPIRA R, 1987, NATURE, V325, P58, DOI 10.1038/325058a0; Siegelbaum S A, 1991, Curr Opin Neurobiol, V1, P113, DOI 10.1016/0959-4388(91)90018-3; VORONIN LL, 1991, NEUROSCI RES COMMUN, V8, P87	55	341	343	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 14	1992	357	6374					134	139		10.1038/357134a0	http://dx.doi.org/10.1038/357134a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU122	1349728				2022-12-01	WOS:A1992HU12200049
J	MOLINA, TJ; KISHIHARA, K; SIDEROVSKI, DP; VANEWIJK, W; NARENDRAN, A; TIMMS, E; WAKEHAM, A; PAIGE, CJ; HARTMANN, KU; VEILLETTE, A; DAVIDSON, D; MAK, TW				MOLINA, TJ; KISHIHARA, K; SIDEROVSKI, DP; VANEWIJK, W; NARENDRAN, A; TIMMS, E; WAKEHAM, A; PAIGE, CJ; HARTMANN, KU; VEILLETTE, A; DAVIDSON, D; MAK, TW			PROFOUND BLOCK IN THYMOCYTE DEVELOPMENT IN MICE LACKING P56(LCK)	NATURE			English	Article							TYROSINE-PROTEIN-KINASE; T-CELL DEVELOPMENT; SIGNAL TRANSDUCTION; CD4; RECEPTOR; TRANSCRIPTS; EXPRESSION; ACTIVATION; P56LCK; GENE	THE protein Lck (p56lck) has a relative molecular mass of 56,000 and belongs to the Src family of tyrosine kinases 1-3. It is expressed exclusively in lymphoid cells, predominantly in thymocytes and peripheral T cells 4-5. Lck associates specifically with the cytoplasmic domains of both CD4 and CD8 T-cell surface glycoproteins 6,7 and interacts with the beta-chain of the interleukin-2 receptor 8, which implicates Lck activity in signal transduction during thymocyte ontogeny 9-13 and activation of mature T cells 14-19. Here we generate an lck null mutation by homologous recombination in embryonic stem cells to evaluate the role of p56lck in T-cell development and activation. Lck-deficient mice show a pronounced thymic atrophy, with a dramatic reduction in the double-positive (CD4+CD8+) thymocyte population. Mature, single-positive thymocytes are not detectable in these mice and there are only very few peripheral T cells. These results illustrate the crucial role of this T-cell-specific tyrosine kinase in the thymocyte development.	UNIV TORONTO, ONTARIO CANC INST, 500 SHERBOURNE ST, TORONTO M4X 1K9, ONTARIO, CANADA; UNIV TORONTO, DEPT IMMUNOL, TORONTO M4X 1K9, ONTARIO, CANADA; UNIV TORONTO, DEPT MED BIOPHYS, TORONTO M4X 1K9, ONTARIO, CANADA; ERASMUS UNIV, DEPT CELL BIOL & IMMUNOL 2, 3000 DR ROTTERDAM, NETHERLANDS; UNIV MARBURG, INST EXPTL IMMUNOL, W-3550 MARBURG, GERMANY; MCGILL UNIV, CTR CANC, MONTREAL H3G 1Y6, QUEBEC, CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; Erasmus University Rotterdam; Philipps University Marburg; McGill University			Siderovski, David Peter/AAA-9603-2019; Molina, Thierry/ABA-5214-2020	Siderovski, David Peter/0000-0002-0688-8210; Molina, Thierry/0000-0002-3929-9754				ABRAHAM KM, 1991, J EXP MED, V173, P1421, DOI 10.1084/jem.173.6.1421; ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; EGERTON M, 1990, P NATL ACAD SCI USA, V87, P2579, DOI 10.1073/pnas.87.7.2579; FERRICK DA, 1989, IMMUNOL TODAY, V10, P403, DOI 10.1016/0167-5699(89)90035-2; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HUESMANN M, 1991, CELL, V66, P533, DOI 10.1016/0092-8674(81)90016-7; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KOGA Y, 1986, EUR J IMMUNOL, V16, P1643, DOI 10.1002/eji.1830161229; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MICELI MC, 1991, P NATL ACAD SCI USA, V88, P2623, DOI 10.1073/pnas.88.7.2623; PAIGE CJ, 1982, J IMMUNOL METHODS, V52, P51, DOI 10.1016/0022-1759(82)90349-0; PERLMUTTER RM, 1988, J CELL BIOCHEM, V38, P117, DOI 10.1002/jcb.240380206; RAHEMTULLA A, 1991, NATURE, V353, P180, DOI 10.1038/353180a0; REYNOLDS PJ, 1990, MOL CELL BIOL, V10, P4266, DOI 10.1128/MCB.10.8.4266; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; TAYLOR IW, 1980, J HISTOCHEM CYTOCHEM, V28, P1021, DOI 10.1177/28.9.6157714; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; Veillette A, 1991, Semin Immunol, V3, P143; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1989, J EXP MED, V170, P1671, DOI 10.1084/jem.170.5.1671; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; VORONOVA AF, 1986, NATURE, V319, P682, DOI 10.1038/319682a0	29	945	982	0	13	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 14	1992	357	6374					161	164		10.1038/357161a0	http://dx.doi.org/10.1038/357161a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU122	1579166				2022-12-01	WOS:A1992HU12200059
J	SELLERS, TA; KUSHI, LH; POTTER, JD; KAYE, SA; NELSON, CL; MCGOVERN, PG; FOLSOM, AR				SELLERS, TA; KUSHI, LH; POTTER, JD; KAYE, SA; NELSON, CL; MCGOVERN, PG; FOLSOM, AR			EFFECT OF FAMILY HISTORY, BODY-FAT DISTRIBUTION, AND REPRODUCTIVE FACTORS ON THE RISK OF POSTMENOPAUSAL BREAST-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GROWTH FACTOR-I; GENETIC EPIDEMIOLOGY; BOUND ESTRADIOL; HORMONE LEVELS; WOMEN; ESTROGEN; DISEASE; OBESITY; AGE; RECEPTORS	Background. A family history of breast cancer reflects shared cultural factors, genetic predisposition, or both. There is evidence that the estimated risk associated with a family history of breast cancer increases multiplicatively in combination with other risk factors. We examined the combined effect of family history and anthropometric and reproductive factors on the risk of breast cancer in postmenopausal women. Methods. Using data from a prospective cohort study, we studied 37,105 women 55 to 69 years of age to determine whether known risk factors for breast cancer are modified by a reported family history at the time of entry into the study. Results. During the first four years of follow-up, 493 new breast cancers were diagnosed. The association of the waist-to-hip ratio (the circumference of the waist divided by that of the hips) with the risk of breast cancer was limited predominantly to women with a family history of breast cancer; the age-adjusted relative risk of breast cancer for the women above the fourth quintile for waist-to-hip ratio as compared with those below the first quintile was 3.2 in women with a family history of breast cancer and 1.2 for women without such a family history. An interaction was observed between a family history of breast cancer and the number of live-born children; the protective effect of higher parity was observed primarily among women with a family history of breast cancer. Similarly, the age-adjusted relative risk of breast cancer associated with a late age at first pregnancy (i.e., greater-than-or-equal-to 30 years) was 5.8 for women with a family history of breast cancer and 2.0 for women without such a family history. Conclusions. The increase in the risk of breast cancer associated with a high waist-to-hip ratio, low parity, or greater age at first pregnancy is more pronounced among women with a family history of breast cancer. These findings suggest etiologic differences between familial breast cancer and the sporadic form.	UNIV MINNESOTA, INST HUMAN GENET, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	SELLERS, TA (corresponding author), UNIV MINNESOTA, SCH PUBL HLTH, DIV EPIDEMIOL, 1300 S 2ND ST, SUITE 300, MINNEAPOLIS, MN 55455 USA.			Kushi, Lawrence/0000-0001-9136-1175; Potter, John/0000-0001-5439-1500	NCI NIH HHS [R01 CA39742, T32 CA099607] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039742] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON DE, 1972, J NATL CANCER I, V48, P1029; ANDERSON DE, 1974, CANCER, V34, P1090, DOI 10.1002/1097-0142(197410)34:4<1090::AID-CNCR2820340419>3.0.CO;2-J; ANDRIEU N, 1989, INT J CANCER, V44, P415, DOI 10.1002/ijc.2910440306; BAIN C, 1980, AM J EPIDEMIOL, V111, P301, DOI 10.1093/oxfordjournals.aje.a112901; BALLARDBARBASH R, 1990, J NATL CANCER I, V82, P286, DOI 10.1093/jnci/82.4.286; BEGG L, 1987, GENET EPIDEMIOL, V4, P233, DOI 10.1002/gepi.1370040402; BOUCHARD C, 1988, INT J OBESITY, V12, P205; Breslow N.E., 1987, STATISTICAL METHODS, VII, P1; BRINTON LA, 1982, J NATL CANCER I, V69, P817; BRYAN RM, 1984, CANCER, V54, P2436, DOI 10.1002/1097-0142(19841201)54:11<2436::AID-CNCR2820541121>3.0.CO;2-H; BULBROOK RD, 1978, EUR J CANCER, V14, P1369, DOI 10.1016/0014-2964(78)90120-2; Byrne C, 1991, Epidemiology, V2, P276, DOI 10.1097/00001648-199107000-00007; CLAUS EB, 1990, AM J EPIDEMIOL, V131, P961, DOI 10.1093/oxfordjournals.aje.a115616; DUPONT WD, 1987, AM J EPIDEMIOL, V125, P769, DOI 10.1093/oxfordjournals.aje.a114594; EVANS DJ, 1983, J CLIN ENDOCR METAB, V57, P304, DOI 10.1210/jcem-57-2-304; FAREWELL VT, 1977, CANCER, V40, P931, DOI 10.1002/1097-0142(197708)40:2<931::AID-CNCR2820400251>3.0.CO;2-Y; FERRELL RE, 1989, CANCER GENET CYTOGEN, V38, P241, DOI 10.1016/0165-4608(89)90665-1; FISHMAN J, 1983, CANCER RES, V43, P1884; FISHMAN J, 1979, SCIENCE, V204, P1089, DOI 10.1126/science.451553; FOEKENS JA, 1989, CANCER, V63, P2139, DOI 10.1002/1097-0142(19890601)63:11<2139::AID-CNCR2820631112>3.0.CO;2-D; FOLSOM AR, 1989, CANCER RES, V49, P6828; FOLSOM AR, 1990, AM J EPIDEMIOL, V131, P794, DOI 10.1093/oxfordjournals.aje.a115570; GO RCP, 1983, J NATL CANCER I, V71, P455; GOLDSTEIN AM, 1989, CLIN GENET, V36, P100; GREENLAND S, 1988, SCAND J WORK ENV HEA, V14, P125, DOI 10.5271/sjweh.1945; GRODIN JM, 1973, J CLIN ENDOCR METAB, V36, P207, DOI 10.1210/jcem-36-2-207; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HENDERSON BE, 1975, NEW ENGL J MED, V293, P790, DOI 10.1056/NEJM197510162931602; HENDERSON BE, 1988, CANCER RES, V48, P246; INGRAM DM, 1990, BRIT J CANCER, V61, P303, DOI 10.1038/bjc.1990.57; KAYE SA, 1991, INT J EPIDEMIOL, V20, P151, DOI 10.1093/ije/20.1.151; KELSEY JL, 1988, CANCER RES, V48, P5615; KEY TJA, 1988, EUR J CANCER CLIN ON, V24, P29, DOI 10.1016/0277-5379(88)90173-3; KING MC, 1984, ANNU REV PUBL HEALTH, V5, P1; KING MC, 1980, SCIENCE, V208, P406, DOI 10.1126/science.7367867; KIRSCHNER MA, 1990, J CLIN ENDOCR METAB, V70, P473, DOI 10.1210/jcem-70-2-473; KUSHI LH, 1988, AM J EPIDEMIOL, V128, P740, DOI 10.1093/oxfordjournals.aje.a115027; LUBIN F, 1985, AM J EPIDEMIOL, V122, P579, DOI 10.1093/oxfordjournals.aje.a114137; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; METTLIN C, 1990, AM J EPIDEMIOL, V131, P973, DOI 10.1093/oxfordjournals.aje.a115617; MOORE JW, 1987, BRIT J CANCER, V56, P661, DOI 10.1038/bjc.1987.262; MORGAN RW, 1978, J NATL CANCER I, V60, P965, DOI 10.1093/jnci/60.5.965; MORRIS RD, 1991, AM J PUBLIC HEALTH, V81, P507, DOI 10.2105/AJPH.81.4.507; NAROD SA, 1991, LANCET, V338, P82; OTA DM, 1986, CANCER, V57, P558, DOI 10.1002/1097-0142(19860201)57:3<558::AID-CNCR2820570326>3.0.CO;2-1; OTTMAN R, 1986, AM J EPIDEMIOL, V123, P15, DOI 10.1093/oxfordjournals.aje.a114209; PEKONEN F, 1988, CANCER RES, V48, P1343; PIKE MC, 1977, J NATL CANCER I, V59, P1351, DOI 10.1093/jnci/59.5.1351; PROSSER J, 1991, BRIT J CANCER, V63, P181, DOI 10.1038/bjc.1991.44; REED MJ, 1983, CANCER RES, V43, P3940; SACKETT DL, 1979, J CHRON DIS, V32, P51, DOI 10.1016/0021-9681(79)90012-2; SATTIN RW, 1985, JAMA-J AM MED ASSOC, V253, P1908, DOI 10.1001/jama.253.13.1908; SCHAPIRA DV, 1990, ANN INTERN MED, V112, P182, DOI 10.7326/0003-4819-112-3-182; SCHNEIDER NR, 1983, AM J HUM GENET, V35, P454; SCHWARTZ AG, 1985, JNCI-J NATL CANCER I, V75, P665; SELBY JV, 1989, HUM BIOL, V61, P179; SKOLNICK M H, 1984, Genetic Epidemiology, V1, P363, DOI 10.1002/gepi.1370010408; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STEWART AJ, 1990, J BIOL CHEM, V265, P21172; STUNKARD AJ, 1986, NEW ENGL J MED, V314, P193, DOI 10.1056/NEJM198601233140401; STUNKARD AJ, 1990, NEW ENGL J MED, V322, P1483, DOI 10.1056/NEJM199005243222102; WILSON AF, 1986, GENET EPIDEMIOL, P87; YEE D, 1989, MOL ENDOCRINOL, V3, P509, DOI 10.1210/mend-3-3-509; ZUPPAN P, 1991, AM J HUM GENET, V48, P1065; 1985, SAS USERS GUIDE STAT	65	223	224	1	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 14	1992	326	20					1323	1329		10.1056/NEJM199205143262004	http://dx.doi.org/10.1056/NEJM199205143262004			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT803	1565145				2022-12-01	WOS:A1992HT80300004
J	SHERMAN, MY; GOLDBERG, AL				SHERMAN, MY; GOLDBERG, AL			HEAT-SHOCK IN ESCHERICHIA-COLI ALTERS THE PROTEIN-BINDING PROPERTIES OF THE CHAPERONIN GROEL BY INDUCING ITS PHOSPHORYLATION	NATURE			English	Article								WHEN bacterial or eukaryotic cells are exposed to high temperatures or other harsh conditions, they respond by synthesis of a specific set of heat-shock proteins 1-3. Certain heat-shock proteins such as groEL, called 'chaperonins', can prevent misfolding and promote the refolding and proper assembly of unfolded polypeptides generated under harmful conditions 2,4. We report here a new aspect of the heat-shock response in Escherichia coli: at high temperatures a fraction of groEL becomes modified covalently, altering its interaction with unfolded proteins. The heat-modified form can be eluted with ATP from an unfolded protein more easily than normal groEL. The critical heat-induced modification seems to be phosphorylation, which is reversed on return to low temperature. Treatment of the modified groEL with phosphatases caused its apparent size, charge and binding properties to resemble those of the unmodified form. Thus during heat shock some groEL is reversibly phosphorylated, which allows its ATP-dependent release from protein substrates in the absence of its usual cofactor (groES), and probably promotes the repair of damaged polypeptides.			SHERMAN, MY (corresponding author), HARVARD UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02115, USA.							ALTSCHULER M, 1982, HEAT SHOCK BACTERIA, P321; ANANTHAN J, 1986, SCIENCE, V232, P522, DOI 10.1126/science.3083508; BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; HELLEBUST H, 1989, J BIOTECHNOL, V12, P275, DOI 10.1016/0168-1656(89)90047-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MACKEY BM, 1990, J APPL BACTERIOL, V69, P373, DOI 10.1111/j.1365-2672.1990.tb01527.x; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; Morimoto RI, 1990, STRESS PROTEINS BIOL; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PHILLIPS TA, 1987, ESCHERICHIA COLI SAL, V2, P919; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SHERMAN M, 1991, J BACTERIOL, V173, P4249; SHERMAN MY, 1992, EMBO J, V11, P71; SMITH BJ, 1991, P NATL ACAD SCI USA, V88, P11091, DOI 10.1073/pnas.88.24.11091; WATSON K, 1984, FEBS LETT, V169, P267	18	97	98	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 14	1992	357	6374					167	169		10.1038/357167a0	http://dx.doi.org/10.1038/357167a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU122	1349729				2022-12-01	WOS:A1992HU12200061
J	YOST, HJ				YOST, HJ			REGULATION OF VERTEBRATE LEFT RIGHT ASYMMETRIES BY EXTRACELLULAR-MATRIX	NATURE			English	Article							XENOPUS-LAEVIS; PROSPECTIVE AREAS; FIBRONECTIN; GASTRULATION; HANDEDNESS; MOVEMENTS; MIGRATION; NEURULA; EMBRYOS; LAYER	THE vertebrate body is organized along three geometric axes: anterior-posterior, dorsal-ventral and left-right. Left-right axis formation, displayed in heart and gut development, is the least understood, even though it has been studied for many years 1-4. In Xenopus laevis gastrulae, a fibronectin-rich extracellular matrix is deposited on the basal surface of ectoderm cells 5,6 over which cardiac and visceral primordia move during development. Here I report experiments in which localized perturbation of a small patch of extracellular matrix by microsurgery was correlated with localized randomization of left-right asymmetries. Global perturbation of the extracellular matrix by microinjection of Arg-Gly-Asp peptides or heparinase into the blastocoel resulted in global randomization of left-right asymmetries. From these observations, I suggest that left-right axial information is contained in the extracellular matrix early in development and is independently transmitted to cardiac and visceral primordia.			YOST, HJ (corresponding author), UNIV MINNESOTA,DEPT CELL BIOL & NEUROANAT,4-135 JACKSON HALL,321 CHURCH ST SE,MINNEAPOLIS,MN 55455, USA.							BOUCAUT JC, 1984, J CELL BIOL, V99, P1822, DOI 10.1083/jcb.99.5.1822; BRICKMAN M, 1990, J CELL BIOL, V111, P484; BRIVANLOU AH, 1989, DEVELOPMENT, V106, P611; BROWN NA, 1990, DEVELOPMENT, V109, P1; BRUECKNER M, 1989, P NATL ACAD SCI USA, V86, P5035, DOI 10.1073/pnas.86.13.5035; Clark RAF, 1989, CURR OPIN CELL BIOL, V1, P1000, DOI 10.1016/0955-0674(89)90072-0; FEY J, 1990, DIFFERENTIATION, V42, P144, DOI 10.1111/j.1432-0436.1990.tb00755.x; Flaumenhaft R, 1991, CURR OPIN CELL BIOL, V3, P817, DOI 10.1016/0955-0674(91)90055-4; GALLOWAY J, 1990, NATURE, V346, P223, DOI 10.1038/346223a0; GERHART J, 1989, DEVELOPMENT, V107, P37; Keller R., 1990, Seminars in Developmental Biology, V1, P25; KELLER RE, 1976, DEV BIOL, V51, P118, DOI 10.1016/0012-1606(76)90127-5; KELLER RE, 1975, DEV BIOL, V42, P222, DOI 10.1016/0012-1606(75)90331-0; KELLER RE, 1985, J EMBRYOL EXP MORPH, V89, P185; LEE G, 1984, CELL, V36, P729, DOI 10.1016/0092-8674(84)90353-2; LINASK KK, 1988, DEV BIOL, V129, P315, DOI 10.1016/0012-1606(88)90378-8; Nieuwkoop P.D., 1994, NORMAL TABLES XENOPU; OPPENHEIMER JM, 1974, AM ZOOL, V15, P867; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SCHEFLER WC, 1968, STATISTICS BIOL SCI, P1; Spemann Hans., 1906, VERH DEUT ZOOL GES, V16, P195; Takaya H., 1953, Annotationes Zoologicae Japonenses, V26, P38; VONWOELLWARTH C, 1950, ROUX ARCH ENTWICKLUN, V144, P178; WEHRMAKER A, 1969, ROUX ARCH DEV BIOL, V163, P1; WINKLBAUER R, 1991, DEV BIOL, V148, P573, DOI 10.1016/0012-1606(91)90275-8; WOOD WB, 1991, NATURE, V349, P536, DOI 10.1038/349536a0; YOST HJ, 1990, DEVELOPMENT, V110, P865; YOST HJ, 1991, BIOL ASYMMETRY HANDE, P165	28	110	110	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 14	1992	357	6374					158	161		10.1038/357158a0	http://dx.doi.org/10.1038/357158a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU122	1579165				2022-12-01	WOS:A1992HU12200058
J	JOHNSON, WG; BRENNAN, TA; NEWHOUSE, JP; LEAPE, LL; LAWTHERS, AG; HIATT, HH; WEILER, PC				JOHNSON, WG; BRENNAN, TA; NEWHOUSE, JP; LEAPE, LL; LAWTHERS, AG; HIATT, HH; WEILER, PC			THE ECONOMIC CONSEQUENCES OF MEDICAL INJURIES - IMPLICATIONS FOR A NO-FAULT INSURANCE PLAN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TORT	Background. - There has been little research into the actual economic consequences of medical injuries. This inhibits informed discussion of alternatives to malpractice litigation. For example, the cost of no-fault medical accident insurance has been thought to be prohibitive. Method. - As part of a comprehensive analysis of medical injury and litigation, we interviewed a random sample of 794 individuals who had suffered medical adverse events in New York hospitals in 1984 and used their responses to calculate the cost of injuries. We then estimated the costs of a simulated no-fault insurance program that would operate as a second payer to direct insurance sources and would compensate for all financial losses attributed to medical injury. Results. - The estimated costs that would be paid by a simulated no-fault program were $161 million for medical care, $276 million for lost wages, and $441 million in lost household production, or a total of $878 million in 1989 dollars for the cohort of patients who were injured in 1984. Conclusion. - Although our estimate does not include administrative costs, it nonetheless indicates that a no-fault program would not be notably costlier than the more than $1 billion New York physicians now spend annually on malpractice insurance.	BRIGHAM & WOMENS HOSP,DIV GEN MED,BOSTON,MA 02115; HARVARD UNIV,JOHN F KENNEDY SCH GOVT,CAMBRIDGE,MA 02138; HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT HLTH CARE POLICY,BOSTON,MA 02115; HARVARD UNIV,SCH LAW,CAMBRIDGE,MA 02138	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University	JOHNSON, WG (corresponding author), ARIZONA STATE UNIV,COLL BUSINESS,SCH HLTH ADM & POLICY,TEMPE,AZ 85287, USA.		Newhouse, Joseph/AGJ-5632-2022					[Anonymous], 1986, COSTS COMPENSATION P; BERKOWITZ M, 1990, EC CONSEQUENCES TRAU; BOMBAUGH RL, 1971, COLUMBIA LAW REV, V71, P207, DOI 10.2307/1121170; BOVBJERG RR, 1989, NORTHWEST U LAW REV, V83, P908; BRENNAN TA, 1990, CLIN RES, V35, P551; DOUGLASS J, 1990, J FORENSIC EC, V4, P25, DOI DOI 10.5085/0898-5510-4.1.25; FELDSTEIN M, 1978, BROOKINGS PAPERS EC, V1, P1; HENSLER DR, 1991, R3999HHSICJ RAND COR; JOHNSON WG, 1984, IND LABOR RELAT REV, V37, P529, DOI 10.2307/2523670; JOHNSON WG, 1979, RES REPORT US INTERD; JOHNSON WG, 1984, MILBANK Q, V61, P177; Kakalik James S., 1988, COSTS COMPENSATION P; LAMBRINOS J, 1985, J RISK INSUR, V52, P464, DOI 10.2307/252781; LOCALIO AR, 1991, NEW ENGL J MED, V325, P245, DOI 10.1056/NEJM199107253250405; MANNE H, 1985, MED MALPRACTICE POLI; PRIEST GL, 1987, YALE LAW J, V96, P1521, DOI 10.2307/796494; RICE DP, 1990, EC COSTS ALCOHOL DRU; SCHWARTZ A, 1988, YALE LAW J, V97, P353, DOI 10.2307/796411; SCHWARTZ WB, 1978, NEW ENGL J MED, V298, P1282, DOI 10.1056/NEJM197806082982304; Viscusi W. Kip, 1988, INTL REV L EC, V8, P203, DOI DOI 10.1016/0144-8188(88)90006-3; WALKER KE, 1976, TIME USE MEASURE HOU; WEILER PC, 1991, MED MALPRACTICE TRIA; 1987, MED EC          1005; 1985, MED EC          1007; 1965, REPORTING HOSPITALIZ; 1986, WORK LIFE ESTIMATES; 1986, MED EC          1006; 1989, AVERAGE CHARGES HOME; 1980, VITAL STATISTICS US; 1985, EMPLOYEE BENEFITS 19; 1988, MED EC          1003; 1990, PATIENTS DOCTORS LAW; 1982, US BUREAU CENSUS P60, V139	33	72	72	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 13	1992	267	18					2487	2492		10.1001/jama.267.18.2487	http://dx.doi.org/10.1001/jama.267.18.2487			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HT068	1573726				2022-12-01	WOS:A1992HT06800028
J	LUNGU, O; SUN, XW; FELIX, J; RICHART, RM; SILVERSTEIN, S; WRIGHT, TC				LUNGU, O; SUN, XW; FELIX, J; RICHART, RM; SILVERSTEIN, S; WRIGHT, TC			RELATIONSHIP OF HUMAN PAPILLOMAVIRUS TYPE TO GRADE OF CERVICAL INTRAEPITHELIAL NEOPLASIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GENITAL-TRACT; LESIONS	Objective. - To determine the relationship of human papillomavirus (HPV) type to grade of cervical intraepithelial neoplasia (CIN) in a large series of cases. Design. - A survey of HPV types in CIN lesions detected using a new, highly accurate method for typing HPV that is based on restriction fragment length polymorphism analysis of amplimers produced during polymerase chain amplification of the conserved L1 region of HPV using consensus primers. Setting. - Private gynecologists' offices and inner-city colposcopy clinics. Patients. - A convenience sample of 276 HPV DNA-positive cervical biopsy specimens or samples from patients undergoing colposcopy for abnormal Papanicolaou smears. Intervention. - None. Main Outcome Measure(s). - Human papillomavirus type(s). Results. - Cervical intraepithelial neoplasia 1 lesions were relatively heterogeneous with regard to associated HPV types. Nineteen percent of CIN 1 lesions were associated with HPV types 6 or 11; 29% contained HPV types 16, 18, or 33; and 19% were associated with "novel types" of HPV. It was also found that 22% of CIN 1 lesions were associated with more than one HPV type. In contrast to CIN 1, both CIN 2 and CIN 3 were relatively homogeneous with regard to associated HPV types. Eighty-eight percent of CIN 2 and 3 lesions contained HPV types 16,18, or 33. Unlike CIN 1 lesions, which often contained multiple types of HPV, only 7% of CIN 2 and 3 lesions were associated with multiple HPV types. Conclusions. - Cervical intraepithelial neoplasia should be classified into two separate categories-low-grade and high-grade CIN. Since only 29% of low-grade lesions are associated with HPV types 16,18, or 33, HPV type could potentially play a role in determining the most appropriate clinical management of patients with low-grade CIN. However, prospective follow-up studies of lesional behavior based on HPV type are required before clinical recommendations can be made.	COLUMBIA UNIV COLL PHYS & SURG, DEPT PATHOL, DIV OBSTET GYNECOL PATHOL, ROOM 16-402 P&S, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT MICROBIOL, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT OBSTET & GYNECOL, NEW YORK, NY 10032 USA; COLUMBIA PRESBYTERIAN MED CTR, NEW YORK, NY 10032 USA; CORNELL MED SCH, DEPT PATHOL, NEW YORK, NY USA	Columbia University; Columbia University; Columbia University; Columbia University; NewYork-Presbyterian Hospital; Cornell University					NCI NIH HHS [CA27367] Funding Source: Medline; PHS HHS [CCU206822] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BARRON BA, 1968, J NATL CANCER I, V41, P1343; BAUER HM, 1991, JAMA-J AM MED ASSOC, V265, P472, DOI 10.1001/jama.265.4.472; BURMER GC, 1990, AM J CLIN PATHOL, V94, P554, DOI 10.1093/ajcp/94.5.554; CAMPION MJ, 1986, LANCET, V2, P237; CRUM CP, 1985, J VIROL, V54, P675, DOI 10.1128/JVI.54.3.675-681.1985; FERENCZY A, 1987, BLAUSTEINS PATHOLOGY, P191; FRANQUEMONT DW, 1989, AM J CLIN PATHOL, V92, P577, DOI 10.1093/ajcp/92.5.577; GRAVITT P, 1991, MOL CELL PROBE, V5, P65, DOI 10.1016/0890-8508(91)90039-M; KOUTSKY LA, 1988, EPIDEMIOL REV, V10, P122, DOI 10.1093/oxfordjournals.epirev.a036020; LORINCZ AT, 1987, J NATL CANCER I, V79, P671; LORINCZ AT, 1992, OBSTET GYNECOL, V79, P328, DOI 10.1097/00006250-199203000-00002; LUNGU O, IN PRESS MOL CELL PR; Manos M. M., 1990, PCR PROTOCOLS GUIDE, P356; NASIELL K, 1986, OBSTET GYNECOL, V67, P665, DOI 10.1097/00006250-198605000-00012; NUOVO GJ, 1990, GYNECOL ONCOL, V36, P256, DOI 10.1016/0090-8258(90)90184-M; REID R, 1987, AM J OBSTET GYNECOL, V156, P212, DOI 10.1016/0002-9378(87)90241-9; REID R, 1991, J FAM PRACTICE, V32, P183; RICHART RM, 1990, OBSTET GYNECOL, V75, P223; RICHART RM, 1990, OBSTET GYNECOL, V75, P131; ROMAN A, 1989, CLIN MICROBIOL REV, V2, P166, DOI 10.1128/CMR.2.2.166-190.1989; SINGER A, 1991, BRIT MED J, V302, P251, DOI 10.1136/bmj.302.6771.251; SOLOMON D, 1989, JAMA-J AM MED ASSOC, V262, P931; SYRJANEN KJ, 1991, PAPILLOMAVIRUS REP, V1, P1; WILLETT GD, 1989, INT J GYNECOL PATHOL, V8, P18, DOI 10.1097/00004347-198903000-00003; WRIGHT TC, 1990, GYNECOL ONCOL, V37, P151, DOI 10.1016/0090-8258(90)90327-H	25	108	114	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 13	1992	267	18					2493	2496		10.1001/jama.267.18.2493	http://dx.doi.org/10.1001/jama.267.18.2493			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT068	1349360				2022-12-01	WOS:A1992HT06800029
J	NIGHTINGALE, SL				NIGHTINGALE, SL			WARNINGS ON USE OF ACE INHIBITORS IN 2ND AND 3RD TRIMESTER OF PREGNANCY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.								0	17	17	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 13	1992	267	18					2445	2445		10.1001/jama.267.18.2445	http://dx.doi.org/10.1001/jama.267.18.2445			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT068	1349355				2022-12-01	WOS:A1992HT06800005
J	NIGHTINGALE, SL				NIGHTINGALE, SL			NEW REQUIREMENT FOR MANUFACTURERS TO TRACK CERTAIN MEDICAL DEVICES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.								0	17	17	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 13	1992	267	18					2445	2445		10.1001/jama.267.18.2445	http://dx.doi.org/10.1001/jama.267.18.2445			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT068	1349355				2022-12-01	WOS:A1992HT06800004
J	NIGHTINGALE, SL				NIGHTINGALE, SL			2 NEW THERAPIES AVAILABLE UNDER TREATMENT IND	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.								0	17	17	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 13	1992	267	18					2445	2445		10.1001/jama.267.18.2445	http://dx.doi.org/10.1001/jama.267.18.2445			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT068	1349355				2022-12-01	WOS:A1992HT06800006
J	ROSENBLUM, L; DARROW, W; WITTE, J; COHEN, J; FRENCH, J; GILL, PS; POTTERAT, J; SIKES, K; REICH, R; HADLER, S				ROSENBLUM, L; DARROW, W; WITTE, J; COHEN, J; FRENCH, J; GILL, PS; POTTERAT, J; SIKES, K; REICH, R; HADLER, S			SEXUAL PRACTICES IN THE TRANSMISSION OF HEPATITIS-B VIRUS AND PREVALENCE OF HEPATITIS-DELTA VIRUS-INFECTION IN FEMALE PROSTITUTES IN THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; HOMOSEXUAL MEN; SALIVA; ANTIGEN; SEMEN; NONOXYNOL-9; OUTBREAK; CONTACTS; MARKERS	Objective.- To evaluate heterosexual transmission of hepatitis B virus (HBV) and the prevalence of hepatitis delta virus (HDV) infection in female prostitutes. Design.-Survey. Setting. - Sexually transmitted disease clinics, drug treatment programs, detention centers, and/or outreach efforts in eight areas in the United States. Participants. - A total of 1368 female prostitutes 18 years of age or older. Outcome Measures. - Seropositivity for HBV and HDV infection. Results. - The overall prevalence of past or present HBV infection was 56%: 74% in women who were injecting-drug users (IDUs), 38% in women reporting no history of injecting-drug use (non-IDUs), 51% in whites, 55% in blacks, and 67% in Hispanics. Of 21 HBV carrier IDUs, 21% had HDV infection; of 18 HBV carrier non-IDUs, 6% had HDV infection. In non-IDUs (49%), risk factors for HBV infection were a history of having penile-anal intercourse (odds ratio [OR], 3.1; 95% confidence limits [CL], 1.3, 7.3) and seropositivity for syphilis and human immunodeficiency virus (HIV) infection. In IDUs, factors associated with an increased risk of infection, in addition to behaviors related to injecting-drug use, were the number of lifetime sexual partners, having sexual partners from groups at high risk for HBV infection, and seropositivity for syphilis and HIV infection; spermicide and/or diaphragm use was associated with a markedly decreased risk of HBV infection among blacks (OR, 0.1; 95% CL, 0.03, 0.4) and Hispanics (OR, 0.2; 95% CL, 0.06, 0.9). Conclusion. - This is the first study to suggest that having anal intercourse and failing to use vaginal contraceptives may facilitate transmission of HBV to women. Our data support guidelines that recommend hepatitis B vaccination for prostitutes and persons with a history of sexually transmitted diseases or multiple sexual partners.	CTR DIS CONTROL,NATL CTR INFECT DIS,DIV HIV AIDS,ATLANTA,GA 30333; FLORIDA DEPT HLTH & REHAB SERV,TALLAHASSEE,FL; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143; NEW JERSEY DEPT HLTH,TRENTON,NJ; UNIV SO CALIF,LOS ANGELES,CA 90089; EL PASO CTY DEPT HLTH & ENVIRONM,COLORADO SPRINGS,CO; GEORGIA DEPT HUMAN RESOURCES,ATLANTA,GA; CLARK CTY HLTH DIST,LAS VEGAS,NV	Centers for Disease Control & Prevention - USA; Florida Department of Health; University of California System; University of California San Francisco; New Jersey Department of Health & Senior Services; University of Southern California	ROSENBLUM, L (corresponding author), CTR DIS CONTROL,NATL CTR INFECT DIS,DIV VIRAL & RICKETTSIAL DIS,HEPATITIS BRANCH,ATLANTA,GA 30333, USA.		Potterat, John J/B-4680-2009					ALTER HJ, 1977, INFECT IMMUN, V16, P928, DOI 10.1128/IAI.16.3.928-933.1977; ALTER MJ, 1990, JAMA-J AM MED ASSOC, V263, P1218, DOI 10.1001/jama.263.9.1218; ALTER MJ, 1986, JAMA-J AM MED ASSOC, V256, P1307, DOI 10.1001/jama.256.10.1307; BADDOUR LM, 1988, SEX TRANSM DIS, V15, P174, DOI 10.1097/00007435-198807000-00014; COHEN C, 1990, AIDS 2ND DECADE, P253; Darrow William, 1990, AIDS DRUGS PROSTITUT, P18; DAVISON F, 1987, J HEPATOL, V4, P37, DOI 10.1016/S0168-8278(87)80007-7; DECOCK KM, 1988, WESTERN J MED, V148, P307; FIELDS HA, 1986, J CLIN IMMUNOASSAY, V9, P128; GOVINDARAJAN S, 1983, GASTROENTEROLOGY, V85, P160; HEATHCOT.J, 1974, LANCET, V1, P71; HERSH T, 1971, NEW ENGL J MED, V285, P1363, DOI 10.1056/NEJM197112092852408; HICKS DR, 1985, LANCET, V2, P1422; KOFF RS, 1977, GASTROENTEROLOGY, V72, P297; KREISS J, 1989, 5TH P INT C AIDS MON, P36; LETTAU LA, 1987, NEW ENGL J MED, V317, P1256, DOI 10.1056/NEJM198711123172004; LOUV WC, 1988, J INFECT DIS, V158, P518, DOI 10.1093/infdis/158.3.518; MCQUILLAN GM, 1989, AM J MED, V87, pS5; MUSHAWAR IK, 1984, VIRAL HEPATITIS LIVE, P617; NIRUTHISARD S, 1991, 7TH P INT C AIDS FLO, P317; NORTH BB, 1990, HETEROSEXUAL TRANSMI, P273; PADIAN N, 1987, JAMA-J AM MED ASSOC, V258, P788, DOI 10.1001/jama.258.6.788; PETERSEN NJ, 1982, ANN INTERN MED, V96, P170; PONZETTO A, 1984, HEPATOLOGY, V4, P1111, DOI 10.1002/hep.1840040603; REDEKER AG, 1975, NEW ENGL J MED, V293, P1055; ROSENBERG M, 1987, JAMA-J AM MED ASSOC, V258, P2308; ROSENBLUM LS, 1990, J INFECT DIS, V161, P407, DOI 10.1093/infdis/161.3.407; SCHREEDER MT, 1982, J INFECT DIS, V146, P7, DOI 10.1093/infdis/146.1.7; SCOTT RM, 1980, J INFECT DIS, V142, P67, DOI 10.1093/infdis/142.1.67; SINGH B, 1976, AM J OBSTET GYNECOL, V126, P422, DOI 10.1016/0002-9378(76)90630-X; SOLOMON RE, 1988, ANN INTERN MED, V108, P51, DOI 10.7326/0003-4819-108-1-51; VOELLER B, 1991, ARCH SEX BEHAV, V20, P233, DOI 10.1007/BF01541846; WEISFUSE IB, 1989, HEPATOLOGY, V9, P872, DOI 10.1002/hep.1840090614; WRIGHT RA, 1975, JAMA-J AM MED ASSOC, V232, P717, DOI 10.1001/jama.232.7.717; 1991, MMWR SRR13, V40, P1; 1985, SAS USERS GUIDE STAT, P171	36	55	57	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 13	1992	267	18					2477	2481		10.1001/jama.267.18.2477	http://dx.doi.org/10.1001/jama.267.18.2477			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HT068	1573724				2022-12-01	WOS:A1992HT06800026
J	ARIEFF, AI; AYUS, JC; FRASER, CL				ARIEFF, AI; AYUS, JC; FRASER, CL			HYPONATREMIA AND DEATH OR PERMANENT BRAIN-DAMAGE IN HEALTHY-CHILDREN	BRITISH MEDICAL JOURNAL			English	Article							ANTI-DIURETIC HORMONE; WATER-INTOXICATION; NORMAL INFANTS; RAT-BRAIN; HYPONATREMIA; VASOPRESSIN; PATHOGENESIS; MORBIDITY; SURGERY; SALINE	Objective - To determine if hyponatraemia causes permanent brain damage in healthy children and, if so, if the disorder is primarily limited to females, as occurs in adults. Design - Prospective clinical case study of 16 affected children and a review of 24 412 consecutive surgical admissions at one medical centre. Patients - 16 children (nine male, seven female; age 7 (SD 5) years) with generally minor illness were electively hospitalised for primary care. Consultation was obtained for the combination of respiratory arrest with symptomatic hyponatraemia (serum sodium concentration less-than-or-equal-to 128 mmol/l). Main outcome measures - Presence, gender distribution, and classification of permanent brain damage in children with symptomatic hyponatraemia in both prospective and retrospective studies. Results - By retrospective evaluation the incidence of postoperative hyponatraemia among 24 412 patients was 0.34% (83 cases) and mortality of those afflicted was 8.4% (seven deaths). In the prospective population the serum sodium concentration on admission was 138 (SD 2) mmol/l. From three to 120 inpatient hours after hypotonic fluid administration patients developed progressive lethargy, headache, nausea, and emesis with an explosive onset of respiratory arrest. At the time serum sodium concentration was 115 (7) mmol/l and arterial oxygen tension 6 (1.5) kPa. The hyponatraemia was primarily caused by extrarenal loss of electrolytes with replacement by hypotonic fluids. All 16 patients had cerebral oedema detected at either radiological or postmortem examination. All 15 patients not treated for their hyponatraemia in a timely manner either died or were permanently incapacitated by brain damage. The only patient treated in a timely manner was alive but mentally retarded. Conclusions - Symptomatic hyponatraemia can result in a high morbidity in children of both genders, which is due in large part to inadequate brain adaptation and lack of timely treatment.	UNIV CALIF SAN FRANCISCO,SCH MED,SAN FRANCISCO,CA 94143; BAYLOR COLL MED,HOUSTON,TX 77030	University of California System; University of California San Francisco; Baylor College of Medicine					PHS HHS [R01 08575-01A2] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Abramow M, 1984, Adv Nephrol Necker Hosp, V13, P1; ANDERSON RJ, 1985, ANN INTERN MED, V102, P164, DOI 10.7326/0003-4819-102-2-164; ARIEFF AI, 1976, MEDICINE, V55, P121, DOI 10.1097/00005792-197603000-00002; ARIEFF AI, 1986, NEW ENGL J MED, V314, P1529, DOI 10.1056/NEJM198606123142401; ASHRAF N, 1981, AM J MED, V70, P1163, DOI 10.1016/0002-9343(81)90822-6; AYUS JC, 1987, NEW ENGL J MED, V317, P1190, DOI 10.1056/NEJM198711053171905; AYUS JC, 1982, AM J MED, V72, P43, DOI 10.1016/0002-9343(82)90575-7; AYUS JC, 1991, J AM SOC NEPHROL, V2, P278; BURROWS FA, 1983, CRIT CARE MED, V11, P527, DOI 10.1097/00003246-198307000-00009; CHUNG HM, 1986, ARCH INTERN MED, V146, P333, DOI 10.1001/archinte.146.2.333; COWLEY D M, 1988, Australian and New Zealand Journal of Surgery, V58, P485, DOI 10.1111/j.1445-2197.1988.tb06240.x; CRAWFORD JD, 1964, PEDIATR CLIN N AM, V11, P1029; CRUMPACK.RW, 1973, NEUROLOGY, V23, P1251, DOI 10.1212/WNL.23.11.1251; DAVID R, 1981, PEDIATRICS, V68, P349; DEKABAN AS, 1978, ANN NEUROL, V4, P345, DOI 10.1002/ana.410040410; DELCASTILLO AR, 1987, BRAIN RES, V416, P113, DOI 10.1016/0006-8993(87)91502-2; FARACI FM, 1990, AM J PHYSIOL, V258, pR94, DOI 10.1152/ajpregu.1990.258.1.R94; FRASER CL, 1989, AM J PHYSIOL, V256, pR880, DOI 10.1152/ajpregu.1989.256.4.R880; FRASER CL, 1989, AM J PHYSIOL, V257, pE284, DOI 10.1152/ajpendo.1989.257.2.E284; FRASER CL, 1990, ANN INTERN MED, V112, P113, DOI 10.7326/0003-4819-112-2-113; GARCIA JH, 1980, BRAIN EDEMA PATHOLOG, P147; GROSS PA, 1987, EUR J CLIN INVEST, V17, P123, DOI 10.1111/j.1365-2362.1987.tb02391.x; GUERRA M, 1987, NEUROSCI LETT, V78, P97, DOI 10.1016/0304-3940(87)90568-4; GUR RC, 1991, P NATL ACAD SCI USA, V88, P2845, DOI 10.1073/pnas.88.7.2845; JENNETT B, 1972, LANCET, V1, P734; JUDD BA, 1987, ACTA PAEDIATR SCAND, V76, P385; KEATING JP, 1991, AM J DIS CHILD, V145, P985, DOI 10.1001/archpedi.1991.02160090037018; MELTON JE, 1983, AM J PHYSIOL, V244, pR724, DOI 10.1152/ajpregu.1983.244.5.R724; MELTON JE, 1987, AM J PHYSIOL, V252, pF661, DOI 10.1152/ajprenal.1987.252.4.F661; NATTIE EE, 1981, J APPL PHYSIOL, V51, P1086, DOI 10.1152/jappl.1981.51.5.1086; Rosenberg G A, 1990, Adv Neurol, V52, P149; ROSOMOFF HL, 1963, ARCH NEUROL-CHICAGO, V9, P36; SARNAIK AP, 1991, CRIT CARE MED, V19, P758, DOI 10.1097/00003246-199106000-00005; TIEN R, IN PRESS AM J MED; VARAVITHYA W, 1967, J PEDIATR-US, V71, P269, DOI 10.1016/S0022-3476(67)80087-8; WIDDOWSON EM, 1960, BIOCHEM J, V77, P30, DOI 10.1042/bj0770030; WORTHLEY LIG, 1986, BRIT MED J, V292, P168, DOI 10.1136/bmj.292.6514.168; [No title captured]; 1990, STAT ABSTR US 1990, P110; 1991, AM HOSPITAL ASS HOSP, P20; 1985, SAS USERS GUIDE BASI; 1990, STAT ABSTR US 1990, P16	42	268	282	1	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 9	1992	304	6836					1218	1222		10.1136/bmj.304.6836.1218	http://dx.doi.org/10.1136/bmj.304.6836.1218			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT964	1515791	Bronze, Green Published			2022-12-01	WOS:A1992HT96400021
J	BROOK, CGD				BROOK, CGD			DIABETES - WHAT SORT OF PREVENTION	LANCET			English	Editorial Material											BROOK, CGD (corresponding author), UCL, DEPT PAEDIAT ENDOCRINOL, LONDON WC1, ENGLAND.								0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 9	1992	339	8802					1156	1157		10.1016/0140-6736(92)90745-O	http://dx.doi.org/10.1016/0140-6736(92)90745-O			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT236	1349378				2022-12-01	WOS:A1992HT23600015
J	BUCHWALD, H				BUCHWALD, H			CHOLESTEROL INHIBITION, CANCER, AND CHEMOTHERAPY	LANCET			English	Note							CORONARY HEART-DISEASE; SERUM-CHOLESTEROL; PLASMA-CHOLESTEROL; MORTALITY; SUPPRESSION; MEVALONATE; LOVASTATIN; MORBIDITY; MEVINOLIN; PROGRAM	An important feature of malignant transformation is loss of the cholesterol feedback inhibition mechanism that regulates cholesterol synthesis. Cancer cells seem to require an increase in the concentrations of cholesterol and of cholesterol precursors. Therefore, a reasonable assumption is that prevention of tumour-cell growth can be achieved by restricting either cholesterol availability or cholesterol synthesis. In-vivo and cell-culture experiments have shown that lowering the plasma cholesterol concentration or intervening in the mevalonate pathway with 3-hydroxy-3-methylglutaryl (HMG) CoA reductase inhibitors decreases tumour growth. Currently prescribed doses of HMG-CoA reductase inhibitors given orally or continuously by an implantable infusion pump could achieve tumour therapeutic tissue concentrations of these agents. My hypothesis is that cholesterol inhibition can inhibit tumour cell growth, can act as an adjuvant to cancer chemotherapy, and, possibly, can prevent carcinogenesis.			BUCHWALD, H (corresponding author), UNIV MINNESOTA,DEPT SURG,BOX 290 UMHC,420 DELAWARE ST SE,MINNEAPOLIS,MN 55455, USA.							ADDLEMAN W, 1972, NEW ENGL J MED, V287, P1047; BLAU L, 1978, J BIOL CHEM, V253, P8366; BUCHWALD H, 1990, NEW ENGL J MED, V323, P946, DOI 10.1056/NEJM199010043231404; BUCHWALD H, 1989, INTERN MED SPECIALIS, V10, P182; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; Chen H W, 1978, Prog Exp Tumor Res, V22, P275; COWAN LD, 1990, AM J EPIDEMIOL, V131, P468, DOI 10.1093/oxfordjournals.aje.a115521; DUGGAN DE, 1989, DRUG METAB DISPOS, V17, P166; FAIRBANKS KP, 1986, J CELL PHYSIOL, V127, P216, DOI 10.1002/jcp.1041270205; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GORE IRENE YOUHOTSKY, 1962, BIOCHEM JOUR, V84, P93; ISLES CG, 1989, BMJ-BRIT MED J, V298, P920, DOI 10.1136/bmj.298.6678.920; KORT WJ, 1989, CLIN EXP METASTAS, V7, P517, DOI 10.1007/BF01753812; LITTMAN M. L., 1966, CANCER CHEMOTHERAP REP, V50, P25; MACDONALD JS, 1988, AM J CARDIOL, V62, pJ16, DOI 10.1016/0002-9149(88)90003-3; MALTESE WA, 1985, J CLIN INVEST, V76, P1748, DOI 10.1172/JCI112165; MORRIS PJ, 1992, EFFECT LOVASTATIN AD; MORRIS T J, 1991, Surgical Forum (Chicago), V42, P452; REINHART MP, 1987, J BIOL CHEM, V262, P9649; ROSE G, 1980, LANCET, V1, P523; SALONEN JT, 1982, AM J EPIDEMIOL, V116, P622, DOI 10.1093/oxfordjournals.aje.a113445; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SCHNEIDER PD, 1980, SURGERY, V87, P409; SIPERSTEIN MD, 1964, CANCER RES, V24, P1108; TORNBERG SA, 1989, JNCI-J NATL CANCER I, V81, P1917, DOI 10.1093/jnci/81.24.1917; VATTEN LJ, 1990, CANCER RES, V50, P2341; WINGARD DL, 1984, J CHRON DIS, V37, P401, DOI 10.1016/0021-9681(84)90107-3	27	118	120	5	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 9	1992	339	8802					1154	1156		10.1016/0140-6736(92)90744-N	http://dx.doi.org/10.1016/0140-6736(92)90744-N			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT236	1349377				2022-12-01	WOS:A1992HT23600014
J	BUNTINX, F; KNOTTNERUS, JA; CREBOLDER, HFJM; ESSED, GGM; SCHOUTEN, H				BUNTINX, F; KNOTTNERUS, JA; CREBOLDER, HFJM; ESSED, GGM; SCHOUTEN, H			RELATION BETWEEN QUALITY OF CERVICAL SMEARS AND PROBABILITY OF ABNORMAL RESULTS	BRITISH MEDICAL JOURNAL			English	Article									UNIV LIMBURG,DEPT GYNAECOL,6200 MD MAASTRICHT,NETHERLANDS; UNIV LIMBURG,DEPT MED STAT,6200 MD MAASTRICHT,NETHERLANDS	Hasselt University; Hasselt University	BUNTINX, F (corresponding author), UNIV LIMBURG,DEPT GEN PRACTICE,POB 616,6200 MD MAASTRICHT,NETHERLANDS.		Buntinx, Frank/E-4950-2011; Knottnerus, Andre/F-4866-2013; Knottnerus, Johannes A/A-3829-2009					BUNTINX F, 1991, ACTA CYTOL, V35, P64; MITCHELL H, 1991, LANCET, V337, P265, DOI 10.1016/0140-6736(91)90870-U; STEINER C, 1989, ACTA CYTOL, V33, P471; VOOIJS GP, 1988, NEW FRONTIERS CYTOLO, P412; ZUNA RE, 1984, POSTGRAD MED, V76, P36, DOI 10.1080/00325481.1984.11698775	5	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 9	1992	304	6836					1224	1224		10.1136/bmj.304.6836.1224	http://dx.doi.org/10.1136/bmj.304.6836.1224			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT964	1515793	Bronze, Green Published			2022-12-01	WOS:A1992HT96400024
J	CHALE, SS; SWAI, ABM; MUJINJA, PGM; MCLARTY, DG				CHALE, SS; SWAI, ABM; MUJINJA, PGM; MCLARTY, DG			MUST DIABETES BE A FATAL DISEASE IN AFRICA - STUDY OF COSTS OF TREATMENT	BRITISH MEDICAL JOURNAL			English	Article							TROPICAL AFRICA; TANZANIA; HEALTH	Objective - To estimate the costs of diagnosis and treatment of diabetes in Tanzania. Design - Costs estimated from the reported and recorded experience of patients with newly presenting diabetes in 1989-90 and of diabetic patients first seen in 1981-2. Setting - Muhimbili Medical Centre, Dar es Salaam. Subjects-464 patients (315 men and 149 women). 262 patients diagnosed during 1 September 1989-31 August 1990 (group 1) and 202 during 1 June 1981-31 August 1982 (group 2). Results-The average annual direct cost of diabetes care in 1989-90 was $287 for a patient requiring insulin and $103 for a patient not requiring insulin. Purchase of insulin accounted for 68.2% ($156) of the average annual outpatient costs for patients requiring insulin. For patients not requiring insulin the cost of oral hypoglycaemic drugs and treatment of chronic complications and infections accounted for 42.5% ($29.3) and 48.8% ($33.7) of costs respectively. Cost of outpatient care of diabetic patients for the whole of Tanzania was estimated at $2.7 m, $875 128 (32.2%) of which was for insulin. Doctors' and nurses' costs accounted for 0.2% of total costs of outpatient care. The annual direct inpatient care costs were estimated at $1.25m. Around 0.2% of the Tanzanian population aged 15 years and over used the equivalent of 8% of the total government health expenditure, which was $47 408 382. Conclusion - Diabetes places a severe strain on the limited resources of developing countries. If African patients with diabetes have to pay for their treatment most will be unable to do so and will die.	MUHIMBILI MED CTR,DEPT BEHAV SCI,DAR ES SALAAM,TANZANIA		CHALE, SS (corresponding author), MUHIMBILI MED CTR,DEPT MED,POB 65001,DAR ES SALAAM,TANZANIA.							AARON H, 1990, SCIENCE, V247, P418, DOI 10.1126/science.2300804; CORRIGAN CB, 1987, E AFR MED J, V64, P772; Enthoven A., 1984, HLTH DIS, P335; FOX NA, 1988, DIRECT INDIRECT COST; JOHNSON B, 1983, ACTA MED SCAND S, V671, P19; LAING W, 1989, DIABETES MODEL HLTH, P32; MCLARTY DG, 1989, LANCET, V1, P871; MCLARTY DG, 1990, BRIT MED J, V300, P1107, DOI 10.1136/bmj.300.6732.1107; ROLFE M, 1989, J ROY COLL PHYS LOND, V23, P255; SCOTT RS, 1985, DIABETES CARE, V8, P43, DOI 10.2337/diacare.8.1.43; SWAI ABM, 1990, BMJ-BRIT MED J, V300, P1103, DOI 10.1136/bmj.300.6732.1103; TRIOMPHE A, 1988, HEALTH POLICY, V9, P39, DOI 10.1016/0168-8510(88)90116-9; Vaughan P., 1989, Health Policy and Planning, V4, P97, DOI 10.1093/heapol/4.2.97; 1991, WHO FEATURES, P1; 1990, HALI YA UCHUMI WA TA; 1989, UNITED REPUBLIC TANZ	16	49	49	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 9	1992	304	6836					1215	1218		10.1136/bmj.304.6836.1215	http://dx.doi.org/10.1136/bmj.304.6836.1215			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT964	1515790	Green Published, Bronze			2022-12-01	WOS:A1992HT96400020
J	DAMICO, G; GENTILE, MG; MANNA, G; FELLIN, G; CICERI, R; COFANO, F; PETRINI, C; LAVARDA, F; PEROLINI, S; PORRINI, M				DAMICO, G; GENTILE, MG; MANNA, G; FELLIN, G; CICERI, R; COFANO, F; PETRINI, C; LAVARDA, F; PEROLINI, S; PORRINI, M			EFFECT OF VEGETARIAN SOY DIET ON HYPERLIPEMIA IN NEPHROTIC SYNDROME	LANCET			English	Article							RENAL-DISEASE; HORMONAL RESPONSES; PROTEIN INTAKE; CHOLESTEROL; PLASMA; LIPOPROTEINS; PRESSURE; LIPIDS	Nephrotic patients with persistent proteinuria also have various lipid abnormalities that may promote atherosclerosis and more rapid progression of renal disease. We aimed to find out whether dietary manipulation can correct the hyperlipidaemia found in these patients. After a baseline control period of 8 weeks on their usual diets, 20 untreated patients with chronic glomerular diseases, stable long-lasting severe proteinuria (5.9 [SD 3.4] g/24 h) and hyperlipidaemia (mean serum cholesterol 8.69 [3.34] mmol/l) ate a vegetarian soy diet for 8 weeks. The diet was low in fat (28% of total calories) and protein (0.71 [0.36] g/kg ideal body weight daily), cholesterol free, and rich in monounsaturated and polyunsaturated fatty acids (polyunsaturated/saturated ratio 2.5) and in fibre (40 g/day). After the diet period the patients resumed their usual diets for 8 weeks (washout period). During the soy-diet period there were significant falls in serum cholesterol (total, low-density lipoprotein, and high-density lipoprotein) and apolipoproteins A and B, but serum triglyceride concentrations did not change. Urinary protein excretion fell significantly. The concentrations of all lipid fractions and the amount of proteinuria tended to return towards baseline values during the washout period. We do not know whether the favourable effect of this dietary manipulation on proteinuria was due to the qualitative or quantitative modifications of dietary protein intake or was a direct consequence of the manipulation of dietary lipid intake.	SAN CARLO HOSP,CLIN PATHOL LAB,I-20153 MILAN,ITALY; UNIV MILAN,DEPT FOOD SCI & MICROBIOL,I-20122 MILAN,ITALY	San Carlo Borromeo Hospital; University of Milan	DAMICO, G (corresponding author), SAN CARLO HOSP,DIV NEPHROL,VIA PIO II3,I-20153 MILAN,ITALY.		porrini, marisa/AAF-6788-2021	porrini, marisa/0000-0003-2693-3311				APPEL GB, 1985, NEW ENGL J MED, V312, P1544, DOI 10.1056/NEJM198506133122404; BARCELLI UO, 1991, KIDNEY INT, V39, pS57; BRUSSAARD JH, 1982, ATHEROSCLEROSIS, V42, P205, DOI 10.1016/0021-9150(82)90151-4; CONNOR WE, 1990, NEW ENGL J MED, V322, P193, DOI 10.1056/NEJM199001183220309; DAMICO G, 1991, CLIN NEPHROL, V6, P237; DIAMOND JR, 1988, KIDNEY INT, V33, P917, DOI 10.1038/ki.1988.87; FEEHALLY J, 1988, NEPHRON, V50, P247, DOI 10.1159/000185167; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; KASISKE BL, 1990, AM J KIDNEY DIS, V15, P8, DOI 10.1016/S0272-6386(12)80586-5; KAYSEN GA, 1989, J CLIN INVEST, V83, P1623, DOI 10.1172/JCI114060; KAYSEN GA, 1986, KIDNEY INT, V29, P572, DOI 10.1038/ki.1986.36; KAYSEN GA, 1991, AM J PHYSIOL, V260, pF177, DOI 10.1152/ajprenal.1991.260.2.F177; KEANE WF, 1990, NEW ENGL J MED, V323, P603, DOI 10.1056/NEJM199008303230910; KEANE WF, 1991, KIDNEY INT, V39, pS41; KESTIN M, 1990, AM J CLIN NUTR, V51, P1028, DOI 10.1093/ajcn/51.6.1028; KLAHR S, 1983, KIDNEY INT, V24, P579, DOI 10.1038/ki.1983.197; KONTESSIS P, 1990, KIDNEY INT, V38, P136, DOI 10.1038/ki.1990.178; LEVEY AS, 1989, KIDNEY INT, V36, pS73; MALLICK NP, 1981, NEPHRON, V27, P54, DOI 10.1159/000182024; MARONI BJ, 1985, KIDNEY INT, V27, P58, DOI 10.1038/ki.1985.10; MEINERTZ H, 1989, AM J CLIN NUTR, V50, P786, DOI 10.1093/ajcn/50.4.786; MOORHEAD JF, 1989, AM J MED, V87, P12; NESTEL P, 1983, ARTERIOSCLEROSIS, V3, P132, DOI 10.1161/01.ATV.3.2.132; REMUZZI A, 1991, AM J KIDNEY DIS, V17, P317, DOI 10.1016/S0272-6386(12)80481-1; ROSENBERG ME, 1987, AM J PHYSIOL, V253, pF1083, DOI 10.1152/ajprenal.1987.253.6.F1083; SACKS FM, 1975, NEW ENGL J MED, V292, P1148, DOI 10.1056/NEJM197505292922203; SCHMITZ PG, 1989, SEMIN NEPHROL, V9, P354; SCHREINER GF, 1991, KIDNEY INT, V39, pS49; SHAEFER EJ, 1981, AM J CLIN NUTR, V34, P1758	29	92	93	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 9	1992	339	8802					1131	1134		10.1016/0140-6736(92)90731-H	http://dx.doi.org/10.1016/0140-6736(92)90731-H			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT236	1349366				2022-12-01	WOS:A1992HT23600003
J	FACCHINI, FS; HOLLENBECK, CB; JEPPESEN, J; CHEN, YDI; REAVEN, GM				FACCHINI, FS; HOLLENBECK, CB; JEPPESEN, J; CHEN, YDI; REAVEN, GM			INSULIN RESISTANCE AND CIGARETTE-SMOKING	LANCET			English	Article							CORONARY-ARTERY DISEASE; RISK-FACTORS; DENSITY LIPOPROTEIN; GLUCOSE-TOLERANCE; HYPERTRIGLYCERIDEMIA; TRIGLYCERIDE; CHOLESTEROL; MEN	Cigarette smoking is associated with increases in plasma triglycerides and decreases in plasma high density-lipoprotein-cholesterol concentration. These changes not only increase risk of coronary heart disease but also are secondary to resistance to insulin-stimulated glucose uptake or hyperinsulinaemia. To see whether there is a relation between cigarette smoking and insulin-mediated glucose uptake we measured plasma lipid and lipoprotein concentrations, plasma glucose and insulin response to an oral glucose challenge, and insulin-mediated glucose uptake in 40 matched healthy volunteers (20 non-smokers, 20 smokers). Smokers had significantly higher mean (SEM) very-low-density-lipoprotein triglycerides (0.66 [0.10] vs 0.39 [0.03] mmol/l, p < 0.02) and cholesterol (0.45 [0.06] vs 0.23 [0.04] mmol/l, p < 0.005) concentrations and lower high-density-lipoprotein cholesterol concentrations (1.16 [0.05] vs l.51 [0.08]mmol/l, p < 0.001). Although plasma glucose concentrations in response to the oral glucose load were similar in the two groups, plasma insulin response of the smokers was significantly higher (p < 0.001). Finally, smokers had higher steady-state plasma glucose concentrations in response to a continuous infusion of glucose, insulin, and somatostatin (8.4 [0.2] vs 5.0 [0.3] mmol/l, p < 0.001), despite similar steady-state plasma insulin concentrations. The findings show that chronic cigarette smokers are insulin resistant, hyperinsulinaemic, and dyslipidaemic compared with a matched group of non-smokers, and may help to explain why smoking increases risk of coronary heart disease.	VET AFFAIRS MED CTR,GERIATR RES EDUC & CLIN CTR,PALO ALTO,CA 94304	Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NCRR NIH HHS [RR 00070] Funding Source: Medline; NHLBI NIH HHS [HL 08506] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000070] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AUSTIN MA, 1991, ARTERIOSCLER THROMB, V11, P2, DOI 10.1161/01.ATV.11.1.2; CARLSON LA, 1979, ACTA MED SCAND, V206, P351; CRAIG WY, 1989, BMJ-BRIT MED J, V298, P784, DOI 10.1136/bmj.298.6676.784; DEFRONZO RA, 1979, DIABETES, V28, P1095, DOI 10.2337/diab.28.12.1095; FREEDMAN DS, 1986, AM J EPIDEMIOL, V124, P207; HOFFMAN D, 1986, WHO IARC, P45; JANZON L, 1983, DIABETOLOGIA, V25, P86; KANNEL WB, 1981, AM HEART J, V101, P319, DOI 10.1016/0002-8703(81)90197-6; LAWS A, 1989, J CLIN ENDOCR METAB, V69, P343, DOI 10.1210/jcem-69-2-343; MCGILL CG, 1991, ADV EXP MED BIOL, V273, P9; OLEFSKY J, 1974, J CLIN INVEST, V53, P64, DOI 10.1172/JCI107560; OLEFSKY JM, 1974, AM J MED, V57, P551, DOI 10.1016/0002-9343(74)90006-0; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; ROSENTHAL M, 1983, DIABETES, V32, P408, DOI 10.2337/diabetes.32.5.408; SALLIS JF, 1985, AM J EPIDEMIOL, V121, P91, DOI 10.1093/oxfordjournals.aje.a113987; SHEN DC, 1988, J CLIN ENDOCR METAB, V66, P580, DOI 10.1210/jcem-66-3-580; SHEN SW, 1970, J CLIN INVEST, V49, P2151, DOI 10.1172/JCI106433; SHIRAISHI I, 1991, DIABETOLOGIA, V34, P737, DOI 10.1007/BF00401520; TOBEY TA, 1981, METABOLISM, V30, P165, DOI 10.1016/0026-0495(81)90167-0; WILLETT W, 1983, AM HEART J, V105, P417, DOI 10.1016/0002-8703(83)90358-7; WILLIAMS P, 1979, LANCET, V1, P72; ZAVARONI I, 1989, NEW ENGL J MED, V320, P702, DOI 10.1056/NEJM198903163201105	22	548	565	1	26	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 9	1992	339	8802					1128	1130		10.1016/0140-6736(92)90730-Q	http://dx.doi.org/10.1016/0140-6736(92)90730-Q			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT236	1349365				2022-12-01	WOS:A1992HT23600002
J	FILSHIE, GM; MAYNARD, P; HUTTER, C; COOPER, JC; ROBINSON, G; RUBIN, P				FILSHIE, GM; MAYNARD, P; HUTTER, C; COOPER, JC; ROBINSON, G; RUBIN, P			URINARY 5-HYDROXYINDOLE ACETATE CONCENTRATION IN PREGNANCY INDUCED HYPERTENSION	BRITISH MEDICAL JOURNAL			English	Article							ECLAMPSIA				FILSHIE, GM (corresponding author), UNIV NOTTINGHAM HOSP,QUEENS MED CTR,DEPT PATHOL,NOTTINGHAM NG7 2UH,ENGLAND.							HORN EH, 1990, BRIT MED J, V301, P794, DOI 10.1136/bmj.301.6755.794; JAAMERI KEU, 1965, GYNAECOLOGIA, V160, P315; JELEN I, 1979, BRIT J OBSTET GYNAEC, V86, P468, DOI 10.1111/j.1471-0528.1979.tb10791.x; WEINER CP, 1987, AM J OBSTET GYNECOL, V156, P885, DOI 10.1016/0002-9378(87)90345-0; WHIGHAM KAE, 1978, BRIT J OBSTET GYNAEC, V85, P28, DOI 10.1111/j.1471-0528.1978.tb15820.x	5	13	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 9	1992	304	6836					1223	1223		10.1136/bmj.304.6836.1223	http://dx.doi.org/10.1136/bmj.304.6836.1223			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT964	1381251	Green Published, Bronze			2022-12-01	WOS:A1992HT96400023
J	HARLEY, HG; RUNDLE, SA; REARDON, W; MYRING, J; CROW, S; BROOK, JD; HARPER, PS; SHAW, DJ				HARLEY, HG; RUNDLE, SA; REARDON, W; MYRING, J; CROW, S; BROOK, JD; HARPER, PS; SHAW, DJ			UNSTABLE DNA-SEQUENCE IN MYOTONIC-DYSTROPHY	LANCET			English	Article								A variable DNA sequence has been detected in patients with myotonic dystrophy. We set out to determine whether identification of this specific molecular defect would improve clinical management of patients and families with myotonic dystrophy. 127 affected patients who were studied had an expanded DNA fragment not seen in 73 normal controls. The increase in length of the fragment correlated broadly with disease severity, and we noted expansion of the sequence in successive generations of the same family. Progressive expansion of the affected gene provides a molecular explanation for an apparently earlier onset in successive generations (anticipation) in myotonic dystrophy and supports the role of an unstable repeat sequence as the basis of the defect. The specificity of this finding will assist in accurate diagnosis of myotonic dystrophy and genetic counselling of affected families.	MIT,CTR CANC RES,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)	HARLEY, HG (corresponding author), UNIV WALES COLL CARDIFF,COLL MED,INST MED GENET,HEATH PK,CARDIFF CF4 6EJ,WALES.			Brook, John David/0000-0002-5946-6740	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ASLANIDIS C, 1992, NATURE, V355, P548, DOI 10.1038/355548a0; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; BUXTON J, 1992, NATURE, V355, P547, DOI 10.1038/355547a0; Fleiseher B., 1918, ALBRECHT GRAEFES ARC, V96, P91, DOI DOI 10.1007/BF02018704; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; HARLEY HG, 1991, AM J HUM GENET, V49, P68; HARLEY HG, 1992, NATURE, V355, P545, DOI 10.1038/355545a0; Harper P.S., 1989, MYOTONIC DYSTROPHY; HARPER PS, 1972, LANCET, V2, P53; HARPER PS, IN PRESS AM J HUM GE; HOWELER CJ, 1989, BRAIN, V112, P779, DOI 10.1093/brain/112.3.779; SHAW DJ, 1989, BRIT MED BULL, V45, P745, DOI 10.1093/oxfordjournals.bmb.a072355; SUTHERLAND GR, 1991, LANCET, V338, P289, DOI 10.1016/0140-6736(91)90426-P	13	178	185	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 9	1992	339	8802					1125	1128		10.1016/0140-6736(92)90729-M	http://dx.doi.org/10.1016/0140-6736(92)90729-M			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT236	1349364				2022-12-01	WOS:A1992HT23600001
J	HIRSCHOWITZ, L; RAFFLE, AE; MACKENZIE, EFD; HUGHES, AO				HIRSCHOWITZ, L; RAFFLE, AE; MACKENZIE, EFD; HUGHES, AO			LONG-TERM FOLLOW-UP OF WOMEN WITH BORDERLINE CERVICAL SMEAR TEST-RESULTS - EFFECTS OF AGE AND VIRAL-INFECTION ON PROGRESSION TO HIGH-GRADE DYSKARYOSIS	BRITISH MEDICAL JOURNAL			English	Article							HUMAN PAPILLOMAVIRUS INFECTION; GYNECOLOGICAL CYTO-PATHOLOGY; CANCER; TERMINOLOGY; COLPOSCOPY; MANAGEMENT; ATYPIA; RISK	Objective - To follow up and assess the significance of borderline change in cervical smears. Design - Retrospective study of women undergoing routine cervical cytological screening in 1981. Setting - Avon Cervical Screening Programme, covering 250 000 women in Bristol and Weston super Mare. Subjects - 437 women showing borderline cervical changes in 1981 and 437 age matched controls with normal results in 1981. Main outcome measures - Cytological progression to high grade dyskaryosis (cervical intraepithelial neoplasia grade III or invasive carcinoma). Results - During follow up ranging from 13 to 106 months 98 of the 437 women (22.4%) with borderline cytological changes on routine cervical cytology screening had a subsequent smear test showing high grade dyskaryosis compared with three of the 437 women (0.9%) in the control group. The risk of progression was greater in women aged 20 to 39 than in those aged 40 and over. Human papillomavirus infection had initially been diagnosed cytologically in 101 of the 437 (23%) women with borderline results. Significantly fewer of these women developed high grade dyskaryosis (13/98 (13%) v 88/339 (26%), p < 0.05). Conclusions - Women with borderline smear test results are at increased risk of developing high grade dyskaryosis, particularly if the borderline changes occur without cytological features of human papillomavirus infection. Progression occurs within three years in 50% of cases, although a linearly increasing risk was sustained over the nine years of follow up and was greatest in women aged 20 to 39. Careful follow up of these women is indicated.	BRISTOL ROYAL INFIRM & GEN HOSP,DEPT HISTOPATHOL,BRISTOL BS2 8HW,AVON,ENGLAND; SOUTHMEAD GEN HOSP,DEPT PUBL HLTH MED,BRISTOL BS10 5NB,AVON,ENGLAND; SOUTHMEAD GEN HOSP,DEPT CYTOL,BRISTOL BS10 5NB,AVON,ENGLAND; BRISTOL MED SCH,DEPT EPIDEMIOL,BRISTOL B58 2PR,ENGLAND	Bristol Royal Infirmary; Southmead Hospital; Southmead Hospital; University of Bristol								CAMPION MJ, 1986, LANCET, V2, P237; DAVIS RM, 1972, OBSTET GYNECOL, V40, P23; EVANS DMD, 1987, J CLIN PATHOL, V40, P530, DOI 10.1136/jcp.40.5.530; EVANS DMD, 1986, J CLIN PATHOL, V39, P933, DOI 10.1136/jcp.39.9.933; GILES JA, 1989, BRIT J OBSTET GYNAEC, V96, P1967; HULKA BS, 1968, AM J OBSTET GYNECOL, V101, P190, DOI 10.1016/0002-9378(68)90187-7; JENKINS D, 1987, LANCET, V1, P748; KINLEN LJ, 1978, LANCET, V2, P463; KIRKUP W, 1982, BRIT J OBSTET GYNAEC, V89, P571, DOI 10.1111/j.1471-0528.1982.tb03662.x; KITCHENER HC, 1988, BRIT J OBSTET GYNAEC, V95, P182, DOI 10.1111/j.1471-0528.1988.tb06849.x; KITCHENER HC, 1988, BRIT J OBSTET GYNAEC, V95, P1089, DOI 10.1111/j.1471-0528.1988.tb06783.x; KRISTENSEN GB, 1991, ACTA CYTOL, V35, P47; MITCHELL H, 1986, LANCET, V1, P573; NASIELL K, 1983, OBSTET GYNECOL, V61, P609; NUOVO GJ, 1988, AM J SURG PATHOL, V12, P198, DOI 10.1097/00000478-198803000-00005; NYIRJESY I, 1972, J AMER MED ASSOC, V222, P691; PAIRWUTI S, 1991, ACTA CYTOL, V35, P40; RAFFLE AE, 1990, BMJ-BRIT MED J, V301, P907, DOI 10.1136/bmj.301.6757.907; RICHART RM, 1969, AM J OBSTET GYNECOL, V105, P386, DOI 10.1016/0002-9378(69)90268-3; ROBERTSON JH, 1988, BRIT MED J, V297, P18, DOI 10.1136/bmj.297.6640.18; SINGER A, 1991, BRIT MED J, V302, P251, DOI 10.1136/bmj.302.6771.251; SOUTTER WP, 1986, BRIT J OBSTET GYNAEC, V93, P70, DOI 10.1111/j.1471-0528.1986.tb07816.x; TIDY JA, 1989, LANCET, V1, P434; 1989, LANCET, V2, P1051	24	44	44	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 9	1992	304	6836					1209	1212		10.1136/bmj.304.6836.1209	http://dx.doi.org/10.1136/bmj.304.6836.1209			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT964	1325232	Bronze, Green Published			2022-12-01	WOS:A1992HT96400018
J	HUSSAIN, SF; WATURA, R; CASHMAN, B; CAMPBELL, IA; EVANS, MR				HUSSAIN, SF; WATURA, R; CASHMAN, B; CAMPBELL, IA; EVANS, MR			AUDIT OF A TUBERCULOSIS CONTACT TRACING CLINIC	BRITISH MEDICAL JOURNAL			English	Article								Objective - To determine the efficiency of tuberculosis contact tracing in South Glamorgan 1987-9. Design - Review of records of contact tracing clinic and of data from the Mycobacterium Reference Unit. The clinic's practice was compared with 1983 British Thoracic Society's recommendations. Setting - Health authority tuberculosis control programme. Main outcome measures - Proportion of contacts screened, follow up attendance rates, number of secondary cases detected, and quality of record keeping. Results - 101 index patients and 611 contacts were identified. 596 (97.5%) contacts were screened, of whom 139 should not have been. Of 356 contacts requiring a Heaf test, 237 were tested, seven refused the test, and 112 had chest radiography without a Heaf test. 95 contacts were unnecessarily tested. 87 contacts had chest radiography unnecessarily and seven should have had radiography but did not. 34 contacts were given follow up appointments inappropriately and seven were overlooked for follow up. Tuberculosis was diagnosed in five asymptomatic contacts, all at initial screening and all close contacts of index patients with pulmonary disease. Conclusion - Inadequacy of data, non-adherence to contact tracing guidelines, and failure to define the term highly infectious index case resulted in many contacts being unnecessarily screened or followed up. Implications - The efficiency of tracing contacts would be improved by specifying smear results and ethnic origin of the index case on the notification form, clearly classifying contacts as close or casual, and clearly defining the term highly infectious.	LLANDOUGH HOSP,DEPT CHEST MED,CARDIFF CF6 1XX,WALES; TEMPLE PEACE & HLTH,CTR APPL PUBL HLTH,CARDIFF CF1 3NW,WALES; TEMPLE PEACE & HLTH,DEPT PUBL HLTH MED,CARDIFF CF1 3NW,WALES				Evans, Meirion/C-2990-2008	Evans, Meirion/0000-0003-3578-1866				[Anonymous], 1978, Tubercle, V59, P245; ESMONDE TFG, 1991, RESP MED, V85, P421, DOI 10.1016/S0954-6111(06)80188-5; JONES JS, 1983, LANCET, V1, P232; SELBY CD, 1988, THORAX, V43, pP834; 1990, BMJ, V300, P995; 1983, BMJ, V287, P1118	6	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 9	1992	304	6836					1213	1215		10.1136/bmj.304.6836.1213	http://dx.doi.org/10.1136/bmj.304.6836.1213			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT964	1515789	Green Published, Bronze			2022-12-01	WOS:A1992HT96400019
J	SCAMBLER, PJ; KELLY, D; LINDSAY, E; WILLIAMSON, R; GOLDBERG, R; SHPRINTZEN, R; WILSON, DI; GOODSHIP, JA; CROSS, IE; BURN, J				SCAMBLER, PJ; KELLY, D; LINDSAY, E; WILLIAMSON, R; GOLDBERG, R; SHPRINTZEN, R; WILSON, DI; GOODSHIP, JA; CROSS, IE; BURN, J			VELO-CARDIO-FACIAL SYNDROME ASSOCIATED WITH CHROMOSOME-22 DELETIONS ENCOMPASSING THE DIGEORGE LOCUS	LANCET			English	Note								The large clinical overlap between DiGeorge syndrome and velo-cardio-facial syndrome suggests an aetiological connection. DiGeorge syndrome is associated with microdeletions of chromosome 22q11 and is therefore likely to be caused by reduced dosage of genes within this region. We present preliminary data that velocardiofacial syndrome patients have similar chromosome deletions, a finding consistent with the hypothesis that these disorders represent part of a spectrum of abnormalities seen with monosomy for 22q11.	MONTEFIORE MED CTR,CTR CRANIOFACIAL DISORDERS,BRONX,NY 10467; UNIV NEWCASTLE UPON TYNE,DIV HUMAN GENET & CYTOGENET,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Newcastle University - UK	SCAMBLER, PJ (corresponding author), ST MARYS HOSP,SCH MED,DEPT BIOCHEM & MOLEC GENET,LONDON W2 1PG,ENGLAND.		Scambler, Peter J/C-4998-2008; Wilson, David I/A-6264-2010; Scambler, Peter/AAZ-6026-2020	Scambler, Peter J/0000-0002-1487-4628; Wilson, David I/0000-0001-8779-2060; Scambler, Peter/0000-0002-1487-4628				CAREY AH, 1990, GENOMICS, V7, P299, DOI 10.1016/0888-7543(90)90161-M; CAREY AH, 1991, THESIS U LONDON UK; CAREY AH, IN PRESS MAMMAL GENO; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; McKusick VA, 1990, MENDELIAN INHERITANC; SCAMBLER PJ, 1991, GENOMICS, V10, P201, DOI 10.1016/0888-7543(91)90501-5; SHARKEY AM, IN PRESS HUM GENET; SHPRINTZEN RJ, 1990, BIRTH DEFECTS ENCY, P1744; STEVENS CA, 1990, PEDIATRICS, V85, P526; WILSON DI, 1991, BRIT HEART J, V66, P308	10	366	372	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 9	1992	339	8802					1138	1139		10.1016/0140-6736(92)90734-K	http://dx.doi.org/10.1016/0140-6736(92)90734-K			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT236	1349369				2022-12-01	WOS:A1992HT23600006
J	STRANG, J; GRIFFITHS, P; POWIS, B; GOSSOP, M				STRANG, J; GRIFFITHS, P; POWIS, B; GOSSOP, M			1ST USE OF HEROIN - CHANGES IN ROUTE OF ADMINISTRATION OVER TIME	BRITISH MEDICAL JOURNAL			English	Article											STRANG, J (corresponding author), MAUDSLEY HOSP & INST PSYCHIAT,NATL ADDICT CTR,DRUG TRANSIT STUDY,LONDON SE5 8AF,ENGLAND.		Strang, John/H-5460-2011	Strang, John/0000-0002-5413-2725				BEWLEY TH, 1967, BRIT MED J, V2, P498, DOI 10.1136/bmj.2.5550.498; BRETTLE RP, 1987, BRIT MED J, V295, P421, DOI 10.1136/bmj.295.6595.421; GOSSOP M, 1988, BRIT J ADDICT, V83, P1159; PARKER H, 1987, BRIT J ADDICT, V82, P147; 1991, STATISTICAL B MISUSE	5	39	39	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 9	1992	304	6836					1222	1223		10.1136/bmj.304.6836.1222	http://dx.doi.org/10.1136/bmj.304.6836.1222			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HT964	1515792	Green Published, Bronze			2022-12-01	WOS:A1992HT96400022
J	WORMALD, RPL; WRIGHT, LA; COURTNEY, P; BEAUMONT, B; HAINES, AP				WORMALD, RPL; WRIGHT, LA; COURTNEY, P; BEAUMONT, B; HAINES, AP			VISUAL PROBLEMS IN THE ELDERLY POPULATION AND IMPLICATIONS FOR SERVICES	BRITISH MEDICAL JOURNAL			English	Article							EYE DISEASE; PREVALENCE	Objective - To determine the prevalence of visual disability and common eye disease among elderly people in inner London. Design - Cross sectional random sample survey. Setting - Inner London health centre. Subjects - Random sample of people aged 65 and over taken from practice's computerised age-sex register. Main outcome measures - Presenting binocular Snellen 6 m distance acuity and best monocular 3 m Sonksen-Silver acuity to classify prevalence of blindness by World Health Organisation criteria (less than 3/60 in better eye) and American criteria for legal blindness (better eye equal to 6/60 or less) and of low vision by WHO criteria (best acuity 6/18) and visual impairment by American criteria (less than 6/12 or 20/40 but greater than 6/60 or 20/200 in better eye). Principal cause of visual loss by diagnosis, referral indication by cause to hospital eye service, and proportion of cases known to primary care. Results - 207 of 288 (72%) eligible people were examined. 17 (8%) housebound subjects were examined at home. The prevalence of blindness was 1% by WHO criteria and 3.9% by American criteria. The prevalence of low vision (WHO criteria) was 7.7%. The prevalence of visual impairment (American criteria) was 10.6%. Cataract accounted for 75% of cases of low vision. Only eight out of 16 patients with low vision were known by their general practitioner to have an eye problem. 56 subjects (27%) would probably have benefited from refraction. Comparisons with studies in the United States and Finland suggested higher rates in this sample, mainly due to the prevalence of disabling cataract. Conclusion - There seems to be a considerable amount of undetected ocular disease in elderly people in the community.	INST OPHTHALMOL,DEPT PREVENT MED,LONDON EC1V 9EJ,ENGLAND; WHITTINGTON HOSP,UNIV COLL & MIDDLESEX SCH MED,LONDON N19 5NF,ENGLAND	University of London; University College London; University of London; University College London				Haines, Andy/0000-0002-8053-4605				BRENNAN ME, 1973, BRIT J PREV SOC MED, V27, P154; CULLINAN TR, 1977, 28 HLTH SERV RES UN; FREER CB, 1990, BRIT MED J, V300, P1447, DOI 10.1136/bmj.300.6737.1447; GARDNER S, 1989, CONFIDENCE INTERVAL; GIBSON JM, 1985, T OPHTHAL SOC UK, V104, P196; HAKKINEN L, 1984, SCAND J SOC MED S, V35; HITCHINGS RA, 1989, BRIT MED J, V298, P1126, DOI 10.1136/bmj.298.6681.1126; LESKE MC, 1991, ARCH OPHTHALMOL-CHIC, V109, P244, DOI 10.1001/archopht.1991.01080020090051; MARTINEZ GS, 1982, AM J OPHTHALMOL, V94, P181, DOI 10.1016/0002-9394(82)90073-3; PIZZARELLO LD, 1987, OPHTHALMOLOGY, V94, P1191; SANDERSON D, 1986, CANADIAN NURSE   FEB, P19; TIELSCH JM, 1990, ARCH OPHTHALMOL-CHIC, V108, P286, DOI 10.1001/archopht.1990.01070040138048; 1988, 1 OFF POP CENS SURV; 1980, SURV OPHTHALMOL S, V24, P335	14	116	118	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 9	1992	304	6836					1226	1229		10.1136/bmj.304.6836.1226	http://dx.doi.org/10.1136/bmj.304.6836.1226			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HT964	1515797	Green Published, Bronze			2022-12-01	WOS:A1992HT96400028
J	GAVISH, M; WANG, JL; EISENSTEIN, M; LAHAV, M; LEISEROWITZ, L				GAVISH, M; WANG, JL; EISENSTEIN, M; LAHAV, M; LEISEROWITZ, L			THE ROLE OF CRYSTAL POLARITY IN ALPHA-AMINO-ACID CRYSTALS FOR INDUCED NUCLEATION OF ICE	SCIENCE			English	Article							CONSISTENT FORCE-FIELD; WATER; CRYSTALLIZATION; DENSITIES; PEPTIDES	The hydrophobic faces of single crystals of a series of pairs of racemic and chiral-resolved hydrophobic alpha-amino acids were used as a substrate, onto which water vapor has been cooled to freezing. The morphologies and molecular packing arrangements within each crystal pair are similar but only one of each pair exhibits a polar axis, parallel to the hydrophobic face exposed to water. Those crystals that have a polar axis induce a freezing point higher by 4-degrees to 5-degrees-C than the corresponding crystals that do not have a polar axis. The results are interpreted in terms of an electric field mechanism that helps align the water molecules into ice-like clusters en route to crystallization.	WEIZMANN INST SCI, DEPT MAT & INTERFACES, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science								BARTHAKUR N, 1963, NATURE, V200, P866, DOI 10.1038/200866a0; BENEDETTI E, 1973, ACTA CRYSTALLOGR B, V29, P730, DOI 10.1107/S0567740873003250; Blair D. N., 1973, Journal of Applied Meteorology, V12, P1012, DOI 10.1175/1520-0450(1973)012<1012:CCTOGU>2.0.CO;2; COLL M, 1986, ACTA CRYSTALLOGR C, V42, P599, DOI 10.1107/S0108270186095240; CORRIN ML, 1968, J PHYS CHEM-US, V72, P643, DOI 10.1021/j100848a043; DAVIS BL, 1975, J APPL METEOROL, V14, P891, DOI 10.1175/1520-0450(1975)014<0891:AEFTUN>2.0.CO;2; DESTRO R, 1988, J PHYS CHEM-US, V92, P966, DOI 10.1021/j100315a022; DEVRIES AL, 1984, PHILOS T R SOC B, V304, P575; DIBLASIO B, 1975, ACTA CRYSTALLOGR B, V31, P601, DOI 10.1107/S0567740875003342; DONOHUE J, 1950, J AM CHEM SOC, V72, P949, DOI 10.1021/ja01158a079; EISENSTEIN M, 1988, ACTA CRYSTALLOGR B, V44, P412, DOI 10.1107/S0108768188002356; FEENEY RE, 1986, ANNU REV BIOPHYS BIO, V15, P59; GAVISH M, 1990, SCIENCE, V250, P973, DOI 10.1126/science.250.4983.973; GRAYER S, 1990, THESIS WEIZMANN I SC; GRAYER S, 1986, THESIS WEIZMANN I SC; GREEN RL, 1985, NATURE, V317, P645, DOI 10.1038/317645a0; HAGLER AT, 1974, J AM CHEM SOC, V96, P5319, DOI 10.1021/ja00824a004; HIRSHFELD FL, 1977, THEOR CHIM ACTA, V44, P129, DOI 10.1007/BF00549096; HIRSHFELD FL, 1977, ISRAEL J CHEM, V16, P226; HIRSHFELD FL, 1971, ACTA CRYSTALL B-STRU, VB 27, P769, DOI 10.1107/S0567740871002905; JACQUEMAIN D, 1991, J AM CHEM SOC, V113, P7684, DOI 10.1021/ja00020a034; LIFSON S, 1979, J AM CHEM SOC, V101, P5111, DOI 10.1021/ja00512a001; LINDOW SE, 1983, ANNU REV PHYTOPATHOL, V21, P363, DOI 10.1146/annurev.py.21.090183.002051; MALLIKARJUNAN M, 1969, ACTA CRYSTALL B-STRU, VB 25, P296, DOI 10.1107/S0567740869002147; MATHIESON AM, 1952, ACTA CRYSTALLOGR, V5, P332; MATHIESON AM, 1953, ACTA CRYSTALLOGR, V6, P399; MIZUNO H, 1989, PROTEINS, V5, P47, DOI 10.1002/prot.340050107; MOSTAD A, 1972, ACTA CHEM SCAND, V26, P3819, DOI 10.3891/acta.chem.scand.26-3819; MOSTAD A, 1973, ACTA CHEM SCAND, V27, P401, DOI 10.3891/acta.chem.scand.27-0401; PARUNGO FP, 1965, J ATMOS SCI, V22, P309, DOI 10.1175/1520-0469(1965)022<0309:MSAINO>2.0.CO;2; PARUNGO FP, 1967, J ATMOS SCI, V24, P274, DOI 10.1175/1520-0469(1967)024<0274:AAAIN>2.0.CO;2; POWER BA, 1962, NATURE, V194, P1170, DOI 10.1038/1941170a0; SIMPSON HJ, 1966, ACTA CRYSTALLOGR, V20, P550, DOI 10.1107/S0365110X66001221; STOREY KB, 1990, SCI AM, V263, P92, DOI 10.1038/scientificamerican1290-92; TORII K, 1970, ACTA CRYSTALL B-STRU, VB 26, P1317, DOI 10.1107/S0567740870004065; TORII K, 1971, ACTA CRYSTALL B-STRU, VB 27, P2237, DOI 10.1107/S0567740871005612; TORII K, 1973, ACTA CRYSTALLOGR B, V29, P2799, DOI 10.1107/S0567740873007569; VONNEGUT B, 1947, J APPL PHYS, V18, P593, DOI 10.1063/1.1697813; WANG JC, UNPUB; WEISSBUCH I, 1990, J AM CHEM SOC, V112, P7718, DOI 10.1021/ja00177a036; ZHU SB, 1991, J CHEM PHYS, V94, P1403, DOI 10.1063/1.459998	41	137	143	3	82	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 8	1992	256	5058					815	818		10.1126/science.1589763	http://dx.doi.org/10.1126/science.1589763			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT235	1589763				2022-12-01	WOS:A1992HT23500037
J	GISHIZKY, ML; WITTE, ON				GISHIZKY, ML; WITTE, ON			INITIATION OF DEREGULATED GROWTH OF MULTIPOTENT PROGENITOR CELLS BY BCR-ABL INVITRO	SCIENCE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE KINASE-ACTIVITY; MYELOID-LEUKEMIA; MICE; TRANSFORMATION; INDUCTION; CULTURES; PROTEIN; BCR/ABL; REGION	Expression of the bcr-abl oncogene in multipotent progenitor cells (MPPCs) is implicated as a key event in the development of chronic myelogenous leukemia. Bone marrow enriched for MPPCs was infected with a retrovirus that carried bcr-abl. The mixed-lineage colonies that resulted were responsive to growth factors and could differentiate. These cells later became growth factor-independent but, when injected into severe combined immunodeficient mice, were not leukemogenic. Thus, the presence of bcr-abl alone does not cause growth factor independence, although it initiates a stepwise process. This system may prove useful in the study of other oncogenes that cause leukemia.	UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,DEPT MICROBIOL & MOLEC GENET,LOS ANGELES,CA 90024	Howard Hughes Medical Institute; University of California System; University of California Los Angeles	GISHIZKY, ML (corresponding author), UNIV CALIF LOS ANGELES,DEPT MICROBIOL & MOLEC GENET,LOS ANGELES,CA 90024, USA.							AHUJA H, 1991, J CLIN INVEST, V87, P2042, DOI 10.1172/JCI115234; BODINE DM, 1991, BLOOD, V78, P914; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; COLLINS LS, 1987, J IMMUNOL, V138, P1082; COLLINS SJ, 1990, CHRONIC MYELOGENOUS, P253; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DEVRIES P, 1991, J EXP MED, V173, P1205, DOI 10.1084/jem.173.5.1205; EARLY P, 1980, CELL, V19, P981, DOI 10.1016/0092-8674(80)90089-6; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; EPSTEIN J, 1990, NEW ENGL J MED, V322, P664, DOI 10.1056/NEJM199003083221005; FEINSTEIN E, 1991, P NATL ACAD SCI USA, V88, P6293, DOI 10.1073/pnas.88.14.6293; FIALKOW PJ, 1981, BLOOD, V58, P158, DOI 10.1182/blood.V58.1.158.158; GISHIZKY ML, 1991, ONCOGENE, V6, P1299; GISHIZKY ML, UNPUB; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; Hariharan I K, 1988, Oncogene Res, V3, P387; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; KAWASAKI ES, 1988, P NATL ACAD SCI USA, V85, P5698, DOI 10.1073/pnas.85.15.5698; KEINANEN M, 1988, NEW ENGL J MED, V318, P1153, DOI 10.1056/NEJM198805053181803; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; LIU E, 1988, P NATL ACAD SCI USA, V85, P1952, DOI 10.1073/pnas.85.6.1952; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; MCCARTHY DM, 1984, LANCET, V2, P1362; MIGLIACCIO G, 1991, P NATL ACAD SCI USA, V88, P7420, DOI 10.1073/pnas.88.16.7420; NOWELL PC, 1960, SCIENCE, V132, P1497; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; TOWATARI M, 1991, BLOOD, V78, P2178, DOI 10.1182/blood.V78.9.2178.bloodjournal7892178; YOUNG JC, 1988, MOL CELL BIOL, V8, P4079, DOI 10.1128/MCB.8.10.4079; YOUNG JC, 1991, MOL CELL BIOL, V11, P854, DOI 10.1128/MCB.11.2.854; [No title captured]	36	155	160	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 8	1992	256	5058					836	839		10.1126/science.1375394	http://dx.doi.org/10.1126/science.1375394			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT235	1375394				2022-12-01	WOS:A1992HT23500045
J	ISOM, LL; DEJONGH, KS; PATTON, DE; REBER, BFX; OFFORD, J; CHARBONNEAU, H; WALSH, K; GOLDIN, AL; CATTERALL, WA				ISOM, LL; DEJONGH, KS; PATTON, DE; REBER, BFX; OFFORD, J; CHARBONNEAU, H; WALSH, K; GOLDIN, AL; CATTERALL, WA			PRIMARY STRUCTURE AND FUNCTIONAL EXPRESSION OF THE BETA-1-SUBUNIT OF THE RAT-BRAIN SODIUM-CHANNEL	SCIENCE			English	Article							AMINO-ACID SEQUENCE; PURIFIED CALCIUM CHANNELS; SITE-DIRECTED ANTIBODIES; ALPHA-SUBUNIT; XENOPUS-OOCYTES; ELECTROPHORUS-ELECTRICUS; BIOCHEMICAL-PROPERTIES; SAXITOXIN RECEPTOR; BINDING-PROTEIN; BETA-2 SUBUNITS	Voltage-sensitive sodium channels are responsible for the initiation and propagation of the action potential and therefore are important for neuronal excitability. Complementary DNA clones encoding the beta-1 subunit of the rat brain sodium channel were isolated by a combination of polymerase chain reaction and library screening techniques. The deduced primary structure indicates that the beta-1 subunit is a 22,851 -dalton protein that contains a single putative transmembrane domain and four potential extracellular N-linked glycosylation sites, consistent with biochemical data. Northern blot analysis reveals a 1400-nucleotide messenger RNA in rat brain, heart, skeletal muscle, and spinal cord. Coexpression of beta-1 subunits with alpha-subunits increases the size of the peak sodium current, accelerates its inactivation, and shifts the voltage dependence of inactivation to more negative membrane potentials. These results indicate that the beta-1 subunit is crucial in the assembly, expression, and functional modulation of the heterotrimeric complex of the rat brain sodium channel.	UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195; UNIV CALIF IRVINE,DEPT MICROBIOL & MOLEC GENET,IRVINE,CA 92717; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of California System; University of California Irvine; University of Washington; University of Washington Seattle			; Goldin, Alan/A-8385-2015	Isom, Lori/0000-0002-9479-6729; Goldin, Alan/0000-0001-7159-0288; Offord, James/0000-0003-4180-0146	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026729, R01NS025704, R01NS015751] Funding Source: NIH RePORTER; NINDS NIH HHS [NS15751, NS25704, NS26729] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; AGNEW WS, 1980, BIOCHEM BIOPH RES CO, V92, P860, DOI 10.1016/0006-291X(80)90782-2; AULD VJ, 1988, NEURON, V1, P449, DOI 10.1016/0896-6273(88)90176-6; DEJONGH KS, 1989, P NATL ACAD SCI USA, V86, P8585; DEJONGH KS, 1990, J BIOL CHEM, V265, P14738; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GOLDIN AL, 1986, P NATL ACAD SCI USA, V83, P7503, DOI 10.1073/pnas.83.19.7503; GORDON D, 1988, BIOCHEMISTRY-US, V27, P7032, DOI 10.1021/bi00418a054; GORDON D, 1987, P NATL ACAD SCI USA, V84, P8682, DOI 10.1073/pnas.84.23.8682; HARTSHORNE RP, 1984, J BIOL CHEM, V259, P1667; HARTSHORNE RP, 1981, P NATL ACAD SCI-BIOL, V78, P4620, DOI 10.1073/pnas.78.7.4620; HARTSHORNE RP, 1982, J BIOL CHEM, V257, P3888; Hille B, 1984, IONIC CHANNELS EXCIT; JOHO RH, 1990, MOL BRAIN RES, V7, P105, DOI 10.1016/0169-328X(90)90087-T; KAYANO T, 1988, FEBS LETT, V228, P187, DOI 10.1016/0014-5793(88)80614-8; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRAFTE DS, 1990, J GEN PHYSIOL, V96, P689, DOI 10.1085/jgp.96.4.689; KRANER SD, 1985, J BIOL CHEM, V260, P6341; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CC, 1988, SCIENCE, V239, P1288, DOI 10.1126/science.3344434; LOMBET A, 1984, EUR J BIOCHEM, V141, P651, DOI 10.1111/j.1432-1033.1984.tb08241.x; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MESSNER DJ, 1986, J BIOL CHEM, V261, P211; MESSNER DJ, 1986, J BIOL CHEM, V261, P4882; MESSNER DJ, 1985, J BIOL CHEM, V260, P597; MILLER JA, 1983, BIOCHEMISTRY-US, V22, P462, DOI 10.1021/bi00271a032; NODA M, 1986, NATURE, V322, P826, DOI 10.1038/322826a0; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; PATTON DE, 1991, NEURON, V7, P637, DOI 10.1016/0896-6273(91)90376-B; REBER BFX, 1987, J BIOL CHEM, V262, P11369; SCHEUER T, 1990, SCIENCE, V247, P854, DOI 10.1126/science.2154850; SCHMIDT JW, 1987, J BIOL CHEM, V262, P13713; SCHMIDT JW, 1986, CELL, V46, P437, DOI 10.1016/0092-8674(86)90664-1; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; SUTKOWSKI EM, 1990, J BIOL CHEM, V265, P12393; SUZUKI H, 1988, FEBS LETT, V228, P195, DOI 10.1016/0014-5793(88)80615-X; WEST JW, 1992, NEURON, V8, P59, DOI 10.1016/0896-6273(92)90108-P	39	608	620	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 8	1992	256	5058					839	842		10.1126/science.1375395	http://dx.doi.org/10.1126/science.1375395			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT235	1375395				2022-12-01	WOS:A1992HT23500046
J	KENDRICK, KM; LEVY, F; KEVERNE, EB				KENDRICK, KM; LEVY, F; KEVERNE, EB			CHANGES IN THE SENSORY PROCESSING OF OLFACTORY SIGNALS INDUCED BY BIRTH IN SHEEP	SCIENCE			English	Article							LONG-TERM POTENTIATION; HIPPOCAMPAL SLICES; MATERNAL-BEHAVIOR; BULB; RAT; NOREPINEPHRINE; PARTURITION; STIMULATION; ASPARTATE; OXYTOCIN	After giving birth, sheep and many other species form a selective bond with their offspring based on the sense of smell. Processing of olfactory signals is altered to allow the animals to perform this selective recognition. Lamb odors have little effect on either neurotransmitter release or electrical activity of neurons in the olfactory bulb before birth. However, after birth there is an increase in the number of mitral cells, the principal cells of the olfactory bulb, that respond to lamb odors, which is associated with increased cholinergic and noradrenergic neurotransmitter release. Selective recognition of lambs is accompanied by increased activity of a subset of mitral cells and release of glutamate and gamma-aminobutyric acid (GABA) from the dendrodendritic synapses between the mitral and granule cells. The relation between the release of each transmitter after birth also suggests an increased efficacy of glutamate-evoked GABA release.	INRA,COMPORTEMENT ANIM LAB,F-37380 NOUZILLY,FRANCE; UNIV CAMBRIDGE,SUBDEPT ANIM BEHAV,CAMBRIDGE CB3 8AA,ENGLAND	INRAE; University of Cambridge	KENDRICK, KM (corresponding author), AFRC,INST ANIM PHYSIOL & GENET RES,CAMBRIDGE CB2 4AT,ENGLAND.			Kendrick, Keith/0000-0002-0371-5904				ARTOLA A, 1987, NATURE, V330, P649, DOI 10.1038/330649a0; BALDWIN BA, 1974, ANIM BEHAV, V22, P220, DOI 10.1016/S0003-3472(74)80072-2; BUZSAKI G, 1989, NEUROSCIENCE, V31, P551, DOI 10.1016/0306-4522(89)90423-5; FREEMAN WJ, 1982, PSYCHOPHYSIOLOGY, V19, P44, DOI 10.1111/j.1469-8986.1982.tb02598.x; GERVAIS R, 1984, ELECTROEN CLIN NEURO, V57, P462, DOI 10.1016/0013-4694(84)90076-2; GODFREY DA, 1980, NEUROSCIENCE, V5, P273, DOI 10.1016/0306-4522(80)90103-7; GRAY CM, 1986, BEHAV NEUROSCI, V100, P585, DOI 10.1037/0735-7044.100.4.585; HIGASHIMA M, 1988, EXP BRAIN RES, V72, P37, DOI 10.1007/BF00248498; KENDRICK KM, 1988, BRAIN RES, V439, P1, DOI 10.1016/0006-8993(88)91455-2; KENDRICK KM, 1988, BRAIN RES, V442, P171, DOI 10.1016/0006-8993(88)91447-3; KENDRICK KM, 1991, PHYSIOL BEHAV, V50, P595, DOI 10.1016/0031-9384(91)90551-X; KENDRICK KM, 1991, CURR SEP, V10, P96; KENDRICK KM, 1991, METHODS NEUROSCI, V4, P3; KENDRICK KM, 1991, MICRODIALYSIS NEUROS, P327; KEVERNE EB, 1982, NATURE, V296, P148, DOI 10.1038/296148a0; KEVERNE EB, 1983, SCIENCE, V219, P81, DOI 10.1126/science.6849123; LEVY F, 1983, PHYSIOL BEHAV, V31, P687, DOI 10.1016/S0031-9384(83)80004-3; MORI K, 1987, PROG NEUROBIOL, V29, P275, DOI 10.1016/0301-0082(87)90024-4; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; PISSONNIER D, 1985, PHYSIOL BEHAV, V35, P361, DOI 10.1016/0031-9384(85)90309-9; POINDRON P, 1980, ADV STUD BEHAV, V11, P75; ROSSER AE, 1985, NEUROSCIENCE, V15, P1141, DOI 10.1016/0306-4522(85)90258-1; Rozin P., 1976, NEURAL MECHANISMS LE, P3; SHEPHERD GM, 1972, PHYSIOL REV, V52, P864, DOI 10.1152/physrev.1972.52.4.864; SHIPLEY MT, 1985, BRAIN RES, V329, P294, DOI 10.1016/0006-8993(85)90537-2; SMITH FV, 1966, ANIM BEHAV, V14, P120, DOI 10.1016/S0003-3472(66)80019-2; STANTON PK, 1985, J NEUROSCI, V5, P2169; SULLIVAN RM, 1989, J NEUROSCI, V9, P3998; SULLIVAN RM, 1987, DEV BRAIN RES, V35, P301; TAYLOR JG, 1991, BIOL CYBERN, V64, P301, DOI 10.1007/BF00199593	30	206	207	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 8	1992	256	5058					833	836		10.1126/science.1589766	http://dx.doi.org/10.1126/science.1589766			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT235	1589766				2022-12-01	WOS:A1992HT23500044
J	KERN, SE; PIETENPOL, JA; THIAGALINGAM, S; SEYMOUR, A; KINZLER, KW; VOGELSTEIN, B				KERN, SE; PIETENPOL, JA; THIAGALINGAM, S; SEYMOUR, A; KINZLER, KW; VOGELSTEIN, B			ONCOGENIC FORMS OF P53 INHIBIT P53-REGULATED GENE-EXPRESSION	SCIENCE			English	Article							WILD-TYPE P53; BREAST-CANCER; LUNG-CANCER; CELL-LINE; MUTATIONS; TRANSFORMATION; SARCOMAS; PROTEIN; IDENTIFICATION; ABNORMALITIES	Mutant forms of the gene encoding the tumor suppressor p53 are found in numerous human malignancies, but the physiologic function of p53 and the effects of mutations on this function are unknown. The p53 protein binds DNA in a sequence-specific manner and thus may regulate gene transcription. Cotransfection experiments showed that wild-type p53 activated the expression of genes adjacent to a p53 DNA binding site. The level of activation correlated with DNA binding in vitro. Oncogenic forms of p53 lost this activity. Moreover, all mutants inhibited the activity of coexpressed wild-type p53, providing a basis for the selection of such mutants during tumorigenesis.	JOHNS HOPKINS UNIV,SCH MED,CTR ONCOL,BALTIMORE,MD 21231; JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21231	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University				Thiagalingam, Sam/0000-0001-5211-266X	NATIONAL CANCER INSTITUTE [R37CA035494, R01CA035494, T32CA009243, P30CA006973] Funding Source: NIH RePORTER; NCI NIH HHS [CA06973, CA35494, CA09243] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BARTEK J, 1990, ONCOGENE, V5, P893; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P5086, DOI 10.1128/MCB.8.12.5086; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; KERN S, UNPUB; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MENON AG, 1990, P NATL ACAD SCI USA, V87, P5435, DOI 10.1073/pnas.87.14.5435; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Miller JH., 1972, EXPT MOL GENETICS; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; MURAKAMI Y, 1990, ONCOGENE, V5, P5; NIGRO JM, 1992, MOL CELL BIOL, V12, P1357, DOI 10.1128/MCB.12.3.1357; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; ROMANO JW, 1989, ONCOGENE, V4, P1483; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SAUER F, 1991, NATURE, V353, P563, DOI 10.1038/353563a0; SEGRAVES WA, 1991, CELL, V67, P225, DOI 10.1016/0092-8674(91)90172-U; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STEINGRIMSSON E, 1991, SCIENCE, V254, P418, DOI 10.1126/science.1925599; STEINMEYER K, 1988, ONCOGENE, V3, P501; STRATTON MR, 1990, ONCOGENE, V5, P1297; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAKAHASHI T, 1990, J CLIN INVEST, V86, P363, DOI 10.1172/JCI114710; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741	49	1033	1064	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 8	1992	256	5058					827	830		10.1126/science.1589764	http://dx.doi.org/10.1126/science.1589764			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT235	1589764				2022-12-01	WOS:A1992HT23500042
J	SCHNEIDER, JS; POPE, A; SIMPSON, K; TAGGART, J; SMITH, MG; DISTEFANO, L				SCHNEIDER, JS; POPE, A; SIMPSON, K; TAGGART, J; SMITH, MG; DISTEFANO, L			RECOVERY FROM EXPERIMENTAL PARKINSONISM IN PRIMATES WITH GM1 GANGLIOSIDE TREATMENT	SCIENCE			English	Article							DOPAMINERGIC-NEURONS; NERVOUS-SYSTEM; MPTP; MONKEYS; BRAIN; STRIATUM; DEFICITS; DISEASE; RATS	A parkinsonian syndrome can be produced in nonhuman primates by administration of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Parkinsonian-like symptoms induced acutely by MPTP were ameliorated after treatment with G(M1) ganglioside, a substance shown to have neurotrophic effects on the damaged dopamine system in rodents. Treatment with G(M)1 ganglioside also increased striatal dopamine and metabolite levels and enhanced the dopaminergic innervation of the striatum as demonstrated by tyrosine hydroxylase immunohistochemistry. These results suggest that G(M1) ganglioside may hold promise as a therapeutic agent for the treatment of Parkinson's disease.	HAHNEMANN UNIV, SCH MED, INST NEUROSCI, PHILADELPHIA, PA 19102 USA	Drexel University	SCHNEIDER, JS (corresponding author), HAHNEMANN UNIV, SCH MED, CTR NEUROL RES, DEPT NEUROL, PHILADELPHIA, PA 19102 USA.							AGNATI LF, 1983, ACTA PHYSIOL SCAND, V119, P347, DOI 10.1111/j.1748-1716.1983.tb07350.x; DIAMOND A, 1990, ANN NY ACAD SCI, V608, P637, DOI 10.1111/j.1749-6632.1990.tb48913.x; ELSWORTH JD, 1987, BRAIN RES, V415, P293, DOI 10.1016/0006-8993(87)90211-3; FALARDEAU P, 1988, NEUROSCI LETT, V86, P225, DOI 10.1016/0304-3940(88)90575-7; GHIDONI R, 1989, NEUROCHEM INT, V15, P455, DOI 10.1016/0197-0186(89)90164-2; HADJICONSTANTINOU M, 1989, BRAIN RES, V484, P297, DOI 10.1016/0006-8993(89)90373-9; HADJICONSTANTINOU M, 1986, NEUROPHARMACOLOGY, V25, P1075; Hornykiewicz O., 1986, ADV NEUROL, P19; KISH SJ, 1988, NEW ENGL J MED, V318, P876, DOI 10.1056/NEJM198804073181402; KOFMAN OS, 1991, J CAN SCI NEUROL, V18, P83; KOVELOWSKI CJ, 1990, SOC NEUR ABSTR, V16, P1341; KURLAN R, 1991, MOVEMENT DISORD, V6, P111, DOI 10.1002/mds.870060205; Kurland L. T, 1958, PATHOGENESIS TREATME, P5; MCGEER PL, 1988, ANN NEUROL, V24, P574, DOI 10.1002/ana.410240415; MELAMED E, 1988, PARKINSONS DISEASE M, P87; Nagai Y, 1988, NEW TRENDS GANGLIOSI, P329; RAHMANN H, 1983, NEUROCHEM INT, V5, P539, DOI 10.1016/0197-0186(83)90044-X; RAJPUT AH, 1984, ANN NEUROL, V16, P278, DOI 10.1002/ana.410160303; SABEL BA, 1984, SCIENCE, V225, P340, DOI 10.1126/science.6740316; SCHNEIDER JS, 1990, BRAIN RES, V519, P122, DOI 10.1016/0006-8993(90)90069-N; SCHNEIDER JS, 1992, J NEUROSCI RES, V31, P112, DOI 10.1002/jnr.490310116; SCHNEIDER JS, 1988, BRAIN, V111, P1265, DOI 10.1093/brain/111.6.1265; SCHNEIDER JS, 1990, BRAIN RES, V534, P25, DOI 10.1016/0006-8993(90)90108-N; SCHNEIDER JS, IN PRESS VULNERABLE; SCHOENBERG BS, 1986, ADV NEUROL, V45, P277; SKAPER SD, 1989, MOL NEUROBIOL, V3, P173, DOI 10.1007/BF02935630; STULL N, 1991, Society for Neuroscience Abstracts, V17, P702; TAYLOR JR, 1990, PROG BRAIN RES, V82, P543; TAYLOR JR, 1990, BRAIN, V113, P617, DOI 10.1093/brain/113.3.617; TETRUD JW, 1989, SCIENCE, V245, P519, DOI 10.1126/science.2502843; TETRUD JW, 1989, NEW ENGL J MED, V321, P1364; TILSON HA, 1988, J NEUROSCI RES, V19, P88, DOI 10.1002/jnr.490190112; TOFFANO G, 1984, BRAIN RES, V296, P233, DOI 10.1016/0006-8993(84)90061-1; TOFFANO G, 1983, BRAIN RES, V261, P163, DOI 10.1016/0006-8993(83)91298-2; YU RK, 1988, NEW TRENDS GANGLIOSI, P461; ZIGMOND MJ, 1989, INT REV NEUROBIOL, V31, P1	36	186	188	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 8	1992	256	5058					843	846		10.1126/science.1350379	http://dx.doi.org/10.1126/science.1350379			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT235	1350379				2022-12-01	WOS:A1992HT23500047
J	SCHWEIGHOFFER, F; BARLAT, I; CHEVALLIERMULTON, MC; TOCQUE, B				SCHWEIGHOFFER, F; BARLAT, I; CHEVALLIERMULTON, MC; TOCQUE, B			IMPLICATION OF GAP IN RAS-DEPENDENT TRANSACTIVATION OF A POLYOMA ENHANCER SEQUENCE	SCIENCE			English	Article							GTPASE-ACTIVATING PROTEIN; GENE-PRODUCT; RAS-P21 GTPASE; INHIBITION; DOMAIN; CELLS; P21; TRANSFORMATION; ONCOGENES; MUTANT	Controversy exists as to whether the interaction of a guanosine triphosphatase activating protein (GAP) with Ras proteins functions both to initiate and to terminate Ras-dependent signaling events or only to terminate them. GAP-C, a carboxyl-terminal fragment of GAP that is sufficient to stimulate GTPase activity, inhibited the stimulation of transcription produced by some oncoproteins (v-Src, polyoma middle T, wild-type Ras, and oncogenic Ras) but not that produced by v-Mos. Wild-type GAP did not affect transcription induced by oncogenic Ras but reversed the inhibitory effect of GAP-C on transcription induced by oncogenic Ras. These results indicate that GAP is a negative regulator of wild-type Ras and elicits a downstream signal by interacting with Ras-GTP (guanosine triphosphate).			SCHWEIGHOFFER, F (corresponding author), RHONE POULENC RORER, CTR RECH VITRY ALFORTVILLE, 13 QUAI JULES GUESDE, BP 14, F-94403 Vitry Sur Seine, FRANCE.							BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BORTNER DM, 1991, GENE DEV, V5, P1777, DOI 10.1101/gad.5.10.1777; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; DECLUE JE, 1991, MOL CELL BIOL, V11, P3132, DOI 10.1128/MCB.11.6.3132; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; DOMINGUEZ I, 1991, EMBO J, V10, P3215, DOI 10.1002/j.1460-2075.1991.tb04884.x; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HATA Y, 1990, J BIOL CHEM, V265, P7104; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; MARSHALL CJ, 1991, TRENDS GENET, V7, P91, DOI 10.1016/0168-9525(91)90278-X; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MCCORMICK F, 1990, ONCOGENE, V5, P1281; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; REY I, 1991, ONCOGENE, V6, P347; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SCHWEIGHOFFER F, UNPUB; STACEY DW, 1988, COLD SPRING HARB SYM, V53, P871, DOI 10.1101/SQB.1988.053.01.100; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J	32	57	57	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 8	1992	256	5058					825	827		10.1126/science.1317056	http://dx.doi.org/10.1126/science.1317056			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT235	1317056				2022-12-01	WOS:A1992HT23500041
J	WIERTELAK, EP; MAIER, SF; WATKINS, LR				WIERTELAK, EP; MAIER, SF; WATKINS, LR			CHOLECYSTOKININ ANTIANALGESIA - SAFETY CUES ABOLISH MORPHINE ANALGESIA	SCIENCE			English	Article							SPINAL-CORD; OPIATE ANALGESIA; BINDING-SITES; ANTAGONIST; PAIN; CCK; NEUROPEPTIDE; NOCICEPTION; INHIBITION; L-365,260	Environmental stimuli that signal the occurrence of aversive or dangerous events activate endogenous opiate analgesia systems. Signals for safety (the nonoccurrence of aversive events) produce the opposite and inhibit environmentally produced analgesia. Stimuli that signal safety are now shown to abolish the analgesic effect of morphine, even when morphine is applied directly to spinal cord. Further, this antiopiate effect occurs because the environmental stimulus leads to release of the neuropeptide cholecystokinin in the spinal cord. This process may contribute to the regulation of pain and the development of opiate tolerance.			WIERTELAK, EP (corresponding author), UNIV COLORADO, DEPT PSYCHOL, BOULDER, CO 80309 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH014617] Funding Source: NIH RePORTER; NIMH NIH HHS [5T32MH14617-15] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALLARD M, 1991, NEUROSCIENCE, V40, P81, DOI 10.1016/0306-4522(91)90176-O; ALLARD M, 1989, BRAIN RES, V500, P169, DOI 10.1016/0006-8993(89)90311-9; BABER NS, 1989, PAIN, V39, P307, DOI 10.1016/0304-3959(89)90045-6; BELL JA, 1977, EUR J PHARMACOL, V42, P147, DOI 10.1016/0014-2999(77)90354-5; BOLLES RC, 1980, BEHAV BRAIN SCI, V3, P291, DOI 10.1017/S0140525X0000491X; CHANG RSL, 1986, P NATL ACAD SCI USA, V83, P4923, DOI 10.1073/pnas.83.13.4923; D'amour FE, 1941, J PHARMACOL EXP THER, V72, P74; FARIS PL, 1983, SCIENCE, V219, P310, DOI 10.1126/science.6294831; HARRO J, 1991, EUR J PHARMACOL, V193, P379, DOI 10.1016/0014-2999(91)90156-K; HILL DR, 1990, BRAIN RES, V526, P276, DOI 10.1016/0006-8993(90)91232-6; HILL DR, 1988, NEUROSCI LETT, V89, P133, DOI 10.1016/0304-3940(88)90369-2; KELLY DD, 1986, ANN NY ACAD SCI, V467; LOTTI VJ, 1989, EUR J PHARMACOL, V162, P273, DOI 10.1016/0014-2999(89)90290-2; MAIER SF, 1976, ANIM LEARN BEHAV, V4, P217, DOI 10.3758/BF03214039; MELZACK R, 1988, 5TH P WORLD C PAIN, P4; MILLAN MJ, 1986, PAIN, V27, P303, DOI 10.1016/0304-3959(86)90158-2; PASTERNAK GW, 1988, JAMA-J AM MED ASSOC, V259, P1362, DOI 10.1001/jama.259.9.1362; RATAUD J, 1991, BRAIN RES, V548, P315, DOI 10.1016/0006-8993(91)91139-R; SIEGEL S, 1979, PSYCHOPATHOLOGY ANIM, P143; SOLOMON RL, 1974, PSYCHOL REV, V81, P119, DOI 10.1037/h0036128; TANG J, 1984, P NATL ACAD SCI-BIOL, V81, P5002, DOI 10.1073/pnas.81.15.5002; TWYCROSS RG, 1984, TXB PAIN, P516; WATKINS LR, 1986, BRAIN RES, V362, P308, DOI 10.1016/0006-8993(86)90455-5; WATKINS LR, 1984, SCIENCE, V224, P395, DOI 10.1126/science.6546809; WESTBROOK RF, 1990, Q J EXP PSYCHOL-B, V42, P1; WIERTELAK E P, 1991, Society for Neuroscience Abstracts, V17, P109; WIERTELAK EP, UNPUB; YAKSH TL, 1977, J PHARMACOL EXP THER, V202, P411; YAKSH TL, 1985, ANNU REV PHARMACOL, V25, P433, DOI 10.1146/annurev.pa.25.040185.002245; YAKSH TL, 1976, PHYSIOL BEHAV, V17, P1031, DOI 10.1016/0031-9384(76)90029-9; ZADINA JE, 1987, BRAIN RES, V409, P10, DOI 10.1016/0006-8993(87)90736-0; ZINBERG NE, 1984, DRUG SET SETTING, P12	32	127	128	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 8	1992	256	5058					830	833		10.1126/science.1589765	http://dx.doi.org/10.1126/science.1589765			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT235	1589765				2022-12-01	WOS:A1992HT23500043
J	ZATORRE, RJ; EVANS, AC; MEYER, E; GJEDDE, A				ZATORRE, RJ; EVANS, AC; MEYER, E; GJEDDE, A			LATERALIZATION OF PHONETIC AND PITCH DISCRIMINATION IN SPEECH PROCESSING	SCIENCE			English	Article							POSITRON EMISSION TOMOGRAPHY; HUMAN AUDITORY-CORTEX; CORTICAL AREAS; ORGANIZATION; PERCEPTION; LOCALIZATION; LANGUAGE; MEMORY; BRAIN	Cerebral activation was measured with positron emission tomography in ten human volunteers. The primary auditory cortex showed increased activity in response to noise bursts, whereas acoustically matched speech syllables activated secondary auditory cortices bilaterally. Instructions to make judgments about different attributes of the same speech signal resulted in activation of specific lateralized neural systems. Discrimination of phonetic structure led to increased activity in part of Broca's area of the left hemisphere, suggesting a role for articulatory recoding in phonetic perception. Processing changes in pitch produced activation of the right prefrontal cortex, consistent with the importance of right-hemisphere mechanisms in pitch perception.			ZATORRE, RJ (corresponding author), MCGILL UNIV,MONTREAL NEUROL INST,MCCONNELL BRAIN IMAGING CTR,MONTREAL H3A 2B4,QUEBEC,CANADA.		Gjedde, Albert/U-3751-2019; Gjedde, Albert/I-2452-2019	Gjedde, Albert/0000-0002-3756-7401; 				Alajouanine T., 1939, SYNDROME DESINTEGRAT; BLUMSTEIN SE, 1977, NEUROPSYCHOLOGIA, V15, P19, DOI 10.1016/0028-3932(77)90111-7; BLUMSTEIN SE, 1987, MOTOR SENSORY PROCES, P257; BRUGGE JF, 1985, CEREB CORTEX, V4, P229; BUB D, 1991, J CEREBRAL BLOOD S2, V11, pS850; CELESIA GG, 1976, BRAIN, V99, P403, DOI 10.1093/brain/99.3.403; CHAVIS DA, 1976, BRAIN RES, V117, P379; CHERTKOW H, 1991, Neurology, V41, P300; COLOMBO M, 1990, SCIENCE, V247, P336, DOI 10.1126/science.2296723; EVANS AC, 1991, J CEREBR BLOOD F MET, V11, pA69, DOI 10.1038/jcbfm.1991.40; EVANS AC, 1991, IEEE T MED IMAGING, V10, P90, DOI 10.1109/42.75615; EVANS AC, IN PRESS NEUROLMAGE; FITZPATRICK KA, 1982, CORTICAL SENSORY ORG, V3, P71; FOX PT, 1985, J COMPUT ASSIST TOMO, V9, P141, DOI 10.1097/00004728-198501000-00025; FOX PT, 1988, J CEREBR BLOOD F MET, V8, P642, DOI 10.1038/jcbfm.1988.111; GALABURDA A, 1980, J COMP NEUROL, V190, P597, DOI 10.1002/cne.901900312; GESCHWIN.N, 1970, SCIENCE, V170, P940, DOI 10.1126/science.170.3961.940; LAUTER JL, 1985, HEARING RES, V20, P199, DOI 10.1016/0378-5955(85)90024-3; LECOURS AR, 1976, BRAIN LANG, V3, P88, DOI 10.1016/0093-934X(76)90008-0; LIBERMAN AM, 1989, SCIENCE, V243, P489, DOI 10.1126/science.2643163; LIBERMAN AM, 1967, PSYCHOL REV, V74, P431, DOI 10.1037/h0020279; LIEGEOISCHAUVEL C, 1991, BRAIN, V114, P139; LUDERS H, 1991, BRAIN, V114, P743, DOI 10.1093/brain/114.2.743; MEYER E, 1988, Society for Neuroscience Abstracts, V14, P917; MILNER B, 1962, INTERHEMISPHER RELAT, P177; OJEMANN G, 1979, SCIENCE, V205, P1401, DOI 10.1126/science.472757; Ombredane A, 1951, SURFACE DYSLEXIA; PARDO JV, 1991, NATURE, V349, P61, DOI 10.1038/349061a0; PAUS T, UNPUB; Penfield W., 1959, SPEECH BRAIN MECH; Petersen S E, 1989, J Cogn Neurosci, V1, P153, DOI 10.1162/jocn.1989.1.2.153; PETERSEN SE, 1988, NATURE, V331, P585, DOI 10.1038/331585a0; PETERSEN SE, 1990, SCIENCE, V249, P1041, DOI 10.1126/science.2396097; PETRIDES M, 1988, J COMP NEUROL, V273, P52, DOI 10.1002/cne.902730106; SHALLICE T, 1990, NEUROPSYCHOLOGICAL I, pCH1; Tailarach J., 1988, COPLANAR STEREOTAXIC; Taylor L. B, 1979, FUNCTIONAL NEUROSURG, P165; WHITFIELD IC, 1985, CEREB CORTEX, P329; WISE R, 1991, BRAIN, V114, P1803, DOI 10.1093/brain/114.4.1803; WOOD CC, 1971, SCIENCE, V173, P1248, DOI 10.1126/science.173.4003.1248; WORSLEY KJ, IN PRESS J CEREB BLO; ZATORRE RJ, 1991, BRAIN, V114, P2403, DOI 10.1093/brain/114.6.2403; ZATORRE RJ, 1988, J ACOUST SOC AM, V84, P566, DOI 10.1121/1.396834	43	1170	1189	1	91	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 8	1992	256	5058					846	849		10.1126/science.1589767	http://dx.doi.org/10.1126/science.1589767			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT235	1589767				2022-12-01	WOS:A1992HT23500048
J	ARMITAGE, RJ; FANSLOW, WC; STROCKBINE, L; SATO, TA; CLIFFORD, KN; MACDUFF, BM; ANDERSON, DM; GIMPEL, SD; DAVISSMITH, T; MALISZEWSKI, CR; CLARK, EA; SMITH, CA; GRABSTEIN, KH; COSMAN, D; SPRIGGS, MK				ARMITAGE, RJ; FANSLOW, WC; STROCKBINE, L; SATO, TA; CLIFFORD, KN; MACDUFF, BM; ANDERSON, DM; GIMPEL, SD; DAVISSMITH, T; MALISZEWSKI, CR; CLARK, EA; SMITH, CA; GRABSTEIN, KH; COSMAN, D; SPRIGGS, MK			MOLECULAR AND BIOLOGICAL CHARACTERIZATION OF A MURINE LIGAND FOR CD40	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; GROWTH-FACTOR RECEPTOR; HUMAN B-CELLS; MONOCLONAL-ANTIBODY; CARCINOMA ANTIGEN; GENE-TRANSFER; ACTIVATION; EXPRESSION; CLONING; DIFFERENTIATION	THE CD40 surface molecule is a 277-amino-acid glycoprotein expressed on B lymphocytes, epithelial cells and some carcinoma cell lines. Monoclonal antibodies against CD40 mediate a variety of effects on B lymphocytes, including induction of intercellular adhesion 1,2, short- and long-term proliferation 3-5, differentiation 6,7 and enhanced tyrosine phosphorylation of proteins 8. In addition, germinal centre centrocytes are prevented from undergoing apoptosis by activation through CD40 and receptor for antigen 9. These data indicate that CD40 could be a receptor for an unknown ligand with important functions in B-cell development and activation. This hypothesis is strengthened by the homology of the extracellular region of the CD40 molecule 10 with a family of cell-surface glycoproteins 11,12 that includes the receptors for nerve growth factor 13,14 and tumour necrosis factor 11,15,16. Here we report the cloning of a ligand for CD40 that is expressed on the cell surface of activated T cells and mediates B-cell proliferation in the absence of co-stimulus, as well as IgE production in the presence of interleukin-4.	IMMUNEX RES & DEV CORP,DEPT MOLEC BIOL,SEATTLE,WA 98101; IMMUNEX RES & DEV CORP,DEPT BIOCHEM,SEATTLE,WA 98101; UNIV WASHINGTON,DEPT MICROBIOL SC42,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	ARMITAGE, RJ (corresponding author), IMMUNEX RES & DEV CORP,DEPT IMMUNOL,51 UNIV ST,SEATTLE,WA 98101, USA.			Clark, Edward A/0000-0001-8061-5475				BANCHEREAU J, 1991, SCIENCE, V251, P70, DOI 10.1126/science.1702555; BARRETT TB, 1991, J IMMUNOL, V146, P1722; BRAESCHANDERSEN S, 1989, J IMMUNOL, V142, P562; CLARK EA, 1986, P NATL ACAD SCI USA, V83, P4494, DOI 10.1073/pnas.83.12.4494; COFFMAN RL, 1988, IMMUNOL REV, V102, P5, DOI 10.1111/j.1600-065X.1988.tb00739.x; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FANSLOW WC, IN PRESS J IMMUN; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; PAULIE S, 1989, J IMMUNOL, V142, P590; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SMITH CA, 1991, BIOCHEM BIOPH RES CO, V176, P335, DOI 10.1016/0006-291X(91)90929-2; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SPRIGGS MK, 1990, J BIOL CHEM, V265, P22499; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; THOMAS G, 1988, ANNU REV PHYSIOL, V50, P323; UCKUN FM, 1991, J BIOL CHEM, V266, P17478; VALLE A, 1989, EUR J IMMUNOL, V19, P1463, DOI 10.1002/eji.1830190818; ZHANG K, 1991, J IMMUNOL, V146, P1836	25	1048	1155	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 7	1992	357	6373					80	82		10.1038/357080a0	http://dx.doi.org/10.1038/357080a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT229	1374165				2022-12-01	WOS:A1992HT22900063
J	CARSON, JL; KELLEY, MA; DUFF, A; WEG, JG; FULKERSON, WJ; PALEVSKY, HI; SCHWARTZ, JS; THOMPSON, BT; POPOVICH, J; HOBBINS, TE; SPERA, MA; ALAVI, A; TERRIN, ML				CARSON, JL; KELLEY, MA; DUFF, A; WEG, JG; FULKERSON, WJ; PALEVSKY, HI; SCHWARTZ, JS; THOMPSON, BT; POPOVICH, J; HOBBINS, TE; SPERA, MA; ALAVI, A; TERRIN, ML			THE CLINICAL COURSE OF PULMONARY-EMBOLISM	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VENOUS THROMBOSIS; LATE PROGNOSIS; FILTER	Background. Pulmonary embolism is a potentially fatal disorder. Information about the outcome of clinically recognized pulmonary embolism is sparse, particularly given that new treatments for more seriously ill patients are now available. Methods. We prospectively followed 399 patients with pulmonary embolism diagnosed by lung scanning and pulmonary angiography, who were enrolled in a multicenter diagnostic trial. We reviewed all hospitalizations, all new investigations of pulmonary embolism, and all deaths among the patients within one year of diagnosis. Results. Of the 399 patients, 375 (94 percent) received treatment for pulmonary embolism, usually conventional anticoagulation. Only 10 patients (2.5 percent) died of pulmonary embolism; 9 of them had clinically suspected recurrent pulmonary embolism. Clinically apparent pulmonary embolism recurred in 33 patients (8.3 percent), of whom 45 percent died during follow-up. Ninety-five patients with pulmonary embolism (23.8 percent) died within one year. The conditions associated with these deaths were cancer (relative risk, 3.8; 95 percent confidence interval, 2.3 to 6.4), left-sided congestive heart failure (relative risk, 2.7; 95 percent confidence interval, 1.5 to 4.6), and chronic lung disease (relative risk, 2.2; 95 percent confidence interval, 1.2 to 4.0). The most frequent causes of death in patients with pulmonary embolism were cancer (in 34.7 percent), infection (22.1 percent), and cardiac disease (16.8 percent). Conclusions. When properly diagnosed and treated, clinically apparent pulmonary embolism was an uncommon cause of death, and it recurred in only a small minority of patients. Most deaths were due to underlying diseases. Patients with pulmonary embolism who had cancer, congestive heart failure, or chronic lung disease had a higher risk of dying within one year than did other patients with pulmonary embolism.	UNIV PENN, SCH MED, DEPT MED, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT RADIOL, PHILADELPHIA, PA 19104 USA; LEONARD DAVIS INST HLTH ECON, PHILADELPHIA, PA USA; UNIV MICHIGAN, SCH MED, DEPT MED, ANN ARBOR, MI 48104 USA; DUKE UNIV, SCH MED, DEPT MED, DURHAM, NC 27706 USA; MASSACHUSETTS GEN HOSP, DEPT MED, BOSTON, MA 02114 USA; HENRY FORD HOSP, DEPT MED, DETROIT, MI 48202 USA; MARYLAND MED RES INST, BALTIMORE, MD USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Michigan System; University of Michigan; Duke University; Harvard University; Massachusetts General Hospital; Henry Ford Health System; Henry Ford Hospital	CARSON, JL (corresponding author), UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT MED, DIV GEN INTERNAL MED, NEW BRUNSWICK, NJ 08903 USA.							ALPERT JS, 1976, JAMA-J AM MED ASSOC, V236, P1477, DOI 10.1001/jama.236.13.1477; [Anonymous], 1970, J AMER MED ASSOC, V214, P2163; [Anonymous], 1974, JAMA, V229, P1606; BARRITT DW, 1960, LANCET, V1, P1309; COON WW, 1969, ANN SURG, V170, P559, DOI 10.1097/00000658-196910000-00007; DALEN JE, 1975, PROG CARDIOVASC DIS, V17, P259, DOI 10.1016/S0033-0620(75)80017-X; FIENBERG SE, 1977, ANAL CROSS CLASSIFIE, P9; GOLDMAN L, 1983, NEW ENGL J MED, V308, P1000, DOI 10.1056/NEJM198304283081704; GREENFIELD LJ, 1981, ARCH SURG-CHICAGO, V116, P1451; HALL RJC, 1977, BRIT HEART J, V39, P1128; Harrel F, 1986, SUGI SUPPLEMENTAL LI, P437; HAYS WL, 1973, STATISTICS SOCIAL SC, P404; HERMANN RE, 1961, AM J SURG, V102, P19, DOI 10.1016/0002-9610(61)90680-8; HULL R, 1982, NEW ENGL J MED, V306, P189, DOI 10.1056/NEJM198201283060401; HULL R, 1982, NEW ENGL J MED, V307, P1676, DOI 10.1056/NEJM198212303072704; HULL RD, 1989, ARCH INTERN MED, V149, P2549, DOI 10.1001/archinte.149.11.2549; HYERS TM, 1989, CHEST, V95, pS37, DOI 10.1378/chest.95.2.37S; KANTER B, 1988, CHEST, V93, P170, DOI 10.1378/chest.93.1.170; Kleinbaum D.G, 1988, APPL REGRESSION ANAL; LEE ET, 1980, STATISTICAL METHODS; LIKOFF MJ, 1987, AM J CARDIOL, V59, P634; MACINTYRE D, 1982, POSTGRAD MED J, V58, P222, DOI 10.1136/pgmj.58.678.222; MONREAL M, 1989, CHEST, V95, P976, DOI 10.1378/chest.95.5.976; MORRELL MT, 1963, BRIT MED J, P830, DOI 10.1136/bmj.2.5361.830; MOSER KM, 1987, ANN INTERN MED, V107, P560, DOI 10.7326/0003-4819-107-4-560; MURPHY ML, 1968, CIRCULATION, V38, P1116, DOI 10.1161/01.CIR.38.6.1116; NORRIS RM, 1984, AM J CARDIOL, V53, P408, DOI 10.1016/0002-9149(84)90003-1; PARASKOS JA, 1973, NEW ENGL J MED, V289, P55, DOI 10.1056/NEJM197307122890201; PHEAR D, 1960, LANCET, V2, P832; SECKERWALKER RH, 1970, BRIT MED J, V4, P135; Siegel S., 1956, NONPARAMETRIC STAT, P96; SUTTON GC, 1977, BRIT HEART J, V39, P1135; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753; WHEELER AP, 1988, ARCH INTERN MED, V148, P1321, DOI 10.1001/archinte.148.6.1321; 1988, SAS PROCEDURES GUIDE, P441	35	833	868	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 7	1992	326	19					1240	1245		10.1056/NEJM199205073261902	http://dx.doi.org/10.1056/NEJM199205073261902			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR447	1560799				2022-12-01	WOS:A1992HR44700002
J	GORLICH, D; HARTMANN, E; PREHN, S; RAPOPORT, TA				GORLICH, D; HARTMANN, E; PREHN, S; RAPOPORT, TA			A PROTEIN OF THE ENDOPLASMIC-RETICULUM INVOLVED EARLY IN POLYPEPTIDE TRANSLOCATION	NATURE			English	Article							SIGNAL RECOGNITION PARTICLE; OUTER-MEMBRANE PROTEIN; NASCENT PREPROLACTIN; SECRETORY PROTEIN; SEQUENCE RECEPTOR; IMPORT; SRP; PHOTOCROSSLINKING; IDENTIFICATION; COMPONENT	To identify components of the mammalian endoplasmic reticulum involved in the translocation of secretory proteins, crosslinking and reconstitution methods were combined. A multispanning abundant membrane glycoprotein was found which is in proximity to nascent chains early in translocation. In reconstituted proteoliposomes, this protein is stimulatory or required for the translocation of secretory proteins.	MAX DELBRUCK CTR MOLEC MED, ROBERT ROSSLE STR 10, O-1115 BERLIN, GERMANY; HUMBOLDT UNIV, INST BIOCHEM, O-1040 BERLIN, GERMANY	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Humboldt University of Berlin			Görlich, Dirk/B-8296-2017; Hartmann, Enno/C-5687-2013	Görlich, Dirk/0000-0002-4343-5210; 				BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P581, DOI 10.1073/pnas.83.3.581; GILMORE R, 1982, J CELL BIOL, V95, P470, DOI 10.1083/jcb.95.2.470; GORLICH D, 1990, J CELL BIOL, V111, P2283, DOI 10.1083/jcb.111.6.2283; GREEN N, 1992, J CELL BIOL, V116, P597, DOI 10.1083/jcb.116.3.597; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; HARTMANN E, 1989, EMBO J, V8, P2225, DOI 10.1002/j.1460-2075.1989.tb08346.x; HIGH S, 1991, J CELL BIOL, V113, P35, DOI 10.1083/jcb.113.1.35; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; KURZCHALIA TV, 1986, NATURE, V320, P634, DOI 10.1038/320634a0; MEYER DI, 1982, NATURE, V297, P503; MUSCH A, IN PRESS CELL; NICCHITTA C, 1991, METHOD CELL BIOL, V34, P263; NICCHITTA CV, 1991, CELL, V65, P587, DOI 10.1016/0092-8674(91)90091-C; NICCHITTA CV, 1990, CELL, V60, P259, DOI 10.1016/0092-8674(90)90741-V; PREHN S, 1990, EUR J BIOCHEM, V188, P439, DOI 10.1111/j.1432-1033.1990.tb15421.x; RAPOPORT TA, 1991, FASEB J, V5, P2792, DOI 10.1096/fasebj.5.13.1916103; ROTHBLATT JA, 1989, J CELL BIOL, V72, P61; SANDERS S, IN PRESS CELL; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; THRIFT RN, 1991, J CELL BIOL, V112, P809, DOI 10.1083/jcb.112.5.809; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; WIEDMANN M, 1987, NATURE, V328, P830, DOI 10.1038/328830a0; WIEDMANN M, 1989, FEBS LETT, V257, P263, DOI 10.1016/0014-5793(89)81549-2	31	258	263	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 7	1992	357	6373					47	52		10.1038/357047a0	http://dx.doi.org/10.1038/357047a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT229	1315422				2022-12-01	WOS:A1992HT22900052
J	MCCARRON, JG; MCGEOWN, JG; REARDON, S; IKEBE, M; FAY, FS; WALSH, JV				MCCARRON, JG; MCGEOWN, JG; REARDON, S; IKEBE, M; FAY, FS; WALSH, JV			CALCIUM-DEPENDENT ENHANCEMENT OF CALCIUM CURRENT IN SMOOTH-MUSCLE BY CALMODULIN-DEPENDENT PROTEIN KINASE-II	NATURE			English	Article							LIGHT-CHAIN KINASE; INTRACELLULAR CALCIUM; CA-2+ CURRENT; CELLS; CHANNELS; PHOSPHORYLATION; BINDING; SITE; IDENTIFICATION; ACETYLCHOLINE	CALCIUM entry through voltage-activated Ca2+ channels is important in regulating many cellular functions. Activation of these channels in many cell types results in feedback regulation of channel activity 1. Mechanisms linking Ca2+ channel activity with its downregulation have been described 2,3, but little is known of the events responsible for the enhancement of Ca2+ current that in many cells follows Ca2+ channel activation and an increase in cytoplasmic Ca2+ concentration 4,5. Here we investigate how this positive feedback is achieved in single smooth muscle cells. We find that in these cells voltage-activated calcium current is persistently but reversibly enhanced after periods of activation. This persistent enhancement of the Ca2+ current is mediated by activation of calmodulin-dependent protein kinase II because it is blocked when either the rise in cytoplasmic Ca2+ is inhibited or activation of calmodulin-dependent protein kinase II is prevented by specific peptide inhibitors of calcium-calmodulin or calmodulin-dependent protein kinase II itself. This mechanism may be important in different forms of Ca2+ current potentiation, such as those that depend on prior Ca2+ channel activation or are a result of agonist-induced release of Ca2+ from internal stores.	UNIV MASSACHUSETTS,MED CTR,DEPT PHYSIOL,WORCESTER,MA 01655; CASE WESTERN RESERVE UNIV,COLL MED,DEPT PHYSIOL,CLEVELAND,OH 44106	University of Massachusetts System; University of Massachusetts Worcester; Case Western Reserve University	MCCARRON, JG (corresponding author), UNIV MASSACHUSETTS,MED CTR,PROGRAM MOLEC MED,BIOMED IMAGING GRP,WORCESTER,MA 01655, USA.							ARMSTRONG D, 1988, J GEN PHYSIOL, V92, pA10; ARTALEJO CR, 1990, NATURE, V348, P239, DOI 10.1038/348239a0; BENHAM CD, 1987, CIRC RES, V61, P10; CHAD JE, 1986, J PHYSIOL-LONDON, V378, P31, DOI 10.1113/jphysiol.1986.sp016206; CHEUNG WY, 1980, SCIENCE, V207, P19, DOI 10.1126/science.6243188; CHU A, 1990, BIOCHEMISTRY-US, V29, P5899, DOI 10.1021/bi00477a003; CLAPP LH, 1987, P NATL ACAD SCI USA, V84, P2092, DOI 10.1073/pnas.84.7.2092; COLBRAN RJ, 1989, BIOCHEM J, V258, P313, DOI 10.1042/bj2580313; FAY FS, 1973, P NATL ACAD SCI USA, V70, P641, DOI 10.1073/pnas.70.3.641; FAY FS, 1982, METHOD ENZYMOL, V85, P284; GURNEY AM, 1989, NATURE, V341, P65, DOI 10.1038/341065a0; HIMPENS B, 1988, J PHYSIOL-LONDON, V395, P507, DOI 10.1113/jphysiol.1988.sp016932; IKEBE M, 1990, BIOCHEMISTRY-US, V29, P11242, DOI 10.1021/bi00503a013; IKEBE M, 1990, BIOCHEM BIOPH RES CO, V168, P714, DOI 10.1016/0006-291X(90)92380-I; IKEBE M, 1991, ARCH BIOCHEM BIOPHYS, V288, P538, DOI 10.1016/0003-9861(91)90232-8; IKEBE M, 1990, J BIOL CHEM, V265, P17607; ITOH T, 1989, NATURE, V338, P164, DOI 10.1038/338164a0; JAHN H, 1988, EUR J BIOCHEM, V178, P535, DOI 10.1111/j.1432-1033.1988.tb14480.x; JOHNSON JD, 1983, BIOCHEM J, V211, P473, DOI 10.1042/bj2110473; KALMAN D, 1988, J GEN PHYSIOL, V92, P531, DOI 10.1085/jgp.92.4.531; LUCCHESI P, 1989, AM J PHYSIOL, V255, pC226; LUKAS TJ, 1986, BIOCHEMISTRY-US, V25, P1458, DOI 10.1021/bi00354a041; MARBAN E, 1982, J PHYSIOL-LONDON, V329, P589, DOI 10.1113/jphysiol.1982.sp014321; PAYNE ME, 1988, J BIOL CHEM, V263, P7190; PEARSON RB, 1985, J BIOL CHEM, V260, P4471; REUTER H, 1983, NATURE, V301, P569, DOI 10.1038/301569a0; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; VIVAUDOU MB, 1991, PFLUG ARCH EUR J PHY, V418, P144, DOI 10.1007/BF00370463; VIVAUDOU MB, 1988, FASEB J, V2, P2497, DOI 10.1096/fasebj.2.9.2453389; WALSH JV, 1987, PFLUG ARCH EUR J PHY, V408, P83, DOI 10.1007/BF00581336; WILLIAMS DA, 1985, NATURE, V318, P558, DOI 10.1038/318558a0; WILLIAMS DA, 1986, AM J PHYSIOL, V250, pC779, DOI 10.1152/ajpcell.1986.250.5.C779; YAGI S, 1988, P NATL ACAD SCI USA, V85, P4109, DOI 10.1073/pnas.85.11.4109	33	127	128	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 7	1992	357	6373					74	77		10.1038/357074a0	http://dx.doi.org/10.1038/357074a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT229	1315424				2022-12-01	WOS:A1992HT22900061
J	MEGURO, H; MORI, H; ARAKI, K; KUSHIYA, E; KUTSUWADA, T; YAMAZAKI, M; KUMANISHI, T; ARAKAWA, M; SAKIMURA, K; MISHINA, M				MEGURO, H; MORI, H; ARAKI, K; KUSHIYA, E; KUTSUWADA, T; YAMAZAKI, M; KUMANISHI, T; ARAKAWA, M; SAKIMURA, K; MISHINA, M			FUNCTIONAL-CHARACTERIZATION OF A HETEROMERIC NMDA RECEPTOR CHANNEL EXPRESSED FROM CLONED CDNAS	NATURE			English	Article							CENTRAL-NERVOUS-SYSTEM; METHYL-D-ASPARTATE; EXCITATORY AMINO-ACIDS; SELECTIVE ANTAGONIST; NEURONS; GLYCINE; FAMILY; RESPONSES; CLONING; COMPLEX	THE glutamate receptor (GluR) channel plays a kev part in brain function 1,2. Among GluR channel subtypes, the NMDA (N-methyl-D-aspartate) receptor channel which is highly permeable to Ca2+ is essential for the synaptic plasticity underlying memory, learning and development 3,4. Furthermore, abnormal activation of the NMDA receptor channel may trigger the neuronal cell death observed in various brain disorders 5,6. A complementary DNA encoding a subunit of the rodent NMDA receptor channel (NMDAR1 or zeta-1) has been cloned and its functional properties investigated 7,8. Here we report the identification and primary structure of a novel mouse NMDA receptor channel subunit, designated as epsilon-1, after cloning and sequencing the cDNA. The epsilon-1 subunit shows 11-18% amino-acid sequence identity with rodent GluR channel subunits that have been characterized so far and has structural features common to neurotransmitter-gated ion channels. Expression from cloned cDNAs of the epsilon-1 subunit together with the zeta-1 subunit in Xenopus oocytes yields functional GluR channels with high activity and characteristics of the NMDA receptor channel. Furthermore, the heteromeric NMDA receptor channel can be activated by glycine alone.	NIIGATA UNIV,BRAIN RES INST,DEPT NEUROPHARMACOL,ASAHIMACHI 1,NIIGATA 951,JAPAN; NIIGATA UNIV,BRAIN RES INST,DEPT NEUROPATHOL,NIIGATA 951,JAPAN; NIIGATA UNIV,SCH MED,DEPT MED 2,NIIGATA 951,JAPAN	Niigata University; Niigata University; Niigata University								BETTLER B, 1990, NEURON, V5, P583, DOI 10.1016/0896-6273(90)90213-Y; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; COLLINGRIDGE GL, 1987, TRENDS NEUROSCI, V10, P288, DOI 10.1016/0166-2236(87)90175-5; DAVIES J, 1981, NEUROSCI LETT, V21, P77, DOI 10.1016/0304-3940(81)90061-6; EGEBJERG J, 1991, NATURE, V351, P745, DOI 10.1038/351745a0; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; HONORE T, 1989, EUR J PHARM-MOLEC PH, V172, P239, DOI 10.1016/0922-4106(89)90054-0; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KEMP JA, 1988, P NATL ACAD SCI USA, V85, P6547, DOI 10.1073/pnas.85.17.6547; KLECKNER NW, 1988, SCIENCE, V241, P835, DOI 10.1126/science.2841759; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; MISHINA M, 1991, BIOCHEM BIOPH RES CO, V180, P813, DOI 10.1016/S0006-291X(05)81137-4; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; MORITA T, IN PRESS MOL BRAIN R; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; NAKANISHI N, 1990, NEURON, V5, P569, DOI 10.1016/0896-6273(90)90212-X; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; OLNEY JW, 1990, ANNU REV PHARMACOL, V30, P47; PEARSON RB, 1985, J BIOL CHEM, V260, P4471; PETERS S, 1987, SCIENCE, V236, P589, DOI 10.1126/science.2883728; SAKIMURA K, 1992, NEURON, V8, P267, DOI 10.1016/0896-6273(92)90293-M; SAKIMURA K, 1990, FEBS LETT, V272, P73, DOI 10.1016/0014-5793(90)80452-O; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; WERNER P, 1991, NATURE, V351, P742, DOI 10.1038/351742a0; WESTBROOK GL, 1987, NATURE, V328, P640, DOI 10.1038/328640a0; WISDEN W, 1991, MOL NEUROBIOLOGY PRA, P205; WONG EHF, 1986, P NATL ACAD SCI USA, V83, P7104, DOI 10.1073/pnas.83.18.7104; YAMAZAKI M, IN PRESS FEBS LETT; YAMAZAKI M, IN PRESS BIOCH BIOPH; YOKOYAMA S, 1989, FEBS LETT, V259, P37, DOI 10.1016/0014-5793(89)81488-7	35	771	796	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 7	1992	357	6373					70	74		10.1038/357070a0	http://dx.doi.org/10.1038/357070a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT229	1374164				2022-12-01	WOS:A1992HT22900060
J	MURAKAMI, M; TSUBATA, T; OKAMOTO, M; SHIMIZU, A; KUMAGAI, S; IMURA, H; HONJO, T				MURAKAMI, M; TSUBATA, T; OKAMOTO, M; SHIMIZU, A; KUMAGAI, S; IMURA, H; HONJO, T			ANTIGEN-INDUCED APOPTOTIC DEATH OF LY-1 B-CELLS RESPONSIBLE FOR AUTOIMMUNE-DISEASE IN TRANSGENIC MICE	NATURE			English	Article							ANTIBODY-SECRETING CELLS; LYMPHOCYTES-B; RHEUMATOID-FACTOR; SOMATIC MUTATION; CLONAL DELETION; DNA; MOUSE; AUTOANTIBODIES; ENUMERATION; LINEAGE	STUDIES on transgenic mice expressing immunoglobulins against self-antigens 1-6 have shown that self-tolerance is maintained by active elimination (clonal deletion) 1-3,7, functional inactivation (clonal anergy) 4,5,8 of self-reactive B cells, or a combination of both 6. We have established and characterized a transgenic mouse line expressing an anti-erythrocyte autoantibody 6. In contrast to other autoantibody transgenic lies, about 50% of the animals of this transgenic line suffer from autoimmune disease, indicating a loss of self-tolerance. Here we show that peritoneal Ly-1 B cells (also known as B-1 cells 9) are responsible for this autoimmune disease in our transgenic mice. A few self-reactive Ly-1 B cells that have somehow escaped the deletion mechanism expand in the peritoneum because of the absence of self-antigen. These Ly-1 B cells are eliminated in vivo by apoptosis once exposed to self-antigen. On the basis of these results we propose a novel autoantibody production mechanism whereby self-reactive B cells sequestered in compartments free of self-antigens may survive, proliferate and be activated for generation of pathogenic autoantibodies in autoimmune diseases.	KYOTO UNIV, FAC MED, DEPT INTERNAL MED 2, SAKYO KU, KYOTO 606, JAPAN; KYOTO UNIV, CTR MOLEC BIOL & GENET, SAKYO KU, KYOTO 606, JAPAN	Kyoto University; Kyoto University	MURAKAMI, M (corresponding author), KYOTO UNIV, FAC MED, DEPT MED CHEM, SAKYO KU, KYOTO 606, JAPAN.		Tsubata, Takeshi/AAI-7489-2021; Honjo, Tasuku/N-4470-2016	Tsubata, Takeshi/0000-0003-0760-1258; 				BENHAMOU LE, 1990, EUR J IMMUNOL, V20, P1405, DOI 10.1002/eji.1830200630; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; Burnet FM, 1959, CLONAL SELECTION THE, DOI DOI 10.5962/BHL.TITLE.8281; CASALI P, 1987, SCIENCE, V236, P77, DOI 10.1126/science.3105056; CASALI P, 1989, J IMMUNOL, V143, P3476; CZERKINSKY CC, 1983, J IMMUNOL METHODS, V65, P109, DOI 10.1016/0022-1759(83)90308-3; DIAMOND B, 1984, P NATL ACAD SCI-BIOL, V81, P5841, DOI 10.1073/pnas.81.18.5841; ERIKSON J, 1991, NATURE, V349, P331, DOI 10.1038/349331a0; GIUSTI AM, 1987, P NATL ACAD SCI USA, V84, P2926, DOI 10.1073/pnas.84.9.2926; GOLDSTEIN P, 1991, IMMUNOL REV, V121, P30; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; HARDY RR, 1987, SCIENCE, V236, P81, DOI 10.1126/science.3105057; HARDY RR, 1986, IMMUNOL REV, V93, P53, DOI 10.1111/j.1600-065X.1986.tb01502.x; HARTLEY SB, 1991, NATURE, V353, P765, DOI 10.1038/353765a0; HASBOLD J, 1990, EUR J IMMUNOL, V20, P1685, DOI 10.1002/eji.1830200810; HAYAKAWA K, 1984, P NATL ACAD SCI-BIOL, V81, P2494, DOI 10.1073/pnas.81.8.2494; HAYAKAWA K, 1986, EUR J IMMUNOL, V16, P1313, DOI 10.1002/eji.1830161021; HERZENBERG LA, 1986, IMMUNOL REV, V93, P81, DOI 10.1111/j.1600-065X.1986.tb01503.x; KANTOR AB, 1991, IMMUNOL TODAY, V12, P389, DOI 10.1016/0167-5699(91)90136-H; MARCOS MAR, 1989, EUR J IMMUNOL, V19, P2031, DOI 10.1002/eji.1830191110; NEMAZEE D, 1989, P NATL ACAD SCI USA, V86, P8039, DOI 10.1073/pnas.86.20.8039; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; OKAMOTO M, 1992, J EXP MED, V175, P71, DOI 10.1084/jem.175.1.71; PIKE BL, 1982, P NATL ACAD SCI-BIOL, V79, P2013, DOI 10.1073/pnas.79.6.2013; RUSSELL DM, 1991, NATURE, V354, P308, DOI 10.1038/354308a0; SCHWARTZ RS, 1989, FUNDAMENTAL IMMUNOLO, P819; SEDGWICK JD, 1983, J IMMUNOL METHODS, V57, P301, DOI 10.1016/0022-1759(83)90091-1; SHLOMCHIK M, 1990, J EXP MED, V171, P265, DOI 10.1084/jem.171.1.265; SHLOMCHIK MJ, 1987, NATURE, V328, P805, DOI 10.1038/328805a0; SHLOMCHIK MJ, 1987, P NATL ACAD SCI USA, V84, P9150, DOI 10.1073/pnas.84.24.9150; SMITH HR, 1983, ANNU REV IMMUNOL, V1, P175, DOI 10.1146/annurev.iy.01.040183.001135; WILLIAMS JR, 1974, NATURE, V252, P754, DOI 10.1038/252754a0	32	270	270	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 7	1992	357	6373					77	80		10.1038/357077a0	http://dx.doi.org/10.1038/357077a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT229	1574128				2022-12-01	WOS:A1992HT22900062
J	SAID, G; GOULONGOEAU, C; SLAMA, G; TCHOBROUTSKY, G				SAID, G; GOULONGOEAU, C; SLAMA, G; TCHOBROUTSKY, G			SEVERE EARLY-ONSET POLYNEUROPATHY IN INSULIN-DEPENDENT DIABETES-MELLITUS - A CLINICAL AND PATHOLOGICAL-STUDY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEUROPATHY; DEGENERATION; PATHOGENESIS; PAINFUL	Background and Methods. The pathophysiologic features of diabetic neuropathy, a common and disabling long-term complication of diabetes mellitus, are poorly understood. We studied five patients, 22 to 34 years old, in whom an uncommonly severe symmetric polyneuropathy developed soon after the onset of insulin-dependent diabetes. Their autonomic function and nerve conduction were studied, and sural-nerve biopsy specimens were examined by light and electron microscopy. Other causes of neuropathy were carefully excluded. Results. Four patients had autonomic dysfunction with postural hypotension, fainting, diarrhea, and Argyll Robertson pupils and peripheral neuropathy with loss of sensation of pain and changes in temperature that followed a pattern suggestive of a length-dependent degeneration of nerve fibers. In contrast, the fifth patient had muscle weakness and atrophy of limb extremities, with "glove and stocking" sensory loss, but little autonomic dysfunction. In the biopsy specimens of sural nerves, the mean (+/- SD) density of myelinated fibers was reduced to 20 +/- 14 percent of that measured in five control patients, and the density of unmyelinated fibers was reduced to 6 +/- 4 percent of that in the controls. Regenerating fibers accounted for 38 +/- 11 percent of the myelinated axons. Abnormalities of the myelin sheath affected 33 +/- 21 percent of the isolated fibers, and axonal degeneration 11 +/- 8 percent. Dying-back fibers, a characteristic of the centripetal degeneration of peripheral axons, were also identified. The dying-back process progressed at the rate of a few hundred micrometers per day. Conclusions. Early-onset symptomatic polyneuropathy in patients with diabetes mellitus is characterized by the loss of both myelinated and unmyelinated nerve fibers. Spontaneous axonal regeneration is remarkably frequent, even when neuropathy is severe.	UNIV PARIS 11,HOP BICETRE,SERV NEUROL,PARIS,FRANCE; HOP HOTEL DIEU,SERV DIABETOL,F-75181 PARIS 04,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite								ALI Z, 1989, J NEUROL NEUROSUR PS, V52, P94, DOI 10.1136/jnnp.52.1.94; AZERAD E, 1961, PRESSE MED, V69, P1419; BEHSE F, 1990, ACTA NEUROL SCAND  S, V82, P3; BRITLAND ST, 1990, DIABETES, V39, P898, DOI 10.2337/diabetes.39.8.898; BROWN MJ, 1976, ARCH NEUROL-CHICAGO, V33, P164, DOI 10.1001/archneur.1976.00500030020004; CORNIL V, 1907, MANUEL HISTOLOGIE PA, V3, P527; Dieulafoy G., 1906, CLIN MED HOTEL DIEU, P130; DYCK P J, 1987, P223; DYCK PJ, 1986, ANN NEUROL, V19, P425, DOI 10.1002/ana.410190503; EWING D J, 1987, P66; FAGERBERG SE, 1963, ACTA MED SCAND, V174, P711; FUJIMURA H, 1991, BRAIN, V114, P1929, DOI 10.1093/brain/114.4.1929; GREENE DA, 1987, NEW ENGL J MED, V316, P599; JAMAL GA, 1987, MUSCLE NERVE, V10, P537, DOI 10.1002/mus.880100608; JOHNSON PC, 1986, ANN NEUROL, V19, P450, DOI 10.1002/ana.410190505; KING RHM, 1989, NEUROPATH APPL NEURO, V15, P339, DOI 10.1111/j.1365-2990.1989.tb01234.x; LLEWELYN JG, 1991, BRAIN, V114, P867, DOI 10.1093/brain/114.2.867; MCINTYRE AK, 1980, PHYSL PERIPHERAL NER, P41; MELTON LJ, 1987, DIABETIC NEUROPATHY, P27; PARKHOUSE N, 1988, NEW ENGL J MED, V318, P1306, DOI 10.1056/NEJM198805193182005; PIRART J, 1978, DIABETES CARE, V1, P252; Pirart J., 1978, DIABETES CARE, V1, P168, DOI DOI 10.2337/DIACARE.1.3.168; Sabin T.D., 1978, PHYSL PATHOBIOLOGY A, P431; SAID G, 1984, NEUROLOGY, V34, P1025, DOI 10.1212/WNL.34.8.1025; SAID G, 1983, BRAIN, V106, P791, DOI 10.1093/brain/106.4.791; SIDENIUS P, 1987, P260; THOMAS PK, 1984, PERIPHERAL NEUROPATH, P1773; VERGELY P, 1893, GAZ HEBD MED CHIR, V32, P376	28	111	111	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 7	1992	326	19					1257	1263		10.1056/NEJM199205073261905	http://dx.doi.org/10.1056/NEJM199205073261905			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR447	1560802				2022-12-01	WOS:A1992HR44700005
J	YEW, PR; BERK, AJ				YEW, PR; BERK, AJ			INHIBITION OF P53 TRANSACTIVATION REQUIRED FOR TRANSFORMATION BY ADENOVIRUS EARLY 1B-PROTEIN	NATURE			English	Article							E1B-58KD TUMOR-ANTIGEN; MONOCLONAL-ANTIBODIES; CELLULAR P53; VIRAL-DNA; CELLS; PROTEIN; LOCALIZATION; ASSOCIATION; ACTIVATION; EXPRESSION	THE cellular phosphoprotein p53 inhibits progression through the mammalian cell cycle 1,2. Both p53 alleles are frequently mutated in human tumours 3,4, indicating that p53 is a tumour suppressor. Recent studies have suggested that p53 functions as a transcriptional activator 5-8, but the significance of this activity in cell-cycle control has not been established. The adenovirus 2 (Ad2) early 1B (E1B) 55K protein binds to p53 in transformed cells 9 and contributes to oncogenic transformation by Ad2 (refs 10-12). Here we report that mutants of E1B 55K and wild-type Ad12 E1B 54K proteins show a strong correlation between their ability to inhibit p53-mediated transcriptional activation and their ability to cooperate with adenovirus E1A protein in the transformation of primary cells. These results indicate that p53 probably inhibits cell cycling by functioning as a transcription factor.	UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles	YEW, PR (corresponding author), UNIV CALIF LOS ANGELES,DEPT MICROBIOL & MOLEC GENET,LOS ANGELES,CA 90024, USA.		BERK, ARNOLD/AAF-7052-2020					BARKER DD, 1987, VIROLOGY, V156, P107, DOI 10.1016/0042-6822(87)90441-7; BYRD PJ, 1988, VIROLOGY, V163, P155, DOI 10.1016/0042-6822(88)90242-5; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KAO CC, 1990, VIROLOGY, V179, P806, DOI 10.1016/0042-6822(90)90148-K; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MAK I, 1986, BIOCHEM CELL BIOL, V64, P256, DOI 10.1139/o86-036; MAK I, 1988, VIROLOGY, V163, P201, DOI 10.1016/0042-6822(88)90248-6; OROURKE RW, 1990, ONCOGENE, V5, P1829; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SARNOW P, 1982, VIROLOGY, V120, P510, DOI 10.1016/0042-6822(82)90054-X; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; STILLMAN B, 1986, CANCER SURV, V5, P389; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WHITE E, 1990, MOL CELL BIOL, V10, P120, DOI 10.1128/MCB.10.1.120; YEW PR, 1990, VIROLOGY, V179, P795, DOI 10.1016/0042-6822(90)90147-J; ZANTEMA A, 1985, VIROLOGY, V142, P44, DOI 10.1016/0042-6822(85)90421-0; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084	29	538	558	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 7	1992	357	6373					82	85		10.1038/357082a0	http://dx.doi.org/10.1038/357082a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT229	1533443				2022-12-01	WOS:A1992HT22900064
J	GILLMAN, MW; OLIVERIA, SA; MOORE, LL; ELLISON, RC				GILLMAN, MW; OLIVERIA, SA; MOORE, LL; ELLISON, RC			INVERSE ASSOCIATION OF DIETARY CALCIUM WITH SYSTOLIC BLOOD-PRESSURE IN YOUNG-CHILDREN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HYPERTENSION; CHILDHOOD	Objective.-To investigate the association of dietary calcium with blood pressure in young children. Design.-Cohort. Setting.-General community. Subjects.-Eighty-nine boys and girls, aged 3 to 6 years, from The Framingham Children's Study. Measurements.-During the first year of the study, we derived nutrient data from multiple food diaries (a mean of 9.6 days of recording for each subject). At the beginning of the second year of the study, we obtained anthropometric data and up to five blood pressure readings (mean, 4.5) on each child at a single sitting. Results.-The range of subjects' average daily calcium intake was 4.9 to 19.6 mmol per 4200 kJ, with a mean of 12.8 mmol per 4200 kJ. Subjects' average systolic blood pressure ranged from 73 to 129 mm Hg, with a mean of 95.9 mm Hg; for diastolic blood pressure, the range was 37 to 78 mm Hg, mean 54.6 mm Hg. Multiple linear regression analysis, adjusted for the effects of sex, height, body mass index, and heart rate, showed that for each increment of 2.5 mmol of dietary calcium per 4200 kJ per day, systolic blood pressure was 2.27 mm Hg lower (95% confidence interval, 0.63 to 3.91 mm Hg; P = .008). We found no such association for diastolic blood pressure. Conclusion.-Dietary calcium is inversely related to systolic blood pressure in young children.			GILLMAN, MW (corresponding author), BOSTON UNIV,SCH MED,EVANS SECT PREVENT MED & EPIDEMIOL,B-612,88 E NEWTON ST,BOSTON,MA 02118, USA.			Moore, Lynn/0000-0002-1028-919X; Ellison, Robert Curtis/0000-0002-0582-7467	NHLBI NIH HHS [HL 35653] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035653] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALPERT BS, 1987, CIRCULATION, V76, P360; [Anonymous], 1987, PEDIATRICS, V79, P1; BELIZAN JM, 1991, NEW ENGL J MED, V325, P1399, DOI 10.1056/NEJM199111143252002; CUTLER JA, 1990, AM J HYPERTENS, V3, pS137, DOI 10.1093/ajh/3.8.137; DAHL LK, 1970, P SOC EXP BIOL MED, V133, P1405, DOI 10.3181/00379727-133-34700; DEURENBERG P, 1990, BRIT J NUTR, V63, P293, DOI 10.1079/BJN19900116; ELLISON RC, 1984, AM J EPIDEMIOL, V120, P542, DOI 10.1093/oxfordjournals.aje.a113915; GILLMAN M, 1991, AM J EPIDEMIOL, V134, P730; GILLMAN MW, 1991, PEDIATRICS, V87, P708; JENNER DA, 1988, AM J CLIN NUTR, V47, P1052, DOI 10.1093/ajcn/47.6.1052; KLEINBAUM DJ, 1978, APPLIED REGRESSION A; LAUER RM, 1989, PEDIATRICS, V84, P633; LEE D, 1957, AM J CLIN NUTR, V5, P166, DOI 10.1093/ajcn/5.2.166; LIEBMAN M, 1986, HYPERTENSION, V8, P843, DOI 10.1161/01.HYP.8.10.843; MARMOR JK, 1991, J CLIN EPIDEMIOL, V44, P531, DOI 10.1016/0895-4356(91)90216-V; MCCARRON DA, 1989, KIDNEY INT, V35, P717, DOI 10.1038/ki.1989.44; MCCARRON DA, 1991, AM J CLIN NUTR, V54, pS215, DOI 10.1093/ajcn/54.1.215S; MCGARVEY ST, 1991, HYPERTENSION, V17, P218, DOI 10.1161/01.HYP.17.2.218; MOORE LL, 1991, J PEDIATR-US, V118, P215, DOI 10.1016/S0022-3476(05)80485-8; NICKLAS TA, 1990, FOOD SOURCES NUTRIEN; ROSNER B, 1987, AM J EPIDEMIOL, V126, P1115, DOI 10.1093/oxfordjournals.aje.a114750; ROSNER B, 1988, AM J EPIDEMIOL, V127, P377, DOI 10.1093/oxfordjournals.aje.a114811; SOWERS JR, 1989, J LAB CLIN MED, V114, P338; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; WITSCHI J, 1981, J AM DIET ASSOC, V78, P609; WITTEMAN JCM, 1989, CIRCULATION, V80, P1320, DOI 10.1161/01.CIR.80.5.1320; 1991, NIH912732 US DEP HLT	27	53	54	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 6	1992	267	17					2340	2343		10.1001/jama.267.17.2340	http://dx.doi.org/10.1001/jama.267.17.2340			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR015	1564773				2022-12-01	WOS:A1992HR01500026
J	HUGHES, PH; BRANDENBURG, N; BALDWIN, DC; STORR, CL; WILLIAMS, KM; ANTHONY, JC; SHEEHAN, DV				HUGHES, PH; BRANDENBURG, N; BALDWIN, DC; STORR, CL; WILLIAMS, KM; ANTHONY, JC; SHEEHAN, DV			PREVALENCE OF SUBSTANCE USE AMONG UNITED-STATES PHYSICIANS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							YOUTHFUL PRECURSORS; ALCOHOL-ABUSE; DRUG; STUDENTS	Objective.-To estimate the prevalence of substance use among US physicians. Design.-A mailed, anonymous, self-report survey that assessed use of 13 substances and permitted comparison with results of the National Household Survey on Drug Abuse. Rates of physician substance use were weighted to provide national prevalence estimates. Participants.-A national sample of 9600 physicians, stratified by specialty and career stage, and randomly selected from the American Medical Association master file. The response rate after three mailings was 59%. Demographic characteristics of respondents closely reflected those of the US physician population. Main Outcome Measures.-Subjects' self-reported use of 13 substances in their lifetime, the past year, and the past month; reasons for use; self-admitted substance abuse or dependence; and whether treatment was received. For controlled prescription substances, respondents were asked to report only use "not prescribed by another physician for a legitimate medical or psychiatric condition." Results.-Physicians were less likely to have used cigarettes and illicit substances, such as marijuana, cocaine, and heroin, in the past year than their age and gender counterparts in the National Household Survey on Drug Abuse. They were more likely to have used alcohol and two types of prescription medication-minor opiates and benzodiazepine tranquilizers. Prescription substances were used primarily for self-treatment, whereas illicit substances and alcohol were used primarily for recreation. Current daily use of illicit or controlled substances was rare. Conclusions.-Although physicians were as likely to have experimented with illicit substances in their lifetime as their age and gender peers in society, they were far less likely to be current users of illicit substances. The higher prevalence of alcohol use among respondents may be more a characteristic of their socioeconomic class than of their profession. A unique concern for physicians, however, is their high rate of self-treatment with controlled medications-a practice that could increase their risk of drug abuse or dependence. Uniform national guidelines are needed to sensitize medical students and physicians to the dangers of self-treatment with controlled prescription substances.	UNIV S FLORIDA, INST RES PSYCHIAT, TAMPA, FL 33620 USA; JAMES A HALEY VET HOSP, TAMPA, FL USA; UNIV S FLORIDA, COLL PUBL HLTH, TAMPA, FL 33620 USA; AMER MED ASSOC, DIV MED EDUC RES, CHICAGO, IL 60610 USA; JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, BALTIMORE, MD 21218 USA	State University System of Florida; University of South Florida; US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital; State University System of Florida; University of South Florida; American Medical Association; Johns Hopkins University			Anthony, Jim/H-3637-2011; Sheehan, David V/L-6879-2013	Anthony, Jim/0000-0001-7176-0929; Sheehan, David V/0000-0002-5118-7050	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004877] Funding Source: NIH RePORTER; NIDA NIH HHS [1 RO1 DA04877] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		[Anonymous], 1973, JAMA, V223, P684; [Anonymous], 1987, JAMA-J AM MED ASSOC, V257, P3110; BALDWIN DC, 1991, JAMA-J AM MED ASSOC, V265, P2074, DOI 10.1001/jama.265.16.2074; BALTER M, 1991, MAY ANN M AM PSYCH A; BISSELL L, 1989, American Pharmacy, V29, P19; Bissell L, 1984, ALCOHOLISM PROFESSIO; BREWSTER JM, 1986, JAMA-J AM MED ASSOC, V255, P1913, DOI 10.1001/jama.255.14.1913; CONARD S, 1988, J MED EDUC, V63, P747, DOI 10.1097/00001888-198810000-00002; COTTLER LB, 1987, AM J EPIDEMIOL, V125, P329, DOI 10.1093/oxfordjournals.aje.a114534; Du Pont R.L., 1988, AM J DRUG ALCOHOL S1, V14, P1; Fleiss J. L., 1981, STAT METHODS RATES P, V2nd, DOI 10.1002/0471445428; FRANKEL M, 1983, HDB SURVEY RES; GERBERT B, 1991, JAMA-J AM MED ASSOC, V266, P2837, DOI 10.1001/jama.266.20.2837; HOLT D, 1979, J ROY STAT SOC A STA, V142, P33, DOI 10.2307/2344652; HUGHES PH, 1991, JAMA-J AM MED ASSOC, V265, P2069, DOI 10.1001/jama.265.16.2069; KNUPFER G, 1989, BRIT J ADDICT, V84, P1305; KRAKOWSKI AJ, 1984, PSYCHOTHER PSYCHOSOM, V42, P143, DOI 10.1159/000287838; LAPUMA J, 1991, NEW ENGL J MED, V325, P1290, DOI 10.1056/NEJM199110313251806; MADDUX JF, 1987, J MED EDUC, V62, P852; MCAULIFFE WE, 1986, NEW ENGL J MED, V315, P805, DOI 10.1056/NEJM198609253151305; MCAULIFFE WE, 1991, AM J PUBLIC HEALTH, V81, P177, DOI 10.2105/AJPH.81.2.177; MOORE RD, 1990, AM J MED, V88, P332, DOI 10.1016/0002-9343(90)90485-V; MORSE RM, 1984, JAMA-J AM MED ASSOC, V251, P743, DOI 10.1001/jama.251.6.743; ORENTLICHER D, 1990, JAMA-J AM MED ASSOC, V264, P1039, DOI 10.1001/jama.264.8.1039; REGIER DA, 1990, JAMA-J AM MED ASSOC, V264, P2511; ROBACK G, 1990, PHYSICIAN CHARACTERI; ROUSE B, 1985, RES MONOGRAPH NATION, V57; SHEIKH K, 1981, J EPIDEMIOL COMMUN H, V35, P293, DOI 10.1136/jech.35.4.293; TALBOTT GD, 1987, JAMA-J AM MED ASSOC, V257, P2927, DOI 10.1001/jama.257.21.2927; VAILLANT GE, 1970, NEW ENGL J MED, V282, P365, DOI 10.1056/NEJM197002122820705; 1989, NATIONAL HOUSEHOLD S; 1990, NATIONAL HOUSEHOLD S	32	240	244	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 6	1992	267	17					2333	2339		10.1001/jama.267.17.2333	http://dx.doi.org/10.1001/jama.267.17.2333			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR015	1348789				2022-12-01	WOS:A1992HR01500025
J	JOHNSON, E				JOHNSON, E			ANIMAL-MODEL FOR AIDS DEMENTIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											JOHNSON, E (corresponding author), ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1992, SCIENCE, V255, P1246	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 6	1992	267	17					2293	2293						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR015	1314314				2022-12-01	WOS:A1992HR01500005
